PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bachelet, I; Munitz, A; Mankutad, D; Levi-Schaffer, F				Bachelet, Ido; Munitz, Ariel; Mankutad, David; Levi-Schaffer, Francesca			Mast cell costimulation by CD226/CD112 (DNAM-1/Nectin-2) - A novel interface in the allergic process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD EOSINOPHILS; FC-EPSILON-RI; RECEPTOR IRP60 CD300A; DNAM-1 CD226; T-CELLS; POLIOVIRUS RECEPTOR; ADHESION MOLECULE; HISTAMINE-RELEASE; NECTIN-2 CD112; PVR CD155	Mast cells have critical effector functions in various immune reactions. In allergic inflammation, mast cells interact with tissue-infiltrating eosinophils, forming a regulatory unit in the late and chronic phases of the allergic process. However, the pathways and molecules within this unit are still largely undefined. Here, we show that human mast cells and eosinophils express DNAX accessory molecule 1 (DNAM-1, CD226) and its ligand Nectin-2 (CD112). CD226 synergizes with Fc epsilon RI on mast cells, and its engagement augments degranulation through a pathway involving Fyn, linker of activation of T-cells, phospholipase C gamma 2, and CD18. This pathway is subject to negative interference by inhibitory receptors and is completely inhibited by linking IgE with IRp60 (CD300a) using a bispecific antibody. Moreover, blocking CD112 expressed on eosinophils using neutralizing antibodies normalized the hyperactivity resulting from IgE-dependent activation of mast cells co-cultured with eosinophils. Our findings demonstrate a novel interface between these two effector cells, implicating relevance for in vivo allergic states. Moreover, costimulatory responses might be a critical component in allergic reactions and may therefore become novel targets for anti-allergic therapy.	Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91905 Jerusalem, Israel; Hadassah Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Levi-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91905 Jerusalem, Israel.	fls@cc.huji.ac.il		Levi-Schaffer, Francesca/0000-0003-0620-2810				Astier A, 2000, J IMMUNOL, V164, P6091, DOI 10.4049/jimmunol.164.12.6091; Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; Bachelet I, 2006, J ALLERGY CLIN IMMUN, V117, P1314, DOI 10.1016/j.jaci.2006.04.031; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Hartman ML, 2001, BLOOD, V97, P1086, DOI 10.1182/blood.V97.4.1086; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; Inamura N, 1998, J IMMUNOL, V160, P4026; Kallinich T, 2005, CLIN EXP ALLERGY, V35, P1521, DOI 10.1111/j.1365-2222.2005.02369.x; Kashiwakura J, 2004, J IMMUNOL, V173, P5247, DOI 10.4049/jimmunol.173.8.5247; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Lappalainen H, 2004, ARTERIOSCL THROM VAS, V24, P1880, DOI 10.1161/01.ATV.0000140820.51174.8d; Leyton L, 1999, MOL IMMUNOL, V36, P755, DOI 10.1016/S0161-5890(99)00086-3; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Munitz A, 2005, J IMMUNOL, V174, P110, DOI 10.4049/jimmunol.174.1.110; Nishimoto H, 2005, BLOOD, V106, P4241, DOI 10.1182/blood-2005-04-1358; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; Oskeritzian C, 1996, CELL IMMUNOL, V167, P205, DOI 10.1006/cimm.1996.0028; Pende D, 2006, BLOOD, V107, P2030, DOI 10.1182/blood-2005-07-2696; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Shibuya K, 2003, J EXP MED, V198, P1829, DOI 10.1084/jem.20030958; Shin JS, 2001, FEMS MICROBIOL LETT, V197, P131, DOI 10.1016/S0378-1097(01)00108-2; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Shirakawa J, 2005, INT IMMUNOL, V17, P217, DOI 10.1093/intimm/dxh199; Tahara-Hanaoka S, 2006, BLOOD, V107, P1491, DOI 10.1182/blood-2005-04-1684; Tahara-Hanaoka S, 2004, INT IMMUNOL, V16, P533, DOI 10.1093/intimm/dxh059; Tashiro M, 1997, J IMMUNOL, V158, P2382; Temkin V, 2002, J IMMUNOL, V169, P2662, DOI 10.4049/jimmunol.169.5.2662; Toda M, 2004, J BIOL CHEM, V279, P48443, DOI 10.1074/jbc.M408725200; Tomasec P, 2005, NAT IMMUNOL, V6, P181, DOI 10.1038/ni1156; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	37	58	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27190	27196		10.1074/jbc.M602359200	http://dx.doi.org/10.1074/jbc.M602359200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16831868	hybrid			2022-12-27	WOS:000240397700046
J	Chandor, A; Berteau, O; Douki, T; Gasparutto, D; Sanakis, Y; Ollagnier-De-Choudens, S; Atta, M; Fontecave, M				Chandor, Alexia; Berteau, Olivier; Douki, Thierry; Gasparutto, Didier; Sanakis, Yannis; Ollagnier-de-Choudens, Sandrine; Atta, Mohamed; Fontecave, Marc			Dinucleotide spore photoproduct, a minimal substrate of the DNA repair spore photoproduct lyase enzyme from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; III OXIDASE HEMN; S-ADENOSYLMETHIONINE; RADICAL MECHANISMS; ACTIVATING ENZYME; BIOTIN SYNTHASE; IRON; SULFUR; ACID; PROTEINS	The overwhelming majority of DNA photoproducts in UV-irradiated spores is a unique thymine dimer called spore photoproduct (SP, 5-thymine-5,6-dihydrothymine). This lesion is repaired by the spore photoproduct lyase (SP lyase) enzyme that directly reverts SP to two unmodified thymines. The SP lyase is an S-adenosylmethionine-dependent iron-sulfur protein that belongs to the radical S-adenosylmethionine superfamily. In this study, by using a well characterized preparation of the SP lyase enzyme from Bacillus subtilis, we show that SP in the form of a dinucleoside monophosphate (spore photoproduct of thymidilyl-(3 '-5 ')-thymidine) is efficiently repaired, allowing a kinetic characterization of the enzyme. The preparation of this new substrate is described, and its identity is confirmed by mass spectrometry and comparison with authentic spore photoproduct. The fact that the spore photoproduct of thymidilyl-(3 '-5 ')-thymidine dimer is repaired by SP lyase may indicate that the SP lesion does not absolutely need to be contained within a single or double-stranded DNA for recognition and repaired by the SP lyase enzyme.	Univ Grenoble 1, CNRS, Commissariat Energie Atom, UMR 5047,DRDC CB,Lab Chim & Biochim,Ctr Redox Bio, F-38054 Grenoble 09, France; Univ Grenoble 1, Serv Chim Inorgan & Biol, Commissariat Energie Atom, Dept Rech Fondamentale Mat Condensee,UMR E3, F-38054 Grenoble 09, France; NCSR Demokritos, Inst Mat Sci, Athens 15310, Greece	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); National Centre of Scientific Research "Demokritos"	Fontecave, M (corresponding author), Univ Grenoble 1, CNRS, Commissariat Energie Atom, UMR 5047,DRDC CB,Lab Chim & Biochim,Ctr Redox Bio, 17 Rue Martyrs, F-38054 Grenoble 09, France.	marc.fontecave@cea.fr	Chandor-Proust, Alexia/C-1109-2013; Thierry, Douki/H-2108-2018; Berteau, Olivier/AAF-9080-2019	Chandor-Proust, Alexia/0000-0002-4827-3281; Thierry, Douki/0000-0002-5022-071X; Berteau, Olivier/0000-0002-3434-5168				BEAUCAGE SL, 1992, TETRAHEDRON, V48, P2223, DOI 10.1016/S0040-4020(01)88752-4; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheek J, 2002, J AM CHEM SOC, V124, P2860, DOI 10.1021/ja017784g; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; DONNELLAN JE, 1965, SCIENCE, V149, P308, DOI 10.1126/science.149.3681.308; Douki T, 2005, PHOTOCH PHOTOBIO SCI, V4, P591, DOI 10.1039/b503771a; Douki T, 2005, PHOTOCHEM PHOTOBIOL, V81, P163, DOI 10.1562/2004-08-18-RA-278.1; Douki T, 2003, PHOTOCH PHOTOBIO SCI, V2, P433, DOI 10.1039/b300173c; Douki T, 2001, BIOCHEMISTRY-US, V40, P2495, DOI 10.1021/bi0022543; Douki T, 2000, J PHOTOCH PHOTOBIO B, V54, P145, DOI 10.1016/S1011-1344(00)00009-9; Fajardo-Cavazos P, 2005, CURR MICROBIOL, V51, P331, DOI 10.1007/s00284-005-0052-8; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frey PA, 2001, ADV PROTEIN CHEM, V58, P1; Friedel MG, 2006, CHEM COMMUN, P445, DOI 10.1039/b514103f; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Layer G, 2005, J BIOL CHEM, V280, P29038, DOI 10.1074/jbc.M501275200; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; Mehl RA, 1999, ORG LETT, V1, P1065, DOI 10.1021/ol9908676; Mulliez E, 1999, J BIOL INORG CHEM, V4, P614, DOI 10.1007/s007750050385; NICHOLSON WL, 1991, P NATL ACAD SCI USA, V88, P8288, DOI 10.1073/pnas.88.19.8288; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; Rebeil R, 2001, P NATL ACAD SCI USA, V98, P9038, DOI 10.1073/pnas.161278998; Rebeil R, 1998, J BACTERIOL, V180, P4879, DOI 10.1128/JB.180.18.4879-4885.1998; SETLOW B, 1987, P NATL ACAD SCI USA, V84, P421, DOI 10.1073/pnas.84.2.421; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; Slieman TA, 2000, J BACTERIOL, V182, P6412, DOI 10.1128/JB.182.22.6412-6417.2000; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; VARGHESE AJ, 1970, BIOCHEM BIOPH RES CO, V38, P484, DOI 10.1016/0006-291X(70)90739-4	37	48	49	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26922	26931		10.1074/jbc.M602297200	http://dx.doi.org/10.1074/jbc.M602297200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16829676	hybrid			2022-12-27	WOS:000240397700019
J	Huang, Y; Qiao, F; Abagyan, R; Hazard, S; Tomlinson, S				Huang, Yuxiang; Qiao, Fei; Abagyan, Ruben; Hazard, Starr; Tomlinson, Stephen			Defining the CD59-C9 binding interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN CD59; COMPLEMENT INHIBITORS; CANCER-IMMUNOTHERAPY; ACTIVE-SITE; C9; THERAPEUTICS; INJURY; C5B-9; C8; MOLECULE	CD59 is a membrane glycoprotein that regulates formation of the cytolytic membrane attack complex(MAC or C5b-9) on host cell membranes. It functions by binding to C8 (alpha chain) and C9 after their structural rearrangement during MAC assembly. Previous studies indicated that the CD59 binding site in C9 was located within a 25-residue disulfide-bonded loop, and in C8 alpha was located within a 51-residue sequence that overlaps the CD59 binding region of C9. By peptide screens and the use of peptides in binding assays, functional assays, and computer modeling and docking studies, we have identified a 6-residue sequence of human C9, spanning residues 365-371, as the primary CD59 recognition domain involved in CD59-mediated regulation of MAC formation. The data also indicate that both C8 alpha and C9 bind to a similar or overlapping site on CD59. Furthermore, data from CD59-peptide docking models are consistent with the C9 binding site on CD59 located at a hydrophobic pocket, putatively identified previously by CD59 mutational and modeling studies.	Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Medical University of South Carolina; Medical University of South Carolina; Scripps Research Institute	Tomlinson, S (corresponding author), Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29403 USA.	tomlinss@musc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047386] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 47386] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Bodian DL, 1997, J EXP MED, V185, P507, DOI 10.1084/jem.185.3.507; Cavasotto CN, 2004, J MOL BIOL, V337, P209, DOI 10.1016/j.jmb.2004.01.003; CHANG CP, 1994, J BIOL CHEM, V269, P26424; DECKERT M, 1992, EUR J IMMUNOL, V22, P2943, DOI 10.1002/eji.1830221128; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; Fonsatti E, 2000, Clin Ter, V151, P187; Fraser DA, 2003, J BIOL CHEM, V278, P48921, DOI 10.1074/jbc.M302598200; Gelderman KA, 2004, TRENDS IMMUNOL, V25, P158, DOI 10.1016/j.it.2004.01.008; Ghiran I, 2003, J BIOL CHEM, V278, P21024, DOI 10.1074/jbc.M302306200; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; He C, 2005, J IMMUNOL, V174, P5750, DOI 10.4049/jimmunol.174.9.5750; Huang YX, 2005, J BIOL CHEM, V280, P34073, DOI 10.1074/jbc.M504922200; HUESLER T, 1996, BIOCHEMISTRY-US, V35, P3263; HUESLER T, 1995, J BIOL CHEM, V270, P3483, DOI 10.1074/JBC.270.8.3483; LAMBRIS JD, 2000, THERAPEUTIC INTERVEN; LOCKERT DH, 1995, J BIOL CHEM, V270, P19723, DOI 10.1074/jbc.270.34.19723; Marcenaro E, 2003, EUR J IMMUNOL, V33, P3367, DOI 10.1002/eji.200324425; MERI S, 1990, IMMUNOLOGY, V71, P1; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; Quigg RJ, 2002, TRENDS MOL MED, V8, P430, DOI 10.1016/S1471-4914(02)02386-9; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; TOMLINSON S, 1994, J IMMUNOL, V152, P1927; Yu JH, 1997, J EXP MED, V185, P745, DOI 10.1084/jem.185.4.745	27	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27398	27404		10.1074/jbc.M603690200	http://dx.doi.org/10.1074/jbc.M603690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844690	hybrid			2022-12-27	WOS:000240397700066
J	Bullesbach, EE; Schwabe, C				Bullesbach, Erika E.; Schwabe, Christian			The mode of interaction of the relaxin-like factor (RLF) with the leucine-rich repeat G protein-activated receptor 8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-LIKE PEPTIDE; RECEPTOR-BINDING SITE; SOLID-PHASE SYNTHESIS; TESTICULAR CANCER; INSL3 GENE; CRYPTORCHIDISM; CHAIN; LGR8; DETERMINANTS; CONFORMATION	The relaxin-like factor (RLF, also named INSL3) is a critical component in the chain of events that lead to the normal positioning of the gonads in the male fetus. RLF and relaxin share features of the secondary structure to the extent that relaxin cross-reacts with the LGR8, the RLF receptor. Although both hormones interact with their receptors essentially via the B chain, the sharply defined binding cassette of relaxin is not present in RLF. Structure and function analysis of RLF derivatives with single amino acid replacements revealed that the most important binding residues are tryptophan B27, followed by arginine B16 and valine B19. Single alanine replacements for each individual position resulted in a relative receptor affinity of 4.0% (B16), 6.1% (B19), and 0.5% (B27). Tryptophan B27 is located on an extended structure, and arginine B16 and valine B19 are positioned on the exposed surface of the B chain helix. The 3 residues could be brought together to form a contiguous binding area if the C-terminal end of the B chain were free to fold back against the central portion of the B chain helix. Such a movement depends critically on the flexibility of the C-terminal end, which is controlled by positions B23-25. In as much as these major binding residues seem hardly sufficient to explain the strong binding of RLF to LGR8 we searched for and found an extended region where little contributions by individual residues added up to a strong receptor affinity. This mode of interaction could drive the binding energy sufficiently high to account for the picomolar binding constant of RLF and its receptor.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Schwabe, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	schwabec@musc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040406] Funding Source: NIH RePORTER; NICHD NIH HHS [1-R01-HD40406] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adham IM, 2000, MOL CELL ENDOCRINOL, V160, P11, DOI 10.1016/S0303-7207(99)00188-4; ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Adler A J, 1973, Methods Enzymol, V27, P675; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; Bullesbach EE, 2005, J BIOL CHEM, V280, P14051, DOI 10.1074/jbc.M500030200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Bullesbach EE, 2004, BIOCHEMISTRY-US, V43, P8021, DOI 10.1021/bi049601j; Bullesbach EE, 1999, J BIOL CHEM, V274, P22354, DOI 10.1074/jbc.274.32.22354; Bullesbach EE, 2002, BIOCHEMISTRY-US, V41, P274, DOI 10.1021/bi0117302; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; BULLESBACH EE, 1995, J BIOL CHEM, V270, P16011, DOI 10.1074/jbc.270.27.16011; BULLESBACH EE, 1994, J BIOL CHEM, V269, P13124; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Dawson NF, 1999, J PEPT RES, V53, P542, DOI 10.1034/j.1399-3011.1999.00060.x; Drapeau G R, 1977, Methods Enzymol, V47, P189; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; HUA QX, 1992, BIOCHEMISTRY-US, V31, P11940, DOI 10.1021/bi00162a037; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Lim HN, 2001, EUR J ENDOCRINOL, V144, P129, DOI 10.1530/eje.0.1440129; MARUYAMA K, 1992, J PROTEIN CHEM, V11, P1, DOI 10.1007/BF01025086; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; Moller H, 1996, CANCER CAUSE CONTROL, V7, P264, DOI 10.1007/BF00051302; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Rosengren KJ, 2006, J BIOL CHEM, V281, P5845, DOI 10.1074/jbc.M511210200; Smith KJ, 2001, J PEPT SCI, V7, P495, DOI 10.1002/psc.344; STEINER AL, 1979, METHOD HORM RADIOIMM, P3; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	35	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26136	26143		10.1074/jbc.M601414200	http://dx.doi.org/10.1074/jbc.M601414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844694	hybrid			2022-12-27	WOS:000240249500029
J	Kareta, MS; Botello, ZM; Ennis, JJ; Chou, C; Chedin, F				Kareta, Michael S.; Botello, Zaida M.; Ennis, Joshua J.; Chou, Christina; Chedin, Frederic			Reconstitution and mechanism of the stimulation of de novo methylation by human DNMT3L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLTRANSFERASES DNMT3A; ADENOSYL-L-METHIONINE; ENZYMATIC-PROPERTIES; N-METHYLTRANSFERASE; CATALYTIC-ACTIVITY; BINDING; PROTEIN; FAMILY; EXPRESSION; GENE	The DNMT3-like protein, DNMT3L, is required for germ line DNA methylation, although it is inactive as a DNA methyltransferase per se. Previous studies have shown that DNMT3L physically associates with the active de novo DNA methyltransferases, DNMT3A and DNMT3B, and stimulates their catalytic activities in a cell culture system. However, the mechanism by which DNMT3L stimulates de novo methylation remains unclear. Here, we have purified the full-length human DNMT3A2 and DNMT3L proteins and determined unique conditions that allow for the proper reconstitution of the stimulation of DNMT3A2 de novo methyltransferase activity by DNMT3L. These conditions include the use of buffers resembling physiological conditions and the preincubation of the two proteins. Under these conditions, maximal stimulation is reached at equimolar amounts of DNMT3L and DNMT3A2 proteins, and the catalytic efficiency of DNMT3A2 is increased up to 20-fold. Biochemical analysis revealed that whereas DNMT3L on its own does not significantly bind to the methyl group donor, S-adenosyl-L-methionine (SAM), it strongly increases the binding of SAM to DNMT3A2. DNA binding, on the contrary, was not appreciably improved. Analysis of DNA methyltransferase complexes in solution using size exclusion chromatography revealed that DNMT3A2 forms large structures of heterogeneous sizes, whereas DNMT3L appears as a monomer. Binding of DNMT3L to DNMT3A2 promotes a dramatic reorganization of DNMT3A2 subunits and leads to the formation of specific complexes with enhanced DNA methyltransferase activity and increased SAM binding.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Chedin, F (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	flchedin@ucdavis.edu		Kareta, Michael/0000-0002-6980-9065; Chedin, Frederic/0000-0002-1306-5335				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Chen ZX, 2005, J CELL BIOCHEM, V95, P902, DOI 10.1002/jcb.20447; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DUERRE JA, 1989, BIOCHIM BIOPHYS ACTA, V985, P211, DOI 10.1016/0005-2736(89)90366-0; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; FRANCIS DM, 1980, BIOCHEM J, V187, P819, DOI 10.1042/bj1870819; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Gowher H, 2005, J BIOL CHEM, V280, P13341, DOI 10.1074/jbc.M413412200; Hata K, 2002, DEVELOPMENT, V129, P1983; Hata K, 2006, MOL REPROD DEV, V73, P116, DOI 10.1002/mrd.20387; Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; La Salle S, 2004, DEV BIOL, V268, P403, DOI 10.1016/j.ydbio.2003.12.031; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; LOTTA T, 1995, BIOCHEMISTRY-US, V34, P4202, DOI 10.1021/bi00013a008; Lucifero D, 2004, HUM MOL GENET, V13, P839, DOI 10.1093/hmg/ddh104; Luka Z, 2003, BIOCHEM BIOPH RES CO, V312, P1067, DOI 10.1016/j.bbrc.2003.11.037; Margot JB, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-7; MARTIN RL, 1989, J BIOL CHEM, V264, P11768; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Reik W, 2005, NAT REV GENET, V6, P403, DOI 10.1038/nrg1602; REITZ RC, 1989, J BIOL CHEM, V264, P8097; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; Sakai Y, 2004, GENE EXPR PATTERNS, V5, P231, DOI 10.1016/j.modgep.2004.07.011; Suetake I, 2004, J BIOL CHEM, V279, P27816, DOI 10.1074/jbc.M400181200; Suetake I, 2003, J BIOCHEM, V133, P737, DOI 10.1093/jb/mvg095; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Touyz RM, 2004, FRONT BIOSCI-LANDMRK, V9, P1278, DOI 10.2741/1316; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; Webster KE, 2005, P NATL ACAD SCI USA, V102, P4068, DOI 10.1073/pnas.0500702102; Wilson JR, 2002, CELL, V111, P105, DOI 10.1016/S0092-8674(02)00964-9; Wu Q, 2005, J MED CHEM, V48, P7243, DOI 10.1021/jm050568o; Yokochi T, 2004, BIOORG CHEM, V32, P234, DOI 10.1016/j.bioorg.2004.04.005; Yokochi T, 2002, J BIOL CHEM, V277, P11735, DOI 10.1074/jbc.M106590200	49	131	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25893	25902		10.1074/jbc.M603140200	http://dx.doi.org/10.1074/jbc.M603140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829525	hybrid			2022-12-27	WOS:000240249500004
J	Narvaez, AJ; Voevodskaya, N; Thelander, L; Graeslund, A				Narvaez, Ana J.; Voevodskaya, Nina; Thelander, Lars; Graeslund, Astrid			The involvement of Arg(265) of mouse ribonucleotide reductase R2 protein in proton transfer and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADICAL TRANSFER PATHWAY; SITE-DIRECTED MUTAGENESIS; COUPLED ELECTRON-TRANSFER; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SUBUNIT INTERACTION; BACTERIORHODOPSIN; MECHANISM; PHOTOCYCLE; ARGININE	Ribonucleotide reductase class I enzymes consist of two nonidentical subunits, R1 and R2, the latter containing a diiron carboxylate center and a stable tyrosyl radical (Tyr(.)), both essential for catalysis. Catalysis is known to involve highly conserved amino acid residues covering a range of similar to 35 angstrom and a concerted mechanism involving long range electron transfer, probably coupled to proton transfer. A number of residues involved in electron transfer in both the R1 and R2 proteins have been identified, but no direct model has been presented regarding the proton transfer side of the process. Arg(265) is conserved in all known sequences of class Ia R2. In this study we have used site-directed mutagenesis to gain insight into the role of this residue, which lies close to the catalytically essential Asp(266) and Trp(103). Mutants to Arg(265) included replacement by Ala, Glu, Gln, and Tyr. All mutants of Arg(265) were found to have no or low catalytic activity with the exception of Arg(265) to Glu, which shows similar to 40% of the activity of native R2. We also found that the Arg mutants were capable of stable tyrosyl radical generation, with similar kinetics of radical formation and R1 binding as native R2. Our results, supported by molecular modeling, strongly suggest that Arg(265) is involved in the proton- coupled electron transfer pathway and may act as a proton mediator during catalysis.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Stockholm University; Umea University	Graeslund, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	astrid@dbb.su.se						Andersson K. K., 1995, ADV INORG CHEM, V43, P359; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; CHANG CH, 1979, CANCER RES, V39, P5081; Chang CJ, 2004, BBA-BIOENERGETICS, V1655, P13, DOI 10.1016/j.bbabio.2003.08.010; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Doherty MK, 2000, BIOCHEMISTRY-US, V39, P10695, DOI 10.1021/bi000871l; Ehrenberg A, 2001, BIOSYSTEMS, V62, P9, DOI 10.1016/S0303-2647(01)00133-2; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Ekberg M, 1998, J BIOL CHEM, V273, P21003, DOI 10.1074/jbc.273.33.21003; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; Kolberg M, 2004, BBA-PROTEINS PROTEOM, V1699, P1, DOI 10.1016/j.bbapap.2004.02.007; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; Meredith D, 2004, J BIOL CHEM, V279, P15795, DOI 10.1074/jbc.M313922200; Mowat CG, 2001, BIOCHEMISTRY-US, V40, P12292, DOI 10.1021/bi011360h; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Petkova AT, 1999, BIOCHEMISTRY-US, V38, P1562, DOI 10.1021/bi981968z; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Rova U, 1999, J BIOL CHEM, V274, P23746, DOI 10.1074/jbc.274.34.23746; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; Strand KR, 2004, J BIOL CHEM, V279, P46794, DOI 10.1074/jbc.M407346200; Strand KR, 2002, J BIOL CHEM, V277, P34229, DOI 10.1074/jbc.M203358200; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; Tanimoto T, 2004, BIOCHEMISTRY-US, V43, P9439, DOI 10.1021/bi049368p; THELANDER L, 1993, MET IONS BIOL SYST, V30, P109; THORGEIRSSON TE, 1991, BIOCHEMISTRY-US, V30, P9133, DOI 10.1021/bi00102a003; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uppsten M, 2006, J MOL BIOL, V359, P365, DOI 10.1016/j.jmb.2006.03.035; Xiao YW, 2004, BIOCHEMISTRY-US, V43, P12809, DOI 10.1021/bi049238g; Yun D, 2002, BIOCHEMISTRY-US, V41, P981, DOI 10.1021/bi011797p	47	9	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26022	26028		10.1074/jbc.M604598200	http://dx.doi.org/10.1074/jbc.M604598200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829694	hybrid			2022-12-27	WOS:000240249500017
J	Robertson, AS; Belorgey, D; Gubb, D; Dafforn, TR; Lomas, DA				Robertson, Andrew S.; Belorgey, Didier; Gubb, David; Dafforn, Timothy R.; Lomas, David A.			Inhibitory activity of the Drosophila melanogaster serpin necrotic is dependent on lysine residues in the D-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; HEPARIN ACTIVATION; ANTITHROMBIN; BINDING; MECHANISM; PROTEINASE; PROTEASE; COMPLEX; TOLL	Necrotic is a member of the serine protease inhibitor or serpin superfamily. It is a potent inhibitor of elastase and chymotrypsin type proteases and is responsible for regulating the anti-fungal response in Drosophila melanogaster. Necrotic contains three basic lysine residues within the D-helix that are homologous to those found in the heparin-binding domain of antithrombin and heparin co-factor II. We show here that substitution of all three lysine residues for glutamines caused cellular necrosis and premature death in Drosophila in keeping with a loss of function phenotype. The lysine to glutamine substitutions had no effect on the overall structure of recombinant Necrotic protein but abolished the formation of stable complexes with target proteases. Individual substitutions with either glutamine or alanine demonstrated that lysine 68 was the most critical residue for inhibitory activity. Despite the homology to other serpins, Necrotic did not bind, nor was it activated by sulfated glycans. These data demonstrate a critical role for basic residues within the D-helix (and lysine 68 in particular) in the inhibitory mechanism of the serpin Necrotic.	Univ Cambridge, Dept Med, Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; Univ Birmingham, Birmingham B15 2TT, W Midlands, England; CIC bioGUNE, Derio 48160, Spain	University of Cambridge; University of Cambridge; University of Birmingham; CIC bioGUNE	Lomas, DA (corresponding author), Univ Cambridge, Dept Med, Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	dal16@cam.ac.uk	Gubb, David/F-9793-2011; Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679	MRC [G0500306, G8225539] Funding Source: UKRI; Medical Research Council [G8225539, G0500306] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P65; Green C, 2000, GENETICS, V156, P1117; Green C, 2003, DEVELOPMENT, V130, P1473, DOI 10.1242/dev.00350; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2003, BIOCHEMISTRY-US, V42, P8712, DOI 10.1021/bi034524y; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Meagher JL, 2000, J BIOL CHEM, V275, P2698, DOI 10.1074/jbc.275.4.2698; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; O'Keeffe D, 2004, J BIOL CHEM, V279, P50267, DOI 10.1074/jbc.M408774200; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; Onda M, 2005, J BIOL CHEM, V280, P13735, DOI 10.1074/jbc.M413282200; Robertson AS, 2003, J BIOL CHEM, V278, P6175, DOI 10.1074/jbc.M209277200; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652	27	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26437	26443		10.1074/jbc.M606085200	http://dx.doi.org/10.1074/jbc.M606085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835244	hybrid			2022-12-27	WOS:000240249500061
J	Thomas, JT; Prakash, D; Weih, K; Moos, M				Thomas, J. Terrig; Prakash, David; Weih, Karis; Moos, Malcolm, Jr.			CDMP1/GDF5 has specific processing requirements that restrict its action to joint surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; BONE MORPHOGENETIC PROTEINS; EARLY XENOPUS DEVELOPMENT; TGF-BETA-SUPERFAMILY; BRACHYDACTYLY TYPE-C; PROHORMONE CONVERTASES; EMBRYONIC-DEVELOPMENT; CARTILAGE FORMATION; SPEMANN ORGANIZER; PRO-PROTEIN	CDMP1/GDF5 has not demonstrated biological activity in Xenopus embryos when overexpressed by mRNA injection. We provide biological and biochemical evidence that to become active, the protein requires cleavage by two distinct proteolytic enzymes. We demonstrate a specific overlap in the expression patterns of CDMP1/GDF5 with the proteases required to release the mature peptide at the location of the future articular surface but not in the future joint space. Taken together, these observations provide a plausible mechanism for local action of CDMP1/GDF5 consistent with requirements imposed by current models of pattern formation in the developing limb.	US FDA, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Thomas, JT (corresponding author), US FDA, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.	john.thomas@fda.hhs.gov; malcolm.moos@fda.hhs.gov	Moos, Malcolm C/F-3673-2011	Moos, Malcolm C/0000-0002-9575-9938				Baur ST, 2000, DEVELOPMENT, V127, P605; Beck S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890; Birsoy B, 2005, DEVELOPMENT, V132, P591, DOI 10.1242/dev.01599; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Butler K, 2001, METHODS, V23, P303, DOI 10.1006/meth.2000.1142; Chang CB, 1999, DEVELOPMENT, V126, P3347; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Constam DB, 2000, GENE DEV, V14, P1146; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Cui YZ, 2001, GENE DEV, V15, P2797; Dale L, 1999, BIOESSAYS, V21, P751, DOI 10.1002/(SICI)1521-1878(199909)21:9<751::AID-BIES6>3.0.CO;2-I; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dionne MS, 2001, MOL CELL BIOL, V21, P636, DOI 10.1128/MCB.21.2.636-643.2001; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; EVANS JP, 1991, METHOD CELL BIOL, V36, P117; Everman DB, 2002, AM J MED GENET, V112, P291, DOI 10.1002/ajmg.10777; Faiyaz-Ul-Haque M, 2002, CLIN GENET, V61, P454, DOI 10.1034/j.1399-0004.2002.610610.x; Francis-West PH, 1999, DEVELOPMENT, V126, P1305; Goutel C, 2000, MECH DEVELOP, V99, P15, DOI 10.1016/S0925-4773(00)00470-6; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; Gurdon J. B., 1967, METHODS DEV BIOL, P75; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Irvine KD, 2001, ANNU REV CELL DEV BI, V17, P189, DOI 10.1146/annurev.cellbio.17.1.189; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KAY BL, 1991, METHOD CELL BIOL, V36, P657; KELLER R, 1991, METHOD CELL BIOL, V36, P61; Moos M, 1995, DEVELOPMENT, V121, P4293; Nelsen S, 2005, DEV DYNAM, V233, P1038, DOI 10.1002/dvdy.20378; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Pacifici Maurizio, 2005, Birth Defects Research, V75, P237, DOI 10.1002/bdrc.20050; Pathi S, 1999, DEV BIOL, V209, P239, DOI 10.1006/dbio.1998.9181; Polinkovsky A, 1997, NAT GENET, V17, P18, DOI 10.1038/ng0997-18; Seemann P, 2005, J CLIN INVEST, V115, P2373, DOI 10.1172/JCI25118; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Settle SH, 2003, DEV BIOL, V254, P116, DOI 10.1016/S0012-1606(02)00022-2; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; Tozer Samuel, 2005, Birth Defects Research, V75, P226, DOI 10.1002/bdrc.20049; Tsumaki N, 2002, J BONE MINER RES, V17, P898, DOI 10.1359/jbmr.2002.17.5.898; Wolfman NM, 1997, J CLIN INVEST, V100, P321, DOI 10.1172/JCI119537; Yi SE, 2000, DEVELOPMENT, V127, P621; Zaidi AU, 2000, J HISTOCHEM CYTOCHEM, V48, P1369, DOI 10.1177/002215540004801007	48	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26725	26733		10.1074/jbc.M603851200	http://dx.doi.org/10.1074/jbc.M603851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829522	hybrid			2022-12-27	WOS:000240249500090
J	Zhao, H; Waite, JH				Zhao, Hua; Waite, J. Herbert			Linking adhesive and structural proteins in the attachment plaque of Mytilus californianus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-A2 ELECTROPHORETIC VARIANTS; PHRAGMATOPOMA-CALIFORNICA; CROSS-LINKING; DOPA; EDULIS; QUINOPROTEINS; CEMENT; FAMILY; BYSSUS	The byssal attachment of California mussels Mytilus californianus provides secure adhesion in the presence of moisture, a feat that still eludes most synthetic polymers. Matrix-assisted laser desorption ionization mass spectrometry was used to probe the footprints of byssal attachment plaques on glass cover slips for adhesive proteins. Besides the abundant mcfp-3 protein family (Zhao, H., Robertson, N. B., Jewhurst, S. A., and Waite, J. H. (2006) J. Biol. Chem. 281, 11090 - 11096), two new proteins, mcfp-5 and mcfp-6, with masses of 8.9 kDa and 11.6 kDa, respectively, were identified in footprints, partially characterized and completely sequenced from a cDNA library. mcfp-5 resembles mcfp-3 in its basic pI and abundant 3,4-dihydroxyphenyl-L-alanine (Dopa; 30 mol %), but is distinct in two respects: it is more homogeneous in primary sequence and is polyphosphorylated. mcfp-6 is basic and contains a small amount of Dopa (< 5 mol %). In contrast to mcfp-3 and - 5, tyrosine prevails at 20 mol %, and cysteine is present at 11 mol %, one-third of which remains thiolate. Given the oxidative instability of Dopa and cysteine at pH 8.2 (seawater), we tested the hypothesis that thiols serve to scavenge dopaquinones by adduct formation. Plaque footprints were hydrolyzed and screened for cysteine dopaquinone adducts using phenylboronate affinity chromatography. 5-S-Cysteinyldopa was detected at nearly 1 mol %. The results suggest that mcfp-6 may provide a cohesive link between the surface-coupling Dopa-rich proteins and the bulk of the plaque proteins.	Univ Calif Santa Barbara, Inst Marine Sci, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Waite, JH (corresponding author), Univ Calif Santa Barbara, Inst Marine Sci, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	waite@lifesci.ucsb.edu			NIDCR NIH HHS [DE015415] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015415] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Burzio LA, 2000, BIOCHEMISTRY-US, V39, P11147, DOI 10.1021/bi0002434; Dalsin JL, 2005, LANGMUIR, V21, P640, DOI 10.1021/la048626g; DURKIN JP, 1981, TOXICON, V19, P535, DOI 10.1016/0041-0101(81)90012-X; Hiraoka M, 2005, J LIPID RES, V46, P2441, DOI 10.1194/jlr.M500248-JLR200; INOUE K, 1995, J BIOL CHEM, V270, P6698, DOI 10.1074/jbc.270.12.6698; ISRAELACHVILI JN, 1985, INTERMOLECULAR SURFA, P12; Lee BP, 2006, MACROMOLECULES, V39, P1740, DOI 10.1021/ma0518959; McDowell LM, 1999, J BIOL CHEM, V274, P20293, DOI 10.1074/jbc.274.29.20293; Ohkawa K, 2004, BIOFOULING, V20, P101, DOI 10.1080/08927010410001681246; PAPOV VV, 1995, J BIOL CHEM, V270, P20183, DOI 10.1074/jbc.270.34.20183; PAZ MA, 1991, J BIOL CHEM, V266, P689; RZEPECKI LM, 1992, BIOL BULL, V183, P123, DOI 10.2307/1542413; SHIER WT, 1978, ANAL BIOCHEM, V87, P604, DOI 10.1016/0003-2697(78)90711-X; STERNSON AW, 1973, J ELECTROANAL CHEM, V46, P313, DOI 10.1016/S0022-0728(73)80139-1; Stewart RJ, 2004, J EXP BIOL, V207, P4727, DOI 10.1242/jeb.01330; Thompson JB, 2001, NATURE, V414, P773, DOI 10.1038/414773a; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; Waite JH, 2005, J ADHESION, V81, P297, DOI 10.1080/00218460590944602; WAITE JH, 1995, METHOD ENZYMOL, V258, P1; Waite JH, 2002, INTEGR COMP BIOL, V42, P1172, DOI 10.1093/icb/42.6.1172; Waite JH, 2001, BIOCHEMISTRY-US, V40, P2887, DOI 10.1021/bi002718x; WAITE JH, 1984, METHOD ENZYMOL, V107, P397; WALKER P, 1987, SURF COAT, V1, P189; Yu ME, 1999, J AM CHEM SOC, V121, P5825, DOI 10.1021/ja990469y; Zhang JG, 1997, BIOCHEMISTRY-US, V36, P2380, DOI 10.1021/bi962164r; Zhao H, 2006, J BIOL CHEM, V281, P11090, DOI 10.1074/jbc.M510792200; Zhao H, 2005, J BIOL CHEM, V280, P42938, DOI 10.1074/jbc.M508457200; Zhao H, 2005, BIOCHEMISTRY-US, V44, P15915, DOI 10.1021/bi051530g	28	210	227	5	98	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26150	26158		10.1074/jbc.M604357200	http://dx.doi.org/10.1074/jbc.M604357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844688	hybrid			2022-12-27	WOS:000240249500031
J	Hogg, T; Nagarajan, K; Herzberg, S; Chen, LL; Shen, X; Jiang, HL; Wecke, M; Blohmke, C; Hilgenfeld, R; Schmidt, CL				Hogg, Tanis; Nagarajan, Krishna; Herzberg, Saskia; Chen, Lili; Shen, Xu; Jiang, Hualiang; Wecke, Maria; Blohmke, Christoph; Hilgenfeld, Rolf; Schmidt, Christian L.			Structural and functional characterization of falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE FALCIPAIN-2; CRYSTAL-STRUCTURE; INHIBITORS; PEPTIDE; PAPAIN; BIOSYNTHESIS; DETERMINANTS; SPECIFICITY; PLASMEPSINS; DISRUPTION	Malaria is caused by protozoan erythrocytic parasites of the Plasmodium genus, with Plasmodium falciparum being the most dangerous and widespread disease-causing species. Falcipain-2 (FP-2) of P. falciparum is a papain-family (C1A) cysteine protease that plays an important role in the parasite life cycle by degrading erythrocyte proteins, most notably hemoglobin. Inhibition of FP-2 and its paralogues prevents parasite maturation, suggesting these proteins may be valuable targets for the design of novel antimalarial drugs, but lack of structural knowledge has impeded progress toward the rational discovery of potent, selective, and efficacious inhibitors. As a first step toward this goal, we present here the crystal structure of mature FP-2 at 3.1 angstrom resolution, revealing novel structural features of the FP-2 subfamily proteases including a dynamic beta-hairpin hemoglobin binding motif, a flexible N-terminal alpha-helical extension, and a unique active-site cleft. We also demonstrate by biochemical methods that mature FP-2 can proteolytically process its own precursor in trans at neutral to weakly alkaline pH, that the binding of hemoglobin to FP-2 is strictly pH-dependent, and that FP-2 preferentially binds methemoglobin over hemoglobin. Because the specificity and proteolytic activity of FP-2 toward its multiple targets appears to be pH-dependent, we suggest that environmental pH may play an important role in orchestrating FP-2 function over the different life stages of the parasite. Moreover, it appears that selectivity of FP-2 for methemoglobin may represent an evolutionary adaptation to oxidative stress conditions within the host cell.	Med Univ Lubeck, Inst Biochem, Ctr Struct & Cell Biol Med, D-23538 Lubeck, Germany; Chinese Acad Sci, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai Inst Mat Med,Shanghai Inst Biol Sci, Shanghai 201203, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 201203, Peoples R China	University of Lubeck; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Hilgenfeld, R (corresponding author), Med Univ Lubeck, Inst Biochem, Ctr Struct & Cell Biol Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	hilgenfeld@biochem.uni-luebeck.de	Hilgenfeld, Rolf/C-9675-2011					Akompong T, 2000, ANTIMICROB AGENTS CH, V44, P88, DOI [10.1128/AAC.44.11.3107-3111.2000, 10.1128/AAC.44.1.88-96.2000]; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baird JK, 2005, NEW ENGL J MED, V352, P1565, DOI 10.1056/NEJMra043207; Baird JK, 2004, CLIN INFECT DIS, V39, P1336, DOI 10.1086/424663; Baird JK, 2002, AM J TROP MED HYG, V66, P659, DOI 10.4269/ajtmh.2002.66.659; Banerjee R, 2003, MOL BIOCHEM PARASIT, V129, P157, DOI 10.1016/S0166-6851(03)00119-1; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; BODE W, 2000, BIOCHIM BIOPHYS ACTA, V1343, P160; Brinen LS, 2000, STRUCT FOLD DES, V8, P831, DOI 10.1016/S0969-2126(00)00173-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe Y, 2005, BIOORGAN MED CHEM, V13, P2141, DOI 10.1016/j.bmc.2004.12.053; Dahl EL, 2005, MOL BIOCHEM PARASIT, V139, P205, DOI 10.1016/j.molbiopara.2004.11.009; DeLano W.L, PYMOL MOL GRAPHICS S; Dhawan S, 2003, J BIOL CHEM, V278, P30180, DOI 10.1074/jbc.M305132200; Eksi S, 2004, MOL MICROBIOL, V53, P243, DOI 10.1111/j.1365-2958.2004.04108.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fasan R, 2006, CHEMBIOCHEM, V7, P515, DOI 10.1002/cbic.200500452; Francis SE, 1997, J BIOL CHEM, V272, P14961, DOI 10.1074/jbc.272.23.14961; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gelhaus C, 2004, BIOL CHEM, V385, P435, DOI 10.1515/BC.2004.050; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; Goh LL, 2005, BIOCHEM BIOPH RES CO, V335, P762, DOI 10.1016/j.bbrc.2005.07.147; Goh LL, 2004, BIOCHEM BIOPH RES CO, V323, P565, DOI 10.1016/j.bbrc.2004.08.130; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; Guncar G, 2000, STRUCTURE, V8, P305, DOI 10.1016/S0969-2126(00)00108-8; Hanspal M, 2002, BLOOD, V100, P1048, DOI 10.1182/blood-2002-01-0101; Huang L, 2003, BIOORGAN MED CHEM, V11, P21, DOI 10.1016/S0968-0896(02)00427-3; Jambou R, 2005, LANCET, V366, P1960, DOI 10.1016/S0140-6736(05)67787-2; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Kesavulu MM, 2005, J PEPT RES, V66, P211, DOI 10.1111/j.1399-3011.2005.00288.x; Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Leung-Toung R, 2006, CURR MED CHEM, V13, P547, DOI 10.2174/092986706776055733; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Muller S, 2004, MOL MICROBIOL, V53, P1291, DOI 10.1111/j.1365-2958.2004.04257.x; Murata CE, 2003, MOL BIOCHEM PARASIT, V129, P123, DOI 10.1016/S0166-6851(03)00098-7; Murata CE, 2003, J BIOL CHEM, V278, P38022, DOI 10.1074/jbc.M306842200; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; Pandey KC, 2005, P NATL ACAD SCI USA, V102, P9138, DOI 10.1073/pnas.0502368102; Pandey KC, 2004, J BIOL CHEM, V279, P3484, DOI 10.1074/jbc.M310536200; PICKERSGILL RW, 1992, ACTA CRYSTALLOGR B, V48, P59, DOI 10.1107/S0108768191006572; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Robert A, 2001, PURE APPL CHEM, V73, P1173, DOI 10.1351/pac200173071173; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; ROSENTHAL PJ, 1987, J EXP MED, V166, P816, DOI 10.1084/jem.166.3.816; Sabnis Y, 2002, J BIOMOL STRUCT DYN, V19, P765, DOI 10.1080/07391102.2002.10506783; Schwarzenbacher R, 2004, ACTA CRYSTALLOGR D, V60, P1229, DOI 10.1107/S0907444904010145; Semenov A, 1998, ANTIMICROB AGENTS CH, V42, P2254, DOI 10.1128/AAC.42.9.2254; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2002, J BIOL CHEM, V277, P14910, DOI 10.1074/jbc.M109680200; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Sijwali PS, 2001, PROTEIN EXPRES PURIF, V22, P128, DOI 10.1006/prep.2001.1416; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; Singh A, 2001, ANTIMICROB AGENTS CH, V45, P949, DOI 10.1128/AAC.45.3.949-951.2001; Singh N, 2006, EXP PARASITOL, V112, P187, DOI 10.1016/j.exppara.2005.10.007; Sobolewski P, 2005, INFECT IMMUN, V73, P6704, DOI 10.1128/IAI.73.10.6704-6710.2005; Steller I, 1997, J APPL CRYSTALLOGR, V30, P1036, DOI 10.1107/S0021889897008777; STOCKER R, 1985, P NATL ACAD SCI USA, V82, P548, DOI 10.1073/pnas.82.2.548; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Terwilliger TC, 2004, ACTA CRYSTALLOGR D, V60, P2144, DOI 10.1107/S0907444904019535; Than ME, 2004, J MOL BIOL, V336, P1103, DOI 10.1016/j.jmb.2003.12.075; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; *WHO, 2005, WORLD MAL REP	71	100	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25425	25437		10.1074/jbc.M603776200	http://dx.doi.org/10.1074/jbc.M603776200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16777845	hybrid			2022-12-27	WOS:000240031300045
J	Li, J; Uchida, T; Todo, T; Kitagawa, T				Li, Jiang; Uchida, Takeshi; Todo, Takeshi; Kitagawa, Teizo			Similarities and differences between cyclobutane pyrimidine dimer photolyase and (6-4) photolyase as revealed by resonance Raman spectroscopy - Electron transfer from the FAD cofactor to ultraviolet-damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN ADENINE-DINUCLEOTIDE; ENZYME-SUBSTRATE COMPLEX; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MOLECULAR-DYNAMICS; THYMINE DIMER; HETERO ATOMS; BINDING; REPAIR; SPECTRA	The cyclobutane pyrimidine dimer (CPD) and (6-4) photoproduct, two major types of DNA damage caused by UV light, are repaired under illumination with near UV-visible light by CPD and (6-4) photolyases, respectively. To understand the mechanism of DNA repair, we examined the resonance Raman spectra of complexes between damaged DNA and the neutral semiquinoid and oxidized forms of (6-4) and CPD photolyases. The marker band for a neutral semiquinoid flavin and band I of the oxidized flavin, which are derived from the vibrations of the benzene ring of FAD, were shifted to lower frequencies upon binding of damaged DNA by CPD photolyase but not by ( 6-4) photolyase, indicating that CPD interacts with the benzene ring of FAD directly but that the (6-4) photoproduct does not. Bands II and VII of the oxidized flavin and the 1398/1391 cm(-1) bands of the neutral semiquinoid flavin, which may reflect the bending of U-shaped FAD, were altered upon substrate binding, suggesting that CPD and the (6-4) photoproduct interact with the adenine ring of FAD. When substrate was bound, there was an upshifted 1528 cm(-1) band of the neutral semiquinoid flavin in CPD photolyase, indicating a weakened hydrogen bond at N(5)-H of FAD, and band X seemed to be downshifted in (6-4) photolyase, indicating a weakened hydrogen bond at N(3)-H of FAD. These Raman spectra led us to conclude that the two photolyases have different electron transfer mechanisms as well as different hydrogen bonding environments, which account for the higher redox potential of CPD photolyase.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Grad Univ Adv Studies, Sch Adv Sci, Dept Photosci, Kanagawa 2400193, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Kyoto University	Kitagawa, T (corresponding author), Toyota Phys & Chem Res Inst, Aichi 4801192, Japan.	teizo@ims.ac.jp	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329				ABE M, 1987, SPECTROCHIM ACTA A, V43, P1027, DOI 10.1016/0584-8539(87)80175-7; Antony J, 2000, J AM CHEM SOC, V122, P1057, DOI 10.1021/ja993784t; BENECKY M, 1979, BIOCHEMISTRY-US, V18, P3471, DOI 10.1021/bi00583a006; BOWMAN WD, 1981, BIOCHEMISTRY-US, V20, P3313, DOI 10.1021/bi00514a051; Christine KS, 2002, J BIOL CHEM, V277, P38339, DOI 10.1074/jbc.M206531200; Cichon MK, 2002, ANGEW CHEM INT EDIT, V41, P767, DOI 10.1002/1521-3773(20020301)41:5<767::AID-ANIE767>3.0.CO;2-B; FRANKLIN WA, 1982, J BIOL CHEM, V257, P13535; Gindt YM, 2005, J AM CHEM SOC, V127, P10472, DOI 10.1021/ja051441r; Hahn J, 1998, J MOL MODEL, V4, P73, DOI 10.1007/s008940050133; Hahn J, 1999, J PHYS CHEM B, V103, P2001, DOI 10.1021/jp984197h; Hitomi K, 2001, J BIOL CHEM, V276, P10103, DOI 10.1074/jbc.M008828200; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Kao YT, 2005, P NATL ACAD SCI USA, V102, P16128, DOI 10.1073/pnas.0506586102; Kay CWM, 1999, BIOCHEMISTRY-US, V38, P16740, DOI 10.1021/bi991442u; KIM ST, 1994, J BIOL CHEM, V269, P8535; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIVELY CR, 1990, J PHYS CHEM-US, V94, P3980, DOI 10.1021/j100373a021; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; MacFarlane AW, 2003, BIOCHEMISTRY-US, V42, P8558, DOI 10.1021/bi034015w; MacFarlane AW, 2001, BIOCHEMISTRY-US, V40, P15203, DOI 10.1021/bi0114224; MCFARLAND JT, 1987, BIOL APPL RAMAN SPEC, V2; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; Miura R, 2001, CHEM REC, V1, P183, DOI 10.1002/tcr.1007; MORRIS MD, 1986, ADV SPECTROSCOPY, V13; MULLER F, 1983, J RAMAN SPECTROSC, V14, P106, DOI 10.1002/jrs.1250140211; Murgida DH, 2001, J RAMAN SPECTROSC, V32, P551, DOI 10.1002/jrs.719; NISHIMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V802, P321, DOI 10.1016/0304-4165(84)90178-8; NISHIMOTO K, 1986, J BIOCHEM-TOKYO, V100, P1647, DOI 10.1093/oxfordjournals.jbchem.a121873; NISHINA Y, 1983, J BIOCHEM-TOKYO, V94, P1979, DOI 10.1093/oxfordjournals.jbchem.a134552; NISHINA Y, 1980, J BIOCHEM-TOKYO, V88, P411, DOI 10.1093/oxfordjournals.jbchem.a132987; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, J BIOL CHEM, V262, P492; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; Schelvis JPM, 2003, J PHYS CHEM B, V107, P12352, DOI 10.1021/jp034209l; SCHMIDT J, 1983, BIOCHEMISTRY-US, V22, P76, DOI 10.1021/bi00270a011; SUGIYAMA T, 1985, BIOCHEMISTRY-US, V24, P3012, DOI 10.1021/bi00333a031; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Todo T, 1997, NUCLEIC ACIDS RES, V25, P764, DOI 10.1093/nar/25.4.764; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; WANG BY, 1989, BIOCHEMISTRY-US, V28, P1148, DOI 10.1021/bi00429a032; Weber S, 2005, BBA-BIOENERGETICS, V1707, P1, DOI 10.1016/j.bbabio.2004.02.010; Weber S, 2001, BIOPHYS J, V81, P1195, DOI 10.1016/S0006-3495(01)75777-3; Weber S, 2001, J AM CHEM SOC, V123, P3790, DOI 10.1021/ja003426m; YAGI K, 1987, CHEM SCRIPTA, V27A, P27; YAGI K, 1980, BIOCHEMISTRY-US, V19, P1553, DOI 10.1021/bi00549a003; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580; Zheng YG, 1999, BIOCHEMISTRY-US, V38, P16727, DOI 10.1021/bi9918893; Zheng YJ, 1996, J AM CHEM SOC, V118, P9402, DOI 10.1021/ja9608151	56	34	35	3	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25551	25559		10.1074/jbc.M604483200	http://dx.doi.org/10.1074/jbc.M604483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16816385	hybrid			2022-12-27	WOS:000240031300058
J	Nitto, T; Dyer, KD; Czapiga, M; Rosenberg, HF				Nitto, Takeaki; Dyer, Kimberly D.; Czapiga, Meggan; Rosenberg, Helene F.			Evolution and function of leukocyte RNase A ribonucleases of the avian species, Gallus gallus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; AMINO-ACID-SEQUENCE; ANTIMICROBIAL PROTEIN; MOLECULAR RECOGNITION; CHICKEN HETEROPHILS; CATIONIC PROTEIN; RAPID EVOLUTION; GENE; SUPERFAMILY; EXPRESSION	In this study, we explore the evolution and function of two closely related RNase A ribonucleases from the chicken, Gallus gallus. Separated by similar to 10 kb on chromosome 6, the coding sequences of RNases A-1 and A-2 are diverging under positive selection pressure (d(N) > d(S)) but remain similar to one another ( 81% amino acid identity) and to the mammalian angiogenins. Immunoreactive RNases A-1 and A-2 ( both similar to 16 kDa) were detected in peripheral blood granulocytes and bone marrow. Recombinant proteins are ribonucleolytically active (k(cat) = 2.6 and 0.056 s(-1), respectively), and surprisingly, both interact with human placental ribonuclease inhibitor. RNase A-2, the more cationic (pI 11.0), is both angiogenic and bactericidal; RNase A-1 ( pI 10.2) has neither activity. We demonstrated via point mutation of the catalytic His(110) that ablation of ribonuclease activity has no impact on the bactericidal activity of RNase A-2. We determined that the divergent domains II ( amino acids 71 - 76) and III ( amino acids 89 - 104) of RNase A-2 are both important for bactericidal activity. Furthermore, we demonstrated that these cationic domains can function as independent bactericidal peptides without the tertiary structure imposed by the RNase A backbone. These results suggest that ribonucleolytic activity may not be a crucial constraint limiting the ongoing evolution of this gene family and that the ribonuclease backbone may be merely serving as a scaffold to support the evolution of novel, non-ribonucleolytic proteins.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIAID, Res Technol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rosenberg, HF (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Rm 11C215,9000 Rockville Pike, Bethesda, MD 20892 USA.	hrosenberg@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000942, Z01AI000942] Funding Source: NIH RePORTER; NIAID NIH HHS [AI000942] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beintema JJ, 1998, CELL MOL LIFE SCI, V54, P825, DOI 10.1007/s000180050211; BEINTEMA JJ, 1985, EUR J BIOCHEM, V153, P305, DOI 10.1111/j.1432-1033.1985.tb09301.x; Bojesen AM, 2004, AVIAN DIS, V48, P463, DOI 10.1637/7151; Caldwell RB, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2004-6-1-r6; Castella S, 2004, BIOL REPROD, V71, P1677, DOI 10.1095/biolreprod.104.031666; Castella S, 2004, BIOL REPROD, V70, P319, DOI 10.1095/biolreprod.103.022459; Cho S, 2005, GENOMICS, V85, P208, DOI 10.1016/j.ygeno.2004.10.008; Cho SC, 2006, GENE, V373, P116, DOI 10.1016/j.gene.2006.01.018; Clement PMJ, 2002, INT J CANCER, V100, P491, DOI 10.1002/ijc.10515; Costanzi J, 2005, CANCER INVEST, V23, P643, DOI 10.1080/07357900500283143; Devor EJ, 2004, HUM BIOL, V76, P921, DOI 10.1353/hub.2005.0016; Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1; DIJKSTRA J, 1978, BIOCHIM BIOPHYS ACTA, V521, P363, DOI 10.1016/0005-2787(78)90278-2; Dyer KD, 2004, J MOL EVOL, V59, P657, DOI 10.1007/s00239-004-2657-0; DYER KD, 2006, IN PRESS MOL DIVERS; EVANS EW, 1994, J LEUKOCYTE BIOL, V56, P661, DOI 10.1002/jlb.56.5.661; Farnell MB, 2003, INT IMMUNOPHARMACOL, V3, P1677, DOI 10.1016/S1567-5769(03)00205-4; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; HAYANO K, 1993, J BIOCHEM, V114, P156, DOI 10.1093/oxfordjournals.jbchem.a124132; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Iyer S, 2005, J MOL BIOL, V347, P637, DOI 10.1016/j.jmb.2005.01.035; KLENOVA EM, 1992, BIOCHEM BIOPH RES CO, V185, P231, DOI 10.1016/S0006-291X(05)80980-5; Kogut MH, 2003, J INTERF CYTOK RES, V23, P319, DOI 10.1089/107999003766628160; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Liao YD, 2000, NUCLEIC ACIDS RES, V28, P4097, DOI 10.1093/nar/28.21.4097; Lou YC, 2006, J MOL BIOL, V355, P409, DOI 10.1016/j.jmb.2005.10.069; Matousek J, 2001, COMP BIOCHEM PHYS C, V129, P175, DOI 10.1016/S1532-0456(01)90202-9; Mellata M, 2003, INFECT IMMUN, V71, P494, DOI 10.1128/IAI.71.1.494-503.2003; NAKANO T, 1992, ONCOGENE, V7, P527; Nitto T, 2005, GENE, V352, P36, DOI 10.1016/j.gene.2005.03.002; Nitto T, 2004, GENES IMMUN, V5, P668, DOI 10.1038/sj.gene.6364143; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Penttinen J, 2003, MOL ENDOCRINOL, V17, P2138, DOI 10.1210/me.2003-0008; Rath NC, 1998, VET IMMUNOL IMMUNOP, V64, P83, DOI 10.1016/S0165-2427(98)00122-6; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; Rosenberg HF, 1997, NUCLEIC ACIDS RES, V25, P3532, DOI 10.1093/nar/25.17.3532; ROSENBERG HF, 1995, J BIOL CHEM, V270, P21539, DOI 10.1074/jbc.270.37.21539; Rosenberg HF, 2001, J MOL EVOL, V53, P31, DOI 10.1007/s002390010188; ROSENBERG HF, 1995, NAT GENET, V10, P219, DOI 10.1038/ng0695-219; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; SCHERMER S, 1967, BLOOD MORPHOLOGY LAB, P127; Seo SH, 2000, VIROLOGY, V269, P183, DOI 10.1006/viro.2000.0211; Singhania NA, 1999, J MOL EVOL, V49, P721, DOI 10.1007/PL00006594; Spalletti-Cernia D, 2003, J CLIN ENDOCR METAB, V88, P2900, DOI 10.1210/jc.2002-020373; Strydom DJ, 1998, CELL MOL LIFE SCI, V54, P811, DOI 10.1007/s000180050210; Swaggerty CL, 2005, FEMS IMMUNOL MED MIC, V43, P149, DOI 10.1016/j.femsim.2004.07.013; Swaggerty CL, 2004, IMMUNOLOGY, V113, P139, DOI 10.1111/j.1365-2567.2004.01939.x; WU YN, 1993, J BIOL CHEM, V268, P10686; Yang D, 2003, BLOOD, V102, P3396, DOI 10.1182/blood-2003-01-0151; Zhang JZ, 2000, P NATL ACAD SCI USA, V97, P4701, DOI 10.1073/pnas.080071397; Zhang JZ, 2003, NUCLEIC ACIDS RES, V31, P602, DOI 10.1093/nar/gkg157; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708; ZHAO W, 1994, EUR J BIOCHEM, V219, P641, DOI 10.1111/j.1432-1033.1994.tb19979.x; Zijlstra A, 2006, BLOOD, V107, P317, DOI 10.1182/blood-2005-04-1458	56	55	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25622	25634		10.1074/jbc.M604313200	http://dx.doi.org/10.1074/jbc.M604313200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803891	hybrid			2022-12-27	WOS:000240031300065
J	Punga, T; Bengoechea-Alonso, MT; Ericsson, J				Punga, Tanel; Bengoechea-Alonso, Maria T.; Ericsson, Johan			Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SREBP FAMILY; DEPENDENT DEGRADATION; PROTEASOME PATHWAY; GENE-EXPRESSION; IN-VIVO; ACTIVATION; COACTIVATOR; CHOLESTEROL; RECRUITMENT; PROTEOLYSIS	Members of the sterol regulatory element-binding protein (SREBP) family of transcription factors control cholesterol and lipid metabolism and play critical roles during adipocyte differentiation. The transcription factor SREBP1 is degraded by the ubiquitin-proteasome system following phosphorylation of Thr(426) and Ser(430) in its phosphodegron. We now demonstrate that the glycogen synthase kinase (GSK)-3 beta-dependent phosphorylation of these residues in SREBP1 is enhanced in response to specific DNA binding. DNA binding enhances the direct interaction between the C-terminal domain of SREBP1 and GSK-3 beta. Accordingly, we demonstrate that GSK-3 beta is recruited to the promoters of SREBP target genes in vivo. As a result of the phosphorylation of Thr(426) and Ser(430), the ubiquitin ligase Fbw7 is recruited to SREBP molecules associated with target promoters. Using a reconstituted ubiquitination system, we demonstrate that Fbw7-mediated ubiquitination of SREBP1 is dependent on its DNA binding activity. Thus, DNA binding could provide a mechanistic link between the phosphorylation, ubiquitination, and degradation of active transcription factors.	Univ Uppsala, Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University	Ericsson, J (corresponding author), Univ Uppsala, Ludwig Inst Canc Res, Biomed Ctr, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.	johan.ericsson@licr.uu.se	Ericsson, Johan/AAA-6664-2020; Punga, Tanel/K-9844-2019	Ericsson, Johan/0000-0003-1186-6574; Punga, Tanel/0000-0002-0561-367X				Bengoechea-Alonso MT, 2005, P NATL ACAD SCI USA, V102, P11681, DOI 10.1073/pnas.0501494102; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Espenshade PJ, 2006, J CELL SCI, V119, P973, DOI 10.1242/jcs02866; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kotzka J, 2004, J BIOL CHEM, V279, P22404, DOI 10.1074/jbc.M401198200; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Sundqvist A, 2003, P NATL ACAD SCI USA, V100, P13833, DOI 10.1073/pnas.2335135100; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101	30	92	99	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25278	25286		10.1074/jbc.M604983200	http://dx.doi.org/10.1074/jbc.M604983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825193	hybrid			2022-12-27	WOS:000240031300029
J	Gao, Y; El-Mashtoly, SF; Pal, B; Hayashi, T; Harada, K; Kitagawa, T				Gao, Ying; El-Mashtoly, Samir F.; Pal, Biswajit; Hayashi, Takashi; Harada, Katsuyoshi; Kitagawa, Teizo			Pathway of information transmission from heme to protein upon ligand binding/dissociation in myoglobin revealed by UV resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OXYGEN SENSOR; HEMOGLOBIN; BINDING; MECHANISM; MUTANTS; DOMAIN	Gas sensory heme proteins respond to their environment by binding a specific gas molecule to heme and transmitting this primary binding signal to the protein. How the binding signal is transmitted from the heme to the protein remains to be clarified. Using UV resonance Raman (UVRR) spectroscopy, we investigated this pathway in sperm whale myoglobin as a model gas sensory heme protein. Based on the UVRR data and the effects of deleting one of three important pathways (His-93, 6-propionate, or 7-propionate), we determined the changes in the conformation of globin that occur upon binding of CO, nitric oxide (NO), or O-2 to heme and how they are transmitted from heme to globin. The UVRR results show that heme discriminates different ligands, resulting in different conformations in the globin protein. Specifically, NO induces changes in the spectrum of Trp residues in the A-helix that are significantly different from those induced by O-2 or CO binding. On the other hand, binding of O2 to heme produces changes in the Tyr residues of the H-helix that are different from those induced by CO or NO binding. Furthermore, we found that cleavage of the Fe-His-93 covalent bond eliminates communication to the terminal region of the H-helix and that the 7-propionate hydrogen-bonding network is essential for transmitting the CO or NO binding signal to the N and C termini. Finally, the 6-propionate is important only for NO binding. Thus, the hydrogen-bonding network in the protein appears to be critical for intramolecular signal transduction in gas sensory heme proteins.	Grad Univ Adv Studies, Sch Adv Studies, Kanagawa 2400193, Japan; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan	Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Osaka University	Kitagawa, T (corresponding author), Grad Univ Adv Studies, Sch Adv Studies, Kanagawa 2400193, Japan.	teizo@ims.ac.jp	El-Mashtoly, Samir/C-8761-2014	El-Mashtoly, Samir/0000-0001-6087-8817; Hayashi, Takashi/0000-0002-2215-935X				Aki M, 2000, J PHYS CHEM B, V104, P10765, DOI 10.1021/jp000357p; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; AUSTIN JC, 1993, BIOMOLECULAR SPECT A, V20, P55; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Brucker EA, 1998, PROTEINS, V30, P352, DOI 10.1002/(SICI)1097-0134(19980301)30:4<352::AID-PROT2>3.0.CO;2-L; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; Chan MK, 2000, NAT STRUCT BIOL, V7, P822, DOI 10.1038/79559; Dunham CM, 2003, BIOCHEMISTRY-US, V42, P7701, DOI 10.1021/bi0343370; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Haruta N, 2001, BIOCHEMISTRY-US, V40, P6956, DOI 10.1021/bi002640k; HAUKSSON JB, 1990, J AM CHEM SOC, V112, P6198, DOI 10.1021/ja00173a006; Hayashi T, 2004, CHEM LETT, V33, P1512, DOI 10.1246/cl.2004.1512; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; KILMARTIN JV, 1978, BIOCHIM BIOPHYS ACTA, V534, P15, DOI 10.1016/0005-2795(78)90471-3; Mizutani Y, 2001, CHEM REC, V1, P258, DOI 10.1002/tcr.1012; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; SHIRO Y, 1994, BIOCHEMISTRY-US, V33, P14986, DOI 10.1021/bi00254a006; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; Spiro TG, 2001, ACCOUNTS CHEM RES, V34, P137, DOI 10.1021/ar000108j; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TAKANO T, 1977, J MOL BIOL, V110, P569, DOI 10.1016/S0022-2836(77)80112-5; Takeuchi H, 2003, BIOPOLYMERS, V72, P305, DOI 10.1002/bip.10440; Takeuchi H., 1986, ADV SPECTROSCOPY SPE, V13, P113; Tuckerman JR, 2002, BIOCHEMISTRY-US, V41, P6170, DOI 10.1021/bi025628w; Uchida T, 2005, ACCOUNTS CHEM RES, V38, P662, DOI 10.1021/ar030267d; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6	36	21	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24637	24646		10.1074/jbc.M603198200	http://dx.doi.org/10.1074/jbc.M603198200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16774917	hybrid			2022-12-27	WOS:000239847800058
J	Lin, KI; Kao, YY; Kuo, HK; Yang, WB; Chou, A; Lin, HH; Yu, AL; Wong, CH				Lin, Kuo-I; Kao, Yeong-Yi; Kuo, Hui-Kai; Yang, Wen-Bin; Chou, Alice; Lin, Hsin-Hung; Yu, Alice L.; Wong, Chi-Huey			Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; B-CELL DIFFERENTIATION; SECRETING PLASMA-CELLS; TOLL-LIKE RECEPTORS; NF-KAPPA-B; GANODERMA-LUCIDUM; ANTITUMOR ACTIVITIES; REPRESSOR BLIMP-1; DENDRITIC CELLS; EXPRESSION	The polysaccharides of Ganoderma lucidum ( Reishi) possess immunomodulation activities; however, their mode of molecular action in regulating each cellular subset in the immune system is still not clear. Here, we investigate the function of the main polysaccharide fraction of Reishi (Reishi-F3) in B lymphocyte activation/differentiation. We find that Reishi-F3 causes mouse splenic B cell activation and differentiation to IgM-secreting plasma cells, and the process depends on Reishi-F3-mediated induction of Blimp-1, a master regulator capable of triggering the changes of a cascade of gene expression during plasmacytic differentiation. In human peripheral B lymphocytes, although Reishi-F3 fails to induce their activation, it is able to enhance antibody secretion, which is associated with Blimp-1 mRNA induction. The function of Reishi-F3 depends on the Toll-like receptors TLR4/TLR2 as neutralizing antibodies against TLR4/TLR2 block Reishi-F3-mediated induction of Blimp- 1 mRNA and Ig secretion. We have shown that interaction of Reishi-F3 with TLR4/TLR2 followed by signaling through p38 MAPK is involved in the induction of Blimp- 1 mRNA, whereas signaling through ERK, p38 MAPK, JNK, and IKK complex is involved in Reishi- F3-mediated Ig secretion. Furthermore, the differential mechanism of Reishi-F3 in mouse and human B cell activation is probably due to the presence of Blimp- 1 regulatory site in human CD86 promoter. These results establish the signaling and molecular mechanisms of Reishi- F3 on promoting antibody secretion.	Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan	Academia Sinica - Taiwan	Lin, KI (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sec 2,Nankang Dist, Taipei 115, Taiwan.	kuoilin@gate.sinica.edu.tw	Lin, KUO-I/C-6928-2009; Lin, Hsin-Hung/J-5254-2013	Lin, Hsin-Hung/0000-0001-8327-6835; yu, alice/0000-0003-2444-0505				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bonner S, 2001, INFECT IMMUN, V69, P3143, DOI 10.1128/IAI.69.5.3143-3149.2001; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Cao LZ, 2002, IMMUNOL LETT, V83, P163, DOI 10.1016/S0165-2478(02)00087-1; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; Chang DH, 2002, MECH DEVELOP, V117, P305, DOI 10.1016/S0925-4773(02)00189-2; Chen HS, 2004, BIOORGAN MED CHEM, V12, P5595, DOI 10.1016/j.bmc.2004.08.003; CHENBETTECKEN U, 1985, P NATL ACAD SCI USA, V82, P7384, DOI 10.1073/pnas.82.21.7384; Chien CA, 2004, BIOORGAN MED CHEM, V12, P5603, DOI 10.1016/j.bmc.2004.08.004; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dirsch VM, 2001, CANCER RES, V61, P5817; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Gao YH, 2005, IMMUNOL INVEST, V34, P171, DOI 10.1081/IMM-200055813; Gao YH, 2003, IMMUNOL INVEST, V32, P201, DOI 10.1081/IMM-120022979; Hayashi EA, 2005, J IMMUNOL, V174, P6639, DOI 10.4049/jimmunol.174.11.6639; Hsu HY, 2004, J IMMUNOL, V173, P5989, DOI 10.4049/jimmunol.173.10.5989; Johnson K, 2005, MOL IMMUNOL, V42, P749, DOI 10.1016/j.molimm.2004.06.039; Kallies A, 2006, NAT IMMUNOL, V7, P466, DOI 10.1038/ni1321; Li JF, 2000, HUM IMMUNOL, V61, P486, DOI 10.1016/S0198-8859(00)00099-9; LIEU CW, 1992, ANTICANCER RES, V12, P1211; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Lin YL, 2005, J LEUKOCYTE BIOL, V78, P533, DOI 10.1189/jlb.0804481; Lin ZB, 2004, ACTA PHARMACOL SIN, V25, P1387; Martins GA, 2006, NAT IMMUNOL, V7, P457, DOI 10.1038/ni1320; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; MIYAZAKI T, 1981, CHEM PHARM BULL, V29, P3611; Nick JA, 1996, J IMMUNOL, V156, P4867; Ozaki K, 2004, J IMMUNOL, V173, P5361, DOI 10.4049/jimmunol.173.9.5361; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shao BM, 2004, BIOCHEM BIOPH RES CO, V323, P133, DOI 10.1016/j.bbrc.2004.08.069; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; SIECKMANN DG, 1978, J EXP MED, V147, P814, DOI 10.1084/jem.147.3.814; Tobe M, 2003, BIOORGAN MED CHEM, V11, P383, DOI 10.1016/S0968-0896(02)00440-6; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Wang SY, 1997, INT J CANCER, V70, P699, DOI 10.1002/(SICI)1097-0215(19970317)70:6&lt;699::AID-IJC12&gt;3.0.CO;2-5; Wang YY, 2002, BIOORGAN MED CHEM, V10, P1057, DOI 10.1016/S0968-0896(01)00377-7; Weatherill AR, 2005, J IMMUNOL, V174, P5390, DOI 10.4049/jimmunol.174.9.5390; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Wetzler LM, 2003, VACCINE, V21, pS55, DOI 10.1016/S0264-410X(03)00201-9; Zhang JS, 2002, LIFE SCI, V71, P623, DOI 10.1016/S0024-3205(02)01690-9	47	114	132	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24111	24123		10.1074/jbc.M601106200	http://dx.doi.org/10.1074/jbc.M601106200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798741	Green Submitted, hybrid			2022-12-27	WOS:000239847800006
J	Golinelli-Pimpaneau, B; Luthi, C; Christen, P				Golinelli-Pimpaneau, Beatrice; Luethi, Christine; Christen, Philipp			Structural basis for D-amino acid transamination by the pyridoxal 5 '-phosphate-dependent catalytic antibody 15A9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL-5'-PHOSPHATE-BINDING LYSINE RESIDUE; ASPARTATE-AMINOTRANSFERASE K258H; ACTIVE-SITE; EVOLUTION; ENZYMES; REFINEMENT; RESOLUTION; DIVERSITY; IMMUNE	Antibody 15A9, raised with 5 '-phosphopyridoxyl (PPL)-N-epsilon-acetyl-L-lysine as hapten, catalyzes the reversible transamination of hydrophobic D-amino acids with pyridoxal 5 '-phosphate (PLP). The crystal structures of the complexes of Fab 15A9 with PPL-L-alanine, PPL-D-alanine, and the hapten were determined at 2.3, 2.3, and 2.5 A resolution, respectively, and served for modeling the complexes with the corresponding planar imine adducts. The conformation of the PLP-amino acid adduct and its interactions with 15A9 are similar to those occurring in PLP-dependent enzymes, except that the amino acid substrate is only weakly bound, and, due to the immunization and selection strategy, the lysine residue that covalently binds PLP in these enzymes is missing. However, the N-acetyl-L-lysine moiety of the hapten appears to have selected for aromatic residues in hypervariable loop H3 (Trp-H100e and Tyr-H100b), which, together with Lys-H96, create an anion-binding environment in the active site. The structural situation and mutagenesis experiments indicate that two catalytic residues facilitate the transamination reaction of the PLP-D-alanine aldimine. The space vacated by the absent L-lysine side chain of the hapten can be filled, in both PLP- alanine aldimine complexes, by mobile Tyr-H100b. This group can stabilize a hydroxide ion, which, however, abstracts the C alpha proton only from D-alanine. Together with the absence of any residue capable of deprotonating C alpha of L-alanine, Tyr-H100b thus underlies the enantiomeric selectivity of 15A9. The reprotonation of C4 ' of PLP, the rate-limiting step of 15A9-catalyzed transamination, is most likely performed by a water molecule that, assisted by Lys-H96, produces a hydroxide ion stabilized by the anion-binding environment.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Zurich, Biochem Inst, CH-8057 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Zurich	Golinelli-Pimpaneau, B (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Bat 34,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	beatrice.golinelli@lebs.cnrs-gif.fr	Golinelli, Beatrice/ABB-8347-2021	Golinelli, Beatrice/0000-0001-8248-4704				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Banfield MJ, 1996, ACTA CRYSTALLOGR D, V52, P1107, DOI 10.1107/S0907444996007494; Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; Christen P, 1996, FEBS LETT, V389, P12, DOI 10.1016/0014-5793(96)00298-0; Debler EW, 2005, P NATL ACAD SCI USA, V102, P4984, DOI 10.1073/pnas.0409207102; DUNATHAN HC, 1971, ADV ENZYMOL RAMB, V35, P79; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Golinelli-Pimpaneau B, 2000, P NATL ACAD SCI USA, V97, P9892, DOI 10.1073/pnas.97.18.9892; Golinelli-Pimpaneau B, 2005, ACTA CRYSTALLOGR D, V61, P472, DOI 10.1107/S0907444905003331; Golinelli-Pimpaneau B, 2002, J IMMUNOL METHODS, V269, P157, DOI 10.1016/S0022-1759(02)00240-5; Golinelli-Pimpaneau B, 2000, CURR OPIN STRUC BIOL, V10, P697, DOI 10.1016/S0959-440X(00)00157-3; Gramatikova S, 2002, J IMMUNOL METHODS, V269, P99, DOI 10.1016/S0022-1759(02)00227-2; Gramatikova SI, 1996, J BIOL CHEM, V271, P30583, DOI 10.1074/jbc.271.48.30583; Gramatikova SI, 1997, J BIOL CHEM, V272, P9779; Hilvert D, 2000, ANNU REV BIOCHEM, V69, P751, DOI 10.1146/annurev.biochem.69.1.751; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; MALASHKEVICH VN, 1995, BIOCHEMISTRY-US, V34, P405, DOI 10.1021/bi00002a004; MALASHKEVICH VN, 1993, BIOCHEMISTRY-US, V32, P13451, DOI 10.1021/bi00212a010; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; MORINO Y, 1974, J BIOL CHEM, V249, P6684; Mouratou B, 2004, BIOCHEMISTRY-US, V43, P6612, DOI 10.1021/bi049874e; Mouratou B, 2000, MOL IMMUNOL, V37, P633, DOI 10.1016/S0161-5890(00)00090-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peisach D, 1998, BIOCHEMISTRY-US, V37, P4958, DOI 10.1021/bi972884d; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; STAUB H, 2000, THESIS U ZURICH; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x; ZIAK M, 1990, EUR J BIOCHEM, V187, P329, DOI 10.1111/j.1432-1033.1990.tb15309.x	33	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23969	23977		10.1074/jbc.M602184200	http://dx.doi.org/10.1074/jbc.M602184200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790434	hybrid			2022-12-27	WOS:000239702900071
J	Goto, Y; Hattori, A; Ishii, Y; Mizutani, S; Tsujimoto, M				Goto, Yoshikuni; Hattori, Akira; Ishii, Yasuhiro; Mizutani, Shigehiko; Tsujimoto, Masafumi			Enzymatic properties of human aminopeptidase A - Regulation of its enzymatic activity by calcium and angiotensin IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUROMYCIN-SENSITIVE AMINOPEPTIDASE; PLACENTAL LEUCINE AMINOPEPTIDASE/OXYTOCINASE; SITE-DIRECTED MUTAGENESIS; RECOMBINANT SOLUBLE FORM; HAMSTER OVARY CELLS; C-TERMINAL DOMAIN; EXOPEPTIDASE SPECIFICITY; MOLECULAR-CLONING; OXYTOCINASE SUBFAMILY; AT(4) RECEPTOR	Aminopeptidase A (APA) is a type II membrane-bound protein implicated in the regulation of blood pressure in the brain renin-angiotensin system. In this study, a recombinant soluble form of APA was expressed in a baculovirus system, purified to homogeneity, and characterized. By using synthetic substrates, it was shown that although the enzyme has a rather broad substrate specificity in the absence of Ca2+, the preferential release of acidic amino acid residues was observed in the presence of Ca2+. Moreover, Ca2+ up-or down-regulated the enzymatic activity depending on the substrate. By searching for natural substrates of APA, we found that peptides having acidic amino acids at their N terminus (angiotensin II, neurokinin B, cholecystokinin-8, and chromogranin A) were cleaved by the enzyme efficiently in the presence but not in the absence of Ca2+. Moreover kallidin (Lys-bradykinin) was converted to bradykinin effectively only in the absence of Ca2+. These results suggest that Ca2+ increases the preference of the enzyme for the peptide substrates having N-terminal acidic amino acids. In addition, we found that angiotensin IV could bind to APA both in the presence and absence of Ca2+ and inhibited the enzymatic activity of APA competitively, suggesting that angiotensin IV acts as a negative regulator of the enzyme once generated from angiotensin II by the serial actions of aminopeptidases. Taken together, these results suggest that there exists a complex regulation of the enzymatic activity of APA, which may contribute to homeostasis such as regulation of blood pressure, maintenance of memory, and normal pregnancy by controlling the concentrations of peptide substrates.	RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Tokyo Univ Agr & Technol, Lab Appl Prot Chem, Fuchu, Tokyo 1830054, Japan; Nagoya Univ, Sch Med, Dept Med Sci Proteases, Showa Ku, Nagoya, Aichi 4668550, Japan	RIKEN; Tokyo University of Agriculture & Technology; Nagoya University	Tsujimoto, M (corresponding author), RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan.	tsujimot@riken.jp						Albiston AL, 2003, TRENDS ENDOCRIN MET, V14, P72, DOI 10.1016/S1043-2760(02)00037-1; Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; CONSTAM DB, 1995, J BIOL CHEM, V270, P26931, DOI 10.1074/jbc.270.45.26931; DANIELSEN EM, 1980, BIOCHEM J, V189, P591, DOI 10.1042/bj1890591; FERACCI H, 1981, BIOCHIM BIOPHYS ACTA, V658, P148, DOI 10.1016/0005-2744(81)90258-8; Fruitier-Arnaudin I, 2002, PEPTIDES, V23, P1465, DOI 10.1016/S0196-9781(02)00083-9; Goto Y, 2006, FEBS LETT, V580, P1833, DOI 10.1016/j.febslet.2006.02.041; Hattori A, 1999, J BIOCHEM-TOKYO, V125, P931, DOI 10.1093/oxfordjournals.jbchem.a022371; Hattori A, 2000, J BIOCHEM-TOKYO, V128, P755, DOI 10.1093/oxfordjournals.jbchem.a022812; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; Hesp JR, 1997, BIOCHEMISTRY-US, V36, P3000, DOI 10.1021/bi962401q; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; ITOH S, 1990, DRUG DEVELOP RES, V21, P257, DOI 10.1002/ddr.430210402; Iturrioz X, 2000, BIOCHEMISTRY-US, V39, P3061, DOI 10.1021/bi9925726; Iturrioz X, 2001, BIOCHEMISTRY-US, V40, P14440, DOI 10.1021/bi011409j; LALU K, 1986, BIOCHIM BIOPHYS ACTA, V873, P190, DOI 10.1016/0167-4838(86)90045-2; Lew RA, 2003, J NEUROCHEM, V86, P344, DOI 10.1046/j.1471-4159.2003.01852.x; Matsumoto H, 2000, EUR J BIOCHEM, V267, P46, DOI 10.1046/j.1432-1327.2000.00949.x; Migaud M, 1996, PEPTIDES, V17, P601, DOI 10.1016/0196-9781(96)00036-8; Mitsui T, 2003, MOL MED, V9, P57, DOI 10.1007/BF03402108; MIZUTANI S, 1987, ARCH GYNECOL OBSTET, V240, P27, DOI 10.1007/BF02134061; Nakanishi Y, 2000, PLACENTA, V21, P628, DOI 10.1053/plac.2000.0564; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Nomura M, 2005, AM J HYPERTENS, V18, P538, DOI 10.1016/j.amjhyper.2004.11.010; Nomura S, 2005, BBA-PROTEINS PROTEOM, V1751, P19, DOI 10.1016/j.bbapap.2005.04.006; Ofner LD, 2002, BIOCHEM J, V362, P191, DOI 10.1042/0264-6021:3620191; OKUYAMA T, 1991, CLIN CHIM ACTA, V196, P207, DOI 10.1016/0009-8981(91)90074-M; Osada T, 1999, J NEUROSCI, V19, P6068, DOI 10.1523/JNEUROSCI.19-14-06068.1999; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Reaux A, 1999, P NATL ACAD SCI USA, V96, P13415, DOI 10.1073/pnas.96.23.13415; Rozenfeld R, 2004, J BIOL CHEM, V279, P43285, DOI 10.1074/jbc.M404369200; Rozenfeld R, 2003, BIOCHEMISTRY-US, V42, P14785, DOI 10.1021/bi034358u; Rozenfeld R, 2002, J BIOL CHEM, V277, P29242, DOI 10.1074/jbc.M204406200; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Tanioka T, 2003, J BIOL CHEM, V278, P32275, DOI 10.1074/jbc.M305076200; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Tobler AR, 1997, J NEUROCHEM, V68, P889; Tsujimoto M, 2005, BBA-PROTEINS PROTEOM, V1751, P9, DOI 10.1016/j.bbapap.2004.09.011; TSUJIMOTO M, 1992, ARCH BIOCHEM BIOPHYS, V292, P388, DOI 10.1016/0003-9861(92)90007-J; Vazeux G, 1998, EUR J BIOCHEM, V254, P671, DOI 10.1046/j.1432-1327.1998.2540671.x; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; WANG J, 1998, HDB PROTEOLYTIC ENZY, P1002; WANG JY, 1993, P NATL ACAD SCI USA, V90, P1222, DOI 10.1073/pnas.90.4.1222; Wright JW, 2004, PROG NEUROBIOL, V72, P263, DOI 10.1016/j.pneurobio.2004.03.003; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; YAMADA R, 1988, ENZYME, V40, P223, DOI 10.1159/000469167; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	48	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23503	23513		10.1074/jbc.M603191200	http://dx.doi.org/10.1074/jbc.M603191200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790432	hybrid			2022-12-27	WOS:000239702900025
J	Liu, H; Nakazawa, T; Tezuka, T; Yamamoto, T				Liu, Hui; Nakazawa, Takanobu; Tezuka, Tohru; Yamamoto, Tadashi			Physical and functional interaction of Fyn tyrosine kinase with a brain-enriched Rho GTPase-activating protein TCGAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; D-ASPARTATE RECEPTOR; ACTIN STRESS FIBERS; SRC FAMILY KINASES; NEURITE OUTGROWTH; CELL-ADHESION; C-SRC; NEURONAL MORPHOGENESIS; BINDING-PROTEIN; AXON OUTGROWTH	Fyn, a member of the Src family of tyrosine kinases, is implicated in both brain development and adult brain function. In the present study, we identified a Rho GTPase-activating protein (GAP), TCGAP (Tc10Cdc42 GTPase-activating protein), as a novel Fyn substrate. TCGAP interacted with Fyn and was phosphorylated by Fyn, with Tyr-406 in the GAP domain as a major Fyn-mediated phosphorylation site. Fyn suppressed the GAP activity of wild-type TCGAP but not the Y406F mutant of TCGAP in a phosphorylation-dependent manner, suggesting that Fyn-mediated Tyr-406 phosphorylation negatively regulated the TCGAP activity. In situ hybridization analyses showed that TCGAP mRNA was expressed prominently in both immature and adult mouse brain, with high levels in cortex, corpus striatum, hippocampus, and olfactory bulb. Overexpression of wild-type TCGAP in PC12 cells suppressed nerve growth factor-induced neurite outgrowth, whereas a GAP-defective mutant of TCGAP enhanced the neurite outgrowth. Nerve growth factor enhanced tyrosine phosphorylation of TCGAP through activation of Src family kinases. These results suggest that TCGAP is involved in Fyn-mediated regulation of axon and dendrite outgrowth.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Nakazawa, Takanobu/E-1012-2014	Nakazawa, Takanobu/0000-0002-5049-9140; NAKAZAWA, Takanobu/0000-0003-4863-1277				Aoki K, 2004, J BIOL CHEM, V279, P713, DOI 10.1074/jbc.M306382200; Baron W, 1999, J NEUROBIOL, V41, P385, DOI 10.1002/(SICI)1097-4695(19991115)41:3<385::AID-NEU7>3.0.CO;2-E; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BIXBY JL, 1993, J NEUROSCI, V13, P3421; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chiang SH, 2003, EMBO J, V22, P2679, DOI 10.1093/emboj/cdg262; Dent EW, 1998, J NEUROBIOL, V35, P287, DOI 10.1002/(SICI)1097-4695(19980605)35:3<287::AID-NEU6>3.0.CO;2-V; Derrien A, 2003, J BIOL CHEM, V278, P16107, DOI 10.1074/jbc.M210371200; Dey N, 2005, EXP CELL RES, V307, P1, DOI 10.1016/j.yexcr.2005.02.029; Fukaya M, 1999, NEUROSCI RES, V33, P111, DOI 10.1016/S0168-0102(98)00120-5; Fukazawa' Y, 2003, NEURON, V38, P447, DOI 10.1016/S0896-6273(03)00206-X; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kawa S, 2004, GENES CELLS, V9, P219, DOI 10.1111/j.1356-9597.2004.00714.x; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Knoll B, 2004, J NEUROSCI, V24, P6248, DOI 10.1523/JNEUROSCI.0985-04.2004; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu GF, 2004, NAT NEUROSCI, V7, P1222, DOI 10.1038/nn1331; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Morse WR, 1998, J NEUROBIOL, V36, P53, DOI 10.1002/(SICI)1097-4695(199807)36:1<53::AID-NEU5>3.0.CO;2-9; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nakazawa T, 2003, MOL BIOL CELL, V14, P2921, DOI 10.1091/mbc.e02-09-0623; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oh JS, 2004, J BIOL CHEM, V279, P17980, DOI 10.1074/jbc.M314109200; Okabe T, 2003, J BIOL CHEM, V278, P9920, DOI 10.1074/jbc.M208872200; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Taniguchi S, 2003, BIOCHEM BIOPH RES CO, V306, P151, DOI 10.1016/S0006-291X(03)00923-9; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wolf RM, 2001, J NEUROBIOL, V49, P62, DOI 10.1002/neu.1066; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; YAGI T, 1993, ONCOGENE, V8, P3343; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	67	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23611	23619		10.1074/jbc.M511205200	http://dx.doi.org/10.1074/jbc.M511205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777849	hybrid			2022-12-27	WOS:000239702900036
J	Yasuda, O; Fukuo, K; Sun, X; Nishitani, M; Yotsui, T; Higuchi, M; Suzuki, T; Rakugi, H; Smithies, O; Maeda, N; Ogihara, T				Yasuda, Osamu; Fukuo, Keisuke; Sun, Xin; Nishitani, Masahito; Yotsui, Takamori; Higuchi, Masayoshi; Suzuki, Takashi; Rakugi, Hiromi; Smithies, Oliver; Maeda, Nobuyo; Ogihara, Toshio			Apop-1, a novel protein inducing cyclophilin D-dependent but Bax/Bak-related channel-independent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; SMOOTH-MUSCLE-CELLS; PLAQUE RUPTURE; CYCLOSPORINE-A; BCL-2 FAMILY; DEATH; EXPRESSION; LIFE; ATHEROSCLEROSIS; INHIBITION	In the intrinsic pathway of apoptosis, mitochondria play a crucial role by releasing cytochrome c from the intermembrane space into the cytoplasm. Cytochrome c release through Bax/Bak-dependent channels in mitochondria has been well documented. In contrast, cyclophilin D ( CypD), an important component of permeability transition pore-dependent protein release, remains largely undefined, and no apoptogenic proteins that act specifically in a CypD-dependent manner have been reported to date. Here, we describe a novel and evolutionarily conserved protein, apoptogenic protein ( Apop). Mouse Apop-1 expression induces apoptotic death by releasing cytochrome c from mitochondria into the cytosolic space followed by activation of caspase-9 and -3. Apop-1-induced apoptosis is not blocked by Bcl-2 or Bcl-x(L), inhibitors of Bax/Bak-dependent channels, whereas it is completely blocked by cyclosporin A, an inhibitor of permeability transition pore. Cells lacking CypD were resistant to Apop-induced apoptosis. Moreover, inhibition of Apop expression prevented the cell death induced by apoptosis-inducing substances. Our findings, thus, indicate that the expression of Apop-1 induces apoptosis though CypD-dependent pathway and that Apop-1 plays roles in cell death under physiological conditions.	Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 5650871, Japan; Mukogawa Womens Univ, Sch Human Environm Sci, Dept Food Sci & Nutr, Nishinomiya, Hyogo 6638558, Japan; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	Osaka University; Mukogawa Women's University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Yasuda, O (corresponding author), Osaka Univ, Grad Sch Med, Dept Geriatr Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yasuda@geriat.med.osaka-u.ac.jp	Suzuki, Takashi/B-7656-2014	Suzuki, Takashi/0000-0002-2058-3333; Rakugi, Hiromi/0000-0001-6508-4338				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bauriedel G, 1999, CARDIOVASC RES, V41, P480, DOI 10.1016/S0008-6363(98)00318-6; Bennett MR, 1999, CARDIOVASC RES, V41, P361, DOI 10.1016/S0008-6363(98)00212-0; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dhume AS, 2003, ANN VASC SURG, V17, P1, DOI 10.1007/s10016-001-0331-1; Donners MMPC, 2005, AM J TRANSPLANT, V5, P1204, DOI 10.1111/j.1600-6143.2005.00821.x; EMESON EE, 1993, AM J PATHOL, V142, P1906; FALK E, 1992, CIRCULATION, V86, P30; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Halestrap AP, 2004, NATURE, V430, DOI 10.1038/nature02816; Johnson N, 1999, EUR J BIOCHEM, V263, P353, DOI 10.1046/j.1432-1327.1999.00490.x; Kallen J, 1998, J MOL BIOL, V283, P435, DOI 10.1006/jmbi.1998.2108; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nomura M, 1999, CANCER RES, V59, P5542; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu S, 1996, ONCOGENE, V12, P2251; Stoneman VEA, 2004, CLIN SCI, V107, P343, DOI 10.1042/CS20040086; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; von der Thusen JH, 2002, CIRCULATION, V105, P2064, DOI 10.1161/01.CIR.0000015502.97828.93; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Werner AB, 2004, J BIOL CHEM, V279, P28771, DOI 10.1074/jbc.M400268200; Willis S, 2003, J CELL SCI, V116, P4053, DOI 10.1242/jcs.00754; Yasuda O, 2000, J VASC RES, V37, P158, DOI 10.1159/000025727; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	48	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23899	23907		10.1074/jbc.M512610200	http://dx.doi.org/10.1074/jbc.M512610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782708	hybrid, Green Published			2022-12-27	WOS:000239702900065
J	Garcia-Pedrero, JM; Kiskinis, E; Parker, MG; Belandia, B				Garcia-Pedrero, Juana M.; Kiskinis, Evangelos; Parker, Malcolm G.; Belandia, Borja			The SWI/SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-DEPENDENT PHOSPHORYLATION; P160 COACTIVATOR PROTEINS; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; TUMOR-SUPPRESSOR; EXPRESSION; BETA; PROLIFERATION; ALPHA; COMPLEX	Estrogen receptors (ERs) play critical roles in both normal mammary gland development and in the formation and progression of breast tumors, constituting a major therapeutic target for breast cancer treatment. We have previously described that ER transcriptional activity is potentiated by BAF57, a core subunit of the mammalian SWI/SNF chromatin remodeling complex. Here we provide evidence demonstrating an important role for BAF57 as regulator of ER functions in breast cancer cells. Different experimental manipulations leading to the abrogation of BAF57 expression and/or function severely reduced the expression of various endogenous ER target genes and blocked estrogen-stimulated proliferation in ZR-75-1 breast cancer cells. Moreover, using a structure-function analysis, we have defined the protein domains required for the functional interaction between ER alpha and BAF57, including a key region within the hinge of ER alpha that is essential for BAF57 recruitment and its function on ER-mediated transcription. Interestingly, we found that BAF57 is an ER subtype-selective modulator that specifically regulates ER alpha-mediated transcription. Taken together, our results suggest that targeting BAF57 could represent a new way to effectively inhibit the action of ER alpha.	Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Madrid 28029, Spain; Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Imperial College London	Belandia, B (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Arturo Duperier 4, Madrid 28029, Spain.	bbelandia@iib.uam.es	Belandia, Borja/H-1509-2015; Pedrero, Juana María García/AAP-4251-2021	Belandia, Borja/0000-0003-2448-206X; Pedrero, Juana María García/0000-0002-5891-9488	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arteaga CL, 1996, CANCER RES, V56, P1098; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; del Rio B, 2004, J BIOL CHEM, V279, P38294, DOI 10.1074/jbc.M403140200; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Lu CH, 2005, ONCOGENE, V24, P6516, DOI 10.1038/sj.onc.1208905; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mohrmann L, 2005, BBA-GENE STRUCT EXPR, V1681, P59, DOI 10.1016/j.bbaexp.2004.10.005; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	43	76	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22656	22664		10.1074/jbc.M602561200	http://dx.doi.org/10.1074/jbc.M602561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769725	hybrid			2022-12-27	WOS:000239542600026
J	Atkin, JD; Farg, MA; Turner, BJ; Tomas, D; Lysaght, JA; Nunan, J; Rembach, A; Nagley, P; Beart, PM; Cheema, SS; Horne, MK				Atkin, Julie D.; Farg, Manal A.; Turner, Bradley J.; Tomas, Doris; Lysaght, Judith A.; Nunan, Janelle; Rembach, Alan; Nagley, Phillip; Beart, Philip M.; Cheema, Surindar S.; Horne, Malcolm K.			RETRACTED: Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1 (Retracted article. See vol. 292, pg. 12007, 2017)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							ENDOPLASMIC-RETICULUM STRESS; CU,ZN SUPEROXIDE-DISMUTASE; WILD-TYPE SOD1; CU,ZN-SUPEROXIDE DISMUTASE; MOUSE MODEL; GOLGI-APPARATUS; TRANSGENIC MICE; UP-REGULATION; PARKINSONS-DISEASE; MOTOR-NEURONS	Mutations in Cu/Zn superoxide dismutase (SOD1) are linked to motor neuron death in familial amyotrophic lateral sclerosis (ALS) by an unclear mechanism, although misfolded SOD1 aggregates are commonly associated with disease. Proteomic analysis of the transgenic SOD1(G93A) ALS rat model revealed significant up-regulation of endoplasmic reticulum (ER)-resident protein-disulfide isomerase (PDI) family members in lumbar spinal cords. Expression of SOD1 mutants (mSOD1) led to an up-regulation of PDI in motor neuron-like NSC-34 cells but not other cell lines. Inhibition of PDI using bacitracin increased aggregate production, even in wild type SOD1 transfectants that do not readily form inclusions, suggesting PDI may protect SOD1 from aggregation. Moreover, PDI co-localized with intracellular aggregates of mSOD1 and bound to both wild type and mSOD1. SOD1 was also found in the microsomal fraction of cells despite being a predominantly cytosolic enzyme, confirming ER-Golgi-dependent secretion. In SOD1G93A mice, a significant up-regulation of unfolded protein response entities was also observed during disease, including caspase-12, -9, and -3 cleavage. Our findings therefore implicate unfolded protein response and ER stress-induced apoptosis in the pathophysiology of familial ALS. The possibility that PDI may be a therapeutic target to prevent SOD1 aggregation is also raised by this study.	Univ Melbourne, Howard Florey Inst, Brain Injury & Repair Grp, Parkville, Vic 3010, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; Monash University	Atkin, JD (corresponding author), Univ Melbourne, Howard Florey Inst, Brain Injury & Repair Grp, Parkville, Vic 3010, Australia.	j.atkin@hfi.unimelb.edu.au	Horne, Malcolm/AAL-5214-2020	Horne, Malcolm/0000-0001-9427-2100; Turner, Bradley/0000-0001-6580-7655				Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Bendotti C, 2004, TRENDS MOL MED, V10, P393, DOI 10.1016/j.molmed.2004.06.009; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Conn KJ, 2004, BRAIN RES, V1022, P164, DOI 10.1016/j.brainres.2004.07.026; Cozzolino M, 2006, NEUROBIOL DIS, V21, P69, DOI 10.1016/j.nbd.2005.06.010; DALCANTO MC, 1995, BRAIN RES, V676, P25, DOI 10.1016/0006-8993(95)00063-V; Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Engelhardt JI, 1997, J NEUROPATH EXP NEUR, V56, P21, DOI 10.1097/00005072-199701000-00003; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Fujita Y, 2000, J NEUROL SCI, V174, P137, DOI 10.1016/S0022-510X(00)00265-3; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Furukawa Y, 2006, P NATL ACAD SCI USA, V103, P7148, DOI 10.1073/pnas.0602048103; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hetz C, 2005, J NEUROSCI, V25, P2793, DOI 10.1523/JNEUROSCI.4090-04.2005; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Higuchi T, 2004, BIOCHEM BIOPH RES CO, V318, P46, DOI 10.1016/j.bbrc.2004.04.002; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Inarrea P, 2005, BIOCHEM J, V387, P203, DOI 10.1042/BJ20041683; Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim HT, 2000, ANTIOXID REDOX SIGN, V2, P485, DOI 10.1089/15230860050192260; Lindenau J, 2000, GLIA, V29, P25, DOI 10.1002/(SICI)1098-1136(20000101)29:1<25::AID-GLIA3>3.0.CO;2-G; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; Mondola P, 2003, MOL BRAIN RES, V110, P45, DOI 10.1016/S0169-328X(02)00583-1; Mondola P, 1996, INT J BIOCHEM CELL B, V28, P677, DOI 10.1016/1357-2725(96)00004-0; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; MOURELATOS Z, 1990, P NATL ACAD SCI USA, V87, P4393, DOI 10.1073/pnas.87.11.4393; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Ogawa Y, 1997, BIOCHEM BIOPH RES CO, V241, P251, DOI 10.1006/bbrc.1997.7804; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Parton MJ, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9081; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTH RA, 1981, J BIOL CHEM, V256, P4633; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Ryu EJ, 2002, J NEUROSCI, V22, P10690; SAITO T, 1989, HISTOL HISTOPATHOL, V4, P1; Sathasivam S, 2005, NEUROPATH APPL NEURO, V31, P467, DOI 10.1111/j.1365-2990.2005.00658.x; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Strey CW, 2004, AM J PATHOL, V165, P1701, DOI 10.1016/S0002-9440(10)63426-8; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388; Tiwari A, 2005, J BIOL CHEM, V280, P29771, DOI 10.1074/jbc.M504039200; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Tobisawa S, 2003, BIOCHEM BIOPH RES CO, V303, P496, DOI 10.1016/S0006-291X(03)00353-X; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Turner BJ, 2005, J NEUROSCI, V25, P108, DOI 10.1523/JNEUROSCI.4253-04.2005; Turner BJ, 2006, CURR MOL MED, V6, P79, DOI 10.2174/156652406775574550; Urushitani M, 2006, NAT NEUROSCI, V9, P108, DOI 10.1038/nn1603; Vlug AS, 2005, EUR J NEUROSCI, V22, P1881, DOI 10.1111/j.1460-9568.2005.04389.x; Wate R, 2005, ACTA NEUROPATHOL, V110, P557, DOI 10.1007/s00401-005-1080-y; Wootz H, 2004, BIOCHEM BIOPH RES CO, V322, P281, DOI 10.1016/j.bbrc.2004.07.118; Yoo BC, 2002, NEUROSCI LETT, V334, P196, DOI 10.1016/S0304-3940(02)01071-6	69	226	233	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					30152	30165		10.1074/jbc.M603393200	http://dx.doi.org/10.1074/jbc.M603393200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16847061	hybrid			2022-12-27	WOS:000240896300076
J	Arvisais, EW; Romanelli, A; Hou, XY; Davis, JS				Arvisais, Edward W.; Romanelli, Angela; Hou, Xiaoying; Davis, John S.			AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; TUBEROUS-SCLEROSIS; MAMMALIAN TARGET; TUMOR-SUPPRESSOR; CORPUS-LUTEUM; CELL-GROWTH; FACTOR-I; RECEPTOR; PATHWAY; INSULIN	Prostaglandin F2 alpha (PGF2 alpha) is an important mediator of corpus luteum (CL) regression, although the cellular signaling events that mediate this process have not been clearly identified. It is established that PGF2 alpha binds to a G-protein-coupled receptor (GPCR) to stimulate protein kinase C (PKC) and Raf-MEK-Erk signaling in luteal cells. The present experiments were performed to determine whether PGF2 alpha stimulates the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase 1 (S6K1) signaling pathway in steroidogenic luteal cells. We demonstrate that PGF2 alpha treatment results in a time- and concentration-dependent stimulation of the phosphorylation and activation of S6K1. The stimulation of S6K1 in response to PGF2 alpha treatment was abolished by the mTOR inhibitor rapamycin. Treatment with PGF2 alpha did not increase AKT phosphorylation but increased the phosphorylation of Erk and the tumor suppressor protein tuberous sclerosis complex 2 (TSC2), an upstream regulator of mTOR. The effects of PGF2 alpha were mimicked by the PKC activator PMA and inhibited by U0126, a MEK1 inhibitor. The activation of mTOR/S6K1 and putative down stream processes involving the translational apparatus (i.e. 4EBP1 phosphorylation, release of 4EBP1 binding in m(7)G cap binding assays, and the phosphorylation and synthesis of S6) were completely sensitive to treatment with rapamycin, implicating mTOR in the actions of PGF2 alpha. Taken together, our data suggest that GPCR activation in response to PGF2 alpha stimulates the mTOR pathway which increases the translational machinery in luteal cells. The translation of proteins under the control of mTOR may have implications for luteal development and regression and offer new strategies for therapeutic intervention in PGF2 alpha-target tissues.	Univ Nebraska, Med Ctr, Olson Ctr Womens Hlth, Dept Obstet & Gynecol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Olson Ctr Womens Hlth, Dept Pharmacol, Omaha, NE 68198 USA; Serono Res Inst, Rockland, MA 02370 USA; Dept Vet Affairs Med Ctr, Omaha, NE 68105 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Davis, JS (corresponding author), 983255 Nebraska Med Ctr, Omaha, NE 68189 USA.	jsdavis@unmc.edu	Davis, John S/C-3234-2014	Davis, John/0000-0003-3468-4079	NICHD NIH HHS [R01HD38813] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038813] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Alam H, 2004, J BIOL CHEM, V279, P19431, DOI 10.1074/jbc.M401235200; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; CHAKRAVORTY A, 1993, ENDOCRINOLOGY, V133, P1331, DOI 10.1210/en.133.3.1331; Chen DB, 1998, ENDOCRINOLOGY, V139, P3876, DOI 10.1210/en.139.9.3876; Chen DB, 2001, ENDOCRINOLOGY, V142, P887, DOI 10.1210/en.142.2.887; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; DAVIS JS, 1987, P NATL ACAD SCI USA, V84, P3728, DOI 10.1073/pnas.84.11.3728; Davis JS, 2002, FRONT BIOSCI-LANDMRK, V7, pD1949, DOI 10.2741/davis1; Diaz FJ, 2002, MOL CELL ENDOCRINOL, V191, P65, DOI 10.1016/S0303-7207(02)00056-4; Findlay GM, 2005, CURR OPIN GENET DEV, V15, P69, DOI 10.1016/j.gde.2004.11.002; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fujino H, 2002, J BIOL CHEM, V277, P48786, DOI 10.1074/jbc.M209393200; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gual P, 2003, DIABETOLOGIA, V46, P1532, DOI 10.1007/s00125-003-1223-4; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hakeda Y, 1997, ENDOCRINOLOGY, V138, P1821, DOI 10.1210/en.138.5.1821; HANSEL W, 1991, J REPROD FERTIL, P77; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Ishii Y, 2001, BIOCHEM BIOPH RES CO, V285, P1, DOI 10.1006/bbrc.2001.5106; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Masuda-Robens J, 2001, METHOD ENZYMOL, V333, P45; MCCRACKEN JA, 1970, J CLIN ENDOCR METAB, V30, P544, DOI 10.1210/jcem-30-4-544; McCracken JA, 1999, PHYSIOL REV, V79, P263, DOI 10.1152/physrev.1999.79.2.263; MEYER GT, 1980, ANAT REC, V197, P369, DOI 10.1002/ar.1091970311; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Naegele S, 2004, J BIOL CHEM, V279, P46023, DOI 10.1074/jbc.M404945200; Niswender GD, 2000, PHYSIOL REV, V80, P1, DOI 10.1152/physrev.2000.80.1.1; Olson DM, 2003, PLACENTA, V24, pS47, DOI 10.1053/plac.2002.0938; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; PHARRISS BB, 1969, P SOC EXP BIOL MED, V130, P92; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Sakamoto K, 2002, DNA SEQUENCE, V13, P307, DOI 10.1080/1042517021000011645; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Shao JY, 2004, CANCER RES, V64, P229, DOI 10.1158/0008-5472.CAN-03-1859; Sharif NA, 2003, J OCUL PHARMACOL TH, V19, P501, DOI 10.1089/108076803322660422; Shea-Eaton W, 2002, MOL CELL ENDOCRINOL, V188, P161, DOI 10.1016/S0303-7207(01)00715-8; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Stocco DM, 2005, MOL ENDOCRINOL, V19, P2647, DOI 10.1210/me.2004-0532; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Tang XW, 2003, BIOCHEM J, V374, P137, DOI 10.1042/BJ20021910; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Wang LJ, 2002, CIRC RES, V91, P821, DOI 10.1161/01.RES.0000041029.97988.E9; Westfall SD, 2000, ENDOCRINE, V12, P315, DOI 10.1385/ENDO:12:3:315; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492	64	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26904	26913		10.1074/jbc.M605371200	http://dx.doi.org/10.1074/jbc.M605371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16816403	hybrid			2022-12-27	WOS:000240397700017
J	DeLucia, AM; Chaudhuri, S; Potapova, O; Grindley, NDF; Joyce, CM				DeLucia, Angela M.; Chaudhuri, Santanov; Potapova, Olga; Grindley, Nigel D. F.; Joyce, Catherine M.			The properties of steric gate mutants reveal different constraints within the active sites of Y-family and A-family DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED-FIT MECHANISM; I KLENOW FRAGMENT; NUCLEOTIDE INCORPORATION; SULFOLOBUS-SOLFATARICUS; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; DINB HOMOLOG; FIDELITY; COMPLEX	Y-family (lesion-bypass) DNA polymerases show the same overall structural features seen in other members of the polymerase superfamily, yet their active sites are more open, with fewer contacts to the DNA and nucleotide substrates. This raises the question of whether analogous active-site side chains play equivalent roles in the bypass polymerases and their classical DNA polymerase counterparts. In Klenow fragment, an A-family DNA polymerase, the steric gate side chain (Glu(710)) not only prevents ribonucleotide incorporation but also plays an important role in discrimination against purine-pyrimidine mispairs. In this work we show that the steric gate (Phe(12)) of the Y-family polymerase Dbh plays a very minor role in fidelity, despite its analogous role in sugar selection. Using ribonucleotide discrimination to report on the positioning of a mispaired dNTP, we found that the pyrimidine of a Pu-dPyTP nascent mispair occupies a similar position to that of a correctly paired dNTP in the Dbh active site, whereas in Klenow fragment the mispaired dNTP sits higher in the active site pocket. If purine-pyrimidine mispairs adopt the expected wobble geometry, the difference between the two polymerases can be attributed to the binding of the templating base, with the looser binding site of Dbh permitting a variety of template conformations with only minimal adjustment at the incoming dNTP. In Klenow fragment the templating base is more rigidly held, so that changes in base pair geometry would affect the dNTP position, allowing the Glu(710) side chain to serve as a sensor of nascent mispairs.	Yale Univ, Dept Mol Biophys & Biochem, Bass Ctr Mol & Struct Biol, New Haven, CT 06520 USA	Yale University	Joyce, CM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, Bass Ctr Mol & Struct Biol, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	catherine.joyce@yale.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; Cases-Gonzalez CE, 2000, J BIOL CHEM, V275, P19759, DOI 10.1074/jbc.M910361199; Cramer J, 2005, J BIOL CHEM, V280, P40552, DOI 10.1074/jbc.M504481200; DeLucia AM, 2003, NUCLEIC ACIDS RES, V31, P4129, DOI 10.1093/nar/gkg417; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gardner AF, 1999, NUCLEIC ACIDS RES, V27, P2545, DOI 10.1093/nar/27.12.2545; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kobayashi S, 2002, J BIOL CHEM, V277, P34198, DOI 10.1074/jbc.M204826200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Li Y, 2001, PROTEIN SCI, V10, P1225, DOI 10.1110/ps.250101; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Minnick DT, 2002, P NATL ACAD SCI USA, V99, P1194, DOI 10.1073/pnas.032457899; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Potapova O, 2002, J BIOL CHEM, V277, P28157, DOI 10.1074/jbc.M202607200; Purohit V, 2003, BIOCHEMISTRY-US, V42, P10200, DOI 10.1021/bi0341206; Rothwell PJ, 2005, MOL CELL, V19, P345, DOI 10.1016/j.molcel.2005.06.032; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Vaisman A, 2005, EMBO J, V24, P2957, DOI 10.1038/sj.emboj.7600786; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Yang GW, 2002, BIOCHEMISTRY-US, V41, P10256, DOI 10.1021/bi0202171; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	36	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27286	27291		10.1074/jbc.M604393200	http://dx.doi.org/10.1074/jbc.M604393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16831866	hybrid			2022-12-27	WOS:000240397700055
J	Goyal, P; Pandey, D; Siess, W				Goyal, Pankaj; Pandey, Dharmendra; Siess, Wolfgang			Phosphorylation-dependent regulation of unique nuclear and nucleolar localization signals of LIM kinase 2 in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; COFILIN PHOSPHORYLATION; ACTIN; IDENTIFICATION; ACTIVATION; IMPORT; EXPORT; TRANSLOCATION; RECOGNITION; INHIBITION	LIM kinases (LIMKs) regulate actin dynamics through cofilin phosphorylation and also have a function in the nucleus. Recently we have shown that LIMK2 shuttles between cytoplasm and nucleus in endothelial cells and that nuclear import is inhibited by protein kinase C-mediated phosphorylation of Ser-283. Here we aimed to identify the structural features of LIMK2 responsible for nuclear import. We found that the kinase domain of LIMK2 is localized exclusively in the nucleus and, in contrast to the kinase domain of LIMK1, it accumulated in the nucleolus. Through site-directed mutagenesis, we identified the basic amino acid-rich motif KKRTLRKNDRKKR ( amino acids 491-503) as the functional nuclear and nucleolar localization signal of LIMK2. After fusing this motif to enhanced green fluorescent protein, the fusion protein localized exclusively in the nucleus and nucleolus. Mutagenesis studies showed that phosphorylation of Thr-494, a putative protein kinase C phosphorylation site identified within the nuclear localization signal, inhibits nuclear import of the enhanced green fluorescent protein-PDZ kinase domain of LIMK2. After inhibiting nuclear export with leptomycin B, phosphorylation of either Ser-283 or Thr-494 reduced the nuclear import of LIMK2. Phosphorylation of both Ser-283 and Thr-494 sites inhibited nuclear import completely. Our findings identify a unique basic amino acid-rich motif ( amino acids 491-503) in LIMK2 which is not present in LIMK1 that serves to target the protein not only to the nucleus but also to the nucleolus. Phosphorylation of Thr-494 within this motif negatively regulates nuclear import of LIMK2.	Univ Munich, Inst Prevent Cardiovasc Dis, D-80336 Munich, Germany	University of Munich	Goyal, P (corresponding author), Univ Munich, Klinikum Innenstadt, Inst Prophykaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.	pankaj.goyal@med.uni-muenchen.de	Pandey, Dharmendra/O-9158-2017; Siess, Wolfgang/A-6430-2009; Goyal, Pankaj/C-3567-2012	Pandey, Dharmendra/0000-0002-3172-5923; Siess, Wolfgang/0000-0003-0698-6416; Pandey, Dharmendra/0000-0003-4871-964X				Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Catez F, 2002, MOL CELL BIOL, V22, P1126, DOI 10.1128/MCB.22.4.1126-1139.2002; de Lanerolle P, 2005, NAT STRUCT MOL BIOL, V12, P742, DOI 10.1038/nsmb983; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; Dundr M, 2002, MOL CELL, V9, P5, DOI 10.1016/S1097-2765(02)00433-1; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Gerbi SA, 2003, CURR OPIN CELL BIOL, V15, P318, DOI 10.1016/S0955-0674(03)00049-8; Gettemans J, 2005, TRAFFIC, V6, P847, DOI 10.1111/j.1600-0854.2005.00326.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Goyal P, 2005, J BIOL CHEM, V280, P27569, DOI 10.1074/jbc.M504448200; Guo YX, 2003, VIROLOGY, V306, P225, DOI 10.1016/S0042-6822(02)00081-8; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; Horke S, 2004, J BIOL CHEM, V279, P26563, DOI 10.1074/jbc.M401017200; Hulo N, 2004, NUCLEIC ACIDS RES, V32, pD134, DOI 10.1093/nar/gkh044; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; MIZUNO K, 1994, ONCOGENE, V9, P1605; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Pederson T, 2005, MOL BIOL CELL, V16, P5055, DOI 10.1091/mbc.E05-07-0656; Roovers K, 2003, DEV CELL, V5, P273, DOI 10.1016/S1534-5807(03)00206-5; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P12062, DOI 10.1021/bi00163a014; Sumi T, 2002, BIOCHEM BIOPH RES CO, V290, P1315, DOI 10.1006/bbrc.2002.6346; Takahashi H, 2002, DEV BIOL, V241, P259, DOI 10.1006/dbio.2001.0512; Taniguchi E, 2002, J BIOL CHEM, V277, P48884, DOI 10.1074/jbc.M206307200; Timmers ACJ, 1999, FEBS LETT, V452, P335, DOI 10.1016/S0014-5793(99)00669-9; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053	42	28	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25223	25230		10.1074/jbc.M603399200	http://dx.doi.org/10.1074/jbc.M603399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16820362	hybrid			2022-12-27	WOS:000240031300023
J	Lee, SJ; Marintcheva, B; Hamdan, SM; Richardson, CC				Lee, Seung-Joo; Marintcheva, Boriana; Hamdan, Samir M.; Richardson, Charles C.			The C-terminal residues of bacteriophage T7 gene 4 helicase-primase coordinate helicase and DNA polymerase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DEOXYRIBONUCLEIC-ACID; STRAND-DISPLACEMENT; ESCHERICHIA-COLI; BINDING PROTEIN; PROCESSIVITY; REPLICATION; DOMAIN; REQUIREMENTS; HYDROLYSIS	The gene 4 protein of bacteriophage T7 plays a central role in DNA replication by providing both helicase and primase activities. The C-terminal helicase domain is not only responsible for DNA-dependent dTTP hydrolysis, translocation, and DNA unwinding, but it also interacts with T7 DNA polymerase to coordinate helicase and polymerase activities. The C-terminal 17 residues of gene 4 protein are critical for its interaction with the T7 DNA polymerase/thioredoxin complex. This C terminus is highly acidic; replacement of these residues with uncharged residues leads to a loss of interaction with T7 DNA polymerase/thioredoxin and an increase in oligomerization of the gene 4 protein. Such an alteration on the C terminus results in a reduced efficiency in strand displacement DNA synthesis catalyzed by gene 4 protein and T7 DNA polymerase/thioredoxin. Replacement of the C-terminal amino acid, phenylalanine, with non-aromatic residues also leads to a loss of interaction of gene 4 protein with T7 DNA polymerase/ thioredoxin. However, neither of these modifications of the C terminus affects helicase and primase activities. A chimeric gene 4 protein containing the acidic C terminus of the T7 gene 2.5 single-stranded DNA-binding protein is more active in strand displacement synthesis. Gene 4 hexamers containing even one subunit of a defective C terminus are defective in their interaction with T7 DNA polymerase.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	ccr@hms.harvard.edu		Hamdan, Samir/0000-0001-5192-1852	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andraos N, 2004, J BIOL CHEM, V279, P50609, DOI 10.1074/jbc.M408428200; Crampton DJ, 2006, MOL CELL, V21, P165, DOI 10.1016/j.molcel.2005.11.027; Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102; HUBER HE, 1986, J BIOL CHEM, V261, P5006; Kamtekar S, 2004, MOL CELL, V16, P609, DOI 10.1016/j.molcel.2004.10.019; KIM YT, 1994, J BIOL CHEM, V269, P5270; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200; Lee SJ, 2001, J BIOL CHEM, V276, P49419, DOI 10.1074/jbc.M108443200; Marintcheva B, 2006, J BIOL CHEM, V281, P25831, DOI 10.1074/jbc.M604601200; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Rodriguez I, 2005, P NATL ACAD SCI USA, V102, P6407, DOI 10.1073/pnas.0500597102; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8	19	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25841	25849		10.1074/jbc.M604602200	http://dx.doi.org/10.1074/jbc.M604602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807231	Green Published, hybrid			2022-12-27	WOS:000240031300086
J	Momcilovic, M; Hong, SP; Carlson, M				Momcilovic, Milica; Hong, Seung-Pyo; Carlson, Marian			Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; FATTY-ACID OXIDATION; KAPPA-B; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; UPSTREAM KINASES; FOOD-INTAKE; LKB1; TAB1; PATHWAYS	The Snf1/AMP-activated protein kinase (AMPK) family is important for metabolic regulation and is highly conserved from yeast to mammals. The upstream kinases are also functionally conserved, and the AMPK kinases LKB1 and Ca2+/calmodulindependent protein kinase kinase activate Snf1 in mutant yeast cells lacking the native Snf1-activating kinases, Sak1, Tos3, and Elm1. Here, we exploited the yeast genetic system to identify members of the mammalian AMPK kinase family by their function as Snf1-activating kinases. A mouse embryo cDNA library in a yeast expression vector was used to transform sak1 Delta tos3 Delta elm1 Delta yeast cells. Selection for a Snf(+) growth phenotype yielded cDNA plasmids expressing LKB1, Ca2+/calmodulin-dependent protein kinase kinase, and transforming growth factor-beta-activated kinase (TAK1), a member of the mitogen-activated protein kinase kinase kinase family. We present genetic and biochemical evidence that TAK1 activates Snf1 protein kinase in vivo and in vitro. We further show that recombinant TAK1, fused to the activation domain of its binding partner TAB1, phosphorylates Thr-172 in the activation loop of the AMPK catalytic domain. Finally, expression of TAK1 and TAB1 in HeLa cells or treatment of cells with cytokines stimulated phosphorylation of Thr-172 of AMPK. These findings indicate that TAK1 is a functional member of the Snf1/AMPK kinase family and support TAK1 as a candidate for an authentic AMPK kinase in mammalian cells.	Columbia Univ, Dept Genet & Dev & Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University	Carlson, M (corresponding author), Columbia Univ, Dept Genet & Dev & Microbiol, 701 W 168th St,HSC922, New York, NY 10032 USA.	mbc1@columbia.edu	Hong, Raymond/R-6915-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK070653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK070653, R21 DK070653] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; BLACKETER MJ, 1993, MOL CELL BIOL, V13, P5567, DOI 10.1128/MCB.13.9.5567; Bouquin N, 2000, J CELL SCI, V113, P1435; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hedbacker K, 2004, MOL CELL BIOL, V24, P8255, DOI 10.1128/MCB.24.18.8255-8263.2004; Hedbacker K, 2004, MOL CELL BIOL, V24, P1836, DOI 10.1128/MCB.24.5.1836-1843.2004; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Sakurai H, 2002, BIOCHEM BIOPH RES CO, V297, P1277, DOI 10.1016/S0006-291X(02)02379-3; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; Sreenivasan A, 2003, MOL CELL BIOL, V23, P6327, DOI 10.1128/MCB.23.17.6327-6337.2003; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; WOODS A, 1994, J BIOL CHEM, V269, P19509; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	57	367	383	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25336	25343		10.1074/jbc.M604399200	http://dx.doi.org/10.1074/jbc.M604399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16835226	hybrid			2022-12-27	WOS:000240031300035
J	Tanaka, M; Okudaira, S; Kishi, Y; Ohkawa, R; Iseki, S; Ota, M; Noji, S; Yatomi, Y; Aoki, J; Arai, H				Tanaka, Masayuki; Okudaira, Shinichi; Kishi, Yasuhiro; Ohkawa, Ryunosuke; Iseki, Sachiko; Ota, Masato; Noji, Sumihare; Yatomi, Yutaka; Aoki, Junken; Arai, Hiroyuki			Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHOLIPASE-D; CELL MOTILITY; IDENTIFICATION; EXPRESSION; SPHINGOSINE-1-PHOSPHATE; METASTASIS; CARCINOMA; MIGRATION; MOTOGEN	Autotaxin (ATX) is a cancer-associated motogen that has multiple biological activities in vitro through the production of bioactive small lipids, lysophosphatidic acid (LPA). ATX and LPA are abundantly present in circulating blood. However, their roles in circulation remain to be solved. To uncover the physiological role of ATX we analyzed ATX knock-out mice. In ATX-null embryos, early blood vessels appeared to form properly, but they failed to develop into mature vessels. As a result ATX-null mice are lethal around embryonic day 10.5. The phenotype is much more severe than those of LPA receptor knock-out mice reported so far. In cultured allantois explants, neither ATX nor LPA was angiogenic. However, both of them helped to maintain preformed vessels by preventing disassembly of the vessels that was not antagonized by Ki16425, an LPA receptor antagonist. In serum from heterozygous mice both lysophospholipase D activity and LPA level were about half of those from wild-type mice, showing that ATX is responsible for the bulk of LPA production in serum. The present study revealed a previously unassigned role of ATX in stabilizing vessels through novel LPA signaling pathways.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Med & Dent Univ, Dept Dev Biol, Grad Sch Dent, Bunkyo Ku, Tokyo 1138549, Japan; Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; University of Tokyo; Tokyo Medical & Dental University (TMDU); Tokushima University; Japan Science & Technology Agency (JST)	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp	Noji, Sumihare/E-3047-2010; Ohkawa, Ryunosuke/C-5402-2017	Ohkawa, Ryunosuke/0000-0002-8584-133X; Aoki, Junken/0000-0001-9435-1896; Yatomi, Yutaka/0000-0003-1719-4297				Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Argraves WS, 2002, DEV DYNAM, V225, P298, DOI 10.1002/dvdy.10162; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Clair T, 2003, CANCER RES, V63, P5446; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Euer N, 2002, ANTICANCER RES, V22, P733; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Iseki S, 1997, DEVELOPMENT, V124, P3375; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Kehlen A, 2004, INT J CANCER, V109, P833, DOI 10.1002/ijc.20022; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kishi Y, 2006, J BIOL CHEM, V281, P17492, DOI 10.1074/jbc.M601803200; Kishimoto T, 2003, CLIN CHIM ACTA, V333, P59, DOI 10.1016/S0009-8981(03)00165-7; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Yang Y, 1999, AM J RESP CELL MOL, V21, P216, DOI 10.1165/ajrcmb.21.2.3667; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Zhang GX, 1999, CHINESE MED J-PEKING, V112, P330; Zhao Z, 1999, Zhonghua Gan Zang Bing Za Zhi, V7, P140	40	365	377	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25822	25830		10.1074/jbc.M605142200	http://dx.doi.org/10.1074/jbc.M605142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829511	hybrid			2022-12-27	WOS:000240031300084
J	Kang, BH; Altieri, DC				Kang, Byoung Heon; Altieri, Dario C.			Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE COMPLEX; AH RECEPTOR; CELL-CYCLE; APOPTOSIS; LOCALIZATION; CHECKPOINT; CANCER; HSP90; XAP2	Survivin is a multifunctional member of the IAP ( inhibitor of apoptosis) family, but its molecular interactions in protection from cell death and regulation of cell division have not been completely elucidated. In a proteomics screening to identify novel survivin-binding partners, we found that the aryl hydrocarbon receptor-interacting protein (AIP) directly associates with survivin in vitro and in co-immunoprecipitation experiments in vivo. This interaction is mediated by the carboxyl-terminal end of AIP, which contains three tetratricopeptide motifs, and involves the carboxyl terminus coiled coil in survivin with critical roles of Asp142 in AIP recognition. A survivin mutant lacking only Asp142 fails to bind AIP and exhibits accelerated degradation in vivo in a reaction reversed by a proteasome inhibitor. Acute knock-down of AIP by short interference RNA or competition of the survivin AIP complex by peptidyl mimicry destabilizes survivin levels in cells, with enhanced apoptosis but no changes in cell cycle progression. Therefore, AIP regulates survivin stability, thus elevating a cellular anti-apoptotic threshold. The survivin-AIP complex may influence the cellular xenobiotic response to environmental toxin(s) and contribute to subcellular chaperone trafficking during cell death regulation.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	Kang, Byoung Heon/E-6165-2010	Kang, Byoung Heon/0000-0001-5902-0549	NATIONAL CANCER INSTITUTE [R01CA078810, R01CA090917] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R37HL054131] Funding Source: NIH RePORTER; NCI NIH HHS [CA78810, CA90917] Funding Source: Medline; NHLBI NIH HHS [HL54131] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Andreola F, 1997, CANCER RES, V57, P2835; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Carver LA, 1997, J BIOL CHEM, V272, P11452; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Earnshaw WC, 2005, SCIENCE, V310, P1443, DOI 10.1126/science.1121952; Fortugno P, 2002, J CELL SCI, V115, P575; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Rodriguez JA, 2002, EXP CELL RES, V275, P44, DOI 10.1006/excr.2002.5492; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wall NR, 2003, CANCER RES, V63, P230; Yang L, 2004, GENE THER, V11, P1215, DOI 10.1038/sj.gt.3302280; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	29	62	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24721	24727		10.1074/jbc.M603175200	http://dx.doi.org/10.1074/jbc.M603175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807248	hybrid			2022-12-27	WOS:000239847800068
J	Melloni, E; Averna, M; Stifanese, R; De Tullio, R; Defranchi, E; Salamino, F; Pontremoli, S				Melloni, Edon; Averna, Monica; Stifanese, Roberto; De Tullio, Roberta; Defranchi, Enrico; Salamino, Franca; Pontremoli, Sandro			Association of calpastatin with inactive calpain - A novel mechanism to control the activation of the protease?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE CALPAIN; ENDOGENOUS INHIBITOR; SKELETAL-MUSCLE; MU-CALPAIN; RAT-BRAIN; CRYSTAL-STRUCTURE; COMPLEX-FORMATION; RABBIT LIVER; KINASE-C; CALCIUM	It is generally accepted that the Ca2+-dependent interaction of calpain with calpastatin is the most relevant mechanism involved in the regulation of Ca2+-induced proteolysis. We now report that a calpain-calpastatin association can occur also in the absence of Ca2+ or at very low Ca2+ concentrations, reflecting the physiological conditions under which calpain retains its inactive conformational state. The calpastatin binding region is localized in the non-inhibitory L-domain containing the amino acid sequences encoded by exons 4 - 7. This calpastatin region recognizes a calpain sequence located near the end of the DII-domain. Interaction of calpain with calpastatins lacking these sequences becomes strictly Ca2+-dependent because, under these conditions, the transition to an active state of the protease is an obligatory requirement. The occurrence of the molecular association between Ca2+-free calpain and various recombinant calpastatin forms has been demonstrated by the following experimental results. Addition of calpastatin protected calpain from trypsin digestion. Calpain was coprecipitated when calpastatin was immunoprecipitated. The calpastatin molecular size increased following exposure to calpain. The two proteins comigrated in zymogram analysis. Furthermore, calpain-calpastatin interaction was perturbed by protein kinase C phosphorylation occurring at sites located at the exons involved in the association. At a functional level, calpain-calpastatin interaction at a physiological concentration of Ca2+ represents a novel mechanism for the control of the amount of the active form of the protease potentially generated in response to an intracellular Ca2+ influx.	Univ Genoa, Biochem Sect, Dept Expt Med, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy	University of Genoa; University of Genoa	Pontremoli, S (corresponding author), Univ Genoa, Biochem Sect, Dept Expt Med, Viale Benedetto 15, I-16132 Genoa, Italy.	pontremoli@unige.it	AVERNA, MONICA/R-5719-2019	AVERNA, MONICA/0000-0002-9463-7533; DE TULLIO, ROBERTA/0000-0001-6925-3207				ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; Averna M, 2006, FEBS J, V273, P1660, DOI 10.1111/j.1742-4658.2006.05180.x; Averna M, 1999, FEBS LETT, V450, P13, DOI 10.1016/S0014-5793(99)00461-5; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Barnoy S, 1999, J CELL BIOCHEM, V74, P522, DOI 10.1002/(SICI)1097-4644(19990915)74:4<522::AID-JCB2>3.0.CO;2-I; Betts R, 2004, BIOCHEMISTRY-US, V43, P2596, DOI 10.1021/bi0359832; Betts R, 2003, J BIOL CHEM, V278, P7800, DOI 10.1074/jbc.M208350200; Brandenburg K, 2002, EUR J BIOCHEM, V269, P5414, DOI 10.1046/j.1432-1033.2002.03225.x; COTTIN P, 1981, FEBS LETT, V136, P221, DOI 10.1016/0014-5793(81)80622-9; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dainese E, 2002, J BIOL CHEM, V277, P40296, DOI 10.1074/jbc.M204471200; De Tullio R, 1998, FEBS LETT, V422, P113, DOI 10.1016/S0014-5793(97)01588-3; De Tullio R, 1999, BIOCHEM J, V343, P467; Doroshenko N, 2004, BIOCHEM PHARMACOL, V67, P903, DOI 10.1016/j.bcp.2003.10.005; Dutt P, 2002, BIOCHEM J, V367, P263, DOI 10.1042/BJ20020485; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; EMORI Y, 1988, J BIOL CHEM, V263, P2364; Fabrice R, 2006, INT J BIOCHEM CELL B, V38, P404, DOI 10.1016/j.biocel.2005.09.020; FAHIEN LA, 1974, J BIOL CHEM, V249, P2696; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; GOLL DE, 1992, BIOCHIMIE, V74, P225, DOI 10.1016/0300-9084(92)90121-T; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; IMAJOH S, 1985, FEBS LETT, V187, P47, DOI 10.1016/0014-5793(85)81211-4; ISHIDA S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WJ, 1992, J BIOL CHEM, V267, P8437; LEE WJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P251, DOI 10.1016/0167-4781(92)90500-Y; MA H, 1994, J BIOL CHEM, V269, P24430; MACGREGOR JS, 1980, P NATL ACAD SCI-BIOL, V77, P3889, DOI 10.1073/pnas.77.7.3889; Maddock KR, 2005, J ANIM SCI, V83, P1370; Melloni E, 1998, FEBS LETT, V431, P55, DOI 10.1016/S0014-5793(98)00724-8; Michetti M, 1997, BIOCHEM J, V325, P721, DOI 10.1042/bj3250721; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; Moldoveanu T, 2003, NAT STRUCT BIOL, V10, P371, DOI 10.1038/nsb917; Moldoveanu T, 2001, BBA-PROTEIN STRUCT M, V1545, P245, DOI 10.1016/S0167-4838(00)00286-7; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; MURACHI T, 1989, BIOCHEM INT, V18, P263; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; Parr T, 2001, ARCH BIOCHEM BIOPHYS, V395, P1, DOI 10.1006/abbi.2001.2546; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; PONTREMOLI S, 1991, ARCH BIOCHEM BIOPHYS, V288, P646, DOI 10.1016/0003-9861(91)90247-G; PONTREMOLI S, 1984, P NATL ACAD SCI-BIOL, V81, P53, DOI 10.1073/pnas.81.1.53; RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284; Salamino F, 1997, FEBS LETT, V412, P433, DOI 10.1016/S0014-5793(97)00819-3; SHIGETA K, 1984, BIOCHEM INT, V9, P327; Simon J., 2000, CALPAIN METHODS PROT, P109; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; Takano J, 1999, BIOCHEM BIOPH RES CO, V260, P339, DOI 10.1006/bbrc.1999.0903; Takano J, 2000, J BIOCHEM, V128, P83, DOI 10.1093/oxfordjournals.jbchem.a022733; Temm-Grove CJ, 1999, EXP CELL RES, V247, P293, DOI 10.1006/excr.1998.4362; Tompa P, 2002, J BIOL CHEM, V277, P9022, DOI 10.1074/jbc.C100700200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054	61	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24945	24954		10.1074/jbc.M601449200	http://dx.doi.org/10.1074/jbc.M601449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803906	hybrid			2022-12-27	WOS:000239847800087
J	Myers, SA; Wang, SCM; Muscat, GEO				Myers, Stephen A.; Wang, S. -C. Mary; Muscat, George E. O.			The chicken ovalbumin upstream promoter-transcription factors modulate genes and pathways involved in skeletal muscle cell metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; OXYGEN SPECIES PRODUCTION; ACTIVATED RECEPTOR-ALPHA; RETINOID-X-RECEPTOR; UNCOUPLING PROTEIN-3; NUCLEAR RECEPTORS; LIPID-METABOLISM; COUP-TFII; ORPHAN RECEPTOR; CROSS-TALK	The chicken ovalbumin upstream promoter-transcription factors ( COUP-TFs) are "orphan" members of the nuclear hormone receptor ( NR) superfamily. COUP-TFs are involved in organogenesis and neurogenesis. However, their role in skeletal muscle ( and other major mass tissues) and metabolism remains obscure. Skeletal muscle accounts for similar to 40% of total body mass and energy expenditure. Moreover, this peripheral tissue is a primary site of glucose and fatty acid utilization. We utilize small interfering RNA ( siRNA)-mediated attenuation of Coup-TfI and II ( mRNA and protein) in a skeletal muscle cell culture model to understand the regulatory role of Coup-Tfs in this energy demanding tissue. This targeted NR repression resulted in the significant attenuation of genes that regulate lipid mobilization and utilization ( including Ppar alpha, Fabp3, and Cpt-1). This was coupled to reduced fatty acid beta-oxidation. Additionally we observed significant attenuation of Ucp1, a gene involved in energy expenditure. Concordantly, we observed a 5-fold increase in ATP levels in cells with siRNA-mediated repression of Coup-TfI and II. Furthermore, the expression of "classical" liver X receptor ( LXR) target genes involved in reverse cholesterol transport ( Abca1 and Abcg1) were both significantly repressed. Moreover, we observed that repression of the Coup-Tfs ablated the activation of Abca1, and Abcg1 mRNA expression by the selective LXR agonist, T0901317. In concordance, Coup-Tf-siRNA-transfected cells were refractory to Lxr-mediated reduction of total intracellular cholesterol levels in contrast to the negative control cells. In agreement Lxr-mediated activation of the Abca1 promoter in Coup-Tf-siRNA cells was attenuated. Collectively, these data suggest a pivotal role for Coup-Tfs in the regulation of lipid utilization/cholesterol homeostasis in skeletal muscle cells and the modulation of Lxr-dependent gene regulation.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Myers, SA (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	s.myers@imb.uq.edu.au; g.muscat@imb.uq.edu.au	; Muscat, George/A-6401-2017; Wang, Shu-Ching/C-6082-2017	Myers, Stephen/0000-0003-4793-3820; Muscat, George/0000-0002-5829-5695; Wang, Shu-Ching/0000-0002-7871-3735				Anderson SP, 2004, MOL PHARMACOL, V66, P1440, DOI 10.1124/mol.104.005496; Ando H, 2005, ATHEROSCLEROSIS, V178, P265, DOI 10.1016/j.atherosclerosis.2004.09.016; Bardoux P, 2005, DIABETES, V54, P1357, DOI 10.2337/diabetes.54.5.1357; Bevilacqua L, 2005, AM J PHYSIOL-ENDOC M, V289, pE429, DOI 10.1152/ajpendo.00435.2004; Blanco G, 2004, NEUROMUSCULAR DISORD, V14, P217, DOI 10.1016/j.nmd.2003.09.008; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Chabowski A, 2005, J PHYSIOL PHARMACOL, V56, P381; Cooney AJ, 2001, TRENDS ENDOCRIN MET, V12, P247, DOI 10.1016/S1043-2760(01)00424-6; Crestani M, 1998, J LIPID RES, V39, P2192; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Ferrer-Martinez A, 2004, BBA-GENE STRUCT EXPR, V1678, P157, DOI 10.1016/j.bbaexp.2004.02.003; Furmanczyk PS, 2003, CELL BIOL INT, V27, P845, DOI 10.1016/S1065-6995(03)00172-0; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; GAUDET F, 1995, J BIOL CHEM, V270, P29916; Gonzalez-Muniesa P, 2005, J PHYSIOL BIOCHEM, V61, P389, DOI 10.1007/BF03167056; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gupta S, 2002, BIOCHEM BIOPH RES CO, V293, P338, DOI 10.1016/S0006-291X(02)00229-2; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hegardt FG, 1998, BIOCHIMIE, V80, P803, DOI 10.1016/S0300-9084(00)88874-4; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; HOSHIZAKI DK, 1994, DEVELOPMENT, V120, P2489; Kontani Y, 2005, AGING CELL, V4, P147, DOI 10.1111/j.1474-9726.2005.00157.x; KontrogianniKonstantopoulos A, 1996, DEV BIOL, V177, P371, DOI 10.1006/dbio.1996.0171; Koonen DPY, 2005, BBA-MOL CELL BIOL L, V1736, P163, DOI 10.1016/j.bbalip.2005.08.018; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lau P, 2004, J BIOL CHEM, V279, P36828, DOI 10.1074/jbc.M404927200; Lee CT, 2004, MOL CELL BIOL, V24, P10835, DOI 10.1128/MCB.24.24.10835-10843.2004; Lengacher S, 2004, J CEREBR BLOOD F MET, V24, P780, DOI 10.1097/01.WCB.0000122743.72175.52; MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343; Maxwell MA, 2005, J BIOL CHEM, V280, P12573, DOI 10.1074/jbc.M409580200; Menke JG, 2002, ENDOCRINOLOGY, V143, P2548, DOI 10.1210/en.143.7.2548; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; MUSCAT GEO, 1995, NUCLEIC ACIDS RES, V23, P1311, DOI 10.1093/nar/23.8.1311; Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200; Nakamura T, 1999, J LIPID RES, V40, P1709; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Plomgaard P, 2005, EXERC IMMUNOL REV, V11, P53; QIU Y, 1995, GENOMICS, V29, P240, DOI 10.1006/geno.1995.1237; Quinn LBS, 2005, CELL BIOL INT, V29, P449, DOI 10.1016/j.cellbi.2005.02.005; QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669; Ramakrishnan SN, 2005, J BIOL CHEM, V280, P8651, DOI 10.1074/jbc.M413949200; Schmitt B, 2003, PHYSIOL GENOMICS, V15, P148, DOI 10.1152/physiolgenomics.00089.2003; Schmitz G, 2005, BBA-MOL CELL BIOL L, V1735, P1, DOI 10.1016/j.bbalip.2005.04.004; Schrauwen P, 2004, P NUTR SOC, V63, P287, DOI 10.1079/PNS2003336; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Smith AG, 2005, INT J BIOCHEM CELL B, V37, P2047, DOI 10.1016/j.biocel.2005.03.002; Stroup D, 2000, J LIPID RES, V41, P1; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Stroup D, 1997, J BIOL CHEM, V272, P9833; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Wang S, 2003, DIABETES OBES METAB, V5, P295, DOI 10.1046/j.1463-1326.2003.00273.x; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	55	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24149	24160		10.1074/jbc.M601941200	http://dx.doi.org/10.1074/jbc.M601941200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803904	hybrid			2022-12-27	WOS:000239847800009
J	Qiao, LP; MacDougald, OA; Shao, JH				Qiao, Liping; MacDougald, Ormond A.; Shao, Jianhua			CCAAT/enhancer-binding protein alpha mediates induction of hepatic phosphoenolpyruvate carboxykinase by p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESISTANCE; GENE-TRANSCRIPTION; GTP GENE; LIVER; GLUCOSE; STRESS; GLUCONEOGENESIS; INFLAMMATION; EXPRESSION; ENHANCER	Excessive hepatic gluconeogenesis and glucose production are important contributors to hyperglycemia in both type 1 and type 2 diabetes. In diabetic humans and animal models, elevated levels of p38 mitogen-activated protein kinase (p38) are observed in several tissues. Our study shows that activity of p38 is significantly elevated in livers of db/db or streptozocin-induced type 1 diabetic mice. Using cultured hepatoma cells, we find that activation of p38 enhances expression of hepatic gluconeogenic gene phosphoenolpyruvate carboxykinase (PEPCK). Furthermore, our studies demonstrate that activation of p38 stimulates phosphorylation of CCAAT/enhancer-binding protein alpha (C/EBP alpha) at serine 21 and increases its transactivation activity in the context of PEPCK gene transcription. Our results indicate that C/EBP alpha mediates p38-stimulated PEPCK transcription in liver cells.	Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Kentucky; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Shao, JH (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, 900 S Limestone, Lexington, KY 40536 USA.	JianhuaShao@uky.edu		MacDougald, Ormond/0000-0001-6907-7960				Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Cheong J, 1998, J BIOL CHEM, V273, P22714, DOI 10.1074/jbc.273.35.22714; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; DEFRONZO RA, 1982, DIABETOLOGIA, V23, P313; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Feifel E, 2002, AM J PHYSIOL-RENAL, V283, pF678, DOI 10.1152/ajprenal.00097.2002; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Gum RJ, 2003, MOL ENDOCRINOL, V17, P1131, DOI 10.1210/me.2002-0288; Hanson RW, 2005, J BIOL CHEM, V280, P1705, DOI 10.1074/jbc.X400009200; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; Kondo T, 2004, J BIOL CHEM, V279, P37997, DOI 10.1074/jbc.M401339200; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIU JS, 1991, J BIOL CHEM, V266, P19095; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Qiao LP, 2006, ENDOCRINOLOGY, V147, P3060, DOI 10.1210/en.2005-1507; Qiao LP, 2005, DIABETES, V54, P1744, DOI 10.2337/diabetes.54.6.1744; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Shao JH, 2005, DIABETES, V54, P976, DOI 10.2337/diabetes.54.4.976; Srinivasan S, 2004, J BIOL CHEM, V279, P31930, DOI 10.1074/jbc.M400753200; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Wang D, 2006, ENDOCRINOLOGY, V147, P350, DOI 10.1210/en.2005-1014; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wei YR, 2004, AM J PHYSIOL-ENDOC M, V287, pE926, DOI 10.1152/ajpendo.00185.2004; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	39	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24390	24397		10.1074/jbc.M603038200	http://dx.doi.org/10.1074/jbc.M603038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807249	hybrid			2022-12-27	WOS:000239847800032
J	Yang, MH; Mailhot, G; Birnbaum, MJ; MacKay, CA; Mason-Savas, A; Odgren, PR				Yang, Meiheng; Mailhot, Genevieve; Birnbaum, Mark J.; MacKay, Carole A.; Mason-Savas, April; Odgren, Paul R.			Expression of and role for ovarian cancer G-protein-coupled receptor 1 (OGR1) during osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CAMP ACCUMULATION; IN-VITRO; BONE; RAT; LIGAND; ACID; SPHINGOSYLPHOSPHORYLCHOLINE; DIFFERENTIATION; IDENTIFICATION	Osteoclasts differentiate from hematopoietic mononuclear precursor cells under the control of both colony stimulating factor-1 (CSF-1, or M-CSF) and receptor activator of NF-kappa B ligand (RANKL, or TRANCE, TNFSF11) to carry out bone resorption. Using high density gene microarrays, we followed gene expression changes in long bone RNA when CSF-1 injections were used to restore osteoclast populations in the CSF1-null toothless (csf1(tl)/csf1(tl)) osteopetrotic rat. We found that ovarian cancer G-protein-coupled receptor 1 (OGR1, or GPR68) was strongly up-regulated, rising > 6-fold in vivo after 2 days of CSF-1 treatments. OGR1 is a dual membrane receptor for both protons (extracellular pH) and lysolipids. Strong induction of OGR1 mRNA was also observed by microarray, real-time RT-PCR, and immunoblotting when mouse bone marrow mononuclear cells and RAW 264.7 pre-osteoclast-like cells were treated with RANKL to induce osteoclast differentiation. Anti-OGR1 immunofluorescence showed intense labeling of RANKL-treated RAW cells. The time course of OGR1 mRNA expression suggests that OGR1 induction is early but not immediate, peaking 2 days after inducing osteoclast differentiation both in vivo and in vitro. Specific inhibition of OGR1 by anti-OGR1 antibody and by small inhibitory RNA inhibited RANKL-induced differentiation of both mouse bone marrow mononuclear cells and RAW cells in vitro, as evidenced by a decrease in tartrate-resistant acid phosphatase-positive osteoclasts. Taken together, these data indicate that OGR1 is expressed early during osteoclastogenesis both in vivo and in vitro and plays a role in osteoclast differentiation.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Merrimack Coll, Dept Biol, N Andover, MA 01845 USA	University of Massachusetts System; University of Massachusetts Worcester; Merrimack College	Odgren, PR (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, S7-242,55 Lake Ave N, Worcester, MA 01655 USA.	paul.odgren@umassmed.edu	Mailhot, Genevieve/AAL-1310-2020; Mailhot, Genevieve/AAB-8928-2020	Mailhot, Genevieve/0000-0002-2673-6492; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE007444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE07444] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balemans W, 2005, CALCIFIED TISSUE INT, V77, P263, DOI 10.1007/s00223-005-0027-6; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Dobbins DE, 2002, BIOCHEM BIOPH RES CO, V294, P1114, DOI 10.1016/S0006-291X(02)00598-3; Frick KK, 2005, AM J PHYSIOL-RENAL, V289, pF1005, DOI 10.1152/ajprenal.00420.2004; Frick KK, 2003, J BONE MINER RES, V18, P1317, DOI 10.1359/jbmr.2003.18.7.1317; Jahr H, 2005, BIOCHEM BIOPH RES CO, V337, P349, DOI 10.1016/j.bbrc.2005.09.054; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102; Lemann J, 2003, AM J PHYSIOL-RENAL, V285, pF811, DOI 10.1152/ajprenal.00115.2003; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Mogi C, 2005, J PHARMACOL SCI, V99, P160, DOI 10.1254/jphs.FP0050599; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; Tomura H, 2005, J BIOL CHEM, V280, P34458, DOI 10.1074/jbc.M505287200; Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Xu Y, 2006, NAT CELL BIOL, V8, P299; Yang MH, 2006, BLOOD, V107, P2262, DOI 10.1182/blood-2005-08-3365; Yang MH, 2005, CYTOKINE, V31, P94, DOI 10.1016/j.cyto.2005.04.001	20	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23598	23605		10.1074/jbc.M602191200	http://dx.doi.org/10.1074/jbc.M602191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787916	hybrid			2022-12-27	WOS:000239702900034
J	Balsara, RD; Castellino, FJ; Ploplis, VA				Balsara, Rashna D.; Castellino, Francis J.; Ploplis, Victoria A.			A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED-PROTEIN; GENE DEFICIENT MICE; NF-KAPPA-B; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; TUMOR-GROWTH; APOPTOSIS; SURVIVAL; KINASE; PROLIFERATION	Cell proliferation, an event associated with angiogenesis, involves coordinated activities of a number of proteins. The role of plasminogen activator inhibitor-1 (PAI-1) in angiogenesis remains controversial. Utilizing proliferating PAI-1(-/-) endothelial cells (EC), the impact of a host PAI-1 deficiency on Akt activation was evaluated. Hyperactivation of Akt(Ser(P)(473)) was observed in PAI-1(-/-) EC, and this was probably due to enhanced inactivation of tumor suppressor PTEN, thus rendering the cells resistant to apoptotic signals. Higher levels of inactivated caspase-9 in PAI-1(-/-) EC led to lower levels of procaspase-3 and cleaved caspase-3, thereby promoting survival. These effects were reversed when recombinant PAI-1 was added to PAI-1(-/-) EC. Additional studies demonstrated that regulation of proliferation is dependent on its interaction with low density lipoprotein receptor-related protein. Thus, PAI-1 is a negative regulator of cell growth, exerting its effect on the phosphatidylinositol 3-kinase/Akt pathway and allowing controlled cell proliferation.	Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Notre Dame Canc Inst, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame; University of Notre Dame	Ploplis, VA (corresponding author), Univ Notre Dame, WM Keck Ctr Transgene Res, 230 Raclin Carmicheal Hall, Notre Dame, IN 46556 USA.	vploplis@nd.edu						Al-Fakhri N, 2003, BIOL CHEM, V384, P423, DOI 10.1515/BC.2003.048; Almholt K, 2003, ONCOGENE, V22, P4389, DOI 10.1038/sj.onc.1206601; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Bajou K, 2004, ONCOGENE, V23, P6986, DOI 10.1038/sj.onc.1207859; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Blatt NB, 2001, BIOORGAN MED CHEM, V9, P1371, DOI 10.1016/S0968-0896(01)00041-4; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Chen YB, 2004, J CELL BIOCHEM, V92, P178, DOI 10.1002/jcb.20058; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Dimmeler S, 2000, CIRC RES, V87, P434; Eitzman DT, 1996, BLOOD, V87, P4718; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gutierrez LS, 2000, CANCER RES, V60, P5839; Harbeck N, 2000, INT J BIOL MARKER, V15, P79, DOI 10.1177/172460080001500115; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khor TO, 2004, CANCER LETT, V210, P139, DOI 10.1016/j.canlet.2004.01.017; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; Ploplis VA, 2004, J BIOL CHEM, V279, P6143, DOI 10.1074/jbc.M307297200; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Salameh A, 2005, BLOOD, V106, P3423, DOI 10.1182/blood-2005-04-1388; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Soeda S, 2001, MOL BRAIN RES, V91, P96, DOI 10.1016/S0169-328X(01)00133-4; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Sudarshan C, 1998, J CELL PHYSIOL, V176, P67, DOI 10.1002/(SICI)1097-4652(199807)176:1<67::AID-JCP8>3.0.CO;2-6; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang HT, 2005, HEPATOLOGY, V42, P1099, DOI 10.1002/hep.20903; WILLNOW TE, 1994, J CELL SCI, V107, P719; Xu Z, 2004, J BIOL CHEM, V279, P17914, DOI 10.1074/jbc.M314197200; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	59	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22527	22536		10.1074/jbc.M512819200	http://dx.doi.org/10.1074/jbc.M512819200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785241	hybrid			2022-12-27	WOS:000239542600013
J	Xu, WL; Dunn, CA; O'Handley, SF; Smith, DL; Bessman, MJ				Xu, Wenlian; Dunn, Christopher A.; O'Handley, Suzanne F.; Smith, Denise L.; Bessman, Maurice J.			Three new nudix hydrolases from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC DOMAIN; ADP-RIBOSE; STREPTOCOCCUS-PNEUMONIAE; MUTT FAMILY; GENE; PYROPHOSPHATASE; PURIFICATION; ENZYMES; IDENTIFICATION; SUBFAMILY	Three members of the Nudix (nucleoside diphosphate X) hydrolase superfamily have been cloned from Escherichia coli MG1655 and expressed. The proteins have been purified and identified as enzymes active on nucleoside diphosphate derivatives with the following specificities. Orf141 (yfaO) is a nucleoside triphosphatase preferring pyrimidine deoxynucleoside triphosphates. Orf153 (ymfB) is a nonspecific nucleoside tri- and diphosphatase and atypically releases inorganic orthophosphate from triphosphates instead of pyrophosphate. Orf191 (yffH) is a highly active GDP-mannose pyrophosphatase. All three enzymes require a divalent cation for activity and are optimally active at alkaline pH, characteristic of the Nudix hydrolase superfamily. The question of whether or not Orf1.9 (wcaH) is a bona fide member of the Nudix hydrolase superfamily is discussed.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	zoot@jhu.edu		O'Handley, Suzanne/0000-0001-8373-0065; Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bessman MJ, 2001, J BIOL CHEM, V276, P37834; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Cartwright JL, 2000, J BIOL CHEM, V275, P32925, DOI 10.1074/jbc.M005015200; Ciesla WP, 1998, J BIOL CHEM, V273, P16021, DOI 10.1074/jbc.273.26.16021; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Legler PM, 2000, BIOCHEMISTRY-US, V39, P8603, DOI 10.1021/bi000537p; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; O'Handley SF, 2001, J BIOL CHEM, V276, P5421, DOI 10.1074/jbc.M004100200; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Ranatunga W, 2004, J MOL BIOL, V339, P103, DOI 10.1016/j.jmb.2004.01.065; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; Xu WL, 2004, J BIOL CHEM, V279, P24861, DOI 10.1074/jbc.M403272200; Xu WL, 2003, J BIOL CHEM, V278, P37492, DOI 10.1074/jbc.M307639200	25	30	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22794	22798		10.1074/jbc.M603407200	http://dx.doi.org/10.1074/jbc.M603407200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766526	hybrid			2022-12-27	WOS:000239542600040
J	Zhang, Y; Lyver, ER; Knight, SAB; Pain, D; Lesuisse, E; Dancis, A				Zhang, Yan; Lyver, Elise R.; Knight, Simon A. B.; Pain, Debkumar; Lesuisse, Emmanuel; Dancis, Andrew			Mrs3p, Mrs4p, and frataxin provide iron for Fe-S cluster synthesis in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST FRATAXIN; CRYSTAL-STRUCTURE; PROTEIN IMPORT; BIOGENESIS; DEFICIENCY; HOMOLOG; ACCUMULATION; ACONITASE; CARRIERS; YFH1P	Yeast Mrs3p and Mrs4p are evolutionarily conserved mitochondrial carrier proteins that transport iron into mitochondria under some conditions. Yeast frataxin (Yfh1p), the homolog of the human protein implicated in Friedreich ataxia, is involved in iron homeostasis. However, its precise functions are controversial. Anaerobically grown triple mutant cells (Delta mrs3/4/Delta yfh1) displayed a severe growth defect corrected by in vivo iron supplementation. Because anaerobically grown cells do not synthesize heme, and they do not experience oxidative stress, this growth defect was most likely due to Fe-S cluster deficiency. Fe-S cluster formation was assessed in anaerobically grown cells shifted to air for a brief period. In isolated mitochondria, Fe-S clusters were detected on newly imported yeast ferredoxin precursor and on endogenous aconitase by means of [S-35]cysteine labeling and native gel separation. New cluster formation was dependent on iron addition to mitochondria, and the iron concentration dependence was shifted dramatically upward in the Delta mrs3/4 mutant, indicating a role of Mrs3/4p in iron transport. The frataxin mutant strain lacked protein import capacity because of low mitochondrial membrane potential, although this was partially restored by growth in the presence of high iron. Under these conditions, a kinetic defect in new Fe-S cluster formation was still noted. Import of frataxin into frataxin-minus isolated mitochondria promptly corrected the Fe-S cluster assembly defect without further iron addition. These findings show that Mrs3/4p transports iron into mitochondria, whereas frataxin makes iron already within mitochondria available for Fe-S cluster synthesis.	Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, Newark, NJ 07101 USA; Univ Paris 06, CNRS, Lab Ingn Prot & Controle Metab, Dept Biol Genomes,Inst Jacques Monod,UMR 7592, F-75251 Paris 05, France; Univ Paris 07, CNRS, Lab Ingn Prot & Controle Metab, Dept Biol Genomes,Inst Jacques Monod,UMR 7592, F-75251 Paris 05, France	University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.	adancis@mail.med.upenn.edu	Zhang, Yan/K-1638-2015	Zhang, Yan/0000-0003-2031-0631; Knight, Simon/0000-0001-7407-3390	NIDDK NIH HHS [DK43593] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Aloria K, 2004, EMBO REP, V5, P1096, DOI 10.1038/sj.embor.7400272; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Campanella A, 2004, HUM MOL GENET, V13, P2279, DOI 10.1093/hmg/ddh232; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Geissler A, 2000, MOL BIOL CELL, V11, P3977, DOI 10.1091/mbc.11.11.3977; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; He YN, 2004, BIOCHEMISTRY-US, V43, P16254, DOI 10.1021/bi0488193; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; Irazusta V, 2006, J BIOL CHEM, V281, P12227, DOI 10.1074/jbc.M511649200; Jacobson ES, 2005, MYCOPATHOLOGIA, V159, P1, DOI 10.1007/s11046-004-2223-8; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Li FY, 2001, FEBS LETT, V494, P79, DOI 10.1016/S0014-5793(01)02319-5; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Robinson AJ, 2006, P NATL ACAD SCI USA, V103, P2617, DOI 10.1073/pnas.0509994103; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Shaw GC, 2006, NATURE, V440, P96, DOI 10.1038/nature04512; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Yang M, 2006, EMBO J, V25, P1775, DOI 10.1038/sj.emboj.7601064; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Zhang Y, 2005, J BIOL CHEM, V280, P19794, DOI 10.1074/jbc.M500397200; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	42	81	82	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22493	22502		10.1074/jbc.M604246200	http://dx.doi.org/10.1074/jbc.M604246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769722	hybrid			2022-12-27	WOS:000239542600010
J	Bagaria, A; Surendranath, K; Ramagopal, UA; Ramakumar, S; Karande, AA				Bagaria, Ashima; Surendranath, Kalpana; Ramagopal, Udupi A.; Ramakumar, Suryanarayanarao; Karande, Anjali A.			Structure-function analysis and insights into the reduced toxicity of Abrus precatorius agglutinin I in relation to abrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEIN; RICIN A-CHAIN; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; CELL-DEATH; MECHANISM; APOPTOSIS; TOXINS; REFINEMENT; ANGSTROM	Abrin and agglutinin-I from the seeds of Abrus precatorius are type II ribosome-inactivating proteins that inhibit protein synthesis in eukaryotic cells. The two toxins share a high degree of sequence similarity; however, agglutinin-I is weaker in its activity. We compared the kinetics of protein synthesis inhibition by abrin and agglutinin-I in two different cell lines and found that similar to 200-2000-fold higher concentration of agglutinin-I is needed for the same degree of inhibition. Like abrin, agglutinin-I also induced apoptosis in the cells by triggering the intrinsic mitochondrial pathway, although at higher concentrations as compared with abrin. The reason for the decreased toxicity of agglutinin-I became apparent on the analysis of the crystal structure of agglutinin-I obtained by us in comparison with that of the reported structure of abrin. The overall protein folding of agglutinin-I is similar to that of abrin-a with a single disulfide bond holding the toxic A subunit and the lectin-like B-subunit together, constituting a heterodimer. However, there are significant differences in the secondary structural elements, mostly in the A chain. The substitution of Asn-200 in abrin-a with Pro-199 in agglutinin-I seems to be a major cause for the decreased toxicity of agglutinin-I. This perhaps is not a consequence of any kink formation by a proline residue in the helical segment, as reported by others earlier, but due to fewer interactions that proline can possibly have with the bound substrate.	Indian Inst Sci, Dept Phys, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Bioinformat Ctr, Bangalore 560012, Karnataka, India; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Yeshiva University; Albert Einstein College of Medicine	Ramakumar, S (corresponding author), Indian Inst Sci, Dept Phys, Bangalore 560012, Karnataka, India.	ramak@physics.iisc.ernet.in; anjali@biochem.iisc.ernet.in	Karande, Anjali/C-4880-2009	Bagaria, Ashima/0000-0003-0666-1945; surendranath, kalpana/0000-0002-2915-5001				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bantel H, 1999, CANCER RES, V59, P2083; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; Bolognesi A, 1996, INT J CANCER, V68, P349, DOI 10.1002/(SICI)1097-0215(19961104)68:3<349::AID-IJC13>3.0.CO;2-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Day PJ, 2001, J BIOL CHEM, V276, P7202, DOI 10.1074/jbc.M009499200; Delano W., 2002, PYMOL VERSION 0 99; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Foster DB, 2000, INFECT IMMUN, V68, P3108, DOI 10.1128/IAI.68.6.3108-3115.2000; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004; HEGDE R, 1993, EUR J BIOCHEM, V215, P411, DOI 10.1111/j.1432-1033.1993.tb18048.x; HEGDE R, 1991, ANAL BIOCHEM, V194, P101, DOI 10.1016/0003-2697(91)90156-N; HOSUR MV, 1995, J MOL BIOL, V250, P368, DOI 10.1006/jmbi.1995.0383; HUNG CH, 1993, J MOL BIOL, V229, P263, DOI 10.1006/jmbi.1993.1029; HUSAIN J, 1994, FEBS LETT, V342, P154, DOI 10.1016/0014-5793(94)80491-5; Kim MK, 1999, PROTEIN SCI, V8, P1492, DOI 10.1110/ps.8.7.1492; Kitaoka Y, 1998, EUR J BIOCHEM, V257, P255, DOI 10.1046/j.1432-1327.1998.2570255.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LIN JY, 1981, TOXICON, V19, P41; Liu CL, 2000, J BIOL CHEM, V275, P1897, DOI 10.1074/jbc.275.3.1897; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Mishra V, 2004, ACTA CRYSTALLOGR D, V60, P2295, DOI 10.1107/S0907444904023534; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Narayanan S, 2004, BIOCHEM J, V377, P233, DOI 10.1042/BJ20030797; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niwa H, 2003, EUR J BIOCHEM, V270, P2739, DOI 10.1046/j.1432-1033.2003.03646.x; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Olsnes S, 2004, TOXICON, V44, P361, DOI 10.1016/j.toxicon.2004.05.003; Panneerselvam K, 2000, ACTA CRYSTALLOGR D, V56, P898, DOI 10.1107/S0907444900005047; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; READY M, 1984, J BIOL CHEM, V259, P5252; READY MP, 1991, PROTEINS, V10, P270, DOI 10.1002/prot.340100311; REDDY VVS, 1969, CANCER RES, V29, P1447; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sharma S, 1999, MOL CELL BIOCHEM, V200, P133, DOI 10.1023/A:1007043218769; Shih SF, 2001, J BIOL CHEM, V276, P21870, DOI 10.1074/jbc.M100571200; SPERTI S, 1973, BIOCHEM J, V136, P813, DOI 10.1042/bj1360813; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; Thorburn J, 2003, CLIN CANCER RES, V9, P861; WEI CH, 1975, J BIOL CHEM, V250, P4790; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Zhu HB, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-27	58	63	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34465	34474		10.1074/jbc.M601777200	http://dx.doi.org/10.1074/jbc.M601777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16772301	Green Accepted, hybrid			2022-12-27	WOS:000241767600067
J	Wu, CC; Gardarin, A; Martel, A; Mintz, E; Guillain, F; Catty, P				Wu, Chen-Chou; Gardarin, Aurelie; Martel, Anne; Mintz, Elisabeth; Guillain, Florent; Catty, Patrice			The cadmium transport sites of CadA, the Cd2+-ATPase from Listeria monocytogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; METAL-BINDING DOMAIN; MEMBRANE H+-ATPASE; SARCOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; DISEASE MUTATION; STRUCTURAL BASIS; CA2+-ATPASE; MECHANISM; CA2+	CadA, the Cd2(+)- ATPase from Listeria monocytogenes, belongs to the Zn2(+)/ Cd2(+)/ Pb2(+)- ATPase bacterial subfamily of P-1B-ATPases that ensure detoxification of the bacteria. Whereas it is the major determinant of Listeria resistance to Cd2+, CadA expressed in Saccharomyces cerevisiae severely decreases yeast tolerance to Cd2+ ( Wu, C. C., Bal, N., Perard, J., Lowe, J., Boscheron, C., Mintz, E., and Catty, P. ( 2004) Biochem. Biophys. Res. Commun. 324, 1034 - 1040). This phenotype, which reflects in vivo Cd2+- transport activity, was used to select from 33 point mutations, shared out among the eight transmembrane ( TM) segments of CadA, those that affect the activity of the protein. Six mutations affecting CadA were found: M149A in TM3; E164A in TM4; C354A, P355A, and C356A in TM6; and D692A in TM8. Functional studies of the six mutants produced in Sf9 cells revealed that Cys(354) and Cys(356) in TM6 as well as Asp(692) in TM8 and Met149 in TM3 could participate at the Cd2+- binding site( s). In the canonical Cys- Pro- Cys motif of P-1B- ATPases, the two cysteines act at distinct steps in the transport mechanism, Cys(354) being directly involved in Cd2+ binding, while Cys356 seems to be required for Cd2+ occlusion. This confirms an earlier observation that the two equivalent Cys of Ccc2, the yeast Cu+- ATPase, also act at different steps. In TM4, Glu(164), which is conserved among P1B- ATPases, may be required for Cd2+ release. Finally, analysis of the role of Cd2+ in the phosphorylation from ATP and from Pi of the mutants suggests that two Cd2+ ions are involved in the reaction cycle of CadA.	Univ Grenoble 1, CEA CNRS, UMR 5090,Commissariat Energie Atom,Direct Sci Viv, Lab Biophys Mol & Cellulaire,Dept Reponse & Dynam, F-38054 Grenoble 9, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Catty, P (corresponding author), Univ Grenoble 1, CEA CNRS, UMR 5090,Commissariat Energie Atom,Direct Sci Viv, Lab Biophys Mol & Cellulaire,Dept Reponse & Dynam, 17 Rue Martyrs, F-38054 Grenoble 9, France.	patrice.catty@cea.fr		Martel, Anne/0000-0002-1232-8519				ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; Andersen JP, 1998, ACTA PHYSIOL SCAND, V163, P45; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; Bal N, 2003, BIOCHEM J, V369, P681, DOI 10.1042/BJ20021416; Banci L, 2006, J MOL BIOL, V356, P638, DOI 10.1016/j.jmb.2005.11.055; Banci L, 2002, J MOL BIOL, V323, P883, DOI 10.1016/S0022-2836(02)01007-0; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; Bukrinsky JT, 2001, FEBS LETT, V494, P6, DOI 10.1016/S0014-5793(01)02301-8; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; Dutta SJ, 2006, BIOCHEMISTRY-US, V45, P5923, DOI 10.1021/bi0523456; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; GUIMARAESMOTTA H, 1980, ARCH BIOCHEM BIOPHYS, V203, P395, DOI 10.1016/0003-9861(80)90192-7; Haas R, 1999, Hum Mutat, V14, P88, DOI 10.1002/(SICI)1098-1004(1999)14:1<88::AID-HUMU15>3.0.CO;2-H; Henkel G, 2004, CHEM REV, V104, P801, DOI 10.1021/cr020620d; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; Liu JB, 2006, BIOCHEMISTRY-US, V45, P763, DOI 10.1021/bi051836n; Lowe J, 2004, J BIOL CHEM, V279, P25986, DOI 10.1074/jbc.M308736200; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mandal AK, 2004, J BIOL CHEM, V279, P54802, DOI 10.1074/jbc.M410854200; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Miras R, 2001, PROTEIN EXPRES PURIF, V22, P299, DOI 10.1006/prep.2001.1436; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Myari A, 2004, J INORG BIOCHEM, V98, P1483, DOI 10.1016/j.jinorgbio.2004.05.013; Nies DH, 2003, FEMS MICROBIOL REV, V27, P313, DOI 10.1016/S0168-6445(03)00048-2; PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001; SIKORSKI RS, 1989, GENETICS, V122, P19; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tumer Z, 1999, ADV EXP MED BIOL, V448, P83; Voskoboinik I, 2001, BIOCHEM BIOPH RES CO, V281, P966, DOI 10.1006/bbrc.2001.4445; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WEBER K, 1969, J BIOL CHEM, V244, P4406; Wu CC, 2004, BIOCHEM BIOPH RES CO, V324, P1034, DOI 10.1016/j.bbrc.2004.09.160; WU CC, 2006, BIOCHIMIE PARIS, DOI DOI 10.1016/J.BIOCHI.2006.06.013; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258	48	17	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29533	29541		10.1074/jbc.M604658200	http://dx.doi.org/10.1074/jbc.M604658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16835223	hybrid			2022-12-27	WOS:000240896300015
J	Le Quere, AJL; Deakin, WJ; Schmeisser, C; Carlson, RW; Streit, WR; Broughton, WJ; Forsberg, LS				Le Quere, Antoine J. -L.; Deakin, William J.; Schmeisser, Christel; Carlson, Russell W.; Streit, Wolfgang R.; Broughton, William J.; Forsberg, L. Scott			Structural characterization of a K-antigen capsular polysaccharide essential for normal symbiotic infection in Rhizobium sp NGR234 - Deletion of the rkpMNO locus prevents synthesis of 5,7-diacetamido-3,5,7,9-tetradeoxy-non-2-ulosonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; PSEUDOMONAS-AERUGINOSA; SINORHIZOBIUM-FREDII; BACTERIAL LIPOPOLYSACCHARIDES; SURFACE POLYSACCHARIDE; PROTEIN SECRETION; SOMATIC ANTIGENS; STRAIN NGR234; LIPID-A; MELILOTI	Many early molecular events in symbiotic infection have been documented, although factors enabling Rhizobium to progress within the plant-derived infection thread and ultimately survive within the intracellular symbiosome compartment as mature nitrogen-fixing bacteroids are poorly understood. Rhizobial surface polysaccharides (SPS), including the capsular polysaccharides (K-antigens), exist in close proximity to plant-derived membranes throughout the infection process. SPSs are essential for bacterial survival, adaptation, and as potential determinants of nodulation and/ or host specificity. Relatively few studies have examined the role of K-antigens in these events. However, we constructed a mutant that lacks genes essential for the production of the K-antigen strain-specific sugar precursor, pseudaminicacid, in the broad host range Rhizobium sp. NGR234. The complete structure of the K-antigen of strain NGR234 was established, and it consists of disaccharide repeating units of glucuronic and pseudaminic acid having the structure -> 4)-beta-D-glucuronic acid-(1 -> 4)-beta-5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-manno-nonulosonic acid-(2 ->. Deletion of three genes located in the rkp-3 gene cluster, rkpM, rkpN, and part of rkpO, abolished pseudaminic acid synthesis, yielding a mutant in which the strain-specific K-antigen was totally absent: other surface glycoconjugates, including the lipopolysaccharides, exopolysaccharides, and flagellin glycoprotein appeared unaffected. The NGR Delta rkpMNO mutant was symbiotically defective, showing reduced nodulation efficiency on several legumes. K-antigen production was found to decline after rhizobia were exposed to plant flavonoids, and the decrease coincided with induction of a symbiotically active (bacteroid-specific) rhamnan-LPS, suggesting an exchange of SPS occurs during bacterial differentiation in the developing nodule.	Univ Geneva, LBMPS, CH-1292 Geneva, Switzerland; Univ Hamburg, Inst Mikrobiol, D-22609 Hamburg, Germany; Univ Georgia, Complex Carbohydrate Res, Athens, GA 30602 USA	University of Geneva; University of Hamburg; University System of Georgia; University of Georgia	Broughton, WJ (corresponding author), Univ Geneva, LBMPS, CH-1292 Geneva, Switzerland.	william.broughton@bioveg.unige.ch	Streit, Wolfgang/S-3049-2019; Le Quere, antoine/GOH-0137-2022; Streit, Wolfgang R/K-1366-2012	Streit, Wolfgang/0000-0001-7617-7396; Le Quere, antoine/0000-0001-7470-5730; Deakin, William James/0000-0001-9338-0791	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALATTI PA, 1992, CAN J PLANT SCI, V72, P49, DOI 10.4141/cjps92-006; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Becker A, 2005, MOL PLANT MICROBE IN, V18, P899, DOI 10.1094/MPMI-18-0899; BecquartdeKozak I, 1997, MOL PLANT MICROBE IN, V10, P114, DOI 10.1094/MPMI.1997.10.1.114; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; BEYNON LM, 1994, CARBOHYD RES, V256, P303, DOI 10.1016/0008-6215(94)84215-9; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BREWIN NJ, 1998, RHIZOBIACEAE, P415; Broughton WJ, 2000, J BACTERIOL, V182, P5641, DOI 10.1128/JB.182.20.5641-5652.2000; BROUGHTON WJ, 1971, BIOCHEM J, V125, P1075, DOI 10.1042/bj1251075; BROUGHTON WJ, 1986, J CELL BIOL, V102, P1173, DOI 10.1083/jcb.102.4.1173; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; Castric P, 2001, J BIOL CHEM, V276, P26479, DOI 10.1074/jbc.M102685200; CORZO J, 1991, ELECTROPHORESIS, V12, P439, DOI 10.1002/elps.1150120611; D'Haeze W, 2004, TRENDS MICROBIOL, V12, P555, DOI 10.1016/j.tim.2004.10.009; DABROWSKI U, 1979, TETRAHEDRON LETT, P4637; DAVIS AL, 1991, J MAGN RESON, V94, P637, DOI 10.1016/0022-2364(91)90154-L; Deakin WJ, 2005, MOL PLANT MICROBE IN, V18, P499, DOI 10.1094/MPMI-18-0499; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Forsberg LS, 2003, J BIOL CHEM, V278, P51347, DOI 10.1074/jbc.M309016200; Forsberg LS, 1997, J BACTERIOL, V179, P5366, DOI 10.1128/jb.179.17.5366-5371.1997; Fraysse N, 2005, GLYCOBIOLOGY, V15, P101, DOI 10.1093/glycob/cwh142; Fraysse N, 2003, EUR J BIOCHEM, V270, P1365, DOI 10.1046/j.1432-1033.2003.03492.x; Fraysse N, 2002, GLYCOBIOLOGY, V12, P741, DOI 10.1093/glycob/cwf078; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; Gil-Serrano AM, 1999, BIOCHEM J, V342, P527, DOI 10.1042/0264-6021:3420527; Gryllos I, 2001, INFECT IMMUN, V69, P65, DOI 10.1128/IAI.69.1.65-74.2001; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Kannenberg EL, 2001, MOL MICROBIOL, V39, P379, DOI 10.1046/j.1365-2958.2001.02225.x; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; Kereszt A, 1998, J BACTERIOL, V180, P5426, DOI 10.1128/JB.180.20.5426-5431.1998; Kiss E, 2001, MOL PLANT MICROBE IN, V14, P1395, DOI 10.1094/MPMI.2001.14.12.1395; Kiss E, 1997, J BACTERIOL, V179, P2132, DOI 10.1128/jb.179.7.2132-2140.1997; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; KNIREL YA, 1986, EUR J BIOCHEM, V157, P129, DOI 10.1111/j.1432-1033.1986.tb09648.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Kondakova AN, 2001, CARBOHYD RES, V333, P241, DOI 10.1016/S0008-6215(01)00145-8; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; Marie C, 2004, MOL PLANT MICROBE IN, V17, P958, DOI 10.1094/MPMI.2004.17.9.958; Mathis R, 2005, P NATL ACAD SCI USA, V102, P2655, DOI 10.1073/pnas.0409816102; Niehaus K, 1998, MOL PLANT MICROBE IN, V11, P906, DOI 10.1094/MPMI.1998.11.9.906; Parada M, 2006, MOL PLANT MICROBE IN, V19, P43, DOI 10.1094/MPMI-19-0043; Pellock BJ, 2000, J BACTERIOL, V182, P4310, DOI 10.1128/JB.182.15.4310-4318.2000; PETERSON AA, 1985, J BACTERIOL, V162, P738, DOI 10.1128/JB.162.2.738-745.1985; PETROVICS G, 1993, MOL MICROBIOL, V8, P1083, DOI 10.1111/j.1365-2958.1993.tb01653.x; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Pueppke SG, 1999, MOL PLANT MICROBE IN, V12, P293, DOI 10.1094/MPMI.1999.12.4.293; Putnoky M, 2004, J BACTERIOL, V186, P1591, DOI 10.1128/JB.186.6.1591-1597.2004; PUTNOKY P, 1988, J CELL BIOL, V106, P597, DOI 10.1083/jcb.106.3.597; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; REUHS BL, 1993, J BACTERIOL, V175, P3570, DOI 10.1128/jb.175.11.3570-3580.1993; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Reuhs BL, 2005, J BACTERIOL, V187, P6479, DOI 10.1128/JB.187.18.6479-6487.2005; REUHS BL, 1995, J BACTERIOL, V177, P4289, DOI 10.1128/jb.177.15.4289-4296.1995; Rodriguez-Carvajal MA, 2005, BIOMACROMOLECULES, V6, P1448, DOI 10.1021/bm049264u; Rodriguez-Carvajal MA, 2001, BIOCHEM J, V357, P505, DOI 10.1042/0264-6021:3570505; Roth L. E., 1991, Microbial cell-cell interactions., P255; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Tsvetkov YE, 2001, CARBOHYD RES, V331, P233, DOI 10.1016/S0008-6215(01)00041-6; Viprey V, 1998, MOL MICROBIOL, V28, P1381, DOI 10.1046/j.1365-2958.1998.00920.x; Viprey V, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-6-research0014; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WILLIAMS MNV, 1990, J BACTERIOL, V172, P6596, DOI 10.1128/jb.172.11.6596-6598.1990; YORK WS, 1986, METHOD ENZYMOL, V118, P3	71	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28981	28992		10.1074/jbc.M513639200	http://dx.doi.org/10.1074/jbc.M513639200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16772294	hybrid			2022-12-27	WOS:000240680500053
J	Gasper, R; Scrima, A; Wittinghofer, A				Gasper, Raphael; Scrima, Andrea; Wittinghofer, Alfred			Structural insights into HypB, a GTP-binding protein that regulates metal binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BRADYRHIZOBIUM-JAPONICUM; HYDROGENASE ISOENZYMES; HELICOBACTER-PYLORI; SIGNAL-TRANSDUCTION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; NICKEL; MATURATION; NITROGENASE	HypB is a prokaryotic metal-binding guanine nucleotide-binding protein that is essential for nickel incorporation into hydrogenases. Here we solved the x-ray structure of HypB from Methanocaldococcus jannaschii. It shows that the G-domain has a different topology than the Ras-like proteins and belongs to the SIMIBI (after Signal Recognition Particle, MinD and BioD) class of NTP-binding proteins. We show that HypB undergoes nucleotide-dependent dimerization, which is apparently a common feature of SIMIBI class G-proteins. The nucleotides are located in the dimer interface and are contacted by both subunits. The active site features residues from both subunits arguing that hydrolysis also requires dimerization. Two metal-binding sites are found, one of which is dependent on the state of bound nucleotide. A totally conserved ENV/IGNLV/ICP motif in switch II relays the nucleotide binding with the metal ion-binding site. The homology with NifH, the Fe protein subunit of nitrogenase, suggests a mechanistic model for the switch-dependent incorporation of a metal ion into hydrogenases.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de						Atanassova A, 2005, J BACTERIOL, V187, P4689, DOI 10.1128/JB.187.14.4689-4697.2005; BOCK A, 2006, IN PRESS ADV MICROBI, V51; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; Egea PF, 2004, NATURE, V427, P215, DOI 10.1038/nature02250; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ermler U, 1998, CURR OPIN STRUC BIOL, V8, P749, DOI 10.1016/S0959-440X(98)80095-X; Focia PJ, 2004, SCIENCE, V303, P373, DOI 10.1126/science.1090827; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; Hausinger RP, 1997, J BIOL INORG CHEM, V2, P279, DOI 10.1007/s007750050133; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HUANG WJ, 1994, STRUCTURE, V2, P407, DOI 10.1016/S0969-2126(00)00042-3; Hube M, 2002, J BACTERIOL, V184, P3879, DOI 10.1128/JB.184.14.3879-3885.2002; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lammens A, 2004, CURR BIOL, V14, P1778, DOI 10.1016/j.cub.2004.09.044; Lanzilotta WN, 1997, J BIOL CHEM, V272, P4157, DOI 10.1074/jbc.272.7.4157; Leach MR, 2005, BIOCHEMISTRY-US, V44, P12229, DOI 10.1021/bi050993j; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Leonard TA, 2005, EMBO J, V24, P270, DOI 10.1038/sj.emboj.7600530; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; Ma LY, 2003, J BACTERIOL, V185, P4948, DOI 10.1128/JB.185.16.4948-4955.2003; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; Maier T, 1996, BIOCHEMISTRY-US, V35, P10089, DOI 10.1021/bi960567l; Mehta N, 2003, J BACTERIOL, V185, P726, DOI 10.1128/JB.185.3.726-734.2003; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mulrooney SB, 2003, FEMS MICROBIOL REV, V27, P239, DOI 10.1016/S0168-6445(03)00042-1; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Olson JW, 1997, MOL MICROBIOL, V24, P119, DOI 10.1046/j.1365-2958.1997.3251690.x; Olson JW, 2001, MOL MICROBIOL, V39, P176, DOI 10.1046/j.1365-2958.2001.02244.x; Olson JW, 2000, J BACTERIOL, V182, P1702, DOI 10.1128/JB.182.6.1702-1705.2000; Quisel JD, 2000, J BACTERIOL, V182, P3446, DOI 10.1128/JB.182.12.3446-3451.2000; Quisel JD, 1999, MOL CELL, V4, P665, DOI 10.1016/S1097-2765(00)80377-9; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; Song HK, 2001, J BIOL CHEM, V276, P49359, DOI 10.1074/jbc.M108619200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WAUGH R, 1986, BIOCHIMIE, V68, P157, DOI 10.1016/S0300-9084(86)81080-X; Zhang JW, 2005, J BIOL CHEM, V280, P4360, DOI 10.1074/jbc.M411799200	45	113	116	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27492	27502		10.1074/jbc.M600809200	http://dx.doi.org/10.1074/jbc.M600809200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16807243	Green Published, hybrid			2022-12-27	WOS:000240397700076
J	Shin, JH; Kelman, Z				Shin, Jae-Ho; Kelman, Zvi			The replicative helicases of bacteria, archaea, and eukarya can unwind RNA-DNA hybrid substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; R-LOOP FORMATION; TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; MCM PROTEINS; IFN-GAMMA; DUPLEX; INITIATION; COMPLEX; BINDING	Replicative helicases are hexameric enzymes that unwind DNA during chromosomal replication. They use energy from nucleoside triphosphate hydrolysis to translocate along one strand of the duplex DNA and displace the complementary strand. Here, the ability of a replicative helicase from each of the three domains, bacteria, archaea, and eukarya, to unwind RNA-containing substrate was determined. It is shown that all three helicases can unwind DNA-RNA hybrids while translocating along the single-stranded DNA. No unwinding could be observed when the helicases were provided with a single-stranded RNA overhang. Using DNA, RNA, and DNA-RNA chimeric oligonucleotides it was found that whereas the enzymes can bind both DNA and RNA, they could translocate only along DNA and only DNA stimulates the ATPase activity of the enzymes. Recent observations suggest that helicases may interact with enzymes participating in RNA metabolism and that RNA-DNA hybrids may be present on the chromosomes. Thus, the results presented here may suggest a new role for the replicative helicases during chromosomal replication or in other cellular processes.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	University System of Maryland; University of Maryland Baltimore	Kelman, Z (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	kelman@umbi.umd.edu						Bayne EH, 2005, TRENDS GENET, V21, P370, DOI 10.1016/j.tig.2005.05.007; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Broccoli S, 2004, MOL MICROBIOL, V52, P1769, DOI 10.1111/j.1365-2958.2004.04092.x; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Corey DR, 2005, TRENDS BIOCHEM SCI, V30, P655, DOI 10.1016/j.tibs.2005.09.007; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Holland L, 2002, EUR J BIOCHEM, V269, P5192, DOI 10.1046/j.1432-1033.2002.03224.x; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kelman Z, 2005, CURR OPIN MICROBIOL, V8, P669, DOI 10.1016/j.mib.2005.10.001; Kornberg A., 1992, DNA REPLICATION; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 2001, J CELL SCI, V114, P1447; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Masse E, 1997, J BIOL CHEM, V272, P12816, DOI 10.1074/jbc.272.19.12816; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Morag E, 1996, BIOCHEM J, V316, P193, DOI 10.1042/bj3160193; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; REABAN ME, 1994, J BIOL CHEM, V269, P21850; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; Santamaria D, 1998, J BIOL CHEM, V273, P33386, DOI 10.1074/jbc.273.50.33386; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Snyder M, 2005, P NATL ACAD SCI USA, V102, P14539, DOI 10.1073/pnas.0507479102; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; You ZY, 2003, EMBO J, V22, P6148, DOI 10.1093/emboj/cdg576; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	33	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26914	26921		10.1074/jbc.M605518200	http://dx.doi.org/10.1074/jbc.M605518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16829518	hybrid			2022-12-27	WOS:000240397700018
J	Tolia, A; Chavez-Gutierrez, L; De Strooper, B				Tolia, Alexandra; Chavez-Gutierrez, Lucia; De Strooper, Bart			Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the gamma-secretase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; DISULFIDE CROSS-LINKING; AMYLOID PRECURSOR PROTEIN; ACTIVE-SITE; ALZHEIMERS-DISEASE; P-GLYCOPROTEIN; INTRAMEMBRANE PROTEOLYSIS; HIPPOCAMPAL-NEURONS; TRICHODERMA-REESEI; BINDING SITE	Secretase is a multiprotein complex responsible for the intramembranous cleavage of the amyloid precursor protein and other type I transmembrane proteins. Mutations in Presenilin, the catalytic core of this complex, cause Alzheimer disease. Little is known about the structure of the protein and even less about the catalytic mechanism, which involves proteolytic cleavage in the hydrophobic environment of the cell membrane. It is basically unclear how water, needed to perform hydrolysis, is provided to this reaction. Presenilin transmembrane domains 6 and 7 seem critical in this regard, as each bears a critical aspartate contributing to catalytic activity. Current models imply that both aspartyl groups should closely oppose each other and have access to water. This is, however, still to be experimentally verified. Here, we have performed cysteine-scanning mutagenesis of both domains and have demonstrated that several of the introduced residues are exposed to water, providing experimental evidence for the existence of a water-filled cavity in the catalytic core of Presenilin. In addition, we have demonstrated that the two aspartates reside within this cavity and are opposed to each other in the native complex. We have also identified the conserved tyrosine 389 as a critical partner in the catalytic mechanism. Several additional amino acid substitutions affect differentially the processing of gamma-secretase substrates, implying that they contribute to enzyme specificity. Our data suggest the possibility that more selective gamma-secretase inhibitors could be designed.	VIB4, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium	KU Leuven	De Strooper, B (corresponding author), VIB4, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, Herestr 49, B-3000 Louvain, Belgium.	Bart.destrooper@med.kuleuven.be	Chávez-Gutiérrez, Lucía/E-2657-2017; de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819				Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; Coates L, 2001, BIOCHEMISTRY-US, V40, P13149, DOI 10.1021/bi010626h; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Digby HR, 2005, J NEUROCHEM, V95, P1746, DOI 10.1111/j.1471-4159.2005.03494.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Esselens C, 2004, J CELL BIOL, V166, P1041, DOI 10.1083/jcb.200406060; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; Huang W, 2005, BIOCHEMISTRY-US, V44, P2419, DOI 10.1021/bi048808+; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimura-Someya T, 2000, J BIOL CHEM, V275, P18692, DOI 10.1074/jbc.M000354200; Koivula A, 2002, J AM CHEM SOC, V124, P10015, DOI 10.1021/ja012659q; Koivula A, 1996, PROTEIN ENG, V9, P691, DOI 10.1093/protein/9.8.691; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kornilova AY, 2006, BIOCHEMISTRY-US, V45, P7598, DOI 10.1021/bi060107k; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Kuwabara N, 2004, J BIOL CHEM, V279, P40567, DOI 10.1074/jbc.M401132200; Laudon H, 2005, J BIOL CHEM, V280, P35352, DOI 10.1074/jbc.M507217200; Lazarov VK, 2006, P NATL ACAD SCI USA, V103, P6889, DOI 10.1073/pnas.0602321103; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; Michiels F, 2002, NAT BIOTECHNOL, V20, P1154, DOI 10.1038/nbt746; Mueckler M, 2005, J BIOL CHEM, V280, P39562, DOI 10.1074/jbc.M509050200; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Oh YS, 2005, AM J PHYSIOL-CELL PH, V289, pC576, DOI 10.1152/ajpcell.00636.2004; Ostermann N, 2004, J MOL BIOL, V342, P889, DOI 10.1016/j.jmb.2004.07.073; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Spasic D, 2006, J BIOL CHEM, V281, P26569, DOI 10.1074/jbc.M600592200; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tamura N, 2003, CURR OPIN CHEM BIOL, V7, P570, DOI 10.1016/j.cbpa.2003.08.014; Tedde A, 2003, ARCH NEUROL-CHICAGO, V60, P1541, DOI 10.1001/archneur.60.11.1541; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; Vullo A, 2004, BIOINFORMATICS, V20, P653, DOI 10.1093/bioinformatics/btg463; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Wiltfang J, 2001, J BIOL CHEM, V276, P42645, DOI 10.1074/jbc.M102790200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yuan H, 1999, J NEUROSCI METH, V88, P45, DOI 10.1016/S0165-0270(99)00011-4	56	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27633	27642		10.1074/jbc.M604997200	http://dx.doi.org/10.1074/jbc.M604997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844686	hybrid, Green Published			2022-12-27	WOS:000240397700088
J	Sauna, ZE; Nandigama, K; Ambudkar, SV				Sauna, Zuben E.; Nandigama, Krishnamachary; Ambudkar, Suresh V.			Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; ENZYMATIC TRANSITION-STATES; POWER STROKE STATE; MULTIDRUG-RESISTANCE; CATALYTIC CYCLE; GLUTAMATE RESIDUES; CRYSTAL-STRUCTURE; BERYLLIUM FLUORIDE; ANALOG DESIGN; HYDROLYSIS	The transport cycle of ABC transporters in general and P-glycoprotein in particular has been extensively studied, but the molecular mechanism remains controversial. We identify stable reaction intermediates in the progression of the P-glycoprotein-mediated ATPase reaction equivalent to the enzyme-substrate (E.S, P-glycoprotein.ATP) and enzyme-product (E.P, P.glycoprotein.ADP.P-i) reaction intermediates. These have been characterized using the photoaffinity analog 8-azido-[alpha-P-32] ATP as well as under equilibrium conditions using [alpha-P-32] ATP, in which a cross-linking step is not involved. Similar results were obtained when 8-azido[alpha-32P] ATP or [alpha-32P] ATP was used. The reaction intermediates were characterized basedontheir kinetic properties and the nature (triphosphate/diphosphate) of the trapped nucleotide. Using this defined framework and the Walker B E556Q/ E1201Q mutant that traps nucleotide in the absence of vanadate or beryllium fluoride, the high to low affinity switch in the transport substrate binding site can be attributed to the formation of the E.S reaction intermediate of the ATPase reaction. Importantly, the posthydrolysis E.P state continues to have low affinity for substrate, suggesting that conformational changes that form the E.S complex are coupled to the conformational change at the transport substrate site to do mechanical work. Thus, the formation of E.S reaction intermediate duringasingleturnoverofthecatalyticcycleappearstoprovidethe initial power stroke for movement of drug substrate from inner leaflet to outer leaflet of lipid bilayer. This novel approach applies transition state theory to elucidate the mechanism of P-glycoprotein and other ABC transporters and has wider applications in testing cause-effect hypotheses in coupled systems.	NCI, Cell Biol Lab, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Cell Biol Lab, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Ambudkar, Suresh V/L-1317-2016; Sauna, Zuben E./AAA-7149-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010030, Z01BC010030] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Shawi MK, 2003, J BIOL CHEM, V278, P52629, DOI 10.1074/jbc.M308175200; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ambudkar SV, 1998, METHOD ENZYMOL, V292, P492; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chen C, 2006, J BIOL CHEM, V281, P13777, DOI 10.1074/jbc.M513369200; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Davies DR, 2004, FEBS LETT, V577, P315, DOI 10.1016/j.febslet.2004.10.022; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FERSHT A, 1999, STRUCTURE MECH PROTE, P38; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; Gourinath S, 2003, STRUCTURE, V11, P1621, DOI 10.1016/j.str.2003.10.013; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Highsmith S, 2000, BIOCHEMISTRY-US, V39, P12330, DOI 10.1021/bi001146d; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Kagawa R, 2004, EMBO J, V23, P2734, DOI 10.1038/sj.emboj.7600293; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Kozak L, 2002, J BIOL CHEM, V277, P33580, DOI 10.1074/jbc.M205415200; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Oloo EO, 2004, J BIOL CHEM, V279, P45013, DOI 10.1074/jbc.M405084200; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1345, DOI 10.1021/bi0267745; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schowen RL, 2003, P NATL ACAD SCI USA, V100, P11931, DOI 10.1073/pnas.2235806100; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; Schramm VL, 2005, ARCH BIOCHEM BIOPHYS, V433, P13, DOI 10.1016/j.abb.2004.08.035; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Shih WM, 2000, CELL, V102, P683, DOI 10.1016/S0092-8674(00)00090-8; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Tombline G, 2005, BIOCHEMISTRY-US, V44, P12879, DOI 10.1021/bi0509797; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Tombline G, 2004, J BIOL CHEM, V279, P46518, DOI 10.1074/jbc.M408052200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; van der Does C, 2006, J BIOL CHEM, V281, P5694, DOI 10.1074/jbc.M511730200; WATTERSON JG, 1975, EUR J BIOCHEM, V56, P79, DOI 10.1111/j.1432-1033.1975.tb02209.x; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	59	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26501	26511		10.1074/jbc.M601917200	http://dx.doi.org/10.1074/jbc.M601917200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844693	hybrid			2022-12-27	WOS:000240249500068
J	Altheide, TK; Hayakawa, T; Mikkelsen, TS; Diaz, S; Varki, N; Varki, A				Altheide, Tasha K.; Hayakawa, Toshiyuki; Mikkelsen, Tarjei S.; Diaz, Sandra; Varki, Nissi; Varki, Ajit			System-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents - Evidence for two modes of rapid evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; POLYSIALIC ACID; BINDING; GENE; EXPRESSION; DIVERSITY; MUTATION; OLIGOSACCHARIDE; CHROMATOGRAPHY; GLYCOSYLATION	Numerous vertebrate genes are involved in the biology of the oligosaccharide chains attached to glycoconjugates. These genes fall into diverse groups within the conventional Gene Ontology classification. However, they should be evaluated together from functional and evolutionary perspectives in a "biochemical systems" approach, considering each monosaccharide unit's biosynthesis, activation, transport, modification, transfer, recycling, degradation, and recognition. Sialic acid (Sia) residues are monosaccharides at the outer end of glycans on the cell-surface and secreted molecules of vertebrates, mediating recognition by intrinsic or extrinsic ( pathogen) receptors. The availability of multiple genome sequences allows a system-wide comparison among primates and rodents of all genes directly involved in Sia biology. Taking this approach, we present further evidence for accelerated evolution in Sia-binding domains of CD33-related Sia-recognizing Ig-like lectins. Other gene classes are more conserved, including those encoding the sialyltransferases that attach Sia residues to glycans. Despite this conservation, tissue sialylation patterns are shown to differ widely among these species, presumably because of rapid evolution of sialyltransferase expression patterns. Analyses of N- and O-glycans of erythrocyte and plasma glycopeptides from these and other mammalian taxa confirmed this phenomenon. Sia modifications on these glycopeptides also appear to be undergoing rapid evolution. This rapid evolution of the sialome presumably results from the ongoing need of organisms to evade microbial pathogens that use Sia residues as receptors. The rapid evolution of Sia-binding domains of the inhibitory CD33-related Sia-recognizing Ig-like lectins is likely to be a secondary consequence, as these inhibitory receptors presumably need to keep up with recognition of the rapidly evolving "self"-sialome.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; MIT, Broad Inst, Cambridge, MA 02141 USA; Harvard Univ, Cambridge, MA 02141 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Varki, A (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Mail Code 0687,9500 Gilman Dr, La Jolla, CA 92093 USA.	a1varki@ucsd.edu	Mikkelsen, Tarjei S/A-1306-2007	Mikkelsen, Tarjei S/0000-0002-8133-3135	NHLBI NIH HHS [P01HL57345] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1998, GEN INF SER WORKSH G, V9, P131; Angata K, 2004, J BIOL CHEM, V279, P32603, DOI 10.1074/jbc.M403429200; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Angata T, 2004, P NATL ACAD SCI USA, V101, P13251, DOI 10.1073/pnas.0404833101; ANGATA T, 2006, IN PRESS FASEB J; Appenheimer MM, 2003, GLYCOBIOLOGY, V13, P591, DOI 10.1093/glycob/cwg066; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BEYER TA, 1979, J BIOL CHEM, V254, P2531; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Chiba A, 1997, J BIOL CHEM, V272, P2156; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Chou HH, 2002, P NATL ACAD SCI USA, V99, P11736, DOI 10.1073/pnas.182257399; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Crocker PR, 2005, CURR OPIN PHARMACOL, V5, P431, DOI 10.1016/j.coph.2005.03.003; Dalziel M, 1999, GLYCOBIOLOGY, V9, P1003, DOI 10.1093/glycob/9.10.1003; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; Datta AK, 1997, INDIAN J BIOCHEM BIO, V34, P157; Dorus S, 2004, CELL, V119, P1027, DOI 10.1016/j.cell.2004.11.040; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; Gagneux P, 2003, J BIOL CHEM, V278, P48245, DOI 10.1074/jbc.M309813200; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; Gilad Y, 2003, P NATL ACAD SCI USA, V100, P3324, DOI 10.1073/pnas.0535697100; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; Goodman M, 1999, AM J HUM GENET, V64, P31, DOI 10.1086/302218; GOODMAN M, 1994, AM J PHYS ANTHROPOL, V94, P3, DOI 10.1002/ajpa.1330940103; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; Hayakawa T, 2001, P NATL ACAD SCI USA, V98, P11399, DOI 10.1073/pnas.191268198; Irie A, 1998, J BIOL CHEM, V273, P15866, DOI 10.1074/jbc.273.25.15866; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jeanneau C, 2004, J BIOL CHEM, V279, P13461, DOI 10.1074/jbc.M311764200; Jukes T., 1969, MAMMALIAN PROTEIN ME, P21; Khaitovich P, 2004, PLOS BIOL, V2, P682, DOI 10.1371/journal.pbio.0020132; Kleene R, 2001, J BIOL CHEM, V276, P21656, DOI 10.1074/jbc.M101790200; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; NEI M, 1986, MOL BIOL EVOL, V3, P418; Nguyen DH, 2006, P NATL ACAD SCI USA, V103, P7765, DOI 10.1073/pnas.0510484103; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Rausher MD, 1999, MOL BIOL EVOL, V16, P266, DOI 10.1093/oxfordjournals.molbev.a026108; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; Satta Y, 2000, MOL PHYLOGENET EVOL, V14, P259, DOI 10.1006/mpev.2000.0704; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; Sonnenburg JL, 2004, GLYCOBIOLOGY, V14, P339, DOI 10.1093/glycob/cwh039; Takashima S, 2000, J BIOCHEM-TOKYO, V127, P399, DOI 10.1093/oxfordjournals.jbchem.a022621; Traving C, 1998, CELL MOL LIFE SCI, V54, P1330, DOI 10.1007/s000180050258; VANVALEN L, 1974, NATURE, V252, P298; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Vimr ER, 2004, MICROBIOL MOL BIOL R, V68, P132, DOI 10.1128/MMBR.68.1.132-153.2004	62	47	48	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25689	25702		10.1074/jbc.M604221200	http://dx.doi.org/10.1074/jbc.M604221200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16769723	hybrid			2022-12-27	WOS:000240031300072
J	Bernier, V; Stocco, R; Bogusky, MJ; Joyce, JG; Parachoniak, C; Grenier, K; Arget, M; Mathieu, MC; O'Neill, GP; Slipetz, D; Crackower, MA; Tan, CM; Therien, AG				Bernier, Virginie; Stocco, Rino; Bogusky, Michael J.; Joyce, Joseph G.; Parachoniak, Christine; Grenier, Karl; Arget, Michael; Mathieu, Marie-Claude; O'Neill, Gary P.; Slipetz, Deborah; Crackower, Michael A.; Tan, Christopher M.; Therien, Alex G.			Structure-function relationships in the neuropeptide S receptor - Molecular consequences of the asthma-associated mutation N107I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONFORMATION; POSITIONAL CLONING; SPECTROSCOPY; PEPTIDE; LOCUS; GENE	Neuropeptide S (NPS) and its receptor (NPSR) are thought to have a role in asthma pathogenesis; a number of single nucleotide polymorphisms within NPSR have been shown to be associated with an increased prevalance of asthma. One such single nucleotide polymorphism leads to the missense mutation N107I, which results in an increase in the potency of NPS for NPSR. To gain insight into structure-function relationships within NPS and NPSR, we first carried out a limited structural characterization of NPS and subjected the peptide to extensive mutagenesis studies. Our results show that the NH2-terminal third of NPS, in particular residues Phe-2, Arg-3, Asn-4, and Val-6, are necessary and sufficient for activation of NPSR. Furthermore, part of a nascent helix within the peptide, spanning residues 5 through 13, acts as a regulatory region that inhibits receptor activation. Notably, this inhibition is absent in the asthma-linked N107I variant of NPSR, suggesting that residue 107 interacts with the aforementioned regulatory region of NPS. Whereas this interaction may be at the root of the increase in potency associated with the N107I variant, we show here that the mutation also causes an increase in cell-surface expression of the mutant receptor, leading to a concomitant increase in the maximal efficacy (Emax) of NPS. Our results identify the key residues of NPS involved in NPSR activation and suggest a molecular basis for the functional effects of the N107I mutation and for its putative pathophysiological link with asthma.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9L 3L1, Canada; Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Kirkland, PQ H9L 3L1, Canada; Merck & Co Inc, Dept Med Chem, West Point, PA 19486 USA; Merck & Co Inc, Dept Vaccine & Biol Res, West Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company	Therien, AG (corresponding author), 16711 Trans Canada Hwy, Kirkland, PQ H9H 3L1, Canada.	alex_therien@merck.com	Therien, Alex/AAS-8437-2021					Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Beck B, 2005, BIOCHEM BIOPH RES CO, V332, P859, DOI 10.1016/j.bbrc.2005.05.029; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; Gloriam DEI, 2005, BBA-GEN SUBJECTS, V1722, P235, DOI 10.1016/j.bbagen.2004.12.001; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Gupte J, 2004, P NATL ACAD SCI USA, V101, P1508, DOI 10.1073/pnas.0308250100; HOYER D, 1993, TRENDS PHARMACOL SCI, V14, P270, DOI 10.1016/0165-6147(93)90129-8; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; LEVITT MH, 1982, J MAGN RESON, V47, P328, DOI 10.1016/0022-2364(82)90124-X; Lilly CM, 2005, J ALLERGY CLIN IMMUN, V115, pS526, DOI 10.1016/j.jaci.2005.01.028; Mathieu MC, 2005, IMMUNOL LETT, V100, P139, DOI 10.1016/j.imlet.2005.03.003; Melen E, 2005, AM J RESP CRIT CARE, V171, P1089, DOI 10.1164/rccm.200410-1317OC; Melnyk RA, 2002, J MOL BIOL, V315, P63, DOI 10.1006/jmbi.2001.5214; Reinscheid RK, 2005, J PHARMACOL EXP THER, V315, P1338, DOI 10.1124/jpet.105.093427; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vendelin J, 2005, AM J RESP CELL MOL, V33, P262, DOI 10.1165/rcmb.2004-0405OC; WUTHRICH K, 2005, NMR PROTEINS NUCL AC; Xu YL, 2004, NEURON, V43, P487, DOI 10.1016/j.neuron.2004.08.005; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	28	77	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24704	24712		10.1074/jbc.M603691200	http://dx.doi.org/10.1074/jbc.M603691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790440				2022-12-27	WOS:000239847800066
J	Datta, A; Sinha-Datta, U; Dhillon, NK; Buch, S; Nicot, C				Datta, Abhik; Sinha-Datta, Uma; Dhillon, Navneet Kaur; Buch, Shilpa; Nicot, Christophe			The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro- and anti-inflammatory cytokines from human macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; GLYCOGEN-SYNTHASE KINASE-3; DOMAIN-DNA COMPLEX; HEPATITIS-C VIRUS; TRANSCRIPTION FACTOR; SPASTIC PARAPARESIS; IMMUNE-RESPONSE; EXPRESSION; TYPE-1	Whereas adaptive immunity has been extensively studied, very little is known about the innate immunity of the host to HTLV-I infection. HTLV-I-infected ATL patients have pronounced immunodeficiency associated with frequent opportunistic infections, and in these patients, concurrent infections with bacteria and/ or parasites are known to increase risks of progression to ATL. The Toll-like receptor-4 (TLR4) activation in response to bacterial infection is essential for dendritic cell maturation and links the innate and adaptive immune responses. Recent reports indicate that TLR4 is targeted by viruses such as RSV, HCV, and MMTV. Here we report that HTLV-I has also evolved a protein that interferes with TLR4 signaling; p30 interacts with and inhibits the DNA binding and transcription activity of PU.1 resulting in the down-regulation of the TLR4 expression from the cell surface. Expression of p30 hampers the release of pro-inflammatory cytokines MCP-1, TNF-alpha, and IL-8 and stimulates release of anti-inflammatory IL-10 following stimulation of TLR4 in human macrophage. Finally, we found that p30 increases phosphorylation and inactivation of GSK3-beta a key step for IL-10 production. Our study suggests a novel function of p30, which may instigate immune tolerance by reducing activation of adaptive immunity in ATL patients.	Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Nicot, C (corresponding author), Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, 3025 Wahl Hall W,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	cnicot@kumc.edu		Datta, Abhik/0000-0002-3442-5774; Buch, Shilpa/0000-0002-3103-6685	NCRR NIH HHS [P20 RR016443] Funding Source: Medline; NIAID NIH HHS [R01AI058944, R01 AI058944] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058944] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bangham CRM, 2005, ONCOGENE, V24, P6035, DOI 10.1038/sj.onc.1208970; Chen JL, 1995, AIDS RES HUM RETROV, V11, P1529, DOI 10.1089/aid.1995.11.1529; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Duesberg U, 2002, IMMUNOL LETT, V84, P89, DOI 10.1016/S0165-2478(02)00178-5; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; Feuer G, 1996, J VIROL, V70, P4038, DOI 10.1128/JVI.70.6.4038-4044.1996; Furukawa Y, 2006, INT J CANCER, V118, P381, DOI 10.1002/ijc.21328; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GESSAIN A, 1985, LANCET, V2, P407; Hill SA, 1999, VIROLOGY, V263, P273, DOI 10.1006/viro.1999.9922; HOFFMAN PM, 1992, P NATL ACAD SCI USA, V89, P11784, DOI 10.1073/pnas.89.24.11784; Iwasaki Y, 2004, ACTA NEUROPATHOL, V108, P546, DOI 10.1007/s00401-004-0924-1; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Jude BA, 2003, NAT IMMUNOL, V4, P573, DOI 10.1038/ni926; KANNAGI M, 1994, LEUKEMIA, V8, pS54; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KORALNIK IJ, 1992, AIDS RES HUM RETROV, V8, P1845, DOI 10.1089/aid.1992.8.1845; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Levin MC, 2001, J NEUROVIROL, V7, P61; Li CL, 2002, CELL GROWTH DIFFER, V13, P27; Makino M, 2000, VIROLOGY, V274, P140, DOI 10.1006/viro.2000.0445; MAKINO M, 2000, RYOIKIBETSU SHOKOGUN, V31, P9; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mori N, 2000, CANCER RES, V60, P4939; Mori N, 1999, BLOOD, V94, P2862, DOI 10.1182/blood.V94.8.2862.420k24_2862_2870; Mori N, 1996, BLOOD, V88, P1035; Mosley AJ, 2005, VIRAL IMMUNOL, V18, P293, DOI 10.1089/vim.2005.18.293; Mostoller K, 2004, J NEUROVIROL, V10, P358, DOI 10.1080/13550280490521104; Nagai M, 2001, J INFECT DIS, V183, P197, DOI 10.1086/317932; Nicot C, 2005, AM J HEMATOL, V78, P232, DOI 10.1002/ajh.20307; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Nicot C, 2001, MOL CELL BIOL, V21, P7391, DOI 10.1128/MCB.21.21.7391-7402.2001; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405; WANG JT, 1994, BLOOD, V84, P934; WHITE JD, 1995, CANCER, V75, P1598, DOI 10.1002/1097-0142(19950401)75:7<1598::AID-CNCR2820750708>3.0.CO;2-7; Yamamoto H, 2002, CELL GROWTH DIFFER, V13, P69; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004; Zhang WQ, 2001, J VIROL, V75, P9885, DOI 10.1128/JVI.75.20.9885-9895.2001; Zhang WQ, 2000, J VIROL, V74, P11270, DOI 10.1128/JVI.74.23.11270-11277.2000	52	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23414	23424		10.1074/jbc.M600684200	http://dx.doi.org/10.1074/jbc.M600684200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785240	hybrid			2022-12-27	WOS:000239702900016
J	Dong, C; Muriel, JM; Ramirez, S; Hutter, H; Hedgecock, EM; Breydo, L; Baskakov, IV; Vogel, BE				Dong, Chun; Muriel, Joaquin M.; Ramirez, Sarah; Hutter, Harald; Hedgecock, Edward M.; Breydo, Leonid; Baskakov, Ilia V.; Vogel, Bruce E.			Hemicentin assembly in the extracellular matrix is mediated by distinct structural modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-DOMAIN; FIBRONECTIN; RECOMBINATION; ELEGANS; LAMININ	Hemicentins are conserved extracellular matrix proteins characterized by a single von Willebrand A (VWA) domain at the amino terminus, a long stretch (> 40) of tandem immunoglobulin domains, multiple tandem epidermal growth factors (EGFs), and a single fibulin-like carboxyl-terminal module. In Caenorhabditis elegans, hemicentin is secreted from muscle and gonadal leader cells and assembles at multiple locations into discrete tracks that constrict broad regions of cell contact into adhesive and flexible line-shaped junctions. To determine hemicentin domains critical for function and assembly, we have expressed fragments of hemicentin as GFP tagged fusion proteins in C. elegans. We find that a hemicentin fragment containing the VWA domain can target to multiple assembly sites when expressed under the control of either endogenous hemicentin regulatory sequences or the muscle-specific unc-54 promoter. A hemicentin fragment containing the EGF and fibulin-like carboxyl-terminal modules can co-assemble with existing hemicentin polymers in wild-type animals but has no detectable function in the absence of endogenous hemicentin. The data suggest that the VWA domain is a cell binding domain whose function is to target hemicentin to sites of assembly and the EGF/fibulin-like carboxyl-terminal modules constitute an assembly domain that mediates direct interactions between hemicentin monomers during the hemicentin assembly process.	Univ Maryland, Ctr Med Biotechnol, Inst Biotechnol, Baltimore, MD 21201 USA; Max Planck Inst Med Res, D-69120 Heidelberg, Germany; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	University System of Maryland; University of Maryland Baltimore; Max Planck Society; Johns Hopkins University	Vogel, BE (corresponding author), Univ Maryland, Ctr Med Biotechnol, Inst Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	vogel@umbi.umd.edu	Breydo, Leo/AAJ-7996-2020; Breydo, Leonid/E-6119-2010	Breydo, Leonid/0000-0003-4666-2301	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065184] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65184] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Hopf M, 2001, J MOL BIOL, V311, P529, DOI 10.1006/jmbi.2001.4878; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; Kumanovics A, 2001, IMMUNOGENETICS, V53, P64, DOI 10.1007/s002510100297; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Muriel JM, 2005, DEVELOPMENT, V132, P4223, DOI 10.1242/dev.02007; OKKEMA PG, 1993, GENETICS, V135, P385; Sasaki T, 2004, J CELL BIOL, V164, P959, DOI 10.1083/jcb.200401058; Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; Vogel BE, 2001, DEVELOPMENT, V128, P883; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006	18	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23606	23610		10.1074/jbc.M513589200	http://dx.doi.org/10.1074/jbc.M513589200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16798744	hybrid			2022-12-27	WOS:000239702900035
J	Guffanti, E; Ferrari, R; Preti, M; Forloni, M; Harismendy, O; Lefebvre, O; Dieci, G				Guffanti, Elisa; Ferrari, Roberto; Preti, Milena; Forloni, Matteo; Harismendy, Olivier; Lefebvre, Olivier; Dieci, Giorgio			A minimal promoter for TFIIIC-dependent in vitro transcription of snoRNA and tRNA genes by RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA3LEU GENE; TATA-BINDING PROTEIN; U6 SNRNA GENE; SACCHAROMYCES-CEREVISIAE; FACTOR-TAU; INTRAGENIC PROMOTER; MUTATIONAL ANALYSIS; POINT MUTATIONS; CONTROL REGIONS; S-CEREVISIAE	The Saccharomyces cerevisiae SNR52 gene is unique among the snoRNA coding genes in being transcribed by RNA polymerase III. The primary transcript of SNR52 is a 250-nucleotide precursor RNA from which a long leader sequence is cleaved to generate the mature snR52 RNA. We found that the box A and box B sequence elements in the leader region are both required for the in vivo accumulation of the snoRNA. As expected box B, but not box A, was absolutely required for stable TFIIIC, yet in vitro. Surprisingly, however, the box B was found to be largely dispensable for in vitro transcription of SNR52, whereas the box A-mutated template effectively recruited TFIIIB; yet it was transcriptionally inactive. Even in the complete absence of box B and both upstream TATA-like and T-rich elements, the box A still directed efficient, TFIIIC-dependent transcription. Box B-independent transcription was also observed for two members of the tRNAAsn (GTT) gene family, but not for two tRNA(Pro)(AGG) gene copies. Fully recombinant TFIIIC supported box B-independent transcription of both SNR52 and tRNAAsn genes, but only in the presence of TFIIIB reconstituted with a crude B '' fraction. Non-TFIIIB component(s) in this fraction were also required for transcription of wild-type SNR52. Transcription of the box B-less tRNA(Asn) genes was strongly influenced by their 5 '-flanking regions, and it was stimulated by TBP and Brf1 proteins synergistically. The box A can thus be viewed as a core TFIIIC-interacting element that, assisted by upstream TFIIIB- DNA contacts, is sufficient to promote class III gene transcription.	Univ Parma, Dipartimento Biochim & Biol Mol, I-43100 Parma, Italy; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); University of Parma; CEA; UDICE-French Research Universities; Universite Paris Saclay	Dieci, G (corresponding author), Univ Parma, Dipartimento Biochim & Biol Mol, Parco Area Sci 23-A, I-43100 Parma, Italy.	giorgio.dieci@unipr.it	Ferrari, Roberto/O-8143-2015; Harismendy, Olivier/AAM-2072-2021; LEFEBVRE, Olivier/C-3847-2014; Dieci, Giorgio/B-3434-2012	Ferrari, Roberto/0000-0002-0453-0899; Harismendy, Olivier/0000-0002-8098-9888; LEFEBVRE, Olivier/0000-0002-3903-9450; Dieci, Giorgio/0000-0002-8792-3961; Forloni, Matteo/0000-0003-4858-8491				ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; Bolchi A, 2005, BIOTECHNOL APPL BIOC, V42, P205, DOI 10.1042/BA20050050; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Braglia P, 2005, J BIOL CHEM, V280, P19551, DOI 10.1074/jbc.M412238200; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CARRARA G, 1981, CELL, V27, P371, DOI 10.1016/0092-8674(81)90420-7; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Cloutier TE, 2001, P NATL ACAD SCI USA, V98, P9581, DOI 10.1073/pnas.161292298; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; Dieci G, 2002, J BIOL CHEM, V277, P6903, DOI 10.1074/jbc.M105036200; DIECI G, 1993, J BIOL CHEM, V268, P11199; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; Ducrot C, 2006, J BIOL CHEM, V281, P11685, DOI 10.1074/jbc.M600101200; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; FABRIZIO P, 1987, P NATL ACAD SCI USA, V84, P8763, DOI 10.1073/pnas.84.24.8763; Ferrari R, 2004, P NATL ACAD SCI USA, V101, P13442, DOI 10.1073/pnas.0403851101; FRUSCOLONI P, 1995, NUCLEIC ACIDS RES, V23, P2914, DOI 10.1093/nar/23.15.2914; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; Giuliodori S, 2003, J MOL BIOL, V333, P1, DOI 10.1016/j.jmb.2003.08.016; HALL BD, 1982, CELL, V29, P3, DOI 10.1016/0092-8674(82)90083-6; Hamada M, 2001, MOL CELL BIOL, V21, P6870, DOI 10.1128/MCB.21.20.6870-6881.2001; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Huet J, 1996, METHOD ENZYMOL, V273, P249; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; JOHNSON JD, 1984, MOL GEN GENET, V197, P55, DOI 10.1007/BF00327922; Kassavetis GA, 2006, J BIOL CHEM, V281, P7445, DOI 10.1074/jbc.M512810200; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KOSKI RA, 1982, NUCLEIC ACIDS RES, V10, P8127, DOI 10.1093/nar/10.24.8127; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Kruszka K, 2003, EMBO J, V22, P621, DOI 10.1093/emboj/cdg040; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; Lopez S, 2001, MOL CELL BIOL, V21, P3096, DOI 10.1128/MCB.21.9.3096-3104.2001; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Marck C, 2006, NUCLEIC ACIDS RES, V34, P1816, DOI 10.1093/nar/gkl085; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; Moir RD, 2004, ADV PROTEIN CHEM, V67, P93; Moqtaderi Z, 2004, MOL CELL BIOL, V24, P4118, DOI 10.1128/MCB.24.10.4118-4127.2004; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; NEWMAN AJ, 1983, CELL, V35, P117, DOI 10.1016/0092-8674(83)90214-3; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; PAVESI A, 1994, NUCLEIC ACIDS RES, V22, P1247, DOI 10.1093/nar/22.7.1247; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; Yukawa Y, 2000, PLANT J, V22, P439, DOI 10.1046/j.1365-313X.2000.00752.x; Zecherle GN, 1996, MOL CELL BIOL, V16, P5801	66	23	25	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23945	23957		10.1074/jbc.M513814200	http://dx.doi.org/10.1074/jbc.M513814200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787917	hybrid			2022-12-27	WOS:000239702900069
J	Peshenko, IV; Dizhoor, AM				Peshenko, Igor V.; Dizhoor, Alexander M.			Ca2+ and Mg2+ binding properties of GCAP-1 - Evidence that Mg2+-bound form is the physiological activator of photoreceptor guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE-ROD DYSTROPHY; CA2+-BINDING PROTEINS; EF-HAND; CALCIUM-CONCENTRATION; MOLECULAR-MECHANISMS; OUTER SEGMENTS; RETINAL RODS; SPECIFICITY; DIMERIZATION; RECOVERIN	Guanylyl cyclase-activating protein 1 (GCAP-1) is an EF-hand protein that activates retinal guanylyl cyclase ( RetGC) in photoreceptors at low free Ca2+ in the light and inhibits it in the dark when Ca2+ concentrations rise. We present the first direct evidence that Mg2+-bound form of GCAP-1, not its cation-free form, is the true activator of RetGC-1 under physiological conditions. Of four EF-hand structures in GCAP-1, three bound Ca2+ ions and could exchange Ca2+ for Mg2+. At concentrations of free Ca2+ and Mg2+ typical for the light-adapted photoreceptors, all three metal-binding EF-hands were predominantly occupied by Mg-2, and the presence of bound Mg2+ in GCAP-1 was essential for its ability to stimulate RetGC-1. In the Mg2+- bound form of GCAP-1 all three Trp residues became more exposed to the polar environment compared with its apo form. The replacement of Mg2+ by Ca2+ in the EF-hands 2 and 3 further exposed Trp-21 to the solution in a non-metal-binding EF-hand domain 1 that interacts with RetGC. Contrary to that, replacement of Mg2+ by Ca2+ in the EF-hand 4 moved Trp-94 in the entering alpha-helix of the EF-hand 3 back to the non-polar environment. Our results demonstrate that Mg2+ regulates GCAP-1 not only by adjusting its Ca2+ sensitivity to the physiological conditions in photoreceptors but also by creating the conformation required for RetGC stimulation.	Penn Coll Optometry, Hafter Res Labs, Elkins Pk, PA 19027 USA		Dizhoor, AM (corresponding author), Penn Coll Optometry, Hafter Res Labs, Elkins Pk, PA 19027 USA.	adizhoor@pco.edu		Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011522-11, EY11522] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allouche D, 1999, J MOL BIOL, V285, P857, DOI 10.1006/jmbi.1998.2329; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 2002, ADV EXP MED BIOL, V514, P333; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BABU A, 1992, J BIOL CHEM, V267, P15469; Blumenschein TMA, 2000, BIOCHEMISTRY-US, V39, P3603, DOI 10.1021/bi9924718; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; Cates MS, 2002, BIOPHYS J, V82, P1133, DOI 10.1016/S0006-3495(02)75472-6; Chen CH, 2003, J PHYSIOL-LONDON, V553, P125, DOI 10.1113/jphysiol.2003.053280; DASILVA ACR, 1995, J BIOL CHEM, V270, P6773, DOI 10.1074/jbc.270.12.6773; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gorczyca WA, 2003, ACTA BIOCHIM POL, V50, P367; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Hwang JY, 2004, EUR J BIOCHEM, V271, P3785, DOI 10.1111/j.1432-1033.2004.04320.x; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Olshevskaya EV, 2004, J NEUROSCI, V24, P6078, DOI 10.1523/JNEUROSCI.0963-04.2004; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Peshenko IV, 2004, BIOCHEMISTRY-US, V43, P13796, DOI 10.1021/bi048943m; Peshenko IV, 2004, J BIOL CHEM, V279, P16903, DOI 10.1074/jbc.C400065200; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; Ramamurthy V, 2001, J BIOL CHEM, V276, P26218, DOI 10.1074/jbc.M010495200; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sampath AP, 1999, J GEN PHYSIOL, V113, P267, DOI 10.1085/jgp.113.2.267; Sokal I, 2001, J BIOL CHEM, V276, P43361, DOI 10.1074/jbc.M103614200; Sokal I, 1999, J BIOL CHEM, V274, P19829, DOI 10.1074/jbc.274.28.19829; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Tucker CL, 1999, P NATL ACAD SCI USA, V96, P9039, DOI 10.1073/pnas.96.16.9039; Wilkie SE, 2000, HUM MOL GENET, V9, P3065, DOI 10.1093/hmg/9.20.3065; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; Yu H, 1999, J BIOL CHEM, V274, P15547, DOI 10.1074/jbc.274.22.15547	48	95	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23830	23841		10.1074/jbc.M600257200	http://dx.doi.org/10.1074/jbc.M600257200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793776	hybrid			2022-12-27	WOS:000239702900059
J	El Ghachi, M; Bouhss, A; Barreteau, H; Touze, T; Auger, G; Blanot, D; Mengin-Lecreulx, D				El Ghachi, Meriem; Bouhss, Ahmed; Barreteau, Helene; Touze, Thierry; Auger, Genevieve; Blanot, Didier; Mengin-Lecreulx, Dominique			Colicin M exerts its bacteriolytic effect via enzymatic degradation of undecaprenyl phosphate-linked peptidoglycan precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; CELL-WALL PEPTIDOGLYCAN; REQUIREMENTS ALLOWING DETECTION; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; LIPID INTERMEDIATE; MICROCOCCUS-LYSODEIKTICUS; C55-ISOPRENOID ALCOHOL; STAPHYLOCOCCUS-AUREUS; MUREIN BIOSYNTHESIS	Colicin M was earlier demonstrated to provoke Escherichia coli cell lysis via inhibition of cell wall peptidoglycan (murein) biosynthesis. As the formation of the O-antigen moiety of lipopolysaccharides was concomitantly blocked, it was hypothesized that the metabolism of undecaprenyl phosphate, an essential carrier lipid shared by these two pathways, should be the target of this colicin. However, the exact target and mechanism of action of colicin M was unknown. Colicin M was now purified to near homogeneity, and its effects on cell wall peptidoglycan metabolism reinvestigated. It is demonstrated that colicin M exhibits both in vitro and in vivo enzymatic properties of degradation of lipid I and lipid II peptidoglycan intermediates. Free undecaprenol and either 1-pyrophospho-MurNAc-pentapeptide or 1-pyrophospho-MurNAc-(pentapeptide)-Glc-NAc were identified as the lipid I and lipid II degradation products, respectively, showing that the cleavage occurred between the lipid moiety and the pyrophosphoryl group. This is the first time such an activity is described. Neither undecaprenyl pyrophosphate nor the peptidoglycan nucleotide precursors were substrates of colicin M, indicating that both undecaprenyl and sugar moieties were essential for activity. The bacteriolytic effect of colicin M therefore appears to be the consequence of an arrest of peptidoglycan polymerization steps provoked by enzymatic degradation of the undecaprenyl phosphate-linked peptidoglycan precursors.	Univ Paris 11, CNRS, UMR 8619, IBBMC,Lab Enveloppes Bacteriennes & Antibiot, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mengin-Lecreulx, D (corresponding author), Univ Paris 11, CNRS, UMR 8619, IBBMC,Lab Enveloppes Bacteriennes & Antibiot, Batiment 430, F-91405 Orsay, France.	dominique.mengin-lecreulx@ebp.u-psud.fr	Touzé, Thierry/GLT-1308-2022	Touze, Thierry/0000-0002-2176-6537; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				ABOGHALIA M, 1985, EUR J BIOCHEM, V153, P81, DOI 10.1111/j.1432-1033.1985.tb09269.x; ALEXANDER DC, 1994, J BACTERIOL, V176, P7079, DOI 10.1128/JB.176.22.7079-7084.1994; ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Auger G, 2003, FEMS MICROBIOL LETT, V219, P115, DOI 10.1016/S0378-1097(02)01203-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLANOSGARCIA VM, 2006, IN PRESS BIOCH BIOPH; Bouhss A, 2004, J BIOL CHEM, V279, P29974, DOI 10.1074/jbc.M314165200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN V, 1973, BIOCHIM BIOPHYS ACTA, V323, P87, DOI 10.1016/0005-2736(73)90433-1; Crouvoisier M, 1999, FEBS LETT, V449, P289, DOI 10.1016/S0014-5793(99)00412-3; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; DAI D, 1988, J BACTERIOL, V170, P2197, DOI 10.1128/jb.170.5.2197-2201.1988; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DREHER R, 1985, ARCH MICROBIOL, V140, P343, DOI 10.1007/BF00446975; El Ghachi M, 2005, J BIOL CHEM, V280, P18689, DOI 10.1074/jbc.M412277200; El Ghachi M, 2004, J BIOL CHEM, V279, P30106, DOI 10.1074/jbc.M401701200; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; HARKNESS RE, 1990, MOL GEN GENET, V222, P37, DOI 10.1007/BF00283020; HARKNESS RE, 1989, J BIOL CHEM, V264, P14716; HARKNESS RE, 1989, J BIOL CHEM, V264, P6177; HIGASHI Y, 1970, J BIOL CHEM, V245, P3697; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; JOHNSON JG, 1977, J BACTERIOL, V129, P225, DOI 10.1128/JB.129.1.225-236.1977; KALIN JR, 1979, BIOCHIM BIOPHYS ACTA, V574, P112, DOI 10.1016/0005-2760(79)90090-0; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; KOCK J, 1987, J BACTERIOL, V169, P3358; KOHLRAUSCH U, 1989, J GEN MICROBIOL, V135, P1499; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; LOWE PN, 1982, BIOCHEMISTRY-US, V21, P4073, DOI 10.1021/bi00260a025; Maillard AP, 2005, J BACTERIOL, V187, P3833, DOI 10.1128/JB.187.11.3833-3838.2005; MENGINLECREULX D, 1989, J BACTERIOL, V171, P3282, DOI 10.1128/jb.171.6.3282-3287.1989; MENGINLECREULX D, 1991, J BACTERIOL, V173, P4625, DOI 10.1128/jb.173.15.4625-4636.1991; Miller J. H., 1972, EXPT MOL GENETICS, P431; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; OLSCHLAGER T, 1984, MOL GEN GENET, V196, P482, DOI 10.1007/BF00436196; PILSL H, 1993, MOL GEN GENET, V240, P103, DOI 10.1007/BF00276889; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P203; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P168; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAMEY WD, 1978, J BACTERIOL, V135, P71, DOI 10.1128/JB.135.1.71-77.1978; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Rick PD, 1998, GLYCOBIOLOGY, V8, P557, DOI 10.1093/glycob/8.6.557; ROHR TE, 1977, J BIOL CHEM, V252, P3460; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; SCHALLER K, 1982, J BACTERIOL, V152, P994; SCHALLER K, 1981, J BACTERIOL, V146, P54, DOI 10.1128/JB.146.1.54-63.1981; SCHER M, 1968, P NATL ACAD SCI USA, V59, P1313, DOI 10.1073/pnas.59.4.1313; Schiller J, 1999, ANAL BIOCHEM, V267, P46, DOI 10.1006/abio.1998.3001; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; Stenbak CR, 2004, J IMMUNOL, V173, P7339, DOI 10.4049/jimmunol.173.12.7339; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; STORM DR, 1973, J BIOL CHEM, V248, P3940; TROY FA, 1975, J BIOL CHEM, V250, P156; TROY FA, 1971, J BIOL CHEM, V246, P118; Uehara T, 2006, J BACTERIOL, V188, P1660, DOI 10.1128/JB.188.4.1660-1662.2006; UMBREIT JN, 1972, J BACTERIOL, V112, P1306, DOI 10.1128/JB.112.3.1306-1309.1972; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992; VANHEIJENOORT Y, 1971, FEBS LETT, V15, P137, DOI 10.1016/0014-5793(71)80041-8; WATKINSON RJ, 1971, NATURE-NEW BIOL, V229, P57, DOI 10.1038/newbio229057a0; WIENTJES FB, 1985, J BACTERIOL, V164, P331, DOI 10.1128/JB.164.1.331-337.1985; WILLOUGHBY E, 1972, J BIOL CHEM, V247, P5113; WRIGHT A, 1967, P NATL ACAD SCI USA, V57, P1798, DOI 10.1073/pnas.57.6.1798	67	91	93	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22761	22772		10.1074/jbc.M602834200	http://dx.doi.org/10.1074/jbc.M602834200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16777846	hybrid			2022-12-27	WOS:000239542600037
J	Pontarin, G; Ferraro, P; Valentin, ML; Hirano, M; Reichard, P; Bianchi, V				Pontarin, Giovanna; Ferraro, Paola; Valentin, Maria L.; Hirano, Michio; Reichard, Peter; Bianchi, Vera			Mitochondrial DNA depletion and thymidine phosphate pool dynamics in a cellular model of mitochondrial neurogastrointestinal encephalomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE-DEFICIENCY; DEOXYRIBONUCLEIC ACID; DELETIONS; MNGIE; TRIPHOSPHATE; FIBROBLASTS; MUTATIONS; KINASE; CELLS; MTDNA	Mitochondrial (mt) neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disease associated with depletion, deletions, and point mutations of mtDNA. Patients lack a functional thymidine phosphorylase and their plasma contains high concentrations of thymidine and deoxyuridine; elevation of the corresponding triphosphates probably impairs normal mtDNA replication and repair. To study metabolic events leading to MNGIE we used as model systems skin and lung fibroblasts cultured in the presence of thymidine and/or deoxyuridine at concentrations close to those in the plasma of the patients, a more than 100-fold excess relative to controls. The two deoxynucleosides increased the mt and cytosolic dTTP pools of skin fibroblasts almost 2-fold in cycling cells and 8-fold in quiescent cells. During up to a two-month incubation of quiescent fibroblasts with thymidine (but not with deoxyuridine), mtDNA decreased to similar to 50% without showing deletions or point mutations. When we removed thymidine, but maintained the quiescent state, mtDNA recovered rapidly. With thymidine in the medium, the dTTP pool of quiescent cells turned over rapidly at a rate depending on the concentration of thymidine, due to increased degradation and resynthesis of dTMP in a substrate (=futile) cycle between thymidine kinase and 5'-deoxyribonucleotidase. The cycle limited the expansion of the dTTP pool at the expense of ATP hydrolysis. We propose that the substrate cycle represents a regulatory mechanism to protect cells from harmful increases of dTTP. Thus MNGIE patients may increase their consumption of ATP to counteract an unlimited expansion of the dTTP pool caused by circulating thymidine.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Columbia Univ, Ctr Med, Dept Neurol, New York, NY 10032 USA	University of Padua; Columbia University	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	vbianchi@bio.unipd.it		VALENTINO, MARIA LUCIA/0000-0001-5323-0115	Telethon [GFP03004] Funding Source: Medline	Telethon(Fondazione Telethon)		ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BERK AJ, 1973, J BIOL CHEM, V248, P2722; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; BJURSELL G, 1973, J BIOL CHEM, V248, P3904; Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99; Chabes A, 2003, CELL CYCLE, V2, P172, DOI 10.4161/cc.2.3.354; Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309; COHEN A, 1985, P SOC EXP BIOL MED, V179, P437; Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200; FRIEDKIN M, 1954, J BIOL CHEM, V207, P245; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; Marti R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8; Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9; Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200; Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200; Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192	28	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22720	22728		10.1074/jbc.M604498200	http://dx.doi.org/10.1074/jbc.M604498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774911	hybrid			2022-12-27	WOS:000239542600032
J	Rodriguez, JM; Glozak, MA; Ma, YH; Cress, WD				Rodriguez, Jose M.; Glozak, Michele A.; Ma, Yihong; Cress, W. Douglas			Bok, Bcl-2-related ovarian killer, is cell cycle-regulated and sensitizes to stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F FAMILY-MEMBER; DNA-DAMAGE RESPONSE; S-PHASE; TRANSCRIPTION FACTOR; BCL-2 FAMILY; GROWTH SUPPRESSION; BINDING PROTEIN; UP-REGULATION; EXPRESSION; IDENTIFICATION	Bok/Mtd (Bcl-2-related ovarian killer/Matador) is considered a pro-apoptotic member of the Bcl-2 family. Although identified in 1997, little is known about its biological role. We have previously demonstrated that Bok mRNA is up-regulated following E2F1 overexpression. In the current work, we demonstrate that Bok RNA is low in quiescent cells and rises upon serum stimulation. To determine the mechanism underlying this regulation, we cloned and characterized the mouse Bok promoter. We find that the mouse promoter contains a conserved E2F binding site (-43 to -49) and that a Bok promoter-driven luciferase reporter is activated by serum stimulation dependent on this site. Chromatin immunoprecipitation assays demonstrate that endogenous E2F1 and E2F3 associate with the Bok promoter in vivo. Surprisingly, we find that H1299 cells can stably express high levels of exogenous Bok protein. However, these cells are highly sensitive to chemotherapeutic drug treatment. Taken together these results demonstrate that Bok represents a cell cycle-regulated pro-apoptotic member of the Bcl-2 family, which may predispose growing cells to chemotherapeutic treatment.	Univ Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Tampa, FL 33612 USA; Univ Florida, Res Inst, Tampa, FL 33612 USA; Univ Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ Florida, Canc Biol PhD Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cress, WD (corresponding author), 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NCI NIH HHS [R01 CA090489, R01 CA090489-05S1, R01 CA090489-04S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Brown CY, 2004, DEV COMP IMMUNOL, V28, P619, DOI 10.1016/j.dci.2003.09.017; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Gross A, 2006, CELL CYCLE, V5, P582, DOI 10.4161/cc.5.6.2575; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Ha SH, 2001, MOL CELLS, V12, P368; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; He YW, 2002, J BIOL CHEM, V277, P23493, DOI 10.1074/jbc.M202629200; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Humbert PO, 2000, GENE DEV, V14, P690; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Ma YH, 2004, CANCER BIOL THER, V3, P1262, DOI 10.4161/cbt.3.12.1239; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, MOL CANCER THER, V2, P73; Maglott D, 2005, NUCLEIC ACIDS RES, V33, pD54, DOI 10.1093/nar/gki031; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Neuman E, 1996, GENE, V173, P163, DOI 10.1016/0378-1119(96)00184-9; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Suominen JS, 2001, EUR J ENDOCRINOL, V145, P771, DOI 10.1530/eje.0.1450771; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	64	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22729	22735		10.1074/jbc.M604705200	http://dx.doi.org/10.1074/jbc.M604705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772296	hybrid, Green Accepted			2022-12-27	WOS:000239542600033
J	Aas, FE; Egge-Jacobsen, W; Winther-Larsen, HC; Lovold, C; Hitchen, PG; Dell, A; Koomey, M				Aas, Finn Erik; Egge-Jacobsen, Wolfgang; Winther-Larsen, Hanne C.; Lovold, Cecilia; Hitchen, Paul G.; Dell, Anne; Koomey, Michael			Neisseria gonorrhoeae type IV pili undergo multisite, hierarchical modifications with phosphoethanolamine and phosphocholine requiring an enzyme structurally related to lipopolysaccharide phosphoethanolamine transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE-SECRETED PRODUCT; HAEMOPHILUS-INFLUENZAE; STREPTOCOCCUS-PNEUMONIAE; FLAGELLIN GLYCOSYLATION; NATURAL TRANSFORMATION; PROTEIN GLYCOSYLATION; SALMONELLA-ENTERICA; MENINGOCOCCAL PILIN; MASS-SPECTROMETRY; INNER-CORE	The zwitterionic phospho-forms phosphoethanolamine and phosphocholine are recognized as influential and important substituents of pathogen cell surfaces. PilE, the major pilin subunit protein of the type IV pilus (Tfp) colonization factor of Neisseria gonorrhoeae undergoes unique, post-translational modifications with these moieties. These phospho-form modifications have been shown to be O-linked alternately to a specific, conserved serine residue of PilE. However, the enzymes and precursors involved in their addition are unknown, and the full spectrum of PilE post-translational modifications has yet to be defined. Here, an intact protein-based mass spectrometric approach was integrated with bioinformatics and reverse genetics to address these matters. Specifically we show that a protein limited in its distribution to pathogenic Neisseria species and structurally related to enzymes implicated in phosphoethanolamine modification of lipopolysaccharide is necessary for PilE covalent modification with phosphoethanolamine and phosphocholine. These findings strongly suggest that protein phospho-form modification is mechanistically similar to processes underlying analogous modifications of prokaryotic saccharolipid glycans. We also show that PilE undergoes multisite and hierarchical phospho-form modifications and that the stoichiometries of site occupancy can be influenced by PilE primary structure and the abundance of the pilin-like protein PilV. Together, these findings have important implications for the structure and antigenicity of PilE.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Univ Oslo, Ctr Mol Biol & Neurosci, N-0316 Oslo, Norway; Univ Oslo, Biotechnol Ctr Oslo, N-0317 Oslo, Norway; Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Div Mol Biosci, London SW7 2AZ, England	University of Oslo; University of Oslo; University of Oslo; Imperial College London	Koomey, M (corresponding author), Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway.	johnk@imbv.uio.no		Koomey, Michael/0000-0001-5844-2344				Arora SK, 2005, INFECT IMMUN, V73, P4395, DOI 10.1128/IAI.73.7.4395-4398.2005; Benz I, 2001, MOL MICROBIOL, V40, P1403, DOI 10.1046/j.1365-2958.2001.02487.x; BOSLEGO JW, 1991, VACCINE, V9, P154, DOI 10.1016/0264-410X(91)90147-X; BRILES DE, 1992, INFECT IMMUN, V60, P1957, DOI 10.1128/IAI.60.5.1957-1962.1992; CLOSE TJ, 1982, GENE, V20, P305, DOI 10.1016/0378-1119(82)90048-8; Cox AD, 2003, J BACTERIOL, V185, P3270, DOI 10.1128/JB.185.11.3270-3277.2003; Craig L, 2004, NAT REV MICROBIOL, V2, P363, DOI 10.1038/nrmicro885; Cundell DR, 1996, ADV EXP MED BIOL, V416, P89; Deehan MR, 1998, J IMMUNOL, V160, P2692; Drake SL, 1995, MOL MICROBIOL, V18, P975, DOI 10.1111/j.1365-2958.1995.18050975.x; FREITAG NE, 1995, MOL MICROBIOL, V16, P575, DOI 10.1111/j.1365-2958.1995.tb02420.x; Grass S, 2003, MOL MICROBIOL, V48, P737, DOI 10.1046/j.1365-2958.2003.03450.x; Harnett MM, 1998, PARASITE IMMUNOL, V20, P551, DOI 10.1046/j.1365-3024.1998.00181.x; Hegge FT, 2004, P NATL ACAD SCI USA, V101, P10798, DOI 10.1073/pnas.0402397101; Hendrixson DR, 2004, MOL MICROBIOL, V52, P471, DOI 10.1111/j.1365-2958.2004.03988.x; KOOMEY JM, 1987, J BACTERIOL, V169, P790, DOI 10.1128/jb.169.2.790-795.1987; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Rahman MM, 2000, MICROBIOL-UK, V146, P1901, DOI 10.1099/00221287-146-8-1901; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Schirm M, 2005, ANAL CHEM, V77, P7774, DOI 10.1021/ac051316y; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schmidt KA, 2001, SEX TRANSM DIS, V28, P555, DOI 10.1097/00007435-200110000-00001; Serino L, 2000, MOL MICROBIOL, V35, P1550, DOI 10.1046/j.1365-2958.2000.01825.x; Serino L, 2002, MOL MICROBIOL, V43, P437, DOI 10.1046/j.1365-2958.2002.02755.x; Snyder LAS, 2001, J BACTERIOL, V183, P1233, DOI 10.1128/JB.183.4.1233-1241.2001; Stimson E, 1996, BIOCHEM J, V316, P29, DOI 10.1042/bj3160029; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; SUD IJ, 1975, J BACTERIOL, V124, P713, DOI 10.1128/JB.124.2.713-717.1975; Swords WE, 2001, CELL MICROBIOL, V3, P525, DOI 10.1046/j.1462-5822.2001.00132.x; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; Tamayo R, 2005, J BACTERIOL, V187, P3391, DOI 10.1128/JB.187.10.3391-3399.2005; TONJUM T, 1995, MOL MICROBIOL, V16, P451, DOI 10.1111/j.1365-2958.1995.tb02410.x; Warren MJ, 2003, INFECT IMMUN, V71, P6892, DOI 10.1128/IAI.71.12.6892-6898.2003; Weiser JN, 1998, J EXP MED, V187, P631, DOI 10.1084/jem.187.4.631; Weiser JN, 1998, INFECT IMMUN, V66, P4263; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Winther-Larsen HC, 2001, P NATL ACAD SCI USA, V98, P15276, DOI 10.1073/pnas.261574998; Wolfgang M, 1999, MOL MICROBIOL, V31, P1345, DOI 10.1046/j.1365-2958.1999.01269.x; Wolfgang M, 2000, EMBO J, V19, P6408, DOI 10.1093/emboj/19.23.6408; Wolfgang M, 1998, MOL MICROBIOL, V29, P321, DOI 10.1046/j.1365-2958.1998.00935.x; Wright JC, 2004, J BACTERIOL, V186, P6970, DOI 10.1128/JB.186.20.6970-6982.2004; ZHANG QY, 1992, P NATL ACAD SCI USA, V89, P5366, DOI 10.1073/pnas.89.12.5366	45	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27712	27723		10.1074/jbc.M604324200	http://dx.doi.org/10.1074/jbc.M604324200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16825186	hybrid			2022-12-27	WOS:000240534400007
J	Kamei, N; Tobe, K; Suzuki, R; Ohsugi, M; Watanabe, T; Kubota, N; Ohtsuka-Kowatari, N; Kumagai, K; Sakamoto, K; Kobayashi, M; Yamauchi, T; Ueki, K; Oishi, Y; Nishimura, S; Manabe, I; Hashimoto, H; Ohnishi, Y; Ogata, H; Tokuyama, K; Tsunoda, M; Ide, T; Murakami, K; Nagai, R; Kadowaki, T				Kamei, Nozomu; Tobe, Kazuyuki; Suzuki, Ryo; Ohsugi, Mitsuru; Watanabe, Taku; Kubota, Naoto; Ohtsuka-Kowatari, Norie; Kumagai, Katsuyoshi; Sakamoto, Kentaro; Kobayashi, Masatoshi; Yamauchi, Toshimasa; Ueki, Kohjiro; Oishi, Yumiko; Nishimura, Satoshi; Manabe, Ichiro; Hashimoto, Haruo; Ohnishi, Yasuyuki; Ogata, Hitomi; Tokuyama, Kumpei; Tsunoda, Masaki; Ide, Tomohiro; Murakami, Koji; Nagai, Ryozo; Kadowaki, Takashi			Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; INFLAMMATORY CHANGES; OBESITY; EXPRESSION; ADIPOCYTES; GENE; SUBSTRATE; IDENTIFICATION; DISRUPTION; LIVER	Adipose tissue expression and circulating concentrations of monocyte chemoattractant protein-1 (MCP-1) correlate positively with adiposity. To ascertain the roles of MCP-1 overexpression in adipose, we generated transgenic mice by utilizing the adipocyte P2 (aP2) promoter (aP2-MCP-1 mice). These mice had higher plasma MCP-1 concentrations and increased macrophage accumulation in adipose tissues, as confirmed by immunochemical, flow cytometric, and gene expression analyses. Tumornecrosis factor-alpha and interleukin-6 mRNA levels in white adipose tissue and plasma non-esterified fatty acid levels were increased in transgenic mice. aP2-MCP-1 mice showed insulin resistance, suggesting that inflammatory changes in adipose tissues may be involved in the development of insulin resistance. Insulin resistance in aP2-MCP-1 mice was confirmed by hyperinsulinemic euglycemic clamp studies showing that transgenic mice had lower rates of glucose disappearance and higher endogenous glucose production than wild-type mice. Consistent with this, insulin-induced phosphorylations of Akt were significantly decreased in both skeletal muscles and livers of a P2-MCP-1 mice. MCP-1 pretreatment of isolated skeletal muscle blunted insulin-stimulated glucose uptake, which was partially restored by treatment with the MEK inhibitor U0126, suggesting that circulating MCP-1 may contribute to insulin resistance in aP2MCP-1 mice. We concluded that both paracrine and endocrine effects of MCP-1 may contribute to the development of insulin resistance in aP2-MCP-1 mice.	Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Internal Med, Hiroshima 7348551, Japan; Natl Inst Hlth & Nutr, Div Appl Nutr, Tokyo 1628636, Japan; CREST Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Dis, Tokyo 1138655, Japan; Cent Inst Expt Anim, Kawasaki, Kanagawa 2160001, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; KYORIN Pharmaceut Co Ltd, Shimotsuga 3290114, Japan	University of Tokyo; Hiroshima University; National Institute of Health & Nutrition - Japan; Japan Science & Technology Agency (JST); University of Tokyo; University of Tsukuba	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Suzuki, Ryo/AAA-2736-2019; Manabe, Ichiro/E-1529-2014; Kubota, Naoto/N-7892-2015; Manabe, Ichiro/AAE-5105-2021	Suzuki, Ryo/0000-0002-2965-6906; Kumagai, Katsuyoshi/0000-0003-4072-9907; Watanabe, Taku/0000-0002-3195-2413; Kamei, Nozomu/0000-0002-7686-437X				Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Barlow C, 1997, NUCLEIC ACIDS RES, V25, P2543, DOI 10.1093/nar/25.12.2543; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Christiansen T, 2005, INT J OBESITY, V29, P146, DOI 10.1038/sj.ijo.0802839; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; Fernandez-Real JM, 2003, ENDOCR REV, V24, P278, DOI 10.1210/er.2002-0010; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; GRAVES RA, 1992, J CELL BIOCHEM, V49, P219, DOI 10.1002/jcb.240490303; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kamei N, 2005, METABOLISM, V54, P713, DOI 10.1016/j.metabol.2004.12.016; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; Linton MF, 2003, INT J OBESITY, V27, pS35, DOI 10.1038/sj.ijo.0802498; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Murakami K, 1999, METABOLISM, V48, P1450, DOI 10.1016/S0026-0495(99)90158-0; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Soukas A, 2000, GENE DEV, V14, P963; Suganami T, 2005, ARTERIOSCL THROM VAS, V25, P2062, DOI 10.1161/01.ATV.0000183883.72263.13; Suzuki R, 2004, J BIOL CHEM, V279, P25039, DOI 10.1074/jbc.M311956200; Suzuki R, 2003, J BIOL CHEM, V278, P43691, DOI 10.1074/jbc.M307004200; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Takahashi M, 2005, AM J PHYSIOL-ENDOC M, V288, pE117, DOI 10.1152/ajpendo.00244.2004; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	42	648	674	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26602	26614		10.1074/jbc.M601284200	http://dx.doi.org/10.1074/jbc.M601284200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809344	hybrid			2022-12-27	WOS:000240249500078
J	Yang, ST; Jeong, JH; Brown, AL; Lee, CH; Pandolfi, PP; Chung, JH; Kim, MK				Yang, Shutong; Jeong, Jae-Hoon; Brown, Alexandra L.; Lee, Chang-Hun; Pandolfi, Pier Paolo; Chung, Jay H.; Kim, Myung K.			Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; PML NUCLEAR-BODIES; RETINOIC ACID; RAR-ALPHA; TUMOR-SUPPRESSOR; HISTONE H2AX; CHECKPOINT; PROTEIN; PHOSPHORYLATION; APOPTOSIS	Chk2 is a kinase critical for DNA damage- induced apoptosis and is considered a tumor suppressor. Chk2 is essential for p53 transcriptional and apoptotic activities. Although mutations of p53 are present in more than half of all tumors, mutations of Chk2 in cancers are rare, suggesting that Chk2 may be inactivated by unknown alternative mechanisms. Here we elucidate one such alternative mechanism regulated by PML (promyelocytic leukemia) that is involved in acute promyelocytic leukemia (APL). Although p53 inactivating mutations are extremely rare in APL, t(15; 17) chromosomal translocation which fuses retinoic acid receptor (RAR alpha) to PML is almost always present in APL, while the other PML allele is intact. We demonstrate that PML interacts with Chk2 and activates Chk2 by mediating its autophosphorylation step, an essential step for Chk2 activity that occurs after phosphorylation by the upstream kinase ATM (ataxia telangiectasia- mutated). PML/ RAR alpha in APL suppresses Chk2 by dominantly inhibiting the autophosphorylation step, but inactivation of PML/ RAR alpha with alltrans retinoic acid (ATRA) restores Chk2 autophosphorylation and activity. Thus, by fusing PML with RAR alpha, the APL cells appear to have achieved functional suppression of Chk2 compromising the Chk2- p53 apoptotic pathway.	NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chung, JH (corresponding author), NHLBI, Lab Biochem Genet, NIH, 10 Ctr Dr,Bldg 10,Rm 7D14, Bethesda, MD 20892 USA.	ChungJ@nhlbi.nih.gov; KimM@nhlbi.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002243, Z01HL002243] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; BOND JA, 1994, ONCOGENE, V9, P1885; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Kwok C, 2006, CANCER CELL, V9, P95, DOI 10.1016/j.ccr.2006.01.005; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lombard DB, 2000, CANCER RES, V60, P2331; LONGO L, 1993, LEUKEMIA LYMPHOMA, V11, P405, DOI 10.3109/10428199309067933; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Pandolfi PP, 2001, ONCOGENE, V20, P5726, DOI 10.1038/sj.onc.1204600; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Rego EM, 2006, ONCOGENE, V25, P1974, DOI 10.1038/sj.onc.1209216; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Sternsdorf T, 2006, CANCER CELL, V9, P81, DOI 10.1016/j.ccr.2005.12.030; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Xu ZX, 2005, MOL CELL, V17, P721, DOI 10.1016/j.molcel.2005.02.014; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	46	41	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26645	26654		10.1074/jbc.M604391200	http://dx.doi.org/10.1074/jbc.M604391200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835227	hybrid			2022-12-27	WOS:000240249500082
J	Fernandez, MM; Guan, RJ; Swaminathan, CP; Malchiodi, EL; Mariuzza, RA				Fernandez, Marisa M.; Guan, Rongjin; Swaminathan, Chittoor P.; Malchiodi, Emilio L.; Mariuzza, Roy A.			Crystal structure of staphylococcal enterotoxin I (SEI) in complex with a human major histocompatibility complex class II molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC-SHOCK-SYNDROME; RECEPTOR BETA-CHAIN; T-CELL-ACTIVATION; 3-DIMENSIONAL STRUCTURE; HIGH-AFFINITY; BINDING SITE; SUPERANTIGENS; PEPTIDE; ZINC; TCR	Superantigens are bacterial or viral proteins that elicit massive T cell activation through simultaneous binding to major histocompatibility complex (MHC) class II and T cell receptors. This activation results in uncontrolled release of inflammatory cytokines, causing toxic shock. A remarkable property of superantigens, which distinguishes them from T cell receptors, is their ability to interact with multiple MHC class II alleles independently of MHC-bound peptide. Previous crystallographic studies have shown that staphylococcal and streptococcal superantigens belonging to the zinc family bind to a high affinity site on the class II beta-chain. However, the basis for promiscuous MHC recognition by zinc-dependent superantigens is not obvious, because the beta-chain is polymorphic and the MHC-bound peptide forms part of the binding interface. To understand how zinc-dependent superantigens recognize MHC, we determined the crystal structure, at 2.0 A resolution, of staphylococcal enterotoxin I bound to the human class II molecule HLA-DR1 bearing a peptide from influenza hemagglutinin. Interactions between the superantigen and DR1 beta-chain are mediated by a zinc ion, and 22% of the buried surface of peptide(.)MHC is contributed by the peptide. Comparison of the staphylococcal enterotoxin I(.)peptide(.)DR1 structure with ones determined previously revealed that zinc-dependent superantigens achieve promiscuous binding to MHC by targeting conservatively substituted residues of the polymorphic beta-chain. Additionally, these superantigens circumvent peptide specificity by engaging MHC-bound peptides at their conformationally conserved N-terminal regions while minimizing sequence-specific interactions with peptide residues to enhance cross-reactivity.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Struct Biol Lab, Rockville, MD 20850 USA; Univ Buenos Aires, Fac Farm & Bioquim, Catedra Inmunol, Lab Inmunol Estructural,Consejo Nacl Invest Cient, RA-1113 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Farm & Bioquim, Inst Estudios Inmunidad Humoral, Lab Inmunol Estructural,Consejo Nacl Invest Cient, RA-1113 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Mariuzza, RA (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Struct Biol Lab, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	mariuzza@carb.nist.gov		Fernandez, Marisa/0000-0002-7480-5907; Malchiodi, Emilio/0000-0001-7501-3330	NIAID NIH HHS [R01 AI036900, R37 AI036900, R37 AI036900-12] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036900, R01AI036900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banks MC, 2003, J INFECT DIS, V187, P77, DOI 10.1086/345874; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; Cho SW, 2005, STRUCTURE, V13, P1775, DOI 10.1016/j.str.2005.08.015; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Fernandez MM, 2006, MOL IMMUNOL, V43, P927, DOI 10.1016/j.molimm.2005.06.029; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Hemmer B, 2000, J IMMUNOL, V164, P861, DOI 10.4049/jimmunol.164.2.861; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Jarraud S, 2001, J IMMUNOL, V166, P669, DOI 10.4049/jimmunol.166.1.669; Kieke MC, 2001, J MOL BIOL, V307, P1305, DOI 10.1006/jmbi.2001.4560; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Kotb M, 1998, CURR OPIN MICROBIOL, V1, P56, DOI 10.1016/S1369-5274(98)80143-4; Langley R, 2005, J IMMUNOL, V174, P2926, DOI 10.4049/jimmunol.174.5.2926; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375; Li YL, 2005, EMBO J, V24, P2968, DOI 10.1038/sj.emboj.7600771; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; McCormick JK, 2000, GRAM-POSITIVE PATHOGENS, P43; McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicholson MJ, 2005, IMMUNITY, V23, P351, DOI 10.1016/j.immuni.2005.09.009; Omoe K, 2002, J CLIN MICROBIOL, V40, P857, DOI 10.1128/JCM.40.3.857-862.2002; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; Papageorgiou AC, 2004, J BIOL CHEM, V279, P1297, DOI 10.1074/jbc.M307333200; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; Roussel A, 1997, NAT STRUCT BIOL, V4, P635, DOI 10.1038/nsb0897-635; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Sundberg E, 1999, NAT STRUCT BIOL, V6, P123; Sundberg EJ, 2002, CURR OPIN IMMUNOL, V14, P36, DOI 10.1016/S0952-7915(01)00296-5; Sundberg EJ, 2003, STRUCTURE, V11, P1151, DOI 10.1016/S0969-2126(03)00187-4; Sundberg EJ, 2002, STRUCTURE, V10, P687, DOI 10.1016/S0969-2126(02)00759-1; Sundstrom M, 1996, J BIOL CHEM, V271, P32212, DOI 10.1074/jbc.271.50.32212; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; Zavala-Ruiz Z, 2003, J BIOL CHEM, V278, P44904, DOI 10.1074/jbc.M307652200	48	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25356	25364		10.1074/jbc.M603969200	http://dx.doi.org/10.1074/jbc.M603969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829512	Green Accepted, hybrid			2022-12-27	WOS:000240031300037
J	Hur, GM; Kim, YS; Won, M; Choksi, S; Liu, ZG				Hur, Gang Min; Kim, You-Sun; Won, Minho; Choksi, Swati; Liu, Zheng-Gang			The death domain kinase RIP has an important role in DNA damage-induced, p53-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; RECEPTOR-INTERACTING PROTEIN; JNK ACTIVATION; P53; NECROSIS; STRESS; RESISTANCE; APOPTOSIS; RESPONSES; PATHWAY	Tumor suppressor p53 plays a critical role in cellular responses, such as cell cycle arrest and apoptosis following DNA damage. DNA damage-induced cell death can be mediated by a p53-dependent or p53-independent pathway. Although p53-mediated apoptosis has been well documented, little is known about the signaling components of p53-independent cell death. Here we report that the death domain kinase, RIP (receptor-interacting protein), is important for DNA damage-induced, p53-independent cell death. DNA damage induces cell death in both wild-type and p53(-/-) mouse embryonic fibroblast cells. We found that RIP-/- mouse embryonic fibroblast cells, which have a mutant form of the p53 protein, are resistant to DNA damage-induced cell death. The reconstitution of RIP protein expression in RIP-/- cells restored the sensitivity of cells to DNA damage-induced cell death. We also found that RIP mediates this process through activating mitogen-activated protein kinase, JNK1. Furthermore, knocking down the expression of RIP blocked DNA damage-induced cell death in the human colon cancer cell line, p53 null HCT 116. Taken together, our study demonstrates that RIP is one of the critical components involved in mediating DNA damage-induced, p53-independent cell death.	NCI, Cell & Canc Biol Branch, NIH, Canc Res Ctr, Bethesda, MD 20892 USA; Chungnam Natl Univ, Dept Pharmacol, Coll Med, Taejon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chungnam National University	Liu, ZG (corresponding author), NCI, Cell & Canc Biol Branch, NIH, Canc Res Ctr, 37 Convent Dr,Rm 1066A, Bethesda, MD 20892 USA.	zgliu@helix.nih.gov	Hur, Gang-min/ABF-9263-2021	Hur, Gang-min/0000-0003-4870-6574; Won, Minho/0000-0002-5873-5216	NATIONAL CANCER INSTITUTE [ZIASC010376, Z01SC010376] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Petak Istvan, 2001, Pathology and Oncology Research, V7, P95; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waring P, 1999, IMMUNOL CELL BIOL, V77, P312, DOI 10.1046/j.1440-1711.1999.00837.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zunino F, 1997, PHARMACOL THERAPEUT, V76, P177, DOI 10.1016/S0163-7258(97)00086-7	27	21	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25011	25017		10.1074/jbc.M605577200	http://dx.doi.org/10.1074/jbc.M605577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825191	hybrid			2022-12-27	WOS:000240031300003
J	Izadi-Pruneyre, N; Huche, F; Lukat-Rodgers, GS; Lecroisey, A; Gilli, R; Rodgers, KR; Wandersman, C; Delepelaire, P				Izadi-Pruneyre, Nadia; Huche, Frederic; Lukat-Rodgers, Gudrun S.; Lecroisey, Anne; Gilli, Robert; Rodgers, Kenton R.; Wandersman, Cecile; Delepelaire, Philippe			The heme transfer from the soluble HasA hemophore to its membrane-bound receptor HasR is driven by protein-protein interaction from a high to a lower affinity binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; RESONANCE RAMAN; RESIDUES; IDENTIFICATION; HAEMOPHORE; TRANSPORT; PLUG	HasA is an extracellular heme binding protein, and HasR is an outer membrane receptor protein from Serratia marcescens. They are the initial partners of a heme internalization system allowing S. marcescens to scavenge heme at very low concentrations due to the very high affinity of HasA for heme (K-a = 5,3 x 10(10) M-1). Heme is then transferred to HasR, which has a lower affinity for heme. The mechanism of the heme transfer between HasA and HasR is largely unknown. HasR has been overexpressed and purified in holo and apo forms. It binds one heme molecule with a Ka of 5 x 10(6) M-1 and shows the characteristic absorbance spectrum of a low spin heme iron. Both holoHasA and apoHasA bind tightly to apoHasR in a 1:1 stoichiometry. In this study we show that heme transfer occurs in vitro in the purified HasA (.) HasR complex, demonstrating that heme transfer is energy- and TonB complex-independent and driven by a protein-protein interaction. We also show that heme binding to HasR involves two conserved histidine residues.	Inst Pasteur, CNRS URA 2172, Unite Membranes Bacteriennes, Dept Microbiol, F-75724 Paris 15, France; Inst Pasteur, CNRS URA 2185, Dept Biol Struct & Chim, Unite Resonance Magnet Nucl Biomol, F-75724 Paris 15, France; Univ Aix Marseille 2, CNRS FRE 2737, Fac Pharm, F-13385 Marseille 05, France; N Dakota State Univ, Dept Chem Biochem & Mol Biol, Fargo, ND 58105 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Aix-Marseille Universite; North Dakota State University Fargo	Delepelaire, P (corresponding author), Inst Pasteur, CNRS URA 2172, Unite Membranes Bacteriennes, Dept Microbiol, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	pdelep@pasteur.fr		Izadi-Pruneyre, Nadia/0000-0002-6864-2961; Delepelaire, Philippe/0000-0002-5190-7118	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015566] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015566, P20 RR15556] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Annamalai R, 2004, J BACTERIOL, V186, P3578, DOI 10.1128/JB.186.11.3578-3589.2004; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Bracken CS, 1999, J BACTERIOL, V181, P6063, DOI 10.1128/JB.181.19.6063-6072.1999; Caillet-Saguy C, 2006, J AM CHEM SOC, V128, P150, DOI 10.1021/ja054902h; CHOI SH, 1983, J AM CHEM SOC, V105, P3683, DOI 10.1021/ja00349a056; Cornelissen CN, 2003, FRONT BIOSCI-LANDMRK, V8, pD836, DOI 10.2741/1076; Cwerman H, 2006, J BACTERIOL, V188, P3357, DOI 10.1128/JB.188.9.3357-3364.2006; Deniau C, 2003, BIOCHEMISTRY-US, V42, P10627, DOI 10.1021/bi030015k; Ferguson AD, 2004, CELL, V116, P15, DOI 10.1016/S0092-8674(03)01030-4; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; HURST JK, 1991, J BIOL CHEM, V266, P1627; Izadi N, 1997, BIOCHEMISTRY-US, V36, P7050, DOI 10.1021/bi962577s; Krell T, 2003, J BIOL CHEM, V278, P14712, DOI 10.1074/jbc.M204461200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lansky IB, 2006, J BIOL CHEM, V281, P13652, DOI 10.1074/jbc.M600824200; Letoffe S, 2005, J BACTERIOL, V187, P4637, DOI 10.1128/JB.187.13.4637-4645.2005; Letoffe S, 2004, J BACTERIOL, V186, P4067, DOI 10.1128/JB.186.13.4067-4074.2004; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; Letoffe S, 2003, MOL MICROBIOL, V50, P77, DOI 10.1046/j.1365-2958.2003.03686.x; Letoffe S, 2001, MOL MICROBIOL, V41, P439, DOI 10.1046/j.1365-2958.2001.02530.x; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Liu XY, 2006, INFECT IMMUN, V74, P1222, DOI 10.1128/IAI.74.2.1222-1232.2006; MAITI NC, 1995, J PHYS CHEM-US, V99, P10708, DOI 10.1021/j100027a006; Paoli M, 1999, NAT STRUCT BIOL, V6, P926; Retzer MD, 1999, MOL MICROBIOL, V32, P111, DOI 10.1046/j.1365-2958.1999.01331.x; Schalk IJ, 2001, MOL MICROBIOL, V39, P351, DOI 10.1046/j.1365-2958.2001.02207.x; Sprencel C, 2000, J BACTERIOL, V182, P5359, DOI 10.1128/JB.182.19.5359-5364.2000; Usher KC, 2001, P NATL ACAD SCI USA, V98, P10676, DOI 10.1073/pnas.181353398; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	34	84	86	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25541	25550		10.1074/jbc.M603698200	http://dx.doi.org/10.1074/jbc.M603698200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16774915	hybrid			2022-12-27	WOS:000240031300057
J	Koleva, RI; Conley, BA; Romero, D; Riley, KS; Marto, JA; Lux, A; Vary, CPH				Koleva, Rositsa I.; Conley, Barbara A.; Romero, Diana; Riley, Kristin S.; Marto, Jarrod A.; Lux, Andreas; Vary, Calvin P. H.			Endoglin structure and function - Determinants of endoglin phosphorylation by transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; BINDING PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; I RECEPTORS; EXPRESSION ANALYSIS; MASS-SPECTROMETRY; EPITHELIAL-CELLS; KINASE-1 GENE; COMPLEX; ANGIOGENESIS	Determination of the functional relationship between the transforming growth factor-beta(TGF beta) receptor proteins endoglin and ALK1 is essential to the understanding of the human vascular disease, hereditary hemorrhagic telangiectasia. TGF beta 1 caused recruitment of ALK1 into a complex with endoglin in human umbilical vein endothelial cells (HUVECs). Therefore, we examined TGF beta receptor-dependent phosphorylation of endoglin by the constitutively active forms of the TGF beta type I receptors ALK1, ALK5, and the TGF beta type II receptor, T beta RII. Of these receptors, T beta RII preferentially phosphorylated endoglin on cytosolic domain serine residues Ser(634) and Ser(635). Removal of the carboxyl-terminal tripeptide of endoglin, which comprises a putative PDZ-liganding motif, dramatically increased endoglin serine phosphorylation by all three receptors, suggesting that the PDZ-liganding motif is important for the regulation of endoglin phosphorylation. Constitutively active (ca) ALK1, but not caALK5, phosphorylated endoglin on cytosolic domain threonine residues. caALK1-mediated threonine phosphorylation required prior serine phosphorylation, suggesting a sequential mechanism of endoglin phosphorylation. Wild-type, but not a threonine phosphorylation-defective endoglin mutant blocked cell detachment and the antiproliferative effects of caALK1 expressed inHUVECs. These results suggest that ALK1 is a preferred TGF beta receptor kinase for endoglin threonine phosphorylation in HUVECs and indicate a role for endoglin phosphorylation in the regulation of endothelial cell adhesion and growth by ALK1.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Univ Hosp, D-68163 Mannheim, Germany; Univ Appl Sci, Inst Cell & Mol Biol, D-68163 Mannheim, Germany	Maine Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Ruprecht Karls University Heidelberg	Vary, CPH (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	varyc@mmc.org	Romero, Diana/GWU-9250-2022		PHS HHS [P20 15555] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abdalla SA, 2000, HUM MOL GENET, V9, P1227, DOI 10.1093/hmg/9.8.1227; Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blanco FJ, 2005, J CELL PHYSIOL, V204, P574, DOI 10.1002/jcp.20311; BLOBE GC, 2001, J BIOL CHEM, V23, P23; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Ficarro S, 2003, J BIOL CHEM, V278, P11579, DOI 10.1074/jbc.M202325200; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Lamouille S, 2002, BLOOD, V100, P4495, DOI 10.1182/blood.V100.13.4495; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Meurer SK, 2005, J BIOL CHEM, V280, P3078, DOI 10.1074/jbc.M405411200; Muenzner P, 2005, J CELL BIOL, V170, P825, DOI 10.1083/jcb.200412151; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Paquet ME, 2001, HUM MOL GENET, V10, P1347, DOI 10.1093/hmg/10.13.1347; Pece-Barbara N, 1999, HUM MOL GENET, V8, P2171, DOI 10.1093/hmg/8.12.2171; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Raab U, 1999, BIOCHEM J, V339, P579, DOI 10.1042/0264-6021:3390579; Sanz-Rodriguez F, 2004, CLIN CHEM, V50, P2003, DOI 10.1373/clinchem.2004.035287; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Schmidt-Weber CB, 2005, INT IMMUNOL, V17, P921, DOI 10.1093/intimm/dxh272; Seki T, 2006, LAB INVEST, V86, P116, DOI 10.1038/labinvest.3700376; Seki T, 2004, CIRC RES, V94, pE72, DOI 10.1161/01.RES.0000127048.81744.31; Steen H, 2001, J MASS SPECTROM, V36, P782, DOI 10.1002/jms.174; Tang H, 2005, BLOOD, V105, P1977, DOI 10.1182/blood-2004-08-3308; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995	60	84	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25110	25123		10.1074/jbc.M601288200	http://dx.doi.org/10.1074/jbc.M601288200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16785228	hybrid			2022-12-27	WOS:000240031300012
J	LaVallie, ER; Chockalingam, PS; Collins-Racie, LA; Freeman, BA; Keohan, CC; Leitges, M; Dorner, AJ; Morris, EA; Majumdar, MK; Arai, M				LaVallie, Edward R.; Chockalingam, Priya S.; Collins-Racie, Lisa A.; Freeman, Bethany A.; Keohan, Cristin C.; Leitges, Michael; Dorner, Andrew J.; Morris, Elisabeth A.; Majumdar, Manas K.; Arai, Maya			Protein kinase C zeta is up-regulated in osteoarthritic cartilage and is required for activation of NF-kappa B by tumor necrosis factor and interleukin-1 in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TNF-ALPHA; METALLOPROTEINASE EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PROINFLAMMATORY CYTOKINE; GENE-EXPRESSION; POTENTIAL ROLE; ADAMTS FAMILY; ATYPICAL PKCS; CELLS	Protein kinase C zeta(PKC zeta) is an intracellular serine/threonine protein kinase that has been implicated in the signaling pathways for certain inflammatory cytokines,including interleukin-1 (IL-1) and tumor necrosis factor alpha(TNF-alpha), in some cell types. A study of gene expression in articular chondrocytes from osteoarthritis (OA) patients revealed that PKC zeta is transcriptionally up-regulated in human OA articular cartilage clinical samples. This finding led to the hypothesis that PKC zeta may be an important signaling component of cytokine-mediated cartilage matrix destruction in articular chondrocytes, believed to be an underlying factor in the pathophysiology of OA. IL-1 treatment of chondrocytes in culture resulted in rapidly increased phosphorylation of PKC zeta, implicating PKC zeta activation in the signaling pathway. Chondrocyte cell-based assays were used to evaluate the contribution of PKC zeta activity in NF-kappa B activation and extracellular matrix degradation mediated by IL-1, TNF, or sphingomyelinase. In primary chondrocytes, IL-1 and TNF-alpha caused an increase in NF-kappa B activity resulting in induction of aggrecanase-1 and aggrecanase-2 expression, with consequent increased proteoglycan degradation. This effect was blocked by the pan-specific PKC inhibitors RO 31-8220 and bisindolylmaleimide I, partially blocked by Go 6976, and was unaffected by the PKC zeta- sparing inhibitor calphostin C. A cell-permeable PKC zeta pseudosubstrate peptide inhibitor was capable of blocking TNF- and IL-1-mediated NF-kappa B activation and proteoglycan degradation in chondrocyte pellet cultures. In addition, overexpression of a dominant negative PKC zeta protein effectively prevented cytokine-mediated NF-kappa B activation in primary chondrocytes. These data implicate PKC zeta as a necessary component of the IL-1 and TNF signaling pathways in chondrocytes that result in catabolic destruction of extracellular matrix proteins in osteoarthritic cartilage.	Wyeth Ayerst Res, Dept Biol Technol, Cambridge, MA 02140 USA; Wyeth Ayerst Res, Dept Womens Hlth & Musculoskeletal Biol, Cambridge, MA 02140 USA; Hannover Med Sch, D-30625 Hannover, Germany; Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA	Pfizer; Pfizer; Hannover Medical School; Boston University	LaVallie, ER (corresponding author), Wyeth Ayerst Res, Dept Biol Technol, 35 Cambridge Pk Dr,Rm Y1106, Cambridge, MA 02140 USA.	elavallie@wyeth.com	Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Aigner T, 2002, CURR OPIN RHEUMATOL, V14, P578, DOI 10.1097/00002281-200209000-00018; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Alden TD, 1999, HUM GENE THER, V10, P2245, DOI 10.1089/10430349950017220; Arai M, 2004, OSTEOARTHR CARTILAGE, V12, P599, DOI 10.1016/j.joca.2004.05.001; Attur MG, 2002, OSTEOARTHR CARTILAGE, V10, P1, DOI 10.1053/joca.2001.0488; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; BRANDT KD, 2000, DIAGNOSIS NONSURGICA; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Domm C, 2002, OSTEOARTHR CARTILAGE, V10, P13, DOI 10.1053/joca.2001.0477; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; FARAHAT MN, 1993, ANN RHEUM DIS, V52, P870, DOI 10.1136/ard.52.12.870; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Fernandes JC, 2002, BIORHEOLOGY, V39, P237; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926-000-0021-y; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Goldring MB, 2001, EXPERT OPIN BIOL TH, V1, P817, DOI 10.1517/14712598.1.5.817; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HARDINGHAM TE, 1986, CIBA F SYMP, V124, P30; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Hauselmann HJ, 1996, ARTHRITIS RHEUM, V39, P478, DOI 10.1002/art.1780390316; Hedbom E, 2002, CELL MOL LIFE SCI, V59, P45, DOI 10.1007/s00018-002-8404-z; Hernandez AI, 2003, J BIOL CHEM, V278, P40305, DOI 10.1074/jbc.M307065200; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Kim HY, 2002, INFECT IMMUN, V70, P4132, DOI 10.1128/IAI.70.8.4132-4141.2002; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lisby S, 2002, EXP DERMATOL, V11, P592, DOI 10.1034/j.1600-0625.2002.110612.x; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Martin P, 2002, EMBO J, V21, P4049, DOI 10.1093/emboj/cdf407; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscat J, 2001, ADV ENZYME REGUL, V41, P99, DOI 10.1016/S0065-2571(00)00009-1; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nee LE, 2004, KIDNEY INT, V66, P1376, DOI 10.1111/j.1523-1755.2004.00900.x; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Oster H, 2004, MOL BRAIN RES, V127, P79, DOI 10.1016/j.molbrainres.2004.05.009; Pattoli MA, 2005, J PHARMACOL EXP THER, V315, P382, DOI 10.1124/jpet.105.087569; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Roshak AK, 2002, CURR OPIN PHARMACOL, V2, P316, DOI 10.1016/S1471-4892(02)00165-0; Rybakina E G, 2001, Neurosci Behav Physiol, V31, P439, DOI 10.1023/A:1010448930994; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schneider C, 2001, CYTOKINE, V13, P174, DOI 10.1006/cyto.2000.0817; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shi J, 2004, INFLAMM RES, V53, P377, DOI 10.1007/s00011-004-1271-3; Shibakawa A, 2003, OSTEOARTHR CARTILAGE, V11, P133, DOI 10.1053/joca.2002.0871; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Verbruggen G, 2006, RHEUMATOLOGY, V45, P129, DOI 10.1093/rheumatology/kei171; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Xie ZL, 2003, J BIOL CHEM, V278, P48546, DOI 10.1074/jbc.M302727200; YOSHIMICHI G, 2006, BONE ELMSFORD, V38, P853; Zhang MK, 2000, J CELL BIOCHEM, V76, P290, DOI 10.1002/(SICI)1097-4644(20000201)76:2<290::AID-JCB12>3.0.CO;2-V	76	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24124	24137		10.1074/jbc.M601905200	http://dx.doi.org/10.1074/jbc.M601905200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798739	hybrid			2022-12-27	WOS:000239847800007
J	Bedoukian, MA; Weeks, AM; Partin, KM				Bedoukian, Matthew A.; Weeks, Autumn M.; Partin, Kathryn M.			Different domains of the AMPA receptor direct stargazin-mediated trafficking and stargazin-mediated modulation of kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE EXPRESSION; TERMINAL DOMAIN; GLUTAMATE; DESENSITIZATION; DEACTIVATION; GLUR1; ALPHA-AMINO-3-HYDROXYL-5-METHYL-4-ISOXAZOLEPROPIONATE; DETERMINANT; PLASTICITY; PROTEINS	Stargazin is an accessory protein of AMPA receptors that enhances surface expression and also affects the biophysical properties of the receptor. AMPA receptor domains necessary for either of these two processes have not yet been identified. Here, we used confocal imaging and electrophysiology of heterologously expressed, fluorophore-tagged GluR1, GluR2, and stargazin to study surface expression and desensitization kinetics. Stargazin-mediated trafficking was sensitive to the nature of the AMPA receptor cytoplasmic domain. The insertion of YFP after residue 15 of the truncated cytoplasmic tail of GluR1i perturbed stargazin-mediated trafficking of the receptor but not its modulation of desensitization kinetics. This construct also failed to permit fluorescence resonance energy transfer ( FRET) with stargazin in the endoplasmic reticulum ( ER), whereas FRET between fluorophore-tagged stargazin and non-truncated AMPA receptors demonstrated a specific interaction between these proteins, both in the ER and the plasma membrane. Rather than encoding a specific binding site, the fluorophore-tagged C terminus may restrict access to one or more ER retention sites. Although perturbations of the C terminus impeded stargazin-mediated trafficking to the plasma membrane, the effects of stargazin on the biophysical properties of AMPA receptors ( i.e. modulation of desensitization) remained intact. These data provide strong evidence that the AMPA receptor domains required for stargazin modulation of gating and trafficking are separable.	Colorado State Univ, Dept Biomed Sci, Div Neurosci, Ft Collins, CO 80523 USA	Colorado State University	Partin, KM (corresponding author), Colorado State Univ, Dept Biomed Sci, Div Neurosci, Ft Collins, CO 80523 USA.	kpartin@lamar.colostate.edu	Partin, Kathryn/A-8706-2015; Partin, Kathryn/AAI-5412-2021	Partin, Kathryn/0000-0003-3801-3299; Partin, Kathryn/0000-0003-3801-3299	NIMH NIH HHS [R01MH64700, R01 MH064700] Funding Source: Medline; NINDS NIH HHS [NS43115-02] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS043115] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAI AC, 2005, ABSTRACT VIEWER ITIN; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; Black JL, 2003, J BIOENERG BIOMEMBR, V35, P649, DOI 10.1023/B:JOBB.0000008029.22650.c5; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen L, 2003, MOL PHARMACOL, V64, P703, DOI 10.1124/mol.64.3.703; Coleman SK, 2003, J NEUROSCI, V23, P798; Corboy Michael J., 2005, V301, P305; Dingledine R, 1999, PHARMACOL REV, V51, P7; Gouaux E, 2004, J PHYSIOL-LONDON, V554, P249, DOI 10.1113/jphysiol.2003.054320; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Hall RA, 1997, J NEUROCHEM, V68, P625; Hayashi T, 2005, NEURON, V47, P709, DOI 10.1016/j.neuron.2005.06.035; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Jin RS, 2005, J NEUROSCI, V25, P9027, DOI 10.1523/JNEUROSCI.2567-05.2005; Kang MG, 2006, P NATL ACAD SCI USA, V103, P5561, DOI 10.1073/pnas.0601289103; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Koike M, 2000, J NEUROSCI, V20, P2166; Leever JD, 2003, MOL PHARMACOL, V64, P5, DOI 10.1124/mol.64.1.5; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Letts Verity A, 2005, Epilepsy Curr, V5, P161, DOI 10.1111/j.1535-7511.2005.00051.x; Leuranguer V, 2006, J BIOL CHEM, V281, P3521, DOI 10.1074/jbc.M509566200; Malenka RC, 2003, ANN NY ACAD SCI, V1003, P1, DOI 10.1196/annals.1300.001; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mayer ML, 2005, CURR OPIN NEUROBIOL, V15, P282, DOI 10.1016/j.conb.2005.05.004; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; Nakagawa T, 2006, BIOL CHEM, V387, P179, DOI 10.1515/BC.2006.024; Nakagawa T, 2005, NATURE, V433, P545, DOI 10.1038/nature03328; Nicoll RA, 2006, SCIENCE, V311, P1253, DOI 10.1126/science.1123339; O'Connell KMS, 2005, J CELL SCI, V118, P2155, DOI 10.1242/jcs.02348; Palmer CL, 2005, PHARMACOL REV, V57, P253, DOI 10.1124/pr.57.2.7; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Pasternack A, 2002, J BIOL CHEM, V277, P49662, DOI 10.1074/jbc.M208349200; Price MG, 2005, J BIOL CHEM, V280, P19711, DOI 10.1074/jbc.M500623200; Priel A, 2005, J NEUROSCI, V25, P2682, DOI 10.1523/JNEUROSCI.4834-04.2005; Rouach N, 2005, NAT NEUROSCI, V8, P1525, DOI 10.1038/nn1551; Shen L, 2000, J NEUROSCI, V20, P7932; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Sugiyama Y, 2005, NAT METHODS, V2, P677, DOI 10.1038/NMETH783; Suzuki E, 2005, MOL CELL NEUROSCI, V29, P1, DOI 10.1016/j.mcn.2005.01.004; Tomita S, 2005, NATURE, V435, P1052, DOI 10.1038/nature03624; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Tomita S, 2004, SCIENCE, V303, P1508, DOI 10.1126/science.1090262; Turetsky D, 2005, J NEUROSCI, V25, P7438, DOI 10.1523/JNEUROSCI.1108-05.2005; Vandenberghe W, 2005, P NATL ACAD SCI USA, V102, P485, DOI 10.1073/pnas.0408269102; Xu DS, 2003, NEURON, V39, P513, DOI 10.1016/S0896-6273(03)00463-X; Yachi PP, 2005, NAT IMMUNOL, V6, P785, DOI 10.1038/ni1220; Yamazaki M, 2004, NEUROSCI RES, V50, P369, DOI 10.1016/j.neures.2004.10.002; Zheng F, 2001, NAT NEUROSCI, V4, P894, DOI 10.1038/nn0901-894	51	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23908	23921		10.1074/jbc.M600679200	http://dx.doi.org/10.1074/jbc.M600679200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793768	hybrid			2022-12-27	WOS:000239702900066
J	Gong, P; Martin, CT				Gong, Peng; Martin, Craig T.			Mechanism of instability in abortive cycling by T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; INITIAL BUBBLE COLLAPSE; ELONGATION COMPLEX; TRANSCRIPTION INITIATION; STRUCTURAL BASIS; DNA; RELEASE; BACTERIOPHAGE-T7; STABILITY; FLUORESCENCE	Abortive transcription, the premature release of short transcripts 2-8 bases in length, is a unique feature of transcription, accompanying the transition from initiation to elongation in all RNA polymerases. The current study focuses on major factors that relate to the stability of initially transcribing abortive complexes in T7 RNA polymerase. Building on previous studies, results reveal that collapse of the DNA from the downstream end of the bubble is a major contributor to the characteristic instability of abortive complexes. Furthermore, transcription from a novel DNA construct containing a nick between positions -14 and -13 of the nontemplate strand suggests that the more flexible promoter reduces somewhat the strain inherent in initially transcribing complexes, with a resulting decrease in abortive product release. Finally, as assessed by exonuclease III footprinting and transcription profiles, a DNA construct defective in bubble collapse specifically from the downstream end exhibits less abortive cycling and little perturbation of the final transition to elongation, including the process of promoter release.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Martin, CT (corresponding author), Univ Massachusetts, Dept Chem, 710 N Pleasant St,LGRT 701, Amherst, MA 01003 USA.	CMartin@chem.umass.edu	Martin, Craig T/L-3596-2013; Gong, Peng/ABD-6333-2021	Martin, Craig T/0000-0003-1029-5239; 	NIGMS NIH HHS [R01 GM055002, 1R01 GM55002] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; Esposito EA, 2004, J BIOL CHEM, V279, P44270, DOI 10.1074/jbc.M407688200; Gong P, 2004, J BIOL CHEM, V279, P44277, DOI 10.1074/jbc.M409118200; Guo Q, 2005, J BIOL CHEM, V280, P14956, DOI 10.1074/jbc.M500518200; Guo Q, 2005, J BIOL CHEM, V280, P3474, DOI 10.1074/jbc.M412287200; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Kuzmine I, 2001, J MOL BIOL, V305, P559, DOI 10.1006/jmbi.2000.4316; LESCURE B, 1981, NUCLEIC ACIDS RES, V9, P31, DOI 10.1093/nar/9.1.31; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Martin CT, 2005, PROG NUCLEIC ACID RE, V80, P323, DOI 10.1016/S0079-6603(05)80008-X; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; STRANEY DC, 1987, J MOL BIOL, V193, P279, DOI 10.1016/0022-2836(87)90219-1; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Tang GQ, 2006, BIOCHEMISTRY-US, V45, P4936, DOI 10.1021/bi0522910; Theis K, 2004, BIOCHEMISTRY-US, V43, P12709, DOI 10.1021/bi0486987; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	34	19	19	4	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23533	23544		10.1074/jbc.M604023200	http://dx.doi.org/10.1074/jbc.M604023200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790422	hybrid			2022-12-27	WOS:000239702900028
J	Rapti, M; Knauper, V; Murphy, G; Williamson, RA				Rapti, Magdalini; Knauper, Vera; Murphy, Gillian; Williamson, Richard A.			Characterization of the AB loop region of TIMP-2 - Involvement in pro-MMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE INHIBITOR; I-MATRIX-METALLOPROTEINASE; C-TERMINAL DOMAIN; GELATINASE-A; COMPLEX-FORMATION; 1-MATRIX METALLOPROTEINASE; EFFICIENT ACTIVATION; PROGELATINASE; BINDING; COLLAGENASE	Tissue inhibitor of metalloproteinases-2 (TIMP-2) is unique as it is the only member of the TIMP family that is involved in the cellular activation of promatrix metalloproteinase-2 (proMMP-2) by virtue of forming a trimolecular complex with membrane type 1 matrix metalloproteinase (MT1-MMP) on the cell surface. TIMP-4 is similar in structure to TIMP-2 but is unable to support the activation of the proenzyme. Several reports have highlighted the importance of the TIMP-2 C-terminal domain in the pro-MMP-2 activation complex; however, very little is known about the role of the extended AB loop of TIMP-2 in this mechanism even though it has been shown to interact with MT1-MMP. In this study we show by mutagenesis and kinetic analysis that it is possible to transfer the MT1-MMP binding affinity of the TIMP-2 AB loop to TIMP-4 but that its transplantation into TIMP-4 does not endow the inhibitor with proMMP-2 activating activity. However, transfer of both the AB loop and C-terminal domain of TIMP-2 to TIMP-4 generates a mutant that can activate pro-MMP-2 and so demonstrates that both these regions of TIMP-2 are important for the activation process.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of Kent; University of Cambridge; University of York - UK	Williamson, RA (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	r.a.williamson@kent.ac.uk		Knauper, Vera/0000-0002-3965-9924	MRC [G0400637] Funding Source: UKRI; Medical Research Council [G0400637] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; DORTHO MP, 1997, EUR J BIOCHEM, V250, P51; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; MORRISON JF, 1995, METHOD ENZYMOL, V248, P201; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagase H, 1998, Cell Res, V8, P179; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Williamson RA, 2001, J BIOL CHEM, V276, P32966, DOI 10.1074/jbc.M101843200; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573	36	9	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23386	23394		10.1074/jbc.M604423200	http://dx.doi.org/10.1074/jbc.M604423200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777853	hybrid			2022-12-27	WOS:000239702900013
J	Wild-Bode, C; Fellerer, K; Kugler, J; Haass, C; Capell, A				Wild-Bode, Christine; Fellerer, Katrin; Kugler, Johanna; Haass, Christian; Capell, Anja			A basolateral sorting signal directs ADAM10 to adherens junctions and is required for its function in cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DARBY CANINE KIDNEY; GAMMA-SECRETASE; EPITHELIAL-CELLS; MDCK CELLS; E-CADHERIN; CLEAVAGE; ADHESION; RECEPTOR; METALLOPROTEASE	ADAM10 ( a disintegrin and metalloprotease) initiates regulated intramembrane proteolysis by shedding the ectodomain of a number of different substrates. Shedding is followed by subsequent intramembrane proteolysis leading to the liberation of intracellular domains capable of nuclear signaling. ADAM10 substrates have been found at cell-cell contacts and are apparently involved in cell-cell interaction and cell migration. Here we have investigated the cellular mechanism that guides ADAM10 to substrates at cell-cell contacts. We demonstrate that intracellular trafficking of ADAM10 critically requires a novel sorting signal within its cytoplasmic domain. Sequential deletion of the cytoplasmic domain and site-directed mutagenesis suggest that a potential Src homology 3-binding domain is essential for ADAM10 sorting. In a polarized epithelial cell line this motif not only targets ADAM10 to adherens junctions but is also strictly required for ADAM10 function in E-cadherin processing and cell migration.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	chaass@med.uni-muenchen.de						Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; He C, 2002, J BIOL CHEM, V277, P38284, DOI 10.1074/jbc.M104646200; Ho AT, 2001, J BIOL CHEM, V276, P40215, DOI 10.1074/jbc.M101647200; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Marambaud P, 2005, GENES BRAIN BEHAV, V4, P134, DOI 10.1111/j.1601-183X.2005.00086.x; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Murai M, 2004, INT J ONCOL, V25, P831; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001	30	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23824	23829		10.1074/jbc.M601542200	http://dx.doi.org/10.1074/jbc.M601542200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777847	hybrid			2022-12-27	WOS:000239702900058
J	LoVerme, J; Guzman, M; Gaetani, S; Piomelli, D				LoVerme, Jesse; Guzman, Manuel; Gaetani, Silvana; Piomelli, Daniele			Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CANNABINOID PRECURSOR; SYMPATHETIC-NERVOUS-SYSTEM; PPAR-ALPHA; ACID AMIDASE; RECEPTOR; BIOSYNTHESIS; ANANDAMIDE; LIPOLYSIS; PHOSPHATIDYLETHANOLAMINE; PALMITOYLETHANOLAMIDE	Oleoylethanolamide (OEA) is an endogenous lipid mediator that inhibits feeding and stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activating receptor-alpha. Little is known about the physiological regulation of this compound outside of the gastrointestinal tract, where its production is regulated by feeding. Here we show that cold exposure increases OEA levels in rat white adipose tissue but not in liver or intestine. This change is accompanied by parallel elevations in the activity of N-acyltransferase, a key enzyme responsible for OEA synthesis, without concomitant changes in fatty acid amide hydrolase, an enzyme responsible for OEA degradation. Moreover, cold stimulates the production of two species of N-oleoylphosphatidylethanolamine OEA precursors. The changes in OEA biosynthesis are reversed by pretreatment with the beta-receptor antagonist propranolol, suggesting a role for beta-adrenoreceptors in this response. In agreement with these findings, the beta-agonists noradrenaline and isoproterenol stimulate OEA production in isolated adipocytes, an effect that is mimicked by the adenylyl cyclase activator forskolin. Collectively, these results identify cold exposure as a natural stimulus for OEA formation in white fat and suggest a role for the sympathetic nervous system in regulating OEA biosynthesis.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Drug Discovery, Irvine, CA 92697 USA; Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, Madrid 28040, Spain; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy	University of California System; University of California Irvine; University of California System; University of California Irvine; Complutense University of Madrid; Sapienza University Rome	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, 360 MSRII, Irvine, CA 92697 USA.	piomelli@uci.edu	Gaetani, Silvana/D-3455-2009					Bamshad M, 1998, AM J PHYSIOL-REG I, V275, pR291, DOI 10.1152/ajpregu.1998.275.1.R291; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Cinti S, 2001, P NUTR SOC, V60, P319, DOI 10.1079/PNS200192; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; DAVIDOVIC V, 1981, ARCH INT PHYSIOL BIO, V89, P457, DOI 10.3109/13813458109082642; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Garofalo MAR, 1996, J AUTONOM NERV SYST, V60, P206, DOI 10.1016/0165-1838(96)00037-9; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Guzman M, 2004, J BIOL CHEM, V279, P27849, DOI 10.1074/jbc.M404087200; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Lo Verme J, 2005, CELL MOL LIFE SCI, V62, P708, DOI 10.1007/s00018-004-4494-0; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Murillo-Rodniguez E, 2006, LIFE SCI, V79, P30, DOI 10.1016/j.lfs.2005.12.028; Overton HA, 2006, CELL METAB, V3, P167, DOI 10.1016/j.cmet.2006.02.004; Petersen G, 2006, BBA-MOL CELL BIOL L, V1761, P143, DOI 10.1016/j.bbalip.2005.12.011; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Rayner DV, 2001, P NUTR SOC, V60, P357, DOI 10.1079/PNS2001101; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rosen ED, 2003, CURR BIOL, V13, pR961, DOI 10.1016/j.cub.2003.11.043; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; Sun YX, 2005, BBA-MOL CELL BIOL L, V1736, P211, DOI 10.1016/j.bbalip.2005.08.010; Ueda N, 2001, J BIOL CHEM, V276, P35552, DOI 10.1074/jbc.M106261200; Wang DH, 2005, ACTA PHARMACOL SIN, V26, P286, DOI 10.1111/j.1745-7254.2005.00057.x; YOUNGSTROM TG, 1995, AM J PHYSIOL, V268, P744; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c	29	27	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22815	22818		10.1074/jbc.M604751200	http://dx.doi.org/10.1074/jbc.M604751200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785227	hybrid, Green Published			2022-12-27	WOS:000239542600043
J	Nicoll, DA; Sawaya, MR; Kwon, S; Cascio, D; Philipson, KD; Abramson, J				Nicoll, Debora A.; Sawaya, Michael R.; Kwon, Seunghyug; Cascio, Duilio; Philipson, Kenneth D.; Abramson, Jeff			The crystal structure of the primary Ca2+ sensor of the Na+/Ca2+ exchanger reveals a novel Ca2+ binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; CA2+-BINDING DOMAIN; MUTATIONAL ANALYSIS; SYNAPTOTAGMIN; CALMODULIN; SEQUENCE; MODEL	The Na+/Ca2+ exchanger is a plasma membrane protein that regulates intracellular Ca2+ levels in cardiac myocytes. Transport activity is governed by Ca2+, and the primary Ca2+ sensor (CBD1) is located in a large cytoplasmic loop connecting two transmembrane helices. The binding of Ca2+ to the CBD1 sensory domain results in conformational changes that stimulate the exchanger to extrude Ca2+. Here, we present a crystal structure of CBD1 at 2.5 A resolution, which reveals a novel Ca2+ binding site consisting of four Ca2+ ions arranged in a tight planar cluster. This intricate coordination pattern for a Ca2+ binding cluster is indicative of a highly sensitive Ca2+ sensor and may represent a general platform for Ca2+ sensing.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Dept Energy, Ctr Genom & Proteom,Mol Biol Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Abramson, J (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	jabramson@mednet.ucla.edu			NHLBI NIH HHS [HL-49101] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1982, CELL, V30, P349, DOI 10.1016/0092-8674(82)90232-X; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Bers D. M., 2001, EXCITATION CONTRACTI, V2nd, P133, DOI [10.1007/978-94-010-0658-3_6, DOI 10.1007/978-94-010-0658-3_6]; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dai H, 2004, NAT STRUCT MOL BIOL, V11, P844, DOI 10.1038/nsmb817; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; Hilge M, 2006, MOL CELL, V22, P15, DOI 10.1016/j.molcel.2006.03.008; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levitan IB, 2004, SCIENCE, V304, P394, DOI 10.1126/science.1097507; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Levitsky DO, 1996, MOL CELL BIOCHEM, V161, P27, DOI 10.1007/BF00240027; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Ottolia M, 2005, J BIOL CHEM, V280, P1061, DOI 10.1074/jbc.M411899200; Ottolia M, 2004, BIOPHYS J, V87, P899, DOI 10.1529/biophysj.104.043471; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park S, 2006, PROTEIN SCI, V15, P200, DOI 10.1110/ps.051814306; Philipson KD, 2002, ANN NY ACAD SCI, V976, P1; Ponting CP, 1997, PROTEIN SCI, V6, P464; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	34	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21577	21581		10.1074/jbc.C600117200	http://dx.doi.org/10.1074/jbc.C600117200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16774926	hybrid			2022-12-27	WOS:000239387100002
J	Unno, H; Uchida, T; Sugawara, H; Kurisu, G; Sugiyama, T; Yamaya, T; Sakakibara, H; Hase, T; Kusunoki, M				Unno, Hideaki; Uchida, Tatsuya; Sugawara, Hajime; Kurisu, Genji; Sugiyama, Tatsuo; Yamaya, Tomoyuki; Sakakibara, Hitoshi; Hase, Toshiharu; Kusunoki, Masami			Atomic structure of plant glutamine synthetase - A key enzyme for plant productivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; METHIONINE SULFOXIMINE; ALPHA-POLYPEPTIDE; PROGRAM; INHIBITION; MICROSCOPY; EVOLUTION; MOLSCRIPT; ROOTS; GENES	Plants provide nourishment for animals and other heterotrophs as the sole primary producer in the food chain. Glutamine synthetase (GS), one of the essential enzymes for plant autotrophy catalyzes the incorporation of ammonia into glutamate to generate glutamine with concomitant hydrolysis of ATP, and plays a crucial role in the assimilation and re-assimilation of ammonia derived from a wide variety of metabolic processes during plant growth and development. Elucidation of the atomic structure of higher plant GS is important to understand its detailed reaction mechanism and to obtain further insight into plant productivity and agronomical utility. Here we report the first crystal structures of maize (Zea mays L.) GS. The structure reveals a unique decameric structure that differs significantly from the bacterial GS structure. Higher plants have several isoenzymes of GS differing in heat stability and catalytic properties for efficient responses to variation in the environment and nutrition. A key residue responsible for the heat stability was found to be Ile-161 in GS1a. The three structures in complex with substrate analogues, including phosphinothricin, a widely used herbicide, lead us to propose a mechanism for the transfer of phosphate from ATP to glutamate and to interpret the inhibitory action of phosphinothricin as a guide for the development of new potential herbicides.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; RIKEN, Ctr Plasma Sci, Yokohama, Kanagawa 2300045, Japan	Osaka University; RIKEN	Kusunoki, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kusunoki@protein.osaka-u.ac.jp	Hase, Toshiharu/H-9271-2013; KURISU, GENJI/AAD-7109-2022; KURISU, GENJI/ABA-5960-2020; Sakakibara, Hitoshi/A-6040-2010; Hideaki, UNNO/ABG-9471-2020	KURISU, GENJI/0000-0002-5354-0807; KURISU, GENJI/0000-0002-5354-0807; Sakakibara, Hitoshi/0000-0001-5449-6492; Hideaki, UNNO/0000-0001-5917-269X				Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; Buchanan B.B., 2000, BIOCH MOL BIOL PLANT; Clemente MT, 1999, PLANT MOL BIOL, V40, P835, DOI 10.1023/A:1006257323624; Clemente MT, 1999, EUR J BIOCHEM, V264, P453, DOI 10.1046/j.1432-1327.1999.00636.x; CULLIMORE JV, 1980, PLANTA, V150, P392, DOI 10.1007/BF00390175; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; HASCHEMEYER RH, 1968, T NEW YORK ACAD SCI, V30, P875, DOI 10.1111/j.2164-0947.1968.tb02531.x; Ishiyama K, 2004, J BIOL CHEM, V279, P16598, DOI 10.1074/jbc.M313710200; Ishiyama K, 2004, PLANT CELL PHYSIOL, V45, P1640, DOI 10.1093/pcp/pch190; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawabata T, 2003, NUCLEIC ACIDS RES, V31, P3367, DOI 10.1093/nar/gkg581; Krajewski WW, 2005, P NATL ACAD SCI USA, V102, P10499, DOI 10.1073/pnas.0502248102; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMADA Y, 1993, P NATL ACAD SCI USA, V90, P3009, DOI 10.1073/pnas.90.7.3009; LOGUSCH EW, 1989, BIOCHEMISTRY-US, V28, P3043, DOI 10.1021/bi00433a046; Meister A., 1980, GLUTAMINE METABOLISM, P1; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; RONZIO RA, 1969, BIOCHEMISTRY-US, V8, P1066, DOI 10.1021/bi00831a038; SAKAKIBARA H, 1992, PLANT CELL PHYSIOL, V33, P49; Sakakibara H, 1996, J BIOL CHEM, V271, P29561, DOI 10.1074/jbc.271.47.29561; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TSUPRUN VL, 1980, BIOCHIM BIOPHYS ACTA, V626, P1, DOI 10.1016/0005-2795(80)90190-7	31	112	120	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29287	29296		10.1074/jbc.M601497200	http://dx.doi.org/10.1074/jbc.M601497200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16829528	hybrid			2022-12-27	WOS:000240680500084
J	Downes, BP; Saracco, SA; Lee, SS; Crowell, DN; Vierstra, RD				Downes, Brian P.; Saracco, Scott A.; Lee, Sang Sook; Crowell, Dring N.; Vierstra, Richard D.			MUBs, a family of ubiquitin-fold proteins that are plasma membrane-anchored by prenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; GREEN FLUORESCENT PROTEIN; CRYSTAL-STRUCTURE; ABSCISIC-ACID; ARABIDOPSIS; ISOPRENYLATION; PALMITOYLATION; IDENTIFICATION; SYSTEM; PLANTS	Ubiquitin (Ub)-fold proteins are rapidly emerging as an important class of eukaryotic modifiers, which often exert their influence by post-translational addition to other intracellular proteins. Despite assuming a common beta-grasp three-dimensional structure, their functions are highly diverse because of distinct surface features and targets and include tagging proteins for selective breakdown, nuclear import, autophagic recycling, vesicular trafficking, polarized morphogenesis, and the stress response. Here we describe a novel family of Membrane-anchored Ub-fold (MUB) proteins that are present in animals, filamentous fungi, and plants. Extending from the C terminus of the Ub-fold is typically a cysteine-containing CAAX (where A indicates aliphatic amino acid) sequence that can direct the attachment of either a 15-carbon farnesyl or a 20-carbon geranylgeranyl moiety in vitro. Modified forms of several MUBs were detected in transgenic Arabidopsis thaliana, suggesting that these MUBs are prenylated in vivo. Both cell fractionation and confocal microscopic analyses of Arabidopsis plants expressing GFP-MUB fusions showed that the modified forms are membrane-anchored with a significant enrichment on the plasma membrane. This plasma membrane location was blocked in vivo in prenyltransferase mutants and by mevinolin, which inhibits the synthesis of prenyl groups. In addition to the five MUBs with CAAX boxes, Arabidopsis has one MUB variant with a cysteine-rich C terminus distinct from the CAAX box that is also membrane-anchored, possibly through the attachment of a long chain acyl group. Although the physiological role(s) of MUBs remain unknown, the discovery of these prenylated forms further expands the diversity and potential functions of Ub-fold proteins in eukaryotic biology.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA	University of Wisconsin System; University of Wisconsin Madison; Indiana University System; Indiana University-Purdue University Indianapolis	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Genet, 425 Henry Mall, Madison, WI 53706 USA.	vierstra@wisc.edu			NIGMS NIH HHS [5-F32-GM065736-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM065736] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Andersen KM, 2005, ESSAYS BIOCHEM, V41, P49, DOI 10.1042/EB0410049; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Blanc G, 2003, GENOME RES, V13, P137, DOI 10.1101/gr.751803; Bracha K, 2002, J BIOL CHEM, V277, P29856, DOI 10.1074/jbc.M202916200; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; Cadinanos J, 2003, J BIOL CHEM, V278, P42091, DOI 10.1074/jbc.M306700200; Chadwick BP, 1999, GENE, V233, P189, DOI 10.1016/S0378-1119(99)00138-9; Cort JR, 2002, PROTEINS, V48, P733, DOI 10.1002/prot.10197; Crowell DN, 1998, PLANT PHYSIOL, V118, P115, DOI 10.1104/pp.118.1.115; Crowell DN, 2000, PROG LIPID RES, V39, P393, DOI 10.1016/S0163-7827(00)00010-2; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; Dietrich A, 2003, BIOCHEM J, V376, P449, DOI 10.1042/BJ20030578; Dittmar GAG, 2002, SCIENCE, V295, P2442, DOI 10.1126/science.1069989; Downes B, 2005, BIOCHEM SOC T, V33, P393, DOI 10.1042/BST0330393; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Galichet A, 2003, CURR OPIN PLANT BIOL, V6, P530, DOI 10.1016/j.pbi.2003.09.005; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Hemmerlin A, 2000, PLANT PHYSIOL, V123, P1257, DOI 10.1104/pp.123.4.1257; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Johnson CD, 2005, PLANT PHYSIOL, V139, P722, DOI 10.1104/pp.105.065045; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Komatsu M, 2004, EMBO J, V23, P1977, DOI 10.1038/sj.emboj.7600205; Kouno T, 2005, J BIOL CHEM, V280, P24610, DOI 10.1074/jbc.M413565200; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; KUZNETSOV SA, 1987, FEBS LETT, V212, P145, DOI 10.1016/0014-5793(87)81574-0; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Larsen CN, 2002, J PROTEOME RES, V1, P411, DOI 10.1021/pr025522n; Lavy M, 2002, PLANT CELL, V14, P2431, DOI 10.1105/tpc.005561; Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; LINDER ME, 2000, PROTEIN LIPIDATION, P215; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; McNally T, 2003, PROTEIN SCI, V12, P1562, DOI 10.1110/ps.0382803; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Randall SK, 1999, CRIT REV BIOCHEM MOL, V34, P325, DOI 10.1080/10409239991209336; RANDALL SK, 1993, PLANT CELL, V5, P433, DOI 10.1105/tpc.5.4.433; Rao-Naik C, 1998, J BIOL CHEM, V273, P34976, DOI 10.1074/jbc.273.52.34976; Roskoski R, 2003, BIOCHEM BIOPH RES CO, V303, P1, DOI 10.1016/S0006-291X(03)00323-1; Running MP, 2004, P NATL ACAD SCI USA, V101, P7815, DOI 10.1073/pnas.0402385101; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Singh S, 2005, PROTEIN SCI, V14, P2095, DOI 10.1110/ps.051577605; Smalle J, 2004, ANNU REV PLANT BIOL, V55, P555, DOI 10.1146/annurev.arplant.55.031903.141801; Smalle J, 2002, PLANT CELL, V14, P17, DOI 10.1105/tpc.010381; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Suzuki NN, 2005, AUTOPHAGY, V1, P119, DOI 10.4161/auto.1.2.1859; Umebayashi K, 2003, CELL STRUCT FUNCT, V28, P443, DOI 10.1247/csf.28.443; Valdez-Taubas J, 2005, EMBO J, V24, P2524, DOI 10.1038/sj.emboj.7600724; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Vinarov DA, 2004, NAT METHODS, V1, P149, DOI 10.1038/NMETH716; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Webb JH, 1999, FEBS LETT, V444, P136, DOI 10.1016/S0014-5793(99)00025-3; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yalovsky S, 2000, PLANT CELL, V12, P1257, DOI 10.1105/tpc.12.8.1257; Yoshimoto K, 2004, PLANT CELL, V16, P2967, DOI 10.1105/tpc.104.025395; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557; Ziegelhoffer EC, 2000, P NATL ACAD SCI USA, V97, P7633, DOI 10.1073/pnas.130189397; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	71	40	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27145	27157		10.1074/jbc.M602283200	http://dx.doi.org/10.1074/jbc.M602283200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16831869	hybrid			2022-12-27	WOS:000240397700042
J	Peng, XH; Karna, P; Cao, ZH; Jiang, BH; Zhou, MX; Yang, L				Peng, Xiang-Hong; Karna, Prasanthi; Cao, Zehong; Jiang, Bing-Hua; Zhou, Muxiang; Yang, Lily			Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; EGF RECEPTOR; EPITHELIAL-CELLS; STRUCTURAL BASIS; FAMILY; INHIBITION; COEXPRESSION; ACTIVATION; TARGET	Although increasing evidence supports a link between epidermal growth factor receptor (EGFR) signaling and resistance to apoptosis, the mechanism by which the EGFR signaling pathway inhibits apoptosis is not well understood. In this study, we found that epidermal growth factor (EGF) stimulation increased the level of expression of the inhibitor of apoptosis protein survivin in breast cancer cells but not in normal mammary epithelial cells. We further demonstrated that activation of survivin gene expression is mediated by oxygen-independent hypoxia-inducible factor (HIF)-1 alpha up-regulation in EGF-treated cancer cells. EGFR signaling activated the phosphoinositide 3-kinase/AKT pathway, subsequently increasing the level of HIF-1 alpha under normoxic conditions. HIF-1 alpha then activated survivin gene transcription through direct binding to the survivin promoter. Furthermore, we found that overexpression of HIF-1 alpha small interfering RNA blocks EGF-induced survivin gene up-regulation and increases apoptosis induced by the chemotherapy drug docetaxel. However, transfection of a plasmid expressing HIF-1 alpha gene activates survivin gene expression and reduces the apoptotic response. Our results demonstrate a novel pathway for EGFR signaling-mediated apoptosis resistance in human cancer cells. Although the role of HIF-1 alpha in regulating cell survival under hypoxic conditions has been studied extensively, our results show that normoxic breast cancer cells utilize cross-talk between EGFR signals and HIF-1 alpha to up-regulate the anti-apoptotic survivin gene, providing a strong rationale for the targeting of HIF-1 alpha as a therapeutic approach for both hypoxic and normoxic tumor cells. Understanding key molecular events in EGFR signaling-induced apoptosis resistance should provide new information for the development of novel therapeutic agents targeting EGFR, HIF-1 alpha, and/or survivin.	Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	Emory University; Emory University; Emory University; West Virginia University	Yang, L (corresponding author), Emory Univ, Sch Med, Dept Surg, Rm C-4088,1365 C Clifton Rd NE, Atlanta, GA 30322 USA.	Lyang02@emory.edu		Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL CANCER INSTITUTE [R29CA080017, R01CA095643] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095643-01A1, R29 CA080017-04, R29 CA080017-05, R29 CA080017, R01 CA095643-03, R01 CA095643-02, R01 CA095643-04, R29 CA080017-03, R01 CA95643, R01 CA095643, R29CA80017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abd El-Rehim DM, 2004, BRIT J CANCER, V91, P1532, DOI 10.1038/sj.bjc.6602184; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; Baselga J, 2002, ANN ONCOL, V13, P8, DOI 10.1093/annonc/mdf092; Bucci B, 1997, ANTICANCER RES, V17, P769; Buchholz TA, 2005, CANCER, V104, P676, DOI 10.1002/cncr.21217; Camirand A, 2005, BREAST CANCER RES, V7, pR570, DOI 10.1186/bcr1028; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; HARRIS AL, 1994, BREAST CANCER RES TR, V29, P1, DOI 10.1007/BF00666176; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Navolanic PM, 2003, INT J ONCOL, V22, P237; Normanno N, 2005, FRONT BIOSCI-LANDMRK, V10, P2611, DOI 10.2741/1725; Peng XH, 2005, CANCER RES, V65, P1909, DOI 10.1158/0008-5472.CAN-04-3196; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Qiu LH, 2005, INT J ONCOL, V27, P823; Rae JM, 2004, BREAST CANCER RES TR, V87, P87, DOI 10.1023/B:BREA.0000041585.26734.f9; Reis JS, 2005, BREAST CANCER RES, V7, pR1028, DOI 10.1186/bcr1341; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Tamm I, 1998, CANCER RES, V58, P5315; Tanaka K, 2000, CLIN CANCER RES, V6, P127; Wang Q, 2005, EXP MOL PATHOL, V79, P100, DOI 10.1016/j.yexmp.2005.05.002; Yang L, 2003, CANCER RES, V63, P6815; Yang L, 2004, GENE THER, V11, P1215, DOI 10.1038/sj.gt.3302280; Zhong H, 2000, CANCER RES, V60, P1541	40	244	268	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25903	25914		10.1074/jbc.M603414200	http://dx.doi.org/10.1074/jbc.M603414200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16847054	Green Accepted, hybrid			2022-12-27	WOS:000240249500005
J	Sanderson-Smith, ML; Walker, MJ; Ranson, M				Sanderson-Smith, Martina L.; Walker, Mark J.; Ranson, Marie			The maintenance of high affinity plasminogen binding by group A streptococcal plasminogen-binding M-like protein is mediated by arginine and histidine residues within the a1 and a2 repeat domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL SURFACE PROTEIN; KRINGLE-2 DOMAIN; PAM; INFECTION; POLYPEPTIDES; ACTIVATORS; PYOGENES; IMPETIGO; SEQUENCE; REGION	Subversion of the plasminogen activation system is implicated in the virulence of group A streptococci (GAS). GAS displays receptors for the human zymogen plasminogen on the cell surface, one of which is the plasminogen- binding group A streptococcal M- like protein (PAM). The plasminogen binding domain of PAM is highly variable, and this variation has been linked to host selective immune pressure. Site- directed mutagenesis of full- length PAM protein from an invasive GAS isolate was undertaken to assess the contribution of residues in the a1 and a2 repeat domains to plasminogen binding function. Mutagenesis to alanine of key plasminogen binding lysine residues in the a1 and a2 repeats (Lys(98) and Lys(111)) did not abrogate plasminogen binding by PAM nor did additional mutagenesis of Arg(101) and His(102) and Glu(104), which have previously been implicated in plasminogen binding. Plasminogen binding was only abolished with the additional mutagenesis of Arg(114) and His(115) to alanine. Furthermore, mutagenesis of both arginine (Arg(101) and Arg(114)) and histidine (His(102) and His(115)) residues abolished interaction with plasminogen despite the presence of Lys(98) and Lys(111) in the binding repeats. This study shows for the first time that residues Arg(101), Arg(114), His(102), and His(115) in both the a1 and a2 repeat domains of PAM can mediate high affinity plasminogen binding. These data suggest that highly conserved arginine and histidine residues may compensate for variation elsewhere in the a1 and a2 plasminogen binding repeats, and may explain the maintenance of high affinity plasminogen binding by naturally occurring variants of PAM.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia	University of Wollongong	Ranson, M (corresponding author), Univ Wollongong, Sch Biol Sci, Northfields Ave, Wollongong, NSW 2522, Australia.	mranson@uow.edu.au	Ranson, Marie/A-6324-2008; Walker, Mark J./F-6940-2011; Ranson, Marie/GRO-5792-2022; Sanderson-Smith, Martina L/H-9614-2013; Sanderson-Smith, Martina/O-9387-2019; Ranson, Marie/AAC-4468-2019	Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Sanderson-Smith, Martina L/0000-0002-6366-4993; Ranson, Marie/0000-0002-5570-9645; Walker, Mark/0000-0001-7423-2769				Andronicos NM, 1997, BBA-PROTEIN STRUCT M, V1337, P27, DOI 10.1016/S0167-4838(96)00146-X; [Anonymous], 1982, PHYS BIOCH APPL BIOC; BERGE A, 1993, J BIOL CHEM, V268, P25417; Bessen DE, 1996, J INFECT DIS, V173, P896, DOI 10.1093/infdis/173.4.896; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carapetis JR, 1999, EPIDEMIOL INFECT, V122, P59, DOI 10.1017/S0950268898001952; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; KHANDKE KM, 1988, J BIOL CHEM, V263, P5075; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Rios-Steiner JL, 2001, J MOL BIOL, V308, P705, DOI 10.1006/jmbi.2001.4646; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanderson-Smith M, 2006, J BIOL CHEM, V281, P3217, DOI 10.1074/jbc.M508758200; SANDERSONSMITH ML, 2004, CURR TRENDS MICROBIO, V1, P75; Schenone MM, 2000, J PEPT RES, V56, P438, DOI 10.1034/j.1399-3011.2000.00810.x; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Svensson MD, 1999, INFECT IMMUN, V67, P3915, DOI 10.1128/IAI.67.8.3915-3920.1999; Svensson MD, 2002, MICROBIOL-SGM, V148, P3933, DOI 10.1099/00221287-148-12-3933; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420	29	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25965	25971		10.1074/jbc.M603846200	http://dx.doi.org/10.1074/jbc.M603846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822869	Green Submitted, hybrid			2022-12-27	WOS:000240249500011
J	Pewzner-Jung, Y; Ben-Dor, S; Futerman, AH				Pewzner-Jung, Yael; Ben-Dor, Shifra; Futerman, Anthony H.			When do lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROSTATE-CANCER CELLS; INDUCED APOPTOSIS; DIHYDROCERAMIDE SYNTHASE; ENDOPLASMIC-RETICULUM; LONG-CHAIN; SPHINGOLIPID BIOSYNTHESIS; LIQUID-CHROMATOGRAPHY; QUANTITATIVE-ANALYSIS; FAMILY-MEMBERS; LAG1		Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Serv, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il	BEN-DOR, SHIFRA/M-6718-2019; Pewzner, Faivish/I-6225-2017	BEN-DOR, SHIFRA/0000-0001-9604-1939; Pewzner, Faivish/0000-0002-7490-8121; Futerman, Anthony/0000-0003-0013-0115				BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRANDWAGT BF, 2000, P NATL ACAD SCI USA, V597, P4691; Coderch L, 2003, AM J CLIN DERMATOL, V4, P107, DOI 10.2165/00128071-200304020-00004; COWARTLA, 2006, BIOCH J, V393, P733; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; Esch SW, 2003, CELL MOL BIOL, V49, P779; Eto M, 2006, INT J UROL, V13, P148, DOI 10.1111/j.1442-2042.2006.01249.x; Eto M, 2003, PROSTATE, V57, P66, DOI 10.1002/pros.10275; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Kanto T, 2001, J IMMUNOL, V167, P3773, DOI 10.4049/jimmunol.167.7.3773; KAYEYAMAYAHARA N, 2006, IN PRESS BIOCH J; KLENK EZ, 1942, PHYSIOL CHEM PHYS M, V273, P76; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Koyanagi S, 2003, INT J CANCER, V105, P1, DOI 10.1002/ijc.11024; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Lahiri S, 2005, J BIOL CHEM, V280, P33735, DOI 10.1074/jbc.M506485200; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; Lynch DV, 2004, NEW PHYTOL, V161, P677, DOI 10.1111/j.1469-8137.2004.00992.x; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; MIZUTANI Y, 2006, IN PRESS BIOCH J; MORELL P, 1970, J BIOL CHEM, V245, P342; O'Brien JS., 1964, J LIPID RES, V15, P109; Osawa Y, 2005, J BIOL CHEM, V280, P27879, DOI 10.1074/jbc.M503002200; Perry DK, 2000, ANN NY ACAD SCI, V905, P91; Ranta S, 1999, NAT GENET, V23, P233, DOI 10.1038/13868; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Schulz A, 2006, J BIOL CHEM, V281, P2784, DOI 10.1074/jbc.M509483200; Sot J, 2005, BIOPHYS J, V88, P3368, DOI 10.1529/biophysj.104.057851; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; TRAMS EG, 1962, NATURE, V193, P680, DOI 10.1038/193680a0; Vallee B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562; van Hall T, 2006, NAT MED, V12, P417, DOI 10.1038/nm1381; van Meer G, 2005, EMBO J, V24, P3159, DOI 10.1038/sj.emboj.7600798; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; WANG E, 1991, J BIOL CHEM, V266, P14486; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0; Xu ZW, 2005, J LIPID RES, V46, P1229, DOI 10.1194/jlr.M500001-JLR200; Yano M, 1998, J LIPID RES, V39, P2091; Yu Y, 2006, MICROBIOL RES, V161, P203, DOI 10.1016/j.micres.2005.08.002	57	334	351	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25001	25005		10.1074/jbc.R600010200	http://dx.doi.org/10.1074/jbc.R600010200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16793762	hybrid			2022-12-27	WOS:000240031300001
J	Spurgers, KB; Gold, DL; Coombes, KR; Bohnenstiehl, NL; Mullins, B; Meyn, RE; Logothetis, CJ; McDonnell, TJ				Spurgers, Kevin B.; Gold, David L.; Coombes, Kevin R.; Bohnenstiehl, Nicole L.; Mullins, Brian; Meyn, Raymond E.; Logothetis, Christopher J.; McDonnell, Timothy J.			Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; NEGATIVE REGULATION; DOWN-REGULATION; DIRECT BINDING; CANCER CELLS; EXPRESSION; PROSTATE; BCL-2; MUTATIONS; MICROARRAYS	Historically, most studies attribute p53 function to the transactivation of target genes. That p53 can selectively repress genes to affect a cellular response is less widely appreciated. Available evidence suggests that repression is important for p53-induced apoptosis and cell cycle arrest. To better establish the scope of p53-repressed target genes and the cellular processes they may affect, a global expression profiling strategy was used to identify p53-responsive genes following adenoviral p53 gene transfer (Ad-p53) in PC3 prostate cancer cells. A total of 111 genes, 0.77% of the 14,500 genes represented on the Affymetrix U133A microarray, were repressed more than 2-fold (p <= 0.05). Validation of the array data, using reverse transcription-PCR of 20 randomly selected genes, yielded a confirmation rate of > 95.5% for the complete data set. Functional over-representation analysis revealed that cell cycle regulatory genes exhibited a highly significant enrichment (p <= 5 x 10(-28)) within the transrepressed targets. 41% of the repressed targets are cell cycle regulators. A subset of these genes exhibited repression following DNA damage, preceding cell cycle arrest, in LNCaP cells. The use of a p53 small interfering RNA strategy in LNCaP cells and the use of p53-null cell lines demonstrated that this repression is p53-dependent. These findings identify a set of genes not known previously to be down-regulated by p53 and indicate that p53induced cell cycle arrest is a function of not only the transactivation of cell cycle inhibitors (e.g. p21) but also the repression of targets that regulate proliferation at several distinct phases of the cell cycle.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 089, Houston, TX 77030 USA.	tmcdonne@mdanderson.org		Coombes, Kevin/0000-0002-7630-2123	NCI NIH HHS [P50 CA90270, CA16672, R01 CA69003-9] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069003, P30CA016672, P50CA090270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Badie C, 2000, BRIT J CANCER, V82, P642; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Damia G, 2004, CELL CYCLE, V3, P46; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Gold D, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-2; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lei M, 2001, J CELL SCI, V114, P1447; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li C, 2004, ONCOGENE, V23, P9336, DOI 10.1038/sj.onc.1208114; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1994, CANCER RES, V54, P3131; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Spurgers KB, 2004, ONCOGENE, V23, P1712, DOI 10.1038/sj.onc.1207293; St Clair S, 2004, MOL CELL, V16, P725; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; ZHANG WW, 1994, CANCER GENE THER, V1, P5	51	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25134	25142		10.1074/jbc.M513901200	http://dx.doi.org/10.1074/jbc.M513901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16798743	hybrid			2022-12-27	WOS:000240031300014
J	Wang, D; Portis, AR				Wang, Dafu; Portis, Archie R., Jr.			Increased sensitivity of oxidized large isoform of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) activase to ADP inhibition is due to an interaction between its carboxyl extension and nucleotide-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NADP-MALATE-DEHYDROGENASE; COVALENT CROSS-LINKING; OXYGENASE ACTIVASE; INTRINSIC FLUORESCENCE; COMPLEX-FORMATION; CONTACT SITES; ATP; ARABIDOPSIS; SPINACH	In Arabidopsis, oxidation of the large (46-kDa) isoform activase to form a disulfide bond in the C-terminal extension (C-extension) significantly increases its ADP sensitivity for both ATP hydrolysis and ribulose-1,5-bisphosphate carboxylase/oxygenase ( Rubisco) activation, thereby decreasing both activities at physiological ratios of ADP/ATP. In this study, we demonstrate that the C-extension of the oxidized large activase isoform can be cross-linked with regions containing residues that contribute to the nucleotide-binding pocket, with a higher efficiency in the presence of ADP or the absence of nucleotides than with ATP. Coupled with measurements demonstrating a redox-dependent protease sensitivity of the C-extension and a lower ATP or adenosine 5'-O-(thiotriphosphate) (ATP gamma S) affinity of the oxidized large isoform than either the reduced form or the smaller isoform, the results suggest that the C-extension plays an inhibitory role in ATP hydrolysis, regulated by redox changes. In contrast, the ADP affinities of the small isoform and the reduced or oxidized large isoform were similar, which indicates that the C-extension selectively interferes with the proper binding of ATP, possibly by interfering with the coordination of the gamma-phosphate. Furthermore, replacement of conserved, negatively charged residues (Asp(390), Glu(394), and Asp(401)) in the C-extension with alanine significantly reduced the sensitivities of the mutants to ADP inhibition, which suggests the involvement of electrostatic interactions between them and positively charged residues in or near the nucleotide-binding pocket. These studies provide new insights into the mechanism of redox regulation of activase by the C-extension in the large isoform.	Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; USDA ARS, Photosynth Res Unit, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA)	Portis, AR (corresponding author), Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA.	arportis@uiuc.edu	Wang, Dafu/D-5417-2009					Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; Kallis RP, 2000, PLANT PHYSIOL, V123, P1077, DOI 10.1104/pp.123.3.1077; Keil B., 1992, SPECIFICITY PROTEOLY, P335, DOI DOI 10.1007/978-3-642-48380-6; Li CH, 2005, J BIOL CHEM, V280, P24864, DOI 10.1074/jbc.M503547200; Lilley RM, 1997, PLANT PHYSIOL, V114, P605, DOI 10.1104/pp.114.2.605; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Pioszak AA, 2000, BIOCHEMISTRY-US, V39, P13450, DOI 10.1021/bi000795m; Portis AR, 2003, PHOTOSYNTH RES, V75, P11, DOI 10.1023/A:1022458108678; ROBINSON SP, 1989, ARCH BIOCHEM BIOPHYS, V268, P93, DOI 10.1016/0003-9861(89)90568-7; Ruelland E, 1998, J BIOL CHEM, V273, P33482, DOI 10.1074/jbc.273.50.33482; RUNDLE SJ, 1991, J BIOL CHEM, V266, P4677; SALVUCCI ME, 1992, ARCH BIOCHEM BIOPHYS, V298, P688, DOI 10.1016/0003-9861(92)90467-B; Salvucci ME, 2004, FEBS LETT, V560, P205, DOI 10.1016/S0014-5793(04)00111-5; Salvucci ME, 2003, PLANTA, V216, P736, DOI 10.1007/s00425-002-0923-1; SALVUCCI ME, 1994, ARCH BIOCHEM BIOPHYS, V314, P178, DOI 10.1006/abbi.1994.1427; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; Schuster G.B., 1992, ADV PHOTOCHEM, P69, DOI DOI 10.1002/9780470133484.CH2; SHEN JB, 1991, J BIOL CHEM, V266, P8963; SHEN JB, 1992, PLANT PHYSIOL, V99, P1201, DOI 10.1104/pp.99.3.1201; To KY, 1999, PLANTA, V209, P66, DOI 10.1007/s004250050607; van de Loo FJ, 1998, BIOCHEMISTRY-US, V37, P4621, DOI 10.1021/bi972566e; vandeLoo FJ, 1996, BIOCHEMISTRY-US, V35, P8143, DOI 10.1021/bi9604901; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang DF, 2006, PHOTOSYNTH RES, V88, P185, DOI 10.1007/s11120-006-9051-2; WANG ZY, 1991, BIOCHIM BIOPHYS ACTA, V1079, P263, DOI 10.1016/0167-4838(91)90067-A; WANG ZY, 1992, PLANT PHYSIOL, V99, P1348, DOI 10.1104/pp.99.4.1348; WANG ZY, 1993, BIOCHIM BIOPHYS ACTA, V1202, P47, DOI 10.1016/0167-4838(93)90061-U; WERNEKE JM, 1989, PLANT CELL, V1, P815, DOI 10.1105/tpc.1.8.815; Zhang N, 1999, P NATL ACAD SCI USA, V96, P9438, DOI 10.1073/pnas.96.16.9438; Zhang N, 2002, P NATL ACAD SCI USA, V99, P3330, DOI 10.1073/pnas.042529999; Zhang N, 2001, PHOTOSYNTH RES, V68, P29, DOI 10.1023/A:1011845506196; Zhang ZL, 2000, J BIOCHEM-TOKYO, V128, P383, DOI 10.1093/oxfordjournals.jbchem.a022765	35	27	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25241	25249		10.1074/jbc.M604756200	http://dx.doi.org/10.1074/jbc.M604756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822862	hybrid			2022-12-27	WOS:000240031300025
J	Chen, YR; Glabe, CG				Chen, Yun-Ru; Glabe, Charles G.			Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides A beta 40 and A beta 42 - Stable trimer or tetramer formation by A beta 42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; PROTEIN; DISEASE; OLIGOMERIZATION; THERMODYNAMICS; PATHOGENESIS; DENATURANTS; NUCLEATION; DEPOSITION; MECHANISM	The amyloid beta peptide (A beta), composed of 40 or 42 amino acids, is a critical component in the etiology of the neurodegenerative Alzheimer disease. A beta is prone to aggregate and forms amyloid fibrils progressively both in vitro and in vivo. To understand the process of amyloidogenesis, it is pivotal to examine the initial stages of the folding process. We examined the equilibrium folding properties, assembly states, and stabilities of the early folding stages of A beta 40 and A beta 42 prior to fibril formation. We found that A beta 40 and A beta 42 have different conformations and assembly states upon refolding from their unfolded ensembles. A beta 40 is predominantly an unstable and collapsed monomeric species, whereas A beta 42 populates a stable structured trimeric or tetrameric species at concentrations above similar to 12.5 mu M. Thermodynamic analysis showed that the free energies of A beta 40 monomer and A beta 42 trimer/tetramer are similar to 1.1 and similar to 15/similar to 22kcal/mol, respectively. The early aggregation stages of A beta 40 and A beta 42 contain different solvent-exposed hydrophobic surfaces that are located at the sequences flanking its protease-resistant segment. The amyloidogenic folded structure of A beta is important for the formation of spherical beta oligomeric species. However, beta oligomers are not an obligatory intermediate in the process of fibril formation because oligomerization is inhibited at concentrations of urea that have no effect on fibril formation. The distinct initial folding properties of A beta 40 and A beta 42 may play an important role in the higher aggregation potential and pathological significance of A beta 42.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3438 McGaugh Hall, Irvine, CA 92697 USA.	cglabe@uci.edu	Chen, Yun-Ru/C-9304-2014; Taylor, Graham/A-4027-2012	Chen, Yun-Ru/0000-0002-6596-6338; 	NINDS NIH HHS [NS31320] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Backmann J, 1998, J MOL BIOL, V284, P817, DOI 10.1006/jmbi.1998.2216; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Borreguero JM, 2005, P NATL ACAD SCI USA, V102, P6015, DOI 10.1073/pnas.0502006102; BURDICK D, 1992, J BIOL CHEM, V267, P546; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; Ferrao-Gonzales AD, 2005, J BIOL CHEM, V280, P34747, DOI 10.1074/jbc.M501651200; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Ghosh M, 2001, INT J BIOL MACROMOL, V29, P273, DOI 10.1016/S0141-8130(01)00175-1; Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HONG HY, 2002, PROTEIN PROTOCOLS HD, P387; Hurshman AR, 2004, BIOCHEMISTRY-US, V43, P7365, DOI 10.1021/bi049621l; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jelesarov I, 2001, J MOL BIOL, V307, P637, DOI 10.1006/jmbi.2001.4469; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim JR, 2004, PROTEIN SCI, V13, P2888, DOI 10.1110/ps.04847404; Lazo ND, 2005, PROTEIN SCI, V14, P1581, DOI 10.1110/ps.041292205; LeVine H, 2004, ANAL BIOCHEM, V335, P81, DOI 10.1016/j.ab.2004.08.014; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sciarretta KL, 2005, BIOCHEMISTRY-US, V44, P6003, DOI 10.1021/bi0474867; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; Younkin S G, 1997, Rinsho Shinkeigaku, V37, P1099; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288	41	172	182	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24414	24422		10.1074/jbc.M602363200	http://dx.doi.org/10.1074/jbc.M602363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16809342	hybrid			2022-12-27	WOS:000239847800035
J	Cheng, SJ; Gallie, DR				Cheng, Shijun; Gallie, Daniel R.			Wheat eukaryotic initiation factor 4B organizes assembly of RNA and eIFiso4G, eIF4A, and poly(A)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; CAP-DEPENDENT TRANSLATION; MESSENGER-RNA; HELICASE ACTIVITY; RECOGNITION MOTIF; IN-VITRO; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; BINDING-PROTEIN; RIBOSOMAL ENTRY	The eukaryotic translation initiation factor ( eIF) 4B promotes the RNA-dependent ATP hydrolysis activity and ATP-dependent RNA helicase activity of eIF4A and eIF4F during translation initiation. Although this function is conserved among plants, animals, and yeast, eIF4B is one of the least conserved of initiation factors at the sequence level. To gain insight into its functional conservation, the organization of the functional domains of eIF4B from wheat has been investigated. Plant eIF4B contains three RNA binding domains, one more than reported for mammalian or yeast eIF4B, and each domain exhibits a preference for purine-rich RNA. In addition to a conserved RNA recognition motif and a C-terminal RNA binding domain, wheat eIF4B contains a novel N-terminal RNA binding domain that requires a short, lysine-rich containing sequence. Both the lysine-rich motif and an adjacent, C-proximal motif are conserved with an N-proximal sequence in human and yeast eIF4B. The C-proximal motif within the N-terminal RNA binding domain in wheat eIF4B is required for interaction with eIFiso4G, an interaction not reported for other eIF4B proteins. Moreover, each RNA binding domain requires dimerization for binding activity. Two binding sites for the poly( A)-binding protein were mapped to a region within each of two conserved 41-amino acid repeat domains on either side of the C-terminal RNA binding domain. eIF4A bound to an adjacent region within each repeat, supporting a central role for these conserved eIF4B domains in facilitating interaction with other components of the translational machinery. These results support the notion that eIF4B functions by organizing multiple components of the translation initiation machinery and RNA.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu						ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; BENNE R, 1978, J BIOL CHEM, V253, P3078; Bi XP, 2000, J BIOL CHEM, V275, P17740, DOI 10.1074/jbc.M909464199; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; Bushell M, 2001, J BIOL CHEM, V276, P23922, DOI 10.1074/jbc.M100384200; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; Dmitriev SE, 2003, MOL CELL BIOL, V23, P8925, DOI 10.1128/MCB.23.24.8925-8933.2003; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; Gallie DR, 2004, BIOCHEM SOC T, V32, P585, DOI 10.1042/BST0320585; Gallie DR, 2001, J BIOL CHEM, V276, P36951, DOI 10.1074/jbc.M103869200; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; Khan MA, 2005, BIOCHEMISTRY-US, V44, P4510, DOI 10.1021/bi047298g; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, J BIOL CHEM, V261, P5632; Le H, 2000, J BIOL CHEM, V275, P17452, DOI 10.1074/jbc.M001186200; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Luo YJ, 2001, J BIOL CHEM, V276, P43083, DOI 10.1074/jbc.M104970200; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1996, RNA, V2, P38; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; Metz AM, 1999, BIOCHEM BIOPH RES CO, V266, P314, DOI 10.1006/bbrc.1999.1814; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; NARANDA T, 1994, J BIOL CHEM, V269, P14465; Neff CL, 1999, MOL CELL BIOL, V19, P5557; Niederberger N, 1998, RNA, V4, P1259, DOI 10.1017/S1355838298980487; Park HS, 2004, EMBO J, V23, P1381, DOI 10.1038/sj.emboj.7600140; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; TRAKSHEL GM, 1988, BIOCHEM J, V252, P127, DOI 10.1042/bj2520127; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	54	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24351	24364		10.1074/jbc.M605404200	http://dx.doi.org/10.1074/jbc.M605404200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803875	hybrid			2022-12-27	WOS:000239847800028
J	Kar, A; Havlioglu, N; Tarn, WY; Wu, JY				Kar, Amar; Havlioglu, Necat; Tarn, Woan-Yuh; Wu, Jane Y.			RBM4 interacts with an intronic element and stimulates tau exon 10 inclusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAUSES FRONTOTEMPORAL DEMENTIA; SPLICING REGULATORY ELEMENT; MESSENGER-RNA; NEURODEGENERATIVE DISEASES; MICROTUBULE DYNAMICS; ALZHEIMERS-DISEASE; PROTEIN TAU; MUTATIONS; EXPRESSION; FTDP-17	Tau protein, which binds to and stabilizes microtubules, is critical for neuronal survival and function. In the human brain, tau pre-mRNA splicing is regulated to maintain a delicate balance of exon 10-containing and exon 10-skipping isoforms. Splicing mutations affecting tau exon 10 alternative splicing lead to tauopathies, a group of neurodegenerative disorders including dementia. Molecular mechanisms regulating tau alternative splicing remain to be elucidated. In this study, we have developed an expression cloning strategy to identify splicing factors that stimulate tau exon 10 inclusion. Using this expression cloning approach, we have identified a previously unknown tau exon 10 splicing regulator, RBM4 (RNA binding motif protein 4). In cells transfected with a tau minigene, RBM4 overexpression leads to an increased inclusion of exon 10, whereas RBM4 down-regulation decreases exon 10 inclusion. The activity of RBM4 in stimulating tau exon 10 inclusion is abolished by mutations in its RNA- binding domain. A putative intronic splicing enhancer located in intron 10 of the tau gene is required for the splicing stimulatory activity of RBM4. Immunohistological analyses reveal that RBM4 is expressed in the human brain regions affected in tauopathy, including the hippocampus and frontal cortex. Our study demonstrates that RBM4 is involved in tau exon 10 alternative splicing. Our work also suggests that down-regulating tau exon 10 splicing activators, such as RBM4, may be of therapeutic potential in tauopathies involving excessive tau exon 10 inclusion.	Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Dept Neurol,Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; St Louis Univ, Dept Pathol, St Louis, MO 63103 USA; Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan	Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Saint Louis University; Academia Sinica - Taiwan	Wu, JY (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Dept Neurol,Lurie Comprehens Canc Ctr, 303 e Super St,Lurie 6-117, Chicago, IL 60611 USA.	jane-wu@northwestern.edu	Tarn, Woan-Yuh/N-8464-2018	Kar, Amar/0000-0003-2380-7504	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [EY014576, R01 EY014576-03, R01 EY014576] Funding Source: Medline; NIA NIH HHS [R01 AG017518, AG17518] Funding Source: Medline; NIGMS NIH HHS [GM070967, R01 GM070967, R01 GM070967-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Andreadis A, 2005, BBA-MOL BASIS DIS, V1739, P91, DOI 10.1016/j.bbadis.2004.08.010; Bernert G, 2002, PROTEOMICS, V2, P1752, DOI 10.1002/1615-9861(200212)2:12<1752::AID-PROT1752>3.0.CO;2-Y; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; Cairns NJ, 2004, J PATHOL, V204, P438, DOI 10.1002/path.1650; COUCHIE D, 1986, J NEUROCHEM, V47, P1255; D'Souza I, 2006, J BIOL CHEM, V281, P2460, DOI 10.1074/jbc.M505809200; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 2005, BBA-MOL BASIS DIS, V1739, P104, DOI 10.1016/j.bbadis.2004.08.009; Diederichs S, 2004, J BIOL CHEM, V279, P33727, DOI 10.1074/jbc.M401708200; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Gromak N, 2003, EMBO J, V22, P6356, DOI 10.1093/emboj/cdg609; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Jiang ZH, 2003, J BIOL CHEM, V278, P18997, DOI 10.1074/jbc.M301800200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KAR A, 2005, ALZ DIS ASSOC DIS S1, V19, P29; Lai MC, 2003, EMBO J, V22, P1359, DOI 10.1093/emboj/cdg126; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lin JC, 2005, MOL CELL BIOL, V25, P10111, DOI 10.1128/MCB.25.22.10111-10121.2005; Makrides V, 2003, J BIOL CHEM, V278, P33298, DOI 10.1074/jbc.M305207200; Mandelkow EM, 2003, NEUROBIOL AGING, V24, P1079, DOI 10.1016/j.neurobiolaging.2003.04.007; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Spillantini MG, 2001, ADV EXP MED BIOL, V487, P21; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Varani L, 2000, NUCLEIC ACIDS RES, V28, P710, DOI 10.1093/nar/28.3.710; Wang JN, 2004, J NEUROCHEM, V88, P1078, DOI 10.1046/j.1471-4159.2003.02232.x; WU JY, 2004, ALTERNATIVELY SPLICE, P125	39	42	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24479	24488		10.1074/jbc.M603971200	http://dx.doi.org/10.1074/jbc.M603971200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16777844	Green Accepted, hybrid			2022-12-27	WOS:000239847800043
J	McMahon, S; Charbonneau, M; Grandmont, S; Richard, DE; Dubois, CM				McMahon, Stephanie; Charbonneau, Martine; Grandmont, Sebastien; Richard, Darren E.; Dubois, Claire M.			Transforming growth factor beta 1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; REGULATES GENE-EXPRESSION; SMOOTH-MUSCLE-CELLS; HUMAN BREAST-CANCER; TGF-BETA; FACTOR 1-ALPHA; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNALING PATHWAY; CARCINOMA-CELLS; E-CADHERIN	The hypoxia-inducible transcription factor-1 ( HIF-1) is central to a number of pathological processes through the induction of specific genes such as vascular endothelial growth factor ( VEGF). Even though HIF-1 is highly regulated by cellular oxygen levels, other elements of the inflammatory and tumor microenvironment were shown to influence its activity under normal oxygen concentration. Among others, recent studies indicated that transforming growth factor ( TGF) beta increases the expression of the regulatory HIF-1 alpha subunit, and induces HIF-1 DNA binding activity. Here, we demonstrate that TGF beta acts on HIF-1 alpha accumulation and activity by increasing HIF-1 alpha protein stability. In particular, we demonstrate that TGF beta markedly and specifically decreases both mRNA and protein levels of a HIF-1 alpha-associated prolyl hydroxylase ( PHD), PHD2, through the Smad signaling pathway. As a consequence, the degradation of HIF-1 alpha was inhibited as determined by impaired degradation of a reporter protein containing the HIF-1 alpha oxygen-dependent degradation domain encompassing the PHD-targeted prolines. Moreover, inhibition of the TGF beta 1 converting enzyme, furin, resulted in increased PHD2 expression, and decreased basal HIF-1 alpha and VEGF levels, suggesting that endogenous production of bioactive TGF beta 1 efficiently regulates HIF-1-targeted genes. This was reinforced by results from HIF-1 alpha knock-out or HIF-1 alpha-inhibited cells that show impairment in VEGF production in response to TGF beta. This study reveals a novel mechanism by which a growth factor controls HIF-1 stability, and thereby drives the expression of specific genes, through the regulation of PHD2 levels.	Univ Sherbrooke, Fac Med, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada; Hop Hotel Dieu, Ctr Rech, Quebec City, PQ G1R 2J6, Canada	University of Sherbrooke	Dubois, CM (corresponding author), 3001,12th N Ave, Sherbrooke, PQ J1H 5N4, Canada.	Claire.M.Dubois@USherbrooke.ca	Richard, Darren E./K-6760-2019	Richard, Darren/0000-0003-2690-0480				Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Benckert C, 2003, CANCER RES, V63, P1083; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blancher C, 2000, CANCER RES, V60, P7106; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood-2003-07-2427; Breier G, 2002, INT J CANCER, V97, P142, DOI 10.1002/ijc.1599; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Chiu C, 2001, INT J MOL MED, V8, P251; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chua CC, 2000, BBA-MOL CELL RES, V1497, P69, DOI 10.1016/S0167-4889(00)00040-9; Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; Donovan D, 1997, ANN SURG ONCOL, V4, P621, DOI 10.1007/BF02303745; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuchi M, 2004, CLIN CANCER RES, V10, P2738, DOI 10.1158/1078-0432.CCR-1096-03; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Herrera B, 2004, FREE RADICAL BIO MED, V36, P16, DOI 10.1016/j.freeradbiomed.2003.09.020; Hu B, 2006, ONCOGENE, V25, P1030, DOI 10.1038/sj.onc.1209140; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Janssen HLK, 2002, INT J RADIAT ONCOL, V54, P1537, DOI 10.1016/S0360-3016(02)03935-4; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kim ES, 2004, INT J ONCOL, V25, P1375; Kourembanas S, 1997, KIDNEY INT, V51, P438, DOI 10.1038/ki.1997.58; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Laprise MH, 2002, BLOOD, V100, P3578, DOI 10.1182/blood.V100.10.3578; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; McMahon S, 2005, J BIOL CHEM, V280, P6561, DOI 10.1074/jbc.M413248200; McMahon S, 2003, EXP CELL RES, V291, P326, DOI 10.1016/S0014-4827(03)00407-5; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 2000, J BIOL CHEM, V275, P26765; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Santibanez JF, 2002, BIOCHEM BIOPH RES CO, V296, P267; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; Shimizu S, 1996, CANCER RES, V56, P3366; Siegfried G, 2003, CANCER RES, V63, P1458; Stoeltzing O, 2004, JNCI-J NATL CANCER I, V96, P946, DOI 10.1093/jnci/djh168; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Tacchini L, 2004, CARCINOGENESIS, V25, P2089, DOI 10.1093/carcin/bgh227; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Vukovic V, 2001, CANCER RES, V61, P7394; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598	87	249	266	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24171	24181		10.1074/jbc.M604507200	http://dx.doi.org/10.1074/jbc.M604507200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16815840	hybrid			2022-12-27	WOS:000239847800011
J	He, XQ; Chen, MG; Lin, GX; Ma, Q				He, Xiaoqing; Chen, Michael G.; Lin, Gary X.; Ma, Qiang			Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2 center dot Keap1 center dot CuI3 complex and recruiting Nrf2 center dot Maf to the antioxidant response element enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; ARYL-HYDROCARBON RECEPTOR; SUBSTRATE ADAPTER PROTEIN; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; QUINONE REDUCTASE; ENZYME INDUCERS; GENE-EXPRESSION; KEAP1; INDUCTION	The ubiquitous toxic metalloid arsenic elicits pleiotropic adverse and adaptive responses in mammalian species. The biological targets of arsenic are largely unknown at present. We analyzed the signaling pathway for induction of detoxification gene NAD(P)H-quinone oxidoreductase (Nqo1) by arsenic. Genetic and biochemical evidence revealed that induction required cap 'n' collar basic leucine zipper transcription factor Nrf2 and the antioxidant response element (ARE) of Nqo1. Arsenic stabilized Nrf2 protein, extending the t(1/2) of Nrf2 from 21 to 200 min by inhibiting the Keap1(.)Cul3-dependent ubiquitination and proteasomal turnover of Nrf2. Arsenic markedly inhibited the ubiquitination of Nrf2 but did not disrupt the Nrf2(.)Keap1(.)Cul3 association in the cytoplasm. In the nucleus, arsenic, but not phenolic antioxidant tert-butylhydroquinone, dissociated Nrf2 from Keap1 and Cul3 followed by dimerization of Nrf2 with a Maf protein (Maf G/Maf K). Chromatin immunoprecipitation demonstrated that Nrf2 and Maf associated with the endogenous Nqo1 ARE enhancer constitutively. Arsenic substantially increased the ARE occupancy by Nrf2 and Maf. In addition, Keap1 was shown to be ubiquitinated in the cytoplasm and deubiquitinated in the nucleus in the presence of arsenic without changing the protein level, implicating nuclear-cytoplasmic recycling of Keap1. Our data reveal that arsenic activates the Nrf2/Keap1 signaling pathway through a distinct mechanism from that by antioxidants and suggest an "onswitch" model of Nqo1 transcription in which the binding of Nrf2(.)Maf to ARE controls both the basal and inducible expression of Nqo1.	NIOSH, Ctr Dis Control & Prevent, HELD, TMBB,Receptor Biol Lab, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Ma, Q (corresponding author), NIOSH, CDC, HELD, TMBB,Receptor Biol Lab, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	qam1@cdc.gov	ma, qiang/HCI-1013-2022					Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; Bianco NR, 2005, BIOCHEM J, V385, P279, DOI 10.1042/BJ20040959; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chappell WR, 1997, ENVIRON HEALTH PERSP, V105, P1060, DOI 10.1289/ehp.971051060; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Duker AA, 2005, ENVIRON INT, V31, P631, DOI 10.1016/j.envint.2004.10.020; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; Evens AM, 2004, LEUKEMIA RES, V28, P891, DOI 10.1016/j.leukres.2004.01.011; FARBER EM, 1992, J AM ACAD DERMATOL, V27, P640, DOI 10.1016/0190-9622(92)70232-5; Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101; Golub MS, 1998, J TOXICOL ENV HEAL B, V1, P199, DOI 10.1080/10937409809524552; Gomez-Caminero A. P., 2001, ENV HLTH CRITERIA, V224; Hu XM, 2006, MOL CELL BIOL, V26, P940, DOI 10.1128/MCB.26.3.940-954.2006; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, PHARMACOGENETICS, V4, P1, DOI 10.1097/00008571-199402000-00001; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; LEONARD A, 1980, MUTAT RES, V75, P49, DOI 10.1016/0165-1110(80)90027-5; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 2004, BIOCHEM J, V377, P205, DOI 10.1042/BJ20031123; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; Mastin JP, 2005, CARDIOVASC TOXICOL, V5, P91, DOI 10.1385/CT:5:2:091; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Pi JB, 2003, EXP CELL RES, V290, P234, DOI 10.1016/S0014-4827(03)00341-0; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; Tabacova S, 1996, TOXICOL APPL PHARM, V138, P298, DOI 10.1006/taap.1996.0128; TAYLOR PR, 1989, BRIT J IND MED, V46, P881; Tseng CH, 2005, J ENVIRON SCI HEAL C, V23, P55, DOI 10.1081/GNC-200051860; Wood TC, 2006, J BIOL CHEM, V281, P7364, DOI 10.1074/jbc.M512227200; Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	41	131	138	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23620	23631		10.1074/jbc.M604120200	http://dx.doi.org/10.1074/jbc.M604120200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785233	hybrid			2022-12-27	WOS:000239702900037
J	Lee, JW; Helmann, JD				Lee, Jin-Won; Helmann, John D.			Biochemical characterization of the structural Zn2+ site in the Bacillus subtilis peroxide sensor PerR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC UPTAKE REGULATOR; MASS-SPECTROMETRY ANALYSIS; ANTI-SIGMA FACTOR; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; FUR PROTEIN; METAL-IONS; STREPTOMYCES-COELICOLOR; CRYSTAL-STRUCTURE; ZINC RELEASE	In Bacillus subtilis most peroxide-inducible oxidative stress genes are regulated by a metal-dependent repressor, PerR. PerR is a dimeric, Zn2+-containing metalloprotein with a regulatory metal-binding site that binds Fe2+ (PerR:Zn,Fe) or Mn2+ (PerR:Zn,Mn). Reaction of PerR:Zn,Fe with low levels of hydrogen peroxide (H2O2) leads to oxidation of two His residues thereby leading to derepression. When bound to Mn2+, the resulting PerR: Zn, Mn is much less sensitive to oxidative inactivation. Here we demonstrate that the structural Zn2+ is coordinated in a highly stable, intrasubunit Cys(4):Zn2+ site. Oxidation of this Cys(4):Zn2+ site by H2O2 leads to the formation of intrasubunit disulfide bonds. The rate of oxidation is too slow to account for induction of the peroxide stress response by micromolar levels of H2O2 but could contribute to induction under severe oxidative stress conditions. In vivo studies demonstrated that inactivation of PerR:Zn,Mn required 10 mM H2O2, a level at least 1000 times greater than that needed for inactivation of PerR:Zn,Fe. Surprisingly even under these severe oxidation conditions there was little if any detectable oxidation of cysteine residues in vivo: derepression was correlated with oxidation of the regulatory site. Because oxidation at this site required bound Fe2+ in vitro, we suggest that treatment of cells with 10 mM H2O2 released sufficient Fe2+ into the cytosol to effect a transition of PerR from the PerR:Zn,Mn form to the peroxide-sensitive PerR:Zn,Fe form. This model is supported by metal ion affinity measurements demonstrating that PerR bound Fe2+ with higher affinity than Mn2+.	Cornell Univ, Dept Microbiol, Ithaca, NY 14853 USA	Cornell University	Helmann, JD (corresponding author), Cornell Univ, Dept Microbiol, 370 Wing Hall, Ithaca, NY 14853 USA.	jdh9@cornell.edu	LEE, JIN-WON/L-1116-2016	LEE, JIN-WON/0000-0002-1201-8254; Helmann, John/0000-0002-3832-3249				Bae JB, 2004, J MOL BIOL, V335, P425, DOI 10.1016/j.jmb.2003.10.065; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; Bsat N, 1999, J BACTERIOL, V181, P4299, DOI 10.1128/JB.181.14.4299-4307.1999; CHEN L, 1995, P NATL ACAD SCI USA, V92, P8190, DOI 10.1073/pnas.92.18.8190; CHEN L, 1993, J BACTERIOL, V175, P5428, DOI 10.1128/JB.175.17.5428-5437.1993; COY M, 1994, BIOMETALS, V7, P292; COY M, 1991, BIOCHEMISTRY-US, V30, P8201, DOI 10.1021/bi00247a016; de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283; Friedman YE, 2004, J BIOL CHEM, V279, P32100, DOI 10.1074/jbc.M404924200; Fuangthong M, 2003, J BACTERIOL, V185, P6348, DOI 10.1128/JB.185.21.6348-6357.2003; Fuangthong M, 2002, J BACTERIOL, V184, P3276, DOI 10.1128/JB.184.12.3276-3286.2002; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Green J, 2004, NAT REV MICROBIOL, V2, P954, DOI 10.1038/nrmicro1022; Hahn JS, 2000, J BIOL CHEM, V275, P38254, DOI 10.1074/jbc.M006079200; Harvie DR, 2005, CURR MICROBIOL, V50, P246, DOI 10.1007/s00284-004-4442-0; Helmann JD, 2003, J BACTERIOL, V185, P243, DOI 10.1128/JB.185.1.243-253.2003; Herbig AF, 2001, MOL MICROBIOL, V41, P849, DOI 10.1046/j.1365-2958.2001.02543.x; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Imlay JA, 2006, MOL MICROBIOL, V59, P1073, DOI 10.1111/j.1365-2958.2006.05028.x; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Janda I, 2004, STRUCTURE, V12, P1901, DOI 10.1016/j.str.2004.08.003; Kaltwasser M, 2002, APPL ENVIRON MICROB, V68, P2624, DOI 10.1128/AEM.68.5.2624-2628.2002; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kiley PJ, 2004, PLOS BIOL, V2, P1714, DOI 10.1371/journal.pbio.0020400; Kliegman JI, 2006, BIOCHEMISTRY-US, V45, P3493, DOI 10.1021/bi0524215; Lee JW, 2006, NATURE, V440, P363, DOI 10.1038/nature04537; Lucana DOD, 2000, MOL GEN GENET, V264, P341; MichaudSoret I, 1997, FEBS LETT, V413, P473, DOI 10.1016/S0014-5793(97)00963-0; Moore CM, 2004, J BACTERIOL, V186, P4655, DOI 10.1128/JB.186.14.4655-4664.2004; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; PECQUEUR L, 2006, J BIOL CHEM; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sen KI, 2006, BIOCHEMISTRY-US, V45, P4295, DOI 10.1021/bi052288g; Stone JR, 2004, ARCH BIOCHEM BIOPHYS, V422, P119, DOI 10.1016/j.abb.2003.12.029; Winter J, 2005, MOL CELL, V17, P381, DOI 10.1016/j.molcel.2004.12.027; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Woodmansee AN, 2002, METHOD ENZYMOL, V349, P3, DOI 10.1016/S0076-6879(02)49316-0	42	102	105	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23567	23578		10.1074/jbc.M603968200	http://dx.doi.org/10.1074/jbc.M603968200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16766519	hybrid			2022-12-27	WOS:000239702900031
J	Stiehl, DP; Wirthner, R; Koditz, J; Spielmann, P; Camenisch, G; Wenger, RH				Stiehl, Daniel P.; Wirthner, Renato; Koeditz, Jens; Spielmann, Patrick; Camenisch, Gieri; Wenger, Roland H.			Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels - Evidence for an autoregulatory oxygen-sensing system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; MESSENGER-RNA EXPRESSION; TRANSCRIPTIONAL ACTIVITY; DEPENDENT DEGRADATION; HYDROXYLASE-ACTIVITY; HYPOXIA; HIF; GENE; FACTOR-1-ALPHA; HIF-1-ALPHA	Prolyl 4-hydroxylase domain (PHD) proteins are oxygen-dependent enzymes that hydroxylate hypoxia-inducible transcription factor (HIF) alpha-subunits, leading to their subsequent ubiquitination and degradation. Paradoxically, the expression of two family members (PHD2 and PHD3) is induced in hypoxic cell culture despite the reduced availability of the oxygen co-substrate, and it has been suggested that they become functionally relevant following re-oxygenation to rapidly terminate the HIF response. Here we show that PHDs are also induced in hypoxic mice in vivo, albeit in a tissue-specific manner. As demonstrated under chronically hypoxic conditions in vitro, PHD2 and PHD3 show a transient maximum but remain upregulated over more than 10 days, suggesting a feedback down-regulation of HIF-1 alpha which then levels off at a novel set point. Indeed, hypoxic induction of PHD2 and PHD3 is paralleled by the attenuation of endogenous HIF-1 alpha. Using an engineered oxygen-sensitive reporter gene in a cellular background lacking endogenous HIF-1 alpha and hence inducible PHD expression, we could show that increased exogenous PHD levels can compensate for a wide range of hypoxic conditions. Similar data were obtained in a reconstituted cell-free system in vitro. In summary, these results suggest that due to their high O-2 K-m values, PHDs have optimal oxygen-sensing properties under all physiologically relevant oxygen concentrations; increased PHDs play a functional role even under oxygen-deprived conditions, allowing the HIF system to adapt to a novel oxygen threshold and to respond to another hypoxic insult. Furthermore, such an autoregulatory oxygen-sensing system would explain how a single mechanism works in a wide variety of differently oxygenated tissues.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; Univ Gottingen, Dept Cardiovasc Physiol, D-37073 Gottingen, Germany	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Gottingen	Stiehl, DP (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	daniel.stiehl@access.unizh.ch	Stiehl, Daniel/A-3622-2008; Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Stiehl, Daniel/0000-0002-0076-4874; Spielmann, Patrick/0000-0001-7056-0351				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chilov D, 1999, J CELL SCI, V112, P1203; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Karhausen J, 2005, J CELL BIOCHEM, V95, P1264, DOI 10.1002/jcb.20489; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martin F, 2005, BLOOD, V105, P4613, DOI 10.1182/blood-2004-10-3980; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Masson N, 2004, FEBS LETT, V570, P166, DOI 10.1016/j.febslet.2004.06.040; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Oehme F, 2004, ANAL BIOCHEM, V330, P74, DOI 10.1016/j.ab.2004.03.066; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Safran M, 2006, P NATL ACAD SCI USA, V103, P105, DOI 10.1073/pnas.0509459103; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Svastova E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; Unruh A, 2003, ONCOGENE, V22, P3213, DOI 10.1038/sj.onc.1206385; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, INT J MOL MED, V2, P317; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WENGER RH, 1999, ENV STRESS GENE REGU, P25; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; WOLFF M, 1993, AM J PHYSIOL, V265, pC1266, DOI 10.1152/ajpcell.1993.265.5.C1266	43	226	233	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23482	23491		10.1074/jbc.M601719200	http://dx.doi.org/10.1074/jbc.M601719200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790428	hybrid, Green Published			2022-12-27	WOS:000239702900023
J	Umlauf, E; Mairhofer, M; Prohaska, R				Umlauf, Ellen; Mairhofer, Mario; Prohaska, Rainer			Characterization of the stomatin domain involved in homo-oligomerization and lipid raft association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; C-TERMINAL DOMAIN; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; CELL-MEMBRANES; LIVING CELLS; SPFH DOMAIN; BAND 7.2B; IN-VIVO; PHOSPHORYLATION	The cytoplasmically oriented monotopic integral membrane protein stomatin forms high-order oligomers and associates with lipid rafts. To characterize the domains that are involved in oligomerization and detergent-resistant membrane (DRM) association, we expressed truncation and point mutants of stomatin and analyzed their size and buoyancy by ultracentrifugation methods. A small C-terminal region of stomatin that is largely hydrophobic, Ser-Thr-Ile-Val-Phe-Pro-Leu-Pro-Ile (residues 264-272), proved to be crucial for oligomerization, whereas the N-terminal domain (residues 1-20) and the last 12 C-terminal amino acids (residues 276 287) were not essential. The introduction of alanine substitutions in the region 264-272 resulted in the appearance of monomers. Remarkably, only three of these residues, Ile-Val-Phe (residues 266-268), were found to be indispensable for the DRM association. Interestingly, the exchange of Pro-269 and to some extent the residues 270-272, which are essential for oligomerization, did not affect the DRM association of stomatin. This suggests that the formation of oligomers is not necessary for the association of stomatin with DRMs. Internal deletions near the membrane anchoring domain resulted in the formation of intermediate size oligomers suggesting a conformational interdependence of large parts of the C-terminal region. Fluorescence recovery after photobleaching analysis of the tagged, monomeric, non-DRM mutant ST-(1-262)-green fluorescent protein and wild type stomatin Stom GFP showed a significantly higher lateral mobility of the truncation mutant in the plasma membrane suggesting a membrane interaction of the respective C-terminal region also in vivo.	Med Univ Vienna, Dept Biochem Med, Max F Perutz Labs, Vienna Bioctr, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Prohaska, R (corresponding author), Med Univ Vienna, Dept Biochem Med, Max F Perutz Labs, Vienna Bioctr, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.	rainer.prohaska@meduniwien.ac.at		Mairhofer, Mario/0000-0002-7218-6284				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Back JW, 2002, PROTEIN SCI, V11, P2471, DOI 10.1110/ps.0212602; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; Falk J, 2004, MOL BIOL CELL, V15, P4695, DOI 10.1091/mbc.E04-03-0171; Fernandez I, 2002, P NATL ACAD SCI USA, V99, P11193, DOI 10.1073/pnas.172196599; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; GALLAGHER PG, 1995, J BIOL CHEM, V270, P26358, DOI 10.1074/jbc.270.44.26358; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Goodwin JS, 2005, METHODS, V37, P154, DOI 10.1016/j.ymeth.2005.05.013; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1065, P195, DOI 10.1016/0005-2736(91)90230-6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; Huber TB, 2003, HUM MOL GENET, V12, P3397, DOI 10.1093/hmg/ddg360; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Khan TK, 2003, BIOCHEMISTRY-US, V42, P4780, DOI 10.1021/bi0265877; Langhorst MF, 2005, CELL MOL LIFE SCI, V62, P2228, DOI 10.1007/s00018-005-5166-4; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Morrow IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Rivera-Milla E, 2006, CELL MOL LIFE SCI, V63, P343, DOI 10.1007/s00018-005-5434-3; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; Shimi T, 2004, J STRUCT BIOL, V147, P31, DOI 10.1016/j.jsb.2003.11.013; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Snyers L, 1997, EUR J CELL BIOL, V73, P281; Snyers L, 1999, FEBS LETT, V449, P101, DOI 10.1016/S0014-5793(99)00417-2; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; Snyers L, 1999, EUR J CELL BIOL, V78, P802, DOI 10.1016/S0171-9335(99)80031-4; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; Suchanek M, 2005, NAT METHODS, V2, P261, DOI 10.1038/NMETH752; Suzuki K, 2001, BIOPHYS J, V81, P2181, DOI 10.1016/S0006-3495(01)75866-3; Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.e04-09-0807; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Unfried I, 1995, GENOMICS, V30, P521, DOI 10.1006/geno.1995.1273; Wang XB, 2004, BIOCHEMISTRY-US, V43, P13694, DOI 10.1021/bi049295+	54	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23349	23356		10.1074/jbc.M513720200	http://dx.doi.org/10.1074/jbc.M513720200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16766530	hybrid			2022-12-27	WOS:000239702900009
J	Dance, M; Montagner, A; Yart, A; Masri, B; Audigier, Y; Perret, B; Salles, JP; Raynal, P				Dance, Marie; Montagner, Alexandra; Yart, Armelle; Masri, Bernard; Audigier, Yves; Perret, Bertrand; Salles, Jean-Pierre; Raynal, Patrick			The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SIGNAL-REGULATED KINASE; NITRIC-OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPIDERMAL-GROWTH; TYROSINE KINASE; C-MET; EPITHELIAL MORPHOGENESIS; LYSOPHOSPHATIDIC ACID; TUMOR ANGIOGENESIS	Phosphoinositide 3-kinase (PI3K) mediates essential functions of vascular endothelial growth factor (VEGF), including the stimulation of endothelial cell proliferation and migration. Nevertheless, the mechanisms coupling the receptor VEGFR-2 to PI3K remain obscure. We observed that the Grb2-bound adapter Gab1 is tyrosine-phosphorylated and relocated to membrane fractions upon VEGF stimulation of endothelial cells. We could detect the PI3K regulatory subunit p85 in immunoprecipitates of endogenous Gab1, and vice versa, and measure a Gab1-associated lipid kinase activity upon VEGF stimulation. Furthermore, transfection of the Gab1-YF3 mutant lacking all p85-binding sites strongly repressed PI3K activation measured in vitro. Moreover, Gab1-YF3 severely decreased the cellular amount of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) generated in response to VEGF. Furthermore, adenoviral expression of Gab1-YF3 suppressed both Akt phosphorylation and recovery of wounded human umbilical vein endothelial cell monolayers, a VEGF-dependent process involving cell migration and proliferation under PI3K control. Transfection of other Gab1 mutants, lacking Grb2-binding sites or the pleckstrin homology (PH) domain, also prevented Akt activation, further demonstrating Gab1 involvement in PI3K activation. These mutants were also used to show that interactions with both Grb2 and PtdIns(3,4,5)P-3 mediate Gab1 recruitment by VEGFR-2. Importantly, Gab1 mobilization was impaired by (i) PI3K inhibitors, (ii) deletion of Gab1 PH domain, (iii) PTEN (phosphatase and tensin homolog deleted on chromosome 10) overexpression to repress PtdIns(3,4,5)P-3 production, and (iv) overexpression of a competitor PH domain for PtdIns(3,4,5)P-3 binding, which altogether demonstrated that PI3K is also an upstream regulator of Gab1. Gab1 thus appears as a primary actor in coupling VEGFR-2 to PI3K/Akt, recruited through an amplification loop involving PtdIns(3,4,5)P-3 and its PH domain.	Hop Purpan, Fac Med Toulouse, INSERM, Dept Lipoprot & Mediateurs Lipid,U563, F-31024 Toulouse, France; Hop Rangueil, INSERM, U589, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Raynal, P (corresponding author), Hop Purpan, Fac Med Toulouse, INSERM, Dept Lipoprot & Mediateurs Lipid,U563, Bat C,BP 3028, F-31024 Toulouse, France.	raynal@toulouse.inserm.fr	SALLES, Jean Pierre/K-2998-2014; Masri, Bernard/N-9856-2018; PERRET, Bertrand/Y-2326-2019; YART, Armelle/A-5656-2016; Raynal, Patrick/O-1926-2018	Masri, Bernard/0000-0002-4027-2604; YART, Armelle/0000-0002-2412-9840; Bertrand, PERRET/0000-0001-7568-445X; Raynal, Patrick/0000-0002-6731-3007; Montagner, Alexandra/0000-0002-4800-5105				ABID MR, 2004, ARTERIOSCLER THROMB, V24, P294, DOI DOI 10.1161/01.ATV.0000110502.10593.06; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dixit M, 2005, CIRC RES, V97, P1236, DOI 10.1161/01.RES.0000195611.59811.ab; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Vincent L, 2005, J CLIN INVEST, V115, P2992, DOI 10.1172/JCI24586; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yart A, 2003, CURR CANCER DRUG TAR, V3, P177, DOI 10.2174/1568009033481976	49	52	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23285	23295		10.1074/jbc.M600987200	http://dx.doi.org/10.1074/jbc.M600987200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16787925	hybrid			2022-12-27	WOS:000239542600091
J	Kheifets, V; Bright, R; Inagaki, K; Schechtman, D; Mochly-Rosen, D				Kheifets, Viktoria; Bright, Rachel; Inagaki, Koichi; Schechtman, Deborah; Mochly-Rosen, Daria			Protein kinase C delta (delta PKC)-annexin V interaction - A required step in delta PKC translocation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; ANNEXIN-V; INTRACELLULAR RECEPTORS; EPSILON TRANSLOCATION; REPERFUSION INJURY; CARDIAC ISCHEMIA; PLASMA-MEMBRANE; RAT HEARTS; ALPHA; CELLS	Protein kinase C (PKC) plays a critical role in diseases such as cancer, stroke, and cardiac ischemia, and participates in a variety of signal transduction pathways such as apoptosis, cell proliferation, and tumor suppression. Though much is known about PKC downstream signaling events, the mechanisms of regulation of PKC activation and subsequent translocation have not been elucidated. Protein-protein interactions regulate and determine the specificity of many cellular signaling events. Such a specific protein-protein interaction is described here between delta PKC and annexin V. We demonstrate, at physiologically relevant conditions, that a transient interaction between annexin V and delta PKC occurs in cells after delta PKC stimulation, but before delta PKC translocates to the particulate fraction. Evidence of delta PKC-annexin V binding is provided also by FRET and by in vitro binding studies. Dissociation of the delta PKC-annexin V complex requires ATP and microtubule integrity. Furthermore, depletion of endogenous annexin V, but not annexin IV, with siRNA inhibits delta PKC translocation following PKC stimulation. A rationally designed eight amino acid peptide, corresponding to the interaction site for delta PKC on annexin V, inhibits delta PKC translocation and delta PKC-mediated function as evidenced by its protective effect in a model of myocardial infarction. Our data indicate that translocation of delta PKC is not simply a diffusion-driven process, but is instead a multi-step event regulated by protein-protein interactions. We show that following cell activation, delta PKC-annexin V binding is a transient and an essential step in the function of delta PKC, thus identifying a new role for annexin V in PKC signaling and a new step in PKC activation.	Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol,CCSR, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol,CCSR, Rm 3145A,269 Campus Dr, Stanford, CA 94305 USA.	mochly@stanford.edu	schechtman, deborah/B-7572-2012	Mochly-Rosen, Daria/0000-0002-6691-8733; Schechtman, Deborah/0000-0002-8874-7023	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONICELLI F, 1990, REPROD NUTR DEV, V30, P297, DOI 10.1051/rnd:19900302; BARNES JA, 1991, BIOCHEM CELL BIOL, V69, P163, DOI 10.1139/o91-024; Battistella-Patterson AS, 2000, ACTA PHYSIOL SCAND, V170, P87, DOI 10.1046/j.1365-201x.2000.00755.x; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Hayes MJ, 2004, TRAFFIC, V5, P571, DOI 10.1111/j.1600-0854.2004.00210.x; HONDEGHEM LM, 1978, AM J PHYSIOL, V235, pH574, DOI 10.1152/ajpheart.1978.235.5.H574; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Inagaki K, 2000, CARDIOVASC DRUG THER, V14, P489, DOI 10.1023/A:1007884905461; Inagaki K, 2003, CIRCULATION, V108, P2304, DOI 10.1161/01.CIR.0000101682.24138.36; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; Inagaki K, 2000, CIRCULATION, V101, P797, DOI 10.1161/01.CIR.101.7.797; John C, 2002, ENDOCRINOLOGY, V143, P3060, DOI 10.1210/en.143.8.3060; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kaneko N, 1997, BBA-BIOMEMBRANES, V1330, P1, DOI 10.1016/S0005-2736(97)00132-6; Kaneko N, 1997, J MOL BIOL, V274, P16, DOI 10.1006/jmbi.1997.1375; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; KONDO T, 1979, J LAB CLIN MED, V94, P617; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Miettinen S, 1996, J NEUROSCI, V16, P6236; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-219; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Prevostel C, 2000, J CELL SCI, V113, P2575; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Schechtman D, 2004, J BIOL CHEM, V279, P15831, DOI 10.1074/jbc.M310696200; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; Schechtman Deborah, 2003, Methods Mol Biol, V233, P351; Schmitz-Peiffer C, 1998, BIOCHEM J, V330, P675, DOI 10.1042/bj3300675; Scott JD, 1997, SOC GEN PHY, V52, P227; Shirai Y, 1998, JPN J PHARMACOL, V78, P411, DOI 10.1254/jjp.78.411; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; STOEHR SJ, 1990, J IMMUNOL, V144, P3936; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Weinstein I B, 1991, Princess Takamatsu Symp, V22, P277; Xu TR, 2004, FEBS LETT, V570, P20, DOI 10.1016/j.febslet.2004.05.080; Yoshida K, 1997, J BIOCHEM, V122, P506; Zal T, 2004, BIOPHYS J, V86, P3923, DOI 10.1529/biophysj.103.022087	62	54	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23218	23226		10.1074/jbc.M602075200	http://dx.doi.org/10.1074/jbc.M602075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785226	hybrid			2022-12-27	WOS:000239542600084
J	Werner, E; Kowalczyk, AP; Faundez, V				Werner, Erica; Kowalczyk, Andrew P.; Faundez, Victor			Anthrax toxin receptor 1/tumor endothelium marker 8 mediates cell spreading by coupling extracellular ligands to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRAX TOXIN RECEPTOR; CAPILLARY MORPHOGENESIS; SIGNAL-TRANSDUCTION; TUMOR ENDOTHELIUM; GENE-EXPRESSION; COLLAGEN; INTEGRINS; ADHESION; BINDING; MATRIX	Tumor endothelial marker 8 (TEM8) is induced in tumor-associated vasculature and acts as a receptor for Protective Antigen (PA), the cell-binding component of the anthrax toxin determinant for toxin entrance into cells. However, the normal function for TEM8 remains unknown. We show that TEM8 functions as an adhesion molecule mediating cell spreading on immobilized PA and collagen I. The mechanism for TEM8 interaction with collagen I was cell type-specific, because binding to collagen I was abrogated by beta 1 integrin function blocking antibody in HEK293 cells, but not in primary synovial rabbit fibroblasts. Binding to PA remained unaffected by the addition of beta 1 integrin function blocking antibody. Whereas the extracellular and transmembrane domains of TEM8 were sufficient to provide cell attachment, the intracellular domain was critical for spreading. Fusion of the cytosolic domain of TEM8 to the IL-2 receptor, conferred cell-spreading capability on IL-2 receptor antibody substrates. The cytoplasmic domain mediated linkage with the actin cytoskeleton as it co-precipitated actin and determined partitioning of TEM8 to the actin-containing detergent insoluble cellular fraction. TEM8 anchorage to actin was relevant as spreading was inhibited by the cytoskeleton-disrupting drug cytochalasin D, but persisted in the presence of the microtubule-depolymerizing drug nocodazole, and in cells lacking intermediate filaments. Thus, our results indicate that TEM8 is a new adhesion molecule linking collagen I or PA to the actin cytoskeleton.	Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Dept Dermatol, Atlanta, GA 30322 USA	Emory University; Emory University	Werner, E (corresponding author), Emory Univ, Dept Cell Biol, Whitehead Biomed Res Bldg,Rm 455,615 Michael St, Atlanta, GA 30322 USA.	ericaw@cellbio.emory.edu		Faundez, Victor/0000-0002-2114-5271; Werner, Erica/0000-0002-8183-1601	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042599] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR050501] Funding Source: Medline; NINDS NIH HHS [R01NS42599] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Bell SE, 2001, J CELL SCI, V114, P2755; Bonuccelli G, 2005, AM J PHYSIOL-CELL PH, V288, pC1402, DOI 10.1152/ajpcell.00582.2004; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Bradley KA, 2003, J BIOL CHEM, V278, P49342, DOI 10.1074/jbc.M307900200; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; CHUN JS, 1992, MOL BIOL CELL, V3, P481, DOI 10.1091/mbc.3.5.481; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Dowling O, 2003, AM J HUM GENET, V73, P957, DOI 10.1086/378781; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Feng XD, 2002, J IMMUNOL, V168, P2441, DOI 10.4049/jimmunol.168.5.2441; Gates J, 2005, CELL, V123, P769, DOI 10.1016/j.cell.2005.11.009; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hotchkiss KA, 2005, EXP CELL RES, V305, P133, DOI 10.1016/j.yexcr.2004.12.025; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Liu SH, 2005, NAT BIOTECHNOL, V23, P725, DOI 10.1038/nbt1091; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Meredith JE, 1999, J BIOL CHEM, V274, P8111, DOI 10.1074/jbc.274.12.8111; MOONEY DJ, 1995, J CELL SCI, V108, P2311; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; St Croix B, 2000, SCIENCE, V289, P1197; Styers ML, 2004, MOL BIOL CELL, V15, P5369, DOI 10.1091/mbc.E04-03-0272; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wei W, 2006, CELL, V124, P1141, DOI 10.1016/j.cell.2005.12.045; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200	49	63	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23227	23236		10.1074/jbc.M603676200	http://dx.doi.org/10.1074/jbc.M603676200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16762926	hybrid			2022-12-27	WOS:000239542600085
J	Guffanti, E; Percudani, R; Harismendy, O; Soutourina, J; Werner, M; Iacovella, MG; Negri, R; Dieci, G				Guffanti, Elisa; Percudani, Riccardo; Harismendy, Olivier; Soutourina, Julie; Werner, Michel; Iacovella, Maria Giuseppina; Negri, Rodolfo; Dieci, Giorgio			Nucleosome depletion activates poised RNA polymerase III at unconventional transcription sites in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GENOME; HEAT-SHOCK; GENE; PROMOTER; EXPRESSION; UPSTREAM; U6; RETROTRANSPOSON; REINITIATION; ORGANIZATION	RNA polymerase (pol) III, assisted by the transcription factors TFIIIC and TFIIIB, transcribes small untranslated RNAs, such as tRNAs. In addition to known pol III-transcribed genes, the Saccharomyces cerevisiae genome contains loci (ZOD1, ETC1-8) associated to incomplete pol III transcription complexes (Moqtaderi, Z., and Struhl, K. (2004) Mol. Cell. Biol. 24, 4118-4127). We show that a short segment of the ZOD1 locus, containing box A and box B promoter elements and a termination signal between them, directs the pol III-dependent production of a small RNA both in vitro and in vivo. In yeast cells, the levels of both ZOD1- and ETC5-specific transcripts were dramatically enhanced upon nucleosome depletion. Remarkably, transcription factor and pol III occupancy at the corresponding loci did not change significantly upon derepression, thus suggesting that chromatin opening activates poised pol III to transcription. Comparative genomic analysis revealed that the ZOD1 promoter is the only surviving portion of a tDNA(Ile) ancestor, whose transcription capacity has been preserved throughout evolution independently from the encoded RNA product. Similarly, another TFIIIC/TFIIIB-associated locus, close to the YGR033c open reading frame, was found to be the strictly conserved remnant of an ancient tDNA(Arg). The maintenance, by eukaryotic genomes, of chromatin-repressed, non-coding transcription units has implications for both genome expression and organization.	Univ Parma, Dipartimento Biochim & Biol Mol, I-43100 Parma, Italy; CEA Saclay, Commiss Energie Atom, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Univ Roma La Sapienza, Dipartimento Biol Cellulare, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); University of Parma; CEA; UDICE-French Research Universities; Universite Paris Saclay; Fondazione Cenci Bolognetti; Sapienza University Rome	Dieci, G (corresponding author), Univ Parma, Dipartimento Biochim & Biol Mol, Parco Area Sci 23-A, I-43100 Parma, Italy.	giorgio.dieci@unipr.it	Soutourina, Julie/F-8305-2014; Werner, Michel/B-7316-2009; Dieci, Giorgio/B-3434-2012; percudani, riccardo/B-4872-2011; Harismendy, Olivier/AAM-2072-2021	Soutourina, Julie/0000-0001-5218-2350; Werner, Michel/0000-0002-2965-5858; Dieci, Giorgio/0000-0002-8792-3961; percudani, riccardo/0000-0001-8452-1062; Harismendy, Olivier/0000-0002-8098-9888; Iacovella, Maria Giuseppina/0000-0003-4564-9519				Allen TA, 2004, NAT STRUCT MOL BIOL, V11, P816, DOI 10.1038/nsmb813; Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Bachman N, 2005, GENE DEV, V19, P955, DOI 10.1101/gad.1299105; Bolton EC, 2003, GENOME RES, V13, P254, DOI 10.1101/gr.612203; Braglia P, 2005, J BIOL CHEM, V280, P19551, DOI 10.1074/jbc.M412238200; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; Conesa C, 2005, MOL CELL BIOL, V25, P8631, DOI 10.1128/MCB.25.19.8631-8642.2005; Devine SE, 1996, GENE DEV, V10, P620, DOI 10.1101/gad.10.5.620; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; Dieci G, 2002, J BIOL CHEM, V277, P6903, DOI 10.1074/jbc.M105036200; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Ferrari R, 2004, P NATL ACAD SCI USA, V101, P13442, DOI 10.1073/pnas.0403851101; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Huet J, 1996, METHOD ENZYMOL, V273, P249; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kuras Laurent, 2004, Methods Mol Biol, V284, P147; Kurtzman CP, 2003, FEMS YEAST RES, V3, P417, DOI 10.1016/S1567-1356(03)00012-6; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; Martens JA, 2004, NATURE, V429, P571, DOI 10.1038/nature02538; Moqtaderi Z, 2004, MOL CELL BIOL, V24, P4118, DOI 10.1128/MCB.24.10.4118-4127.2004; Noma KI, 2006, CELL, V125, P859, DOI 10.1016/j.cell.2006.04.028; Olivas WM, 1997, NUCLEIC ACIDS RES, V25, P4619, DOI 10.1093/nar/25.22.4619; Radonjic M, 2005, MOL CELL, V18, P171, DOI 10.1016/j.molcel.2005.03.010; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Simms TA, 2004, NUCLEIC ACIDS RES, V32, P5206, DOI 10.1093/nar/gkh858; WHITE RJ, 2002, RNA POLYM 3 TRANSCRI; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	39	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29155	29164		10.1074/jbc.M600387200	http://dx.doi.org/10.1074/jbc.M600387200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16816405	hybrid			2022-12-27	WOS:000240680500070
J	Khasawneh, FT; Huang, JS; Turek, JW; Le Breton, GC				Khasawneh, Fadi T.; Huang, Jin-Sheng; Turek, Joseph W.; Le Breton, Guy C.			Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A(2) receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND EXTRACELLULAR LOOP; MUSCARINIC ACETYLCHOLINE-RECEPTORS; SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; 13-AZAPROSTANOIC ACID; PROSTAGLANDIN; RESIDUES; ACTIVATION; EXPRESSION; BIOSYNTHESIS	Despite the well documented involvement of thromboxane A(2) receptor (TPR) signaling in the pathogenesis of thrombotic diseases, there are currently no rationally designed antagonists available for clinical use. To a large extent, this derives from a lack of knowledge regarding the topography of the TPR ligand binding pocket. On this basis, the purpose of the current study was to identify the specific amino acid residues in the TPR protein that regulate ligand coordination and binding. The sites selected for mutation reside within or in close proximity to a region we previously defined as a TPR ligand binding region (i.e. the C terminus of the second extracellular loop and the leading edge of the fifth transmembrane domain). Mutation of these residues caused varying effects on the TPR-ligand coordination process. Specifically, the D193A, D193Q, and D193R mutants lost SQ29,548 (antagonist) binding and exhibited a dramatically reduced calcium response, which could not be restored by elevated U46619 (agonist) doses. The F184Y mutant lost SQ29,548 binding and exhibited a reduced calcium response (which could be restored by elevated U46619); and the T186A and S191T mutants lost SQ29,548 binding and retained a normal U46619-induced calcium response. Furthermore, these last three mutants also revealed a divergence in the binding of two structurally different antagonists, SQ29,548 and BM13.505. Two separate mutants that exhibited SQ29,548 binding yielded either a normal (F196Y) or reduced (S201T) U46619 response. Finally, mutation of other residues directly adjacent to those described above (e. g. E190A and F200A) produced no detectable effects on either SQ29,548 binding or the U46619-induced response. In summary, these results identify key amino acids (in particular Asp(193)) involved in TPR ligand coordination. These findings also demonstrate that TPR-specific ligands interact with different residues in the ligand-binding pocket.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Le Breton, GC (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.	gcl@uic.edu		Turek, Joseph/0000-0002-4006-7555	NHLBI NIH HHS [HL23540-23] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ARMSTRONG RA, 1993, BRIT J PHARMACOL, V110, P548, DOI 10.1111/j.1476-5381.1993.tb13845.x; Audoly L, 1997, J BIOL CHEM, V272, P13475, DOI 10.1074/jbc.272.21.13475; Betz SF, 2006, J MED CHEM, V49, P637, DOI 10.1021/jm0506928; Brandoli C, 1998, J NEUROSCI, V18, P7953; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1033.2000.01472.x; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; Dorn GW, 1997, J BIOL CHEM, V272, P12399, DOI 10.1074/jbc.272.19.12399; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FITZGERALD GA, 1987, FASEB J, V46, P154; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; Hoffmann SH, 2000, MOL ENDOCRINOL, V14, P1099, DOI 10.1210/me.14.7.1099; Huang JS, 2006, CELL SIGNAL, V18, P564, DOI 10.1016/j.cellsig.2005.06.011; HUNG SC, 1983, BIOCHIM BIOPHYS ACTA, V728, P171, DOI 10.1016/0005-2736(83)90468-6; JIN B, 1994, J CHEM INF COMP SCI, V34, P1014, DOI 10.1021/ci00020a041; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; Komiotis D, 1996, BIOCHEM PHARMACOL, V52, P763, DOI 10.1016/0006-2952(96)00359-0; LEBRETON GC, 1979, P NATL ACAD SCI USA, V76, P4097; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Lin X, 2005, J NEUROCHEM, V93, P257, DOI 10.1111/j.1471-4159.2004.02969.x; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OGLETREE ML, 1987, FED PROC, V46, P133; Okuma Minoru, 1996, Polish Journal of Pharmacology, V48, P77; OLAH ME, 1994, J BIOL CHEM, V269, P24692; PAGE KM, 1995, EUR J PHARM-MOLEC PH, V289, P429, DOI 10.1016/0922-4106(95)90151-5; PATRONO C, 1990, STROKE, V21, P130; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; So SP, 2003, J BIOL CHEM, V278, P10922, DOI 10.1074/jbc.M209337200; Stillman BA, 1998, EUR J PHARMACOL, V357, P73, DOI 10.1016/S0014-2999(98)00522-6; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; SVENSSON J, 1976, ACTA PHYSIOL SCAND, V98, P285, DOI 10.1111/j.1748-1716.1976.tb10313.x; Taylor DM, 2003, EUR J MED CHEM, V38, P1015, DOI 10.1016/j.ejmech.2003.07.003; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; Turek JW, 2002, J BIOL CHEM, V277, P16791, DOI 10.1074/jbc.M105872200; USHIKUBI F, 1993, J EXP MED, V178, P1825, DOI 10.1084/jem.178.5.1825; YAMAMOTO Y, 1993, J MED CHEM, V36, P820, DOI 10.1021/jm00059a005	47	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26951	26965		10.1074/jbc.M507469200	http://dx.doi.org/10.1074/jbc.M507469200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16837469	hybrid			2022-12-27	WOS:000240397700022
J	Li, WG; Yu, SW; Kong, ANT				Li, Wenge; Yu, Si-Wang; Kong, A. -N. Tony			Nrf2 possesses a redox-sensitive nuclear exporting signal in the Neh5 transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-MEDIATED EXPRESSION; TRANSCRIPTION FACTOR NRF2; INDUCIBLE EXPRESSION; FUNCTIONAL-CHARACTERIZATION; ANTIOXIDANT INDUCTION; RESPONSIVE ELEMENT; GENE-EXPRESSION; SMALL-INTESTINE; DNA-BINDING; KEAP1	NF-E2-related factor 2 (Nrf2) is the key transcription factor regulating the antioxidant response. Previous studies identified a nuclear localization signal (NLS) in the basic region and a nuclear exporting signal (NES) in the leucine zipper domain of Nrf2. In this study, we characterize a new functional NES ((175)LLSIPELQCLNI(186)) in the transactivation (TA) domain of Nrf2. A green fluorescence protein (GFP)-tagged Nrf2 segment (amino acids162-295) called GFP-NESTA exhibited a cytosolic distribution that could be disrupted by L184A mutation or leptomycin B treatment. Chimeric expression of this NESTA with a nuclear protein GAL4DBD could expel GAL4DBD into the cytoplasm. A variety of oxidants, including sulforaphane, tert-butylhydroquinone, and H2O2, could effectively induce nuclear translocation of GFP-NESTA. Mutational studies showed that cysteine 183 may mediate the redox response of NESTA. The discovery of multiple NLS/NES motifs in Nrf2 and the redox sensitivity of NESTA imply Nrf2 may be self-sufficient to sense and transduce oxidative signals into the nucleus, consequently initiating antioxidant gene transcription.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kong, ANT (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	KongT@rci.rutgers.edu	Kong, Ah-Ng Tony/AAX-2828-2020	Yu, Siwang/0000-0002-3336-202X	NCI NIH HHS [R01 CA94828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee TD, 2005, BIOCHEM J, V390, P521, DOI 10.1042/BJ20050439; Li WG, 2005, J BIOL CHEM, V280, P28430, DOI 10.1074/jbc.M410601200; Magin TM, 2003, NAT GENET, V35, P202, DOI 10.1038/ng1103-202; McMahon M, 2001, CANCER RES, V61, P3299; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; NISHI K, 1994, J BIOL CHEM, V269, P6320; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Shen GX, 2006, MOL CANCER THER, V5, P39, DOI 10.1158/1535-7163.MCT-05-0293; Shen GX, 2005, PHARM RES-DORDR, V22, P1805, DOI 10.1007/s11095-005-7546-8; Shen GX, 2004, J BIOL CHEM, V279, P23052, DOI 10.1074/jbc.M401368200; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; YOUVAN DC, 1984, CELL, V39, P1, DOI 10.1016/0092-8674(84)90185-5; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	62	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27251	27263		10.1074/jbc.M602746200	http://dx.doi.org/10.1074/jbc.M602746200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16790425	hybrid			2022-12-27	WOS:000240397700052
J	Johnson, D; Bennett, ES				Johnson, Daniel; Bennett, Eric S.			Isoform-specific effects of the beta(2) subunit on voltage-gated sodium channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHERITED CARDIAC-ARRHYTHMIA; LONG-QT SYNDROME; SIALIC-ACID; CONGENITAL DISORDERS; BETA-2 SUBUNIT; NA+ CHANNEL; HUMAN BRAIN; GLYCOSYLATION DEFECTS; AUXILIARY SUBUNIT; SKELETAL-MUSCLE	Voltage-gated sodium channels (Na-v) are complex glycoproteins comprised of an alpha subunit and often one to several beta subunits. We have shown that sialic acid residues linked to Na-v alpha and beta(1) subunits alter channel gating. To determine whether beta(2)-linked sialic acids similarly impact Na-v gating, we co-expressed beta(2) with Na(v)1.5 or Na(v)1.2 in Pro5 (complete sialylation) and in Lec2 (essentially no sialylation) cells. beta(2) sialic acids caused a significant hyperpolarizing shift in Na(v)1.5 voltage-dependent gating, thus describing for the first time an effect of beta(2) on Na(v)1.5 gating. In contrast, beta(2) caused a sialic acid-independent depolarizing shift in Na(v)1.2 gating. A deglycosylated mutant, beta(2-Delta N), had no effect on Na(v)1.5 gating, indicating further the impact of beta(2) N-linked sialic acids on Na(v)1.5 gating. Conversely, beta(2-Delta N) modulated Na(v)1.2 gating virtually identically to beta(2), confirming that beta(2) N-linked sugars have no impact on Na(v)1.2 gating. Thus, beta(2) modulates Na-v gating through multiple mechanisms possibly determined by the associated alpha subunit. beta(1) and beta(2) were expressed together with Na(v)1.5 or Na(v)1.2 in Pro5 and Lec2 cells. Together beta(1) and beta(2) produced a significantly larger sialic acid-dependent hyperpolarizing shift in Nav1.5 gating. Under fully sialylating conditions, the Na(v)1.2(.)beta(.)(1)beta(2) complex behaved like Na(v)1.2 alone. When sialylation was reduced, only the sialic acid-independent depolarizing effects of beta(2) on Na(v)1.2 gating were apparent. Thus, the varied effects of beta(1) and beta(2) on Na(v)1.5 and Na(v)1.2 gating are apparently synergistic and highlight the complex manner, through subunit-and sugar-dependent mechanisms, by which Na-v activity is modulated.	Univ S Florida, Dept Mol Pharmacol & Physiol, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Programs Cardiovasc Sci & Neurosci, Coll Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Bennett, ES (corresponding author), Univ S Florida, Dept Mol Pharmacol & Physiol, Coll Med, MDC 8, Tampa, FL 33612 USA.	esbennet@hsc.usf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045169] Funding Source: NIH RePORTER; NIAMS NIH HHS [R-01AR45169] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abriel H, 2001, CIRC RES, V88, P740, DOI 10.1161/hh0701.089668; Barresi R, 2004, NAT MED, V10, P696, DOI 10.1038/nm1059; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; Bennett ES, 2002, J PHYSIOL-LONDON, V538, P675, DOI 10.1113/jphysiol.2001.013285; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Blackburn-Munro G, 1999, NEUROSCIENCE, V90, P153, DOI 10.1016/S0306-4522(98)00415-1; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen CL, 2002, P NATL ACAD SCI USA, V99, P17072, DOI 10.1073/pnas.212638099; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOBYNS WB, 1989, AM J MED GENET, V32, P195, DOI 10.1002/ajmg.1320320213; Donahue LM, 2000, BRAIN RES, V887, P335, DOI 10.1016/S0006-8993(00)03033-X; Dubowitz T, 2000, ANN NEUROL, V47, P143, DOI 10.1002/1531-8249(200002)47:2<143::AID-ANA2>3.0.CO;2-Y; Eubanks J, 1997, NEUROREPORT, V8, P2775, DOI 10.1097/00001756-199708180-00025; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; Gastaldi M, 1998, NEUROSCI LETT, V249, P53, DOI 10.1016/S0304-3940(98)00394-2; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jaeken J, 2004, CURR OPIN PEDIATR, V16, P434, DOI 10.1097/01.mop.0000133636.56790.4a; Jaeken J, 2003, J INHERIT METAB DIS, V26, P99, DOI 10.1023/A:1024431131208; Johnson D, 2004, J BIOL CHEM, V279, P44303, DOI 10.1074/jbc.M408900200; Maier SKG, 2004, CIRCULATION, V109, P1421, DOI 10.1161/01.CIR.0000121421.61896.24; Malhotra JD, 2001, CIRCULATION, V103, P1303; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; Marquardt T, 2003, EUR J PEDIATR, V162, P359, DOI 10.1007/s00431-002-1136-0; Martinez-Duncker I, 2005, BLOOD, V105, P2671, DOI 10.1182/blood-2004-09-3509; Meadows LS, 2002, NEUROSCIENCE, V114, P745, DOI 10.1016/S0306-4522(02)00242-7; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Qu Y, 2001, MOL CELL NEUROSCI, V18, P570, DOI 10.1006/mcne.2001.1039; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; ROBERTS RH, 1987, J BIOL CHEM, V262, P2298; Schaller KL, 2003, CEREBELLUM, V2, P2, DOI 10.1080/14734220309424; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; Spampanato J, 2003, NEUROSCIENCE, V116, P37, DOI 10.1016/S0306-4522(02)00698-X; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STANLEY P, 1985, MOL CELL BIOL, V5, P923, DOI 10.1128/MCB.5.5.923; Stocker PJ, 2006, J GEN PHYSIOL, V127, P253, DOI 10.1085/jgp.200509423; Tyrrell L, 2001, J NEUROSCI, V21, P9629, DOI 10.1523/JNEUROSCI.21-24-09629.2001; Vijayaragavan K, 2004, BIOCHEM BIOPH RES CO, V319, P531, DOI 10.1016/j.bbrc.2004.05.026; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WOLLNER DA, 1987, J BIOL CHEM, V262, P14709; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhang Y, 1999, J MEMBRANE BIOL, V171, P195, DOI 10.1007/s002329900571	47	55	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25875	25881		10.1074/jbc.M605060200	http://dx.doi.org/10.1074/jbc.M605060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16847056	hybrid			2022-12-27	WOS:000240249500002
J	Nelson, EA; Walker, SR; Li, W; Liu, XS; Frank, DA				Nelson, Erik A.; Walker, Sarah R.; Li, Wei; Liu, X. Shirley; Frank, David A.			Identification of human STAT5-dependent gene regulatory elements based on interspecies homology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; BINDING-SITES; SIGNAL TRANSDUCER; STAT PROTEINS; ONCOSTATIN M; PROMOTER; INTERLEUKIN-2; ACTIVATION; EXPRESSION; CELLS	STAT5 is a transcription factor essential for hematopoietic physiology. STAT5 functions to transduce signals from cytokines to the nucleus where it regulates gene expression. Although several important transcriptional targets of STAT5 are known, most remain unidentified. To identify novel STAT5 targets, we searched chromosomes 21 and 22 for clusters of STAT5 binding sites contained within regions of interspecies homology. We identified four such regions, including one with tandem STAT5 binding sites in the first intron of the NCAM2 gene. Unlike known STAT5 binding sites, this site is found within a very large intron and resides similar to 200 kb from the first coding exon of NCAM2. We demonstrate that this region confers STAT5-dependent transcriptional activity. We show that STAT5 binds in vivo to the NCAM2 intron in the NKL natural killer cell line and that this binding is induced by cytokines that activate STAT5. Neither STAT1 nor STAT3 bind to this region, despite sharing a consensus binding sequence with STAT5. Activation of STAT4 and STAT5 causes the accumulation of both of these STATs to the NCAM2 regulatory region. Therefore, using an informatics based approach to identify STAT5 targets, we have identified NCAM2 as both a STAT4- and STAT5-regulated gene, and we show that its expression is regulated by cytokines essential for natural killer cell survival and differentiation. This strategy may be an effective way to identify functional binding regions for transcription factors with known cognate binding sites anywhere in the genome.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biostat & Computat Biol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health	Frank, DA (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	david_frank@dfci.harvard.edu	Li, Wei/A-8544-2009	Li, Wei/0000-0001-9931-5990	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004069] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG004069, R01 HG004069-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Becknell B, 2005, ADV IMMUNOL, V86, P209, DOI 10.1016/S0065-2776(04)86006-1; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bream JH, 2004, J BIOL CHEM, V279, P41249, DOI 10.1074/jbc.M401168200; Brudno M, 2004, GENOME RES, V14, P685, DOI 10.1101/gr.2067704; Bulyk ML, 2004, GENOME BIOL, V5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Cho SS, 1996, J IMMUNOL, V157, P4781; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Crnic I, 2004, CANCER RES, V64, P8630, DOI 10.1158/0008-5472.CAN-04-2523; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Frank David A, 2003, Cancer Treat Res, V115, P267; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; John S, 1999, MOL CELL BIOL, V19, P1910; Kaiser U, 1996, LEUKEMIA LYMPHOMA, V20, P389, DOI 10.3109/10428199609052420; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; LeBaron MJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-6; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Ma YS, 1999, NUCLEIC ACIDS RES, V27, P4649, DOI 10.1093/nar/27.23.4649; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; NITTA T, 1989, J EXP MED, V170, P1757, DOI 10.1084/jem.170.5.1757; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Perl AK, 1999, NAT MED, V5, P286, DOI 10.1038/6502; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Rascle A, 2003, NUCLEIC ACIDS RES, V31, P6882, DOI 10.1093/nar/gkg907; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Takasaki S, 2000, CELL BIOL INT, V24, P101, DOI 10.1006/cbir.1999.0457; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Walmod PS, 2004, NEUROCHEM RES, V29, P2015, DOI 10.1007/s11064-004-6875-z; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Yu CR, 1996, J IMMUNOL, V157, P126; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200	45	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26216	26224		10.1074/jbc.M605001200	http://dx.doi.org/10.1074/jbc.M605001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840779	Green Accepted, hybrid			2022-12-27	WOS:000240249500038
J	Seidler, DG; Goldoni, S; Agnew, C; Cardi, C; Thakur, ML; Owens, RT; McQuillan, DJ; Iozzo, RV				Seidler, Daniela G.; Goldoni, Silvia; Agnew, Christopher; Cardi, Christopher; Thakur, Mathew L.; Owens, Rick T.; McQuillan, David J.; Iozzo, Renato V.			Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; CHICK-EMBRYO FIBROBLASTS; DOWN-REGULATION; EGF RECEPTOR; CELL-GROWTH; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; UP-REGULATION; SUPPRESSION; INDUCTION	Decorin is not only a regulator of matrix assembly but also a key signaling molecule that modulates the activity of tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR). Decorin evokes protracted internalization of the EGFR via a caveolar-mediated endocytosis, which leads to EGFR degradation and attenuation of its signaling pathway. In this study, we tested if systemic delivery of decorin protein core would affect the biology of an orthotopic squamous carcinoma xenograft. After tumor engraftment, the animals were given intraperitoneal injections of either vehicle or decorin protein core (2.5-10 mg kg(-1)) every 2 days for 18-38 days. This regimen caused a significant and dose-dependent inhibition of the tumor xenograft growth, with a concurrent decrease in mitotic index and a significant increase in apoptosis. Positron emission tomography showed that the metabolic activity of the tumor xenografts was significantly reduced by decorin treatment. Decorin protein core specifically targeted the tumor cells enriched in EGFR and caused a significant downregulation of EGFR and attenuation of its activity. In vitro studies showed that the uptake of decorin by the A431 cells was rapid and caused a protracted down-regulation of the EGFR to levels similar to those observed in the tumor xenografts. Furthermore, decorin induced apoptosis via activation of caspase-3. This could represent an additional mechanism whereby decorin might influence cell growth and survival.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Radiat, Radiopharmaceut Res Ctr, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Thomas Jefferson Univ, Cellular Biol & Signaling Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249 JAH, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Thakur, Mathew/0000-0003-2409-039X; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Biglari A, 2004, CANCER GENE THER, V11, P721, DOI 10.1038/sj.cgt.7700783; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Dharmawardana PG, 2006, ANTI-CANCER DRUG, V17, P13, DOI 10.1097/01.cad.0000185180.72604.ac; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; Iozzo RV, 1999, PROG NUCLEIC ACID RE, V62, P19; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang XN, 2004, J HISTOCHEM CYTOCHEM, V52, P1575, DOI 10.1369/jhc.4A6353.2004; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; Kolettas E, 1998, EUR J BIOCHEM, V254, P266, DOI 10.1046/j.1432-1327.1998.2540266.x; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Nash MA, 1999, CANCER RES, V59, P6192; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Petit AMV, 1997, AM J PATHOL, V151, P1523; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reed CC, 2005, ONCOGENE, V24, P1104, DOI 10.1038/sj.onc.1208329; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Seidler DG, 2005, BIOCHEM BIOPH RES CO, V332, P1162, DOI 10.1016/j.bbrc.2005.04.175; Shridhar V, 2001, CANCER RES, V61, P5895; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tikhomirov O, 2004, J BIOL CHEM, V279, P12988, DOI 10.1074/jbc.M311655200; Tralhao JG, 2003, FASEB J, V17, P464, DOI 10.1096/fj.02-0534fje; Troup S, 2003, CLIN CANCER RES, V9, P207; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200	60	145	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26408	26418		10.1074/jbc.M602853200	http://dx.doi.org/10.1074/jbc.M602853200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835231	hybrid			2022-12-27	WOS:000240249500058
J	Cai, BB; Chang, SH; Becker, EBE; Bonni, A; Xia, ZG				Cai, Beibei; Chang, Sandra H.; Becker, Esther B. E.; Bonni, Azad; Xia, Zhengui			p38 MAP kinase mediates apoptosis through phosphorylation of Bim(EL) at Ser-65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; RAT CEREBELLAR NEURONS; C-JUN; CORTICAL-NEURONS; BH3-ONLY PROTEIN; GENE-EXPRESSION; CELL-DEATH; HEME OXYGENASE-1; BCL-2 FAMILY	The stress-activated c-Jun N-terminal protein kinase (JNK) and p38 mitogen-activated protein ( MAP) kinase ( p38) regulate apoptosis induced by several forms of cellular insults. Potential targets for these kinases include members of the Bcl-2 family proteins, which mediate apoptosis generated through the mitochondria-initiated, intrinsic cell death pathway. Indeed, the activities of several Bcl-2 family proteins, both pro-and antiapoptotic, are controlled by JNK phosphorylation. For example, the pro-apoptotic activity of Bim(EL), a member of the Bcl-2 family, is stimulated by JNK phosphorylation at Ser-65. In contrast, there is no reported evidence that p38-induced apoptosis is due to direct phosphorylation of Bcl-2 family proteins. Here we report evidence that sodium arsenite-induced apoptosis in PC12 cells may be due to direct phosphorylation of BimEL at Ser-65 by p38. This conclusion is supported by data showing that ectopic expression of a wild type, but not a non-phosphorylatable S65A mutant of BimEL, potentiates sodium arsenite-induced apoptosis and by experiments showing direct phosphorylation of BimEL at Ser-65 by p38 in vitro. Furthermore, sodium arsenite induced BimEL phosphorylation at Ser-65, which was blocked by p38 inhibition. This study provides the first example whereby p38 induces apoptosis by phosphorylating a member of the Bcl-2 family and illustrates that phosphorylation of BimEL on Ser-65 may be a common regulatory point for cell death induced by both JNK and p38 pathways.	Univ Washington, Dept Environm & Occupat Hlth Sci, Toxicol Program, Box 357234, Seattle, WA 98195 USA; Univ Washington, Grad Program Neurobiol & Behav, Seattle, WA 98195 USA; Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School	Xia, ZG (corresponding author), Univ Washington, Dept Environm & Occupat Hlth Sci, Toxicol Program, Box 357234, Seattle, WA 98195 USA.	zxia@u.washington.edu		Becker, Esther B E/0000-0002-5238-4902	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007032, R01ES012215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044069] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES007032, ES 012215] Funding Source: Medline; NINDS NIH HHS [NS421021, NS44069] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amato SF, 1998, CANCER RES, V58, P241; Bantounas I, 2005, J NEUROSCI RES, V79, P661, DOI 10.1002/jnr.20389; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Bhakar AL, 2003, J NEUROSCI, V23, P11373; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Caughlan A, 2004, TOXICOL SCI, V78, P125, DOI 10.1093/toxsci/kfh038; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grethe S, 2006, CELL SIGNAL, V18, P531, DOI 10.1016/j.cellsig.2005.05.023; Grethe S, 2004, EXP CELL RES, V298, P632, DOI 10.1016/j.yexcr.2004.05.007; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KUNIMOTO M, 1994, BIOCHEM BIOPH RES CO, V204, P310, DOI 10.1006/bbrc.1994.2461; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee PC, 2005, TOXICOL SCI, V85, P541, DOI 10.1093/toxsci/kfi101; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2005, J BIOL CHEM, V280, P17657, DOI 10.1074/jbc.M412342200; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Li SP, 2003, CANCER RES, V63, P3473; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Namgung U, 2001, TOXICOL APPL PHARM, V174, P130, DOI 10.1006/taap.2001.9200; Newhouse K, 2004, TOXICOL SCI, V79, P137, DOI 10.1093/toxsci/kfh089; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oberto A, 1996, J PHARMACOL EXP THER, V279, P435; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; SARAFIAN TA, 1994, TOXICOL LETT, V74, P149, DOI 10.1016/0378-4274(94)90093-0; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	65	164	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25215	25222		10.1074/jbc.M512627200	http://dx.doi.org/10.1074/jbc.M512627200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16818494	hybrid			2022-12-27	WOS:000240031300022
J	Marintcheva, B; Hamdan, SM; Lee, SJ; Richardson, CC				Marintcheva, Boriana; Hamdan, Samir M.; Lee, Seung-Joo; Richardson, Charles C.			Essential residues in the C terminus of the bacteriophage T7 gene 2.5 single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; LAGGING-STRAND; LIMITED PROTEOLYSIS; HELICASE-PRIMASE; REPLICATION; DOMAIN; POLYMERASE; PURIFICATION; PROCESSIVITY	Gene 2.5 of bacteriophage T7 encodes a single-stranded DNA (ssDNA)-binding protein (gp2.5) that is an essential component of the phage replisome. Similar to other prokaryotic ssDNA-binding proteins, gp2.5 has an acidic C terminus that is involved in protein-protein interactions at the replication fork and in modulation of the ssDNA binding properties of the molecule. We have used genetic and biochemical approaches to identify residues critical for the function of the C terminus of gp2.5. The presence of an aromatic residue in the C-terminal position is essential for gp2.5 function. Deletion of the C-terminal residue, phenylalanine, is detrimental to its function, as is the substitution of this residue with non-aromatic amino acids. Placing the C-terminal phenylalanine in the penultimate position also results in loss of function. Moderate shortening of the length of the acidic portion of the C terminus is tolerated when the aromatic nature of the C-terminal residue is preserved. Gradual removal of the acidic C terminus of gp2.5 results in a higher affinity for ssDNA and a decreased ability to interact with T7 DNA polymerase/thioredoxin. The replacement of the charged residues in the C terminus with neutral amino acids abolishes gp2.5 function. Our data show that both the C-terminal aromatic residue and the overall acidic charge of the C terminus of gp2.5 are critical for its function.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	ccr@hms.harvard.edu		Hamdan, Samir/0000-0001-5192-1852	NIGMS NIH HHS [F32GM72305, GM 54397] Funding Source: Medline; OHS HRSA HHS [ST32A107245-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM072305, R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BURKE RL, 1980, J BIOL CHEM, V255, P1484; Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Hyland EM, 2003, J BIOL CHEM, V278, P7247, DOI 10.1074/jbc.M210605200; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lee SJ, 2006, J BIOL CHEM, V281, P25841, DOI 10.1074/jbc.M604602200; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Milburn CC, 2004, NAT STRUCT MOL BIOL, V11, P193, DOI 10.1038/nsmb716; NAKAI H, 1986, J BIOL CHEM, V261, P5217; Pant K, 2005, J MOL BIOL, V349, P317, DOI 10.1016/j.jmb.2005.03.065; Rezende LF, 2003, J BIOL CHEM, V278, P29098, DOI 10.1074/jbc.M303374200; Rezende LF, 2002, J BIOL CHEM, V277, P50643, DOI 10.1074/jbc.M207359200; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; TABOR S, 1987, J BIOL CHEM, V262, P16212; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	32	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25831	25840		10.1074/jbc.M604601200	http://dx.doi.org/10.1074/jbc.M604601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807232	hybrid, Green Published			2022-12-27	WOS:000240031300085
J	Vazquez, G; Bird, GSJ; Mori, Y; Putney, JW				Vazquez, Guillermo; Bird, Gary St. J.; Mori, Yasuo; Putney, James W., Jr.			Native TRPC7 channel activation by an inositol trisphosphate receptor-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DT40 B-LYMPHOCYTES; TRANSIENT RECEPTOR; 1,4,5-TRISPHOSPHATE RECEPTORS; CATION CHANNELS; PROTEIN; CELLS; ENTRY; EXPRESSION	In DT40 B lymphocytes, Canonical Transient Receptor Potential 7 (TRPC7) functions as a diacylglycerol-activated non-selective cation channel. However, previous work indicated that the non-store-operated Ca2+ entry in this cell type depends upon inositol trisphosphate receptors ( IP3R). With the cell-attached configuration oleyl-acetyl-glycerol (OAG) induced single channel activity ( 75 pS) that was not observed in TRPC7(-/-) cells but was rescued by expression of TRPC7 under conditions expected to produce relatively low levels of expression ((LowT7)TRPC7(-/-)). A DT40 cell line lacking IP3R (IP3R-/- cells) showed no OAG-induced single channel activity, but this activity was rescued by transient expression of an IP3R ((IP3R-/-)-I-IP3R). Single channel properties in (LowT7)TRPC7(-/-) or (IP3R-/-)-I-IP3R DT40 cells were indistinguishable from one another and from wildtype cells. Thus, TRPC7 forms, or is part of, the channel underlying endogenous diacylglycerol-activated currents in DT40 B lymphocytes, and this activity of native TRPC7 requires IP3R. However, with conditions expected to produce greater expression levels, TRPC7 functioned independently of the presence of IP3R. This finding may serve to resolve previously conflicting reports from expression studies of TRPC channels.	NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Mol Biol Lab, Kyoto 6158510, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Kyoto University	Vazquez, G (corresponding author), NIEHS, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	vazquez1@niehs.nih.gov	Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748	Intramural NIH HHS [Z99 ES999999] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090087] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; COLQUHOUN D, 1995, SINGLE CHANNELL RECO; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lemonnier L, 2006, FASEB J, V20, P503, DOI 10.1096/fj.05-4714fje; Lievremont JP, 2005, J BIOL CHEM, V280, P35346, DOI 10.1074/jbc.M507606200; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Mery L, 2001, FEBS LETT, V487, P377, DOI 10.1016/S0014-5793(00)02362-0; Morita T, 2004, BIOCHEM J, V382, P793, DOI 10.1042/BJ20031970; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Shi J, 2004, J PHYSIOL-LONDON, V561, P415, DOI 10.1113/jphysiol.2004.075051; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Trebak M, 2005, MOL PHARMACOL, V67, P558, DOI 10.1124/mol.104.007252; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467	26	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25250	25258		10.1074/jbc.M604994200	http://dx.doi.org/10.1074/jbc.M604994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822861	Green Accepted, hybrid			2022-12-27	WOS:000240031300026
J	Bhattacharyya, N; Pechhold, K; Shahjee, H; Zappala, G; Elbi, C; Raaka, B; Wiench, M; Hong, J; Rechler, MM				Bhattacharyya, Nisan; Pechhold, Klaus; Shahjee, Hanief; Zappala, Giovanna; Elbi, Cem; Raaka, Bruce; Wiench, Malgorzata; Hong, Jiang; Rechler, Matthew M.			Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HORMONE-RELATED PEPTIDE; FACTOR-BETA; FACTOR-I; SURFACE BINDING; TARGETED DISRUPTION; TGF-BETA; INHIBITION; RECEPTOR; EXPRESSION	Insulin-like growth factor binding protein-3 (IGFBP-3), a secreted protein, has the intrinsic ability to induce apoptosis directly without binding insulin-like growth factors. Previous studies suggested that IGFBP-3 must be secreted to exert its biological functions. IGFBP-3 contains a nuclear localization signal (NLS), and exogenous IGFBP-3 is translocated into the nucleus, suggesting that both secretion and nuclear localization may play important roles in IGFBP-3 action. To address these questions, we fused yellow fluorescent protein (YFP) to mature IGFBP-3 lacking its signal peptide so that it would remain intracellular and mutated the C-terminal NLS of IGFBP-3, 228KGRKR232, to MDGEA. Following transfection of PC-3 human prostate cancer cells with these constructs, Western blots indicated that YFP-IGFBP-3 lacking a signal peptide was cell-associated and not present in the extracellular media. Moreover, the fusion protein was not N- glycosylated, indicating that it had not entered the secretory pathway. Confocal imaging showed that intracellular YFP-MDGEA-IGFBP-3 was predominantly cytoplasmic. Transient transfection of nonsecreted YFP-wild-type IGFBP-3 decreased cell viability, as assessed by staining with annexin V followed by flow cytometry. Induction of cell death was caspase-dependent, indicative of apoptosis. Apoptosis also was induced by the nonsecreted NLS mutant (YFP-MDGEA-IGFBP-3) alone and when the IGF-binding site also had been mutated. These results indicate that IGFBP-3 can induce apoptosis in an IGF-independent manner without being secreted or concentrated in the nucleus.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Islet Autoimmun Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rechler, MM (corresponding author), NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA.	mrechler@helix.nih.gov		Wiench, Malgorzata/0000-0002-0202-9881	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055006] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Baker KM, 2004, REGUL PEPTIDES, V120, P5, DOI 10.1016/j.regpep.2004.04.004; Besset V, 1996, ENDOCRINOLOGY, V137, P296, DOI 10.1210/en.137.1.296; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 2005, ENDOCRINOLOGY, V146, P3113, DOI 10.1210/en.2004-1408; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chang YS, 2002, CLIN CANCER RES, V8, P3796; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274; Devi GR, 2002, PROSTATE, V51, P141, DOI 10.1002/pros.10068; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; Fanayan S, 2002, J BIOL CHEM, V277, P7255, DOI 10.1074/jbc.M108038200; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Firth SM, 1999, J ENDOCRINOL, V160, P379, DOI 10.1677/joe.0.1600379; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Giovannucci E, 2000, CANCER EPIDEM BIOMAR, V9, P345; Grimberg A, 2002, INT J ONCOL, V21, P327; Gucev ZS, 1996, CANCER RES, V56, P1545; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Hanafusa T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-9; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hochscheid R, 2000, J ENDOCRINOL, V166, P553, DOI 10.1677/joe.0.1660553; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; INGERMANN AR, 2000, GROWTH HORM IGF RES, V10, pA27; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Johnson HM, 2004, BIOESSAYS, V26, P993, DOI 10.1002/bies.20086; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kim HS, 2004, CANCER RES, V64, P2229, DOI 10.1158/0008-5472.CAN-03-1675; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lee KW, 2004, J BIOL CHEM, V279, P469, DOI 10.1074/jbc.M307316200; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Lillis AP, 2005, J THROMB HAEMOST, V3, P1884, DOI 10.1111/j.1538-7836.2005.01371.x; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu BR, 2005, CLIN CANCER RES, V11, P4851, DOI 10.1158/1078-0432.CCR-04-2160; LOGAN A, 1990, J ENDOCRINOL, V125, P339, DOI 10.1677/joe.0.1250339; Lu XF, 2005, J BIOL CHEM, V280, P22606, DOI 10.1074/jbc.M412073200; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Nguyen MTA, 2001, ENDOCRINOLOGY, V142, P694, DOI 10.1210/en.142.2.694; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rajah R, 2002, CELL GROWTH DIFFER, V13, P163; Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906; Rechler MM, 1998, TRENDS ENDOCRIN MET, V9, P176, DOI 10.1016/S1043-2760(98)00047-2; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Ricort JM, 2004, GROWTH HORM IGF RES, V14, P277, DOI 10.1016/j.ghir.2004.02.002; Rozen F, 1998, INT J ONCOL, V13, P865; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silha JV, 2006, ENDOCRINOLOGY, V147, P2112, DOI 10.1210/en.2005-1270; Singh B, 2004, J BIOL CHEM, V279, P477, DOI 10.1074/jbc.M307322200; SMITH EP, 1992, ENDOCRINOLOGY, V131, P2733, DOI 10.1210/en.131.6.2733; Spagnoli A, 2002, J BIOL CHEM, V277, P18860, DOI 10.1074/jbc.M200218200; Spagnoli A, 2001, J BIOL CHEM, V276, P5533, DOI 10.1074/jbc.M005088200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vasylyeva TL, 2005, GROWTH HORM IGF RES, V15, P207, DOI 10.1016/j.ghir.2005.02.008; Wang LZ, 2003, CANCER RES, V63, P4407; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J; Yan Q, 1999, BIOCHEM BIOPH RES CO, V266, P684, DOI 10.1006/bbrc.1999.1886; Yang YWH, 1996, ENDOCRINOLOGY, V137, P4363, DOI 10.1210/en.137.10.4363; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069; Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819	86	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24588	24601		10.1074/jbc.M509463200	http://dx.doi.org/10.1074/jbc.M509463200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793770	hybrid			2022-12-27	WOS:000239847800054
J	Cousins, RJ; Liuzzi, JP; Lichten, LA				Cousins, Robert J.; Liuzzi, Juan P.; Lichten, Louis A.			Mammalian zinc transport, trafficking, and signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DIETARY ZINC; ACRODERMATITIS-ENTEROPATHICA; FUNCTIONAL-CHARACTERIZATION; CONFERS RESISTANCE; ANTIPORT MECHANISM; GOLGI-APPARATUS; LIV-1 SUBFAMILY; FINGER PEPTIDE; CELLS; EXPRESSION		Univ Florida, Nutr Genom Lab, Dept Food Sci & Human Nutr, Ctr Nutr Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Cousins, RJ (corresponding author), Univ Florida, Nutr Genom Lab, Dept Food Sci & Human Nutr, Ctr Nutr Sci, Gainesville, FL 32611 USA.	cousins@ufl.edu	Liuzzi, Juan/AAG-5057-2019					Andreini C, 2006, J PROTEOME RES, V5, P196, DOI 10.1021/pr050361j; Aydemir TB, 2006, P NATL ACAD SCI USA, V103, P1699, DOI 10.1073/pnas.0510407103; Begum NA, 2002, GENOMICS, V80, P630, DOI 10.1006/geno.2002.7000; Blasie CA, 2002, BIOCHEMISTRY-US, V41, P15068, DOI 10.1021/bi026621h; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; Bruinsma JJ, 2002, DEV CELL, V2, P567, DOI 10.1016/S1534-5807(02)00151-X; Chao Y, 2004, J BIOL CHEM, V279, P12043, DOI 10.1074/jbc.M313510200; Chimienti F, 2004, DIABETES, V53, P2330, DOI 10.2337/diabetes.53.9.2330; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; Cragg RA, 2002, J BIOL CHEM, V277, P22789, DOI 10.1074/jbc.M200577200; Croix CMS, 2004, FREE RADICAL BIO MED, V37, P785, DOI 10.1016/j.freeradbiomed.2004.06.004; Cui L, 2003, J NUTR, V133, P51, DOI 10.1093/jn/133.1.51; Davis SR, 1998, J NUTR, V128, P825, DOI 10.1093/jn/128.5.825; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P50142, DOI 10.1074/jbc.M304163200; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; Franklin RB, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-32; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Guffanti AA, 2002, MOL MICROBIOL, V45, P145, DOI 10.1046/j.1365-2958.2002.02998.x; Huang LP, 2005, J BIOL CHEM, V280, P15456, DOI 10.1074/jbc.M412188200; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Jirakulaporn T, 2004, J BIOL CHEM, V279, P27807, DOI 10.1074/jbc.M401210200; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kelleher SL, 2005, AM J PHYSIOL-CELL PH, V288, pC1042, DOI 10.1152/ajpcell.00471.2004; Kim AH, 2000, BRAIN RES, V886, P99, DOI 10.1016/S0006-8993(00)02944-9; KING JC, 2005, MODERN NUTR HLTH DIS, P271; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kroncke KD, 2002, J BIOL CHEM, V277, P13294, DOI 10.1074/jbc.M111216200; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lee SM, 2002, FEMS MICROBIOL LETT, V215, P273, DOI 10.1016/S0378-1097(02)00961-8; Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402; Liuzzi JP, 2005, P NATL ACAD SCI USA, V102, P6843, DOI 10.1073/pnas.0502257102; Liuzzi JP, 2004, P NATL ACAD SCI USA, V101, P14355, DOI 10.1073/pnas.0406216101; Liuzzi JP, 2001, J NUTR, V131, P46, DOI 10.1093/jn/131.1.46; Maret W, 2004, BIOCHEMISTRY-US, V43, P3301, DOI 10.1021/bi036340p; Mathews WR, 2006, DEVELOPMENT, V133, P1143, DOI 10.1242/dev.02256; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Nolte C, 2004, GLIA, V48, P145, DOI 10.1002/glia.20065; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; Ripa S, 1995, Minerva Med, V86, P37; Roesijadi G, 1998, J BIOL CHEM, V273, P17425, DOI 10.1074/jbc.273.28.17425; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Seve M, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-32; Sim DLC, 1999, GENOMICS, V59, P224, DOI 10.1006/geno.1999.5856; Spahl DU, 2003, P NATL ACAD SCI USA, V100, P13952, DOI 10.1073/pnas.2335190100; Suzuki T, 2005, J BIOL CHEM, V280, P30956, DOI 10.1074/jbc.M506902200; Taylor KM, 2005, FEBS LETT, V579, P427, DOI 10.1016/j.febslet.2004.12.006; Taylor KM, 2004, TRENDS ENDOCRIN MET, V15, P461, DOI 10.1016/j.tem.2004.10.003; Taylor KM, 2003, BBA-BIOMEMBRANES, V1611, P16, DOI 10.1016/S0005-2736(03)00048-8; Tsuda M, 1997, J NEUROSCI, V17, P6678; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Wimmer U, 2005, NUCLEIC ACIDS RES, V33, P5715, DOI 10.1093/nar/gki881; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Zangger K, 2001, FASEB J, V15, P1303, DOI 10.1096/fj.00-0641fje	64	499	522	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24085	24089		10.1074/jbc.R600011200	http://dx.doi.org/10.1074/jbc.R600011200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793761	hybrid			2022-12-27	WOS:000239847800002
J	Martinez-Fleites, C; Guerreiro, CIPD; Baumann, MJ; Taylor, EJ; Prates, JAM; Ferreira, LMA; Fontes, CMGA; Brumer, H; Davies, GJ				Martinez-Fleites, Carlos; Guerreiro, Catarina I. P. D.; Baumann, Martin J.; Taylor, Edward J.; Prates, Jose A. M.; Ferreira, Luis M. A.; Fontes, Carlos M. G. A.; Brumer, Harry; Davies, Gideon J.			Crystal structures of Clostridium thermocellum xyloglucanase, XGH74A, reveal the structural basis for xyloglucan recognition and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOSE SURFACES; EXPRESSION; CLONING; CLASSIFICATION; BIOSYNTHESIS; PURIFICATION; NOMENCLATURE; MOLSCRIPT; ALIGNMENT; TOOLS	The enzymatic degradation of the plant cell wall is central both to the natural carbon cycle and, increasingly, to environmentally friendly routes to biomass conversion, including the production of biofuels. The plant cell wall is a complex composite of cellulose microfibrils embedded in diverse polysaccharides collectively termed hemicelluloses. Xyloglucan is one such polysaccharide whose hydrolysis is catalyzed by diverse xyloglucanases. Here we present the structure of the Clostridium thermocellum xyloglucanase Xgh74A in both apo and ligand-complexed forms. The structures, in combination with mutagenesis data on the catalytic residues and the kinetics and specificity of xyloglucan hydrolysis reveal a complex subsite specificity accommodating seventeen monosaccharide moieties of the multibranched substrate in an open substrate binding terrain.	Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Tecn Lisboa, CIISA, Fac Vet Med, P-1300477 Lisbon, Portugal; Royal Inst Technol, AlbaNova Univ Ctr, Sch Biotechnol, S-10691 Stockholm, Sweden	University of York - UK; Universidade de Lisboa; Royal Institute of Technology	Davies, GJ (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Prates, José A M/K-9934-2013; Davies, Gideon J/A-9042-2011; Martinez Fleites, Carlos/F-8526-2010	Prates, José A M/0000-0003-1032-5987; Davies, Gideon J/0000-0002-7343-776X; Ferreira, Luis/0000-0002-3543-9166; Taylor, Edward/0000-0003-4024-0976; Fontes, Carlos/0000-0002-1219-9753	Biotechnology and Biological Sciences Research Council [BB/D522511/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		[Anonymous], 2003, Current Trends in Polymer Science, V8, P27; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer S, 2005, CARBOHYD RES, V340, P2590, DOI 10.1016/j.carres.2005.09.014; BAYER EA, 1985, J BACTERIOL, V163, P552, DOI 10.1128/JB.163.2.552-559.1985; Bayer EA, 1998, J STRUCT BIOL, V124, P221, DOI 10.1006/jsbi.1998.4065; Brumer H, 2004, J AM CHEM SOC, V126, P5715, DOI 10.1021/ja0316770; Carpita N., 2000, BIOCH MOL BIOL PLANT, P52; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Chhabra SR, 2002, FEBS LETT, V531, P375, DOI 10.1016/S0014-5793(02)03493-2; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Demain AL, 2005, MICROBIOL MOL BIOL R, V69, P124, DOI 10.1128/MMBR.69.1.124-154.2005; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Irwin DC, 2003, EUR J BIOCHEM, V270, P3083, DOI 10.1046/j.1432-1033.2003.03695.x; KATO Y, 1985, J BIOCHEM, V97, P801, DOI 10.1093/oxfordjournals.jbchem.a135120; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Milkowski K, 2004, GREEN CHEM, V6, P189, DOI 10.1039/b316322a; Miyazaki S, 1998, J CONTROL RELEASE, V56, P75, DOI 10.1016/S0168-3659(98)00079-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nelson N, 1944, J BIOL CHEM, V153, P375; Reiter WD, 2002, CURR OPIN PLANT BIOL, V5, P536, DOI 10.1016/S1369-5266(02)00306-0; Scheible WR, 2004, CURR OPIN PLANT BIOL, V7, P285, DOI 10.1016/j.pbi.2004.03.006; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Thompson DS, 2005, J EXP BOT, V56, P2275, DOI 10.1093/jxb/eri247; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vincken JP, 1997, PLANT PHYSIOL, V114, P9, DOI 10.1104/pp.114.1.9; VINCKEN JP, 1995, PLANT PHYSIOL, V108, P1579, DOI 10.1104/pp.108.4.1579; Yaoi K, 2005, APPL ENVIRON MICROB, V71, P7670, DOI 10.1128/AEM.71.12.7670-7678.2005; Yaoi K, 2004, STRUCTURE, V12, P1209, DOI 10.1016/j.str.2004.04.020; Yaoi K, 2004, FEBS LETT, V560, P45, DOI 10.1016/S0014-5793(04)00068-7; Yaoi K, 2002, J BIOL CHEM, V277, P48276, DOI 10.1074/jbc.M208443200; Yokoyama R, 2004, PLANT PHYSIOL, V134, P1088, DOI 10.1104/pp.103.035261; Zhou Q, 2005, MACROMOLECULES, V38, P3547, DOI 10.1021/ma047712k; Zhou Q, 2006, BIOCATAL BIOTRANSFOR, V24, P107, DOI 10.1080/10242420500538217; Zverlov VV, 2005, PROTEOMICS, V5, P3646, DOI 10.1002/pmic.200401199; Zverlov VV, 2005, MICROBIOL-SGM, V151, P3395, DOI 10.1099/mic.0.28206-0	44	75	76	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24922	24933		10.1074/jbc.M603583200	http://dx.doi.org/10.1074/jbc.M603583200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16772298	hybrid			2022-12-27	WOS:000239847800085
J	Perez-Victoria, FJ; Sanchez-Canete, MP; Castanys, S; Gamarro, F				Perez-Victoria, F. Javier; Sanchez-Canete, Maria P.; Castanys, Santiago; Gamarro, Francisco			Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PLASMA-MEMBRANE; PUTATIVE AMINOPHOSPHOLIPID TRANSLOCASE; SACCHAROMYCES-CEREVISIAE; VISCERAL LEISHMANIASIS; POLARIZED GROWTH; BETA-SUBUNITS; ATPASE; GENE; IDENTIFICATION; EXPRESSION	The antitumor drug miltefosine has been recently approved as the first oral drug active against visceral leishmaniasis. We have previously identified the L. donovani miltefosine transporter (LdMT) as a P-type ATPase involved in phospholipid translocation at the plasma membrane of Leishmania parasites. Here we show that this protein is essential but not sufficient for the phospholipid translocation activity and, thus, for the potency of the drug. Based on recent findings in yeast, we have identified the putative beta subunit of LdMT, named LdRos3, as another protein factor required for the translocation activity. LdRos3 belongs to the CDC50/Lem3 family, proposed as likely beta subunits for P-4-ATPases. The phenotype of LdRos3-defective parasites was identical to that of the LdMT-/-, including a defect in the uptake of 7-nitrobenz-2-oxa-1,3-diazol-4-yl-amino)phosphatidylserine, generally considered as not affected in Lem3p-deficient yeast. Both LdMT and LdRos3 normally localized to the plasma membrane but were retained inside the endoplasmic reticulum in the absence of the other protein or when inactivating point mutations were introduced in LdMT. Modulating the expression levels of either protein independently, we show that any one of them could behave as the protein limiting the level of flippase activity. Thus, LdMT and LdRos3 seem to form part of the same translocation machinery that determines flippase activity and miltefosine sensitivity in Leishmania, further supporting the consideration of CDC50/Lem3 proteins as beta subunits required for the normal functioning of P-4-ATPases.	CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18100, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Gamarro, F (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Avda Conocimiento S-N, Granada 18100, Spain.	gamarro@ipb.csic.es	Castanys, Santiago/Y-3981-2019	Castanys, Santiago/0000-0002-3460-844X; Sanchez-Canete, Maria P./0000-0002-9418-8942; Gamarro, Francisco/0000-0003-1347-3440				Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BANGS JD, 1993, J CELL SCI, V105, P1101; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Ding JT, 2000, J BIOL CHEM, V275, P23378, DOI 10.1074/jbc.M910319199; DWYER DM, 1983, J CELL BIOCHEM, V23, P35, DOI 10.1002/jcb.240230105; Ganguly N., 2002, TDR NEWS, V68, P2; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Graham TR, 2004, TRENDS CELL BIOL, V14, P670, DOI 10.1016/j.tcb.2004.10.008; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Halleck MS, 1999, PHYSIOL GENOMICS, V1, P139, DOI 10.1152/physiolgenomics.1999.1.3.139; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; Kato U, 2002, J BIOL CHEM, V277, P37855, DOI 10.1074/jbc.M205564200; Katoh Y, 2004, ONCOL REP, V12, P939; Meguro M, 2001, NAT GENET, V28, P19, DOI 10.1038/ng0501-19; Misu K, 2003, MOL BIOL CELL, V14, P730, DOI 10.1091/mbc.E02-06-0314; Noguchi S, 2003, J CELL SCI, V116, P1875, DOI 10.1242/jcs.00392; Perez-Victoria FJ, 2003, J BIOL CHEM, V278, P49965, DOI 10.1074/jbc.M308352200; Perez-Victoria FJ, 2003, ANTIMICROB AGENTS CH, V47, P2397, DOI 10.1128/AAC.47.8.2397-2403.2003; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Saito K, 2004, MOL BIOL CELL, V15, P3418, DOI 10.1091/mbc.E03-11-0829; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; Singh Sarman, 2004, Journal of Infection and Chemotherapy, V10, P307, DOI 10.1007/s10156-004-0348-9; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; Sundar S, 2003, J Postgrad Med, V49, P29; Sundar S, 2005, B WORLD HEALTH ORGAN, V83, P394; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; WHO, 2001, WORLD HLTH REPORT 20	33	119	120	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23766	23775		10.1074/jbc.M605214200	http://dx.doi.org/10.1074/jbc.M605214200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785229	hybrid			2022-12-27	WOS:000239702900052
J	Wei, YN; Fu, D				Wei, Yinan; Fu, Dax			Binding and transport of metal ions at the dimer interface of the Escherichia coli metal transporter YiiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; ZINC TRANSPORTER; CALCIUM-PUMP; CRYSTAL-STRUCTURE; PROTEINS; CHEMISTRY; MECHANISM; COMPLEX; FAMILY; ATPASE	YiiP is a representative member of the cation diffusion facilitator (CDF) family, a class of ubiquitous metal transporters that play an essential role in metal homeostasis. Recently, a pair of Zn2+/Cd2+-selective binding sites has been localized to two highly conserved aspartyl residues (Asp(157)), each in a 2-fold-symmetry-related transmembrane segment 5 (TM5) of a YiiP homodimer. Here we report the functional and structural interactions between Asp(157) and yet another highly conserved Asp(49) in the TM2. Calorimetric binding analysis indicated that Asp(49) and Asp(157) contribute to a common Cd2+ binding site in each subunit. Copper phenanthroline oxidation of YiiP(D49C), YiiP(D157C), and YiiP(D49C/D157C) yielded inter-and intra-subunit cross-links among Cys(49) and Cys(157), consistent with the spatial proximity of two (Asp(49)-Asp(157)) sites at the dimer interface. Hg2+ binding to YiiP(D49C) or YiiP(D49C/D157C) also yielded a Cys(49)-Hg2+ -Cys(49) biscysteinate complex across the dimer interface, further establishing the interfacial location of a (Asp(49)-Asp(157))(2) bimetal binding center. Two bound Cd2+ ions were found transported cooperatively with a sigmoidal dependence on the Cd2+ concentration (n = 1.4). The binding affinity, transport cooperativity, and rate were modestly reduced by either a D49C or D157C mutation, but greatly diminished when all the bidentate aspartate O-ligands in (Asp(49)-Asp(157))(2) were replaced by the monodentate cysteine S-ligands. The functional significance of these findings is discussed based on the unique coordination chemistry of aspartyl residues and a model for the translocation pathway of metal ions at the YiiP dimer interface.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Fu, D (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	dax@bnl.gov		Fu, Dax/0000-0002-2663-1316	NIGMS NIH HHS [R01 GM65137] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065137] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anton A, 2004, J BACTERIOL, V186, P7499, DOI 10.1128/JB.186.22.7499-7507.2004; BERTINI I, 2001, HDB METALLOPROTEINS, P884; Chao Y, 2004, J BIOL CHEM, V279, P12043, DOI 10.1074/jbc.M313510200; Chao Y, 2004, J BIOL CHEM, V279, P17173, DOI 10.1074/jbc.M400208200; COAN C, 1994, BIOCHEMISTRY-US, V33, P3722, DOI 10.1021/bi00178a032; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DASILVA JF, 2001, BIOL CHEM ELEMENTS I, P118; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Gouaux E, 2005, SCIENCE, V310, P1461, DOI 10.1126/science.1113666; Grass G, 2005, ARCH MICROBIOL, V183, P9, DOI 10.1007/s00203-004-0739-4; Grass G, 2001, J BACTERIOL, V183, P4664, DOI 10.1128/JB.183.15.4664-4667.2001; Guan L, 2002, P NATL ACAD SCI USA, V99, P3475, DOI 10.1073/pnas.052703699; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; PIERCE DH, 1983, BIOCHEMISTRY-US, V22, P5254, DOI 10.1021/bi00292a003; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Wei YN, 2005, J BIOL CHEM, V280, P33716, DOI 10.1074/jbc.M506107200; Wei YN, 2004, J BIOL CHEM, V279, P39251, DOI 10.1074/jbc.M407044200; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	24	62	64	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23492	23502		10.1074/jbc.M602254200	http://dx.doi.org/10.1074/jbc.M602254200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790427	hybrid			2022-12-27	WOS:000239702900024
J	Maroun, M; Delelis, O; Coadou, G; Bader, T; Segeral, E; Mbemba, G; Petit, C; Sonigo, P; Rain, JC; Mouscadet, JF; Benarous, R; Emiliani, S				Maroun, Marlene; Delelis, Olivier; Coadou, Gael; Bader, Thomas; Segeral, Emmanuel; Mbemba, Gladys; Petit, Caroline; Sonigo, Pierre; Rain, Jean-Christophe; Mouscadet, Jean-Francois; Benarous, Richard; Emiliani, Stephane			Inhibition of early steps of HIV-1 replication by SNF5/Ini1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHROMATIN-REMODELING COMPLEX; STRAND BREAK REPAIR; PREINTEGRATION COMPLEXES; SWI/SNF COMPLEX; HUMAN-CELLS; HUMAN GENOME; DNA-BINDING; IN-VITRO; RETROVIRAL INFECTION	To replicate, human immunodeficiency virus, type 1 (HIV-1) needs to integrate a cDNA copy of its RNA genome into a chromosome of the host cell, a step controlled by the viral integrase (IN) protein. Viral integration involves the participation of several cellular proteins. SNF5/Ini1, a subunit of the SWI/SNF chromatin remodeling complex, was the first cofactor identified to interact with IN. We report here that SNF5/Ini1 interferes with early steps of HIV-1 replication. Inhibition of SNF5/Ini1 expression by RNA interference increases HIV-1 replication. Using quantitative PCR, we show that both the 2-long terminal repeat circle and integrated DNA forms accumulate upon SNF5/Ini1 knock down. By yeast two-hybrid assay, we screened a library of HIV-1 IN random mutants obtained by PCR random mutagenesis using SNF5/Ini1 as prey. Two different mutants of interaction, IN E69G and IN K71R, were impaired for SNF5/Ini1 interaction. The E69G substitution completely abolished integrase catalytic activity, leading to a replication-defective virus. On the contrary, IN K71R retained in vitro integrase activity. K71R substitution stimulates viral replication and results in higher infectious titers. Taken together, these results suggest that, by interacting with IN, SNF5/Ini1 interferes with early steps of HIV-1 infection.	Inst Cochin, Dept Maladies Infect, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France; CNRS, Unite Mixte Rech 8104, F-75014 Paris, France; Univ Paris Descartes, Fac Med Rene Descartes, UMR S 8104, F-75014 Paris, France; CNRS, UMR 8532, Ecole Normale Super Cachan, Lab Biotechnol & Genet Appl, F-94235 Cachan, France; Hybrigenics SA, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Emiliani, S (corresponding author), Inst Cochin, Dept Maladies Infect, 27 Rue Faubourg St Jacques Bat Gustave Roussy, F-75014 Paris, France.	emiliani@cochin.inserm.fr	COADOU, Gael/M-3042-2015	COADOU, Gael/0000-0003-0979-6706; RAIN, Jean-Christophe/0000-0001-8110-0641; Sonigo, Pierre/0000-0003-2686-1303				Berthoux L, 2003, J VIROL, V77, P3167, DOI 10.1128/JVI.77.5.3167-3180.2003; Boese A, 2004, FEBS LETT, V578, P291, DOI 10.1016/j.febslet.2004.11.016; Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124.2003; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Busschots K, 2005, J BIOL CHEM, V280, P17841, DOI 10.1074/jbc.M411681200; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Emiliani S, 2005, J BIOL CHEM, V280, P25517, DOI 10.1074/jbc.M501378200; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Imbalzano AN, 2005, CANCER CELL, V7, P294, DOI 10.1016/j.ccr.2005.04.001; Jeanson L, 2002, VIROLOGY, V300, P100, DOI 10.1006/viro.2002.1515; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kilzer JM, 2003, VIROLOGY, V314, P460, DOI 10.1016/S0042-6822(03)00455-0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUIKEN CL, 2002, HIV SEQUENCE COMPEND; Lau A, 2004, EMBO J, V23, P3421, DOI 10.1038/sj.emboj.7600348; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Lu R, 2005, J VIROL, V79, P2493, DOI 10.1128/JVI.79.4.2493-2505.2005; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Mahmoudi T, 2006, J BIOL CHEM, V281, P19960, DOI 10.1074/jbc.M603336200; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Mulder LCF, 2002, J BIOL CHEM, V277, P27489, DOI 10.1074/jbc.M203061200; Parissi V, 2001, J VIROL, V75, P11344, DOI 10.1128/JVI.75.23.11344-11353.2001; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Treand C, 2006, EMBO J, V25, P1690, DOI 10.1038/sj.emboj.7601074; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Turlure F, 2004, FRONT BIOSCI-LANDMRK, V9, P3187, DOI 10.2741/1472; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Violot S, 2003, J VIROL, V77, P12507, DOI 10.1128/JVI.77.23.12507-12522.2003; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yung E, 2004, J VIROL, V78, P2222, DOI 10.1128/JVI.78.5.2222-2231.2004; Yung E, 2001, NAT MED, V7, P920, DOI 10.1038/90959; Zhou GC, 2001, METHODS, V25, P54, DOI 10.1006/meth.2001.1215	57	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22736	22743		10.1074/jbc.M604849200	http://dx.doi.org/10.1074/jbc.M604849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772295	Green Published, hybrid			2022-12-27	WOS:000239542600034
J	Miyauchi, Y; Daiho, T; Yamasaki, K; Takahashi, H; Ishida-Yamamoto, A; Danko, S; Suzuki, H; Iizuka, H				Miyauchi, Yuki; Daiho, Takashi; Yamasaki, Kazuo; Takahashi, Hidetoshi; Ishida-Yamamoto, Akemi; Danko, Stefania; Suzuki, Hiroshi; Iizuka, Hajime			Comprehensive analysis of expression and function of 51 sarco(endo) plasmic reticulum Ca2+-ATPase mutants associated with Darier disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE PHOSPHOENZYME INTERMEDIATE; MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; AMINO-ACIDS; ATP2A2 MUTATIONS; CA2+ OCCLUSION; CATALYTIC SITE; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL CHANGE; TRANSMEMBRANE DOMAIN	We examined possible defects of sarco(endo) plasmic reticulum Ca2+-ATPase 2b (SERCA2b) associated with its 51 mutations found in Darier disease (DD) pedigrees, i.e. most of the substitution and deletion mutations of residues reported so far. COS-1 cells were transfected with each of the mutant cDNAs, and the expression and function of the SERCA2b protein was analyzed with microsomes prepared from the cells and compared with those of the wild type. Fifteen mutants showed markedly reduced expression. Among the other 36, 29 mutants exhibited completely abolished or strongly inhibited Ca2+-ATPase activity, whereas the other seven possessed fairly high or normal ATPase activity. In four of the aforementioned seven mutants, Ca2+ transport activity was significantly reduced or almost completely lost, therefore uncoupled from ATP hydrolysis. The other three were exceptional cases as they were seemingly normal in protein expression and Ca2+ transport function, but were found to have abnormalities in the kinetic properties altered by the three mutations, which happened to be in the three DD pedigrees found by us previously (Sato, K., Yamasaki, K., Daiho, T., Miyauchi, Y., Takahashi, H., Ishida-Yamamoto, A., Nakamura, S., Iizuka, H., and Suzuki, H. (2004) J. Biol. Chem. 279, 35595 - 35603). Collectively, our results indicated that in most cases (48 of 51) DD mutations cause severe disruption of Ca2+ homeostasis by the defects in protein expression and/or transport function and hence DD, but even a slight disturbance of the homeostasis will result in the disease. Our results also provided further insight into the structure-function relationship of SERCAs and revealed critical regions and residues of the enzyme.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; Chao SC, 2002, BRIT J DERMATOL, V146, P958, DOI 10.1046/j.1365-2133.2002.04786.x; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Clausen JD, 2004, J BIOL CHEM, V279, P54426, DOI 10.1074/jbc.M410204200; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; Dhitavat J, 2003, J INVEST DERMATOL, V121, P486, DOI 10.1046/j.1523-1747.2003.12410.x; Dode L, 2003, J BIOL CHEM, V278, P47877, DOI 10.1074/jbc.M306784200; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; Einholm AP, 2004, J BIOL CHEM, V279, P15888, DOI 10.1074/jbc.M400158200; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ikeda S, 2003, J INVEST DERMATOL, V121, P475, DOI 10.1046/j.1523-1747.2003.12400.x; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; Jacobsen NJO, 1999, HUM MOL GENET, V8, P1631, DOI 10.1093/hmg/8.9.1631; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Ma HL, 2005, BIOCHEMISTRY-US, V44, P8090, DOI 10.1021/bi050332m; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Onozuka T, 2004, BRIT J DERMATOL, V150, P652, DOI 10.1111/j.0007-0963.2004.05868.x; Peeraer Y, 2004, EUR J BIOCHEM, V271, P3421, DOI 10.1111/j.0014-2956.2004.04277.x; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; Picard M, 2005, J BIOL CHEM, V280, P18745, DOI 10.1074/jbc.M501596200; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Ruiz-Perez VL, 1999, HUM MOL GENET, V8, P1621, DOI 10.1093/hmg/8.9.1621; Sakuntabhai A, 2000, J INVEST DERMATOL, V115, P1144, DOI 10.1046/j.1523-1747.2000.00182.x; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sakuntabhai A, 1999, HUM MOL GENET, V8, P1611, DOI 10.1093/hmg/8.9.1611; Sato K, 2004, J BIOL CHEM, V279, P35595, DOI 10.1074/jbc.M404887200; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; STEWART JMM, 1989, BIOCHEMISTRY-US, V28, P4695, DOI 10.1021/bi00437a028; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; Takahashi H, 2001, J DERMATOL SCI, V26, P169, DOI 10.1016/S0923-1811(00)00173-0; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wada T, 2003, BRIT J DERMATOL, V149, P185, DOI 10.1046/j.1365-2133.2003.05412.x; Wang GL, 2005, J BIOL CHEM, V280, P26508, DOI 10.1074/jbc.M503789200; WEBER K, 1969, J BIOL CHEM, V244, P4406; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200; Yang Y, 2001, J INVEST DERMATOL, V116, P482, DOI 10.1046/j.1523-1747.2001.127910.x; Youngburg GE, 1930, J LAB CLIN MED, V16, P158; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	78	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22882	22895		10.1074/jbc.M601966200	http://dx.doi.org/10.1074/jbc.M601966200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766529	Green Submitted, hybrid			2022-12-27	WOS:000239542600051
J	Sastry, KSR; Karpova, Y; Kulik, G				Sastry, Konduru S. R.; Karpova, Yelena; Kulik, George			Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH AGONIST BAD; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; MAP KINASE; SURVIVAL; ACTIVATION; RAS; EXPRESSION; INACTIVATION; MITOCHONDRIA	Protection from apoptosis by receptor tyrosine kinases, resistant to the inhibition of phosphatidylinositol 3'-kinase/Akt and Ras/MEK pathways, has been reported in several cell types, including fibroblasts and epithelial prostate cancer cells; however, mechanisms of this effect were not clear. Here we report that in prostate cancer cells, epidermal growth factor activates two antiapoptotic signaling pathways that impinge on the proapoptotic protein BAD. One signaling cascade operates via the Ras/MEK module and induces BAD phosphorylation on Ser(112). Another pathway predominantly relies on Rac/ PAK1 signaling that leads to BAD phosphorylation on Ser(136). Each of these two pathways is sufficient to protect cells from apoptosis, and therefore both have to be inhibited simultaneously to block epidermal growth factor-dependent survival. Redundancy of antiapoptotic signaling pathways should be considered when therapies targeting antiapoptotic mechanisms are designed.	Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	Wake Forest University	Kulik, G (corresponding author), Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.	gkulik@wfubmc.edu	Sastry, Konduru Seetharama/GQY-6005-2022					Baker NE, 2001, CELL, V104, P699, DOI 10.1016/S0092-8674(02)06076-2; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cairns P, 1997, CANCER RES, V57, P4997; CARSON JP, 2002, THESIS U VIRGINIA CH; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gioeli D, 1999, CANCER RES, V59, P279; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Kari C, 2003, CANCER RES, V63, P1; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim HG, 1999, HISTOL HISTOPATHOL, V14, P1175, DOI 10.14670/HH-14.1175; Kulik G, 2001, CANCER RES, V61, P2713; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Lin JQ, 1999, CANCER RES, V59, P2891; Lorenzo Giuseppe Di, 2003, Clin Prostate Cancer, V2, P50; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Maslyar DJ, 2001, ONCOGENE, V20, P5087, DOI 10.1038/sj.onc.1204662; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; McMenamin ME, 1999, CANCER RES, V59, P4291; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Royuela M, 2001, EUR CYTOKINE NETW, V12, P654; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sastry KSR, 2006, J BIOL CHEM, V281, P20891, DOI 10.1074/jbc.M602928200; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tang DG, 1997, PROSTATE, V32, P284; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uzgare AR, 2005, INT J BIOCHEM CELL B, V37, P707, DOI 10.1016/j.biocel.2004.11.018; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638	70	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27367	27377		10.1074/jbc.M511485200	http://dx.doi.org/10.1074/jbc.M511485200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16847055	hybrid			2022-12-27	WOS:000240397700063
J	Graham, WV; Wang, FJ; Clayburgh, DR; Cheng, JX; Yoon, B; Wang, YM; Lin, AN; Turner, JR				Graham, W. Vallen; Wang, Fengjun; Clayburgh, Daniel R.; Cheng, Jason X.; Yoon, Bora; Wang, Yingmin; Lin, Anning; Turner, Jerrold R.			Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events - Characterization of the human long myosin light chain kinase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TIGHT JUNCTION BARRIER; CELL-DIFFERENTIATION; INTESTINAL DISEASE; EPITHELIAL BARRIER; ALPHA MODULATION; GENE-EXPRESSION; HOMEOBOX GENE; IN-VIVO; PHOSPHORYLATION	Myosin light chain kinase (MLCK) is expressed as long and short isoforms from unique transcriptional start sites within a single gene. Tumor necrosis factor (TNF) augments intestinal epithelial long MLCK expression, which is critical to cytoskeletal regulation. We found that TNF increases long MLCK mRNA transcription, both in human enterocytes in vitro and murine enterocytes in vivo. 5'-RACE identified two novel exons, 1A and 1B, which encode alternative long MLCK transcriptional start sites. Chromatin immunoprecipitation (ChIP) and site-directed mutagenesis identified two essential Sp1 sites upstream of the exon 1A long MLCK transcriptional start site. Analysis of deletion and truncation mutants showed that a 102-bp region including these Sp1 sites was necessary for basal transcription. A promoter construct including 4-kb upstream of exon 1A was responsive to TNF, AP-1, or NF kappa B, but all except NF kappa B responses were absent in a shorter 2-kb construct, and all responses were absent in a 1-kb construct. Electrophoretic mobility shift assays, ChIP, and site-directed mutagenesis explained these data by identifying three functional AP-1 sites between 2- and 4-kb upstream of exon 1A and two NF kappa B sites between 1- and 2-kb upstream of exon 1A. Analysis of differentiating epithelia showed that only well differentiated enterocytes activated the 4-kb long MLCK promoter in response to TNF, and consensus promoter reporters demonstrated that TNF-induced NF kappa B activation decreased during differentiation while TNF-induced AP-1 activation increased. Thus either AP-1 or NF kappa B can up-regulate long MLCK transcription, but the mechanisms by which TNF up-regulates intestinal epithelial long MLCK transcription from exon 1A are differentiation-dependent.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Inst Burn Res, Southwest Hosp, Chongqing 400038, Peoples R China	University of Chicago; University of Chicago; Army Medical University	Turner, JR (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.	jturner@bsd.uchicago.edu	Graham, W Vallen/C-4315-2019; Turner, Jerrold/H-1502-2019; Turner, Jerrold R/A-6895-2009; Wang, Fengjun/A-4114-2009; Graham, W/L-2301-2019; wang, yingying/GRS-3058-2022	Graham, W Vallen/0000-0003-3815-7532; Turner, Jerrold R/0000-0003-0627-9455; Graham, W/0000-0003-3815-7532; Clayburgh, Daniel/0000-0002-3296-4926	NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, R01DK068271, R01DK061931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER; NCI NIH HHS [CA14599] Funding Source: Medline; NIDDK NIH HHS [DK68271, DK61931, DK42086] Funding Source: Medline; NIGMS NIH HHS [T32 GM07281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487; Blair SA, 2006, LAB INVEST, V86, P191, DOI 10.1038/labinvest.3700373; Blue EK, 2002, AM J PHYSIOL-CELL PH, V282, pC451, DOI 10.1152/ajpcell.00333.2001; CHANDRASENA G, 1992, CELL MOL BIOL, V38, P243; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Clayburgh DR, 2005, J CLIN INVEST, V115, P2702, DOI 10.1172/JCI24970; Clayburgh DR, 2004, LAB INVEST, V84, P282, DOI 10.1038/labinvest.3700050; Clayburgh DR, 2004, J BIOL CHEM, V279, P55506, DOI 10.1074/jbc.M408822200; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Fleet JC, 2003, PHYSIOL GENOMICS, V13, P57, DOI 10.1152/physiolgenomics.00152.2002; GALLAGHER PJ, 1995, J BIOL CHEM, V270, P29090, DOI 10.1074/jbc.270.49.29090; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Hecht G, 1996, AM J PHYSIOL-CELL PH, V271, pC1678, DOI 10.1152/ajpcell.1996.271.5.C1678; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; Kudryashov DS, 1999, FEBS LETT, V463, P67, DOI 10.1016/S0014-5793(99)01591-4; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Ma TY, 2005, AM J PHYSIOL-GASTR L, V288, pG422, DOI 10.1152/ajpgi.00412.2004; Peterson LJ, 2004, MOL BIOL CELL, V15, P3497, DOI 10.1091/mbc.E03-09-0696; PETERSON MD, 1993, J CELL SCI, V105, P461; PETERSON MD, 1992, J CELL SCI, V102, P581; PINTO M, 1983, BIOL CELL, V47, P323; Russo JM, 2005, GASTROENTEROLOGY, V128, P987, DOI 10.1053/j.gastro.2005.01.004; Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915; SHORTER RG, 1964, AM J DIG DIS, V9, P760, DOI 10.1007/BF02231983; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Suenaert P, 2002, AM J GASTROENTEROL, V97, P2000; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Turner JR, 1996, J BIOL CHEM, V271, P7738, DOI 10.1074/jbc.271.13.7738; VANBEERS EH, 1995, BIOCHEM J, V308, P769, DOI 10.1042/bj3080769; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wang FJ, 2005, AM J PATHOL, V166, P409, DOI 10.1016/S0002-9440(10)62264-X; YAMAGUCHI Y, 1991, AM J PHYSIOL, V261, pG312, DOI 10.1152/ajpgi.1991.261.2.G312; Ye DM, 2006, AM J PHYSIOL-GASTR L, V290, pG496, DOI 10.1152/ajpgi.00318.2005; Yin F, 2006, AM J PHYSIOL-CELL PH, V290, pC1599, DOI 10.1152/ajpcell.00289.2005; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; Zolotarevsky Y, 2002, GASTROENTEROLOGY, V123, P163, DOI 10.1053/gast.2002.34235	47	102	108	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26205	26215		10.1074/jbc.M602164200	http://dx.doi.org/10.1074/jbc.M602164200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835238	hybrid			2022-12-27	WOS:000240249500037
J	Dias-Gunasekara, S; van Lith, M; Williams, JAG; Kataky, R; Benham, AM				Dias-Gunasekara, Sanjika; van Lith, Marcel; Williams, J. A. Gareth; Kataky, Ritu; Benham, Adam M.			Mutations in the FAD binding domain cause stress-induced misoxidation of the endoplasmic reticulum oxidoreductase Ero1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-BOND FORMATION; SECRETORY PATHWAY; PROTEIN; GLUTATHIONE; ERO1P; ISOMERASE; OXIDASE; CFTR; ERO1-L-ALPHA; EXPRESSION	Disulfide bond catalysis is an essential component of protein biogenesis in the secretory pathway, from yeast through to man. In the endoplasmic reticulum (ER), protein-disulfide isomerase (PDI) catalyzes the oxidation and isomerization of disulfide bonds and is re-oxidized by an endoplasmic reticulum oxidoreductase (ERO). The elucidation of ERO function was greatly aided by the genetic analysis of two ero mutants, whose impairment results from point mutations in the FAD binding domain of the Ero protein. The ero1-1 and ero1-2 yeast strains have conditional and dithiothreitol-sensitive phenotypes, but the effects of the mutations on the behavior of Ero proteins has not been reported. Here, we show that these Gly to Ser and His to Tyr mutations do not prevent the dimerization of Ero1 beta or the non-covalent interaction of Ero1 beta with PDI. However, the Gly to Ser mutation abolishes disulfide-dependent PDI-Ero1 beta heterodimers. Both the Gly to Ser and His to Tyr mutations make Ero1 beta susceptible to misoxidation and aggregation, particularly during a temperature or redox stress. We conclude that the Ero FAD binding domain is critical for conformational stability, allowing Ero proteins to withstand stress conditions that cause client proteins to misfold.	Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Durham, Dept Chem, Durham DH1 3LE, England	Durham University; Durham University	Benham, AM (corresponding author), Univ Durham, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.	Adam.benham@durham.ac.uk	Williams, J A Gareth/F-6618-2012; Kataky, Ritu/B-1800-2009; Benham, Adam/AAC-6606-2019	Williams, J A Gareth/0000-0002-4688-3000; Kataky, Ritu/0000-0002-6386-9606; Van Lith, Marcel/0000-0003-0225-5501; Benham, Adam/0000-0002-0919-7431	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; Bertoli G, 2004, J BIOL CHEM, V279, P30047, DOI 10.1074/jbc.M403192200; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Chakravarthi S, 2004, J BIOL CHEM, V279, P39872, DOI 10.1074/jbc.M406912200; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Dias-Gunasekara S, 2005, J BIOL CHEM, V280, P33066, DOI 10.1074/jbc.M505023200; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Gross E, 2006, P NATL ACAD SCI USA, V103, P299, DOI 10.1073/pnas.0506448103; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200; Kleizen B, 2005, MOL CELL, V20, P277, DOI 10.1016/j.molcel.2005.09.007; Kulp MS, 2006, J BIOL CHEM, V281, P876, DOI 10.1074/jbc.M511764200; Magnuson B, 2005, MOL CELL, V20, P289, DOI 10.1016/j.molcel.2005.08.034; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Sevier CS, 2006, MOL BIOL CELL, V17, P2256, DOI 10.1091/mbc.E05-05-0417; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	36	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25018	25025		10.1074/jbc.M602354200	http://dx.doi.org/10.1074/jbc.M602354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822866	hybrid			2022-12-27	WOS:000240031300004
J	Karbowniczek, M; Robertson, GP; Henske, EP				Karbowniczek, Magdalena; Robertson, Gavin P.; Henske, Elizabeth Petri			Rheb inhibits C-Raf activity and B-Raf/C-Raf heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS COMPLEX; FACIO-CUTANEOUS SYNDROME; CELL-GROWTH; MAMMALIAN PROTEIN; KINASE-ACTIVITY; GERMLINE KRAS; DIRECT TARGET; ACTIVATION; MUTATIONS; BRAF	The Ras-Raf-MEK signaling cascade is critical for normal development and is activated in many forms of cancer. We have recently shown that B-Raf kinase interacts with and is inhibited by Rheb, the target of the GTPase-activating domain of the tuberous sclerosis complex 2 gene product tuberin. Here, we demonstrate for the first time that activation of Rheb is associated with decreased B-Raf and C-Raf phosphorylation at residues Ser-446 and Ser-338, respectively, concomitant with a decrease in the activities of both kinases and decreased heterodimerization of B-Raf and C-Raf. Importantly, the impact of Rheb on B-Raf/C-Raf heterodimerization and kinase activity are rapamycin-insensitive, indicating that they are independent of Rheb activation of the mammalian target of rapamycin-Raptor complex. In addition, we found that Rheb inhibits the association of B-Raf with H-Ras. Taken together, these results support a central role of Rheb in the regulation of the Ras/B-Raf/C-Raf/MEK signaling network.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Henske, EP (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Elizabeth.Henske@fccc.edu	Robertson, Gavin P./A-6106-2017	Robertson, Gavin P./0000-0003-0152-2997	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051052, R29DK051052] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51052] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Astrinidis A, 2004, J CHILD NEUROL, V19, P710, DOI 10.1177/08830738040190091201; Beeram M, 2005, J CLIN ONCOL, V23, P6771, DOI 10.1200/JCO.2005.08.036; Brose MS, 2002, CANCER RES, V62, P6997; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Karbowniczek M, 2003, AM J PATHOL, V162, P491, DOI 10.1016/S0002-9440(10)63843-6; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mizutani S, 2001, FEBS LETT, V507, P295, DOI 10.1016/S0014-5793(01)02992-1; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; Staehler M, 2006, UROLOGE, V45, P99, DOI 10.1007/s00120-005-0982-6; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yoon SH, 2004, BIOCHEMISTRY-MOSCOW+, V69, P799, DOI 10.1023/B:BIRY.0000040206.71415.6f; Zebisch A, 2006, CANCER RES, V66, P3401, DOI 10.1158/0008-5472.CAN-05-0115; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	38	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25447	25456		10.1074/jbc.M605273200	http://dx.doi.org/10.1074/jbc.M605273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803888	hybrid			2022-12-27	WOS:000240031300047
J	Liu, HB; Carlsson, L; Grundstrom, T				Liu, Hebin; Carlsson, Leif; Grundstrom, Thomas			Identification of an N-terminal transactivation domain of Runx1 that separates molecular function from global differentiation function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ROOT GANGLION NEURONS; CORE-BINDING-FACTOR; TRANSCRIPTION FACTOR; DNA-BINDING; ADULT HEMATOPOIESIS; DISTINCT ROLES; FAMILY-MEMBERS; IN-VITRO	RUNX1, or AML1, is a transcription factor that is the most frequent target for chromosomal gene translocations in acute leukemias. RUNX1 is essential for definitive hematopoiesis in embryos and profoundly influences adult steady-state hematopoiesis both positively and negatively. To investigate this wide range of normal activities and the pathological role of RUNX1, it is important to define the functions of different domains of the protein. RUNX1, RUNX2, and RUNX3 are highly conserved in their DNA binding runt homology domain and contain divergent sequences of unknown function N-terminal to this domain. Here we analyzed the role of the N-terminal sequence and the alpha-helix of the runt homology domain of Runx1 in DNA binding, transactivation, and megakaryocytopoiesis. Both the N terminus and the alpha-helix were found to reduce DNA binding of Runx1 and be essential for transactivation of the granulocyte-macrophage colony-stimulating factor and I alpha 1 promoters by Runx1. The N terminus of Runx1, including the alpha-helix, was also required for transactivation of a Gal4 reporter when expressed as fusion proteins with a Gal4 DNA binding domain, and the N terminus alone was capable of stimulating transcription when fused to the Gal4DNAbinding domain. The N terminus and the alpha-helix, however, were not required for megakaryocyte development from embryonic stem cells differentiated in vitro. Thus, our findings define a second transactivation domain of Runx1 that is differentially required for activation of transcription of some Runx1-dependent promoters and megakaryocytopoiesis.	Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden; Umea Univ, Umea Ctr Mol Med, SE-90187 Umea, Sweden	Umea University; Umea University	Grundstrom, T (corresponding author), Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden.	Thomas.Grundstrom@molbiol.umu.se						Anglin Ian, 2004, Cancer Treat Res, V119, P189; Backstrom S, 2002, J MOL BIOL, V322, P259, DOI 10.1016/S0022-2836(02)00702-7; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Carlsson L, 2003, METHOD ENZYMOL, V365, P202; Carnicer MJ, 2002, LEUKEMIA, V16, P2329, DOI 10.1038/sj.leu.2402656; Cohen MM, 2001, AM J MED GENET, V104, P185, DOI 10.1002/ajmg.10064; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fukushima-Nakase Y, 2005, BLOOD, V105, P4298, DOI 10.1182/blood-2004-08-3372; Goyama S, 2004, BLOOD, V104, P3558, DOI 10.1182/blood-2004-04-1535; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; HAWLEY RG, 1994, GENE THER, V1, P136; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Inoue K, 2003, BLOOD CELL MOL DIS, V30, P157, DOI 10.1016/S1079-9796(03)00032-9; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kundu M, 2005, BLOOD, V106, P3621, DOI 10.1182/blood-2005-04-1447; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; LARS N, 1993, INT IMMUNOL, V5, P271, DOI 10.1093/intimm/5.3.271; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; Liu HB, 2004, J BIOL CHEM, V279, P29398, DOI 10.1074/jbc.M403173200; Nakao M, 2004, BRIT J HAEMATOL, V125, P709, DOI 10.1111/j.1365-2141.2004.04966.x; North TE, 2004, STEM CELLS, V22, P158, DOI 10.1634/stemcells.22-2-158; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pinto do O P, 1998, EMBO J, V17, P5744, DOI 10.1093/emboj/17.19.5744; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P384, DOI 10.1038/87531; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tang L, 1999, J BIOL CHEM, V274, P33580, DOI 10.1074/jbc.274.47.33580; Telfer JC, 2004, J IMMUNOL, V172, P4359, DOI 10.4049/jimmunol.172.7.4359; Telfer JC, 2001, DEV BIOL, V229, P363, DOI 10.1006/dbio.2000.9991; THORNELL A, 1993, J BIOL CHEM, V268, P21946; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wolf-Watz M, 1999, EUR J BIOCHEM, V261, P251, DOI 10.1046/j.1432-1327.1999.00269.x; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Xu MJ, 2001, BLOOD, V97, P2016, DOI 10.1182/blood.V97.7.2016; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	62	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25659	25669		10.1074/jbc.M603249200	http://dx.doi.org/10.1074/jbc.M603249200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803898	hybrid			2022-12-27	WOS:000240031300069
J	Torrents, E; Westman, M; Sahlin, M; Sjoberg, BM				Torrents, Eduard; Westman, MariAnn; Sahlin, Margareta; Sjoberg, Britt-Marie			Ribonucleotide reductase modularity - Atypical duplication of the ATP-cone domain in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY REGULATION; ESCHERICHIA-COLI; PROTEIN R1; DIPHOSPHATE REDUCTASE; ALLOSTERIC EFFECTORS; SUBUNIT INTERACTION; CRYSTAL-STRUCTURE; IRON; BINDING; ENZYME	The opportunistic pathogen Pseudomonas aeruginosa, which causes serious nosocomial infections, is a gamma-proteobacterium that can live in many different environments. Interestingly P. aeruginosa encodes three ribonucleotide reductases (RNRs) that all differ from other well known RNRs. The RNR enzymes are central for de novo synthesis of deoxyribonucleotides and essential to all living cells. The RNR of this study (class Ia) is a complex of the NrdA protein harboring the active site and the allosteric sites and the NrdB protein harboring a tyrosyl radical necessary to initiate catalysis. P. aeruginosa NrdA contains an atypical duplication of the N-terminal ATP-cone, an allosteric domain that can bind either ATP or dATP and regulates the overall enzyme activity. Here we characterized the wild type NrdA and two truncated NrdA variants with precise N-terminal deletions. The N-terminal ATP-cone (ATP-c1) is allosterically functional, whereas the internal ATP-cone lacks allosteric activity. The P. aeruginosa NrdB is also atypical with an unusually short lived tyrosyl radical, which is efficiently regenerated in presence of oxygen as the iron ions remain tightly bound to the protein. The P. aeruginosa wild type NrdA and NrdB proteins form an extraordinarily tight complex with a suggested alpha(4)beta(4) composition. An alpha(2)beta(2) composition is suggested for the complex of truncated NrdA (lacking ATP-c1) and wild type NrdB. Duplication or triplication of the ATP-cone is found in some other bacterial class Ia RNRs. We suggest that protein modularity built on the common catalytic core of all RNRs plays an important role in class diversification within the RNR family.	Stockholm Univ, Dept Mol Biol & Funct Genom, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, Arrhenius Labs Nat Sci, Svante Arrhenius Vag 16-18 F3, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se	Torrents, Eduard/C-7184-2008	Torrents, Eduard/0000-0002-3010-1609; Sjoberg, Britt-Marie/0000-0001-5953-3360				Aravind L, 2000, J MOL MICROB BIOTECH, V2, P191; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; Birgander PL, 2005, J BIOL CHEM, V280, P14997, DOI 10.1074/jbc.M500565200; Birgander PL, 2004, J BIOL CHEM, V279, P14496, DOI 10.1074/jbc.M310142200; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fraser HB, 2005, NAT GENET, V37, P351, DOI 10.1038/ng1530; Gleason FK, 2002, J BACTERIOL, V184, P6544, DOI 10.1128/JB.184.23.6544-6550.2002; Jordan A, 1999, J BACTERIOL, V181, P3974, DOI 10.1128/JB.181.13.3974-3980.1999; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Larsson KM, 2001, STRUCTURE, V9, P739, DOI 10.1016/S0969-2126(01)00627-X; Lendzian F, 2005, BBA-BIOENERGETICS, V1707, P67, DOI 10.1016/j.bbabio.2004.02.011; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Nikitin F, 2003, COMPUT BIOL CHEM, V27, P481, DOI 10.1016/j.compbiolchem.2003.09.003; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Poole AM, 2002, J MOL EVOL, V55, P180, DOI 10.1007/s00239-002-2315-3; Roshick C, 2000, J BIOL CHEM, V275, P38111, DOI 10.1074/jbc.M006367200; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Stubbe J, 2000, CURR OPIN STRUC BIOL, V10, P731, DOI 10.1016/S0959-440X(00)00153-6; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1973, J BIOL CHEM, V248, P4591; Torrents E, 2005, J BIOL CHEM, V280, P16571, DOI 10.1074/jbc.M501322200; Torrents E, 2002, J MOL EVOL, V55, P138, DOI 10.1007/s00239-002-2311-7; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uppsten M, 2003, J MOL BIOL, V330, P87, DOI 10.1016/S0022-2836(03)00538-2	36	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25287	25296		10.1074/jbc.M601794200	http://dx.doi.org/10.1074/jbc.M601794200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829681	hybrid			2022-12-27	WOS:000240031300030
J	Kingma, PS; Zhang, LQ; Ikegami, M; Hartshorn, K; McCormack, FX; Whitsett, JA				Kingma, Paul S.; Zhang, Liqian; Ikegami, Machiko; Hartshorn, Kevan; McCormack, Francis X.; Whitsett, Jeffrey A.			Correction of pulmonary abnormalities in Sftpd(-/-) mice requires the collagenous domain of surfactant protein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; ALVEOLAR MACROPHAGE APOPTOSIS; TERMINAL DOMAINS; LUNG COLLECTINS; SP-A; HOMEOSTASIS; BINDING; EXPRESSION; DISTINCT; LIPOPOLYSACCHARIDES	Surfactant protein D (SP-D) is a member of the collectin family of innate defense proteins. Members of this family share four distinct structural domains: an N-terminal crosslinking domain, a collagenous domain, a neck region, and a carbohydrate recognition domain. In this study, the function of the collagenous domain was evaluated by expressing a SP-D collagen deletion mutant protein (rSftpdCDM) in wild type and SP-D null mice (Sftpd(-/-)). rSftpdCDM formed disulfide-linked trimers that further oligomerized into higher order structures. The mutant protein effectively bound carbohydrate and aggregated bacteria in vitro. Whereas rSftpdCDM did not disrupt pulmonary morphology or surfactant phospholipid levels in wild type mice, the mutant protein failed to rescue the emphysema or enlarged foamy macrophages that are characteristic of Sftpd(-/-) mice. Moreover, rSftpdCDM partitioned with small aggregate surfactant in a manner similar to SP- D, but rSftpdCDM did not correct the abnormal surfactant ultrastructure or phospholipid levels observed in Sftpd(-/-) mice. In contrast, rSftpdCDM completely corrected viral clearance and the abnormal inflammatory response that occurs following pulmonary influenza A challenge in Sftpd(-/-) mice. Our findings indicate that the collagen domain of SP-D is not required for assembly of disulfide-stabilized oligomers or the innate immune response to viral pathogens. The collagen domain of SP- D is required for the regulation of pulmonary macrophage activation, airspace remodeling, and surfactant lipid homeostasis.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Univ Cincinnati, Med Ctr, Pulm Crit Care Div, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; Boston University; Boston University; University System of Ohio; University of Cincinnati	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org	McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464; Hartshorn, Kevan/0000-0002-7196-7433	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060931, R01HL063329, P01HL056387, P50HL056387, R01HL068861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56387, HL60931, HL63329, HL68861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; Clark H, 2003, ANN NY ACAD SCI, V1010, P113, DOI 10.1196/annals.1299.019; Clark H, 2002, J IMMUNOL, V169, P2892, DOI 10.4049/jimmunol.169.6.2892; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1994, J BIOL CHEM, V269, P15808; DeSilva NS, 2003, AM J RESP CELL MOL, V29, P757, DOI 10.1165/rcmb.2003-0186OC; Ferguson JS, 2002, J IMMUNOL, V168, P1309, DOI 10.4049/jimmunol.168.3.1309; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753, DOI 10.1152/ajplung.1996.271.5.L753; Hartshorn KL, 2002, INFECT IMMUN, V70, P6129, DOI 10.1128/IAI.70.11.6129-6139.2002; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; Hartshorn KL, 2000, AM J PHYSIOL-LUNG C, V278, pL90, DOI 10.1152/ajplung.2000.278.1.L90; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; Ikegami M, 2005, AM J PHYSIOL-LUNG C, V288, pL552, DOI 10.1152/ajplung.00142.2004; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Kishore U, 1996, BIOCHEM J, V318, P505, DOI 10.1042/bj3180505; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LeVine AM, 2004, AM J RESP CELL MOL, V31, P193, DOI 10.1165/rcmb.2003-0107OC; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200; Reed JA, 2000, AM J PHYSIOL-LUNG C, V278, pL1164, DOI 10.1152/ajplung.2000.278.6.L1164; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; Strong P, 1998, J IMMUNOL METHODS, V220, P139, DOI 10.1016/S0022-1759(98)00160-4; van de Wetering JK, 2004, EUR J BIOCHEM, V271, P1229, DOI 10.1111/j.1432-1033.2004.04040.x; Wert S, 2000, CHEST, V117, p248S, DOI 10.1378/chest.117.5_suppl_1.248S; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Whitsett JA, 2005, BIOL NEONATE, V88, P175, DOI 10.1159/000087580; Zhang LQ, 2006, AM J PHYSIOL-LUNG C, V291, pL181, DOI 10.1152/ajplung.00015.2006; Zhang LQ, 2002, J BIOL CHEM, V277, P22453, DOI 10.1074/jbc.M201632200; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200; Zhang LQ, 2002, J BIOL CHEM, V277, P38709, DOI 10.1074/jbc.M206200200; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	45	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24496	24505		10.1074/jbc.M600651200	http://dx.doi.org/10.1074/jbc.M600651200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787926	hybrid			2022-12-27	WOS:000239847800045
J	Pham, XH; Farge, G; Shi, YH; Gaspari, M; Gustafsson, CM; Falkenberg, M				Pham, Xuan Hoi; Farge, Geraldine; Shi, Yonghong; Gaspari, Martina; Gustafsson, Claes M.; Falkenberg, Maria			Conserved sequence box II directs transcription termination and primer formation in mitochondriaw2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; DNA-REPLICATION; MAMMALIAN-CELLS; RNASE-H; PURIFIED PROTEINS; PRIMARY ORIGIN; HUMAN MTDNA; IN-VITRO; POLYMERASE; INITIATION	The human mitochondrial transcription machinery generates the RNA primers needed for initiation of heavy strand DNA synthesis. Most DNA replication events from the heavy strand origin are prematurely terminated, forming a persistent RNA-DNA hybrid, which remains annealed to the parental DNA strand. This triple-stranded structure is called the D-loop and encompasses the conserved sequence box II, a DNA element required for proper primer formation. We here use a purified recombinant mitochondrial transcription system and demonstrate that conserved sequence box II is a sequence-dependent transcription termination element in vitro. Transcription from the light strand promoter is prematurely terminated at positions 300-282 in the mitochondrial genome, which coincide with the major RNA-DNA transition points in the D-loop of human mitochondria. Based on our findings, we propose a model for primer formation at the origin of heavy strand DNA replication.	Novum, Karolinska Inst, Div Metab Dis, Dept Lab Med, SE-14186 Stockholm, Sweden	Karolinska Institutet	Falkenberg, M (corresponding author), Novum, Karolinska Inst, Div Metab Dis, Dept Lab Med, SE-14186 Stockholm, Sweden.	maria.falkenberg@ki.se	farge, geraldine/M-2803-2018; shi, yonghong/E-8254-2017	shi, yonghong/0000-0002-5265-7982; farge, geraldine/0000-0003-1054-4274; Gustafsson, Claes/0000-0003-3531-8468; Pham, Xuan Hoi/0000-0002-9629-2970				BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; BROWN WM, 1978, P NATL ACAD SCI USA, V75, P735, DOI 10.1073/pnas.75.2.735; CANTATORE P, 1995, J BIOL CHEM, V270, P25020, DOI 10.1074/jbc.270.42.25020; Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; Chapados BR, 2001, J MOL BIOL, V307, P541, DOI 10.1006/jmbi.2001.4494; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CREWS S, 1979, NATURE, V277, P192, DOI 10.1038/277192a0; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FULLER CW, 1985, J BIOL CHEM, V260, P3197; FULLER CW, 1985, J BIOL CHEM, V260, P3185; Gaspari M, 2004, BBA-BIOENERGETICS, V1659, P148, DOI 10.1016/j.bbabio.2004.10.003; Gaspari M, 2004, EMBO J, V23, P4606, DOI 10.1038/sj.emboj.7600465; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Kang DC, 1997, J BIOL CHEM, V272, P15275, DOI 10.1074/jbc.272.24.15275; KISS T, 1992, EMBO J, V11, P3737, DOI 10.1002/j.1460-2075.1992.tb05459.x; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257; Lee DY, 1997, GENE DEV, V11, P582, DOI 10.1101/gad.11.5.582; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; TAPPER DP, 1981, J BIOL CHEM, V256, P5109; XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9; Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	35	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24647	24652		10.1074/jbc.M602429200	http://dx.doi.org/10.1074/jbc.M602429200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790426	hybrid			2022-12-27	WOS:000239847800059
J	Sahin, B; Shu, HJ; Fernandez, J; El-Armouche, A; Molkentin, JD; Nairn, AC; Bibb, JA				Sahin, Bogachan; Shu, Hongjun; Fernandez, Joseph; El-Armouche, Ali; Molkentin, Jeffery D.; Nairn, Angus C.; Bibb, James A.			Phosphorylation of protein phosphatase inhibitor-1 by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CAMP-REGULATED PHOSPHOPROTEIN; IMMUNOCYTOCHEMICAL LOCALIZATION; ACETYLCHOLINE-RECEPTOR; MOLECULAR-MECHANISMS; CARDIAC-FUNCTION; HEART-FAILURE; DARPP-32; DOPAMINE; RAT	Inhibitor-1 becomes a potent inhibitor of protein phosphatase 1 when phosphorylated by cAMP-dependent protein kinase at Thr(35). Moreover, Ser(67) of inhibitor-1 serves as a substrate for cyclin-dependent kinase 5 in the brain. Here, we report that dephosphoinhibitor-1 but not phospho-Ser(67) inhibitor-1 was efficiently phosphorylated by protein kinase C at Ser(65) in vitro. In contrast, Ser(67) phosphorylation by cyclin-dependent kinase 5 was unaffected by phospho-Ser(65). Protein kinase C activation in striatal tissue resulted in the concomitant phosphorylation of inhibitor-1 at Ser(65) and Ser(67), but not Ser(65) alone. Selective pharmacological inhibition of protein phosphatase activity suggested that phospho-Ser(65) inhibitor-1 is dephosphorylated by protein phosphatase 1 in the striatum. In vitro studies confirmed these findings and suggested that phospho-Ser(67) protects phospho-Ser(65) inhibitor-1 from dephosphorylation by protein phosphatase 1 in vivo. Activation of group I metabotropic glutamate receptors resulted in the up-regulation of diphospho-Ser(65)/Ser(67) inhibitor-1 in this tissue. In contrast, the activation of N-methyl-D-aspartate-type ionotropic glutamate receptors opposed increases in striatal diphospho-Ser(65)/Ser(67) inhibitor-1 levels. Phosphomimetic mutation of Ser(65) and/or Ser(67) did not convert inhibitor-1 into a protein phosphatase 1 inhibitor. On the other hand, in vitro and in vivo studies suggested that diphospho-Ser(65)/Ser(67) inhibitor-1 is a poor substrate for cAMP-dependent protein kinase. These observations extend earlier studies regarding the function of phospho-Ser(67) and underscore the possibility that phosphorylation in this region of inhibitor-1 by multiple protein kinases may serve as an integrative signaling mechanism that governs the responsiveness of inhibitor-1 to cAMP-dependent protein kinase activation.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Prot Chem Lab, Alliance Cellular Signaling, Dallas, TX 75390 USA; Rockefeller Univ, Prot DNA Technol Ctr, New York, NY 10021 USA; Rockefeller Univ, Lab Cellular & Mol Neurosci, New York, NY 10021 USA; Univ Hamburg, Hosp Eppendorf, Inst Expt & Clin Pharmacol, D-20246 Hamburg, Germany; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Yale Univ, Sch Med, New Haven, CT 06519 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rockefeller University; Rockefeller University; University of Hamburg; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Yale University	Bibb, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.bibb@utsouthwestern.edu	El-Armouche, Ali/H-3161-2018	El-Armouche, Ali/0000-0003-2514-9429; Molkentin, Jeffery/0000-0002-3558-6529; Nairn, Angus/0000-0002-7075-0195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044, R01DA016672] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL077101] Funding Source: Medline; NIDA NIH HHS [P01 DA010044, R01 DA016672, DA10044, DA16672] Funding Source: Medline; NIMH NIH HHS [MH67777, R01 MH067777] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Coe IR, 1996, J BIOL CHEM, V271, P29468, DOI 10.1074/jbc.271.46.29468; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1978, FEBS S, V54, P161; Cohen PTW, 2002, J CELL SCI, V115, P241; CZERNIK AJ, 1997, REGULATORY PROTEIN M, P219; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Genoux D, 2002, NATURE, V418, P970, DOI 10.1038/nature00928; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Kennelly PJ, 2001, CHEM REV, V101, P2291, DOI 10.1021/cr0002543; Li MX, 2001, NAT NEUROSCI, V4, P871, DOI 10.1038/nn0901-871; Liu QR, 2005, PROG NUCLEIC ACID RE, V79, P371, DOI 10.1016/S0079-6603(04)79008-X; Liu QR, 2004, BIOCHEM J, V377, P171, DOI 10.1042/BJ20030128; Lovinger DM, 1996, INT REV NEUROBIOL, V39, P77, DOI 10.1016/S0074-7742(08)60664-9; MACDOUGALL LK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P218, DOI 10.1016/0167-4889(89)90164-X; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MILES K, 1987, P NATL ACAD SCI USA, V84, P6591, DOI 10.1073/pnas.84.18.6591; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nelson PG, 2003, J NEUROCYTOL, V32, P803, DOI 10.1023/B:NEUR.0000020625.70284.a6; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; OUIMET CC, 1984, J NEUROSCI, V4, P111; Pathak A, 2005, CIRC RES, V96, P756, DOI 10.1161/01.RES.0000161256.85833.fa; Pi YQ, 2003, J PHYSIOL-LONDON, V552, P845, DOI 10.1113/jphysiol.2003.045260; Poisbeau P, 1999, J NEUROSCI, V19, P674; SAFRAN A, 1990, BIOCHEMISTRY-US, V29, P6730, DOI 10.1021/bi00480a024; Saito T, 2003, J NEUROSCI, V23, P1189, DOI 10.1523/JNEUROSCI.23-04-01189.2003; SHEA TB, 1992, J NEUROSCI RES, V33, P398, DOI 10.1002/jnr.490330306; SHENOLIKAR S, 1991, ADV 2 MESSENGER PHOS, V23, P1; SIKES S, 2005, CELLSCI REV, V2, P175; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Wei FY, 2005, J NEUROCHEM, V93, P502, DOI 10.1111/j.1471-4159.2005.03058.x; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; Zachariou V, 2002, BIOL PSYCHIAT, V51, P612, DOI 10.1016/S0006-3223(01)01318-X	55	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24322	24335		10.1074/jbc.M603282200	http://dx.doi.org/10.1074/jbc.M603282200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16772299	Green Accepted, hybrid			2022-12-27	WOS:000239847800025
J	Arnaud, N; Murgia, I; Boucherez, J; Briat, JF; Cellier, F; Gaymard, F				Arnaud, Nicolas; Murgia, Irene; Boucherez, Jossia; Briat, Jean-Francois; Cellier, Francoise; Gaymard, Frederic			An iron-induced nitric oxide burst precedes ubiquitin-dependent protein degradation for Arabidopsis AtFer1 ferritin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DIFFERENTIAL EXPRESSION; S-NITROSYLATION; IN-VIVO; NO; METABOLISM; IDENTIFICATION; TRANSFERRIN; STABILITY; COMPLEXES	Ferritins play an essential role in iron homeostasis by sequestering iron in a bioavailable and non-toxic form. In plants, ferritin mRNAs are highly and quickly accumulated in response to iron overload. Such accumulation leads to a subsequent ferritin protein synthesis and iron storage, thus avoiding oxidative stress to take place. By combining pharmacological and imaging approaches in an Arabidopsis cell culture system, we have identified several elements in the signal transduction pathway leading to the increase of AtFer1 transcript level after iron treatment. Nitric oxide quickly accumulates in the plastids after iron treatment. This compound acts downstream of iron and upstream of a PP2A-type phosphatase to promote an increase of AtFer1 mRNA level. The AtFer1 gene transcription has been previously shown to be repressed under low iron conditions with the involvement of the cis-acting element iron-dependent regulatory sequence identified within the AtFer1 promoter sequence. We show here that the repressor is unlikely a transcription factor directly bound to the iron-dependent regulatory sequence; such a repressor is ubiquitinated upon iron treatment and subsequently degraded through a 26 S proteasome-dependent pathway.	Univ Montpellier 2, CNRS,UMR 5004, INRA, Lab Biochim & Physiol Mol Plantes, F-34060 Montpellier 1, France; Univ Milan, Dipartimento Biol, Sez Fisiol & Biochim Piante, I-20133 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; University of Milan	Gaymard, F (corresponding author), Univ Montpellier 2, CNRS,UMR 5004, INRA, Lab Biochim & Physiol Mol Plantes, Bat 7,2 Pl Viala, F-34060 Montpellier 1, France.	gaymard@ensam.inra.fr	Murgia, Irene/ABD-7070-2020	Murgia, Irene/0000-0002-3193-6325; ARNAUD, Nicolas/0000-0001-8571-5862				Barroso JB, 1999, J BIOL CHEM, V274, P36729, DOI 10.1074/jbc.274.51.36729; Beligni MV, 2000, PLANTA, V210, P215, DOI 10.1007/PL00008128; Bethke PC, 2004, PLANTA, V219, P847, DOI 10.1007/s00425-004-1282-x; Bethke PC, 2004, PLANT CELL, V16, P332, DOI 10.1105/tpc.017822; Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403; Bright J, 2006, PLANT J, V45, P113, DOI 10.1111/j.1365-313X.2005.02615.x; Callis J, 2000, CURR OPIN PLANT BIOL, V3, P381, DOI 10.1016/S1369-5266(00)00100-X; Chiou TJ, 2006, PLANT CELL, V18, P412, DOI 10.1105/tpc.105.038943; Crawford NM, 2006, J EXP BOT, V57, P471, DOI 10.1093/jxb/erj050; Crawford NM, 2005, TRENDS PLANT SCI, V10, P195, DOI 10.1016/j.tplants.2005.02.008; Dellagi A, 2005, PLANT J, V43, P262, DOI 10.1111/j.1365-313X.2005.02451.x; Delledonne M, 2005, CURR OPIN PLANT BIOL, V8, P390, DOI 10.1016/j.pbi.2005.05.002; Dordas C, 2003, ANN BOT-LONDON, V91, P173, DOI 10.1093/aob/mcf115; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; FOBISLOISY I, 1995, EUR J BIOCHEM, V231, P609, DOI 10.1111/j.1432-1033.1995.0609d.x; Foissner I, 2000, PLANT J, V23, P817, DOI 10.1046/j.1365-313X.2000.00835.x; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gaymard F, 1996, BIOCHEM J, V318, P67, DOI 10.1042/bj3180067; Gould KS, 2003, PLANT CELL ENVIRON, V26, P1851, DOI 10.1046/j.1365-3040.2003.01101.x; Graziano M, 2005, TRENDS PLANT SCI, V10, P4, DOI 10.1016/j.tplants.2004.12.004; Graziano M, 2002, PLANT PHYSIOL, V130, P1852, DOI 10.1104/pp.009076; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Guo FQ, 2005, PLANT CELL, V17, P3436, DOI 10.1105/tpc.105.037770; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HAUSER M, 1995, PLANT PHYSIOL, V108, P1059, DOI 10.1104/pp.108.3.1059; Hellmann H, 2002, SCIENCE, V297, P793, DOI 10.1126/science.1072831; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hershko DD, 2004, J CELL BIOCHEM, V91, P951, DOI 10.1002/jcb.20014; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Huang X, 2004, PLANTA, V218, P938, DOI 10.1007/s00425-003-1178-1; Ishikawa H, 2005, MOL CELL, V19, P171, DOI 10.1016/j.molcel.2005.05.027; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; Kim S, 1999, J BIOL CHEM, V274, P33035, DOI 10.1074/jbc.274.46.33035; Kim S, 2004, MOL CELL BIOL, V24, P330, DOI 10.1128/MCB.24.1.330-337.2004; Kim S, 2003, BIOMETALS, V16, P125, DOI 10.1023/A:1020788603046; Kim S, 2000, J BIOL CHEM, V275, P6220, DOI 10.1074/jbc.275.9.6220; Kim SW, 2002, P NATL ACAD SCI USA, V99, P12214, DOI 10.1073/pnas.192316099; KLEPPER L, 1990, PLANT PHYSIOL, V93, P26, DOI 10.1104/pp.93.1.26; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamattina L, 2003, ANNU REV PLANT BIOL, V54, P109, DOI 10.1146/annurev.arplant.54.031902.134752; Lamotte O, 2005, PLANTA, V221, P1, DOI 10.1007/s00425-005-1494-8; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LESCURE AM, 1991, P NATL ACAD SCI USA, V88, P8222, DOI 10.1073/pnas.88.18.8222; Lindermayr C, 2005, PLANT PHYSIOL, V137, P921, DOI 10.1104/pp.104.058719; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOBREAUX S, 1993, EMBO J, V12, P651, DOI 10.1002/j.1460-2075.1993.tb05698.x; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; Millar AH, 1996, FEBS LETT, V398, P155, DOI 10.1016/S0014-5793(96)01230-6; MULSCH A, 1993, BIOCHEM BIOPH RES CO, V196, P1303, DOI 10.1006/bbrc.1993.2394; Murgia I, 2004, J PLANT PHYSIOL, V161, P777, DOI 10.1016/j.jplph.2003.12.004; Murgia I, 2002, PLANT J, V30, P521, DOI 10.1046/j.1365-313X.2002.01312.x; Murgia I, 2001, PLANT PHYSIOL BIOCH, V39, P797, DOI 10.1016/S0981-9428(01)01297-9; Navarre DA, 2000, PLANT PHYSIOL, V122, P573, DOI 10.1104/pp.122.2.573; Neill SJ, 2003, NEW PHYTOL, V159, P11, DOI 10.1046/j.1469-8137.2003.00804.x; NISHIMURA H, 1986, ENVIRON SCI TECHNOL, V20, P413, DOI 10.1021/es00146a017; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Perazzolli M, 2004, PLANT CELL, V16, P2785, DOI 10.1105/tpc.104.025379; Petit JM, 2001, J BIOL CHEM, V276, P5584, DOI 10.1074/jbc.M005903200; Petit JM, 2001, BIOCHEM J, V359, P575, DOI 10.1042/0264-6021:3590575; RICHARDSON DR, 1995, BBA-MOL CELL RES, V1266, P250, DOI 10.1016/0167-4889(95)00022-K; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; Savino G, 1997, J BIOL CHEM, V272, P33319, DOI 10.1074/jbc.272.52.33319; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Severina IS, 2003, NITRIC OXIDE-BIOL CH, V8, P155, DOI 10.1016/S1089-8603(03)00002-8; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Song CP, 2004, P NATL ACAD SCI USA, V101, P10211, DOI 10.1073/pnas.0403709101; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Tarantino D, 2003, PLANTA, V217, P709, DOI 10.1007/s00425-003-1038-z; Vanin AF, 2004, J BIOL CHEM, V279, P24100, DOI 10.1074/jbc.M312601200; VANIN AF, 1995, BIOCHEMISTRY-MOSCOW+, V60, P225; Vanin AF, 1996, BBA-PROTEIN STRUCT M, V1295, P5, DOI 10.1016/0167-4838(95)00247-2; Vierstra RD, 2003, TRENDS PLANT SCI, V8, P135, DOI 10.1016/S1360-1385(03)00014-1; WATTS RN, 2002, EUR J BIOCHEM, V290, P693; Wendehenne D, 2004, CURR OPIN PLANT BIOL, V7, P449, DOI 10.1016/j.pbi.2004.04.002; Wendehenne D, 2001, TRENDS PLANT SCI, V6, P177, DOI 10.1016/S1360-1385(01)01893-3; WILKINSON JQ, 1993, MOL GEN GENET, V239, P289, DOI 10.1007/BF00281630; Zancani M, 2004, EUR J BIOCHEM, V271, P3657, DOI 10.1111/j.1432-1033.2004.04300.x	82	141	148	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23579	23588		10.1074/jbc.M602135200	http://dx.doi.org/10.1074/jbc.M602135200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782706	Green Published, hybrid			2022-12-27	WOS:000239702900032
J	Daly, NL; Chen, YK; Foley, FM; Bansal, PS; Bharathi, R; Clark, RJ; Sommerhoff, CP; Craik, DJ				Daly, Norelle L.; Chen, Yi-Kuang; Foley, Fiona M.; Bansal, Paramjit S.; Bharathi, Rekha; Clark, Richard J.; Sommerhoff, Christian P.; Craik, David J.			The absolute structural requirement for a proline in the P3 '-position of Bowman-Birk protease inhibitors is surmounted in the minimized SFTI-1 scaffold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUNFLOWER TRYPSIN INHIBITOR-1; HIGH-RESOLUTION STRUCTURE; MACROCYCLIC PEPTIDES; CHEMICAL-SYNTHESIS; CIRCULAR PROTEINS; PLANT CYCLOTIDES; NMR-SPECTROSCOPY; KNOTTED PROTEINS; SERINE-PROTEASE; DRUG DESIGN	SFTI-1 is a small cyclic peptide from sunflower seeds that is one of the most potent trypsin inhibitors of any naturally occurring peptide and is related to the Bowman-Birk family of inhibitors (BBIs). BBIs are involved in the defense mechanisms of plants and also have potential as cancer chemopreventive agents. At only 14 amino acids in size, SFTI-1 is thought to be a highly optimized scaffold of the BBI active site region, and thus it is of interest to examine its important structural and functional features. In this study, a suite of 12 alanine mutants of SFTI-1 has been synthesized, and their structures and activities have been determined. SFTI-1 incorporates a binding loop that is clasped together with a disulfide bond and a secondary peptide loop making up the circular backbone. We show here that the secondary loop stabilizes the binding loop to the consequences of sequence variations. In particular, full-length BBIs have a conserved cis-proline that has been shown previously to be required for well defined structure and potent activity, but we show here that the SFTI-1 scaffold can accommodate mutation of this residue and still have a well defined native-like conformation and nanomolar activity in inhibiting trypsin. Among the Ala mutants, the most significant structural perturbation occurred when Asp(14) was mutated, and it appears that this residue is important in stabilizing the trans peptide bond preceding Pro(13) and is thus a key residue in maintaining the highly constrained structure of SFTI-1. This aspartic acid residue is thought to be involved in the cyclization mechanism associated with excision of SFTI-1 from its 58-amino acid precursor. Overall, this mutational analysis of SFTI-1 clearly defines the optimized nature of the SFTI-1 scaffold and demonstrates the importance of the secondary loop in maintaining the active conformation of the binding loop.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Australian Res Council Special Res Ctr Funct, Brisbane, Qld 4072, Australia; Univ Munich, Dept Clin Chem & Clin Biochem, D-80336 Munich, Germany	University of Queensland; University of Queensland; University of Munich	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Daly, Norelle L/D-4302-2013; Clark, Richard J/G-8848-2012; Craik, David/B-1695-2010	Daly, Norelle L/0000-0002-4697-6602; Clark, Richard J/0000-0002-6807-5426; Craik, David/0000-0003-0007-6796				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BIETH JG, 1980, CLIN RES PROC, V16, P183; Brauer ABE, 2002, BIOCHEMISTRY-US, V41, P10608, DOI 10.1021/bi026050t; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHASE T, 1970, METHOD ENZYMOL, V19, P20; Craik DJ, 2006, CURR OPIN DRUG DISC, V9, P251; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Daly NL, 2006, BIOCHEM J, V393, P619, DOI 10.1042/BJ20051371; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Descours A, 2002, CHEMBIOCHEM, V3, P318, DOI 10.1002/1439-7633(20020402)3:4<318::AID-CBIC318>3.0.CO;2-W; Dutton JL, 2004, J BIOL CHEM, V279, P46858, DOI 10.1074/jbc.M407421200; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; GRASBERGER BL, 1994, STRUCTURE, V2, P669, DOI 10.1016/S0969-2126(00)00067-8; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h; Kennedy AR, 1998, AM J CLIN NUTR, V68, p1406S, DOI 10.1093/ajcn/68.6.1406S; Korsinczky MLJ, 2005, BIOCHEMISTRY-US, V44, P1145, DOI 10.1021/bi048297r; Korsinczky MLJ, 2004, CURR PROTEIN PEPT SC, V5, P351, DOI 10.2174/1389203043379594; Korsinczky MLJ, 2001, J MOL BIOL, V311, P579, DOI 10.1006/jmbi.2001.4887; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Long YQ, 2001, BIOORG MED CHEM LETT, V11, P2515, DOI 10.1016/S0960-894X(01)00493-0; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Marx UC, 2003, J BIOL CHEM, V278, P21782, DOI 10.1074/jbc.M212996200; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; Mulvenna JP, 2005, J BIOL CHEM, V280, P32245, DOI 10.1074/jbc.M506060200; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Simonsen SM, 2005, PLANT CELL, V17, P3176, DOI 10.1105/tpc.105.034678; Tam JP, 1999, J AM CHEM SOC, V121, P4316, DOI 10.1021/ja984480u; Tam JP, 1997, TETRAHEDRON LETT, V38, P5599, DOI 10.1016/S0040-4039(97)01271-9; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Trabi M, 2004, PLANT CELL, V16, P2204, DOI 10.1105/tpc.104.021790; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wu WJ, 1998, BIOPOLYMERS, V45, P381, DOI 10.1002/(SICI)1097-0282(19980415)45:5<381::AID-BIP6>3.0.CO;2-H; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; YAO J, 1994, J MOL BIOL, V243, P736, DOI 10.1016/0022-2836(94)90044-2; Zablotna E, 2002, BIOCHEM BIOPH RES CO, V292, P855, DOI 10.1006/bbrc.2002.6746	40	56	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23668	23675		10.1074/jbc.M601426200	http://dx.doi.org/10.1074/jbc.M601426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16766795	hybrid			2022-12-27	WOS:000239702900042
J	Jolliffe, NA; Di Cola, A; Marsden, CJ; Lord, JM; Ceriotti, A; Frigerio, L; Roberts, LM				Jolliffe, Nicholas A.; Di Cola, Alessandra; Marsden, Catherine J.; Lord, J. Michael; Ceriotti, Aldo; Frigerio, Lorenzo; Roberts, Lynne M.			The N-terminal ricin propeptide influences the fate of ricin A-chain in tobacco protoplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; VACUOLAR PROCESSING ENZYME; ENDOPLASMIC-RETICULUM; ACTIVE-SITE; B-CHAIN; INTRACELLULAR-TRANSPORT; COMMUNIS AGGLUTININ; TRANSGENIC TOBACCO; PRECURSORS; INHIBITION	The plant toxin ricin is synthesized in castor bean seeds as an endoplasmic reticulum (ER)-targeted precursor. Removal of the signal peptide generates proricin in which the mature A- and B-chains are joined by an intervening propeptide and a 9-residue propeptide persists at the N terminus. The two propeptides are ultimately removed in protein storage vacuoles, where ricin accumulates. Here we have demonstrated that the N-terminal propeptide of proricin acts as a nonspecific spacer to ensure efficient ER import and glycosylation. Indeed, when absent from the N terminus of ricin A-chain, the non-imported material remained tethered to the cytosolic face of the ER membrane, presumably by the signal peptide. This species appeared toxic to ribosomes. The propeptide does not, however, influence catalytic activity per se or the vacuolar targeting of proricin or the rate of retrotranslocation/degradation of A-chain in the cytosol. The likely implications of these findings to the survival of the toxin-producing tissue are discussed.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; CNR, Ist Biol & Biotecnol Agr, I-20133 Milan, Italy	University of Warwick; Consiglio Nazionale delle Ricerche (CNR)	Roberts, LM (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	lynne.roberts@warwick.ac.uk	Frigerio, Lorenzo/D-2685-2009; Ceriotti, Aldo/A-1448-2016; Frigerio, Lorenzo/M-6013-2019	Frigerio, Lorenzo/0000-0003-4100-6022; Ceriotti, Aldo/0000-0002-8230-8863; Frigerio, Lorenzo/0000-0003-4100-6022				Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bismuth C, 2004, TOXICOL LETT, V149, P11, DOI 10.1016/j.toxlet.2003.12.016; BUSTOS MM, 1991, PLANT MOL BIOL, V16, P381, DOI 10.1007/BF00023990; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; Daubenfeld T, 2005, BIOCHEM BIOPH RES CO, V333, P984, DOI 10.1016/j.bbrc.2005.06.008; Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n; Di Cola A, 2005, PLANT PHYSIOL, V137, P287, DOI 10.1104/pp.104.055434; Di Cola A, 2001, P NATL ACAD SCI USA, V98, P14726, DOI 10.1073/pnas.251386098; ENDO Y, 1987, J BIOL CHEM, V262, P8128; FERRINI JB, 1995, EUR J BIOCHEM, V233, P772, DOI 10.1111/j.1432-1033.1995.772_3.x; Frigerio L, 1998, J BIOL CHEM, V273, P14194, DOI 10.1074/jbc.273.23.14194; Frigerio L, 2001, PLANT PHYSIOL, V126, P167, DOI 10.1104/pp.126.1.167; Gietl C, 2001, NATURWISSENSCHAFTEN, V88, P49, DOI 10.1007/s001140000203; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; HARANISHIMURA I, 1995, SEIKAGAKU, V67, P372; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; Hartley MR, 1996, TRENDS PLANT SCI, V1, P254, DOI 10.1016/1360-1385(96)10030-3; Higy M, 2004, BIOCHEMISTRY-US, V43, P12716, DOI 10.1021/bi048368m; Lord J M, 1991, Semin Cell Biol, V2, P15; LORD JM, 1985, EUR J BIOCHEM, V146, P403, DOI 10.1111/j.1432-1033.1985.tb08666.x; LORD JM, 1985, EUR J BIOCHEM, V146, P411, DOI 10.1111/j.1432-1033.1985.tb08667.x; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; Pedrazzini E, 1997, PLANT CELL, V9, P1869, DOI 10.1105/tpc.9.10.1869; RICHARDSON PT, 1989, FEBS LETT, V255, P15, DOI 10.1016/0014-5793(89)81052-X; ROBERTS LM, 1981, EUR J BIOCHEM, V119, P31, DOI 10.1111/j.1432-1033.1981.tb05573.x; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; Schmid M, 2001, P NATL ACAD SCI USA, V98, P5353, DOI 10.1073/pnas.061038298; SEHNKE PC, 1994, J BIOL CHEM, V269, P22473; Slominska-Wojewodzka M, 2006, MOL BIOL CELL, V17, P1664, DOI 10.1091/mbc.E05-10-0961; Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004; Tabe L, 1998, TRENDS PLANT SCI, V3, P282, DOI 10.1016/S1360-1385(98)01267-9; Tagge EP, 1996, PROTEIN EXPRES PURIF, V8, P109, DOI 10.1006/prep.1996.0080; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; TULLY RE, 1976, PLANT PHYSIOL, V58, P710, DOI 10.1104/pp.58.6.710; WALES R, 1991, J BIOL CHEM, V266, P19172; Yamada K, 1999, J BIOL CHEM, V274, P2563, DOI 10.1074/jbc.274.4.2563; YUOLE RJ, 1976, PLANT PHYSIOL, V58, P703	40	17	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23377	23385		10.1074/jbc.M602678200	http://dx.doi.org/10.1074/jbc.M602678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16774920	hybrid			2022-12-27	WOS:000239702900012
J	Kumashiro, KK; Ho, JP; Niemczura, WP; Keeley, FW				Kumashiro, Kristin K.; Ho, Joanna P.; Niemczura, Walter P.; Keeley, Fred W.			Cooperativity between the hydrophobic and cross-linking domains of elastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE; SECONDARY STRUCTURE; CHEMICAL-SHIFTS; CPMAS NMR; C-13; CONFORMATION; RESONANCE; MOBILITY; PEPTIDE; POLYPEPTIDES	The principal protein component of the elastic fiber found in elastic tissues is elastin, an amorphous, cross-linked biopolymer that is assembled from a high molecular weight monomer. The hydrophobic and cross-linking domains of elastin have been considered separate and independent, such that changes to one region are not thought to affect the other. However, results from these solid-state C-13 NMR experiments demonstrate that cooperativity in protein folding exists between the two domain types. The sequence of the EP20-24-24 polypeptide has three hydrophobic sequences from exons 20 and 24 of the soluble monomer tropoelastin, interspersed with cross-linking domains constructed from exons 21 and 23. In the middle of each cross-linking domain is a "hinge" sequence. When this pentapeptide is replaced with alanines, as in EP20-24-24[23U], its properties are changed. In addition to the expected increase in alpha-helical content and the resulting increase in rigidity of the cross-linking domains, changes to the organization of the hydrophobic regions are also observed. Using one-dimensional CPMAS (cross- polarization with magic angle spinning) techniques, including spectral editing and relaxation measurements, evidence for a change in dynamics to both domain types is observed. Furthermore, it is likely that the methyl groups of the leucines of the hydrophobic domains are also affected by the substitution to the hinge region of the cross-linking sequences. This cooperativity between the two domain types brings new questions to the phenomenon of coacervation in elastin polypeptides and strongly suggests that functional models for the protein must include a role for the cross-linking regions.	Univ Hawaii, Dept Chem, Honolulu, HI 96822 USA; Hosp Sick Children, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada	University of Hawaii System; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Kumashiro, KK (corresponding author), Univ Hawaii, Dept Chem, 2545 McCarthy Mall, Honolulu, HI 96822 USA.	kumashir@hawaii.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016453] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 16453] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bellingham CM, 2003, BIOPOLYMERS, V70, P445, DOI 10.1002/bip.10512; Bellingham CM, 2001, BBA-PROTEIN STRUCT M, V1550, P6, DOI 10.1016/S0167-4838(01)00262-X; CHANG DK, 1989, J BIOMOL STRUCT DYN, V6, P851, DOI 10.1080/07391102.1989.10506517; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; ELLIS GE, 1976, BIOPOLYMERS, V15, P813, DOI 10.1002/bip.1976.360150502; FLEMING WW, 1980, BIOPOLYMERS, V19, P597, DOI 10.1002/bip.1980.360190311; KRICHELDORF HR, 1983, MACROMOLECULES, V16, P615, DOI 10.1021/ma00238a025; KRICHELDORF HR, 1984, INT J BIOL MACROMOL, V6, P145, DOI 10.1016/0141-8130(84)90056-4; Kumashiro KK, 2000, J BIOMOL NMR, V18, P139, DOI 10.1023/A:1008334931234; Kumashiro KK, 2003, BIOPOLYMERS, V70, P221, DOI 10.1002/bip.10470; Kumashiro KK, 2001, BIOPOLYMERS, V59, P266, DOI 10.1002/1097-0282(20011005)59:4<266::AID-BIP1023>3.0.CO;2-2; LUAN CH, 1991, INT J QUANTUM CHEM, V40, P183, DOI 10.1002/qua.560400719; LYERLA JR, 1975, BIOCHEMISTRY-US, V14, P5175, DOI 10.1021/bi00694a024; Martino M, 2001, BIOPOLYMERS, V59, P29, DOI 10.1002/1097-0282(200107)59:1<29::AID-BIP1003>3.0.CO;2-F; Martino M, 2000, INT J BIOL MACROMOL, V27, P59, DOI 10.1016/S0141-8130(99)00118-X; Miao M, 2005, BIOCHEMISTRY-US, V44, P14367, DOI 10.1021/bi0510173; Miao M, 2003, J BIOL CHEM, V278, P48553, DOI 10.1074/jbc.M308465200; Ohgo K, 2005, MACROMOLECULES, V38, P6038, DOI 10.1021/ma050052e; Perry A, 2002, J AM CHEM SOC, V124, P6832, DOI 10.1021/ja017711x; Perry A, 2002, BIOPHYS J, V82, P1086, DOI 10.1016/S0006-3495(02)75468-4; Pometun MS, 2004, J BIOL CHEM, V279, P7982, DOI 10.1074/jbc.M310948200; PRETSCH E, 1983, TABLES SPECTRAL DATA, pC205; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SAITO H, 1983, MACROMOLECULES, V16, P1050, DOI 10.1021/ma00241a005; SANDBERG LB, 1976, INT REV CONNECT TISS, V7, P160; SEAVEY B R, 1991, Journal of Biomolecular NMR, V1, P217, DOI 10.1007/BF01875516; TAKI T, 1981, CHEM LETT, P1803, DOI 10.1246/cl.1981.1803; TAMBURRO AM, 1992, J BIOMOL STRUCT DYN, V10, P441, DOI 10.1080/07391102.1992.10508661; TORCHIA DA, 1973, J MOL BIOL, V76, P419, DOI 10.1016/0022-2836(73)90514-7; TORCHIA DA, 1978, J MAGN RESON, V30, P613, DOI 10.1016/0022-2364(78)90288-3; Urry D W, 1977, Adv Exp Med Biol, V79, P685; Urry D W, 1974, Adv Exp Med Biol, V43, P211; VENKATACHALAM CM, 1981, MACROMOLECULES, V14, P1225, DOI 10.1021/ma50006a017; WU XL, 1994, J MAGN RESON SER A, V111, P29, DOI 10.1006/jmra.1994.1222; WU XL, 1993, J MAGN RESON SER A, V102, P205, DOI 10.1006/jmra.1993.1092; WU XL, 1993, J MAGN RESON SER A, V104, P119, DOI 10.1006/jmra.1993.1199; Yang J, 2001, BIOCHEMISTRY-US, V40, P8126, DOI 10.1021/bi0100283; Yao XL, 2004, J AM CHEM SOC, V126, P4199, DOI 10.1021/ja036686n	38	31	31	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23757	23765		10.1074/jbc.M510833200	http://dx.doi.org/10.1074/jbc.M510833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777851	hybrid			2022-12-27	WOS:000239702900051
J	Yamada, SI; Niwa, JI; Ishigaki, S; Takahashi, M; Ito, T; Sone, J; Doyu, M; Sobue, G				Yamada, Shin-ichi; Niwa, Jun-ichi; Ishigaki, Shinsuke; Takahashi, Miho; Ito, Takashi; Sone, Jun; Doyu, Manabu; Sobue, Gen			Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPLASMA-ACIDOPHILUM; MODEL; DYSFUNCTION; EXPRESSION; INHIBITOR; SYNUCLEIN; DISEASE; BRAIN; MICE; TAU	The 20 S proteasome is a ubiquitous, barrel-shaped protease complex responsible for most of cellular proteolysis, and its reduced activity is thought to be associated with accumulations of aberrant or misfolded proteins, resulting in a number of neurodegenerative diseases, including amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy, Parkinson disease, and Alzheimer disease. The 20 S proteasomes of archaebacteria (archaea) are structurally simple and proteolytically powerful and thought to be an evolutionary precursor to eukaryotic proteasomes. We successfully reproduced the archaeal proteasome in a functional state in mammalian cells, and here we show that the archaeal proteasome effectively accelerated species-specific degradation of mutant superoxide dismutase-1 and the mutant polyglutamine tract-extended androgen receptor, causative proteins of familial amyotrophic lateral sclerosis and spinal and bulbar muscular atrophy, respectively, and reduced the cellular toxicities of these mutant proteins. Further, we demonstrate that archaeal proteasome can also degrade other neurodegenerative disease-associated proteins such as alpha-synuclein and tau. Our study showed that archaeal proteasomes can degrade aggregation-prone proteins whose toxic gain of function causes neurodegradation and reduce protein cellular toxicity.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	ISHIGAKI, Shinsuke/I-7305-2014; Sone, Jun/M-5027-2014	Sone, Jun/0000-0002-9057-7609; Ishigaki, Shinsuke/0000-0002-9555-0659				Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Cheng YH, 2005, EUR J PHARM SCI, V26, P9, DOI 10.1016/j.ejps.2005.03.014; Ciechanover A, 2000, J CELL BIOCHEM, P40; DAHLMANN B, 1991, BIOMED BIOCHIM ACTA, V50, P465; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Kabashi E, 2004, J NEUROCHEM, V89, P1325, DOI 10.1111/j.1471-4159.2004.02453.x; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Miller DW, 2004, NEUROLOGY, V62, P1835, DOI 10.1212/01.WNL.0000127517.33208.F4; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Patel YJK, 2005, MOL BRAIN RES, V134, P256, DOI 10.1016/j.molbrainres.2004.10.028; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; Sathasivam S, 2005, NEUROPATH APPL NEURO, V31, P467, DOI 10.1111/j.1365-2990.2005.00658.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Zwickl P, 2000, MOL B INT U, V12, P8; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	35	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23842	23851		10.1074/jbc.M601274200	http://dx.doi.org/10.1074/jbc.M601274200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793767	hybrid			2022-12-27	WOS:000239702900060
J	Deadman, ME; Lundstrom, SL; Schweda, EKH; Moxon, ER; Hood, DW				Deadman, Mary E.; Lundstrom, Susanna L.; Schweda, Elke K. H.; Moxon, E. Richard; Hood, Derek W.			Specific amino acids of the glycosyltransferase LpsA direct the addition of glucose or galactose to the terminal inner core heptose of Haemophilus influenzae lipopolysaccharide via alternative linkages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; SUGAR GLYCOSYLTRANSFERASES; HEMOPHILUS-INFLUENZAE; SIALIC-ACID; STRAIN-RD; BIOSYNTHESIS; MECHANISM; GENES; PHOSPHORYLCHOLINE; CLASSIFICATION	Lipopolysaccharide is the major glycolipid of the cell wall of the bacterium Haemophilus influenzae, a Gram-negative commensal and pathogen of humans. Lipopolysaccharide is both a virulence determinant and a target for host immune responses. Glycosyltransferases have high donor and acceptor substrate specificities that are generally limited to catalysis of one unique glycosidic linkage. The H. influenzae glycosyltransferase LpsA is responsible for the addition of a hexose to the distal heptose of the inner core of the lipopolysaccharide molecule and belongs to the glycosyltransferase family 25. The hexose added can be either glucose or galactose and linkage to the heptose can be either beta 1-2 or beta 1-3. Each H. influenzae strain uniquely produces only one of the four possible combinations of linked sugar in its lipopolysaccharide. We show that, in any given strain, a specific allelic variant of LpsA directs the anomeric linkage and the added hexose, glucose, or galactose. Site-directed mutagenesis of a single key amino acid at position 151 changed the hexose added in vivo from glucose to galactose or vice versa. By constructing chimeric lpsA gene sequences, it was shown that the 3' end of the gene directs the anomeric linkage (beta 1-2 or beta 1-3) of the added hexose. The lpsA gene is the first known example where interstrain variation in lipopolysaccharide core structure is directed by the specific sequence of a genetic locus encoding enzymes directing one of four alternative possible sugar additions from the inner core.	Univ Oxford, Dept Paediat, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Karolinska Inst, Clin Res Ctr, S-14186 Huddinge, Sweden; Univ Coll S Stockholm, Novum, S-14186 Huddinge, Sweden	University of Oxford; Karolinska Institutet; Karolinska Institutet; Sodertorn University	Deadman, ME (corresponding author), Univ Oxford, Dept Paediat, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	mary.deadman@paediatrics.ox.ac.uk		Lundstrom, Susanna/0000-0003-2363-4287; Deadman, Mary/0000-0002-6074-017X				ALEXANDER HE, 1951, P SOC EXP BIOL MED, V78, P625; ALEXANDER HE, 1965, BACTERIAL MYCOTIC IN, P724; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; ANDERSON P, 1972, J CLIN INVEST, V51, P31, DOI 10.1172/JCI106793; Bouchet V, 2003, P NATL ACAD SCI USA, V100, P8898, DOI 10.1073/pnas.1432026100; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cody AJ, 2003, INFECT GENET EVOL, V3, P57, DOI 10.1016/S1567-1348(02)00152-1; Coutinho PM, 1999, ROY SOC CH, P3; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fox KL, 2005, MOL MICROBIOL, V58, P207, DOI 10.1111/j.1365-2958.2005.04814.x; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Griffin R, 2003, MICROBIOL-SGM, V149, P3165, DOI 10.1099/mic.0.26387-0; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; Hood DW, 2004, MICROBIOL-SGM, V150, P2089, DOI 10.1099/mic.0.26912-0; Hood DW, 1999, MOL MICROBIOL, V33, P679, DOI 10.1046/j.1365-2958.1999.01509.x; Hood DW, 2004, J BACTERIOL, V186, P7429, DOI 10.1128/JB.186.21.7429-7439.2004; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; Kroll JS, 1998, P NATL ACAD SCI USA, V95, P12381, DOI 10.1073/pnas.95.21.12381; Kubo A, 2004, ARCH BIOCHEM BIOPHYS, V429, P198, DOI 10.1016/j.abb.2004.06.021; Lazarus BD, 2002, GLYCOBIOLOGY, V12, P793, DOI 10.1093/glycob/cwf092; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Lysenko E, 2000, MOL MICROBIOL, V35, P234, DOI 10.1046/j.1365-2958.2000.01707.x; Mansson M, 2003, EUR J BIOCHEM, V270, P2979, DOI 10.1046/j.1432-1033.2003.03675.x; Mansson M, 2001, EUR J BIOCHEM, V268, P2148, DOI 10.1046/j.1432-1327.2001.02094.x; Mansson M, 2002, EUR J BIOCHEM, V269, P808, DOI 10.1046/j.0014-2956.2001.02707.x; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Richards JC, 2001, ADV EXP MED BIOL, V491, P515; Risberg A, 1999, EUR J BIOCHEM, V261, P171, DOI 10.1046/j.1432-1327.1999.00248.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Schweda EKH, 2003, CARBOHYD RES, V338, P2731, DOI 10.1016/S0008-6215(03)00385-9; Schweda EKH, 2002, CARBOHYD RES, V337, P409, DOI 10.1016/S0008-6215(02)00002-2; SCHWEDA EKH, 1993, CARBOHYD RES, V246, P319, DOI 10.1016/0008-6215(93)84043-6; Schweda Elke K H, 2003, Methods Mol Med, V71, P161; Shibayama K, 1998, J BACTERIOL, V180, P5313, DOI 10.1128/JB.180.20.5313-5318.1998; Smith HO, 1999, RES MICROBIOL, V150, P603, DOI 10.1016/S0923-2508(99)00130-8; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; VANALPHEN L, 1983, J INFECT DIS, V148, P75, DOI 10.1093/infdis/148.1.75; Wakarchuk WW, 2001, J BIOL CHEM, V276, P12785, DOI 10.1074/jbc.M011293200; Weiser JN, 1997, INFECT IMMUN, V65, P943, DOI 10.1128/IAI.65.3.943-950.1997; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yildirim HH, 2005, CARBOHYD RES, V340, P2598, DOI 10.1016/j.carres.2005.09.005	45	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29455	29467		10.1074/jbc.M604908200	http://dx.doi.org/10.1074/jbc.M604908200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16847057	hybrid			2022-12-27	WOS:000240896300008
J	Edwards, JC; Cohen, C; Xu, WB; Schlesinger, PH				Edwards, John C.; Cohen, Christopher; Xu, Weibing; Schlesinger, Paul H.			c-Src control of chloride channel support for osteoclast HCl transport and bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; EXPRESS HIGH-LEVELS; IN-VITRO; MOLECULAR-CLONING; CELL BIOLOGY; CLIC FAMILY; ION-CHANNEL; KINASE; PROTEIN; P64	Bone degradation by osteoclasts depends upon active transport of hydrogen ions to solubilize bone mineral. This transport is supported by the parallel actions of a proton ATPase and a chloride channel located in the osteoclast ruffled membrane. We have previously identified a novel chloride channel, p62, which appears to be the avian counterpart to CLIC-5b and is expressed coincident with the appearance of acid secretion as avian osteoclasts differentiate in culture. In this article, we show that suppression of CLIC-5b in differentiating avian osteoclasts results in decreased acidification by vesicles derived from these cells and decreased ability of the cells to resorb bone. Acidification is rescued by the presence of valinomycin, consistent with a selective loss of chloride channel but not proton pump activity. Osteoclast bone resorption is known to be dependent on the expression of the tyrosine kinase, c-Src. We show that CLIC-5b from osteoclasts has affinity for both Src SH2 and SH3 domains. We find that suppression of expression of Src in developing osteoclasts results in decreased vesicular acidification, which is rescued by valinomycin, consistent with the loss of chloride conductance in the proton pump-containing vesicles. Suppression of c-Src causes no change in the steady state level of CLIC-5b expression, but does result in failure of proton pump and CLIC-5b to colocalize in cultured osteoclast precursors. We conclude that suppression of c-Src interferes with osteoclast bone resorption by disrupting functional co-localization of proton pump and CLIC-5b.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Kidney Ctr, Chapel Hill, NC 27599 USA; St Louis Univ, Sch Med, Dept Med, St Louis, MO 63104 USA	Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Saint Louis University	Schlesinger, PH (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	paul@cellbiology.wustl.edu	Schlesinger, Paul H/C-6049-2012		NIAMS NIH HHS [R01 AR046539, AR4653904] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046539] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; ARNETT TR, 1987, ENDOCRINOLOGY, V120, P602, DOI 10.1210/endo-120-2-602; Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BARRY ELR, 1993, BIOTECHNIQUES, V15, P1016; Bastani B, 1996, CALCIFIED TISSUE INT, V58, P332, DOI 10.1007/s002239900054; Berryman M, 2004, J BIOL CHEM, V279, P34794, DOI 10.1074/jbc.M402835200; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1990, BIOCHEM BIOPH RES CO, V171, P920, DOI 10.1016/0006-291X(90)90771-E; Blair HC, 2004, J BONE MINER RES, V19, P1329, DOI 10.1359/JBMR.040403; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; Blair HC, 1996, J CELL BIOCHEM, V61, P629, DOI 10.1002/(SICI)1097-4644(19960616)61:4<629::AID-JCB17>3.0.CO;2-A; Boyce BF, 1999, LAB INVEST, V79, P83; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.e04-12-1117; CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200; Cho GY, 2003, SCIENCE, V300, P1123, DOI 10.1126/science.1078470; Chuang JZ, 1999, J NEUROSCI, V19, P2919; Clerc S, 1998, ANAL BIOCHEM, V259, P104, DOI 10.1006/abio.1998.2639; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; DEMPSTER DW, 1987, J BONE MINER RES, V2, P443; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards JC, 2000, J BIOL CHEM, V275, P31826, DOI 10.1074/jbc.M005275200; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002-9440(10)63712-1; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Inoue M, 1999, CELL TISSUE RES, V298, P527; Jentsch TJ, 2005, ANNU REV PHYSIOL, V67, P779, DOI 10.1146/annurev.physiol.67.032003.153245; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KONG YY, 1999, NATURE, V345, P442; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LEE B, 1996, AM J PHYSIOL, pC382; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Li XH, 2002, ANNU REV PHYSIOL, V64, P609, DOI 10.1146/annurev.physiol.64.090501.145429; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nakamura I, 2003, J ELECTRON MICROSC, V52, P527, DOI 10.1093/jmicro/52.6.527; Neuman W.F., 1958, CHEM DYNAMICS BONE M; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; ORCHARD PJ, 2002, AM SOC BONE MINER RE, pSA390; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; PRALLET B, 1992, J BONE MINER RES, V7, P405; Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Sahni M, 1996, J BIOL CHEM, V271, P33141, DOI 10.1074/jbc.271.51.33141; Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04-06-0522; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; SCHLESINGER P, 1994, MINER ELECTOLYTE MET, P31; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Shanks RA, 2002, J BIOL CHEM, V277, P40973, DOI 10.1074/jbc.M112277200; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Vaananen HK, 2000, J CELL SCI, V113, P377; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Warton K, 2002, J BIOL CHEM, V277, P26003, DOI 10.1074/jbc.M203666200; XING L, 1996, J BONE MINER RES, V11, P40; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	92	44	45	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28011	28022		10.1074/jbc.M605865200	http://dx.doi.org/10.1074/jbc.M605865200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16831863	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000240534400038
J	Yang, MY; Horii, K; Herr, AB; Kirley, TL				Yang, Mingyan; Horii, Katsunori; Herr, Andrew B.; Kirley, Terence L.			Calcium-dependent dimerization of human soluble calcium activated nucleotidase - Characterization of the dimer interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BRAIN ECTO-APYRASE; E-TYPE ATPASES; ENDOPLASMIC-RETICULUM; MACROMOLECULAR STRUCTURES; BACTERIAL EXPRESSION; CLONING; RESIDUES; BINDING; ENZYME	Mammals express a protein homologous to soluble nucleotidases used by blood-sucking insects to inhibit host blood clotting. These vertebrate nucleotidases may play a role in protein glycosylation. The activity of this enzyme family is strictly dependent on calcium, which induces a conformational change in the secreted, soluble human nucleotidase. The crystal structure of this human enzyme was recently solved; however, the mechanism of calcium activation and the basis for the calcium-induced changes remain unclear. In this study, using analytical ultracentrifugation and chemical cross-linking, we show that calcium or strontium induce noncovalent dimerization of the soluble human enzyme. The location and nature of the dimer interface was elucidated using a combination of site-directed mutagenesis and chemical cross-linking, coupled with crystallographic analyses. Replacement of Ile(170), Ser(172), and Ser(226) with cysteine residues resulted in calcium-dependent, sulfhydryl-specific intermolecular cross- linking, which was not observed after cysteine introduction at other surface locations. Analysis of a super-active mutant, E130Y,revealed that this mutant dimerized more readily than the wild-type enzyme. The crystal structure of the E130Y mutant revealed that the mutated residue is found in the dimer interface. In addition, expression of the full-length nucleotidase revealed that this membrane-bound form can also dimerize and that these dimers are stabilized by spontaneous oxidative cross- linking of Cys(30), located between the single transmembrane helix and the start of the soluble sequence. Thus, calcium-mediated dimerization may also represent a mechanism for regulation of the activity of this nucleotidase in the physiological setting of the endoplasmic reticulum or Golgi.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Kirley, TL (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	terry.kirley@uc.edu	Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Kirley, Terence/0000-0002-6211-1414	NHLBI NIH HHS [HL72882] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burdakov D, 2005, CELL CALCIUM, V38, P303, DOI 10.1016/j.ceca.2005.06.010; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; Dai JY, 2004, CELL, V116, P649, DOI 10.1016/S0092-8674(04)00172-2; Ellgaard L, 2004, BIOCHEM SOC T, V32, P663, DOI 10.1042/BST0320663; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; Fiske CH, 1925, J BIOL CHEM, V66, P375; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Ivanenkov VV, 2003, BIOCHEMISTRY-US, V42, P11726, DOI 10.1021/bi035137r; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Mans BJ, 1998, EXP APPL ACAROL, V22, P353, DOI 10.1023/A:1024517209621; Murphy DM, 2003, BIOCHEMISTRY-US, V42, P2412, DOI 10.1021/bi026763b; Murphy DM, 2002, J BIOL CHEM, V277, P6162, DOI 10.1074/jbc.M110105200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Salerno WJ, 2004, NUCLEIC ACIDS RES, V32, pW566, DOI 10.1093/nar/gkh434; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Smith Thomas M, 2006, Purinergic Signal, V2, P327, DOI 10.1007/s11302-005-5300-7; Smith TM, 1999, BIOCHEMISTRY-US, V38, P5849, DOI 10.1021/bi990171k; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; Smith TM, 2002, ARCH BIOCHEM BIOPHYS, V406, P105, DOI 10.1016/S0003-9861(02)00420-4; STOSCHECK CM, 1990, ANAL BIOCHEM, V184, P111, DOI 10.1016/0003-2697(90)90021-Z; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; Van Baelen K, 2004, BBA-MOL CELL RES, V1742, P103, DOI 10.1016/j.bbamcr.2004.08.018; Yang MY, 2004, BIOCHEMISTRY-US, V43, P9185, DOI 10.1021/bi049565o	24	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28307	28317		10.1074/jbc.M604413200	http://dx.doi.org/10.1074/jbc.M604413200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16835225	hybrid			2022-12-27	WOS:000240534400068
J	Han, W; Nattel, S; Noguchi, T; Shrier, A				Han, Wei; Nattel, Stanley; Noguchi, Tomohiro; Shrier, Alvin			C-terminal domain of Kv4.2 and associated KChIP2 interactions regulate functional expression and gating of Kv4.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; TRANSIENT OUTWARD CURRENT; POTASSIUM CHANNELS; K+ CHANNEL; CRYSTAL-STRUCTURE; T1 DOMAIN; I-TO; SUBUNIT; FAMILY; CANINE	The Kv4.2 transient voltage-dependent potassium current contributes to the morphology of the cardiac action potential as well as to neuronal excitability and firing frequency. Here we report profound effects of the Kv4.2 C terminus on the surface expression and activation gating properties of Kv4.2 that are modulated by the direct interaction between KChIP2, an auxiliary regulatory subunit, and the C terminus of Kv4.2. We show that increasingly large truncations of the C terminus of rat Kv4.2 (wild type) cause a progressive decrease of Kv4.2 current along with a shift in voltage-dependent activation that is closely correlated with negative charge deletion. Co-expression of more limited Kv4.2 C-terminal truncation mutants (T588 and T528) with KChIP2 results in a doubling of Kv4.2 protein expression and up to an 8-fold increase in Kv4.2 current amplitude. Pulse-chase experiments show that co-expression with KChIP2 slows Kv4.2 wild type degradation 8-fold. Co-expression of KChIP2 with an intermediate-length C-terminal truncation mutant (T474) shifts Kv4.2 activation voltage dependence and enhances expression of Kv4.2 current. The largest truncation mutants (T417 and Delta C) show an intracellular localization with no measurable currents and no response to KChIP2 co-expression. Co-immunoprecipitation and competitive glutathione S-transferase-binding assays indicate a direct interaction between KChIP2 and the Kv4.2 C terminus with a relative binding affinity comparable with that of the N terminus. Overall, these results suggest that the C-terminal domain of Kv4.2 plays a critical role in voltage-dependent activation and functional expression that is mediated by direct interaction between the Kv4.2 C terminus and KChIP2.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Montreal Heart Inst, Dept Med, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Montreal, PQ H1T 1C8, Canada	McGill University; McGill University; Universite de Montreal; Universite de Montreal	Shrier, A (corresponding author), McGill Univ, Dept Physiol, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	alvin.shrier@mcgill.ca	Noguchi, Tomohiro/B-6185-2011	Nattel, Stanley/0000-0002-5565-3311; Noguchi, Tomohiro/0000-0002-9354-9793				Akhavan A, 2003, J BIOL CHEM, V278, P40105, DOI 10.1074/jbc.M307837200; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Callsen B, 2005, J PHYSIOL-LONDON, V568, P397, DOI 10.1113/jphysiol.2005.094359; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Han W, 2002, CIRC RES, V91, P790, DOI 10.1161/01.RES.0000039534.18114.D9; Hatano N, 2004, J BIOL CHEM, V279, P5450, DOI 10.1074/jbc.M302034200; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Johnston D, 2000, J PHYSIOL-LONDON, V525, P75, DOI 10.1111/j.1469-7793.2000.00075.x; Kim LA, 2004, NEURON, V41, P513, DOI 10.1016/S0896-6273(04)00050-9; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kunjilwar K, 2004, J BIOL CHEM, V279, P54542, DOI 10.1074/jbc.M409721200; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Marten I, 1997, P NATL ACAD SCI USA, V94, P3448, DOI 10.1073/pnas.94.7.3448; Neyroud N, 2002, J MEMBRANE BIOL, V190, P133, DOI 10.1007/s00232-002-1033-5; Ohya S, 2001, LIFE SCI, V68, P1703, DOI 10.1016/S0024-3205(01)00958-4; Patel SP, 2002, J PHYSIOL-LONDON, V539, P649, DOI 10.1113/jphysiol.2001.015156; Petrecca K, 2000, J NEUROSCI, V20, P8736; Rivera JF, 2003, NAT NEUROSCI, V6, P243, DOI 10.1038/nn1020; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Scannevin RH, 2004, NEURON, V41, P587, DOI 10.1016/S0896-6273(04)00049-2; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Sokolova O, 2003, P NATL ACAD SCI USA, V100, P12607, DOI 10.1073/pnas.2235650100; Strang C, 2001, J BIOL CHEM, V276, P28493, DOI 10.1074/jbc.M010540200; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; Yi BA, 2001, P NATL ACAD SCI USA, V98, P11016, DOI 10.1073/pnas.191351798; Zicha S, 2004, J PHYSIOL-LONDON, V561, P735, DOI 10.1113/jphysiol.2004.075861	38	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27134	27144		10.1074/jbc.M604843200	http://dx.doi.org/10.1074/jbc.M604843200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16820361	hybrid			2022-12-27	WOS:000240397700041
J	Lee, H; Zeng, SYX; Lu, H				Lee, Hunjoo; Zeng, Shelya X.; Lu, Hua			UV induces p21 rapid turnover independently of ubiquitin and Skp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DEGRADATION; PROTEASOMAL TURNOVER; CYCLIN KINASES; DNA-DAMAGE; CELL-CYCLE; P53; MDM2; P21(WAF1/CIP1); EXPRESSION; INHIBITOR	It was previously reported that low doses, but not high doses, of UV trigger the Skp2-mediated proteasomal degradation of the cyclin-dependent kinase inhibitor p21 in mammalian cells. Here we show that both UV-C and UV-B lead to decrease of p21 protein, but not mRNA, level in a dose-dependent fashion in all of six human cell lines and five mouse cell lines tested. Also, high doses of UV reduce the half-life of p21. High doses, but not low doses, of UV induced p21 degradation in both skp2-proficient and -deficient murine embryonic fibroblast cells. UV-induced p21 reduction was rescued by proteasome inhibitors in all human and mouse cell lines tested. Neither a caspase inhibitor nor small interfering RNA against skp2 had an effect on the UV-induced p21 decrease, suggesting that this p21 degradation pathway may not involve caspases, or Skp2. Finally, UV did not induce p21 ubiquitination but still induced its degradation when the E1-activating enzyme was inactivated in an E1 temperature-sensitive mouse embryonic fibroblast cell line. Altogether, these results demonstrate that UV induces p21 degradation through an Skp2- and ubiquitin-independent pathway.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Lu, H (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	luh@ohsu.edu			NCI NIH HHS [CA079721, CA095441, CA93614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095441, R01CA093614, R01CA079721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; HARPER JW, 1993, CELL, V75, P805; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; LANDAIS I, 2006, CELL DEATH DIFFER, P1; LI Y, 1994, ONCOGENE, V9, P2261; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Nakanishi Y, 2000, AM J RESP CELL MOL, V22, P747, DOI 10.1165/ajrcmb.22.6.3877; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Schwartz GK, 2002, CELL CYCLE, V1, P122, DOI 10.4161/cc.1.2.112; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zeng XY, 2000, CANCER RES, V60, P6184; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26876	26883		10.1074/jbc.M605366200	http://dx.doi.org/10.1074/jbc.M605366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16803887	hybrid			2022-12-27	WOS:000240397700014
J	Matsui, T; Kinoshita-Ida, Y; Hayashi-Kisumi, F; Hata, M; Matsubara, K; Chiba, M; Katahira-Tayama, S; Morita, K; Miyachi, Y; Tsukita, S				Matsui, Takeshi; Kinoshita-Ida, Yoko; Hayashi-Kisumi, Fumie; Hata, Masaki; Matsubara, Kaho; Chiba, Megumi; Katahira-Tayama, Sayaka; Morita, Kazumasa; Miyachi, Yoshiki; Tsukita, Shoichiro			Mouse homologue of skin-specific retroviral-like aspartic protease involved in wrinkle formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; STRATUM-CORNEUM; DIFFERENTIATION; KERATINOCYTE; PROTEINASES; INHIBITORS; IDENTIFICATION; DESQUAMATION; CHECKPOINT; EPIDERMIS	Retroviral proteases are encoded in the retroviral genome and are responsible for maturation and assembly of infectious virus particles. A number of retroviral protease sequences with retroviral elements are integrated in every eukaryoticgenomeas endogenous retroviruses. Recently, retroviral-like aspartic proteases that were not embedded within endogenous retroviral elements were identified throughout the eukaryotic and prokaryotic genomes. However, the physiological role of this novel protease family, especially in mammals, is not known. During the high throughput in situ hybridization screening of mouse epidermis, as a granular layer-expressing clone, we identified a mouse homologue of SASPase (SkinASparticProtease), a recently identified retroviral-like aspartic protease. We detected and purified the endogenous 32-kDa (mSASP32) and 15-kDa (mSASP15) forms of mSASP from mouse stratum corneum extracts and determined their amino acid sequences. Next, we bacterially produced recombinant mSASP15 via autoprocessing of GST-mSASP32. Purified recombinant mSASP15 cleaved a quenched fluorogenic peptide substrate, designed from the autoprocessing site for mSASP32 maximally at pH 5.77, which is close to the pH of the epidermal surface. Finally, we generated mSASP-deficient mice that at 5 weeks of age showed fine wrinkles that ran parallel on the lateral trunk without apparent epidermal differentiation defects. These results indicate that the retroviral-like aspartic protease, SASPase, is involved in prevention of fine wrinkle formation via activation in a weakly acidic stratum corneum environment. This study provides the first evidence that retroviral-like aspartic protease is functionally important in mammalian tissue organization.	KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan; Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan	KAN Research Institute; Kyoto University; Kyoto University	Matsui, T (corresponding author), KAN Res Inst Inc, Shimogyo Ku, Sci Ctr Bldg 3,Kyoto Res Pk 93, Kyoto 6008815, Japan.	t-matui@kan.gr.jp	Matsui, Takeshi/C-4730-2017					ANDERSON DS, 1951, BRIT J DERMATOL, V63, P283, DOI 10.1111/j.1365-2133.1951.tb13728.x; Barret AJ, 1998, HDB PROTEOLYTIC ENZY; Bernard D, 2005, J INVEST DERMATOL, V125, P278, DOI 10.1111/j.0022-202X.2005.23816.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Christner PJ, 2006, J INVEST DERMATOL, V126, P595, DOI 10.1038/sj.jid.5700100; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; DARKE PL, 1994, METHOD ENZYMOL, V241, P104; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gardner RD, 2000, TRENDS CELL BIOL, V10, P154, DOI 10.1016/S0962-8924(00)01727-X; Greiner EF, 2000, P NATL ACAD SCI USA, V97, P7160, DOI 10.1073/pnas.97.13.7160; Hashizume H, 2004, J DERMATOL, V31, P603, DOI 10.1111/j.1346-8138.2004.tb00565.x; HELEN CUT, 1994, METHOD ENZYMOL, V241, P46; IMAYAMA S, 1989, AM J PATHOL, V134, P1019; KLIGMAN AM, 1985, BRIT J DERMATOL, V113, P37, DOI 10.1111/j.1365-2133.1985.tb02042.x; Komiya T, 1997, ANAL BIOCHEM, V254, P23, DOI 10.1006/abio.1997.2399; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; Krylov DM, 2001, CURR BIOL, V11, pR584, DOI 10.1016/S0960-9822(01)00357-8; LORINCZ ALLAN L., 1960, ILLINOIS MED JOUR, V117, P59; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; Matsui T, 2004, GENOMICS, V84, P384, DOI 10.1016/j.ygeno.2004.03.010; Milstone LM, 2004, J DERMATOL SCI, V36, P131, DOI 10.1016/j.jdermsci.2004.05.004; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; OHMAN H, 1994, ACTA DERM-VENEREOL, V74, P375; Pierard GE, 2000, INT J MOL MED, V6, P217; Puente XS, 2004, GENOME RES, V14, P609, DOI 10.1101/gr.1946304; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; RAO JKM, 1991, BIOCHEMISTRY-US, V30, P4663, DOI 10.1021/bi00233a005; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rawlings A. V., 2003, International Journal of Cosmetic Science, V25, P63, DOI 10.1046/j.1467-2494.2003.00174.x; SCHADE H., 1928, KLIN WOCHENSCHR, V7, P12, DOI 10.1007/BF01711684; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TSUJI T, 1987, J CUTAN PATHOL, V14, P158, DOI 10.1111/j.1600-0560.1987.tb00491.x; TSUJI T, 1986, BRIT J DERMATOL, V114, P329, DOI 10.1111/j.1365-2133.1986.tb02824.x; Tsukahara K, 2001, J INVEST DERMATOL, V117, P671, DOI 10.1046/j.0022-202x.2001.01450.x; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; Weber J, 1997, ARCH BIOCHEM BIOPHYS, V341, P62, DOI 10.1006/abbi.1997.9945; WEISS R, 1985, RNA TUMORS VIRUSES; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388	45	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27512	27525		10.1074/jbc.M603559200	http://dx.doi.org/10.1074/jbc.M603559200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16837463	hybrid			2022-12-27	WOS:000240397700078
J	Gaidhu, MP; Fediuc, S; Ceddia, RB				Gaidhu, Mandeep Pinky; Fediuc, Sergiu; Ceddia, Rolando Bacis			5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside-induced AMP-activated protein kinase phosphorylation inhibits basal and insulin-stimulated glucose uptake, lipid synthesis, and fatty acid oxidation in isolated rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; SKELETAL-MUSCLE CELLS; MALONYL-COA; 3T3-L1 ADIPOCYTES; WHITE ADIPOCYTES; LEPTIN; AICAR; METABOLISM; TRANSPORT; ADIPOSITY	The objective of this study was to investigate the effects of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)-induced AMP-activated protein kinase (AMPK) activation on basal and insulin-stimulated glucose and fatty acid metabolism in isolated rat adipocytes. AICAR-induced AMPK activation profoundly inhibited basal and insulin-stimulated glucose uptake, lipogenesis, glucose oxidation, and lactate production in fat cells. We also describe the novel findings that AICAR-induced AMPK phosphorylation significantly reduced palmitate (32%) and oleate uptake (41%), which was followed by a 50% reduction in palmitate oxidation despite a marked increase in AMPK and acetyl-CoA carboxylase phosphorylation. Compound C, a selective inhibitor of AMPK, not only completely prevented the inhibitory effect of AICAR on palmitate oxidation but actually caused a 2.2-fold increase in this variable. Compound C also significantly increased palmitate oxidation in the presence of inhibitory concentrations of malonyl-CoA and etomoxir indicating an increase in CPT1 activity. In contrast to skeletal muscle in which AMPK stimulates fatty acid oxidation to provide ATP as a fuel, we propose that AMPK activation inhibits lipogenesis and fatty acid oxidation in adipocytes. Inhibition of lipogenesis would conserve ATP under conditions of cellular stress, although suppression of intra-adipocyte oxidation would spare fatty acids for exportation to other tissues where their utilization is crucial for energy production. Additionally, the stimulatory effect of compound C on long chain fatty acid oxidation provides a novel pharmacological approach to promote energy dissipation in adipocytes, which may be of therapeutic importance for obesity and type II diabetes.	York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada	York University - Canada	Ceddia, RB (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.	roceddia@yorku.ca						ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331; Campbell SE, 2004, J BIOL CHEM, V279, P36235, DOI 10.1074/jbc.M400566200; Ceddia RB, 2000, EUR J BIOCHEM, V267, P5952, DOI 10.1046/j.1432-1327.2000.01664.x; Ceddia RB, 2005, INT J OBESITY, V29, P1175, DOI 10.1038/sj.ijo.0803025; Ceddia RB, 2004, J PHYSIOL-LONDON, V555, P409, DOI 10.1113/jphysiol.2003.056291; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Daval M, 2005, J BIOL CHEM, V280, P25250, DOI 10.1074/jbc.M414222200; Fediuc S, 2006, J LIPID RES, V47, P412, DOI 10.1194/jlr.M500438-JLR200; Frayn KN, 2003, INT J OBESITY, V27, P875, DOI 10.1038/sj.ijo.0802326; Geelen MJH, 2005, ANAL BIOCHEM, V347, P1, DOI 10.1016/j.ab.2005.03.032; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Luiken JJFP, 2004, PFLUG ARCH EUR J PHY, V448, P1, DOI 10.1007/s00424-003-1199-4; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MOELLERING H, 1966, ANAL BIOCHEM, V17, P369, DOI 10.1016/0003-2697(66)90172-2; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Munday MR, 2002, BIOCHEM SOC T, V30, P1059, DOI 10.1042/bst0301059; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Pold R, 2005, DIABETES, V54, P928, DOI 10.2337/diabetes.54.4.928; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; SELBY PL, 1989, TRENDS PHARMACOL SCI, V10, P495, DOI 10.1016/0165-6147(89)90049-7; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Villena JA, 2004, DIABETES, V53, P2242, DOI 10.2337/diabetes.53.9.2242; William WN, 2002, J ENDOCRINOL, V175, P735, DOI 10.1677/joe.0.1750735; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Yu X, 2004, DIABETOLOGIA, V47, P2012, DOI 10.1007/s00125-004-1570-9; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	35	96	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25956	25964		10.1074/jbc.M602992200	http://dx.doi.org/10.1074/jbc.M602992200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16816404	hybrid			2022-12-27	WOS:000240249500010
J	Meyer-Lipp, K; Sery, N; Ganea, C; Basquin, C; Fendler, K; Leblanc, G				Meyer-Lipp, Kerstin; Sery, Natacha; Ganea, Constanta; Basquin, Cecile; Fendler, Klaus; Leblanc, Gerard			The inner interhelix loop 4-5 of the melibiose permease from Escherichia coli takes part in conformational changes after sugar binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL OXALATE TRANSPORTER; TRANSFORM-INFRARED-SPECTROSCOPY; MEMBRANE-SPANNING SEGMENTS; RESONANCE ENERGY-TRANSFER; PROJECTION STRUCTURE; UNIDIRECTIONAL RECONSTITUTION; 3-DIMENSIONAL STRUCTURE; CHARGE TRANSLOCATION; ANGSTROM RESOLUTION; LACTOSE PERMEASE	Cytoplasmic loop 4-5 of the melibiose permease from Escherichia coli is essential for the process of Na+-sugar translocation (Abdel-Dayem, M., Basquin, C., Pourcher, T., Cordat, E., and Leblanc, G. (2003) J. Biol. Chem. 278, 1518-1524). In the present report, we analyze functional consequences of mutating each of the three acidic amino acids in this loop into cysteines. Among the mutants, only the E142C substitution impairs selectively Na+-sugar translocation. Because R141C has a similar defect, we investigated these two mutants in more detail. Liposomes containing purified mutated melibiose permease were adsorbed onto a solid supported lipid membrane, and transient electrical currents resulting from different substrate concentration jumps were recorded. The currents evoked by a melibiose concentration jump in the presence of Na+, previously assigned to an electrogenic conformational transition (Meyer-Lipp, K., Ganea, C., Pourcher, T., Leblanc, G., and Fendler, K. (2004) Biochemistry 43, 12606-12613), were much smaller for the two mutants than the corresponding signals in cysteineless MelB. Furthermore, in R141C the stimulating effect of melibiose on Na+ affinity was lost. Finally, whereas tryptophan fluorescence spectroscopy revealed impaired conformational changes upon melibiose binding in the mutants, fluorescence resonance energy transfer measurements indicated that the mutants still show cooperative modification of their sugar binding sites by Na+. These data suggest that: 1) loop 4-5 contributes to the coordinated interactions between the ion and sugar binding sites; 2) it participates in an electrogenic conformational transition after melibiose binding that is essential for the subsequent obligatory coupled translocation of substrates. A two-step mechanism for substrate translocation in the melibiose permease is suggested.	Max Planck Inst Biophys, D-60438 Frankfurt, Germany; Univ Nice Sophia Antipolis, CEA, LRC 16V, F-06230 Villefranche Sur Mer, France; Carol Davila Med Univ, Dept Biophys, Bucharest 050474, Romania; Univ Nice Sophia Antipolis, CEA, Fac Med, Unite TIRO, F-06107 Nice, France	Max Planck Society; CEA; UDICE-French Research Universities; Universite Cote d'Azur; Carol Davila University of Medicine & Pharmacy; CEA; UDICE-French Research Universities; Universite Cote d'Azur	Fendler, K (corresponding author), Max Planck Inst Biophys, Max Von Laue Str 3, D-60438 Frankfurt, Germany.	klaus.fendler@mpibp-frankfurt.mpg.de	Ganea, Constanta/A-8561-2011	Ganea, Constanta/0000-0003-3489-6901; Fendler, Klaus/0000-0002-5699-7060				Abramson J, 2003, FEBS LETT, V555, P96, DOI 10.1016/S0014-5793(03)01087-1; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Ambroise Y, 2000, BIOCHEMISTRY-US, V39, P1338, DOI 10.1021/bi9916224; BASSILANA M, 1985, BIOCHEM BIOPH RES CO, V129, P626, DOI 10.1016/0006-291X(85)91937-0; BASSILANA M, 1988, J BIOL CHEM, V263, P9663; BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; Cordat E, 1998, J BIOL CHEM, V273, P33198, DOI 10.1074/jbc.273.50.33198; Cordat E, 2000, BIOCHEMISTRY-US, V39, P4493, DOI 10.1021/bi991852i; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; Dave N, 2002, J BIOL CHEM, V277, P3380, DOI 10.1074/jbc.M105466200; Dave N, 2000, BIOPHYS J, V79, P747, DOI 10.1016/S0006-3495(00)76332-6; Dayem MA, 2003, J BIOL CHEM, V278, P1518, DOI 10.1074/jbc.M210053200; Ding PZ, 2004, BBA-BIOMEMBRANES, V1660, P106, DOI 10.1016/j.bbamem.2003.11.005; Ding PZ, 2000, J MEMBRANE BIOL, V174, P135, DOI 10.1007/s002320001038; Ding PZ, 2000, BIOCHEM BIOPH RES CO, V268, P409, DOI 10.1006/bbrc.2000.2149; Ding PZ, 2000, BBA-BIOMEMBRANES, V1509, P123, DOI 10.1016/S0005-2736(00)00286-8; Fang G, 1999, MOL MEMBR BIOL, V16, P297, DOI 10.1080/096876899294517; Ganea C, 2001, BIOCHEMISTRY-US, V40, P13744, DOI 10.1021/bi011223k; Gwizdek C, 1997, BIOCHEMISTRY-US, V36, P8522, DOI 10.1021/bi970312n; Hacksell I, 2002, EMBO J, V21, P3569, DOI 10.1093/emboj/cdf378; HAMA H, 1994, J BIOL CHEM, V269, P1063; Heymann JAW, 2003, J STRUCT BIOL, V144, P320, DOI 10.1016/j.jsb.2003.09.002; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; Hirai T, 2004, BIOPHYS J, V87, P3600, DOI 10.1529/biophysj.104.049320; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Leon X, 2005, BIOCHEMISTRY-US, V44, P3506, DOI 10.1021/bi048301z; Loo DDF, 2005, J GEN PHYSIOL, V125, P13, DOI 10.1085/jgp.200409150; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; Maehrel C, 1998, J BIOL CHEM, V273, P33192, DOI 10.1074/jbc.273.50.33192; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; MUSVETEAU I, 1995, BIOCHEMISTRY-US, V34, P6775, DOI 10.1021/bi00020a024; MusVeteau I, 1996, BIOCHEMISTRY-US, V35, P12053, DOI 10.1021/bi961372g; Pintschovius J, 1999, BIOPHYS J, V76, P827, DOI 10.1016/S0006-3495(99)77246-2; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1993, J BIOL CHEM, V268, P3209; POURCHER T, 1995, BIOCHEMISTRY-US, V34, P4412, DOI 10.1021/bi00013a033; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; Purhonen P, 2005, J STRUCT BIOL, V152, P76, DOI 10.1016/j.jsb.2005.07.003; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; Weissborn AC, 1997, BBA-BIOMEMBRANES, V1329, P237, DOI 10.1016/S0005-2736(97)00116-8; ZANI ML, 1993, J BIOL CHEM, V268, P3216; ZANI ML, 1994, J BIOL CHEM, V269, P24883	53	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25882	25892		10.1074/jbc.M601259200	http://dx.doi.org/10.1074/jbc.M601259200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822867	hybrid			2022-12-27	WOS:000240249500003
J	Policha, A; Daneshtalab, N; Chen, L; Dale, LB; Altier, C; Khosravani, H; Thomas, WG; Zamponi, GW; Ferguson, SSG				Policha, Aleksandra; Daneshtalab, Noriko; Chen, Lina; Dale, Lianne B.; Altier, Christophe; Khosravani, Houman; Thomas, Walter G.; Zamponi, Gerald W.; Ferguson, Stephen S. G.			Role of angiotensin II type 1A receptor phosphorylation, phospholipase D, and extracellular calcium in isoform-specific protein kinase C membrane translocation responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; CA2+; OSCILLATIONS; CHANNEL; TRAFFICKING; ACTIVATION	The angiotensin II type 1A receptor (AT(1A)R) plays an important role in cardiovascular function and as such represents a primary target for therapeutic intervention. The AT(1A)R is coupled via G(q) to the activation of phospholipase C, the hydrolysis of phosphoinositides, release of calcium from intracellular stores, and the activation of protein kinase C (PKC). We show here that PKC beta I and PKC beta II exhibit different membrane translocation patterns in response to AT(1A)R agonist activation. Whereas PKC beta II translocation to the membrane is transient, PKC beta I displays additional translocation responses: persistent membrane localization and oscillations between the membrane and cytosol following agonist removal. The initial translocation of PKC beta I requires the release of calcium from intracellular stores and the activation of phospholipase C, but persistent membrane localization is dependent upon extracellular calcium influx. The mutation of any of the three PKC phosphorylation consensus sites (Ser-331, Ser-338, and Ser-348) localized within the AT(1A)R C-tail significantly increases the probability that persistent increases in diacylglycerol levels and PKC beta I translocation responses will be observed. The persistent increase in AT(1A)R-mediated diacylglycerol formation is mediated by the activation of phospholipase D. Although the persistent PKC beta I membrane translocation response is absolutely dependent upon the PKC activity-dependent recruitment of an extracellular calcium current, it does not require the activation of phospholipase D. Taken together, we show that the patterning of AT(1A)R second messenger response patterns is regulated by heterologous desensitization and PKC isoform substrate specificity.	Univ Western Ontario, Cell Biol Res Grp, Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5K8, Canada; Univ Calgary, Dept Physiol, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; Baker Heart Res Inst, Melbourne, Vic 8008, Australia	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Calgary; Baker Heart and Diabetes Institute	Ferguson, SSG (corresponding author), Univ Western Ontario, Cell Biol Res Grp, Robarts Res Inst, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	ferguson@robarts.ca	Khosravani, Houman/X-2391-2019; Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952; Zamponi, Gerald W./0000-0002-0644-9066				Babwah AV, 2003, J BIOL CHEM, V278, P5419, DOI 10.1074/jbc.M211053200; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Cummings R, 2002, MOL CELL BIOCHEM, V234, P99, DOI 10.1023/A:1015944828973; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson Stephen S. G., 2003, V237, P121; Gaborik Z, 2004, TRENDS ENDOCRIN MET, V15, P286, DOI 10.1016/j.tem.2004.06.009; Huang P, 2005, MOL BIOL CELL, V16, P2614, DOI 10.1091/mbc.E04-12-1124; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; McNaughton NCL, 1997, NEUROPHARMACOLOGY, V36, P895, DOI 10.1016/S0028-3908(97)00085-3; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Qian HW, 1999, BIOCHEM J, V343, P637, DOI 10.1042/0264-6021:3430637; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; Thomas WG, 2003, TRENDS ENDOCRIN MET, V14, P130, DOI 10.1016/S1043-2760(03)00023-7; Touyz RM, 2000, PHARMACOL REV, V52, P639; Toyz RM, 2002, BRAZ J MED BIOL RES, V35, P1001, DOI 10.1590/S0100-879X2002000900001; Uchino M, 2004, J BIOL CHEM, V279, P2254, DOI 10.1074/jbc.M309894200	28	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26340	26349		10.1074/jbc.M605437200	http://dx.doi.org/10.1074/jbc.M605437200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831865	hybrid			2022-12-27	WOS:000240249500051
J	Choi, JY; Stover, JS; Angel, KC; Chowdhury, G; Rizzo, CJ; Guengerich, FP				Choi, Jeong-Yun; Stover, James S.; Angel, Karen C.; Chowdhury, Goutam; Rizzo, Carmelo J.; Guengerich, F. Peter			Biochemical basis of genotoxicity of heterocyclic arylamine food mutagens - Human DNA polymerase eta selectively produces a two-base deletion in copying the N-2-guanyl adduct of 2-amino-3-methylimidazo[4,5-f] quinoline but not the C-8 adduct at the NarI G3 site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATION HOT-SPOT; ERROR-PRONE BYPASS; TRANSLESION SYNTHESIS; ESCHERICHIA-COLI; FRAMESHIFT MUTAGENESIS; SEQUENCE CONTEXT; ACETYLAMINOFLUORENE ADDUCT; CRYSTAL-STRUCTURES; MAMMALIAN-CELLS; KAPPA	Heterocyclic arylamines are highly mutagenic and cause tumors in animal models. The mutagenicity is attributed to the C-8- and N-2-G adducts, the latter of which accumulates due to slower repair. The C-8- and N-2-G adducts derived from 2-amino-3- methylimidazo[4,5-f] quinoline (IQ) were placed at the G(1) and G(3) sites of the NarI sequence, in which the G3 site is an established hot spot for frameshift mutation with the model arylamine derivative 2-acetylaminofluorene but G1 is not. Human DNA polymerase (pol) eta extended primers beyond template G-IQ adducts better than did pol kappa and much better than pol iota or delta. In 1-base incorporation studies, pol eta inserted C and A, pol iota inserted T, and pol kappa inserted G. Steady-state kinetic parameters were measured for these dNTPs opposite the C-8- and N-2-IQ adducts at both sites, being most favorable for pol eta. Mass spectrometry of pol eta extension products revealed a single major product in each of four cases; with the G(1) and G(3) C-8- IQ adducts, incorporation was largely error-free. With the G(3) N-2-IQ adduct, a - 2 deletion occurred at the site of the adduct. With the G(3) N-2-IQ adduct, the product was error-free at the site opposite the base and then stalled. Thus, the pol eta products yielded frame-shifts with the N-2 but not the C-8 IQ adducts. We show a role for pol eta and the complexity of different chemical adducts of IQ, DNA position, and DNA polymerases.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Nashville, TN 37232 USA; Ewha Womans Univ, Dept Pharmacol, Seoul 158710, South Korea	Vanderbilt University; Vanderbilt University; Vanderbilt University; Ewha Womans University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [P30 ES000267, R01 ES010375, T32 ES007028] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028, P30ES000267, R01ES010375] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamson R.H., 2000, FOOD BORNE CARCINOGE, P229; BELAND FA, 1985, ENVIRON HEALTH PERSP, V62, P19, DOI 10.2307/3430089; Bol SAM, 2000, CARCINOGENESIS, V21, P1, DOI 10.1093/carcin/21.1.1; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; Burnouf DY, 1999, CHEM RES TOXICOL, V12, P144, DOI 10.1021/tx9801920; Cho BP, 1999, BIOCHEMISTRY-US, V38, P7572, DOI 10.1021/bi990182d; Choi JY, 2006, J BIOL CHEM, V281, P21062, DOI 10.1074/jbc.M602246200; Choi JY, 2006, J BIOL CHEM, V281, P12315, DOI 10.1074/jbc.M600112200; Choi JY, 2005, J MOL BIOL, V352, P72, DOI 10.1016/j.jmb.2005.06.079; Dutta S, 2004, P NATL ACAD SCI USA, V101, P16186, DOI 10.1073/pnas.0406516101; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Elmquist CE, 2004, J AM CHEM SOC, V126, P11189, DOI 10.1021/ja0487022; FELTON JS, 1990, PROG CLIN BIOL RES, V347, P19; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; Gill JP, 2005, BIOCHEMISTRY-US, V44, P15387, DOI 10.1021/bi051437s; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Guengerich FP, 2006, CHEM REV, V106, P420, DOI 10.1021/cr0404693; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Hsu GW, 2004, J BIOL CHEM, V279, P50280, DOI 10.1074/jbc.M409224200; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010; KOEHL P, 1989, J MOL BIOL, V207, P355, DOI 10.1016/0022-2836(89)90259-3; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Leong-Morgenthaler PM, 1998, CARCINOGENESIS, V19, P1749, DOI 10.1093/carcin/19.10.1749; MaenhautMichel G, 1997, MOL GEN GENET, V253, P634, DOI 10.1007/s004380050366; Mao B, 1997, BIOCHEMISTRY-US, V36, P14491, DOI 10.1021/bi972206r; MILLER EC, 1966, SCIENCE, V153, P1125, DOI 10.1126/science.153.3740.1125; NAGAO M, 1977, CANCER LETT, V2, P221, DOI 10.1016/S0304-3835(77)80025-6; NAPOLITANO RL, 1994, BIOCHEMISTRY-US, V33, P1311, DOI 10.1021/bi00172a004; Ni JS, 1996, ANAL CHEM, V68, P1989, DOI 10.1021/ac960270t; NOVAK M, 1995, J AM CHEM SOC, V117, P574, DOI 10.1021/ja00106a083; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Ramos KS, 2005, DRUG METAB REV, V37, P595, DOI 10.1080/03602530500251253; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Rehn L, 1895, ARCH KLIN CHIR, V50, P588; Shibutani S, 1999, J BIOL CHEM, V274, P27433, DOI 10.1074/jbc.274.39.27433; Stover JS, 2004, ORG LETT, V6, P4985, DOI 10.1021/ol047851m; Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Tan XZ, 2002, BIOCHEMISTRY-US, V41, P14255, DOI 10.1021/bi0202878; TEBBS RS, 1994, BIOCHEMISTRY-US, V33, P8998, DOI 10.1021/bi00196a018; Tretyakova N, 2001, CHEM RES TOXICOL, V14, P1058, DOI 10.1021/tx010062i; Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053; Turesky RJ, 2002, DRUG METAB REV, V34, P625, DOI 10.1081/DMR-120005665; Turesky RJ, 1997, MUTAT RES-FUND MOL M, V376, P235, DOI 10.1016/S0027-5107(97)00048-1; Valadez JG, 2004, J BIOL CHEM, V279, P13435, DOI 10.1074/jbc.M312358200; Wang ZW, 2001, ORG LETT, V3, P565, DOI 10.1021/ol006968h; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200; Zhang YB, 2002, MUTAT RES-FUND MOL M, V510, P23, DOI 10.1016/S0027-5107(02)00249-X; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1	56	34	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25297	25306		10.1074/jbc.M605699200	http://dx.doi.org/10.1074/jbc.M605699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16835218	hybrid			2022-12-27	WOS:000240031300031
J	Fosset, C; Chauveau, MJ; Guillon, B; Canal, F; Drapier, JC; Bouton, C				Fosset, Cedric; Chauveau, Marie-Jeanne; Guillon, Blanche; Canal, Frederic; Drapier, Jean-Claude; Bouton, Cecile			RNA silencing of mitochondrial m-Nfs1 reduces Fe-S enzyme activity both in mitochondria and cytosol of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; REGULATORY PROTEIN-1; CYSTEINE DESULFURASE; ESCHERICHIA-COLI; FRIEDREICH ATAXIA; SCAFFOLD PROTEIN; DOWN-REGULATION; BINDING; NFS1P; NIFS	In prokaryotes and yeast, the general mechanism of biogenesis of iron-sulfur (Fe-S) clusters involves activities of several proteins among which IscS and Nfs1p provide, through cysteine desulfuration, elemental sulfide for Fe-S core formation. Although these proteins have been well characterized, the role of their mammalian homolog in Fe-S cluster biogenesis has never been evaluated. We report here the first functional study that implicates the putative cysteine desulfurase m-Nfs1 in the biogenesis of both mitochondrial and cytosolic mammalian Fe-S proteins. Depletion of m-Nfs1 in cultured fibroblasts through small interfering RNA-based gene silencing significantly inhibited the activities of mitochondrial NADH-ubiquinone oxidoreductase (complex I) and succinate-ubiquinone oxidoreductase (complex II) of the respiratory chain, as well as aconitase of the Krebs cycle, with no alteration in their protein levels. Activity of cytosolic xanthine oxidase, which holds a [2Fe2S] cluster, was also specifically reduced, and iron-regulatory protein-1 was converted from its [4Fe-4S] aconitase form to its apo- or RNA-binding form. Reduction of Fe-S enzyme activities occurred earlier and more markedly in the cytosol than in mitochondria, suggesting that there is a mechanism that primarily dedicates m-Nfs1 to the biogenesis of mitochondrial Fe-S clusters in order to maintain cell survival. Finally, depletion of m-Nfs1, which conferred on apo-IRP-1 a high affinity for ferritin mRNA, was associated with the down-regulation of the iron storage protein ferritin.	CNRS, Inst Chim Subst Nat, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bouton, C (corresponding author), CNRS, Inst Chim Subst Nat, Ave Terrasse, F-91190 Gif Sur Yvette, France.	cecile.bouton@icsn.cnrs-gif.fr	Bouton, Cecile/J-8663-2013					Anderson PR, 2005, HUM MOL GENET, V14, P3397, DOI 10.1093/hmg/ddi367; Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Bekri S, 2000, BLOOD, V96, P3256; Bouton C, 1999, CELL MOL LIFE SCI, V55, P1043, DOI 10.1007/s000180050355; Bouton C, 2002, J BIOL CHEM, V277, P31220, DOI 10.1074/jbc.M203276200; BOUTON C, 2003, SCI STKE, pPE17; Chen OS, 2004, J BIOL CHEM, V279, P29513, DOI 10.1074/jbc.M403209200; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Demple B, 1996, GENE, V179, P53, DOI 10.1016/S0378-1119(96)00329-0; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fillebeen C, 2002, REDOX REP, V7, P15, DOI 10.1179/135100002125000136; Fillebeen C, 2003, MOL CELL BIOL, V23, P6973, DOI 10.1128/MCB.23.19.6973-6981.2003; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li KY, 2006, J BIOL CHEM, V281, P12344, DOI 10.1074/jbc.M600582200; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Muhlenhoff U, 2004, J BIOL CHEM, V279, P36906, DOI 10.1074/jbc.M406516200; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; Nakai Y, 2004, J BIOL CHEM, V279, P12363, DOI 10.1074/jbc.M312448200; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Oliveira L, 2000, P NATL ACAD SCI USA, V97, P6550, DOI 10.1073/pnas.120571797; PANTOPOULOS K, 1995, RNA, V1, P155; Pondarre C, 2006, HUM MOL GENET, V15, P953, DOI 10.1093/hmg/ddl012; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Schueck ND, 2001, MITOCHONDRION, V1, P51, DOI 10.1016/S1567-7249(01)00004-6; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; SIEGEL L, 1962, BIOCHIM BIOPHYS ACTA, V64, P101, DOI 10.1016/0006-3002(62)90763-1; Starzynski RR, 2005, J BIOL CHEM, V280, P4207, DOI 10.1074/jbc.M411055200; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Unden G, 1997, MOL MICROBIOL, V25, P205, DOI 10.1046/j.1365-2958.1997.4731841.x; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weil A, 2002, BIOTECHNIQUES, V33, P1244, DOI 10.2144/02336st01; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	50	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25398	25406		10.1074/jbc.M602979200	http://dx.doi.org/10.1074/jbc.M602979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16787928	hybrid			2022-12-27	WOS:000240031300042
J	Held, DM; Kissel, JD; Saran, D; Michalowski, D; Burke, DH				Held, Daniel M.; Kissel, Jay D.; Saran, Dayal; Michalowski, Daniel; Burke, Donald H.			Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STRAND DISPLACEMENT SYNTHESIS; NONNUCLEOSIDE INHIBITORS; DNA-SYNTHESIS; STEADY-STATE; IN-VITRO; NUCLEOTIDE INCORPORATION; AVIAN-MYELOBLASTOSIS; PSEUDOKNOT INHIBITOR; MOLECULAR-MECHANISM	Nucleic acid aptamers to HIV-1 reverse transcriptase (RT) are potent inhibitors of DNA polymerase function in vitro, and they have been shown to inhibit viral replication when expressed in cultured T-lymphoid lines. We monitored RT inhibition by five RNA pseudoknot RNA aptamers in a series of biochemical assays designed to mimic discrete steps of viral reverse transcription. Our results demonstrate potent aptamer inhibition (IC50 values in the low nanomolar range) of all RT functions assayed, including RNA- and DNA-primed DNA polymerization, strand displacement synthesis, and polymerase-independent RNase H activity. Additionally, we observe differences in the time dependence of aptamer inhibition. Polymerase-independent RNase H activity is the most resistant to long term aptamer suppression, and RNA- dependent DNA polymerization is the most susceptible. Finally, when DNA polymerization was monitored in the presence of an RNA aptamer in combination with each of four different small molecule inhibitors, significant synergy was observed between the aptamer and the two nucleoside analog RT inhibitors (azidothymidine triphosphate or ddCTP), whereas two non-nucleoside analog RT inhibitors showed either weak synergy (efavirenz) or antagonism (nevirapine). Together, these results support a model wherein aptamers suppress viral replication by cumulative inhibition of RT at every stage of genome replication.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Burke, DH (corresponding author), 471h Life Sci Ctr, 1201 E Rollins Rd, Columbia, MO 65211 USA.	burkedh@missouri.edu			NIAID NIH HHS [AI62513] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599; Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; Avidan O, 1998, NUCLEIC ACIDS RES, V26, P1713, DOI 10.1093/nar/26.7.1713; Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BAVAND MR, 1993, BIOCHEMISTRY-US, V32, P10543, DOI 10.1021/bi00091a003; BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1; Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667; Chaloin L, 2002, NUCLEIC ACIDS RES, V30, P4001, DOI 10.1093/nar/gkf522; CHEN H, 1994, BIOCHEMISTRY-US, V33, P8746, DOI 10.1021/bi00195a016; Chen H, 1996, BIOCHEMISTRY-US, V35, P6923, DOI 10.1021/bi9600106; CHONG KT, 1994, ANTIMICROB AGENTS CH, V38, P288, DOI 10.1128/AAC.38.2.288; Cruchaga C, 2005, BIOCHEMISTRY-US, V44, P3535, DOI 10.1021/bi048129z; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Fisher TS, 2002, J VIROL, V76, P4068, DOI 10.1128/JVI.76.8.4068-4072.2002; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; Gerondelis P, 1999, J VIROL, V73, P5803, DOI 10.1128/JVI.73.7.5803-5813.1999; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; Hannoush RN, 2004, CHEMBIOCHEM, V5, P527, DOI 10.1002/cbic.200300831; Held DM, 2006, FRONT BIOSCI-LANDMRK, V11, P89, DOI 10.2741/1782; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jaeger J, 1998, EMBO J, V17, P4535, DOI 10.1093/emboj/17.15.4535; Joshi P, 2002, J VIROL, V76, P6545, DOI 10.1128/JVI.76.13.6545-6557.2002; Joshi P. J., 2003, Current Drug Targets - Infectious Disorders, V3, P383, DOI 10.2174/1568005033481060; Joshi PJ, 2005, MOL THER, V11, P677, DOI 10.1016/j.ymthe.2005.01.013; KATI WM, 1992, J BIOL CHEM, V267, P25988; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Maga G, 2001, J BIOL CHEM, V276, P44653, DOI 10.1074/jbc.M106702200; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037; Schneider MF, 2005, AIDS, V19, P2009, DOI 10.1097/01.aids.0000189864.90053.22; Somasunderam A, 2005, BIOCHEMISTRY-US, V44, P10388, DOI 10.1021/bi0507074; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Temiz NA, 2002, PROTEINS, V49, P61, DOI 10.1002/prot.10183; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; Witvrouw M, 1998, ANTIMICROB AGENTS CH, V42, P618, DOI 10.1128/AAC.42.3.618; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; Yazdanpanah Y, 2004, BMJ-BRIT MED J, V328, P249, DOI 10.1136/bmj.37995.435787.A6	49	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25712	25722		10.1074/jbc.M604460200	http://dx.doi.org/10.1074/jbc.M604460200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16798747	hybrid			2022-12-27	WOS:000240031300074
J	Mayanil, CSK; Pool, A; Nakazaki, H; Reddy, AC; Mania-Farnell, B; Yun, B; George, D; McLone, DG; Bremer, EG				Mayanil, Chandra S. K.; Pool, Angela; Nakazaki, Hiromichi; Reddy, Anvesh C.; Mania-Farnell, Barbara; Yun, Beth; George, David; McLone, David G.; Bremer, Eric G.			Regulation of murine TGF beta 2 by Pax3 during early embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL-TUBE; P53; EXPRESSION; ACTIVATION; PROMOTER; DEFECTS; MICE; IDENTIFICATION; MIGRATION; MUTATION	Previously our laboratory identified TGF beta 2 as a potential downstream target of Pax3 by utilizing microarray analysis and promoter data base mining (Mayanil, C.S.K., George, D., Freilich, L., Miljan, E. J., Mania-Farnell, B. J., McLone, D. G., and Bremer, E. G. (2001) J. Biol. Chem. 276, 49299-49309). Here we report that Pax3 directly regulates TGF beta 2 transcription by binding to cis-regulatory elements within its promoter. Chromatin immunoprecipitation revealed that Pax3 bound to the cis-regulatory elements on the TGF beta 2 promoter (GenBank (TM) accession number AF118263). Both TGF beta 2 promoter-luciferase activity measurements in transient cotransfection experiments and electromobility shift assays supported the idea that Pax3 regulates TGF beta 2 by directly binding to its cis-regulatory regions. Additionally, by using a combination of co-immunoprecipitation and chromatin immunoprecipitation, we show that the TGF beta 2 cis-regulatory elements between bp 741-940 and bp 1012-1212 bind acetylated Pax3 and are associated with p300/CBP and histone deacetylases. The cis-regulatory elements between bp 741 and 940 in addition to associating with acetylated Pax3 and HDAC1 also associated with SIRT1. Whole mount in situ hybridization and quantitative real time reverse transcription-PCR showed diminished levels of TGF beta 2 transcripts in Pax3(-/-) mouse embryos (whose phenotype is characterized by neural tube defects) as compared with Pax3(+/+) littermates (embryonic day 10.0; 30 somite stage), suggesting that Pax3 regulation of TGF beta 2 may play a pivotal role during early embryonic development.	Northwestern Univ, Neurobiol Program, Childrens Mem Res Ctr, Lab Neural Tube Res,Dept Pediat Neurosurg, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60614 USA; Purdue Univ Calumet, Dept Biol, Hammond, IN 46323 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60616 USA	Northwestern University; Northwestern University; Feinberg School of Medicine; Purdue University System; Purdue University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Mayanil, CSK (corresponding author), Northwestern Univ, Neurobiol Program, Childrens Mem Res Ctr, Lab Neural Tube Res,Dept Pediat Neurosurg, M-c 226,2430 N Halsted, Chicago, IL 60614 USA.	smayanil@northwestern.edu						Basch Martin L, 2004, Birth Defects Res C Embryo Today, V72, P109, DOI 10.1002/bdrc.20015; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Colas JF, 2001, DEV DYNAM, V221, P117, DOI 10.1002/dvdy.1144; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Corry GN, 2005, PIGM CELL RES, V18, P427, DOI 10.1111/j.1600-0749.2005.00275.x; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Epstein JA, 2000, DEVELOPMENT, V127, P1869; EPSTEIN JA, 1996, J BIOL CHEM, V93, P4213; Erickson CA, 1998, CURR TOP DEV BIOL, V40, P177, DOI 10.1016/S0070-2153(08)60367-1; Gammill LS, 2003, NAT REV NEUROSCI, V4, P795, DOI 10.1038/nrn1219; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Itokawa M, 2003, NEUROSCI LETT, V345, P53, DOI 10.1016/S0304-3940(03)00501-9; Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292; Lang D, 2003, HUM MOL GENET, V12, P937, DOI 10.1093/hmg/ddg107; Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; LEBLANC GG, 1995, J NEUROBIOL, V26, P497, DOI 10.1002/neu.480260404; Levine M, 2005, P NATL ACAD SCI USA, V102, P4936, DOI 10.1073/pnas.0408031102; LOU J, 2001, CELL, V107, P137; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Meulemans D, 2004, DEV CELL, V7, P291, DOI 10.1016/j.devcel.2004.08.007; Monsoro-Burq AH, 2005, DEV CELL, V8, P167, DOI 10.1016/j.devcel.2004.12.017; Mori-Akiyama Y, 2003, P NATL ACAD SCI USA, V100, P9360, DOI 10.1073/pnas.1631288100; Pani L, 2002, GENE DEV, V16, P676, DOI 10.1101/gad.969302; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sato T, 2005, DEVELOPMENT, V132, P2355, DOI 10.1242/dev.01823; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Serbedzija GN, 1997, DEV BIOL, V185, P139, DOI 10.1006/dbio.1997.8551; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wight TN, 2002, CURR OPIN CELL BIOL, V14, P617, DOI 10.1016/S0955-0674(02)00375-7; Wilder PJ, 2001, GENE, V270, P201, DOI 10.1016/S0378-1119(01)00475-9; Wilkinson D.G., 1992, SITU HYBRIDIZATION P, P1; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	45	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24544	24552		10.1074/jbc.M512449200	http://dx.doi.org/10.1074/jbc.M512449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787918	hybrid			2022-12-27	WOS:000239847800050
J	Rondard, P; Liu, JF; Huang, SL; Malhaire, F; Vol, C; Pinault, A; Labesse, G; Pin, JP				Rondard, Philippe; Liu, Jianfeng; Huang, Siluo; Malhaire, Fanny; Vol, Claire; Pinault, Alexia; Labesse, Gilles; Pin, Jean-Philippe			Coupling of agonist binding to effector domain activation in metabotropic glutamate-like receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; GABA(B) RECEPTOR; ALLOSTERIC MODULATOR; HEPTAHELICAL DOMAIN; LIGAND-BINDING; DIMERIZATION; CHANNEL; GLUTAMATE-RECEPTOR-1-ALPHA; IDENTIFICATION; EXPRESSION	Many membrane receptors are made of a ligand binding domain and an effector domain mediating intracellular signaling. This is the case for the metabotropic glutamate-like G-protein-coupled receptors. How ligand binding leads to the active conformation of the effector domain in such receptors is largely unknown. Here, we used an evolutionary trace analysis and mutagenesis to identify critical residues involved in the allosteric coupling between the Venus flytrap ligand binding domain (VFT) and the heptahelical G-protein activating domain of the metabotropic glutamate-like receptors. We have shown that a conserved interdomain disulfide bridge is required for this allosteric interaction. Taking into account that these receptors are homodimers, this finding provides important new information explaining how the different conformations of the dimer of VFT lead to different signaling of such dimeric receptors.	Univ Montpellier 1, CNRS, UMR 5203, INSERM,U661, F-34094 Montpellier, France; Univ Montpellier 2, F-34094 Montpellier, France; Inst Geom Fonct, Dept Mol Pharmacol, F-34094 Montpellier, France; Huazhong Univ Sci & Technol, Inst Biochem & Biophys, Wuhan 430074, Hubei, Peoples R China; Univ Montpellier 1, INSERM, CNRS, U414,UMR 5048,Plate Forme RIO Biol Struct,Ctr Bio, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Huazhong University of Science & Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Rondard, P (corresponding author), Univ Montpellier 1, CNRS, UMR 5203, INSERM,U661, F-34094 Montpellier, France.	prondard@igf.cnrs.fr	Rondard, Philippe/N-9720-2018	Pin, Jean-Philippe/0000-0002-1423-345X; RONDARD, Philippe/0000-0003-1134-2738; Labesse, Gilles/0000-0002-6861-3300; MALHAIRE, Fanny/0000-0001-5930-9879				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Goudet C., 2004, DRUG DISCOV TODAY TH, V1, P125, DOI DOI 10.1016/J.DDSTR.2004.08.017; Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Johnson MP, 2005, PSYCHOPHARMACOLOGY, V179, P271, DOI 10.1007/s00213-004-2099-9; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2004, NAT STRUCT MOL BIOL, V11, P706, DOI 10.1038/nsmb794; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lee WY, 2005, NATURE, V438, P243, DOI 10.1038/nature04156; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Maurel D, 2004, ANAL BIOCHEM, V329, P253, DOI 10.1016/j.ab.2004.02.013; O'Brien JA, 2004, J PHARMACOL EXP THER, V309, P568, DOI 10.1124/jpet.103.061747; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Ray K, 2000, J BIOL CHEM, V275, P34245, DOI 10.1074/jbc.M005581200; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schaffhauser H, 2003, MOL PHARMACOL, V64, P798, DOI 10.1124/mol.64.4.798; Tateyama M, 2006, P NATL ACAD SCI USA, V103, P1124, DOI 10.1073/pnas.0505925103; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Yu L, 2004, TRENDS BIOCHEM SCI, V29, P458, DOI 10.1016/j.tibs.2004.07.009; Zhang PS, 1999, MOL BRAIN RES, V72, P195, DOI 10.1016/S0169-328X(99)00241-7	33	65	82	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24653	24661		10.1074/jbc.M602277200	http://dx.doi.org/10.1074/jbc.M602277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787923	hybrid			2022-12-27	WOS:000239847800060
J	Sikorski, EM; Uo, T; Morrison, RS; Agarwal, A				Sikorski, Eric M.; Uo, Takuma; Morrison, Richard S.; Agarwal, Anupam			Pescadillo interacts with the cadmium response element of the human heme oxygenase-1 promoter in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MEDIATED INDUCTION; RIBOSOME BIOGENESIS; ENDOTHELIAL-CELLS; NUCLEAR-PROTEIN; GENE; RAT; EXPRESSION; METALLOTHIONEIN; PROLIFERATION	Renal tubular cells elicit adaptive responses following exposure to nephrotoxins, such as cadmium. One response is the up-regulation of the 32-kDa redox-sensitive protein, heme oxygenase-1. Exposure of renal proximal tubular epithelial cells to 10 mu M cadmium demonstrated induction (similar to 20-fold) of heme oxygenase-1 mRNA and protein. Using a 4.5-kb human heme oxygenase-1 promoter construct, the importance of a previously identified cadmium response element (TGCTAGAT) in HeLa cells was verified in renal epithelial cells. Specific protein-DNA interaction with this sequence was demonstrated using nuclear extracts from cadmium-treated cells. Yeast one-hybrid screen of a human kidney cDNA library resulted in the identification of pescadillo, a unique nucleolar, developmental protein, as an interacting protein with the cadmium response element and was confirmed by chromatin immunoprecipitation in vivo and gel shift assays with purified glutathione S-transferase-pescadillo protein in vitro. The specificity of the DNA- protein interaction was verified by the absence of a binding complex when the core sequence of the cadmium response element was mutated or deleted. In addition, B23/nucleophosmin, another nucleolar protein, did not interact with the cadmium response sequence. Overexpression of pescadillo resulted in increased activity of the 4.5-kb human heme oxygenase-1 promoter construct but failed to activate this construct when the cadmium response sequence was mutated. The findings demonstrate the important and previously unrecognized role of pescadillo as a DNA-binding protein interacting specifically with the cadmium response element of the human heme oxygenase-1 gene.	Univ Alabama Birmingham, Div Nephrol, Nephrol Res & Training Ctr, Birmingham, AL 35294 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle	Agarwal, A (corresponding author), Univ Alabama Birmingham, Div Nephrol, Nephrol Res & Training Ctr, 703 S 19th St,Zeigler Res Bldg,Rm 614, Birmingham, AL 35294 USA.	agarwal@uab.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035533, R01NS042123] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL068157] Funding Source: Medline; NIDDK NIH HHS [DK59600] Funding Source: Medline; NINDS NIH HHS [NS35533, NS42123] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; Agarwal A, 2000, J AM SOC NEPHROL, V11, P965, DOI 10.1681/ASN.V115965; Agarwal A, 1998, J AM SOC NEPHROL, V9, P1990; Alam J, 2000, J BIOL CHEM, V275, P27694; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELINDER CG, 1992, IARC SCI PUBL, V118, P123; Funakoshi T, 1997, TOXICOLOGY, V116, P99, DOI 10.1016/S0300-483X(96)03533-0; Gong Q, 1997, TOXICOLOGY, V119, P179, DOI 10.1016/S0300-483X(96)03608-6; Haque J, 2000, GENOMICS, V70, P201, DOI 10.1006/geno.2000.6375; Hassoun EA, 1996, TOXICOLOGY, V112, P219, DOI 10.1016/0300-483X(96)03404-X; Hayashi S, 2003, PROTEIN EXPRES PURIF, V29, P1, DOI 10.1016/S1046-5928(03)00023-8; Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI 10.1007/s00418-005-0046-4; Hill-Kapturczak N, 2003, ARTERIOSCL THROM VAS, V23, P1416, DOI 10.1161/01.ATV.0000081656.76378.A7; Hill-Kapturczak N, 2003, AM J PHYSIOL-RENAL, V285, pF515, DOI 10.1152/ajprenal.00137.2003; Hock TD, 2004, BIOCHEM J, V383, P209, DOI 10.1042/BJ20040794; IMBERT J, 1989, MOL CELL BIOL, V9, P5315, DOI 10.1128/MCB.9.12.5315; Ishikawa T, 1999, BIOCHEM BIOPH RES CO, V254, P566, DOI 10.1006/bbrc.1998.9979; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Koizumi T, 1996, TOXICOLOGY, V114, P125, DOI 10.1016/S0300-483X(96)03477-4; Kumar R, 2004, MOL BIOCHEM PARASIT, V133, P297, DOI 10.1016/j.molbiopara.2003.11.005; KUTTY RK, 1994, GENOMICS, V20, P513, DOI 10.1006/geno.1994.1213; Lapik YR, 2004, MOL CELL, V15, P17, DOI 10.1016/j.molcel.2004.05.020; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Maiorana A, 2004, ONCOGENE, V23, P7116, DOI 10.1038/sj.onc.1207916; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; NORBERG GF, 1972, ARCH ENVIRON HEALTH, V24, P209, DOI 10.1080/00039896.1972.10666071; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sikorski EM, 2004, AM J PHYSIOL-RENAL, V286, pF425, DOI 10.1152/ajprenal.00297.2003; Stein GS, 2000, J CELL SCI, V113, P2527; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TEMPLETON DM, 1990, J BIOL CHEM, V265, P21764; Waisberg M, 2003, TOXICOLOGY, V192, P95, DOI 10.1016/S0300-483X(03)00305-6; Xie JX, 2006, TOXICOL SCI, V91, P299, DOI 10.1093/toxsci/kfj131; Zhang H, 2005, SCI CHINA SER C, V48, P270, DOI 10.1360/062004-86	41	32	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24423	24430		10.1074/jbc.M602287200	http://dx.doi.org/10.1074/jbc.M602287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16816389	hybrid			2022-12-27	WOS:000239847800036
J	Jesch, SA; Liu, P; Zhao, X; Wells, MT; Henry, SA				Jesch, Stephen A.; Liu, Peng; Zhao, Xin; Wells, Martin T.; Henry, Susan A.			Multiple endoplasmic reticulum-to-nucleus signaling pathways coordinate phospholipid metabolism with gene expression by distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							UNFOLDED-PROTEIN RESPONSE; ENCODING PEROXISOMAL PROTEINS; FATTY-ACID DESATURASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; TRANSCRIPTION FACTOR; MICROARRAY EXPERIMENTS; TRANSMEMBRANE PROTEIN; LIPID BIOSYNTHESIS; HYPOXIC INDUCTION	In many organisms the coordinated synthesis of membrane lipids is controlled by feedback systems that regulate the transcription of target genes. However, a complete description of the transcriptional changes that accompany the remodeling of membrane phospholipids has not been reported. To identify metabolic signaling networks that coordinate phospholipid metabolism with gene expression, we profiled the sequential and temporal changes in genome-wide expression that accompany alterations in phospholipid metabolism induced by inositol supplementation in yeast. This analysis identified six distinct expression responses, which included phospholipid biosynthetic genes regulated by Opi1p, endoplasmic reticulum (ER) luminal protein folding chaperone and oxidoreductase genes regulated by the unfolded protein response pathway, lipid-remodeling genes regulated by Mga2p, as well as genes involved in ribosome biogenesis, cytosolic stress response, and purine and amino acid metabolism. We also report that the unfolded protein response pathway is rapidly inactivated by inositol supplementation and demonstrate that the response of the unfolded protein response pathway to inositol is separable from the response mediated by Opi1p. These data indicate that altering phospholipid metabolism produces signals that are relayed through numerous distinct ER-to-nucleus signaling pathways and, thereby, produce an integrated transcriptional response. We propose that these signals are generated in the ER by increased flux through the pathway of phosphatidylinositol synthesis.	Cornell Univ, Coll Agr & Life Sci, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Henry, SA (corresponding author), Cornell Univ, Coll Agr & Life Sci, 260 Roberts Hall, Ithaca, NY 14853 USA.	sah42@cornell.edu	Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; Almaguer C, 2004, J BIOL CHEM, V279, P31937, DOI 10.1074/jbc.M403648200; Almaguer C, 2003, EUKARYOT CELL, V2, P729, DOI 10.1128/EC.2.4.729-736.2003; Alvarez-Vasquez F, 2005, NATURE, V433, P425, DOI 10.1038/nature03232; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Bedalov A, 2003, MOL CELL BIOL, V23, P7044, DOI 10.1128/MCB.23.19.7044-7054.2003; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; Boumann HA, 2006, FEMS MICROBIOL LETT, V258, P297, DOI 10.1111/j.1574-6968.2006.00233.x; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Brachmann CB, 1998, YEAST, V14, P115; Brickner JH, 2004, PLOS BIOL, V2, P1843, DOI 10.1371/journal.pbio.0020342; Burnett WV, 1997, BIOTECHNIQUES, V22, P668, DOI 10.2144/97224st01; Carman GM, 2005, BIOCHEM SOC T, V33, P1150, DOI 10.1042/BST0331150; Chang HJ, 2004, GENETICS, V168, P1899, DOI 10.1534/genetics.104.032961; Chang HJ, 2002, GENETICS, V162, P29; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Chellappa R, 2001, J BIOL CHEM, V276, P43548, DOI 10.1074/jbc.M107845200; CONZELMANN A, 2005, CELL BIOL DYNAMICS Y, P133; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Credle JJ, 2005, P NATL ACAD SCI USA, V102, P18773, DOI 10.1073/pnas.0509487102; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Dudoit S, 2002, STAT SINICA, V12, P111; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gardenour KR, 2004, MOL MICROBIOL, V52, P1271, DOI 10.1111/j.1365-2958.2004.04069.x; GASPAR ML, 2006, J BIOL CHEM; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Han SH, 2005, J BIOL CHEM, V280, P29017, DOI 10.1074/jbc.M505881200; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Heyken WT, 2005, MOL MICROBIOL, V56, P696, DOI 10.1111/j.1365-2958.2004.04499.x; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Horsted MW, 1998, YEAST, V14, P793, DOI 10.1002/(SICI)1097-0061(19980630)14:9<793::AID-YEA277>3.3.CO;2-5; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; Iwanyshyn WM, 2004, J BIOL CHEM, V279, P21976, DOI 10.1074/jbc.M402047200; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; JESCH SA, 2005, CELL BIOL DYNAMICS Y, P105; Jiang YD, 2002, EUKARYOT CELL, V1, P481, DOI 10.1128/EC.1.3.481-490.2002; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kandasamy P, 2004, J BIOL CHEM, V279, P36586, DOI 10.1074/jbc.M401557200; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kersting MC, 2006, J BIOL CHEM, V281, P13110, DOI 10.1074/jbc.M601612200; Kimata Y, 2004, J CELL BIOL, V167, P445, DOI 10.1083/jcb.200405153; Kimata Y, 2003, MOL BIOL CELL, V14, P2559, DOI 10.1091/mbc.E02-11-0708; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; Lyons TJ, 2004, P NATL ACAD SCI USA, V101, P5506, DOI 10.1073/pnas.0306324101; Martin CE, 2002, BIOCHEM SOC T, V30, P1080, DOI 10.1042/bst0301080; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; MORI K, 1993, CELL, V74, P743; Natter K, 2005, MOL CELL PROTEOMICS, V4, P662, DOI 10.1074/mcp.M400123-MCP200; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; Ogawa N, 2004, GENES CELLS, V9, P95, DOI 10.1111/j.1365-2443.2004.00704.x; Papa FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031; Patil CK, 2004, PLOS BIOL, V2, P1208, DOI 10.1371/journal.pbio.0020246; Resnick AC, 2005, P NATL ACAD SCI USA, V102, P12783, DOI 10.1073/pnas.0506184102; Ron D, 2004, J CELL BIOL, V167, P23, DOI 10.1083/jcb.200408117; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shcherbik N, 2004, J BIOL CHEM, V279, P53892, DOI 10.1074/jbc.M410325200; Shcherbik N, 2003, CURR BIOL, V13, P1227, DOI 10.1016/S0960-9822(03)00457-3; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SPASSIEVA S, 2005, CELL BIOL DYNAMICS Y, P201; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P269, DOI 10.1080/10409230500315352; Van der Sanden MHM, 2003, BIOCHEM J, V369, P643, DOI 10.1042/BJ20020285; van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567; Vasconcelles MJ, 2001, J BIOL CHEM, V276, P14374, DOI 10.1074/jbc.M009546200; Vemula M, 2003, J BIOL CHEM, V278, P45269, DOI 10.1074/jbc.M308812200; Verstrepen KJ, 2004, YEAST, V21, P367, DOI 10.1002/yea.1100; Wang XJ, 2003, BIOINFORMATICS, V19, P1341, DOI 10.1093/bioinformatics/btg154; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200; Zhang SR, 1999, GENETICS, V151, P473; Zhang SR, 1997, MOL CELL BIOL, V17, P4718, DOI 10.1128/MCB.17.8.4718; Zhao X, 2004, STAT SINICA, V14, P789	106	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					24070	24083		10.1074/jbc.M604541200	http://dx.doi.org/10.1074/jbc.M604541200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777852	hybrid			2022-12-27	WOS:000239702900080
J	Magnusdottir, A; Stenmark, P; Flodin, S; Nyman, T; Hammarstrom, M; Ehn, M; Bakali-H, MA; Berglund, H; Nordlund, P				Magnusdottir, Audur; Stenmark, Pal; Flodin, Susanne; Nyman, Tomas; Hammarstrom, Martin; Ehn, Maria; Bakali H, M. Amin; Berglund, Helena; Nordlund, Par			The crystal structure of a human PP2A phosphatase activator reveals a novel fold and highly conserved cleft implicated in protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PHOSPHATASES; SACCHAROMYCES-CEREVISIAE; 2A PHOSPHATASES; CELL-GROWTH; IDENTIFICATION; TRANSFORMATION; REFINEMENT; COMPLEXES; MECHANISM; CANCER	Protein phosphatase 2A (PP2A) is a heterotrimeric Ser/Thr phosphatase that is involved in regulating a plethora of signaling pathways in the cell, making its regulation a critical part of the well being of the cell. For example, three of the non-catalytic PP2A subunits have been linked to carcinogenic events. Therefore, the molecular basis for the complicated protein-protein interaction pattern of PP2A and its regulators is of special interest. The PP2A phosphatase activator (PTPA) protein is highly conserved from humans to yeast. It is an activator of PP2A and has been shown to be essential for a fully functional PP2A, but its mechanism of activation is still not well defined. We have solved the crystal structure of human PTPA to 1.6 angstrom. It reveals a two-domain protein with a novel fold comprised of 13 alpha-helices. We have identified a highly conserved cleft as a potential region for interaction with peptide segments of other proteins. Binding studies with ATP and its analogs are not consistent with ATP being a cofactor/substrate for PTPA as had previously been proposed. The structure of PTPA can serve as a basis for structure-function studies directed at elucidating its mechanism as an activator of PP2A.	Karolinska Inst, Dept Med Biochem & Biophys, Struct Genom Consortium, S-17177 Stockholm, Sweden; Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Nordlund, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Struct Genom Consortium, S-17177 Stockholm, Sweden.	par.nordlund@mbb.ki.se		Stenmark, Pal/0000-0003-4777-3417	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fanghanel J, 2004, FRONT BIOSCI-LANDMRK, V9, P3453, DOI 10.2741/1494; Fellner T, 2003, GENE DEV, V17, P2138, DOI 10.1101/gad.259903; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2000, EUR J BIOCHEM, V267, P4406, DOI 10.1046/j.1432-1327.2000.01486.x; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jordens J, 2006, J BIOL CHEM, V281, P6349, DOI 10.1074/jbc.M507760200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Laskowski RA, 2005, J MOL BIOL, V351, P614, DOI 10.1016/j.jmb.2005.05.067; Longin S, 2004, BIOCHEM J, V380, P111, DOI 10.1042/BJ20031643; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rempola B, 2000, MOL GEN GENET, V262, P1081, DOI 10.1007/PL00008651; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Van Hoof C, 2005, BIOCHEM J, V386, P93, DOI 10.1042/BJ20040887; Van Hoof C, 2000, J MOL BIOL, V302, P103, DOI 10.1006/jmbi.2000.4062; VANHOOF C, 1994, EUR J BIOCHEM, V226, P899; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Zheng Y, 2005, MOL BIOL CELL, V16, P2119, DOI 10.1091/mbc.e04-09-0797	35	13	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22434	22438		10.1074/jbc.C600100200	http://dx.doi.org/10.1074/jbc.C600100200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16782712	Green Published, hybrid			2022-12-27	WOS:000239542600003
J	Evans, EJ; Castro, MAA; O'Brien, R; Kearney, A; Walsh, H; Sparks, LM; Tucknott, MG; Davies, EA; Carmo, AM; van der Merwe, PA; Stuart, DI; Jones, EY; Ladbury, JE; Ikemizu, S; Davis, SJ				Evans, Edward J.; Castro, Monica A. A.; O'Brien, Ronan; Kearney, Alice; Walsh, Heather; Sparks, Lisa M.; Tucknott, Michael G.; Davies, Elizabeth A.; Carmo, Alexandre M.; van der Merwe, P. Anton; Stuart, David I.; Jones, E. Yvonne; Ladbury, John E.; Ikemizu, Shinji; Davis, Simon J.			Crystal structure and binding properties of the CD2 and CD244 (2B4)-binding protein, CD48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE CD2; LINKED LYMPHOPROLIFERATIVE-DISEASE; CELL ANTIGEN RECOGNITION; VERY-LOW AFFINITY; T-CELLS; NATURAL-KILLER; PEPTIDE-MHC; IMMUNE-RESPONSES; SLAM FAMILY; SUBTLE ROLE	The structural analysis of surface proteins belonging to the CD2 subset of the immunoglobulin superfamily has yielded important insights into transient cellular interactions. In mice and rats, CD2 and CD244 (2B4), which are expressed predominantly on T cells and natural killer cells, respectively, bind the same, broadly expressed ligand, CD48. Structures of CD2 and CD244 have been solved previously, and we now present the structure of the receptor-binding domain of rat CD48. The receptor-binding surface of CD48 is unusually flat, as in the case of rat CD2, and shares a high degree of electrostatic complementarity with the equivalent surface of CD2. The relatively simple arrangement of charged residues and this flat topology explain why CD48 cross-reacts with CD2 and CD244 and, in rats, with the CD244-related protein, 2B4R. Comparisons of modeled complexes of CD2 and CD48 with the complex of human CD2 and CD58 are suggestive of there being substantial plasticity in the topology of ligand binding by CD2. Thermodynamic analysis of the native CD48-CD2 interaction indicates that binding is driven by equivalent, weak enthalpic and entropic effects, in contrast to the human CD2-CD58 interaction, for which there is a large entropic barrier. Overall, the structural and biophysical comparisons of the CD2 homologues suggest that the evolutionary diversification of interacting cell surface proteins is rapid and constrained only by the requirement that binding remains weak and specific.	Univ Oxford, Nuffield Dept Clin Med, Oxford OX3 9DS, England; John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England; Univ Porto, Grp Cell Activat & Gene Express, IBMC, P-4099003 Oporto, Portugal; Univ Porto, ICBAS, P-4099003 Oporto, Portugal; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Kumamoto Univ, Grad Sch Pharmaceut Sci, Div Struct Biol, Kumamoto 8620973, Japan	University of Oxford; University of Oxford; Universidade do Porto; Universidade do Porto; University of London; University College London; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; Kumamoto University	Ikemizu, S (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Oxford OX3 9DS, England.	ikemizu@gpo.kumamoto-u.ac.jp; simon.davis@ndm.ox.ac.uk	Lima, Marta T/C-7042-2009; van der Merwe, P. Anton/F-8539-2011; Jones, Yvonne/J-2293-2016; Carmo, Alexandre/B-5191-2011; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Carmo, Alexandre/0000-0002-2508-9799; Jones, Yvonne/0000-0002-3834-1893; Ladbury, John/0000-0002-6328-7200; Stuart, David/0000-0002-3426-4210	MRC [G9722488, G0500365, G9900061] Funding Source: UKRI; Medical Research Council [G9722488, G19/31, G0500365, G9900061] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ames JB, 2005, BIOCHEMISTRY-US, V44, P6416, DOI 10.1021/bi050139s; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butters TD, 1999, PROTEIN SCI, V8, P1696, DOI 10.1110/ps.8.8.1696; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DAVIS SJ, 1993, PROTEIN ENG, V6, P229, DOI 10.1093/protein/6.2.229; Davis SJ, 2003, NAT IMMUNOL, V4, P217, DOI 10.1038/ni0303-217; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; Dumont C, 2001, TRANSPLANT P, V33, P199, DOI 10.1016/S0041-1345(00)01974-6; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; Gonzalez-Cabrero J, 1999, P NATL ACAD SCI USA, V96, P1019, DOI 10.1073/pnas.96.3.1019; HARLOS K, 1992, J APPL CRYSTALLOGR, V25, P536, DOI 10.1107/S0021889892002656; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; KILLEEN N, 1992, EMBO J, V11, P4329, DOI 10.1002/j.1460-2075.1992.tb05532.x; Kitao A, 2000, P NATL ACAD SCI USA, V97, P2064, DOI 10.1073/pnas.030540397; Kumaresan PR, 2000, IMMUNOGENETICS, V51, P306, DOI 10.1007/s002510050624; Kumaresan PR, 2000, MOL IMMUNOL, V37, P735, DOI 10.1016/S0161-5890(00)00103-6; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Mavaddat N, 2000, J BIOL CHEM, V275, P28100; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SCHUHMACHERS G, 1995, EUR J IMMUNOL, V25, P1117, DOI 10.1002/eji.1830250440; SCHUHMACHERS G, 1995, J INVEST DERMATOL, V105, P592, DOI 10.1111/1523-1747.ep12323533; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Sun ZYJ, 1999, EMBO J, V18, P2941, DOI 10.1093/emboj/18.11.2941; Teh SJ, 1997, BLOOD, V89, P1308, DOI 10.1182/blood.V89.4.1308; van der Merwe PA, 1999, J EXP MED, V190, P1371, DOI 10.1084/jem.190.10.1371; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; Veillette A, 2003, CURR OPIN IMMUNOL, V15, P277, DOI 10.1016/S0952-7915(03)00041-4; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wang N, 2001, IMMUNOGENETICS, V53, P382, DOI 10.1007/s002510100337; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030	64	28	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29309	29320		10.1074/jbc.M601314200	http://dx.doi.org/10.1074/jbc.M601314200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16803907	hybrid			2022-12-27	WOS:000240680500086
J	Loeb, CRK; Harris, JL; Craik, CS				Loeb, Carly R. K.; Harris, Jennifer L.; Craik, Charles S.			Granzyme B proteolyzes receptors important to proliferation and survival, tipping the balance toward apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; MEDIATED APOPTOSIS; CELL-DEATH; INTRAEPITHELIAL NEOPLASIA; LYMPHOCYTE PROTEASE; T-LYMPHOCYTES; KEY MEDIATORS; ACTIVATION; CLEAVAGE; SPECIFICITY	Granzyme B is critical to the ability of natural killer cells and cytotoxic T lymphocytes to induce efficient cell death of virally infected or tumor cell targets. Although granzyme B can cleave and activate caspases to induce apoptosis, granzyme B can also cause caspase-independent cell death. Thirteen prospective granzyme B substrates were identified from a cDNA expression-cleavage screen, including Hsp70, Notch1, fibroblast growth factor receptor-1 (FGFR1), poly-A-binding protein, cAbl, heterogeneous nuclear ribonucleoprotein H', Br140, and intersectin-1. Validation revealed that Notch1 is a substrate of both granzyme B and caspases, whereas FGFR1 is a caspase-independent substrate of granzyme B. Proteolysis of FGFR1 in prostate cancer cells has functionally relevant consequences that indicate its cleavage may be advantageous for granzyme B to kill prostate cancer cells. Therefore, granzyme B not only activates pro-death functions within a target, but also has a previously unidentified role in inactivating pro-growth signals to cause cell death.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94131 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Tetrad Grad Program, San Francisco, CA 94131 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, MC 2280,Genentech Hall,Rm S512,600 16th St, San Francisco, CA 94131 USA.	craik@cgl.ucsf.edu			NCI NIH HHS [CA072006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Allman D, 2002, CELL, V109, pS1, DOI 10.1016/S0092-8674(02)00689-X; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Freeman KW, 2003, CANCER RES, V63, P8256; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Gorak-Stolinska P, 2001, J LEUKOCYTE BIOL, V70, P756; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Jehn BM, 1999, J IMMUNOL, V162, P635; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Kwabi-Addo B, 2001, PROSTATE, V46, P163, DOI 10.1002/1097-0045(20010201)46:2<163::AID-PROS1020>3.0.CO;2-T; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Opferman JT, 2001, INT IMMUNOL, V13, P411, DOI 10.1093/intimm/13.4.411; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; Polnaszek N, 2003, CANCER RES, V63, P5754; Ropiquet F, 1997, INT J CANCER, V72, P543, DOI 10.1002/(SICI)1097-0215(19970729)72:3<543::AID-IJC26>3.0.CO;2-B; Rotonda J, 2001, CHEM BIOL, V8, P357, DOI 10.1016/S1074-5521(01)00018-7; Ruchalski K, 2006, J BIOL CHEM, V281, P7873, DOI 10.1074/jbc.M513728200; Rugles SW, 2004, J BIOL CHEM, V279, P30751, DOI 10.1074/jbc.M400949200; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; Thiery J, 2003, J IMMUNOL, V170, P5919, DOI 10.4049/jimmunol.170.12.5919; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992; Willoughby CA, 2002, BIOORG MED CHEM LETT, V12, P2197, DOI 10.1016/S0960-894X(02)00363-3; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598	48	61	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28326	28335		10.1074/jbc.M604544200	http://dx.doi.org/10.1074/jbc.M604544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16798735	hybrid			2022-12-27	WOS:000240534400070
J	Hothorn, M; Wachter, A; Gromes, R; Stuwe, T; Rausch, T; Scheffzek, K				Hothorn, Michael; Wachter, Andreas; Gromes, Roland; Stuwe, Tobias; Rausch, Thomas; Scheffzek, Klaus			Structural basis for the redox control of plant glutamate cysteine ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ARABIDOPSIS-THALIANA; GLUTATHIONE HOMEOSTASIS; MACROMOLECULAR STRUCTURES; MODIFIER SUBUNIT; GENE-EXPRESSION; MECHANISM; BIOSYNTHESIS; METABOLISM; REFINEMENT	Glutathione (GSH) plays a crucial role in plant metabolism and stress response. The rate-limiting step in the biosynthesis of GSH is catalyzed by glutamate cysteine ligase (GCL) the activity of which is tightly regulated. The regulation of plant GCLs is poorly understood. The crystal structure of substrate-bound GCL from Brassica juncea at 2.1-angstrom resolution reveals a plant-unique regulatory mechanism based on two intramolecular redox-sensitive disulfide bonds. Reduction of one disulfide bond allows a beta-hairpin motif to shield the active site of B. juncea GCL, thereby preventing the access of substrates. Reduction of the second disulfide bond reversibly controls dimer to monomer transition of B. juncea GCL that is associated with a significant inactivation of the enzyme. These regulatory events provide a molecular link between high GSH levels in the plant cell and associated down-regulation of its biosynthesis. Furthermore, known mutations in the Arabidopsis GCL gene affect residues in the close proximity of the active site and thus explain the decreased GSH levels in mutant plants. In particular, the mutation in rax1-1 plants causes impaired binding of cysteine.	European Mol Biol Lab, Struct & Computat Biol Unit, D-69117 Heidelberg, Germany; Heidelberg Inst Plant Sci, Dept Mol Ecophysiol, D-69120 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg	Scheffzek, K (corresponding author), European Mol Biol Lab, Struct & Computat Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	scheffzek@embl.de	Gromes, Roland/H-9041-2012; Hothorn, Michael/C-6807-2011; Wachter, Andreas/P-9038-2014	Gromes, Roland/0000-0002-4693-6491; Wachter, Andreas/0000-0002-3132-5161; Hothorn, Michael/0000-0002-3597-5698				Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; Ball L, 2004, PLANT CELL, V16, P2448, DOI 10.1105/tpc.104.022608; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Cobbett CS, 1998, PLANT J, V16, P73, DOI 10.1046/j.1365-313x.1998.00262.x; Dall'Antonia F, 2003, ACTA CRYSTALLOGR D, V59, P1987, DOI 10.1107/S0907444903017670; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dixon DP, 2005, PLANT PHYSIOL, V138, P2233, DOI 10.1104/pp.104.058917; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Foyer CH, 2005, PLANT CELL, V17, P1866, DOI 10.1105/tpc.105.033589; Fraser JA, 2003, J BIOL CHEM, V278, P46369, DOI 10.1074/jbc.M308035200; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Grosse-Kunstleve RW, 2003, ACTA CRYSTALLOGR D, V59, P1966, DOI 10.1107/S0907444903018043; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HELL R, 1990, PLANTA, V180, P603, DOI 10.1007/BF02411460; Hibi T, 2004, P NATL ACAD SCI USA, V101, P15052, DOI 10.1073/pnas.0403277101; Hothorn M, 2003, ACTA CRYSTALLOGR D, V59, P2279, DOI 10.1107/S0907444903021036; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Jez JM, 2004, J BIOL CHEM, V279, P33463, DOI 10.1074/jbc.M405127200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; Kopriva S, 2004, J EXP BOT, V55, P1831, DOI 10.1093/jxb/erh203; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; May MJ, 1998, P NATL ACAD SCI USA, V95, P12049, DOI 10.1073/pnas.95.20.12049; MAY MJ, 1994, P NATL ACAD SCI USA, V91, P10059, DOI 10.1073/pnas.91.21.10059; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Meyer AJ, 2005, PHOTOSYNTH RES, V86, P435, DOI 10.1007/s11120-005-8425-1; Michelet L, 2005, P NATL ACAD SCI USA, V102, P16478, DOI 10.1073/pnas.0507498102; Milla MAR, 2003, PLANT J, V36, P602, DOI 10.1046/j.1365-313X.2003.01901.x; Mullineaux PM, 2005, PHOTOSYNTH RES, V86, P459, DOI 10.1007/s11120-005-8811-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Noctor G, 1998, PLANT PHYSIOL, V118, P471, DOI 10.1104/pp.118.2.471; Peltier JB, 2006, MOL CELL PROTEOMICS, V5, P114, DOI 10.1074/mcp.M500180-MCP200; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rausch T, 2005, TRENDS PLANT SCI, V10, P503, DOI 10.1016/j.tplants.2005.08.006; Saito K, 2004, PLANT PHYSIOL, V136, P2443, DOI 10.1104/pp.104.046755; SanchezFernandez R, 1997, P NATL ACAD SCI USA, V94, P2745, DOI 10.1073/pnas.94.6.2745; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tu ZH, 1998, BIOCHEM J, V336, P675, DOI 10.1042/bj3360675; Ullmann P, 1996, EUR J BIOCHEM, V236, P662, DOI 10.1111/j.1432-1033.1996.00662.x; Vernoux T, 2000, PLANT CELL, V12, P97, DOI 10.1105/tpc.12.1.97; Wachter A, 2005, PLANT J, V41, P15, DOI 10.1111/j.1365-313X.2004.02269.x; Wagner U, 2002, PLANT MOL BIOL, V49, P515, DOI 10.1023/A:1015557300450; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539	50	83	87	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27557	27565		10.1074/jbc.M602770200	http://dx.doi.org/10.1074/jbc.M602770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16766527	Green Published, hybrid			2022-12-27	WOS:000240397700081
J	Vaid, A; Sharma, P				Vaid, Ankush; Sharma, Pushkar			PfPKB, a protein kinase B-like enzyme from Plasmodium falciparum II. Identification of calcium/calmodulin as its upstream activator and dissection of a novel signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MALARIA PARASITES; CALCIUM HOMEOSTASIS; GAMETE FORMATION; CALMODULIN; INVASION; ERYTHROCYTES; MECHANISM; SEQUENCE; PEPTIDE; INSULIN	Intracellular cell signaling cascades of protozoan parasite Plasmodium falciparum are not clearly understood. We have reported previously (Kumar, A., Vaid, A., Syin, C., and Sharma, P. (2004) J. Biol. Chem. 279, 24255-24264) the identification and characterization of a protein kinase B-like enzyme in P. falciparum (PfPKB). PfPKB lacks the phosphoinositide-interacting pleckstrin homology domain present in mammalian protein kinase B. Therefore, the mechanism of PfPKB regulation was expected to be different from that of the host and had remained unknown. We have identified calmodulin (CaM) as the regulator of PfPKB activity. A CaM binding domain was mapped in the N-terminal region of PfPKB. CaM, in a calcium-dependent manner, interacts with this domain and activates PfPKB. CaM associates with PfPKB in the parasite and regulates its activity. Furthermore phospholipase C acts as an upstream regulator of this cascade as it facilitates the release of calcium from intracellular stores. This is one of the first multicomponent signaling pathways to be dissected in the malaria parasite.	Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Sharma, P (corresponding author), Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India.	pushkar@nii.res.in			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Biagini GA, 2003, J BIOL CHEM, V278, P27910, DOI 10.1074/jbc.M304193200; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; COWMAN AF, 1991, EXP PARASITOL, V73, P269, DOI 10.1016/0014-4894(91)90098-H; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Garcia CRS, 1996, EUR J CELL BIOL, V71, P409; Garcia CRS, 1999, PARASITOL TODAY, V15, P488, DOI 10.1016/S0169-4758(99)01571-9; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gazarini ML, 2003, J CELL BIOL, V161, P103, DOI 10.1083/jcb.200212130; Harrison T, 2003, SCIENCE, V301, P1734, DOI 10.1126/science.1089324; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hotta CT, 2003, BRAZ J MED BIOL RES, V36, P1583, DOI 10.1590/S0100-879X2003001100016; Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027; Kumar A, 2004, J BIOL CHEM, V279, P24255, DOI 10.1074/jbc.M312855200; MATSUMOTO Y, 1987, EUR J CELL BIOL, V45, P36; MCCALLUMDEIGHTON N, 1992, MOL BIOCHEM PARASIT, V50, P317, DOI 10.1016/0166-6851(92)90229-D; Merckx A, 2003, J BIOL CHEM, V278, P39839, DOI 10.1074/jbc.M301625200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Reininger L, 2005, J BIOL CHEM, V280, P31957, DOI 10.1074/jbc.M504523200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROBSON KJH, 1993, PHILOS T R SOC B, V340, P39, DOI 10.1098/rstb.1993.0047; SCHEIBEL LW, 1987, P NATL ACAD SCI USA, V84, P7310, DOI 10.1073/pnas.84.20.7310; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sun XT, 2000, PLANT CELL PHYSIOL, V41, P804, DOI 10.1093/pcp/41.6.804; Tewari R, 2005, MOL MICROBIOL, V58, P1253, DOI 10.1111/j.1365-2958.2005.04793.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WARD GE, 1994, EXP PARASITOL, V79, P480, DOI 10.1006/expr.1994.1109; Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79; Yamauchi E, 2003, NAT STRUCT BIOL, V10, P226, DOI 10.1038/nsb900	31	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27126	27133		10.1074/jbc.M601914200	http://dx.doi.org/10.1074/jbc.M601914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16809343	hybrid			2022-12-27	WOS:000240397700040
J	Cao, SJ; Zhang, X; Edwards, JP; Mosser, DM				Cao, Shanjin; Zhang, Xia; Edwards, Justin P.; Mosser, David M.			NF-kappa B1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IL-10 GENE-EXPRESSION; C-REACTIVE PROTEIN; TRANSCRIPTIONAL COACTIVATOR; BINDING; ACTIVATION; PROMOTER; GAMMA; INTERLEUKIN-10; BCL-3	NF-kappa B/Rel is a family of transcription factors whose activation has long been linked to the production of inflammatory cytokines. Here, we studied NF-kappa B signaling in the regulation of the anti-inflammatory cytokine, interleukin-10 (IL-10). We identified a role for a single NF-kappa B family member, NF-kappa B1 (p50), in promoting the transcription of IL-10. The NF-kappa B cis-element on IL-10 proximal promoter was located to -55/-46, where p50 can homodimerize and form a complex with the transcriptional co-activator CREB-binding protein to activate transcription. The other Rel family members appear to play a negligible role in IL-10 transcription. Mice lacking p50 were more susceptible to lethal endotoxemia, and macrophages taken from p50(-/)-mice exhibit skewed cytokine responses to lipopolysaccharide, characterized by decreased IL-10 and increased tumor necrosis factor and IL-12. Taken together, our studies demonstrate that NF-kappa B1 (p50) homodimers can be transcriptional activators of IL-10. The reciprocal regulation of pro-and anti-inflammatory cytokine production by NF-kappa B1 (p50) may provide potential new ways to manipulate the innate immune response.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Mosser, DM (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, 1103 Microbiol Bldg, College Pk, MD 20742 USA.	dmosser@umd.edu	Zhang, Xia/B-8152-2008; Mosser, David M/I-6697-2016	Zhang, Xia/0000-0002-9040-1486; Mosser, David M/0000-0002-9503-4187; Edwards, Justin/0000-0001-8936-2136	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049383] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI049383, AI49383, R01 AI049383-06A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 2001, J IMMUNOL, V166, P2378, DOI 10.4049/jimmunol.166.4.2378; Anderson CF, 2002, J IMMUNOL, V168, P3697, DOI 10.4049/jimmunol.168.8.3697; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; Bleharski JR, 2003, SCIENCE, V301, P1527, DOI 10.1126/science.1087785; Bondeson J, 1999, J IMMUNOL, V162, P2939; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Cao SJ, 2005, J IMMUNOL, V174, P3484, DOI 10.4049/jimmunol.174.6.3484; Cappiello MG, 2001, J IMMUNOL, V166, P4498, DOI 10.4049/jimmunol.166.7.4498; Cha-Molstad H, 2000, J IMMUNOL, V165, P4592, DOI 10.4049/jimmunol.165.8.4592; Conti P, 2003, IMMUNOL LETT, V88, P171, DOI 10.1016/S0165-2478(03)00087-7; Deng WG, 2003, J IMMUNOL, V171, P6581, DOI 10.4049/jimmunol.171.12.6581; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; Feng Biao, 2004, Med Immunol, V3, P1, DOI 10.1186/1476-9433-3-1; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Fu DX, 2004, J BIOL CHEM, V279, P12819, DOI 10.1074/jbc.M312572200; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grutz G, 2005, J LEUKOCYTE BIOL, V77, P3, DOI 10.1189/jlb.0904484; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kaisho T, 2000, CRIT REV IMMUNOL, V20, P393; Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kemper JK, 2004, MOL CELL BIOL, V24, P7707, DOI 10.1128/MCB.24.17.7707-7719.2004; Kollet JI, 2006, MOL IMMUNOL, V43, P623, DOI 10.1016/j.molimm.2005.04.004; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li-Weber M, 2004, EUR J IMMUNOL, V34, P1111, DOI 10.1002/eji.200324687; Lin SC, 2006, MOL IMMUNOL, V43, P1325, DOI 10.1016/j.molimm.2005.09.007; Liu JJ, 2003, J IMMUNOL, V170, P4489, DOI 10.4049/jimmunol.170.9.4489; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Liu YW, 2003, J IMMUNOL, V171, P821, DOI 10.4049/jimmunol.171.2.821; Lucas M, 2005, J IMMUNOL, V175, P469, DOI 10.4049/jimmunol.175.1.469; Maloney G, 2005, J BIOL CHEM, V280, P30838, DOI 10.1074/jbc.M501917200; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mori N, 1997, EUR J HAEMATOL, V59, P162; Nemeth ZH, 1998, SHOCK, V10, P49, DOI 10.1097/00024382-199807000-00009; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Riemann M, 2005, J IMMUNOL, V175, P3560, DOI 10.4049/jimmunol.175.6.3560; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Saraiva M, 2005, J IMMUNOL, V175, P1041, DOI 10.4049/jimmunol.175.2.1041; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sutterwala FS, 1998, J EXP MED, V188, P217, DOI 10.1084/jem.188.1.217; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	57	290	293	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26041	26050		10.1074/jbc.M602222200	http://dx.doi.org/10.1074/jbc.M602222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835236	Green Accepted, hybrid			2022-12-27	WOS:000240249500019
J	Ding, X; Lichti, K; Kim, I; Gonzalez, FJ; Staudinger, JL				Ding, Xunshan; Lichti, Kristin; Kim, Insook; Gonzalez, Frank J.; Staudinger, Jeff L.			Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; THYROID-HORMONE METABOLISM; BILE-ACIDS; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; FACTOR 4-ALPHA; ADAPTIVE THERMOGENESIS; XENOBIOTIC RESPONSE; DRUG-METABOLISM; AGONIST GC-1	Animal studies reveal that fasting and caloric restriction produce increased activity of specific metabolic pathways involved in resistance to weight loss in liver. Evidence suggests that this phenomenon may in part occur through the action of the constitutive androstane receptor ( CAR, NR1I3). Currently, the precise molecular mechanisms that activate CAR during fasting are unknown. We show that fasting coordinately induces expression of genes encoding peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), CAR, cytochrome P-450 2b10 (Cyp2b10), UDP-glucuronosyltransferase 1a1 (Ugt1a1), sulfotransferase 2a1 (Sult2a1), and organic anion-transporting polypeptide 2 (Oatp2) in liver in mice. Treatments that elevate intracellular cAMP levels also produce increased expression of these genes in cultured hepatocytes. Our data show that PGC-1 alpha interaction with hepatocyte nuclear factor 4 alpha(HNF4 alpha, NR2A1) directly regulates CAR gene expression through a novel and evolutionarily conserved HNF4-response element (HNF4RE) located in its proximal promoter. Expression of PGC-1 alpha in cells increases CAR expression and ligand-independent CAR activity. Genetic studies reveal that hepatic expression of HNF4 alpha is required to produce fasting-inducible CAR expression and activity. Taken together, our data show that fasting produces increased expression of genes encoding key metabolic enzymes and an uptake transporter protein through a network of interactions involving cAMP, PGC-1 alpha, HNF4 alpha, CAR, and CAR target genes in liver. Given the recent finding that mice lacking CAR exhibit a profound decrease in resistance to weight loss during extended periods of caloric restriction, our findings have important implications in the development of drugs for the treatment of obesity and related diseases.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Kansas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staudinger, JL (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 1251 Wescoe Hall Dr,5044 Malott Hall, Lawrence, KS 66045 USA.	stauding@ku.edu			NCRR NIH HHS [RR17708, P20 RR017708] Funding Source: Medline; NIDDK NIH HHS [R01 DK068443, R01 DK068443-01A1, R01DK068443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005561] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068443] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; Assem M, 2004, J BIOL CHEM, V279, P22250, DOI 10.1074/jbc.M314111200; Baxter JD, 2004, TRENDS ENDOCRIN MET, V15, P154, DOI 10.1016/j.tem.2004.03.008; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Blaxter K, 1989, ENERGY METABOLISM AN; Brobst DE, 2004, J PHARMACOL EXP THER, V310, P528, DOI 10.1124/jpet.103.064329; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; Ding XS, 2005, J PHARMACOL EXP THER, V314, P120, DOI 10.1124/jpet.105.085225; Ding XS, 2005, BIOCHEM PHARMACOL, V69, P867, DOI 10.1016/j.bcp.2004.11.025; Ding XS, 2005, J PHARMACOL EXP THER, V312, P849, DOI 10.1124/jpet.104.076331; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Goodwin B, 2003, P NATL ACAD SCI USA, V100, P223, DOI 10.1073/pnas.0237082100; Greene M. E., 1995, Gene Expression, V4, P281; Grover GJ, 2004, ENDOCRINOLOGY, V145, P1656, DOI 10.1210/en.2003-0973; Grover GJ, 2003, P NATL ACAD SCI USA, V100, P10067, DOI 10.1073/pnas.1633737100; Handschin C, 2005, CELL, V122, P505, DOI 10.1016/j.cell.2005.06.040; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Hosseinpour F, 2006, MOL PHARMACOL, V69, P1095, DOI 10.1124/mol.105.019505; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Inoue Y, 2006, J LIPID RES, V47, P215, DOI 10.1194/jlr.M500430-JLR200; Jia YZ, 2005, P NATL ACAD SCI USA, V102, P12531, DOI 10.1073/pnas.0506000102; Kahaly GJ, 2005, ENDOCR REV, V26, P704, DOI 10.1210/er.2003-0033; Kamiya A, 2004, FEBS LETT, V578, P63, DOI 10.1016/j.febslet.2004.10.070; Krotkiewski M, 2000, INT J OBESITY, V24, pS116, DOI 10.1038/sj.ijo.0801294; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Maglich JM, 2004, J BIOL CHEM, V279, P19832, DOI 10.1074/jbc.M313601200; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Mitchell AM, 2005, J ENDOCRINOL, V185, P93, DOI 10.1677/joe.1.06096; MOL JA, 1985, ENDOCRINOLOGY, V117, P8, DOI 10.1210/endo-117-1-8; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pascussi JM, 2003, MOL ENDOCRINOL, V17, P42, DOI 10.1210/me.2002-0244; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2005, INT J OBESITY, V29, pS5, DOI 10.1038/sj.ijo.0802905; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qatanani M, 2005, ENDOCRINOLOGY, V146, P995, DOI 10.1210/en.2004-1350; RABAST U, 1981, INT J OBESITY, V5, P305; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rivera-Rivera I, 2003, BBA-GEN SUBJECTS, V1619, P254, DOI 10.1016/S0304-4165(02)00484-1; Rosenbaum M, 2000, AM J CLIN NUTR, V71, P1421; Saini SPS, 2004, MOL PHARMACOL, V65, P292, DOI 10.1124/mol.65.2.292; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Staudinger JL, 2003, DRUG METAB DISPOS, V31, P523, DOI 10.1124/dmd.31.5.523; Stroup D, 2000, J LIPID RES, V41, P1; Sugatani J, 2005, MOL PHARMACOL, V67, P845, DOI 10.1124/mol.104.007161; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wong H, 2005, TOXICOL SCI, V84, P232, DOI 10.1093/toxsci/kfi094; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Xiong H, 2002, DRUG METAB DISPOS, V30, P918, DOI 10.1124/dmd.30.8.918; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	67	110	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26540	26551		10.1074/jbc.M600931200	http://dx.doi.org/10.1074/jbc.M600931200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825189	hybrid, Green Accepted			2022-12-27	WOS:000240249500072
J	Hildebrandt, ER; Gheber, L; Kingsbury, T; Hoyt, MA				Hildebrandt, Emily R.; Gheber, Larisa; Kingsbury, Tami; Hoyt, M. Andrew			Homotetrameric form of Cin8p, a Saccharomyces cerevisiae kinesin-5 motor, is essential for its in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PREDICTING COILED COILS; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; MICROTUBULE MOTOR; MOLECULAR MOTORS; BIMC FAMILY; PROTEIN; EG5; BIPOLAR	Kinesin-5 motor proteins are evolutionarily conserved and perform essential roles in mitotic spindle assembly and spindle elongation during anaphase. Previous studies demonstrated a specialized homotetrameric structure with two pairs of catalytic domains, one at each end of a dumbbell-shaped molecule. This suggests that they perform their spindle roles by cross-linking and sliding antiparallel spindle microtubules. However, the exact kinesin-5 sequence elements that are important for formation of the tetrameric complexes have not yet been identified. In addition, it has not been demonstrated that the homotetrameric form of these proteins is essential for their biological functions. Thus, we investigated a series of Saccharomyces cerevisiae Cin8p truncations and internal deletions, in order to identify structural elements in the Cin8p sequence that are required for Cin8p functionality, spindle localization, and multimerization. We found that all variants of Cin8p that are functional in vivo form tetrameric complexes. The first coiled-coil domain in the stalk of Cin8p, a feature that is shared by all kinesin-5 homologues, is required for its dimerization, and sequences in the last part of the stalk, specifically those likely involved in coiled-coil formation, are required for Cin8p tetramerization. We also found that dimeric forms of Cin8p that are nonfunctional in vivo can nonetheless bind to microtubules. These findings suggest that binding of microtubules is not sufficient for the functionality of Cin8p and that microtubule cross-linking by the tetrameric complex is essential for Cin8p mitotic functions.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Ben Gurion Univ Negev, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	Johns Hopkins University; Ben Gurion University; Ben Gurion University	Hoyt, MA (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	hoyt@jhu.edu			NIGMS NIH HHS [GM40714, GM18745] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714, F32GM018745] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asada T, 1997, J CELL SCI, V110, P179; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P539; Chui KK, 2000, J BIOL CHEM, V275, P38005, DOI 10.1074/jbc.M005948200; Cochran JC, 2004, J BIOL CHEM, V279, P38861, DOI 10.1074/jbc.M404203200; COLE DG, 1994, J BIOL CHEM, V269, P22913; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; Drummond DR, 1998, J CELL SCI, V111, P853; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Ferhat L, 1998, J NEUROSCI, V18, P7822; Gheber L, 1999, J BIOL CHEM, V274, P9564, DOI 10.1074/jbc.274.14.9564; Gordon DM, 1999, J BIOL CHEM, V274, P28779, DOI 10.1074/jbc.274.40.28779; Goshima G, 2005, MOL BIOL CELL, V16, P3896, DOI 10.1091/mbc.E05-02-0118; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Higuchi H, 2002, CURR OPIN CELL BIOL, V14, P50, DOI 10.1016/S0955-0674(01)00293-9; Hildebrandt ER, 2000, BBA-MOL CELL RES, V1496, P99, DOI 10.1016/S0167-4889(00)00012-4; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Kasprzak AA, 2002, ACTA BIOCHIM POL, V49, P813; KOHAMA K, 1986, J BIOL CHEM, V261, P8022; KOZIELSKI F, 1997, BIOCHIM BIOPHYS ACTA, V1359, P181; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Nicolas G, 1997, BIOTECHNIQUES, V22, P430, DOI 10.2144/97223bm11; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; Sherman F., 1983, METHODS YEAST GENETI; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Stock MF, 2003, J BIOL CHEM, V278, P52315, DOI 10.1074/jbc.M309419200; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Touitou I, 2001, J CELL SCI, V114, P481; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	51	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26004	26013		10.1074/jbc.M604817200	http://dx.doi.org/10.1074/jbc.M604817200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829678	hybrid			2022-12-27	WOS:000240249500015
J	Pop, SM; Gupta, N; Raza, AS; Ragsdale, SW				Pop, Stelian M.; Gupta, Nirupama; Raza, Ashraf S.; Ragsdale, Stephen W.			Transcriptional activation of dehalorespiration - Identification of redox-active cysteines regulating dimerization and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTIVE DEHALOGENASE; ANAEROBIC BACTERIUM; ESCHERICHIA-COLI; DESULFITOBACTERIUM; PURIFICATION; PROTEIN; CLUSTER; FNR; DECHLORINATION; ENZYME	Desulfitobacterium dehalogenans can use chlorinated aromatics including polychlorinated biphenyls as electron acceptors in a process called dehalorespiration. Expression of the cpr gene cluster involved in this process is regulated by CprK, which is a member of the CRP/FNR (cAMP-binding protein/fumarate nitrate reduction regulatory protein) family of helix-turn-helix transcriptional regulators. High affinity interaction of the chlorinated aromatic compound with the effector domain of CprK triggers binding of CprK to an upstream target DNA sequence, which leads to transcriptional activation of the cpr gene cluster. When incubated with oxygen or diamide, CprK undergoes inactivation; subsequent treatment with dithiothreitol restores activity. Using mass spectrometry, this study identifies two classes of redox-active thiol groups that form disulfide bonds upon oxidation. Under oxidative conditions, Cys(105), which is conserved in FNR and most other CprK homologs, forms an intramolecular disulfide bond with Cys(111), whereas an intermolecular disulfide bond is formed between Cys(11) and Cys(200). SDS-PAGE and site-directed mutagenesis experiments indicate that the Cys(11)/Cys(200) disulfide bond links two CprK subunits in an inactive dimer. Isothermal calorimetry and intrinsic fluorescence quenching studies show that oxidation does not change the affinity of CprK for the effector. Therefore, reversible redox inactivation is manifested at the level of DNA binding. Our studies reveal a strategy for limiting expression of a redox-sensitive pathway by using a thiol-based redox switch in the transcription factor.	Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Pop, SM (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr, 19th & Vine St, Lincoln, NE 68588 USA.	sragsdale1@unl.edu	Raza, Faisal/AAG-4567-2021; gupta, nirupama/H-2297-2012	Raza, Faisal/0000-0001-5569-3535; 	NCRR NIH HHS [1P20RR17675] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Boyer A, 2003, BIOCHEM J, V373, P297, DOI 10.1042/BJ20021837; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Christiansen N, 1998, FEBS LETT, V436, P159, DOI 10.1016/S0014-5793(98)01114-4; Das A, 2005, J BACTERIOL, V187, P2020, DOI 10.1128/JB.187.6.2020-2029.2005; Djaman O, 2004, J BIOL CHEM, V279, P44590, DOI 10.1074/jbc.M406487200; Gostick DO, 1998, MICROBIOL-SGM, V144, P705, DOI 10.1099/00221287-144-3-705; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; Holliger C, 1998, FEMS MICROBIOL REV, V22, P383, DOI 10.1016/S0168-6445(98)00030-8; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Joyce MG, 2006, J BIOL CHEM, V281, P28318, DOI 10.1074/jbc.M602654200; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Krasotkina J, 2001, J BIOL CHEM, V276, P40991, DOI 10.1074/jbc.M106217200; Miller E, 1998, ARCH MICROBIOL, V169, P497, DOI 10.1007/s002030050602; MOHN WW, 1991, ARCH MICROBIOL, V157, P1; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Polit A, 2003, J BIOL CHEM, V278, P43020, DOI 10.1074/jbc.M306398200; Pop SM, 2004, J BIOL CHEM, V279, P49910, DOI 10.1074/jbc.M409435200; Roberts GP, 2004, MICROBIOL MOL BIOL R, V68, P453, DOI 10.1128/MMBR.68.3.453-473.2004; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smidt H, 2004, ANNU REV MICROBIOL, V58, P43, DOI 10.1146/annurev.micro.58.030603.123600; Smidt H, 2000, J BACTERIOL, V182, P5683, DOI 10.1128/JB.182.20.5683-5691.2000; Unden G, 1997, MOL MICROBIOL, V25, P205, DOI 10.1046/j.1365-2958.1997.4731841.x; UTKIN I, 1994, INT J SYST BACTERIOL, V44, P612, DOI 10.1099/00207713-44-4-612; van de Pas BA, 2001, APPL ENVIRON MICROB, V67, P3958, DOI 10.1128/AEM.67.9.3958-3963.2001; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; Wiegel J, 2000, FEMS MICROBIOL ECOL, V32, P1, DOI 10.1111/j.1574-6941.2000.tb00693.x; Wiegel J, 1999, APPL ENVIRON MICROB, V65, P2217	30	26	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26382	26390		10.1074/jbc.M602158200	http://dx.doi.org/10.1074/jbc.M602158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840784	hybrid			2022-12-27	WOS:000240249500055
J	Suzuki, N; Nishii, K; Okazaki, T; Ikeno, M				Suzuki, Nobutaka; Nishii, Kazuhiro; Okazaki, Tuneko; Ikeno, Masashi			Human artificial chromosomes constructed using the bottom-up strategy are stably maintained in mitosis and efficiently transmissible to progeny mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMLINE TRANSMISSION; GENETIC DEFICIENCY; ALPHA-SATELLITE; GENERATION; DNA; HUMAN-CHROMOSOME-21; MINICHROMOSOME; EXPRESSION; MEIOSIS; CELLS	Human artificial chromosomes (HACs) are alternative vectors that promise to overcome problematic transgene expression often occurring with conventional vectors in mammalian cells and bodies. We have successfully generated HACs by multimerization of a cloned long alphoid stretch in a human cell line, HT1080. Furthermore, we developed technologies for cloning large genomic regions into HACs by means of co-transfection of clones with the alphoid array and clones encoding the genomic region of interest. The purpose of this study was to investigate the mitotic and meiotic stability of such HACs in mouse cells and bodies. We transferred a circular HAC containing the guanosine triphosphate cyclohydolase I gene (GCH1-HAC) and a linear HAC containing the human globin gene cluster (globin-HAC) from HT1080 cells into mouse embryonic stem (ES) cells by microcell-mediated chromosome transfer. The HACs were stably maintained in mouse ES cells for 3 months. GCH1-HACs in every ES cell line and globin-HACs in most ES cell lines maintained their structures without detectable rearrangement or acquisition of mouse genomic DNA except one globin-HAC in an ES cell line rearranged and acquired mouse-type centromeric sequences and long telomeres. Creation of chimeric mice using ES cells containing HAC and subsequent crossing showed that both the globin-HAC that had rearranged and acquired mouse type centromeric sequences/ long telomeres and GCH1-HACs were retained in tissues of mice and transmitted to progeny. These results indicate that human artificial chromosomes constructed using the bottom-up strategy based on alphoid DNA are stable in mouse bodies and are transmissible.	Fujita Hlth Univ, Inst Comprehens Med Sci, Toyoake, Aichi 4701192, Japan; Fujita Hlth Univ, Educ & Res Ctr Anim Models Human Dis, Toyoake, Aichi 4701192, Japan	Fujita Health University; Fujita Health University	Ikeno, M (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, 1-98 Kutsukake Cho, Toyoake, Aichi 4701192, Japan.	mikeno@fujita-hu.ac.jp						Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Ebersole TA, 2000, HUM MOL GENET, V9, P1623, DOI 10.1093/hmg/9.11.1623; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; Grimes BR, 2005, CHROMOSOMA, V114, P230, DOI 10.1007/s00412-005-0017-5; Grimes BR, 2001, EMBO REP, V2, P910, DOI 10.1093/embo-reports/kve187; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; Henning KA, 1999, P NATL ACAD SCI USA, V96, P592, DOI 10.1073/pnas.96.2.592; IKENO M, 1994, HUM MOL GENET, V3, P1245, DOI 10.1093/hmg/3.8.1245; Ikeno M, 2002, GENES CELLS, V7, P1021, DOI 10.1046/j.1365-2443.2002.00580.x; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Kazuki Y, 2001, J HUM GENET, V46, P600, DOI 10.1007/s100380170028; Koehler KE, 2002, GENETICS, V162, P1367; Kuroiwa Y, 2002, NAT BIOTECHNOL, V20, P889, DOI 10.1038/nbt727; Larin Z, 2002, TRENDS GENET, V18, P313, DOI 10.1016/S0168-9525(02)02679-3; Mee PJ, 2003, CHROMOSOMA, V112, P183, DOI 10.1007/s00412-003-0260-6; Mejia JE, 2001, AM J HUM GENET, V69, P315, DOI 10.1086/321977; Mills W, 1999, HUM MOL GENET, V8, P751, DOI 10.1093/hmg/8.5.751; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; O'Doherty A, 2005, SCIENCE, V309, P2033, DOI 10.1126/science.1114535; Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112; Pfeifer A, 2001, ANNU REV GENOM HUM G, V2, P177, DOI 10.1146/annurev.genom.2.1.177; Shen MH, 2000, CURR BIOL, V10, P31, DOI 10.1016/S0960-9822(99)00261-4; Shen MH, 1997, HUM MOL GENET, V6, P1375, DOI 10.1093/hmg/6.8.1375; Shinohara T, 2000, CHROMOSOME RES, V8, P713, DOI 10.1023/A:1026741321193; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; Voet T, 2003, J CELL BIOL, V162, P795, DOI 10.1083/jcb.200305065; Voet T, 2001, GENOME RES, V11, P124, DOI 10.1101/gr.159901; Wade-Martins R, 2000, NAT BIOTECHNOL, V18, P1311, DOI 10.1038/82444; Willard HF, 1996, P NATL ACAD SCI USA, V93, P6847, DOI 10.1073/pnas.93.14.6847; Wong LH, 2005, J BIOL CHEM, V280, P3954, DOI 10.1074/jbc.M410047200; Yoshimi K, 2000, NAT BIOTECHNOL, V18, P1086, DOI 10.1038/80287	34	54	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26615	26623		10.1074/jbc.M603053200	http://dx.doi.org/10.1074/jbc.M603053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837455	hybrid			2022-12-27	WOS:000240249500079
J	Bhor, VM; Dev, S; Vasanthakumar, GR; Kumar, P; Sinha, S; Surolia, A				Bhor, Vikrant M.; Dev, Sagarika; Vasanthakumar, Ganga Ramu; Kumar, Parimal; Sinha, Sharmistha; Surolia, Avadhesha			Broad substrate stereospecificity of the Mycobacterium tuberculosis 7-keto-8-aminopelargonic acid synthase - Spectroscopic and kinetic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							8-AMINO-7-OXONONANOATE SYNTHASE; 8-AMINO-7-OXOPELARGONATE SYNTHASE; CRYSTAL-STRUCTURE; BIOTIN; BIOSYNTHESIS; BINDING; ENZYME; INTERMEDIATE; SPECIFICITY; INHIBITION	Biotin is an essential enzyme cofactor required for carboxylation and transcarboxylation reactions. The absence of the biotin biosynthesis pathway in humans suggests that it can be an attractive target for the development of novel drugs against a number of pathogens. 7-Keto-8-aminopelargonic acid (KAPA) synthase (EC 2.3.1.47), the enzyme catalyzing the first committed step in the biotin biosynthesis pathway, is believed to exhibit high substrate stereospecificity. A comparative kinetic characterization of the interaction of the Mycobacterium tuberculosis KAPA synthase with both L- and D-alanine was carried out to investigate the basis of the substrate stereospecificity exhibited by the enzyme. The formation of the external aldimine with D-alanine (k = 82.63 M-1 s(-1)) is similar to 5 times slower than that with L-alanine (k = 399.4 M-1 s(-1)). In addition to formation of the external aldimine, formation of substrate quinonoid was also observed upon addition of pimeloyl-CoA to the preformed D-alanine external aldimine complex. However, the formation of this intermediate was extremely slow compared with the substrate quinonoid with L- alanine and pimeloyl-CoA (k = 16.9 x 10(4) M-1 s(-1)). Contrary to earlier reports, these results clearly show that D-alanine is not a competitive inhibitor but a substrate for the enzyme and thereby demonstrate the broad substrate stereospecificity of the M. tuberculosis KAPA synthase. Further, D-KAPA, the product of the reaction utilizing D-alanine inhibits both KAPA synthase (K-i = 114.83 mu M) as well as 7,8-diaminopelargonic acid synthase (IC50 = 43.9 mu M), the next enzyme of the pathway.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Natl Inst Immunol, New Delhi 110067, India	Indian Institute of Science (IISC) - Bangalore; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Aruna Asaf Ali Marg, Bangalore 560012, Karnataka, India.	surolia@nii.res.in	SUROLIA, AVADESHA/C-5442-2009; Kumar, Parimal/AAG-9653-2019	BHOR, VIKRANT/0000-0001-9897-4505; Sinha, Sharmistha/0000-0003-2459-650X				ACHARYA S, 1990, J BIOL CHEM, V265, P11586; Alexeev D, 2006, ORG BIOMOL CHEM, V4, P1209, DOI 10.1039/b517922j; Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Astner I, 2005, EMBO J, V24, P3166, DOI 10.1038/sj.emboj.7600792; Bhor VM, 2006, IUBMB LIFE, V58, P225, DOI 10.1080/15216540600746997; CLEGG RM, 1977, BIOCHEMISTRY-US, V16, P167, DOI 10.1021/bi00621a002; CRAMER F, 1967, J AM CHEM SOC, V89, P14, DOI 10.1021/ja00977a003; EISENBERG M, 1987, ESCHERICHIA COLI SAL, P544; EISENBERG MA, 1971, J BACTERIOL, V108, P1135, DOI 10.1128/JB.108.3.1135-1140.1971; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FEDERIUK CS, 1983, J BIOL CHEM, V258, P5372; Hiromi K., 1979, KINETICS FAST ENZYME; Hunter GA, 1999, J BIOL CHEM, V274, P12222, DOI 10.1074/jbc.274.18.12222; Kerbarh O, 2006, CHEM COMMUN, P60, DOI 10.1039/b511837a; KLOSS RA, 1963, BIOCHIM BIOPHYS ACTA, V70, P90; KRMER L, 2002, EXPERT OPIN INV DRUG, V11, P1; Lim YH, 1998, J BIOL CHEM, V273, P4001, DOI 10.1074/jbc.273.7.4001; Malthouse JPG, 2003, BBA-PROTEINS PROTEOM, V1647, P138, DOI 10.1016/S1570-9639(03)00080-3; Marquet A, 2001, VITAM HORM, V61, P51; Nudelman A, 1998, BIOORG CHEM, V26, P157, DOI 10.1006/bioo.1998.1094; Pinon V, 2005, PLANT PHYSIOL, V139, P1666, DOI 10.1104/pp.105.070144; Ploux O, 1996, EUR J BIOCHEM, V236, P301, DOI 10.1111/j.1432-1033.1996.00301.x; Ploux O, 1999, EUR J BIOCHEM, V259, P63, DOI 10.1046/j.1432-1327.1999.00006.x; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; Schmidt A, 2001, BIOCHEMISTRY-US, V40, P5151, DOI 10.1021/bi002204y; Schneider G, 2001, FEBS LETT, V495, P7, DOI 10.1016/S0014-5793(01)02325-0; Segel IH, 1993, ENZYME KINETICS BEHA, P161; SILVERMAN RB, 1987, J BIOL CHEM, V262, P3192; Soda K, 2001, CHEM REC, V1, P373, DOI 10.1002/tcr.1021; WATANABE Y, 1980, BIOCHEM J, V189, P393, DOI 10.1042/bj1890393; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j	32	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25076	25088		10.1074/jbc.M604477200	http://dx.doi.org/10.1074/jbc.M604477200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16769720	hybrid			2022-12-27	WOS:000240031300009
J	Jeske, M; Meyer, S; Temme, C; Freudenreich, D; Wahle, E				Jeske, Mandy; Meyer, Sylke; Temme, Claudia; Freudenreich, Dorian; Wahle, Elmar			Rapid ATP-dependent deadenylation of nanos mRNA in a cell-free system from Drosophila embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) TAIL LENGTH; AU-RICH ELEMENTS; BINDING-PROTEIN; TRANSLATIONAL REPRESSION; POSTERIOR DETERMINANT; CAF1 PROTEINS; YEAST; DEGRADATION; SMAUG; COMPLEX	Shortening of the poly(A) tail (deadenylation) is the first and often rate-limiting step in the degradation pathway of most eukaryotic mRNAs and is also used as a means of translational repression, in particular in early embryonic development. The nanos mRNA is translationally repressed by the protein Smaug in Drosophila embryos. The RNA has a short poly(A) tail at steady state and decays gradually during the first 2-3 h of development. Smaug has recently also been implicated in mRNA deadenylation. To study the mechanism of sequence-dependent deadenylation, we have developed a cell-free system from Drosophila embryos that displays rapid deadenylation of nanos mRNA. The Smaug response elements contained in the nanos 3'-untranslated region are necessary and sufficient to induce deadenylation; thus, Smaug is likely to be involved. Unexpectedly, deadenylation requires the presence of an ATP regenerating system. The activity can be pelleted by ultracentrifugation, and both the Smaug protein and the CCR4(.)NOT complex, a known deadenylase, are enriched in the active fraction. The same extracts show pronounced translational repression mediated by the Smaug response elements. RNAs lacking a poly(A) tail are poorly translated in the extract; therefore, SRE-dependent deadenylation contributes to translational repression. However, repression is strong even with RNAs either bearing a poly(A) tract that cannot be removed or lacking poly(A) altogether; thus, an additional aspect of translational repression functions independently of deadenylation.	Univ Halle, Inst Biochem, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg	Wahle, E (corresponding author), Univ Halle, Inst Biochem, Kurt Mothes Str 3, D-06120 Halle, Germany.	ewahle@biochemtech.uni-halle.de		Wahle, Elmar/0000-0003-2504-0677; Jeske, Mandy/0000-0002-1107-9442				Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Bashirullah A, 1999, EMBO J, V18, P2610, DOI 10.1093/emboj/18.9.2610; Bergsten SE, 1999, DEVELOPMENT, V126, P659; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Cao QP, 2002, EMBO J, V21, P3852, DOI 10.1093/emboj/cdf353; Chagnovich D, 2001, P NATL ACAD SCI USA, V98, P11359, DOI 10.1073/pnas.201284398; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chekulaeva M, 2006, CELL, V124, P521, DOI 10.1016/j.cell.2006.01.031; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Clark IE, 2000, CURR BIOL, V10, P1311, DOI 10.1016/S0960-9822(00)00754-5; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Crucs S, 2000, MOL CELL, V5, P457, DOI 10.1016/S1097-2765(00)80440-2; Dahanukar A, 1996, GENE DEV, V10, P2610, DOI 10.1101/gad.10.20.2610; Dahanukar A, 1999, MOL CELL, V4, P209, DOI 10.1016/S1097-2765(00)80368-8; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Dean KA, 2002, TRENDS GENET, V18, P572, DOI 10.1016/S0168-9525(02)02792-0; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; Forrest KM, 2004, DEVELOPMENT, V131, P5849, DOI 10.1242/dev.01460; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; Gavis ER, 1996, DEVELOPMENT, V122, P2791; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; GOLSTROHM AC, 2006, NAT STRUCT MOL BIOL, V13, P533; Gorgoni Barbara, 2004, Briefings in Functional Genomics & Proteomics, V3, P125, DOI 10.1093/bfgp/3.2.125; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GRONER B, 1974, BIOCHEMISTRY-US, V13, P5378, DOI 10.1021/bi00723a020; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kalifa Y, 2006, DEV CELL, V10, P291, DOI 10.1016/j.devcel.2006.01.001; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Legagneux V, 1995, RNA, V1, P1001; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Macdonald PM, 1996, CURR OPIN GENET DEV, V6, P403, DOI 10.1016/S0959-437X(96)80060-8; Markesich DC, 2000, DEVELOPMENT, V127, P559; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Morris JZ, 2005, DEVELOPMENT, V132, P1165, DOI 10.1242/dev.01672; Muhlrad D, 2005, EMBO J, V24, P1033, DOI 10.1038/sj.emboj.7600560; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Nakamura A, 2001, DEVELOPMENT, V128, P3233; Nelson MR, 2004, EMBO J, V23, P150, DOI 10.1038/sj.emboj.7600026; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Paillard L, 2003, BIOL CELL, V95, P107, DOI 10.1016/S0248-4900(03)00010-8; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Reverdatto SV, 2004, RNA, V10, P1200, DOI 10.1261/rna.7540204; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; Semotok JL, 2005, CURR BIOL, V15, P284, DOI 10.1016/j.cub.2005.01.048; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Smibert CA, 1999, RNA, V5, P1535, DOI 10.1017/S1355838299991392; Smibert CA, 1996, GENE DEV, V10, P2600, DOI 10.1101/gad.10.20.2600; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Temme C, 2004, EMBO J, V23, P2862, DOI 10.1038/sj.emboj.7600273; Thompson SR, 2000, MOL CELL BIOL, V20, P2129, DOI 10.1128/MCB.20.6.2129-2137.2000; Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020; Till DD, 1998, MECH DEVELOP, V79, P51, DOI 10.1016/S0925-4773(98)00173-7; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Viswanathan P, 2004, J BIOL CHEM, V279, P23988, DOI 10.1074/jbc.M402803200; Voeltz GK, 1998, MOL CELL BIOL, V18, P7537, DOI 10.1128/MCB.18.12.7537; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wickens M, 2000, TRANSLATIONAL CONTRO; Wilhelm JE, 2003, J CELL BIOL, V163, P1197, DOI 10.1083/jcb.200309088; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wreden C, 1997, DEVELOPMENT, V124, P3015; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016; Zappavigna V, 2004, P NATL ACAD SCI USA, V101, P14800, DOI 10.1073/pnas.0406451101	88	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25124	25133		10.1074/jbc.M604802200	http://dx.doi.org/10.1074/jbc.M604802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16793774	hybrid			2022-12-27	WOS:000240031300013
J	Nam, HJ; Gurda-Whitaker, B; Gan, WY; Ilaria, S; McKenna, R; Mehta, P; Alvarez, RA; Agbandje-McKenna, M				Nam, Hyun-Joo; Gurda-Whitaker, Brittney; Gan, Wand Yee; Ilaria, Shawen; McKenna, Robert; Mehta, Padmaja; Alvarez, Richard A.; Agbandje-McKenna, Mavis			Identification of the sialic acid structures recognized by minute virus of mice and the role of binding affinity in virulence adaptation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING; FELINE PARVOVIRUSES; INFLUENZA HEMAGGLUTININ; PROTOTYPE STRAIN; THEILERS-VIRUS; INFECTION; PATHOGENESIS; PARTICLES; RESIDUES; CANINE	Sialic acid binding is required for infectious cell surface receptor recognition by parvovirus minute virus of mice (MVM). We have utilized a glycan array consisting of similar to 180 different carbohydrate structures to identify the specific sialosides recognized by the prototype (MVMp) and immunosuppressive (MVMi) strains of MVM plus three virulent mutants of MVMp, MVMp-I362S, MVMp-K368R, and MVMp-I362S/K368R. All of the MVM capsids specifically bound to three structures with a terminal sialic acid-linked alpha 2-3 to a common Gal beta 1-4GlcNAc motif: Neu5Ac alpha 2-3Gal beta 1-4GlcNAc beta 1-4Gal beta 1-4GlcNAc (3 ' SiaLN-LN), Neu5Ac alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc (3 ' SiaLN-LN-LN), and Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)-GlcNAc(sLe(x)-Le(x)-Le(x)). In addition, MVMi also recognized four multisialylated glycans with terminal alpha 2-8 linkages: Neu5Ac alpha 2-8Neu5Ac alpha 2-8Neu5Ac alpha((Sia)(3)), Neu5Ac alpha 2-8Neu5Ac alpha 2-3Gal beta 1-4Glc(GD3), Neu5Ac alpha 2-8Neu5Ac alpha 2-8Neu5Ac alpha 2-3Gal beta 1-4Glc(GT3), and Neu5Ac alpha 2-8Neu5Ac alpha 2-3(GalNAc alpha 1-4)Gal beta 1-4Glc(GD2). Interestingly, the virulent MVMp-K368R mutant also recognized GT3. Analysis of the relative binding affinities using a surface plasmon resonance biospecific interaction (BIAcore) assay showed the wild-type MVMp and MVMi capsids binding with higher affinity to selected glycans compared with the virulent MVMp mutants. The reduced affinity of the virulent MVMp mutants are consistent with previous in vitro cell binding assays that had shown weaker binding to permissive cells compared with wild-type MVMp. This study identifies the sialic acid structures recognized by MVM. It also provides rationale for the tropism of MVM for malignant transformed cells that contain sLe(x) motifs and the neurotropism of MVMi, which is likely mediated via interactions with multisialylated glycans known to be tumor cell markers. Finally, the observations further implicate a decreased binding affinity for sialic acid in the in vivo adaptation of MVMp to a virulent phenotype.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	State University System of Florida; University of Florida; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Agbandje-McKenna, M (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.	mckenna@ufl.edu		Gurda, Brittney/0000-0002-0174-9385; Ilaria, Shawen/0000-0002-0935-8303	NIGMS NIH HHS [GM62116] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agbandje-McKenna M, 1998, STRUCT FOLD DES, V6, P1369, DOI 10.1016/S0969-2126(98)00137-3; ASTELL CR, 1986, J VIROL, V57, P656, DOI 10.1128/JVI.57.2.656-669.1986; BALLGOODRICH LJ, 1992, J VIROL, V66, P3415, DOI 10.1128/JVI.66.6.3415-3423.1992; Bauer PH, 1999, J VIROL, V73, P5826, DOI 10.1128/JVI.73.7.5826-5832.1999; BAUER PH, 1995, J VIROL, V69, P7925, DOI 10.1128/JVI.69.12.7925-7931.1995; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; BROWNSTEIN DG, 1991, LAB INVEST, V65, P357; BROWNSTEIN DG, 1992, J VIROL, V66, P3118, DOI 10.1128/JVI.66.5.3118-3124.1992; Chipman PR, 1998, STRUCTURE, V6, P135, DOI 10.1016/S0969-2126(98)00016-1; Cornelis JJ, 2004, CURR GENE THER, V4, P249; COTMORE SF, 1989, J VIROL, V63, P3902, DOI 10.1128/JVI.63.9.3902-3911.1989; D'Abramo AM, 2005, VIROLOGY, V340, P143, DOI 10.1016/j.virol.2005.06.019; GOTTSCHALK A, 1959, CHEM VIRUS RECEPTORS, P51; Govindasamy L, 2003, J VIROL, V77, P12211, DOI 10.1128/JVI.77.22.12211-12221.2003; Hernando E, 2000, VIROLOGY, V267, P299, DOI 10.1006/viro.1999.0123; Hueffer K, 2003, J VIROL, V77, P10099, DOI 10.1128/JVI.77.18.10099-10105.2003; Jnaoui K, 2002, J VIROL, V76, P8138, DOI 10.1128/JVI.76.16.8138-8147.2002; Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x; Kern A, 2003, J VIROL, V77, P11072, DOI 10.1128/JVI.77.20.11072-11081.2003; Kontou M, 2005, J VIROL, V79, P10931, DOI 10.1128/JVI.79.17.10931-10943.2005; Korchagina EY, 2005, GLYCOCONJUGATE J, V22, P127, DOI 10.1007/s10719-005-0508-x; Lopez-Bueno A, 2006, J VIROL, V80, P1563, DOI 10.1128/JVI.80.3.1563-1573.2006; Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; Opie SR, 2003, J VIROL, V77, P6995, DOI 10.1128/JVI.77.12.6995-7006.2003; Palermo LA, 2003, J VIROL, V77, P8915, DOI 10.1128/JVI.77.16.8915-8923.2003; Ramirez JC, 1996, J VIROL, V70, P8109; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; Rubio MP, 2005, J VIROL, V79, P11280, DOI 10.1128/JVI.79.17.11280-11290.2005; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Segovia JC, 1999, J VIROL, V73, P1774, DOI 10.1128/JVI.73.3.1774-1784.1999; SEGOVIA JC, 1995, J VIROL, V69, P3229, DOI 10.1128/JVI.69.5.3229-3232.1995; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; TATTERSALL P, 1977, J MOL BIOL, V111, P375, DOI 10.1016/S0022-2836(77)80060-0; TATTERSALL P, 1976, J VIROL, V20, P273, DOI 10.1128/JVI.20.1.273-289.1976; Xie Q, 2003, ACTA CRYSTALLOGR D, V59, P959, DOI 10.1107/S0907444903005675; Zhou L, 2000, J VIROL, V74, P1477, DOI 10.1128/JVI.74.3.1477-1485.2000	37	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25670	25677		10.1074/jbc.M604421200	http://dx.doi.org/10.1074/jbc.M604421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822863	hybrid			2022-12-27	WOS:000240031300070
J	Wu, ZR; Xing, X; Bohl, CE; Wisler, JW; Dalton, JT; Bell, CE				Wu, Zengru; Xing, Xu; Bohl, Casey E.; Wisler, James W.; Dalton, James T.; Bell, Charles E.			Domain structure and DNA binding regions of beta protein from bacteriophage lambda	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; COLI RECA PROTEIN; ESCHERICHIA-COLI; PHAGE-LAMBDA; RECOMBINATION; IDENTIFICATION; GENE; RENATURATION; EXONUCLEASE; SYSTEM	beta protein from bacteriophage lambda promotes a single- strand annealing reaction that is central to Red-mediated recombination at double-strand DNA breaks and chromosomal ends. beta protein binds most tightly to an intermediate of annealing formed by the sequential addition of two complementary oligonucleotides. Here we have characterized the domain structure of beta protein in the presence and absence of DNA using limited proteolysis. Residues 1 - 130 form an N-terminal "core" domain that is resistant to proteases in the absence of DNA, residues 131 - 177 form a central region with enhanced resistance to proteases upon DNA complex formation, and the C-terminal residues 178 - 261 of beta protein are sensitive to proteases in both the presence and absence of DNA. We probed the DNA binding regions of beta protein further using biotinylation of lysine residues and mass spectrometry. Several lysine residues within the first 177 residues of beta protein are protected from biotinylation in the DNA complex, whereas none of the lysine residues in the C-terminal portion are protected. The results lead to a model for the domain structure and DNA binding of beta protein in which a stable N-terminal core and a more flexible central domain come together to bind DNA, whereas a C-terminal tail remains disordered. A fragment consisting of residues 1 - 177 of beta protein maintains normal binding to sequentially added complementary oligonucleotides and has significantly enhanced binding to single- strand DNA.	Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Dalton, JT (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 1645 Neil Ave, Columbus, OH 43210 USA.	dalton.1@osu.edu; bell.489@osu.edu		Dalton, James T/0000-0002-3915-7326	NIGMS NIH HHS [GM067947, R01 GM067947-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067947] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; CARTER DM, 1971, J BIOL CHEM, V246, P2502; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Iyer LM, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-8; Karakousis G, 1998, J MOL BIOL, V276, P721, DOI 10.1006/jmbi.1997.1573; KMIEC E, 1981, J BIOL CHEM, V256, P2636; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KULKARNI SK, 1989, GENETICS, V123, P249; KUZMINOV A, 1999, ANNU REV GENET, V28, P49; Kvaratskhelia M, 2002, P NATL ACAD SCI USA, V99, P15988, DOI 10.1073/pnas.252550199; Li Z, 1998, J MOL BIOL, V276, P733, DOI 10.1006/jmbi.1997.1572; LITTLE JW, 1967, J BIOL CHEM, V242, P679; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MARSIC N, 1993, J BACTERIOL, V175, P4738; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; Muyrers JPP, 2001, TRENDS BIOCHEM SCI, V26, P325, DOI 10.1016/S0968-0004(00)01757-6; Mythili E, 1996, GENE, V182, P81, DOI 10.1016/S0378-1119(96)00518-5; Passy SI, 1999, P NATL ACAD SCI USA, V96, P4279, DOI 10.1073/pnas.96.8.4279; Poteete AR, 2001, FEMS MICROBIOL LETT, V201, P9, DOI 10.1016/S0378-1097(01)00242-7; Rybalchenko N, 2004, P NATL ACAD SCI USA, V101, P17056, DOI 10.1073/pnas.0408046101; Shell SM, 2005, BIOCHEMISTRY-US, V44, P971, DOI 10.1021/bi048208a; Stone KL, 2002, PROTEIN PROTOCOLS HD, P511; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	30	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25205	25214		10.1074/jbc.M512450200	http://dx.doi.org/10.1074/jbc.M512450200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16820360	Green Accepted, hybrid			2022-12-27	WOS:000240031300021
J	Yoon, D; Pastore, YD; Divoky, V; Liu, EL; Mlodnicka, AE; Rainey, K; Ponka, P; Semenza, GL; Schumacher, A; Prchal, JT				Yoon, Donghoon; Pastore, Yves D.; Divoky, Vladimir; Liu, Enli; Mlodnicka, Agnieszka E.; Rainey, Karin; Ponka, Premysl; Semenza, Gregg L.; Schumacher, Armin; Prchal, Josef T.			Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSCRIPTION; EMBRYOS LACKING; YOLK-SAC; OXYGEN; VEGF; POLYCYTHEMIA; ACTIVATION; EXPRESSION; HEPCIDIN; GROWTH	Hypoxia-inducible factor-1 (HIF-1) regulates the transcription of genes whose products play critical roles in energy metabolism, erythropoiesis, angiogenesis, and cell survival. Limited information is available concerning its function in mammalian hematopoiesis. Previous studies have demonstrated that homozygosity for a targeted null mutation in the Hif1 alpha gene, which encodes the hypoxia-responsive alpha subunit of HIF-1, causes cardiac, vascular, and neural malformations resulting in lethality by embryonic day 10.5 (E10.5). This study revealed reduced myeloid multilineage and committed erythroid progenitors in HIF-1 alpha-deficient embryos, as well as decreased hemoglobin content in erythroid colonies from HIF-1 alpha-deficient yolk sacs at E9.5. Dysregulation of erythropoietin (Epo) signaling was evident from a significant decrease in mRNA levels of Epo receptor (EpoR) in Hif1 alpha(-/-) yolk sac as well as Epo and EpoR mRNA in Hif1 alpha(-/-) embryos. The erythropoietic defects in HIF-1 alpha-deficient erythroid colonies could not be corrected by cytokines, such as vascular endothelial growth factor and Epo, but were ameliorated by Fe-SIH, a compound delivering iron into cells independently of iron transport proteins. Consistent with profound defects in iron homeostasis, Hif1 alpha(-/-) yolk sac and/or embryos demonstrated aberrant mRNA levels of hepcidin, Fpn1, Irp1, and frascati. We conclude that dysregulated expression of genes encoding Epo, EpoR, and iron regulatory proteins contributes to defective erythropoiesis in Hif1 alpha(-/-) yolk sacs. These results identify a novel role for HIF-1 in the regulation of iron homeostasis and reveal unexpected regulatory differences in Epo/EpoR signaling in yolk sac and embryonic erythropoiesis.	Univ Utah, Hematol Sect, Salt Lake City, UT 84132 USA; CHU Vaudois, CH-1005 Lausanne, Switzerland; Palacky Univ, Fac Med, Olomouc 77200, Czech Republic; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Vasc Biol Program,Inst Cell Engn,Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Radiat Oncol, Baltimore, MD 21205 USA; McGill Univ, Montreal, PQ H3T 1E2, Canada	Utah System of Higher Education; University of Utah; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Palacky University Olomouc; Baylor College of Medicine; Baylor College of Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; McGill University	Prchal, JT (corresponding author), Univ Utah, Hematol Sect, 30 North 1900 E,4C416 SOM, Salt Lake City, UT 84132 USA.	Josef.Prchal@hsc.utah.edu	Pastore, Yves Dominique/AAE-2427-2019; Ponka, Prem/A-4123-2011	Ponka, Prem/0000-0001-5835-1477	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338, R01HL050077] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL55338, R01HL50077-11] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Adelman DM, 1999, GENE DEV, V13, P2478, DOI 10.1101/gad.13.19.2478; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Ang SO, 2002, BLOOD CELL MOL DIS, V28, P57, DOI 10.1006/bcmd.2002.0488; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bichet S, 1999, FASEB J, V13, P285, DOI 10.1096/fasebj.13.2.285; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Choi K, 1998, DEVELOPMENT, V125, P725; Cianetti L, 2005, HAEMATOLOGICA, V90, P1595; Compernolle V, 2003, CARDIOVASC RES, V60, P569, DOI 10.1016/j.cardiores.2003.07.003; CORREA PN, 1991, BLOOD, V78, P2823; Dallalio G, 2006, BLOOD, V107, P2702, DOI 10.1182/blood-2005-07-2854; Damert A, 2002, DEVELOPMENT, V129, P1881; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Lee R, 2001, BLOOD, V98, P1408, DOI 10.1182/blood.V98.5.1408; Liu XB, 2002, BLOOD CELL MOL DIS, V29, P315, DOI 10.1006/bcmd.2002.0572; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maxwell PH, 2004, CELL CYCLE, V3, P156; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Mok H, 2006, J BIOL CHEM, V281, P7946, DOI 10.1074/jbc.M509857200; Mok H, 2004, DEVELOPMENT, V131, P4871, DOI 10.1242/dev.01342; Mok H, 2004, DEVELOPMENT, V131, P1859, DOI 10.1242/dev.01081; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Palis J, 1999, DEVELOPMENT, V126, P5073; PONKA P, 1979, BIOCHIM BIOPHYS ACTA, V586, P278, DOI 10.1016/0304-4165(79)90100-4; PONKA P, 1985, J BIOL CHEM, V260, P4717; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Scortegagna M, 2005, BLOOD, V105, P3133, DOI 10.1182/blood-2004-05-1695; Semenza GL, 2000, GENE DEV, V14, P1983; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xie XD, 2003, BLOOD, V101, P1329, DOI 10.1182/blood-2002-05-1468	47	166	184	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25703	25711		10.1074/jbc.M602329200	http://dx.doi.org/10.1074/jbc.M602329200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16787915	hybrid			2022-12-27	WOS:000240031300073
J	Carneiro, AMD; Blakely, RD				Carneiro, Ana Marin D.; Blakely, Randy D.			Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; MEMBRANE SKELETON; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; TERMINAL REGION; UP-REGULATION; LIPID RAFTS; PHOSPHORYLATION; TRAFFICKING; HIC-5	Emerging data indicate the existence of multiple regulatory processes supporting serotonin (5HT) transporter (SERT) capacity including regulated trafficking and catalytic activation, influenced by post-translational modifications and transporter-associated proteins. In the present study, using differential extraction and sedimentation procedures optimized for the purification of cytoskeletal and membrane-skeletal associated proteins, we analyze SERT localization in platelets. Wefind that most of the plasma membrane SERT is associated with themembrane skeleton. This association can be enhanced by both transporter activation and 5HT2A receptor activation. Inactivation of transport activity by phorbol ester treatment of intact platelets relocates SERT to the cytoskeleton fraction, consequently leading to transporter internalization. The translocation of SERT between these compartments is correlated with changes in the interaction with the LIM domain adaptor protein Hic-5. Co-immunoprecipitation and uptake activity studies suggest that Hic-5 is a determinant of transporter inactivation and relocation to a compartment subserving endocytic regulation. Associations of SERT with Hic-5 are evident in brain synaptosomes, suggesting the existence of parallel mechanisms operating to regulate SERT at serotonergic synapses.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Psychiat, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 7140 MRBIII, Nashville, TN 37232 USA.	randy.blakely@vanderbilt.edu		MD Carneiro, Ana/0000-0002-7470-7047; Marin Dias Carneiro, Ana/0000-0002-1204-9202	NCI NIH HHS [P30 CA068485] Funding Source: Medline; NIDA NIH HHS [R01 DA007390, R01 DA007390-10, DA07390] Funding Source: Medline; NIDDK NIH HHS [P60 DK020593, P30 DK020593] Funding Source: Medline; NIMH NIH HHS [T32 MH065215, T32 MH065782, T32 MH65782, T32 MH65215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065782, T32MH065215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bauman AL, 2000, J NEUROSCI, V20, P7571; Blakely RD, 1998, BIOL PSYCHIAT, V44, P169, DOI 10.1016/S0006-3223(98)00124-3; Carneiro AM, 2002, J NEUROSCI, V22, P7045; DASH D, 1995, FEBS LETT, V363, P231, DOI 10.1016/0014-5793(95)00320-9; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; Duan SM, 1999, J NEUROSCI, V19, P10193; Fox JEB, 2001, THROMB HAEMOSTASIS, V86, P198; FOX JEB, 1993, J BIOL CHEM, V268, P25973; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Jayanthi LD, 2005, MOL PHARMACOL, V67, P2077, DOI 10.1124/mol.104.009555; Jess U, 2002, BIOCHEM BIOPH RES CO, V294, P272, DOI 10.1016/S0006-291X(02)00460-6; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Koob GF, 2000, ANN NY ACAD SCI, V909, P170, DOI 10.1111/j.1749-6632.2000.tb06682.x; Kusumi A, 1996, CURR OPIN CELL BIOL, V8, P566, DOI 10.1016/S0955-0674(96)80036-6; Lohi O, 1998, FEBS LETT, V436, P419, DOI 10.1016/S0014-5793(98)01171-5; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Melikian HE, 2004, PHARMACOL THERAPEUT, V104, P17, DOI 10.1016/j.pharmthera.2004.07.006; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; MIYAMOTO S, 1995, JPN CIRC J, V59, P693, DOI 10.1253/jcj.59.693; Mochizuki H, 2005, NEUROCHEM INT, V46, P93, DOI 10.1016/j.neuint.2004.08.008; Murphy DL, 2003, GENES BRAIN BEHAV, V2, P350, DOI 10.1046/j.1601-1848.2003.00049.x; Murphy DL, 2004, MOL INTERV, V4, P109, DOI 10.1124/mi.4.2.8; Najimi M, 2002, FEBS LETT, V523, P224, DOI 10.1016/S0014-5793(02)02981-2; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Nishiya N, 2002, J BIOCHEM, V132, P279, DOI 10.1093/oxfordjournals.jbchem.a003222; Osada M, 2001, BIOCHEM J, V355, P691, DOI 10.1042/bj3550691; Pollock B G, 2001, Expert Opin Pharmacother, V2, P681, DOI 10.1517/14656566.2.4.681; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 2003, NEURON, V40, P537, DOI 10.1016/S0896-6273(03)00605-6; Quick MW, 2002, INT J DEV NEUROSCI, V20, P219, DOI 10.1016/S0736-5748(02)00021-7; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; RUDNICK G, 1977, J BIOL CHEM, V252, P2170; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Sagot I, 1997, FEBS LETT, V410, P229, DOI 10.1016/S0014-5793(97)00594-2; Sakai N, 2000, NEUROCHEM INT, V36, P567, DOI 10.1016/S0197-0186(99)00160-6; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Scanlon SM, 2001, BIOCHEMISTRY-US, V40, P10507, DOI 10.1021/bi010730z; Schatzberg AF, 2000, J CLIN PSYCHIAT, V61, P9; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Sur C, 1996, EUR J NEUROSCI, V8, P2753, DOI 10.1111/j.1460-9568.1996.tb01570.x; TOLLEFSON GD, 1989, PSYCHOPATHOLOGY, V22, P37, DOI 10.1159/000284625; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Wang JW, 2004, BIOCHEMISTRY-US, V43, P1010, DOI 10.1021/bi035696y; Zhou FC, 1996, MOL BRAIN RES, V43, P267, DOI 10.1016/S0169-328X(96)00209-4; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462; Zohar J, 2000, World J Biol Psychiatry, V1, P92, DOI 10.3109/15622970009150571	52	84	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24769	24780		10.1074/jbc.M603877200	http://dx.doi.org/10.1074/jbc.M603877200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803896	Green Accepted, hybrid			2022-12-27	WOS:000239847800073
J	Le Gac, G; Esteve, PO; Ferec, C; Pradhan, S				Le Gac, Gerald; Esteve, Pierre-Olivier; Ferec, Claude; Pradhan, Sriharsa			DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; CPG-BINDING-PROTEIN; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; HISTONE METHYLTRANSFERASE; CANCER-CELLS; METHYLATION; COMPLEX; DNMT1; EXPRESSION	The Cdc25C phosphatase mediates cellular entry into mitosis in mammalian cells. Cdc25C activates Cdc2 for entry into mitosis by dephosphorylating Thr and Tyr at the site of inhibitory phosphorylation. The Cdc25C gene contains tumor suppressor p53 binding sites and is demonstrated to contribute to the p53-dependent cell cycle arrest upon DNA damage. Here we show that both Cdc25C and Cdc2 were down-regulated in wild-type HCT116 cells but not in p53-null, DNMT1-null or DNMT1- and DNMT3b-null cells, upon p53 stabilization following doxorubicin-mediated DNA damage. Furthermore, zebularine, a drug that selectively traps and depletes nuclear DNMT1 and DNMT3b, relieved p53-mediated repression of endogenous Cdc25C and Cdc2. Methylation analysis of the Cdc25C and Cdc2 promoter displayed internal CG methylation proximal to the p53 binding site upon DNA damage in a p53-dependent manner. Chromatin immunoprecipitation of doxorubicin treated wild- type HCT116 cells showed the presence of DNMT1, p53, H3K9me2, and the transcriptional repressor HDAC1 on the Cdc25C and Cdc2 promoters, suggesting their involvement as repressive complexes in Cdc25C and Cdc2 gene silencing. Thus, the general mechanism of p53-mediated gene repression may involve recruitment of other repressive factors.	New England Biolabs Inc, Ipswich, MA 01938 USA; INSERM, U613, Dept Genet, Etab Francais Sang, F-29275 Brest, France	New England Biolabs; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale	Pradhan, S (corresponding author), New England Biolabs Inc, 240 Cty Rd, Ipswich, MA 01938 USA.	pradhan@neb.com	Le Gac, Gérald/AFQ-1679-2022; Ferec, Claude/ABG-9699-2020	Ferec, Claude/0000-0002-2325-0710; LE GAC, Gerald/0000-0003-3236-7280				Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Ma L, 2005, P NATL ACAD SCI USA, V102, P14266, DOI 10.1073/pnas.0501352102; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mortusewicz O, 2005, P NATL ACAD SCI USA, V102, P8905, DOI 10.1073/pnas.0501034102; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pradhan S, 2003, CLIN IMMUNOL, V109, P6, DOI 10.1016/S1521-6616(03)00204-3; Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; St Clair S, 2004, MOL CELL, V16, P725; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; TAN NW, 1990, BIOCHEMISTRY-US, V29, P9234, DOI 10.1021/bi00491a018; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Winters ZE, 2001, EUR J CANCER, V37, P2405, DOI 10.1016/S0959-8049(01)00327-6; Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9	46	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24161	24170		10.1074/jbc.M603724200	http://dx.doi.org/10.1074/jbc.M603724200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807237				2022-12-27	WOS:000239847800010
J	Hodel, AE; Harreman, MT; Pulliam, KF; Harben, ME; Holmes, JS; Hodel, MR; Berland, KM; Corbett, AH				Hodel, Alec E.; Harreman, Michelle T.; Pulliam, Kanika F.; Harben, Mary Elizabeth; Holmes, Jordan S.; Hodel, Mary R.; Berland, Keith M.; Corbett, Anita H.			Nuclear localization signal receptor affinity correlates with in vivo localization in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORTIN-ALPHA; KARYOPHERIN-ALPHA; STRUCTURAL BASIS; SYSTEMS-ANALYSIS; TERMINAL DOMAIN; PROTEIN IMPORT; TRANSPORT; BETA; EXPORT; COMPLEX	Nuclear localization signals (NLSs) target proteins into the nucleus through mediating interactions with nuclear import receptors. Here, we perform a quantitative analysis of the correlation between NLS receptor affinity and the steady-state distribution of NLS-bearing cargo proteins between the cytoplasm and the nucleus of live yeast, which reflects the relative import rates of various NLS sequences. We find that there is a complicated, but monotonic quantitative relationship between the affinity of an NLS for the import receptor, importin alpha, and the steady-state accumulation of the cargo in the nucleus. This analysis takes into consideration the impact of protein size. In addition, the hypothetical upper limit to an NLS affinity for the receptors is explored through genetic approaches. Overall, our results indicate that there is a correlation between the binding affinity of an NLS cargo for the NLS receptor, importin alpha, and the import rate for this cargo. This correlation, however, is not maintained for cargoes that bind to the NLS receptor with very weak or very strong affinity.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Phys, Atlanta, GA 30322 USA	Emory University; Emory University	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE,Rm 4117, Atlanta, GA 30322 USA.	acorbe2@emory.edu	Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Gilchrist D, 2003, J BIOL CHEM, V278, P51937, DOI 10.1074/jbc.M307371200; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Matsuura Y, 2003, EMBO J, V22, P5358, DOI 10.1093/emboj/cdg538; Matsuura Y, 2004, NATURE, V432, P872, DOI 10.1038/nature03144; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Quimby BB, 2001, J BIOL CHEM, V276, P38820, DOI 10.1074/jbc.M105054200; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; So PTC, 2000, ANNU REV BIOMED ENG, V2, P399, DOI 10.1146/annurev.bioeng.2.1.399; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	53	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23545	23556		10.1074/jbc.M601718200	http://dx.doi.org/10.1074/jbc.M601718200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785238	hybrid			2022-12-27	WOS:000239702900029
J	Noordeen, NA; Carafoli, F; Hohenester, E; Horton, MA; Leitinger, B				Noordeen, Nafeesa A.; Carafoli, Federico; Hohenester, Erhard; Horton, Michael A.; Leitinger, Birgit			A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCOIDIN DOMAIN RECEPTOR; GROWTH-FACTOR RECEPTORS; ERYTHROPOIETIN RECEPTOR; PROLIFERATION; ASSOCIATION; BINDING; MOTIF; OLIGOMERIZATION; IDENTIFICATION; EXPRESSION	Receptor tyrosine kinases of the discoidin domain family, DDR1 and DDR2, are activated by different types of collagen and play important roles in cell adhesion, migration, proliferation, and matrix remodeling. In a previous study, we found that collagen binding by the discoidin domain receptors (DDRs) requires dimerization of their extracellular domains (Leitinger, B. (2003) J. Biol. Chem. 278, 16761 - 16769), indicating that the paradigm of ligand-induced receptor dimerization may not apply to the DDRs. Using chemical cross-linking and co-immunoprecipitation of differently tagged DDRs, we now show that the DDRs form ligand-independent dimers in the biosynthetic pathway and on the cell surface. We further show that both the extracellular and the cytoplasmic domains are individually dispensable for DDR1 dimerization. The DDR1 transmembrane domain contains two putative dimerization motifs, a leucine zipper and a GXXXG motif. Mutations disrupting the leucine zipper strongly impaired collagen-induced transmembrane signaling, although the mutant DDR1 proteins were still able to dimerize, whereas mutation of the GXXXG motif had no effect. A bacterial reporter assay (named TOXCAT) showed that the DDR1 transmembrane domain has a strong potential for self-association in a biological membrane and that this interaction occurs via the leucine zipper and not the GXXXG motif. Our results demonstrate that the DDRs exist as stable dimers in the absence of ligand and that receptor activation requires specific interactions made by the transmembrane leucine zipper.	UCL, Dept Med, London WC1E 6JJ, England; Univ London Imperial Coll Sci & Technol, Div Cell & Mol Biol, London SW7 2AZ, England; Univ London Imperial Coll Sci & Technol, Div Biomed Sci, London SW7 2AZ, England	University of London; University College London; Imperial College London; Imperial College London	Leitinger, B (corresponding author), UCL, Dept Med, 5 Univ St, London WC1E 6JJ, England.	b.leitinger@imperial.ac.uk			Wellcome Trust [054334] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brown RJ, 2005, NAT STRUCT MOL BIOL, V12, P814, DOI 10.1038/nsmb977; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Curat CA, 2001, J BIOL CHEM, V276, P45952, DOI 10.1074/jbc.M104360200; Dejmek J, 2005, CLIN CANCER RES, V11, P520; Evtimova V, 2003, TUMOR BIOL, V24, P189, DOI 10.1159/000074429; Ferri N, 2004, AM J PATHOL, V164, P1575, DOI 10.1016/S0002-9440(10)63716-9; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Gerber D, 2004, J BIOL CHEM, V279, P21177, DOI 10.1074/jbc.M400847200; Gurezka R, 2001, J BIOL CHEM, V276, P45580, DOI 10.1074/jbc.M105362200; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; Huber O, 1999, J CELL SCI, V112, P4415; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; Leitinger B, 2004, J MOL BIOL, V344, P993, DOI 10.1016/j.jmb.2004.09.089; Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Martin-Fernandez M, 2002, BIOPHYS J, V82, P2415, DOI 10.1016/S0006-3495(02)75585-9; Mason JM, 2004, CHEMBIOCHEM, V5, P170, DOI 10.1002/cbic.200300781; Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; Ram R, 2006, J NEURO-ONCOL, V76, P239, DOI 10.1007/s11060-005-6874-1; Ruan WM, 2004, J BIOL CHEM, V279, P3273, DOI 10.1074/jbc.M309311200; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2002, FEBS LETT, V514, P175, DOI 10.1016/S0014-5793(02)02360-8; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Wall SJ, 2005, J BIOL CHEM, V280, P40187, DOI 10.1074/jbc.M508226200; Xu L, 2005, J BIOL CHEM, V280, P548, DOI 10.1074/jbc.M411036200; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	42	88	91	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22744	22751		10.1074/jbc.M603233200	http://dx.doi.org/10.1074/jbc.M603233200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774916	hybrid			2022-12-27	WOS:000239542600035
J	Stewart, JJ; Fischbeck, JA; Chen, X; Stargell, LA				Stewart, Jennifer J.; Fischbeck, Julie A.; Chen, Xu; Stargell, Laurie A.			Non-optimal TATA elements exhibit diverse mechanistic consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROMOTER DATABASE; BOX-BINDING PROTEIN; GENE-EXPRESSION; HAPLOINSUFFICIENCY; SEQUENCE; COMPLEX	To reveal mechanistic differences in transcription initiation between variant TATA elements, in vivo and in vitro assays of the functional activity of 14 different sequences were compared. Variant elements exhibited particular degrees of activation in vivo but universally were unable to support the -fold activation observed for an element consisting of TATAAA. Each element was classified by its functional activity for in vitro interaction with TATA-binding protein (TBP), TFIIA, and TFIIB. Certain off-consensus TATA elements form poor binding sites for TBP and this compromised interaction interferes with higher order complex formation with TFIIA and/or TFIIB. Other elements are only modestly decreased for TBP binding but dramatically affected for higher order complex formation. Another distinct category is comprised of two elements (CATAAA and TATAAG), which are not affected in the initial formation of the TBP, TFIIA-TBP, or TFIIB-TBP complexes. However, CATAAA and TATAAG are unable to form a stable TFIIA-TBP-DNA complex in vitro. Moreover, fusion of TFIIA to TBP specifically restores activity from these two elements in vivo. Taken together, these results indicate that the interplay between the sequence of the TATA element and the components of the general transcription machinery can lead to variations in the formation of functional complexes and/or the stability of these complexes. These differences offer distinct opportunities for an organism to exploit diverse steps in the regulation of gene expression depending on the precise TATA element sequence at a given gene.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Stargell, LA (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA.	Laurie.Stargell@Colostate.edu	Stargell, Laurie/GWC-7423-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056884] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56884] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Cabelof DC, 2003, CANCER RES, V63, P5799; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; Chirala SS, 2003, P NATL ACAD SCI USA, V100, P6358, DOI 10.1073/pnas.0931394100; Deutschbauer AM, 2005, GENETICS, V169, P1915, DOI 10.1534/genetics.104.036871; Diagana TT, 1997, J MOL BIOL, V265, P480, DOI 10.1006/jmbi.1996.0752; Gershenzon NI, 2005, BIOINFORMATICS, V21, P1295, DOI 10.1093/bioinformatics/bti172; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IYER V, 1995, MOL CELL BIOL, V15, P7059; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Kim JW, 2004, MOL CELL BIOL, V24, P8104, DOI 10.1128/MCB.24.18.8104-8112.2004; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Molina C, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-25; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; Ohler U., 2002, GENOME BIOL, V3, pRESEARCH0087, DOI [10.1186/gb-2002-3-12-research0087, DOI 10.1186/GB-2002-3-12-RESEARCH0087]; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Powell RM, 2001, J BIOL CHEM, V276, P29782, DOI 10.1074/jbc.M104099200; Praz V, 2002, NUCLEIC ACIDS RES, V30, P322, DOI 10.1093/nar/30.1.322; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Stewart JJ, 2001, J BIOL CHEM, V276, P30078, DOI 10.1074/jbc.M105276200; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Wu JO, 2001, J BIOL CHEM, V276, P14623, DOI 10.1074/jbc.M004401200	32	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22665	22673		10.1074/jbc.M603237200	http://dx.doi.org/10.1074/jbc.M603237200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772290	hybrid			2022-12-27	WOS:000239542600027
J	Renart, ML; Barrera, FN; Molina, ML; Encinar, JA; Poveda, JA; Fernandez, AM; Gomez, J; Gonzalez-Ros, JM				Renart, Maria L.; Barrera, Francisco N.; Molina, Maria L.; Encinar, Jose A.; Poveda, Jose A.; Fernandez, Asia M.; Gomez, Javier; Gonzalez-Ros, Jose M.			Effects of conducting and blocking ions on the structure and stability of the potassium channel KcsA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; PROKARYOTIC K+ CHANNEL; C-TYPE-INACTIVATION; STREPTOMYCES-LIVIDANS; MONOVALENT CATIONS; PROTEIN; PORE; BINDING; SELECTIVITY; AFFINITY	This article reports on the interaction of conducting ( K (+)) and blocking (Na+) monovalent metal ions with detergent- solubilized and lipid-reconstituted forms of the K (+) channel KcsA. Monitoring of the protein intrinsic fluorescence reveals that the two ions bind competitively to KcsA with distinct affinities ( dissociation constants for the KcsA . K+ and KcsA(+) Na+ complexes of similar to 8 and 190mM, respectively) and induce different conformations of the ion- bound protein. The differences in binding affinity as well as the higher K+ concentration bathing the intracellular mouth of the channel, through which the cations gain access to the protein binding sites, should favor that only KcsA . K+ complexes are formed under physiological- like conditions. Nevertheless, despite such prediction, it was also found that concentrations of Na+ well below its dissociation constant and even in the presence of higher K+ concentrations, cause a remarkable decrease in the protein thermal stability and facilitate thermal dissociation into subunits of the tetrameric KcsA, as concluded from the temperature dependence of the protein infrared spectra and from gel electrophoresis, respectively. These latter observations cannot be explained based on the occupancy of the binding sites from above and suggest that there must be additional ion binding sites, whose occupancy could not be detected by fluorescence and in which the affinity for Na+ must be higher or at least similar to that of K+. Moreover, cation binding as reported by means of fluorescence does not suffice to explain the large differences in free energy of stabilization involved in the formation of the KcsA(+) Na+ and KcsA . K+ complexes, which for the most part should arise from synergistic effects of the ion- mediated intersubunit interactions.	Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain	Universidad Miguel Hernandez de Elche	Gonzalez-Ros, JM (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain.	gonzalez.ros@umh.es	Carvajal, Asia Fernandez/G-8877-2015; Encinar, José A/F-2946-2013; Gallego, María Luisa Molina/K-4810-2017; Encinar, José Antonio/AAE-9141-2020; Gomez, Javier/N-9820-2013; Poveda Larrosa, Jose Antonio/H-5925-2015	Encinar, José A/0000-0002-7219-3863; Gallego, María Luisa Molina/0000-0001-9190-6948; Encinar, José Antonio/0000-0002-7219-3863; Gomez, Javier/0000-0001-9612-5075; Poveda Larrosa, Jose Antonio/0000-0003-0722-3752; Barrera, Francisco N./0000-0002-5200-7891; Gonzalez Ros, Jose Manuel/0000-0002-4804-6855; Fernandez-Carvajal, Asia/0000-0003-2741-1427; Renart, Maria Lourdes/0000-0002-6717-4756				ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; Barrera FN, 2005, BIOCHEMISTRY-US, V44, P14344, DOI 10.1021/bi050845t; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Echabe I, 1997, BIOSPECTROSCOPY, V3, P469; Encinar JA, 2005, FEBS LETT, V579, P5199, DOI 10.1016/j.febslet.2005.08.038; FRENCH RJ, 1977, J GEN PHYSIOL, V70, P707, DOI 10.1085/jgp.70.6.707; Gomez-Lagunas F, 2001, J GEN PHYSIOL, V118, P639, DOI 10.1085/jgp.118.6.639; GomezLagunas F, 1997, J PHYSIOL-LONDON, V499, P3, DOI 10.1113/jphysiol.1997.sp021907; GONZALEZROS JM, 1984, BIOCHEM BIOPH RES CO, V120, P368, DOI 10.1016/0006-291X(84)91263-4; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B., 1992, IONIC CHANNELS EXCIT; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; Krishnan MN, 2005, J GEN PHYSIOL, V126, P271, DOI 10.1085/jgp.200509323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MacKinnon R, 2003, FEBS LETT, V555, P62, DOI 10.1016/S0014-5793(03)01104-9; Martell A., 1982, CRITICAL STABILITY C, V5; Meuser D, 1999, FEBS LETT, V462, P447, DOI 10.1016/S0014-5793(99)01579-3; Molina ML, 2004, BIOCHEMISTRY-US, V43, P14924, DOI 10.1021/bi048889+; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; Nimigean CM, 2002, J GEN PHYSIOL, V120, P323, DOI 10.1085/jgp.20028614; Ogielska EM, 1999, J GEN PHYSIOL, V113, P347, DOI 10.1085/jgp.113.2.347; Pace C. N., 1997, PROTEIN STRUCTURE PR; RIQUELME G, 1990, BIOCHEMISTRY-US, V29, P11215, DOI 10.1021/bi00503a009; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Royer C A, 1995, Methods Mol Biol, V40, P65; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Shrivastava IH, 2002, EUR BIOPHYS J BIOPHY, V31, P207, DOI 10.1007/s00249-002-0209-3; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Splitt H, 2000, FEBS LETT, V472, P83, DOI 10.1016/S0014-5793(00)01429-0; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; van den Brink-van der Laan E, 2004, BIOCHEMISTRY-US, V43, P4240, DOI 10.1021/bi036129d; Yellen G, 1997, J GEN PHYSIOL, V110, P83, DOI 10.1085/jgp.110.2.83; Zhou Y, 2004, BIOCHEMISTRY-US, V43, P4978, DOI 10.1021/bi049876z; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	48	24	24	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29905	29915		10.1074/jbc.M602636200	http://dx.doi.org/10.1074/jbc.M602636200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16815844	hybrid, Green Published			2022-12-27	WOS:000240896300052
J	Cruchaga, C; Anso, E; Rouzaut, A; Martinez-Irujo, JJ				Cruchaga, Carlos; Anso, Elena; Rouzaut, Ana; Martinez-Irujo, Juan J.			Selective excision of chain-terminating nucleotides by HIV-1 reverse transcriptase with phosphonoformate as substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER UNBLOCKING ACTIVITY; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; SYNERGISTIC INHIBITION; DRUG-RESISTANCE; DNA-POLYMERASE; NONNUCLEOSIDE INHIBITORS; REPLICATION INVITRO; ANTIVIRAL ACTIVITY; AIDS DRUGS	A major mechanism for human immunodeficiency virus 1 (HIV-1) reverse transcriptase (RT) resistance to nucleoside analogs involves the phosphorolytical removal of the chain-terminating nucleotide from the 3'-end of the primer. In this work, we analyzed the effect of phosphonoformate (PFA) and other pyrophosphate (PPi) analogs on PPi- and ATP-dependent phosphorolysis catalyzed by HIV-1 RT. Our experimental data demonstrated that PFA did not behave as a linear inhibitor but as an alternative substrate, allowing RT to remove AZT from a terminated primer through a PFA-dependent mechanism. Interestingly, in non-terminated primers, PFA was not a substrate for this reaction and competitively inhibited PPi- and ATP-dependent phosphorolysis. In fact, binding of PFA to the RT(.)template/primer complex was hindered by the presence of a chain terminator at the 3'-end of the primer. Other pyrophosphate analogs, such as phosphonoacetate, were substrates for the excision reaction with both terminated and non-terminated primers, whereas pamidronate, a bisphosphonate that prevents bone resorption, was not a substrate for these reactions and competitively inhibited the phosphorolytic activity of RT. As expected from their mechanisms of action, pamidronate (but not PFA) synergistically inhibits HIV-1 RT in combination with AZT-triphosphate in the presence of PPi or ATP. These results provide new clues about the mechanism of action of PFA and demonstrate that only certain pyrophosphate analogs can enhance the effect of nucleosidic inhibitors by blocking the excision of chain-terminating nucleotides catalyzed by HIV-1 RT. The relevance of these findings in combined chemotherapy is discussed.	Univ Navarra, Dept Bioquim & Biol Mol, Byron, GA 31008 USA	University of Navarra	Martinez-Irujo, JJ (corresponding author), Univ Navarra, Dept Bioquim & Biol Mol, Calle Irunlarrea S-N, Byron, GA 31008 USA.	jjmirujo@unav.es	Rouzaut, Ana/I-2576-2017; Cruchaga, Carlos/ABF-4065-2020; Martinez-Irujo, Juan/N-3193-2014	Rouzaut, Ana/0000-0003-3226-9162; Cruchaga, Carlos/0000-0002-0276-2899; Martinez-Irujo, Juan/0000-0003-4576-8139				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arion D, 2000, J BIOL CHEM, V275, P9251, DOI 10.1074/jbc.275.13.9251; Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200; BISSWANGER H, 2002, ENZYME KINETICS PRIN, P106; Borkow G, 1999, ANTIMICROB AGENTS CH, V43, P259, DOI 10.1128/AAC.43.2.259; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Crespan E, 2005, ANTIMICROB AGENTS CH, V49, P342, DOI 10.1128/AAC.49.1.342-349.2005; Cruchaga C, 2005, BIOCHEMISTRY-US, V44, P3535, DOI 10.1021/bi048129z; DERSE D, 1982, J BIOL CHEM, V257, P251; ERIKSSON B, 1980, BIOCHIM BIOPHYS ACTA, V607, P53, DOI 10.1016/0005-2787(80)90220-8; ERIKSSON BFH, 1989, ANTIMICROB AGENTS CH, V33, P663, DOI 10.1128/AAC.33.5.663; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; Goldschmidt V, 2004, INT J BIOCHEM CELL B, V36, P1687, DOI 10.1016/j.biocel.2004.02.028; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; Gotte Matthias, 2004, Expert Rev Anti Infect Ther, V2, P707, DOI 10.1586/14789072.2.5.707; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBSON MA, 1991, J INFECT DIS, V163, P1219, DOI 10.1093/infdis/163.6.1219; Jamburuthugoda VK, 2005, BIOCHEMISTRY-US, V44, P10635, DOI 10.1021/bi050611+; KONG XB, 1991, ANTIMICROB AGENTS CH, V35, P2003, DOI 10.1128/AAC.35.10.2003; KOSHIDA R, 1989, ANTIMICROB AGENTS CH, V33, P778, DOI 10.1128/AAC.33.5.778; Kukhanova MK, 2005, BIOCHEM BIOPH RES CO, V338, P1335, DOI 10.1016/j.bbrc.2005.10.092; LEINBACH SS, 1976, BIOCHEMISTRY-US, V15, P426, DOI 10.1021/bi00647a029; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; Martinez-Irujo JJ, 1998, BIOCHEM J, V329, P689, DOI 10.1042/bj3290689; Meyer PR, 2003, J VIROL, V77, P6127, DOI 10.1128/JVI.77.11.6127-6137.2003; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; OBERG B, 1989, PHARMACOL THERAPEUT, V40, P213, DOI 10.1016/0163-7258(89)90097-1; Odriozola L, 2003, J BIOL CHEM, V278, P42710, DOI 10.1074/jbc.M212673200; Palmer S, 1996, ANTIMICROB AGENTS CH, V40, P1285, DOI 10.1128/AAC.40.5.1285; PARNIAK MA, 2004, ANTIVIR THER LOND, V9, P32; Ray AS, 2003, BIOCHEMISTRY-US, V42, P8831, DOI 10.1021/bi034435l; Sarafianos SG, 2004, INT J BIOCHEM CELL B, V36, P1706, DOI 10.1016/j.biocel.2004.02.027; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; Tchesnokov EP, 2006, J VIROL, V80, P1440, DOI 10.1128/JVI.80.3.1440-1450.2006; Villahermosa ML, 1997, BIOCHEMISTRY-US, V36, P13223, DOI 10.1021/bi970852k; Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x	39	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27744	27752		10.1074/jbc.M603360200	http://dx.doi.org/10.1074/jbc.M603360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16829515	hybrid			2022-12-27	WOS:000240534400010
J	Kiyonari, S; Takayama, K; Nishida, H; Ishino, Y				Kiyonari, Shinichi; Takayama, Kohei; Nishida, Hirokazu; Ishino, Yoshizumi			Identification of a novel binding motif in Pyrococcus furiosus DNA ligase for the functional interaction with proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-FACTOR-C; BIOCHEMICAL-CHARACTERIZATION; HYPERTHERMOPHILIC ARCHAEON; PCNA; PROTEINS; MECHANISM; PARTNERS; COMPLEX; CLAMP	DNA ligase is an essential enzyme for all organisms and catalyzes a nick-joining reaction in the final step of the DNA replication, repair, and recombination processes. Herein, we show the physical and functional interaction between DNA ligase and proliferating cell nuclear antigen ( PCNA) from the hyperthermophilic Euryarchaea Pyrococcus furiosus. The stimulatory effect of P. furiosus PCNA on the enzyme activity of P. furiosus DNA ligase was observed not at low ionic strength, but at a high salt concentration, at which a DNA ligase alone cannot bind to a nicked DNA substrate. On the basis of mutational analyses, we identified the amino acid residues that are critical for PCNA binding in a loop structure located in the N-terminal DNA-binding domain of P. furiosus DNA ligase. We propose that the pentapeptide motif QKSFF is involved in the PCNA-interacting motifs, in which Gln and the first Phe are especially important for stable binding with PCNA.	Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Fukuoka 8128581, Japan; Japan Sci & Technol Agcy, BIRD, Fukuoka 8128581, Japan; Hitachi Ltd, Cent Res Lab, Kokubunji, Tokyo 1858581, Japan	Kyushu University; Japan Science & Technology Agency (JST); Hitachi Limited	Ishino, Y (corresponding author), Kyushu Univ, Fac Agr, Dept Genet Resources Technol, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	ishino@agr.kyushu-u.ac.jp	Kiyonari, Shinichi/I-7329-2014	Nishida, Hirokazu/0000-0003-1738-8331; Ishino, Yoshizumi/0000-0001-9419-0826				Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Dionne I, 2005, BIOCHEM J, V387, P859, DOI 10.1042/BJ20041661; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Hethke C, 1999, GENETICS, V152, P1325; Ho CK, 1997, J VIROL, V71, P1931, DOI 10.1128/JVI.71.3.1931-1937.1997; Jeon SJ, 2003, FEBS LETT, V550, P69, DOI 10.1016/S0014-5793(03)00821-4; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kanoksilapatham Wirojne, 2004, Archaea, V1, P277, DOI 10.1155/2004/513563; Keppetipola N, 2005, J BACTERIOL, V187, P6902, DOI 10.1128/JB.187.20.6902-6908.2005; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; Komori K, 2000, NUCLEIC ACIDS RES, V28, P4544, DOI 10.1093/nar/28.22.4544; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Lai XQ, 2002, EXTREMOPHILES, V6, P469, DOI 10.1007/s00792-002-0284-5; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Martin RC, 2002, EPILEPSY BEHAV, V3, P4, DOI 10.1006/ebeh.2001.0316; Martins A, 2004, J BIOL CHEM, V279, P50654, DOI 10.1074/jbc.M407657200; MATHUR EJ, 1996, Patent No. 5506137; Matsumiya S, 2003, PROTEIN SCI, V12, P823, DOI 10.1110/ps.0234503; Matsumiya S, 2002, GENES CELLS, V7, P911, DOI 10.1046/j.1365-2443.2002.00572.x; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Nakatani M, 2000, J BACTERIOL, V182, P6424, DOI 10.1128/JB.182.22.6424-6433.2000; Nishida H, 2005, GENES GENET SYST, V80, P83, DOI 10.1266/ggs.80.83; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Rolland JL, 2004, FEMS MICROBIOL LETT, V236, P267, DOI 10.1016/j.femsle.2004.05.045; SCHOLZ S, 1992, FEBS LETT, V306, P239, DOI 10.1016/0014-5793(92)81008-A; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tomkinson AE, 2006, CHEM REV, V106, P687, DOI 10.1021/cr040498d; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+	38	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28023	28032		10.1074/jbc.M603403200	http://dx.doi.org/10.1074/jbc.M603403200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16829513	hybrid			2022-12-27	WOS:000240534400039
J	Born, P; Breukink, E; Vollmer, W				Born, Petra; Breukink, Eefjan; Vollmer, Waldemar			In vitro synthesis of cross-linked murein and its attachment to sacculi by PBP1A from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; CELL-WALL PEPTIDOGLYCAN; TRANSGLYCOSYLASE; TRANSPEPTIDASE; DIVISION; COMPONENT; MUTANTS; GROWTH; GLYCOSYLTRANSFERASE; BIOSYNTHESIS	The penicillin-binding protein (PBP) 1A is a major murein (peptidoglycan) synthase in Escherichia coli. The murein synthesis activity of PBP1A was studied in vitro with radioactive lipid II substrate. PBP1A produced murein glycan strands by transglycosylation and formed peptide cross-links by transpeptidation. Time course experiments revealed that PBP1A, unlike PBP1B, required the presence of polymerized glycan strands carrying monomeric peptides for cross-linking activity. PBP1A was capable of attaching nascent murein synthesized from radioactive lipid II to nonlabeled murein sacculi. The attachment of the new material occurred by transpeptidation reactions in which monomeric tri- and tetrapeptides in the sacculi were the acceptors.	Univ Tubingen, D-72076 Tubingen, Germany; Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands	Eberhard Karls University of Tubingen; Utrecht University	Vollmer, W (corresponding author), Univ Tubingen, Morgenstelle 28, D-72076 Tubingen, Germany.	waldemar.vollmer@uni-tuebingen.de	Breukink, Eefjan/I-3039-2016	Breukink, Eefjan/0000-0002-7311-0660				Barrett DS, 2004, BIOCHEMISTRY-US, V43, P12375, DOI 10.1021/bi049142m; Bertsche U, 2005, J BIOL CHEM, V280, P38096, DOI 10.1074/jbc.M508646200; BISHOP RE, 1993, FEMS MICROBIOL LETT, V114, P349, DOI 10.1111/j.1574-6968.1993.tb06597.x; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; BURMAN LG, 1984, P NATL ACAD SCI-BIOL, V81, P1844, DOI 10.1073/pnas.81.6.1844; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Charpentier X, 2002, J BACTERIOL, V184, P3749, DOI 10.1128/JB.184.13.3749-3752.2002; COOPER S, 1988, J BACTERIOL, V170, P422, DOI 10.1128/jb.170.1.422-430.1988; DARGIS M, 1994, ANTIMICROB AGENTS CH, V38, P973, DOI 10.1128/AAC.38.5.973; DEJONGE BLM, 1989, J BACTERIOL, V171, P5783, DOI 10.1128/jb.171.11.5783-5794.1989; DELPORTILLO FG, 1990, J BACTERIOL, V172, P5863; DIBERARDINO M, 1996, FEBS LETT, V392, P184; GLAUNER B, 1990, J BIOL CHEM, V265, P18988; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; KATO J, 1984, MOL GEN GENET, V196, P449, DOI 10.1007/BF00436192; KOHLRAUSCH U, 1991, FEMS MICROBIOL LETT, V78, P253; KRAUS W, 1987, J BACTERIOL, V169, P3099, DOI 10.1128/jb.169.7.3099-3103.1987; KRAUS W, 1985, J BACTERIOL, V162, P1000, DOI 10.1128/JB.162.3.1000-1004.1985; MATSUHASHI M, 1990, RES MICROBIOL, V141, P89, DOI 10.1016/0923-2508(90)90101-U; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; NAKAGAWA J, 1982, BIOCHEM BIOPH RES CO, V105, P1546, DOI 10.1016/0006-291X(82)90964-0; ROJO F, 1984, EUR J BIOCHEM, V144, P571, DOI 10.1111/j.1432-1033.1984.tb08503.x; Schiffer G, 1999, J BIOL CHEM, V274, P32031, DOI 10.1074/jbc.274.45.32031; SPRATT BG, 1977, FEBS LETT, V79, P374, DOI 10.1016/0014-5793(77)80824-7; SUZUKI H, 1978, P NATL ACAD SCI USA, V75, P664, DOI 10.1073/pnas.75.2.664; Terrak M, 1999, MOL MICROBIOL, V34, P350, DOI 10.1046/j.1365-2958.1999.01612.x; TOMIOKA S, 1982, BIOCHEM BIOPH RES CO, V106, P1175, DOI 10.1016/0006-291X(82)91236-0; Vollmer W, 2001, CURR OPIN MICROBIOL, V4, P625, DOI 10.1016/S1369-5274(01)00261-2; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; YOUSIF SY, 1985, J GEN MICROBIOL, V131, P2839	33	84	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26985	26993		10.1074/jbc.M604083200	http://dx.doi.org/10.1074/jbc.M604083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16840781	Green Published, hybrid			2022-12-27	WOS:000240397700025
J	Duchesne, L; Tissot, B; Rudd, TR; Dell, A; Fernig, DG				Duchesne, Laurence; Tissot, Berangere; Rudd, Timothy R.; Dell, Anne; Fernig, David G.			N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FACTOR FGF; IDENTIFICATION; ACTIVATION; MUTATION; CELLS; OLIGOSACCHARIDES; PROLIFERATION; EXPRESSION; PHOSPHORYLATION	The regulation of cell function by fibroblast growth factors (FGF) occurs through a dual receptor system consisting of a receptor-tyrosine kinase, FGFR and the glycosaminoglycan heparan sulfate (HS). Mutations of some potential N-glycosylation sites in human fgfr lead to phenotypes characteristic of receptor overactivation. To establish how N-glycosylation may affect FGFR function, soluble- and membrane-bound recombinant receptors corresponding to the extracellular ligand binding domain of FGFR1-IIIc were produced in Chinese Hamster Ovary cells. Both forms of FGFR1-IIIc were observed to be heavily N-glycosylated and migrated on SDS-PAGE as a series of multiple bands between 50 and 75 kDa, whereas the deglycosylated receptors migrated at 32 kDa, corresponding to the expected molecular weight of the polypeptides. Optical biosensor and quartz crystal microbalance-dissipation binding assays show that the removal of the N-glycans from FGFR1-IIIc caused an increase in the binding of the receptor to FGF-2 and to heparin-derived oligosaccharides, a proxy for cellular HS. This effect is mediated by N-glycosylation reducing the association rate constant of the receptor for FGF-2 and heparin oligosaccharides. N-Glycans were analyzed by mass spectrometry, which demonstrates a predominance of bi- and tri-antennary core-fucosylated complex type structures carrying one, two, and/or three sialic acids. Modeling of such glycan structures on the receptor protein suggests that at least some may be strategically positioned to interfere with interactions of the receptor with FGF ligand and/or the HS co-receptor. Thus, the N-glycans of the receptor represent an additional pathway for the regulation of the activity of FGFs.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England	University of Liverpool; Imperial College London	Duchesne, L (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	lduchesn@liv.ac.uk	Fernig, David G/A-3590-2008; Rudd, Tim/M-6129-2019	Fernig, David G/0000-0003-4875-4293; Rudd, Tim/0000-0003-4434-0333; Duchesne, Laurence/0000-0003-1985-6266	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker KN, 2001, BIOTECHNOL BIOENG, V73, P188, DOI 10.1002/bit.1051; Bohne-Lang A, 2005, NUCLEIC ACIDS RES, V33, pW214, DOI 10.1093/nar/gki385; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; Delehedde M, 2000, J BIOL CHEM, V275, P33905, DOI 10.1074/jbc.M005949200; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Delehedde M, 2002, J BIOL CHEM, V277, P12456, DOI 10.1074/jbc.M111345200; Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085; Detillieux KA, 2003, CARDIOVASC RES, V57, P8, DOI 10.1016/S0008-6363(02)00708-3; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FERNIG DG, 1990, J CELL PHYSIOL, V142, P108, DOI 10.1002/jcp.1041420114; FERNIG DG, 2001, PROTEOGLYCAN PROTOCA; Freeman KW, 2003, CANCER RES, V63, P6237; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Gonzalez-Martinez D, 2004, J NEUROSCI, V24, P10384, DOI 10.1523/JNEUROSCI.3400-04.2004; GOOCHEE CF, 1990, BIO-TECHNOL, V8, P421, DOI 10.1038/nbt0590-421; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; Groth C, 2002, INT J DEV BIOL, V46, P393; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Harmer NJ, 2004, J MOL BIOL, V339, P821, DOI 10.1016/j.jmb.2004.04.031; HORTON RM, 1991, DIRECTED MUTAGENESIS; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KE YQ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P307, DOI 10.1016/0167-4781(92)90029-Y; Lodge AP, 2000, MOL BRAIN RES, V82, P84, DOI 10.1016/S0169-328X(00)00184-4; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Mangasarian K, 1997, J CELL PHYSIOL, V172, P117, DOI 10.1002/(SICI)1097-4652(199707)172:1<117::AID-JCP13>3.3.CO;2-S; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Robinson S, 2005, RAPID COMMUN MASS SP, V19, P3681, DOI 10.1002/rcm.2246; Rodahl M, 1997, FARADAY DISCUSS, V107, P229, DOI 10.1039/a703137h; SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Steinberger D, 1996, HUM MUTAT, V8, P386, DOI 10.1002/(SICI)1098-1004(1996)8:4<386::AID-HUMU18>3.3.CO;2-A; Sutton-Smith M, 2005, CELL BIOL LAB HDB; Tuominen H, 2001, PROTEIN EXPRES PURIF, V21, P275, DOI 10.1006/prep.2000.1375; van Rhijn BWG, 2001, CANCER RES, V61, P1265; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Winterpacht A, 2000, PHYSIOL GENOMICS, V2, P9, DOI 10.1152/physiolgenomics.2000.2.1.9; YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A	56	85	88	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27178	27189		10.1074/jbc.M601248200	http://dx.doi.org/10.1074/jbc.M601248200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16829530	hybrid			2022-12-27	WOS:000240397700045
J	Marx, A; Nugoor, C; Muller, J; Panneerselvam, S; Timm, T; Bilang, M; Mylonas, E; Svergun, DI; Mandelkow, EM; Mandelkow, E				Marx, Alexander; Nugoor, Chanakya; Mueller, Jens; Panneerselvam, Saravanan; Timm, Thomas; Bilang, Matthias; Mylonas, Efstratios; Svergun, Dmitri I.; Mandelkow, Eva-Maria; Mandelkow, Eckhard			Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (MARK) 1 and MARK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; UBA DOMAIN; C-SRC; MARK/PAR-1; POLARITY; ACTIVATION; FAMILY; RECOGNITION; SCATTERING	The microtubule-associated protein (MAP)/microtubule affinity regulating kinase (MARK)/Par-1 phosphorylates microtubule-associated proteins tau, MAP2, and MAP4 and is involved in the regulation of microtubule-based transport. Par-1, a homologue of MARK in Drosophila and Caenorhabditis elegans, is essential for the development of embryonic polarity. Four isoforms of MARK are found in humans. Recently, we reported the crystal structure of the catalytic and ubiquitin-associated domains of MARK2, an isoform enriched in brain (Panneerselvam, S., Marx, A., Mandelkow, E.-M., and Mandelkow, E. (2006) Structure 14, 173-183). It showed that the ubiquitin-associated domain (UBA) domain has an unusual fold and binds to the N-terminal lobe of the catalytic domain. This is at variance with a previous low resolution structure derived from small angle solution scattering (Jaleel, M., Villa, F., Deak, M., Toth, R., Prescott, A. R., Van Aalten, D. M., and Alessi, D. R. (2006) Biochem. J. 394, 545-555), which predicts binding of the UBA domain to the larger, C-terminal lobe. Here we report the crystal structure of the catalytic and UBA domain of another isoform, MARK1. Although the crystal packing of the two isoforms are unrelated, the overall conformations of the molecules are similar. Notably, the UBA domain has the same unusual conformation as in MARK2, and it binds at the same site. Remarkable differences occur in the catalytic domain at helix C, the catalytic loop, and the activation segment.	Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany; European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	Max Planck Society; European Molecular Biology Laboratory (EMBL); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Mandelkow, E (corresponding author), DESY, MPG ASMB, Notkestr 85, D-22607 Hamburg, Germany.	mand@mpasmb.desy.de		Mylonas, Efstratios/0000-0003-4476-3010; Svergun, Dmitri/0000-0003-0830-5696				Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Benton R, 2002, DEV CELL, V3, P659, DOI 10.1016/S1534-5807(02)00320-9; Beullens M, 2005, J BIOL CHEM, V280, P40003, DOI 10.1074/jbc.M507274200; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; Brajenovic M, 2004, J BIOL CHEM, V279, P12804, DOI 10.1074/jbc.M312171200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Guinier A., 1939, ANN PHYS-NEW YORK, V11, P161, DOI DOI 10.1051/ANPHYS/193911120161; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007; Jaleel M, 2006, BIOCHEM J, V394, P545, DOI 10.1042/BJ20051844; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kusakabe M, 2004, EMBO J, V23, P4190, DOI 10.1038/sj.emboj.7600381; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matenia D, 2005, MOL BIOL CELL, V16, P4410, DOI 10.1091/mbc.E05-01-0081; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Munro EM, 2006, CURR OPIN CELL BIOL, V18, P86, DOI 10.1016/j.ceb.2005.12.007; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nayak V, 2006, STRUCTURE, V14, P477, DOI 10.1016/j.str.2005.12.008; Ohno A, 2005, STRUCTURE, V13, P521, DOI 10.1016/j.str.2005.01.011; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Pellettieri J, 2002, SCIENCE, V298, P1946, DOI 10.1126/science.1072162; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Rudolph MJ, 2005, BIOCHEM BIOPH RES CO, V337, P1224, DOI 10.1016/j.bbrc.2005.09.181; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sessa F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; Varadan R, 2005, MOL CELL, V18, P687, DOI 10.1016/j.molcel.2005.05.013; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	42	47	48	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27586	27599		10.1074/jbc.M604865200	http://dx.doi.org/10.1074/jbc.M604865200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16803889	Green Published, hybrid			2022-12-27	WOS:000240397700084
J	Vaidehi, N; Schlyer, S; Trabanino, RJ; Floriano, WB; Abrol, R; Sharma, S; Kochanny, M; Koovakat, S; Dunning, L; Liang, M; Fox, JM; de Mendonca, FL; Pease, JE; Goddard, WA; Horuk, R				Vaidehi, Nagarajan; Schlyer, Sabine; Trabanino, Rene J.; Floriano, Wely B.; Abrol, Ravinder; Sharma, Shantanu; Kochanny, Monica; Koovakat, Sunil; Dunning, Laura; Liang, Meina; Fox, James M.; Lopes de Mendonca, Filipa; Pease, James E.; Goddard, William A., III; Horuk, Richard			Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FUNCTIONAL EXPRESSION; 3D STRUCTURE; IDENTIFICATION; SITE; MIP-1-ALPHA; MUTAGENESIS; RHODOPSIN; DATABASES; AGONISTS	A major challenge in the application of structure-based drug design methods to proteins belonging to the superfamily of G protein-coupled receptors (GPCRs) is the paucity of structural information (1). The 19 chemokine receptors, belonging to the Class A family of GPCRs, are important drug targets not only for autoimmune diseases like multiple sclerosis but also for the blockade of human immunodeficiency virus type 1 entry (2). Using the MembStruk computational method (3), we predicted the three-dimensional structure of the human CCR1 receptor. In addition, we predicted the binding site of the small molecule CCR1 antagonist BX 471, which is currently in Phase II clinical trials (4). Based on the predicted antagonist binding site we designed 17 point mutants of CCR1 to validate the predictions. Subsequent competitive ligand binding and chemotaxis experiments with these mutants gave an excellent correlation to these predictions. In particular, we find that Tyr-113 and Tyr-114 on transmembrane domain 3 and Ile-259 on transmembrane 6 contribute significantly to the binding of BX 471. Finally, we used the predicted and validated structure of CCR1 in a virtual screening validation of the Maybridge data base, seeded with selective CCR1 antagonists. The screen identified 63% of CCR1 antagonists in the top 5% of the hits. Our results indicate that rational drug design for GPCR targets is a feasible approach.	Berlex Biosci, Dept Immunol, Richmond, CA 94806 USA; Berlex Biosci, Dept Chem, Richmond, CA 94806 USA; Berlex Biosci, Dept Drug Metab & Pharmacol, Richmond, CA 94806 USA; CALTECH, Mat & Proc Simulat Ctr, Pasadena, CA 91125 USA; Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, London SW7 2AZ, England	California Institute of Technology; Imperial College London	Horuk, R (corresponding author), Berlex Biosci, Dept Immunol, 2600 Hilltop Dr, Richmond, CA 94806 USA.	Horuk@pacbell.net	Floriano, Wely/GOK-1319-2022; Pease, James/X-4521-2018; Abrol, Ravinder/B-4980-2010; Abrol, Ravinder/R-3458-2019	Floriano, Wely/0000-0001-8913-0458; Pease, James/0000-0003-3749-0341; Abrol, Ravinder/0000-0001-7333-6793; Fox, James/0000-0002-2473-7029				Auger GA, 2002, EUR J IMMUNOL, V32, P1052, DOI 10.1002/1521-4141(200204)32:4<1052::AID-IMMU1052>3.0.CO;2-L; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bissantz C, 2004, J CHEM INF COMP SCI, V44, P1162, DOI 10.1021/ci034181a; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; de Mendonca FL, 2005, J BIOL CHEM, V280, P4808, DOI 10.1074/jbc.M412267200; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Evers A, 2005, J MED CHEM, V48, P1088, DOI 10.1021/jm0491804; Floriano WB, 2004, J MED CHEM, V47, P56, DOI 10.1021/jm030271v; Freddolino PL, 2004, P NATL ACAD SCI USA, V101, P2736, DOI 10.1073/pnas.0308751101; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Kalani MYS, 2004, P NATL ACAD SCI USA, V101, P3815, DOI 10.1073/pnas.0400100101; Liang M, 2000, J BIOL CHEM, V275, P19000, DOI 10.1074/jbc.M001222200; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Moro S, 2005, TRENDS PHARMACOL SCI, V26, P44, DOI 10.1016/j.tips.2004.11.006; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOLLERT P, 2004, DRUG DISCOV TODAY-TA, V4, P2; Onuffer J, 2003, J IMMUNOL, V170, P1910, DOI 10.4049/jimmunol.170.4.1910; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pease JE, 2005, EXPERT OPIN INV DRUG, V14, P785, DOI 10.1517/13543784.14.7.785; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Ribeiro S, 2005, PHARMACOL THERAPEUT, V107, P44, DOI 10.1016/j.pharmthera.2005.01.004; Shacham S, 2004, PROTEINS, V57, P51, DOI 10.1002/prot.20195; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Trabanino RJ, 2004, BIOPHYS J, V86, P1904, DOI 10.1016/S0006-3495(04)74256-3; TRABANINO RJ, 2004, THESIS CALTECH; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Zoffmann S, 2002, MOL PHARMACOL, V62, P729, DOI 10.1124/mol.62.3.729	30	85	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27613	27620		10.1074/jbc.M601389200	http://dx.doi.org/10.1074/jbc.M601389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16837468	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000240397700086
J	Warren, CM; Kani, K; Landgraf, R				Warren, Carmen M.; Kani, Kian; Landgraf, Ralf			The N-terminal domains of neuregulin 1 confer signal attenuation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; EGF-LIKE DOMAIN; FACTOR RECEPTOR; ERBB RECEPTORS; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; HEREGULIN BETA-1; OVARIAN-CANCER; CELL-SURFACE	Degradation of activated ERBB receptors is an important mechanism for signal attenuation. However, compared with epidermal growth factor (EGF) receptor, the ERBB2/ERBB3 signaling pair is considered to be attenuation-deficient. The ERBB2/ERBB3 ligands of the neuregulin family rely on an EGF-like domain for signaling and are generated from larger membrane-bound precursors. In contrast to EGF, which is processed to yield a 6-kDa peptide ligand, mature neuregulins retain a variety of segments N-terminal to the EGF-like domain. Here we evaluate the role of the N-terminal domain of neuregulin 1 in signaling and turnover of ERBB2/ERBB3. Our data suggest that whereas the EGF-like domain of neuregulin 1 is required and sufficient for the formation of active receptor heterodimers, the presence of the N-terminal Ig-like domain is required for efficient signal attenuation. This manifests itself for both ERBB2 and ERBB3 but is more pronounced and coupled directly to degradation for ERBB3. When stimulated with only the EGF-like domain, ERBB3 shows degradation rates comparable with constitutive turnover, but stimulation with full-length neuregulin 1 resulted in receptor degradation at rates that are comparable with activated EGF receptor. Most of the enhancement in down-regulation was maintained after replacing the Ig-like domain with a thioredoxin protein of comparable size but different amino acid composition, suggesting that the physical presence but not specific properties of the Ig-like domain are needed. This sequence-independent effect of the N-terminal domain correlates with an enhanced ability of full-size neuregulin 1 to disrupt higher order oligomers of the ERBB3 extracellular domains in vitro.	Univ Calif Los Angeles, Dept Med Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Landgraf, R (corresponding author), Univ Calif Los Angeles, Dept Med Hematol Oncol, Box 951678, Los Angeles, CA 90095 USA.	rlandgraf@mednet.ucla.edu		Kani, Kian/0000-0001-7774-265X	NATIONAL CANCER INSTITUTE [R01CA098881] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098881] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Aguilar Z, 2001, J BIOL CHEM, V276, P44099, DOI 10.1074/jbc.M103442200; Baulida J, 1997, EXP CELL RES, V232, P167, DOI 10.1006/excr.1997.3515; Baulida J, 1996, J BIOL CHEM, V271, P5251; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERCHUCK A, 1990, CANCER RES, V50, P4087; Berger MB, 2004, FEBS LETT, V569, P332, DOI 10.1016/j.febslet.2004.06.014; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Clayton AHA, 2005, J BIOL CHEM, V280, P30392, DOI 10.1074/jbc.M504770200; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Fischer D, 1997, P NATL ACAD SCI USA, V94, P11929, DOI 10.1073/pnas.94.22.11929; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HO WH, 1995, J BIOL CHEM, V270, P26722; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kani K, 2005, J BIOL CHEM, V280, P8238, DOI 10.1074/jbc.M410944200; Landgraf R, 1998, BIOCHEMISTRY-US, V37, P3220, DOI 10.1021/bi972326z; Landgraf R, 2000, BIOCHEMISTRY-US, V39, P8503, DOI 10.1021/bi000953+; Le Gall SM, 2004, REGUL PEPTIDES, V122, P119, DOI 10.1016/j.regpep.2004.06.008; Li QF, 2001, J BIOL CHEM, V276, P38068; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; Magnifico A, 1998, FEBS LETT, V422, P129, DOI 10.1016/S0014-5793(97)01612-8; Mallick P, 2002, P NATL ACAD SCI USA, V99, P16041, DOI 10.1073/pnas.252626399; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Stove C, 2004, CLIN EXP METASTAS, V21, P665, DOI 10.1007/s10585-004-6917-6; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Whitson KB, 2004, ANAL BIOCHEM, V324, P227, DOI 10.1016/j.ab.2003.09.023; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOKOTA J, 1988, ONCOGENE, V2, P283	52	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27306	27316		10.1074/jbc.M512887200	http://dx.doi.org/10.1074/jbc.M512887200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16825199	hybrid			2022-12-27	WOS:000240397700057
J	Fahling, M; Mrowka, R; Steege, A; Nebrich, G; Perlewitz, A; Persson, PB; Thiele, BJ				Faehling, Michael; Mrowka, Ralf; Steege, Andreas; Nebrich, Grit; Perlewitz, Andrea; Persson, Pontus B.; Thiele, Bernd J.			Translational control of collagen prolyl 4-hydroxylase-alpha(I) gene expression under hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PROTEIN DISULFIDE-ISOMERASE; BINDING-PROTEIN; POSTTRANSCRIPTIONAL CONTROL; ENDOTHELIAL-CELLS; ALPHA-SUBUNIT; 3'-UNTRANSLATED REGION; GROWTH-FACTOR; K+ CHANNELS; NUCLEOLIN	Hypoxia is a pro-fibrotic stimulus, which is associated with enhanced collagen synthesis, as well as with augmented collagen prolyl 4-hydroxylase (C-P4H) activity. C-P4H activity is controlled mainly by regulated expression of the alpha C-P4H subunit. In this study we demonstrate that the increased synthesis of C-P4H-alpha(I) protein in human HT1080 fibroblasts under long term hypoxia (36 h, 1% oxygen) is controlled at the translational level. This is mediated by an interaction of RNA-binding protein nucleolin (similar to 64 kDa form) at the 5'-and 3'-untranslated regions (UTR) of themRNA. The 5'/3'-UTR-dependent mechanism elevates the C-P4H-alpha(I) expression rate 2.3-fold, and participates in a 5.3-fold increased protein level under long term hypoxia. The interaction of nucleolin at the 5'-UTR occurs directly and depends on the existence of an AU-rich element. Statistical evaluation of the similar to 64-kDa nucleolin/ RNA interaction studies revealed a core binding sequence, corresponding to UAAAUC or AAAUCU. At the 3'-UTR, nucleolin assembles indirectly via protein/ protein interaction, with the help of another 3'-UTR-binding protein, presumably annexin A2. The increased protein level of the similar to 64-kDa nucleolin under hypoxia can be attributed to an autocatalytic cleavage of a high molecular weight nucleolin form, without alterations in nucleolin mRNA concentration. Thus, the alteration of translational efficiency by nucleolin, which occurs through a hypoxia inducible factor independent pathway, is an important step in C-P4H-alpha(I) regulation under hypoxia.	Univ Med Berlin, Charite, Inst Vegetat Physiol, D-10117 Berlin, Germany; Free Univ Berlin, Inst Biol, D-14195 Berlin, Germany; Univ Med Berlin, Charite, Inst Humangenet, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Fahling, M (corresponding author), Tucholskystr 2, D-10117 Berlin, Germany.	michael.faehling@charite.de	Mrowka, Ralf/AAW-1480-2021; Fähling, Michael/E-5018-2011; Steege, Andreas/F-3885-2010	Mrowka, Ralf/0000-0002-0991-3418; Persson, Pontus/0000-0003-0926-2878; Fahling, Michael/0000-0003-1079-5049				Aley PK, 2005, J BIOL CHEM, V280, P13349, DOI 10.1074/jbc.M413674200; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Bouvet P, 2001, J MOL BIOL, V309, P763, DOI 10.1006/jmbi.2001.4691; Chen CY, 2000, GENE DEV, V14, P1236; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; Conforti L, 2000, J PHYSIOL-LONDON, V524, P783, DOI 10.1111/j.1469-7793.2000.00783.x; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fahling M, 2006, J BIOL CHEM, V281, P9279, DOI 10.1074/jbc.M510925200; Fahling M, 2005, BBA-GENE STRUCT EXPR, V1731, P32, DOI 10.1016/j.bbaexp.2005.08.005; Fahling M, 2004, COMP BIOCHEM PHYS C, V139, P119, DOI 10.1016/j.cca.2004.09.013; Falanga V, 2002, J CELL PHYSIOL, V191, P42, DOI 10.1002/jcp.10065; FALANGA V, 1993, J CELL PHYSIOL, V157, P408, DOI 10.1002/jcp.1041570225; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Filipenko NR, 2004, J BIOL CHEM, V279, P8723, DOI 10.1074/jbc.M311951200; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Fouraux MA, 2002, J MOL BIOL, V320, P475, DOI 10.1016/S0022-2836(02)00518-1; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Gilchrist JSC, 2002, J CELL BIOCHEM, V85, P268, DOI 10.1002/jcb.10121; Ginisty H, 1999, J CELL SCI, V112, P761; Hand SC, 1998, J EXP BIOL, V201, P1233; Hartley R, 2002, BMC MOL BIOL, V3, DOI 10.1186/1471-2199-3-8; HELAAKOSKI T, 1994, J BIOL CHEM, V269, P27847; Izumi RE, 2001, VIRUS RES, V76, P17, DOI 10.1016/S0168-1702(01)00240-4; Jiang Y, 2006, MOL CELL BIOL, V26, P2419, DOI 10.1128/MCB.26.6.2419-2429.2006; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; Koritzinsky M, 2005, RADIOTHER ONCOL, V76, P177, DOI 10.1016/j.radonc.2005.06.036; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Lo SJ, 2006, CELL RES, V16, P530, DOI 10.1038/sj.cr.7310070; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; MIRANDA GA, 1995, EXP CELL RES, V217, P294, DOI 10.1006/excr.1995.1090; MochizukiOda N, 1997, J NEUROCHEM, V69, P377; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Papakonstantinou E, 2003, CYTOKINE, V24, P25, DOI 10.1016/S1043-4666(03)00253-9; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Sakaguchi M, 2003, J CELL BIOL, V163, P825, DOI 10.1083/jcb.200304017; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Seta KA, 2004, CELL CALCIUM, V36, P331, DOI 10.1016/j.ceca.2004.02.006; Singh K, 2004, J IMMUNOL, V173, P976, DOI 10.4049/jimmunol.173.2.976; Skalweit A, 2003, CIRC RES, V92, P419, DOI 10.1161/01.RES.0000059300.67152.4E; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Storey KB, 2004, BIOL REV, V79, P207, DOI 10.1017/S1464793103006195; Tajima R, 2001, BBA-MOL CELL RES, V1540, P179, DOI 10.1016/S0167-4889(01)00114-8; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Thiele BJ, 2004, CIRC RES, V95, P1058, DOI 10.1161/01.RES.0000149166.33833.08; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Wouters BG, 2005, SEMIN CELL DEV BIOL, V16, P487, DOI 10.1016/j.semcdb.2005.03.009	62	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26089	26101		10.1074/jbc.M604939200	http://dx.doi.org/10.1074/jbc.M604939200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837461	hybrid			2022-12-27	WOS:000240249500024
J	Kelly, P; Stemmle, LN; Madden, JF; Fields, TA; Daaka, Y; Casey, PJ				Kelly, Patrick; Stemmle, Laura N.; Madden, John F.; Fields, Timothy A.; Daaka, Yehia; Casey, Patrick J.			A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; RHO; ACTIVATION; RECEPTOR; CELLS; G-ALPHA(13); MOTILITY; PATHWAY; KINASE; DOMAIN	Many studies have suggested a role for the members of the G(12) family of heterotrimeric G proteins (G alpha(12) and G alpha(13)) in oncogenesis and tumor cell growth. However, few studies have examined G(12) signaling in actual human cancers. In this study, we examined the role of G(12) signaling in prostate cancer. We found that expression of the G(12) proteins is significantly elevated in prostate cancer. Interestingly, expression of the activated forms of G alpha(12) or G alpha(13) in the PC3 and DU145 prostate cancer cell lines did not promote cancer cell growth. Instead, expression of the activated forms of G alpha(12) or G alpha(13) in these cell lines induced cell invasion through the activation of the RhoA family of G proteins. Furthermore, inhibition of G(12) signaling by expression of the RGS domain of the p115-Rho-specific guanine nucleotide exchange factor (p115-RGS) in the PC3 and DU145 cell lines did not reduce cancer cell growth. However, inhibition of G(12) signaling with p115-RGS in these cell lines blocked thrombin-and thromboxane A2-stimulated cell invasion. These observations identify the G(12) family proteins as important regulators of prostate cancer invasion and suggest that these proteins may be targeted to limit invasion- and metastasis-induced prostate cancer patient mortality.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA	Duke University; Duke University; University System of Georgia; Augusta University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309	NCI NIH HHS [CA100869] Funding Source: Medline; NIA NIH HHS [AG17952] Funding Source: Medline; NIDDK NIH HHS [DK60917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Caceres M, 2005, EXP CELL RES, V309, P229, DOI 10.1016/j.yexcr.2005.05.020; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Chunthapong J, 2004, J CELL BIOCHEM, V91, P649, DOI 10.1002/jcb.20032; DAAKA Y, 2004, SCI STKE, pRE2; DASSESSE T, 2006, IN PRESS EUR UROL; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hodge JC, 2003, CANCER RES, V63, P1359; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hwang YS, 2006, MOL CARCINOGEN, V45, P518, DOI 10.1002/mc.20183; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Kaushal V, 2006, PROSTATE, V66, P273, DOI 10.1002/pros.20326; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Lin F, 2005, J CELL BIOL, V169, P777, DOI 10.1083/jcb.200501104; Liu J, 2006, BIOCHEM BIOPH RES CO, V343, P183, DOI 10.1016/j.bbrc.2006.02.136; Liu J, 2003, UROL RES, V31, P163, DOI 10.1007/s00240-003-0309-2; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nie DT, 2004, AM J PATHOL, V164, P429, DOI 10.1016/S0002-9440(10)63133-1; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Rohrer DK, 1998, PHYSIOL REV, V78, P35, DOI 10.1152/physrev.1998.78.1.35; Ruppel KM, 2005, P NATL ACAD SCI USA, V102, P8281, DOI 10.1073/pnas.0503326102; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Shi XL, 2004, MOL CANCER RES, V2, P395; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Taichman RS, 2002, CANCER RES, V62, P1832; Tantivejkul K, 2005, J CELL BIOCHEM, V96, P641, DOI 10.1002/jcb.20533; Taub JS, 2003, CANCER RES, V63, P2037; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van Golen KL, 2002, CLIN EXP METASTAS, V19, P301, DOI 10.1023/A:1015518114931; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Weng JS, 2005, INT J CANCER, V113, P811, DOI 10.1002/ijc.20635; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yao H, 2006, ONCOGENE, V25, P2285, DOI 10.1038/sj.onc.1209260; YOSHIDA E, 1994, CANCER RES, V54, P3300; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	56	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26483	26490		10.1074/jbc.M604376200	http://dx.doi.org/10.1074/jbc.M604376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16787920	hybrid			2022-12-27	WOS:000240249500066
J	Martins, SM; Frosoni, DJ; Martinez, AMB; De Felice, FG; Ferreira, ST				Martins, Samantha M.; Frosoni, Doris J.; Martinez, Ana M. Blanco; De Felice, Fernanda G.; Ferreira, Sergio T.			Formation of soluble oligomers and amyloid fibrils with physical properties of the scrapie isoform of the prion protein from the C-terminal domain of recombinant murine prion protein mPrP-(121-231)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; MOLECULAR-BASIS; CONVERSION; PRPSC; PH; CONFORMATION; DISEASES; AGGREGATION; MODULATION; TRANSITION	Prion diseases are fatal neurodegenerative disorders associated with conformational conversion of the cellular prion protein, PrPC, into a misfolded, protease-resistant form, PrPSc. Here we show, for the first time, the oligomerization and fibrillization of the C-terminal domain of murine PrP, mPrP-(121-231), which lacks the entire unstructured N-terminal domain of the protein. In particular, the construct we used lacks amino acid residues 106-120 from the so-called amyloidogenic core of PrP (residues 106-126). Amyloid formation was accompanied by acquisition of resistance to proteinase K digestion. Aggregation of mPrP-(121-231) was investigated using a combination of biophysical and biochemical techniques at pH 4.0, 5.5, and 7.0 and at 37 and 65 degrees C. Under partially denaturing conditions (65 degrees C), aggregates of different morphologies ranging from soluble oligomers to mature amyloid fibrils of mPrP-(121-231) were formed. Transmission electron microscopy analysis showed that roughly spherical aggregates were readily formed when the protein was incubated at pH 5.5 and 65 degrees C for 1 h, whereas prolonged incubation led to the formation of mature amyloid fibrils. Samples incubated at 65 degrees C at pH 4.0 or 7.0 presented an initial mixture of oligomers and protofibrils or fibrils. Electrophoretic analysis of samples incubated at 65 degrees C revealed formation of sodium dodecyl sulfate-resistant oligomers (dimers, trimers, and tetramers) and higher molecular weight aggregates of mPrP-(121-231). These results demonstrate that formation of an amyloid form with physical properties of PrPSc can be achieved in the absence of the flexible N-terminal domain and, in particular, of residues 106-120 of PrP and does not require other cellular factors or a PrPSc template.	Univ Fed Rio de Janeiro, Programa Bioquim & Biofis Celular, Inst Bioquim Med, BR-21944590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Histol & Embryol, Inst Ciencias Biomed, BR-21944590 Rio De Janeiro, Brazil; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Northwestern University	Martins, SM (corresponding author), Univ Fed Rio de Janeiro, Programa Bioquim & Biofis Celular, Inst Bioquim Med, BR-21944590 Rio De Janeiro, Brazil.	ferreira@bioqmed.ufrj.br	Ferreira, Sergio/AAZ-1576-2020; Martinez, Ana/C-6318-2014; De Felice, Fernanda G/M-1074-2017	Ferreira, Sergio/0000-0001-7160-9866; 				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Alvarez-Martinez MT, 2003, BBA-PROTEINS PROTEOM, V1645, P228, DOI 10.1016/S1570-9639(02)00536-8; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2004, J BIOL CHEM, V279, P7671, DOI 10.1074/jbc.M310594200; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Calzolai L, 2000, P NATL ACAD SCI USA, V97, P8340, DOI 10.1073/pnas.97.15.8340; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Dobson CM, 2006, PROTEIN PEPTIDE LETT, V13, P219, DOI 10.2174/092986606775338362; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ferreira ST, 2001, FEBS LETT, V498, P129, DOI 10.1016/S0014-5793(01)02491-7; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Klein WL, 2004, NEUROBIOL AGING, V25, P569, DOI 10.1016/j.neurobiolaging.2004.02.010; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; Lee RJ, 1996, BBA-MOL CELL RES, V1312, P237, DOI 10.1016/0167-4889(96)00041-9; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lu BY, 2002, BIOCHEM J, V364, P81, DOI 10.1042/bj3640081; Martins SM, 2003, J BIOL CHEM, V278, P50449, DOI 10.1074/jbc.M307354200; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; Norstrom EM, 2005, J BIOL CHEM, V280, P27236, DOI 10.1074/jbc.M413441200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sokolowski F, 2003, J BIOL CHEM, V278, P40481, DOI 10.1074/jbc.M304391200; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Walsh DM, 2004, PROTEIN PEPTIDE LETT, V11, P213, DOI 10.2174/0929866043407174; Weissmann C, 2005, CELL, V122, P165, DOI 10.1016/j.cell.2005.07.001; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	54	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26121	26128		10.1074/jbc.M605367200	http://dx.doi.org/10.1074/jbc.M605367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844683	hybrid			2022-12-27	WOS:000240249500027
J	Schay, G; Smeller, L; Tsuneshige, A; Yonetani, T; Fidy, J				Schay, Gusztav; Smeller, Laszlo; Tsuneshige, Antonio; Yonetani, Takashi; Fidy, Judit			Allosteric effectors influence the tetramer stability of both R- and T-states of hemoglobin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; HETEROTROPIC EFFECTORS; SUBUNIT INTERACTIONS; STRUCTURAL-CHANGES; HYBRID HEMOGLOBIN; CRYSTAL-STRUCTURE; ELECTRIC-FIELDS; PRESSURE FIELDS; BINDING; FLUORESCENCE	The contribution of heterotropic effectors to hemoglobin allostery is still not completely understood. With the recently proposed global allostery model, this question acquires crucial significance, because it relates tertiary conformational changes to effector binding in both the R- and T-states. In this context, an important question is how far the induced conformational changes propagate from the binding site(s) of the allosteric effectors. We present a study in which we monitored the interdimeric interface when the effectors such as Cl-, 2,3-diphosphoglycerate, inositol hexaphosphate, and bezafibrate were bound. We studied oxy-Hb and a hybrid form (alpha FeO2)(2)-(beta Zn)(2) as the T-state analogue by monitoring heme absorption and Trp intrinsic fluorescence under hydrostatic pressure. We observed a pressure-dependent change in the intrinsic fluorescence, which we attribute to a pressure-induced tetramer to dimer transition with characteristic pressures in the 70 -200-megapascal range. The transition is sensitive to the binding of allosteric effectors. We fitted the data with a simple model for the tetramer-dimer transition and determined the dissociation constants at atmospheric pressure. In the R-state, we observed a stabilizing effect by the allosteric effectors, although in the T-analogue a stronger destabilizing effect was seen. The order of efficiency was the same in both states, but with the opposite trend as inositol hexaphosphate > 2,3-diphosphoglycerate > Cl-. We detected intrinsic fluorescence from bound bezafibrate that introduced uncertainty in the comparison with other effectors. The results support the global allostery model by showing that conformational changes propagate from the effector binding site to the interdimeric interfaces in both quaternary states.	Semmelweis Univ, Dept Biophys & Radiat Biol, H-1444 Budapest, Hungary; Semmelweis Univ, Biophys Res Grp, Hungarian Acad Sci, Fac Med, H-1444 Budapest, Hungary; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Johnson Res Fdn, Philadelphia, PA 19104 USA	Semmelweis University; Hungarian Academy of Sciences; Semmelweis University; University of Pennsylvania	Fidy, J (corresponding author), Semmelweis Univ, Dept Biophys & Radiat Biol, POB 263, H-1444 Budapest, Hungary.	judit@puskin.sote.hu	Smeller, László/G-6205-2011	Smeller, László/0000-0002-3643-3268	FOGARTY INTERNATIONAL CENTER [R03TW005924] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL014508, R01HL014508] Funding Source: NIH RePORTER; FIC NIH HHS [TW005924] Funding Source: Medline; NHLBI NIH HHS [HL14508] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1976, BIOCHEM BIOPH RES CO, V69, P135, DOI 10.1016/S0006-291X(76)80283-5; ADLEN RG, 1989, J BIOL CHEM, V264, P1933; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P110; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ATHA DH, 1976, J BIOL CHEM, V251, P5537; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; Balny C, 2002, BBA-PROTEIN STRUCT M, V1595, P3, DOI 10.1016/S0167-4838(01)00331-4; BERJIS M, 1991, ANAL BIOCHEM, V196, P223, DOI 10.1016/0003-2697(91)90457-5; BERMAN M, 1971, ARCH BIOCHEM BIOPHYS, V145, P236; BRITTAIN T, 1994, BIOCHEM J, V300, P553, DOI 10.1042/bj3000553; CHU AH, 1981, J BIOL CHEM, V256, P1199; Coletta M, 1999, BIOPHYS J, V76, P1532, DOI 10.1016/S0006-3495(99)77312-1; DRABKIN DL, 1946, J BIOL CHEM, V164, P703; Fidy J, 1998, BBA-PROTEIN STRUCT M, V1386, P289, DOI 10.1016/S0167-4838(98)00099-5; GOODFORD PJ, 1980, BRIT J PHARMACOL, V68, P741, DOI 10.1111/j.1476-5381.1980.tb10867.x; GRAY RD, 1971, J BIOL CHEM, V249, P4770; GRYCZYNSKI Z, 1992, BIOPHYS J, V63, P648, DOI 10.1016/S0006-3495(92)81657-0; Gryczynski Z, 1997, BIOPHYS CHEM, V64, P81, DOI 10.1016/S0301-4622(96)02224-7; HAIRE RN, 1977, P NATL ACAD SCI USA, V74, P4135, DOI 10.1073/pnas.74.10.4135; Hamdane D, 2005, J BIOL CHEM, V280, P36809, DOI 10.1074/jbc.M506253200; Heremans K, 1998, BBA-PROTEIN STRUCT M, V1386, P353, DOI 10.1016/S0167-4838(98)00102-2; HERSKOVITS TT, 1976, BIOCHEMISTRY-US, V15, P5715, DOI 10.1021/bi00671a006; HIRSCH RE, 1981, J BIOL CHEM, V256, P1080; HIRSCH RE, 1994, BBA-PROTEIN STRUCT M, V1205, P248, DOI 10.1016/0167-4838(94)90240-2; HIRSCH RE, 1980, BIOCHEM BIOPH RES CO, V93, P432, DOI 10.1016/0006-291X(80)91096-7; Huang YW, 1996, BIOPHYS J, V71, P2094, DOI 10.1016/S0006-3495(96)79408-0; IMAI K, 1982, ALLOSTERIC EFFECTS H, P106; JUNG C, 1995, EUR J BIOCHEM, V233, P600, DOI 10.1111/j.1432-1033.1995.600_2.x; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; Kohler M, 1998, BBA-PROTEIN STRUCT M, V1386, P255, DOI 10.1016/S0167-4838(98)00098-3; Kovesi I, 2006, BBA-PROTEINS PROTEOM, V1764, P516, DOI 10.1016/j.bbapap.2005.12.002; Laberge M, 2005, FEBS LETT, V579, P627, DOI 10.1016/j.febslet.2004.12.033; LAIRD BB, 1989, J CHEM PHYS, V90, P3274, DOI 10.1063/1.455881; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; MCLEAN JG, 1975, RES VET SCI, V19, P259, DOI 10.1016/S0034-5288(18)33499-4; Meersman F, 2005, HELV CHIM ACTA, V88, P546, DOI 10.1002/hlca.200590037; Miyazaki G, 1999, J MOL BIOL, V292, P1121, DOI 10.1006/jmbi.1999.3124; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OGUNMOLA GB, 1977, P NATL ACAD SCI USA, V74, P1, DOI 10.1073/pnas.74.1.1; Park SY, 1996, J MOL BIOL, V255, P726, DOI 10.1006/jmbi.1996.0059; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1964, NATURE, V203, P687, DOI 10.1038/203687a0; PIN S, 1990, BIOCHEMISTRY-US, V29, P9194, DOI 10.1021/bi00491a013; POYART C, 1994, METHOD ENZYMOL, V232, P496; Reshetnyak Ya. K., 1997, Biophysics, V42, P267; Ruan KC, 2000, BIOCHEM BIOPH RES CO, V269, P681, DOI 10.1006/bbrc.2000.2345; Samuni U, 2006, BIOCHEMISTRY-US, V45, P2820, DOI 10.1021/bi050010i; Samuni U, 2004, BIOCHEMISTRY-US, V43, P13674, DOI 10.1021/bi048531d; Samuni U, 2003, BIOCHEMISTRY-US, V42, P8272, DOI 10.1021/bi020648j; Seixas FAV, 1999, ACTA CRYSTALLOGR D, V55, P1914, DOI 10.1107/S0907444999009750; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; Shibayama N, 2002, J BIOL CHEM, V277, P38791, DOI 10.1074/jbc.M205461200; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; SMELLER L, 1995, APPL SPECTROSC, V49, P1538, DOI 10.1366/0003702953965533; Smeller L, 2002, BBA-PROTEIN STRUCT M, V1595, P11, DOI 10.1016/S0167-4838(01)00332-6; SMELLER L, 1996, HIGH PRESSURE SCI TE, P863; STEFANO B, 2000, PROTEIN SCI, V9, P683; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; Tanaka N, 2000, BIOCHEMISTRY-US, V39, P12063, DOI 10.1021/bi001009g; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4; TSUNESHIGE A, 1994, METHOD ENZYMOL, V231, P215; VANBEEK GGM, 1979, EUR J BIOCHEM, V100, P497; Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8; WHITE SL, 1976, J BIOL CHEM, V251, P4763; WONG PTT, 1989, APPL SPECTROSC, V43, P1279, DOI 10.1366/0003702894203642; Yonetani T, 2002, J BIOL CHEM, V277, P34508, DOI 10.1074/jbc.M203135200; ZOLLFRANK J, 1991, J CHEM PHYS, V94, P8600, DOI 10.1063/1.460042; ZOLLFRANK J, 1991, BIOPHYS J, V59, P305, DOI 10.1016/S0006-3495(91)82224-X	71	23	23	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25972	25983		10.1074/jbc.M604216200	http://dx.doi.org/10.1074/jbc.M604216200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822864	hybrid			2022-12-27	WOS:000240249500012
J	Xu, Y; Chen, XB				Xu, Yang; Chen, Xinbin			Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INDUCED APOPTOSIS; OXIDATIVE STRESS; DNA-DAMAGE; CELLS; GENE; EXPRESSION; ACTIVATION; VARIANT; P21	The p53 family proteins are transcription factors and have both common and distinct functions. p53 is a classic tumor suppressor, whereas p63 and p73 have fundamental functions in development. To gain an insight into the functional diversities among the p53 family, target genes specifically regulated by p63 and p73 were examined. Here, we found that the GLX2 gene, which encodes glyoxalase II enzyme, is up-regulated by p63 and p73. Accordingly, a specific responsive element was found in intron 1 of the GLX2 gene, which can be activated and bound by p63 and p73. Wealso found that, upon overexpression, the cytosolic, but not the mitochondrial, GLX2 inhibits the apoptotic response of a cell to methylglyoxal, a by-product of glycolysis. Likewise, we showed that cells deficient in GLX2 are hypersensitive to methylglyoxal-induced apoptosis. Interestingly, a deficiency in GLX2 also enhances the susceptibility of a cell to DNA damage-induced apoptosis in a p53-dependent manner. These observations reveal a novel link between the p53 family and the glyoxalase system. Given that methylglyoxal is frequently generated under both physiological and pathological conditions, we postulate that GLX2 serves as a pro-survival factor of the p53 family and plays a critical role in the normal development and in the pathogenesis of various human diseases, including cancer, diabetes, and neurodegenerative diseases.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama, Dept Cell Biol, MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu			NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069, R01CA076069, R01CA102188] Funding Source: NIH RePORTER; NCI NIH HHS [CA076069, CA102188, CA081237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amicarelli F, 1998, CHEM-BIOL INTERACT, V114, P177, DOI 10.1016/S0009-2797(98)00048-9; Bito A, 1999, PROTEIN EXPRES PURIF, V17, P456, DOI 10.1006/prep.1999.1151; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen F, 2004, P NATL ACAD SCI USA, V101, P7687, DOI 10.1073/pnas.0402338101; CHEN XB, 1995, CANCER RES, V55, P4257; Cordell PA, 2004, J BIOL CHEM, V279, P28653, DOI 10.1074/jbc.M403470200; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DEARRIBA SG, 2006, IN PRESS NEUROBIOL A; Dohn Michael, 2003, Methods Mol Biol, V223, P221; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukunaga M, 2004, BIOCHEM BIOPH RES CO, V320, P689, DOI 10.1016/j.bbrc.2004.06.011; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Godbout JP, 2002, J BIOL CHEM, V277, P2554, DOI 10.1074/jbc.M100385200; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Hovatta I, 2005, NATURE, V438, P662, DOI 10.1038/nature04250; Hsuuw YD, 2005, J CELL PHYSIOL, V205, P379, DOI 10.1002/jcp.20408; Jan CR, 2005, CELL SIGNAL, V17, P847, DOI 10.1016/j.cellsig.2004.11.007; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Martins AM, 2001, EUR J BIOCHEM, V268, P3930, DOI 10.1046/j.1432-1327.2001.02304.x; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; Mearini E, 2002, EUR J CANCER, V38, P1946, DOI 10.1016/S0959-8049(02)00236-8; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemet I, 2005, CLIN BIOCHEM, V38, P379, DOI 10.1016/j.clinbiochem.2004.12.008; Nozell S, 2003, ONCOGENE, V22, P4333, DOI 10.1038/sj.onc.1206470; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Rulli A, 2001, BREAST CANCER RES TR, V66, P67, DOI 10.1023/A:1010632919129; Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; Thornalley PJ, 1996, GEN PHARMACOL-VASC S, V27, P565, DOI 10.1016/0306-3623(95)02054-3; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	44	43	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26702	26713		10.1074/jbc.M604758200	http://dx.doi.org/10.1074/jbc.M604758200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831876	hybrid			2022-12-27	WOS:000240249500088
J	Nakerakanti, SS; Kapanadze, B; Yamasaki, M; Markiewicz, M; Trojanowska, M				Nakerakanti, Sashidhar S.; Kapanadze, Bagrat; Yamasaki, Masaomi; Markiewicz, Margaret; Trojanowska, Maria			Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; INDUCED EXPRESSION; PROMOTER; FAMILY; BINDING; FIBROBLASTS; ACTIVATION; PROTEINS	CCN2 (connective tissue growth factor), an important regulator of angiogenesis, chondrogenesis, and wound healing, is over-expressed in a majority of fibrotic diseases and in various tumors. This study investigated regulation of CCN2 gene expression by Ets family of transcription factors, focusing on two members, Fli1 and Ets1, with deregulated expression during fibrosis and tumorigenesis. We show that Ets1 and Fli1 have opposite effects on CCN2 gene expression. Ets1 functions as an activator of CCN2 transcription, whereas Fli1 acts as a repressor. A functional Ets binding site was mapped at -114 within the CCN2 promoter. This site not only mediates stimulation by Ets factors, including Ets1, Ets2, and GABP alpha/beta, but is also required for the transforming growth factor ( TGF)-beta response. The contrasting functions of Ets1 and Fli1 in regulation of the CCN2 gene were confirmed by suppressing their endogenous levels using adenoviral vectors expressing specific small interfering RNAs. Additional experiments using chromatin immunoprecipitation assays have revealed that in fibroblasts both Ets1 and Fli1 occupy the CCN2 promoter. TGF-beta stimulation resulted in displacement of Fli1 from the CCN2 promoter and a transient inhibition of Fli1 synthesis. Moreover, reduction of Fli1 expression resulted in up-regulation of COL1A1 and COL1A2 genes and down-regulation of the MMP1 gene. Thus, inhibition of Fli1 recapitulated some of the key effects of TGF-beta, suggesting that Fli1 suppression is involved in activation of the profibrotic gene program in fibroblasts. On the other hand, activation of the CCN2 gene downstream of Ets1 is consistent with its role in angiogenesis and extracellular matrix remodeling. This study strongly supports a critical role of Fli1 and Ets1 in the pathological extracellular matrix regulation during fibrosis and cancer.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA	Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St, Charleston, SC 29425 USA.	trojanme@musc.edu		Trojanowska, Maria/0000-0001-9550-7178	NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044883] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA78582] Funding Source: Medline; NIAMS NIH HHS [AR-44883, AR-423341] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aurrekoetxea-Hernandez K, 2004, J VIROL, V78, P2201, DOI 10.1128/JVI.78.5.2201-2211.2004; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Bu Shizhong, 2006, FASEB J, V20, P184; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chambers RC, 2000, J BIOL CHEM, V275, P35584, DOI 10.1074/jbc.M003188200; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Finckenberg P, 2003, AM J PATHOL, V163, P355, DOI 10.1016/S0002-9440(10)63659-0; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Graness A, 2006, CELL SIGNAL, V18, P433, DOI 10.1016/j.cellsig.2005.05.011; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; He ZH, 2005, J BIOL CHEM, V280, P15719, DOI 10.1074/jbc.M413493200; Hollenhorst PC, 2004, NUCLEIC ACIDS RES, V32, P5693, DOI 10.1093/nar/gkh906; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Jinnin M, 2004, ONCOGENE, V23, P1656, DOI 10.1038/sj.onc.1207064; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Kubo M, 2003, AM J PATHOL, V163, P571, DOI 10.1016/S0002-9440(10)63685-1; Leivonen SK, 2005, J INVEST DERMATOL, V124, P1162, DOI 10.1111/j.0022-202X.2005.23750.x; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Macauley MS, 2006, J BIOL CHEM, V281, P4164, DOI 10.1074/jbc.M510488200; Masuya M, 2005, BLOOD, V105, P95, DOI 10.1182/blood-2003-12-4345; Muehlich S, 2004, ATHEROSCLEROSIS, V175, P261, DOI 10.1016/j.atherosclerosis.2004.04.011; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Rachfal AW, 2005, VITAM HORM, V70, P69, DOI 10.1016/S0083-6729(05)70003-0; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Xu SW, 2004, J BIOL CHEM, V279, P23098, DOI 10.1074/jbc.M311430200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhan YM, 2005, J CLIN INVEST, V115, P2508, DOI 10.1172/JCI24403	44	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25259	25269		10.1074/jbc.M600466200	http://dx.doi.org/10.1074/jbc.M600466200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829517	hybrid			2022-12-27	WOS:000240031300027
J	Collins, QF; Xiong, Y; Lupo, EG; Liu, HY; Cao, WH				Collins, Qu Fan; Xiong, Yan; Lupo, Edgar G., Jr.; Liu, Hui-Yu; Cao, Wenhong			p38 mitogen-activated protein kinase mediates free fatty acid-induced gluconeogenesis in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC INSULIN-RESISTANCE; MAP KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLUCOSE-PRODUCTION; SKELETAL-MUSCLE; INDUCED APOPTOSIS; BINDING-PROTEIN; POTENTIAL ROLE; METABOLISM; LIVER	Free fatty acids ( FFA) are considered as a causative link between obesity and diabetes. In various animal models and in humans FFA can stimulate hepatic gluconeogenesis. Although the in vivo role of FFA in hepatic gluconeogenesis has been clearly established, the intracellular role of FFA and related signaling pathway remain unclear in the regulation of hepatic gluconeogenic gene transcription. In this study, we have identified p38 mitogen-activated protein kinase ( p38) as a critical signaling component in FFA-induced transcription of key gluconeogenic genes. We show in primary hepatocytes that both mid- and long-chain fatty acids ( saturated or unsaturated) could activate p38 and increase levels of phosphoenolpyruvate carboxykinase ( PEPCK), glucose-6-phosphatase, and peroxisome proliferator-activated receptor gamma coactivator alpha( PGC-1 alpha) gene transcripts. The FFA-induced expression of PEPCK and PGC-1 alpha genes and gluconeogenesis in isolated hepatocytes could be blocked by the inhibition of p38. Furthermore, PGC-1 alpha phosphorylation by p38 was necessary for FFA-induced activation of the PEPCK promoter. Additionally, FFA stimulated phosphorylation of cAMP-response element-binding protein ( CREB) through p38. The overexpression of the dominant-negative CREB prevented FFA-induced activation of the PEPCK promoter. Finally, we show that FFA activation of p38 requires protein kinase C delta. Together, our results indicate that p38 plays a critical role in FFA-induced transcription of gluconeogenic genes, and the known gluconeogenic regulators, PGC-1 alpha and CREB, are also integral parts of FFA-stimulated transcription of gluconeogenic genes.	Chem Ind Inst Toxicol, Ctr Hlth Res, Div Biol Sci, Endocrine Biol Program, Res Triangle Pk, NC 27709 USA; Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410078, Hunan, Peoples R China; Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27708 USA	Central South University; Duke University	Cao, WH (corresponding author), Chem Ind Inst Toxicol, Ctr Hlth Res, Div Biol Sci, Endocrine Biol Program, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	wcao@ciit.org						Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Al-Regaiey KA, 2005, ENDOCRINOLOGY, V146, P851, DOI 10.1210/en.2004-1120; ANTRASFERRY J, 1994, BIOCHEM BIOPH RES CO, V203, P385, DOI 10.1006/bbrc.1994.2194; Baldeweg SE, 2000, EUR J CLIN INVEST, V30, P45; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; BEVILACQUA S, 1987, METABOLISM, V36, P502, DOI 10.1016/0026-0495(87)90051-5; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bizeau ME, 1999, J NUTR BIOCHEM, V10, P709, DOI 10.1016/S0955-2863(99)00060-1; Blaak EE, 2003, P NUTR SOC, V62, P753, DOI 10.1079/PNS2003290; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Boden G, 2003, LIFE SCI, V72, P977, DOI 10.1016/S0024-3205(02)02350-0; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boden Guenther, 2005, Curr Diab Rep, V5, P167, DOI 10.1007/s11892-005-0004-5; Bolinder J, 2000, DIABETES, V49, P797, DOI 10.2337/diabetes.49.5.797; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Bysted A, 2005, EUR J CLIN NUTR, V59, P24, DOI 10.1038/sj.ejcn.1602028; Cahill GF., 1976, GLUCONEOGENESIS ITS, P515; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; COPPACK SW, 1992, METABOLISM, V41, P264, DOI 10.1016/0026-0495(92)90269-G; De Almeida IT, 2002, CLIN NUTR, V21, P219, DOI 10.1054/clnu.2001.0529; Dersch K, 2005, CELL DEATH DIFFER, V12, P1107, DOI 10.1038/sj.cdd.4401633; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Engel FB, 2005, GENE DEV, V19, P1175, DOI 10.1101/gad.1306705; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gum RJ, 2003, MOL ENDOCRINOL, V17, P1131, DOI 10.1210/me.2002-0288; Hakimi Parvin, 2005, Nutr Metab (Lond), V2, P33, DOI 10.1186/1743-7075-2-33; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HENRY RR, 1995, J CLIN INVEST, V95, P1427, DOI 10.1172/JCI117812; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Iglesias MA, 2002, DIABETES, V51, P2886, DOI 10.2337/diabetes.51.10.2886; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Katsuma S, 2005, J BIOL CHEM, V280, P19507, DOI 10.1074/jbc.M412385200; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kobayashi M, 2004, BIOCHEMISTRY-US, V43, P7522, DOI 10.1021/bi035966c; Lam TKT, 2005, NAT MED, V11, P320, DOI 10.1038/nm1201; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE281, DOI 10.1152/ajpendo.00332.2002; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lewis GF, 1997, DIABETES, V46, P1111, DOI 10.2337/diabetes.46.7.1111; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Miller TA, 2005, BIOCHEM BIOPH RES CO, V336, P309, DOI 10.1016/j.bbrc.2005.08.088; Nguyen MTA, 2005, J BIOL CHEM, V280, P35361, DOI 10.1074/jbc.M504611200; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; Robidoux J, 2005, MOL CELL BIOL, V25, P5466, DOI 10.1128/MCB.25.13.5466-5479.2005; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; SALORANTA C, 1993, AM J PHYSIOL, V264, pE599, DOI 10.1152/ajpendo.1993.264.4.E599; SEGLEN PO, 1979, J TOXICOL ENV HEALTH, V5, P551, DOI 10.1080/15287397909529766; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Tordjman J, 2003, BIOCHIMIE, V85, P1213, DOI 10.1016/j.biochi.2003.11.010; Uji Yoshinori, 2004, Nihon Rinsho, V62 Suppl 12, P57; Wiesenthal SR, 1999, DIABETES, V48, P766, DOI 10.2337/diabetes.48.4.766; Wyne KL, 2003, AM J MED, V115, P29, DOI 10.1016/j.amjmed.2003.09.004; Yamaguchi H, 2004, ARTERIOSCL THROM VAS, V24, P2095, DOI 10.1161/01.ATV.0000144009.35400.65; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhou H, 2005, BIOCHEM BIOPH RES CO, V338, P793, DOI 10.1016/j.bbrc.2005.10.007	71	98	103	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24336	24344		10.1074/jbc.M602177200	http://dx.doi.org/10.1074/jbc.M602177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803882	hybrid			2022-12-27	WOS:000239847800026
J	Loughnan, M; Nicke, A; Jones, A; Schroeder, CI; Nevin, ST; Adams, DJ; Alewood, PF; Lewis, RJ				Loughnan, Marion; Nicke, Annette; Jones, Alun; Schroeder, Christina I.; Nevin, Simon T.; Adams, David J.; Alewood, Paul F.; Lewis, Richard J.			Identification of a novel class of nicotinic receptor antagonists - Dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus vexillum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-BINDING PROTEIN; CRYSTAL-STRUCTURE; ALPHA-CONOTOXINS; BIOLOGICAL-ACTIVITY; KAPPA-BUNGAROTOXIN; POLYPEPTIDE TOXIN; VENOM NEUROTOXINS; MASS-SPECTROMETRY; NMR-SPECTROSCOPY; PLATYPUS VENOM	The venoms of predatory marine snails ( Conus spp.) contain diverse mixtures of peptide toxins with high potency and selectivity for a variety of voltage-gated and ligand-gated ion channels. Here we describe the chemical and functional characterization of three novel conotoxins, alpha D-VxXIIA, alpha D-VxXIIB, and alpha D-VxXIIC, purified from the venom of Conus vexillum. Each toxin was observed as an similar to 11-kDa protein by LC/MS, size exclusion chromatography, and SDS-PAGE. After reduction, the peptide sequences were determined by Edman degradation chemistry and tandem MS. Combining the sequence data together with LC/MS and NMR data revealed that in solution these toxins are pseudo-homodimers of paired 47-50-residue peptides. The toxin subunitsexhibited a novel arrangement of 10 conserved cystine residues, and additional post-translational modifications contributed heterogeneity to the proteins. Binding assays and two-electrode voltage clamp analyses showed that alpha D-VxXIIA, alpha D-VxXIIB, and alpha D-VxXIIC are potent inhibitors of nicotinic acetylcholine receptors (nAChRs) with selectivity for alpha 7 and alpha 2 containing neuronal nAChR subtypes. These dimeric conotoxins represent a fifth and highly divergent structural class of conotoxins targeting nAChRs.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Max Planck Inst Brain Res, D-60528 Frankfurt, Germany	University of Queensland; University of Queensland; Max Planck Society	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard/T-8763-2019; Adams, David/J-9125-2014; Alewood, Paul F/J-2412-2014; Lewis, Richard J/E-8674-2013; Schroeder, Cristina I./K-2042-2014; Loughnan, Marion/B-4508-2009; Nevin, Simon/B-2663-2014; Adams, David John/K-3578-2019	Lewis, Richard/0000-0003-3470-923X; Adams, David/0000-0002-7030-2288; Lewis, Richard J/0000-0003-3470-923X; Schroeder, Cristina I./0000-0002-6737-6374; Adams, David John/0000-0002-7030-2288; Alewood, Paul/0000-0001-7454-6522; Nicke, Annette/0000-0001-6798-505X				Arias HR, 2000, INT J BIOCHEM CELL B, V32, P1017, DOI 10.1016/S1357-2725(00)00051-0; Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Brandwijk RJMGE, 2005, BIOCHEM BIOPH RES CO, V333, P1261, DOI 10.1016/j.bbrc.2005.06.029; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Campopiano DJ, 2004, J BIOL CHEM, V279, P48671, DOI 10.1074/jbc.M404690200; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; Corona M, 2001, TOXICON, V39, P1893, DOI 10.1016/S0041-0101(01)00174-X; Craig AG, 1999, EUR J BIOCHEM, V264, P271, DOI 10.1046/j.1432-1327.1999.00624.x; Craig AG, 2000, J TOXICOL-TOXIN REV, V19, P53, DOI 10.1081/TXR-100100315; Czerwiec E, 2002, EUR J BIOCHEM, V269, P6162, DOI 10.1046/j.1432-1033.2002.03335.x; Davies NW, 2004, TOXICON, V43, P173, DOI 10.1016/j.toxicon.2003.11.021; Decker MW, 2004, CURR TOP MED CHEM, V4, P369, DOI 10.2174/1568026043451447; Dutertre S, 2005, J BIOL CHEM, V280, P30460, DOI 10.1074/jbc.M504229200; England LJ, 1998, SCIENCE, V281, P575, DOI 10.1126/science.281.5376.575; Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4; Escoubas P, 2003, PROTEIN SCI, V12, P1332, DOI 10.1110/ps.0307003; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; Gawade SP, 2004, J TOXICOL-TOXIN REV, V23, P37, DOI 10.1081/TXR-120030647; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; Grant GA, 1997, BIOCHEMISTRY-US, V36, P3353, DOI 10.1021/bi9629687; Grant GA, 1998, J TOXICOL-TOXIN REV, V17, P239, DOI 10.3109/15569549809009251; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Hao CJ, 2005, BIOTECHNOL LETT, V27, P1929, DOI 10.1007/s10529-005-3905-0; Jacobsen R, 1997, J BIOL CHEM, V272, P22531, DOI 10.1074/jbc.272.36.22531; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kashiwagi T, 2000, J AM SOC MASS SPECTR, V11, P54, DOI 10.1016/S1044-0305(99)00119-1; Kauferstein S, 2004, TOXICON, V44, P539, DOI 10.1016/j.toxicon.2004.07.006; KOBAYASHI J, 1985, TOXICON, V23, P783, DOI 10.1016/0041-0101(85)90009-1; KOBAYASHI J, 1982, BIOCHEM BIOPH RES CO, V105, P1389, DOI 10.1016/0006-291X(82)90941-X; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lewis RJ, 2003, NAT REV DRUG DISCOV, V2, P790, DOI 10.1038/nrd1197; Lewis RJ, 2004, IUBMB LIFE, V56, P89, DOI 10.1080/15216540410001668055; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; Loughnan ML, 2004, EUR J BIOCHEM, V271, P2294, DOI 10.1111/j.1432-1033.2004.04146.x; Loughnan ML, 2004, J MED CHEM, V47, P1234, DOI 10.1021/jm031010o; Maggio F, 2002, J BIOL CHEM, V277, P22806, DOI 10.1074/jbc.M202297200; MCINTOSH JM, 1995, J BIOL CHEM, V270, P3518, DOI 10.1074/jbc.270.8.3518; Milne TJ, 2003, J BIOL CHEM, V278, P31105, DOI 10.1074/jbc.M304843200; Moffatt F, 2000, J CHROMATOGR A, V891, P235, DOI 10.1016/S0021-9673(00)00620-8; Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; Nirthanan S, 2004, J PHARMACOL SCI, V94, P1, DOI 10.1254/jphs.94.1; Olivera BM, 2002, ANNU REV ECOL SYST, V33, P25, DOI 10.1146/annurev.ecolsys.33.010802.150424; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POSSANI LD, 1992, TOXICON, V30, P1343, DOI 10.1016/0041-0101(92)90511-3; Santos AD, 2004, J BIOL CHEM, V279, P17596, DOI 10.1074/jbc.M309654200; SAXENA VK, 1992, NEUROCHEM INT, V20, P69, DOI 10.1016/0197-0186(92)90127-D; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Smit AB, 2003, ANN NY ACAD SCI, V998, P81, DOI 10.1196/annals.1254.010; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Teichert RW, 2004, TOXICON, V44, P207, DOI 10.1016/j.toxicon.2004.05.026; Teichertt RW, 2005, BIOCHEMISTRY-US, V44, P7897, DOI 10.1021/bi047274+; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Torres AM, 2000, BIOCHEM J, V348, P649, DOI 10.1042/0264-6021:3480649; Torres AM, 1999, BIOCHEM J, V341, P785, DOI 10.1042/0264-6021:3410785; Ulens C, 2006, P NATL ACAD SCI USA, V103, P3615, DOI 10.1073/pnas.0507889103; Valdez-Cruz NA, 2004, EUR J BIOCHEM, V271, P1453, DOI 10.1111/j.1432-1033.2004.04047.x; Van Wagoner RM, 2003, BIOCHEMISTRY-US, V42, P6353, DOI 10.1021/bi0272757; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wu JJ, 2002, BIOCHEMISTRY-US, V41, P2844, DOI 10.1021/bi011367z; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yuki Y, 2005, BIOTECHNOL BIOENG, V92, P803, DOI 10.1002/bit.20654; Zamudio FZ, 1997, FEBS LETT, V405, P385, DOI 10.1016/S0014-5793(97)00227-5	70	65	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24745	24755		10.1074/jbc.M603703200	http://dx.doi.org/10.1074/jbc.M603703200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790424	hybrid			2022-12-27	WOS:000239847800071
J	Nakanishi, K; Aono, S; Hirano, K; Kuroda, Y; Ida, M; Tokita, Y; Matsui, F; Oohira, A				Nakanishi, Keiko; Aono, Sachiko; Hirano, Kanako; Kuroda, Yoshiyuki; Ida, Michiru; Tokita, Yoshihito; Matsui, Fumiko; Oohira, Atsuhiko			Identification of neurite outgrowth-promoting domains of neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, and involvement of phosphatidylinositol 3-kinase and protein kinase C signaling pathways in neuritogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TENASCIN-C; NEOCORTICAL NEURONS; SMI CORTEX; EXPRESSION; ACTIVATION; MOUSE; RAT; DIFFERENTIATION; FAMILY; CALEB	Neuroglycan C (NGC) is a transmembrane-type chondroitin sulfate proteoglycan that is exclusively expressed in the central nervous system. We report that the recombinant ectodomain of NGC core protein enhances neurite outgrowth from rat neocortical neurons in culture. Both protein kinase C (PKC) inhibitors and phosphatidylinositol 3-kinase (PI3K) inhibitors attenuated the NGC-mediated neurite outgrowth in a dose-dependent manner, suggesting that NGC promotes neurite outgrowth via PI3K and PKC pathways. The active sites of NGC for neurite outgrowth existed in the epidermal growth factor (EGF)-like domain and acidic amino acid (AA)-domain of the NGC ectodomain. The EGF-domain caused cells to extend preferentially one neurite from a soma, whereas the AA-domain caused several neurites to develop. The EGF-domain also enhanced neurite outgrowth from GABA-positive neurons, but the AA-domain did not. These results suggest that the EGF-domain and AA-domain have distinct functions in terms of neuritogenesis. From these findings, NGC can be considered to be involved in neuritogenesis in the developing central nervous system.	Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Kasugai, Aichi 4800392, Japan		Nakanishi, K (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Kasugai, Aichi 4800392, Japan.	nakanishi@inst-hsc.jp		Ida-Eto, Michiru/0000-0002-2469-4006				Aono S, 2000, J BIOL CHEM, V275, P337, DOI 10.1074/jbc.275.1.337; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DOU CL, 1994, J NEUROSCI, V14, P7616; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Garwood J, 1999, J NEUROSCI, V19, P3888; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Hoffman-Kim D, 2002, MOL CELL NEUROSCI, V21, P81, DOI 10.1006/mcne.2002.1157; Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P4338; Juttner R, 2005, NEURON, V46, P233, DOI 10.1016/j.neuron.2005.02.027; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kinugasa Y, 2004, BIOCHEM BIOPH RES CO, V321, P1045, DOI 10.1016/j.bbrc.2004.07.066; Kornblum HI, 2000, DEV NEUROSCI-BASEL, V22, P16, DOI 10.1159/000017423; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; LIN CS, 1985, J NEUROSCI, V5, P1934; Martinez MC, 2003, J CELL BIOL, V162, P99, DOI 10.1083/jcb.200211025; Matsui Fumiko, 2004, Congenital Anomalies, V44, P181, DOI 10.1111/j.1741-4520.2004.00038.x; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Menager C, 2004, J NEUROCHEM, V89, P109, DOI 10.1046/j.1471-4159.2004.02302.x; Mercado MLT, 2004, J NEUROSCI, V24, P238, DOI 10.1523/JNEUROSCI.4519-03.2004; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nakanishi K, 1999, BRAIN RES PROTOC, V4, P105, DOI 10.1016/S1385-299X(99)00003-3; Nakanishi K, 2001, NEUROSCI LETT, V304, P85, DOI 10.1016/S0304-3940(01)01767-0; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Oohira A, 2004, GLYCOCONJUGATE J, V21, P53, DOI 10.1023/B:GLYC.0000043748.90896.83; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Rigato F, 2002, J NEUROSCI, V22, P6596; Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; SIMONS DJ, 1984, J COMP NEUROL, V230, P119, DOI 10.1002/cne.902300111; SMITHTHOMAS LC, 1994, J CELL SCI, V107, P1687; TOKITA Y, 2001, NEUROSCI RES, V25, pS4; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; White EL, 1997, SOMATOSENS MOT RES, V14, P34, DOI 10.1080/08990229771204; Wu YJ, 2004, MOL BIOL CELL, V15, P2093, DOI 10.1091/mbc.E03-09-0667; Yamagata M, 2005, J NEUROSCI, V25, P8457, DOI 10.1523/JNEUROSCI.1976-05.2005; Yamauchi S, 2002, J BIOL CHEM, V277, P20583, DOI 10.1074/jbc.M200909200	46	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24970	24978		10.1074/jbc.M601498200	http://dx.doi.org/10.1074/jbc.M601498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803884	hybrid			2022-12-27	WOS:000239847800089
J	Osvath, S; Herenyi, L; Zavodszky, P; Fidy, J; Kohler, G				Osvath, Szabolcs; Herenyi, Levente; Zavodszky, Peter; Fidy, Judit; Koehler, Gottfried			Hierarchic finite level energy landscape model - To describe the refolding kinetics of phosphoglycerate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-FOLDING RATES; COLD DENATURATION; MICROSCOPIC THEORY; BIPHASIC KINETICS; DOMAIN; RELAXATION; TRYPTOPHAN; INTENSITY; DYNAMICS; PROLINE	One of the most intriguing predictions of energy landscape models is the existence of non-exponential protein folding kinetics caused by hierarchical structures in the landscapes. Here we provide the strongest evidence so far of such hierarchy and determine the time constants and weights of the kinetic components of the suggested hierarchic energy landscape. To our knowledge, the idea of hierarchical folding energy barriers has never been tested over such a broad timescale. Refolding of yeast phosphoglycerate kinase was initiated from the guanidine-unfolded state by stopped-flow or manual mixing and monitored by tryptophan fluorescence from 1 ms to 15 min. The strategy to build a model that describes folding of yeast phosphoglycerate kinase was to start from the simplest paradigm and modify it stepwise to the necessary minimal extent after repeated comparisons with the experiments. We made no a priori assumptions about the folding landscape. The result was a hierarchic finite level landscape model that quantitatively describes the refolding of yeast phosphoglycerate kinase from 1 ms to 15 min. The early steps of the folding process happen in the upper region of the landscape, where the surface has a hierarchic structure. This leads to stretched kinetics in the early phase of the folding. The lower region of the energy landscape is dominated by a trap that reflects the accumulation of molten globule intermediate state. From this intermediate, the protein can reach the global energy minimum corresponding to the native state through a cross-barrier folding step.	Semmelweis Univ, Dept Biophys & Radiat Biol, H-1088 Budapest, Hungary; Biol Res Ctr Szeged, Inst Enzymol, H-1113 Budapest, Hungary; Semmelweis Univ, Hungarian Acad Sci, Res Grp Biophys, H-1088 Budapest, Hungary; Univ Vienna, Max F Perutz Labs, Dept Chem, A-1090 Vienna, Austria	Semmelweis University; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Hungarian Academy of Sciences; Semmelweis University; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Osvath, S (corresponding author), Semmelweis Univ, Dept Biophys & Radiat Biol, Puskin 9, H-1088 Budapest, Hungary.	osvath@puskin.sote.hu	Osváth, Szabolcs/H-6823-2012	Osvath, Szabolcs/0000-0003-2304-3284				Basharov MA, 2003, J CELL MOL MED, V7, P223, DOI 10.1111/j.1582-4934.2003.tb00223.x; BEECHEM JM, 1995, BIOCHEMISTRY-US, V34, P13943, DOI 10.1021/bi00042a028; BETTON JM, 1992, ARCH BIOCHEM BIOPHYS, V296, P95, DOI 10.1016/0003-9861(92)90549-C; Brooks CL, 1998, P NATL ACAD SCI USA, V95, P11037, DOI 10.1073/pnas.95.19.11037; Bustamante C, 2004, ANNU REV BIOCHEM, V73, P705, DOI 10.1146/annurev.biochem.72.121801.161542; Cecconi C, 2005, SCIENCE, V309, P2057, DOI 10.1126/science.1116702; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; CHARDOT T, 1988, FEBS LETT, V228, P65, DOI 10.1016/0014-5793(88)80586-6; Damaschun G, 1998, BIOCHEMISTRY-MOSCOW+, V63, P259; DAMASCHUN G, 1993, BIOCHEMISTRY-US, V32, P7739, DOI 10.1021/bi00081a019; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Finkelstein AV, 2004, PHYS LIFE REV, V1, P23, DOI 10.1016/j.plrev.2004.03.001; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; Gast K, 1997, EUR BIOPHYS J BIOPHY, V25, P211, DOI 10.1007/s002490050033; GAST K, 1993, BIOCHEMISTRY-US, V32, P7747, DOI 10.1021/bi00081a020; Gillespie B, 2004, ANNU REV BIOCHEM, V73, P837, DOI 10.1146/annurev.biochem.73.011303.073904; GRIKO YV, 1989, FEBS LETT, V244, P276, DOI 10.1016/0014-5793(89)80544-7; Gruebele M, 1999, ANNU REV PHYS CHEM, V50, P485, DOI 10.1146/annurev.physchem.50.1.485; Karanicolas J, 2004, P NATL ACAD SCI USA, V101, P3432, DOI 10.1073/pnas.0304825101; Karanicolas J, 2003, P NATL ACAD SCI USA, V100, P3954, DOI 10.1073/pnas.0731771100; KLAFTER J, 1986, P NATL ACAD SCI USA, V83, P848, DOI 10.1073/pnas.83.4.848; Lee JC, 2002, J MOL BIOL, V320, P159, DOI 10.1016/S0022-2836(02)00466-7; Lillo MP, 1998, BIOPHYS J, V74, pA168; Lyubovitsky JG, 2002, J AM CHEM SOC, V124, P5481, DOI 10.1021/ja017399r; Ma HR, 2005, P NATL ACAD SCI USA, V102, P2283, DOI 10.1073/pnas.0409270102; McHarg J, 1999, EUR J BIOCHEM, V259, P939, DOI 10.1046/j.1432-1327.1999.00133.x; Metzler R, 1999, P NATL ACAD SCI USA, V96, P11085, DOI 10.1073/pnas.96.20.11085; Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; Osvath S, 2005, PROTEIN SCI, V14, P1609, DOI 10.1110/ps.051359905; Osvath S, 2003, J MOL BIOL, V333, P187, DOI 10.1016/j.jmb.2003.08.011; Osvath S, 2003, BIOPHYS J, V85, P1215, DOI 10.1016/S0006-3495(03)74557-3; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Plotkin SS, 2002, J CHEM PHYS, V116, P5263, DOI 10.1063/1.1449866; Portman JJ, 2001, J CHEM PHYS, V114, P5082, DOI 10.1063/1.1334663; Portman JJ, 2001, J CHEM PHYS, V114, P5069, DOI 10.1063/1.1334662; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Sabelko J, 1999, P NATL ACAD SCI USA, V96, P6031, DOI 10.1073/pnas.96.11.6031; SABELKO JJ, 2000, THESIS U ILLINOIS UR; Tezcan FA, 2002, P NATL ACAD SCI USA, V99, P8626, DOI 10.1073/pnas.132254499; Wolynes PG, 2005, PHILOS T R SOC A, V363, P453, DOI 10.1098/rsta.2004.1502; Yang WY, 2004, J MOL BIOL, V336, P241, DOI 10.1016/j.jmb.2003.11.033	45	13	13	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24375	24380		10.1074/jbc.M601915200	http://dx.doi.org/10.1074/jbc.M601915200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807241	hybrid, Green Published			2022-12-27	WOS:000239847800030
J	Shen, F; Hu, ZH; Goswami, J; Gaffen, SL				Shen, Fang; Hu, Zihua; Goswami, Jaya; Gaffen, Sarah L.			Identification of common transcriptional regulatory elements in interleukin-17 target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; T-CELL INTERLEUKIN-17; NECROSIS-FACTOR-ALPHA; AIRWAY SMOOTH-MUSCLE; CXC CHEMOKINE; MESSENGER-RNA; INFLAMMATORY CYTOKINE; DESTRUCTIVE ARTHRITIS; IL-17; EXPRESSION	Interleukin (IL)-17 is the founding member of a novel family of inflammatory cytokines. Although produced by T cells, IL-17 activates genes and signals typical of innate immune mediators such as tumor necrosis factor (TNF)-alpha and IL-1 beta. Most IL-17 target genes characterized to date are cytokines or neutrophilattractive chemokines. Our recent microarray studies identified an acute phase response gene, 24p3/lipocalin 2, as a novel IL-17-induced gene. Here we describe a detailed analysis of the 24p3 promoter. We find that, unlike cytokine or chemokine gene target genes, 24p3 is regulated primarily at the level of transcription rather than mRNA stability and that synergy between IL-17 and TNF alpha occurs at the level of the 24p3 promoter. Two key transcription factor binding sites (TFBS) were identified, corresponding to NF-kappa B and CCAAT/enhancer-binding protein (C/EBP). Deletion of either site eliminated 24p3 promoter activity in response to IL-17. These findings were strikingly similar to the IL-6 promoter, where IL-17-mediated regulation of both NF-kappa B and C/EBP is essential. To determine whether joint use of NF-kappa B and C/EBP is common to all IL-17 target genes, we performed a computational analysis on 18 well documented IL-17 target promoters to assess statistical enrichment of specific TFBSs. Indeed, NF-kappa B and C/EBP sites were over-represented in these genes, as were AP1 and OCT1 sites. Moreover, these promoters fell into three definable subcategories based on TFBS location and usage. Analysis of IL-17 target gene regulation is key for understanding this important host-defense molecule and also contributes to an understanding of upstream signaling mechanisms used by IL-17, either alone or in concert with TNF alpha.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biostat, Ctr Computat Res, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gaffen, SL (corresponding author), 36 Foster Hall,3435 Main St, Buffalo, NY 14214 USA.	sgaffen@buffalo.edu	Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041; Shen, Fang/0000-0003-0084-7933	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050458] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050458] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Bettelli E, 2005, J EXP MED, V201, P169, DOI 10.1084/jem.20042279; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Cowland JB, 2006, J IMMUNOL, V176, P5559, DOI 10.4049/jimmunol.176.9.5559; Cowland JB, 2003, J IMMUNOL, V171, P6630, DOI 10.4049/jimmunol.171.12.6630; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Frith MC, 2004, NUCLEIC ACIDS RES, V32, P1372, DOI 10.1093/nar/gkh299; Gaffen SL, 2004, ARTHRITIS RES THER, V6, P240, DOI 10.1186/ar1444; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hata K, 2002, AM J PHYSIOL-GASTR L, V282, pG1035, DOI 10.1152/ajpgi.00494.2001; Henness S, 2004, J ALLERGY CLIN IMMUN, V114, P958, DOI 10.1016/j.jaci.2004.06.023; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019; Kelly MN, 2005, INFECT IMMUN, V73, P617, DOI 10.1128/IAI.73.1.617-621.2005; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Lubberts E, 2002, INFLAMM RES, V51, P102, DOI 10.1007/BF02684010; Lubberts E, 2005, ARTHRITIS RES THER, V7, P29, DOI 10.1186/ar1478; Lubberts Erik, 2003, Curr Opin Investig Drugs, V4, P572; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Miljkovic D, 2004, CYTOKINE GROWTH F R, V15, P21, DOI 10.1016/j.cytogfr.2003.10.003; Miossec P, 2003, ARTHRITIS RHEUM-US, V48, P594, DOI 10.1002/art.10816; Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Nardone J, 2004, NAT IMMUNOL, V5, P768, DOI 10.1038/ni0804-768; Nilsen-Hamilton M, 2003, ANN NY ACAD SCI, V995, P94, DOI 10.1111/j.1749-6632.2003.tb03213.x; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Rahman MS, 2005, CLIN IMMUNOL, V115, P268, DOI 10.1016/j.clim.2005.01.014; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; Richardson DR, 2005, CELL, V123, P1175, DOI 10.1016/j.cell.2005.12.008; Ruddy MJ, 2004, J LEUKOCYTE BIOL, V76, P135, DOI 10.1189/jlb.0204065; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Shen F, 2005, J LEUKOCYTE BIOL, V77, P388, DOI 10.1189/jlb.0904490; Shimada M, 2002, J IMMUNOL, V168, P861, DOI 10.4049/jimmunol.168.2.861; Smith JB, 2002, IMMUNOGENETICS, V54, P599, DOI 10.1007/s00251-002-0501-5; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; Tokuda H, 2004, J CELL BIOCHEM, V91, P1053, DOI 10.1002/jcb.20004; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Witowski J, 2000, J IMMUNOL, V165, P5814, DOI 10.4049/jimmunol.165.10.5814; Xuan ZY, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r72; Yamada T, 1998, BIOCHEM BIOPH RES CO, V242, P88, DOI 10.1006/bbrc.1997.7915; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404	63	231	244	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24138	24148		10.1074/jbc.M604597200	http://dx.doi.org/10.1074/jbc.M604597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798734	hybrid			2022-12-27	WOS:000239847800008
J	Lin, Y; Yang, QF; Wang, X; Liu, ZG				Lin, Yong; Yang, Qingfeng; Wang, Xia; Liu, Zheng-gang			The essential role of the death domain kinase receptor-interacting protein in insulin growth factor-I-induced c-Jun N-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; TNF-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CELL-DEATH; DNA-DAMAGE; NH2-TERMINAL KINASE; MEDIATED APOPTOSIS; GENE-EXPRESSION; IGF-1 RECEPTOR; JNK ACTIVATION	Insulin-like growth factor I (IGF-I) plays an important role in cell survival, proliferation, and differentiation. Diverse kinases, including AKT/ protein kinase B, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), can be activated by IGF-I. Here, we show that the receptor-interacting protein (RIP), a key mediator of tumor necrosis factor-induced NF-kappa B and JNK activation, plays a key role in IGF-I receptor signaling. IGF-I induced a robust JNK activation in wild type but not RIP null (RIP-/-) mouse embryonic fibroblast cells. Reconstitution of RIP expression in the RIP-/- cells restored the induction of JNK by IGF-I, suggesting that RIP is essential in IGF-I-induced JNK activation. Reconstitution experiments with different RIP mutants further revealed that the death domain and the kinase activity of RIP are not required for IGF-I-induced JNK activation. Interestingly, the AKT and ERK activation by IGF-I was normal in RIP-/- cells. The phosphatidylinositol 3-kinase inhibitor, wortmannin, did not affect IGF-I-induced JNK activation. These results agree with previous studies showing that the IGF-I-induced JNK activation pathway is distinct from that of ERK and AKT activation. Additionally, physical interaction of ectopically expressed RIP and IGF-IR beta was detected by co-immunoprecipitation assays. More importantly, RIP was recruited to the IGF-I receptor complex during IGF-I-induced signaling. Furthermore, we found that IGF-I-induced cell proliferation was impaired in RIP-/- cells. Taken together, our results indicate that RIP, a key factor in tumor necrosis factor signaling, also plays a pivotal role in IGF-I-induced JNK activation and cell proliferation.	Lovelace Fdn Med Educ & Res, Mol Biol & Lung Canc Program, Albuquerque, NM 87108 USA; NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA	Lovelace Respiratory Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lin, Y (corresponding author), Lovelace Fdn Med Educ & Res, Mol Biol & Lung Canc Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	ylin@lrri.org	Yang, Heroine/GRY-2630-2022		NATIONAL CANCER INSTITUTE [Z01SC010376, ZIASC010376] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Che WY, 2002, CIRC RES, V90, P1222, DOI 10.1161/01.RES.0000021127.83364.7D; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FANG P, 2004, NOVART FDN SYMP, V262, P230; FANG P, 2004, NOVART FDN SYMP, V262, P265; Fang Peng, 2004, Novartis Found Symp, V262, P215; Fischer-Posovszky P, 2004, ENDOCRINOLOGY, V145, P1849, DOI 10.1210/en.2003-0985; Grimberg A, 2003, CANCER BIOL THER, V2, P630; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Krajcik RA, 2002, CANCER EPIDEM BIOMAR, V11, P1566; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Linseman DA, 2002, J NEUROSCI, V22, P9287; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Meylan E, 2005, TRENDS BIOCHEM SCI, V30, P151, DOI 10.1016/j.tibs.2005.01.003; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sekharam M, 2003, CANCER RES, V63, P7708; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Vallee S, 2003, BIOCHEM BIOPH RES CO, V305, P831, DOI 10.1016/S0006-291X(03)00866-0; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Vivarelli MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446; Wajant H, 2004, VITAM HORM, V67, P101; Walsh PT, 2002, IMMUNOLOGY, V107, P461, DOI 10.1046/j.1365-2567.2002.01525.x; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	53	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23525	23532		10.1074/jbc.M601487200	http://dx.doi.org/10.1074/jbc.M601487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793775	hybrid			2022-12-27	WOS:000239702900027
J	Reinberg, D; Sims, RJ				Reinberg, Danny; Sims, Robert J., III			de FACTo nucleosome dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RNA-POLYMERASE-II; TRANSCRIPTION ELONGATION-FACTORS; HISTONE LYSINE METHYLATION; SACCHAROMYCES-CEREVISIAE; IN-VIVO; CHROMATIN-STRUCTURE; DNA-REPLICATION; PAF1 COMPLEX; CHD1 INTERACTS; PROTEIN	The factors required for the delivery of RNA polymerase II to class II promoters using naked DNA were all identified by 1998, yet their exact mechanisms of action were not fully understood in all cases, and in some instances, their precise function still remains unknown. Nonetheless, a complete understanding of the complexity of the RNA polymerase II transcription cycle necessitated the development of assays that include chromatinized DNA templates. At this time, the field was actively searching for factors that allow transcription initiation on chromatinized templates. We began studies using chromatin templates in an attempt to identify factor(s) that permit RNA polymerase II to traverse nucleosomes, i.e. that allow elongation on chromatinized DNA templates. The challenge herein was to develop an assay that directly measured the ability of transcriptionally engaged RNA polymerase II to traverse nucleosomes. This approach resulted in the isolation of FACT, a heterodimer in humans comprised of Spt16 and SSRP1. Defined functional biochemical assays corroborated genetic studies in yeast that allowed the elucidation of FACT function in vivo. Collectively, these approaches demonstrate that FACT is a factor that allows RNA polymerase II to traverse nucleosomes in vitro and in vivo by removing one H2A/H2B dimer. More recent studies using a fully defined chromatin reconstitution/transcription assay revealed that FACT activity is greatly stimulated by post-translational modification of the histone polypeptides, specifically by monoubiquitination of lysine 120 of human histone H2B.	Rutgers State Univ, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Robert Wood Johnson Med Sch, Div Nucle Acids Enzymol, Dept Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Reinberg, D (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037120, R37GM037120, F32GM071166] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37120, GM71166] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2006, MOL CELL BIOL, V26, P250, DOI 10.1128/MCB.26.1.250-260.2006; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Biswas D, 2005, MOL CELL BIOL, V25, P5812, DOI 10.1128/MCB.25.14.5812-5822.2005; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Costa PJ, 2000, GENETICS, V156, P535; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Eriksson P, 2004, MOL CELL BIOL, V24, P6419, DOI 10.1128/MCB.24.14.6419-6429.2004; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Formosa T, 2002, GENETICS, V162, P1557; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; GONZALEZ PJ, 1989, J BIOL CHEM, V264, P18457; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kelley DE, 1999, CHROMOSOMA, V108, P10, DOI 10.1007/s004120050347; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Li YP, 2005, J BIOL CHEM, V280, P11869, DOI 10.1074/jbc.M413944200; Lusser A, 2005, NAT STRUCT MOL BIOL, V12, P160, DOI 10.1038/nsmb884; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Schlesinger MB, 2000, GENETICS, V155, P1593; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Shi XM, 1996, MOL CELL BIOL, V16, P669; Shi XM, 1997, MOL CELL BIOL, V17, P1160, DOI 10.1128/MCB.17.3.1160; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; VanDemark AP, 2006, MOL CELL, V22, P363, DOI 10.1016/j.molcel.2006.03.025; WINSTON F, 1984, GENETICS, V107, P179; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; XU QL, 1995, MOL CELL BIOL, V15, P6025; Zhou YJ, 2004, MOL CELL BIOL, V24, P9568, DOI 10.1128/MCB.24.21.9568-9579.2004; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025; Zhu B, 2005, GENE DEV, V19, P1668, DOI 10.1101/gad.1292105	64	180	183	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23297	23301		10.1074/jbc.R600007200	http://dx.doi.org/10.1074/jbc.R600007200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16766522	hybrid			2022-12-27	WOS:000239702900002
J	Shafat, I; Vlodavsky, I; Ilan, N				Shafat, Itay; Vlodavsky, Israel; Ilan, Neta			Characterization of mechanisms involved in secretion of active heparanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; FIBROBLAST-GROWTH-FACTOR; MAMMALIAN HEPARANASE; SULFATE DEGRADATION; BINDING DOMAINS; CELL-SURFACE; EXPRESSION; PROTEIN; GENE; ACTIVATION	Heparanase is an endo-beta-D-glucuronidase involved in extracellular matrix remodeling and degradation and implicated in tumor metastasis, angiogenesis, inflammation, and autoimmunity. The enzyme is synthesized as a latent 65-kDa protein and is processed in the lysosomal compartment to an active 58-kDa heterodimer, where it is stored in a stable form. In contrast, its heparan sulfate substrate is localized extracellularly, suggesting the existence of mechanisms that trigger heparanase secretion. Here we show that secretion of the active enzyme is mediated by the protein kinase A and C pathways. Moreover, secretion of active heparanase was observed upon cell stimulation with physiological concentrations of adenosine, ADP, and ATP, as well as by the noncleavable ATP analogue adenosine 5'-O-( thiotriphosphate). Indeed, heparanase secretion was noted upon cell stimulation with a specific P2Y1 receptor agonist and was inhibited by P2Y receptor antagonists. The kinetics of heparanase secretion resembled the secretion of cathepsin D, a lysosomal enzyme, indicating that the secreted heparanase is of lysosomal origin. We suggest that secretion of active heparanase is initiated by extracellular cues activating the protein kinase A and C signaling pathways. The secreted enzyme(s) then facilitate cell invasion associated with cancer metastasis, angiogenesis, and inflammation.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01-CA106456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Abbracchio MP, 1998, JPN J PHARMACOL, V78, P113, DOI 10.1254/jjp.78.113; Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Baraz L, 2006, ONCOGENE, V25, P3939, DOI 10.1038/sj.onc.1209425; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chen JQ, 2004, WORLD J GASTROENTERO, V10, P776; Cohen E, 2005, FEBS LETT, V579, P2334, DOI 10.1016/j.febslet.2005.03.030; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; de Mestre AM, 2005, J BIOL CHEM, V280, P35136, DOI 10.1074/jbc.M503414200; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Levy-Adam F, 2005, J BIOL CHEM, V280, P20457, DOI 10.1074/jbc.M414546200; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Munoz EM, 2004, ARTERIOSCL THROM VAS, V24, P1549, DOI 10.1161/01.ATV.0000137189.22999.3f; Nadav L, 2002, J CELL SCI, V115, P2179; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; van der Weyden L, 2000, IMMUNOL CELL BIOL, V78, P369, DOI 10.1046/j.1440-1711.2000.00918.x; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Vreys V, 2005, J BIOL CHEM, V280, P33141, DOI 10.1074/jbc.M503007200; Werry TD, 2002, BRIT J PHARMACOL, V135, P1199, DOI 10.1038/sj.bjp.0704566; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	47	57	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23804	23811		10.1074/jbc.M602762200	http://dx.doi.org/10.1074/jbc.M602762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790442	hybrid			2022-12-27	WOS:000239702900056
J	Amado, L; Kuzminov, A				Amado, Luciana; Kuzminov, Andrei			The replication intermediates in Escherichia coli are not the product of DNA processing or uracil excision	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND SYNTHESIS; CHAIN GROWTH; DEOXYRIBONUCLEIC-ACID; LEADING-STRAND; POLYMERASE-I; RECBC ENZYME; NASCENT DNA; RNASE-H; MECHANISM; MUTANTS	The current model of DNA replication in Escherichia coli postulates continuous synthesis of the leading strand, based on in vitro experiments with purified enzymes. In contrast, in vivo experiments in E. coli and its bacteriophages, in which maturation of replication intermediates was blocked, report discontinuous DNA synthesis of both the lagging and the leading strands. To address this discrepancy, we analyzed nascent DNA species from ThyA(+) E. coli cells replicating their DNA in ligase-deficient conditions to block maturation of replication intermediates. We report here that the bulk of the newly synthesized DNA isolated from ligase-deficient cells have a length between 0.3 and 3 kb, with a minor fraction being longer that 11 kb but shorter than the chromosome. The low molecular weight of the replication intermediates is unchanged by blocking linear DNA processing with a recBCD mutation or by blocking uracil excision with an ung mutation. These results are consistent with the previously proposed discontinuous replication of the leading strand in E. coli.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Kuzminov, A (corresponding author), Univ Illinois, Dept Microbiol, B103 C&LSL,601 S Goodwin Ave, Urbana, IL 61801 USA.	kuzminov@life.uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283, F31GM075425] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07283, F31 GM075425] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad SI, 1998, ANNU REV MICROBIOL, V52, P591, DOI 10.1146/annurev.micro.52.1.591; ALBERTS B, 1977, NATURE, V269, P655, DOI 10.1038/269655a0; BIRD RE, 1970, J MOL BIOL, V49, P343, DOI 10.1016/0022-2836(70)90249-4; BOYCE RP, 1962, BIOCHIM BIOPHYS ACTA, V61, P618, DOI 10.1016/0926-6550(62)90117-2; CHA TA, 1989, J BIOL CHEM, V264, P12220; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DERMODY JJ, 1979, J BACTERIOL, V139, P701, DOI 10.1128/JB.139.2.701-704.1979; DUNCAN BK, 1985, J BACTERIOL, V164, P689, DOI 10.1128/JB.164.2.689-695.1985; Gottesman M. M., 1973, DNA SYNTHESIS IN VIT, P107; HANAWALT PC, 1964, P NATL ACAD SCI USA, V52, P125, DOI 10.1073/pnas.52.1.125; HERRMANN R, 1972, NATURE-NEW BIOL, V240, P235, DOI 10.1038/newbio240235a0; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOCHHAUSER SJ, 1978, J BACTERIOL, V134, P157, DOI 10.1128/JB.134.1.157-166.1978; IYER VN, 1970, P NATL ACAD SCI USA, V67, P629, DOI 10.1073/pnas.67.2.629; JACOBSON MK, 1973, J MOL BIOL, V73, P371, DOI 10.1016/0022-2836(73)90088-0; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; JOHNSTON LH, 1978, NATURE, V274, P891, DOI 10.1038/274891a0; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KONRAD EB, 1973, J MOL BIOL, V77, P519, DOI 10.1016/0022-2836(73)90220-9; KONRAD EB, 1975, P NATL ACAD SCI USA, V72, P2150, DOI 10.1073/pnas.72.6.2150; Kornberg A., 1992, DNA REPLICATION; Kornberg Arthur, 1974, DNA SYNTHESIS; Kouzminova EA, 2006, J MOL BIOL, V355, P20, DOI 10.1016/j.jmb.2005.10.044; Kouzminova EA, 2004, MOL MICROBIOL, V51, P1279, DOI 10.1111/j.1365-2958.2003.03924.x; KUEMPEL PL, 1970, BIOCHEM BIOPH RES CO, V41, P973, DOI 10.1016/0006-291X(70)90180-4; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUROSAWA Y, 1975, J MOL BIOL, V94, P229, DOI 10.1016/0022-2836(75)90080-7; KUROSAWA Y, 1975, J MOL BIOL, V96, P653, DOI 10.1016/0022-2836(75)90144-8; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LARK KG, 1972, NATURE-NEW BIOL, V240, P237, DOI 10.1038/newbio240237a0; LOUARN JM, 1974, P NATL ACAD SCI USA, V71, P329, DOI 10.1073/pnas.71.2.329; MACKAY V, 1976, J BIOL CHEM, V251, P3716; MACKAY V, 1974, J BIOL CHEM, V249, P4286; Maniatis T., 1982, MOL CLONING; MANOR H, 1969, J MOL BIOL, V39, P1, DOI 10.1016/0022-2836(69)90329-5; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; OISHI M, 1968, P NATL ACAD SCI USA, V60, P329, DOI 10.1073/pnas.60.1.329; OKAZAKI R, 1968, P NATL ACAD SCI USA, V59, P598, DOI 10.1073/pnas.59.2.598; OKAZAKI R, 1968, COLD SPRING HARB SYM, V33, P129, DOI 10.1101/SQB.1968.033.01.017; OKAZAKI R, 1971, P NATL ACAD SCI USA, V68, P2954, DOI 10.1073/pnas.68.12.2954; OKAZAKI R, 1974, METHOD MOL BIOL, V7, P1; OKAZAKI T, 1969, P NATL ACAD SCI USA, V64, P1242, DOI 10.1073/pnas.64.4.1242; OLIVERA BM, 1972, NATURE-NEW BIOL, V240, P233, DOI 10.1038/newbio240233a0; OLIVERA BM, 1978, P NATL ACAD SCI USA, V75, P238, DOI 10.1073/pnas.75.1.238; OLIVERA BM, 1979, J MOL BIOL, V128, P265, DOI 10.1016/0022-2836(79)90087-1; ROWEN L, 1978, J BIOL CHEM, V253, P758; SAKABE K, 1966, BIOCHIM BIOPHYS ACTA, V129, P651, DOI 10.1016/0005-2787(66)90088-8; SILVERSTEIN JL, 1976, VIROLOGY, V72, P212, DOI 10.1016/0042-6822(76)90324-X; Sriskanda V, 2001, NUCLEIC ACIDS RES, V29, P4930, DOI 10.1093/nar/29.24.4930; STENT GS, 1978, MOL GENET, P248; SUGIMOTO K, 1969, P NATL ACAD SCI USA, V63, P1343, DOI 10.1073/pnas.63.4.1343; SUGIMOTO K, 1968, P NATL ACAD SCI USA, V60, P1356, DOI 10.1073/pnas.60.4.1356; TAMANOI F, 1978, P NATL ACAD SCI USA, V75, P2195, DOI 10.1073/pnas.75.5.2195; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; TYE BK, 1977, J MOL BIOL, V117, P293, DOI 10.1016/0022-2836(77)90128-0; Wang TCV, 2005, BIOESSAYS, V27, P633, DOI 10.1002/bies.20233; WANG TCV, 1989, BIOCHEM BIOPH RES CO, V165, P685, DOI 10.1016/S0006-291X(89)80020-8; WARNER HR, 1981, J BACTERIOL, V145, P687, DOI 10.1128/JB.145.2.687-695.1981; WERNER R, 1971, NATURE-NEW BIOL, V233, P99, DOI 10.1038/newbio233099a0; WICKNER W, 1972, P NATL ACAD SCI USA, V69, P965, DOI 10.1073/pnas.69.4.965; WU CA, 1992, J BIOL CHEM, V267, P4030; YUDELEVICH A, 1968, P NATL ACAD SCI USA, V61, P1129, DOI 10.1073/pnas.61.3.1129	68	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22635	22646		10.1074/jbc.M602320200	http://dx.doi.org/10.1074/jbc.M602320200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772291	hybrid			2022-12-27	WOS:000239542600024
J	Baker, DL; Fujiwara, Y; Pigg, KR; Tsukahara, R; Kobayashi, S; Murofushi, H; Uchiyama, A; Murakami-Murofushi, K; Koh, E; Bandle, RW; Byun, HS; Bittman, R; Fan, D; Murph, M; Mills, GB; Tigyi, G				Baker, Daniel L.; Fujiwara, Yuko; Pigg, Kathryn R.; Tsukahara, Ryoko; Kobayashi, Susumu; Murofushi, Hiromu; Uchiyama, Ayako; Murakami-Murofushi, Kimiko; Koh, Eunjin; Bandle, Russell W.; Byun, Hoe-Sup; Bittman, Robert; Fan, Dominic; Murph, Mandi; Mills, Gordon B.; Tigyi, Gabor			Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY ALCOHOL PHOSPHATES; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPASE-D; PPAR-GAMMA; IDENTIFICATION; MOTILITY; EXPRESSION; RECEPTOR; PHYLPA; SERUM	Autotaxin (ATX, nucleotide pyrophosphate/phosphodiesterase-2) is an autocrine motility factor initially characterized from A2058 melanoma cell-conditioned medium. ATX is known to contribute to cancer cell survival, growth, and invasion. Recently ATX was shown to be responsible for the lysophospholipase D activity that generates lysophosphatidic acid (LPA). Production of LPA is sufficient to explain the effects of ATX on tumor cells. Cyclic phosphatidic acid (cPA) is a naturally occurring analog of LPA in which the sn-2 hydroxy group forms a 5-membered ring with the sn-3 phosphate. Cellular responses to cPA generally oppose those of LPA despite activation of apparently overlapping receptor populations, suggesting that cPA also activates cellular targets distinct from LPA receptors. cPA has previously been shown to inhibit tumor cell invasion in vitro and cancer cell metastasis in vivo. However, the mechanism governing this effect remains unresolved. Here we show that 3-carba analogs of cPA lack significant agonist activity at LPA receptors yet are potent inhibitors of ATX activity, LPA production, and A2058 melanoma cell invasion in vitro and B16F10 melanoma cell metastasis in vivo.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Vasc Biol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Genom, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Bioinformat Ctr Excellence, Memphis, TN 38163 USA; Tokyo Univ Sci, Fac Pharmaceut, Dept Med Chem, Chiba 2788510, Japan; Yamaguchi Univ, Fac Nat Sci, Dept Biol Sci, Yamaguchi 7538511, Japan; Ochanomizu Univ, Fac Sci, Dept Biol, Tokyo 1128610, Japan; NCI, Lab Pathol, NIH, Bethesda, MD 20892 USA; City Univ New York, Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA; Univ Texas, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, Dept Mol Therapeut, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Tokyo University of Science; Yamaguchi University; Ochanomizu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City University of New York (CUNY) System; Queens College NY (CUNY); University of Texas System; University of Texas System; UTMD Anderson Cancer Center	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu		Koh, Eunjin/0000-0001-8967-6266; Baker, Daniel/0000-0003-1482-0416	NATIONAL CANCER INSTITUTE [P01CA064602, Z01BC010673, R01CA092160] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079004, R01HL061469] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA092160, P01 CA64602, P01 CA064602, R01 CA092160-08, CA92160] Funding Source: Medline; NHLBI NIH HHS [HL79004, HL61469, R01 HL061469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005; Clair T, 2003, CANCER RES, V63, P5446; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; Debies MT, 2001, J MAMMARY GLAND BIOL, V6, P441, DOI 10.1023/A:1014739131690; Deissler H, 1999, FASEB J, V13, P657, DOI 10.1096/fasebj.13.6.657; Durgam GG, 2005, J MED CHEM, V48, P4919, DOI 10.1021/jm049609r; ERUKULLA RK, 1994, TETRAHEDRON LETT, V35, P5783; Euer N, 2002, ANTICANCER RES, V22, P733; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Friedman P, 1996, J BIOL CHEM, V271, P953, DOI 10.1074/jbc.271.2.953; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; Ishihara R, 2004, INT J CANCER, V110, P188, DOI 10.1002/ijc.20069; Klominek J, 1998, ANTICANCER RES, V18, P759; KOBAYASHI S, 1993, TETRAHEDRON LETT, V34, P4047, DOI 10.1016/S0040-4039(00)60612-3; KOBAYASHI S, 2004, Patent No. 1402894; Kobayashi T, 1999, LIFE SCI, V65, P2185, DOI 10.1016/S0024-3205(99)00483-X; KOHN EC, 1993, INT J CANCER, V53, P968; Liliom K, 1996, AM J PHYSIOL-CELL PH, V270, pC772, DOI 10.1152/ajpcell.1996.270.3.C772; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mukai M, 2000, FEBS LETT, V484, P69, DOI 10.1016/S0014-5793(00)02129-3; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2; MURAKAMIMUROFUSHI K, 1992, J BIOL CHEM, V267, P21512; MURAKAMIMUROFUSHI K, 1993, CELL STRUCT FUNCT, V18, P363, DOI 10.1247/csf.18.363; MURATA J, 1994, J BIOL CHEM, V269, P30479; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Tokumura A, 2002, J LIPID RES, V43, P307; Tokumura A, 2000, ANN NY ACAD SCI, V905, P347; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2005, J BIOL CHEM, V280, P21155, DOI 10.1074/jbc.M413183200; Virag T, 2003, MOL PHARMACOL, V63, P1032, DOI 10.1124/mol.63.5.1032; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Yang Y, 1999, AM J RESP CELL MOL, V21, P216, DOI 10.1165/ajrcmb.21.2.3667; Zhang GX, 1999, CHINESE MED J-PEKING, V112, P330	54	136	149	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22786	22793		10.1074/jbc.M512486200	http://dx.doi.org/10.1074/jbc.M512486200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16782709	hybrid, Green Accepted			2022-12-27	WOS:000239542600039
J	Dobi, A; Szemes, M; Lee, C; Palkovits, M; Lim, F; Gyorgy, A; Mahan, MA; Agoston, DV				Dobi, Albert; Szemes, Marianna; Lee, Cheol; Palkovits, Miklos; Lim, Francis; Gyorgy, Andrea; Mahan, Mark A.; Agoston, Denes V.			AUF1 ls expressed in the developing brain, binds to AT-rich double-stranded DNA, and regulates enkephalin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; MESSENGER-RNA DECAY; TRANSCRIPTION FACTORS; CHROMATIN DOMAINS; PROTEIN ISOFORMS; HNRNP PROTEINS; ARID PROTEINS; IN-VIVO; MATRIX; REGION	During our search for transcriptional regulators that control the developmentally regulated expression of the enkephalin (ENK) gene, we identified AUF1. ENK, a peptide neurotransmitter, displays precise cell-specific expression in the adult brain. AUF1 (also known as heterogeneous nuclear ribonucleoprotein D) has been known to regulate gene expression through altering the stability of AU-rich mRNAs. We show here that in the developing brain AUF1 proteins are expressed in a spatiotemporally defined manner, and p37 and p40/42 isoforms bind to an AT-rich double-stranded (ds) DNA element of the rat ENK (rENK) gene. This AT-rich dsDNA sequence acts as a cis-regulatory DNA element and is involved in regulating the cell-specific expression of the ENK gene in primary neuronal cultures. The AT-rich dsDNA elements are present at similar to 2.5 kb 5' upstream of the rat, human, and mouse ENK genes. AUF1 proteins are shown here to provide direct interaction between these upstream AT-rich DNA sequences and the TATA region of the rENK gene. Double immunohistochemistry demonstrated that in the developing brain AUF1 proteins are expressed by proliferating neural progenitors and by differentiating neurons populating brain regions, which will not express the ENK gene in the adult, suggesting a repressor role for AUF1 proteins during enkephalinergic differentiation. Their subnuclear distribution and interactions with AT-rich DNA suggest that in the developing brain they can be involved in complex nuclear regulatory mechanisms controlling the development- and cell-specific expression of the ENK gene.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; NIMH, Bethesda, MD 20892 USA; Univ New Mexico, Dept Biochem, Albuquerque, NM 87131 USA; Columbia Univ, Dept Neurol, New York, NY 10027 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of New Mexico; Columbia University	Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, B2036, Bethesda, MD 20814 USA.	vagoston@usuhs.mil	Palkovits, Miklos/F-2707-2013	Palkovits, Miklos/0000-0003-0578-0387				AGOSTON D, 1998, DNA SEQUENCE, V9, P217; AGOSTON DV, 1991, J NEUROSCI RES, V28, P140, DOI 10.1002/jnr.490280115; Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Bernstein BE, 2004, METHOD ENZYMOL, V376, P349; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Boulikas T, 1995, INT REV CYTOL, V162A, P279; Boussif O, 1996, GENE THER, V3, P1074; Brewer G, 2002, AGEING RES REV, V1, P607, DOI 10.1016/S1568-1637(02)00023-5; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Comb M J, 1992, NIDA Res Monogr, V126, P98; Comings DE, 1999, NEUROREPORT, V10, P1133, DOI 10.1097/00001756-199904060-00042; Comings DE, 2000, PROG BRAIN RES, V126, P325; Cremer T, 2000, CRIT REV EUKAR GENE, V10, P179; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Dobi A, 2002, BIOTECHNIQUES, V33, P868, DOI 10.2144/02334rr03; Dobi A, 1997, MOL BRAIN RES, V52, P98, DOI 10.1016/S0169-328X(97)00238-6; Dobi A, 2000, J NEUROSCI, V20, P1073, DOI 10.1523/JNEUROSCI.20-03-01073.2000; Dobi A, 1998, P NATL ACAD SCI USA, V95, P5981, DOI 10.1073/pnas.95.11.5981; DONOVAN DM, 1992, P NATL ACAD SCI USA, V89, P2345, DOI 10.1073/pnas.89.6.2345; Gindullis F, 1999, PLANT CELL, V11, P1117, DOI 10.1105/tpc.11.6.1117; Hart CM, 1998, CURR OPIN GENET DEV, V8, P519, DOI 10.1016/S0959-437X(98)80005-1; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; Hyman S E, 1996, NIDA Res Monogr, V161, P59; Ishii K, 2003, MOL CELL, V11, P237, DOI 10.1016/S1097-2765(03)00010-8; Johnson TA, 2001, BIOTECHNIQUES, V31, P740, DOI 10.2144/01314bm05; JOSHI J, 1991, MOL ENDOCRINOL, V5, P1069, DOI 10.1210/mend-5-8-1069; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; KAPLITT MG, 1994, P NATL ACAD SCI USA, V91, P8979, DOI 10.1073/pnas.91.19.8979; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Kumar NV, 2001, ANAL BIOCHEM, V299, P203, DOI 10.1006/abio.2001.5433; Laemmli UK, 1996, CURR OPIN CELL BIOL, V8, P299, DOI 10.1016/S0955-0674(96)80001-9; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; PAULI U, 1989, J CELL PHYSIOL, V139, P320, DOI 10.1002/jcp.1041390214; PAXINOS G, 1995, ATLAS DEV RAT NERVOU; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; Sarkar B, 2003, J BIOL CHEM, V278, P20700, DOI 10.1074/jbc.M301176200; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; SONG DD, 1994, DEV BRAIN RES, V83, P247, DOI 10.1016/0165-3806(94)00145-6; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; SUMMERS RW, 1993, DEV BRAIN RES, V73, P185, DOI 10.1016/0165-3806(93)90137-Y; Szemes M, 2006, NEUROCHEM RES, V31, P237, DOI 10.1007/s11064-005-9012-8; Taylor A, 1997, MOL CELL BIOCHEM, V169, P61, DOI 10.1023/A:1006898812618; Tolnay M, 2000, BIOCHEM J, V348, P151, DOI 10.1042/0264-6021:3480151; Tolnay M, 2002, BIOCHEM J, V363, P127, DOI 10.1042/0264-6021:3630127; Vaccarino AL, 1999, PEPTIDES, V20, P1527, DOI 10.1016/S0196-9781(99)00166-7; Von Agoston D, 2000, BIOCHEM SOC T, V28, P446; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95; Woynarowski JM, 2004, CURR CANCER DRUG TAR, V4, P219, DOI 10.2174/1568009043481524; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	65	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28889	28900		10.1074/jbc.M511858200	http://dx.doi.org/10.1074/jbc.M511858200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16769718	hybrid			2022-12-27	WOS:000240680500043
J	Hiromura, M; Suizu, F; Narita, M; Kinowaki, K; Noguchi, M				Hiromura, Makoto; Suizu, Futoshi; Narita, Masumi; Kinowaki, Keiichi; Noguchi, Masayuki			Identification of nerve growth factor-responsive element of the TCL1 promoter as a novel negative regulatory element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN STEROID-RECEPTOR; AKT KINASE-ACTIVITY; T-CELL; NGFI-B; DIFFERENTIAL REGULATION; TRANSCRIPTION FACTOR; EXPRESSION; GENE; ACTIVATION; APOPTOSIS	The serine/threonine kinase, Akt ( protein kinase B) plays a central role in the regulation of intracellular cell survival. Recently, we demonstrated that the proto-oncogene TCL1, overexpressed in human T-cell prolymphocytic leukemia, is an Akt kinase co-activator. Tightly restricted TCL1 gene expression in early developmental cells suggested that the TCL1 gene is regulated at a transcriptional level. To characterize how TCL1 gene expression is regulated, we cloned the 5'-promoter of the TCL1 gene located at human chromosome 14q32. The 5'-TCL1 promoter region contains a TATA box with cis-regulatory elements for Nur77/NGFI-B (nerve growth factor-responsive element (NBRE), CCAAGGTCA), NF kappa B, and fork head transcription factor. Nur77/NGFI-B, an orphan receptor superfamily transcription factor implicated in T-cell apoptosis, is a substrate for Akt. We hypothesized that TCL1 transactivity is regulated through Akt-induced phosphorylation of Nur77/NGFI-B in vivo. In an electrophoretic mobility shift assay with chromosomal immunoprecipitation assays, wild-type Nur77, but not S350A mutant Nur77, could specifically bind to TCL1-NBRE. A luciferase assay demonstrated that TCL1-NBRE is required for inhibition of TCL1 transactivity upon nerve growth factor/platelet-derived growth factor stimulation, which activates Akt and phosphorylates Nur77. Using a chromosomal immunoprecipitation assay with reverse transcription-PCR, nerve growth factor stimulation inhibited binding of endogenous Nur77 to TCL1-NBRE, in turn, suppressing TCL1 gene expression. The results together establish that TCL1-NBRE is a novel negative regulatory element of Nur77 (NGFI-B). To the best of our knowledge, TCL1-NBRE is the first direct target of Nur77 involving the regulation of intracellular cell death survival. This Akt-induced inhibitory mechanism of TCL1 should play an important role in immunological and/or neuronal development in vivo.	Hokkaido Univ, Inst Med Genet, Div Canc Biol, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Noguchi, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Canc Biol, Sapporo, Hokkaido 0600815, Japan.	m_noguch@igm.hokudai.ac.jp	Suizu, Futoshi/G-3530-2019	Suizu, Futoshi/0000-0003-0206-4289				Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; Croce CM, 1999, CANCER RES, V59, p1778S; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; French SW, 2003, J BIOL CHEM, V278, P948, DOI 10.1074/jbc.M207166200; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hoyer KK, 2005, J IMMUNOL, V175, P864, DOI 10.4049/jimmunol.175.2.864; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Kang SM, 2005, BLOOD, V105, P1288, DOI 10.1182/blood-2004-04-1453; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Lock RB, 2003, INT J BIOCHEM CELL B, V35, P1614, DOI 10.1016/S1357-2725(03)00146-8; Maruyama K, 1997, NEUROENDOCRINOLOGY, V65, P2, DOI 10.1159/000127158; Maruyama K, 1998, INT J ONCOL, V12, P1237; MATSUYAMA N, 2001, J BIOL CHEM, V274, P32799; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Narducci MG, 2000, CANCER RES, V60, P2095; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Takizawa J, 1998, JPN J CANCER RES, V89, P712, DOI 10.1111/j.1349-7006.1998.tb03275.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0	45	11	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27753	27764		10.1074/jbc.M602420200	http://dx.doi.org/10.1074/jbc.M602420200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16835233	hybrid, Green Published			2022-12-27	WOS:000240534400011
J	Buis, JM; Cheek, J; Kalliri, E; Broderick, JB				Buis, Jeffrey M.; Cheek, Jennifer; Kalliri, Efthalia; Broderick, Joan B.			Characterization of an active spore photoproduct lyase, a DNA repair enzyme in the radical S-adenosylmethionine superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; BACILLUS-SUBTILIS SPORES; IRON-SULFUR PROTEINS; ACTIVATING ENZYME; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; LIPOYL SYNTHASE; 4FE-4S CLUSTERS; THYMINE DIMERS; BINDS	The major photoproduct in UV-irradiated Bacillus spore DNA is a unique thymine dimer called spore photoproduct (SP, 5-thyminyl-5,6-dihydrothymine). The enzyme spore photoproduct lyase (SP lyase) has been found to catalyze the repair of SP dimers to thymine monomers in a reaction that requires S-adenosylmethionine. We present here the first detailed characterization of catalytically active SP lyase, which has been anaerobically purified from overexpressing Escherichia coli. Anaerobically purified SP lyase is monomeric and is red-brown in color. The purified enzyme contains similar to 3.1 iron and 3.0 acid-labile S-2-per protein and has a UV-visible spectrum characteristic of iron-sulfur proteins (410 nm (11.9 mM(-1) cm(-1)) and 450 nm (10.5 mM(-1) cm(-1))). The X-band EPR spectrum of the purified enzyme shows a nearly isotropic signal (g = 2.02) characteristic of a [3Fe-4S](1+) cluster; reduction of SP lyase with dithionite results in the appearance of a new EPR signal (g = 2.03, 1.93, and 1.89) with temperature dependence and g values consistent with its assignment to a [4Fe-4S](1+) cluster. The reduced purified enzyme is active in SP repair, with a specific activity of 0.33 mu mol/min/mg. Only a catalytic amount of S-adenosylmethionine is required for DNA repair, and no irreversible cleavage of S-adenosylmethionine into methionine and 5'-deoxyadenosine is observed during the reaction. Label transfer from [5'-3H] S-adenosylmethionine to repaired thymine is observed, providing evidence to support a mechanism in which a 5'-deoxyadenosyl radical intermediate directly abstracts a hydrogen from SP C-6 to generate a substrate radical, and subsequent to radical-mediated beta-scission, a product thymine radical abstracts a hydrogen from 5'-deoxyadenosine to regenerate the 5'-deoxyadenosyl radical. Together, our results support a mechanism in which S-adenosylmethionine acts as a catalytic cofactor, not a substrate, in the DNA repair reaction.	Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Montana State University System; Montana State University Bozeman; Michigan State University	Broderick, JB (corresponding author), Montana State Univ, Dept Chem & Biochem, Gaines Hall 108, Bozeman, MT 59717 USA.	jbroderick@chemistry.montana.edu		Broderick, Joan/0000-0001-7057-9124	NIGMS NIH HHS [R01 GM067804, GM20315, GM67804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067804] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1978, Methods Enzymol, V54, P435; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick J. B, 2004, COMPREHENSIVE COORDI, V1st, P739, DOI [10.1016/B0-08-043748-6/08214-1, DOI 10.1016/B0-08-043748-6/08214-1]; Broderick JB, 2000, BIOCHEM BIOPH RES CO, V269, P451, DOI 10.1006/bbrc.2000.2313; Cheek J, 2002, J AM CHEM SOC, V124, P2860, DOI 10.1021/ja017784g; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Cicchillo RM, 2004, BIOCHEMISTRY-US, V43, P11770, DOI 10.1021/bi0488505; DONNELLAN JE, 1965, SCIENCE, V149, P308, DOI 10.1126/science.149.3681.308; DONNELLAN JE, 1968, BIOPHYS J, V8, P17, DOI 10.1016/S0006-3495(68)86471-9; FAJARDOCAVAZOS P, 1993, J BACTERIOL, V175, P1735, DOI 10.1128/JB.175.6.1735-1744.1993; FISH WW, 1978, METHOD ENZYMOL, V54, P357; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Freire E., 1995, DNA REPAIR MUTAGENES, P191; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; Friedel MG, 2006, CHEM COMMUN, P445, DOI 10.1039/b514103f; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; Henshaw TF, 2000, J AM CHEM SOC, V122, P8331, DOI 10.1021/ja002012q; IRETON K, 1992, J BACTERIOL, V174, P3185, DOI 10.1128/jb.174.10.3185-3195.1992; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Krebs C, 2000, J AM CHEM SOC, V122, P12497, DOI 10.1021/ja003335p; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Lepore BW, 2005, P NATL ACAD SCI USA, V102, P13819, DOI 10.1073/pnas.0505726102; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; Mehl RA, 1999, ORG LETT, V1, P1065, DOI 10.1021/ol9908676; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; MUNAKATA N, 1972, J BACTERIOL, V11, P192, DOI 10.1128/JB.111.1.192-198.1972; MUNAKATA N, 1974, MOL GEN GENET, V130, P239, DOI 10.1007/BF00268802; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; Nicholson WL, 1997, MOL GEN GENET, V255, P587, DOI 10.1007/s004380050532; NICHOLSON WL, 1991, P NATL ACAD SCI USA, V88, P8288, DOI 10.1073/pnas.88.19.8288; Padovani D, 2001, BIOCHEMISTRY-US, V40, P6713, DOI 10.1021/bi002936q; Rebeil R, 2001, P NATL ACAD SCI USA, V98, P9038, DOI 10.1073/pnas.161278998; Rebeil R, 1998, J BACTERIOL, V180, P4879, DOI 10.1128/JB.180.18.4879-4885.1998; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SETLOW B, 1992, J BACTERIOL, V174, P2312, DOI 10.1128/JB.174.7.2312-2322.1992; SETLOW P, 1994, REGULATION OF BACTERIAL DIFFERENTIATION, P181; SETLOW P, 1992, MOL MICROBIOL, V6, P563, DOI 10.1111/j.1365-2958.1992.tb01501.x; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; Slieman TA, 2000, J BACTERIOL, V182, P6412, DOI 10.1128/JB.182.22.6412-6417.2000; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; STUY JH, 1955, BIOCHIM BIOPHYS ACTA, V17, P206, DOI 10.1016/0006-3002(55)90351-6; SUN YB, 1994, ANAL BIOCHEM, V221, P61, DOI 10.1006/abio.1994.1379; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; VARGHESE AJ, 1970, BIOCHEM BIOPH RES CO, V38, P484, DOI 10.1016/0006-291X(70)90739-4; Walsby CJ, 2002, J AM CHEM SOC, V124, P11270, DOI 10.1021/ja027078v; Walsby CJ, 2005, INORG CHEM, V44, P727, DOI 10.1021/ic0484811; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; Yasbin Ronald E., 1993, P529	54	58	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25994	26003		10.1074/jbc.M603931200	http://dx.doi.org/10.1074/jbc.M603931200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829680	hybrid			2022-12-27	WOS:000240249500014
J	Okumura, K; Mendoza, M; Bachoo, RM; DePinho, RA; Cavenee, WK; Furnari, FB				Okumura, Koichi; Mendoza, Michelle; Bachoo, Robert M.; DePinho, Ronald A.; Cavenee, Webster K.; Furnari, Frank B.			PCAF modulates PTEN activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; PHOSPHATASE-ACTIVITY; HISTONE ACETYLASES; GROWTH SUPPRESSION; CHROMOSOME-10 PTEN; PROTEIN STABILITY; NUCLEAR PTEN; MUTATIONS; GENE; PHOSPHORYLATION	The PTEN protein has a single catalytic domain possessing both lipid phosphoinositol and protein phosphatase activities. The lipid phosphoinositol phosphatase activity is essential for PTEN to block the cell cycle in the G1 phase and thereby to suppress tumor formation and progression (Cantley, L. C., and Neel, B. G. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 4240-4245), although the mechanisms governing PTEN activity under normal and neoplastic growth conditions remain unclear. Here, we report that PTEN interacts physically and functionally with PCAF, a histone acetyltransferase that regulates gene transcription through interaction with p300/CBP and various sequence-specific transcription factors (Nakatani, Y. (2001) Genes Cells 6, 79 -86). Expression of PCAF results in increased acetylation of lysine residues (Lys(125) and Lys(128)) within the catalytic cleft of PTEN, a structure essential for phosphatidylinositol 3,4,5-trisphosphate specificity (Lee, J. O., Yang, H., Georgescu, M. M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J. E., Pandolfi, P., and Pavletich, N. P. (1999) Cell 99, 323 -334). The acetylation of PTEN caused by PCAF expression depends on the presence of growth factors. Reduction of endogenous PCAF activity using shRNA results in a loss of PTEN acetylation in response to growth factors and restores the ability of PTEN to down-regulate phosphatidylinositol 3-kinase signaling and to induce G1 cell cycle arrest. The retention of phosphatidylinositol 3-kinase/AKT signaling and cell cycle regulatory activities of acetylation-resistant PTEN K125R and K128R mutants in the presence of enforced PCAF expression suggest a causal relationship. Together, these findings indicate a mechanism of PTEN regulation that forges a link between distinct cancer-relevant pathways central to the control of growth factor signaling and gene expression.	Univ Calif San Diego, Ludwig Inst Canc Res, San Diego Branch, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75390 USA; Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Furnari, FB (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, San Diego Branch, La Jolla, CA 92093 USA.	ffurnari@ucsd.edu		Furnari, Frank/0000-0003-1909-4361; DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA95616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Debes JD, 2003, CANCER RES, V63, P7638; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Nishimori H, 2000, J NEURO-ONCOL, V46, P17, DOI 10.1023/A:1006404110073; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	34	159	169	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26562	26568		10.1074/jbc.M605391200	http://dx.doi.org/10.1074/jbc.M605391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829519	hybrid			2022-12-27	WOS:000240249500074
J	Yamniuk, AP; Ishida, H; Vogel, HJ				Yamniuk, Aaron P.; Ishida, Hiroaki; Vogel, Hans J.			The interaction between calcium- and integrin-binding protein 1 and the alpha IIb integrin cytoplasmic domain involves a novel C-terminal displacement mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-RESONANCE EXPERIMENTS; NMR-SPECTROSCOPY; METHIONINE RESIDUES; BACKBONE DYNAMICS; CIB BINDING; CALMODULIN; N-15; ACTIVATION; ALPHA(IIB)BETA(3); RECOGNITION	Calcium- and integrin-binding protein 1 (CIB1) regulates platelet aggregation in hemostasis through a specific interaction with the alpha IIb cytoplasmic domain of platelet integrin alpha IIb alpha 3. In this work we report the structural characteristics of CIB1 in solution and the mechanistic details of its interaction with a synthetic peptide derived from the alpha IIb cytoplasmic domain. NMR spectroscopy experiments using perdeuterated CIB1 together with heteronuclear nuclear Overhauser effect experiments have revealed a well folded alpha-helical structure for both the ligand-free and alpha IIb-bound forms of the protein. Residual dipolar coupling experiments have shown that the N and C domains of CIB1 are positioned side by side, and chemical shift perturbation mapping has identified the alpha IIb-binding site as a hydrophobic channel spanning the entire C domain and part of the N domain. Data obtained with a truncated version of CIB1 suggest that the extreme C-terminal end of the protein weakly interacts with this channel in the absence of a biological target, but it is displaced by the alpha IIb cytoplasmic domain, suggesting a novel mechanism to increase binding specificity.	Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca						ANGLISTER J, 1995, FEBS LETT, V375, P108, DOI 10.1016/0014-5793(95)01192-H; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Barry WT, 2002, J BIOL CHEM, V277, P28877, DOI 10.1074/jbc.M202983200; Behan MWH, 2004, POSTGRAD MED J, V80, P155, DOI 10.1136/pgmj.2003.007062; Blamey CJ, 2005, PROTEIN SCI, V14, P1214, DOI 10.1110/ps.041270805; BLAZEJCZYK M, 2005, BIOCHIM BIOPHYS ACTA, V1762, P66; CALVETE JJ, 1990, FEBS LETT, V263, P43, DOI 10.1016/0014-5793(90)80701-J; Cordier F, 1999, J BIOMOL NMR, V13, P175, DOI 10.1023/A:1008301415843; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DRAKENBERG T, 1987, J BIOL CHEM, V262, P672; Eletsky A, 2001, J BIOMOL NMR, V20, P177, DOI 10.1023/A:1011265430149; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gardner KH, 1998, ANNU REV BIOPH BIOM, V27, P357, DOI 10.1146/annurev.biophys.27.1.357; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; Gentry HR, 2005, J BIOL CHEM, V280, P8407, DOI 10.1074/jbc.M411515200; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hers I, 2000, ARTERIOSCL THROM VAS, V20, P1651, DOI 10.1161/01.ATV.20.6.1651; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hwang PM, 2000, J MOL RECOGNIT, V13, P83, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<83::AID-JMR491>3.0.CO;2-A; Ikura M, 2006, P NATL ACAD SCI USA, V103, P1159, DOI 10.1073/pnas.0508640103; Jiang GH, 2003, BIOL CHEM, V384, P1299, DOI 10.1515/BC.2003.145; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; Liu SC, 2000, J CELL SCI, V113, P3563; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; Naik UP, 2003, BLOOD, V102, P1355, DOI 10.1182/blood-2003-02-0591; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Naoe Y, 2005, J BIOL CHEM, V280, P32372, DOI 10.1074/jbc.M503390200; Ni HY, 2003, TRANSFUS APHER SCI, V28, P257, DOI 10.1016/S1473-0502(03)00044-2; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Shan X, 1998, J BIOMOL NMR, V11, P307, DOI 10.1023/A:1008257803130; Shan X, 1996, J AM CHEM SOC, V118, P6570, DOI 10.1021/ja960627a; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Sobczak A, 2005, ACTA BIOCHIM POL, V52, P469; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Stefansson A, 2004, J BIOL CHEM, V279, P21200, DOI 10.1074/jbc.M400771200; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; Tsuboi S, 2002, J BIOL CHEM, V277, P1919, DOI 10.1074/jbc.M110643200; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WALSH M, 1978, BIOCHEMISTRY-US, V17, P3924, DOI 10.1021/bi00612a006; Weljie AM, 2003, PROTEIN SCI, V12, P228, DOI 10.1110/ps.0226203; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wishart DS, 1998, BIOCHEM CELL BIOL, V76, P153, DOI 10.1139/bcb-76-2-3-153; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Yamniuk AP, 2005, PROTEIN SCI, V14, P1429, DOI 10.1110/ps.041312805; Yamniuk AP, 2004, BIOCHEMISTRY-US, V43, P2558, DOI 10.1021/bi035432b; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Yuan T, 1999, J BIOL CHEM, V274, P8411, DOI 10.1074/jbc.274.13.8411; Yuan WP, 2006, J CELL BIOL, V172, P169, DOI 10.1083/jcb.200505131; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	56	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26455	26464		10.1074/jbc.M603963200	http://dx.doi.org/10.1074/jbc.M603963200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825200	hybrid			2022-12-27	WOS:000240249500063
J	Hsieh, CF; Chang, BJ; Pai, CH; Chen, HY; Tsai, JW; Yi, YH; Chiang, YT; Wang, DW; Chi, S; Hsu, L; Lin, CH				Hsieh, Chia-Fen; Chang, Bo-Jui; Pai, Chyi-Huey; Chen, Hsuan-Yi; Tsai, Jin-Wu; Yi, Yung-Hsiang; Chiang, Yi-Ting; Wang, Da-Wei; Chi, Sien; Hsu, Long; Lin, Chi-Hung			Stepped changes of monovalent ligand-binding force during ligand-induced clustering of integrin alpha(IIB)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; PLATELET-AGGREGATION INHIBITOR; GLYCOPROTEIN IB-IX; RECOMBINANT RHODOSTOMIN; CALCIUM OSCILLATION; SIGNAL-TRANSDUCTION; AVIDITY REGULATION; ADHESION FORCE; CELL-ADHESION; OUTSIDE-IN	Recent evidence demonstrated that conformational changes of the integrin during receptor activation affected its binding to extracellular matrix; however, experimental assessment of ligand-receptor binding following the initial molecular interaction has rarely been carried out at a single-molecule resolution. In the present study, laser tweezers were used to measure the binding force exerted by a live Chinese hamster ovary cell that expressed integrin alpha(IIb)beta(3) (CHO alpha(IIb)beta(3)), to the bead carrier coated with the snake venom rhodostomin that served as an activated ligand for integrin alpha(IIb)beta(3). A progressive increase of total binding force over time was noticed when the bead interacted with the CHO alpha(IIb)beta(3) cell; such an increase was due mainly to the recruitment of more integrin molecules to the bead-cell interface. When the binding strength exerted by a single ligand-receptor pair was derived from the "polyvalent" measurements, surprisingly, a stepped decrease of the "monovalent binding force" was noted (from 4.15 to 2.54 piconewtons (pN)); such decrease appeared to occur during the ligand-induced integrin clustering process. On the other hand, the mutant rhodostomin defective in clustering integrins exhibited only one (1.81 pN) unit binding strength.	Natl Yang Ming Univ, Inst Biophoton Engn, Inst Microbiol & Immunol, Taipei, Taiwan; Natl Chiao Tung Univ, Dept Photon, Hsinchu, Taiwan; Natl Chiao Tung Univ, Inst Electroopt Engn, Hsinchu 30050, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Inst Sci Informat, Taipei 115, Taiwan; Natl Cent Univ, Dept Phys, Taoyuan, Taiwan; Yuan Ze Univ, Dept Elect Engn, Taoyuan, Taiwan; Natl Chiao Tung Univ, Dept Electrophys, Hsinchu 30050, Taiwan; Natl Yang Ming Univ, Inst Biophoton Engn, Taipei 112, Taiwan; Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan; Taipei City Hosp, Div Med Res, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Central University; Yuan Ze University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei City Hospital	Lin, CH (corresponding author), Natl Yang Ming Univ, Inst Biophoton Engn, Inst Microbiol & Immunol, Taipei, Taiwan.	linch@ym.edu.tw	Tsai, Jin W/A-6428-2009	Chang, Bo-Jui/0000-0002-5513-7106; Chi, Sien/0000-0002-8674-1963; Tsai, Jin-Wu/0000-0003-0135-759X				ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; Arya M, 2005, BIOPHYS J, V88, P4391, DOI 10.1529/biophysj.104.046318; Arya M, 2003, J THROMB HAEMOST, V1, P1150, DOI 10.1046/j.1538-7836.2003.00295.x; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; ASHKIN A, 1970, PHYS REV LETT, V24, P156, DOI 10.1103/PhysRevLett.24.156; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; CANTARERO LA, 1980, ANAL BIOCHEM, V105, P375, DOI 10.1016/0003-2697(80)90473-X; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Chang CP, 2001, BIOCHEM J, V357, P57, DOI 10.1042/0264-6021:3570057; Chang HH, 1999, EXP CELL RES, V250, P387, DOI 10.1006/excr.1999.4547; Chang HH, 1997, TOXICON, V35, P195, DOI 10.1016/S0041-0101(96)00121-3; Chang HH, 1998, TOXICON, V36, P1087, DOI 10.1016/S0041-0101(98)00088-9; CHIANG HS, 1995, BRIT J CANCER, V71, P265, DOI 10.1038/bjc.1995.54; CLEVELAND WS, 1988, J ECONOMETRICS, V37, P87, DOI 10.1016/0304-4076(88)90077-2; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Gergely C, 2000, P NATL ACAD SCI USA, V97, P10802, DOI 10.1073/pnas.180293097; Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; HUANG TF, 1987, BIOCHIM BIOPHYS ACTA, V925, P248, DOI 10.1016/0304-4165(87)90189-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KAUFMAN L, 1990, FINDING GROUPS DATA, P69; Larrucea S, 2002, BLOOD, V99, P2819, DOI 10.1182/blood.V99.8.2819; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; Mekrache M, 2002, BRIT J HAEMATOL, V116, P636, DOI 10.1046/j.0007-1048.2001.03332.x; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; Payrastre B, 2000, BIOCHEM PHARMACOL, V60, P1069, DOI 10.1016/S0006-2952(00)00417-2; Sagvolden G, 1999, BIOPHYS J, V77, P526, DOI 10.1016/S0006-3495(99)76909-2; SHETZ MP, 1999, LASER TWEEZERS CELL, P1; Sun DS, 2005, J BIOMED SCI, V12, P321, DOI 10.1007/s11373-005-0979-6; SUNG KLP, 1993, BLOOD, V81, P419; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tsai JW, 2000, P SOC PHOTO-OPT INS, V4082, P213, DOI 10.1117/12.390549; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351	41	6	6	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25466	25474		10.1074/jbc.M601793200	http://dx.doi.org/10.1074/jbc.M601793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16793773	hybrid			2022-12-27	WOS:000240031300049
J	Jones, LL; Brophy, SE; Bankovich, AJ; Colf, LA; Hanick, NA; Garcia, KC; Kranz, DM				Jones, Lindsay L.; Brophy, Susan E.; Bankovich, Alexander J.; Colf, Leremy A.; Hanick, Nicole A.; Garcia, K. Christopher; Kranz, David M.			Engineering and characterization of a stabilized alpha 1/alpha 2 module of the class I major histocompatibility complex product L-d	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; YEAST SURFACE-DISPLAY; SINGLE-CHAIN TRIMERS; HIGH-AFFINITY; DIRECTED EVOLUTION; MONOCLONAL-ANTIBODIES; PEPTIDE SPECIFICITY; MHC MOLECULES; ANTIGEN; CD8	The major histocompatibility complex (MHC) is the most polymorphic locus known, with thousands of allelic variants. There is considerable interest in understanding the diversity of structures and peptide-binding features represented by this class of proteins. Although many MHC proteins have been crystallized, others have not been amenable to structural or biochemical studies due to problems with expression or stability. In the present study, yeast display was used to engineer stabilizing mutations into the class I MHC molecule, L-d. The approach was based on previous studies that showed surface levels of yeast-displayed fusion proteins are directly correlated with protein stability. To engineer a more stable L-d, we selected L-d mutants with increased surface expression from randomly mutated yeast display libraries using anti-L-d antibodies or high affinity, soluble T-cell receptors (TCRs). The most stable L-d mutant, L-d-m31, consisted of a single-chain MHC module containing only the alpha 1 and alpha 2 domains. The enhanced stability was in part due to a single mutation (Trp-973 -> Arg), shown previously to be present in the allele L-q. Mutant Ld-m31 could bind to L-d peptides, and the specific peptide (.) L-d-m31 complex (QL9(.)L(d)-m31) was recognized by alloreactive TCR2C. A soluble form of the L-d-m31 protein was expressed in Escherichia coli and refolded from inclusion bodies at high yields. Surface plasmon resonance showed that TCRs bound to peptide(.)L(d)-m31 complexes with affinities similar to those of native full-length L-d. The TCR and QL9(.)L(d)-m31 formed complexes that could be resolved by native gel electrophoresis, suggesting that stabilized alpha 1/alpha 2 class I platforms may enable various structural studies.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA	University of Illinois System; University of Illinois Urbana-Champaign; Stanford University	Kranz, DM (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	d-kranz@uiuc.edu		Jones, Lindsay/0000-0003-4360-6451; Bankovich, Alexander/0000-0003-2368-4479	NIAID NIH HHS [T32 AI007290, AI048540] Funding Source: Medline; NIGMS NIH HHS [GM55767] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI048540, R01AI048540, T32AI007290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055767] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Balendiran GK, 1997, P NATL ACAD SCI USA, V94, P6880, DOI 10.1073/pnas.94.13.6880; BECK JC, 1986, J IMMUNOL, V137, P916; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Boder ET, 2005, BIOTECHNOL BIOENG, V92, P485, DOI 10.1002/bit.20616; Brophy SE, 2003, J IMMUNOL METHODS, V272, P235, DOI 10.1016/S0022-1759(02)00439-8; Buonpane RA, 2005, J MOL BIOL, V353, P308, DOI 10.1016/j.jmb.2005.08.041; Burrows GG, 1999, PROTEIN ENG, V12, P771, DOI 10.1093/protein/12.9.771; Chang JW, 2001, J BIOL CHEM, V276, P24170, DOI 10.1074/jbc.M101808200; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; Cronan JE, 2000, METHOD ENZYMOL, V326, P440; Cull MG, 2000, METHOD ENZYMOL, V326, P430; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; DOWER SK, 1985, J IMMUNOL, V134, P431; Esteban O, 2004, J MOL BIOL, V340, P81, DOI 10.1016/j.jmb.2004.04.054; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hansen NJV, 2001, EUR J IMMUNOL, V31, P32, DOI 10.1002/1521-4141(200101)31:1<32::AID-IMMU32>3.0.CO;2-6; Hansen T, 2000, IMMUNOL TODAY, V21, P83, DOI 10.1016/S0167-5699(98)01426-1; Hansen TH, 2006, CANCER IMMUNOL IMMUN, V55, P235, DOI 10.1007/s00262-005-0091-9; Holler PD, 2000, P NATL ACAD SCI USA, V97, P5387, DOI 10.1073/pnas.080078297; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Holler PD, 2003, NAT IMMUNOL, V4, P55, DOI 10.1038/ni863; Holman PO, 2005, J IMMUNOL, V174, P3986, DOI 10.4049/jimmunol.174.7.3986; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kieke MC, 1999, P NATL ACAD SCI USA, V96, P5651, DOI 10.1073/pnas.96.10.5651; Kulski JK, 2002, IMMUNOL REV, V190, P95, DOI 10.1034/j.1600-065X.2002.19008.x; Kurokawa MS, 2002, IMMUNOL LETT, V80, P163, DOI 10.1016/S0165-2478(01)00325-X; Le Doussal JM, 2000, J IMMUNOL METHODS, V241, P147, DOI 10.1016/S0022-1759(00)00211-8; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; Lybarger L, 2003, J BIOL CHEM, V278, P27105, DOI 10.1074/jbc.M303716200; MAGE MG, 1992, P NATL ACAD SCI USA, V89, P10658, DOI 10.1073/pnas.89.22.10658; Maile R, 2005, J IMMUNOL, V174, P619, DOI 10.4049/jimmunol.174.2.619; Mason PM, 1998, TISSUE ANTIGENS, V51, P417; Maynard J, 2005, J IMMUNOL METHODS, V306, P51, DOI 10.1016/j.jim.2005.07.022; Maynard J, 2005, IMMUNITY, V22, P81, DOI 10.1016/j.immuni.2004.11.015; MOTTEZ E, 1995, J EXP MED, V181, P493, DOI 10.1084/jem.181.2.493; MOTTEZ E, 1991, EUR J IMMUNOL, V21, P467, DOI 10.1002/eji.1830210232; OZATO K, 1980, J IMMUNOL, V125, P2473; POTTER TA, 1981, J IMMUNOL, V127, P580; Reche PA, 2003, J MOL BIOL, V331, P623, DOI 10.1016/S0022-2836(03)00750-2; Shiina T, 2004, TISSUE ANTIGENS, V64, P631, DOI 10.1111/j.1399-0039.2004.00327.x; Shusta EV, 1999, J MOL BIOL, V292, P949, DOI 10.1006/jmbi.1999.3130; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; Smith RA, 2002, J IMMUNOL, V169, P3105, DOI 10.4049/jimmunol.169.6.3105; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; Starwalt SE, 2003, PROTEIN ENG, V16, P147, DOI 10.1093/proeng/gzg018; Stones JD, 2006, J IMMUNOL, V176, P1498, DOI 10.4049/jimmunol.176.3.1498; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Vukmanovic S, 2003, TRENDS MOL MED, V9, P139, DOI 10.1016/S1471-4914(03)00029-7; Weber KS, 2005, P NATL ACAD SCI USA, V102, P19033, DOI 10.1073/pnas.0507554102; Wooldridge L, 2005, J BIOL CHEM, V280, P27491, DOI 10.1074/jbc.M500555200; Yu YYL, 2002, J IMMUNOL, V168, P3145, DOI 10.4049/jimmunol.168.7.3145	59	42	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25734	25744		10.1074/jbc.M604343200	http://dx.doi.org/10.1074/jbc.M604343200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16815841	hybrid			2022-12-27	WOS:000240031300076
J	Lee, TS; Karl, R; Moosmang, S; Lenhardt, P; Klugbauer, N; Hofmann, F; Kleppisch, T; Welling, A				Lee, Tae-Seong; Karl, Rosi; Moosmang, Sven; Lenhardt, Peter; Klugbauer, Norbert; Hofmann, Franz; Kleppisch, Thomas; Welling, Andrea			Calmodulin kinase II is involved in voltage-dependent facilitation of the L-type Ca(v)1.2 calcium channel - Identification of the phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CA2+ CHANNELS; RABBIT VENTRICULAR MYOCYTES; SLOW INWARD CURRENT; EF-HAND MOTIF; PROTEIN-KINASE; SMOOTH-MUSCLE; CA2+-DEPENDENT INACTIVATION; CA2+-SENSITIVE INACTIVATION; FUNCTIONAL EXPRESSION; CHROMAFFIN CELLS	Calcium-dependent facilitation of L-type calcium channels has been reported to depend on the function of calmodulin kinase II. In contrast, the mechanism for voltage-dependent facilitation is not clear. In HEK 293 cells expressing Ca(v)1.2, Ca-v beta 2a, and calmodulin kinase II, the calcium current measured at +30mV was facilitated up to 1.5-fold by a 200-ms-long prepulse to +160mV. This voltage dependent facilitation was prevented by the calmodulin kinase II inhibitors KN93 and the autocamtide-2-related peptide. In cells expressing the Cav1.2 mutation I1649E, a residue critical for the binding of Ca2+-bound calmodulin, facilitation was also abolished. Calmodulin kinase II was coimmunoprecipitated with the Cav1.2 channel from murine heart and HEK 293 cells expressing Cav1.2 and calmodulin kinase II. The precipitated Ca(v)1.2 channel was phosphorylated in the presence of calmodulin and Ca2+. Fifteen putative calmodulin kinase II phosphorylation sites were identified mostly in the carboxyl-terminal tail of Ca(v)1.2. Neither truncation at amino acid 1728 nor changing the II-III loop serines 808 and 888 to alanines affected facilitation of the calcium current. In contrast, facilitation was decreased by the single mutations S1512A and S1570A and abolished by the double mutation S1512A/ S1570A. These serines flank the carboxyl-terminal EF-hand motif. Immunoprecipitation of calmodulin kinase II with the Ca(v)1.2 channel was not affected by the mutation S1512A/S1570A. The phosphorylation of the Ca(v)1.2 protein was strongly decreased in the S1512A/ S1570A double mutant. These results suggest that voltage dependent facilitation of the Ca(v)1.2 channel depends on the phosphorylation of Ser1512/Ser1570 by calmodulin kinase II.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Tech Univ Munich, Inst Mol Med, D-80802 Munich, Germany	Technical University of Munich; Technical University of Munich	Welling, A (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	Welling@ipt.med.tu-muenchen.de	Welling, Andrea/K-6674-2017	Welling, Andrea/0000-0002-5364-4980				Anderson ME, 2004, TRENDS CARDIOVAS MED, V14, P152, DOI 10.1016/j.tcm.2004.02.005; ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; Bartel S, 2000, J MOL CELL CARDIOL, V32, P2173, DOI 10.1006/jmcc.2000.1243; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Catterall WA, 2003, PHARMACOL REV, V55, P579, DOI 10.1124/pr.55.4.8; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; Dai SP, 1999, FEBS LETT, V442, P70, DOI 10.1016/S0014-5793(98)01632-9; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Dzhura I, 2002, J PHYSIOL-LONDON, V545, P399, DOI 10.1113/jphysiol.2002.021881; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Erxleben C, 2006, P NATL ACAD SCI USA, V103, P3932, DOI 10.1073/pnas.0511322103; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; Garcia AG, 1996, TRENDS NEUROSCI, V19, P383, DOI 10.1016/S0166-2236(96)20035-9; Hamilton S. L., 2005, SCI STKE; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Hudmon A, 2005, J CELL BIOL, V171, P537, DOI 10.1083/jcb.200505155; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hutchins JRA, 2003, MOL BIOL CELL, V14, P4003, DOI 10.1091/mbc.E03-02-0061; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; KLEPPISCH T, 1994, EMBO J, V13, P2502, DOI 10.1002/j.1460-2075.1994.tb06538.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Markoulaki S, 2004, DEV BIOL, V272, P15, DOI 10.1016/j.ydbio.2004.04.008; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; NOBLE S, 1981, J PHYSIOL-LONDON, V310, P57, DOI 10.1113/jphysiol.1981.sp013537; NOBLE S, 1981, J PHYSIOL-LONDON, V310, P77, DOI 10.1113/jphysiol.1981.sp013538; O-Uchi J, 2005, P NATL ACAD SCI USA, V102, P9400, DOI 10.1073/pnas.0503569102; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; SEISENBERGER C, 1995, N-S ARCH PHARMACOL, V352, P662; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Tang W, 2003, BIOPHYS J, V85, P1538, DOI 10.1016/S0006-3495(03)74586-X; Van Petegem F, 2005, NAT STRUCT MOL BIOL, V12, P1108, DOI 10.1038/nsmb1027; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	57	91	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25560	25567		10.1074/jbc.M508661200	http://dx.doi.org/10.1074/jbc.M508661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16820363	hybrid			2022-12-27	WOS:000240031300059
J	Li, H; Xu, DK; Li, JH; Berndt, MC; Liu, JP				Li, He; Xu, Dakang; Li, Jinhua; Berndt, Michael C.; Liu, Jun-Ping			Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; BREAST-CANCER CELLS; TGF-BETA; CATALYTIC SUBUNIT; SIGNALING PATHWAY; LYMPHOBLASTIC-LEUKEMIA; TARGETED DISRUPTION; DIRECT ACTIVATION; STEM-CELLS; DIFFERENTIATION	Telomerase underpins stem cell renewal and proliferation and is required for most neoplasia. Recent studies suggest that hormones and growth factors play physiological roles in regulating telomerase activity. In this report we show a rapid repression of the telomerase reverse transcriptase ( TERT) gene by transforming growth factor beta(TGF-beta) in normal and neoplastic cells by a mechanism depending on the intracellular signaling protein Smad3. In human breast cancer cells TGF-beta induces rapid entry of Smad3 into the nucleus where it binds to the TERT gene promoter and represses TERT gene transcription. Silencing Smad3 gene expression or genetically deleting the Smad3 gene disrupts TGF-beta repression of TERT gene expression. Expression of the Smad3 antagonist, Smad7, also interrupts TGF-beta-mediated Smad3-induced repression of the TERT gene. Mutational analysis identified the Smad3 site on the TERT gene promoter, mediating TERT repression. In response to TGF-beta, Smad3 binds to c-Myc; knocking down c-Myc, Smad3 does not bind to the TERT gene, suggesting that c-Myc recruits Smad3 to the TERT promoter. Thus, TGF-beta negatively regulates telomerase activity via Smad3 interactions with c-Myc and the TERT gene promoter. Modifying the interaction between Smad3 and TERT gene may, thus, lead to novel strategies to regulate telomerase.	Monash Univ, Dept Immunol, Melbourne, Vic 3181, Australia; Monash Univ, Monash Inst Med Res, Melbourne, Vic 3181, Australia	Monash University; Monash University	Liu, JP (corresponding author), Monash Univ Sch Med, AMREP, Dept Immunol, Commercial Rd, Prahran, Vic 3181, Australia.	jun-ping.liu@med.monash.edu.au	Berndt, Michael C/D-5580-2012; Liu, Jun-Ping/AAA-5521-2020; Li, Jinhua/I-2741-2014	Liu, Jun-Ping/0000-0001-7442-2116; Li, Jinhua/0000-0003-4039-5759; Xu, Dakang/0000-0003-2415-4920				Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Armstrong L, 2005, STEM CELLS, V23, P516, DOI 10.1634/stemcells.2004-0269; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Budiyanto A, 2003, J INVEST DERMATOL, V121, P1088, DOI 10.1046/j.1523-1747.2003.12529.x; Cerezo A, 2002, J CELL SCI, V115, P1305; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chiang YJ, 2004, MOL CELL BIOL, V24, P7024, DOI 10.1128/MCB.24.16.7024-7031.2004; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Debacq-Chainlaux F, 2005, J CELL SCI, V118, P743, DOI 10.1242/jcs.01651; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Downing JR, 2004, NEW ENGL J MED, V351, P528, DOI 10.1056/NEJMp048121; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ebisui O, 1999, J HYPERTENS, V17, P1535, DOI 10.1097/00004872-199917110-00005; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Hahn WC, 2005, CURR MOL MED, V5, P227, DOI 10.2174/1566524053586572; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; Hu B, 2006, ONCOGENE, V25, P1030, DOI 10.1038/sj.onc.1209140; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Li H, 2005, J NEUROCHEM, V95, P891, DOI 10.1111/j.1471-4159.2005.03439.x; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Nosek J, 2005, J BIOL CHEM, V280, P10840, DOI 10.1074/jbc.M409295200; Prior RL, 2002, FASEB J, V16, pA1009; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, V1, P419; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005; Vijayachandra K, 2003, CANCER RES, V63, P3447; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yago M, 2002, FEBS LETT, V520, P40, DOI 10.1016/S0014-5793(02)02757-6; Yang H, 2001, CELL GROWTH DIFFER, V12, P119; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhang H, 2004, GENE DEV, V18, P3028, DOI 10.1101/gad.1253004; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	66	102	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25588	25600		10.1074/jbc.M602381200	http://dx.doi.org/10.1074/jbc.M602381200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16785237	hybrid			2022-12-27	WOS:000240031300062
J	Schaaf, G; Honsbein, A; Meda, AR; Kirchner, S; Wipf, D; von Wiren, N				Schaaf, Gabriel; Honsbein, Annegret; Meda, Anderson R.; Kirchner, Silvia; Wipf, Daniel; von Wiren, Nicolaus			AtIREG2 encodes a tonoplast transport protein involved in iron-dependent nickel detoxification in Arabidopsis thaliana roots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; METAL TRANSPORTER; CONFERRING RESISTANCE; PLANT TRANSFORMATION; YEAST; CLONING; DEFICIENCY; EXPRESSION; FAMILY; ACCUMULATION	dIron acquisition in Arabidopsis depends mainly on AtIRT1, a Fe2+ transporter in the plasma membrane of root cells. However, substrate specificity of AtIRT1 is low, leading to an excess accumulation of other transition metals in iron-deficient plants. In the present study we describe AtIREG2 as a nickel transporter at the vacuolar membrane that counterbalances the low substrate specificity of AtIRT1 and possibly other iron transport systems in iron-deficient root cells. AtIREG2 is co-regulated with AtIRT1 by the transcription factor FRU/FIT1, encodes a membrane protein, which has 10 putative transmembrane domains and shares homology with vertebrate Fe2+ exporters. Heterologous expression of AtIREG2 in various yeast mutants, however, did not demonstrate an iron transport function. Instead, expression in wild-type and nickel-sensitive cot1 yeast cells conferred enhanced tolerance to elevated concentrations of nickel at acidic pH. A role in vacuolar substrate transport was further supported by localization of AtIREG2-GFP fusion proteins to the tonoplast in Arabidopsis suspension cells and root cells of intact plants. Transgenic plants overexpressing AtIREG2 showed an increased tolerance to elevated concentrations of nickel, whereas T-DNA insertion lines lacking AtIREG2 expression were more sensitive to nickel, particularly under iron deficiency, and accumulated less nickel in roots. We therefore propose a role of AtIREG2 in vacuolar loading of nickel under iron deficiency and thus identify it as a novel component in the iron deficiency stress response.	Univ Hohenheim, Inst Pflanzenernahrung, D-70593 Stuttgart, Germany; Univ Bonn, Inst Zellulare & Mol Bot, D-53115 Bonn, Germany	University Hohenheim; University of Bonn	von Wiren, N (corresponding author), Univ Hohenheim, Inst Pflanzenernahrung, Postfach 700562, D-70593 Stuttgart, Germany.	vonwiren@uni-hohenheim.de	Schaaf, Gabriel/F-1956-2014	Schaaf, Gabriel/0000-0001-9022-4515; von Wiren, Nicolaus/0000-0002-4966-425X; Wipf, Daniel/0000-0001-7197-5612				AGARWALA SC, 1977, CAN J BOT, V55, P1299, DOI 10.1139/b77-151; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Cheng NH, 2003, J BIOL CHEM, V278, P6503, DOI 10.1074/jbc.M210883200; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cohen CK, 1998, PLANT PHYSIOL, V116, P1063, DOI 10.1104/pp.116.3.1063; Colangelo EP, 2004, PLANT CELL, V16, P3400, DOI 10.1105/tpc.104.024315; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; CROOKE WM, 1954, ANN APPL BIOL, V41, P311, DOI 10.1111/j.1744-7348.1954.tb01124.x; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Fontes RLF, 1998, J PLANT NUTR, V21, P1723, DOI 10.1080/01904169809365517; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Jakoby M, 2004, FEBS LETT, V577, P528, DOI 10.1016/j.febslet.2004.10.062; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Kim S, 2005, PLANT CELL PHYSIOL, V46, P1809, DOI 10.1093/pcp/pci196; Kukier U, 2001, J ENVIRON QUAL, V30, P1949, DOI 10.2134/jeq2001.1949; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Liu LH, 2003, PLANT CELL, V15, P790, DOI 10.1105/tpc.007120; Loque D, 2005, PLANT PHYSIOL, V137, P671, DOI 10.1104/pp.104.051268; Marschner H., 1995, MINERAL NUTR HIGHER, P313, DOI DOI 10.1016/B978-012473542-2/50011-0; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2004, PFLUG ARCH EUR J PHY, V447, P801, DOI 10.1007/s00424-003-1102-3; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Pianelli K, 2005, TRANSGENIC RES, V14, P739, DOI 10.1007/s11248-005-7159-3; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAAF G, 2005, PLANT CELL PHYSL, V46, P672; Spizzo T, 1997, MOL GEN GENET, V256, P547; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Takano J, 2005, P NATL ACAD SCI USA, V102, P12276, DOI 10.1073/pnas.0502060102; Thomine S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/pnas.97.9.4991; Vacchina V, 2003, ANAL CHEM, V75, P2740, DOI 10.1021/ac020704m; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; Vert GA, 2003, PLANT PHYSIOL, V132, P796, DOI 10.1104/pp.102.016089; VONWIREN N, 1994, PLANT PHYSIOL, V106, P71, DOI 10.1104/pp.106.1.71	44	157	164	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25532	25540		10.1074/jbc.M601062200	http://dx.doi.org/10.1074/jbc.M601062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16790430	hybrid			2022-12-27	WOS:000240031300056
J	Clark, SJ; Higman, VA; Mulloy, B; Perkins, SJ; Lea, SM; Sim, RB; Day, AJ				Clark, Simon J.; Higman, Victoria A.; Mulloy, Barbara; Perkins, Stephen J.; Lea, Susan M.; Sim, Robert B.; Day, Anthony J.			His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; BOUND C3B; SULFATE; IDENTIFICATION; POLYMORPHISM; PROTEIN; COMMON; MEMBRANE	A polymorphism in complement factor H has recently been associated with age-related macular degeneration (AMD), the leading cause of blindness in the elderly. A histidine rather than a tyrosine at residue position 384 in the mature protein increases the risk of AMD. Here, using a recombinant construct, we show that amino acid 384 is adjacent to a heparin-binding site in CCP7 of factor H and demonstrate that the allotypic variants differentially recognize heparin. This functional alteration may affect binding of factor H to polyanionic patterns on host surfaces, potentially influencing complement activation, immune complex clearance, and inflammation in the macula of AMD patients.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Mol Biophys Lab, Oxford OX1 3QU, England; Natl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of Manchester; University of Oxford; University of Oxford; National Institute for Biological Standards & Control; University of London; University College London	Day, AJ (corresponding author), Univ Manchester, Fac Life Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	anthony.day@manchester.ac.uk	Sim, Bob/A-1354-2008; Lea, Susan M/B-7678-2009; Day, Anthony/O-1658-2015; Higman, Victoria/H-3795-2011	Sim, Bob/0000-0002-2855-7455; Lea, Susan M/0000-0001-9287-8053; Day, Anthony/0000-0002-1415-3134; Higman, Victoria/0000-0002-3204-2665; Clark, Simon/0000-0001-8394-8355	Medical Research Council [MC_U138274352] Funding Source: Medline; MRC [MC_U138274352] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CARRENO MP, 1989, EUR J IMMUNOL, V19, P2145, DOI 10.1002/eji.1830191126; Carrino DA, 2003, J BIOL CHEM, V278, P17566, DOI 10.1074/jbc.M300124200; Cavallotti C, 2004, OPHTHALMIC RES, V36, P211, DOI 10.1159/000078779; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Girardin EP, 2005, J BIOL CHEM, V280, P38059, DOI 10.1074/jbc.M507997200; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86; Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021; Lauder RM, 1998, BIOCHEM J, V330, P753; Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200; Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; MULLOY B, 1994, CARBOHYD RES, V255, P1, DOI 10.1016/S0008-6215(00)90968-6; Mulloy B, 2000, THROMB HAEMOSTASIS, V84, P1052; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; Saito A, 2005, J BIOCHEM, V137, P225, DOI 10.1093/jb/mvi025; SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205; SIM RB, 1993, METHOD ENZYMOL, V223, P13; THOMAS DP, 1984, THROMB HAEMOSTASIS, V52, P148; White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604	44	148	153	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24713	24720		10.1074/jbc.M605083200	http://dx.doi.org/10.1074/jbc.M605083200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787919	hybrid			2022-12-27	WOS:000239847800067
J	Dai, MS; Shi, DD; Jin, YT; Sun, XX; Zhang, YP; Grossman, SR; Lu, H				Dai, Mu-Shui; Shi, Dingding; Jin, Yetao; Sun, Xiao-Xin; Zhang, Yanping; Grossman, Steven R.; Lu, Hua			Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; AUTOREGULATORY FEEDBACK LOOP; DNA-DAMAGE; ONCOPROTEIN MDM2; P53-MDM2 INTERACTION; GENE AMPLIFICATION; LIGASE ACTIVITY; GROWTH-CONTROL; CELL-CYCLE; IN-VIVO	Inhibition of the MDM2-p53 feedback loop is critical for p53 activation in response to cellular stresses. The ribosomal proteins L5, L11, and L23 can block this loop by inhibiting MDM2-mediated p53 ubiquitination and degradation in response to ribosomal stress. Here, we show that L11, but not L5 and L23, leads to a drastic accumulation of ubiquitinated and native MDM2. This effect is dependent on the ubiquitin ligase activity of MDM2, but not p53, and requires the central MDM2 binding domain ( residues 51-108) of L11. We further show that L11 inhibited 26 S proteasome-mediated degradation of ubiquitinated MDM2 in vitro and consistently prolonged the half-life of MDM2 in cells. These results suggest that L11, unlike L5 and L23, differentially regulates the levels of ubiquitinated p53 and MDM2 and inhibits the turnover and activity of MDM2 through a post-ubiquitination mechanism.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Sch Med, Portland, OR 97239 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA	Oregon Health & Science University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of North Carolina; University of North Carolina Chapel Hill	Lu, H (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Sch Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	luh@ohsu.edu			NCI NIH HHS [R01 CA100302, R01 CA095441, CA107532, CA93614, R01 CA093614, R01 CA107532, CA095441, CA079721, R01 CA079721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100302, R01CA107532, R01CA093614, R01CA079721, R01CA095441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chene P, 2004, MOL CANCER RES, V2, P20; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; CORDONCARDO C, 1994, CANCER RES, V54, P794; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Deb SP, 2003, MOL CANCER RES, V1, P1009; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Dworakowska D, 2004, LUNG CANCER, V43, P285, DOI 10.1016/j.lungcan.2003.09.010; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moss T, 2004, CURR OPIN GENET DEV, V14, P210, DOI 10.1016/j.gde.2004.02.005; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	57	91	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24304	24313		10.1074/jbc.M602596200	http://dx.doi.org/10.1074/jbc.M602596200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803902	hybrid, Green Submitted, Green Accepted			2022-12-27	WOS:000239847800023
J	Flemming, D; Hellwig, P; Lepper, S; Kloer, DP; Friedrich, T				Flemming, Dirk; Hellwig, Petra; Lepper, Simone; Kloer, Daniel P.; Friedrich, Thorsten			Catalytic importance of acidic amino acids on subunit NuoB of the Escherichia coli NADH: Ubiquinone oxidoreductase (complex I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; PROTON-TRANSLOCATING NADH; RESPIRATORY-CHAIN; YARROWIA-LIPOLYTICA; PARACOCCUS-DENITRIFICANS; QUINONE OXIDOREDUCTASE; CONFORMATION-DRIVEN; MODULAR EVOLUTION; 49-KDA SUBUNIT; CYTOCHROME-C	The NADH:ubiquinone oxidoreductase (complex I) from Escherichia coli is composed of 13 subunits called NuoA through NuoN and contains one FMN and 9 iron-sulfur clusters as redox groups. Electron transfer from NADH to ubiquinone is coupled with the translocation of protons across the membrane by a yet unknown mechanism. Redox-induced Fourier transform infrared difference spectroscopy showed that the oxidation of iron-sulfur cluster N2 located on NuoB is accompanied by the protonation of acidic amino acid(s). Here, we describe the effect of mutating the conserved acidic amino acids on NuoB. The complex was assembled in all mutants but the electron transfer activity was completely abolished in the mutants E67Q, D77N, and D94N. The complex isolated from these mutants contained N2 although in diminished amounts. The protonation of acidic amino acid(s) coupled with the oxidation of N2 was not detectable in the complex from the mutant E67Q. However, the conservative mutations E67D and D77E did not disturb the enzymatic activity, and the signals because of the protonation of acidic amino acid(s) were detectable in the E67D mutant. We discuss the possible participation of Glu(67) in a proton pathway coupled with the redox reaction of N2.	Univ Freiburg, Inst Org Chem & Biochem, D-79104 Freiburg, Germany; Univ Strasbourg 1, Lab Electrochim, UMR7177 LC3, Inst Chim, F-67000 Strasbourg, France	University of Freiburg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Friedrich, T (corresponding author), Univ Freiburg, Inst Org Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	tfriedri@uni-freiburg.de	Flemming, Dirk/AAP-3274-2021	hellwig, petra/0000-0001-6294-5163				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; Bertsova YV, 2004, FEBS LETT, V563, P207, DOI 10.1016/S0014-5793(04)00312-6; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Duarte M, 2002, BIOCHEM J, V364, P833, DOI 10.1042/BJ20011750; DUNBAR BS, 1987, 2 DIMENSIONAL ELECTR, P1; Flemming D, 2005, J MOL MICROB BIOTECH, V10, P208, DOI 10.1159/000091566; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Flemming D, 2003, J BIOL CHEM, V278, P3055, DOI 10.1074/jbc.M208849200; FRIEDRICH T, 1989, EUR J BIOCHEM, V180, P173, DOI 10.1111/j.1432-1033.1989.tb14629.x; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Grgic L, 2004, J BIOL CHEM, V279, P21193, DOI 10.1074/jbc.M313180200; Gurrath M, 2004, PROTEINS, V56, P556, DOI 10.1002/prot.20155; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hellwig P, 1998, BIOCHEMISTRY-US, V37, P7390, DOI 10.1021/bi9725576; Hellwig P, 2000, BIOCHEMISTRY-US, V39, P10884, DOI 10.1021/bi000842a; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; Marshall D, 2006, BIOCHEMISTRY-US, V45, P5458, DOI 10.1021/bi052561e; Mathiesen C, 2003, FEBS LETT, V549, P7, DOI 10.1016/S0014-5793(03)00767-1; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MOSS D, 1990, EUR J BIOCHEM, V187, P565, DOI 10.1111/j.1432-1033.1990.tb15338.x; Nakamaru-Ogiso E, 2005, J BIOL CHEM, V280, P301, DOI 10.1074/jbc.M410377200; OHNISHI T, 1985, J BIOL CHEM, V260, P2782; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Ohnishi T, 2005, FEBS LETT, V579, P4555, DOI 10.1016/j.febslet.2005.06.086; Ohnishi T, 2005, FEBS LETT, V579, P500, DOI 10.1016/j.febslet.2004.11.107; RAGAN CI, 1978, BIOCHEM J, V172, P539, DOI 10.1042/bj1720539; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; Stolpe S, 2004, J BIOL CHEM, V279, P18377, DOI 10.1074/jbc.M311242200; TOWBIN H, 1979, P NATL ACAD SCI USA, V1320, P217; Uhlmann M, 2005, BIOCHEMISTRY-US, V44, P1653, DOI 10.1021/bi048136n; vanBelzen R, 1997, BIOCHEMISTRY-US, V36, P886, DOI 10.1021/bi9612982; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yano T, 2005, BIOCHEMISTRY-US, V44, P1744, DOI 10.1021/bi048132i; Yano T, 2003, J BIOL CHEM, V278, P15514, DOI 10.1074/jbc.M212275200; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	51	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24781	24789		10.1074/jbc.M602499200	http://dx.doi.org/10.1074/jbc.M602499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807239	hybrid			2022-12-27	WOS:000239847800074
J	Song, M; Balakrishnan, M; Chen, Y; Roques, BP; Bambara, RA				Song, Min; Balakrishnan, Mini; Chen, Yan; Roques, Bernard P.; Bambara, Robert A.			Stimulation of HIV-1 minus strand strong stop DNA transfer by genomic sequences 3 ' of the primer binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 NUCLEOCAPSID PROTEIN; ACID-CHAPERONE ACTIVITY; RNA SECONDARY STRUCTURE; ZINC-FINGER STRUCTURES; REVERSE-TRANSCRIPTASE; LEADER RNA; IN-VITRO; CONFORMATIONAL-CHANGES; INVASION MECHANISM; INFECTED-CELLS	The mechanism of human immunodeficiency virus 1 ( HIV-1) minus strand transfer was examined using a genomic RNA sequence-based donor-acceptor template system. The donor RNA, D199, was a 199- nucleotide sequence from the 5'-end of the genome to the primer binding site ( PBS) and shared 97 nucleotides of homology with the acceptor RNA. To investigate the influence of RNA structure on transfer, a second donor RNA, D520, was generated by extending the 3'-end of D199 to include an additional 321 nucleotides of the genome. The position of priming, length of homology with the acceptor, and length of cDNA synthesized were identical with the two donors. Interestingly, at 200% NC coating, donor D520 yielded a transfer efficiency of about 75% compared with about 35% with D199. A large proportion of the D520 promoted transfers occurred after the donor RNA was copied to the end. Analysis of donor RNA cleavage, the acceptor invasion site and R homology requirements indicated that transfers with D520 involved a similar but more efficient acceptor invasion mechanism compared with D199. RNA structure probing by RNase T1 and the RT pause profile during synthesis indicated conformational differences between D199 and D520 in the starting structure, and in dynamic structures formed during synthesis within the R region. Overall observations suggest that regions 3' of the primer binding site influence the conformation of the R region of D520 to facilitate steps that promote strand transfer.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA; CNRS, UMR 8600, Fac Pharm, INSERM,U266,Dept Pharmacochim Mol & Struct, F-75270 Paris, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	Robert_bambara@urmc.rochester.edu	so, strawberry/F-6515-2012		NIGMS NIH HHS [GM 049573] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; Berkhout B, 2002, J BIOL CHEM, V277, P19967, DOI 10.1074/jbc.M200950200; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Chen Y, 2005, J BIOL CHEM, V280, P14443, DOI 10.1074/jbc.M412190200; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Cui Y, 1999, J VIROL, V73, P6171, DOI 10.1128/JVI.73.7.6171-6176.1999; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; Das AT, 1998, J VIROL, V72, P9217, DOI 10.1128/JVI.72.11.9217-9223.1998; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Harrich D, 2000, J VIROL, V74, P5639, DOI 10.1128/JVI.74.12.5639-5646.2000; Heath MJ, 2005, BIOCHEMISTRY-US, V44, P3915, DOI 10.1021/bi0477945; Heilman-Miller SL, 2004, J BIOL CHEM, V279, P44154, DOI 10.1074/jbc.M401646200; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; Lanciault C, 2005, J BIOL CHEM, V280, P2413, DOI 10.1074/jbc.M410718200; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6; Lodmell JS, 2001, J MOL BIOL, V311, P475, DOI 10.1006/jmbi.2001.4879; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; Ooms M, 2004, NUCLEIC ACIDS RES, V32, P819, DOI 10.1093/nar/gkh206; Paillart JC, 2004, J BIOL CHEM, V279, P48397, DOI 10.1074/jbc.M408294200; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Sakuragi J, 2003, J VIROL, V77, P4060, DOI 10.1128/JVI.77.7.4060-4069.2003; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Telesnitsky A., 1997, P121; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Topping R, 1998, J MOL BIOL, V281, P1, DOI 10.1006/jmbi.1998.1929; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; VARMUS H, 1989, MOBILE DNA, P53; VARMUS HE, 1978, J MOL BIOL, V120, P55, DOI 10.1016/0022-2836(78)90295-4; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; YOU JC, 1994, J BIOL CHEM, V269, P31491	55	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24227	24235		10.1074/jbc.M603097200	http://dx.doi.org/10.1074/jbc.M603097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16782713	hybrid			2022-12-27	WOS:000239847800016
J	Yan, P; Hu, XY; Song, HW; Yin, KJ; Bateman, RJ; Cirrito, JR; Xiao, QL; Hsu, FF; Turk, JW; Xu, J; Hsu, CY; Holtzman, DM; Lee, JM				Yan, Ping; Hu, Xiaoyan; Song, Haowei; Yin, Kejie; Bateman, Randall J.; Cirrito, John R.; Xiao, Qingli; Hsu, Fong F.; Turk, John W.; Xu, Jan; Hsu, Chung Y.; Holtzman, David M.; Lee, Jin-Moo			Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIN-CONVERTING ENZYME; FOCAL CEREBRAL-ISCHEMIA; X-RAY-DIFFRACTION; ALZHEIMERS-DISEASE; A-BETA; MATRIX METALLOPROTEINASES; SENILE PLAQUES; GELATINASE-B; MULTIPLE-SCLEROSIS; SPINAL-CORD	The pathological hallmark of Alzheimer disease is the senile plaque principally composed of tightly aggregated amyloid-beta fibrils (fA beta), which are thought to be resistant to degradation and clearance. In this study, we explored whether proteases capable of degrading soluble A beta (sA beta) could degrade fA beta as well. We demonstrate that matrix metalloproteinase-9 (MMP-9) can degrade fA beta and that this ability is not shared by other sA beta-degrading enzymes examined, including endothelin-converting enzyme, insulin-degrading enzyme, and neprilysin. fA beta was decreased in samples incubated with MMP-9compared with other proteases, assessed using thioflavin-T. Furthermore, fA beta breakdown with MMP-9 but not with other proteases was demonstrated by transmission electron microscopy. Proteolytic digests of purified fA beta were analyzed with matrix-assisted laser desorption ionization time-of-flight mass spectrometry to identify sites of A beta that are cleaved during its degradation. Only MMP-9 digests contained fragments (A beta(1-20) and A beta(1-30)) from fA beta(1-42) substrate; the corresponding cleavage sites are thought to be important for beta-pleated sheet formation. To determine whether MMP-9 can degrade plaques formed in vivo, fresh brain slices from aged APP/PS1 mice were incubated with proteases. MMP-9 digestion resulted in a decrease in thioflavin-S (ThS) staining. Consistent with a role for endogenous MMP-9 in this process in vivo, MMP-9 immunoreactivity was detected in astrocytes surrounding amyloid plaques in the brains of aged APP/PS1 and APPsw mice, and increased MMP activity was selectively observed in compact ThS-positive plaques. These findings suggest that MMP-9 can degrade fA beta and may contribute to ongoing clearance of plaques from amyloid-laden brains.	Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Hope Ctr Neurol Disorders, Sch Med, St Louis, MO 63110 USA; Washington Univ, Div Endocrinol Diabet Metab & Lipid Res, Dept Internal Med, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, Sch Med, St Louis, MO 63110 USA; Taipei Med Univ, Taipei, Taiwan	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Taipei Medical University	Lee, JM (corresponding author), Washington Univ, Dept Neurol, Sch Med, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	leejm@neuro.wustl.edu	; Lee, Jin-Moo/K-2024-2015	Yin, Ke-Jie/0000-0002-7169-3858; Lee, Jin-Moo/0000-0002-3979-0906; Hsu, Chung Y./0000-0002-5632-2733; Hsu, Fong-Fu/0000-0001-5368-0183; Bateman, Randall/0000-0002-7729-1702	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013956, K08AG027091, R37AG013956] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR00954] Funding Source: Medline; NIA NIH HHS [K08 AG027091-01, AG13956, L30 AG024455-01, K08 AG027091, L30 AG024455] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341, P30 DK056341-06, P30 DK056341-05S2, P30-DK56341, P60-DK20579] Funding Source: Medline; NINDS NIH HHS [NS048283] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Backstrom JR, 1996, J NEUROSCI, V16, P7910; Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261; Betsuyaku T, 2000, AM J PATHOL, V157, P525, DOI 10.1016/S0002-9440(10)64563-4; Bond JP, 2003, J STRUCT BIOL, V141, P156, DOI 10.1016/S1047-8477(02)00625-1; Christie RH, 2001, J NEUROSCI, V21, P858, DOI 10.1523/JNEUROSCI.21-03-00858.2001; Cruz L, 1997, P NATL ACAD SCI USA, V94, P7612, DOI 10.1073/pnas.94.14.7612; Deb S, 2003, BRAIN RES, V970, P205, DOI 10.1016/S0006-8993(03)02344-8; Dubois B, 1999, ACTA NEUROL BELG, V99, P53; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Goussev S, 2003, J NEUROSURG, V99, P188, DOI 10.3171/spi.2003.99.2.0188; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; HYMAN BT, 1993, J NEUROPATH EXP NEUR, V52, P594, DOI 10.1097/00005072-199311000-00006; Iannone F, 2003, J RHEUMATOL, V30, P2294; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kelly EA, 2003, CURR OPIN PULM MED, V9, P28, DOI 10.1097/00063198-200301000-00005; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Lee JM, 2003, ANN NEUROL, V54, P379, DOI 10.1002/ana.10671; LeVine H, 1997, ARCH BIOCHEM BIOPHYS, V342, P306, DOI 10.1006/abbi.1997.0137; Liu RT, 2004, J NEUROSCI RES, V75, P162, DOI 10.1002/jnr.10859; Lorenzl S, 2003, J NEUROL SCI, V207, P71, DOI 10.1016/S0022-510X(02)00398-2; Lorenzo A, 1996, ANN NY ACAD SCI, V777, P89, DOI 10.1111/j.1749-6632.1996.tb34406.x; Maier CM, 2004, STROKE, V35, P1169, DOI 10.1161/01.STR.0000125861.55804.f2; McGeer E G, 2001, Mol Interv, V1, P22; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagele RG, 2004, NEUROBIOL AGING, V25, P663, DOI 10.1016/j.neurobiolaging.2004.01.007; Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Serpell LC, 2000, BIOCHEMISTRY-US, V39, P13269, DOI 10.1021/bi000637v; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SHIRAHAMA T, 1967, J CELL BIOL, V33, P679, DOI 10.1083/jcb.33.3.679; Shivaprasad S, 2004, BIOCHEMISTRY-US, V43, P15310, DOI 10.1021/bi048019s; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Sun AY, 2002, J HISTOCHEM CYTOCHEM, V50, P463, DOI 10.1177/002215540205000403; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Thal DR, 1998, NEUROBIOL AGING, V19, P517, DOI 10.1016/S0197-4580(98)00090-6; Tucker HM, 2000, J NEUROSCI, V20, P3937; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yan P, 1999, J NEUROSCI, V19, P9355; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Zhang X, 2004, NEUROSCI LETT, V356, P140, DOI 10.1016/j.neulet.2003.10.084	58	271	275	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24566	24574		10.1074/jbc.M602440200	http://dx.doi.org/10.1074/jbc.M602440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787929	hybrid			2022-12-27	WOS:000239847800052
J	Yoda, A; Xu, XZ; Onishi, N; Toyoshima, K; Fujimoto, H; Kato, N; Oishi, I; Kondo, T; Minami, Y				Yoda, Akinori; Xu, Xiao Zhou; Onishi, Nobuyuki; Toyoshima, Kyoko; Fujimoto, Hiroko; Kato, Naoko; Oishi, Isao; Kondo, Takeshi; Minami, Yasuhiro			Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; TUMOR-SUPPRESSOR; THREONINE-68 PHOSPHORYLATION; GENOMIC INSTABILITY; IONIZING-RADIATION; PPM1D; ACTIVATION; APOPTOSIS; CDS1	The anti-oncogenic Chk2 kinase plays a crucial role in DNA damage-induced cell cycle checkpoint regulation. Recently, we have shown that Chk2 associates with the oncogenic Wip1 (PPM1D) phosphatase and that Wip1 acts as a negative regulator of Chk2 during DNA damage response by dephosphorylating phosphorylated Thr-68 in activated Chk2 (Fujimoto, H., Onishi, N., Kato, N., Takekawa, M., Xu, X. Z., Kosugi, A., Kondo, T., Imamura, M., Oishi, I., Yoda, A., and Minami, Y. (2006) Cell Death Differ. 13, 1170 - 1180). Here, we performed structure-function analyses of Chk2 and Wip1 by using a series of deletion or amino acid-substituted mutant proteins of Chk2 and Wip1. We show that nuclear localization of both Chk2 and Wip1 is required for their association in cultured cells and that the serine-glutamine(SQ)/threonine-glutamine (TQ) domain of Chk2, containing Thr-68, and the N-terminal domain of Wip1, comprising about 100 amino acids, are necessary and sufficient for the association of both molecules. However, it was found that an intrinsic kinase activity of Chk2, but not phosphatase activity of Wip1, is required for the association of full-length Chk2 and Wip1. Interestingly, we also show that the mutant Wip1 proteins, bearing the N-terminal domain of Wip1 alone or lacking an intrinsic phosphatase activity, exhibit dominant negative effects on the functions of the wild-type Wip1, i.e. ectopic expression of either of these Wip1 mutants inhibits dephosphorylation of Thr-68 in Chk2 by Wip1 and anti-apoptotic function of Wip1. These results provide a molecular basis for developing novel anti-cancer drugs, targeting oncogenic Wip1 phosphatase.	Kobe Univ, Grad Sch Med, Fac Med Sci, Dept Genome Sci,Chuo Ku, Kobe, Hyogo 6500017, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Kobe University; Hokkaido University	Minami, Y (corresponding author), Kobe Univ, Grad Sch Med, Fac Med Sci, Dept Genome Sci,Chuo Ku, 7-5-1,Kusunokicho, Kobe, Hyogo 6500017, Japan.	minami@kobe-u.ac.jp	ONISHI, Nobuyuki/L-6296-2013; Oishi, Isao/L-8639-2018; Kondo, Takeshi/G-2103-2012	Oishi, Isao/0000-0003-3682-5349; Kondo, Takeshi/0000-0001-7455-5824				Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jackson MD, 2001, CHEM REV, V101, P2313, DOI 10.1021/cr000247e; Kato N, 2004, CELL DEATH DIFFER, V11, pS153, DOI 10.1038/sj.cdd.4401461; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; MacQueen AJ, 2001, GENE DEV, V15, P1674, DOI 10.1101/gad.902601; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Oishi I, 1998, MECH DEVELOP, V71, P49, DOI 10.1016/S0925-4773(97)00200-1; Oishi I, 2001, MOL CELL BIOL, V21, P1329, DOI 10.1128/MCB.21.4.1329-1335.2001; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shieh SY, 2000, GENE DEV, V14, P289; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Xu JH, 2001, FEBS LETT, V508, P394, DOI 10.1016/S0014-5793(01)03103-9; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zannini L, 2003, J BIOL CHEM, V278, P42346, DOI 10.1074/jbc.M303304200	59	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24847	24862		10.1074/jbc.M600403200	http://dx.doi.org/10.1074/jbc.M600403200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798742	hybrid			2022-12-27	WOS:000239847800079
J	Li, WQ; Miller, WT				Li, Wanqing; Miller, W. Todd			Role of the activation loop tyrosines in regulation of the insulin-like growth factor I receptor-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DOMAIN; AUTOPHOSPHORYLATION; INHIBITION; SPECIFICITY; MUTATIONS; CANCER; IGF-1	The tyrosine kinase activity of insulin-like growth factor I receptor (IGF1R) is under tight control. Ligand binding to the extracellular portion of IGF1R stimulates autophosphorylation at three sites (Tyr(1131), Tyr(1135), and Tyr(1136)) in the activation loop within the tyrosine kinase catalytic domain. Autophosphorylation at all three sites is required for maximum enzyme activity, and for IGF1-stimulated cellular activity of the receptor. Previous studies have not clarified the contributions of the individual tyrosines to enzymatic activation. Here, we produced single Tyr-to-Phe mutations at these positions, and compared activities of the purified kinase domains (unphosphorylated and phosphorylated) with wild-type IGF1R. Rates of autophosphorylation of the three mutants were more rapid than for wild-type IGF1R; this was most apparent for the Y1135F mutant. Substrate phosphorylation studies on the unphosphorylated forms of IGF1R confirmed that the value of Vmax for Y1135F was elevated relative to wild- type IGF1R, consistent with a disruption of an autoinhibitory interaction. In contrast, activity measurements on the fully phosphorylated enzymes indicated that k(cat)/K-m values were lowered relative to wild- type IGF1R; this effect was most dramatic for Y1136F. We confirmed these findings using limited proteolysis and tryptophan fluorescence experiments. The results demonstrate that Tyr1135 plays a particularly important role in stabilizing the autoinhibited conformation of the activation loop, while Tyr1136 plays the key role in stabilizing the open, activated conformation of IGF1R.	SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bishop SM, 1999, BIOCHEMISTRY-US, V38, P3079, DOI 10.1021/bi982546s; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Frankel M, 1999, PROTEIN SCI, V8, P2158, DOI 10.1110/ps.8.10.2158; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Leroith Derek, 1992, Biological Signals, V1, P173; LI SW, 1994, J BIOL CHEM, V269, P32558; Li WQ, 2004, BIOCHEM PHARMACOL, V68, P145, DOI 10.1016/j.bcp.2004.03.013; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Munshi S, 2002, J BIOL CHEM, V277, P38797, DOI 10.1074/jbc.M205580200; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065	29	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23785	23791		10.1074/jbc.M605269200	http://dx.doi.org/10.1074/jbc.M605269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793764	hybrid			2022-12-27	WOS:000239702900054
J	Safiulina, VF; Afzalov, R; Khiroug, L; Cherubini, E; Giniatullin, R				Safiulina, Victoria F.; Afzalov, Ramil; Khiroug, Leonard; Cherubini, Enrico; Giniatullin, Rashid			Reactive oxygen species mediate the potentiating effects of ATP on GABAergic synaptic transmission in the immature hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIANT DEPOLARIZING POTENTIALS; CENTRAL-NERVOUS-SYSTEM; FROG NEUROMUSCULAR-JUNCTION; NEONATAL-RAT HIPPOCAMPUS; NITRIC-OXIDE; HYDROGEN-PEROXIDE; GLUTAMATERGIC SYNAPSES; NEURONAL NETWORKS; EXTRACELLULAR ATP; PROTEIN-KINASE	Reactive oxygen species (ROS) constitute important signaling molecules in the central nervous system. They regulate a number of different functions both under physiological conditions and under pathological conditions. Here we tested the hypothesis that in the immature hippocampus ATP, the most diffuse neurotransmitter in the brain, modulates synaptic transmission via ROS. We show that ATP, acting on metabotropic P2Y(1) receptors, increased the frequency of GABA(A)-mediated spontaneous postsynaptic currents (SPSCs) in CA3 principal cells, an effect that was prevented by the antioxidant N-acetyl-cysteine or by catalase, an enzyme that breaks down H2O2. The effect of ATP on SPSCs was mimicked by H2O2 or by the pro-oxidant, Fe2+, which, through the Fentol reaction, catalyzes the conversion of H2O2 into highly reactive hydroxyl radicals. MRS-2179, a P2Y(1) receptor antagonist, removed the facilitatory action of Fe2+ on SPSCs, suggesting that endogenous ATP acting on P2Y(1) receptors is involved in Fe2+-induced modulation of synaptic transmission. Imaging ROS with the H2O2-sensitive dye DCF revealed that ATP induces generation of peroxide in astrocytes via activation of P2Y(1) receptors coupled to intracellular calcium rise. Neither N-acetyl-cysteine nor catalase prevented Ca2+ transients induced by ATP in astrocytes. Since a single hippocampal astrocyte can contact many neurons, ATP-induced ROS signaling may control thousands of synapses. This may be crucial for information processing in the immature brain when GABAergic activity is essential for the proper wiring of the hippocampal network.	Scuola Int Super Studi Avanzati, Dept Neurobiol, I-34014 Trieste, Italy; Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland	International School for Advanced Studies (SISSA); University of Helsinki	Giniatullin, R (corresponding author), Scuola Int Super Studi Avanzati, Dept Neurobiol, Via Beirut 2-4, I-34014 Trieste, Italy.	rashid@sissa.it	Giniatullin, Rashid/Y-9687-2018	Giniatullin, Rashid/0000-0002-1580-6280	Telethon [GGP04037] Funding Source: Medline	Telethon(Fondazione Telethon)		Abramov AY, 2005, J NEUROSCI, V25, P9176, DOI 10.1523/JNEUROSCI.1632-05.2005; Adam-Vizi V, 2005, ANTIOXID REDOX SIGN, V7, P1140, DOI 10.1089/ars.2005.7.1140; Arbogast S, 2004, AM J PHYSIOL-REG I, V287, pR698, DOI 10.1152/ajpregu.00072.2004; Auerbach JM, 1997, J NEUROSCI, V17, P8695; Avshalumov MV, 2005, J NEUROSCI, V25, P4222, DOI 10.1523/JNEUROSCI.4701-04.2005; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Buonocore G, 2001, BIOL NEONATE, V79, P180; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Chen BT, 2001, J NEUROPHYSIOL, V85, P2468, DOI 10.1152/jn.2001.85.6.2468; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Eder C, 2005, J NEUROSCI RES, V81, P314, DOI 10.1002/jnr.20476; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Fabbro A, 2004, J PHYSIOL-LONDON, V560, P505, DOI 10.1113/jphysiol.2004.068924; FERRARI G, 1995, J NEUROSCI, V15, P2857; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Giniatullin AR, 2005, J PHYSIOL-LONDON, V565, P229, DOI 10.1113/jphysiol.2005.084186; Giniatullin AR, 2003, J PHYSIOL-LONDON, V552, P283, DOI 10.1113/jphysiol.2003.050690; GINIATULLIN AR, 2006, IN PRESS J NEUROCHEM; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; He ML, 2003, J BIOL CHEM, V278, P46270, DOI 10.1074/jbc.M309005200; Hennou S, 2002, EUR J NEUROSCI, V16, P197, DOI 10.1046/j.1460-9568.2002.02073.x; Hirase H, 2004, PLOS BIOL, V2, P494, DOI 10.1371/journal.pbio.0020096; HOSOKAWA Y, 1994, EUR J NEUROSCI, V6, P805, DOI 10.1111/j.1460-9568.1994.tb00991.x; HYSLOP PA, 1995, BRAIN RES, V671, P181, DOI 10.1016/0006-8993(94)01291-O; Illes P, 2004, EUR J PHARMACOL, V483, P5, DOI 10.1016/j.ejphar.2003.10.030; Kasyanov AM, 2004, P NATL ACAD SCI USA, V101, P3967, DOI 10.1073/pnas.0305974101; Kawamura M, 2004, J NEUROSCI, V24, P10835, DOI 10.1523/JNEUROSCI.3028-04.2004; Knapp LT, 2002, J NEUROSCI, V22, P674, DOI 10.1523/JNEUROSCI.22-03-00674.2002; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Li NZ, 2003, J NEUROSCI, V23, P10302; Maggi L, 2001, J PHYSIOL-LONDON, V536, P89, DOI 10.1111/j.1469-7793.2001.00089.x; Murakami K, 2003, NEUROSCIENCE, V117, P37, DOI 10.1016/S0306-4522(02)00804-7; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Peng TI, 2004, ANN NY ACAD SCI, V1011, P112, DOI 10.1196/annals.1293.012; Poisbeau P, 1996, J NEUROSCI, V16, P4835; Ralevic V, 1998, PHARMACOL REV, V50, P413; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Safiulina VF, 2006, J NEUROSCI, V26, P597, DOI 10.1523/JNEUROSCI.4493-05.2006; Safiulina VF, 2005, J NEUROPHYSIOL, V94, P2797, DOI 10.1152/jn.00445.2005; Safiulina VF, 2005, J PHYSIOL-LONDON, V565, P981, DOI 10.1113/jphysiol.2005.085621; Stosiek C, 2003, P NATL ACAD SCI USA, V100, P7319, DOI 10.1073/pnas.1232232100; Tyzio R, 1999, J NEUROSCI, V19, P10372; Verderio C, 2004, NEURON, V41, P599, DOI 10.1016/S0896-6273(04)00077-7; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Winterbourn CC, 1995, TOXICOL LETT, V82-3, P969, DOI 10.1016/0378-4274(95)03532-X	51	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23464	23470		10.1074/jbc.M601627200	http://dx.doi.org/10.1074/jbc.M601627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787924	hybrid			2022-12-27	WOS:000239702900021
J	Guiot, E; Carayon, K; Delelis, O; Simon, F; Tauc, P; Zubin, E; Gottikh, M; Mouscadet, JF; Brochon, JC; Deprez, E				Guiot, Elvire; Carayon, Kevin; Delelis, Olivier; Simon, Francoise; Tauc, Patrick; Zubin, Evgenii; Gottikh, Marina; Mouscadet, Jean-Francois; Brochon, Jean-Claude; Deprez, Eric			Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RESOLVED FLUORESCENCE ANISOTROPY; VIRAL-DNA; IN-VITRO; CONCERTED INTEGRATION; PREINTEGRATION COMPLEXES; COOPERATIVE BINDING; TERMINAL DOMAINS; ENERGY-TRANSFER; PROTEIN	The 3'-processing of the extremities of viral DNA is the first of two reactions catalyzed by HIV-1 integrase (IN). High order IN multimers (tetramers) are required for complete integration, but it remains unclear which oligomer is responsible for the 3'-processing reaction. Moreover, IN tends to aggregate, and it is unknown whether the polymerization or aggregation of this enzyme on DNA is detrimental or beneficial for activity. We have developed a fluorescence assay based on anisotropy for monitoring release of the terminal dinucleotide product in real-time. Because the initial anisotropy value obtained after DNA binding and before catalysis depends on the fractional saturation of DNA sites and the size of IN center dot DNA complexes, this approach can be used to study the relationship between activity and binding/multimerization parameters in the same assay. By increasing the IN: DNA ratio, we found that the anisotropy increased but the 3'-processing activity displayed a characteristic bell-shaped behavior. The anisotropy values obtained in the first phase were predictive of subsequent activity and accounted for the number of complexes. Interestingly, activity peaked and then decreased in the second phase, whereas anisotropy continued to increase. Time-resolved fluorescence anisotropy studies showed that the most competent form for catalysis corresponds to a dimer bound to one viral DNA end, whereas higher order complexes such as aggregates predominate during the second phase when activity drops off. We conclude that a single IN dimer at each extremity of viral DNA molecules is required for 3'-processing, with a dimer of dimers responsible for the subsequent full integration.	Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, F-94235 Cachan, France; Moscow MV Lomonosov State Univ, Belozersky Inst Phys Chem Biol, Moscow 119992, Russia	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Lomonosov Moscow State University	Deprez, E (corresponding author), Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, 61 Av President Wilson, F-94235 Cachan, France.	deprez@lbpa.ens-cachan.fr	Zubin, Evgeny/I-3880-2012; Gottikh, Marina/D-7575-2012					Agapkina J, 2006, J BIOL CHEM, V281, P11530, DOI 10.1074/jbc.M512271200; AGRAWAL S, 1986, NUCLEIC ACIDS RES, V14, P6227, DOI 10.1093/nar/14.15.6227; ANTSYPOVICH SI, 1995, BIOORG KHIM+, V21, P774; Bera S, 2005, BIOCHEMISTRY-US, V44, P15106, DOI 10.1021/bi0508340; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BROCHON JC, 1994, METHOD ENZYMOL, V240, P262; Chen AP, 2006, J BIOL CHEM, V281, P4173, DOI 10.1074/jbc.M510628200; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Cherepanov P, 2005, P NATL ACAD SCI USA, V102, P17308, DOI 10.1073/pnas.0506924102; Ciubotaru M, 2003, J BIOL CHEM, V278, P5584, DOI 10.1074/jbc.M209758200; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; Deprez E, 2004, MOL PHARMACOL, V65, P85, DOI 10.1124/mol.65.1.85; Deprez E, 2001, P NATL ACAD SCI USA, V98, P10090, DOI 10.1073/pnas.181024498; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Etzkorn C, 2004, BIOCHEMISTRY-US, V43, P13256, DOI 10.1021/bi0490082; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; GOODARZI G, 1995, J VIROL, V69, P6090, DOI 10.1128/JVI.69.10.6090-6097.1995; Grillo AO, 1999, J MOL BIOL, V287, P539, DOI 10.1006/jmbi.1999.2625; HAWKINS ME, 1995, NUCLEIC ACIDS RES, V23, P2872, DOI 10.1093/nar/23.15.2872; HAZUDA DJ, 1994, J BIOL CHEM, V269, P3999; Holman AG, 2005, P NATL ACAD SCI USA, V102, P6103, DOI 10.1073/pnas.0501646102; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; KUZNETSOVA LG, 1993, BIOORG KHIM+, V19, P455; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10205, DOI 10.1021/bi00032a014; LEE SP, 1995, ANAL BIOCHEM, V227, P295, DOI 10.1006/abio.1995.1284; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005; Li M, 2005, J BIOL CHEM, V280, P29334, DOI 10.1074/jbc.M505367200; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Pinskaya M, 2004, BIOCHEMISTRY-US, V43, P8735, DOI 10.1021/bi049706m; Podtelezhnikov AA, 2003, BIOPOLYMERS, V68, P110, DOI 10.1002/bip.10217; Sinha S, 2002, J VIROL, V76, P3105, DOI 10.1128/JVI.76.7.3105-3113.2002; Sinha S, 2005, J VIROL, V79, P8208, DOI 10.1128/JVI.79.13.8208-8216.2005; Smolov M, 2006, FEBS J, V273, P1137, DOI 10.1111/j.1742-4658.2006.05139.x; Tramontano E, 1998, BIOCHEMISTRY-US, V37, P7237, DOI 10.1021/bi972792o; van den Ent FMI, 1999, J VIROL, V73, P3176, DOI 10.1128/JVI.73.4.3176-3183.1999; Vercammen J, 2002, J BIOL CHEM, V277, P38045, DOI 10.1074/jbc.M205842200; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wang Y, 2005, J BIOMOL SCREEN, V10, P456, DOI 10.1177/1087057105275212; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wielens J, 2005, J COMPUT AID MOL DES, V19, P301, DOI 10.1007/s10822-005-5256-2; Wu XL, 2005, J VIROL, V79, P5211, DOI 10.1128/JVI.79.8.5211-5214.2005; Yang JS, 2005, J BIOL CHEM, V280, P25416, DOI 10.1074/jbc.M501847200; Zouhiri F, 2000, J MED CHEM, V43, P1533, DOI 10.1021/jm990467o	54	127	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22707	22719		10.1074/jbc.M602198200	http://dx.doi.org/10.1074/jbc.M602198200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774912	hybrid			2022-12-27	WOS:000239542600031
J	Murata, T; Tsuboi, M; Hikita, K; Kaneda, N				Murata, Tomiyasu; Tsuboi, Masaru; Hikita, Kiyomi; Kaneda, Norio			Protective effects of neurotrophic factors on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of murine adrenal chromaffin cell line tsAM5D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CD120A P55; PHOSPHATIDYLINOSITOL 3-KINASE; NEURONAL DIFFERENTIATION; SIGNALING COMPLEX; TYROSINE-HYDROXYLASE; CASPASE-8 CLEAVAGE; DIRECT ACTIVATION; DEATH RECEPTORS; GROWTH-FACTOR; TRAIL	We previously established the murine adrenal chromaffin cell line tsAM5D, which was immortalized with the temperature-sensitive simian virus 40 large T-antigen. tsAM5D cells have the capacity to differentiate into neuron-like cells in response to neurotrophic factors when the culture temperature is shifted from 33 to 39 degrees C. In this model system, the temperature shift in the absence of neurotrophic factors led to cell death. Hoechst staining analysis revealed that typical apoptotic nuclei appeared in a time-dependent manner after the temperature shift. Upon shifting to 39 degrees C, the degradation of T-antigen was accompanied by the transcriptional activation of p53 protein. Among the p53 target genes, death receptor 5 (DR5), which is the receptor for tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL), showed the highest level of induction. Interestingly, TRAIL-neutralizing antibody protected tsAM5D cells from the temperature shift-induced apoptotic cell death by blocking the activation of caspase-8 and -3, indicating the involvement of TRAIL-mediated death signaling in the temperature shift-induced apoptosis. Glial cell line-derived neurotrophic factor (GDNF) inhibited the TRAIL-mediated activation of caspase-8 in tsAM5D cells exposed to 39 degrees C and cooperated with basic fibroblast growth factor and ciliary neurotrophic factor. Interestingly, the temperature shift induced oligomerization of DR5, which is the earliest process necessary for transduction of the death signal. This oligomerization was inhibited by treatment with GDNF plus ciliary neurotrophic factor but not by that with GDNF alone or GDNF plus basic fibroblast growth factor. These results are discussed with respect to the intracellular mechanism underlying the protective function of neurotrophic factors against TRAIL-mediated death signaling.	Meijo Univ, Fac Pharm, Dept Analyt Neurobiol, Tempa Ku, Nagoya, Aichi 4688503, Japan	Meijo University	Kaneda, N (corresponding author), Meijo Univ, Fac Pharm, Dept Analyt Neurobiol, Tempa Ku, Nagoya, Aichi 4688503, Japan.	nkaneda@ccmfs.meijo-u.ac.jp						Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Barber RD, 2000, J NEUROSCI, V20, P3695, DOI 10.1523/JNEUROSCI.20-10-03695.2000; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Cantarella G, 2003, CELL DEATH DIFFER, V10, P134, DOI 10.1038/sj.cdd.4401143; CHOU JY, 1989, MOL ENDOCRINOL, V3, P1511, DOI 10.1210/mend-3-10-1511; Cottin V, 1999, J BIOL CHEM, V274, P32975, DOI 10.1074/jbc.274.46.32975; Cottin V, 2001, J BIOL CHEM, V276, P17252, DOI 10.1074/jbc.M010681200; Dolcet X, 2001, MOL CELL NEUROSCI, V18, P619, DOI 10.1006/mcne.2001.1058; Dorr J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-04-j0001.2002; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Frankel SK, 2001, BIOCHEM BIOPH RES CO, V288, P313, DOI 10.1006/bbrc.2001.5761; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Herr I, 2000, ONCOGENE, V19, P4255, DOI 10.1038/sj.onc.1203776; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Hilliard B, 2001, J IMMUNOL, V166, P1314, DOI 10.4049/jimmunol.166.2.1314; Hossain MA, 2002, J NEUROCHEM, V81, P365, DOI 10.1046/j.1471-4159.2002.00837.x; Huang WX, 2000, NEUROLOGY, V55, P928, DOI 10.1212/WNL.55.7.928; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Jones RG, 2002, J EXP MED, V196, P335, DOI 10.1084/jem.20020307; KANEDA N, 1991, NEURON, V6, P583, DOI 10.1016/0896-6273(91)90061-4; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; Mao YW, 2005, J CELL BIOL, V170, P305, DOI 10.1083/jcb.200505061; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; McManus MF, 1999, J NEUROSCI, V19, P9004, DOI 10.1523/JNEUROSCI.19-20-09004.1999; Miura Y, 2003, P NATL ACAD SCI USA, V100, P2777, DOI 10.1073/pnas.2628048100; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Murata T, 2003, J NEUROCHEM, V85, P1126, DOI 10.1046/j.1471-4159.2003.01765.x; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Obinata M, 1997, GENES CELLS, V2, P235, DOI 10.1046/j.1365-2443.1997.1160314.x; Obinata M, 2001, BIOCHEM BIOPH RES CO, V286, P667, DOI 10.1006/bbrc.2001.5247; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Ryan LA, 2004, J NEUROIMMUNOL, V148, P127, DOI 10.1016/j.jneuroim.2003.11.019; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Soler RM, 1999, J NEUROSCI, V19, P9160; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Suzuki A, 2000, HEPATOLOGY, V32, P796, DOI 10.1053/jhep.2000.17738; Tavelin S, 1999, J PHARMACOL EXP THER, V290, P1212; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TEGTMEYE.P, 1971, J VIROL, V8, P516, DOI 10.1128/JVI.8.4.516-524.1971; Uberti D, 2004, NEUROREPORT, V15, P579, DOI 10.1097/00001756-200403220-00002; Varadhachary AS, 2001, J IMMUNOL, V166, P6564, DOI 10.4049/jimmunol.166.11.6564; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade SB, 1999, J NEUROSCI, V19, P6994, DOI 10.1523/JNEUROSCI.19-16-06994.1999; Walther N, 1999, BIOL REPROD, V60, P1078, DOI 10.1095/biolreprod60.5.1078; WHITE LA, 1994, J NEUROSCI, V14, P6744; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; ZHENG DQ, 1994, ONCOGENE, V9, P3345	74	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22503	22516		10.1074/jbc.M602579200	http://dx.doi.org/10.1074/jbc.M602579200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772303	hybrid			2022-12-27	WOS:000239542600011
J	Stefansson, B; Brautigan, DL				Stefansson, Bjarki; Brautigan, David L.			Protein phosphatase 6 subunit with conserved sit4-associated protein domain targets I kappa B epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PHOSPHATASE 2A; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SIT4; IDENTIFICATION; APOPTOSIS; RECEPTOR; KINASE; ASSOCIATION	Protein Ser/Thr phosphatases compose a PPP family that includes type-2 PP2A, PP4, and PP6, each with essential functions. The human PP6 gene rescues sit4(ts) mutants of Saccharomyces cerevisiae, and Sit4 phosphatase function depends on multiple Sit4-associated protein (SAP) subunits. We report here finding a SAPS sequence domain encoded in only a single gene each in Schizosaccharomyces pombe, Caenorhabditis elegans, and Drosophila but in three distinct open reading frames in Xenopus, Mus musculus, and Homo sapiens. The SAPS proteins are more divergent in sequence than PP6. Northern hybridization showed differential distribution of the human SAPS-related mRNA in multiple human tissues, named as PP6R1, PP6R2, and PP6R3. Antibodies were generated, distribution of endogenous PP6, PP6R1, PP6R2, and PP6R3 proteins was examined by immunoblotting, and the abundance of mRNA and protein in various tissues did not match. FLAG-tagged PP6R1 and PP6R2 expressed in HEK293 cells co-precipitated endogenous PP6, but not PP2A or PP4, showing specificity for recognition of phosphatases. The SAPS domain of PP6R1 alone was sufficient for association with PP6, and this predicts that conserved sequence motifs in the SAPS domain accounts for the specificity. FLAG-PP6R1 and FLAG-PP6R2 co-precipitated HA-I kappa B epsilon. Knockdown of PP6 or PP6R1 but not PP6R3 with siRNA significantly enhanced degradation of endogenous I kappa B epsilon in response to tumor necrosis factor-alpha. The results show SAPS domain subunits recruit substrates such as I kappa B epsilon as one way to determine specific functions for PP6.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577,W Complex MSB 7225, Charlottesville, VA 22908 USA.	db8g@virginia.edu		Stefansson, Bjarki/0000-0002-0363-5162	NATIONAL CANCER INSTITUTE [R01CA077584] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adeyinka A, 2002, CLIN CANCER RES, V8, P3788; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Astier AL, 2003, BLOOD, V101, P1118, DOI 10.1182/blood-2002-05-1519; Bastians H, 1996, J CELL SCI, V109, P2865; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Clotet J, 1999, MOL CELL BIOL, V19, P2408; Cohen PTW, 2005, FEBS LETT, V579, P3278, DOI 10.1016/j.febslet.2005.04.070; Ferguson RE, 2005, PROTEOMICS, V5, P566, DOI 10.1002/pmic.200400941; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hastie CJ, 2000, BIOCHEM J, V347, P845, DOI 10.1042/0264-6021:3470845; Hayashi N, 2005, CURR GENET, V47, P359, DOI 10.1007/s00294-005-0577-1; Jablonowski D, 2001, GENETICS, V159, P1479; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jarai G, 2004, EUR J PHARMACOL, V497, P255, DOI 10.1016/j.ejphar.2004.06.055; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Luke MM, 1996, MOL CELL BIOL, V16, P2744; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Manlandro CMA, 2005, EUKARYOT CELL, V4, P1041, DOI 10.1128/EC.4.6.1041-1049.2005; MANN DJ, 1993, EMBO J, V12, P4833, DOI 10.1002/j.1460-2075.1993.tb06173.x; Masuda CA, 2000, J BIOL CHEM, V275, P30957, DOI 10.1074/jbc.M004869200; Moynagh Paul N, 2005, J Cell Sci, V118, P4589, DOI 10.1242/jcs.02579; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1999, FEBS LETT, V446, P108, DOI 10.1016/S0014-5793(99)00189-1; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; Prickett TD, 2004, J BIOL CHEM, V279, P38912, DOI 10.1074/jbc.M401444200; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Shirra MK, 2005, GENETICS, V169, P1957, DOI 10.1534/genetics.104.038075; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Tackels-Horne D, 2001, CANCER-AM CANCER SOC, V92, P395, DOI 10.1002/1097-0142(20010715)92:2<395::AID-CNCR1335>3.0.CO;2-U; Twells RCJ, 2001, GENOMICS, V72, P231, DOI 10.1006/geno.2000.6492; UHLER MD, 1987, J BIOL CHEM, V262, P15202; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; Zabrocki P, 2002, MOL MICROBIOL, V43, P835, DOI 10.1046/j.1365-2958.2002.02786.x	48	86	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22624	22634		10.1074/jbc.M601772200	http://dx.doi.org/10.1074/jbc.M601772200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769727	hybrid			2022-12-27	WOS:000239542600023
J	Anderson, JP; Walker, DE; Goldstein, JM; de Laat, R; Banducci, K; Caccavello, RJ; Barbour, R; Huang, JP; Kling, K; Lee, M; Diep, L; Keim, PS; Shen, XF; Chataway, T; Schlossmacher, MG; Seubert, P; Schenk, D; Sinha, S; Gai, WP; Chilcote, TJ				Anderson, John P.; Walker, Donald E.; Goldstein, Jason M.; de laat, Rian; Banducci, Kelly; Caccavello, Russell J.; Barbour, Robin; Huang, Jiping; Kling, Kristin; Lee, Michael; Diep, Linnea; Keim, Pamela S.; Shen, Xiaofeng; Chataway, Tim; Schlossmacher, Michael G.; Seubert, Peter; Schenk, Dale; Sinha, Sukanto; Gai, Wei Ping; Chilcote, Tamie J.			Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; UBIQUITINATION; INCLUSIONS; BODIES; AGGREGATION; DUPLICATION; PROTEASOME	A comprehensive, unbiased inventory of synuclein forms present in Lewy bodies from patients with dementia with Lewy bodies was carried out using two- dimensional immunoblot analysis, novel sandwich enzyme- linked immunosorbent assays with modification- specific synuclein antibodies, and mass spectroscopy. The predominant modification of alpha-synuclein in Lewy bodies is a single phosphorylation at Ser-129. In addition, there is a set of characteristic modifications that are present to a lesser extent, including ubiquitination at Lys residues 12, 21, and 23 and specific truncations at Asp- 115, Asp- 119, Asn-122, Tyr- 133, and Asp- 135. No other modifications are detectable by tandem mass spectrometry mapping, except for a ubiquitous N- terminal acetylation. Small amounts of Ser- 129 phosphorylated and Asp- 119- truncated alpha- synuclein are present in the soluble fraction of both normal and disease brains, suggesting that these Lewy body-associated forms are produced during normal metabolism of alpha-synuclein. In contrast, ubiquitination is only detected in Lewy bodies and is primarily present on phosphorylated synuclein; it therefore likely occurs after phosphorylated synuclein has deposited into Lewy bodies. This invariant pattern of specific phosphorylation, truncation, and ubiquitination is also present in the detergent- insoluble fraction of brain from patients with familial Parkinson's disease ( synuclein A53T mutation) as well as multiple system atrophy, suggesting a common pathogenic pathway for both genetic and sporadic Lewy body diseases. These observations are most consistent with a model in which preferential accumulation of normally produced Ser- 129 phosphorylated alpha- synuclein is the key event responsible for the formation of Lewy bodies in various Lewy body diseases.	Elan Pharmaceut, San Francisco, CA 94080 USA; Flinders Univ S Australia, Sch Med, Bedford Pk, SA 5042, Australia; Harvard Univ, Brigham & Womens Hosp, Ctr Neurol Dis, Sch Med, Boston, MA 02115 USA	Flinders University South Australia; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Chilcote, TJ (corresponding author), ActiveSite Pharmaceut, 187 Megellan Ave, San Francisco, CA 94116 USA.	tamie.chilcote@activesitepharma.com	Gai, Wei-Ping/A-3700-2008	Chataway, Tim/0000-0003-0254-8099; Schlossmacher, Michael/0000-0002-0394-0300	NINDS NIH HHS [P50-NS40256] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS040256] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADSHAW RA, 1989, TRENDS BIOCHEM SCI, V14, P276, DOI 10.1016/0968-0004(89)90063-7; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Duda JE, 2002, ACTA NEUROPATHOL, V104, P7, DOI 10.1007/s00401-002-0563-3; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Gai WP, 1999, J NEUROCHEM, V73, P2093; Golbe LI, 1996, ANN NEUROL, V40, P767, DOI 10.1002/ana.410400513; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kahle PJ, 2002, EMBO REP, V3, P583, DOI 10.1093/embo-reports/kvf109; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Li WX, 2005, P NATL ACAD SCI USA, V102, P2162, DOI 10.1073/pnas.0406976102; Liu CW, 2005, J BIOL CHEM, V280, P22670, DOI 10.1074/jbc.M501508200; Miake H, 2002, J BIOL CHEM, V277, P19213, DOI 10.1074/jbc.M110551200; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; Murray IVJ, 2003, BIOCHEMISTRY-US, V42, P8530, DOI 10.1021/bi027363r; Nonaka T, 2005, BIOCHEMISTRY-US, V44, P361, DOI 10.1021/bi0485528; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rideout HJ, 2004, J BIOL CHEM, V279, P46915, DOI 10.1074/jbc.M405146200; Sampathu DM, 2003, AM J PATHOL, V163, P91, DOI 10.1016/S0002-9440(10)63633-4; Schlossmacher Michael G., 2005, V301, P351; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spira PJ, 2001, ANN NEUROL, V49, P313, DOI 10.1002/ana.67; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200	35	862	888	1	62	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29739	29752		10.1074/jbc.M600933200	http://dx.doi.org/10.1074/jbc.M600933200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16847063	hybrid			2022-12-27	WOS:000240896300036
J	Adli, M; Baldwin, AS				Adli, Mazhar; Baldwin, Albert S.			IKK-i/IKK epsilon controls constitutive, cancer cell-associated NF-kappa B activity via regulation of Ser-536 p65/RelA phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-RELATED KINASES; RELA/P65 SUBUNIT; ACTIVATION; P65; TRANSACTIVATION; TBK1; LIPOPOLYSACCHARIDE; EXPRESSION; SERINE-536; SIGNALS	Nuclear factor kappa B(NF-kappa B) has been studied extensively as an inducible transcriptional regulator of the immune and inflammatory response. NF-kappa B activation downstream of lipopolysaccharide or cytokine stimulation is controlled by the I kappa B kinase complex, which contains IKK alpha and IKK beta. Significantly, the constitutive activity of NF-kappa B has been implicated as an important aspect of many cancer cells, but mechanisms associated with this activity are poorly understood. An inducible kinase, IKK-i/IKK epsilon, related to the catalytic forms of the I kappa B kinase, has been studied as an anti-viral, innate immune regulator through its ability to control the activity of the transcription factors IRF-3 and IRF-7. Here, we demonstrate that IKK-i/IKK epsilon is expressed in a number of cancer cells and is involved in regulating NF-kappa B activity through its ability to control basal/constitutive, but not cytokine-induced, p65/RelA phosphorylation at Ser-536, a modification proposed to contribute to the transactivation function of NF-kappa B. Knockdown of IKK-i/IKK epsilon or expression of a S536A mutant form of p65 suppresses HeLa cell proliferation. The data indicate a role for IKK-i/IKK epsilon in controlling proliferation of certain cancer cells through regulation of constitutive NF-kappa B activity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Ctr 22000, CB 7295, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu			NATIONAL CANCER INSTITUTE [R01CA075080, R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA75080, CA73756] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Campbell KJ, 2004, BIOCHEM SOC T, V32, P1087, DOI 10.1042/BST0321087; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Natoli G, 2006, FEBS LETT, V580, P2843, DOI 10.1016/j.febslet.2006.02.072; Nomura F, 2000, GENES CELLS, V5, P191; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sankar S, 2006, CELL SIGNAL, V18, P982, DOI 10.1016/j.cellsig.2005.08.006; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Takeuchi O, 2004, J ENDOTOXIN RES, V10, P252, DOI 10.1179/096805104225005896; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang NZ, 2005, GENE, V353, P118, DOI 10.1016/j.gene.2005.04.013; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	40	125	139	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26976	26984		10.1074/jbc.M603133200	http://dx.doi.org/10.1074/jbc.M603133200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16840782	Green Published, hybrid			2022-12-27	WOS:000240397700024
J	Senn, JJ				Senn, Joseph J.			Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACID; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; INFLAMMATORY CYTOKINES; SKELETAL-MUSCLE; ACTIVATION; INTERLEUKIN-6; EXPRESSION; POLYMORPHISM; RECOGNITION	Fatty acids can activate proinflammatory pathways leading to the development of insulin resistance, but the mechanism is undiscovered. Toll like receptor 2 (TLR2) recognizes lipids, activates proinflammatory pathways, and is genetically associated with inflammatory diseases. This study aimed to examine the role of TLR2 in palmitate-induced insulin resistance in C2C12 myotubes. Treatment with palmitate rapidly induced the association of myeloid differentiation factor 88 (MyD88) with the TLR2 receptor, activated the stress-linked kinases p38, JNK, and protein kinase C, induced degradation of I kappa B alpha, and increased NF-kappa B DNA binding. The activation of these pathways by palmitate was sensitive and temporally regulated and occurred within the upper physiologic range of saturated fatty acid concentrations in vivo, suggesting a receptor-mediated event and not simple lipotoxicity. When compared with an equimolar concentration of palmitate, fibroblast-stimulating lipopeptide-1, a known TLR2 ligand, was a slightly more potent activator of signal transduction and interleukin (IL)-6 production. Palmitate inhibited insulin signal transduction in C2C12 cells beginning 1-2 h after exposure and reached a maximum at 12-16 h. An antagonist TLR2 antibody, mAb 2.5, led to a 50-60% decrease in palmitate- induced IL-6 production and partially restored insulin signal transduction, whereas an isotype-matched control antibody had no effect. RNA interference-resulted in a near complete inhibition of palmitate- induced insulin resistance and IL-6 production. This study provides strong evidence that TLR2 mediates the initial events of fatty acid-induced insulin resistance in muscle.	Med Univ S Carolina, Dept Pediat, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA	Medical University of South Carolina	Senn, JJ (corresponding author), Med Univ S Carolina, Dept Pediat Endocrinol, Rm 316,Clin Sci Bldg,96 Jonathon Lucas St, Charleston, SC 29425 USA.	sennj@musc.edu						Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Ajuwon KM, 2005, J NUTR, V135, P1841, DOI 10.1093/jn/135.8.1841; Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Bajaj M, 2005, DIABETES, V54, P3148, DOI 10.2337/diabetes.54.11.3148; Belfort R, 2005, DIABETES, V54, P1640, DOI 10.2337/diabetes.54.6.1640; Boden G, 2003, EXP CLIN ENDOCR DIAB, V111, P121, DOI 10.1055/s-2003-39781; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Fraser DA, 1999, RHEUMATOLOGY, V38, P948, DOI 10.1093/rheumatology/38.10.948; Frost RA, 2005, ALCOHOL CLIN EXP RES, V29, P1247, DOI 10.1097/01.ALC.0000171935.06914.5D; Frost RA, 2004, AM J PHYSIOL-CELL PH, V287, pC1605, DOI 10.1152/ajpcell.00010.2004; Fujita M, 2003, J IMMUNOL, V171, P3675, DOI 10.4049/jimmunol.171.7.3675; Ghanim H, 2004, CIRCULATION, V110, P1564, DOI 10.1161/01.CIR.0000142055.53122.FA; Illig T, 2003, DIABETES, V52, P2861, DOI 10.2337/diabetes.52.11.2861; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Jimenez R, 2005, P NATL ACAD SCI USA, V102, P4637, DOI 10.1073/pnas.0407655101; Jove M, 2005, ENDOCRINOLOGY, V146, P3087, DOI 10.1210/en.2004-1560; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Lang CH, 2003, SHOCK, V19, P538, DOI 10.1097/01.shk.0000055237.25446.80; Lee JY, 2004, J BIOL CHEM, V279, P16971, DOI 10.1074/jbc.M312990200; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Liu RH, 2002, INT J OBESITY, V26, P318, DOI 10.1038/sj.ijo.0801924; Miller YI, 2003, CURR OPIN LIPIDOL, V14, P437, DOI 10.1097/00041433-200310000-00004; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Muller SDC, 2004, INT IMMUNOPHARMACOL, V4, P1287, DOI 10.1016/j.intimp.2004.04.012; Muzio M, 2000, MICROBES INFECT, V2, P251, DOI 10.1016/S1286-4579(00)00303-8; Muzio M, 2000, BIOCHEM SOC T, V28, P563, DOI 10.1042/bst0280563; Nakao Y, 2005, J IMMUNOL, V174, P1566, DOI 10.4049/jimmunol.174.3.1566; Netea MG, 2004, J LEUKOCYTE BIOL, V75, P749, DOI 10.1189/jlb.1103543; Nishimura M, 2005, BIOL PHARM BULL, V28, P886, DOI 10.1248/bpb.28.886; Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004; Park Y, 2004, ANN NY ACAD SCI, V1037, P170, DOI 10.1196/annals.1337.028; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; RIETSCHEL ET, 1987, REV INFECT DIS, V9, pS527; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Rook GAW, 2003, CURR OPIN ALLERGY CL, V3, P337, DOI 10.1097/01.all.0000092602.76804.ad; Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Sewter CP, 1999, J ENDOCRINOL, V163, P33, DOI 10.1677/joe.0.1630033; Sinha S, 2004, J BIOL CHEM, V279, P41294, DOI 10.1074/jbc.M406514200; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Tomas E, 2004, P NUTR SOC, V63, P381, DOI 10.1079/PNS2004356; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; YAMAKAWA T, 1995, CLIN IMMUNOL IMMUNOP, V75, P51, DOI 10.1006/clin.1995.1052; Yang X, 2005, AM J PHYSIOL-HEART C, V289, pH1069, DOI 10.1152/ajpheart.00143.2005; Yim JJ, 2004, FEMS IMMUNOL MED MIC, V40, P163, DOI 10.1016/S0928-8244(03)00342-0; Zuany-Amorim C, 2002, NAT REV DRUG DISCOV, V1, P797, DOI 10.1038/nrd914	53	204	211	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26865	26875		10.1074/jbc.M513304200	http://dx.doi.org/10.1074/jbc.M513304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16798732	hybrid			2022-12-27	WOS:000240397700013
J	Smith, MJ; Pozo, K; Brickley, K; Stephenson, FA				Smith, Miriam J.; Pozo, Karine; Brickley, Kieran; Stephenson, F. Anne			Mapping the GRIF-1 binding domain of the kinesin, KIF5C, substantiates a role for GRIF-1 as an adaptor protein in the anterograde trafficking of cargoes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; AXONAL-TRANSPORT; HEAVY-CHAIN; GLCNAC TRANSFERASE; TAIL DOMAIN; O-GLCNAC; IN-VIVO; MITOCHONDRIA; RECEPTOR; NEURONS	gamma-Aminobutyric acid, type A (GABA(A)) receptor interacting factor-1 (GRIF-1) and N-acetylglucosamine transferase interacting protein (OIP) 106 are both members of a newly identified coiled-coil family of proteins. They are kinesin-associated proteins proposed to function as adaptors in the anterograde trafficking of organelles to synapses. Here we have studied in more detail the interaction between the prototypic kinesin heavy chain, KIF5C, kinesin light chain, and GRIF-1. The GRIF-1 binding site of KIF5C was mapped using truncation constructs in yeast two-hybrid interaction assays, co-immunoprecipitations, and co-localization studies following expression in mammalian cells. Using these approaches, it was shown that GRIF-1 and the KIF5C binding domain of GRIF-1, GRIF-1-(124-283), associated with the KIF5C non-motor domain. Refined studies using yeast two-hybrid interactions and co-immunoprecipitations showed that GRIF-1 and GRIF-1-(124-283) associated with the cargo binding region within the KIF5C non-motor domain. Substantiation that the GRIF-1-KIF5C interaction was direct was shown by fluorescence resonance energy transfer analyses using fluorescently tagged GRIF-1 and KIF5C constructs. A significant fluorescence resonance energy transfer value was found between the C-terminal EYFP-tagged KIF5C and ECFP-GRIF-1, the C-terminal EYFP-tagged KIF5C non-motor domain and ECFP-GRIF-1, but not between the N-terminal EYFP-tagged KIF5C nor the EYFP-KIF5C motor domain and ECFP-GRIF-1, thus confirming direct association between the two proteins at the KIF5C C-terminal and GRIF-1 N-terminal regions. Co-immunoprecipitation and confocal imaging strategies further showed that GRIF-1 can bind to the tetrameric kinesin light-chain/kinesin heavy-chain complex. These findings support a role for GRIF-1 as a kinesin adaptor molecule requisite for the anterograde delivery of defined cargoes such as mitochondria and/or vesicles incorporating beta 2 subunit-containing GABA(A) receptors, in the brain.	Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Stephenson, FA (corresponding author), Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, 29-39 Brunswick Sq, London WC1N 1AX, England.	anne.stephenson@pharmacy.ac.uk	Smith, Miriam/J-4001-2015; Pozo, Karine/J-2943-2019	Smith, Miriam/0000-0002-3184-0817; 				Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Brickley K, 2005, J BIOL CHEM, V280, P14723, DOI 10.1074/jbc.M409095200; Cai Q, 2005, J CELL BIOL, V170, P959, DOI 10.1083/jcb.200506042; Ceccarini M, 2005, J MOL BIOL, V354, P872, DOI 10.1016/j.jmb.2005.09.069; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Fransson A, 2006, BIOCHEM BIOPH RES CO, V344, P500, DOI 10.1016/j.bbrc.2006.03.163; Gilbert SL, 2006, NAT GENET, V38, P245, DOI 10.1038/ng1715; Glater EE, 2006, J CELL BIOL, V173, P545, DOI 10.1083/jcb.200601067; Goldstein LSB, 2003, NEURON, V40, P415, DOI 10.1016/S0896-6273(03)00630-5; Gorska-Andrzejak J, 2003, J COMP NEUROL, V463, P372, DOI 10.1002/cne.10750; Guillaud L, 2003, J NEUROSCI, V23, P131; Guo XF, 2005, NEURON, V47, P379, DOI 10.1016/j.neuron.2005.06.027; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; He LS, 2003, CYTOM PART A, V53A, P39, DOI 10.1002/cyto.a.10037; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Liu J, 2004, J BIOL CHEM, V279, P55924, DOI 10.1074/jbc.M410024200; Love DC, 2003, J CELL SCI, V116, P647, DOI 10.1242/jcs.00246; Macioce P, 2003, J CELL SCI, V116, P4847, DOI 10.1242/jcs.00805; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Nashmi R, 2003, J NEUROSCI, V23, P11554; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Pozo K, 2006, BIOCHEM SOC T, V34, P48, DOI 10.1042/BST0340048; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; Su QN, 2004, NAT CELL BIOL, V6, P941, DOI 10.1038/ncb1169; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714	30	67	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27216	27228		10.1074/jbc.M600522200	http://dx.doi.org/10.1074/jbc.M600522200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835241	hybrid			2022-12-27	WOS:000240397700049
J	Isenberg, JS; Ridnour, LA; Dimitry, J; Frazier, WA; Wink, DA; Roberts, DD				Isenberg, Jeff S.; Ridnour, Lisa A.; Dimitry, Julie; Frazier, William A.; Wink, David A.; Roberts, David D.			CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; INTEGRIN-ASSOCIATED PROTEIN; FACTOR-INDUCED ANGIOGENESIS; C-TERMINAL DOMAIN; TYPE-1 REPEATS; IN-VITRO; RECEPTOR; ADHESION; ALPHA(V)BETA(3); PROLIFERATION	CD36 is necessary for inhibition of some angiogenic responses by the matricellular glycoprotein thrombospondin-1 and is therefore assumed to be the receptor that mediates its anti-angiogenic activities. Although ligation of CD36 by antibodies, recombinant type 1 repeats of thrombospondin-1, or CD36-binding peptides was sufficient to inhibit nitric oxide (NO)-stimulated responses in both endothelial and vascular smooth muscle cells, picomolar concentrations of native thrombospondin-1 similarly inhibited NO signaling in vascular cells from wild-type and CD36-null mice. Ligation of the thrombospondin-1 receptor CD47 by recombinant C-terminal regions of thrombospondin-1, thrombospondin-1 peptides, or CD47 antibodies was also sufficient to inhibit NO-stimulated phenotypic responses and cGMP signaling in vascular cells. Thrombospondin-1 did not inhibit NO signaling in CD47-null vascular cells or NO-stimulated vascular outgrowth from CD47-null muscle explants in three-dimensional cultures. Furthermore, the CD36-binding domain of thrombospondin-1 and anti-angiogenic peptides derived from this domain failed to inhibit NO signaling in CD47-null cells. Therefore, ligation of either CD36 or CD47 is sufficient to inhibit NO-stimulated vascular cell responses and cGMP signaling, but only CD47 is necessary for this activity of thrombospondin-1 at physiological concentrations.	NCI, Pathol Lab, Canc Res Ctr, Lab Pathol,NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Canc Res Ctr, Radiat Biol Branch,NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington University (WUSTL)	Roberts, DD (corresponding author), NCI, Pathol Lab, Canc Res Ctr, Lab Pathol,NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Wink, David/0000-0002-5652-7480; Ridnour, Lisa A./0000-0001-9446-8349; Azad, Mahan/0000-0002-8633-3513	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL54390] Funding Source: Medline; NIGMS NIH HHS [GM57573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC009172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054390, R56HL054390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Bocci G, 2003, P NATL ACAD SCI USA, V100, P12917, DOI 10.1073/pnas.2135406100; Bonnefoy A, 2001, J BIOL CHEM, V276, P5605, DOI 10.1074/jbc.M010091200; Calzada MJ, 2004, J BIOL CHEM, V279, P41734, DOI 10.1074/jbc.M406267200; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Carlson CB, 2005, NAT STRUCT MOL BIOL, V12, P910, DOI 10.1038/nsmb997; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chen DH, 1999, CIRCULATION, V100, P849, DOI 10.1161/01.CIR.100.8.849; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; Crombie R, 1998, J BIOL CHEM, V273, P4855, DOI 10.1074/jbc.273.9.4855; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Elzie CA, 2004, INT J BIOCHEM CELL B, V36, P1090, DOI 10.1016/j.biocel.2003.12.012; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Isenberg JS, 2005, P NATL ACAD SCI USA, V102, P13141, DOI 10.1073/pnas.0502977102; Isenberg JS, 2005, MATRIX BIOL, V24, P110, DOI 10.1016/j.matbio.2005.01.002; ISENBERG JS, 2006, IN PRESS CARDIOVASC; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lawler J, 2001, AM J PATHOL, V159, P1949, DOI 10.1016/S0002-9440(10)63042-8; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Li ZQ, 2001, J IMMUNOL, V166, P2427, DOI 10.4049/jimmunol.166.4.2427; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Magnetto S, 1998, CELL BIOCHEM FUNCT, V16, P211, DOI 10.1002/(SICI)1099-0844(199809)16:3<211::AID-CBF788>3.3.CO;2-Q; MAMKOONG S, 2005, EXP MOL MED, V37, P588; McDonald JF, 2004, J BIOL CHEM, V279, P17301, DOI 10.1074/jbc.M312782200; McDonald JF, 2003, BIOCHEMISTRY-US, V42, P10001, DOI 10.1021/bi0341408; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; MOSHER DF, 1992, ANN NY ACAD SCI, V667, P64, DOI 10.1111/j.1749-6632.1992.tb51598.x; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Ray Jenna Lynn, 2001, Methods in Cell Science, V23, P185; Ridnour LA, 2005, P NATL ACAD SCI USA, V102, P13147, DOI 10.1073/pnas.0502979102; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; Short SM, 2005, J CELL BIOL, V168, P643, DOI 10.1083/jcb.200407060; Stenina OI, 2004, INT J BIOCHEM CELL B, V36, P1013, DOI 10.1016/j.biocel.2004.01.005; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; Wang SJ, 2003, DEV DYNAM, V228, P630, DOI 10.1002/dvdy.10412; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wilson KE, 1999, J IMMUNOL, V163, P3621; Yano K, 2004, J INVEST DERMATOL, V122, P201, DOI 10.1046/j.0022-202X.2003.22101.x; Zeng YC, 2003, J BIOL CHEM, V278, P45931, DOI 10.1074/jbc.M307722200; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	57	192	203	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26069	26080		10.1074/jbc.M605040200	http://dx.doi.org/10.1074/jbc.M605040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835222	hybrid			2022-12-27	WOS:000240249500022
J	Slaaby, R; Schaffer, L; Lautrup-Larsen, I; Andersen, AS; Shaw, AC; Mathiasen, IS; Brandt, J				Slaaby, Rita; Schaffer, Lauge; Lautrup-Larsen, Inger; Andersen, Asser Sloth; Shaw, Allan Christian; Mathiasen, Ida Stenfeldt; Brandt, Jakob			Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; FACTOR SYSTEM; BETA-SUBUNIT; EXPRESSION; ISOFORM; CANCER; DETERMINANTS; PURIFICATION; SPECIFICITY; ANTIBODIES	sInsulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) are both from the same subgroup of receptor tyrosine kinases that exist as covalently bound receptor dimers at the cell surface. For both IR and IGF-IR, the most described forms are homodimer receptors. However, hybrid receptors consisting of one-half IR and one-half IGF-IR are also present at the cell surface. Two splice variants of IR are expressed that enable formation of two isoforms of the IGF-IR/IR hybrid receptor. In this study, these two splice variants of hybrid receptors were studied with respect to binding affinities of insulin, insulin-like growth factor I (IGF-I), and insulin-like growth factor II (IGF-II). Unlike previously published data, in which semipurified receptors have been studied, we found that the two hybrid receptor splice variants had similar binding characteristics with respect to insulin, IGF-I, and IGF-II binding. We studied both semipurified and purified hybrid receptors. In all cases we found that IGF-I had at least 50-fold higher affinity than insulin, irrespective of the splice variant. The binding characteristics of insulin and IGF-I to both splice variants of the hybrid receptors were similar to classical homodimer IGF-IR.	Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Novo Nordisk	Slaaby, R (corresponding author), Novo Nordisk AS, Novo Alle, DK-2880 Bagsvaerd, Denmark.	risl@novonordisk.com						Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; Chisalita SI, 2005, DIABETOLOGIA, V48, P2155, DOI 10.1007/s00125-005-1890-4; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Denley A, 2005, CYTOKINE GROWTH F R, V16, P421, DOI 10.1016/j.cytogfr.2005.04.004; Entingh-Pearsall A, 2004, J BIOL CHEM, V279, P38016, DOI 10.1074/jbc.M313201200; Federici M, 1999, DIABETES, V48, P2277, DOI 10.2337/diabetes.48.12.2277; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; Heald A, 2006, DIABETIC MED, V23, P19, DOI 10.1111/j.1464-5491.2006.01833f.x; KASUYA J, 1993, BIOCHEMISTRY-US, V32, P13531, DOI 10.1021/bi00212a019; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Li GL, 2005, ENDOCRINOLOGY, V146, P4690, DOI 10.1210/en.2005-0505; Modan-Moses D, 1998, BIOCHEM J, V333, P825, DOI 10.1042/bj3330825; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Nitert MD, 2005, MOL CELL ENDOCRINOL, V229, P31, DOI 10.1016/j.mce.2004.10.003; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sachdev D, 2006, CANCER RES, V66, P2391, DOI 10.1158/0008-5472.CAN-05-3126; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SEELY BL, 1995, ENDOCRINOLOGY, V136, P1635, DOI 10.1210/en.136.4.1635; Siddle Kenneth, 1999, V17, P199; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valensise H, 1996, DIABETOLOGIA, V39, P952; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952	32	140	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25869	25874		10.1074/jbc.M605189200	http://dx.doi.org/10.1074/jbc.M605189200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831875	hybrid			2022-12-27	WOS:000240249500001
J	Tsuda, S; Okudaira, S; Moriya-Ito, K; Shimamoto, C; Tanaka, M; Aoki, J; Arai, H; Murakami-Murofushi, K; Kobayashi, T				Tsuda, Satomi; Okudaira, Shinichi; Moriya-Ito, Keiko; Shimamoto, Chie; Tanaka, Masayuki; Aoki, Junken; Arai, Hiroyuki; Murakami-Murofushi, Kimiko; Kobayashi, Tetsuyuki			Cyclic phosphatidic acid is produced by autotaxin in blood	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSARUM LYSOPHOSPHATIDIC ACID; DNA POLYMERASE-ALPHA; LYSOPHOSPHOLIPASE-D; PHOSPHOLIPASE-D; NUCLEOTIDE PYROPHOSPHATASES/PHOSPHODIESTERASES; ESCHERICHIA-COLI; LIPID MEDIATOR; RAT PLASMA; INHIBITION; PHYLPA	Cyclic phosphatidic acid (cPA), an analog of lysophosphatidic acid (LPA), was previously identified in human serum. Although cPA possesses distinct physiological activities not elicited by LPA, its biochemical origins have scarcely been studied. In the present study, we assayed cPA formation from lysophosphatidylcholine in fetal bovine serum and found significant activity of transphosphatidylation that generated cPA. The cPA-producing enzyme was purified from fetal bovine serum using five chromatographic steps yielding a 100-kDa protein with cPA biosynthetic activity. Matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry of its tryptic peptides revealed that the enzyme shared identical fragments with human autotaxin, a serum lysophospholipase D that produces LPA. Western blot analysis demonstrated that the 100-kDa protein was specifically recognized by an anti-human autotaxin antibody. Moreover, recombinant rat autotaxin was found to generate cPA in addition to LPA. No significant cPA-or LPA-producing activity was detected in autotaxin-depleted serum from bovine or human prepared by immunoprecipitation with an anti-autotaxin monoclonal antibody. These results indicate that the generation of cPA and LPA in serum is mainly attributed to autotaxin.	Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, Precur Res Embryon Sci & Technol, Saitama 3320012, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Saitama 3320012, Japan	Ochanomizu University; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Kobayashi, T (corresponding author), Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, 2-1-1 Ohtsuka, Tokyo 1128610, Japan.	tetkoba@cc.ocha.ac.jp	Kobayashi, Tetsuyuki/AAH-2985-2020	Kobayashi, Tetsuyuki/0000-0002-9285-0859; Aoki, Junken/0000-0001-9435-1896				Altman P.L., 1974, BIOL DATA BOOK, P1598; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Cimpean A, 2004, BIOCHEM J, V381, P71, DOI 10.1042/BJ20040465; Clair T, 2003, CANCER RES, V63, P5446; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Friedman P, 1996, J BIOL CHEM, V271, P953, DOI 10.1074/jbc.271.2.953; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Fujiwara Y, 2003, J NEUROCHEM, V87, P1272, DOI 10.1046/j.1471-4159.2003.02106.x; HOMMA H, 1981, BIOCHIM BIOPHYS ACTA, V663, P1, DOI 10.1016/0005-2760(81)90189-2; Ishihara R, 2004, INT J CANCER, V110, P188, DOI 10.1002/ijc.20069; Kishimoto T, 2003, CLIN CHIM ACTA, V333, P59, DOI 10.1016/S0009-8981(03)00165-7; Kobayashi T, 2001, WORLD REV NUTR DIET, V88, P228; Kobayashi T, 1999, LIFE SCI, V65, P2185, DOI 10.1016/S0024-3205(99)00483-X; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Mukai M, 2003, INT J ONCOL, V22, P1247; Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2; MURAKAMIMUROFUSHI K, 1992, J BIOL CHEM, V267, P21512; MURAKAMIMUROFUSHI K, 1995, BBA-LIPID LIPID MET, V1258, P57; MURAKAMIMUROFUSHI K, 1993, CELL STRUCT FUNCT, V18, P363, DOI 10.1247/csf.18.363; NISHIJIMA M, 1978, BIOCHIM BIOPHYS ACTA, V528, P107; NISHIJIMA M, 1974, J BIOL CHEM, V249, P5658; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Rich JO, 2001, BIOTECHNOL BIOENG, V72, P374, DOI 10.1002/1097-0290(20010205)72:3<374::AID-BIT16>3.0.CO;2-E; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAHASHI Y, 1993, CELL STRUCT FUNCT, V18, P135, DOI 10.1247/csf.18.135; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Tokumura A, 2004, J CELL BIOCHEM, V92, P869, DOI 10.1002/jcb.20147; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xu J, 2000, J BIOL CHEM, V275, P27520; YANG SF, 1967, J BIOL CHEM, V242, P477	42	54	57	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26081	26088		10.1074/jbc.M602925200	http://dx.doi.org/10.1074/jbc.M602925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837466	hybrid			2022-12-27	WOS:000240249500023
J	Song, BL; DeBose-Boyd, RA				Song, Bao-Liang; DeBose-Boyd, Russell A.			Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase stimulated by delta- and gamma-tocotrienols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; STEROL-SENSING DOMAIN; PREGNANE-X-RECEPTOR; CLEAVAGE-ACTIVATING PROTEIN; OMEGA-HYDROXYLASE PATHWAY; VITAMIN-E; CHOLESTEROL-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; FEEDBACK-REGULATION; MESSENGER-RNA	Sterol-regulated ubiquitination marks 3-hydroxy-3-methylglutaryl coenzyme A reductase, a rate-determining enzyme in cholesterol synthesis, for endoplasmic reticulum (ER)-associated degradation by 26 S proteasomes. This degradation, which results from sterol-induced binding of reductase to ER membrane proteins called Insigs, contributes to the complex, multivalent feedback regulation of the enzyme. Degradation of HMG-CoA reductase is also stimulated by various forms of vitamin E, a generic term for alpha-, beta-, delta-, and gamma-tocopherols and tocotrienols, which are primarily recognized for their potent antioxidant activity. Here, we show that gamma-tocotrienol stimulates ubiquitination and degradation of reductase and blocks processing of sterol regulatory element-binding proteins (SREBPs), another sterolmediated action of Insigs. The gamma-tocotrienol analog is more selective in enhancing reductase ubiquitination and degradation than blocking SREBP processing. Other forms of vitamin E neither accelerate reductase degradation nor block SREBP processing. In vitro assays indicate that gamma- and gamma-tocotrienol trigger reductase ubiquitination directly and do not require further metabolism for activity. Taken together, these results provide a biochemical mechanism for the hypocholesterolemic effects of vitamin E that have been observed in animals and humans.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Song, BL (corresponding author), Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China.	BLSONG@sibs.ac.cn; Russell.DeBose-Boyd@utsouthwestern.edu		Song, Bao-Liang/0000-0002-6397-5935	NHLBI NIH HHS [HL20948, HL70441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, K01HL070441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; Berkhout TA, 1997, ATHEROSCLEROSIS, V133, P203, DOI 10.1016/S0021-9150(97)00131-7; Birringer M, 2002, J NUTR, V132, P3113, DOI 10.1093/jn/131.10.3113; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; CHIKU S, 1984, J LIPID RES, V25, P40; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Engelking LJ, 2005, J CLIN INVEST, V115, P2489, DOI 10.1172/JCI25614; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gould AL, 1998, CIRCULATION, V97, P946; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Illingworth DR, 2001, ADV PROTEIN CHEM, V56, P77; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; Kliewer SA, 2003, J NUTR, V133, p2444S, DOI 10.1093/jn/133.7.2444S; Landes N, 2003, BIOCHEM PHARMACOL, V65, P269, DOI 10.1016/S0006-2952(02)01520-4; Lee PCW, 2005, J BIOL CHEM, V280, P25242, DOI 10.1074/jbc.M502989200; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Lodge JK, 2001, LIPIDS, V36, P43, DOI 10.1007/s11745-001-0666-z; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nesaretnam K, 1998, LIPIDS, V33, P461, DOI 10.1007/s11745-998-0229-3; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; PARKER RA, 1993, J BIOL CHEM, V268, P11230; Parker RS, 2004, ANN NY ACAD SCI, V1031, P13, DOI 10.1196/annals.1331.002; PEARCE BC, 1994, J MED CHEM, V37, P526, DOI 10.1021/jm00030a012; PEARCE BC, 1992, J MED CHEM, V35, P3595, DOI 10.1021/jm00098a002; PEDERSEN TR, 1994, LANCET, V344, P1383; QURESHI AA, 1991, AM J CLIN NUTR, V53, pS1021, DOI 10.1093/ajcn/53.4.1021S; QURESHI AA, 1995, LIPIDS, V30, P1171, DOI 10.1007/BF02536620; QURESHI AA, 1986, J BIOL CHEM, V261, P544; Qureshi AA, 1996, J NUTR, V126, P389, DOI 10.1093/jn/126.2.389; QURESHI AA, 1991, AM J CLIN NUTR, V53, pS1042, DOI 10.1093/ajcn/53.4.1042S; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SCHULTZ M, 1995, AM J CLIN NUTR, V62, P1527, DOI 10.1093/ajcn/62.6.1527S; Sen CK, 2006, LIFE SCI, V78, P2088, DOI 10.1016/j.lfs.2005.12.001; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; SINGER II, 1984, P NATL ACAD SCI-BIOL, V81, P5556, DOI 10.1073/pnas.81.17.5556; Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001; Song BL, 2004, J BIOL CHEM, V279, P28798, DOI 10.1074/jbc.M402442200; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Sontag TJ, 2002, J BIOL CHEM, V277, P25290, DOI 10.1074/jbc.M201466200; SUZUKI Y, 1993, BIOCHEMISTRY-US, V32, P10692, DOI 10.1021/bi00091a020; Theriault A, 1999, CLIN BIOCHEM, V32, P309, DOI 10.1016/S0009-9120(99)00027-2; Wechter WJ, 1996, P NATL ACAD SCI USA, V93, P6002, DOI 10.1073/pnas.93.12.6002; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ylitalo R, 2000, GEN PHARMACOL-VASC S, V35, P287, DOI 10.1016/S0306-3623(01)00121-5; Zhou CC, 2004, DRUG METAB DISPOS, V32, P1075, DOI 10.1124/dmd.104.000299	66	133	137	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25054	25061		10.1074/jbc.M605575200	http://dx.doi.org/10.1074/jbc.M605575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16831864	hybrid			2022-12-27	WOS:000240031300007
J	Frank, DJ; Martin, SR; Gruender, BNT; Lee, YSR; Simonette, RA; Bayley, PM; Miller, KG; Beckingham, KM				Frank, Deborah J.; Martin, Stephen R.; Gruender, Bridget N. T.; Lee, Yung-Sheng R.; Simonette, Rebecca A.; Bayley, Peter M.; Miller, Kathryn G.; Beckingham, Kathleen M.			Androcam is a tissue-specific light chain for myosin VI in the Drosophila testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-RELATED PROTEIN; UNCONVENTIONAL MYOSIN; MOTOR FUNCTION; CA2+ BINDING; HAIR-CELLS; SPERMATOGENESIS; SEQUENCE; SITES; TRANSLOCATION; LOCALIZATION	Myosin VI, a ubiquitously expressed unconventional myosin, has roles in a broad array of biological processes. Unusual for this motor family, myosin VI moves toward the minus (pointed) end of actin filaments. Myosin VI has two light chain binding sites that can both bind calmodulin (CaM). However unconventional myosins could use tissue-specific light chains to modify their activity. In the Drosophila testis, myosin VI is important for maintenance of moving actin structures, called actin cones, which mediate spermatid individualization. ACaM-related protein, Androcam (Acam), is abundantly expressed in the testis and like myosin VI, accumulates on these cones. We have investigated the possibility that Acam is a testis-specific light chain of Drosophila myosin VI. We find that Acam and myosin VI precisely colocalize at the leading edge of the actin cones and that myosin VI is necessary for this Acam localization. Further, myosin VI and Acam co-immunoprecipitate from the testis and interact in yeast two-hybrid assays. Finally Acam binds with high affinity to peptide versions of both myosin VI light chain binding sites. In contrast, although Drosophila CaM also shows high affinity interactions with these peptides, we cannot detect a CaM/myosin VI interaction in the testis. We conclude that Acam and not CaM acts as a myosin VI light chain in the Drosophila testis and hypothesize that it may alter the regulation of myosin VI in this tissue.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA; Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	Rice University; Washington University (WUSTL); MRC National Institute for Medical Research	Beckingham, KM (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS-140,POB 1892, Houston, TX 77251 USA.	kate@bioc.rice.edu			Medical Research Council [MC_U117570592] Funding Source: Medline; NICHD NIH HHS [HD39766] Funding Source: Medline; NIGMS NIH HHS [GM 60494] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060494] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Andruss BF, 2004, GENESIS, V38, P93, DOI 10.1002/gene.20002; ANDRUSS BF, 1997, THESIS RICE U; Aschenbrenner L, 2003, MOL BIOL CELL, V14, P2728, DOI 10.1091/mbc.E02-11-0767; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Bahloul A, 2004, P NATL ACAD SCI USA, V101, P4787, DOI 10.1073/pnas.0306892101; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; DOYLE KE, 1990, J MOL BIOL, V213, P599, DOI 10.1016/S0022-2836(05)80245-1; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frank DJ, 2004, CURR OPIN CELL BIOL, V16, P189, DOI 10.1016/j.ceb.2004.02.001; FYRBERG C, 1994, BIOCHEM GENET, V32, P119, DOI 10.1007/BF00554420; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; Hicks JL, 1999, MOL BIOL CELL, V10, P4341, DOI 10.1091/mbc.10.12.4341; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Kelleher JF, 2000, CURR BIOL, V10, P1489, DOI 10.1016/S0960-9822(00)00828-9; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Lu AQ, 2000, MECH DEVELOP, V94, P171, DOI 10.1016/S0925-4773(00)00262-8; Martin SR, 2002, PROTEIN SCI, V11, P2909, DOI 10.1110/ps.0210402; Martin SR, 2000, PROTEIN SCI, V9, P2477, DOI 10.1110/ps.9.12.2477; Martin SR, 1999, PROTEIN SCI, V8, P2444; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; Menetrey J, 2005, NATURE, V435, P779, DOI 10.1038/nature03592; MILLER KG, 1989, J CELL BIOL, V109, P2963, DOI 10.1083/jcb.109.6.2963; Morris CA, 2003, J BIOL CHEM, V278, P23324, DOI 10.1074/jbc.M208957200; Petritsch C, 2003, DEV CELL, V4, P273, DOI 10.1016/S1534-5807(03)00020-0; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rogat AD, 2002, J CELL SCI, V115, P4855, DOI 10.1242/jcs.00149; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481	39	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24728	24736		10.1074/jbc.M602094200	http://dx.doi.org/10.1074/jbc.M602094200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790438	hybrid			2022-12-27	WOS:000239847800069
J	Nikolaev, VO; Hoffmann, C; Bunemann, M; Lohse, MJ; Vilardaga, JP				Nikolaev, Viacheslav O.; Hoffmann, Carsten; Buenemann, Moritz; Lohse, Martin J.; Vilardaga, Jean-Pierre			Molecular basis of partial agonism at the neurotransmitter alpha(2A)-adrenergic receptor and G(i)-protein heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIVING CELLS; CONFORMATIONS; ACTIVATION; MODEL	To characterize the mechanism by which heterotrimeric G-proteins interpret the signals coming from various neurotransmitters of diverse efficacies (agonists and partial agonists) acting on alpha(2A)-adrenergic receptors, we used a fluorescent resonance energy transfer-based approach to study the effects of these partial agonists on the activation process of both the alpha(2A)-adrenergic receptor and its cognate G(i)-protein. We show that ligands of different efficacies switch the receptor into distinct conformational states, which in turn set the speed and extent of the G(i)-protein signaling. Thus, in cells the efficacy by which a receptor responds to diverse ligands is caused by the ability of the G-protein to differentiate between distinct receptor conformations. The data provide a new key characteristic underlying the mechanism of partial agonism at G-protein-coupled receceptors.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Nephrol, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	University of Wurzburg; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Vilardaga, JP (corresponding author), Simches Res Ctr, Program Membrane Biol, 185 Cambridge St,CPZN-8218, Boston, MA 02114 USA.	jvilardaga@partners.org	Lohse, Martin J/A-7160-2012; Nikolaev, Vyacheslav/AAT-7746-2020	Lohse, Martin J/0000-0002-0599-3510; Vilardaga, Jean-Pierre/0000-0002-1217-1435				Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; Watson C, 2000, MOL PHARMACOL, V58, P1230, DOI 10.1124/mol.58.6.1230; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005	16	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24506	24511		10.1074/jbc.M603266200	http://dx.doi.org/10.1074/jbc.M603266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787921	hybrid			2022-12-27	WOS:000239847800046
J	Sakamoto, K; Ito, Y; Mori, T; Sugimura, K				Sakamoto, Kotaro; Ito, Yuji; Mori, Toshiyuki; Sugimura, Kazuhisa			Interaction of human lactoferrin with cell adhesion molecules through RGD motif elucidated by lactoferrin-binding epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; PROTEIN; LIPOPOLYSACCHARIDE; ANGIOGENESIS; ACTIVATION; COMPLEX; CLONING; ARG(4); FAMILY	Lactoferrin (LF) is an iron-binding secretory protein, which is distributed in the secondary granules of polynuclear lymphocytes as well as in the milk produced by female mammals. Although it has multiple functions, for example antimicrobial, immunomodulatory, antiviral, and anti-tumor metastasis activities, the receptors responsible for these activities are not fully understood. In this study, the binding epitopes for human LF were first isolated from a hexameric random peptide library displayed on T7 phage. Interestingly, two of the four isolated peptides had a representative cell adhesion motif, Arg-Gly-Asp (RGD), implying that human LF interacts with proteins with the RGD motif. We found that human LF bound to the RGD-containing human extracellular matrix proteins, fibronectin and vitronectin. Furthermore, human LF inhibited cell adhesion to these matrix proteins in a concentration-dependent manner but not to the RGD-independent cell adhesion molecule like laminin or collagen. These results indicate that a function of human LF is to block the various interactions between the cell surface and adhesion molecules. This may explain the multifunctionality of LF.	Kagoshima Univ, Fac Engn, Kagoshima 8900065, Japan; NCI, Mol Targets Dev Program, Canc Res Ctr, NIH, Frederick, MD 21702 USA	Kagoshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ito, Y (corresponding author), Kagoshima Univ, Fac Engn, Kagoshima 8900065, Japan.	yito@be.kagoshima-u.ac.jp			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Caccavo D, 2002, J ENDOTOXIN RES, V8, P403, DOI 10.1179/096805102125001000; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Elass-Rochard E, 1998, INFECT IMMUN, V66, P486, DOI 10.1128/IAI.66.2.486-491.1998; Haversen L, 2002, CELL IMMUNOL, V220, P83, DOI 10.1016/S0008-8749(03)00006-6; Iigo M, 2004, CYTOKINE, V25, P36, DOI 10.1016/j.cyto.2003.09.009; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kawabata H, 2004, BRIT J HAEMATOL, V127, P464, DOI 10.1111/j.1365-2141.2004.05224.x; Legrand D, 1997, BIOCHEM J, V327, P841, DOI 10.1042/bj3270841; Legrand D, 2004, EUR J BIOCHEM, V271, P303, DOI 10.1046/j.1432-1033.2003.03929.x; Li RH, 2003, PROTEIN ENG, V16, P65, DOI 10.1093/proeng/gzg002; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; Na YJ, 2004, INT IMMUNOPHARMACOL, V4, P1187, DOI 10.1016/j.intimp.2004.05.009; Norrby K, 2001, INT J CANCER, V91, P236, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1024&gt;3.3.CO;2-K; Salcedo R, 1997, EXP CELL RES, V233, P25, DOI 10.1006/excr.1997.3544; Shimamura M, 2004, INT J CANCER, V111, P111, DOI 10.1002/ijc.20187; Suzuki YA, 2001, BIOCHEMISTRY-US, V40, P15771, DOI 10.1021/bi0155899; van der Strate BWA, 2001, ANTIVIR RES, V52, P225, DOI 10.1016/S0166-3542(01)00195-4; van Well RM, 2003, BIOORG MED CHEM LETT, V13, P331, DOI 10.1016/S0960-894X(02)01022-3; vanBerkel PHC, 1997, BIOCHEM J, V328, P145, DOI 10.1042/bj3280145; Varadhachary A, 2004, INT J CANCER, V111, P398, DOI 10.1002/ijc.20271; Weng TY, 2005, ANTIVIR RES, V67, P31, DOI 10.1016/j.antiviral.2005.03.005; Yi MY, 1997, J VIROL, V71, P5997, DOI 10.1128/JVI.71.8.5997-6002.1997; Zhao TM, 2001, J CELL BIOL, V152, P65, DOI 10.1083/jcb.152.1.65	24	37	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24472	24478		10.1074/jbc.M604974200	http://dx.doi.org/10.1074/jbc.M604974200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787913	hybrid			2022-12-27	WOS:000239847800042
J	Tessier, M; Woodgett, JR				Tessier, Maude; Woodgett, James R.			Role of the Phox homology domain and phosphorylation in activation of serum and glucocorticoid-regulated kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SGK; 3-KINASE; SERUM; PDK1; FAMILY; IDENTIFICATION; STAUROSPORINE; LOCALIZATION	Serum and glucocorticoid-regulated kinases (SGKs) form a family of serine/threonine protein kinases that exhibit structural and sequence similarity to the protein kinase B (PKB)/Akt family. The major difference between these two families is the absence of a lipid-binding, pleckstrin homology domain in the SGKs. Despite the absence of the pleckstrin homology domain, activation of the three human isoforms is, like PKB, dependent upon the phosphatidylinositol 3 '-kinase (PI3K) pathway that is induced by growth factors and mitogens. Full-length SGK3 contains a complete Phox homology (PX) domain that targets the protein to endosomes. Both a functional PX domain and PI3K activation are necessary for phosphorylation of SGK3 at two regulatory sites (Thr-320 and Ser-486) and subsequent induction of kinase activity. PDK1 phosphorylates endosome-associated SGK3 at Thr- 320, whereas diversion of SGK3 to the plasma membrane, where PDK1 normally activates PKB, interferes with PDK1 phosphorylation of SGK3. A chimeric protein in which the carboxyl-terminal hydrophobic motif (HM) of SGK3 has been exchanged for the HM of PRK2 is constitutively active. Finally, we demonstrate that SGK3 activation becomes PX domain-independent once the HM is phosphorylated. Taken together, these data indicate that the targeting of SGK3 to endosomes, mediated by its PX domain, is essential for proper SGK3 activation, likely due to co-localization of SGK3 with an endosomal, PI3K-dependent and staurosporine-sensitive HM kinase.	Univ Toronto, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Woodgett, JR (corresponding author), Univ Toronto, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	woodgett@mshri.on.ca	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Clague MJ, 2005, TRAFFIC, V6, P1063, DOI 10.1111/j.1600-0854.2005.00338.x; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; DOWLER S, 2002, SCI STKE, pPL6, DOI DOI 10.1126/STKE.2002.129.PL6; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; Gillooly DJ, 2003, HISTOCHEM CELL BIOL, V120, P445, DOI 10.1007/s00418-003-0591-7; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Xing Y, 2004, J BIOL CHEM, V279, P30662, DOI 10.1074/jbc.M404107200; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6	32	44	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23978	23989		10.1074/jbc.M604333200	http://dx.doi.org/10.1074/jbc.M604333200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790420	hybrid			2022-12-27	WOS:000239702900072
J	Binder, M; Liebisch, G; Langmann, T; Schmitz, G				Binder, Marion; Liebisch, Gerhard; Langmann, Thomas; Schmitz, Gerd			Metabolic profiling of glycerophospholipid synthesis in fibroblasts loaded with free cholesterol and modified low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; HIGH-THROUGHPUT QUANTIFICATION; PHOSPHATIDYLCHOLINE SYNTHESIS; PHOSPHOLIPID BIOSYNTHESIS; MEMBRANE CURVATURE; MAMMALIAN-CELLS; UP-REGULATION; FATTY-ACIDS; MACROPHAGES	Currently, the detailed regulation of major pathways of glycerophospholipid synthesis upon cholesterol loading is largely unknown. Therefore, a detailed lipid metabolic profiling using stable isotope-labeled choline, ethanolamine, and serine was performed by quantitative electrospray ionization tandem mass spectrometry (ESI-MS/MS) in free cholesterol (FC), oxidized (Ox-LDL) and enzymatically modified LDL (E-LDL)-loaded primary human skin fibroblasts. As previously described, an adaptive induction of phosphatidylcholine ( PC) synthesis via CDP-choline was found upon FC loading. In contrast to PC, CDP-ethanolamine-mediated phosphatidylethanolamine ( PE) synthesis was inhibited by FC incubation. Furthermore, FC induced a shift toward polyunsaturated PE and PC species, which was mediated primarily by PE biosynthesis but not PE remodeling, whereas PC species were shifted mainly by fatty acid ( FA) remodeling of existing PC. Modified lipoprotein incubation revealed rather different effects on glycerophospholipid synthesis. E-LDL greatly enhanced PC synthesis, whereas OxLDL did not change PC synthesis. Addition of different free FAs (FFA) with and without FC coincubation, as major components of E-LDL, clearly indicated an incorporation of FFA into newly synthesized PC and PE species as well as FFA as important driving force for PC synthesis. Because FC and FFA are known to affect lipid membrane properties including membrane curvature, these data support that CTP: phosphocholine cytidylyltransferase activity and consequently PC synthesis are regulated by modulation of membrane characteristics at the cellular level. In conclusion, the application of high throughput metabolic profiling of major glycerophospholipid pathways by ES-IMS/MS is a powerful tool to unravel mechanisms underlying the regulation of cellular lipid metabolism.	Univ Regensburg, Inst Clin Chem, D-93042 Regensburg, Germany	University of Regensburg	Schmitz, G (corresponding author), Univ Regensburg, Inst Clin Chem, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	gerd.schmitz@klinik.uni-regensburg.de	Liebisch, Gerhard/G-6130-2010; Langmann, Thomas/HHZ-9814-2022	Liebisch, Gerhard/0000-0003-4886-0811; Langmann, Thomas/0000-0001-6826-529X; Schmitz, Gerd/0000-0002-1325-1007				Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; Baird SK, 2004, FEBS LETT, V578, P169, DOI 10.1016/j.febslet.2004.11.007; Bhakdi S, 2004, THROMB HAEMOSTASIS, V91, P639, DOI 10.1160/TH-03-12-d733; Bhakdi S, 2004, CIRCULATION, V109, P1870, DOI 10.1161/01.CIR.0000124228.08972.26; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blom TS, 2001, BIOCHEMISTRY-US, V40, P14635, DOI 10.1021/bi0156714; Boumann HA, 2006, MOL BIOL CELL, V17, P1006, DOI 10.1091/mbc.E05-04-0344; Boumann HA, 2005, BIOCHEM SOC T, V33, P1146, DOI 10.1042/BST0331146; Brown AJ, 2000, J LIPID RES, V41, P226; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; de Boschero MGI, 2000, EXP GERONTOL, V35, P653, DOI 10.1016/S0531-5565(00)00104-2; Dhaliwal BS, 2000, J LIPID RES, V41, P1658; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Giusto NM, 2000, PROG LIPID RES, V39, P315, DOI 10.1016/S0163-7827(00)00009-6; Huang CH, 1999, BBA-REV BIOMEMBRANES, V1422, P273, DOI 10.1016/S0005-2736(99)00099-1; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Jessup W, 2002, VASC PHARMACOL, V38, P239, DOI 10.1016/S1537-1891(02)00174-X; Johnson CA, 2005, BBA-MOL CELL BIOL L, V1735, P230, DOI 10.1016/j.bbalip.2005.06.002; JONES HE, 1992, LIPIDS, V27, P984, DOI 10.1007/BF02535576; Kapinsky M, 2001, ARTERIOSCL THROM VAS, V21, P1004, DOI 10.1161/01.ATV.21.6.1004; Leppimaki P, 2000, EUR J BIOCHEM, V267, P6385, DOI 10.1046/j.1432-1327.2000.01726.x; Leppimaki P, 1998, BIOCHEM J, V335, P285, DOI 10.1042/bj3350285; Liebisch G, 2006, BBA-MOL CELL BIOL L, V1761, P121, DOI 10.1016/j.bbalip.2005.12.007; Liebisch G, 2002, CLIN CHEM, V48, P2217; Liebisch G, 2004, BBA-MOL CELL BIOL L, V1686, P108, DOI 10.1016/j.bbalip.2004.09.003; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Salvayre R, 2002, BBA-MOL CELL BIOL L, V1585, P213, DOI 10.1016/S1388-1981(02)00343-8; SCHMITZ G, 1990, J LIPID RES, V31, P1741; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; Suriyaphol P, 2002, CIRCULATION, V106, P2581, DOI 10.1161/01.CIR.0000038366.11851.D0; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; WIELAND E, 1993, P NATL ACAD SCI USA, V90, P5929, DOI 10.1073/pnas.90.13.5929; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1; Yu A, 2000, BBA-MOL CELL BIOL L, V1487, P296, DOI 10.1016/S1388-1981(00)00100-1	47	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21869	21877		10.1074/jbc.M603025200	http://dx.doi.org/10.1074/jbc.M603025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16766520	hybrid			2022-12-27	WOS:000239387100033
J	Maklashina, E; Hellwig, P; Rothery, RA; Kotlyar, V; Sher, Y; Weiner, JH; Cecchini, G				Maklashina, Elena; Hellwig, Petra; Rothery, Richard A.; Kotlyar, Violetta; Sher, Yelizaveta; Weiner, Joel H.; Cecchini, Gary			Differences in protonation of ubiquinone and menaquinone in fumarate reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; SITE-DIRECTED MUTAGENESIS; FTIR SPECTROSCOPIC CHARACTERIZATION; ELECTRON-PARAMAGNETIC-RESONANCE; PHOTOSYNTHETIC REACTION CENTERS; QUINONE BINDING-SITES; SUCCINATE-DEHYDROGENASE; RHODOPSEUDOMONAS-VIRIDIS; PARACOCCUS-DENITRIFICANS; WOLINELLA-SUCCINOGENES	Escherichia coli quinol-fumarate reductase operates with both natural quinones, ubiquinone (UQ) and menaquinone (MQ), at a single quinone binding site. We have utilized a combination of mutagenesis, kinetic, EPR, and Fourier transform infrared methods to study the role of two residues, Lys-B228 and Glu-C29, at the quinol-fumarate reductase quinone binding site in reactions with MQ and UQ. The data demonstrate that LysB228 provides a strong hydrogen bond to MQ and is essential for reactions with both quinone types. Substitution of Glu-C29 with Leu and Phe caused a dramatic decrease in enzymatic reactions with MQ in agreement with previous studies, however, the succinate-UQ reductase reaction remains unaffected. Elimination of a negative charge in Glu-C29 mutant enzymes resulted in significantly increased stabilization of both UQ. and MQ(-.) semiquinones. The data presented here suggest similar hydrogen bonding of the C1 carbonyl of both MQ and UQ, whereas there is different hydrogen bonding for their C4 carbonyls. The differences are shown by a single point mutation of Glu-C29, which transforms the enzyme from one that is predominantly a menaquinol-fumarate reductase to one that is essentially only functional as a succinate-ubiquinone reductase. These findings represent an example of how enzymes that are designed to accommodate either UQ or MQ at a single Q binding site may nevertheless develop sufficient plasticity at the binding pocket to react differently with MQ and UQ.	Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Goethe Univ Frankfurt, Inst Biophys, D-60438 Frankfurt, Germany; Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Goethe University Frankfurt; University of Alberta	Cecchini, G (corresponding author), Vet Affairs Med Ctr, Div Mol Biol, 4150 Clement St,151-S, San Francisco, CA 94121 USA.	Gary.Cecchini@ucsf.edu		Rothery, Richard/0000-0003-3265-1783; hellwig, petra/0000-0001-6294-5163	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061606] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61606] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Baymann F, 1999, BIOCHEMISTRY-US, V38, P13188, DOI 10.1021/bi990565b; Berry EA, 2003, FEBS LETT, V555, P13, DOI 10.1016/S0014-5793(03)01099-8; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; BRETON J, 1994, BIOCHEMISTRY-US, V33, P4953, DOI 10.1021/bi00182a026; BRETON J, 1994, BIOCHEMISTRY-US, V33, P14378, DOI 10.1021/bi00252a002; Brondijk THC, 2002, MOL MICROBIOL, V44, P245, DOI 10.1046/j.1365-2958.2002.02875.x; BUCHANAN S, 1992, BIOCHEMISTRY-US, V31, P1314, DOI 10.1021/bi00120a006; CAMMACK R, 1986, BIOCHIM BIOPHYS ACTA, V870, P545, DOI 10.1016/0167-4838(86)90264-5; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; CONDON C, 1988, MOL MICROBIOL, V2, P43, DOI 10.1111/j.1365-2958.1988.tb00005.x; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; Grimaldi S, 2003, BIOCHEMISTRY-US, V42, P5632, DOI 10.1021/bi034010z; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; Haas AH, 2005, BIOCHEMISTRY-US, V44, P13949, DOI 10.1021/bi051011d; Hagerhall C, 1999, J BIOL CHEM, V274, P26157, DOI 10.1074/jbc.274.37.26157; Hastings SF, 2000, EUR J BIOCHEM, V267, P5638, DOI 10.1046/j.1432-1327.2000.01643.x; Hastings SF, 1998, EUR J BIOCHEM, V255, P317, DOI 10.1046/j.1432-1327.1998.2550317.x; Hellwig P, 1999, BIOCHEMISTRY-US, V38, P14683, DOI 10.1021/bi991267h; Hellwig P, 2003, BIOCHEMISTRY-US, V42, P6179, DOI 10.1021/bi0205348; Hellwig P, 1998, BIOCHEMISTRY-US, V37, P7390, DOI 10.1021/bi9725576; Hellwig P, 2002, BIOCHEMISTRY-US, V41, P10675, DOI 10.1021/bi012146w; Hellwig P, 2000, BIOCHEMISTRY-US, V39, P10884, DOI 10.1021/bi000842a; Horsefield R, 2006, J BIOL CHEM, V281, P7309, DOI 10.1074/jbc.M508173200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lancaster CRD, 2002, BBA-BIOENERGETICS, V1553, P84, DOI 10.1016/S0005-2728(01)00230-4; Maklashina E, 2006, J BIOL CHEM, V281, P11357, DOI 10.1074/jbc.M512544200; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P329, DOI 10.1016/0005-2728(88)90092-8; MCPHERSON PH, 1988, BIOCHIM BIOPHYS ACTA, V934, P348, DOI 10.1016/0005-2728(88)90093-X; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MOSS D, 1990, EUR J BIOCHEM, V187, P565, DOI 10.1111/j.1432-1033.1990.tb15338.x; Mulkidjanian AY, 2005, BBA-BIOENERGETICS, V1709, P5, DOI 10.1016/j.bbabio.2005.03.009; Nabedryk E, 2005, BIOCHEMISTRY-US, V44, P14519, DOI 10.1021/bi051328d; Nabedryk E, 2004, BIOCHEMISTRY-US, V43, P7236, DOI 10.1021/bi049342y; Ohnishi T, 2005, FEBS LETT, V579, P500, DOI 10.1016/j.febslet.2004.11.107; PINCHAS S, 1977, INFRARED SPECTRA LAB; Ritter M, 2003, BIOCHEMISTRY-US, V42, P12391, DOI 10.1021/bi035103j; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; Rothery RA, 2005, FEBS J, V272, P313, DOI 10.1111/j.1742-4658.2004.04469.x; SALERNO JC, 1980, BIOCHEM J, V192, P769, DOI 10.1042/bj1920769; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; Waldeck AR, 1997, J BIOL CHEM, V272, P19373, DOI 10.1074/jbc.272.31.19373; WERTH MT, 1990, P NATL ACAD SCI USA, V87, P8965, DOI 10.1073/pnas.87.22.8965; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; Wolpert M, 2006, SPECTROCHIM ACTA A, V64, P987, DOI 10.1016/j.saa.2005.08.025; Wraight CA, 2005, RSC BIOMOLEC SCI, P273; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; Zhang J, 2002, BIOCHEMISTRY-US, V41, P4612, DOI 10.1021/bi011784b	64	32	32	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26655	26664		10.1074/jbc.M602938200	http://dx.doi.org/10.1074/jbc.M602938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829675	hybrid			2022-12-27	WOS:000240249500083
J	Thomson, JM; Distler, AM; Prati, F; Bonomo, RA				Thomson, Jodi M.; Distler, Anne M.; Prati, Fabio; Bonomo, Robert A.			Probing active site chemistry in SHV beta-lactamase variants at ambler position 244 - Understanding unique properties of inhibitor resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CLAVULANIC ACID; CLINICAL ISOLATE; TAZOBACTAM; MECHANISM; ARGININE-244; INACTIVATION; CEFTAZIDIME; RECOGNITION; RESOLUTION	Inhibitor-resistant class A beta-lactamases are an emerging threat to the use of beta-lactam/beta-lactamase inhibitor combinations (e.g. amoxicillin/clavulanate) in the treatment of serious bacterial infections. In the TEM family of Class A beta-lactamases, single amino acid substitutions at Arg-244 confer resistance to clavulanate inactivation. To understand the amino acid sequence requirements in class A beta-lactamases that confer resistance to clavulanate, we performed site-saturation mutagenesis of Arg-244 in SHV-1, a related class A beta-lactamase found in Klebsiella pneumoniae. Twelve SHV enzymes with amino acid substitutions at Arg-244 resulted in significant increases in minimal inhibitory concentrations to ampicillin/clavulanate when expressed in Escherichia coli. Kinetic analyses of SHV-1, R244S, R244Q, R244L, and R244E beta-lactamases revealed that the main determinant of clavulanate resistance was reduced inhibitor affinity. In contrast to studies in the highly similar TEM enzyme, we observed increases in clavulanate k(inact) for all mutants. Electrospray ionization mass spectrometry of clavulanate inhibited SHV-1 and R244S showed nearly identical mass adducts, arguing against a difference in the inactivation mechanism. Testing a wide range of substrates with C3-4 carboxylates in different stereochemical orientations, we observed impaired affinity for all substrates among inhibitor resistant variants. Lastly, we synthesized two boronic acid transition state analogs that mimic cephalothin and found substitutions at Arg-244 markedly affect both the affinity and kinetics of binding to the chiral, deacylation transition state inhibitor. These data define a role for Arg-244 in substrate and inhibitor binding in the SHV beta-lactamase.	Louis Stokes Cleveland Vet Affairs Med Ctr, Div Res Serv, Cleveland, OH 44106 USA; Univ Modena, Dept Chem, I-41100 Modena, Italy; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Universita di Modena e Reggio Emilia; Case Western Reserve University	Bonomo, RA (corresponding author), Louis Stokes Cleveland Vet Affairs Med Ctr, Div Res Serv, 10701 E Blvd, Cleveland, OH 44106 USA.	robert.bonomo@med.va.gov	Prati, Fabio/B-7532-2015	Prati, Fabio/0000-0002-0650-9540	NIGMS NIH HHS [T32 GM07250] Funding Source: Medline; PHS HHS [1R01 A1063517-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BLAZQUEZ J, 1993, ANTIMICROB AGENTS CH, V37, P2059, DOI 10.1128/AAC.37.10.2059; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; Buynak JD, 2004, CURR MED CHEM, V11, P1951, DOI 10.2174/0929867043364847; Caselli E, 2001, CHEM BIOL, V8, P17, DOI 10.1016/S1074-5521(00)00052-1; Chen Y, 2006, J AM CHEM SOC, V128, P2970, DOI 10.1021/ja056806m; Chen Y, 2005, J AM CHEM SOC, V127, P5423, DOI 10.1021/ja042850a; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DELAIRE M, 1992, J BIOL CHEM, V267, P20600; Hall DG, 2005, BORONIC ACIDS: PREPARATION AND APPLICATIONS IN ORGANIC SYNTHESIS AND MEDICINE, P1, DOI 10.1002/3527606548.ch1; Helfand MS, 2003, BIOCHEMISTRY-US, V42, P13386, DOI 10.1021/bi035716w; Hujer AM, 2002, ANTIMICROB AGENTS CH, V46, P3971, DOI 10.1128/AAC.46.12.3971-3977.2002; IMTIAZ U, 1994, ANTIMICROB AGENTS CH, V38, P1134, DOI 10.1128/AAC.38.5.1134; IMTIAZ U, 1993, J AM CHEM SOC, V115, P4435, DOI 10.1021/ja00064a003; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Lin S, 1998, BIOCHEM J, V333, P395, DOI 10.1042/bj3330395; Morandi F, 2003, J AM CHEM SOC, V125, P685, DOI 10.1021/ja0288338; Pagan-Rodriguez D, 2004, J BIOL CHEM, V279, P19494, DOI 10.1074/jbc.M311669200; Powers RA, 2001, BIOCHEMISTRY-US, V40, P9207, DOI 10.1021/bi0109358; Rice LB, 2000, ANTIMICROB AGENTS CH, V44, P362, DOI 10.1128/AAC.44.2.362-367.2000; Sulton D, 2005, J BIOL CHEM, V280, P35528, DOI 10.1074/jbc.M501251200; Sun T, 2004, BIOCHEMISTRY-US, V43, P14111, DOI 10.1021/bi0487903; Thomson JM, 2005, CURR OPIN MICROBIOL, V8, P518, DOI 10.1016/j.mib.2005.08.014; Wang XJ, 2003, BIOCHEMISTRY-US, V42, P8434, DOI 10.1021/bi034242y; Weiss WJ, 2004, ANTIMICROB AGENTS CH, V48, P4589, DOI 10.1128/AAC.48.12.4589-4596.2004; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016; ZHOU XY, 1994, ANTIMICROB AGENTS CH, V38, P1085, DOI 10.1128/AAC.38.5.1085	29	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26734	26744		10.1074/jbc.M603222200	http://dx.doi.org/10.1074/jbc.M603222200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16803899	hybrid			2022-12-27	WOS:000240249500091
J	Chaudhry, Y; Nayak, A; Bordeleau, ME; Tanaka, J; Pelletier, J; Belsham, GJ; Roberts, LO; Goodfellow, IG				Chaudhry, Yasmin; Nayak, Arabinda; Bordeleau, Marie-Eve; Tanaka, Junichi; Pelletier, Jerry; Belsham, Graham J.; Roberts, Lisa O.; Goodfellow, Ian G.			Caliciviruses differ in their functional requirements for eIF4F components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TRANSLATION INITIATION; PORCINE ENTERIC CALICIVIRUS; RIBOSOME ENTRY SITES; CAP-BINDING PROTEIN; HEPATITIS-C VIRUS; FELINE CALICIVIRUS; MAMMALIAN TRANSLATION; MOSAIC-VIRUS; IN-VITRO; RNA	Two classes of viruses, namely members of the Potyviridae and Caliciviridae, use a novel mechanism for the initiation of protein synthesis that involves the interaction of translation initiation factors with a viral protein covalently linked to the viral RNA, known as VPg. The calicivirus VPg proteins can interact directly with the initiation factors eIF4E and eIF3. Translation initiation on feline calicivirus (FCV) RNA requires eIF4E because it is inhibited by recombinant 4E-BP1. However, to date, there have been no functional studies carried out with respect to norovirus translation initiation, because of a lack of a suitable source of VPg-linked viral RNA. We have now used the recently identified murine norovirus (MNV) as a model system for norovirus translation and have extended our previous studies with FCV RNA to examine the role of the other eIF4F components in translation initiation. We now demonstrate that, as with FCV, MNV VPg interacts directly with eIF4E, although, unlike FCV RNA, translation of MNV RNA is not sensitive to 4E-BP1, eIF4E depletion, or foot-and-mouth disease virus Lb protease-mediated cleavage of eIF4G. We also demonstrate that both FCV and MNV RNA translation require the RNA helicase component of the eIF4F complex, namely eIF4A, because translation was sensitive (albeit to different degrees) to a dominant negative form and to a small molecule inhibitor of eIF4A (hippuristanol). These results suggest that calicivirus RNAs differ with respect to their requirements for the components of the eIF4F translation initiation complex.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; Biotechnol & Biol Sci Res Council, Inst Anim Hlth, Woking GU24 0NF, Surrey, England; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Ryukyus, Dept Chem Biol & Marine Sci, Nishihara, Okinawa 9030213, Japan; Univ Surrey, Sch Biomed & Mol Sci, Guildford GU2 7XH, Surrey, England	Imperial College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; McGill University; University of the Ryukyus; University of Surrey	Goodfellow, IG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	I.Goodfellow@imperial.ac.uk	Roberts, Lisa/E-6365-2010; Belsham, Graham/J-3132-2019; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Belsham, Graham J./0000-0003-1187-4873; Goodfellow, Ian/0000-0002-9483-510X; Tanaka, Junichi/0000-0002-8672-7379	BBSRC [BB/D007755/1, BB/D007607/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D007607/1, BB/D007755/1] Funding Source: Medline; Wellcome Trust [069526] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Asanaka M, 2005, P NATL ACAD SCI USA, V102, P10327, DOI 10.1073/pnas.0408529102; Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; Bordeleau ME, 2006, NAT CHEM BIOL, V2, P213, DOI 10.1038/nchembio776; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; Chang KO, 2005, J VIROL, V79, P1409, DOI 10.1128/JVI.79.3.1409-1416.2005; Chang KO, 2004, P NATL ACAD SCI USA, V101, P8733, DOI 10.1073/pnas.0401126101; Chang KO, 2002, VIROLOGY, V304, P302, DOI 10.1006/viro.2002.1665; Chard LS, 2006, J VIROL, V80, P1271, DOI 10.1128/JVI.80.3.1271-1279.2006; Daughenbaugh KF, 2003, EMBO J, V22, P2852, DOI 10.1093/emboj/cdg251; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; GEHRKE L, 1983, BIOCHEMISTRY-US, V22, P5157, DOI 10.1021/bi00291a015; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Goodfellow I, 2005, EMBO REP, V6, P968, DOI 10.1038/sj.embor.7400510; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Herbert TP, 1997, J GEN VIROL, V78, P1033, DOI 10.1099/0022-1317-78-5-1033; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Karst SM, 2003, SCIENCE, V299, P1575, DOI 10.1126/science.1077905; Korneeva NL, 2005, J BIOL CHEM, V280, P1872, DOI 10.1074/jbc.M406168200; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; Leonard S, 2000, J VIROL, V74, P7730, DOI 10.1128/JVI.74.17.7730-7737.2000; Leonard S, 2004, J GEN VIROL, V85, P1055, DOI 10.1099/vir.0.19706-0; Leonard S, 2002, J GEN VIROL, V83, P2085, DOI 10.1099/0022-1317-83-8-2085; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; Lopmam BA, 2003, EMERG INFECT DIS, V9, P90; Low WK, 2005, MOL CELL, V20, P709, DOI 10.1016/j.molcel.2005.10.008; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Pisarev AV, 2004, J VIROL, V78, P4487, DOI 10.1128/JVI.78.9.4487-4497.2004; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; RAY BK, 1985, J BIOL CHEM, V260, P7651; Richter-Cook NJ, 1998, J BIOL CHEM, V273, P7579, DOI 10.1074/jbc.273.13.7579; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; SOSNOVTSEV S, 1995, VIROLOGY, V210, P383, DOI 10.1006/viro.1995.1354; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; Svitkin YV, 2001, RNA, V7, P1743; Willcocks MM, 2004, J GEN VIROL, V85, P1125, DOI 10.1099/vir.0.19564-0; Wittmann S, 1997, VIROLOGY, V234, P84, DOI 10.1006/viro.1997.8634; Wobus CE, 2004, PLOS BIOL, V2, P2076, DOI 10.1371/journal.pbio.0020432	45	99	102	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25315	25325		10.1074/jbc.M602230200	http://dx.doi.org/10.1074/jbc.M602230200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16835235	hybrid, Green Submitted			2022-12-27	WOS:000240031300033
J	Polychronopoulos, S; Verykokakis, M; Yazicioglu, MN; Sakarellos-Daitsiotis, M; Cobb, MH; Mavrothalassitis, G				Polychronopoulos, Sarantis; Verykokakis, Mihalis; Yazicioglu, Mustafa N.; Sakarellos-Daitsiotis, Maria; Cobb, Melanie H.; Mavrothalassitis, George			The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE ERK2; DOCKING SITES; CELL-CYCLE; PROTEIN-KINASES; SIGNAL; PHOSPHORYLATION; SPECIFICITY; BINDING; IDENTIFICATION; ACTIVATION	The transcriptional ETS2 repressor factor (ERF) is phosphorylated by Erks both in vivo and in vitro. This phosphorylation determines the subcellular localization and biological function of ERF. Here, we show that active and inactive Erk2 proteins bind ERF with high affinity through a hydrophobic pocket formed by the alpha F and alpha G helices and the activation loop of Erk2. We have identified two FXF motifs on ERF that mediate the specific interaction with Erks. One of these motifs is utilized only by active Erks, whereas the other mediates the association with inactive Erks but also contributes to interaction with active Erks. Mutation of the phenylalanines of these motifs to alanines resulted in decreased association and phosphorylation of ERF by Erks both in cells and in vitro. ERF proteins carrying these mutations exhibited increased nuclear accumulation and increased inhibition of cellular proliferation. Expression of ERF regions harboring these motifs could inhibit Erk activity in cells. Our data suggest that, in the proper context, FXF motifs can mediate a strong and specific interaction not only with active but also inactive Erks and that these interactions determine protein function in vivo.	Univ Crete, Sch Med, Iraklion 71003, Crete, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71003, Crete, Greece; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Ioannina, Dept Chem, Sect Organ Chem & Biochem, GR-45110 Ioannina, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Ioannina	Mavrothalassitis, G (corresponding author), Univ Crete, Sch Med, Iraklion 71003, Crete, Greece.	mavro@imbb.forth.gr		Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dimitri CA, 2005, CURR BIOL, V15, P1319, DOI 10.1016/j.cub.2005.06.037; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1998, GENETICS, V149, P1809; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Le Gallic L, 2004, MOL CELL BIOL, V24, P1206, DOI 10.1128/MCB.24.3.1206-1218.2004; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pawson T, 2000, GENE DEV, V14, P1027; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Robinson MJ, 2002, J BIOL CHEM, V277, P5094, DOI 10.1074/jbc.M110935200; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stewart M, 2000, CELL STRUCT FUNCT, V25, P217, DOI 10.1247/csf.25.217; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Volmat V, 2001, J CELL SCI, V114, P3433; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	48	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25601	25611		10.1074/jbc.M605185200	http://dx.doi.org/10.1074/jbc.M605185200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16799155	hybrid			2022-12-27	WOS:000240031300063
J	Dizin, E; Gressier, C; Magnard, C; Ray, H; Decimo, D; Ohlmann, T; Dalla Venezia, N				Dizin, Eva; Gressier, Celine; Magnard, Clemence; Ray, Hind; Decimo, Didier; Ohlmann, Theophile; Dalla Venezia, Nicole			BRCA1 interacts with poly(A)-binding protein - Implication of BRCA1 in translation regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; NUCLEAR EXPORT SEQUENCE; SPORADIC BREAST-CANCER; ACETYL-COA CARBOXYLASE; MESSENGER-RNA; INITIATION-FACTOR; SUBCELLULAR-LOCALIZATION; DNA-REPAIR; FUNCTIONAL INTERACTION; TUMOR-FORMATION	BRCA1 has been implicated in a number of cellular processes, including transcription regulation, DNA damage repair, cell cycle control, and apoptosis. We identified poly( A)-binding protein 1 ( PABP) as a novel BRCA1-interacting protein in a yeast two-hybrid screen and confirmed the interaction by in vitro assays and coimmunoprecipitation in mammalian cells. Endogenous interaction between BRCA1 and PABP was also observed. This interaction was abolished by BRCA1 cancer-associated mutations, suggesting that it may be physiologically relevant. Deletion mapping demonstrated that the RNA recognition motifs 1-4 region of PABP is required to mediate the interaction with BRCA1. To understand the biological function of the BRCA1-PABP complex, we sought to determine whether BRCA1 is a modulator of translation. We showed here that inhibition of endogenous BRCA1 using a small interfering RNA-based approach decreased protein synthesis. Conversely, overexpression of BRCA1 activated translation. Using a RNA transfection approach, we clearly showed that BRCA1 modulates translation, independently of any transcriptional activity. The data presented here suggest that BRCA1 modulates protein synthesis via its interaction with PABP, providing a novel mechanism by which BRCA1 may exert its tumor suppressor function.	Univ Lyon 1, Fac Med Rockefeller, CNRS, UMR 5201,Lab Genet Mol Signalisat & Canc, F-69373 Lyon 08, France; Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Dalla Venezia, N (corresponding author), Univ Lyon 1, Fac Med Rockefeller, CNRS, UMR 5201,Lab Genet Mol Signalisat & Canc, 8 Ave Rockefeller, F-69373 Lyon 08, France.	dalla@rockefeller.univ-lyon1.fr	ohlmann, Theophile/M-4463-2014; VENEZIA, Nicole DALLA/C-6542-2017; Ohlmann, Theophile/H-6522-2016	ohlmann, Theophile/0000-0002-2001-8916; VENEZIA, Nicole DALLA/0000-0002-4553-3535; Decimo, Didier/0000-0002-0390-1205				Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Collier B, 2005, EMBO J, V24, P2656, DOI 10.1038/sj.emboj.7600738; Copeland PR, 2001, RNA, V7, P875, DOI 10.1017/S1355838201010020; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Feng ZH, 2004, J BIOL CHEM, V279, P28574, DOI 10.1074/jbc.M404137200; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Koloteva-Levine N, 2004, MOL CELL BIOL, V24, P3577, DOI 10.1128/MCB.24.9.3577-3587.2004; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magnard C, 2002, ONCOGENE, V21, P6729, DOI 10.1038/sj.onc.1205915; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moreau K, 2006, J BIOL CHEM, V281, P3172, DOI 10.1074/jbc.M504652200; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Okochi K, 2005, GENES CELLS, V10, P151, DOI 10.1111/j.1365-2443.2005.00826.x; Ralser M, 2005, J MOL BIOL, V346, P203, DOI 10.1016/j.jmb.2004.11.024; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shuda M, 2000, ANTICANCER RES, V20, P2489; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Verlaet M, 2001, BIOCHEM BIOPH RES CO, V283, P12, DOI 10.1006/bbrc.2001.4731; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	62	22	22	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24236	24246		10.1074/jbc.M602176200	http://dx.doi.org/10.1074/jbc.M602176200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16782705	hybrid			2022-12-27	WOS:000239847800017
J	Guo, MX; Wang, D; Shao, HJ; Qiu, HL; Xue, L; Zhao, ZZ; Zhu, CG; Shi, YB; Li, WX				Guo, Ming-Xiong; Wang, Di; Shao, Huan-Jie; Qiu, Hong-Ling; Xue, Lu; Zhao, Zhou-Zhou; Zhu, Chen-Gang; Shi, Yun-Bo; Li, Wen-Xin			Transcription of human zinc finger ZNF268 gene requires an intragenic promoter element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; CANDIDATE GENE; NUCLEAR FACTOR; HUMAN EMBRYO; CYCLIC-AMP; DNA; CREB; LEUKEMIA; IDENTIFICATION; CAMP	Human ZNF268 gene is a typical Kruppel-associated box/C2H2 zinc finger gene whose homolog has been found only in higher mammals and not in lower mammals such as mouse. Its expression profiles have suggested that it plays a role in the differentiation of blood cells during early human embryonic development and the pathogenesis of leukemia. To gain additional insight into the molecular mechanisms controlling the expression of the ZNF268 gene and to provide the necessary tools for further genetic studies of leukemia, we have mapped the 5'-end of the human ZNF268 mRNA by reverse transcription-PCR and primer extension assays. We then cloned the 5'-flanking genomic-DNA-containing the putative ZNF268 gene promoter and analyzed its function in several different human and mouse tissue culture cell lines. Interestingly, our studies show that the ZNF268 gene lacks a typical eukaryotic promoter that is present upstream of the transcription start site and directs a basal level of transcription. Instead, the functional promoter requires an essential element that is located within the first exon of the gene. Deletion and mutational analysis reveals the requirement for a cAMP response-element-binding protein (CREB)-binding site within this element for promoter function. Gel mobility shift and chromatin immunoprecipitation assays confirm that CREB-2 binds to the site in vitro and in vivo. Furthermore, overexpression of CREB-2 enhances the promoter activity. These results demonstrate that the human ZNF268 gene promoter is atypical and requires an intragenic element located within the first exon that mediates the effect of CREB for its activity.	Wuhan Univ, Coll Life Sci, State Key Virol, Wuhan 430072, Peoples R China; NICHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Wuhan University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Li, WX (corresponding author), Wuhan Univ, Coll Life Sci, State Key Virol, Wuhan 430072, Peoples R China.	Liwxlab@whu.edu.cn	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Shi, Yun-Bo/0000-0002-6330-0639				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, P425; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CAREY M, 2000, TRANSCRIPTIONAL REGU, P99; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; Courtes C, 2000, J BIOL CHEM, V275, P949, DOI 10.1074/jbc.275.2.949; Dai KS, 1999, J MOL CELL CARDIOL, V31, P1749, DOI 10.1006/jmcc.1999.1011; Dreyer SD, 1998, MAMM GENOME, V9, P458; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Gou DM, 2001, GENE, V278, P141, DOI 10.1016/S0378-1119(01)00701-6; Gou DM, 2001, BBA-GENE STRUCT EXPR, V1518, P306, DOI 10.1016/S0167-4781(01)00194-4; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hiraiwa N, 2003, BLOOD, V101, P3615, DOI 10.1182/blood-2002-07-2301; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JEFFERS M, 1994, BBA-GENE STRUCT EXPR, V1219, P623, DOI 10.1016/0167-4781(94)90221-6; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; Krackhardt AM, 2002, BLOOD, V100, P2123, DOI 10.1182/blood-2002-02-0513; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Mora-Garcia P, 2003, STEM CELLS, V21, P123, DOI 10.1634/stemcells.21-2-123; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; Peng Xiao, 2004, Acta Genetica Sinica, V31, P221; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Riese U, 2000, MOL CELL BIOCHEM, V212, P45, DOI 10.1023/A:1007196602659; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Rousseau-Merck MF, 2002, CYTOGENET GENOME RES, V98, P147, DOI 10.1159/000069802; Sambrook J., 2001, MOL CLONING LAB MANU, P463; Shankar DB, 2005, CANCER-AM CANCER SOC, V104, P1819, DOI 10.1002/cncr.21401; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sun Y, 2004, INT J MOL MED, V14, P971; Sun Y, 2003, IUBMB LIFE, V55, P127, DOI 10.1080/1521654031000110208; Takase K, 2001, SCHIZOPHR RES, V52, P161, DOI 10.1016/S0920-9964(00)00191-2; TOMMERUP N, 1993, HUM MOL GENET, V2, P1571, DOI 10.1093/hmg/2.10.1571; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZHENG YW, 1994, J BIOL CHEM, V269, P22593; Zhou L, 2002, BIOCHEM BIOPH RES CO, V295, P862, DOI 10.1016/S0006-291X(02)00759-3	54	15	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24623	24636		10.1074/jbc.M602753200	http://dx.doi.org/10.1074/jbc.M602753200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787922	Green Submitted, hybrid			2022-12-27	WOS:000239847800057
J	Masuda, Y; Kamiya, K				Masuda, Yuji; Kamiya, Kenji			Role of single-stranded DNA in targeting REV1 to primer termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCYTIDYL TRANSFERASE-ACTIVITY; POLYMERASE-ZETA; ABASIC SITES; YEAST REV1; SACCHAROMYCES-CEREVISIAE; TRANSLESION SYNTHESIS; CATALYTIC SUBUNIT; Y-FAMILY; IN-VIVO; ESCHERICHIA-COLI	Cellular functions of the REV1 gene have been conserved in evolution and appear important for maintaining genetic integrity through translesion DNA synthesis. This study documents a novel biochemical activity of human REV1 protein, due to higher affinity for single-stranded DNA ( ssDNA) than the primer terminus. Preferential binding to long ssDNA regions of the template strand means that REV1 is targeted specifically to the included primer termini, a property not shared by other DNA polymerases, including human DNA polymerases alpha, beta, and eta. Furthermore, a mutant REV1 lacking N- and C-terminal domains, but catalytically active, lost this function, indicating that control is not due to the catalytic core. The novel activity of REV1 protein might imply a role for ssDNA in the regulation of translesion DNA synthesis.	Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University	Kamiya, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	kkamiya@hiroshima-u.ac.jp	Masuda, Yuji/I-6315-2014	Masuda, Yuji/0000-0002-6229-1988				Acharya N, 2005, MOL CELL BIOL, V25, P9734, DOI 10.1128/MCB.25.21.9734-9740.2005; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Auerbach P, 2005, P NATL ACAD SCI USA, V102, P17711, DOI 10.1073/pnas.0504643102; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Clark DR, 2003, NUCLEIC ACIDS RES, V31, P4981, DOI 10.1093/nar/gkg725; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Guo DY, 2004, NUCLEIC ACIDS RES, V32, P1122, DOI 10.1093/nar/gkh279; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Jansen JG, 2005, NUCLEIC ACIDS RES, V33, P356, DOI 10.1093/nar/gki189; Jansen JG, 2003, DNA REPAIR, V2, P1075, DOI 10.1016/S1568-7864(03)00119-8; LAWRENCE CW, 1985, MOL GEN GENET, V200, P80, DOI 10.1007/BF00383316; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; LEMONTT JF, 1971, GENETICS, V68, P21; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; Masuda Y, 2003, J BIOL CHEM, V278, P12356, DOI 10.1074/jbc.M211765200; Masuda Y, 2002, FEBS LETT, V520, P88, DOI 10.1016/S0014-5793(02)02773-4; Masuda Y, 2002, J BIOL CHEM, V277, P3040, DOI 10.1074/jbc.M110149200; Masuda Y, 2001, J BIOL CHEM, V276, P15051, DOI 10.1074/jbc.M008082200; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Niimi A, 2004, MOL CELL BIOL, V24, P2734, DOI 10.1128/MCB.24.7.2734-2746.2004; Ohashi E, 2004, GENES CELLS, V9, P523, DOI 10.1111/j.1356-9597.2004.00747.x; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Okada T, 2005, MOL CELL BIOL, V25, P6103, DOI 10.1128/MCB.25.14.6103-6111.2005; Otsuka C, 2005, MUTAT RES-FUND MOL M, V578, P79, DOI 10.1016/j.mrfmmm.2005.03.005; Otsuka C, 2002, NUCLEIC ACIDS RES, V30, P5129, DOI 10.1093/nar/gkf666; Otsuka C, 2002, MUTAT RES-FUND MOL M, V502, P53, DOI 10.1016/S0027-5107(02)00023-4; Poltoratsky V, 2005, DNA REPAIR, V4, P1182, DOI 10.1016/j.dnarep.2005.05.002; Ross AL, 2005, NUCLEIC ACIDS RES, V33, P1280, DOI 10.1093/nar/gki279; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Simpson LJ, 2003, EMBO J, V22, P1654, DOI 10.1093/emboj/cdg161; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tissier A, 2004, DNA REPAIR, V3, P1503, DOI 10.1016/j.dnarep.2004.06.015; Van Sloun PPH, 1999, MUTAT RES-DNA REPAIR, V433, P109, DOI 10.1016/S0921-8777(98)00067-6; Waters LS, 2006, P NATL ACAD SCI USA, V103, P8971, DOI 10.1073/pnas.0510167103; YASUDA S, 1983, J BACTERIOL, V154, P1153, DOI 10.1128/JB.154.3.1153-1161.1983; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630; Zhao B, 2004, NUCLEIC ACIDS RES, V32, P3984, DOI 10.1093/nar/gkh710	52	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24314	24321		10.1074/jbc.M602967200	http://dx.doi.org/10.1074/jbc.M602967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803901	hybrid			2022-12-27	WOS:000239847800024
J	Talley, TT; Olivera, BM; Han, KH; Christensen, SB; Dowell, C; Tsigelny, I; Ho, KY; Taylor, P; McIntosh, JM				Talley, Todd T.; Olivera, Baldomero M.; Han, Kyou-Hoon; Christensen, Sean B.; Dowell, Cheryl; Tsigelny, Igor; Ho, Kwok-Yiu; Taylor, Palmer; McIntosh, J. Michael			alpha-Conotoxin OmIA is a potent ligand for the acetylcholine-binding protein as well as alpha 3 beta 2 and alpha 7 nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; REVEALS; ACHBP; COMPLEX; INHIBITION; ANTAGONIST; AGONISTS; PEPTIDE	The molluskan acetylcholine-binding protein ( AChBP) is a homolog of the extracellular binding domain of the pentameric ligand-gated ion channel family. AChBP most closely resembles the alpha-subunit of nicotinic acetylcholine receptors and in particular the homomeric alpha 7 nicotinic receptor. We report the isolation and characterization of an alpha-conotoxin that has the highest known affinity for the Lymnaea AChBP and also potently blocks the alpha 7 nAChR subtype when expressed in Xenopus oocytes. Remarkably, the peptide also has high affinity for the alpha 3 beta 2 nAChR indicating that alpha-conotoxin OmIA in combination with the AChBP may serve as a model system for understanding the binding determinants of alpha 3 beta 2 nAChRs. alpha-Conotoxin OmIA was purified from the venom of Conus omaria. It is a 17-amino-acid, two-disulfide bridge peptide. The ligand is the first alpha-conotoxin with higher affinity for the closely related receptor subtypes, alpha 3 beta 2 versus alpha 6 beta 2, and selectively blocks these two subtypes when compared with alpha 2 beta 2, alpha 4 beta 2, and alpha 1 beta 1 delta epsilon nAChRs.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Calif La Jolla, Dept Pharmacol, La Jolla, CA 92093 USA; Korea Res Inst Biosci & Biotechnol, Mol Anti Canc Res Ctr, Div Mol Therapeut, Taejon, South Korea; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; University of California System; University of California San Diego; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Utah System of Higher Education; University of Utah	McIntosh, JM (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.	mcintosh.mike@gmail.com	Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U01DA019372] Funding Source: NIH RePORTER; NIDA NIH HHS [U01 DA019372, U01-DA019372] Funding Source: Medline; NIGMS NIH HHS [GM48677, R37-GM18360, P01 GM048677, R37 GM018360] Funding Source: Medline; NIMH NIH HHS [R29 MH053631, MH53631, R01 MH053631-11S1, R01 MH053631-11, R01 MH053631] Funding Source: Medline; NINDS NIH HHS [NS 043063, F32 NS043063-01, F32 NS043063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; Changeux J-P, 2005, NICOTINIC ACETYLCHOL; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chi SW, 2006, BIOCHEM BIOPH RES CO, V345, P248, DOI 10.1016/j.bbrc.2006.04.099; CRUZ LJ, 1985, J TOXICOL-TOXIN REV, V4, P107, DOI 10.3109/15569548509014416; Dowell C, 2003, J NEUROSCI, V23, P8445; Dutertre S, 2005, J BIOL CHEM, V280, P30460, DOI 10.1074/jbc.M504229200; Dutertre S, 2004, J MOL RECOGNIT, V17, P339, DOI 10.1002/jmr.683; Ellison M, 2003, J BIOL CHEM, V278, P757, DOI 10.1074/jbc.M204565200; Gao F, 2005, J BIOL CHEM, V280, P8443, DOI 10.1074/jbc.M412389200; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Hibbs RE, 2005, BIOCHEMISTRY-US, V44, P16602, DOI 10.1021/bi051735p; Hibbs RE, 2004, J BIOL CHEM, V279, P28483, DOI 10.1074/jbc.M403713200; Hogg RC, 1999, J BIOL CHEM, V274, P36559, DOI 10.1074/jbc.274.51.36559; Janes RW, 2005, CURR OPIN PHARMACOL, V5, P280, DOI 10.1016/j.coph.2005.01.013; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Kehoe J, 1998, J NEUROSCI, V18, P8198; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; Luo SQ, 1998, J NEUROSCI, V18, P8571; McIntosh JM, 2005, J BIOL CHEM, V280, P30107, DOI 10.1074/jbc.M504102200; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; McIntosh JM, 2002, J BIOL CHEM, V277, P33610, DOI 10.1074/jbc.M205102200; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Quik M, 2005, MOL PHARMACOL, V67, P32, DOI 10.1124/mol.104.006015; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; Shi JX, 2006, J BIOL CHEM, V281, P12170, DOI 10.1074/jbc.M600154200; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Taylor P, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P271; Vulfius CA, 2005, NEUROSCI LETT, V373, P232, DOI 10.1016/j.neulet.2004.10.010; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664	43	49	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24678	24686		10.1074/jbc.M602969200	http://dx.doi.org/10.1074/jbc.M602969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803900	Green Accepted, hybrid			2022-12-27	WOS:000239847800063
J	Allison, SJ; Baldock, P; Sainsbury, A; Enriquez, R; Lee, NJ; Lin, EJD; Klugman, M; During, M; Eisman, JA; Li, M; Pan, LC; Herzog, H; Gardiner, EM				Allison, Susan J.; Baldock, Paul; Sainsbury, Amanda; Enriquez, Ronaldo; Lee, Nicola J.; Lin, En-Ju Deborah; Klugman, Matthias; During, Matthew; Eisman, John A.; Li, Mei; Pan, Lydia C.; Herzog, Herbert; Gardiner, Edith M.			Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; Y2 RECEPTORS; OB/OB MICE; OSTEOPOROSIS; BODY; EXPRESSION; OSTEOBLASTS; OVARIECTOMY; ALENDRONATE	Reduction in levels of sex hormones at menopause in women is associated with two common, major outcomes, the accumulation of white adipose tissue, and the progressive loss of bone because of excess osteoclastic bone resorption exceeding osteoblastic bone formation. Current antiresorptive therapies can reduce osteoclastic activity but have only limited capacity to stimulate osteoblastic bone formation and restore lost skeletal mass. Likewise, the availability of effective pharmacological weight loss treatments is currently limited. Here we demonstrate that conditional deletion of hypothalamic neuropeptide Y2 receptors can prevent ongoing bone loss in sex hormone-deficient adult male and female mice. This benefit is attributable solely to activation of an anabolic osteoblastic bone formation response that counterbalances persistent elevation of bone resorption, suggesting the Y2-mediated anabolic pathway to be independent of sex hormones. Furthermore, the increase in fat mass that typically occurs after ovariectomy is prevented by germ line deletion of Y2 receptors, whereas in male mice body weight and fat mass were consistently lower than wild-type regardless of sex hormone status. Therefore, this study indicates a role for Y2 receptors in the accumulation of adipose tissue in the hypogonadal state and demonstrates that hypothalamic Y2 receptors constitutively restrain osteoblastic activity even in the absence of sex hormones. The increase in bone formation after release of this tonic inhibition suggests a promising new avenue for osteoporosis treatment.	St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia; Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand; Univ Queensland, Princess Alexandra Hosp, Sch Med, Brisbane, Qld 4120, Australia; Pfizer Global Res & Dev Inc, Groton, CT 06340 USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Auckland; University of Queensland; Pfizer	Herzog, H (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	h.herzog@garvan.org.au	During, Matthew/AAC-1388-2020; /E-2900-2010; Baldock, Paul/B-3840-2012; Eisman, John A/C-2886-2014; /B-2038-2013; Salis, Amanda/A-3187-2011; Herzog, Herbert/B-8294-2008	/0000-0001-7766-6095; Salis, Amanda/0000-0001-9176-1574; , Herbert/0000-0002-1713-1029				Ainslie DA, 2001, INT J OBESITY, V25, P1680, DOI 10.1038/sj.ijo.0801806; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Baldock PAJ, 1998, J BONE MINER RES, V13, P1451, DOI 10.1359/jbmr.1998.13.9.1451; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Denes A, 2005, NEUROSCIENCE, V134, P947, DOI 10.1016/j.neuroscience.2005.03.060; Escobar CM, 2004, J CLIN ENDOCR METAB, V89, P2338, DOI 10.1210/jc.2003-031899; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; Godsland IF, 2004, CLIN ENDOCRINOL, V60, P541, DOI 10.1111/j.1365-2265.2004.02017.x; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; Inoue K, 1997, J BONE MINER RES, V12, P989, DOI 10.1359/jbmr.1997.12.6.989; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; McCarthy TL, 2001, GROWTH HORM IGF RES, V11, P213, DOI 10.1054/ghir.2001.0236; Naveilhan P, 2002, PEPTIDES, V23, P1087, DOI 10.1016/S0196-9781(02)00042-6; POEHLMAN ET, 1995, ANN INTERN MED, V123, P673, DOI 10.7326/0003-4819-123-9-199511010-00005; REHMAN MTA, 1994, J CLIN PATHOL, V47, P529, DOI 10.1136/jcp.47.6.529; REID IR, 1992, J CLIN ENDOCR METAB, V75, P45, DOI 10.1210/jc.75.1.45; ROHOLL PJM, 1994, J BONE MINER RES, V9, P355; Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299; Sainsbury A, 2002, DIABETES, V51, P3420, DOI 10.2337/diabetes.51.12.3420; Shimizu H, 1996, NEUROSCI LETT, V204, P81, DOI 10.1016/0304-3940(96)12322-3; Toth MJ, 2000, ANN NY ACAD SCI, V904, P502; Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002-9343(99)00420-9; WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756-3282(86)90683-6; WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007; Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453	26	51	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23436	23444		10.1074/jbc.M604839200	http://dx.doi.org/10.1074/jbc.M604839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785231	Green Published, hybrid			2022-12-27	WOS:000239702900018
J	Hinoi, E; Ueshima, T; Hojo, H; Iemata, M; Takarada, T; Yoneda, Y				Hinoi, Eiichi; Ueshima, Taichi; Hojo, Hironori; Iemata, Mika; Takarada, Takeshi; Yoneda, Yukio			Up-regulation of per mRNA expression by parathyroid hormone through a protein kinase A-CREB-dependent mechanism in chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE; CIRCADIAN CLOCK; GENE-EXPRESSION; GROWTH-PLATE; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; MOLECULAR CLOCK; IN-VIVO; CELLS; TRANSCRIPTION	In bone, clock genes are involved in the circadian oscillation of bone formation and extracellular matrix expression. However, to date little attention has been paid to circadian rhythm in association with expression of clock genes during chondrogenesis in cartilage. In this study, we investigated the functional expression of different clock genes by chondrocytes in the course of cartilage development. The mRNA expression of types I, II, and X collagens exhibited a 24-h rhythm with a peak at zeitgeber time 6, in addition to a 24-h rhythmicity of all the clock genes examined in mouse femurs in vivo. Marked expression of different clock genes was seen in both osteoblastic MC3T3-E1 and chondrogenic ATDC5 cells in vitro, whereas parathyroid hormone (PTH) transiently increased period 1 (per1) mRNA expression at 1 h inboth cell lines. Similar increases were seen in the mRNA levels for both per1 and per2 in prehypertrophic chondrocytes in metatarsal organotypic cultures within 2 h of exposure to PTH. PTH significantly activated the mouse per1 (mper1) and mper2 promoters but not the mper3 promoter in a manner sensitive to both a protein kinase A inhibitor and deletion of the cAMP-responsive element sequence (CRE) in ATDC5cells. In HEK293 cells, introduction of brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein 1 (bmal1)/clock enhanced mouse type II collagen first intron reporter activity without affecting promoter activity, with reduction effected by either per1 or per2. These results suggest that PTH directly stimulates mper expression through a protein kinase A-CRE-binding protein signaling pathway for subsequent regulation of bmal1/clock-dependent extracellular matrix expression in cartilage.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Yoneda, Y (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.	yyoneda@p.kanazawa-u.ac.jp	Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X; Takarada-Iemata, Mika/0000-0002-2113-0707; Takarada, Takeshi/0000-0002-2363-7704; Hojo, Hironori/0000-0003-2245-6853				BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Greenfield EM, 1996, J BIOL CHEM, V271, P10984, DOI 10.1074/jbc.271.18.10984; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem-60-4-736; Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534-5807(02)00218-6; Hinoi E, 2003, FASEB J, V17, P1532, DOI 10.1096/fj.02-0820fje; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200; Muhlbauer E, 2004, FEBS LETT, V564, P91, DOI 10.1016/S0014-5793(04)00322-9; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; Oishi K, 2005, BIOCHEM J, V386, P575, DOI 10.1042/BJ20041150; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Ripperger JA, 2000, GENE DEV, V14, P679; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz Z, 1997, BONE, V21, P249, DOI 10.1016/S8756-3282(97)00123-3; Shimba S, 2005, P NATL ACAD SCI USA, V102, P12071, DOI 10.1073/pnas.0502383102; SIMMONS DJ, 1966, AM J PHYSIOL, V210, P411, DOI 10.1152/ajplegacy.1966.210.2.411; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; Wang LY, 2005, BRIT J PHARMACOL, V146, P732, DOI 10.1038/sj.bjp.0706358; Yamaguchi S, 2000, CURR BIOL, V10, P873, DOI 10.1016/S0960-9822(00)00602-3; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Yoshida E, 2001, EXP CELL RES, V265, P64, DOI 10.1006/excr.2001.5161; Young ME, 2001, CIRC RES, V88, P1142, DOI 10.1161/hh1101.091190; Zhen XC, 2001, J BIOL CHEM, V276, P4879, DOI 10.1074/jbc.M004990200	34	54	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23632	23642		10.1074/jbc.M512362200	http://dx.doi.org/10.1074/jbc.M512362200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777848	hybrid			2022-12-27	WOS:000239702900038
J	Bittencourt, VCB; Figueiredo, RT; da Silva, RB; Mourao-Sa, DS; Fernandez, PL; Sassaki, GL; Mulloy, B; Bozza, MT; Barreto-Bergter, E				Bittencourt, Vera Carolina B.; Figueiredo, Rodrigo T.; da Silva, Rosana B.; Mourao-Sa, Diego S.; Fernandez, Patricia L.; Sassaki, Guilherme L.; Mulloy, Barbara; Bozza, Marcelo T.; Barreto-Bergter, Eliana			An alpha-glucan of Pseudallescheria boydii is involved in fungal phagocytosis and toll-like receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE CELLS; CANDIDA; TLR4; RECOGNITION; DECTIN-1; MICE; CD14; SUSCEPTIBILITY; INDUCTION; RESPONSES	The host response to fungi is in part dependent on activation of evolutionarily conserved receptors, including toll-like receptors and phagocytic receptors. However, the molecular nature of fungal ligands responsible for this activation is largely unknown. Herein, we describe the isolation and structural characterization of an alpha-glucan from Pseudallescheria boydii cell wall and evaluate its role in the induction of innate immune response. These analyses indicate that alpha-glucan of P. boydii is a glycogen-like polysaccharide consisting of linear 4-linked alpha-D-Glcp residues substituted at position 6 with alpha-D-Glcp branches. Soluble alpha-glucan, but not alpha-glucan, led to a dose-dependent inhibition of conidia phagocytosis. Furthermore, a significant decrease in the phagocytic index occurred when alpha-glucan from conidial surface was removed by enzymatic treatment with alpha-amyloglucosidase, thus indicating an essential role of alpha-glucan in P. boydii internalization by macrophages. alpha-Glucan stimulates the secretion of inflammatory cytokines by macrophages and dendritic cells; again this effect is abolished by treatment with alpha-amyloglucosidase. Finally, alpha-glucan induces cytokine secretion by cells of the innate immune system in a mechanism involving toll-like receptor 2, CD14, and MyD88. These results might have relevance in the context of infections with P. boydii and other fungi, and alpha-glucan could be a target for intervention during fungal infections.	Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Microbiol Geral, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Parana, Dept Bioquim, BR-81531990 Curitiba, Parana, Brazil; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Parana; National Institute for Biological Standards & Control	Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Ave Brigadeiro Trompowsky S-N,CCS Bloco 1, BR-21941590 Rio De Janeiro, Brazil.	mbozza@micro.ufrj.br; eliana.bergter@micro.ufrj.br	Sassaki, Guilherme/AAM-1112-2020; Mourao-Sa, Diego/C-5977-2009; Bergter, Eliana Barreto/E-2664-2013; Bittencourt, Vera CB/A-7921-2019; Figueiredo, Rodrigo/F-5176-2016	Sassaki, Guilherme/0000-0001-7420-168X; Bozza, Marcelo/0000-0003-3683-7550; Mourao, Diego/0000-0001-6618-6969; bittencourt, vera/0000-0002-7403-9747; Llanes Fernandez, Patricia/0000-0002-0762-0566; Figueiredo, Rodrigo/0000-0002-7551-8782				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bahia MCFD, 1997, MYCOPATHOLOGIA, V137, P17, DOI 10.1023/A:1006862420963; Balloy V, 2005, INFECT IMMUN, V73, P5420, DOI 10.1128/IAI.73.9.5420-5425.2005; Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059; BJORNDAL H, 1967, U STOCKOL CHEM COMMU, V8, P1; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Cano LE, 1998, INFECT IMMUN, V66, P800, DOI 10.1128/IAI.66.2.800-806.1998; Cenci E, 1998, J IMMUNOL, V161, P3543; Cenci E, 1999, J INFECT DIS, V180, P1957, DOI 10.1086/315142; CHEETHAM NWH, 1991, CARBOHYD RES, V215, P59, DOI 10.1016/0008-6215(91)84007-2; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dinadayala P, 2004, J BIOL CHEM, V279, P12369, DOI 10.1074/jbc.M308908200; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; Flo TH, 2000, INFECT IMMUN, V68, P6770, DOI 10.1128/IAI.68.12.6770-6776.2000; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gil-Lamaignere C, 2003, INFECT IMMUN, V71, P6472, DOI 10.1128/IAI.71.11.6472-6478.2003; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784; Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; Mambula SS, 2002, J BIOL CHEM, V277, P39320, DOI 10.1074/jbc.M201683200; Means TK, 1999, J IMMUNOL, V163, P6748; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x; Morgenstern DE, 1997, J EXP MED, V185, P207, DOI 10.1084/jem.185.2.207; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Netea MG, 2002, J INFECT DIS, V185, P1483, DOI 10.1086/340511; NEWMAN SL, 1995, J IMMUNOL, V154, P753; Park JM, 2004, J EXP MED, V200, P1647, DOI 10.1084/jem.20041215; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Popi AF, 2002, CELL IMMUNOL, V218, P87, DOI 10.1016/S0008-8749(02)00576-2; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255; SASADA M, 1980, J EXP MED, V152, P85, DOI 10.1084/jem.152.1.85; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Tischer CA, 2002, CARBOHYD POLYM, V47, P151, DOI 10.1016/S0144-8617(01)00173-4; Villamon E, 2004, MICROBES INFECT, V6, P1, DOI 10.1016/j.micinf.2003.09.020; WANG RH, 1995, BIOCHEM J, V311, P867, DOI 10.1042/bj3110867; WASHBURN RG, 1987, INFECT IMMUN, V55, P2088, DOI 10.1128/IAI.55.9.2088-2092.1987; ZANG LH, 1991, CARBOHYD RES, V220, P1, DOI 10.1016/0008-6215(91)80001-4	53	106	109	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22614	22623		10.1074/jbc.M511417200	http://dx.doi.org/10.1074/jbc.M511417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766532	hybrid			2022-12-27	WOS:000239542600022
J	Roman, LJ; Masters, BSS				Roman, Linda J.; Masters, Bettie Sue S.			Electron transfer by neuronal nitric-oxide synthase is regulated by concerted interaction of calmodulin and two intrinsic regulatory elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITORY CONTROL ELEMENT; LIGHT-CHAIN KINASE; REDUCTASE DOMAIN; BINDING DOMAIN; FLOW-THROUGH; FLAVIN; ACTIVATION; ISOFORMS; NADPH; IDENTIFICATION	The nitric-oxide synthases (NOSs) are modular, cofactor-containing enzymes, divided into a heme-containing oxygenase domain and an FMN- and FAD-containing reductase domain. The domains are connected by a calmodulin (CaM)-binding sequence, occupancy of which is required for nitric oxide (NO) production. Two additional CaM-modulated regulatory elements are present in the reductase domains of the constitutive isoforms, the autoregulatory region (AR) and the C-terminal tail region. Deletion of the AR reduces CaM stimulation of electron flow through the reductase domain from 10-fold in wild-type nNOS to 2-fold in the mutant. Deletion of the C terminus yields an enzyme with greatly enhanced reductase activity in the absence of CaM but with activity equivalent to that of wild-type enzyme in its presence. A mutant in which both the AR and C terminus were deleted completely loses CaM modulation through the reductase domain. Thus, transduction of the CaM effect through the reductase domain of nNOS is dependent on these elements. Formation of nitric oxide is, however, still stimulated by CaM in all three mutants. A CaM molecule in which the N-terminal lobe was replaced by the C-terminal lobe (CaMCC) supported NO synthesis by the deletion mutants but not by wild-type nNOS. We propose a model in which the AR, the C-terminal tail, and CaM interact directly to regulate the conformational state of the reductase domain of nNOS.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Roman, LJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	roman@uthscsa.edu			NIGMS NIH HHS [GM52419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ALEXANDER LM, 1980, MICROSOMES DRUG OXID, P285; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Bruckdorfer Richard, 2005, Molecular Aspects of Medicine, V26, P3, DOI 10.1016/j.mam.2004.09.002; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Jones RJ, 2004, J BIOL CHEM, V279, P36876, DOI 10.1074/jbc.M402808200; Knight K, 2002, BIOCHEM J, V367, P19, DOI 10.1042/BJ20020667; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Li HY, 2005, J INORG BIOCHEM, V99, P293, DOI 10.1016/j.jinorgbio.2004.10.016; LINSE S, 1991, J BIOL CHEM, V266, P8050; Martasek P, 1999, METHOD ENZYMOL, V301, P70; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; MUNRO AW, 1999, METHODS MOL BIOL FLA, P1; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; Persechini A, 1996, J BIOL CHEM, V271, P32217, DOI 10.1074/jbc.271.50.32217; PIETTA P, 1982, J CHROMATOGR, V229, P445, DOI 10.1016/S0378-4347(00)84288-7; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Roman LJ, 2003, J BIOL CHEM, V278, P25700, DOI 10.1074/jbc.M212309200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Tiso M, 2005, J BIOL CHEM, V280, P39208, DOI 10.1074/jbc.M507775200; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901	53	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23111	23118		10.1074/jbc.M603671200	http://dx.doi.org/10.1074/jbc.M603671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16782703	hybrid			2022-12-27	WOS:000239542600075
J	Wang, W; Mulakala, C; Ward, SC; Jung, G; Luong, H; Pham, D; Waring, AJ; Kaznessis, Y; Lu, WY; Bradley, KA; Lehrer, RI				Wang, Wei; Mulakala, Chandrika; Ward, Sabrina C.; Jung, Grace; Luong, Hai; Pham, Duy; Waring, Alan J.; Kaznessis, Yiannis; Lu, Wuyuan; Bradley, Kenneth A.; Lehrer, Robert I.			Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THETA-DEFENSINS; ANTIMICROBIAL PEPTIDES; PROTECTIVE ANTIGEN; LIPID-BILAYERS; PROTEOLYTIC ACTIVATION; ADENYLATE-CYCLASE; EDEMA FACTOR; BINDING; MEMBRANE; PROTEINS	theta-defensins are cyclic octadecapeptides encoded by the modified alpha-defensin genes of certain nonhuman primates. The recent demonstration that human alpha-defensins could prevent deleterious effects of anthrax lethal toxin in vitro and in vivo led us to examine the effects of theta-defensins on Bacillus anthracis (Sterne). We tested rhesus theta-defensins 1-3, retrocyclins 1-3, and several analogues of RC-1. Low concentrations of theta-defensins not only killed vegetative cells of B. anthracis (Sterne) and rendered their germinating spores nonviable, they also inactivated the enzymatic activity of anthrax lethal factor and protected murine RAW-264.7 cells from lethal toxin, a mixture of lethal factor and protective antigen. Structure-function studies indicated that the cyclic backbone, intramolecular tri-disulfide ladder, and arginine residues of theta-defensins contributed substantially to these protective effects. Surface plasmon resonance studies showed that retrocyclins bound the lethal factor rapidly and with high affinity. Retrocyclin-mediated inhibition of the enzymatic activity of lethal factor increased substantially if the enzyme and peptide were preincubated before substrate was added. The temporal discrepancy between the rapidity of binding and the slowly progressive extent of lethal factor inhibition suggest that post-binding events, perhaps in situ oligomerization, contribute to the antitoxic properties of retrocyclins. Overall, these findings suggest that theta-defensins provide molecular templates that could be used to create novel agents effective against B. anthracis and its toxins.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Minnesota System; University of Minnesota Twin Cities; University System of Maryland; University of Maryland Baltimore	Lehrer, RI (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 10833 LeConte Ave, Los Angeles, CA 90095 USA.	rlehrer@mednet.ucla.edu	Lu, Wuyuan/B-2268-2010; Lu, Wuyuan/J-8452-2017; Kaznessis, Yiannis N/H-1795-2015	Lu, Wuyuan/0000-0003-1318-9968; Kaznessis, Yiannis/0000-0002-5088-1104	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057870, R01AI061482, R01AI056921, R21AI056921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070989] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 061482, AI 056921, R01 AI061482, R01 AI056921, R21 AI056921, AI 057870, R01 AI057870] Funding Source: Medline; NIGMS NIH HHS [GM 070989, R01 GM070989, R01 GM070989-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banks DJ, 2005, CELL MICROBIOL, V7, P1173, DOI 10.1111/j.1462-5822.2005.00545.x; Beauregard KE, 2000, CELL MICROBIOL, V2, P251, DOI 10.1046/j.1462-5822.2000.00052.x; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Buffy JJ, 2004, BIOCHEMISTRY-US, V43, P9800, DOI 10.1021/bi036243w; Buffy JJ, 2003, BIOCHEMISTRY-US, V42, P13725, DOI 10.1021/bi035187w; Buffy JJ, 2003, BIOPHYS J, V85, P2363, DOI 10.1016/S0006-3495(03)74660-8; Chong-Cerrillo C, 2003, J PEPT RES, V61, P237, DOI 10.1034/j.1399-3011.2003.00053.x; COHN EJ, 1943, PROTEINS AMINO ACIDS, P374; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Craik DJ, 2006, SCIENCE, V311, P1563, DOI 10.1126/science.1125248; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Demchick P, 1996, J BACTERIOL, V178, P768, DOI 10.1128/jb.178.3.768-773.1996; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Friedlander AM, 2002, CURR TOP MICROBIOL, V271, P33; Ganz T, 2004, CR BIOL, V327, P539, DOI 10.1016/j.crvi.2003.12.007; Gidalevitz D, 2003, P NATL ACAD SCI USA, V100, P6302, DOI 10.1073/pnas.0934731100; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; GREEN BD, 1985, INFECT IMMUN, V49, P291, DOI 10.1128/IAI.49.2.291-297.1985; Heller WT, 2000, BIOCHEMISTRY-US, V39, P139, DOI 10.1021/bi991892m; Kim C, 2005, P NATL ACAD SCI USA, V102, P4830, DOI 10.1073/pnas.0500508102; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; LEHRER RI, 1992, CIBA F SYMP, V171, P276; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Leikina E, 2005, NAT IMMUNOL, V6, P995, DOI 10.1038/ni1248; Leonova L, 2001, J LEUKOCYTE BIOL, V70, P461; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Mani R, 2004, BIOCHEMISTRY-US, V43, P13839, DOI 10.1021/bi048650t; Mayer-Scholl A, 2005, PLOS PATHOG, V1, P179, DOI 10.1371/journal.ppat.0010023; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mulvenna JP, 2006, NUCLEIC ACIDS RES, V34, pD192, DOI 10.1093/nar/gkj005; Nguyen TX, 2003, PEPTIDES, V24, P1647, DOI 10.1016/j.peptides.2003.07.023; Okinaka RT, 1999, J BACTERIOL, V181, P6509, DOI 10.1128/JB.181.20.6509-6515.1999; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; RICE WG, 1987, BLOOD, V70, P757; Scheetz T, 2002, IMMUNOL REV, V190, P137, DOI 10.1034/j.1600-065X.2002.19010.x; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Selsted ME, 2004, CURR PROTEIN PEPT SC, V5, P365, DOI 10.2174/1389203043379459; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Shoop WL, 2005, P NATL ACAD SCI USA, V102, P7958, DOI 10.1073/pnas.0502159102; SOLIS FJ, 1981, MATH OPER RES, V6, P19, DOI 10.1287/moor.6.1.19; STOTE RH, 1995, PROTEINS, V23, P12, DOI 10.1002/prot.340230104; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Tran D, 2002, J BIOL CHEM, V277, P3079, DOI 10.1074/jbc.M109117200; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang W, 2003, J IMMUNOL, V170, P4708, DOI 10.4049/jimmunol.170.9.4708; Weiss TM, 2002, BIOCHEMISTRY-US, V41, P10070, DOI 10.1021/bi025853d; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wu ZB, 2003, J AM CHEM SOC, V125, P2402, DOI 10.1021/ja0294257; Yasin B, 2004, J VIROL, V78, P5147, DOI 10.1128/JVI.78.10.5147-5156.2004	64	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32755	32764		10.1074/jbc.M603614200	http://dx.doi.org/10.1074/jbc.M603614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16790431	hybrid, Green Accepted			2022-12-27	WOS:000241414500074
J	Belotserkovskii, BP; Arimondo, PB; Cozzarelli, NR				Belotserkovskii, Boris P.; Arimondo, Paola B.; Cozzarelli, Nicholas R.			Topoisomerase action on short DNA duplexes reveals requirements for gate and transfer DNA segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; ESCHERICHIA-COLI; II TOPOISOMERASES; NALIDIXIC-ACID; BINDING-SITE; SUBUNIT-A; GYRASE; MECHANISM; CLEAVAGE; IV	Type II topoisomerases change DNA topology by passage of one DNA duplex (the transfer, T-segment) through a transient double-stranded break in another (the gate, G-segment). Here we monitor the passage between short double-stranded DNA segments within long single-stranded DNA circles that leads to catenation of the circles. To facilitate catenation, the circles were brought into close proximity using a tethering oligonucleotide, which was removed after the reaction was complete. We varied the length and the composition of the reacting DNA segments. The minimal DNA duplex length at which we detected catenation was 50-60 bp for DNA gyrase and 40 bp for topoisomerase IV (Topo IV). For Topo IV, catenation was observed when one, but not both, of the DNA-DNA duplexes was replaced by a DNA-RNA duplex. Topo IV cleaved the DNA-DNA duplex, but not the DNA-RNA duplex implying that the DNA-RNA duplex can be a T-segment but not a G-segment.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Arimondo, PB (corresponding author), Museum Natl Hist Nat, USM0503, INSERM, CNRS,UMR 5153,UR565, 43 Rue Cuvier, F-75231 Paris 05, France.	arimondo@mnhn.fr	Arimondo, Paola B/R-9095-2017	Arimondo, Paola B/0000-0001-5175-4396; Belotserkovskii, Boris/0000-0002-1570-9923	NCI NIH HHS [R37 CM31657] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2003, P NATL ACAD SCI USA, V100, P9820, DOI 10.1073/pnas.1631550100; CHUNG IK, 1992, NUCLEIC ACIDS RES, V20, P1973, DOI 10.1093/nar/20.8.1973; Corbett KD, 2005, J MOL BIOL, V351, P545, DOI 10.1016/j.jmb.2005.06.029; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; Cove ME, 1997, NUCLEIC ACIDS RES, V25, P2716, DOI 10.1093/nar/25.14.2716; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Gmunder H, 1997, NUCLEIC ACIDS RES, V25, P604, DOI 10.1093/nar/25.3.604; Hardy CD, 2004, PHILOS T R SOC B, V359, P39, DOI 10.1098/rstb.2003.1363; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KHODURSKY AB, 2000, P NATL ACAD SCI USA, V97, P9149; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; LEE MP, 1989, J BIOL CHEM, V264, P21779; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; LUND K, 1990, J BIOL CHEM, V265, P13856; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; ORPHANIDES G, 1994, NUCLEIC ACIDS RES, V22, P1567, DOI 10.1093/nar/22.9.1567; PATO ML, 1990, P NATL ACAD SCI USA, V87, P8716, DOI 10.1073/pnas.87.22.8716; Pong H, 1999, METH MOL B, V94, P163; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Ruthenburg AJ, 2005, J BIOL CHEM, V280, P26177, DOI 10.1074/jbc.M502838200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schoeffler AJ, 2005, BIOCHEM SOC T, V33, P1465, DOI 10.1042/BST0331465; Stone MD, 2003, P NATL ACAD SCI USA, V100, P8654, DOI 10.1073/pnas.1133178100; SUGINO A, 1980, NUCLEIC ACIDS RES, V8, P3865, DOI 10.1093/nar/8.17.3865; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang Y, 1999, J BIOL CHEM, V274, P22839, DOI 10.1074/jbc.274.32.22839; Wang Y, 2000, NUCLEIC ACIDS RES, V28, P4815, DOI 10.1093/nar/28.24.4815; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	45	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25407	25415		10.1074/jbc.M603977200	http://dx.doi.org/10.1074/jbc.M603977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16798730	hybrid			2022-12-27	WOS:000240031300043
J	Matsuda, K; Matsuda, S; Gladding, CM; Yuzaki, M				Matsuda, Keiko; Matsuda, Shinji; Gladding, Clare M.; Yuzaki, Michisuke			Characterization of the delta 2 glutamate receptor-binding protein delphilin - Splicing variants with differential palmitoylation and an additional PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; CRYSTAL-STRUCTURE; PURKINJE-CELLS; MEDIATED MULTIMERIZATION; SYNAPTIC PLASTICITY; TARGET RECOGNITION; STRUCTURAL BASIS; COMPLEX REVEALS; FIBER SYNAPSES; PSD-95	The glutamate receptor delta 2 (GluR delta 2) is predominantly expressed at parallel fiber-Purkinje cell postsynapses and plays crucial roles in synaptogenesis and synaptic plasticity. Although the mechanism by which GluR delta 2 functions remains unclear, its lack of channel activity and its role in controlling the endocytosis of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate ( AMPA) receptors have suggested that GluR delta 2 may convey signals by interacting with intracellular signaling molecules. Among several proteins that interact with GluR delta 2, delphilin is unique in that it is selectively expressed at parallel fiber-Purkinje cell synapses and that, in addition to a single PDZ domain, it contains a formin homology domain that is thought to regulate actin dynamics. Here, we report a new isoform of delphilin, designated as L-delphilin, that has alternatively spliced N-terminal exons encoding an additional PDZ domain. Although original delphilin, designated S-delphilin, was palmitoylated at the N terminus, this region was spliced out in L-delphilin. As a result, S-delphilin was associated with plasma membranes in COS cells and dendritic spines in hippocampal neurons, whereas L-delphilin formed clusters in soma and dendritic shafts. In addition, S-delphilin, but not L-delphilin, facilitated the expression of GluR delta 2 on the cell surface. These results indicate that, like PSD-95 and GRIP/ABP, delphilin isoforms with differential palmitoylation and clustering capabilities may provide two separate intracellular and surface GluR delta 2 pools and may control GluR delta 2 signaling in Purkinje cells.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Bristol, Dept Anat, Bristol BS8 1TD, Avon, England	Keio University; University of Bristol	Yuzaki, M (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	myuzaki@sc.itc.keio.ac.jp	Yuzaki, Michisuke/K-5328-2013; Matsuda, Shinji/GRR-5226-2022; Matsuda, Shinji/L-4727-2013; Gladding, Clare/E-9719-2012; Matsuda, Keiko/L-5778-2013	Yuzaki, Michisuke/0000-0002-5750-3544; 				Boudin H, 2001, J BIOL CHEM, V276, P30270, DOI 10.1074/jbc.M102991200; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DeSouza S, 2002, J NEUROSCI, V22, P3493; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Feng W, 2003, NAT STRUCT BIOL, V10, P972, DOI 10.1038/nsb992; Hirai H, 2003, NAT NEUROSCI, V6, P869, DOI 10.1038/nn1086; Hirai H, 2001, EUR J NEUROSCI, V14, P73, DOI 10.1046/j.0953-816x.2001.01630.x; Hironaka K, 2000, J BIOL CHEM, V275, P16167, DOI 10.1074/jbc.M909302199; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Im YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Long JF, 2003, J MOL BIOL, V327, P203, DOI 10.1016/S0022-2836(03)00113-X; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Matsuda K, 2003, J NEUROSCI, V23, P10064; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Matsuda S, 2004, EUR J NEUROSCI, V19, P1683, DOI 10.1111/j.1460-9568.2004.03307.x; Matsuda S, 2002, EUR J NEUROSCI, V16, P1507, DOI 10.1046/j.1460-9568.2002.02219.x; MAYAT E, 1995, J NEUROSCI, V15, P2533, DOI 10.1523/JNEUROSCI.15-03-02533.1995; Miyagi Y, 2002, J NEUROSCI, V22, P803, DOI 10.1523/JNEUROSCI.22-03-00803.2002; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Roche KW, 1999, J NEUROSCI, V19, P3926; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Uemura T, 2004, MOL CELL NEUROSCI, V26, P330, DOI 10.1016/j.mcn.2004.02.007; Van't Hof W, 2000, METHOD ENZYMOL, V327, P317, DOI 10.1016/S0076-6879(00)27287-X; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yamashita T, 2005, MOL BRAIN RES, V141, P83, DOI 10.1016/j.molbrainres.2005.08.006; Yamazaki M, 2001, NEUROSCI LETT, V304, P81, DOI 10.1016/S0304-3940(01)01766-9; Yuzaki M, 2004, CEREBELLUM, V3, P89, DOI 10.1080/14734220410028921; Yuzaki M, 2003, NEUROSCI RES, V46, P11, DOI 10.1016/S0168-0102(03)00036-1; Zhao HM, 1997, J NEUROCHEM, V68, P1041	40	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25577	25587		10.1074/jbc.M602044200	http://dx.doi.org/10.1074/jbc.M602044200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16835239	hybrid			2022-12-27	WOS:000240031300061
J	Singh, RR; Kaluarachchi, K; Chen, MZ; Rayala, SK; Balasenthil, S; Ma, JP; Kumar, R				Singh, Rajesh R.; Kaluarachchi, Kumaralal; Chen, Mingzhi; Rayala, Suresh K.; Balasenthil, Seetharaman; Ma, Jianpeng; Kumar, Rakesh			Solution structure and antiestrogenic activity of the unique C-terminal, NR-box motif-containing region of MTA1s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURGICAL ADJUVANT BREAST; HUMAN ESTROGEN-RECEPTOR; CANCER; TAMOXIFEN; SUPPRESSION; EXPRESSION; RESOLUTION; PROTEIN-1; BINDING; GROWTH	Metastasis tumor-associated 1 short form (MTA1s) is a naturally occurring, alternatively spliced variant of MTA1 that functions as a repressor of estrogen receptor ( ER) alpha transcriptional functions, at least in part by binding and sequestering ER alpha in the cytoplasm. A unique C-terminal 33-amino acid region containing a nuclear receptor (NR)-box motif (-LRILL-) mediates binding of MTA1s with ER alpha and is indispensable in this interaction. Here, we elucidated the solution structure of this 33-amino acid region by NMR spectroscopy. We found a predominance of the alpha-helical region toward the N-terminal region, which includes the NR-box motif. In silico docking and comparison studies showed similarities between the NR-box motif of MTA1s and a similar motif of coregulators, both in structure and mode of ER alpha binding. In MCF-7 breast cancer cells, the MTA1s peptide effectively repressed ER alpha transactivation function, as evidenced by the estrogen response element-luc assay and down-regulation of estrogen-induced genes. In mechanistic studies, we found that the antiestrogenic effects of the MTA1s peptide were due to its ability to compete with the coactivator recruitment to ER alpha. Furthermore, the peptide efficiently repressed estrogen-induced proliferation and anchorage-independent growth of MCF-7 cells. In addition, the MTA1s peptide blocked the progression of tumors formed by MCF-7 cells overexpressing an ER alpha coactivator in a xenograft-based assay. In brief, the characterization of structure and antiestrogenic activity of MTA1s peptide highlight its therapeutic potential.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Struct & Computat Biol, Houston, TX 77030 USA; Rice Univ, Dept Bioengn, Houston, TX 77251 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Rice University; Baylor College of Medicine; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; Rayala, Suresh/0000-0003-4394-4450	NCI NIH HHS [CA65746, CA98823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746, R01CA098823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Chang CY, 1999, MOL CELL BIOL, V19, P8226; COLE MP, 1971, BRIT J CANCER, V25, P270, DOI 10.1038/bjc.1971.33; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Manavathi B, 2005, CANCER RES, V65, P5571, DOI 10.1158/0008-5472.CAN-04-4664; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; MCGUIRE WL, 1975, ESTROGEN RECEPTOR HU, P57; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Singh RR, 2005, J CELL BIOCHEM, V96, P490, DOI 10.1002/jcb.20566; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Warnmark A, 2002, J BIOL CHEM, V277, P21862, DOI 10.1074/jbc.M200764200; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	37	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25612	25621		10.1074/jbc.M604444200	http://dx.doi.org/10.1074/jbc.M604444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807247	Green Published, hybrid			2022-12-27	WOS:000240031300064
J	Cook, AC; Chambers, AF; Turley, EA; Tuck, AB				Cook, Amy C.; Chambers, Ann F.; Turley, Eva A.; Tuck, Alan B.			Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; MAMMARY EPITHELIAL-CELLS; METASTATIC PROSTATE; PERICELLULAR MATRIX; MIGRATION; RECEPTOR; ACTIVATION; ADHESION; INVASIVENESS; PROGRESSION	Osteopontin (OPN) is a tumor-associated, secreted phosphoprotein that has been implicated in breast cancer progression and metastasis. Research concerning how OPN functions in tumor progression has led to the identification of a limited number of genes that contribute functionally to OPN-induced cellular behaviors. Recent microarray analysis, comparing 21NT breast cancer cells transfected to constitutively overexpress OPN with control cells, revealed hyaluronan synthase 2 (HAS2) to be a gene highly up-regulated in OPN-overexpressing cells. In this study, we further examined the relationship between OPN and HAS2. We show that 21NT OPN-transfected cells express high levels of HAS2, which is associated with increased HA production and matrix retention and is necessary for tumor cell adhesion to bone marrow endothelial cells and anchorage-independent growth. Finally, stable transfection of antisense HAS2 into 21NT cells overexpressing OPN resulted in a reduction in HAS2 expression, HA production, and pericellular retention. Antisense-mediated down-regulation of HAS2 also resulted in a significant decrease in cellular proliferation and colony growth in soft agar. To our knowledge, this is the first report of the ability of OPN to regulate HAS2 expression and HA production in breast cancer cells and further illustrates a unique functional relationship by which enhanced HA production facilitates OPN-mediated cell behaviors.	Univ Western Ontario, Dept Pathol, London, ON N6A 5C1, Canada; London Hlth Sci Ctr, London Reg Canc Program, London, ON N6A 4L6, Canada; London Hlth Sci Ctr, Dept Pathol, London, ON N6A 5A5, Canada	Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre	Tuck, AB (corresponding author), Univ Hosp London, Dept Pathol, London Hlth Sci Ctr, London, ON N6A 5A5, Canada.	Alan.Tuck@Lhsc.on.ca	Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				Adwan H, 2004, CANCER GENE THER, V11, P109, DOI 10.1038/sj.cgt.7700659; Allan AL, 2005, CANC DRUG DISC DEV, P107; BAND V, 1990, CANCER RES, V50, P7351; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HE B, 2005, ONCOGENE; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KNUDSON W, 1991, J CELL SCI, V99, P227; Kosaki R, 1999, CANCER RES, V59, P1141; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Liu NF, 2001, CANCER RES, V61, P5207; McDonald JA, 2002, GLYCOCONJUGATE J, V19, P331, DOI 10.1023/A:1025369004783; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Rilla K, 2002, J CELL SCI, V115, P3633, DOI 10.1242/jcs.00042; Senger DR, 1996, AM J PATHOL, V149, P293; Simpson MA, 2002, J BIOL CHEM, V277, P10050, DOI 10.1074/jbc.M110069200; Simpson MA, 2001, J BIOL CHEM, V276, P17949, DOI 10.1074/jbc.M010064200; Singhal H, 1997, CLIN CANCER RES, V3, P605; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, BREAST CANCER RES TR, V70, P197, DOI 10.1023/A:1013095329825; Udabage L, 2005, CANCER RES, V65, P6139, DOI 10.1158/0008-5472.CAN-04-1622; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zeng CX, 1998, INT J CANCER, V77, P396; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	38	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24381	24389		10.1074/jbc.M602694200	http://dx.doi.org/10.1074/jbc.M602694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807238	hybrid			2022-12-27	WOS:000239847800031
J	Potter, CS; Peterson, RL; Barth, JL; Pruett, ND; Jacobs, DF; Kern, MJ; Argraves, WS; Sundberg, JP; Awgulewitsch, A				Potter, Christopher S.; Peterson, Ron L.; Barth, Jeremy L.; Pruett, Nathanael D.; Jacobs, Donna F.; Kern, Michael J.; Argraves, W. Scott; Sundberg, John P.; Awgulewitsch, Alexander			Evidence that the satin hair mutant gene Foxq1 is among multiple and functionally diverse regulatory targets for Hoxc13 during hair follicle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER-ROOT-SHEATH; MURINE HAIR; STEM-CELLS; EXPRESSION; PROTEINS; KERATIN; MICE; MODEL; MOUSE; IDENTIFICATION	It is increasingly evident that the molecular mechanisms underlying hair follicle differentiation and cycling recapitulate principles of embryonic patterning and organ regeneration. Here we used Hoxc13-overexpressing transgenic mice (also known as GC13 mice), known to develop severe hair growth defects and alopecia, as a tool for defining pathways of hair follicle differentiation. Gene array analysis performed with RNA from postnatal skin revealed differential expression of distinct subsets of genes specific for cells of the three major hair shaft compartments ( cuticle, cortex, and medulla) and their precursors. This finding correlates well with the structural defects observed in each of these compartments and implicates Hoxc13 in diverse pathways of hair follicle differentiation. The group of medulla-specific genes was particularly intriguing because this included the developmentally regulated transcription factor-encoding gene Foxq1 that is altered in the medulla-defective satin mouse hair mutant. We provide evidence that Foxq1 is a downstream target for Hoxc13 based on DNA binding studies as well as co-transfection and chromatin immunoprecipitation assays. Expression of additional medulla-specific genes down-regulated upon overexpression of Hoxc13 requires functional Foxq1 as their expression is ablated in hair follicles of satin mice. Combined, these results demonstrate that Hoxc13 and Foxq1 control medulla differentiation through a common regulatory pathway. The apparent regulatory interactions between members of the mammalian Hox and Fox gene families shown here may establish a paradigm for "cross-talk" between these two conserved regulatory gene families in different developmental contexts including embryonic patterning as well as organ development and renewal.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol, Charleston, SC 29425 USA; Novartis Inst Biomed Res, Div Integrat Express Profiling, Cambridge, MA 02139 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Medical University of South Carolina; Medical University of South Carolina; Novartis; Jackson Laboratory	Awgulewitsch, A (corresponding author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St,Suite 912 CSB, Charleston, SC 29425 USA.	awgulewa@musc.edu			NCI NIH HHS [R24CA95841] Funding Source: Medline; NCRR NIH HHS [RR00173, P20 RR016434, C06-RR015455, RR-16434] Funding Source: Medline; NIAMS NIH HHS [AR47204-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095841] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Awgulewitsch A, 2003, NATURWISSENSCHAFTEN, V90, P193, DOI 10.1007/s00114-003-0417-4; Bechtold LS, 2000, SYSTEMATIC APPROACH TO EVALUATION OF MOUSE MUTATIONS, P121; BIEBERICH CJ, 1991, ANN NY ACAD SCI, V642, P346; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; Chuong CM, 1999, J INVEST DERM SYMP P, V4, P307, DOI 10.1038/sj.jidsp.5640235; CHUONG CM, 1990, DEVELOPMENT, V110, P1021; CHUONG CM, 1993, BIOESSAYS, V15, P513, DOI 10.1002/bies.950150804; DasGupta R, 1999, DEVELOPMENT, V126, P4557; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; Frank S, 1998, DNA CELL BIOL, V17, P679, DOI 10.1089/dna.1998.17.679; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; Galant R, 2002, DEVELOPMENT, V129, P3115; Gebelein B, 2004, NATURE, V431, P653, DOI 10.1038/nature02946; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hong HK, 2001, GENESIS, V29, P163, DOI 10.1002/gene.1020; Jave-Suarez LF, 2006, ARCH DERMATOL RES, V297, P372, DOI 10.1007/s00403-005-0623-3; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; Johns SA, 2005, DEV DYNAM, V232, P1062, DOI 10.1002/dvdy.20278; KANZLER B, 1994, INT J DEV BIOL, V38, P633; KOZAK M, 1983, MICROBIOL REV, V47, P1; Langbein L, 2005, INT REV CYTOL, V243, P1, DOI 10.1016/S0074-7696(05)43001-6; Langbein L, 2003, J INVEST DERMATOL, V120, P512, DOI 10.1046/j.1523-1747.2003.12087.x; Langbein L, 2002, J INVEST DERMATOL, V118, P789, DOI 10.1046/j.1523-1747.2002.01711.x; Legue E, 2005, DEVELOPMENT, V132, P4143, DOI 10.1242/dev.01975; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin KK, 2004, P NATL ACAD SCI USA, V101, P15955, DOI 10.1073/pnas.0407114101; Liu X, 2001, P NATL ACAD SCI USA, V98, P9139, DOI 10.1073/pnas.161016098; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; MANN SJ, 1962, ANAT RECORD, V144, P135, DOI 10.1002/ar.1091440208; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Merabet S, 2005, TRENDS GENET, V21, P477, DOI 10.1016/j.tig.2005.07.001; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Norris RA, 2001, J BIOL CHEM, V276, P26829, DOI 10.1074/jbc.M100239200; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Pennisi D, 2000, MOL CELL BIOL, V20, P9331, DOI 10.1128/MCB.20.24.9331-9336.2000; Peterson RL, 2005, J INVEST DERM SYMP P, V10, P238, DOI 10.1111/j.1087-0024.2005.10114.x; PETERSON RL, 2002, PHARMACOGENOMICS, V2, P283; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Pruett ND, 2004, J BIOL CHEM, V279, P51524, DOI 10.1074/jbc.M404331200; Reid AI, 2002, INT J DEV BIOL, V46, P209; Ren B, 2004, METHOD ENZYMOL, V376, P304; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Schlake T, 2005, DEVELOPMENT, V132, P2981, DOI 10.1242/dev.01873; Schmidt-Ullrich R, 2005, BIOESSAYS, V27, P247, DOI 10.1002/bies.20184; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; STENN KS, 1988, CELL TISSUE BIOL, P541; Sundberg JP., 1994, HDB MOUSE MUTATIONS, P57; Suzuki M, 2003, J BIOL CHEM, V278, P30148, DOI 10.1074/jbc.M303932200; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Williams TM, 2005, DEV BIOL, V277, P457, DOI 10.1016/j.ydbio.2004.10.004; WOOD L, 1990, J BIOL CHEM, V265, P21375	60	53	60	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29245	29255		10.1074/jbc.M603646200	http://dx.doi.org/10.1074/jbc.M603646200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16835220	hybrid			2022-12-27	WOS:000240680500080
J	Chen, H; Yong, WD; Ren, SX; Shen, WH; He, YZ; Cox, KA; Zhu, WQ; Li, W; Soonpaa, M; Payne, RM; Franco, D; Field, LJ; Rosen, V; Wang, YB; Shou, WN				Chen, Hanying; Yong, Weidong; Ren, Shuxun; Shen, Weihua; He, Yongzheng; Cox, Karen A.; Zhu, Wuqiang; Li, Wei; Soonpaa, Mark; Payne, R. Mark; Franco, Diego; Field, Loren J.; Rosen, Vicki; Wang, Yibin; Shou, Weinian			Overexpression of bone morphogenetic protein 10 in myocardium disrupts cardiac postnatal hypertrophic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOMYOCYTE DNA-SYNTHESIS; SIGNALING PATHWAYS; PHYSIOLOGICAL LOADS; GENE-EXPRESSION; TRANSGENIC MICE; HEART-FAILURE; CELL-CYCLE; RAT-HEART; IN-VIVO; RECEPTOR	Postnatal cardiac hypertrophies have traditionally been classified into physiological or pathological hypertrophies. Both of them are induced by hemodynamic load. Cardiac postnatal hypertrophic growth is regarded as a part of the cardiac maturation process that is independent of the cardiac working load. However, the functional significance of this biological event has not been determined, mainly because of the difficulty in creating an experimental condition for testing the growth potential of functioning heart in the absence of hemodynamic load. Recently, we generated a novel transgenic mouse model (alpha MHC-BMP10) in which the cardiac-specific growth factor bone morphogenetic protein 10 (BMP10) is overexpressed in postnatal myocardium. These alpha MHC-BMP10 mice appear to have normal cardiogenesis throughout embryogenesis, but develop to smaller hearts within 6 weeks after birth. alpha MHC-BMP10 hearts are about half the normal size with 100% penetrance. Detailed morphometric analysis of cardiomyocytes clearly indicated that the compromised cardiac growth in alpha MHC-BMP10 mice was solely because of defect in cardiomyocyte postnatal hypertrophic growth. Physiological analysis further demonstrated that the responses of these hearts to both physiological (e.g. exercise-induced hypertrophy) and pathological hypertrophic stimuli remain normal. In addition, the alpha MHC-BMP10 mice develop subaortic narrowing and concentric myocardial thickening without obstruction by four weeks of age. Systematic analysis of potential intracellular pathways further suggested a novel genetic pathway regulating this previously undefined cardiac postnatal hypertrophic grow the vent. This is the first demonstration that cardiac postnatal hypertrophic growth can be specifically modified genetically and dissected out from physiological and pathological hypertrophies.	Indiana Univ, Sch Med, Dept Pediat, Hermann B Wells Ctr Pediat Res,Div Pediat Cardiol, Indianapolis, IN 46202 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Med, Los Angeles, CA 90095 USA; Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Univ Jaen, Dept Expt Biol, Jaen 23071, Spain	Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard School of Dental Medicine; Universidad de Jaen	Shou, WN (corresponding author), Indiana Univ, Sch Med, Dept Pediat, Hermann B Wells Ctr Pediat Res,Div Pediat Cardiol, Indianapolis, IN 46202 USA.	wshou@iupui.edu		Franco, Diego/0000-0002-5669-7164; Wang, Yibin/0000-0003-0852-0767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070259, P01HL085098, R01HL081092] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070259-04, R01 HL070259, R01 HL081092, P01 HL085098-01A1, R01 HL081092-01A2, P01 HL085098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; BISHOP SP, 1990, CIRC RES, V66, P84, DOI 10.1161/01.RES.66.1.84; BUTTRICK PM, 1994, J MOL CELL CARDIOL, V26, P61, DOI 10.1006/jmcc.1994.1008; Chen HY, 2004, DEVELOPMENT, V131, P2219, DOI 10.1242/dev.01094; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Cohn JN, 1997, CIRCULATION, V95, P766; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; Field LJ, 2004, ANN NY ACAD SCI, V1015, P160, DOI 10.1196/annals.1302.013; Gaussin V, 2005, CIRC RES, V97, P219, DOI 10.1161/01.RES.0000177862.85474.63; Gaussin V, 2002, P NATL ACAD SCI USA, V99, P2878, DOI 10.1073/pnas.042390499; Gerdes A M, 1998, J Card Fail, V4, P343, DOI 10.1016/S1071-9164(98)90240-8; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; JACKSON T, 1990, MOL CELL BIOL, V10, P3709, DOI 10.1128/MCB.10.7.3709; KAPLAN ML, 1994, AM J PHYSIOL, V267, pH1167, DOI 10.1152/ajpheart.1994.267.3.H1167; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Luo J, 2005, MOL CELL BIOL, V25, P9491, DOI 10.1128/MCB.25.21.9491-9502.2005; MacLellan WB, 1999, HEART DEV, P405; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mazerbourg S, 2005, J BIOL CHEM, V280, P32122, DOI 10.1074/jbc.M504629200; McMullen JR, 2004, J BIOL CHEM, V279, P4782, DOI 10.1074/jbc.M310405200; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; Nakajima H, 2000, CIRC RES, V86, P571, DOI 10.1161/01.RES.86.5.571; Neuhaus H, 1999, MECH DEVELOP, V80, P181, DOI 10.1016/S0925-4773(98)00221-4; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rodriguez P, 2005, ARCH MAL COEUR VAISS, V98, P1239; Rubart M, 2003, CIRC RES, V92, P1217, DOI 10.1161/01.RES.0000075089.39335.8C; RUMYANTSEV PP, 1991, SOVIET MED REV S SER; SCHEUER J, 1987, CIRCULATION, V75, P63; Shen WH, 2005, J ENDOCRINOL, V185, P275, DOI 10.1677/joe.1.06080; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1997, AM J PHYSIOL-HEART C, V272, pH220, DOI 10.1152/ajpheart.1997.272.1.H220; SOONPAA MH, 1994, AM J PHYSIOL, V266, pH1439, DOI 10.1152/ajpheart.1994.266.4.H1439; TUCKER DC, 1995, J MOL CELL CARDIOL, V27, P1415, DOI 10.1006/jmcc.1995.0134; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Yi SE, 2000, DEVELOPMENT, V127, P621; Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102	45	44	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27481	27491		10.1074/jbc.M604818200	http://dx.doi.org/10.1074/jbc.M604818200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16798733	Green Accepted, hybrid			2022-12-27	WOS:000240397700075
J	Sammons, M; Wan, SS; Vogel, NL; Mientjes, EJ; Grosveld, G; Ashburner, BP				Sammons, Morgan; Wan, Shan Shan; Vogel, Nancy L.; Mientjes, Edwin J.; Grosveld, Gerard; Ashburner, Brian P.			Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL COACTIVATORS; DEACETYLASE INHIBITORS; MEDIATED TRANSCRIPTION; PROTEIN; ACTIVATION; ALPHA; P300; INDUCTION; CHROMATIN	NF-kappa B-mediated transcriptional activation is controlled at several levels including interaction with coregulatory proteins. To identify new proteins capable of modulating NF-kappa B-mediated activation, a cytoplasmic two-hybrid screen was performed using the p65 C-terminal transactivation domain as bait and identified the product of the DEK proto-oncogene. DEK is a ubiquitous nuclear protein that has been implicated in several types of cancer and autoimmune diseases. DEK appears to function in several nuclear processes including transcriptional repression and modulation of chromatin structure. Our data indicate that DEK functions as a transcriptional corepressor to repress NF-kappa B activity. DEK expression blocked p65-mediated activation of an NF-kappa B-dependent reporter gene and also inhibited TNF alpha-induced activation of the reporter gene. Chromatin Immunoprecipitation (ChIP) assays showed that DEK associates with the promoters of the NF-kappa B-regulated cIAP2 and IL-8 genes in untreated cells and dissociates from these promoters upon NF-kappa B-binding in response to TNF alpha treatment. Moreover, the expression levels of an NF-kappa B-dependent reporter gene as well as the NF-kappa B-regulated Mcp-1 and I kappa B alpha genes is increased in DEK-/- cells compared with wild-type cells. ChIP assays on these promoters show enhanced and prolonged binding of p65 and increased recruitment of the P/CAF coactivator. Overall, these data provide further evidence that DEK functions to negatively regulate transcription.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Univ Toledo, Undergrad Honors Program, Toledo, OH 43606 USA; St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA	University System of Ohio; University of Toledo; University System of Ohio; University of Toledo; St Jude Children's Research Hospital	Ashburner, BP (corresponding author), Univ Toledo, Dept Biol Sci, MS 601,2801 W Bancroft St, Toledo, OH 43606 USA.	brian.ashburner@utoledo.edu	Wan, Shanshan/C-3800-2013		NIGMS NIH HHS [1 R15 GM071405-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM071405] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam E, 2003, MOL CELL BIOL, V23, P6200, DOI 10.1128/MCB.23.17.6200-6209.2003; Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Alexiadis V, 2000, GENE DEV, V14, P1308; Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bubulya A, 2001, J BIOL CHEM, V276, P44704, DOI 10.1074/jbc.M107346200; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Cleary J, 2005, J BIOL CHEM, V280, P31760, DOI 10.1074/jbc.M500884200; Dong XW, 2000, ARTHRITIS RHEUM-US, V43, P85, DOI 10.1002/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D; Faulkner NE, 2001, J BIOL CHEM, V276, P25804, DOI 10.1074/jbc.M006454200; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko SI, 2006, FEBS LETT, V580, P3217, DOI 10.1016/j.febslet.2006.04.081; Lee C, 1999, J BIOL CHEM, V274, P26767, DOI 10.1074/jbc.274.38.26767; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sitwala KV, 2003, ANTICANCER RES, V23, P2155; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Waldmann T, 2004, GENE, V343, P1, DOI 10.1016/j.gene.2004.08.029; Waldmann T, 2003, NUCLEIC ACIDS RES, V31, P7003, DOI 10.1093/nar/gkg864; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	54	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26802	26812		10.1074/jbc.M600915200	http://dx.doi.org/10.1074/jbc.M600915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16829531	hybrid			2022-12-27	WOS:000240397700007
J	Vertii, A; Hakim, C; Kotlyarov, A; Gaestel, M				Vertii, Anastassiia; Hakim, Cosima; Kotlyarov, Alexey; Gaestel, Matthias			Analysis of properties of small heat shock protein Hsp25 in MAPK-activated protein kinase 2 (MK2)-deficient cells - MK2-dependent insolubilization of Hsp25 oligomers correlates with susceptibility to stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; ACTIN POLYMERIZATION; OXIDATIVE STRESS; CELLULAR THERMORESISTANCE; PROTECTIVE ACTIVITY; KINASE INHIBITORS; CRYSTAL-STRUCTURE; MOTOR NEUROPATHY; PHOSPHORYLATION; SUBSTRATE	Small heat shock proteins (sHsps) exist in dynamic oligomeric complexes and display diverse biological functions ranging from chaperone properties to modulator of apoptosis. So far, the role of stress-dependent phosphorylation of mammalian sHsps for its structure and function has been analyzed by using various phosphorylation site mutants overexpressed in different cell types as well as by non-exclusive inhibitors of the p38 MAPK cascade. Here we investigate the role of phosphorylation of endogenous sHsp in a genetic model lacking the major Hsp25 kinase, the MAP kinase-activated protein kinase MK2. We demonstrate that in MK2- deficient fibroblasts, where no stress-dependent phosphorylation of Hsp25 at Ser(86) and no in vitro binding to 14-3-3 was detectable, stress-dependent disaggregation of endogenous Hsp25 complexes is impared and kinetics of arsenite-dependent, H2O2-dependent, and sublethal heat shock-induced insolubilization of Hsp25 is delayed. Similarly, green fluorescent protein- tagged Hsp25 shows retarded subcellular accumulation into stress granules in MK2-deficient cells after arsenite treatment. Decreased insolubilization of Hsp25 in MK2-deficient cells correlates with increased resistance against arsenite, H2O2, and sublethal heat shock treatment and with decreased apoptosis. In contrast, after severe, lethal heat shock MK2-deficient embryonic fibroblasts cells show fast and complete insolubilization of Hsp25 independent of MK2 and no increased stress resistance. Hence, MK2-dependent formation of insoluble stress granules and irreversible cell damage by oxidative stresses and sublethal heat shock correlate and only upon severe, lethal heat shock MK2-independent processes could determine insolubilization of Hsp25 and are more relevant for cellular stress damage.	Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	Hannover Medical School	Gaestel, M (corresponding author), Hannover Med Sch, Inst Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gaestel.matthias@mh-hannover.de	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Vertii, Anastassiia/0000-0002-0939-0389				Abraham RT, 2005, MOL CELL, V17, P163, DOI 10.1016/j.molcel.2005.01.005; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; Cuesta R, 2000, GENE DEV, V14, P1460; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Dreiza CM, 2004, FASEB J, V18, P261, DOI 10.1096/fj.04-2911fje; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Eyers CE, 2005, BIOCHEM J, V389, P127, DOI 10.1042/BJ20050387; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Gaestel M, 2002, Prog Mol Subcell Biol, V28, P151; Garrido C, 2002, CELL DEATH DIFFER, V9, P483, DOI 10.1038/sj.cdd.4401005; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Guay J, 1997, J CELL SCI, V110, P357; Haslbeck M, 2005, NAT STRUCT MOL BIOL, V12, P842, DOI 10.1038/nsmb993; Huot J, 1996, CANCER RES, V56, P273; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Loktionova SA, 1996, FEBS LETT, V392, P100, DOI 10.1016/0014-5793(96)00792-2; Lukas SM, 2004, BIOCHEMISTRY-US, V43, P9950, DOI 10.1021/bi049508v; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Preville X, 1998, CELL STRESS CHAPERON, V3, P177, DOI 10.1379/1466-1268(1998)003<0177:PINEFP>2.3.CO;2; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Shi Y, 2003, MOL CELL BIOL, V23, P7732, DOI 10.1128/MCB.23.21.7732-7741.2003; Singh S, 2003, J BIOL CHEM, V278, P36410, DOI 10.1074/jbc.M306428200; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	60	32	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26966	26975		10.1074/jbc.M602134200	http://dx.doi.org/10.1074/jbc.M602134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16840785	hybrid			2022-12-27	WOS:000240397700023
J	El-Tanani, MK; Campbell, FC; Crowe, P; Erwin, P; Harkin, DP; Pharoah, P; Ponder, B; Rudland, PS				El-Tanani, Mohamed K.; Campbell, Frederick Charles; Crowe, Paul; Erwin, Pauline; Harkin, Denis Paul; Pharoah, Paul; Ponder, Bruce; Rudland, Philip S.			BRCA1 suppresses osteopontin-mediated breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE TUMOR-SUPPRESSOR; GENE-EXPRESSION; NEOPLASTIC TRANSFORMATION; OVARIAN-CANCER; ESTROGEN; GROWTH; TRANSCRIPTION; METASTASIS; INHIBITION; PROTEIN	BRCA1 is a well described breast cancer susceptibility gene thought to be involved primarily in DNA repair. However, mutation within the BRCA1 transcriptional domain is also implicated in neoplastic transformation of mammary epithelium, but responsible mechanisms are unclear. Here we show in a rat mammary model system that wild type (WT) BRCA1 specifically represses the expression of osteopontin (OPN), a multifunctional estrogen-responsive gene implicated in oncogenic transformation, particularly that of the breast. WT. BRCA1 selectively binds OPN-activating transcription factors estrogen receptor alpha, AP-1, and PEA3, inhibits OPN promoter transactivation, and suppresses OPN mRNA and protein both from an endogenous gene and a relevant model inducible gene. WT. BRCA1 also inhibits OPN-mediated neoplastic transformation characterized by morphology change, anchorage-independent growth, adhesion to fibronectin, and invasion through Matrigel. A mutant BRCA1 allele (Mut. BRCA1) associated with familial breast cancer lacks OPN suppressor effects, binds to WT. BRCA1, and impedes WT. BRCA1 suppression of OPN. Stable transfection of rat breast tumor cell lines with Mut. BRCA1 dramatically up-regulates OPN protein and induces anchorage-independent growth. In human primary breast cancer, BRCA1 mutation is significantly associated with OPN overexpression. Taken together, these data suggest that BRCA1 mutation may confer increased tissue-specific cancer risk, in part by disruption of BRCA1 suppression of OPN gene transcription.	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT12 6BJ, Antrim, North Ireland; Univ Cambridge, Strangeways Res Lab, Cambridge CB1 8RN, England; Univ Liverpool, Sch Biol Sci, Canc & Polio Res Fund Labs, Liverpool L69 7ZB, Merseyside, England	Queens University Belfast; University of Cambridge; University of Liverpool	El-Tanani, MK (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.	m.el-tanani@qub.ac.uk	Pharoah, Paul/V-6658-2019	Pharoah, Paul/0000-0001-8494-732X; El-Tanani, Mohamed/0000-0002-4735-5445; Campbell, Frederick/0000-0002-0363-9964	Medical Research Council [G0200103] Funding Source: Medline; MRC [G0200103] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Al-Mulla F, 2005, J HISTOCHEM CYTOCHEM, V53, P621, DOI 10.1369/jhc.4A6544.2005; BEHREND EI, 1994, CANCER RES, V54, P832; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; Chan YJ, 1996, J VIROL, V70, P8590, DOI 10.1128/JVI.70.12.8590-8605.1996; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Chen YM, 1996, CANCER RES, V56, P3168; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Devoll RE, 1999, J ORAL PATHOL MED, V28, P97; Dulic A, 2001, BIOCHEMISTRY-US, V40, P5906, DOI 10.1021/bi002701e; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; Euer N, 2002, ANTICANCER RES, V22, P733; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Gayther SA, 1999, AM J HUM GENET, V65, P1021, DOI 10.1086/302583; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kachhap SK, 2000, CANCER LETT, V154, P115, DOI 10.1016/S0304-3835(00)00371-2; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Krishnan VV, 2001, BIOCHEMISTRY-US, V40, P13158, DOI 10.1021/bi010979g; Kurpios NA, 2003, J MAMMARY GLAND BIOL, V8, P177, DOI 10.1023/A:1025948823955; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Meier JL, 1996, INTERVIROLOGY, V39, P331, DOI 10.1159/000150504; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 2003, TRENDS GENET, V19, P312, DOI 10.1016/S0168-9525(03)00110-0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Oates AJ, 1996, ONCOGENE, V13, P97; Oates AJ, 1996, BIOCHEM SOC T, V24, pS353, DOI 10.1042/bst024353s; Orian-Rousseau V, 1998, J CELL SCI, V111, P1993; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Perez-Valles A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Rao VN, 1996, ONCOGENE, V12, P523; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; Rudland PS, 2002, CANCER RES, V62, P3417; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; SENGER DR, 1985, CANCER RES, V45, P5818; SENGER DR, 1988, CANCER RES, V48, P5770; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Sun Xian-jun, 2005, Zhonghua Zhongliu Zazhi, V27, P292; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, BREAST CANCER RES TR, V70, P197, DOI 10.1023/A:1013095329825; Uht Rosalie M, 2004, Nucl Recept, V2, P2, DOI 10.1186/1478-1336-2-2; Zhang Dong-tao, 2005, Zhonghua Zhongliu Zazhi, V27, P167; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	66	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26587	26601		10.1074/jbc.M604403200	http://dx.doi.org/10.1074/jbc.M604403200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16807234	hybrid			2022-12-27	WOS:000240249500077
J	Frangie, C; Zhang, WH; Perez, J; Dubois, YCX; Haymann, JP; Baud, L				Frangie, Carlos; Zhang, Wenhui; Perez, Joelle; Dubois, Yi-Chun Xu; Haymann, Jean-Philippe; Baud, Laurent			Extracellular calpains increase tubular epithelial cell mobility - Implications for kidney repair after ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; INTEGRIN; MIGRATION; ADHESION; INJURY; DEATH; PATHOPHYSIOLOGY; DEGRADATION; PROTEOLYSIS; INHIBITION	Calpains are intracellular Ca2+-dependent cysteine proteases that are released in the extracellular milieu by tubular epithelial cells following renal ischemia. Here we show that externalized calpains increase epithelial cell mobility and thus are critical for tubule repair. In vitro, exposure of human tubular epithelial cells (HK-2 cells) to mu-calpain limited their adhesion to extracellular matrix and increased their mobility. Calpains acted primarily by promoting the cleavage of fibronectin, thus preventing fibronectin binding to the integrin alpha(v)beta(3). Analyzing downstream integrin effects, we found that the cyclic AMP-dependent protein kinase A pathway was activated in response to alpha(v)beta(3) disengagement and was essential for calpain-mediated increase in HK-2 cell mobility. In a murine model of ischemic acute renal failure, injection of a fragment of calpastatin, which specifically blocked calpain activity in extracellular milieu, markedly delayed tubule repair, increasing functional and histological lesions after 24 and 48 h of reperfusion. These findings suggest that externalized calpains are critical for tubule repair process in acute renal failure.	INSERM, U702, F-75020 Paris, France; Univ Paris 06, F-75020 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Baud, L (corresponding author), Hop Tenon, INSERM, U702, 4 Rue Chine, F-75020 Paris, France.	laurent.baud@tnn.ap-hop-paris.fr						Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Bellocq A, 1999, J BIOL CHEM, V274, P36891, DOI 10.1074/jbc.274.52.36891; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; Bush KT, 2000, J CLIN INVEST, V106, P621, DOI 10.1172/JCI10968; Chatterjee PK, 2005, BIOCHEM PHARMACOL, V69, P1121, DOI 10.1016/j.bcp.2005.01.003; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; DESHPANDE RV, 1995, J BIOL CHEM, V270, P2497, DOI 10.1074/jbc.270.6.2497; Dourdin N, 1997, EXP CELL RES, V235, P385, DOI 10.1006/excr.1997.3684; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Fushimi K, 2004, OSTEOARTHR CARTILAGE, V12, P895, DOI 10.1016/j.joca.2004.08.001; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Glynne PA, 2001, J AM SOC NEPHROL, V12, P2370, DOI 10.1681/ASN.V12112370; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Harriman JF, 2002, CELL DEATH DIFFER, V9, P734, DOI 10.1038/sj.cdd.4401029; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; KARTHA S, 1992, J CLIN INVEST, V90, P288, DOI 10.1172/JCI115851; Kifor O, 2003, J BIOL CHEM, V278, P31167, DOI 10.1074/jbc.M303377200; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Lee HT, 2002, AM J PHYSIOL-RENAL, V282, pF844, DOI 10.1152/ajprenal.00195.2001; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Letavernier E, 2005, J AM SOC NEPHROL, V16, P2395, DOI 10.1681/ASN.2004090802; Li XH, 2002, P NATL ACAD SCI USA, V99, P9260, DOI 10.1073/pnas.132051799; Liu XL, 2003, J PHARMACOL EXP THER, V304, P63, DOI 10.1124/jpet.102.043406; Liu XL, 2001, AM J PHYSIOL-RENAL, V281, pF728, DOI 10.1152/ajprenal.2001.281.4.F728; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; McDonald JF, 2004, J BIOL CHEM, V279, P17301, DOI 10.1074/jbc.M312782200; Mehendale HM, 2005, TRENDS PHARMACOL SCI, V26, P232, DOI 10.1016/j.tips.2005.03.008; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022; Padanilam BJ, 2003, AM J PHYSIOL-RENAL, V284, pF608, DOI 10.1152/ajprenal.00284.2002; Paller MS, 1997, KIDNEY INT, pS52; Schrier RW, 2004, J CLIN INVEST, V114, P5, DOI 10.1172/JC1200422353; Seiffert D, 1996, J BIOL CHEM, V271, P11170, DOI 10.1074/jbc.271.19.11170; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Shi YX, 2000, AM J PHYSIOL-RENAL, V279, pF509, DOI 10.1152/ajprenal.2000.279.3.F509; Zuk A, 1998, AM J PHYSIOL-CELL PH, V275, pC711, DOI 10.1152/ajpcell.1998.275.3.C711	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26624	26632		10.1074/jbc.M603007200	http://dx.doi.org/10.1074/jbc.M603007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822870	hybrid			2022-12-27	WOS:000240249500080
J	O'Brien, JE; Peterson, TJ; Tong, MH; Lee, EJ; Pfaff, LE; Hewitt, SC; Korach, KS; Weiss, J; Jameson, JL				O'Brien, Jeanne E.; Peterson, Theresa J.; Tong, Ming Han; Lee, Eun-Jig; Pfaff, Liza E.; Hewitt, Sylvia C.; Korach, Kenneth S.; Weiss, Jeffrey; Jameson, J. Larry			Estrogen-induced proliferation of uterine epithelial cells is independent of estrogen receptor alpha binding to classical estrogen response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CYCLIN D1; BETA ER-BETA; PROGESTERONE-RECEPTOR; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; MOUSE; DISRUPTION; KNOCKOUT; UTERUS	Acting via the estrogen receptor (ER), estradiol exerts pleomorphic effects on the uterus, producing cyclical waves of cellular proliferation and differentiation in preparation for embryo implantation. In the classical pathway, the ER binds directly to an estrogen response element to activate or repress gene expression. However, emerging evidence supports the existence of nonclassical pathways in which the activated ER alters gene expression through protein-protein tethering with transcription factors such as c-Fos/ c-Jun B (AP-1) and Sp1. In this report, we examined the relative roles of classical and nonclassical ER signaling in vivo by comparing the estrogen-dependent uterine response in mice that express wild-type ER alpha, a mutant ER alpha (E207A/G208A) that selectively lacks ERE binding, or ER alpha null. In the compound heterozygote (AA/-) female, the nonclassical allele (AA) was insufficient to mediate an acute uterotrophic response to 17 beta-estradiol (E-2). The uterine epithelial proliferative response to E-2 and 4-hydroxytamoxifen was retained in the AA/-females, and uterine luminal epithelial height increased commensurate with the extent of ER alpha signaling. This proliferative response was confirmed by 5-bromo-2 '-deoxyuridine incorporation. Microarray experiments identified cyclin-dependent kinase inhibitor 1A as a nonclassical pathway-responsive gene, and transient expression experiments using the cyclin-dependent kinase inhibitor 1A promoter confirmed transcriptional responses to the ER alpha (E207A/ G208A) mutant. These results indicate that nonclassical ER alpha signaling is sufficient to restore luminal epithelial proliferation but not other estrogen-responsive events, such as fluid accumulation and hyperemia. We conclude that nonclassical pathway signaling via ER alpha plays a critical physiologic role in the uterine response to estrogen.	Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Div Reprod Endocrinol & Infertil, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; Yonsei Univ, Coll Med, Div Endocrinol, Seoul 120749, South Korea; NIEHS, NIH, Receptor Biol Sect, Lab Reprod & Dev Toxicol, Res Triangle Pk, NC 27709 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Yonsei University; Yonsei University Health System; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jameson, JL (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Div Reprod Endocrinol & Infertil, Lurie 7-220,303 E Superior St, Chicago, IL 60611 USA.	ljameson@northwestern.edu	Hewitt, Sylvia/W-8752-2019	Hewitt, Sylvia/0000-0001-7713-0805; Lee, Eun Jig/0000-0002-9876-8370; Jameson, James/0000-0001-9538-4059; Korach, Kenneth/0000-0002-7765-418X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070065] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NICHD NIH HHS [P01 HD21921, T32 HD07068] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Carthew P, 1999, TOXICOL APPL PHARM, V158, P24, DOI 10.1006/taap.1999.8679; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Chen B, 2003, MOL ENDOCRINOL, V17, P1368, DOI 10.1210/me.2003-0036; Coleman KM, 2001, FRONT BIOSCI, V6, pD1379, DOI 10.2741/Coleman; Cooke PS, 1997, P NATL ACAD SCI USA, V94, P6535, DOI 10.1073/pnas.94.12.6535; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; Dupont S, 2000, DEVELOPMENT, V127, P4277; Enmark E, 1999, J INTERN MED, V246, P133, DOI 10.1046/j.1365-2796.1999.00545.x; Geum DH, 1997, MOL REPROD DEV, V46, P450, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;450::AID-MRD2&gt;3.0.CO;2-N; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; Igarashi TM, 2005, FERTIL STERIL, V84, P67, DOI 10.1016/j.fertnstert.2005.01.113; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jakacka M, 2002, MOL ENDOCRINOL, V16, P2188, DOI 10.1210/me.2001-0174; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Jordan VC, 2002, CANCER CELL, V1, P215, DOI 10.1016/S1535-6108(02)00050-8; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurita T, 2000, BIOL REPROD, V62, P821, DOI 10.1095/biolreprod62.4.831; Kurita T, 2001, BIOL REPROD, V64, P272, DOI 10.1095/biolreprod64.1.272; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lai MD, 2002, ENDOCRINE, V17, P233, DOI 10.1385/ENDO:17:3:233; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MARTIN L, 1973, J ENDOCRINOL, V56, P133, DOI 10.1677/joe.0.0560133; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; POLLARD JW, 1987, CELL TISSUE RES, V249, P533; RAY A, 1994, J BIOL CHEM, V269, P12940; RIDER V, 1994, J ENDOCRINOL, V140, P239, DOI 10.1677/joe.0.1400239; Rockwell LC, 2002, BIOL REPROD, V67, P1804, DOI 10.1095/biolreprod.102.006700; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tong W, 1999, MOL CELL BIOL, V19, P2251; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; Zhang HF, 2005, J ENDOCRINOL, V184, P129, DOI 10.1677/joe.1.05987	54	94	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26683	26692		10.1074/jbc.M601522200	http://dx.doi.org/10.1074/jbc.M601522200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16847062	hybrid			2022-12-27	WOS:000240249500086
J	Quick, M; Yano, H; Goldberg, NR; Duan, LH; Beuming, T; Shi, L; Weinstein, H; Javitch, JA				Quick, Matthias; Yano, Hideaki; Goldberg, Naomi R.; Duan, Lihua; Beuming, Thijs; Shi, Lei; Weinstein, Harel; Javitch, Jonathan A.			State-dependent conformations of the translocation pathway in the tyrosine transporter Tyt1, a novel neurotransmitter : sodium symporter from Fusobacterium nucleatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE TRANSPORT; ISOLATED MEMBRANE-VESICLES; NA+ GLUCOSE COTRANSPORTER; AMINO-ACID TRANSPORTER; ESCHERICHIA-COLI; MELIBIOSE PERMEASE; SEROTONIN TRANSPORTER; NA+/PROLINE PERMEASE; DOPAMINE TRANSPORTER; BACTERIAL HOMOLOG	The gene of a novel prokaryotic member (Tyt1) of the neurotransmitter: sodium symporter (NSS) family has been cloned from Fusobacterium nucleatum. In contrast to eukaryotic and some prokaryotic NSSs, which contain 12 transmembrane domains (TMs), Tyt1 contains only 11 TMs, a characteristic shared by similar to 70% of prokaryotic NSS homologues. Nonetheless upon heterologous expression in an engineered Escherichia coli host, Tyt1 catalyzes robust Na+-dependent, highly selective L-tyrosine transport. Genetic engineering of Tyt1 variants devoid of cysteines or with individually retained endogenous cysteines at positions 18 or 238, at the cytoplasmic ends of TM1 and TM6, respectively, preserved normal transport activity. Whereas cysteine-less Tyt1 was resistant to the inhibitory effect of sulfhydryl-alkylating reagents, N-ethylmaleimide inhibited transport by Tyt1 variants containing either one or both of the endogenous cysteines, and this inhibition was altered by the substrates sodium and tyrosine, consistent with substrate-induced dynamics in the transport pathway. Our findings support a binding model of Tyt1 function in which an ordered sequence of substrate-induced structural changes reflects distinct conformational states of the transporter. This work identifies Tyt1 as the first functional bacterial NSS member putatively consisting of only 11 TMs and shows that Tyt1 is a suitable model for the study of NSS dynamics with relevance to structure/function relationships of human NSSs, including the dopamine, norepinephrine, serotonin, and gamma-aminobutyric acid transporters.	Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Cornell Univ, Dept Physiol & Biophys, Weill Med Coll, New York, NY 10021 USA; Cornell Univ, Dept Physiol & Biophys, Weill Med Coll, His Royal Highness Prince Alwaleed Bin Talal Bin, New York, NY 10021 USA	Columbia University; Columbia University; Columbia University; Cornell University; Cornell University	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, P&S 11-401,Box 7, New York, NY 10032 USA.	jaj2@columbia.edu	Shi, Lei/AAV-1321-2020; WEINSTEIN, HAREL/O-8245-2019	Shi, Lei/0000-0002-4137-096X; WEINSTEIN, HAREL/0000-0003-3473-9818; Yano, Hideaki/0000-0001-9242-3884; Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408, R01DA017293] Funding Source: NIH RePORTER; NIDA NIH HHS [DA17293, DA12408] Funding Source: Medline; NIMH NIH HHS [MH57324] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amara SG, 1998, DRUG ALCOHOL DEPEN, V51, P87, DOI 10.1016/S0376-8716(98)00068-4; Androutsellis-Theotokis A, 2003, J BIOL CHEM, V278, P12703, DOI 10.1074/jbc.M206563200; BARNES EM, 1970, P NATL ACAD SCI USA, V66, P1190, DOI 10.1073/pnas.66.4.1190; BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Broer A, 2006, BIOCHEM J, V393, P421, DOI 10.1042/BJ20051273; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Do CB, 2005, GENOME RES, V15, P330, DOI 10.1101/gr.2821705; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Feldman DH, 2000, J BIOL CHEM, V275, P24518, DOI 10.1074/jbc.M907582199; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Goldberg NR, 2003, EUR J PHARMACOL, V479, P3, DOI 10.1016/j.ejphar.2003.08.052; GU H, 1994, J BIOL CHEM, V269, P7124; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; Iversen L, 2006, BRIT J PHARMACOL, V147, pS82, DOI 10.1038/sj.bjp.0706428; Jensdottir T, 2005, CARIES RES, V39, P468, DOI 10.1159/000088181; KABACK HR, 1971, J BIOL CHEM, V246, P5523; Kapatral V, 2002, J BACTERIOL, V184, P2005, DOI 10.1128/JB.184.7.2005-2018.2002; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; KRUEGER BK, 1990, J NEUROCHEM, V55, P260, DOI 10.1111/j.1471-4159.1990.tb08847.x; Li LB, 2002, N-S ARCH PHARMACOL, V365, P303, DOI 10.1007/s00210-001-0526-6; Loo DDF, 2005, J GEN PHYSIOL, V125, P13, DOI 10.1085/jgp.200409150; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Masson J, 1999, PHARMACOL REV, V51, P439; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; Quick M, 2002, P NATL ACAD SCI USA, V99, P8597, DOI 10.1073/pnas.132266599; Quick M, 2001, J BIOL CHEM, V276, P1728, DOI 10.1074/jbc.M005521200; Rees DC, 2000, J BIOL CHEM, V275, P713, DOI 10.1074/jbc.275.2.713; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 2002, NEUROTRANSMITTER TRA; Saier MH, 1999, J CELL BIOCHEM, P84; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schenk JO, 2005, J NEUROSCI METH, V143, P41, DOI 10.1016/j.jneumeth.2004.09.021; Sonders MS, 2005, CURR OPIN NEUROBIOL, V15, P296, DOI 10.1016/j.conb.2005.05.009; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; Tate CG, 2003, BBA-BIOMEMBRANES, V1610, P141, DOI 10.1016/S0005-2736(02)00719-8; Tate CG, 2001, FEBS LETT, V504, P94, DOI 10.1016/S0014-5793(01)02711-9; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; VANDERREST ME, 1992, J BACTERIOL, V174, P4893, DOI 10.1128/JB.174.15.4893-4898.1992; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991	64	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26444	26454		10.1074/jbc.M602438200	http://dx.doi.org/10.1074/jbc.M602438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16798738	hybrid			2022-12-27	WOS:000240249500062
J	Simon, GM; Cravatt, BF				Simon, Gabriel M.; Cravatt, Benjamin F.			Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL ARACHIDONYL FLUOROPHOSPHONATE; ACID AMIDE HYDROLASE; CANNABINOID RECEPTOR; PHOSPHOLIPASE-D; MOLECULAR CHARACTERIZATION; ACYLETHANOLAMINE PHOSPHOLIPIDS; ANANDAMIDE HYDROLYSIS; BRAIN; A(2); PHOSPHODIESTERASE	N-Acyl ethanolamines (NAEs) are a large class of signaling lipids implicated in diverse physiological processes, including nociception, cognition, anxiety, appetite, and inflammation. It has been proposed that NAEs are biosynthesized from their corresponding N-acyl phosphatidylethanolamines (NAPEs) in a single enzymatic step catalyzed by a phospholipase D (NAPE-PLD). The recent generation of NAPE-PLD(-/-) mice has revealed that these animals possess lower brain levels of saturated NAEs but essentially unchanged concentrations of polyunsaturated NAEs, including the endogenous cannabinoid anandamide. These findings suggest the existence of additional enzymatic routes for the production of NAEs in vivo. Here, we report evidence for an alternative pathway for NAE biosynthesis that proceeds through the serine hydrolase-catalyzed double-deacylation of NAPE to generate glycerophospho-NAE, followed by the phosphodiesterase-mediated cleavage of this intermediate to liberate NAE. Furthermore, we describe the functional proteomic isolation and identification of a heretofore uncharacterized enzyme alpha/beta-hydrolase 4 (Abh4) as a lysophospholipase/phospholipase B that selectively hydrolyzes NAPEs and lysoNAPEs. Abh4 accepts lysoNAPEs bearing both saturated and polyunsaturated N-acyl chains as substrates and displays a distribution that closely mirrors lysoNAPE-lipase activity in mouse tissues. These results support the existence of an NAPE-PLD-independent route for NAE biosynthesis and suggest that Abh4 plays a role in this metabolic pathway by acting as a (lyso) NAPE-selective lipase.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cravatt@scripps.edu			NIDA NIH HHS [R01 DA015197, P01 DA017259, DA017259, R01 DA015197-04, P01 DA017259-03, DA015197] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015197, P01DA017259] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Fernandez Jose R, 2004, Curr Opin Investig Drugs, V5, P430; Gaetani S, 2003, TRENDS MOL MED, V9, P474, DOI 10.1016/j.molmed.2003.09.005; Jessani N, 2005, NAT METHODS, V2, P691, DOI 10.1038/NMETH778; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Leiros I, 2000, STRUCTURE, V8, P655, DOI 10.1016/S0969-2126(00)00150-7; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Lichtman AH, 2004, PAIN, V109, P319, DOI 10.1016/j.pain.2004.01.022; Lichtman AH, 2002, PROSTAG LEUKOTR ESS, V66, P269, DOI 10.1054/plef.2001.0351; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; NATARAJAN V, 1982, BIOCHIM BIOPHYS ACTA, V712, P342, DOI 10.1016/0005-2760(82)90352-6; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Renault L, 2005, CHEM-BIOL INTERACT, V157, P339, DOI 10.1016/j.cbi.2005.10.100; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SIEGEL GJ, 1994, BASIC NEUROCHEMISTRY, P182; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; Ueda N, 2001, BBA-MOL CELL BIOL L, V1532, P121, DOI 10.1016/S1388-1981(01)00120-2; WAITE M, 1985, J LIPID RES, V26, P1379; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; WALSH CT, 1979, ENZYMATIC REACTION M, P92	38	274	284	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26465	26472		10.1074/jbc.M604660200	http://dx.doi.org/10.1074/jbc.M604660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16818490	hybrid			2022-12-27	WOS:000240249500064
J	Yi, XP; Hargett, SR; Frankel, LK; Bricker, TM				Yi, Xiaoping; Hargett, Stefan R.; Frankel, Laurie K.; Bricker, Terry M.			The PsbQ protein is required in Arabidopsis for photosystem II assembly/stability and photoautotrophy under low light conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN EVOLUTION; STABILIZING PROTEIN; EVOLVING COMPLEX; CHLOROPLAST; TRANSFORMATION; TRANSITIONS; COMPONENTS; RNA	RNA interference was used to simultaneously suppress the expression of the two genes that encode the PsbQ proteins of Photosystem II (PS II) in Arabidopsis thaliana, psbQ-1 (At4g21280) and psbQ-2 (At4g05180). Two independent PsbQ-deficient plant lines were examined. These plant lines produced little detectable PsbQ protein. Under normal growth light conditions, the wild type and mutant plants were visually indistinguishable. Additionally, analysis of steady state oxygen evolution rates and chlorophyll fluorescence characteristics indicated little alteration of photosynthetic capacity in the mutant plants. No loss of other PS II proteins was evident. Interestingly, flash oxygen yield analysis performed on thylakoid membranes isolated from the mutant and wild type plants indicated that the oxygen-evolving complex was quite unstable in the mutants. Furthermore, the lifetime of the S-2 state of the oxygen-evolving complex appeared to be increased in these plants. Incubation of the wild type and mutant plants under low light growth conditions led to a significantly stronger observed phenotype in the mutants. The mutant plants progressively yellowed (after 2 weeks) and eventually died (after 3-4 weeks). The wild type plants exhibited only slight yellowing after 4 weeks under low light conditions. The mutant plants exhibited a large loss of a number of PS II components, including CP47 and the D2 protein, under low light conditions. Additionally, significant alterations of their fluorescence characteristics were observed, including an increased F-O and decreased F-V, yielding a large loss in PS II quantum efficiency (F-V/F-M). Analysis of Q(A)(-) decay kinetics in the absence of 3-(3,4-dichlorophenyl)-1,1-dimethyl urea indicated a defect in electron transfer from Q(A)(-) to Q(B), whereas experiments performed in the presence of this herbicide indicated that the recombination rate between Q(A)(-) and the S2 state was strongly retarded. These results indicate that the loss of the PsbQ protein induces significant changes in Photosystem II function, particularly in low light-grown plants, and that the PsbQ protein is required for photoautotrophic growth under low light conditions.	Louisiana State Univ, Dept Biol Sci, Biochem & Mol Biol Sect, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Bricker, TM (corresponding author), Louisiana State Univ, Dept Biol Sci, Biochem & Mol Biol Sect, Baton Rouge, LA 70803 USA.	btbric@lsu.edu						ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Bricker TM, 2005, ADV PHOTO RESPIRAT, V22, P95; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DEMMIG B, 1983, PLANT PHYSIOL, V73, P169, DOI 10.1104/pp.73.1.169; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; FRANKEL LK, 1990, CURRENT RESEARCH IN PHOTOSYNTHESIS, VOLS 1-4, pA639; HAILTON AJ, 1999, SCIENCE, V286, P950; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; Ifuku K, 2005, PLANT PHYSIOL, V139, P1175, DOI 10.1104/pp.105.068643; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; Lazar D, 2006, FUNCT PLANT BIOL, V33, P9, DOI 10.1071/FP05095; MEUNIER PC, 1993, PHOTOSYNTH RES, V36, P111, DOI 10.1007/BF00016276; MIYAO M, 1985, FEBS LETT, V180, P303, DOI 10.1016/0014-5793(85)81091-7; MURATA N, 1984, BIOCHIM BIOPHYS ACTA, V765, P363, DOI 10.1016/0005-2728(84)90177-4; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; SCHULDINER S, 1971, EUR J BIOCHEM, V19, P227, DOI 10.1111/j.1432-1033.1971.tb01308.x; Suorsa M, 2006, J BIOL CHEM, V281, P145, DOI 10.1074/jbc.M510600200; Thornton LE, 2004, PLANT CELL, V16, P2164, DOI 10.1105/tpc.104.023515; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; Wincencjusz H, 1997, BIOCHEMISTRY-US, V36, P3663, DOI 10.1021/bi9626719; Yi XP, 2005, J BIOL CHEM, V280, P16170, DOI 10.1074/jbc.M501550200; ZHAO D, 2003, PLANT PHYSIOL, V133, P1	29	79	85	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26260	26267		10.1074/jbc.M603582200	http://dx.doi.org/10.1074/jbc.M603582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16822865	Green Published, hybrid			2022-12-27	WOS:000240249500043
J	Gao, S; Laughon, A				Gao, Sheng; Laughon, Allen			Decapentaplegic-responsive silencers contain overlapping Mad-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DNA-BINDING; SMAD7 PROMOTER; DROSOPHILA EMBRYO; TRANSCRIPTIONAL ACTIVATION; MORPHOGEN GRADIENT; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DPP TARGETS; STEM-CELLS	Smad proteins regulate transcription in response to transforming growth factor-beta signaling pathways by binding to two distinct types of DNA sites. The sequence GTCT is recognized by all receptor-activated Smads and by Smad4. The subset of Smads that responds to bone morphogenetic protein signaling recognizes a distinct class of GC-rich sites in addition to GTCT. Recent work has shown that Drosophila Mad protein, the homologue of bone morphogenetic protein rSmads, binds to GRCGNC sites through the same MH1 domain beta-hairpin interface used to contact GTCT sites. However, binding to GRCGNC requires base-specific contact by two Mad proteins, and here we provide evidence that this is achieved by contact of the two Mad subunits that overlap across the two central base pairs of the site. This topology is supported by results indicating that His-93, which is located at the tip of the Mad beta-hairpin, is in close proximity to base pairs 2 and 5. Also consistent with the model is disruption of binding by mutation of Glu-39 and Glu-40, which are predicted to lie at the interface of the two overlapping Mad MH1 domains. As predicted from the overlapping model, binding is disrupted by insertion of 1 bp in the middle of the site, whereas insertion of 2 bp creates abutting sites that can be bound by the Mad-Medea heterotrimer without requiring Glu-39 and Glu-40. Overlapping Mad sites predominate in decapentaplegic response elements, consistent with a high degree of specificity in response to signaling.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Laughon, A (corresponding author), Univ Wisconsin, Genet Lab, 425G Henry Mall, Madison, WI 53706 USA.	alaughon@wisc.edu						Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298; Ashe HL, 2000, DEVELOPMENT, V127, P3305; Benchabane H, 2003, MOL CELL BIOL, V23, P6646, DOI 10.1128/MCB.23.18.6646-6661.2003; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Brugger SM, 2004, DEVELOPMENT, V131, P5153, DOI 10.1242/dev.01390; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chai JJ, 2003, J BIOL CHEM, V278, P20327, DOI 10.1074/jbc.C300134200; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; Chen DH, 2003, DEVELOPMENT, V130, P1159, DOI 10.1242/dev.00325; De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Dorfman R, 2001, DEVELOPMENT, V128, P965; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gao S, 2005, J BIOL CHEM, V280, P36158, DOI 10.1074/jbc.M506882200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirkpatrick H, 2001, J BIOL CHEM, V276, P18216, DOI 10.1074/jbc.M101365200; Knirr S, 2001, DEV BIOL, V238, P13, DOI 10.1006/dbio.2001.0397; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Kusanagi K, 2001, J BIOL CHEM, V276, P28155, DOI 10.1074/jbc.M103371200; Lee HH, 2005, DEVELOPMENT, V132, P1429, DOI 10.1242/dev.01687; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Mishra L, 2005, SCIENCE, V310, P68, DOI 10.1126/science.1118389; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Niswander L, 2003, NAT REV GENET, V4, P133, DOI 10.1038/nrg1001; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; Pyrowolakis G, 2004, DEV CELL, V7, P229, DOI 10.1016/j.devcel.2004.07.008; Raftery LA, 2003, TRENDS GENET, V19, P701, DOI 10.1016/j.tig.2003.10.009; Rushlow C, 2001, GENE DEV, V15, P340, DOI 10.1101/gad.861401; Rusten TE, 2002, DEVELOPMENT, V129, P3575; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Seki K, 2004, J BIOL CHEM, V279, P18544, DOI 10.1074/jbc.M311592200; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Sivasankaran R, 2000, EMBO J, V19, P6162, DOI 10.1093/emboj/19.22.6162; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Vlahovicek K, 2003, NUCLEIC ACIDS RES, V31, P3686, DOI 10.1093/nar/gkg559; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wharton SJ, 2004, CURR BIOL, V14, P1550, DOI 10.1016/j.cub.2004.08.053; Xu M, 2005, DEVELOPMENT, V132, P1637, DOI 10.1242/dev.01722; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang HL, 2001, GENE DEV, V15, P261, DOI 10.1101/gad.861201	61	9	11	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25781	25790		10.1074/jbc.M603371200	http://dx.doi.org/10.1074/jbc.M603371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829514	hybrid			2022-12-27	WOS:000240031300080
J	Utepbergenov, DI; Fanning, AS; Anderson, JM				Utepbergenov, Darkhan I.; Fanning, Alan S.; Anderson, James M.			Dimerization of the scaffolding protein ZO-1 through the second PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION; MEDIATED MULTIMERIZATION; CRYSTAL-STRUCTURE; COMPLEX REVEALS; EXPRESSION; OCCLUDIN; CELLS; ASSOCIATION; PSD-95; ACTIN	The tight junction protein ZO-1 is known to link the transmembrane proteins occludin, claudins, and JAMs to many cytoplasmic proteins and the actin cytoskeleton. Although specific roles for ZO-1 at the tight junction are unknown, it is widely assumed that ZO-1, together with its homologs ZO-2 and ZO-3, serves as a platform to scaffold various transmembrane and cytoplasmic tight junction proteins. Thus the manner in which the zonula occludens (ZO) proteins multimerize has implications for the protein networks they can coordinate. The purpose of our study was to determine whether ZO-1 forms homodimers and to determine the protein interaction region. Using laser light scattering and analytical centrifugation, we show that protein sequences corresponding to the NH2- terminal half of ZO-1 form stable homodimers with a submicromolar equilibrium dissociation constant. Analysis of the molecular weight of different truncated forms of ZO-1 revealed that the second PDZ domain is both necessary and sufficient for dimerization. This interaction does not use the beta-finger motif described for other PDZ dimers. Furthermore, ZO-1 does not dimerize via an Src homology 3 to Guk domain interaction as was demonstrated previously for MAGUKs, like PSD-95. Results from immunoprecipitation experiments with polarized Madin-Darby canine kidney epithelial cells stably transfected with full-length GFP-ZO-1 indicate that a substantial portion of ZO-1 forms homodimers in vivo. As described previously, ZO-1 also forms heterodimers with ZO-2 and ZO-3. We conclude that the dimerization of ZO proteins is unlike that of other MAGUKs and that the previously unrecognized ZO-1 homodimers may allow formation of protein networks distinct from those of heterodimers with ZO-2 and ZO-3.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Anderson, JM (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, Med & Biomol Res Bldg,CB 7545, Chapel Hill, NC 27599 USA.	jandersn@med.unc.edu	Utepbergenov, Darkhan/N-9881-2014; Utepbergenov, Darkhan/AAA-1249-2021	Utepbergenov, Darkhan/0000-0002-9005-4103; Utepbergenov, Darkhan/0000-0002-9005-4103; Anderson, James/0000-0003-2765-7996	NIDDK NIH HHS [DK61397, R01 DK061397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061397, R56DK061397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Gonzalez-Mariscal L, 2000, KIDNEY INT, V57, P2386, DOI 10.1046/j.1523-1755.2000.00098.x; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Im YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; Inoko A, 2003, GENES CELLS, V8, P837, DOI 10.1046/j.1365-2443.2003.00681.x; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; Kausalya PJ, 2001, FEBS LETT, V505, P92, DOI 10.1016/S0014-5793(01)02786-7; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; Nielsen PA, 2003, MOL BIOL CELL, V14, P2470, DOI 10.1091/mbc.E02-10-0637; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Riesen FK, 2002, HISTOCHEM CELL BIOL, V117, P307, DOI 10.1007/s00418-002-0398-y; Ryeom SW, 2000, MOL BIOL CELL, V11, P1687, DOI 10.1091/mbc.11.5.1687; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179	23	74	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24671	24677		10.1074/jbc.M512820200	http://dx.doi.org/10.1074/jbc.M512820200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790439	Green Published, hybrid			2022-12-27	WOS:000239847800062
J	Lee, CW; Rivera, R; Gardell, S; Dubin, AE; Chun, J				Lee, Chang-Wook; Rivera, Richard; Gardell, Shannon; Dubin, Adrienne E.; Chun, Jerold			GPR92 as a new G(12/13)- and G(q)-coupled lysophosphatidic acid receptor that increases cAMP, LPA(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-GAMMA-SUBUNITS; LYSOPHOSPHOLIPID RECEPTORS; CELLULAR-RESPONSES; MOLECULAR-CLONING; ADENYLYL-CYCLASE; MESSENGER-RNA; EDG-FAMILY; EXPRESSION; SYSTEM	The signaling effects of lysophospholipids such as lysophosphatidic acid (LPA) are mediated by G protein-coupled receptors (GPCRs). There are currently four LPA receptors known as LPA(1-4). Genetic deletion studies have identified essential biological functions for LPA receptors in mice. However, these studies have also revealed phenotypes consistent with the existence of as yet unidentified receptors. Toward identifying new LPA receptors, we have screened collections of GPCR cDNAs using reverse transfection and cell-based assays. Here we report an interim result of one screen to identify receptors that produced LPA-dependent changes in cell shape: the orphan receptor GPR92 has properties of a new LPA receptor. Sequence analyses of human GPR92 and its mouse homolog have similar to 35% amino acid identity with LPA(4)/GPR23. The same cell-based approaches that were used to identify and/or characterize LPA(1-4), particularly heterologous expression in B103 cells or RH7777 cells, were utilized and compared with known LPA receptors. Retroviral-mediated expression of epitope-tagged receptors was further combined with G protein minigenes and pharmacological intervention, along with calcium imaging and whole-cell patch clamp electrophysiology. LPA-dependent receptor internalization following exposure to LPA but not related lysophospholipids was observed. Furthermore, LPA induced concentration dependent activation of G(12/13) and G(q) and increased cAMP levels. Specific [H-3]LPA binding was detected in cell membranes heterologously expressing GPR92 but not control membranes. Northern blot and reverse transcriptase-PCR studies indicated a broad low level of expression in many tissues including embryonic brain and enrichment in small intestine and sensory dorsal root ganglia, as well as embryonic stem cells. These results support GPR92 as a fifth LPA receptor, LPA(5), which likely has distinct physiological functions in view of its expression pattern.	Scripps Res Inst, Dept Mol Biol, Helen L Dorris Inst Neurol & Psychiat Disorders, La Jolla, CA 92037 USA	Scripps Research Institute	Chun, J (corresponding author), Scripps Res Inst, Dept Mol Biol, Helen L Dorris Inst Neurol & Psychiat Disorders, 10550 N Torrey Pines Rd,ICND-118, La Jolla, CA 92037 USA.	jchun@scripps.edu	Chun, Jerold/Y-4670-2019	Lee, Chang-Wook/0000-0002-0907-8475	NIMH NIH HHS [MH51699] Funding Source: Medline; NINDS NIH HHS [NS048478] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH051699, R01MH051699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048478] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Chun J, 2006, CURR PHARM DESIGN, V12, P161, DOI 10.2174/138161206775193109; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; DOLECKI GJ, 1995, PROSTAGLANDINS, V49, P397, DOI 10.1016/0090-6980(95)00067-K; Dubin AE, 1999, J NEUROSCI, V19, P1371; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fukushima N, 2002, MOL CELL NEUROSCI, V20, P271, DOI 10.1006/mcne.2002.1123; Fukushima N, 2002, MOL BIOL CELL, V13, P2692, DOI 10.1091/mbc.01-09-0465; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gardell SE, 2006, TRENDS MOL MED, V12, P65, DOI 10.1016/j.molmed.2005.12.001; Gilchrist A., 2002, SCI STKE, pPL1; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Huang QS, 1997, GENE THER, V4, P797, DOI 10.1038/sj.gt.3300476; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Nordengren J, 1998, INT J CANCER, V79, P195; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Pear Warren S., 1997, P41; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Toman RE, 2002, NEUROCHEM RES, V27, P619, DOI 10.1023/A:1020219915922; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	46	364	375	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23589	23597		10.1074/jbc.M603670200	http://dx.doi.org/10.1074/jbc.M603670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16774927	hybrid			2022-12-27	WOS:000239702900033
J	Turanov, AA; Su, D; Gladyshev, VN				Turanov, Anton A.; Su, Dan; Gladyshev, Vadim N.			Characterization of alternative cytosolic forms and cellular targets of mouse mitochondrial thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; ESCHERICHIA-COLI; SPLICING VARIANT; CRYSTAL-STRUCTURES; RAT-LIVER; SELENOCYSTEINE; EXPRESSION; SELENOPROTEINS; MECHANISM; CLONING	Thioredoxin reductase (TR) and thioredoxin (Trx) define a major cellular redox system that maintains cysteine residues in numerous proteins in the reduced state. Both cytosolic (TR1 and Trx1) and mitochondrial (TR3 and Trx2) enzymes are essential in mammals, but the function of the mitochondrial system is less understood. In this study, we characterized subcellular localization of three TR3 forms that are generated by alternative first exon splicing and that differ in their N-terminal sequences. Only one of these forms resides in mitochondria, whereas the two other isoforms are cytosolic. Consistent with this finding, TR3 did not have catalytic preferences for mitochondrial Trx2 versus cytosolic Trx1, both of which could serve as TR3 substrates. Similarly, TR1 was equally active with Trx1, Trx2, or a bacterial Trx. We generated recombinant selenoprotein forms of TR1 and TR3 and found that these enzymes were inhibited by zinc, but not by calcium or cobalt ions. We further developed a proteomic method for identification of targets of TRs in mammalian cells utilizing affinity columns containing recombinant TR3 forms differing in C-terminal sequences. Using this procedure, we found that Trx1 was the major target of TR3 in both rat and mouse liver cytosol. The truncated form of TR3 lacking selenocysteine was particularly efficient in binding Trx1, consistent with the previously observed role of truncated TR1 in apoptosis. Overall, these data establish that the function of TR3 is not limited to its role in Trx2 reduction.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Gladyshev, VN (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, N151, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013; Su, Dan/B-1972-2010	Gladyshev, Vadim/0000-0002-0372-7016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM065204, R01GM065204] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65204] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arner ESJ, 2002, METHOD ENZYMOL, V347, P226; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; Chang EY, 2005, FREE RADICAL BIO MED, V39, P1666, DOI 10.1016/j.freeradbiomed.2005.08.008; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Damdimopoulos AE, 2004, J BIOL CHEM, V279, P38721, DOI 10.1074/jbc.M402753200; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GASDASKA PY, 1995, FEBS LETT, V379, P5; Gitler C, 2002, BIOCHEM BIOPH RES CO, V290, P624, DOI 10.1006/bbrc.2001.6214; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Halvey PJ, 2005, BIOCHEM J, V386, P215, DOI 10.1042/BJ20041829; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Johansson L, 2004, NAT METHODS, V1, P61, DOI 10.1038/NMETH707; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Miranda-Vizuete A, 2002, MOL CELLS, V13, P488; Miranda-Vizuete A, 1999, BBA-GENE STRUCT EXPR, V1447, P113, DOI 10.1016/S0167-4781(99)00129-3; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; OBLONG JE, 1993, FEBS LETT, V334, P1, DOI 10.1016/0014-5793(93)81667-O; Rengby O, 2004, APPL ENVIRON MICROB, V70, P5159, DOI 10.1128/AEM.70.9.5159-5167.2004; Rigobello MP, 2006, BIOCHEM BIOPH RES CO, V343, P873, DOI 10.1016/j.bbrc.2006.03.050; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; SCHALLREUTER KU, 1989, BIOCHEM BIOPH RES CO, V162, P1311, DOI 10.1016/0006-291X(89)90816-4; SCHALLREUTER KU, 1989, BIOCHIM BIOPHYS ACTA, V967, P242; Smeets A, 2005, PROTEIN SCI, V14, P2610, DOI 10.1110/ps.051632905; Su D, 2005, J BIOL CHEM, V280, P26491, DOI 10.1074/jbc.M503638200; Su D, 2004, BIOCHEMISTRY-US, V43, P12177, DOI 10.1021/bi048478t; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; VALCARCE C, 1994, J BIOL CHEM, V269, P26011; Yamamoto M, 2003, J CLIN INVEST, V112, P1395, DOI 10.1172/JCI200317700; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	41	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22953	22963		10.1074/jbc.M604326200	http://dx.doi.org/10.1074/jbc.M604326200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774913	Green Submitted, hybrid			2022-12-27	WOS:000239542600057
J	Schumacher, MA; Mizuno, K; Bachinger, HP				Schumacher, Maria A.; Mizuno, Kazunori; Bachinger, Hans Peter			The crystal structure of a collagen-like polypeptide with 3(S)-hydroxyproline residues in the Xaa position forms a standard 7/2 collagen triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL 4-HYDROXYLASES; ANGSTROM RESOLUTION; MOLECULAR-STRUCTURE; REPEATING SEQUENCE; MODEL PEPTIDE; PROLINE RING; X-RAY; STABILITY; HYDRATION; ENZYMES	Collagen has a triple helical structure comprising strands with a repeating Xaa-Yaa-Gly sequence. L-Proline (Pro) and 4(R)-hydroxyl-L-proline (4(R)Hyp) residues are found most frequently in the Xaa and Yaa positions. However, in natural collagen, 3(S)hydroxyl-L-proline ( 3( S) Hyp) occurs in the Xaa positions to varying extents and is most common in collagen types IV and V. Although 4(R) Hyp residues in the Yaa positions have been shown to be critical for the formation of a stable triple helix, the role of 3(S) Hyp residues in the Xaa position is not well understood. Indeed, recent studies have demonstrated that the presence of 3(S) Hyp in the Xaa positions of collagen-like peptides actually has a destabilizing effect relative to peptides with Pro in these locations. Whether this destabilization is reflected in a local unfolding or in other structural alterations of the collagen triple helix is unknown. Thus, to determine what effect the presence of 3(S) Hyp residues in the Xaa positions has on the overall conformation of the collagen triple helix, we determined the crystal structure of the polypeptide H-(Gly-Pro-4(R)Hyp)(3)(Gly-3(S)Hyp-4(R)Hyp)(2)-(Gly-Pro-4(R)Hyp)(4)-OH to 1.80 angstrom resolution. The structure shows that, despite the presence of the 3(S) Hyp residues, the peptide still adopts a typical 7/2 superhelical symmetry similar to that observed in other collagen structures. The puckering of the Xaa position 3( S) Hyp residues, which are all down (C gamma-endo), and the phi/psi dihedral angles of the Xaa 3(S) Hyp residues are also similar to those of typical collagen Pro Xaa residues. Thus, the presence of 3(S) Hyp in the Xaa positions does not lead to large structural alterations in the collagen triple helix.	Shriners Hosp Children, Res Dept, Portland, OR 97239 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Dept, Portland, OR 97239 USA.	hpb@shcc.org	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264; Brennan, Richard/0000-0001-7647-485X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Bos KJ, 1999, MATRIX BIOL, V18, P149, DOI 10.1016/S0945-053X(99)00015-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L, PYMOL MOL GRAPHICS S; DeRider ML, 2002, J AM CHEM SOC, V124, P2497, DOI 10.1021/ja0166904; Engel J, 1998, MATRIX BIOL, V17, P679, DOI 10.1016/S0945-053X(98)90119-6; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Holmgren SK, 1999, CHEM BIOL, V6, P63, DOI 10.1016/S1074-5521(99)80003-9; Hongo C, 2001, POLYM J, V33, P812; Improta R, 2002, J AM CHEM SOC, V124, P7857, DOI 10.1021/ja020187p; Jenkins CL, 2003, J AM CHEM SOC, V125, P6422, DOI 10.1021/ja034015j; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawahara K, 2005, BIOCHEMISTRY-US, V44, P15812, DOI 10.1021/bi051619m; Kefalides N A, 1973, Int Rev Connect Tissue Res, V6, P63; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCCP4 ESF EAMC, V26; Mayo KH, 1996, BIOPOLYMERS, V40, P359, DOI 10.1002/(SICI)1097-0282(1996)40:4<359::AID-BIP2>3.0.CO;2-V; Mizuno K, 2004, J BIOL CHEM, V279, P282, DOI 10.1074/jbc.M308181200; Mogilner IG, 2002, J MOL GRAPH MODEL, V21, P209, DOI 10.1016/S1093-3263(02)00145-6; MORELLO R, 2006, IN PRESS CELL; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nagarajan V, 1998, J BIOCHEM-TOKYO, V124, P1117, DOI 10.1093/oxfordjournals.jbchem.a022229; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; Okuyama K, 2004, BIOPOLYMERS, V76, P367, DOI 10.1002/bip.20107; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; RHODES RK, 1978, BIOCHEMISTRY-US, V17, P3442, DOI 10.1021/bi00610a003; Schumacher M, 2005, J BIOL CHEM, V280, P20397, DOI 10.1074/jbc.M501453200; Vranka JA, 2004, J BIOL CHEM, V279, P23615, DOI 10.1074/jbc.M312807200; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	45	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27566	27574		10.1074/jbc.M602797200	http://dx.doi.org/10.1074/jbc.M602797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16798737	hybrid			2022-12-27	WOS:000240397700082
J	Sikder, D; Johnston, SA; Kodadek, T				Sikder, Devanjan; Johnston, Stephen Albert; Kodadek, Thomas			Widespread, but non-identical, association of proteasomal 19 and 20 S proteins with yeast chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; REGULATORY PARTICLE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; 26S PROTEASOME; TRANSCRIPTION; ACTIVATION; TURNOVER; COMPLEX	It has recently become clear that various aspects of nucleic acid metabolism and the ubiquitin-proteasome pathway intersect in several direct and important ways. To begin to assess the scope of some of these activities in the yeast Saccharomyces cerevisiae, we assessed the physical and functional association of proteasomal proteins from both the 20 S core and 19 S regulatory particles with similar to 6400 yeast genes. Genome-wide chromatin immunoprecipitation analyses revealed that proteasome substituents are associated with the majority of yeast genes. Many of these associations correlated strongly with expression levels and the presence of RNA polymerase II. Although the data support the presence of the intact 26 S proteasome on most genes, several hundred yeast genes were cross-linked to either the 20 or 19 S complex but not both, consistent with some degree of independent function for the proteasomal subcomplexes.	Univ Texas, SW Med Ctr, Div Translat Res, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Ctr Biomed Invent, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Kodadek@utsouthwestern.edu		Kodadek, Thomas/0000-0003-1930-4795	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066380] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HV-28185] Funding Source: Medline; NIGMS NIH HHS [GM066380] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auld KL, 2006, MOL CELL, V21, P861, DOI 10.1016/j.molcel.2006.02.020; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMBLARAJPAL N, 2004, BIOCHIM BIOPHYS ACTA, V1680, P33; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Ferdous A, 2002, BIOCHEMISTRY-US, V41, P12798, DOI 10.1021/bi020425t; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1999, MOL BIOL REP, V26, P21, DOI 10.1023/A:1006928316738; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Horak CE, 2002, METHOD ENZYMOL, V350, P469, DOI 10.1016/S0076-6879(02)50979-4; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Ottosen S, 2002, SCIENCE, V296, P479, DOI 10.1126/science.1071270; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sikder D, 2005, CURR OPIN CHEM BIOL, V9, P38, DOI 10.1016/j.cbpa.2004.12.008; Sulahian R, 2006, NUCLEIC ACIDS RES, V34, P1351, DOI 10.1093/nar/gkl012; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Tanaka K, 1998, IMMUNOL REV, V163, P161; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; XU QL, 1995, MOL CELL BIOL, V15, P6025	42	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27346	27355		10.1074/jbc.M604706200	http://dx.doi.org/10.1074/jbc.M604706200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16837462	hybrid			2022-12-27	WOS:000240397700061
J	Wang, XD; Bryan, NS; MacArthur, PH; Rodriguez, J; Gladwin, MT; Feelisch, M				Wang, Xunde; Bryan, Nathan S.; MacArthur, Peter H.; Rodriguez, Juan; Gladwin, Mark T.; Feelisch, Martin			Measurement of nitric oxide levels in the red cell - Validation of tri-iodide-based chemiluminescence with acid-sulfanilamide pretreatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSOTHIOLS; BLOOD-CELLS; NO; NITROSOHEMOGLOBIN; NITROSOALBUMIN; HEMOGLOBIN; FLOW; TRANSDUCTION; PROTEINS; IRON	The tri-iodide-based chemiluminescence assay is the most widely used methodology for the detection of S-nitrosothiols (RSNOs) in biological samples. Because of the low RSNO levels detected in a number of biological compartments using this assay, criticism has been raised that this method underestimates the true values in biological samples. This claim is based on the beliefs that (i) acidified sulfanilamide pretreatment, required to remove nitrite, leads to RSNO degradation and (ii) that there is auto- capture of released NO by heme in the reaction vessel. Because our laboratories have used this assay extensively without ever encountering evidence that corroborated these claims, we sought to experimentally address these issues using several independent techniques. We find that RSNOs of glutathione, cysteine, albumin, and hemoglobin are stable in acidified sulfanilamide as determined by the tri-iodide method, copper/cysteine assay, Griess-Saville assay and spectrophotometric analysis. Quantitatively there was no difference in S-nitroso-hemoglobin (SNOHb) or S-nitroso-albumin (SNOA1b) using the tri-iodide method and a recently described modified assay using a ferricyanide-enhanced reaction mix at biologically relevant NO: heme ratios. Levels of SNOHb detected in human blood ranged from 20-100 nM with no arterial-venous gradient. We further find that 90% of the total NO-related signal in blood is caused by erythrocytic nitrite, which may partly be bound to hemoglobin. We conclude that all claims made thus far that the tri-iodide assay underestimates RSNO levels are unsubstantiated and that this assay remains the "gold standard" for sensitive and specific measurement of RSNOs in biological matrices.	NHLBI, Vasc Med Branch, NIH, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Gladwin, MT (corresponding author), NHLBI, Vasc Med Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	mgladwin@nhlbi.nih.gov; feelisch@bu.edu	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158	Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [P20 RR16456] Funding Source: Medline; NHLBI NIH HHS [HL 69029] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016456] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069029] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL008050] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CLINICAL CENTER		Baker PRS, 2004, P NATL ACAD SCI USA, V101, P11577, DOI 10.1073/pnas.0402587101; Bjorne H, 2004, J CLIN INVEST, V113, P106, DOI [10.1172/JCI200419019, 10.1172/JCI19019]; Bryan NS, 2004, NITRIC OXIDE-BIOL CH, V10, P221, DOI 10.1016/j.niox.2004.04.008; Bryan NS, 2005, NAT CHEM BIOL, V1, P290, DOI 10.1038/nchembio734; Crawford JH, 2004, BLOOD, V104, P1375, DOI 10.1182/blood-2004-03-0880; Daiber A, 2003, NITRIC OXIDE-BIOL CH, V9, P44, DOI 10.1016/j.niox.2003.08.002; Dejam A, 2005, BLOOD, V106, P734, DOI 10.1182/blood-2005-02-0567; Dejam A, 2003, FREE RADICAL BIO MED, V35, P1551, DOI 10.1016/j.freeradbiomed.2003.09.009; Doctor A, 2005, P NATL ACAD SCI USA, V102, P5709, DOI 10.1073/pnas.0407490102; DRABKIN DL, 1971, P NATL ACAD SCI USA, V68, P609, DOI 10.1073/pnas.68.3.609; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; Giustarini D, 2004, TRENDS PHARMACOL SCI, V25, P311, DOI 10.1016/j.tips.2004.04.009; Giustarini D, 2003, CLIN CHIM ACTA, V330, P85, DOI 10.1016/S0009-8981(03)00046-9; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2004, CIRC RES, V94, P851, DOI 10.1161/01.RES.0000126697.64381.37; Ishibashi T, 2000, NITRIC OXIDE-BIOL CH, V4, P516, DOI 10.1006/niox.2000.0302; Kleinbongard P, 2006, BLOOD, V107, P2943, DOI 10.1182/blood-2005-10-3992; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Rassaf T, 2002, J CLIN INVEST, V109, P1241, DOI 10.1172/JCI200214995; Rassaf T, 2004, FREE RADICAL BIO MED, V36, P413, DOI 10.1016/j.freeradbiomed.2003.11.011; Rassaf T, 2003, NAT MED, V9, P481, DOI 10.1038/nm0503-481; Rassaf T, 2002, FREE RADICAL BIO MED, V33, P1590, DOI 10.1016/S0891-5849(02)01183-8; Rogers SC, 2005, J BIOL CHEM, V280, P26720, DOI 10.1074/jbc.M501179200; Rossi R, 2001, CIRC RES, V89; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Schopfer FJ, 2005, J BIOL CHEM, V280, P19289, DOI 10.1074/jbc.M414689200; Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 2004, CIRC RES, V94, P414, DOI 10.1161/01.RES.0000122071.55721.BC; Svensson PH, 2003, CHEM REV, V103, P1649, DOI 10.1021/cr0204101; Tsikas D, 2003, NITRIC OXIDE-BIOL CH, V9, P53, DOI 10.1016/S1089-8603(03)00044-2; Tsikas D, 2002, CIRC RES, V90, pE39; Tyurin VA, 2001, CIRC RES, V88, P1210, DOI 10.1161/hh1101.092179; Wang XD, 2004, P NATL ACAD SCI USA, V101, P11477, DOI 10.1073/pnas.0402201101; Xu XL, 2003, P NATL ACAD SCI USA, V100, P11303, DOI 10.1073/pnas.2033883100; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101	41	71	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26994	27002		10.1074/jbc.M603953200	http://dx.doi.org/10.1074/jbc.M603953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16845122	hybrid			2022-12-27	WOS:000240397700026
J	Pak, JE; Arnoux, P; Zhou, SH; Sivarajah, P; Satkunarajah, M; Xing, XK; Rini, JM				Pak, John E.; Arnoux, Pascal; Zhou, Sihong; Sivarajah, Prashanth; Satkunarajah, Malathy; Xing, Xuekun; Rini, James M.			X-ray crystal structure of leukocyte type core 2 beta 1,6-N-acetylglucosaminyltransferase - Evidence for a convergence of metal ion-independent glycosyltransferase mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; ELECTRON-DENSITY MAPS; SULFATE BIOSYNTHESIS; MOLECULAR-CLONING; MUCIN SYNTHESIS; UDP-GLUCOSE; CHO-CELLS; EXPRESSION; BETA-6-N-ACETYLGLUCOSAMINYLTRANSFERASE; GLUCOSYLTRANSFERASE	Leukocyte type core 2 beta 1,6-N-acetylglucosaminyltransferase (C2GnT-L) is a key enzyme in the biosynthesis of branched O-glycans. It is an inverting, metal ion-independent family 14 glycosyltransferase that catalyzes the formation of the core 2 O-glycan (Gal beta 1-3[GlcNAc beta 1-6]GalNAc-O-Ser/ Thr) from its donor and acceptor substrates, UDP-GlcNAc and the core 1 O-glycan (Gal beta 1-3GalNAc-O-Ser/ Thr), respectively. Reported here are the x-ray crystal structures of murine C2GnT-L in the absence and presence of the acceptor substrate Gal beta 1 -3GalNAc at 2.0 and 2.7 angstrom resolution, respectively. C2GnT-L was found to possess the GT-A fold; however, it lacks the characteristic metal ion binding DXD motif. The Gal beta 1-3GalNAc complex defines the determinants of acceptor substrate binding and shows that Glu-320 corresponds to the structurally conserved catalytic base found in other inverting GT-A fold glycosyltransferases. Comparison of the C2GnT-L structure with that of other GT-A fold glycosyltransferases further suggests that Arg-378 and Lys-401 serve to electrostatically stabilize the nucleoside disphosphate leaving group, a role normally played by metalionin GT-A structures. The use of basic amino acid side chains in this way is strikingly similar to that seen in a number of metal ion-independent GT-B fold glycosyltransferases and suggests a convergence of catalytic mechanism shared by both GT-A and GT-B fold glycosyltransferases.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Rini, JM (corresponding author), Univ Toronto, Dept Mol & Med Genet, Med Sci Bldg,Rm 5360,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	james.rini@utoronto.ca	Arnoux, Pascal/B-3600-2010	ARNOUX, Pascal/0000-0003-4609-4893				BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Chiu CPC, 2004, NAT STRUCT MOL BIOL, V11, P163, DOI 10.1038/nsmb720; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; El-Battari A, 2003, GLYCOBIOLOGY, V13, P941, DOI 10.1093/glycob/cwg117; Flint J, 2005, NAT STRUCT MOL BIOL, V12, P608, DOI 10.1038/nsmb950; Garinot-Schneider C, 2000, J BIOL CHEM, V275, P31407, DOI 10.1074/jbc.M004524200; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gibson RP, 2004, J BIOL CHEM, V279, P1950, DOI 10.1074/jbc.M307643200; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Hagisawa S, 2005, GLYCOBIOLOGY, V15, P1016, DOI 10.1093/glycob/cwi086; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima H, 2005, NAT IMMUNOL, V6, P1096, DOI 10.1038/ni1259; KLEYWEGT GJ, 1994, CCP4 P, P59; KUHNS W, 1993, GLYCOCONJUGATE J, V10, P381, DOI 10.1007/BF00731043; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lairson LL, 2004, J BIOL CHEM, V279, P28339, DOI 10.1074/jbc.M400451200; Lairson LL, 2004, CHEM COMMUN, P2243, DOI 10.1039/b406490a; Lariviere L, 2003, J MOL BIOL, V330, P1077, DOI 10.1016/S0022-2836(03)00635-1; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Lutteke T, 2005, NUCLEIC ACIDS RES, V33, pD242; Machida E, 2001, CANCER RES, V61, P2226; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mulichak AM, 2004, BIOCHEMISTRY-US, V43, P5170, DOI 10.1021/bi036130c; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; RINI JM, 1995, CURR OPIN STRUC BIOL, V5, P617, DOI 10.1016/0959-440X(95)80053-0; ROPP PA, 1991, J BIOL CHEM, V266, P23863; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; SEGEL IH, 1993, ENZYME KINETICS, P818; Shimodaira K, 1997, CANCER RES, V57, P5201; Sinacore MS, 2000, MOL BIOTECHNOL, V15, P249, DOI 10.1385/MB:15:3:249; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; Takahashi T, 2000, GLYCOBIOLOGY, V10, P503, DOI 10.1093/glycob/10.5.503; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; WILLIAMS D, 1980, J BIOL CHEM, V255, P1253; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200; Yang XJ, 2003, BBA-PROTEINS PROTEOM, V1648, P62, DOI 10.1016/S1570-9639(03)00105-5; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yen TY, 2003, J BIOL CHEM, V278, P45864, DOI 10.1074/jbc.M303851200; Zeng S, 1997, BIOCHEM BIOPH RES CO, V237, P653, DOI 10.1006/bbrc.1997.7209; [No title captured]	58	48	49	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26693	26701		10.1074/jbc.M603534200	http://dx.doi.org/10.1074/jbc.M603534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829524	hybrid			2022-12-27	WOS:000240249500087
J	Spasic, D; Tolia, A; Dillen, K; Baert, V; De Strooper, B; Vrijens, S; Annaert, W				Spasic, Dragana; Tolia, Alexandra; Dillen, Katleen; Baert, Veerle; De Strooper, Bart; Vrijens, Stefan; Annaert, Wim			Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; GOLGI COMPARTMENTS; CELL-SURFACE; C-TERMINUS; PRE-GOLGI; NICASTRIN; COMPLEX; TRAFFICKING; EXPRESSION	Presenilin-1 is a polytopic membrane protein that assembles with nicastrin, PEN-2, and APH-1 into an active gamma-secretase complex required for intramembrane proteolysis of type I transmembrane proteins. Although essential for a correct understanding of structure-function relationships, its exact topology remains an issue of strong controversy. We revisited presenilin-1 topology by inserting glycosylation consensus sequences in human PS1 and expressing the obtained mutants in a presenilin-1 and 2 knock-out background. Based on the glycosylation status of these variants we provide evidence that presenilin-1 traffics through the Golgi after a conformational change induced by complex assembly. Based on our glycosylation variants of presenilin-1 we hypothesize that complex assembly occurs during transport between the endoplasmic reticulum and the Golgi apparatus. Furthermore, our data indicate that presenilin-1 has a nine-transmembrane domain topology with the COOH terminus exposed to the lumen/ extracellular surface. This topology is independently underscored by lysine mutagenesis, cell surface biotinylation, and cysteine derivation strategies and is compatible with the different physiological functions assigned to presenilin-1.	Katholieke Univ Leuven VIB, Lab Membrane Trafficking, Dept & Ctr Human Genet, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Lab Neuronal Cell Biol, Dept Human Genet, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Annaert, W (corresponding author), Katholieke Univ Leuven VIB, Lab Membrane Trafficking, Dept & Ctr Human Genet, Rm 9-969, B-3000 Louvain, Belgium.	Willem.Annaert@med.kuleuven.be	De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; Spasic, Dragana/0000-0001-9882-5091				Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Bonnon C, 2003, J BIOL CHEM, V278, P48339, DOI 10.1074/jbc.M309120200; Capell A, 2005, J BIOL CHEM, V280, P6471, DOI 10.1074/jbc.M409106200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dewji NN, 2004, P NATL ACAD SCI USA, V101, P1057, DOI 10.1073/pnas.0307290101; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Esselens C, 2004, J CELL BIOL, V166, P1041, DOI 10.1083/jcb.200406060; Hauri HP, 2002, BIOCHEM SOC SYMP, V69, P73; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Heusser K, 2005, CURR OPIN NEUROBIOL, V15, P364, DOI 10.1016/j.conb.2005.04.001; Juschke C, 2005, J CELL BIOL, V169, P613, DOI 10.1083/jcb.200503033; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Kim J, 2004, P NATL ACAD SCI USA, V101, P905, DOI 10.1073/pnas.0307297101; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Ladinsky MS, 2002, MOL BIOL CELL, V13, P2810, DOI 10.1091/mbc.01-12-0593; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Laudon H, 2005, J BIOL CHEM, V280, P35352, DOI 10.1074/jbc.M507217200; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Oh YS, 2005, BIOCHEMISTRY-US, V44, P11821, DOI 10.1021/bi0509494; Oh YS, 2005, AM J PHYSIOL-CELL PH, V289, pC576, DOI 10.1152/ajpcell.00636.2004; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Raemaekers T, 2005, BIOCHEM SOC T, V33, P559, DOI 10.1042/BST0330559; Rechards M, 2003, TRAFFIC, V4, P553, DOI 10.1034/j.1600-0854.2003.t01-1-00114.x; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Vullo A, 2004, BIOINFORMATICS, V20, P653, DOI 10.1093/bioinformatics/btg463; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Xu XM, 1999, J BIOL CHEM, V274, P32543, DOI 10.1074/jbc.274.46.32543; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200	39	96	101	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26569	26577		10.1074/jbc.M600592200	http://dx.doi.org/10.1074/jbc.M600592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16846981	hybrid			2022-12-27	WOS:000240249500075
J	Allen, MD; Buchberger, A; Bycroft, M				Allen, Mark D.; Buchberger, Alexander; Bycroft, Mark			The PUB domain functions as a p97 binding module in human peptide N-glycanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBX DOMAIN; AAA-ATPASE; PROTEIN; UBIQUITIN; COMPLEX; IDENTIFICATION; DEGLYCOSYLATION; DEGRADATION; MECHANISM; SUBSTRATE	The AAA ATPase p97 is a ubiquitin-selective molecular machine involved in multiple cellular processes, including protein degradation through the ubiquitin-proteasome system and homotypic membrane fusion. Specific p97 functions are mediated by a variety of cofactors, among them peptide N-glycanase, an enzyme that removes glycans from misfolded glycoproteins. Here we report the three-dimensional structure of the amino-terminal PUB domain of human peptide N-glycanase. We demonstrate that the PUB domain is a novel p97 binding module interacting with the D1 and/or D2 ATPase domains of p97 and identify an evolutionary conserved surface patch required for p97 binding. Furthermore, we show that the PUB and UBX domains do not bind to p97 in a mutually exclusive manner. Our results suggest that PUB domain-containing proteins constitute a widespread family of diverse p97 cofactors.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany; MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	Max Planck Society; University of Cambridge	Buchberger, A (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	buchberg@biochem.mpg.de; mb10031@cus.cam.ac.uk	Buchberger, Alexander/AAF-4728-2019; Bycroft, Mark/D-9446-2017; Buchberger, Alexander/J-4070-2019	Buchberger, Alexander/0000-0002-2836-0820; Buchberger, Alexander/0000-0002-2836-0820; Bycroft, Mark/0000-0002-0673-2216	MRC [MC_U105459896] Funding Source: UKRI; Medical Research Council [MC_U105459896] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; BEURON F, 2006, EMBO J; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Carim-Todd L, 2001, BBA-GENE STRUCT EXPR, V1517, P298, DOI 10.1016/S0167-4781(00)00248-7; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; DeLaBarre B, 2005, J MOL BIOL, V347, P437, DOI 10.1016/j.jmb.2005.01.060; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201; Dreveny I, 2004, BIOCHEM SOC T, V32, P715, DOI 10.1042/BST0320715; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Iyer LM, 2004, CELL CYCLE, V3, P1440, DOI 10.4161/cc.3.11.1206; Katiyar S, 2005, MOL BIOL CELL, V16, P4584, DOI 10.1091/mbc.E05-04-0345; Katiyar S, 2004, P NATL ACAD SCI USA, V101, P13774, DOI 10.1073/pnas.0405663101; Kim I, 2006, J CELL BIOL, V172, P211, DOI 10.1083/jcb.200507149; Lee JH, 2005, P NATL ACAD SCI USA, V102, P9144, DOI 10.1073/pnas.0502082102; LESLIE AGW, 1991, CCP4 ESF EACMB NEWSL; Li GT, 2005, P NATL ACAD SCI USA, V102, P15809, DOI 10.1073/pnas.0507155102; McNeill H, 2004, BIOCHEM J, V384, P391, DOI 10.1042/BJ20041498; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Olsen BB, 2003, FEBS LETT, V546, P218, DOI 10.1016/S0014-5793(03)00575-1; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Suzuki T, 2001, BIOCHEM BIOPH RES CO, V287, P1083, DOI 10.1006/bbrc.2001.5688; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TURK D, 1992, THESIS TU MUNCHEN; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Weihl CC, 2006, HUM MOL GENET, V15, P189, DOI 10.1093/hmg/ddi426; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864; Zhao G, 2006, J BIOL CHEM, V281, P13751, DOI 10.1074/jbc.M600137200	37	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25502	25508		10.1074/jbc.M601173200	http://dx.doi.org/10.1074/jbc.M601173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807242	hybrid			2022-12-27	WOS:000240031300053
J	Bird, AJ; Swierczek, S; Qiao, W; Eide, DJ; Winge, DR				Bird, Amanda J.; Swierczek, Sabina; Qiao, Wei; Eide, David J.; Winge, Dennis R.			Zinc metalloregulation of the zinc finger pair domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZAP1 TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; PROTEIN; YEAST; EXPRESSION; GENOME	The yeast transcriptional activator Zap1 contains two uncommon structural motifs designated zinc finger pair domains. The hallmark of this domain is the packing of two zinc finger motifs in one globular unit. One finger pair domain in Zap1 contains the AD2 transactivation domain. Zn(II) binding to this domain (ZF1/2) is kinetically labile yielding a zinc-regulated transactivator. The second finger pair domain (ZF3/4) lies within the DNA-binding domain, and it stably binds Zn(II). The goal of this study was to map the determinant conferring lability in Zn(II) binding by using finger pair chimeras. Whereas ZF2 contains the transactivation function, zinc regulation is dependent on the presence of ZF1. ZF3 can functionally replace ZF1, and a ZF3/2 finger pair retains limited zinc regulation. Replacement of ZF3 by ZF1 creating a ZF1/4 chimera was found to stably bind Zn(II), suggesting that the presence of a stable motif (ZF4) can impart binding stability on a labile motif (ZF1). Zn(II) binding in finger pair domains is dependent on the presence of both motifs. Mutations in one finger motif markedly attenuate Zn( II) binding to the second motif. Kinetic lability in Zn(II) binding was mapped to the alpha-helix of ZF2. A ZF1/ZF beta 2 alpha 4 chimera resembles ZF3/4 in Zn(II) binding stability in incubation studies with the Zn(II) chelators. The present results demonstrate that zinc regulation of AD activity of ZF2 is dependent on determinants in ZF1 as well as the alpha-helix segment of ZF2.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Eide, DJ (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr,Rm 340B, Madison, WI 53706 USA.	eide@nutrisci.wisc.edu; dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010; Bird, Amanda Jane/ABD-2295-2021	Bird, Amanda Jane/0000-0002-1846-7050	NIGMS NIH HHS [GM56285] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bird A, 2000, J BIOL CHEM, V275, P16160, DOI 10.1074/jbc.M000664200; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bird AJ, 2003, EMBO J, V22, P5137, DOI 10.1093/emboj/cdg484; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; Fernandez-Martinez J, 2003, J MOL BIOL, V334, P667, DOI 10.1016/j.jmb.2003.09.072; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Herbig A, 2005, MOL MICROBIOL, V57, P834, DOI 10.1111/j.1365-2958.2005.04734.x; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Wang ZH, 2006, J MOL BIOL, V357, P1167, DOI 10.1016/j.jmb.2006.01.010; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	17	15	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25326	25335		10.1074/jbc.M600655200	http://dx.doi.org/10.1074/jbc.M600655200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829533	hybrid			2022-12-27	WOS:000240031300034
J	Black, LW; Peng, GH				Black, Lindsay W.; Peng, Guihong			Mechanistic coupling of bacteriophage T4 DNA packaging to components of the replication-dependent late transcription machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAD MATURATION PATHWAY; PHAGE-T4 TERMINASE; LARGE SUBUNIT; PROTEIN; GP17; T4; INITIATION; PARTICLES; MUTANTS; PURIFICATION	Regulation of the terminal stage of viral DNA development, DNA packaging, is poorly understood. A new phage T4 in vitro DNA packaging assay employed purified proheads, terminase (gp17 + gp16), and ATP to encapsidate DNA resistant to nuclease. Mature phage T4 DNA and linearized plasmid DNAs containing or lacking a cloned T4 gene were packaged with high (similar to 10%) efficiency. Supercoiled, relaxed covalently closed, and nicked circular plasmid DNAs were packaged inefficiently, if at all, by these components. However, efficient packaging is achieved for nicked circular plasmid DNA, but not covalently closed plasmid DNA, upon addition to packaging mixtures of the purified T4 late transcription-replication machinery proteins: gp45 ( sliding clamp), gp44/gp62 ( clamp loader complex), gp55 ( late sigma-factor), and gp33 ( transcriptional co-activator). The small terminase subunit ( gp16) is inhibitory for packaging linear DNAs, but enhances the transcription-replication protein packaging of nicked plasmid DNA. Taken together with genetic and biochemical evidence of a requirement for gp55 for concatemer packaging to assemble active wild-type phage particles ( 1), the plasmid packaging results show that initiation of phage T4 packaging on "endless" concatemeric DNA in vivo by terminase depends upon interaction with the DNA loaded gp45 coupled late transcription-replication machinery. The results suggest a close mechanistic connection in vivo between DNA packaging and developmentally concurrent replication-dependent late transcription.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Black, LW (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Rm 408,108 N Greene St, Baltimore, MD 21201 USA.	lblack@umaryland.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011676, R21AI011676, R37AI011676] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baumann RG, 2003, J BIOL CHEM, V278, P4618, DOI 10.1074/jbc.M208574200; BHATTACHARYYA SP, 1993, VIROLOGY, V196, P34, DOI 10.1006/viro.1993.1452; BLACK LW, 1986, GENE, V46, P97, DOI 10.1016/0378-1119(86)90171-X; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BLACK LW, 1981, VIROLOGY, V113, P336, DOI 10.1016/0042-6822(81)90160-4; BLACK LW, 1994, MOL BIOL BACTERIOP T, V4, P481; CARRASCOSA JL, 1978, J VIROL, V25, P831, DOI 10.1128/JVI.25.3.831-844.1978; CARRASCOSA JL, 1978, J VIROL, V26, P420, DOI 10.1128/JVI.26.2.420-428.1978; CASJENS S, 1992, J MOL BIOL, V227, P1086, DOI 10.1016/0022-2836(92)90523-M; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; CHUNG YB, 1990, J MOL BIOL, V216, P939, DOI 10.1016/S0022-2836(99)80012-6; Geiduschek E.P., 1997, MECH TRANSCRIPTION, P135; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; Jardine PJ, 1998, J MOL BIOL, V284, P661, DOI 10.1006/jmbi.1998.2179; Kanamaru S, 2004, J BIOL CHEM, V279, P40795, DOI 10.1074/jbc.M403647200; Kreuzer KN, 2005, ANNU REV MICROBIOL, V59, P43, DOI 10.1146/annurev.micro.59.030804.121255; Leffers G, 1996, J MOL BIOL, V258, P839, DOI 10.1006/jmbi.1996.0291; Leffers G, 2000, J BIOL CHEM, V275, P37127, DOI 10.1074/jbc.M003357200; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; Lin HC, 1998, VIROLOGY, V242, P118, DOI 10.1006/viro.1997.9019; Malys N, 2002, J MOL BIOL, V319, P289, DOI 10.1016/S0022-2836(02)00298-X; Mitchell MS, 2002, NUCLEIC ACIDS RES, V30, P4009, DOI 10.1093/nar/gkf524; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; RAO VB, 1985, J MOL BIOL, V185, P565, DOI 10.1016/0022-2836(85)90072-5; Rao Venigalla B., 2005, P40; Rentas FJ, 2003, J MOL BIOL, V334, P37, DOI 10.1016/j.jmb.2003.09.028; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanders GM, 1997, EMBO J, V16, P3124, DOI 10.1093/emboj/16.11.3124; SANDERS GM, 1994, P NATL ACAD SCI USA, V91, P7703, DOI 10.1073/pnas.91.16.7703; WILLIAMS KP, 1994, MOL BIOL BACTERIOP T, V4, P161; Wong K, 1998, J MOL BIOL, V284, P195, DOI 10.1006/jmbi.1998.2166; WU CHH, 1995, J MOL BIOL, V247, P523; YOUNG MC, 1994, MOL BIOL BACTERIOP T, V4, P313; Zhang X, 2004, J MOL BIOL, V340, P707, DOI 10.1016/j.jmb.2004.05.006	36	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25635	25643		10.1074/jbc.M602093200	http://dx.doi.org/10.1074/jbc.M602093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807240	hybrid			2022-12-27	WOS:000240031300066
J	Estrada, M; Varshney, A; Ehrlich, BE				Estrada, Manuel; Varshney, Anurag; Ehrlich, Barbara E.			Elevated testosterone induces apoptosis in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ANABOLIC-ANDROGENIC STEROIDS; MESSENGER-RIBONUCLEIC-ACID; SENSITIVE G-PROTEIN; CYTOCHROME-C; KENNEDYS-DISEASE; CALCIUM SIGNALS; GENE-EXPRESSION; SPINAL NUCLEUS; DEATH	Testosterone plays a crucial role in neuronal function, but elevated concentrations can have deleterious effects. Here we show that supraphysiological levels of testosterone (micromolar range) initiate the apoptotic cascade. We used three criteria, annexin V labeling, caspase activity, and DNA fragmentation, to determine that apoptotic pathways were activated by testosterone. Micromolar, but not nanomolar, testosterone concentrations increased the response in all three assays of apoptosis. In addition, testosterone induced different concentration-dependent Ca2+ signaling patterns: at low concentrations of testosterone (100 nM), Ca2+ oscillations were produced, whereas high concentrations (1-10 mu M) induced a sustained Ca2+ increase. Elevated testosterone concentrations increase cell death, and this effect was abolished in the presence of either inhibitors of caspases or the inositol 1,4,5-trisphosphate receptor (InsP(3)R)-mediated Ca2+ release. Knockdown of InsP(3)R type 1 with specific small interfering RNA also abolished the testosterone-induced cell death and the prolonged Ca2+ signals. In contrast, knockdown of InsP(3)R type 3 modified neither the apoptotic response nor the Ca2+ signals. These results support our hypothesis that elevated testosterone alters InsP(3)R type 1-mediated intracellular Ca2+ signaling and that the prolonged Ca2+ signals lead to apoptotic cell death. These effects of testosterone on neurons will have long term effects on brain function.	Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Ehrlich, BE (corresponding author), Yale Univ, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	iestrada@med.uchile.cl; barbara.ehrlich@yale.edu	Estrada, Manuel/AAS-5605-2020; Varshney, Anurag/Y-6381-2019; /AAX-8408-2021; Estrada, Manuel/C-1269-2014	Estrada, Manuel/0000-0001-7877-8160; Varshney, Anurag/0000-0001-8509-0882; /0000-0001-9657-9704; Estrada, Manuel/0000-0001-7877-8160	NIDDK NIH HHS [DK61747] Funding Source: Medline; NIGMS NIH HHS [GM63496] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063496] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Aragno M, 2000, DIABETES, V49, P1924, DOI 10.2337/diabetes.49.11.1924; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; Bhuyan AK, 2001, CELL DEATH DIFFER, V8, P63, DOI 10.1038/sj.cdd.4400773; Blackshaw S, 2000, FASEB J, V14, P1375, DOI 10.1096/fj.14.10.1375; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boehning D, 2005, P NATL ACAD SCI USA, V102, P1466, DOI 10.1073/pnas.0409650102; Boehning D, 2004, CELL CYCLE, V3, P252; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; Darrington RS, 2002, NEUROREPORT, V13, P2117, DOI 10.1097/00001756-200211150-00025; DUVAL D, 1983, BIOCHIM BIOPHYS ACTA, V737, P409, DOI 10.1016/0304-4157(83)90008-4; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Estrada M, 2006, J CELL SCI, V119, P733, DOI 10.1242/jcs.02775; Estrada M, 2003, ENDOCRINOLOGY, V144, P3586, DOI 10.1210/en.2002-0164; Estrada M, 2000, AM J PHYSIOL-ENDOC M, V279, pE132, DOI 10.1152/ajpendo.2000.279.1.E132; Freeman LM, 1996, HORM BEHAV, V30, P424, DOI 10.1006/hbeh.1996.0047; Frye CA, 2004, PSYCHONEUROENDOCRINO, V29, P1019, DOI 10.1016/j.psyneuen.2003.10.004; Garic-Stankovic A, 2005, ALCOHOL CLIN EXP RES, V29, P1237, DOI 10.1097/01.ALC.0000172460.05756.D9; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Gould E, 1993, Curr Opin Neurobiol, V3, P676, DOI 10.1016/0959-4388(93)90138-O; Greenland KJ, 2004, INTERN MED J, V34, P279, DOI 10.1111/j.1444-0903.2004.00588.x; Guo Q, 1997, J NEUROSCI, V17, P4212; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Jacob SN, 2005, J NEUROSCI, V25, P2853, DOI 10.1523/JNEUROSCI.4313-04.2005; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Johenning FW, 2004, BIOCHEM J, V382, P687, DOI 10.1042/BJ20040418; Kajstura J, 1997, J MOL CELL CARDIOL, V29, P859, DOI 10.1006/jmcc.1996.0333; Kelly SJ, 1999, PHARMACOL BIOCHEM BE, V64, P655, DOI 10.1016/S0091-3057(99)00167-7; KERR JE, 1995, ENDOCRINOLOGY, V136, P3213, DOI 10.1210/en.136.8.3213; Lafevre-Bernt MA, 2003, J BIOL CHEM, V278, P34918, DOI 10.1074/jbc.M302841200; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Marron TU, 2005, J NEUROCHEM, V92, P10, DOI 10.1111/j.1471-4159.2004.02836.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUMOTO A, 1993, J NEUROENDOCRINOL, V5, P357, DOI 10.1111/j.1365-2826.1993.tb00495.x; MATSUMOTO A, 1994, HORM BEHAV, V28, P357, DOI 10.1006/hbeh.1994.1032; McEwen B S, 1972, Adv Behav Biol, V4, P41; McEwen BS, 1997, ANN NY ACAD SCI, V823, P201, DOI 10.1111/j.1749-6632.1997.tb48392.x; MENDES CC, 2005, J BIOL CHEM; Minagawa N, 2005, J BIOL CHEM, V280, P33637, DOI 10.1074/jbc.M503210200; Mong JA, 1999, J NEUROSCI, V19, P1464; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; Morales AJ, 1998, CLIN ENDOCRINOL, V49, P421, DOI 10.1046/j.1365-2265.1998.00507.x; Nagata S, 2005, ANNU REV IMMUNOL, V23, P853, DOI 10.1146/annurev.immunol.23.021704.115811; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PFAFF DW, 1983, SCIENCE, V219, P808, DOI 10.1126/science.6297008; Ramsden M, 2003, NEUROSCIENCE, V122, P573, DOI 10.1016/j.neuroscience.2003.08.048; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; Rubinow DR, 1996, AM J PSYCHIAT, V153, P974; SAR M, 1990, ENDOCRINOLOGY, V127, P3180, DOI 10.1210/endo-127-6-3180; Sharp AH, 1999, J COMP NEUROL, V406, P207; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tabori NE, 2005, NEUROSCIENCE, V130, P151, DOI 10.1016/j.neuroscience.2004.08.048; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Tang TS, 2005, P NATL ACAD SCI USA, V102, P2602, DOI 10.1073/pnas.0409402102; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Thiblin I, 2000, J FORENSIC SCI, V45, P16; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tirassa P, 1997, J NEUROSCI RES, V47, P198, DOI 10.1002/(SICI)1097-4547(19970115)47:2<198::AID-JNR8>3.0.CO;2-A; Tovey SC, 2001, J CELL SCI, V114, P3979; Varshney A, 2003, NEURON, V39, P195, DOI 10.1016/S0896-6273(03)00425-2; Verkhratsky A, 2003, J CELL MOL MED, V7, P351, DOI 10.1111/j.1582-4934.2003.tb00238.x; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wozniak A, 1998, STEROIDS, V63, P263, DOI 10.1016/S0039-128X(98)00029-4; YERRAMILLIRAO P, 1995, J NEUROL SCI, V129, P131, DOI 10.1016/0022-510X(95)00083-E	68	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25492	25501		10.1074/jbc.M603193200	http://dx.doi.org/10.1074/jbc.M603193200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803879	hybrid			2022-12-27	WOS:000240031300052
J	Hu, L; Wada, K; Mores, N; Krsmanovic, LZ; Catt, KJ				Hu, Lian; Wada, Keiko; Mores, Nadia; Krsmanovic, Lazar Z.; Catt, Kevin J.			Essential role of G protein-gated inwardly rectifying potassium channels in gonadotropin-induced regulation of GnRH neuronal firing and pulsatile neurosecretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; HYPOTHALAMIC NEURONS; RAT HYPOTHALAMUS; RHESUS-MONKEY; GIRK CHANNELS; 5-HYDROXYTRYPTAMINE1A RECEPTORS; PRESYNAPTIC INHIBITION; SIGNALING PATHWAYS; ADENYLYL-CYCLASE; PULSE-GENERATOR	Activation of the luteinizing hormone/human chorionic gonadotropin (LH/hCG) receptor (LHR) in cultured hypothalamic cells and immortalized GnRH ( gonadotropin-releasing hormone) neurons (GT1-7 cells) transiently stimulates and subsequently inhibits cAMP production and pulsatile GnRH release. The marked and delayed impairment of cAMP signaling and episodic GnRH release in GT1-7 cells is prevented by pertussis toxin (PTX). This, and the LH-induced release of membrane-bound G alpha(s) and G alpha(i3) subunits, are indicative of differential G protein coupling to the LHR. Action potential (AP) firing in identified GnRH neurons also initially increased and then progressively decreased during LH treatment. The inhibitory action of LH on AP firing was also prevented by PTX. Reverse transcriptase-PCR analysis of GT1-7 neurons revealed the expression of G protein-gated inwardly rectifying potassium (GIRK) channels in these cells. The LH-induced currents were inhibited by PTX and were identified as GIRK currents. These responses indicate that agonist stimulation of endogenous LHR expressed in GnRH neurons activates GIRK channels, leading to suppression of membrane excitability and inhibition of AP firing. These findings demonstrate that regulation of GIRK channel function is a dominant factor in gonadotropin-induced abolition of pulsatile GnRH release. Furthermore, this mechanism could contribute to the suppression of pituitary function during pregnancy.	NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mores, N (corresponding author), NICHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A-36, Bethesda, MD 20892 USA.	lazar@mail.nih.gov		MORES, Nadia/0000-0002-4197-0914	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000184] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000184] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AlHader AA, 1997, BIOL REPROD, V56, P1071, DOI 10.1095/biolreprod56.5.1071; ARANEDA R, 1991, NEUROSCIENCE, V40, P399, DOI 10.1016/0306-4522(91)90128-B; BEYER C, 1967, EXP NEUROL, V18, P313, DOI 10.1016/0014-4886(67)90051-9; Blackmer T, 2005, NAT NEUROSCI, V8, P421, DOI 10.1038/nn1423; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Charles A, 2001, MOL ENDOCRINOL, V15, P997, DOI 10.1210/me.15.6.997; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DELAESCALERA G, 1995, NEUROENDOCRINOLOGY, V61, P310, DOI 10.1159/000126853; DROUVA SV, 1981, NEUROENDOCRINOLOGY, V32, P155, DOI 10.1159/000123149; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; El Majdoubi M, 2002, ENDOCRINOLOGY, V143, P2441, DOI 10.1210/en.143.6.2441; EMANUELE N, 1984, BRAIN RES, V309, P271; FUJITA K, 1979, J BIOL CHEM, V254, P8567; Gerachshenko T, 2005, NAT NEUROSCI, V8, P597, DOI 10.1038/nn1439; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAMON M, 1990, NEUROPSYCHOPHARMACOL, V3, P349; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Hill RH, 2003, EUR J NEUROSCI, V18, P2919, DOI 10.1111/j.1460-9568.2003.03051.x; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hiruma H, 1997, J NEUROENDOCRINOL, V9, P835, DOI 10.1046/j.1365-2826.1997.00645.x; Ikeda K, 2000, NEUROSCI RES, V38, P113, DOI 10.1016/S0168-0102(00)00144-9; Kalra SP, 1997, J NEUROENDOCRINOL, V9, P569, DOI 10.1046/j.1365-2826.1997.00619.x; KNOBIL E, 1988, HUM REPROD, V3, P29, DOI 10.1093/oxfordjournals.humrep.a136647; Krsmanovic LZ, 1999, ENDOCRINOLOGY, V140, P1423, DOI 10.1210/en.140.3.1423; KRSMANOVIC LZ, 1991, P NATL ACAD SCI USA, V88, P11124, DOI 10.1073/pnas.88.24.11124; KRSMANOVIC LZ, 1992, P NATL ACAD SCI USA, V89, P8462, DOI 10.1073/pnas.89.18.8462; Krsmanovic LZ, 2003, P NATL ACAD SCI USA, V100, P2969, DOI 10.1073/pnas.0535708100; Krsmanovic LZ, 1998, ENDOCRINOLOGY, V139, P4037, DOI 10.1210/en.139.10.4037; Leaney JL, 2004, AM J PHYSIOL-CELL PH, V287, pC182, DOI 10.1152/ajpcell.00540.2003; Lewis DL, 1997, NEUROENDOCRINOLOGY, V66, P235, DOI 10.1159/000127244; LUKACS H, 1995, HORM BEHAV, V29, P42, DOI 10.1006/hbeh.1995.1004; Martinez-Fuentes AJ, 2004, MOL ENDOCRINOL, V18, P1808, DOI 10.1210/me.2003-0321; MARTINEZFUENTES AJ, 2000, 82 ANN M END SOC CHE, P21; MARTINI L, 1968, ENDOCRINOLOGY HUMAN, P175; McArdle C. A., 2002, Archives of Physiology and Biochemistry, V110, P113, DOI 10.1076/apab.110.1.113.893; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MILENKOVIC I, 1994, P NATL ACAD SCI USA, V91, P1244, DOI 10.1073/pnas.91.4.1244; Mores N, 1996, ENDOCRINOLOGY, V137, P5731, DOI 10.1210/en.137.12.5731; ORDOG T, 1995, P NATL ACAD SCI USA, V92, P5813, DOI 10.1073/pnas.92.13.5813; PORTER JC, 1978, CLIN OBSTET GYNAECOL, V5, P271; Pun RYK, 2003, BIOPHYS J, V84, P3425, DOI 10.1016/S0006-3495(03)70064-2; RAMIREZ VD, 1980, J ENDOCRINOL INVEST, V3, P29, DOI 10.1007/BF03348214; Sadja R, 2003, NEURON, V39, P9, DOI 10.1016/S0896-6273(03)00402-1; Skynner MJ, 1999, ENDOCRINOLOGY, V140, P5195, DOI 10.1210/en.140.11.5195; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; Terasawa E, 1998, GEN COMP ENDOCR, V112, P283, DOI 10.1006/gcen.1998.7155; Terasawa E, 1999, J NEUROSCI, V19, P5898, DOI 10.1523/JNEUROSCI.19-14-05898.1999; TERASAWA E, 1969, AM J PHYSIOL, V217, P1119, DOI 10.1152/ajplegacy.1969.217.4.1119; TURGEON JL, 1976, ENDOCRINOLOGY, V98, P639, DOI 10.1210/endo-98-3-639; URBAN RJ, 1989, ENDOCRINOLOGY, V124, P2541, DOI 10.1210/endo-124-5-2541; Van Goor F, 1999, P NATL ACAD SCI USA, V96, P4101, DOI 10.1073/pnas.96.7.4101; Van Goor F, 1999, MOL ENDOCRINOL, V13, P587, DOI 10.1210/me.13.4.587; Vitalis EA, 2000, P NATL ACAD SCI USA, V97, P1861, DOI 10.1073/pnas.040545197; Wada K, 2006, MOL ENDOCRINOL, V20, P125, DOI 10.1210/me.2005-0109; WEINER RI, 1992, FRONT NEUROENDOCRIN, V13, P95; WUTTKE W, 1974, EXP BRAIN RES, V19, P205; ZGOMBICK JM, 1989, MOL PHARMACOL, V35, P484; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	59	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25231	25240		10.1074/jbc.M603768200	http://dx.doi.org/10.1074/jbc.M603768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825187	hybrid			2022-12-27	WOS:000240031300024
J	Hu, ZH; Wang, YM; Graham, WV; Su, LP; Musch, MW; Turner, JR				Hu, Zhihong; Wang, Yingmin; Graham, W. Vallen; Su, Liping; Musch, Mark W.; Turner, Jerrold R.			MAPKAPK-2 is a critical signaling intermediate in NHE3 activation following Na+-glucose cotransport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAPK; AKT ACTIVATION; CANCER CELLS; KINASE; PROTEIN; TRANSLOCATION; ABSORPTION; PATHWAY; EZRIN; DIFFERENTIATION	Villus enterocyte nutrient absorption occurs via precisely orchestrated interactions among multiple transporters. For example, transport by the apical Na+-glucose cotransporter, SGLT1, triggers translocation of NHE3, Na+-H+ antiporter isoform 3, to the plasma membrane. This translocation requires activation of p38 mitogen-activated protein kinase ( MAPK), Akt2, and ezrin. Akt2 directly phosphorylates ezrin, but the precise role of p38 MAPK in this process remains to be defined. Sequence analysis suggested that p38 MAPK could not directly phosphorylate Akt2. We hypothesized that MAPKAPK-2 might link p38 MAPK and Akt2 activation. MAPKAPK-2 was phosphorylated after initiation of Na+-glucose cotransport with kinetics that paralleled activation of p38 MAPK, Akt2, and ezrin. MAPKAPK-2, Akt2, and ezrin phosphorylation were all attenuated by p38 MAPK inhibition but were unaffected by dominant negative ezrin expression. Akt2 inhibition blocked ezrin but not p38 MAPK or MAPKAPK-2 phosphorylation, suggesting that MAPKAPK-2 could be an intermediate in p38 MAPK-dependent Akt2 activation. Consistent with this, MAPKAPK-2 could phosphorylate an Akt2-derived peptide in vitro. siRNA-mediated MAPKAPK-2 knockdown inhibited phosphorylation of Akt2 and ezrin but not p38 MAPK. MAPKAPK-2 knockdown also blocked NHE3 translocation. Thus, MAPKAPK-2 controls Akt2 phosphorylation. In so doing, MAPKAPK-2 links p38 MAPK to Akt2, ezrin, and NHE3 activation after SGLT1-mediated transport.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Turner, JR (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.	jturner@bsd.uchicago.edu	wang, yingying/GRS-3058-2022; Graham, W Vallen/C-4315-2019; Turner, Jerrold/H-1502-2019; Graham, W/L-2301-2019; Turner, Jerrold R/A-6895-2009	Graham, W Vallen/0000-0003-3815-7532; Graham, W/0000-0003-3815-7532; Turner, Jerrold R/0000-0003-0627-9455	NCI NIH HHS [CA14599] Funding Source: Medline; NIDDK NIH HHS [DK42086, DK61931, DK68271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068271, R01DK061931, P30DK042086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn EH, 2006, ANTICANCER RES, V26, P121; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; An SS, 2005, AM J PHYSIOL-CELL PH, V289, pC521, DOI 10.1152/ajpcell.00429.2004; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; De la Horra MC, 1998, PFLUG ARCH EUR J PHY, V436, P112, DOI 10.1007/s004240050611; Duggan C, 2004, JAMA-J AM MED ASSOC, V291, P2628, DOI 10.1001/jama.291.21.2628; Gawenis LR, 2002, AM J PHYSIOL-GASTR L, V282, pG776, DOI 10.1152/ajpgi.00297.2001; Gueorguiev VD, 2006, J BIOL CHEM, V281, P10188, DOI 10.1074/jbc.M513806200; Hokari R, 2005, AM J PHYSIOL-GASTR L, V289, pG949, DOI 10.1152/ajpgi.00142.2005; HUNT JB, 1992, GUT, V33, P479, DOI 10.1136/gut.33.4.479; Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; MacCorkle RA, 2005, CELL BIOCHEM BIOPHYS, V43, P451, DOI 10.1385/CBB:43:3:451; Maher MM, 1997, GASTROENTEROLOGY, V112, P174, DOI 10.1016/S0016-5085(97)70232-4; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Segarra J, 2006, J BIOL CHEM, V281, P4771, DOI 10.1074/jbc.M508298200; Shiue H, 2005, J BIOL CHEM, V280, P1688, DOI 10.1074/jbc.M409471200; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Taniyama Y, 2004, AM J PHYSIOL-CELL PH, V287, pC494, DOI 10.1152/ajpcell.00439.2003; Thwaites DT, 2002, GASTROENTEROLOGY, V122, P1322, DOI 10.1053/gast.2002.32992; Tilly BC, 1996, FEBS LETT, V395, P133, DOI 10.1016/0014-5793(96)01028-9; Turner JR, 2000, ADV DRUG DELIVER REV, V41, P265, DOI 10.1016/S0169-409X(00)00046-6; Turner JR, 2001, AM J PHYSIOL-CELL PH, V281, pC1533, DOI 10.1152/ajpcell.2001.281.5.C1533; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; Woo PL, 1999, J BIOL CHEM, V274, P32818, DOI 10.1074/jbc.274.46.32818; Xia Q, 2006, CLIN EXP DERMATOL, V31, P260, DOI 10.1111/j.1365-2230.2006.02050.x; Zhao HR, 2004, P NATL ACAD SCI USA, V101, P9485, DOI 10.1073/pnas.0308400101	35	29	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24247	24253		10.1074/jbc.M602898200	http://dx.doi.org/10.1074/jbc.M602898200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793766	hybrid			2022-12-27	WOS:000239847800018
J	Marques, JM; Rodrigues, RJ; de Magalhaes-Sant'Ana, AC; Goncalves, T				Marques, Joana M.; Rodrigues, Ricardo J.; de Magalhaes-Sant'Ana, Augusto C.; Goncalves, Teresa			Saccharomyces cerevisiae Hog1 protein phosphorylation upon exposure to bacterial endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADE; OSMOSENSING SIGNAL-TRANSDUCTION; OSMOTIC-STRESS RESPONSE; TYROSINE PHOSPHATASES; OXIDATIVE STRESS; GENE-EXPRESSION; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; TRANSCRIPTIONAL RESPONSE; 2-COMPONENT SYSTEM; BUDDING YEAST	The yeast Hog1 protein is both functionally and structurally similar to the mammalian p38, belonging to the same family of mitogen-activated protein (MAP) kinases and responding to extracellular changes in osmolarity. Since p38 mediates lipopolysaccharide (LPS) effects in mammalian cells, we now tested the responsiveness of Hog1 upon exposure of the yeast Saccharomyces cerevisiae to bacterial LPS. In the presence of Escherichia coli LPS (100 ng/ml) and an endotoxically active, hexaacylated, synthetic lipid A (compound 506; 100 ng/ml), Hog1 becomes phosphorylated with a maximum of phosphorylation between 3 and 6 h, whereas a tetraacylated, inactive form of lipid A (compound 406) did not cause any modification in the phosphorylation state of Hog1. A triple labeling immunocytochemical study showed that phosphorylated Hog1 translocates into the nucleus after a 90-min incubation and becomes sparsely located in the cytoplasm. The translocation of the phospho-Hog1 is preceded by an increased expression of the HOG1gene and concomitant with the expression of the Hog1 target gene, GPD1. We also observed that cells unable to synthesize Hog1 do not resist LPS as efficiently as wild-type cells. We conclude that the yeast S. cerevisiae is able to respond to the presence of Gram-negative bacteria endotoxin and that Hog1 is involved in this response.	Univ Coimbra, Ctr Neurosci & Cell Biol Coimbra, P-3004504 Coimbra, Portugal; Univ Coimbra, Inst Microbiol, P-3004504 Coimbra, Portugal; Univ Coimbra, Inst Biochem, Fac Med, P-3004504 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra	Goncalves, T (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol Coimbra, P-3004504 Coimbra, Portugal.	tmfog@ci.uc.pt	Marques, Joana M/AAW-2711-2020; Gonçalves, Teresa/F-5146-2011; Rodrigues, Ricardo J/B-3847-2008	Marques, Joana M/0000-0002-7234-9477; Gonçalves, Teresa/0000-0001-9347-0535; Rodrigues, Ricardo J/0000-0002-7631-743X				Akhtar N, 2000, FEBS LETT, V483, P87, DOI 10.1016/S0014-5793(00)02087-1; ALBERTYN J, 1994, CURR GENET, V25, P12, DOI 10.1007/BF00712960; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alonso-Monge R, 2003, EUKARYOT CELL, V2, P351, DOI 10.1128/EC.2.2.351-361.2003; Bilsland E, 2004, MOL MICROBIOL, V53, P1743, DOI 10.1111/j.1365-2958.2004.04238.x; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; Bohm M, 2002, CELL TISSUE RES, V308, P431, DOI 10.1007/s00441-002-0535-x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GASCH AP, 2000, FUNCT INTEGR GENOMIC, V2, P181; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; Lawrence CL, 2004, MOL CELL BIOL, V24, P3307, DOI 10.1128/MCB.24.8.3307-3323.2004; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Mattison CP, 2000, GENE DEV, V14, P1229; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; O'Rourke SM, 2004, MOL BIOL CELL, V15, P532, DOI 10.1091/mbc.E03-07-0521; Ogura M, 1998, J IMMUNOL, V161, P3569; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; PRINTEN JA, 1994, GENETICS, V138, P609; Proft M, 2004, CELL, V118, P351, DOI 10.1016/j.cell.2004.07.016; Proft M, 1999, MOL CELL BIOL, V19, P537; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Seydel U, 2005, FEBS J, V272, P327, DOI 10.1111/j.1742-4658.2004.04471.x; Sharma P, 2005, CURR GENET, V48, P162, DOI 10.1007/s00294-005-0010-9; Sheikh-Hamad D, 2004, AM J PHYSIOL-RENAL, V287, pF1102, DOI 10.1152/ajprenal.00225.2004; Singh KK, 2000, FREE RADICAL BIO MED, V29, P1043, DOI 10.1016/S0891-5849(00)00432-9; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Teige M, 2001, P NATL ACAD SCI USA, V98, P5625, DOI 10.1073/pnas.091610798; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; Winkler A, 2002, EUKARYOT CELL, V1, P163, DOI 10.1128/EC.1.2.163-173.2002	56	20	21	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24687	24694		10.1074/jbc.M603753200	http://dx.doi.org/10.1074/jbc.M603753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790423	Green Published, hybrid			2022-12-27	WOS:000239847800064
J	Zhou, Y; Martin, CT				Zhou, Yi; Martin, Craig T.			Observed instability of T7 RNA polymerase elongation complexes can be dominated by collision-induced "bumping"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CONFORMATIONAL-CHANGES; LAC UV5 PROMOTER; TRANSCRIPTION ELONGATION; STRUCTURAL TRANSITIONS; INITIATION; MECHANISM; RELEASE; TRANSLOCATION; DISPLACEMENT; PROCESSIVITY	T7 RNA polymerase elongates RNA at a relatively high rate and can displace many tightly bound protein-DNA complexes. Despite these properties, measurements of the stability of stalled elongation complexes have shown lifetimes that are much shorter than those of the multisubunit RNA polymerases. In this work, we demonstrate that the apparent instability of stalled complexes actually arises from the action of trailing RNA polymerases (traveling in the same direction) displacing the stalled complex. Moreover, the instability caused by collision between two polymerases is position dependent. A second polymerase is blocked from promoter binding when a leading complex is stalled 12 bp or less from the promoter. The trailing complex can bind and make abortive transcripts when the leading complex is between 12 and 20 bp from the promoter, but it cannot displace the first complex since it is in a unstable initiation conformation. Only when the leading complex is stalled more than 20 bp away from the promoter can a second polymerase bind, initiate, and displace the leading complex.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Program Mol & Cellular Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Martin, CT (corresponding author), Univ Massachusetts, Dept Chem, 701 LGRC,710 N Pleasant St, Amherst, MA 01003 USA.	cmartin@chem.umass.edu	Martin, Craig T/L-3596-2013	Martin, Craig T/0000-0003-1029-5239	NIGMS NIH HHS [1R01 GM55002, T32 GM008515, T32 GM08515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008515, R01GM055002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAMPBELL FE, 1991, MOL CELL BIOL, V11, P3978, DOI 10.1128/MCB.11.8.3978; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; Epshtein V, 2003, EMBO J, V22, P4719, DOI 10.1093/emboj/cdg452; Epshtein V, 2003, SCIENCE, V300, P801, DOI 10.1126/science.1083219; Ferrari R, 2004, BIOCHEM BIOPH RES CO, V315, P376, DOI 10.1016/j.bbrc.2004.01.071; GALLEGO F, 1995, BIOCHEMISTRY-US, V34, P6711, DOI 10.1021/bi00020a016; Gong P, 2004, J BIOL CHEM, V279, P44277, DOI 10.1074/jbc.M409118200; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; Guo Q, 2005, J MOL BIOL, V353, P256, DOI 10.1016/j.jmb.2005.08.016; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; Jiang ML, 2004, MOL CELL, V15, P777, DOI 10.1016/j.molcel.2004.07.019; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kubori T, 1997, NUCLEIC ACIDS RES, V25, P2640, DOI 10.1093/nar/25.13.2640; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; Martin CT, 2005, PROG NUCLEIC ACID RE, V80, P323, DOI 10.1016/S0079-6603(05)80008-X; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1993, CELL MOL BIOL RES, V39, P385; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; OAKLEY JL, 1977, P NATL ACAD SCI USA, V74, P4266, DOI 10.1073/pnas.74.10.4266; Santangelo TJ, 2004, MOL CELL, V14, P117, DOI 10.1016/S1097-2765(04)00154-6; SCHICK C, 1993, BIOCHEMISTRY-US, V32, P4275, DOI 10.1021/bi00067a016; Song HS, 2001, GENES CELLS, V6, P291, DOI 10.1046/j.1365-2443.2001.00420.x; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Theis K, 2004, BIOCHEMISTRY-US, V43, P12709, DOI 10.1021/bi0486987; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG FJ, 1993, BIOCHEM MOL BIOL INT, V30, P969; Wilson KS, 1999, J MOL BIOL, V289, P1179, DOI 10.1006/jmbi.1999.2814; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; Zhang X, 1997, J MOL BIOL, V269, P10, DOI 10.1006/jmbi.1997.1016	36	26	26	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24441	24448		10.1074/jbc.M604369200	http://dx.doi.org/10.1074/jbc.M604369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16816387	hybrid			2022-12-27	WOS:000239847800038
J	Contreras-Alcantara, S; Godby, JA; Delos, SE				Contreras-Alcantara, Susana; Godby, Jesse A.; Delos, Sue E.			The single ligand-binding repeat of Tva, a low density lipoprotein receptor-related protein, contains two ligand-binding surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-A MODULE; VIRUS ENVELOPE GLYCOPROTEIN; GROUP HUMAN RHINOVIRUS; CYSTEINE-RICH REPEAT; SUBGROUP-A; APOLIPOPROTEIN-E; LEUKOSIS VIRUS; AVIAN-SARCOMA; ALPHA-2-MACROGLOBULIN RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA	The receptor for avian sarcoma/leukosis virus subtype A (ASLV-A), Tva, is the simplest member of the low density lipoprotein receptor family containing a single ligand-binding repeat (LBR). Most LBRs contain a central Trp (Trp(33) in Tva) that is important for ligand binding and, for the low density lipoprotein receptor, is associated with familial hypercholesterolemia. The Tva ligand-binding module contains a second Trp (Trp(48)) that is part of a DEW motif present in a subset of LBRs. Trp(48) is important for ASLV-A infectivity. A soluble Tva (sTva) ligand-binding module is sufficient for ASLV-A infectivity. Tva interacts with the viral glycoprotein, and a soluble receptor-binding domain (SUA) binds sTva with picomolar affinity. We investigated whether Tva, a retroviral receptor, could behave as a classic LBR by assessing sTva interactions with the universal receptor-associated protein (RAP) and comparing these interactions with those between sTva and its viral ligand (SUA). To address the role of the two Trp residues in Tva function, we prepared sTva harboring mutations of Trp(33), Trp(48), or both and determined the binding kinetics with RAP and SUA. We found that sTva behaved as a "normal" receptor toward RAP, requiring both calcium and Trp(33) for binding. However, sTva binding to SUA required neither calcium nor Trp(33). Furthermore, sTva could bind both RAP and SUA simultaneously. These results show that the single LBR of Tva has two ligand-binding sites, raising the possibility that other LBRs may also.	Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Delos, SE (corresponding author), Univ Virginia, Sch Med, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.	sed7a@virginia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022470] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22470] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdul-Aziz D, 2005, BIOCHEMISTRY-US, V44, P5075, DOI 10.1021/bi047575j; Adler A J, 1973, Methods Enzymol, V27, P675; Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Andersen OM, 2003, CHEMBIOCHEM, V4, P1137, DOI 10.1002/cbic.200300580; Andersen OM, 2001, BIOCHEMISTRY-US, V40, P15408, DOI 10.1021/bi0110692; Andersen OM, 2001, BIOCHEM J, V357, P289, DOI 10.1042/0264-6021:3570289; Arandjelovic S, 2005, ARCH BIOCHEM BIOPHYS, V438, P29, DOI 10.1016/j.abb.2005.03.019; Avramoglu RK, 1998, J BIOL CHEM, V273, P6057, DOI 10.1074/jbc.273.11.6057; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Beglova N, 2001, BIOCHEMISTRY-US, V40, P2808, DOI 10.1021/bi0027276; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Bu GJ, 2001, INT REV CYTOL, V209, P79; Croy JE, 2003, BIOCHEMISTRY-US, V42, P13049, DOI 10.1021/bi034752s; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Damico RL, 1998, P NATL ACAD SCI USA, V95, P2580, DOI 10.1073/pnas.95.5.2580; Delos SE, 2000, J VIROL, V74, P9738, DOI 10.1128/JVI.74.20.9738-9741.2000; Delos SE, 2005, J VIROL, V79, P3488, DOI 10.1128/JVI.79.6.3488-3499.2005; Delos SE, 2002, VIROLOGY, V294, P354, DOI 10.1006/viro.2001.1339; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; Earp LJ, 2003, METHOD ENZYMOL, V372, P428; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fisher C, 2004, BIOCHEMISTRY-US, V43, P1037, DOI 10.1021/bi035529y; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GRUENBERGER M, 1995, J VIROL, V69, P7244, DOI 10.1128/JVI.69.11.7244-7247.1995; Guo Y, 2004, J BIOL CHEM, V279, P16629, DOI 10.1074/jbc.M400157200; Hernandez LD, 1997, J CELL BIOL, V139, P1455, DOI 10.1083/jcb.139.6.1455; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; Herz J, 2000, CURR OPIN LIPIDOL, V11, P161, DOI 10.1097/00041433-200004000-00009; Hiesberger T, 1996, J BIOL CHEM, V271, P28792, DOI 10.1074/jbc.271.46.28792; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Jensen HK, 1996, ATHEROSCLEROSIS, V120, P57, DOI 10.1016/0021-9150(95)05680-7; Koduri V, 2001, BIOCHEMISTRY-US, V40, P12801, DOI 10.1021/bi011344k; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Kurniawan ND, 2000, PROTEIN SCI, V9, P1282, DOI 10.1110/ps.9.7.1282; Kvaratskhelia M, 2004, VIROLOGY, V326, P171, DOI 10.1016/j.virol.2004.05.020; Lazic A, 2003, BIOCHEMISTRY-US, V42, P14913, DOI 10.1021/bi035779e; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; Matsuyama S, 2004, J VIROL, V78, P8201, DOI 10.1128/JVI.78.15.8201-8209.2004; May P, 2005, CELL MOL LIFE SCI, V62, P2325, DOI 10.1007/s00018-005-5231-z; McCormick LM, 2005, BIOCHEMISTRY-US, V44, P5794, DOI 10.1021/bi047652a; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; Migliorini MM, 2003, J BIOL CHEM, V278, P17986, DOI 10.1074/jbc.M212592200; North CL, 2000, BIOCHEMISTRY-US, V39, P13127, DOI 10.1021/bi0015156; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Nykjaer A, 2002, TRENDS CELL BIOL, V12, P273, DOI 10.1016/S0962-8924(02)02282-1; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Prevost M, 2004, PROTEINS, V55, P874, DOI 10.1002/prot.20080; Raffai R, 2000, J BIOL CHEM, V275, P7109, DOI 10.1074/jbc.275.10.7109; Rai T, 2005, J VIROL, V79, P14962, DOI 10.1128/JVI.79.23.14962-14966.2005; Rai T, 2004, J VIROL, V78, P683, DOI 10.1128/JVI.78.2.683-691.2004; RALL SC, 1983, J CLIN INVEST, V72, P1288, DOI 10.1172/JCI111085; Rong LJ, 1997, J VIROL, V71, P3458, DOI 10.1128/JVI.71.5.3458-3465.1997; Rong LJ, 1998, J VIROL, V72, P4552, DOI 10.1128/JVI.72.6.4552-4559.1998; Rong LJ, 1998, P NATL ACAD SCI USA, V95, P8467, DOI 10.1073/pnas.95.15.8467; Rudenko G, 2003, CURR OPIN STRUC BIOL, V13, P683, DOI 10.1016/j.sbi.2003.10.001; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Simonovic M, 2001, BIOCHEMISTRY-US, V40, P15127, DOI 10.1021/bi015688m; Smith JG, 2004, J VIROL, V78, P1403, DOI 10.1128/JVI.78.3.1403-1410.2004; Tonelli M, 2001, FEBS LETT, V509, P161, DOI 10.1016/S0014-5793(01)03086-1; Verdaguer N, 2004, NAT STRUCT MOL BIOL, V11, P429, DOI 10.1038/nsmb753; Vlasak M, 2003, J VIROL, V77, P6923, DOI 10.1128/JVI.77.12.6923-6930.2003; Wang QY, 2002, PROTEIN SCI, V11, P2596, DOI 10.1110/ps.0219802; Wang QY, 2001, J VIROL, V75, P2051, DOI 10.1128/JVI.75.5.2051-2058.2001; Weaver AM, 1997, J LIPID RES, V38, P1841; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993; Yu XM, 2003, J VIROL, V77, P7517, DOI 10.1128/JVI.77.13.7517-7526.2003; Zaiou M, 2000, J LIPID RES, V41, P1087; Zingler K, 1996, J VIROL, V70, P7510, DOI 10.1128/JVI.70.11.7510-7516.1996	76	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22827	22838		10.1074/jbc.M512599200	http://dx.doi.org/10.1074/jbc.M512599200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769730	hybrid			2022-12-27	WOS:000239542600045
J	Zimny, J; Sikora, M; Guranowski, A; Jakubowski, H				Zimny, Jaroslaw; Sikora, Marta; Guranowski, Andrzej; Jakubowski, Hieronim			Protective mechanisms against homocysteine toxicity - The role of bleomycin hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEIN HOMOCYSTEINYLATION; PATHOLOGICAL CONSEQUENCES; CYSTEINE PROTEASE; ENDOTHELIAL-CELLS; AMINO-ACID; THIOLACTONE; METABOLISM; HUMANS; AUTOANTIBODIES	Homocysteine (Hcy) editing by methionyl-tRNA synthetase results in the formation of Hcy-thiolactone and initiates a pathway that has been implicated in human disease. In addition to being cleared from the circulation by urinary excretion, Hcy-thiolactone is detoxified by the serum Hcy-thiolactonase/paraoxonase carried on high density lipoprotein. Whether Hcy-thiolactone is detoxified inside cells was unknown. Here we show that Hcy-thiolactone is hydrolyzed by an intracellular enzyme, which we have purified to homogeneity from human placenta and identified by proteomic analyses as human bleomycin hydrolase (hBLH). We have also purified an Hcy-thiolactonase from the yeast Saccharomyces cerevisiae and identified it as yeast bleomycin hydrolase (yBLH). BLH belongs to a family of evolutionarily conserved cysteine aminopeptidases, and its only known biologically relevant function was deamidation of the anticancer drug bleomycin. Recombinant hBLH or yBLH, expressed in Escherichia coli, exhibits Hcy-thiolactonase activity similar to that of the native enzymes. Active site mutations, C73A for hBLH and H369A for yBLH, inactivate Hcy-thiolactonase activities. Yeast blh1 mutants are deficient in Hcy-thiolactonase activity in vitro and in vivo, produce more Hcy-thiolactone, and exhibit greater sensitivity to Hcy toxicity than wild type yeast cells. Our data suggest that BLH protects cells against Hcy toxicity by hydrolyzing intracellular Hcy-thiolactone.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; Univ Agr, Dept Biochem & Biotechnol, PL-60637 Poznan, Poland; Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Poznan University of Life Sciences; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; Zimny, Jaroslaw/0000-0001-6236-8562; Guranowski, Andrzej/0000-0002-8515-5153				Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; Chwatko G, 2005, CLIN CHEM, V51, P408, DOI 10.1373/clinchem.2004.042531; Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; DOMAGALA TB, 2006, IN PRESS CELL MOL BI, V52; EACINSKI M, 2004, CELL MOL BIOL, V50, P885; Glowacki R, 2004, J BIOL CHEM, V279, P10864, DOI 10.1074/jbc.M313268200; Hossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2005, CLIN CHEM LAB MED, V43, P1011, DOI 10.1515/CCLM.2005.177; Jakubowski H, 2004, CELL MOL LIFE SCI, V61, P470, DOI 10.1007/s00018-003-3204-7; Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200; Jakubowski H, 2003, J BIOL CHEM, V278, P6765, DOI 10.1074/jbc.M211819200; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; JAKUBOWSKI H, 2005, CELL MOL LIFE SCI, P384; Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S; Jakubowsky H., 2005, AMINOACYL TRNA SYNTH, P384; Koldamova RP, 1998, MOL PHARMACOL, V54, P954, DOI 10.1124/mol.54.6.954; Koldamova RP, 1998, BIOCHEMISTRY-US, V37, P2282, DOI 10.1021/bi9722204; Koldamova RP, 1999, BIOCHEMISTRY-US, V38, P7111, DOI 10.1021/bi990135l; Lefterov IM, 2001, BIOCHEM BIOPH RES CO, V283, P994, DOI 10.1006/bbrc.2001.4860; Lefterov IM, 2000, FASEB J, V14, P1837, DOI 10.1096/fj.99-0938com; Lentz SR, 2005, J THROMB HAEMOST, V3, P1646, DOI 10.1111/j.1538-7836.2005.01364.x; Loscalzo J, 2006, NEW ENGL J MED, V354, P1629, DOI 10.1056/NEJMe068060; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Niemer I, 1997, CURR GENET, V32, P41, DOI 10.1007/s002940050246; O'Farrell PA, 1999, STRUCT FOLD DES, V7, P619, DOI 10.1016/S0969-2126(99)80083-5; PEI ZD, 1995, MOL PHARMACOL, V48, P676; PERDZIAK M, 2005, ACTA BIOCH POL S1, V50, P184; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; Schwartz DR, 1999, P NATL ACAD SCI USA, V96, P4680, DOI 10.1073/pnas.96.8.4680; Senger B, 2001, J MOL BIOL, V311, P205, DOI 10.1006/jmbi.2001.4844; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Spence JD, 2005, STROKE, V36, P2404, DOI 10.1161/01.STR.0000185929.38534.f3; Tuite NL, 2005, J BACTERIOL, V187, P4362, DOI 10.1128/JB.187.13.4362-4371.2005; Undas A, 2005, THROMB HAEMOSTASIS, V93, P346, DOI 10.1160/TH04-08-0493; Undas A, 2004, STROKE, V35, P1299, DOI 10.1161/01.STR.0000128412.59768.6e; Wang HJ, 2002, BIOCHEM CELL BIOL, V80, P789, DOI 10.1139/O02-167; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zheng WJ, 1998, CELL, V93, P103, DOI 10.1016/S0092-8674(00)81150-2; Zheng WJ, 1998, MOL CELL BIOL, V18, P3580, DOI 10.1128/MCB.18.6.3580; ZIMNY J, 2005, CLIN CHEM LAB MED, V43, pA23	49	74	75	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22485	22492		10.1074/jbc.M603656200	http://dx.doi.org/10.1074/jbc.M603656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769724	hybrid			2022-12-27	WOS:000239542600009
J	Aisenbrey, C; Sizun, C; Koch, J; Herget, M; Abele, R; Bechinger, B; Tampe, R				Aisenbrey, Christopher; Sizun, Christina; Koch, Joachim; Herget, Meike; Abele, Rupert; Bechinger, Burkhard; Tampe, Robert			Structure and dynamics of membrane-associated ICP47, a viral inhibitor of the MHC I antigen-processing machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE NMR-SPECTROSCOPY; VIRUS PROTEIN ICP47; MAGNETIC-RESONANCE-SPECTROSCOPY; PEPTIDE-BINDING; ATP HYDROLYSIS; ACTIVE DOMAIN; TAP; POLYPEPTIDES; COMPLEX; N-15	To evade the host's immune response, herpes simplex virus employs the immediate early gene product ICP47 (IE12) to suppress antigen presentation to cytotoxic T-lymphocytes by inhibition of the ATP-binding cassette transporter associated with antigen processing (TAP). ICP47 is a membrane-associated protein adopting an alpha-helical conformation. Its active domain was mapped to residues 3-34 and shown to encode all functional properties of the full-length protein. The active domain of ICP47 was reconstituted into oriented phospholipid bilayers and studied by proton-decoupled N-15 and H-2 solid-state NMR spectroscopy. In phospholipid bilayers, the protein adopts a helix-loop-helix structure, where the average tilt angle of the helices relative to the membrane surface is similar to 15 degrees (+/- 7 degrees). The alignment of both structured domains exhibits a mosaic spread of similar to 10 degrees. A flexible dynamic loop encompassing residues 17 and 18 separates the two helices. Refinement of the experimental data indicates that helix 1 inserts more deeply into the membrane. These novel insights into the structure of ICP47 represent an important step toward a molecular understanding of the immune evasion mechanism of herpes simplex virus and are instrumental for the design of new therapeutics.	Univ Strasbourg 1, Inst Fac Chim, CNRS, LC3,UMR 7177, F-67070 Strasbourg, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Frankfurt, Inst Biochem, Bioctr, D-60438 Frankfurt, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society; Goethe University Frankfurt	Bechinger, B (corresponding author), Univ Strasbourg 1, Inst Fac Chim, CNRS, LC3,UMR 7177, 4 Rue Blaise Pascal, F-67070 Strasbourg, France.	bechinger@chimie.u-strasbg.fr; tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160; Sizun, Christina/0000-0002-5760-2614				Abele R, 2004, PHYSIOLOGY, V19, P216, DOI 10.1152/physiol.00002.2004; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Aisenbrey C, 2004, J AM CHEM SOC, V126, P16676, DOI 10.1021/ja0468675; Aisenbrey C, 2004, BIOCHEMISTRY-US, V43, P10502, DOI 10.1021/bi049409h; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Bangia N, 2005, IMMUNOLOGY, V114, P346, DOI 10.1111/j.1365-2567.2005.02103.x; Bechinger B, 1999, BIOPOLYMERS, V51, P174, DOI 10.1002/(SICI)1097-0282(1999)51:3<174::AID-BIP2>3.0.CO;2-7; Bechinger B, 2004, BBA-BIOMEMBRANES, V1666, P190, DOI 10.1016/j.bbamem.2004.08.008; BECHINGER B, 1991, J MAGN RESON, V95, P585, DOI 10.1016/0022-2364(91)90173-Q; Bechinger B., 2003, CONCEPT MAGN RESON A, V18A, P130; Beinert D, 1997, BIOCHEMISTRY-US, V36, P4694, DOI 10.1021/bi962940v; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; Davis JH, 1999, PROG NUCL MAG RES SP, V35, P1, DOI 10.1016/S0079-6565(99)00009-6; Ducarme P, 1998, PROTEINS, V30, P357, DOI 10.1002/(SICI)1097-0134(19980301)30:4<357::AID-PROT3>3.0.CO;2-G; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Galocha B, 1997, J EXP MED, V185, P1565, DOI 10.1084/jem.185.9.1565; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; Koch J, 2006, CELL MOL LIFE SCI, V63, P653, DOI 10.1007/s00018-005-5462-z; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lehner PJ, 2004, CURR OPIN IMMUNOL, V16, P82, DOI 10.1016/j.coi.2003.11.012; LEVITT MH, 1986, J CHEM PHYS, V84, P4243, DOI 10.1063/1.450046; Luca S, 2003, ACCOUNTS CHEM RES, V36, P858, DOI 10.1021/ar020232y; Neumann L, 1997, J MOL BIOL, V272, P484, DOI 10.1006/jmbi.1997.1282; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pfander R, 1999, BIOCHEMISTRY-US, V38, P13692, DOI 10.1021/bi9909647; SCHWYZER R, 1995, BIOPOLYMERS, V37, P5, DOI 10.1002/bip.360370104; TENG Q, 1989, J MAGN RESON, V85, P439, DOI 10.1016/0022-2364(89)90235-7; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; Watts A, 1999, CURR OPIN BIOTECH, V10, P48, DOI 10.1016/S0958-1669(99)80009-3; Whitley RJ, 1998, CLIN INFECT DIS, V26, P541, DOI 10.1086/514600; Yewdell JW, 2005, ANNU REV IMMUNOL, V23, P651, DOI 10.1146/annurev.immunol.23.021704.115702; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	38	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2006	281	41					30365	30372		10.1074/jbc.M603000200	http://dx.doi.org/10.1074/jbc.M603000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	092CZ	16835230	hybrid			2022-12-27	WOS:000241075900010
J	MirAfzali, Z; Leipprandt, JR; McCracken, JL; DeWitt, DL				MirAfzali, Zahra; Leipprandt, Jeffrey R.; McCracken, John L.; DeWitt, David L.			Topography of the prostaglandin endoperoxide H-2 synthase-2 in membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE; H SYNTHASES-1; C2 DOMAIN; SPIN; SITE; DYNAMICS; CYCLOOXYGENASES; ASSOCIATION; ORIENTATION	The topology of association of the monotopic protein cyclooxygenase-2 (COX-2) with membranes has been examined using EPR spectroscopy of spin-labeled recombinant human COX-2. Twenty-four mutants, each containing a single free cysteine substituted for an amino acid in the COX-2 membrane binding domain were expressed using the baculovirus system and purified, then conjugated with a nitroxide spin label and reconstituted into liposomes. Determining the relative accessibility of the nitroxide-tagged amino acid side chains for the solubilized COX-2 mutants, or COX-2 reconstituted into liposomes to nonpolar (oxygen) and polar (NiEDDA or CrOx) paramagnetic reagents allowed us to map the topology of COX-2 interaction with the lipid bilayer. When spin-labeled COX-2 was reconstituted into liposomes, EPR power saturation curves showed that side chains for all but two of the 24 mutants tested had limited accessibility to both polar and nonpolar paramagnetic relaxation agents, indicating that COX-2 associates primarily with the interfacial membrane region near the glycerol backbone and phospholipid head groups. Two amino acids, Phe(66) and Leu(67), were readily accessible to the non-polar relaxation agent oxygen, and thus likely inserted into the hydrophobic core of the lipid bilayer. However these residues are co-linear with amino acids in the interfacial region, so their extension into the hydrophobic core must be relatively shallow. EPR and structural data suggest that membrane interaction of COX-2 is also aided by partitioning of 4 aromatic amino acids, Phe(59), Phe(66), Tyr(76), and Phe(84) to the interfacial region, and by the electrostatic interactions of two basic amino acids, Arg(62) and Lys(64), with the phospholipid head groups.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Encapsula NanoSci, Nashville, TN 37203 USA	Michigan State University; Michigan State University	DeWitt, DL (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 519 Biochem Bldg, E Lansing, MI 48824 USA.	dewittd@msu.edu						ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Clayton AHA, 1999, EUR BIOPHYS J BIOPHY, V28, P133, DOI 10.1007/s002490050192; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Hristova K, 1999, J MOL BIOL, V290, P99, DOI 10.1006/jmbi.1999.2840; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; HUBBELL WL, 1994, MEMBRANE PROTEIN STR, P00224; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; KENNEDY TA, 1994, J BIOL CHEM, V269, P27357; Li Y, 1998, J BIOL CHEM, V273, P29830, DOI 10.1074/jbc.273.45.29830; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MirAfzali Z, 2005, ARCH BIOCHEM BIOPHYS, V443, P60, DOI 10.1016/j.abb.2005.08.014; Otto JC, 1996, J BIOL CHEM, V271, P9906, DOI 10.1074/jbc.271.17.9906; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	23	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28354	28364		10.1074/jbc.M605206200	http://dx.doi.org/10.1074/jbc.M605206200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16809339	hybrid			2022-12-27	WOS:000240534400073
J	Raine, A; Lovmar, M; Wikberg, J; Ehrenberg, M				Raine, Amanda; Lovmar, Martin; Wikberg, Jarl; Ehrenberg, Mans			Trigger factor binding to ribosomes with nascent peptide chains of varying lengths and sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI RIBOSOME; PROTEINS; CHAPERONE; DNAK; L23; ISOMERASE; MEMBRANE; DOMAIN; SITE	Trigger factor (TF) is the first protein-folding chaperone to interact with a nascent peptide chain as it emerges from the ribosome. Here, we have used a spin down assay to estimate the affinities for the binding of TF to ribosome nascent chain complexes (RNCs) with peptides of varying lengths and sequences. An in vitro system for protein synthesis assembled from purified Escherichia coli components was used to produce RNCs stalled on truncated mRNAs. The affinity of TF to RNCs exposing RNA polymerase sequences increased with the length of the nascent peptides. TF bound to RNA polymerase RNCs with significantly higher affinity than to inner membrane protein leader peptidase and bacterioopsin RNCs. The latter two RNCs are substrates for signal recognition particle, suggesting complementary affinities of TF and signal recognition particle to nascent peptides targeted for cytoplasm and membrane.	Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Pharmaceut Biosci, Biomed Ctr, S-75124 Uppsala, Sweden	Uppsala University; Uppsala University	Ehrenberg, M (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, Box 596, S-75124 Uppsala, Sweden.	ehrenberg@xray.bmc.uu.se	Raine, Amanda/L-1354-2019	Raine, Amanda/0000-0002-2775-6516				Antoun Ayman, 2004, Biol Proced Online, V6, P35, DOI 10.1251/bpo71; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Hundley HA, 2005, SCIENCE, V308, P1032, DOI 10.1126/science.1109247; Kramer G, 2004, J BIOL CHEM, V279, P14165, DOI 10.1074/jbc.M313635200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Lovmar M, 2004, J BIOL CHEM, V279, P53506, DOI 10.1074/jbc.M401625200; Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101; Maier R, 2003, J MOL BIOL, V326, P585, DOI 10.1016/S0022-2836(02)01427-4; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; Pal S, 1999, J BIOL CHEM, V274, P32771, DOI 10.1074/jbc.274.46.32771; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Raine A, 2003, BIOCHIMIE, V85, P659, DOI 10.1016/S0300-9084(03)00130-5; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; Rauch T, 2005, MOL MICROBIOL, V57, P357, DOI 10.1111/j.1365-2958.2005.04690.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Ullers RS, 2004, P NATL ACAD SCI USA, V101, P7583, DOI 10.1073/pnas.0402398101; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2	28	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28033	28038		10.1074/jbc.M605753200	http://dx.doi.org/10.1074/jbc.M605753200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16829677	hybrid			2022-12-27	WOS:000240534400040
J	Ma, K; Forbes, JG; Gutierrez-Cruz, G; Wang, K				Ma, Kan; Forbes, Jeffrey G.; Gutierrez-Cruz, Gustavo; Wang, Kuan			Titin as a giant scaffold for integrating stress and Src homology domain 3-mediated signaling pathways - The clustering of novel overlap ligand motifs in the elastic PEVK segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE TITIN; POLYPROLINE-II HELIX; SH3 DOMAIN; BINDING-SPECIFICITY; PEPTIDE RECOGNITION; MOLECULAR-DYNAMICS; AFFINITY PROFILES; KINASE DOMAIN; TERMINAL SH3; IN-VITRO	The richness of proline sequences in titins qualifies these giant proteins as the largest source of intrinsically disordered structures in nature. An extensive search and analysis for Src homology domain 3 (SH3) ligand motifs revealed a myriad of broadly distributed SH3 ligand motifs, with the highest density in the PEVK segments of human titin. Besides the canonical class I and II motifs with opposite orientations, novel overlapping motifs consisting of one or more of each canonical motif are abundant. Experimentally, the binding affinity and critical residues of these putative titin-based SH3 ligands toward nebulin SH3 and other SH3-containing proteins in muscle and non-muscle cell extracts were validated with peptide array technology and by the sarcomere distribution of SH3-containing proteins. A 28-mer overlapping motif-containing PEVK module binds to nebulin SH3 in and around the canonical cleft, especially to the acidic residues in the loops, as revealed by NMR titration. Molecular dynamics and molecular docking studies indicated that the overlapping motif can bind in opposite orientations with comparable energy and contact areas and predicts correctly orientation-specific contacts in NMR data. We propose that the overlap ligand motifs are a new class of ligands with innate ability to dictate SH3 domain orientation and to facilitate the rate, strength, and stereospecificity of receptor interactions. Proline-rich sequences of titins are candidates as major hubs of SH3- dependent signaling pathways. The interplay of elasticity and dense clustering of mixed receptor orientations in titin PEVK segment have important implications for the mechanical sensing, force sensitivity, and inter-adapter interactions in signaling pathways.	NIAMS, Muscle Proteom & Nanotechnol Sect, Muscle Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Wang, K (corresponding author), NIAMS, Muscle Proteom & Nanotechnol Sect, Muscle Biol Lab, NIH, Bldg 50,Rm 1140, Bethesda, MD 20892 USA.	wangk@exchange.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041118, Z01AR041119, ZIAAR041118] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adhikari BB, 2001, FEBS LETT, V497, P95, DOI 10.1016/S0014-5793(01)02444-9; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Bullard B, 2004, J BIOL CHEM, V279, P7917, DOI 10.1074/jbc.M307473200; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fernandez-Ballester G, 2004, J MOL BIOL, V335, P619, DOI 10.1016/j.jmb.2003.10.060; Flaherty DB, 2002, J MOL BIOL, V323, P533, DOI 10.1016/S0022-2836(02)00970-1; Forbes JG, 2005, J MUSCLE RES CELL M, V26, P291, DOI 10.1007/s10974-005-9035-4; GAUTEL M, 1993, EMBO J, V12, P3827, DOI 10.1002/j.1460-2075.1993.tb06061.x; Granzier HL, 2005, ADV PROTEIN CHEM, V71, P89, DOI 10.1016/S0065-3233(04)71003-7; Greaser M, 2001, PROTEINS, V43, P145, DOI 10.1002/1097-0134(20010501)43:2<145::AID-PROT1026>3.0.CO;2-B; Gutierrez-Cruz G, 2001, J BIOL CHEM, V276, P7442, DOI 10.1074/jbc.M008851200; Ho BK, 2005, PROTEIN SCI, V14, P1011, DOI 10.1110/ps.041156905; Hoshijima M, 2006, AM J PHYSIOL-HEART C, V290, pH1313, DOI 10.1152/ajpheart.00816.2005; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kim K, 2002, J CELL BIOL, V156, P101, DOI 10.1083/jcb.200107037; Kontrogianni-Konstantopoulos A, 2004, AM J PHYSIOL-CELL PH, V287, pC209, DOI 10.1152/ajpcell.00497.2003; Kramer A, 1998, METH MOL B, V87, P25; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Landgraf C, 2004, PLOS BIOL, V2, P94, DOI 10.1371/journal.pbio.0020014; Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463; Leake MC, 2004, BIOPHYS J, V87, P1112, DOI 10.1529/biophysj.103.033571; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Linke WA, 2002, J STRUCT BIOL, V137, P194, DOI 10.1006/jsbi.2002.4468; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Ma K, 2003, BIOCHEM J, V374, P687, DOI 10.1042/BJ20030702; Ma K, 2002, FEBS LETT, V532, P273, DOI 10.1016/S0014-5793(02)03655-4; Ma K, 2001, BIOCHEMISTRY-US, V40, P3427, DOI 10.1021/bi0022792; Mayer BJ, 2001, J CELL SCI, V114, P1253; McElhinny AS, 2002, J CELL BIOL, V157, P125, DOI 10.1083/jcb.200108089; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nagy A, 2005, BIOPHYS J, V89, P329, DOI 10.1529/biophysj.104.057737; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Nicholas G, 2002, J CELL PHYSIOL, V193, P120, DOI 10.1002/jcp.10158; Pires JR, 2003, J MOL BIOL, V326, P1427, DOI 10.1016/S0022-2836(03)00039-1; Politou AS, 2002, J MOL BIOL, V316, P305, DOI 10.1006/jmbi.2001.5312; Politou AS, 1998, J MOL BIOL, V276, P189, DOI 10.1006/jmbi.1997.1521; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SOMERVILLE LL, 1988, ARCH BIOCHEM BIOPHYS, V262, P118, DOI 10.1016/0003-9861(88)90174-9; Tskhovrebova L, 2003, NAT REV MOL CELL BIO, V4, P679, DOI 10.1038/nrm1198; Wang K, 1996, J BIOL CHEM, V271, P4304; Wang K, 1985, Cell Muscle Motil, V6, P315; Wang K, 2001, PROG BIOPHYS MOL BIO, V77, P1, DOI 10.1016/S0079-6107(01)00009-8; Watanabe K, 2002, J BIOL CHEM, V277, P11549, DOI 10.1074/jbc.M200356200; Yamasaki R, 2001, BIOPHYS J, V81, P2297, DOI 10.1016/S0006-3495(01)75876-6; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zastrow MS, 2006, J CELL SCI, V119, P239, DOI 10.1242/jcs.02728	61	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27539	27556		10.1074/jbc.M604525200	http://dx.doi.org/10.1074/jbc.M604525200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16766517	hybrid			2022-12-27	WOS:000240397700080
J	Schuttelkopf, AW; Andersen, OA; Rao, FV; Allwood, M; Lloyd, C; Eggleston, IM; Van Aalten, DMF				Schuttelkopf, Alexander W.; Andersen, Ole A.; Rao, Francesco V.; Allwood, Matthew; Lloyd, Clare; Eggleston, Ian M.; Van Aalten, Daan M. F.			Screening-based discovery and structural dissection of a novel family 18 chitinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRODUCT CYCLOPENTAPEPTIDE INHIBITORS; PLASMA CHITOTRIOSIDASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; CELL-SEPARATION; DRUG DISCOVERY; ALLOSAMIDIN; RESOLUTION; SUBSTRATE; COMPLEX; MIMICRY	Family 18 chitinases play key roles in the life cycles of a variety of organisms ranging from bacteria to man. Very recently it has been shown that one of the mammalian chitinases is highly overexpressed in the asthmatic lung and contributes to the pathogenic process through recruitment of inflammatory cells. Although several potent natural product chitinase inhibitors have been identified, their chemotherapeutic potential or their use as cell biological tools is limited due to their size, complex chemistry, and limited availability. We describe a virtual screening-based approach to identification of a novel, purine-based, chitinase inhibitor. This inhibitor acts in the low micromolar (K-i = 2.8 +/- 0.2 mu M) range in a competitive mode. Dissection of the binding mode by x-ray crystallography reveals that the compound, which consists of two linked caffeine moieties, binds in the active site through extensive and not previously observed stacking interactions with conserved, solvent exposed tryptophans. Such exposed aromatics are also present in the structures of many other carbohydrate processing enzymes. The compound exhibits favorable chemical properties and is likely to be useful as a general scaffold for development of pan-family 18 chitinase inhibitors.	Univ Dundee, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ London Imperial Coll Sci & Technol, Leukocyte Biol Sect, Fac Med, London SW7 2AZ, England	University of Dundee; Imperial College London	Van Aalten, DMF (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk	eggleston, Ian/E-2375-2011	van Aalten, Daan/0000-0002-1499-6908; Lloyd, Clare/0000-0001-8977-6726; Eggleston, Ian/0000-0003-0569-0082; Andersen, Ole Andreas/0000-0002-0408-645X	Medical Research Council [G0400503B] Funding Source: researchfish; Wellcome Trust [087618] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		Andersen OA, 2005, NAT PROD REP, V22, P563, DOI 10.1039/b416660b; Arai N, 2000, CHEM PHARM BULL, V48, P1442, DOI 10.1248/cpb.48.1442; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Braendvang M, 2005, BIOORGAN MED CHEM, V13, P6360, DOI 10.1016/j.bmc.2005.06.054; CABIB E, 1992, J GEN MICROBIOL, V138, P97, DOI 10.1099/00221287-138-1-97; Carr RAE, 2005, DRUG DISCOV TODAY, V10, P987, DOI 10.1016/S1359-6446(05)03511-7; Cavallaro RA, 1999, J MED CHEM, V42, P2527, DOI 10.1021/jm980469t; Chiosis G, 2003, CURR CANCER DRUG TAR, V3, P371, DOI 10.2174/1568009033481778; Erlanson DA, 2004, J MED CHEM, V47, P3463, DOI 10.1021/jm040031v; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; Gray N, 1999, CURR MED CHEM, V6, P859; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7; Houston DR, 2002, BIOCHEM J, V368, P23, DOI 10.1042/BJ20021034; Houston DR, 2002, P NATL ACAD SCI USA, V99, P9127, DOI 10.1073/pnas.132060599; Izumida H, 1996, J ANTIBIOT, V49, P76, DOI 10.7164/antibiotics.49.76; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Labadaridis I, 2005, ARCH DIS CHILD-FETAL, V90, pF531, DOI 10.1136/adc.2004.051284; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Rao FV, 2005, CHEM BIOL, V12, P973, DOI 10.1016/j.chembiol.2005.07.009; Rao FV, 2005, CHEM BIOL, V12, P65, DOI 10.1016/j.chembiol.2004.10.013; Rao FV, 2003, J BIOL CHEM, V278, P20110, DOI 10.1074/jbc.M300362200; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Shiomi K, 2000, TETRAHEDRON LETT, V41, P2141, DOI 10.1016/S0040-4039(00)00099-X; Takaya N, 1998, BIOSCI BIOTECH BIOCH, V62, P60, DOI 10.1271/bbb.62.60; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x	37	48	54	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27278	27285		10.1074/jbc.M604048200	http://dx.doi.org/10.1074/jbc.M604048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844689	hybrid			2022-12-27	WOS:000240397700054
J	Kammanadiminti, SJ; Chadee, K				Kammanadiminti, Srinivas J.; Chadee, Kris			Suppression of NF-kappa B activation by Entamoeba histolytica in intestinal epithelial cells is mediated by heat shock Protein 27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CYSTEINE PROTEINASES; APOPTOSIS UPSTREAM; GENE-EXPRESSION; KINASE PATHWAY; TISSUE-DAMAGE; IMMUNE CELLS; IN-VITRO; ALPHA; INDUCTION	Little is known about the pathogenesis of Entamoeba histolytica and how epithelial cells respond to the parasite. Herein, we characterized the interactions between E. histolytica and colonic epithelial cells and the role macrophages play in modulating epithelial cell responses. The human colonic epithelial cell lines Caco-2 and T84 were grown either as monoculture or co-cultured in transwell plates with differentiated human THP-1 macrophages for 24 h before stimulation with soluble amebic proteins (SAP). In naive epithelial cells, prolonged stimulation with SAP reduced the levels of heat shock protein (Hsp) 27 and 72. However in THP-1 conditioned intestinal epithelial cells SAP enhanced Hsp27 and Hsp72, which was dependent on the activation of ERK MAP kinase. Hsp synthesis induced by SAP conferred protection against oxidative and apoptotic injuries. Treatment with SAP inhibited NF-kappa B activation induced by interleukin-1 beta; specifically, the NF-kappa B-DNA binding, nuclear translocation of p65 subunit, and phosphorylation of I kappa B-alpha were reduced. Gene silencing by small interfering RNA confirmed the role of Hsp27 in suppressing NF-kappa B activation at I kappa B kinase ( IKK) level. By co-immunoprecipitation studies, we found that Hsp27 interacts with IKK-alpha and IKK-beta, and this association was increased in SAP-treated conditioned epithelial cells. Overexpression of wild type Hsp27 amplified the effects of SAP, whereas a phosphorylation-deficient mutant of Hsp27 abrogated SAP-induced NF-kappa B inhibition. In conditioned epithelial cells, Hsp27 was phosphorylated at serine 15 after prolonged exposure to SAP. This mechanism may explain the absence of colonic inflammation seen in the majority of individuals infected with E. histolytica.	Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary	Chadee, K (corresponding author), Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kchadee@ucalgary.ca						ASSEFFA A, 1993, ONCOL RES, V5, P11; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Boettner DR, 2005, INFECT IMMUN, V73, P3422, DOI 10.1128/IAI.73.6.3422-3430.2005; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Clemons NJ, 2005, J BIOL CHEM, V280, P9005, DOI 10.1074/jbc.M414165200; DEITCH EA, 1995, CRIT CARE MED, V23, P1371, DOI 10.1097/00003246-199508000-00010; ECKMANN L, 1995, J CLIN INVEST, V96, P1269, DOI 10.1172/JCI118161; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; Gerhard R, 2005, J BIOL CHEM, V280, P1499, DOI 10.1074/jbc.M406014200; Gilchrist CA, 1999, CURR OPIN MICROBIOL, V2, P433, DOI 10.1016/S1369-5274(99)80076-9; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; Haller D, 2004, IMMUNOLOGY, V112, P310, DOI 10.1111/j.1365-2567.2004.01874.x; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC351, DOI 10.1152/ajpcell.1999.277.3.C351; HOSOKAWA N, 1992, MOL CELL BIOL, V12, P3490, DOI 10.1128/MCB.12.8.3490; Hurley Bryan P, 2004, Curr Gastroenterol Rep, V6, P355, DOI 10.1007/s11894-004-0050-1; Huston CD, 2003, INFECT IMMUN, V71, P964, DOI 10.1128/IAI.71.2.964-972.2003; Kanzato H, 2001, BIOSCI BIOTECH BIOCH, V65, P449, DOI 10.1271/bbb.65.449; Kim SH, 1999, BIOCHEM BIOPH RES CO, V262, P516, DOI 10.1006/bbrc.1999.1229; Kohn G, 2002, SHOCK, V17, P91, DOI 10.1097/00024382-200202000-00002; Kojima K, 2003, GASTROENTEROLOGY, V124, P1395, DOI 10.1016/S0016-5085(03)00215-4; Liu TS, 2003, AM J PHYSIOL-CELL PH, V284, pC1073, DOI 10.1152/ajpcell.00134.2002; Malago JJ, 2002, CELL STRESS CHAPERON, V7, P191, DOI 10.1379/1466-1268(2002)007<0191:THSRAC>2.0.CO;2; Malhotra V, 2002, BIOCHEM BIOPH RES CO, V291, P453, DOI 10.1006/bbrc.2002.6470; McKay DM, 1996, AM J PHYSIOL-CELL PH, V270, pC418, DOI 10.1152/ajpcell.1996.270.2.C418; Moncada D, 2003, INFECT IMMUN, V71, P838, DOI 10.1128/IAI.71.2.838-844.2003; Musch MW, 2004, INFECT IMMUN, V72, P3187, DOI 10.1128/IAI.72.6.3187-3194.2004; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Sasaki H, 2002, J IMMUNOL, V168, P5178, DOI 10.4049/jimmunol.168.10.5178; Schmitz H, 2002, AIDS, V16, P983, DOI 10.1097/00002030-200205030-00004; Schutze N, 2004, MOL CELL ENDOCRINOL, V213, P115, DOI 10.1016/j.mce.2003.10.078; Seydel KB, 1998, GASTROENTEROLOGY, V115, P1446, DOI 10.1016/S0016-5085(98)70023-X; Seydel KB, 1997, INFECT IMMUN, V65, P1631, DOI 10.1128/IAI.65.5.1631-1639.1997; Sim S, 2005, J IMMUNOL, V174, P4279, DOI 10.4049/jimmunol.174.7.4279; Stauffer W, 2003, CURR OPIN INFECT DIS, V16, P479, DOI 10.1097/00001432-200310000-00016; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Tao Y, 2006, AM J PHYSIOL-CELL PH, V290, pC1018, DOI 10.1152/ajpcell.00131.2005; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; World Health Organization W, 1998, QUAL CONTR METH MED; Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416; Yu Y, 1997, GASTROENTEROLOGY, V112, P1536, DOI 10.1016/S0016-5085(97)70035-0; Zhang Z, 2000, MOL MICROBIOL, V37, P542, DOI 10.1046/j.1365-2958.2000.02037.x	46	61	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26112	26120		10.1074/jbc.M601988200	http://dx.doi.org/10.1074/jbc.M601988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840786	hybrid			2022-12-27	WOS:000240249500026
J	Latreille, M; Larose, L				Latreille, Mathieu; Larose, Louise			Nck in a complex containing the catalytic subunit of protein phosphatase 1 regulates eukaryotic initiation factor 2 alpha signaling and cell survival to endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; INDUCED GENE-EXPRESSION; MESSENGER-RNA; TRANSLATIONAL CONTROL; ADAPTER PROTEIN; ER STRESS; GAMMA(1)34.5 PROTEIN; INHIBITION; ATF6; BINDING	Stress imposed on the endoplasmic reticulum (ER) induces the phosphorylation of the alpha-subunit of the eukaryotic initiation factor 2 (eIF2) on Ser(51). This results in transient inhibition of general translation initiation while concomitantly activating a signaling pathway that promotes the expression of genes whose products improve ER function. Conversely, dephosphorylation of eIF2 alpha Ser(51) is accomplished by protein phosphatase 1 (PP1c) complexes containing either the protein CReP or GADD34, which target PP1c to eIF2. Here, we demonstrate that the Src homology (SH) domain-containing adaptor Nck is a key component of a molecular complex that controls eIF2 alpha phosphorylation and signaling in response to ER stress. We show that overexpression of Nck decreases basal and ER stress-induced eIF2 alpha phosphorylation and the attendant induction of ATF4 and CHOP. In contrast, we demonstrate that the mouse embryonic fibroblasts lacking both isoforms of Nck (Nck1(-/)-Nck2(-/-)) show higher levels of eIF2 alpha phosphorylation and premature induction of ATF4, CHOP, and GADD34 in response to ER stress and finally, are more resistant to cell death induced by prolonged ER stress conditions. We establish that a significant amount of Nck protein localizes at the ER and is in a complex with eIF2 subunits. Further analysis of this complex revealed that it also contains the Ser/ Thr phosphatase PP1c, its regulatory subunit CReP, and dephosphorylates eIF2 alpha on Ser(51) in vitro. Overall, we demonstrate that Nck as a component of the CReP/ PP1c holophosphatase complex contributes to maintain eIF2 alpha in a hypophosphorylated state. In this manner, Nck modulates translation and eIF2 alpha signaling in response to ER stress.	McGill Univ, Polypeptide Lab, Dept Med, Montreal, PQ H3A 2B2, Canada	McGill University	Larose, L (corresponding author), McGill Univ, Polypeptide Lab, Dept Med, Strathcona Bldg,3640 Univ St,Rm W315 Montreal, Montreal, PQ H3A 2B2, Canada.	louise.larose@mcgill.ca		Latreille, Mathieu/0000-0001-8542-749X				Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; CHEN J, 2000, HEME REGULATED EIF2A, P529; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Iyer S, 2004, ACTA PAEDIATR, V93, P1195, DOI 10.1080/08035250410029362; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; KAUFMAN RJ, 2000, DOUBLE STANDED RNA A; Kebache S, 2004, J BIOL CHEM, V279, P9662, DOI 10.1074/jbc.M310535200; Kebache S, 2002, P NATL ACAD SCI USA, V99, P5406, DOI 10.1073/pnas.082483399; Kudo T, 2002, ANN NY ACAD SCI, V977, P349, DOI 10.1111/j.1749-6632.2002.tb04837.x; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Li XD, 2002, J BIOL CHEM, V277, P37788, DOI 10.1074/jbc.M205428200; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; O'Loghlen A, 2003, ARCH BIOCHEM BIOPHYS, V417, P194, DOI 10.1016/S0003-9861(03)00368-0; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Piper M, 2004, ANNU REV CELL DEV BI, V20, P505, DOI 10.1146/annurev.cellbio.20.010403.111746; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203; Stephens SB, 2005, MOL BIOL CELL, V16, P5819, DOI 10.1091/mbc.E05-07-0685; Tan S, 2001, J CELL BIOL, V152, P997, DOI 10.1083/jcb.152.5.997; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; VOROBIEVA N, 1995, CYTOGENET CELL GENET, V68, P91, DOI 10.1159/000133898; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	65	49	56	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26633	26644		10.1074/jbc.M513556200	http://dx.doi.org/10.1074/jbc.M513556200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835242	hybrid			2022-12-27	WOS:000240249500081
J	Li, LL; Heldin, CH; Heldin, P				Li, Lingli; Heldin, Carl-Henrik; Heldin, Paraskevi			Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CELL-MIGRATION; INTEGRIN; ADHESION; PHOSPHORYLATION; TRANSMEMBRANE; MECHANISMS; MESENCHYME; EXPRESSION; INCREASES	The extracellular matrix molecule hyaluronan was found to suppress platelet-derived growth factor (PDGF) beta-receptor activation and PDGF-BB-induced migration of primary human dermal fibroblasts. The suppressive effect of hyaluronan was neutralized by a monoclonal antibody that specifically inhibits hyaluronan binding to its receptor CD44. Moreover, co-immunoprecipitation experiments showed that the PDGF beta-receptor and CD44 can form a complex. Interestingly, the inhibitory effect of hyaluronan on PDGF beta-receptor activation was not seen in the presence of the tyrosine phosphatase inhibitor pervanadate. Our observations suggest that hyaluronan suppresses PDGF beta-receptor activation by recruiting a CD44-associated tyrosine phosphatase to the receptor.	Uppsala Univ, Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, S-75123 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University	Heldin, P (corresponding author), Uppsala Univ, Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden.	Paraskevi.Heldin@imbim.uu.se	Li, Lingli/HIR-7951-2022					Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Cichy J, 2004, FEBS LETT, V556, P69, DOI 10.1016/S0014-5793(03)01370-X; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Greiling D, 1997, J CELL SCI, V110, P861; Hamada Jun-Ichi, 1998, Frontiers in Bioscience, V3, pD657; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; Heldin P, 1996, ONCOL REP, V3, P1011; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Jacobson A, 2002, INT J CANCER, V102, P212, DOI 10.1002/ijc.10683; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Knudson W., 1998, FRONT BIOSCI, V3, P604; Kubens BS, 1997, CANCER LETT, V118, P189, DOI 10.1016/S0304-3835(97)00330-3; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; SARAS J, 1994, J BIOL CHEM, V269, P24082; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shenoi H, 1999, J IMMUNOL, V162, P7120; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; TEDER P, 1995, CANCER RES, V55, P3908; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Udabage L, 2005, CANCER RES, V65, P6139, DOI 10.1158/0008-5472.CAN-04-1622; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Woodard AS, 1998, J CELL SCI, V111, P469; Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622	41	66	66	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26512	26519		10.1074/jbc.M605607200	http://dx.doi.org/10.1074/jbc.M605607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809345	hybrid			2022-12-27	WOS:000240249500069
J	Liu, J; Qian, N; Morrical, SW				Liu, Jie; Qian, Na; Morrical, Scott W.			Dynamics of bacteriophage T4 presynaptic filament assembly from extrinsic fluorescence measurements of GP32-single-stranded DNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PROTEIN-PROTEIN INTERACTIONS; UVSY RECOMBINATION PROTEIN; GENE 59 PROTEIN; BINDING-PROTEIN; NONCOOPERATIVE BINDING; MEDIATOR PROTEINS; REPLICATION FORK; NUCLEIC-ACIDS; GP32	In the bacteriophage T4 homologous recombination system, presynaptic filament assembly on single-stranded (ssDNA) DNA requires UvsX recombinase, UvsY mediator, and Gp32 ssDNA-binding proteins. Gp32 exerts both positive and negative effects on filament assembly: positive by denaturing ssDNA secondary structure, and negative by competing with UvsX for ssDNA binding sites. UvsY is believed to help UvsX displace Gp32 from the ssDNA. To test this model we developed a real-time fluorescence assay for Gp32-ssDNA interactions during presynapsis, based on changes in the fluorescence of a 6-iodoacetamidofluorescein-Gp32 conjugate. Results demonstrate that the formation of UvsX presynaptic filaments progressively disrupts Gp32-ssDNA interactions. Under stringent salt conditions the disruption of Gp32-ssDNA by UvsX is both ATP- and UvsY-dependent. The displacement of Gp32 from ssDNA during presynapsis requires ATP binding, but not ATP hydrolysis, by UvsX protein. Likewise, UvsY-mediated presynapsis strongly requires UvsY-ssDNA interactions, and is optimal at a 1: 1 stoichiometry of UvsY to UvsX and/or ssDNA binding sites. Presynaptic filaments formed in the presence of UvsY undergo assembly/collapse that is tightly coupled to the ATP hydrolytic cycle and to stringent competition for ssDNA binding sites between Gp32 and various nucleotide-liganded forms of UvsX. The data directly support the Gp32 displacement model of UvsY-mediated presynaptic filament assembly, and demonstrate that the transient induction of high affinity UvsX-ssDNA interactions by ATP are essential, although not sufficient, for Gp32 displacement. The underlying dynamics of protein-ssDNA interactions within presynaptic filaments suggests that rearrangements of UvsX, UvsY, and Gp32 proteins on ssDNA may be coupled to central processes in T4 recombination metabolism.	Univ Vermont, Coll Med, Dept Biochem & Microbiol, Vermont Canc Ctr, Winooski, VT 05404 USA; Univ Vermont, Coll Med, Dept Mol Genet, Vermont Canc Ctr, Winooski, VT 05404 USA	University of Vermont; University of Vermont	Morrical, SW (corresponding author), Univ Vermont, Coll Med, Dept Biochem & Microbiol, Vermont Canc Ctr, B407 Given Bldg, Winooski, VT 05404 USA.	smorrica@zoo.uvm.edu			NIGMS NIH HHS [GM48847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM048847, R01GM048847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando RA, 1998, J MOL BIOL, V283, P785, DOI 10.1006/jmbi.1998.2124; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; Bleuit JS, 2004, J BIOL CHEM, V279, P6077, DOI 10.1074/jbc.M311557200; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; JIANG H, 1993, J BIOL CHEM, V268, P7904; Jiang H, 1997, BIOCHEM BIOPH RES CO, V231, P600, DOI 10.1006/bbrc.1997.6160; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; Karpel RL, 2002, IUBMB LIFE, V53, P161, DOI 10.1080/15216540212332; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN NUM, P244; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; Liu J, 2006, BIOCHEMISTRY-US, V45, P5493, DOI 10.1021/bi0525167; LOHMAN TM, 1981, J MOL BIOL, V152, P67, DOI 10.1016/0022-2836(81)90096-6; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MCGHEE JD, 1976, J MOL BIOL, V103, P679; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MELAMEDE RJ, 1977, J VIROL, V24, P28, DOI 10.1128/JVI.24.1.28-40.1977; MELAMEDE RJ, 1978, FEBS LETT, V87, P12, DOI 10.1016/0014-5793(78)80122-7; MELAMEDE RJ, 1980, MOL GEN GENET, V177, P501, DOI 10.1007/BF00271490; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MORRICA LS, 2003, Patent No. 60440059; MORRICAL S, 2004, Patent No. 2004000665; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1997, VIROLOGY, V230, P72, DOI 10.1006/viro.1997.8464; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; Sweezy MA, 1999, BIOCHEMISTRY-US, V38, P936, DOI 10.1021/bi9817055; Williams Kenneth R., 1994, P301; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; XU H, 2005, BIOCHEMISTRY; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yassa DS, 1997, BIOCHIMIE, V79, P275, DOI 10.1016/S0300-9084(97)83515-8; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	61	26	26	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26308	26319		10.1074/jbc.M604349200	http://dx.doi.org/10.1074/jbc.M604349200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829679	hybrid			2022-12-27	WOS:000240249500048
J	Pochynyuk, O; Medina, J; Gamper, N; Genth, H; Stockand, JD; Staruschenko, A				Pochynyuk, Oleh; Medina, Jorge; Gamper, Nikita; Genth, Harald; Stockand, James D.; Staruschenko, Alexander			Rapid translocation and insertion of the epithelial Na+ channel in response to RhoA signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; SUBUNIT STOICHIOMETRY; SECRETORY GRANULES; MAST-CELLS; EXOCYTOSIS; ACTIVATION; GTPASES; RAS	Activity of the epithelial Na+ channel (ENaC) is limiting for Na+ absorption across many epithelia. Consequently, ENaC is a central effector impacting systemic blood volume and pressure. Two members of the Ras superfamily of small GTPases, K-Ras and RhoA, activate ENaC. K-Ras activates ENaC via a signaling pathway involving phosphatidylinositol 3-kinase and production of phosphatidylinositol 3,4,5-trisphosphate with the phospholipid directly interacting with the channel to increase open probability. How RhoA increases ENaC activity is less clear. Here we report that RhoA and K-Ras activate ENaC through independent signaling pathways and final mechanisms of action. Activation of RhoA signaling rapidly increases the membrane levels of ENaC likely by promoting channel insertion. This process dramatically increases functional ENaC current, resulting in tight spatial-temporal control of these channels. RhoA signals to ENaC via a transduction pathway, including the downstream effectors Rho kinase and phosphatidylinositol-4-phosphate 5-kinase. Phosphatidylinositol 4,5-biphosphate produced by activated phosphatidylinositol 4-phosphate 5-kinase may play a role in targeting vesicles containing ENaC to the plasma membrane.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England; Hannover Med Sch, Inst Toxikol, D-30625 Hannover, Germany	University of Texas System; University of Texas Health San Antonio; University of Leeds; Hannover Medical School	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu	Genth, Harald/HHS-0118-2022	Stockand, James/0000-0002-3817-4319; Staruschenko, Alexander/0000-0002-5190-8356; Gamper, Nikita/0000-0001-5806-0207	NIDDK NIH HHS [R01-DK-59594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander RT, 2005, P NATL ACAD SCI USA, V102, P12253, DOI 10.1073/pnas.0409197102; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Aoyagi K, 2005, J BIOL CHEM, V280, P17346, DOI 10.1074/jbc.M413307200; Bender K, 2002, FEBS LETT, V529, P356, DOI 10.1016/S0014-5793(02)03426-9; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Doussau F, 2000, J BIOL CHEM, V275, P7764, DOI 10.1074/jbc.275.11.7764; Doussau F, 2000, BIOCHIMIE, V82, P353, DOI 10.1016/S0300-9084(00)00217-0; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gamper Nikita, 2005, Journal of Pharmacological and Toxicological Methods, V51, P177, DOI 10.1016/j.vascn.2004.08.008; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Imamura Y, 2004, NEUROSCIENCE, V127, P973, DOI 10.1016/j.neuroscience.2004.05.051; Imamura Y, 2003, NEUROREPORT, V14, P1203, DOI 10.1097/00001756-200307010-00003; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Li Y, 2005, J NEUROSCI, V25, P9825, DOI 10.1523/JNEUROSCI.2597-05.2005; Pinxteren JA, 2000, BIOCHIMIE, V82, P385, DOI 10.1016/S0300-9084(00)00197-8; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2005, BBA-BIOMEMBRANES, V1669, P108, DOI 10.1016/j.bbamem.2005.01.005; Staruschenko A, 2004, J BIOL CHEM, V279, P49989, DOI 10.1074/jbc.M409812200; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Storey NM, 2002, CURR BIOL, V12, P27, DOI 10.1016/S0960-9822(01)00625-X; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Waselle L, 2005, MOL ENDOCRINOL, V19, P3097, DOI 10.1210/me.2004-0530; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; Yang SA, 2004, J BIOL CHEM, V279, P42331, DOI 10.1074/jbc.M404335200; Yatani A, 2005, AM J PHYSIOL-HEART C, V288, pH650, DOI 10.1152/ajpheart.00268.2004; YATANI A, 1991, J BIOL CHEM, V266, P22222	52	54	56	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26520	26527		10.1074/jbc.M603716200	http://dx.doi.org/10.1074/jbc.M603716200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829523	hybrid			2022-12-27	WOS:000240249500070
J	Reynolds, KA; Thomson, JM; Corbett, KD; Bethel, CR; Berger, JM; Kirsch, JF; Bonomo, RA; Handel, TM				Reynolds, Kimberly A.; Thomson, Jodi M.; Corbett, Kevin D.; Bethel, Christopher R.; Berger, James M.; Kirsch, Jack F.; Bonomo, Robert A.; Handel, Tracy M.			Structural and computational characterization of the SHV-1 beta-lactamase-beta- lactamase inhibitor protein interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-AFFINITY; ENERGY FUNCTIONS; DESIGN; BACKBONE; RESIDUES; TEM-1; SPECIFICITY; REFINEMENT; RESISTANCE; COMPLEX	beta-Lactamase inhibitor protein (BLIP) binds a variety of class A beta-lactamases with affinities ranging from micromolar to picomolar. Whereas the TEM-1 and SHV-1 beta-lactamases are almost structurally identical, BLIP binds TEM-1 similar to 1000-fold tighter than SHV-1. Determining the underlying source of this affinity difference is important for understanding the molecular basis of beta-lactamase inhibition and mechanisms of protein-protein interface specificity and affinity. Here we present the 1.6 angstrom resolution crystal structure of SHV-1(.)BLIP. In addition, a point mutation was identified, SHV D104E, that increases (SHVBLIP)-B-. binding affinity from micromolar to nanomolar. Comparison of the SHV-1(.)BLIP structure with the published TEM-1(.)BLIP structure suggests that the increased volume of Glu-104 stabilizes a key binding loop in the interface. Solution of the 1.8 angstrom SHV D104K(.)BLIP crystal structure identifies a novel conformation in which this binding loop is removed from the interface. Using these structural data, we evaluated the ability of EGAD, a program developed for computational protein design, to calculate changes in the stability of mutant beta-lactamase(.)BLIP complexes. Changes in binding affinity were calculated within an error of 1.6 kcal/ mol of the experimental values for 112 mutations at the TEM-1(.) BLIP interface and within an error of 2.2 kcal/ mol for 24 mutations at the SHV-1(.)BLIP interface. The reasonable success of EGAD in predicting changes in interface stability is a promising step toward understanding the stability of the beta-lactamase(.)BLIP complexes and computationally assisted design of tight binding BLIP variants.	Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Calif Berkeley, Biophys Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Louis Stokes Vet Affaris Med Ctr, Res Serv, Cleveland, OH 44106 USA	University of California System; University of California San Diego; Case Western Reserve University; University of California System; University of California Berkeley; University of California System; University of California Berkeley; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Handel, TM (corresponding author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.	thandel@ucsd.edu		Corbett, Kevin/0000-0001-5854-2388; Reynolds, Kimberly/0000-0003-4805-0317	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250, R01GM035393] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01AI635172] Funding Source: Medline; NIGMS NIH HHS [GM35393, T32 GM07250] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; DeLano W.L, PYMOL MOL GRAPHICS S; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; Holton J, 2004, P NATL ACAD SCI USA, V101, P1537, DOI 10.1073/pnas.0306241101; Horn JR, 2004, J MOL BIOL, V336, P1283, DOI 10.1016/j.jmb.2003.12.068; Huang WZ, 2003, PROTEIN ENG, V16, P853, DOI 10.1093/protein/gzg108; Hujer AM, 2001, BBA-PROTEIN STRUCT M, V1547, P37, DOI 10.1016/S0167-4838(01)00164-9; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; JONES TA, 1997, O MANUAL VERSION 7 0; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; Joughin BA, 2005, PROTEIN SCI, V14, P1363, DOI 10.1110/ps.041283105; KLEYWEGT GJ, 1994, JOINT CCP4 ESF EACBM, V31, P9; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Kuhlman B, 2002, J MOL BIOL, V315, P471, DOI 10.1006/jmbi.2001.5229; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Larson SM, 2002, PROTEIN SCI, V11, P2804, DOI 10.1110/ps.0203902; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EACBM, V26; Lin S, 1998, BIOCHEM J, V333, P395, DOI 10.1042/bj3330395; MacDowell AA, 2004, J SYNCHROTRON RADIAT, V11, P447, DOI 10.1107/S0909049504024835; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; Offredi F, 2003, J MOL BIOL, V325, P163, DOI 10.1016/S0022-2836(02)01206-8; OTWINOWSKI Z, 1997, METHOD ENZYMOL, V276, P472, DOI DOI 10.1016/S0076-6879(97)76073-7; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Pokala N, 2005, J MOL BIOL, V347, P203, DOI 10.1016/j.jmb.2004.12.019; Pokala N, 2004, PROTEIN SCI, V13, P925, DOI 10.1110/ps.03486104; Reichmann D, 2005, P NATL ACAD SCI USA, V102, P57, DOI 10.1073/pnas.0407280102; Rice LB, 2000, ANTIMICROB AGENTS CH, V44, P362, DOI 10.1128/AAC.44.2.362-367.2000; Rudgers GW, 1999, J BIOL CHEM, V274, P6963, DOI 10.1074/jbc.274.11.6963; Rudgers GW, 2001, PROTEIN ENG, V14, P487, DOI 10.1093/protein/14.7.487; Rudgers GW, 2001, ANTIMICROB AGENTS CH, V45, P3279, DOI 10.1128/AAC.45.12.3279-3286.2001; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 2001, PROTEINS, V45, P190, DOI 10.1002/prot.1139; Sosa-Peinado A, 2000, PROTEIN EXPRES PURIF, V19, P235, DOI 10.1006/prep.2000.1243; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Zhang Z, 2004, J BIOL CHEM, V279, P42860, DOI 10.1074/jbc.M406157200; Zhang Z, 2003, J BIOL CHEM, V278, P45706, DOI 10.1074/jbc.M308572200	45	44	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26745	26753		10.1074/jbc.M603878200	http://dx.doi.org/10.1074/jbc.M603878200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809340	hybrid			2022-12-27	WOS:000240249500092
J	Li, L; Dworkowski, FSN; Cook, PF				Li, Lei; Dworkowski, Florian S. N.; Cook, Paul F.			Importance in catalysis of the 6-phosphate-binding site of 6-phosphogluconate in sheep liver 6-phosphogluconate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME MECHANISMS; ISOTOPE; SUBSTRATE; COENZYME; BINDING; NADP	The 6-phosphate of 6-phosphogluconate (6PG) is proposed to anchor the sugar phosphate in the active site and aid in orientating the substrate for catalysis. In order to test this hypothesis, alanine mutagenesis was used to probe the contribution of residues in the vicinity of the 6-phosphate to binding of 6PG and catalysis. The crystal structure of sheep liver 6-phosphogluconate dehydrogenase shows that Tyr-191, Lys-260, Thr-262, Arg-287, and Arg-446 contribute a mixture of ionic and hydrogen bonding interactions to the 6-phosphate, and these interactions are likely to provide the majority of the binding energy for 6PG. All mutant enzymes, with the exception of T262A, exhibit an increase in K-6PG that ranges from 5- to 800-fold. There is also a less pronounced increase in KNADP, ranging from 3- to 15-fold, with the exception of T262A. The R287A and R446A mutant enzymes exhibit a dramatic decrease in V/E-t (600- and 300-fold, respectively) as well as in V/K6PGEt(10(5)- and 10(4)- fold), and therefore no further characterization was carried out with these two mutant enzymes. No change in V/E-t was observed for the Y191A mutant enzyme, whereas 20 and 3- fold decreases were obtained for the K260A and T262A mutant enzymes, respectively, resulting in a decrease in V/K6PGEt range from 3- to 120-fold. All mutant enzymes also exhibit at least an order of magnitude increase in C-13-isotope effect -1, indicating that the decarboxylation step has become more rate-limiting. Data are consistent with significant roles for Tyr-191, Lys-260, Thr-262, Arg-287, and Arg-446 in providing the binding energy for 6PG. In addition, these residues also likely ensure proper orientation of 6PG for catalysis and aid in inducing the conformation change that precedes, and sets up the active site for, catalysis.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Cook, PF (corresponding author), Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.	pcook@chemdept.chem.ou.edu	Dworkowski, Florian/D-2807-2011; Dworkowski, Florian/H-6017-2019	Dworkowski, Florian/0000-0001-5004-8684; Dworkowski, Florian/0000-0001-5004-8684				ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; BERDIS AJ, 1993, BIOCHEMISTRY-US, V32, P2036, DOI 10.1021/bi00059a021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cervellati C, 2005, BIOCHEMISTRY-US, V44, P2432, DOI 10.1021/bi0476679; Chooback L, 1998, PROTEIN EXPRES PURIF, V13, P251, DOI 10.1006/prep.1998.0896; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; COOK PF, 1980, BIOCHEMISTRY-US, V19, P4853, DOI 10.1021/bi00562a023; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; Hwang CC, 1998, BIOCHEMISTRY-US, V37, P15698, DOI 10.1021/bi981288w; Hwang CC, 1998, BIOCHEMISTRY-US, V37, P12596, DOI 10.1021/bi980611s; Karsten WE, 1998, BIOCHEMISTRY-US, V37, P15691, DOI 10.1021/bi9812827; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; O'Leary M H, 1980, Methods Enzymol, V64, P83; PARKIN DW, 1991, ENZYME MECH ISOTOPE, P284; Price NE, 1996, ARCH BIOCHEM BIOPHYS, V336, P215, DOI 10.1006/abbi.1996.0551; Tetaud E, 1999, BIOCHEM J, V338, P55, DOI 10.1042/0264-6021:3380055; Weiss PM, 1991, ENZYME MECH ISOTOPE, P291; ZHANG L, 1999, BIOCHEMISTRY-US, V36, P11231	20	13	13	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25568	25576		10.1074/jbc.M601154200	http://dx.doi.org/10.1074/jbc.M601154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803886	hybrid			2022-12-27	WOS:000240031300060
J	Hayashida, K; Johnston, DR; Goldberger, O; Park, PW				Hayashida, Kazutaka; Johnston, Douglas R.; Goldberger, Olga; Park, Pyong Woo			Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; HEPARAN-SULFATE PROTEOGLYCANS; NECROSIS-FACTOR-ALPHA; PSEUDOMONAS-AERUGINOSA; SURFACE PROTEOGLYCAN; FACTOR RECEPTOR; MICE; PHOSPHORYLATION; ACTIVATION; MEMBRANE	Syndecans comprise a major family of cell surface heparan sulfate proteoglycans (HSPGs). Syndecans bind and modulate a wide variety of biological molecules through their heparan sulfate (HS) moiety. Although all syndecans contain the ligand binding HS chains, they likely perform specific functions in vivo because their temporal and spatial expression patterns are different. However, how syndecan expression is regulated has yet to be clearly defined. In this study, we examined how syndecan-1 expression is regulated in epithelial cells. Our results showed that among several bioactive agents tested, only forskolin and three isoforms of TGF beta (TGF beta 1-TGF beta 3) significantly induced syndecan-1, but not syndecan-4, expression on various epithelial cells. Steady-state syndecan-1 mRNA was not increased by TGF beta treatment and cycloheximide did not inhibit syndecan-1 induction by TGF beta, indicating that TGF beta induces syndecan-1 in a post-translational manner. However, TGF beta induction of syndecan-1 was inhibited by transient expression of a dominant-negative construct of protein kinase A (PKA) and by specific inhibitors of PKA. Further (i) syndecan-1 cytoplasmic domains were Ser-phosphorylated when cells were treated with TGF beta and this was inhibited by a PKA inhibitor, (ii) PKA was co-immunoprecipitated from cell lysates by anti-syndecan-1 antibodies, (iii) PKA phosphorylated recombinant syndecan-1 cytoplasmic domains in vitro, and (iv) expression of a syndecan-1 construct with its invariant Ser(286) replaced with a Gly was not induced by TGF beta. Together, these findings define a regulatory mechanism where TGF beta signals through PKA to phosphorylate the syndecan-1 cytoplasmic domain and increases syndecan-1 expression on epithelial cells.	Baylor Coll Med, Sect Infect Dis, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Boston Children's Hospital; Harvard Medical School	Park, PW (corresponding author), Baylor Coll Med, Sect Infect Dis, Dept Med, 1 Baylor Plaza,Rm N1319, Houston, TX 77030 USA.	pwpark@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073725, R01HL069050] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL069050, R01 HL073725, HL69050, HL73725] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Asundi VK, 1997, BIOCHEM BIOPH RES CO, V240, P502, DOI 10.1006/bbrc.1997.7684; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bouchard JF, 2004, J NEUROSCI, V24, P3040, DOI 10.1523/JNEUROSCI.4934-03.2004; BRADBURY NA, 1992, BIOCHEM BIOPH RES CO, V184, P1173, DOI 10.1016/S0006-291X(05)80006-3; Carey DJ, 1997, BIOCHEM J, V327, P1; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; Couchman JR, 2002, J BIOL CHEM, V277, P49296, DOI 10.1074/jbc.M209679200; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Granes F, 2000, J CELL SCI, V113, P1267; Haynes A, 2005, INFECT IMMUN, V73, P7914, DOI 10.1128/IAI.73.12.7914-7921.2005; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; Ishiguro K, 2001, J BIOL CHEM, V276, P47483, DOI 10.1074/jbc.M106268200; Kaksonen M, 2002, MOL CELL NEUROSCI, V21, P158, DOI 10.1006/mcne.2002.1167; Katsura T, 1997, Am J Physiol, V272, pF817; Kramer KL, 2002, CELL, V111, P981, DOI 10.1016/S0092-8674(02)01200-X; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Massague J, 2000, GENE DEV, V14, P627; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Murakami M, 2002, J BIOL CHEM, V277, P20367, DOI 10.1074/jbc.M202501200; Oh ES, 1997, ARCH BIOCHEM BIOPHYS, V344, P67, DOI 10.1006/abbi.1997.0180; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Park PW, 2004, J BIOL CHEM, V279, P251, DOI 10.1074/jbc.M308537200; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Park PW, 2000, J BIOL CHEM, V275, P3057, DOI 10.1074/jbc.275.5.3057; Pursiheimo JP, 2000, P NATL ACAD SCI USA, V97, P168, DOI 10.1073/pnas.97.1.168; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; Salazar G, 2002, MOL BIOL CELL, V13, P1677, DOI 10.1091/mbc.01-08-0403; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; Varela LM, 1996, ENDOCRINOLOGY, V137, P4915, DOI 10.1210/en.137.11.4915; Wang LW, 1998, J BIOL CHEM, V273, P8522, DOI 10.1074/jbc.273.14.8522; Xu J, 2005, J IMMUNOL, V174, P5758, DOI 10.4049/jimmunol.174.9.5758; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941; Zhang LZ, 2004, MOL CELL BIOL, V24, P2169, DOI 10.1128/MCB.24.5.2169-2180.2004	54	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24365	24374		10.1074/jbc.M509320200	http://dx.doi.org/10.1074/jbc.M509320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807246	hybrid			2022-12-27	WOS:000239847800029
J	Finlin, BS; Correll, RN; Pang, CY; Crump, SM; Satin, J; Andres, DA				Finlin, Brian S.; Correll, Robert N.; Pang, Chunyan; Crump, Shawn M.; Satin, Jonathan; Andres, Douglas A.			Analysis of the complex between Ca2+ channel beta-subunit and the Rem GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RGK FAMILY; PROTEIN; BINDING; RAD; CALMODULIN; EXPRESSION; GEM; MEMBER; PHOSPHORYLATION; MODULATION	Voltage-gated calcium channels are multiprotein complexes that regulate calcium influx and are important contributors to cardiac excitability and contractility. The auxiliary beta-subunit (CaVB) binds a conserved domain (the alpha-interaction domain (AID)) of the pore-forming Ca-V alpha(1) subunit to modulate channel gating properties and promote cell surface trafficking. Recently, members of the RGK family of small GTPases (Rem, Rem2, Rad, Gem/Kir) have been identified as novel contributors to the regulation of L-type calcium channel activity. Here, we describe the Rem-association domain within Ca-V beta(2a). The Rem interaction module is located in a similar to 130-residue region within the highly conserved guanylate kinase domain that also directs AID binding. Importantly, Ca-V beta mutants were identified that lost the ability to bind AID but retained their association with Rem, indicating that the AID and Rem association sites of Ca-V beta(2a) are structurally distinct. In vitro binding studies indicate that the affinity of Rem for Ca-V beta(2a) interaction is lower than that of AID for Ca-V beta(2a). Furthermore, in vitro binding studies indicate that Rem association does not inhibit the interaction of Ca-V beta(2a) with AID. Instead, CaV beta can simultaneously associate with both Rem and Ca-V alpha(1)-AID. Previous studies had suggested that RGK proteins may regulate Ca2+ channel activity by blocking the association of Ca-V beta subunits with Ca-V alpha(1) to inhibit plasma membrane trafficking. However, surface biotinylation studies in HIT-T15 cells indicate that Rem can acutely modulate channel function without decreasing the density of L-type channels at the plasma membrane. Together these data suggest that Rem-dependent Ca2+ channel modulation involves formation of a Rem(.)Ca(V)beta(.)AID regulatory complex without the need to disrupt Ca-V alpha Ca-.(1)V beta association or alter Ca-V alpha(1) expression at the plasma membrane.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, BBSRB Rm R-179,741 S Limestone St, Lexington, KY 40536 USA.	dandres@pop.uky.edu			NCRR NIH HHS [P20 RR20171] Funding Source: Medline; NHLBI NIH HHS [HL072936, R01 HL072936, HL074091, R01 HL072936-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072936, R01HL074091, R56HL074091] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; Balijepalli RC, 2004, CIRC RES, V95, P337, DOI 10.1161/01.RES.0000141018.33292.21; Beguin P, 2005, BIOCHEM J, V390, P67, DOI 10.1042/BJ20050414; Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen HM, 2005, J NEUROSCI, V25, P9762, DOI 10.1523/JNEUROSCI.3111-05.2005; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Cohen RM, 2005, AM J PHYSIOL-HEART C, V288, pH2363, DOI 10.1152/ajpheart.00348.2004; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; CRUMP SM, 2006, IN PRESS AM J PHYSL; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Harry JB, 2004, J BIOL CHEM, V279, P46367, DOI 10.1074/jbc.M409523200; Hibino H, 2003, P NATL ACAD SCI USA, V100, P307, DOI 10.1073/pnas.0136791100; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; Kelly K, 2005, TRENDS CELL BIOL, V15, P640, DOI 10.1016/j.tcb.2005.10.002; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Maltez JM, 2005, NAT STRUCT MOL BIOL, V12, P372, DOI 10.1038/nsmb909; McGee AW, 2004, NEURON, V42, P89, DOI 10.1016/S0896-6273(04)00149-7; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Murata M, 2004, CIRC RES, V95, P398, DOI 10.1161/01.RES.0000138449.85324.c5; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Richards MW, 2004, TRENDS PHARMACOL SCI, V25, P626, DOI 10.1016/j.tips.2004.10.008; ROUSSET M, 2005, SCI STKE, pPE11; Sasaki T, 2005, J BIOL CHEM, V280, P9308, DOI 10.1074/jbc.M413773200; Takahashi SX, 2004, P NATL ACAD SCI USA, V101, P7193, DOI 10.1073/pnas.0306665101; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; Yanuar A, 2005, ACTA CRYSTALLOGR F, V61, P978, DOI 10.1107/S1744309105031982	41	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23557	23566		10.1074/jbc.M604867200	http://dx.doi.org/10.1074/jbc.M604867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790445	hybrid			2022-12-27	WOS:000239702900030
J	Schilling, B; Gafni, J; Torcassi, C; Cong, X; Row, RH; LaFevre-Bernt, MA; Cusack, MP; Ratovitski, T; Hirschhorn, R; Ross, CA; Gibson, BW; Ellerby, LM				Schilling, Birgit; Gafni, Juliette; Torcassi, Cameron; Cong, Xin; Row, Richard H.; LaFevre-Bernt, Michelle A.; Cusack, Michael P.; Ratovitski, Tamara; Hirschhorn, Ricky; Ross, Christopher A.; Gibson, Bradford W.; Ellerby, Lisa M.			Huntingtin phosphorylation sites mapped by mass spectrometry - Modulation of cleavage and toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUNTINGTIN; CASPASE CLEAVAGE; PROTEIN-PHOSPHORYLATION; REDUCES TOXICITY; WIDE PREDICTION; DISEASE; IDENTIFICATION; FRAGMENTS; SEQUENCE; DEHYDROGENASE	Huntingtin (Htt) is a large protein of 3144 amino acids, whose function and regulation have not been well defined. Polyglutamine (polyQ) expansion in the N terminus of Htt causes the neurodegenerative disorder Huntington disease (HD). The cytotoxicity of mutant Htt is modulated by proteolytic cleavage with caspases and calpains generating N-terminal polyQ-containing fragments. We hypothesized that phosphorylation of Htt may modulate cleavage and cytotoxicity. In the present study, we have mapped the major phosphorylation sites of Htt using cell culture models (293T and PC12 cells) expressing full-length myc-tagged Htt constructs containing 23Q or 148Q repeats. Purified myc-tagged Htt was subjected to mass spectrometric analysis including matrix-assisted laser desorption/ionization mass spectrometry and nano- HPLC tandem mass spectrometry, used in conjunction with on-target alkaline phosphatase and protease digestions. We have identified more than six novel serine phosphorylation sites within Htt, one of which lies in the proteolytic susceptibility domain. Three of the sites have the consensus sequence for ERK1 phosphorylation, and addition of ERK1 inhibitor blocks phosphorylation at those sites. Other observed phosphorylation sites are possibly substrates for CDK5/CDC2 kinases. Mutation of amino acid Ser536, which is located in the proteolytic susceptibility domain, to aspartic acid, inhibited calpain cleavage and reduced mutant Htt toxicity. The results presented here represent the first detailed mapping of the phosphorylation sites in full-length Htt. Dissection of phosphorylation modifications in Htt may provide clues to Huntington disease pathogenesis and targets for therapeutic development.	Buck Inst Age Res, Novato, CA 94945 USA; Johns Hopkins Univ, Sch Med, Div Neurobiol, Dept Psychiat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Hood Coll, Frederick, MD 21701 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Buck Institute for Research on Aging; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Francisco	Ellerby, LM (corresponding author), 8001 Redwood Blvd, Novato, CA 94945 USA.	lellerby@buckinstitute.org	Ross, Christopher A/H-8395-2013		NINDS NIH HHS [NS40251A, F32 NS043937, RL1 NS062413, NS 38144, NS 16375] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251, RL1NS062413, F32NS043937, P50NS016375, R01NS038144, P01NS016375] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aronin N, 1999, PHILOS T ROY SOC B, V354, P995, DOI 10.1098/rstb.1999.0451; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Chang EJ, 2004, ANAL CHEM, V76, P4472, DOI 10.1021/ac049637h; Corthals GL, 2005, METHOD ENZYMOL, V405, P66, DOI 10.1016/S0076-6879(05)05004-4; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hermel E, 2004, CELL DEATH DIFFER, V11, P424, DOI 10.1038/sj.cdd.4401358; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Igarashi S, 2003, NEUROREPORT, V14, P565, DOI 10.1097/00001756-200303240-00007; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kaytor MD, 2005, HUM MOL GENET, V14, P1095, DOI 10.1093/hmg/ddi122; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Lafevre-Bernt MA, 2003, J BIOL CHEM, V278, P34918, DOI 10.1074/jbc.M302841200; Larsen MR, 2001, PROTEOMICS, V1, P223; Luo SQ, 2005, J CELL BIOL, V169, P647, DOI 10.1083/jcb.200412071; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rangone H, 2004, EUR J NEUROSCI, V19, P273, DOI 10.1111/j.0953-816X.2003.03131.x; Schilling B, 2006, BBA-MOL BASIS DIS, V1762, P213, DOI 10.1016/j.bbadis.2005.07.003; Schilling B, 2005, MOL CELL PROTEOMICS, V4, P84, DOI 10.1074/mcp.M400143-MCP200; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Tanaka Y, 2006, NEUROBIOL DIS, V21, P381, DOI 10.1016/j.nbd.2005.07.014; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	41	98	100	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23686	23697		10.1074/jbc.M513507200	http://dx.doi.org/10.1074/jbc.M513507200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782707	hybrid			2022-12-27	WOS:000239702900044
J	Szatmari, I; Vamosi, G; Brazda, P; Balint, BL; Benko, S; Szeles, L; Jeney, V; Ozvegy-Laczka, C; Szanto, A; Barta, E; Balla, J; Sarkadi, B; Nagy, L				Szatmari, Istvan; Vamosi, Gyoergy; Brazda, Peter; Balint, Balint L.; Benko, Szilvia; Szeles, Lajos; Jeney, Viktoria; Oezvegy-Laczka, Csilla; Szanto, Attila; Barta, Endre; Balla, Jozsef; Balazs Sarkadi; Nagy, Laszlo			Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-RESISTANCE-PROTEIN; PPAR-GAMMA; TRANSPORTER; GENE; EFFLUX; ORGANIZATION; INFLAMMATION; CHOLESTEROL; MACROPHAGES; PROMOTER	ABCG2, a member of the ATP-binding cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells and variably regulated during cell differentiation. Here we demonstrate that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPAR gamma. We identified and characterized a 150-base pair long conserved enhancer region, containing three functional PPAR response elements (PPARE), upstream of the human ABCG2 gene. We confirmed the binding of the PPAR gamma(.) RXR heterodimer to this enhancer region, suggesting that PPAR gamma directly regulates the transcription of ABCG2. Consistent with these results, elevated expression of ABCG2 mRNA was coupled to enhanced protein production, resulting in increased xenobiotic extrusion capacity via ABCG2 in PPAR gamma-activated cells. Furthermore PPAR gamma instructed dendritic cells showed increased Hoechst dye extrusion and resistance to mitoxantrone. Collectively, these results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid-activated transcription factor, PPAR gamma. The increased expression of the promiscuous ABCG2 transporter can significantly modify the xenobiotic and drug resistance of human myeloid dendritic cells.	Hungarian Acad Sci, Dept Biochem & Mol Biol, H-4032 Debrecen, Hungary; Hungarian Acad Sci, Cell Biophys Res Grp, H-4032 Debrecen, Hungary; Univ Debrecen, Dept Immunol, H-4032 Debrecen, Hungary; Univ Debrecen, Dept Internal Med, Res Ctr Mol Med, Med & Hlth Sci Ctr, H-4032 Debrecen, Hungary; Hungarian Acad Sci, Membrane Res Grp, Inst Haematol & Immunol, Natl Med Ctr, H-1113 Budapest, Hungary; Ctr Agr Biotechnol, H-2100 Godollo, Hungary	Hungarian Academy of Sciences; Hungarian Academy of Sciences; University of Debrecen; University of Debrecen; Hungarian Academy of Sciences	Nagy, L (corresponding author), Hungarian Acad Sci, Dept Biochem & Mol Biol, Egyetem Ter 1, H-4032 Debrecen, Hungary.	lnagy@indi.biochem.dote.hu	Barta, Endre/B-1166-2008; Szanto, Attila/B-2198-2012; Széles, Lajos/B-4165-2012; Széles, Lajos/B-3309-2010; Vamosi, Gyorgy/C-9351-2009; Laczka, Csilla/AAE-5543-2021; Nagy, Laszlo/A-3814-2008; Balint, Balint/A-3853-2010; Jeney, Viktória/AAF-5355-2019; Jeney, Viktoria/A-6779-2011; Sarkadi, Balazs/I-5024-2013; Szatmari, Istvan/B-3152-2010	Barta, Endre/0000-0002-6753-0714; Nagy, Laszlo/0000-0001-6653-2155; Szatmari, Istvan/0000-0001-5260-1498; Szeles, Lajos/0000-0003-1206-8515; Balla, Jozsef/0000-0001-7923-2645; Vamosi, Gyorgy/0000-0002-7940-2787; Balint, Balint/0000-0002-6163-7190	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allikmets R, 1998, GENE, V215, P111, DOI 10.1016/S0378-1119(98)00269-8; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Benko S, 2003, J BIOL CHEM, V278, P43797, DOI 10.1074/jbc.M306199200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Dubsky P, 2005, J CLIN IMMUNOL, V25, P551, DOI 10.1007/s10875-005-8216-7; Ee PLR, 2004, CANCER RES, V64, P1247, DOI 10.1158/0008-5472.CAN-03-3583; GERLIER D, 1986, J IMMUNOL METHODS, V94, P57, DOI 10.1016/0022-1759(86)90215-2; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Jonker JW, 2000, JNCI-J NATL CANCER I, V92, P1651, DOI 10.1093/jnci/92.20.1651; Kawabata S, 2001, BIOCHEM BIOPH RES CO, V280, P1216, DOI 10.1006/bbrc.2001.4267; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Maliepaard M, 2001, CANCER RES, V61, P3458; Miyake K, 1999, CANCER RES, V59, P8; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nencioni A, 2002, J IMMUNOL, V169, P1228, DOI 10.4049/jimmunol.169.3.1228; Niemi M, 2004, CLIN PHARMACOL THER, V76, P239, DOI 10.1016/j.clpt.2004.05.001; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Sarkadi B, 2004, FEBS LETT, V567, P116, DOI 10.1016/j.febslet.2004.03.123; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Szanto A, 2004, MOL CELL BIOL, V24, P8154, DOI 10.1128/MCB.24.18.8154-8166.2004; Szatmari I, 2004, IMMUNITY, V21, P95, DOI 10.1016/j.immuni.2004.06.003; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; ZHOU S, 2004, BLOOD	34	142	149	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23812	23823		10.1074/jbc.M604890200	http://dx.doi.org/10.1074/jbc.M604890200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785230	hybrid			2022-12-27	WOS:000239702900057
J	Takata, K; Shimizu, T; Iwai, S; Wood, RD				Takata, Kei-ichi; Shimizu, Tatsuhiko; Iwai, Shigenori; Wood, Richard D.			Human DNA polymerase N (POLN) is a low fidelity enzyme capable of error-free bypass of 5S-thymine glycol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; HUMAN CELL-EXTRACTS; ESCHERICHIA-COLI; THYMINE GLYCOL; TRANSLESION SYNTHESIS; CROSS-LINK; PURIFIED PROTEINS; HELICASE ACTIVITY; OXIDATIVE DAMAGE; KLENOW FRAGMENT	Human DNA polymerase N (POLN or pol nu) is the most recently discovered nuclear DNA polymerase in the human genome. It is an A-family DNA polymerase related to Escherichia coli pol I, human POLQ, and Drosophila Mus308. We report the first purification of the recombinant enzyme and examination of its biochemical properties, as a step toward understanding the functions of POLN. Unusual for an A-family DNA polymerase, POLN is a low fidelity enzyme incorporating T opposite template G with a frequency of 0.45 and G opposite template T with a frequency of 0.021. The frequency of misincorporation of T opposite template G is higher than any other known DNA polymerase. POLN has a processivity of DNA synthesis (1-100 nucleotides) similar to the exonuclease-deficient Klenow fragment of E. coli pol I, is inhibited by dideoxynucleotides, and resistant to aphidicolin. The strand displacement activity of POLN was higher than exonuclease-deficient Klenow fragment. Furthermore, POLN can perform translesion synthesis past thymine glycol, a common endogenous and radiation-induced product of reactive oxygen species damage to DNA. Thymine glycol blocks DNA synthesis by most DNA polymerases, but POLN was particularly adept at efficient and accurate translesion synthesis past a 5S-thymine glycol.	Univ Pittsburgh, Sch Med, Hillman Canc Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA; Osaka Univ, Grad Sch Engn Sci, Div Chem, Toyonaka, Osaka 5608531, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Osaka University	Wood, RD (corresponding author), Univ Pittsburgh, Sch Med, Hillman Canc Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA.	rdwood@pitt.edu	; Wood, Richard/M-6319-2018	Takata, Kei-ichi/0000-0002-8272-3397; Wood, Richard/0000-0002-9495-6892	NCI NIH HHS [CA101980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn B, 2004, J BIOL CHEM, V279, P53465, DOI 10.1074/jbc.M409624200; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Camps M, 2003, P NATL ACAD SCI USA, V100, P9727, DOI 10.1073/pnas.1333928100; Cannistraro VJ, 2004, J BIOL CHEM, V279, P18288, DOI 10.1074/jbc.M400282200; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECKERT KA, 1993, J BIOL CHEM, V268, P13462; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Harris PV, 1996, MOL CELL BIOL, V16, P5764; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Iwai S, 2001, CHEM-EUR J, V7, P4343, DOI 10.1002/1521-3765(20011015)7:20<4343::AID-CHEM4343>3.0.CO;2-H; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Katafuchi A, 2004, J BIOL CHEM, V279, P14464, DOI 10.1074/jbc.M400393200; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kusumoto R, 2002, BIOCHEMISTRY-US, V41, P6090, DOI 10.1021/bi025549k; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; McDonald JP, 2003, J EXP MED, V198, P635, DOI 10.1084/jem.20030767; McTigue MM, 2004, DNA REPAIR, V3, P313, DOI 10.1016/j.dnarep.2003.11.009; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Pang M, 2005, DNA REPAIR, V4, P971, DOI 10.1016/j.dnarep.2005.04.020; Parlanti E, 2004, DNA REPAIR, V3, P703, DOI 10.1016/j.dnarep.2003.12.009; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; Schleiermacher G, 2005, ONCOGENE, V24, P3377, DOI 10.1038/sj.onc.1208486; Seki M, 2005, EMBO REP, V6, P1143, DOI 10.1038/sj.embor.7400582; Seki M, 2004, EMBO J, V23, P4484, DOI 10.1038/sj.emboj.7600424; Seki M, 2003, NUCLEIC ACIDS RES, V31, P6117, DOI 10.1093/nar/gkg814; Shimizu T, 2006, NUCLEIC ACIDS RES, V34, P313, DOI 10.1093/nar/gkj443; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Tissier A, 2000, GENE DEV, V14, P1642; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Yang GW, 2002, BIOCHEMISTRY-US, V41, P10256, DOI 10.1021/bi0202171	49	131	132	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23445	23455		10.1074/jbc.M604317200	http://dx.doi.org/10.1074/jbc.M604317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787914	hybrid			2022-12-27	WOS:000239702900019
J	Camozzi, M; Rusnati, M; Bugatti, A; Bottazzi, B; Mantovani, A; Bastone, A; Inforzato, A; Vincenti, S; Bracci, L; Mastroianni, D; Presta, M				Camozzi, Maura; Rusnati, Marco; Bugatti, Antonella; Bottazzi, Barbara; Mantovani, Alberto; Bastone, Antonio; Inforzato, Antonio; Vincenti, Silvia; Bracci, Luisa; Mastroianni, Domenico; Presta, Marco			Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; LONG PENTRAXIN PTX3; C-REACTIVE PROTEIN; T-LYMPHOCYTES; CELLS; RELEASE; MATRIX	Long-pentraxin 3 (PTX3) is a soluble pattern recognition receptor with non-redundant functions in inflammation and innate immunity. PTX3 comprises a pentraxin-like C-terminal domain involved in complement activation via C1q interaction and an N-terminal extension with unknown functions. PTX3 binds fibroblast growth factor-2 (FGF2), inhibiting its pro-angiogenic and pro-restenotic activity. Here, retroviral transduced endothelial cells (ECs) overexpressing the N-terminal fragment PTX3-(1-178) showed reduced mitogenic activity in response to FGF2. Accordingly, purified recombinant PTX3-(1-178) binds FGF2, prevents PTX3/FGF2 interaction, and inhibits FGF2 mitogenic activity in ECs. Also, the monoclonal antibody mAb-MNB4, which recognizes the PTX3-(87-99) epitope, prevents FGF2/PTX3 interaction and abolishes the FGF2 antagonist activity of PTX3. Consistently, the synthetic peptides PTX3-(82-110) and PTX3-(97-110) bind FGF2 and inhibit the interaction of FGF2 with PTX3 immobilized to a BIAcore sensor chip, FGF2-dependent EC proliferation, and angiogenesis in vivo. Thus, the data identify a FGF2-binding domain in the N-terminal extension of PTX3 spanning the PTX3-(97-110) region, pointing to a novel function for the N-terminal extension of PTX3 and underlining the complexity of the PTX3 molecule for modular humoral pattern recognition.	Univ Brescia, Dept Biomed Sci & Biotechnol, Sch Med, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Milan, Inst Gen Pathol, I-20133 Milan, Italy; Ist Clin Humanitas, I-20089 Milan, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Sigma Tau Res Dept, I-0040 Rome, Italy; Univ Siena, Dept Mol Biol, I-53100 Siena, Italy; Tecnogen SCpA, I-81015 Piana Di Monte Verna, Caserta, Italy	University of Brescia; University of Milan; IRCCS Humanitas Research Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Rome Tor Vergata; University of Siena	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Sch Med, Unit Gen Pathol & Immunol, Viale Europa 11, I-25123 Brescia, Italy.	presta@med.unibs.it	Rusnati, Marco/F-1168-2010; Inforzato, Antonio/ABG-4513-2020; Inforzato, Antonio/K-6954-2012; Bracci, Luisa/V-9913-2018; Presta, Marco/B-4345-2010; Mantovani, Alberto/HCI-7449-2022; bottazzi, barbara/ABH-9274-2020	Rusnati, Marco/0000-0001-9968-5908; Inforzato, Antonio/0000-0001-8110-0027; Bracci, Luisa/0000-0002-0738-5746; Mantovani, Alberto/0000-0001-5578-236X; bottazzi, barbara/0000-0002-1930-9257; PRESTA, Marco/0000-0002-4398-8376				Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; Camozzi M, 2005, ARTERIOSCL THROM VAS, V25, P1837, DOI 10.1161/01.ATV.0000177807.54959.7d; Frank R, 1996, Methods Mol Biol, V66, P149; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; Knoll A, 1999, MICROVASC RES, V58, P1, DOI 10.1006/mvre.1999.2149; LEE GW, 1993, J IMMUNOL, V150, P1804; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; Mantovani A, 2003, VACCINE, V21, pS43, DOI 10.1016/S0264-410X(03)00199-3; Nauta AJ, 2003, TRENDS IMMUNOL, V24, P148, DOI 10.1016/S1471-4906(03)00030-9; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Peri G, 2000, CIRCULATION, V102, P636, DOI 10.1161/01.CIR.102.6.636; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; PRESTA M, 1989, J CELL PHYSIOL, V141, P517, DOI 10.1002/jcp.1041410310; Ravizza T, 2001, NEUROSCIENCE, V105, P43, DOI 10.1016/S0306-4522(01)00177-4; REIDY MA, 1992, CIRCULATION, V86, P43; Rolph MS, 2002, ARTERIOSCL THROM VAS, V22, pE10, DOI 10.1161/01.ATV.0000015595.95497.2F; Rusnati M, 2004, BLOOD, V104, P92, DOI 10.1182/blood-2003-10-3433; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4	26	96	99	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22605	22613		10.1074/jbc.M601023200	http://dx.doi.org/10.1074/jbc.M601023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769728	hybrid			2022-12-27	WOS:000239542600021
J	Hsu, JL; Rho, SB; Vannella, KM; Martinis, SA				Hsu, Jennifer L.; Rho, Seung Bae; Vannella, Kevin M.; Martinis, Susan A.			Functional divergence of a unique C-terminal domain of leucyl-tRNA synthetase to accommodate its splicing and aminoacylation roles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CRYSTAL-STRUCTURE; TRNA(LEU); CEREVISIAE; IDENTITY; SELECTION; PROTEINS; SEQUENCE; MATURASE; ELEMENTS	Leucyl-tRNA synthetase (LeuRS) performs dual essential roles in group I intron RNA splicing as well as protein synthesis within the yeast mitochondria. Deletions of the C terminus differentially impact the two functions of the enzyme in splicing and aminoacylation in vivo. Herein, we determined that a five-amino acid C-terminal deletion of LeuRS, which does not complement a null strain, can form a ternary complex with the bI4 intron and its maturase splicing partner. However, the complex fails to stimulate splicing activity. The x-ray co-crystal structure of LeuRS showed that a C-terminal extension of about 60 amino acids forms a discrete domain, which is unique among the LeuRSs and interacts with the corner of the L-shaped tRNA(Leu). Interestingly, deletion of the entire yeast mitochondrial LeuRS C-terminal domain enhanced its aminoacylation and amino acid editing activities. In striking contrast, deletion of the corresponding C-terminal domain of Escherichia coli LeuRS abolished aminoacylation of tRNALeu and also amino acid editing of mischarged tRNA molecules. These results suggest that the role of the leucine-specific C-terminal domain in tRNA recognition for aminoacylation and amino acid editing has adapted differentially and with surprisingly opposite effects. We propose that the secondary role of yeast mitochondrial LeuRS in RNA splicing has impacted the functional evolution of this critical C-terminal domain.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Martinis, SA (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	martinis@life.uiuc.edu		Martinis, Susan/0000-0001-5730-8346	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063107, R01GM063789] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63107, GM63789] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asahara H, 1998, J MOL BIOL, V283, P605, DOI 10.1006/jmbi.1998.2111; ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; BREITSCHOPF K, 1995, NUCLEIC ACIDS RES, V23, P3633, DOI 10.1093/nar/23.18.3633; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fukunaga R, 2005, J MOL BIOL, V346, P57, DOI 10.1016/j.jmb.2004.11.060; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; Houman F, 2000, P NATL ACAD SCI USA, V97, P13743, DOI 10.1073/pnas.240465597; LABOUESSE M, 1984, EUR J BIOCHEM, V144, P85, DOI 10.1111/j.1432-1033.1984.tb08434.x; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; Larkin DC, 2002, NUCLEIC ACIDS RES, V30, P2103, DOI 10.1093/nar/30.10.2103; Li GY, 1996, MOL GEN GENET, V252, P667, DOI 10.1007/BF02173972; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; LINCECUM TL, 2005, AMINOACYL TRNA SYNTH, P36; Lue SW, 2005, BIOCHEMISTRY-US, V44, P3010, DOI 10.1021/bi047901v; Martinis S A, 1997, Nucleic Acids Symp Ser, V36, P125; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, P887; Michael G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mursinna RS, 2002, J AM CHEM SOC, V124, P7286, DOI 10.1021/ja025879s; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Rho SB, 2000, RNA, V6, P1882, DOI 10.1017/S1355838200001254; Roy H, 2005, J BIOL CHEM, V280, P38186, DOI 10.1074/jbc.M508281200; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; Soma A, 1996, J MOL BIOL, V263, P707, DOI 10.1006/jmbi.1996.0610; Tukalo M, 2005, NAT STRUCT MOL BIOL, V12, P923, DOI 10.1038/nsmb986; Zhai YX, 2005, BIOCHEMISTRY-US, V44, P15437, DOI 10.1021/bi0514461; Zheng YG, 2004, NUCLEIC ACIDS RES, V32, P3294, DOI 10.1093/nar/gkh665	35	31	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23075	23082		10.1074/jbc.M601606200	http://dx.doi.org/10.1074/jbc.M601606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774921	hybrid			2022-12-27	WOS:000239542600071
J	Blake, AW; McCartney, L; Flint, JE; Bolam, DN; Boraston, AB; Gilbert, HJ; Knox, JP				Blake, Anthony W.; McCartney, Lesley; Flint, James E.; Bolam, David N.; Boraston, Alisdair B.; Gilbert, Harry J.; Knox, J. Paul			Understanding the biological rationale for the diversity of cellulose-directed carbohydrate-binding modules in prokaryotic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELL WALL; REESEI CELLOBIOHYDROLASE-I; TRICHODERMA-REESEI; PSEUDOMONAS XYLANASE; CLOSTRIDIUM-CELLULOVORANS; NONCRYSTALLINE CELLULOSE; CATALYTIC-ACTIVITY; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; FAMILY	Plant cell walls are degraded by glycoside hydrolases that often contain noncatalytic carbohydrate-binding modules (CBMs), which potentiate degradation. There are currently 11 sequence-based cellulose-directed CBM families; however, the biological significance of the structural diversity displayed by these protein modules is uncertain. Here we interrogate the capacity of eight cellulose-binding CBMs to bind to cell walls. These modules target crystalline cellulose (type A) and are located in families 1, 2a, 3a, and 10 (CBM1, CBM2a, CBM3a, and CBM10, respectively); internal regions of amorphous cellulose (type B; CBM4-1, CBM17, CBM28); and the ends of cellulose chains (type C; CBM9-2). Type A CBMs bound particularly effectively to secondary cell walls, although they also recognized primary cell walls. Type A CBM2a and CBM10, derived from the same enzyme, displayed differential binding to cell walls depending upon cell type, tissue, and taxon of origin. Type B CBMs and the type C CBM displayed much weaker binding to cell walls than type A CBMs. CBM17 bound more extensively to cell walls than CBM4-1, even though these type B modules display similar binding to amorphous cellulose in vitro. The thickened primary cell walls of celery collenchyma showed significant binding by some type B modules, indicating that in these walls the cellulose chains do not form highly ordered crystalline structures. Pectate lyase treatment of sections resulted in an increased binding of cellulose-directed CBMs, demonstrating that decloaking cellulose microfibrils of pectic polymers can increase CBM access. The differential recognition of cell walls of diverse origin provides a biological rationale for the diversity of cellulose-directed CBMs that occur in cell wall hydrolases and conversely reveals the variety of cellulose microstructures in primary and secondary cell walls.	Univ Leeds, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England; Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Leeds; Newcastle University - UK; University of Victoria	Knox, JP (corresponding author), Univ Leeds, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England.	j.p.knox@leeds.ac.uk	Knox, Paul/H-4577-2012	Knox, Paul/0000-0002-9231-6891; Boraston, Alisdair/0000-0001-6417-0592; Bolam, David/0000-0003-0314-3122; Flint, James/0000-0003-2923-7813	Biotechnology and Biological Sciences Research Council [BB/C005074/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; Black GW, 1997, J BIOTECHNOL, V57, P59, DOI 10.1016/S0168-1656(97)00089-8; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, J BIOL CHEM, V278, P6120, DOI 10.1074/jbc.M209554200; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2002, BIOCHEM J, V361, P35, DOI 10.1042/0264-6021:3610035; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P6240, DOI 10.1021/bi0101695; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boraston AB, 2000, BIOCHEMISTRY-US, V39, P11129, DOI 10.1021/bi0007728; Brown IE, 2001, BIOCHEM J, V355, P155, DOI 10.1042/0264-6021:3550155; Carrard G, 2000, P NATL ACAD SCI USA, V97, P10342, DOI 10.1073/pnas.160216697; Clausen MH, 2003, CARBOHYD RES, V338, P1797, DOI 10.1016/S0008-6215(03)00272-6; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; GILBERT HJ, 1990, MOL MICROBIOL, V4, P759, DOI 10.1111/j.1365-2958.1990.tb00646.x; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Hilden L, 2003, BIOTECHNOL LETT, V25, P553, DOI 10.1023/A:1022846304826; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Jamal S, 2004, J MOL BIOL, V339, P253, DOI 10.1016/j.jmb.2004.03.069; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; Kormos J, 2000, BIOCHEMISTRY-US, V39, P8844, DOI 10.1021/bi000607s; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Lehtio J, 2003, P NATL ACAD SCI USA, V100, P484, DOI 10.1073/pnas.212651999; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; MAGLIONE G, 1992, APPL ENVIRON MICROB, V58, P3593, DOI 10.1128/AEM.58.11.3593-3597.1992; McCartney L, 2006, P NATL ACAD SCI USA, V103, P4765, DOI 10.1073/pnas.0508887103; McCartney L, 2004, ANAL BIOCHEM, V326, P49, DOI 10.1016/j.ab.2003.11.011; McKie VA, 2001, BIOCHEM J, V355, P167, DOI 10.1042/0264-6021:3550167; McLean BW, 2002, J BIOL CHEM, V277, P50245, DOI 10.1074/jbc.M204433200; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Murashima K, 2005, J BACTERIOL, V187, P7146, DOI 10.1128/JB.187.20.7146-7149.2005; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Ponyi T, 2000, BIOCHEMISTRY-US, V39, P985, DOI 10.1021/bi9921642; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; REINIKAINEN T, 1992, PROTEINS, V14, P475, DOI 10.1002/prot.340140408; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; Tomme P, 1996, BIOCHEMISTRY-US, V35, P13885, DOI 10.1021/bi961185i; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Willats WGT, 2001, PLANTA, V213, P37, DOI 10.1007/s004250000481; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	42	195	211	1	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29321	29329		10.1074/jbc.M605903200	http://dx.doi.org/10.1074/jbc.M605903200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16844685	hybrid			2022-12-27	WOS:000240680500087
J	Liang, F; Seyrantepe, V; Landry, K; Ahmad, R; Ahmad, A; Stamatos, NM; Pshezhetsky, AV				Liang, Feng; Seyrantepe, Volkan; Landry, Karine; Ahmad, Rasheed; Ahmad, Ali; Stamatos, Nicholas M.; Pshezhetsky, Alexey V.			Monocyte differentiation up-regulates the expression of the lysosomal sialidase, Neu1, and triggers its targeting to the plasma membrane via major histocompatibility complex class II-positive compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; TRANSCRIPTION FACTOR AP-1; LEUKEMIA-CELL LINE; GENE-EXPRESSION; T-CELLS; PROTECTIVE PROTEIN; DENDRITIC CELLS; C-FOS; NEURAMINIDASE; JUN	Human sialidase (neuraminidase) Neu1 catalyzes lysosomal catabolism of sialylated glycoconjugates. Here we show that during the differentiation of monocytes and the monocytic cell line, THP-1, into macrophages, the majority of Neu1 relocalizes from the lysosomes to the cell surface. In contrast to other cellular sialidases Neu2, Neu3, and Neu4, whose expression either remains unchanged or is down-regulated, Neu1 mRNA, protein and activity are specifically increased during the phorbol 12-myristate 13-acetate-induced differentiation, consistent with a significant induction of the transcriptional activity of the Neu1 gene promoter. The lysosomal carboxypeptidase, cathepsin A, which forms a complex with and activates Neu1 in the lysosome, is sorted to the plasma membrane of the differentiating cells similarly to Neu1. Both proteins are first targeted to the lysosome and then are sorted to the LAMP-2-negative, major histocompatibility complex II-positive vesicles, which later merge with the plasma membrane. Similar trafficking was observed for the internalized fluorescent dextran or horseradish peroxidase initially stored in the lysosomal/endosomal compartment. The suppression of Neu1 expression in the THP-1-derived macrophages by small interfering RNA or with anti-Neu1 antibodies significantly reduced the ability of the cells to engulf bacteria or to produce cytokines. Altogether our data suggest that the upregulation of the Neu1 expression is important for the primary function of macrophages and establish the link between Neu1 and the cellular immune response.	Hop St Justine, Serv Genet Med, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Univ Maryland, Med Ctr, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA	Universite de Montreal; Universite de Montreal; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Pshezhetsky, AV (corresponding author), Hop St Justine, Serv Genet Med, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	alexei.pchejetski@umontreal.ca		Ahmad, Ali/0000-0001-7689-7115; A, Pshezhetsky/0000-0002-6612-1062	NHLBI NIH HHS [K08 HL72176-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL072176] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V2, P495; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryant P, 2004, CURR OPIN IMMUNOL, V16, P96, DOI 10.1016/j.coi.2003.11.011; Chen XP, 1997, J IMMUNOL, V158, P3070; Chen XP, 2000, CYTOKINE, V12, P972, DOI 10.1006/cyto.1999.0596; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; Gee K, 2003, J BIOL CHEM, V278, P37275, DOI 10.1074/jbc.M302309200; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; Katoh S, 1999, J IMMUNOL, V162, P5058; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; LANDOLFI NF, 1985, IMMUNOGENETICS, V22, P159, DOI 10.1007/BF00563513; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li SC, 2001, BIOCHEM J, V360, P233, DOI 10.1042/0264-6021:3600233; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Lukong KE, 1999, BIOCHEMISTRY-US, V38, P73, DOI 10.1021/bi981324r; MANZI AE, 2003, CURRENT PROTOCOLS MO, V3; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; Pshezhetsky AV, 2001, PROG NUCLEIC ACID RE, V69, P81, DOI 10.1016/S0079-6603(01)69045-7; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Rottier RJ, 1998, HUM MOL GENET, V7, P313, DOI 10.1093/hmg/7.2.313; RYAZANOV AG, 1988, EUR J BIOCHEM, V171, P301, DOI 10.1111/j.1432-1033.1988.tb13790.x; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SCHNEIDERJAKOB HR, 1991, BIOL CHEM H-S, V372, P443, DOI 10.1515/bchm3.1991.372.1.443; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Seyrantepe V, 2004, J BIOL CHEM, V279, P37021, DOI 10.1074/jbc.M404531200; Seyrantepe V, 2003, HUM MUTAT, V22, P343, DOI 10.1002/humu.10268; Stamatos NM, 2005, FEBS J, V272, P2545, DOI 10.1111/j.1742-4658.2005.04679.x; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; Thomas G.H., METABOLIC MOL BASES, V3, P3507; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; Vinogradova MV, 1998, BIOCHEM J, V330, P641; Wang P, 2004, BIOCHEM J, V380, P425, DOI 10.1042/BJ20031896; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; YAMAMOTO N, 1993, J IMMUNOL, V151, P2794	59	108	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27526	27538		10.1074/jbc.M605633200	http://dx.doi.org/10.1074/jbc.M605633200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835219	hybrid			2022-12-27	WOS:000240397700079
J	Pani, B; Banerjee, S; Chalissery, J; Abishek, M; Loganathan, RM; Suganthan, RB; Sen, R				Pani, Bibhusita; Banerjee, Sharmistha; Chalissery, Jisha; Abishek, Muralimohan; Loganathan, Ramya Malarini; Suganthan, Ragan Babu; Sen, Ranjan			Mechanism of inhibition of Rho-dependent transcription termination by bacteriophage P4 protein Psu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-BINDING; ANTIBIOTIC BICYCLOMYCIN; ATP HYDROLYSIS; POLARITY; ANTITERMINATION; MUTANTS; P4; SUPPRESSION; DOMAIN	Psu, a coat protein from bacteriophage P4, has been shown to inhibit Rho-dependent transcription termination in vivo. Co-overexpression of Psu and Rho led to the loss of viability of the cells, which is the consequence of the anti-Rho activity of the protein. The antitermination property of Psu is abolished either by the deletion of 10 or 20 amino acids from its C terminus or by a mutation, Y80C, in Rho. All these experiments indicated probable interactions between Rho and Psu. Purified Psu protein is alpha-helical in nature and appeared to be a dimer. Co-purification of Rho and wild-type Psu on an affinity matrix and co-elution of both of them in Superose-6 gel filtration suggests a direct association of these proteins, whereas a C terminus 10-amino acid deletion derivative of Psu failed to be pulled down in this assay. This indicates that the loss of the function of these mutants is correlated with their inability to interact with each other. In vitro termination assays revealed that Psu can inhibit Rho-dependent termination specifically in a concentration-dependent manner. The presence of Psu affected the affinity of ATP and reduced the rate of ATPase activity of Rho but did not affect either primary or secondary RNA binding activities. In the presence of Psu, Rho was also observed to release RNA very slowly from a stalled elongation complex. We propose that Psu inhibits Rho-dependent termination by slowing down the translocation of Rho along the RNA because of its slow ATPase activity.	Ctr DNA Fingerprinting & Diagnost, Lab Transcript Biol, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Sen, R (corresponding author), Ctr DNA Fingerprinting & Diagnost, Lab Transcript Biol, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.	rsen@cdfd.org.in	Chalissery, Jisha/AAI-3438-2021; Sen, Ranjan/AAP-7075-2021	Chalissery, Jisha/0000-0002-1738-2987; Pani, Bibhusita/0000-0003-1513-5189	Wellcome Trust [070012] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Banerjee S, 2006, J MICROBIOL, V44, P11; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Cheeran A, 2005, J MOL BIOL, V352, P28, DOI 10.1016/j.jmb.2005.06.052; Chen X, 2004, J BIOL CHEM, V279, P16301, DOI 10.1074/jbc.M313640200; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; DOKLAND T, 1993, VIROLOGY, V194, P682, DOI 10.1006/viro.1993.1308; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Harinarayanan R, 2003, J MOL BIOL, V332, P31, DOI 10.1016/S0022-2836(03)00753-8; ISAKSEN ML, 1992, VIROLOGY, V188, P831, DOI 10.1016/0042-6822(92)90538-Z; LINDEROTH NA, 1991, J BACTERIOL, V173, P6722, DOI 10.1128/jb.173.21.6722-6731.1991; Linderoth NA, 1997, VIROLOGY, V227, P131, DOI 10.1006/viro.1996.8325; Magyar A, 1999, J BIOL CHEM, V274, P7316, DOI 10.1074/jbc.274.11.7316; Magyar A, 1996, J BIOL CHEM, V271, P25369, DOI 10.1074/jbc.271.41.25369; Martinez A, 1996, J MOL BIOL, V257, P895, DOI 10.1006/jmbi.1996.0210; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 2003, CELL, V114, P157, DOI 10.1016/S0092-8674(03)00554-3; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; SAUER B, 1981, J MOL BIOL, V145, P29, DOI 10.1016/0022-2836(81)90333-8; Skordalakes E, 2005, STRUCTURE, V13, P99, DOI 10.1016/j.str.2004.10.013; STITT BL, 1988, J BIOL CHEM, V263, P11130; SUNSHINE M, 1976, J MOL BIOL, V106, P673, DOI 10.1016/0022-2836(76)90258-8; Wei RR, 2001, J MOL BIOL, V314, P1007, DOI 10.1006/jmbi.2000.5207; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; YANG JT, 1986, METHOD ENZYMOL, V130, P208	30	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26491	26500		10.1074/jbc.M603982200	http://dx.doi.org/10.1074/jbc.M603982200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829521	Green Accepted, hybrid			2022-12-27	WOS:000240249500067
J	Crown, SE; Yu, YH; Sweeney, MD; Leary, JA; Handel, TM				Crown, Susan E.; Yu, Yonghao; Sweeney, Matthew D.; Leary, Julie A.; Handel, Tracy M.			Heterodimerization of CCR2 chemokines and regulation by glycosaminoglycan binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; ICR MASS-SPECTROMETRY; CHEMOTACTIC PROTEIN-2; INCREASED EXPRESSION; RECEPTOR-BINDING; IN-VIVO; MCP-1; CELLS; PLATELET-FACTOR-4; OLIGOMERIZATION	Despite the wide range of sequence diversity among chemokines, their tertiary structures are remarkably similar. Furthermore, many chemokines form dimers or higher order oligomers, but all characterized oligomeric structures are based primarily on two dimerization motifs represented by CC-chemokine or CXC-chemokine dimer interfaces. These observations raise the possibility that some chemokines could form unique hetero-oligomers using the same oligomerization motifs. Such interactions could modulate the overall signaling response of the receptors, thereby providing a general mechanism for regulating chemokine function. For some chemokines, homo-oligomerization has also been shown to be coupled to glycosaminoglycan (GAG)-binding. However, the effect of GAG binding on chemokine hetero-oligomerization has not yet been demonstrated. In this report, we characterized the heterodimerization of the CCR2 ligands MCP-1 (CCL2), MCP-2 (CCL8), MCP-3 (CCL7), MCP-4 (CCL13), and eotaxin (CCL11), as well as the effects of GAG binding, using electrospray ionization Fourier transform ion cyclotron resonance (ESI-FTICR) mass spectrometry. Strong heterodimerization was observed between CCL2 and CCL8 at the expense of homodimer formation. Using NMR, we showed that the heterodimer is predominant in solution and forms a specific CC chemokine-like dimer. By contrast, only moderate heterodimer formation was observed between CCL2(.)CCL13, CCL2(.)CCL11 and CCL8(.)CCL13, and no heterodimerization was observed when any other CCR2 ligand was added to CCL7. To investigate the effect of a highly sulfated GAG on the formation of heterodimers, each chemokine pair was mixed with the heparin pentasaccharide, Arixtra, and assayed by ESI-FTICR mass spectrometry. Although no abundant ions corresponding to the ternary complex, CCL8(.)CCL11(.)Arixtra, were observed upon addition of Arixtra. Heterodimerization between CCL2 and CCL11 was also enhanced in the presence of Arixtra. In summary, these results indicate that some CCR2 ligands can form stable heterodimers in preference to homodimers and that these interactions, like those of homo-oligomers, can be influenced by some GAGs.	Univ Calif Davis, Dept Chem, Genome Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Mol Cell Biol, Genome Ctr, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Diego	Leary, JA (corresponding author), Univ Calif Davis, Dept Chem, Genome Ctr, Davis, CA 95616 USA.	jaleary@ucdavis.edu; thandel@ucsd.edu			NIAID NIH HHS [R01-AI37113-09] Funding Source: Medline; NIGMS NIH HHS [GM63581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Banisor I, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-7; Blaszczyk J, 2000, BIOCHEMISTRY-US, V39, P14075, DOI 10.1021/bi0009340; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Devalaraja MN, 1999, TRENDS PHARMACOL SCI, V20, P151, DOI 10.1016/S0165-6147(99)01342-5; Dudek AZ, 2003, BLOOD, V101, P4687, DOI 10.1182/blood-2002-08-2363; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Fulkerson PC, 2004, J IMMUNOL, V173, P7565, DOI 10.4049/jimmunol.173.12.7565; Garcia G, 2005, CURR ALLERGY ASTHM R, V5, P155, DOI 10.1007/s11882-005-0090-0; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; Guan E, 2001, J BIOL CHEM, V276, P12404, DOI 10.1074/jbc.M006327200; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Inston NG, 2002, NEPHROL DIAL TRANSPL, V17, P1374, DOI 10.1093/ndt/17.8.1374; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Kawaguchi S, 2002, SPINE, V27, P1511, DOI 10.1097/00007632-200207150-00006; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lau EK, 2004, ADV PROTEIN CHEM, V68, P351; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; McCornack MA, 2004, BIOCHEMISTRY-US, V43, P10090, DOI 10.1021/bi049751u; McCornack MA, 2003, J BIOL CHEM, V278, P1946, DOI 10.1074/jbc.M207440200; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; Moore UM, 1997, J LEUKOCYTE BIOL, V62, P911, DOI 10.1002/jlb.62.6.911; Nasu K, 2003, FERTIL STERIL, V79, P821, DOI 10.1016/S0015-0282(02)04831-8; Nesmelova IV, 2005, J BIOL CHEM, V280, P4948, DOI 10.1074/jbc.M405364200; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Paoletti S, 2005, BLOOD, V105, P3405, DOI 10.1182/blood-2004-04-1648; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Renninger ML, 2005, EXP DERMATOL, V14, P906, DOI 10.1111/j.1600-0625.2005.00378.x; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Ruotolo BT, 2005, SCIENCE, V310, P1658, DOI 10.1126/science.1120177; Shaw JP, 2004, STRUCTURE, V12, P2081, DOI 10.1016/j.str.2004.08.014; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Struyf S, 1998, J LEUKOCYTE BIOL, V63, P364; Swaminathan GJ, 2003, STRUCTURE, V11, P521, DOI 10.1016/S0969-2126(03)00070-4; Uguccioni M, 1999, AM J PATHOL, V155, P331, DOI 10.1016/S0002-9440(10)65128-0; Van Coillie E, 1999, CYTOKINE GROWTH F R, V10, P61, DOI 10.1016/S1359-6101(99)00005-2; VANDAMME J, 1994, J IMMUNOL, V152, P5495; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; von Hundelshausen P, 2005, BLOOD, V105, P924, DOI 10.1182/blood-2004-06-2475; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; Yu YH, 2006, J AM SOC MASS SPECTR, V17, P524, DOI 10.1016/j.jasms.2005.12.008; Yu YH, 2005, J BIOL CHEM, V280, P32200, DOI 10.1074/jbc.M505738200; Yu YH, 2004, J AM SOC MASS SPECTR, V15, P1400, DOI 10.1016/j.jasms.2004.06.002	56	87	88	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25438	25446		10.1074/jbc.M601518200	http://dx.doi.org/10.1074/jbc.M601518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803905	hybrid			2022-12-27	WOS:000240031300046
J	Leupold, D; Teuchner, K; Ehlert, J; Irrgang, KD; Renger, G; Lokstein, H				Leupold, Dieter; Teuchner, Klaus; Ehlert, Juergen; Irrgang, Klaus-Dieter; Renger, Gernot; Lokstein, Heiko			Stepwise two-photon excited fluorescence from higher excited states of chlorophylls in photosynthetic antenna complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; NONLINEAR POLARIZATION SPECTROSCOPY; PHOTOSYSTEM-II; CRYSTAL-STRUCTURE; ENERGY-TRANSFER; HIGHER-PLANTS; GREEN PLANTS; PROTEIN; CP29; ARCHITECTURE	Stepwise two-photon excited fluorescence (TPEF) spectra of the photosynthetic antenna complexes PCP, CP47, CP29, and light-harvesting complex II (LHCII) were measured. TPEF emitted from higher excited states of chlorophyll (Chl) a and b was elicited via consecutive absorption of two photons in the Chl a/b Q(y) range induced by tunable 100-fs laser pulses. Global analyses of the TPEF line shapes with a model function for monomeric Chl a in a proteinaceous environment allow distinction between contributions from monomeric Chls a and b, strongly excitonically coupled Chls a, and Chl a/b heterodimers/-oligomers. The analyses indicate that the longest wavelength-absorbing Chl species in the Qy region of LHC II is a Chl a homodimer with additional contributions from adjacent Chl b. Likewise, in CP47 a spectral form at similar to 680nm (that is, however, not the red-most species) is also due to strongly coupled Chls a. In contrast to LHC II, the red-most Chl subband of CP29 is due to a monomeric Chl a. The two Chls b in CP29 exhibit marked differences: a Chl b absorbing at similar to 650 nm is not excitonically coupled to other Chls. Based on this finding, the refractive index of its microenvironment can be determined to be 1.48. The second Chl b in CP29 (absorbing at similar to 640 nm) is strongly coupled to Chl a. Implications of the findings with respect to excitation energy transfer pathways and rates are discussed. Moreover, the results will be related to most recent structural analyses.	Univ Potsdam, Inst Biochem & Biol Pflanzenphysiol, D-14476 Golm, Germany; Tech Univ Berlin, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; Max Born Inst Nichtlineare Opt & Kurzzeitspektros, D-12489 Berlin, Germany; Gesell Forderung Angew Opt Optoelekt Quantenelekt, D-12489 Berlin, Germany; Univ Potsdam, Inst Phys Photon, D-14415 Potsdam, Germany	University of Potsdam; Technical University of Berlin; Max Born Institute for Nonlinear Optics & Short Term Spectroscopy; University of Potsdam	Lokstein, H (corresponding author), Univ Potsdam, Inst Biochem & Biol Pflanzenphysiol, Karl Liebknecht Str 24-25,Haus 20, D-14476 Golm, Germany.	lokstein@uni-potsdam.de	Lokstein, Heiko/H-7702-2013; Lokstein, Heiko/AAK-1930-2021; Lokstein, Heiko/P-2788-2019	Lokstein, Heiko/0000-0001-6739-4612; Lokstein, Heiko/0000-0001-6739-4612				Cinque G, 2000, BIOPHYS J, V79, P1706, DOI 10.1016/S0006-3495(00)76423-X; Croce R, 2003, BIOPHYS J, V84, P2508, DOI 10.1016/S0006-3495(03)75056-5; de Weerd FL, 2002, BIOPHYS J, V82, P1586, DOI 10.1016/S0006-3495(02)75510-0; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Eichwurzel I, 2000, PHOTOCHEM PHOTOBIOL, V72, P204, DOI 10.1562/0031-8655(2000)072<0204:PCOCBA>2.0.CO;2; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Gradinaru CC, 1998, BIOCHEMISTRY-US, V37, P1143, DOI 10.1021/bi9722655; Gruszecki WI, 1999, BBA-BIOENERGETICS, V1412, P173, DOI 10.1016/S0005-2728(99)00055-9; Hofmann E, 1996, SCIENCE, V272, P1788, DOI 10.1126/science.272.5269.1788; Huyer J, 2004, J PHYS CHEM B, V108, P3326, DOI 10.1021/jp030944l; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Knox RS, 2002, J PHYS CHEM B, V106, P5289, DOI 10.1021/jp013927+; Krikunova M, 2002, BBA-BIOENERGETICS, V1556, P1, DOI 10.1016/S0005-2728(02)00326-2; Leupold D, 1996, PHYS REV LETT, V77, P4675, DOI 10.1103/PhysRevLett.77.4675; Leupold D, 2002, BIOPHYS J, V82, P1580, DOI 10.1016/S0006-3495(02)75509-4; LEUPOLD D, 1990, CHEM PHYS LETT, V170, P478, DOI 10.1016/S0009-2614(90)87088-9; Leupold D, 2000, FEBS LETT, V480, P73, DOI 10.1016/S0014-5793(00)01892-5; Leupold Dieter, 2006, V25, P413; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Loll B, 2005, PHOTOSYNTH RES, V86, P175, DOI 10.1007/s11120-005-4117-0; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; Pieper J, 2000, PHOTOCHEM PHOTOBIOL, V71, P574, DOI 10.1562/0031-8655(2000)071<0574:AOTLQY>2.0.CO;2; Rogl H, 2002, BIOCHEMISTRY-US, V41, P2281, DOI 10.1021/bi015875k; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; Schubert A, 2002, BIOPHYS J, V82, P1030, DOI 10.1016/S0006-3495(02)75462-3; Sharples FP, 1996, BBA-BIOENERGETICS, V1276, P117, DOI 10.1016/0005-2728(96)00066-7; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; Teuchner K, 2000, J FLUORESC, V10, P275, DOI 10.1023/A:1009453228102; Voigt B, 2002, BIOCHEMISTRY-US, V41, P3049, DOI 10.1021/bi0155854; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	31	8	8	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25381	25387		10.1074/jbc.M600080200	http://dx.doi.org/10.1074/jbc.M600080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16799157	hybrid			2022-12-27	WOS:000240031300040
J	Steger, HK; Root, MJ				Steger, H. Kirby; Root, Michael J.			Kinetic dependence to HIV-1 entry inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; POTENT INHIBITORS; MEMBRANE-FUSION; NONNEUTRALIZING ANTIBODIES; SYNTHETIC PEPTIDE; ATOMIC-STRUCTURE; 6-HELIX BUNDLE; HELICAL DOMAIN; COILED-COIL	Infection by human immunodeficiency virus type 1 (HIV-1) involves the fusion of viral and cellular membranes mediated by formation of the gp41 trimer-of-hairpins. A designed protein, 5-Helix, targets the C-terminal region of the gp41 ectodomain, disrupting trimer-of-hairpins formation and blocking viral entry. Here we show that the nanomolar inhibitory potency of 5-Helix (IC50 similar to 6 nM) is 4 orders of magnitude larger than its subpicomolar binding affinity (K-D similar to 0.6 pm). This discrepancy results from the transient exposure of the 5-Helix binding site on gp41. As a consequence, inhibitory potency is determined by the association rate, not by binding affinity. For a series of 5-Helix variants with mutations in their gp41 binding sites, the IC50 and KD values poorly correlate. By contrast, an inverse relationship between IC50 values and association rate constants (kon) extends for over 2 orders of magnitude. The kinetic dependence to inhibition places temporal restrictions on an intermediate state of HIV-1 membrane fusion and suggests that access to the C-terminal region of the gp41 ectodomain is largely free from steric hindrance. Our results support the importance of association kinetics in the development of improved HIV-1 fusion inhibitors.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Root, MJ (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, 233 S 10th St,Rm 802, Philadelphia, PA 19107 USA.	mroot@mail.jci.tju.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066682] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066682, R01 GM66682] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahamyan LG, 2005, J VIROL, V79, P106, DOI 10.1128/JVI.79.1.106-115.2005; Bianchi E, 2005, P NATL ACAD SCI USA, V102, P12903, DOI 10.1073/pnas.0502449102; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Follis KE, 2002, J VIROL, V76, P7356, DOI 10.1128/JVI.76.14.7356-7362.2002; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Hamburger AE, 2005, J BIOL CHEM, V280, P12567, DOI 10.1074/jbc.M412770200; Herrera C, 2003, J VIROL, V77, P1084, DOI 10.1128/JVI.77.2.1084-1091.2003; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Kilgore NR, 2003, J VIROL, V77, P7669, DOI 10.1128/JVI.77.13.7669-7672.2003; Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1; Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Root MJ, 2004, CURR PHARM DESIGN, V10, P1805, DOI 10.2174/1381612043384448; Root MJ, 2003, P NATL ACAD SCI USA, V100, P5016, DOI 10.1073/pnas.0936926100; Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024; Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	41	62	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25813	25821		10.1074/jbc.M601457200	http://dx.doi.org/10.1074/jbc.M601457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803885	hybrid			2022-12-27	WOS:000240031300083
J	Wang, LF; Rhodes, CJ; Lawrence, JC				Wang, Lifu; Rhodes, Christopher J.; Lawrence, John C., Jr.			Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; REPRESSOR PHAS-I; P70 S6 KINASE; PROTEIN-KINASE; MESSENGER-RNA; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; DEPENDENT PHOSPHORYLATION; TRANSLATIONAL REGULATOR; INDEPENDENT PATHWAY	Insulin stimulates protein synthesis by promoting phosphorylation of the eIF4E-binding protein, 4EBP1. This effect is rapamycin-sensitive and mediated by mammalian target of rapamycin ( mTOR) complex 1 ( mTORC1), a signaling complex containing mTOR, raptor, and mLST8. Here we demonstrate that insulin produces a stable increase in the kinase activity of mTORC1 in 3T3-L1 adipocytes. The response was associated with a marked increase in 4EBP1 binding to raptor in mTORC1, and it was abolished by disrupting the TOR signaling motif in 4EBP1. The stimulatory effects of insulin on both 4EBP1 kinase activity and binding occurred rapidly and at physiological concentrations of insulin, and both effects required an intact mTORC1. Results of experiments involving size exclusion chromatography and coimmunoprecipitation of epitope-tagged subunits provide evidence that the major insulin-responsive form is dimeric mTORC1, a structure containing two heterotrimers of mTOR, raptor, and mLST8.	Univ Virginia, Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Washington, Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	University of Virginia; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lawrence, JC (corresponding author), Univ Virginia, Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jcl3p@virginia.edu	wang, lifu/E-1436-2012		NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK052753] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Harris Thurl E, 2003, Sci STKE, V2003, pre15; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball SR, 2006, J NUTR, V136, p227S, DOI 10.1093/jn/136.1.227S; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979	51	92	95	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24293	24303		10.1074/jbc.M603566200	http://dx.doi.org/10.1074/jbc.M603566200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798736	hybrid			2022-12-27	WOS:000239847800022
J	Ayrapetov, MK; Wang, YH; Lin, XF; Gu, XF; Parang, K; Sun, GQ				Ayrapetov, Marina K.; Wang, Yue-Hao; Lin, Xiaofeng; Gu, Xianfeng; Parang, Keykavous; Sun, Gongqin			Conformational basis for SH2-Tyr(P)(527) binding in Src inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE HCK; CRYSTAL-STRUCTURE; C-SRC; SUBSTRATE-SPECIFICITY; STRUCTURAL BASIS; SH3 DOMAIN; PROTEIN; CSK; ACTIVATION; PHOSPHORYLATION	Src protein-tyrosine kinase contains a myristoylation motif, a unique region, an Src homology (SH) 3 domain, an SH2 domain, a catalytic domain, and a C-terminal tail. The C-terminal tail contains a Tyr residue, Tyr(527). Phosphorylation of Tyr(527) triggers Src inactivation, caused by Tyr(P)(527) binding to the SH2 domain. In this study, we demonstrated that a conformational contribution, not affinity, is the predominant force for the intramolecular SH2-Tyr(P)(527) binding, and we characterized the structural basis for this conformational contribution. First, a phosphopeptide mimicking the C-terminal tail is an 80-fold weaker ligand than the optimal phosphopeptide, pYEEI, and similar to a phosphopeptide containing three Ala residues following Tyr( P) in binding to the Src SH2 domain. Second, the SH2-Tyr(P)(527) binding is largely independent of the amino acid sequence surrounding Tyr(P)(527), and only slightly decreased by an inactivating mutation in the SH2 domain. Furthermore, even the unphosphorylated C-terminal tail with the sequence of YEEI suppresses Src activity by binding to the SH2 domain. These experiments demonstrate that very weak affinity is sufficient for the SH2-Tyr(P)(527) binding in Src inactivation. Third, the effective intramolecular SH2-Tyr(P)(527) binding is attributed to a conformational contribution that requires residues Trp(260) and Leu(255). Although the SH3 domain is essential for Src inactivation by Tyr(P)(527), it does not contribute to the SH2-Tyr(P)(527) binding. These findings suggest a conformation-based Src inactivation model, which provides a unifying framework for understanding Src activation by a variety of mechanisms.	Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA; Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA	University of Rhode Island; University of Rhode Island	Sun, GQ (corresponding author), Univ Rhode Isl, Dept Cell & Mol Biol, 117 Morrill Sci Bldg,45 Lower Coll Rd, Kingston, RI 02881 USA.	gsun@uri.edu	Parang, Keykavous/F-9236-2010; Parang, Keykavous/ABC-1584-2021	Parang, Keykavous/0000-0001-8600-0893	NATIONAL CANCER INSTITUTE [R01CA111687] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA111687] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Ayrapetov MK, 2005, J BIOL CHEM, V280, P25780, DOI 10.1074/jbc.M504022200; Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Cowan-Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Lee SS, 2006, J BIOL CHEM, V281, P8183, DOI 10.1074/jbc.M508120200; Lerner EC, 2005, J BIOL CHEM, V280, P40832, DOI 10.1074/jbc.M508782200; Levin Victor A, 2004, Cancer Treat Res, V119, P89; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma YC, 2002, CELL MOL LIFE SCI, V59, P456, DOI 10.1007/s00018-002-8438-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; OKADA M, 1991, J BIOL CHEM, V266, P24249; Parang K, 2004, CURR OPIN DRUG DISC, V7, P617; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Sun GQ, 2002, ARCH BIOCHEM BIOPHYS, V397, P11, DOI 10.1006/abbi.2001.2627; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Wang DX, 2002, J BIOL CHEM, V277, P40428, DOI 10.1074/jbc.M206467200; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P606, DOI 10.1016/j.bbrc.2006.05.180; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23776	23784		10.1074/jbc.M604219200	http://dx.doi.org/10.1074/jbc.M604219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790421	hybrid			2022-12-27	WOS:000239702900053
J	Kriska, T; Levchenko, VV; Korytowski, W; Atshaves, BP; Schroeder, F; Girotti, AW				Kriska, Tamas; Levchenko, Vladislav V.; Korytowski, Witold; Atshaves, Barbara P.; Schroeder, Friedhelm; Girotti, Albert W.			Intracellular dissemination of peroxidative stress - Internalization, transport, and lethal targeting of a cholesterol hydroperoxide species by sterol carrier protein-2-overexpressing hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER; INTERMEMBRANE TRANSFER; GENE-EXPRESSION; PROTEIN-2 GENE; GLUTATHIONE; HYPERRESISTANCE; MECHANISMS; OXIDATION; TURNOVER; EXCHANGE	Sterol carrier protein-2 (SCP-2) plays a crucial role in the trafficking and metabolism of cholesterol and other lipids in mammalian cells. Lipid hydroperoxides generated under oxidative stress conditions are relatively long-lived intermediates that damage cell membranes and play an important role in redox signaling. We hypothesized that SCP-2-facilitated translocation of lipid hydroperoxides in oxidatively stressed cells might enhance cytolethality if highly sensitive sites are targeted and detoxification capacity is insufficient. We tested this using a clone (SC2A) of rat hepatoma cells that overexpress mature immunodetectable SCP-2. When challenged with liposomal cholesterol-7 alpha-hydroperoxide (7 alpha-OOH), SC2A cells were found to be much more sensitive to viability loss than vector control ( VC) counterparts. Correspondingly, SC2A cells imported [C-14]7 alpha-OOH more rapidly. The clones were equally sensitive to tert-butyl hydroperoxide, suggesting that the 7 alpha-OOH effect was SCP-2-specific. Fluorescence intensity of the probes 2',7'-dichlorofluorescein and C11-BODIPY increased more rapidly in SC2A than VC cells after 7 alpha-OOH exposure, consistent with more rapid internalization and oxidative turnover in the former. [C-14]7 alpha-OOH radioactivity accumulated much faster in SC2A mitochondria than in VC, whereas other subcellular fractions showed little rate difference. In keeping with this, 7 alpha-OOHstressed SC2A cells exhibited a faster loss of mitochondrial membrane potential and development of apoptosis. This is the first reported evidence that peroxidative stress damage can be selectively targeted and exacerbated by an intracellular lipid transfer protein.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Jagiellonian Univ, Inst Mol Biol, PL-31120 Krakow, Poland; Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA	Medical College of Wisconsin; Jagiellonian University; Texas A&M University System; Texas A&M University College Station	Girotti, AW (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	agirotti@mcw.edu	Girotti, Albert/AAF-6910-2020		NCI NIH HHS [CA72630] Funding Source: Medline; NIGMS NIH HHS [GM31651] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atshaves BP, 1999, J LIPID RES, V40, P610; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BAUM CL, 1993, J LIPID RES, V34, P729; BILLHEIMER JT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P136, DOI 10.1016/0005-2760(90)90180-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; BROWN RE, 1992, BIOCHIM BIOPHYS ACTA, V1113, P375, DOI 10.1016/0304-4157(92)90007-W; Dansen TB, 2004, J LIPID RES, V45, P81, DOI 10.1194/jlr.M300111-JLR200; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; Drummen GPC, 2002, FREE RADICAL BIO MED, V33, P473, DOI 10.1016/S0891-5849(02)00848-1; Flohe L, 2003, BIOFACTORS, V19, P3, DOI 10.1002/biof.5520190102; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Gallegos AM, 2000, CHEM PHYS LIPIDS, V105, P9, DOI 10.1016/S0009-3084(99)00128-0; Girotti AW, 2004, ANTIOXID REDOX SIGN, V6, P301, DOI 10.1089/152308604322899369; Girotti AW, 1998, J LIPID RES, V39, P1529; Girotti AW, 2000, METHOD ENZYMOL, V319, P85; Girotti AW, 2002, STEROLS OXYSTEROLS C, P121; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; Huang H, 2002, BIOCHEMISTRY-US, V41, P12149, DOI 10.1021/bi0260536; Huang H, 1999, BIOCHEMISTRY-US, V38, P13231, DOI 10.1021/bi990870x; Hurst R, 2001, FREE RADICAL BIO MED, V31, P1051, DOI 10.1016/S0891-5849(01)00685-2; Korytowski W, 1999, METHOD ENZYMOL, V300, P23; Korytowski W, 1999, ANAL BIOCHEM, V270, P123, DOI 10.1006/abio.1999.4070; Kriska T, 2005, ARCH BIOCHEM BIOPHYS, V433, P435, DOI 10.1016/j.abb.2004.09.025; Kriska T, 2002, FREE RADICAL BIO MED, V33, P1389, DOI 10.1016/S0891-5849(02)01078-X; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V269, P390, DOI 10.1016/0003-9861(89)90122-7; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; NICHOLS JW, 1987, J BIOL CHEM, V262, P14172; Nishimura Y, 2001, CELL DEATH DIFFER, V8, P850, DOI 10.1038/sj.cdd.4400877; Niziolek M, 2006, FREE RADICAL BIO MED, V40, P1323, DOI 10.1016/j.freeradbiomed.2005.11.022; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; Ossendorp BC, 1996, ARCH BIOCHEM BIOPHYS, V334, P251, DOI 10.1006/abbi.1996.0453; Pap EHW, 1999, FEBS LETT, V453, P278, DOI 10.1016/S0014-5793(99)00696-1; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; SMITH LL, 1978, J AM CHEM SOC, V100, P6206, DOI 10.1021/ja00487a042; Srinivas KS, 2004, J BIOCHEM BIOPH METH, V60, P23, DOI 10.1016/j.jbbm.2004.04.011; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; Stolowich NJ, 2002, CELL MOL LIFE SCI, V59, P193, DOI 10.1007/s00018-002-8416-8; TENG JI, 1973, J CHROMATOGR, V75, P108, DOI 10.1016/S0021-9673(01)83418-X; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; Vila A, 2000, ARCH BIOCHEM BIOPHYS, V380, P208, DOI 10.1006/abbi.2000.1928; Vila A, 2004, BIOCHEMISTRY-US, V43, P12592, DOI 10.1021/bi0491200; Vila A, 2001, BIOCHEMISTRY-US, V40, P14715, DOI 10.1021/bi011408r; WILCOX AL, 1993, CHEM RES TOXICOL, V6, P413, DOI 10.1021/tx00034a003; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; ZILVERSMIT DB, 1984, J LIPID RES, V25, P1563	52	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23643	23651		10.1074/jbc.M600744200	http://dx.doi.org/10.1074/jbc.M600744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16772292	hybrid			2022-12-27	WOS:000239702900039
J	Botta, D; Shi, S; White, CC; Dabrowski, MJ; Keener, CL; Srinouanprachanh, SL; Farin, FM; Ware, CB; Ladiges, WC; Pierce, RH; Fausto, N; Kavanagh, TJ				Botta, Dianne; Shi, Shengli; White, Collin C.; Dabrowski, Michael J.; Keener, Cassie L.; Srinouanprachanh, Sengkeo L.; Farin, Federico M.; Ware, Carol B.; Ladiges, Warren C.; Pierce, Robert H.; Fausto, Nelson; Kavanagh, Terrance J.			Acetaminophen-induced liver injury is attenuated in male glutamate-cysteine ligase transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; HAMSTER V79 CELLS; MITOCHONDRIAL PERMEABILITY TRANSITION; INDUCED HEPATIC NECROSIS; MODIFIER SUBUNIT GENE; NITRIC-OXIDE SYNTHASE; INDUCED HEPATOTOXICITY; GLUTATHIONE SYNTHESIS; CATALYTIC SUBUNIT; PEROXYNITRITE FORMATION	Acetaminophen overdose is a leading cause of drug-related acute liver failure in the United States. Glutathione, a tripeptide antioxidant protects cells against oxidative damage from reactive oxygen species and plays a crucial role in the detoxification of xenobiotics, including acetaminophen. Glutathione is synthesized in a two-step enzymatic reaction. Glutamate-cysteine ligase carries out the rate-limiting and first step in glutathione synthesis. We have generated C57Bl/6 mice that conditionally overexpress glutamate-cysteine ligase, and report here their resistance to acetaminophen-induced liver injury. Indices of liver injury included histopathology and serum alanine aminotransferase activity. Male transgenic mice induced to overexpress glutamate-cysteine ligase exhibited resistance to acetaminophen-induced liver injury when compared with acetaminophen-treated male mice carrying, but not expressing glutamate-cysteine ligase transgenes, or to female glutamate-cysteine ligase transgenic mice. We conclude that glutamate-cysteine ligase activity is an important factor in determining acetaminophen-induced liver injury in C57Bl/6 male mice. Because people are known to vary in their glutamate-cysteine ligase activity, this enzyme may also be an important determinant of sensitivity to acetaminophen-induced liver injury in humans.	Univ Washington, NIEHS, Ctr Ecogenet & Environm Hlth, Seattle, WA 98105 USA; Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98105 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98105 USA; Univ Washington, Dept Pathol, Seattle, WA 98105 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Rochester	Kavanagh, TJ (corresponding author), Univ Washington, Box 354695, Seattle, WA 98195 USA.	tjkav@u.washington.edu		Pierce, MD, Robert Hamilton/0000-0002-2677-144X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033, P42ES004696, R01ES010849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER; NIA NIH HHS [5P01AG001751] Funding Source: Medline; NIEHS NIH HHS [5R01ES010849, 5P42ES004696, 2P30ES007033] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bajt ML, 2003, J PHARMACOL EXP THER, V307, P67, DOI 10.1124/jpet.103.052506; BARTOLONE JB, 1988, BIOCHEM PHARMACOL, V37, P4763, DOI 10.1016/0006-2952(88)90350-4; Bessems JGM, 2001, CRIT REV TOXICOL, V31, P55, DOI 10.1080/20014091111677; Botta D, 2004, FREE RADICAL BIO MED, V37, P632, DOI 10.1016/j.freeradbiomed.2004.05.027; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; Dai GL, 2006, TOXICOL SCI, V92, P33, DOI 10.1093/toxsci/kfj192; Dickinson DA, 2004, FREE RADICAL BIO MED, V37, P1152, DOI 10.1016/j.freeradbiomed.2004.06.011; Eaton DL, 1999, TOXICOL SCI, V49, P156, DOI 10.1093/toxsci/49.2.156; Franklin CC, 2003, FASEB J, V17, P1535, DOI 10.1096/fj.02-0867fje; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; Gardner CR, 2002, TOXICOL APPL PHARM, V184, P27, DOI 10.1006/taap.2002.9474; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hinson JA, 1998, CHEM RES TOXICOL, V11, P604, DOI 10.1021/tx9800349; Hinson JA, 2004, DRUG METAB REV, V36, P805, DOI 10.1081/DMR-200033494; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Ito Y, 2003, MICROCIRCULATION, V10, P391, DOI 10.1038/sj.mn.7800204; Ito Yoshiya, 2004, Comp Hepatol, V3 Suppl 1, pS33, DOI 10.1186/1476-5926-2-S1-S33; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; Jaeschke H, 2003, TOXICOL LETT, V144, P279, DOI 10.1016/S0378-4274(03)00239-X; James LP, 2003, DRUG METAB DISPOS, V31, P1499, DOI 10.1124/dmd.31.12.1499; James LP, 2003, FREE RADICAL RES, V37, P1289, DOI 10.1080/10715760310001617776; James LP, 2003, TOXICOL SCI, V75, P458, DOI 10.1093/toxsci/kfg181; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; Kitteringham NR, 2000, HEPATOLOGY, V32, P321, DOI 10.1053/jhep.2000.9602; Knight Tamara R, 2004, Comp Hepatol, V3 Suppl 1, pS46, DOI 10.1186/1476-5926-2-S1-S46; Knight TR, 2003, TOXICOL SCI, V76, P229, DOI 10.1093/toxsci/kfg220; Knight TR, 2002, J PHARMACOL EXP THER, V303, P468, DOI 10.1124/jpet.102.038968; Knight TR, 2001, TOXICOL SCI, V62, P212, DOI 10.1093/toxsci/62.2.212; Koide S, 2003, J AM COLL CARDIOL, V41, P539, DOI 10.1016/S0735-1097(02)02866-8; Lee WM, 2004, HEPATOLOGY, V40, P6, DOI 10.1002/hep.20293; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Michael SL, 2001, NITRIC OXIDE-BIOL CH, V5, P432, DOI 10.1006/niox.2001.0385; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; Muldrew KL, 2002, DRUG METAB DISPOS, V30, P446, DOI 10.1124/dmd.30.4.446; Nakamura S, 2002, CIRCULATION, V105, P2968, DOI 10.1161/01.CIR.0000019739.66514.1E; Nakamura S, 2003, CIRCULATION, V108, P1425, DOI 10.1161/01.CIR.0000091255.63645.98; NELSON SD, 1990, SEMIN LIVER DIS, V10, P267, DOI 10.1055/s-2008-1040482; Ochi T, 1995, ARCH TOXICOL, V70, P96, DOI 10.1007/BF02733669; Ochi T, 1997, ARCH TOXICOL, V71, P730, DOI 10.1007/s002040050454; Ochi T, 1996, TOXICOLOGY, V112, P45, DOI 10.1016/0300-483X(96)03348-3; ODwyer PJ, 1996, J CLIN INVEST, V98, P1210, DOI 10.1172/JCI118904; PUMFORD NR, 1990, TOXICOL APPL PHARM, V104, P521, DOI 10.1016/0041-008X(90)90174-S; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Reid AB, 2005, J PHARMACOL EXP THER, V312, P509, DOI 10.1124/jpet.104.075945; Reid LL, 1997, BBA-GENE STRUCT EXPR, V1352, P233, DOI 10.1016/S0167-4781(97)00058-4; Reid LL, 1997, BBA-GENE STRUCT EXPR, V1353, P107, DOI 10.1016/S0167-4781(97)00092-4; Rzucidlo SJ, 2000, VET HUM TOXICOL, V42, P146; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; Thompson SA, 1999, TOXICOL LETT, V110, P1, DOI 10.1016/S0378-4274(99)00133-2; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; White CC, 2003, ANAL BIOCHEM, V318, P175, DOI 10.1016/S0003-2697(03)00143-X; WHITE CC, 1999, CURRENT PROTOCOLS TO	56	46	48	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28865	28875		10.1074/jbc.M605143200	http://dx.doi.org/10.1074/jbc.M605143200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16840778	hybrid			2022-12-27	WOS:000240680500041
J	Hall, BS; Gabernet-Castello, C; Voak, A; Goulding, D; Natesan, SK; Field, MC				Hall, Belinda S.; Gabernet-Castello, Carme; Voak, Andrew; Goulding, David; Natesan, Senthil Kumar; Field, Mark C.			TbVps34, the trypanosome orthologue of Vps34, is required for Golgi complex segregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; RETROGRADE TRANSPORT; RNA INTERFERENCE; RAB5 EFFECTORS; FYVE FINGERS; PI 3-KINASE; CELL-CYCLE; YEAST; BRUCEI	Phosphoinositides are important regulators of numerous cellular functions. The yeast class III phosphatidylinositol 3-kinase Vps34p, and its human orthologue hVPS34, are implicated in control of several key pathways, including endosome to lysosome transport, retrograde endosome to Golgi traffic, multivesicular body formation, and autophagy. We have identified the Vps34p orthologue in the African trypanosome, TbVps34. Knockdown of TbVps34 expression by RNA interference induces a severe growth defect, with a post-mitotic block to cytokinesis accompanied by a variety of morphological abnormalities. GFP2xFYVE, a chimeric protein that specifically binds phosphatidylinositol 3-phosphate, localizes to the trypanosome endosomal system and is delocalized under TbVps34 RNA interference (RNAi), confirming that TbVps34 is an authentic phosphatidylinositol 3-kinase. Expression of GFP2xFYVE enhances the TbVps34 RNAi-associated growth defect, suggesting a synthetic interaction via competition for phosphatidylinositol 3-phosphate-binding sites with endogenous FYVE domain proteins. Endocytosis of a fluid phase marker is unaffected by TbVps34 RNAi, but receptor-mediated endocytosis of transferrin and transport of concanavalin A to the lysosome are both impaired, confirming a role in membranous endocytic trafficking for TbVps34. TbVps34 knockdown inhibits export of variant surface glycoprotein, indicating a function in exocytic transport. Ultrastructural analysis revealed a highly extended Golgi apparatus following TbVps34 RNAi, whereas expression of the Golgi marker red fluorescent protein-GRASP (Grp1 (general receptor for phosphoinositides-1)-associated scaffold protein) demonstrated that trypanosomes are able to duplicate the Golgi complex but failed to complete segregation during mitosis, despite faithful replication and segregation of basal bodies and the kinetoplast. These observations implicate TbVps34 as having a role in coordinating segregation of the Golgi complex at cell division.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England	University of Cambridge; Imperial College London	Field, MC (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	mcf34@cam.ac.uk	Field, Mark/AAD-6455-2021; Hall, Belinda/AGU-6214-2022	Field, Mark/0000-0002-4866-2885; Hall, Belinda/0000-0002-3753-1978; Voak, Andrew/0000-0002-1010-4781	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERGGREN MI, 1993, CANCER RES, V53, P4297; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; BRICKMAN MJ, 1995, J CELL SCI, V108, P3611; Brown RA, 2001, BIOCHEM SOC T, V29, P535, DOI 10.1042/BST0290535; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Bunney TD, 2000, PLANT CELL, V12, P1679, DOI 10.1105/tpc.12.9.1679; Burda P, 2002, J CELL SCI, V115, P3889, DOI 10.1242/jcs.00090; Carlton J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077; Carlton JG, 2005, TRENDS CELL BIOL, V15, P540, DOI 10.1016/j.tcb.2005.08.005; Cheung PCF, 2001, BIOCHEM J, V355, P113, DOI 10.1042/bj3550113; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; di Campli A, 1999, CELL MOTIL CYTOSKEL, V43, P334, DOI 10.1002/(SICI)1097-0169(1999)43:4<334::AID-CM6>3.0.CO;2-3; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Engstler M, 2004, J CELL SCI, V117, P1105, DOI 10.1242/jcs.00938; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; Field MC, 2005, TRENDS PARASITOL, V21, P447, DOI 10.1016/j.pt.2005.08.008; FIELD MC, 2006, EVOLUTION EUKARYOTIC; Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; GALE M, 1993, MOL BIOCHEM PARASIT, V59, P111, DOI 10.1016/0166-6851(93)90012-M; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; GRAB DJ, 1992, EUR J CELL BIOL, V59, P398; Grunfelder CG, 2003, MOL BIOL CELL, V14, P2029, DOI 10.1091/mbc.E02-10-0640; Hall B, 2004, MOL BIOCHEM PARASIT, V138, P67, DOI 10.1016/j.molbiopara.2004.07.007; Hall BS, 2005, EUKARYOT CELL, V4, P971, DOI 10.1128/EC.4.5.971-980.2005; Hall BS, 2004, J BIOL CHEM, V279, P45047, DOI 10.1074/jbc.M407271200; He CY, 2004, J CELL BIOL, V165, P313, DOI 10.1083/jcb.200311076; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Hirosako K, 2004, BIOCHEM BIOPH RES CO, V316, P845, DOI 10.1016/j.bbrc.2004.02.119; Kelley RJ, 1995, MOL BIOCHEM PARASIT, V74, P167, DOI 10.1016/0166-6851(95)02493-X; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Marone Maria, 2001, Biological Procedures Online, V3, P19, DOI 10.1251/bpo20; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Morgan GW, 2002, TRENDS PARASITOL, V18, P491, DOI 10.1016/S1471-4922(02)02391-7; Pal A, 2003, BIOCHEM J, V374, P443, DOI 10.1042/BJ20030469; Pal A, 2002, J BIOL CHEM, V277, P9529, DOI 10.1074/jbc.M110055200; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Petiot A, 2003, J CELL BIOL, V162, P971, DOI 10.1083/jcb.200303018; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Redmond S, 2003, MOL BIOCHEM PARASIT, V128, P115, DOI 10.1016/S0166-6851(03)00045-8; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Rog O, 2005, CURR GENET, V47, P18, DOI 10.1007/s00294-004-0548-y; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Santa-Rita RM, 2004, J ANTIMICROB CHEMOTH, V54, P704, DOI 10.1093/jac/dkh380; Sheader K, 2005, P NATL ACAD SCI USA, V102, P8716, DOI 10.1073/pnas.0501886102; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stein MP, 2003, TRAFFIC, V4, P754, DOI 10.1034/j.1600-0854.2003.00133.x; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Thyberg J, 1998, EUR J CELL BIOL, V76, P33, DOI 10.1016/S0171-9335(98)80015-0; Vassella E, 2001, MOL MICROBIOL, V41, P33, DOI 10.1046/j.1365-2958.2001.02471.x; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wetzker R, 2004, CURR PHARM DESIGN, V10, P1915, DOI 10.2174/1381612043384402; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9	68	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27600	27612		10.1074/jbc.M602183200	http://dx.doi.org/10.1074/jbc.M602183200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835237	hybrid			2022-12-27	WOS:000240397700085
J	Oddo, C; Freire, E; Frappier, L; de Prat-Gay, G				Oddo, Cristian; Freire, Eleonora; Frappier, Lori; de Prat-Gay, Gonzalo			Mechanism of DNA recognition at a viral replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; CRYSTAL-STRUCTURE; BINDING-PROTEIN; NUCLEAR ANTIGEN-1; SURFACE-AREAS; EBNA1; SEQUENCE; DOMAINS; TARGET; HEAT	Recognition of the DNA origin by the Epstein- Barr nuclear antigen 1 (EBNA1) protein is the primary event in latent-phase genome replication of the Epstein-Barr virus, a model for replication initiation in eukaryotes. We carried out an extensive thermodynamic and kinetic characterization of the binding mechanism of the DNA binding domain of EBNA1, EBNA1(452-641), to a DNA fragment containing a single specific origin site. The interaction displays a binding energy of 12.7 kcal mol(-1), with 11.9 kcal mol(-1) coming from the enthalpic change with a minimal entropic contribution. Formation of the EBNA1(452-641), DNA complex is accompanied by a heat capacity change of -1.22 kcal mol(-1) K-1, a very large value considering the surface area buried, which we assign to an unusually apolar protein-DNA interface. Kinetic dissociation experiments, including fluorescence anisotropy and a continuous native electrophoretic mobility shift assay, confirmed that two EBNA1(452-641)(.)DNA complex conformers are in slow equilibrium; one dissociates slowly (t(1/2)similar to 41 min) through an undissociated intermediate species and the other corresponds to a fast two-step dissociation route (t(1/2)similar to 0.8 min). In line with this, at least two parallel association events from two populations of protein conformers are observed, with on-rates of 0.25-1.6 x 10(8) M(-1)s(-1), which occur differentially either in excess protein or DNA molecules. Both parallel complexes undergo subsequent first-order rearrangements of similar to 2.0s(-1) to yield two consolidated complexes. These parallel association and dissociation routes likely allow additional flexible regulatory events for site recognition depending on site availability according to nucleus environmental conditions, which may lock a final recognition event, dissociate and re- bind, or slide along the DNA.	Inst Leloir, RA-1405 Buenos Aires, DF, Argentina; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Leloir Institute; University of Toronto	de Prat-Gay, G (corresponding author), Inst Leloir, Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	gpratgay@leloir.org.ar		Prat Gay, Gonzalo/0000-0001-5748-6863; Freire Espeleta, Eleonora/0000-0002-6026-8696	Wellcome Trust [066649/Z/01/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Bergqvist S, 2004, J MOL BIOL, V336, P829, DOI 10.1016/j.jmb.2003.12.061; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; Bochkarev A, 1998, J MOL BIOL, V284, P1273, DOI 10.1006/jmbi.1998.2247; Cruickshank J, 2000, J BIOL CHEM, V275, P22273, DOI 10.1074/jbc.M001414200; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P6218, DOI 10.1021/bi026866u; Ferreiro DU, 2005, J BIOL CHEM, V280, P32480, DOI 10.1074/jbc.M505706200; Ferreiro DU, 2000, BIOCHEMISTRY-US, V39, P14692, DOI 10.1021/bi001694r; Ferreiro DU, 2003, J MOL BIOL, V331, P89, DOI 10.1016/S0022-2836(03)00720-4; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7964, DOI 10.1021/bi00191a025; Gray D. M., 1996, CIRCULAR DICHROISM C, P469; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Hegde RS, 2002, ANNU REV BIOPH BIOM, V31, P343, DOI 10.1146/annurev.biophys.31.100901.142129; Holowaty MN, 2003, J BIOL CHEM, V278, P47753, DOI 10.1074/jbc.M307200200; JONES CH, 1989, J VIROL, V63, P101, DOI 10.1128/JVI.63.1.101-110.1989; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; Kozlov AG, 1998, J MOL BIOL, V278, P999, DOI 10.1006/jmbi.1998.1738; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Lundback T, 2000, BIOCHEMISTRY-US, V39, P7570, DOI 10.1021/bi000377h; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	34	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26893	26903		10.1074/jbc.M602083200	http://dx.doi.org/10.1074/jbc.M602083200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16815848	hybrid, Green Published			2022-12-27	WOS:000240397700016
J	Al-Ramahi, I; Lam, YC; Chen, HK; de Gouyon, B; Zhang, MH; Perez, AM; Branco, J; de Haro, M; Patterson, C; Zoghbi, HY; Botas, J				Al-Ramahi, Ismael; Lam, Yung C.; Chen, Hung-Kai; de Gouyon, Beatrice; Zhang, Minghang; Perez, Alma M.; Branco, Joana; de Haro, Maria; Patterson, Cam; Zoghbi, Huda Y.; Botas, Juan			CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCA1 TRANSGENIC MICE; POLYGLUTAMINE-INDUCED DISEASE; QUALITY-CONTROL; MEDIATES NEURODEGENERATION; MOLECULAR CHAPERONES; CARBOXYL-TERMINUS; AXH DOMAIN; LIGASE; AGGREGATION; PROTEINS	CHIP (C terminus of Hsc-70 interacting protein) is an E3 ligase that links the protein folding machinery with the ubiquitin-proteasome system and has been implicated in disorders characterized by protein misfolding and aggregation. Here we investigate the role of CHIP in protecting from ataxin-1-induced neurodegeneration. Ataxin-1 is a polyglutamine protein whose expansion causes spinocerebellar ataxia type-1 (SCA1) and triggers the formation of nuclear inclusions (NIs). We find that CHIP and ataxin-1 proteins directly interact and co-localize in NIs both in cell culture and SCA1 postmortem neurons. CHIP promotes ubiquitination of expanded ataxin-1 both in vitro and in cell culture. The Hsp70 chaperone increases CHIP-mediated ubiquitination of ataxin-1 in vitro, and the tetratricopeptide repeat domain, which mediates CHIP interactions with chaperones, is required for ataxin-1 ubitiquination in cell culture. Interestingly, CHIP also interacts with and ubiquitinates unexpanded ataxin-1. Overexpression of CHIP in a Drosophila model of SCA1 decreases the protein steady-state levels of both expanded and unexpanded ataxin-1 and suppresses their toxicity. Finally we investigate the ability of CHIP to protect against toxicity caused by expanded polyglutamine tracts in different protein contexts. We find that CHIP is not effective in suppressing the toxicity caused by a bare 127Q tract with only a short hemaglutinin tag, but it is very efficient in suppressing toxicity caused by a 128Q tract in the context of an N-terminal huntingtin backbone. These data underscore the importance of the protein framework for modulating the effects of polyglutamine-induced neurodegeneration.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Autonoma Madrid, Dept Biol, Fac Ciencias, E-28049 Madrid, Spain	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Autonomous University of Madrid	Botas, J (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	jbotas@bcm.tmc.edu	Perez, Alma/AAG-7616-2021; Al-Ramahi, Ismael/B-4000-2017	Al-Ramahi, Ismael/0000-0002-1275-1114; Chen, Hung-Kai/0000-0002-2169-4924; de Haro, Maria/0000-0002-8654-2526; Perez, Alma/0000-0002-0746-5439; Zoghbi, Huda/0000-0002-0700-3349	NICHD NIH HHS [HD24062] Funding Source: Medline; NINDS NIH HHS [NS42179, NS27699] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042179, R56NS042179, R01NS027699, R37NS027699] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Choi JS, 2004, BIOCHEM BIOPH RES CO, V321, P574, DOI 10.1016/j.bbrc.2004.07.010; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Hatakeyama S, 2004, J NEUROCHEM, V91, P299, DOI 10.1111/j.1471-4159.2004.02713.x; Hatakeyama S, 2004, GENES CELLS, V9, P533, DOI 10.1111/j.1356-9597.2004.00742.x; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Matilla A, 1998, J NEUROSCI, V18, P5508, DOI 10.1523/JNEUROSCI.18-14-05508.1998; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Mizutani A, 2005, EMBO J, V24, P3339, DOI 10.1038/sj.emboj.7600785; Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Tsuda H, 2005, CELL, V122, P633, DOI 10.1016/j.cell.2005.06.012; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zu T, 2004, J NEUROSCI, V24, P8853, DOI 10.1523/JNEUROSCI.2978-04.2004	38	154	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26714	26724		10.1074/jbc.M601603200	http://dx.doi.org/10.1074/jbc.M601603200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831871	hybrid			2022-12-27	WOS:000240249500089
J	Cheng, NH; Liu, JZ; Brock, A; Nelsono, RS; Hirschi, KD				Cheng, Ning-Hui; Liu, Jian-Zhong; Brock, Amanda; Nelsono, Richard S.; Hirschi, Kendal D.			AtGRXcp, an Arabidopsis chloroplastic glutaredoxin, is critical for protection against protein oxidative damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRX5 MONOTHIOL GLUTAREDOXIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; H+/CA2+ ANTIPORTER; HOMOLOGY DOMAIN; PLANT-GROWTH; STRESS; THIOREDOXIN; GLUTATHIONE	Glutaredoxins (Grxs) are ubiquitous small heat-stable disulfide oxidoreductases and members of the thioredoxin (Trx) fold protein family. In bacterial, yeast, and mammalian cells, Grxs appear to be involved in maintaining cellular redox homeostasis. However, in plants, the physiological roles of Grxs have not been fully characterized. Recently, an emerging subgroup of Grxs with one cysteine residue in the putative active motif (monothiol Grxs) has been identified but not well characterized. Here we demonstrate that a plant protein, AtGRXcp, is a chloroplast-localized monothiol Grx with high similarity to yeast Grx5. In yeast expression assays, AtGRXcp localized to the mitochondria and suppressed the sensitivity of yeast grx5 cells to H2O2 and protein oxidation. AtGRXcp expression can also suppress iron accumulation and partially rescue the lysine auxotrophy of yeast grx5 cells. Analysis of the conserved monothiol motif suggests that the cysteine residue affects AtGRXcp expression and stability. In planta, AtGRXcp expression was elevated in young cotyledons, green tissues, and vascular bundles. Analysis of atgrxcp plants demonstrated defects in early seedling growth under oxidative stresses. In addition, atgrxcp lines displayed increased protein carbonylation within chloroplasts. Thus, this work describes the initial functional characterization of a plant monothiol Grx and suggests a conserved biological function in protecting cells against protein oxidative damage.	USDA ARS, Plant Physiol Grp, Childrens Nutr Res Ctr, Dept Pediat,Baylor Coll Med, Houston, TX 77030 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Noble Research Institute; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Cheng, NH (corresponding author), USDA ARS, Plant Physiol Grp, Childrens Nutr Res Ctr, Dept Pediat,Baylor Coll Med, 1100 Bates St, Houston, TX 77030 USA.	ncheng@bcm.tmc.edu	hirschi, kendal/GNP-0351-2022	Liu, Jianzhong/0000-0001-7826-7045				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; AUSUBEL F, 1996, CURRENT PROTOCOLS MO, V2, P5; Balk J, 2005, TRENDS PLANT SCI, V10, P324, DOI 10.1016/j.tplants.2005.05.002; Becamel C, 2002, EMBO J, V21, P2332, DOI 10.1093/emboj/21.10.2332; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; Buchanan BB, 2005, ANNU REV PLANT BIOL, V56, P187, DOI 10.1146/annurev.arplant.56.032604.144246; Buchanan BB, 2002, PHOTOSYNTH RES, V73, P215, DOI 10.1023/A:1020407432008; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Cheng NH, 2004, FEBS LETT, V559, P99, DOI 10.1016/S0014-5793(04)00036-5; Cheng NH, 2003, J BIOL CHEM, V278, P6503, DOI 10.1074/jbc.M210883200; Cheng NH, 2003, PLANT CELL, V15, P347, DOI 10.1105/tpc.007385; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Fernandes AP, 2005, J BIOL CHEM, V280, P24544, DOI 10.1074/jbc.M500678200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; Fladvad M, 2005, J BIOL CHEM, V280, P24553, DOI 10.1074/jbc.M500679200; Fobert PR, 2005, CURR OPIN PLANT BIOL, V8, P378, DOI 10.1016/j.pbi.2005.05.003; Foyer CH, 2005, PLANT CELL, V17, P1866, DOI 10.1105/tpc.105.033589; Gechev TS, 2005, J CELL BIOL, V168, P17, DOI 10.1083/jcb.200409170; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Havlin J.L., 1989, COMMUN SOIL SCI PLAN, V14, P969, DOI DOI 10.1080/00103628009367096; Henmi K, 2005, PLANT CELL PHYSIOL, V46, P1757, DOI 10.1093/pcp/pci198; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Isakov N, 2000, TRENDS BIOCHEM SCI, V25, P537, DOI 10.1016/S0968-0004(00)01685-6; Jablonowski D, 2001, GENETICS, V159, P1479; Job C, 2005, PLANT PHYSIOL, V138, P790, DOI 10.1104/pp.105.062778; Johansson E, 2004, J BIOL CHEM, V279, P22204, DOI 10.1074/jbc.M402652200; Lemaire SD, 2004, PHOTOSYNTH RES, V79, P305, DOI 10.1023/B:PRES.0000017174.60951.74; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lopreiato R, 2004, BIOCHEM J, V377, P395, DOI 10.1042/BJ20030638; Molina MM, 2004, J BIOL CHEM, V279, P51923, DOI 10.1074/jbc.M410219200; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Nystrom T, 2005, EMBO J, V24, P1311, DOI 10.1038/sj.emboj.7600599; Ogawa K, 2005, ANTIOXID REDOX SIGN, V7, P973, DOI 10.1089/ars.2005.7.973; Ortenberg R, 2004, P NATL ACAD SCI USA, V101, P7439, DOI 10.1073/pnas.0401965101; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rhoads DM, 2006, PLANT PHYSIOL, V141, P357, DOI 10.1104/pp.106.079129; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rouhier N, 2004, CELL MOL LIFE SCI, V61, P1266, DOI 10.1007/s00018-004-3410-y; Rouhier N, 2003, ANTIOXID REDOX SIGN, V5, P15, DOI 10.1089/152308603321223504; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Trelease RN, 1996, PROTOPLASMA, V195, P156, DOI 10.1007/BF01279194; Versaw WK, 2002, PLANT CELL, V14, P1751, DOI 10.1105/tpc.002220; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; Vranova E, 2002, J EXP BOT, V53, P1227, DOI 10.1093/jexbot/53.372.1227; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Xing SP, 2005, DEVELOPMENT, V132, P1555, DOI 10.1242/dev.01725; Yanagida M, 2004, PLANT CELL PHYSIOL, V45, P129, DOI 10.1093/pcp/pch030	57	114	121	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26280	26288		10.1074/jbc.M601354200	http://dx.doi.org/10.1074/jbc.M601354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829529	hybrid			2022-12-27	WOS:000240249500045
J	Nair, RR; Solway, J; Boyd, DD				Nair, Rajesh R.; Solway, Julian; Boyd, Douglas D.			Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA STABILITY; SQUAMOUS-CELL CARCINOMA; IN-SITU HYBRIDIZATION; HUMAN PROSTATE-CANCER; HUMAN COLON-CANCER; GENE-EXPRESSION; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; EPITHELIAL-CELLS	The 92-kDa gelatinase (MMP-9) expression is prerequisite for tissue remodeling in physiology and cancer. However, there are few known regulators of MMP-9 expression. Using an expression cloning strategy, we identified transgelin (SM22), a 22-25-kDa actin-binding protein localized to the cell membrane and cytoplasm, as a novel regulator of MMP-9 expression. Overexpression of a SM22 cDNA in HT1080 cells decreased MMP-9 mRNA/protein levels and diminished in vitro invasion of the latter rescued with exogenous MMP-9. Conversely, small interfering RNA-mediated knockdown of SM22 elevated MMP-9 synthesis, and uterus from SM22-null mice showed strong MMP-9 immunoreactivity compared with wild type animals. The ability of SM22 to repress MMP-9 expression required an intact amino terminus calponin homology domain. MMP-9 expression is driven by ERK signaling and SM22 targeted this pathway as evidenced by (a) the transience in MAPK activation and (b) blunted stimulation of the MMP-9 promoter by a constitutively active MEK expression vector. Progressive deletion analysis located the SM22 responsive region of the MMP-9 promoter to the proximal 90-bp region harboring an AP-1 motif subsequently implicated by site-directed mutagenesis. Furthermore, nuclear extract from the SM22 transfectants showed diminished c-Fos binding to this motif and SM22 expression reduced the activity of an AP-1-driven reporter by 75%. Thus, SM22 adds to a short list of repressors of MMP-9 expression, achieving this by reducing AP-1-dependent trans-activation of the gene by way of compromised ERK activation. Diminished transgelin expression in several cancers may thus partly account for the elevated MMP-9 expression evident in these tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Texas System; UTMD Anderson Cancer Center; University of Chicago	Boyd, DD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org	Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530	NATIONAL CANCER INSTITUTE [R01CA058311, R56CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Deryugina EI, 2005, CANCER RES, V65, P10959, DOI 10.1158/0008-5472.CAN-05-2228; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Fu YP, 2000, J APPL PHYSIOL, V89, P1985, DOI 10.1152/jappl.2000.89.5.1985; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Goodman A, 2003, MOL BIOL CELL, V14, P2617, DOI 10.1091/mbc.E03-01-0028; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Handsley MM, 2005, INT J CANCER, V115, P849, DOI 10.1002/ijc.20945; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Higashi N, 2004, GENES CELLS, V9, P233, DOI 10.1111/j.1356-9597.2004.00715.x; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Hua J, 1996, CANCER RES, V56, P5279; HURWITZ A, 1993, ENDOCRINOLOGY, V132, P2709, DOI 10.1210/en.132.6.2709; Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708; Jiang Y, 2002, CANCER RES, V62, P1910; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kobayashi T, 2004, J INVEST DERMATOL, V122, P278, DOI 10.1046/j.0022-202X.2004.22210.x; LaTulippe E, 2002, CANCER RES, V62, P4499; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Linn R, 1996, CYTOGENET CELL GENET, V72, P159, DOI 10.1159/000134175; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Moses MA, 1998, CANCER RES, V58, P1395; Mukhopadhyay S, 2004, J BIOL CHEM, V279, P33139, DOI 10.1074/jbc.M405194200; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nielsen BS, 1996, INT J CANCER, V65, P57, DOI 10.1002/(SICI)1097-0215(19960103)65:1<57::AID-IJC10>3.0.CO;2-F; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; PUTNINS EE, 1995, J INVEST DERMATOL, V104, P989, DOI 10.1111/1523-1747.ep12606233; PYKE C, 1993, AM J PATHOL, V142, P359; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; Sato T, 2002, CANCER RES, V62, P1025; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHAPLAND C, 1993, J CELL BIOL, V121, P1065, DOI 10.1083/jcb.121.5.1065; Shields JM, 2002, J BIOL CHEM, V277, P9790, DOI 10.1074/jbc.M110086200; Simon C, 1998, CANCER RES, V58, P1135; SOINI Y, 1994, J HISTOCHEM CYTOCHEM, V42, P945, DOI 10.1177/42.7.8014478; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; TESTA JE, 1992, CANCER RES, V52, P5597; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang H, 2004, J BIOL CHEM, V279, P22674, DOI 10.1074/jbc.M401257200; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03-0960fje; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yao PM, 1996, J BIOL CHEM, V271, P15580, DOI 10.1074/jbc.271.26.15580; Yu Q, 2000, GENE DEV, V14, P163; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103; ZUCKER S, 1993, CANCER RES, V53, P140	70	98	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26424	26436		10.1074/jbc.M602703200	http://dx.doi.org/10.1074/jbc.M602703200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835221	hybrid			2022-12-27	WOS:000240249500060
J	Jin, XS; Touhey, J; Gaudet, R				Jin, Xiangshu; Touhey, Jason; Gaudet, Rachelle			Structure of the N-terminal ankyrin repeat domain of the TRPV2 ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CAPSAICIN-RECEPTOR; VANILLOID RECEPTOR-1; CATION CHANNEL; HEAT; ARCHITECTURE; DESENSITIZATION; RECOGNITION; EXPRESSION; MICE	The TRPV ion channels mediate responses to many sensory stimuli including heat, low pH, neuropeptides, and chemical ligands. All TRPV subfamily members contain an intracellular N-terminal ankyrin repeat domain (ARD), a prevalent protein interaction motif. The 1.6-angstrom crystal structure of the TRPV2-ARD, with six ankyrin repeats, reveals several atypical structural features. Repeats one through three display unusually long and flexible fingers with a large number of exposed aromatic residues, whereas repeats five and six have unusually long outer helices. Furthermore, a large counterclockwise twist observed in the stacking of repeats four and five breaks the regularity of the domain, altering the shape of surfaces available for interactions with proteins or other cellular ligands. Both solution studies and crystal packing interactions indicate that the TRPV2-ARD does not form homo-oligomers, suggesting that the ARD of TRPV ion channels may be used for interactions with regulatory factors rather than in promoting tetrameric assembly of the ion channels.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Gaudet, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	gaudet@mcb.harvard.edu	Gaudet, Rachelle/I-4133-2014; Gaudet, Rachelle/Y-3985-2019	Gaudet, Rachelle/0000-0002-9177-054X; Gaudet, Rachelle/0000-0002-9177-054X; Jin, Xiangshu/0000-0002-6551-8850	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-15301] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barnhill JC, 2004, J CELL BIOCHEM, V91, P808, DOI 10.1002/jcb.10775; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chang Q, 2004, J BIOL CHEM, V279, P54304, DOI 10.1074/jbc.M406222200; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Cuajungco MP, 2006, J BIOL CHEM, V281, P18753, DOI 10.1074/jbc.M602452200; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; MCCLEVERTY CJ, 2006, IN PRESS PROTEIN SCI; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Mohapatra DP, 2005, J BIOL CHEM, V280, P13424, DOI 10.1074/jbc.M410917200; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy I, 2004, EUR J PHARMACOL, V500, P351, DOI 10.1016/j.ejphar.2004.07.037; Nijenhuis T, 2005, PFLUG ARCH EUR J PHY, V451, P181, DOI 10.1007/s00424-005-1430-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Stokes AJ, 2005, J CELL BIOCHEM, V94, P669, DOI 10.1002/jcb.20331; Stokes AJ, 2004, J EXP MED, V200, P137, DOI 10.1084/jem.20032082; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Zhang XM, 2005, EMBO J, V24, P4211, DOI 10.1038/sj.emboj.7600893	37	103	108	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25006	25010		10.1074/jbc.C600153200	http://dx.doi.org/10.1074/jbc.C600153200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16809337	hybrid, Green Published			2022-12-27	WOS:000240031300002
J	Linggi, B; Carpenter, G				Linggi, Bryan; Carpenter, Graham			ErbB-4s80 intracellular domain abrogates ETO2-dependent transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NUCLEAR-LOCALIZATION; GENE; DIFFERENTIATION; PROTEINS; CLEAVAGE; FRAGMENT; BREAST; ERBB4; ETO	ErbB-4 is cleaved by alpha- and gamma-secretases to release a soluble 80-kDa intracellular domain, termed s80, which translocates to the nucleus. s80 is present in the nucleus of normal and cancerous mammary cells and is predicted to have a role in cell differentiation. To further investigate the mechanism by which s80 may mediate differentiation, we tested whether s80 regulates Eto2, a transcriptional corepressor that is involved in erythrocyte differentiation and is also implicated in human breast cancer. Here we show that ligand binding to ErbB-4 causes s80 translocation to the nucleus, where it colocalizes and interacts with Eto2. Expression of s80 blocks Eto2-mediated transcriptional repression of a heterologous promoter. This effect on Eto2 does not require s80 kinase activity and is mediated by the carboxyl-terminal region of s80. Although other cell surface receptors regulate transcription by activating signal transduction cascades, these data present a novel mechanism of corepressor regulation and suggest a role for Eto2 in ErbB-4 dependent differentiation.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 647 Light Hall, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu			NCI NIH HHS [CA97456, T32 CA009582, P30 CA6845] Funding Source: Medline; NIDDK NIH HHS [P30 DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582, R01CA097456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amann JM, 2005, MOL CELL BIOL, V25, P9576, DOI 10.1128/MCB.25.21.9576-9585.2005; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hoogeveen AT, 2002, ONCOGENE, V21, P6703, DOI 10.1038/sj.onc.1205882; Jankiewicz M, 2006, MOL ENDOCRINOL, V20, P2369, DOI 10.1210/me.2006-0071; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; Kochetkova M, 2002, CANCER RES, V62, P4599; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; Takahashi S, 2004, BLOOD, V103, P4650, DOI 10.1182/blood-2003-08-2759; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Zhang LQ, 2005, EMBO J, V24, P766, DOI 10.1038/sj.emboj.7600532	31	50	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25373	25380		10.1074/jbc.M603998200	http://dx.doi.org/10.1074/jbc.M603998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16815842	hybrid			2022-12-27	WOS:000240031300039
J	Morita, YS; Sena, CBC; Waller, RF; Kurokawa, K; Sernee, MF; Nakatani, F; Haites, RE; Billman-Jacobe, H; McConville, MJ; Maeda, Y; Kinoshita, T				Morita, Yasu S.; Sena, Chubert B. C.; Waller, Ross F.; Kurokawa, Ken; Sernee, M. Fleur; Nakatani, Fumiki; Haites, Ruth E.; Billman-Jacobe, Helen; McConville, Malcolm J.; Maeda, Yusuke; Kinoshita, Taroh			PimE is a polyprenol-phosphate-mannose-dependent mannosyltransferase that transfers the fifth mannose of phosphatidylinositol mannoside in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; LIPOARABINOMANNAN BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; GPI ANCHOR; GLYCOSYLPHOSPHATIDYLINOSITOL; IDENTIFICATION; TUBERCULOSIS; SMEGMATIS; PROTEIN; GROWTH	Phosphatidylinositol mannosides (PIMs) are a major class of glycolipids in all mycobacteria. AcPIM2, a dimannosyl PIM, is both an end product and a precursor for polar PIMs, such as hexamannosyl PIM (AcPIM6) and the major cell wall lipoglycan, lipoarabinomannan (LAM). The mannosyltransferases that convert AcPIM2 to AcPIM6 or LAM are dependent on polyprenol-phosphate-mannose (PPM), but have not yet been characterized. Here, we identified a gene, termed pimE that is present in all mycobacteria, and is required for AcPIM6 biosynthesis. PimE was initially identified based on homology with eukaryotic PIG-M mannosyltransferases. PimE-deleted Mycobacterium smegmatis was defective in AcPIM6 synthesis, and accumulated the tetramannosyl PIM, AcPIM4. Loss of PimE had no affect on cell growth or viability, or the biosynthesis of other intracellular and cell wall glycans. However, changes in cell wall hydrophobicity and plasma membrane organization were detected, suggesting a role for AcPIM6 in the structural integrity of the cell wall and plasma membrane. These defects were corrected by ectopic expression of the pimE gene. Metabolic pulse-chase radiolabeling and cell-free PIM biosynthesis assays indicated that PimE catalyzes the alpha 1,2-mannosyl transfer for the AcPIM5 synthesis. Mutation of an Asp residue in PimE that is conserved in and required for the activity of human PIG-M resulted in loss of PIM-biosynthetic activity, indicating that PimE is the catalytic component. Finally, PimE was localized to a distinct membrane fraction enriched in AcPIM4-6 biosynthesis. Taken together, PimE represents the first PPM-dependent mannosyltransferase shown to be involved in PIM biosynthesis, where it mediates the fifth mannose transfer.	Osaka Univ, Dept Immunoregulat, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Univ Melbourne, Plant Cell Biol Res Ctr, Sch Bot, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Nara Inst Sci & Technol, Lab Comparat Genom, Grad Sch Informat Sci, Nara 6300192, Japan	Osaka University; University of Melbourne; University of Melbourne; University of Melbourne; Nara Institute of Science & Technology	Kinoshita, T (corresponding author), Osaka Univ, Dept Immunoregulat, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009; Waller, Ross F/D-5761-2016; Shingakujyutsu, Kurokawaken/G-1378-2011	Waller, Ross F/0000-0001-6961-9344; Sena, Chubert/0000-0002-2328-9885; Billman-Jacobe, Helen/0000-0001-5713-4657; Sernee, Marijke/0000-0002-4846-9268; Morita, Yasu/0000-0002-4514-9242				Alexander DC, 2004, J BIOL CHEM, V279, P18824, DOI 10.1074/jbc.M400791200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Billman-Jacobe H, 1999, ANTIMICROB AGENTS CH, V43, P3011, DOI 10.1128/AAC.43.12.3011; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Burguiere A, 2005, J BIOL CHEM, V280, P42124, DOI 10.1074/jbc.M507500200; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chua J, 2004, CURR OPIN MICROBIOL, V7, P71, DOI 10.1016/j.mib.2003.12.011; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; de la Salle H, 2005, SCIENCE, V310, P1321, DOI 10.1126/science.1115301; Dinadayala P, 2006, J BIOL CHEM, V281, P20027, DOI 10.1074/jbc.M603395200; Dmitriev BA, 2000, INT J MED MICROBIOL, V290, P251; Fabre AL, 2005, FEBS J, V272, P1160, DOI 10.1111/j.1742-4658.2005.04551.x; Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Haites RE, 2005, J BIOL CHEM, V280, P10981, DOI 10.1074/jbc.M413443200; HILL DL, 1966, J BIOL CHEM, V241, P895; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1111/j.1574-6968.1994.tb07194.x; Jeevarajah D, 2004, J BACTERIOL, V186, P6792, DOI 10.1128/JB.186.20.6792-6799.2004; Kang JY, 2005, J BIOL CHEM, V280, P9489, DOI 10.1074/jbc.M413867200; Kordulakova J, 2003, J BIOL CHEM, V278, P36285, DOI 10.1074/jbc.M303639200; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kovacevic S, 2006, J BIOL CHEM, V281, P9011, DOI 10.1074/jbc.M511709200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Marques MAM, 1998, INFECT IMMUN, V66, P2625, DOI 10.1128/IAI.66.6.2625-2631.1998; Morita YS, 2005, J BIOL CHEM, V280, P21645, DOI 10.1074/jbc.m414181200; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Patterson JH, 2000, J BIOL CHEM, V275, P24900, DOI 10.1074/jbc.M000147200; Patterson JH, 2003, BIOCHEM J, V372, P77, DOI 10.1042/BJ20021700; ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; Taron BW, 2004, J BIOL CHEM, V279, P36083, DOI 10.1074/jbc.M405081200; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	54	100	107	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25143	25155		10.1074/jbc.M604214200	http://dx.doi.org/10.1074/jbc.M604214200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803893	hybrid			2022-12-27	WOS:000240031300015
J	Seyit, G; Rockel, B; Baumeister, W; Peters, J				Seyit, Goenuel; Rockel, Beate; Baumeister, Wolfgang; Peters, Juergen			Size matters for the tripeptidylpeptidase II complex from Drosophila - The 6-MDa spindle form stabilizes the activated state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALOVIRUS PROTEASE; PEPTIDASE-II; CRYSTAL-STRUCTURE; ELECTRON-MICROSCOPY; SERINE-PROTEASE; ENZYME-ACTIVITY; GIANT PROTEASE; DEGRADATION; SPECIFICITY; AMINOPEPTIDASE	Tripeptidylpeptidase II (TPP II) is an exopeptidase of the subtilisin type of serine proteases, a key component of the protein degradation cascade in many eukaryotes, which cleaves tripeptides from the N terminus of proteasome-released products. The Drosophila TPP II is a large homooligomeric complex (similar to 6 MDa) that is organized in a unique repetitive structure with two strands each composed of ten stacked homodimers; two strands intertwine to form a spindle-shaped structure. We report a novel procedure of preparing an active, structurally homogeneous TPP II holo-complex overexpressed in Escherichia coli. Assembly studies revealed that the specific activity of TPP II increases with oligomer size, which in turn is strongly concentration-dependent. At a TPP II concentration such as prevailing in Drosophila, equilibration of size and activity proceeds on a time scale of hours and leads to spindle formation at a TPP II concentration of >= 0.03 mg/ml. Before equilibrium is reached, activation lags behind assembly, suggesting that activation occurs in a two-step process consisting of (i) assembly and (ii) a subsequent conformational change leading to a switch from basal to full activity. We propose a model consistent with the hyperbolic increase of activity with oligomer size. Spindle formation by strand pairing causes both significant thermodynamic and kinetic stabilization. The strands inherently heterogeneous in length are thus locked into a discrete oligomeric state. Our data indicate that the unique spindle form of the holo-complex represents an assembly motif stabilizing a highly active state.	Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany	Max Planck Society	Peters, J (corresponding author), Max Planck Inst Biochem, Dept Mol Struct Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	Peters@biochem.mpg.de						BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Book AJ, 2005, PLANT PHYSIOL, V138, P1046, DOI 10.1104/pp.104.057406; Borissenko L, 2005, J MOL BIOL, V346, P1207, DOI 10.1016/j.jmb.2004.12.056; CHANDU D, 2002, APPL GENOM PROTEOM, V1, P235; Ciszak EM, 2003, J BIOL CHEM, V278, P21240, DOI 10.1074/jbc.M300339200; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; EGAN RM, 1981, J BIOL CHEM, V256, P4877; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; HARRIS JR, 1990, MICRON MICROSC ACTA, V21, P77, DOI 10.1016/0739-6260(90)90008-4; Hasselgren PO, 2002, BIOCHEM BIOPH RES CO, V290, P1, DOI 10.1006/bbrc.2001.5849; Hilbi H, 2000, INFECT IMMUN, V68, P5502, DOI 10.1128/IAI.68.10.5502-5508.2000; Hong X, 2003, J EXP MED, V197, P1731, DOI 10.1084/jem.20020801; Levy F, 2002, J IMMUNOL, V169, P4161, DOI 10.4049/jimmunol.169.8.4161; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; Mayr J, 1996, CURR BIOL, V6, P739, DOI 10.1016/S0960-9822(09)00455-2; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Pettit SC, 2003, J VIROL, V77, P366, DOI 10.1128/JVI.77.1.366-374.2003; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; Princiotta MF, 2001, P NATL ACAD SCI USA, V98, P513, DOI 10.1073/pnas.021132398; Ray K, 2004, J BIOL CHEM, V279, P20480, DOI 10.1074/jbc.M400795200; Reits E, 2004, IMMUNITY, V20, P495, DOI 10.1016/S1074-7613(04)00074-3; Renn SCP, 1998, J BIOL CHEM, V273, P19173, DOI 10.1074/jbc.273.30.19173; Rockel B, 2005, P NATL ACAD SCI USA, V102, P10135, DOI 10.1073/pnas.0504569102; Rockel B, 2002, EMBO J, V21, P5979, DOI 10.1093/emboj/cdf601; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Shieh HS, 1996, NATURE, V383, P279, DOI 10.1038/383279a0; Snoussi K, 2005, BIOPHYS J, V88, P2855, DOI 10.1529/biophysj.104.055871; Tomkinson B, 2005, INT J BIOCHEM CELL B, V37, P1933, DOI 10.1016/j.biocel.2005.02.009; Tomkinson B, 2000, ARCH BIOCHEM BIOPHYS, V376, P275, DOI 10.1006/abbi.2000.1713; Tomkinson B, 2002, EUR J BIOCHEM, V269, P1438, DOI 10.1046/j.1432-1033.2002.02783.x; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Voorhorst WGB, 1996, J BIOL CHEM, V271, P20426, DOI 10.1074/jbc.271.34.20426; Walz J, 1997, MOL CELL, V1, P59, DOI 10.1016/S1097-2765(00)80007-6; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Warburton MJ, 2002, NEUROSCI LETT, V331, P99, DOI 10.1016/S0304-3940(02)00841-8; Wray CJ, 2002, BIOCHEM BIOPH RES CO, V296, P41, DOI 10.1016/S0006-291X(02)00834-3	43	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25723	25733		10.1074/jbc.M602722200	http://dx.doi.org/10.1074/jbc.M602722200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16799156	hybrid			2022-12-27	WOS:000240031300075
J	Yaar, M; Wu, C; Park, HY; Panova, I; Schutz, G; Gilchrest, BA				Yaar, Mina; Wu, Christina; Park, Hee-Young; Panova, Izabela; Schutz, Gunther; Gilchrest, Barbara A.			Bone morphogenetic protein-4, a novel modulator of melanogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MOUSE MELANOMA-CELLS; GROWTH-FACTOR; HUMAN MELANOCYTES; DNA-DAMAGE; TRANSCRIPTION FACTORS; ULTRAVIOLET-LIGHT; TYROSINASE GENE; HUMAN-SKIN; PROLIFERATION	Bone morphogenetic proteins (BMPs), members of the transforming growth factor-beta family, signal in many cells including neural precursors. Two receptors, types 1 and 2, coordinately mediate BMP signaling, and type 1 receptor has two forms: A and B. Using RT-PCR we found that neural crest-derived human melanocytes express BMP receptor-1A, -1B, and -2. Furthermore, melanocytes and the surrounding keratinocytes express BMP-4, suggesting both autocrine and paracrine effects of this molecule. Moreover, BMP-4 supplementation of cultured human melanocytes decreases melanin synthesis, tyrosinase mRNA, and protein. The mechanism of this BMP-4 effect on tyrosinase and ultimately on melanogenesis involves modest decreases of tyrosinase transcription rate and mRNA stability. Moreover, ultraviolet irradiation, the best recognized environmental stimulator of melanogenesis, down-regulated the mRNA of BMP receptor-1B in melanocytes. Our data provide evidence of a novel regulatory pathway for melanogenesis in human skin.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, J-508,609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu		Park, Hee-Young/0000-0001-8981-6484				BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BHARDWAJ RS, 1994, ARCH DERMATOL RES, V287, P85, DOI 10.1007/BF00370724; Bilodeau ML, 2001, PIGM CELL RES, V14, P328, DOI 10.1034/j.1600-0749.2001.140504.x; Botchkarev VA, 2003, J INVEST DERMATOL, V120, P36, DOI 10.1046/j.1523-1747.2003.12002.x; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GILCHREST BA, 1979, J INVEST DERMATOL, V72, P219, DOI 10.1111/1523-1747.ep12530769; GILCHREST BA, 1985, IN VITRO CELL DEV B, V21, P114; Graham A, 1996, MOL CELL NEUROSCI, V8, P76, DOI 10.1006/mcne.1996.0046; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; HALABAN R, 1988, ANN NY ACAD SCI, V548, P180, DOI 10.1111/j.1749-6632.1988.tb18805.x; Halaban R, 2003, FITZPATRICKS DERMATO, V1, P127; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671; Imokawa G, 2004, PIGM CELL RES, V17, P96, DOI 10.1111/j.1600-0749.2003.00126.x; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; KLUPPEL M, 1991, P NATL ACAD SCI USA, V88, P3777, DOI 10.1073/pnas.88.9.3777; Krishnan V, 2001, ENDOCRINOLOGY, V142, P940, DOI 10.1210/en.142.2.940; Li H, 1998, ENDOCRINOLOGY, V139, P3855, DOI 10.1210/en.139.9.3855; Li WW, 1998, J NEUROSCI, V18, P8853; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Martinez-Esparza M, 2001, INT J BIOCHEM CELL B, V33, P971, DOI 10.1016/S1357-2725(01)00068-1; MartinezEsparza M, 1997, J BIOL CHEM, V272, P3967, DOI 10.1074/jbc.272.7.3967; Mehler MF, 2000, DEV NEUROSCI-BASEL, V22, P74, DOI 10.1159/000017429; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Mohan RR, 1998, INVEST OPHTH VIS SCI, V39, P2626; MORELLI JG, 1993, J INVEST DERMATOL, V100, pS191; NORDLUND JJ, 1986, J INVEST DERMATOL, V86, P433, DOI 10.1111/1523-1747.ep12285717; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Park HY, 1999, J BIOL CHEM, V274, P16470, DOI 10.1074/jbc.274.23.16470; POMERANTZ SH, 1964, BIOCHEM BIOPH RES CO, V16, P188, DOI 10.1016/0006-291X(64)90359-6; Reinartz J, 1996, EXP CELL RES, V228, P334, DOI 10.1006/excr.1996.0333; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; Sharov AA, 2005, P NATL ACAD SCI USA, V102, P93, DOI 10.1073/pnas.0408455102; STIERNER U, 1988, PHOTODERMATOLOGY, V5, P218; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; SWOPE VB, 1994, J INVEST DERMATOL, V102, P749, DOI 10.1111/1523-1747.ep12376970; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Verdier-Sevain S, 2004, FASEB J, V18, P1252, DOI 10.1096/fj.03-1088fje; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAAR M, 1993, CLIN RES, V41, pA486, DOI 10.1006/excr.1993.1143; Yoshida K, 2004, ONCOGENE, V23, P6250, DOI 10.1038/sj.onc.1207829; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhao HC, 2000, CANCER RES, V60, P6276	56	30	32	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25307	25314		10.1074/jbc.M600580200	http://dx.doi.org/10.1074/jbc.M600580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16837459	hybrid			2022-12-27	WOS:000240031300032
J	Reynolds, PA; Sigaroudinia, M; Zardo, G; Wilson, MB; Benton, GM; Miller, CJ; Hong, CB; Fridlyand, J; Costello, JF; Tlsty, TD				Reynolds, Paul A.; Sigaroudinia, Mahvash; Zardo, Giuseppe; Wilson, Matthew B.; Benton, Geoffrey M.; Miller, Caroline J.; Hong, Chibo; Fridlyand, Jane; Costello, Joseph F.; Tlsty, Thea D.			Tumor suppressor p16(INK4A) regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN EZH2; P16 EXPRESSION; SELF-RENEWAL; METHYLATION; CANCER; GENE; GROWTH; SENESCENCE; RECEPTOR; TARGET	Alterations in DNA methylation are important in cancer, but the acquisition of these alterations is poorly understood. Using an unbiased global screen for CpG island methylation events, we have identified a non-random pattern of DNA hypermethylation acquired in p16-repressed cells. Interestingly, this pattern included loci located upstream of a number of homeobox genes. Upon removal of p16(INK4A) activity in primary human mammary epithelial cells, polycomb repressors, EZH2 and SUZ12, are upregulated and recruited to HOXA9, a locus expressed during normal breast development and epigenetically silenced in breast cancer. We demonstrate that at this targeted locus, the up-regulation of polycomb repressors is accompanied by the recruitment of DNA methyltransferases and the hypermethylation of DNA, an endpoint, which we show to be dependent on SUZ12 expression. These results demonstrate a causal role of p16INK4A disruption in modulating DNA hypermethylation, and identify a dynamic and active process whereby epigenetic modulation of gene expression is activated as an early event in breast tumor progression.	Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tlsty, TD (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW501, San Francisco, CA 94143 USA.	thea.tlsty@ucsf.edu		Reynolds, Paul/0000-0001-8738-1245	NCI NIH HHS [R01 CA97214, P50 CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, R01CA097214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664; Belinsky SA, 2002, CANCER RES, V62, P2370; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2002, NAT GENET, V31, P123, DOI 10.1038/ng0602-123; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Felsenfeld G, 2004, COLD SPRING HARB SYM, V69, P245, DOI 10.1101/sqb.2004.69.245; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gadd M, 2001, CANCER RES, V61, P8811; Gauthier ML, 2005, CANCER RES, V65, P1792, DOI 10.1158/0008-5472.CAN-04-3507; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holst CR, 2003, CANCER RES, V63, P1596; Huschtscha LI, 1998, CANCER RES, V58, P3508; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim MH, 1998, DNA CELL BIOL, V17, P407, DOI 10.1089/dna.1998.17.407; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Meluh PB, 1999, METHOD ENZYMOL, V304, P414; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nikolova Z, 1998, J CELL SCI, V111, P2741; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shim YH, 2003, MODERN PATHOL, V16, P430, DOI 10.1097/01.mp.0000066799.99032.A7; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f; UNGER MA, 2002, THESIS U PENNSYLVANI; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Westfall P.H., 1993, RESAMPLING BASED MUL; Wong DJ, 2001, CANCER RES, V61, P8284	58	103	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24790	24802		10.1074/jbc.M604175200	http://dx.doi.org/10.1074/jbc.M604175200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16766534	Green Published, hybrid			2022-12-27	WOS:000239847800075
J	Schug, ZT; Joseph, SK				Schug, Zachary T.; Joseph, Suresh K.			The role of the S4-S5 linker and C-terminal tail in inositol 1,4,5-trisphosphate receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL RYANODINE RECEPTOR; LIGAND-BINDING; POTASSIUM CHANNELS; K+ CHANNEL; CRYSTAL-STRUCTURE; ACTIVATION GATE; FAMILY; DOMAIN; CA2+; OLIGOMERIZATION	In previous studies we have suggested that spatial proximity of the C- and N-terminal domains of inositol 1,4,5-trisphosphate receptors (IP3Rs) may be critical for the channel gating mechanism. In the present study we have examined the sites of C-N interaction in more detail. We report that deletion mutations within the S4-S5 linker (amino acids 2418-2437) prevent co-immunoprecipitation of the C- and N-terminal domains, inhibit channel activity and enhance IP3 binding. We also show that a region of the C- terminal tail (amino acids 2694-2721), predicted to be a coiled-coil, is also required for channel activity. Circular dichroism spectroscopy and gel filtration studies confirm that this region has a helical structure with the ability to form tetramers. We propose a model in which IP3-induced conformational changes in the N-terminal domain are mechanically transmitted to the opening of the pore through an attachment to the S4-S5 linker. The coiled-coil domain in the C- terminal tail may play a critical role in maintaining the structural integrity of the channel.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sch Med, Philadelphia, PA 19107 USA	Jefferson University	Joseph, SK (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sch Med, 1020 Locust St,JAH 230A, Philadelphia, PA 19107 USA.	suresh.joseph@mail.tju.edu		Schug, Zachary/0000-0003-4197-8227	NIAAA NIH HHS [T32-AA07463] Funding Source: Medline; NIDDK NIH HHS [R01-DK34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Choy N, 2003, J MOL BIOL, V334, P527, DOI 10.1016/j.jmb.2003.09.059; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Decher N, 2004, J BIOL CHEM, V279, P13859, DOI 10.1074/jbc.M313704200; Engeland B, 1998, J PHYSIOL-LONDON, V513, P647, DOI 10.1111/j.1469-7793.1998.647ba.x; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Galvan DL, 2002, J BIOL CHEM, V277, P48248, DOI 10.1074/jbc.M209990200; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Joseph SK, 2005, CELL CALCIUM, V38, P539, DOI 10.1016/j.ceca.2005.07.007; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Kuo AL, 2005, STRUCTURE, V13, P1463, DOI 10.1016/j.str.2005.07.011; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Stewart R, 2003, BIOCHEM J, V376, P795, DOI 10.1042/BJ20030597; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; Varnai P, 2005, P NATL ACAD SCI USA, V102, P7859, DOI 10.1073/pnas.0407535102; Wang RW, 2004, J BIOL CHEM, V279, P3635, DOI 10.1074/jbc.M311367200; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316	46	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24431	24440		10.1074/jbc.M604190200	http://dx.doi.org/10.1074/jbc.M604190200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16815846	hybrid			2022-12-27	WOS:000239847800037
J	Wally, J; Halbrooks, PJ; Vonrhein, C; Rould, MA; Everse, SJ; Mason, AB; Buchanan, SK				Wally, Jeremy; Halbrooks, Peter J.; Vonrhein, Clemens; Rould, Mark A.; Everse, Stephen J.; Mason, Anne B.; Buchanan, Susan K.			The crystal structure of iron-free human serum transferrin provides insight into inter-lobe communication and receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGE; CARBOXYL-TERMINAL LOBES; C-LOBE; N-LOBE; ANION-BINDING; DUCK OVOTRANSFERRIN; MUTATIONAL ANALYSIS; HEN OVOTRANSFERRIN; HUMAN LACTOFERRIN; RELEASE	Serum transferrin reversibly binds iron in each of two lobes and delivers it to cells by a receptor-mediated, pH-dependent process. The binding and release of iron result in a large conformational change in which two subdomains in each lobe close or open with a rigid twisting motion around a hinge. We report the structure of human serum transferrin (hTF) lacking iron (apo-hTF), which was independently determined by two methods: 1) the crystal structure of recombinant non-glycosylated apo-hTF was solved at 2.7-angstrom resolution using a multiple wavelength anomalous dispersion phasing strategy, by substituting the nine methionines in hTF with selenomethionine and 2) the structure of glycosylated apo-hTF (isolated from serum) was determined to a resolution of 2.7 angstrom by molecular replacement using the human apo-N-lobe and the rabbit holo-C1-subdomain as search models. These two crystal structures are essentially identical. They represent the first published model for full-length human transferrin and reveal that, in contrast to family members (human lactoferrin and hen ovotransferrin), both lobes are almost equally open: 59.4 degrees and 49.5 degrees rotations are required to open the N- and C-lobes, respectively (compared with closed pig TF). Availability of this structure is critical to a complete understanding of the metal binding properties of each lobe of hTF; the apo-hTF structure suggests that differences in the hinge regions of the N- and C-lobes may influence the rates of iron binding and release. In addition, we evaluate potential interactions between apo-hTF and the human transferrin receptor.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Global Phasing Ltd, Cambridge CB3 0AX, England; Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Vermont; Global Phasing Limited; University of Vermont	Buchanan, SK (corresponding author), NIDDK, Mol Biol Lab, NIH, 50 S Dr,Rm 4503, Bethesda, MD 20892 USA.	skbuchan@helix.nih.gov	Mason, Anne B/A-6754-2008		Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [R01 DK21739, Z01 DK011003-04, R01 DK021739] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011003, Z01DK036143, R01DK021739] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdallah FB, 2000, J MOL BIOL, V303, P255, DOI 10.1006/jmbi.2000.4101; Abdallah FB, 1999, EUR J BIOCHEM, V263, P912, DOI 10.1046/j.1432-1327.1999.00596.x; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams TE, 2003, J BIOL CHEM, V278, P6027, DOI 10.1074/jbc.M210349200; AISEN P, 1978, J BIOL CHEM, V253, P1930; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Baker EN, 2002, BIOCHEM CELL BIOL, V80, P27, DOI 10.1139/o01-153; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BALDWIN DA, 1982, BIOCHIM BIOPHYS ACTA, V719, P140, DOI 10.1016/0304-4165(82)90317-8; BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BALI PK, 1992, BIOCHEMISTRY-US, V31, P3963, DOI 10.1021/bi00131a011; BATES GW, 1967, J BIOL CHEM, V242, P2810; Beatty EJ, 1996, BIOCHEMISTRY-US, V35, P7635, DOI 10.1021/bi960684g; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAHINE JME, 1994, EUR J BIOCHEM, V223, P581; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Cheng YF, 2005, J STRUCT BIOL, V152, P204, DOI 10.1016/j.jsb.2005.10.006; DAY CL, 1992, J BIOL CHEM, V267, P13857; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; EVANS RW, 1994, BIOCHEMISTRY-US, V33, P12512, DOI 10.1021/bi00207a019; Giannetti AM, 2005, STRUCTURE, V13, P1613, DOI 10.1016/j.str.2005.07.016; Giannetti AM, 2003, PLOS BIOL, V1, P341, DOI 10.1371/journal.pbio.0000051; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guha Thakurta Piyali, 2003, Acta Crystallogr D Biol Crystallogr, V59, P1773, DOI 10.1107/S0907444903016652; Gumerov DR, 2003, BIOCHEMISTRY-US, V42, P5421, DOI 10.1021/bi020660b; Halbrooks PJ, 2005, BIOCHEMISTRY-US, V44, P15451, DOI 10.1021/bi0518693; Halbrooks PJ, 2003, BIOCHEMISTRY-US, V42, P3701, DOI 10.1021/bi027071q; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Hamilton DH, 2004, J BIOL INORG CHEM, V9, P936, DOI 10.1007/s00775-004-0592-6; HARRIS DC, 1989, IRON CARRIERS IRON P, P241; Harris WR, 2003, INORG CHEM, V42, P5880, DOI 10.1021/ic034009o; Harris WR, 2003, INORG CHEM, V42, P3262, DOI 10.1021/ic026027w; He QY, 2000, BIOCHEM J, V350, P909, DOI 10.1042/0264-6021:3500909; He QY, 1999, BIOCHEMISTRY-US, V38, P9704, DOI 10.1021/bi990134t; HE QY, 2002, MOL CELLULAR IRON TR, P95; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Khan JA, 2001, J MOL BIOL, V309, P751, DOI 10.1006/jmbi.2001.4692; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kurokawa H, 1999, J BIOL CHEM, V274, P28445, DOI 10.1074/jbc.274.40.28445; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; KUROKAWA H, 1994, J BIOL CHEM, V269, P6671; Lambert LA, 2005, COMP BIOCHEM PHYS B, V142, P129, DOI 10.1016/j.cbpb.2005.07.007; Lambert LA, 2005, COMP BIOCHEM PHYS B, V140, P11, DOI 10.1016/j.cbpc.2004.09.012; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESTAS AN, 1976, BRIT J HAEMATOL, V32, P341, DOI 10.1111/j.1365-2141.1976.tb00937.x; LIN LN, 1991, BIOCHEMISTRY-US, V30, P11660, DOI 10.1021/bi00114a008; LIN LN, 1994, BIOCHEMISTRY-US, V33, P1881, DOI 10.1021/bi00173a035; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; MARQUES HM, 1991, INORG CHEM, V30, P3758, DOI 10.1021/ic00019a037; MASON AB, 1993, BIOCHEMISTRY-US, V32, P5472, DOI 10.1021/bi00071a025; Mason AB, 2005, BIOCHEMISTRY-US, V44, P8013, DOI 10.1021/bi050015f; Mason AB, 2004, PROTEIN EXPRES PURIF, V36, P318, DOI 10.1016/j.pep.2004.04.013; Mason AB, 2002, BIOCHEMISTRY-US, V41, P9448, DOI 10.1021/bi025927l; Mason AB, 1998, BIOCHEM J, V330, P35; Mason AB, 2001, PROTEIN EXPRES PURIF, V23, P142, DOI 10.1006/prep.2001.1480; Mason AB, 1997, BIOCHEM J, V326, P77, DOI 10.1042/bj3260077; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Okamoto I, 2004, BIOCHEMISTRY-US, V43, P11118, DOI 10.1021/bi049147j; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENHALLOW RC, 1986, J CELL PHYSIOL, V128, P251, DOI 10.1002/jcp.1041280217; PRINCIOTTO JV, 1975, NATURE, V255, P87, DOI 10.1038/255087a0; Rawas A, 1996, ACTA CRYSTALLOGR D, V52, P631, DOI 10.1107/S0907444996000212; Rawas A, 1997, ACTA CRYSTALLOGR D, V53, P464, DOI 10.1107/S0907444997000838; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Teh EM, 2005, FEBS J, V272, P6344, DOI 10.1111/j.1742-4658.2005.05028.x; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; VONRHEIN C, 2006, CRYSTALLOGRAPHIC MET, P215; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Ward PP, 1996, J BIOL CHEM, V271, P12790, DOI 10.1074/jbc.271.22.12790; WILLIAMS J, 1978, BIOCHEM J, V173, P535, DOI 10.1042/bj1730533; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu GZ, 2005, MOL CELL PROTEOMICS, V4, P1959, DOI 10.1074/mcp.M500095-MCP200; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505; YOUNG SP, 1990, BIOCHEM J, V265, P587, DOI 10.1042/bj2650587; Zak O, 2003, BIOCHEMISTRY-US, V42, P12330, DOI 10.1021/bi034991f; Zak O, 2002, BIOCHEMISTRY-US, V41, P7416, DOI 10.1021/bi0160258; Zak O, 1997, BIOCHEMISTRY-US, V36, P11036, DOI 10.1021/bi970628v; Zuccola H. J., 1993, CRYSTAL STRUCTURE MO	89	192	196	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24934	24944		10.1074/jbc.M604592200	http://dx.doi.org/10.1074/jbc.M604592200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793765	Green Accepted, hybrid			2022-12-27	WOS:000239847800086
J	Wang, LY; Hinoi, E; Takemori, A; Nakamichi, N; Yoneda, Y				Wang, Liyang; Hinoi, Eiichi; Takemori, Akihiro; Nakamichi, Noritaka; Yoneda, Yukio			Glutamate inhibits chondral mineralization through apoptotic cell death mediated by retrograde operation of the cystine/glutamate antiporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; HORMONE-RELATED PEPTIDE; FUNCTIONAL EXPRESSION; HUMAN OSTEOARTHRITIS; CHONDROCYTE DEATH; RODENT CARTILAGE; PLASMA-MEMBRANE; RAT; RECEPTORS; ARTHRITIS	Although we have previously demonstrated the functional significance of excitatory amino acid transporters as well as glutamate (Glu) receptors (GluRs) expressed by chondrocytes, little attention has been paid to the possible expression of the cystine/Glu antiporter responsible for the bi-directional transmembrane transport of Glu in chondrocytes to date. In organotypic cultured mouse embryonic metatarsals isolated before vascularization, the chondral mineralization was significantly decreased in the presence of Glu at a high concentration. Apoptotic cells were detected within the late proliferating and prehypertrophic chondrocytic layers in metatarsals cultured in the presence of Glu. A group III metabotropic GluR (mGluR) antagonist partially, but significantly, prevented the inhibition of mineralization by Glu in metatarsals without affecting the number of apoptotic cells. Both decreased mineralization and apoptosis by Glu were significantly prevented by the addition of the cystine/Glu antiporter inhibitor homocysteic acid, as well as reduced glutathione (GSH) and cystine. Expression of mRNA for xCT and 4F2hc subunits, which are components of the cystine/Glu antiporter, was seen in both cultured mouse metatarsals and rat costal chondrocytes. In chondrocytes cultured with Glu, a significant decrease was seen in intracellular GSH levels, together with increases in the number of apoptotic cells and the level of intracellular reactive oxygen species. These results suggest that Glu could regulate chondrogenic differentiation toward mineralization through a mechanism associated with apoptosis mediated by the depletion of intracellular GSH after the retrograde operation of the cystine/ Glu antiporter, in addition to the activation of group III mGluR, in chondrocytes.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Lab Mol Pharmacol, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Yoneda, Y (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Lab Mol Pharmacol, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan.	yyoneda@p.kanazawa-u.ac.jp	Nakamichi, Noritaka/D-8403-2015; Nakamichi, Noritaka/AAB-7388-2020; Yoneda, Yukio/ABI-1864-2020	Nakamichi, Noritaka/0000-0002-0283-3546; Yoneda, Yukio/0000-0002-4624-177X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Genever PG, 2001, FASEB J, V15, P1586, DOI 10.1096/fj.00-0594fje; Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534-5807(02)00218-6; Haaijman A, 1999, BONE, V25, P397, DOI 10.1016/S8756-3282(99)00189-1; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; Heraud F, 2000, ANN RHEUM DIS, V59, P959, DOI 10.1136/ard.59.12.959; HERLIN PM, 1982, J NEUROCHEM, V38, P1170, DOI 10.1111/j.1471-4159.1982.tb05367.x; Hinoi E, 2005, BIOCHEM PHARMACOL, V70, P1744, DOI 10.1016/j.bcp.2005.09.010; Hinoi E, 2005, BIOCHEM PHARMACOL, V70, P70, DOI 10.1016/j.bcp.2005.04.025; Hinoi E, 2004, EUR J BIOCHEM, V271, P1, DOI 10.1046/j.1432-1033.2003.03907.x; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; Kim HA, 1999, ARTHRITIS RHEUM, V42, P1528, DOI 10.1002/1529-0131(199907)42:7<1528::AID-ANR28>3.0.CO;2-9; Kim HA, 2000, J RHEUMATOL, V27, P455; KLEMENT BJ, 1993, J EXP ZOOL, V265, P285, DOI 10.1002/jez.1402650309; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lawand NB, 2000, PAIN, V86, P69, DOI 10.1016/S0304-3959(99)00311-5; Lawand NB, 1997, EUR J PHARMACOL, V324, P169, DOI 10.1016/S0014-2999(97)00072-1; MacLean HE, 2004, J CLIN INVEST, V113, P1334, DOI 10.1172/JCI200421252; McNearney T, 2000, J RHEUMATOL, V27, P739; Moriguchi N, 2006, HISTOL HISTOPATHOL, V21, P969, DOI 10.14670/HH-21.969; PLAITAKIS A, 1982, SCIENCE, V216, P193, DOI 10.1126/science.6121377; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang LY, 2005, BRIT J PHARMACOL, V146, P732, DOI 10.1038/sj.bjp.0706358; Wang LY, 2005, BIOL PHARM BULL, V28, P990, DOI 10.1248/bpb.28.990; Yoneda Y, 2001, PROG NEUROBIOL, V63, P697, DOI 10.1016/S0301-0082(00)00036-8	35	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24553	24565		10.1074/jbc.M600939200	http://dx.doi.org/10.1074/jbc.M600939200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790444	hybrid			2022-12-27	WOS:000239847800051
J	Wu, Q; Chen, X; Zhang, JQ; Loh, YH; Low, TY; Zhang, WW; Zhang, WS; Sze, SK; Lim, B; Ng, HH				Wu, Qiang; Chen, Xi; Zhang, Jinqiu; Loh, Yuin-Han; Low, Teck-Yew; Zhang, Weiwei; Zhang, Wensheng; Sze, Siu-Kwan; Lim, Bing; Ng, Huck-Hui			Sall4 interacts with nanog and co-occupies nanog genomic sites in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-OCULAR SYNDROME; OKIHIRO-SYNDROME; TRANSCRIPTIONAL REGULATION; PLURIPOTENCY; EXPRESSION; MUTATIONS; OCT4; SOX2; DIFFERENTIATION; CLONING	Embryonic stem (ES) cells are pluripotent cells with self-renewing property. Nanogis a homeobox transcription factor required to maintain ES cells in a non-differentiated state. Using affinity purification coupled to liquid chromatography-tandem mass spectrometry analysis, we identified Sall4 as a Nanog co-purified protein. Co-immunoprecipitation and glutathione S-transferase pulldown experiments confirmed the interaction between Nanog and Sall4. We showed that Nanog and Sall4 co-occupied Nanog and Sall4 enhancer regions in living ES cells. Knockdown of Nanog or Sall4 by RNA interference led to a reduction in Nanog and Sall4 enhancer activities, providing evidence that these factors are positively regulating these enhancers. Importantly, co-transfection of Sall4 with these ES cell-specific enhancers led to transactivation in heterologous somatic cells. Chromatin immunoprecipitation experiments also showed that Sall4 co-occupied many Nanog binding sites in ES cells. Our data implicate Sall4 as an important component of the transcription regulatory networks in ES cells by cooperating with Nanog. We suggest that Sall4 and Nanog form a regulatory circuit similar to that of Oct4 and Sox2. This study highlights the extensive regulatory loops connecting genes, which encode for key transcription factors in ES cells.	Genome Inst Singapore, Gene Regulat Lab, Singapore 138672, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Ng, HH (corresponding author), Genome Inst Singapore, Gene Regulat Lab, 60 Biopolis St,02-01,Genome Bldg, Singapore 138672, Singapore.	nghh@gis.a-star.edu.sg	Low, Teck Yew/J-4403-2014; Chen, Xi/C-6889-2012; Ng, Huck Hui/A-1135-2009; Loh, Yuin-Han/E-1096-2014; Low, Teck Yew/Q-5946-2019; Sze, Siu Kwan/AAO-3342-2020; Sze, Siu_kwan Newman/A-2199-2011	Low, Teck Yew/0000-0001-7878-7534; Loh, Yuin-Han/0000-0002-4715-6454; Low, Teck Yew/0000-0001-7878-7534; Sze, Siu Kwan/0000-0002-5652-1687; Sze, Siu_kwan Newman/0000-0002-5652-1687; Wu, Qiang/0000-0003-2049-1639; NG, HUCK HUI/0000-0001-6352-8417; Chen, Xi/0000-0002-7995-6202				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Kohlhase J, 2002, HUM MOL GENET, V11, P2979, DOI 10.1093/hmg/11.23.2979; Kohlhase J, 2005, HUM MUTAT, V26, P176, DOI 10.1002/humu.20215; Kohlhase J, 2002, CYTOGENET GENOME RES, V98, P274, DOI 10.1159/000071048; Kohlhase J, 2003, J MED GENET, V40, P473, DOI 10.1136/jmg.40.7.473; Koshiba-Takeuchi K, 2006, NAT GENET, V38, P175, DOI 10.1038/ng1707; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Yoshikawa T, 2006, GENE EXPR PATTERNS, V6, P213, DOI 10.1016/j.modgep.2005.06.003	21	224	246	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24090	24094		10.1074/jbc.C600122200	http://dx.doi.org/10.1074/jbc.C600122200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16840789	hybrid			2022-12-27	WOS:000239847800003
J	Sethi, G; Ahn, KS; Sandur, SK; Lin, X; Chaturvedi, MM; Aggarwal, BB				Sethi, Gautam; Ahn, Kwang Seok; Sandur, Santosh K.; Lin, Xin; Chaturvedi, Madan M.; Aggarwal, Bharat B.			Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ALPHA KINASE; P65 PHOSPHORYLATION; DOWN-REGULATION; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; TNF-ALPHA; ACTIVATION; INHIBITOR; INDUCTION	Although indirubin is known to exhibit anti-cancer and antiinflammatory activities, very little is known about its mechanism of action. In this study, we investigated whether indirubin mediates its effects through interference with the NF-kappa B pathway. As examined by the DNA binding of NF-kappa B, we found that indirubin suppressed tumor necrosis factor (TNF)-induced NF-kappa B activation in a dose-and time-dependent manner. Indirubin also suppressed the NF-kappa B activation induced by various inflammatory agents and carcinogens. Further studies showed that indirubin blocked the phosphorylation and degradation of I kappa B alpha through the inhibition of activation of I kappa B alpha kinase and phosphorylation and nuclear translocation of p65. NF-kappa B reporter activity induced by TNFR1, TNF receptor-associated death domain, TRAF2, TAK1, NF-kappa B-inducing kinase, and IKK beta was inhibited by indirubin but not that induced by p65 transfection. We also found that indirubin inhibited the expression of NF-kappa B-regulated gene products involved in antiapoptosis (IAP1, IAP2, Bcl-2, Bcl-x(L), and TRAF1), proliferation (cyclin D1 and c-Myc), and invasion (COX-2 and MMP-9). This correlated with enhancement of the apoptosis induced by TNF and the chemotherapeutic agent taxol in human leukemic KBM-5 cells. Indirubin also suppressed cytokine-induced cellular invasion. Overall, our results indicate that anti-cancer and anti-inflammatory activities previously assigned to indirubin may be mediated in part through the suppression of the NF-kappa B activation pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Sethi, Gautam/F-2372-2011; Ahn, Kwang Seok/G-4249-2013; Aggarwal, Bharat B/G-3388-2013	Sethi, Gautam/0000-0002-8677-8475; 	NATIONAL CANCER INSTITUTE [P50CA097007, P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844, P50CA97007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Danz H, 2001, PLANTA MED, V67, P411, DOI 10.1055/s-2001-15805; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Eisenbrand G, 2004, J CANCER RES CLIN, V130, P627, DOI 10.1007/s00432-004-0579-2; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hirschowitz E, 2002, GENE THER, V9, P81, DOI 10.1038/sj.gt.3301621; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jautelat R, 2005, CHEMBIOCHEM, V6, P531, DOI 10.1002/cbic.200400108; Knockaert M, 2004, ONCOGENE, V23, P4400, DOI 10.1038/sj.onc.1207535; Kosmopoulou MN, 2004, EUR J BIOCHEM, V271, P2280, DOI 10.1111/j.1432-1033.2004.04173.x; Kunikata T, 2000, EUR J PHARMACOL, V410, P93, DOI 10.1016/S0014-2999(00)00879-7; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee JW, 2005, BIOORG MED CHEM LETT, V15, P3948, DOI 10.1016/j.bmcl.2005.05.105; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Liu XM, 1996, BIOCHEM PHARMACOL, V51, P1545, DOI 10.1016/0006-2952(96)00098-6; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Mak NK, 2004, BIOCHEM PHARMACOL, V67, P167, DOI 10.1016/j.bcp.2003.08.020; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Moon MJ, 2006, BIOORGAN MED CHEM, V14, P237, DOI 10.1016/j.bmc.2005.08.008; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shiraga M, 2002, CANCER RES, V62, P5967; Shishodia S, 2005, CANCER RES, V65, P9555, DOI 10.1158/0008-5472.CAN-05-1585; Shishodia S, 2003, CANCER RES, V63, P4375; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sugihara K, 2004, BIOCHEM BIOPH RES CO, V318, P571, DOI 10.1016/j.bbrc.2004.04.066; Suzuki K, 2005, BRIT J HAEMATOL, V130, P681, DOI 10.1111/j.1365-2141.2005.05655.x; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanaka H, 2005, J BIOL CHEM, V280, P40965, DOI 10.1074/jbc.M506235200; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Xie YB, 2004, NEUROSCI LETT, V367, P355, DOI 10.1016/j.neulet.2004.06.044; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8	69	92	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23425	23435		10.1074/jbc.M602627200	http://dx.doi.org/10.1074/jbc.M602627200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785236	hybrid			2022-12-27	WOS:000239702900017
J	Gaspar, ML; Aregullin, MA; Jesch, SA; Henry, SA				Gaspar, Maria L.; Aregullin, Manuel A.; Jesch, Stephen A.; Henry, Susan A.			Inositol induces a profound alteration in the pattern and rate of synthesis and turnover of membrane lipids in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPATHY TARGET ESTERASE; PROTEIN N-MYRISTOYLATION; CROSS-PATHWAY REGULATION; ACETYL-COA CARBOXYLASE; COENZYME-A CARBOXYLASE; EXOGENOUS FATTY-ACIDS; PHOSPHOLIPID BIOSYNTHESIS; INO1 PROMOTER; YEAST; GENE	The addition of inositol to actively growing yeast cultures causes a rapid increase in the rate of synthesis of phosphatidylinositol and, simultaneously, triggers changes in the expression of hundreds of genes. We now demonstrate that the addition of inositol to yeast cells growing in the presence of choline leads to a dramatic reprogramming of cellular lipid synthesis and turnover. The response to inositol includes a 5-6-fold increase in cellular phosphatidylinositol content within a period of 30 min. The increase in phosphatidylinositol content appears to be dependent upon fatty acid synthesis. Phosphatidylcholine turnover increased rapidly following inositol addition, a response that requires the participation of Nte1p, an endoplasmic reticulum-localized phospholipase B. Mass spectrometry revealed that the acyl species composition of phosphatidylinositol is relatively constant regardless of supplementation with inositol or choline, whereas phosphatidylcholine acyl species composition is influenced by both inositol and choline. In medium containing inositol, but lacking choline, high levels of dimyristoylphos-phatidylcholine were detected. Within 60 min following the addition of inositol, dimyristoylphosphatidylcholine levels had decreased from similar to 40% of total phosphatidylcholine to a basal level of less than 5%. nte1 Delta cells grown in the absence of inositol and in the presence of choline exhibited lower levels of dimyristoylphosphatidylcholine than wild type cells grown under these same conditions, but these levels remained largely constant after the addition of inositol. These results are discussed in relationship to transcriptional regulation known to be linked to lipid metabolism in yeast.	Cornell Univ, Coll Agr & Life Sci, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University; Cornell University	Henry, SA (corresponding author), Cornell Univ, Coll Agr & Life Sci, 260 Roberts Hall, Ithaca, NY 14853 USA.	sah42@cornell.edu	Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez-Vasquez F, 2005, NATURE, V433, P425, DOI 10.1038/nature03232; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; Athenstaedt K, 2005, J BIOL CHEM, V280, P37301, DOI 10.1074/jbc.M507261200; Athenstaedt K, 2003, J BIOL CHEM, V278, P23317, DOI 10.1074/jbc.M302577200; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1978, THESIS YESHIVA U NEW; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Brachmann CB, 1998, YEAST, V14, P115; Burnett WV, 1997, BIOTECHNIQUES, V22, P668, DOI 10.2144/97224st01; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Christie W.W., 2003, LIPID ANAL ISOLATION, P105; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Glynn P, 2005, BBA-MOL CELL BIOL L, V1736, P87, DOI 10.1016/j.bbalip.2005.08.002; GREENBERG ML, 1982, GENETICS, V100, P19; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; JESCH SA, 2005, CELL BIOL DYNAMICS Y, P105; Jesch SA, 2006, J BIOL CHEM, V281, P24070, DOI 10.1074/jbc.M604541200; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KAMIRYO T, 1973, FEBS LETT, V38, P29, DOI 10.1016/0014-5793(73)80505-8; KAMIRYO T, 1976, P NATL ACAD SCI USA, V73, P386, DOI 10.1073/pnas.73.2.386; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MCGRAW P, 1989, GENETICS, V122, P317; Natter K, 2005, MOL CELL PROTEOMICS, V4, P662, DOI 10.1074/mcp.M400123-MCP200; NOMURA S, 1972, J BIOCHEM-TOKYO, V71, P783, DOI 10.1093/oxfordjournals.jbchem.a129827; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Santiago TC, 2003, J BIOL CHEM, V278, P38723, DOI 10.1074/jbc.M303008200; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; Shirra MK, 2001, MOL CELL BIOL, V21, P5710, DOI 10.1128/MCB.21.17.5710-5722.2001; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; SUMMERS EF, 1988, GENETICS, V120, P909; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Weerheim AM, 2002, ANAL BIOCHEM, V302, P191, DOI 10.1006/abio.2001.5552; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WOODS A, 1994, J BIOL CHEM, V269, P19509; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200	47	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22773	22785		10.1074/jbc.M603548200	http://dx.doi.org/10.1074/jbc.M603548200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16777854	hybrid			2022-12-27	WOS:000239542600038
J	Gordon, MD; Nusse, R				Gordon, Michael D.; Nusse, Roel			Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BETA-CATENIN; LOCUS ENCODES; GENE FAMILY; DROSOPHILA; PROTEIN; PYGOPUS; KINASE; TARGET; AXIN; TCF		Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Nusse, R (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.	rnusse@stanford.edu	Gordon, Michael D/H-9586-2012	Gordon, Michael D/0000-0002-5440-986X				Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bodmer WF, 2006, J HUM GENET, V51, P391, DOI 10.1007/s10038-006-0373-x; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Halford MM, 2001, BIOESSAYS, V23, P34, DOI 10.1002/1521-1878(200101)23:1<34::AID-BIES1005>3.3.CO;2-4; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hoffmans R, 2005, CURR BIOL, V15, P1207, DOI 10.1016/j.cub.2005.05.054; Holmen SL, 2005, BIOCHEM BIOPH RES CO, V328, P533, DOI 10.1016/j.bbrc.2005.01.009; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Kilian B, 2003, MECH DEVELOP, V120, P467, DOI 10.1016/S0925-4773(03)00004-2; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Kusserow A, 2005, NATURE, V433, P156, DOI 10.1038/nature03158; Liu YB, 2005, NAT NEUROSCI, V8, P1151, DOI 10.1038/nn1520; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Nusse R, 2001, TRENDS GENET, V17, P443, DOI 10.1016/S0168-9525(01)02349-6; Olson LE, 2006, CELL, V125, P593, DOI 10.1016/j.cell.2006.02.046; Parker DS, 2002, DEVELOPMENT, V129, P2565; Penton A, 2002, GENETICS, V161, P747; Prud'homme B, 2002, CURR BIOL, V12, P1395, DOI 10.1016/S0960-9822(02)01068-0; Schmitt AM, 2006, NATURE, V439, P31, DOI 10.1038/nature04334; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tada M, 2000, DEVELOPMENT, V127, P2227; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Townsley FM, 2004, NAT CELL BIOL, V6, P626, DOI 10.1038/ncb1141; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wallingford JB, 2004, NAT CELL BIOL, V6, P687, DOI 10.1038/ncb0804-687; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	54	1057	1140	3	117	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22429	22433		10.1074/jbc.R600015200	http://dx.doi.org/10.1074/jbc.R600015200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16793760	hybrid, Green Submitted			2022-12-27	WOS:000239542600002
J	Markham, JE; Li, J; Cahoon, EB; Jaworski, JG				Markham, Jonathan E.; Li, Jia; Cahoon, Edgar B.; Jaworski, Jan G.			Separation and identification of major plant sphingolipid classes from leaves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; PROGRAMMED CELL-DEATH; PERFORMANCE LIQUID-CHROMATOGRAPHY; LONG-CHAIN BASES; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TOBACCO-LEAVES; LIPID RAFTS; FATTY-ACIDS; SPHINGOSINE-1-PHOSPHATE	Sphingolipids are major components of the plasma membrane, tonoplast, and other endomembranes of plant cells. Previous compositional analyses have focused only on individual sphingolipid classes because of the widely differing polarities of plant sphingolipids. Consequently, the total content of sphingolipid classes in plants has yet to be quantified. In addition, the major polar sphingolipid class in the model plant Arabidopsis thaliana has not been previously determined. In this report, we describe the separation and quantification of sphingolipid classes from A. thaliana leaves using hydrolysis of sphingolipids and high performance liquid chromatography (HPLC) analysis of o-phthaldialdehyde derivatives of the released long-chain bases to monitor the separation steps. An extraction solvent that contained substantial proportions of water was used to solubilized > 95% of the sphingolipids from leaves. Neutral and charged sphingolipids were then partitioned by anion exchange solid phase extraction. HPLC analysis of the charged lipid fraction from A. thaliana revealed only one major anionic sphingolipid class, which was identified by mass spectrometry as hexose-hexuronic-inositolphosphoceramide. The neutral sphingolipids were predominantly composed of monohexosylceramide with lesser amounts of ceramides. Extraction and separation of sphingolipids from soybean and tomato showed that, like A. thaliana, the neutral sphingolipids consisted of ceramide and monohexosylceramides; however, the major polar sphingolipid was found to be N-acetyl-hexosamine-hexuronic-inositolphosphoceramide. In extracts from A. thaliana leaves, hexose-hexuronic-inositolphosphoceramides, monohexosylceramides, and ceramides accounted for similar to 64, 34, and 2% of the total sphingolipids, respectively, suggesting an important role for the anionic sphingolipids in plant membranes.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; United State Dept Agr Agr Res Serv Plant, Genet Res Unit, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Markham, JE (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jmarkham@danforthcenter.org	Jaworski, Jan/N-2255-2014	Markham, Jennifer/0000-0003-2397-3131; Jaworski, Jan/0000-0003-3309-4915				[Anonymous], 2003, LIPID ANAL; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonaventure G, 2003, PLANT CELL, V15, P1020, DOI 10.1105/tpc.008946; Borner GHH, 2005, PLANT PHYSIOL, V137, P104, DOI 10.1104/pp.104.053041; CAHOON EB, 1991, PLANT PHYSIOL, V95, P58, DOI 10.1104/pp.95.1.58; CARTER HE, 1969, BIOCHEMISTRY-US, V8, P383, DOI 10.1021/bi00829a053; CARTER HE, 1958, J BIOL CHEM, V233, P1309; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; Coursol S, 2005, PLANT PHYSIOL, V137, P724, DOI 10.1104/pp.104.055806; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dunn TM, 2004, ANN BOT-LONDON, V93, P483, DOI 10.1093/aob/mch071; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; HANSON BA, 1980, J LIPID RES, V21, P309; Imai H, 2000, J PLANT PHYSIOL, V157, P453, DOI 10.1016/S0176-1617(00)80031-0; IRO S, 1985, AGR BIOL CHEM TOKYO, V49, P539; KAUL K, 1978, BIOCHEMISTRY-US, V17, P3569, DOI 10.1021/bi00610a023; KAUL K, 1975, PLANT PHYSIOL, V55, P120, DOI 10.1104/pp.55.1.120; Lester RL, 2001, ANAL BIOCHEM, V298, P283, DOI 10.1006/abio.2001.5368; Levery SB, 2001, RAPID COMMUN MASS SP, V15, P2240, DOI 10.1002/rcm.505; Liang H, 2003, GENE DEV, V17, P2636, DOI 10.1101/gad.1140503; Maceyka M, 2005, PROSTAG OTH LIPID M, V77, P15, DOI 10.1016/j.prostaglandins.2004.09.010; Merrill AH, 2000, METHOD ENZYMOL, V312, P3; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Mongrand S, 2004, J BIOL CHEM, V279, P36277, DOI 10.1074/jbc.M403440200; MORRISON WR, 1970, BIOCHIM BIOPHYS ACTA, V202, P460, DOI 10.1016/0005-2760(70)90116-5; Ng CKY, 2001, NATURE, V410, P596, DOI 10.1038/35069092; NICHOLS BW, 1963, BIOCHIM BIOPHYS ACTA, V70, P417, DOI 10.1016/0926-6542(63)90060-X; OHNISHI M, 1983, BIOCHIM BIOPHYS ACTA, V752, P416; OHNISHI M, 1982, LIPIDS, V17, P803, DOI 10.1007/BF02535357; SASTRY PS, 1964, BIOCHEMISTRY-US, V3, P1271, DOI 10.1021/bi00897a015; SINGH BN, 1991, ARCH BIOCHEM BIOPHYS, V286, P409, DOI 10.1016/0003-9861(91)90059-R; Spassieva SD, 2002, PLANT J, V32, P561, DOI 10.1046/j.1365-313X.2002.01444.x; Sperling P, 2005, PLANT PHYSIOL BIOCH, V43, P1031, DOI 10.1016/j.plaphy.2005.10.004; TOLEDO MS, 1995, J MED VET MYCOL, V33, P247; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996	37	239	248	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22684	22694		10.1074/jbc.M604050200	http://dx.doi.org/10.1074/jbc.M604050200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772288	hybrid			2022-12-27	WOS:000239542600029
J	Ogburn, KD; Figueiredo-Pereira, ME				Ogburn, Kenyon D.; Figueiredo-Pereira, Maria E.			Cytoskeleton/endoplasmic reticulum collapse induced by prostaglandin J2 parallels centrosomal deposition of ubiquitinated protein aggregates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL-O-METHYLTRANSFERASE; AMINO-ACID-SEQUENCE; CYCLOPENTENONE PROSTAGLANDINS; ENDOGENOUS ELECTROPHILE; INCLUSION-BODIES; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ENDOPLASMIC-RETICULUM; PARKINSONS-DISEASE; OXIDATIVE STRESS; NEURONAL CELLS	Many neurodegenerative disorders, such as Parkinson disease, exhibit inclusion bodies containing ubiquitinated proteins. The mechanisms implicated in this aberrant protein deposition remain elusive. In these disorders signs of inflammation are also apparent in the affected central nervous system areas. We show that prostaglandin-J2(PGJ2), an endogenous product of inflammation, disrupts the cytoskeleton in neuronal cells. Furthermore, PGJ2 perturbed microtubule polymerization in vitro and decreased the number of free sulfhydryl groups on tubulin cysteines. A direct effect of PGJ2 on actin was not apparent, although actin filaments were altered in cells treated with PGJ2. This cyclopentenone prostaglandin triggered endoplasmic reticulum (ER) collapse and the redistribution of ER proteins, such as calnexin and catechol-O-methyltransferase, into a large centrosomal aggregate containing ubiquitinated proteins and alpha-synuclein. The PGJ2-dependent cytoskeletal rearrangement paralleled the development of the large centrosomal aggregate. Both of these events were replicated by treating cells with colchicine, which disrupts the microtubule/ER network, but not with brefeldin A, which impairs ER/Golgi transport. PGJ2 also perturbed 26 S proteasome assembly and activity, which preceded the accumulation of ubiquitinated proteins as detergent/salt-insoluble aggregates. Our data support a mechanism by which, upon PGJ2 treatment, cytoskeleton/ER collapse coincides with the relocation of ER proteins, other potentially neighboring proteins, and ubiquitinated proteins into centrosomal aggregates. Development of these large perinuclear aggregates is associated with disruption of the microtubule/ER network. This aberrant protein deposition, triggered by a product of inflammation, may be common to other compounds that disrupt microtubules and induce protein aggregation, such as MPP+ and rotenone, found to be associated with neurodegeneration.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Figueiredo-Pereira, ME (corresponding author), 695 Pk Ave, New York, NY 10021 USA.	pereira@genectr.hunter.cuny.edu			NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM060665, GM60654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM060665, S06GM060654] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldini G, 2005, J MASS SPECTROM, V40, P946, DOI 10.1002/jms.872; Alim MA, 2004, J ALZHEIMERS DIS, V6, P435; Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; BIEDLER JL, 1978, CANCER RES, V38, P3751; Cappelletti G, 2001, CELL BIOL INT, V25, P981, DOI 10.1006/cbir.2001.0772; Diaz-Corrales FJ, 2005, NEUROSCIENCE, V133, P117, DOI 10.1016/j.neuroscience.2005.01.044; Farooqui AA, 2006, NEUROSCIENTIST, V12, P245, DOI 10.1177/1073858405285923; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIMES RH, 1977, J BIOL CHEM, V252, P6222; Ishii T, 2005, BIOCHEMISTRY-US, V44, P13893, DOI 10.1021/bi051336u; Ishii T, 2004, CHEM RES TOXICOL, V17, P1313, DOI 10.1021/tx049860+; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; Landino LM, 2002, ARCH BIOCHEM BIOPHYS, V398, P213, DOI 10.1006/abbi.2001.2729; Li ZM, 2004, J NEUROSCI RES, V78, P824, DOI 10.1002/jnr.20346; Li ZM, 2004, BIOCHEM BIOPH RES CO, V319, P1171, DOI 10.1016/j.bbrc.2004.05.098; Li ZM, 2003, INT J BIOCHEM CELL B, V35, P547, DOI 10.1016/S1357-2725(02)00384-9; Liu CL, 2005, NEUROSCIENCE, V134, P1273, DOI 10.1016/j.neuroscience.2005.05.015; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Musiek ES, 2005, BRAIN PATHOL, V15, P149; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Ogburn KD, 2006, NEUROBIOL DIS, V22, P294, DOI 10.1016/j.nbd.2005.11.006; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; Pignatelli M, 2005, CARCINOGENESIS, V26, P81, DOI 10.1093/carcin/bgh308; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; Ren Y, 2003, J NEUROSCI, V23, P3316; Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742; Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Shibata T, 2003, BIOCHEMISTRY-US, V42, P13960, DOI 10.1021/bi035215a; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Wigley WC, 1999, J CELL BIOL, V145, P481; Yang F, 2005, J BIOL CHEM, V280, P17154, DOI 10.1074/jbc.M500843200; Zhu BT, 2004, INT J MOL MED, V13, P343	46	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23274	23284		10.1074/jbc.M600635200	http://dx.doi.org/10.1074/jbc.M600635200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774923	hybrid			2022-12-27	WOS:000239542600090
J	Reinehr, R; Becker, S; Braun, J; Eberle, A; Grether-Beck, S; Haussinger, D				Reinehr, Roland; Becker, Stephan; Braun, Juliane; Eberle, Andrea; Grether-Beck, Susanne; Haeussinger, Dieter			Endosomal acidification and activation of NADPH oxidase isoforms are upstream events in hyperosmolarity-induced hepatocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHIOCYANATE-DEXTRAN FLUORESCENCE; ACIDIC CELLULAR COMPARTMENTS; GROWTH-FACTOR RECEPTOR; RAT HEPATOCYTES; CL-CHANNELS; SIGNAL-TRANSDUCTION; CHLORIDE CHANNELS; VOLUME REGULATION; INTRACELLULAR PH; STRESS-RESPONSE	Hyperosmotic exposure of rat hepatocytes induced a rapid oxidativestress(ROS) response as an upstream signal for proapoptotic CD95 activation. This study shows that hyperosmotic ROS formation involves a rapid ceramide- and protein kinase C zeta (PKC zeta)-dependent serine phosphorylation of p47(phox) and subsequent activation of NADPH oxidase isoforms. Hyperosmotic p47(phox) phosphorylation and ROS formation were sensitive to inhibition of sphingomyelinases and were strongly blunted after knockdown of acidic sphingomyelinase (ASM) or of p47(phox) protein. Hyperosmolarity induced a rapid bafilomycin- and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid disodium salt (DIDS)-sensitive acidification of a vesicular compartment, which was accessible to endocytosed fluorescein isothiocyanate-dextran and colocalized with ASM, PKC zeta, and the NADPH oxidase isoform Nox 2 (gp91(phox)). Bafilomycin and DIDS prevented the hyperosmolarity-induced increase in ceramide formation, p47(phox) phosphorylation, and ROS formation. As shown recently (Reinehr, R., Becker, S., Hongen, A., and Haussinger, D. (2004) J. Biol. Chem. 279, 23977 - 23987), hyperosmolarity induced a Yes-dependent activation of JNK and the epidermal growth factor receptor (EGFR), followed by EGFR-CD95 association, EGFR-catalyzed CD95-tyrosine phosphorylation, and translocation of the EGFR-CD95 complex to the plasma membrane, where formation of the death-inducing signaling complex occurs. These proapoptotic responses were not only sensitive to inhibitors of sphingomyelinase, PKC zeta, or NADPH oxidases but also to ASM knock-down, bafilomycin, and DIDS, i.e. maneuvers largely preventing hyperosmolarity-induced endosomal acidification and/or ceramide formation. In hepatocytes from p47(phox) knock-out mice, hyperosmolarity failed to activate the CD95 system. The data suggest that hyperosmolarity induces endosomal acidification as an important upstream event for CD95 activation through stimulation of ASM-dependent ceramide formation and activation of NADPH oxidase isoforms.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany; Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016					ALBOUZ S, 1983, NEUROSCI LETT, V36, P311, DOI 10.1016/0304-3940(83)90018-6; Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Brock P, 1999, CYTOMETRY, V35, P353, DOI 10.1002/(SICI)1097-0320(19990401)35:4<353::AID-CYTO8>3.0.CO;2-M; BUSCH GL, 1994, P NATL ACAD SCI USA, V91, P9165, DOI 10.1073/pnas.91.19.9165; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; Dickinson ME, 2003, J BIOMED OPT, V8, P329, DOI 10.1117/1.1583734; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Eberle A, 2005, HEPATOLOGY, V41, P315, DOI 10.1002/hep.20564; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Edwards JC, 2000, J BIOL CHEM, V275, P31826, DOI 10.1074/jbc.M005275200; Faundez Victor, 2004, Sci STKE, V2004, pre8, DOI 10.1126/stke.2332004re8; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Gomez-Munoz A, 1998, BBA-LIPID LIPID MET, V1391, P92, DOI 10.1016/S0005-2760(97)00201-4; Goni FM, 2002, FEBS LETT, V531, P38, DOI 10.1016/S0014-5793(02)03482-8; Graf J, 1996, J HEPATOL, V24, P53; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Gupta S, 2004, J BIOL CHEM, V279, P5821, DOI 10.1074/jbc.M310979200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; Haussinger D, 1996, BIOCHEM J, V313, P697; HAUSSINGER D, 1990, HEPATOLOGY, V11, P243, DOI 10.1002/hep.1840110214; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Jentsch TJ, 2005, ANNU REV PHYSIOL, V67, P779, DOI 10.1146/annurev.physiol.67.032003.153245; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KOJIMA S, 1993, FEBS LETT, V329, P125, DOI 10.1016/0014-5793(93)80207-B; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LANG F, 1993, RENAL PHYSIOL BIOCH, V16, P48; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li XH, 2002, ANNU REV PHYSIOL, V64, P609, DOI 10.1146/annurev.physiol.64.090501.145429; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MUALLEM S, 1988, J BIOL CHEM, V263, P14703; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Pani G, 2001, IUBMB LIFE, V52, P7, DOI 10.1080/15216540252774702; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Pazoles C J, 1980, Ann N Y Acad Sci, V358, P354, DOI 10.1111/j.1749-6632.1980.tb15417.x; QUINTERN LE, 1991, METHOD ENZYMOL, V197, P536; Ramstedt B, 2002, FEBS LETT, V531, P33, DOI 10.1016/S0014-5793(02)03406-3; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Reinehr R, 2005, J BIOL CHEM, V280, P27179, DOI 10.1074/jbc.M414361200; Reinehr R, 2004, J BIOL CHEM, V279, P23977, DOI 10.1074/jbc.M401519200; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Reinehr R, 2005, GASTROENTEROLOGY, V129, P2009, DOI 10.1053/j.gastro.2005.09.023; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; SCHREIBER R, 1994, BIOCHEM J, V303, P113, DOI 10.1042/bj3030113; Schreiber R, 1996, BIOCHEM J, V315, P385, DOI 10.1042/bj3150385; SCHREIBER R, 1995, BIOCHEM J, V309, P19, DOI 10.1042/bj3090019; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TIMMER A, 2004, PLANAR CHROMATOGR, V93, P2; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; VOLKL H, 1994, FEBS LETT, V338, P27, DOI 10.1016/0014-5793(94)80110-X; VOLKL H, 1993, BIOCHEM J, V295, P11; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; Yerushalmi B, 2001, HEPATOLOGY, V33, P616, DOI 10.1053/jhep.2001.22702; YOSHIDA Y, 1985, J BIOCHEM-TOKYO, V98, P1669, DOI 10.1093/oxfordjournals.jbchem.a135438; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; Zsembery A, 2002, HEPATOLOGY, V35, P95, DOI 10.1053/jhep.2002.30423; Zsembery A, 2000, FASEB J, V14, P2345, DOI 10.1096/fj.99-0509com	80	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23150	23166		10.1074/jbc.M601451200	http://dx.doi.org/10.1074/jbc.M601451200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772302	hybrid			2022-12-27	WOS:000239542600079
J	Valdes, R; Liu, W; Ullman, B; Landfear, SM				Valdes, Raquel; Liu, Wei; Ullman, Buddy; Landfear, Scott M.			Comprehensive examination of charged intramembrane residues in a nucleoside transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE-GUANOSINE TRANSPORTER; TRYPANOSOMA-BRUCEI-BRUCEI; LEISHMANIA-DONOVANI; ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; NUCLEOBASE TRANSPORTER; LACTOSE PERMEASE; PLASMODIUM-FALCIPARUM; CHIMERIC CONSTRUCTS; DEFICIENT MUTANT	Permeases of the equilibrative nucleoside transporter family mediate the uptake of nucleosides and/or nucleobases in a diverse array of eukaryotes and transport a host of drugs used for treatment of cancer, heart disease, AIDS, and parasitic infections. To identify residues that play central roles in transport function, we have systematically substituted by site-directed mutagenesis all the charged residues located within predicted transmembrane domains of the Leishmania donovani nucleoside transporter 1.1, LdNT1.1, which transports adenosine and the pyrimidine nucleosides. Substitution of three of these ten residues by uncharged amino acids resulted in loss of > 95% transport activity, and we hence designated them "key" residues. These amino acids were Glu(94), Lys(153), and Arg(404) located in transmembrane domains 2, 4, and 9, respectively. In addition, previous studies on the related LdNT2 inosine/guanosine transporter identified the highly conserved Asp(389) and Arg(393) (equivalent to Asp(374) and Arg(378) in LdNT1.1) in transmembrane domain 8 as key residues. Among these residues, the mutants in Arg(393) (LdNT2) and Arg(404) were strongly impaired in trafficking to the plasma membrane, but the other mutants were expressed with high to moderate efficiency at the cell surface, indicating that their mutation impaired transport activity per se. A conservative K153R substitution exhibited a change in substrate specificity, acquiring the ability to transport inosine, a nucleoside that is not a substrate for the wild-type LdNT1.1 permease. These results imply that the Glu(94), Lys(153), and Asp(374) residues may play central roles in the mechanism of substrate translocation in LdNT1.1.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Landfear, SM (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	landfear@ohsu.edu		Landfear, Scott/0000-0002-1643-6664	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044138, R01AI025920] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25920, AI 44138, R01 AI044138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramson J, 2003, FEBS LETT, V555, P96, DOI 10.1016/S0014-5793(03)01087-1; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Arastu-Kapur S, 2005, J BIOL CHEM, V280, P2213, DOI 10.1074/jbc.M408224200; Arastu-Kapur S, 2003, J BIOL CHEM, V278, P33327, DOI 10.1074/jbc.M305141200; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BERENS RL, 1995, BIOCH MOL BIOL PARAS; Burchmore RJS, 2003, J BIOL CHEM, V278, P23502, DOI 10.1074/jbc.M301252200; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; Carter NS, 2000, J BIOL CHEM, V275, P20935, DOI 10.1074/jbc.M002418200; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CASS CE, 1995, DRUG TRANSPORT ANTIM, P404; Chaudary N, 2004, J PHARMACOL EXP THER, V310, P1190, DOI 10.1124/jpet.104.067157; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; De Koning HP, 1999, MOL PHARMACOL, V56, P1162, DOI 10.1124/mol.56.6.1162; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Henriques C, 2003, MOL BIOCHEM PARASIT, V130, P101, DOI 10.1016/S0166-6851(03)00167-1; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; IOVANNISCI DM, 1984, MOL CELL BIOL, V4, P1013, DOI 10.1128/MCB.4.6.1013; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Kong W, 2004, CURR DRUG METAB, V5, P63, DOI 10.2174/1389200043489162; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; LEBOWITZ JH, 1994, METHOD CELL BIOL, V45, P65; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Mackey JR, 1998, CANCER RES, V58, P4349; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Parker MD, 2000, BIOCHEM J, V349, P67, DOI 10.1042/0264-6021:3490067; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; Sambrook J, 1989, MOL CLONING LAB MANU, V3, P18; Sanchez MA, 1999, J BIOL CHEM, V274, P30244, DOI 10.1074/jbc.274.42.30244; Sanchez MA, 2004, MOL MEMBR BIOL, V21, P11, DOI 10.1080/0968768031000140845; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Snell BJ, 2004, LIFE SCI, V75, P225, DOI 10.1016/j.lfs.2003.12.012; Stein A, 2003, J BIOL CHEM, V278, P35127, DOI 10.1074/jbc.M306188200; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; Taniguchi M, 2004, J AM COLL SURGEONS, V198, P758, DOI 10.1016/j.jamcollsurg.2003.12.002; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valdes R, 2004, BIOCHEMISTRY-US, V43, P6793, DOI 10.1021/bi049873m; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22647	22655		10.1074/jbc.M602366200	http://dx.doi.org/10.1074/jbc.M602366200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769726	hybrid			2022-12-27	WOS:000239542600025
J	Iwamoto, M; Shimizu, H; Inoue, F; Konno, T; Sasaki, YC; Oiki, S				Iwamoto, Masayuki; Shimizu, Hirofumi; Inoue, Fumiko; Konno, Takashi; Sasaki, Yuji C.; Oiki, Shigetoshi			Surface structure and its dynamic rearrangements of the KcsA potassium channel upon gating and tetrabutylammonium blocking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; K+-CHANNEL; RECEPTOR; DOMAIN; SITE	KcsA is the first potassium channel for which the molecular structure was revealed. However, the high resolution structural information is limited to the transmembrane domain, and the dynamic picture of the full KcsA channel remains unsolved. We have developed a new approach to investigate the surface structure of proteins, and we applied this method to investigate the full length of the KcsA channel. Single-cysteine substitution was introduced into 25 sites, and specific reaction of these mutated channels to a bare surface of a flat gold plate was evaluated by surface plasmon resonance measurements. The surface plasmon resonance signals revealed the highest exposure for the mutant of the C-terminal end. When the gate of the KcsA channel is kept closed at pH 7.5, the extent of exposure showed periodic patterns for the consecutive sites located in the cytoplasmic (CP) and N-terminal domain. This suggests that these stretches take the alpha-helical structure. When the channel was actively gated at pH 4.0, many sites in the CP domain became exposed. Compared with the rigid structure in pH 7.5, these results indicate that the CP domain became loosely packed upon active gating. The C-terminal end of the M2 helix is a moving part of the gate, and it is exposed to the outer surface slightly at pH 4.0. By adding a channel blocker, tetrabutylammonium, the gate is further exposed. This suggests that in the active gating tetrabutylammonium keeps the gate open rather than being trapped in the central cavity.	Univ Fukui, Fac Med Sci, Dept Mol Physiol & Biophys, JST,CREST, Eiheiji, Fukui 9101193, Japan; Japan Synchrotron Radiat Res Inst, Mikazuki, Hyogo 6795198, Japan	Japan Science & Technology Agency (JST); University of Fukui; Japan Synchrotron Radiation Research Institute	Oiki, S (corresponding author), Univ Fukui, Fac Med Sci, Dept Mol Physiol & Biophys, JST,CREST, 23-3 Matsuoka Shimoaizuki, Eiheiji, Fukui 9101193, Japan.	oiki-fki@umin.ac.jp	SASAKI, Yuji/N-6880-2016	SASAKI, Yuji/0000-0003-3403-237X; Iwamoto, Masayuki/0000-0001-9505-2652				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Chill JH, 2006, PROTEIN SCI, V15, P684, DOI 10.1110/ps.051954706; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Corvini PFX, 2000, MICROBIOL-SGM, V146, P2671, DOI 10.1099/00221287-146-10-2671; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; IWAMOTO M, 2003, RECENT RES DEV CHEM, V1, P15; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; Lenaeus MJ, 2005, NAT STRUCT MOL BIOL, V12, P454, DOI 10.1038/nsmb929; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Shi N, 2006, NATURE, V440, P570, DOI 10.1038/nature04508; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500; Zimmer J, 2006, BIOPHYS J, V90, P1752, DOI 10.1529/biophysj.105.071175	27	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28379	28386		10.1074/jbc.M602018200	http://dx.doi.org/10.1074/jbc.M602018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16835240	hybrid			2022-12-27	WOS:000240534400075
J	Majerciak, V; Yamanegi, K; Nie, SH; Zheng, ZM				Majerciak, Vladimir; Yamanegi, Koji; Nie, Sarah H.; Zheng, Zhi-Ming			Structural and functional analyses of Kaposi sarcoma-associated herpesvirus ORF57 nuclear localization signals in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN ICP27; MESSENGER-RNA EXPORT; OPEN READING FRAME; VIRUS SM PROTEIN; MULTICENTRIC CASTLEMANS-DISEASE; PRIMARY EFFUSION LYMPHOMA; SIMPLEX-VIRUS; GENE-EXPRESSION; IN-VIVO; POSTTRANSCRIPTIONAL REGULATOR	Kaposi sarcoma-associated herpesvirus (KSHV) ORF57 is a multifunctional, nuclear protein involved in post-transcriptional regulation of a subset of viral genes during lytic replication. Three nuclear localization signals (NLSs), NLS1 (amino acids (aa 101 - 107), NLS2 (aa 121 - 130), and NLS3 (aa 143 - 152), were identified in the N terminus of the ORF57 protein, and each of the three represents a short stretch of basic amino acid residues. Disruption of all three NLSs prevented localization of ORF57 in the nucleus. Insertion of individual NLSs into a heterologous cytoplasmic protein converted it into a nuclear protein, confirming that each NLS functions independently and is sufficient to promote protein nuclear localization. Although it exhibits a function similar to that of Epstein-Barr virus EB2 in promoting KSHV ORF59 expression, KSHV ORF57 differs from the herpes simplex virus ICP27 protein, and its function could be disrupted by point mutations of single or two NLSs in random combination, despite the proper localization of the mutant protein in the nucleus. The dysfunctional ORF57 containing NLS mutations also had low affinity with ORF59 RNA and the RNA export factor REF. However, the REF binding of ORF57 in vivo appeared to have no effect on ORF57-mediated enhancement of ORF59 expression. Thus, the three NLSs identified in ORF57 provide at least two functions, nuclear localization of ORF57 and up-regulation of ORF59 expression.	NCI, HIV & AIDS Malignancy Branch, Canc Res Ctr, Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zheng, ZM (corresponding author), NCI, HIV & AIDS Malignancy Branch, Canc Res Ctr, Natl Inst Hlth, 10 Ctr Dr,Rm 10 S255,MSC-1868, Bethesda, MD 20892 USA.	zhengt@exchange.nih.gov	Zheng, Zhi-Ming/L-6383-2019	Zheng, Zhi-Ming/0000-0001-5547-7912; Majerciak, Vladimir/0000-0003-2907-4583	NATIONAL CANCER INSTITUTE [Z01SC010357, ZIASC010357] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bryant HE, 2001, J VIROL, V75, P4376, DOI 10.1128/JVI.75.9.4376-4385.2001; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cannon JS, 2000, J VIROL, V74, P10187, DOI 10.1128/JVI.74.21.10187-10193.2000; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen IHB, 2005, J VIROL, V79, P3949, DOI 10.1128/JVI.79.7.3949-3961.2005; COOK ID, 1994, VIROLOGY, V205, P217, DOI 10.1006/viro.1994.1637; Cooper M, 1999, J GEN VIROL, V80, P1311, DOI 10.1099/0022-1317-80-5-1311; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Goodwin DJ, 1999, J VIROL, V73, P10519, DOI 10.1128/JVI.73.12.10519-10524.1999; Goodwin DJ, 2001, J BIOL CHEM, V276, P19905, DOI 10.1074/jbc.M009513200; Gupta AK, 2000, J VIROL, V74, P1038, DOI 10.1128/JVI.74.2.1038-1044.2000; HARDY WR, 1994, J VIROL, V68, P7790, DOI 10.1128/JVI.68.12.7790-7799.1994; Hayward GS, 2003, CANCER CELL, V3, P1, DOI 10.1016/S1535-6108(03)00002-3; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; HIBBARD MK, 1995, J VIROL, V69, P4656, DOI 10.1128/JVI.69.8.4656-4667.1995; Hiriart E, 2003, J BIOL CHEM, V278, P335, DOI 10.1074/jbc.M208656200; Kirshner JR, 2000, J VIROL, V74, P3586, DOI 10.1128/JVI.74.8.3586-3597.2000; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; Lindberg A, 2002, VIROLOGY, V294, P189, DOI 10.1006/viro.2001.1301; Longman D, 2003, RNA, V9, P881, DOI 10.1261/rna.5420503; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; Malik P, 2004, NUCLEIC ACIDS RES, V32, P5553, DOI 10.1093/nar/gkh876; Malik P, 2004, J BIOL CHEM, V279, P33001, DOI 10.1074/jbc.M313008200; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Nishimura K, 2004, VIROLOGY, V325, P364, DOI 10.1016/j.virol.2004.04.041; Pearson A, 2004, J VIROL, V78, P23, DOI 10.1128/JVI.78.1.23-32.2004; PERERA LP, 1994, J VIROL, V68, P2468, DOI 10.1128/JVI.68.4.2468-2477.1994; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Ruvolo V, 1998, P NATL ACAD SCI USA, V95, P8852, DOI 10.1073/pnas.95.15.8852; Ruvolo V, 2001, J VIROL, V75, P6033, DOI 10.1128/JVI.75.13.6033-6041.2001; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; SandriGoldin RM, 1996, J VIROL, V70, P108, DOI 10.1128/JVI.70.1.108-118.1996; SANDRIGOLDIN RM, 1995, J VIROL, V69, P6063, DOI 10.1128/JVI.69.10.6063-6076.1995; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Sokolowski M, 2003, J BIOL CHEM, V278, P33540, DOI 10.1074/jbc.M302063200; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1999, J VIROL, V73, P4181, DOI 10.1128/JVI.73.5.4181-4187.1999; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Tao MF, 2003, J VIROL, V77, P13232, DOI 10.1128/JVI.77.24.13232-13247.2003; Viejo-Borbolla Abel, 2003, Curr Infect Dis Rep, V5, P169, DOI 10.1007/s11908-003-0054-2; Whitehouse A, 1998, J VIROL, V72, P857, DOI 10.1128/JVI.72.1.857-861.1998; Williams BJL, 2005, BIOCHEM J, V387, P295, DOI 10.1042/BJ20041223; WINKLER M, 1994, J VIROL, V68, P3943, DOI 10.1128/JVI.68.6.3943-3954.1994; Zheng ZM, 2000, J VIROL, V74, P10612, DOI 10.1128/JVI.74.22.10612-10622.2000; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; Zhou FC, 2002, J VIROL, V76, P6185, DOI 10.1128/JVI.76.12.6185-6196.2002	52	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28365	28378		10.1074/jbc.M603095200	http://dx.doi.org/10.1074/jbc.M603095200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16829516	hybrid			2022-12-27	WOS:000240534400074
J	Kim, YM; Park, KI; Choi, KS; Alvarez, RA; Cummings, RD; Cho, M				Kim, Young Mee; Park, Kyung-Il; Choi, Kwang-Sik; Alvarez, Richard A.; Cummings, Richard D.; Cho, Moonjae			Lectin from the manila clam Ruditapes philippinarum is induced upon infection with the protozoan parasite Perkinsus olseni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; C-TYPE LECTIN; INVERTEBRATE CUCUMARIA ECHINATA; COLLECTIN-LIKE PROTEIN; BINDING LECTIN; INNATE IMMUNITY; MARINE MUSSEL; SEA-CUCUMBER; CEL-III; HEMOCYTES	Glycan-binding proteins (lectins) are widely expressed in many invertebrates, although the biosynthesis and functions of the lectins are not well understood. Here we report that Manila clam (Ruditapes philippinarum) synthesizes a lectin termed Manila clam lectin (MCL) upon infection with the protozoan parasite Perkinsus olseni. MCL is synthesized in hemocytes as a similar to 74-kDa precursor and secreted into hemolymph where it is converted to 30- and 34-kDa polypeptides. The synthesis of MCL in hemocytes is stimulated by one or more factors in Perkinsus-infected hemolymph, but not directly by Perkinsus itself. MCL can bind to the surfaces of purified hypnospores and zoospores of the parasite, and this binding is inhibitable by either EDTA or GalNAc. Fluorescent beads coated with purified MCL were actively phagocytosed by hemocytes from the clam. Immunohistochemistry showed that secreted MCL is concentrated within cyst-like structures. To define the glycan binding specificity of MCL we examined its binding to an array of biotinylated glycans. MCL recognizes terminal non-reducing beta-linked GalNAc as expressed within the LacdiNAc motif GalNAc beta 1-4GlcNAc beta 1-R and glycans with terminal, non-reducing beta-linked Gal residues. Our results show that the synthesis of MCL is specifically up-regulated upon parasite infection of the clams and may serve as an opsonin through recognition of terminal GalNAc/Gal residues on the parasites.	Jeju Natl Univ, Dept Med, Cheju 690756, South Korea; Jeju Natl Univ, Sch Appl Marine Sci, Cheju 690756, South Korea; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; O Wayne Rollins Res Ctr, Atlanta, GA 30322 USA	Jeju National University; Jeju National University; Emory University	Cho, M (corresponding author), Jeju Natl Univ, Dept Med, Cheju 690756, South Korea.	moonjcho@cheju.ac.kr	Choi, Kwang-Sik Albert/B-5367-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62116] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asokan R, 1997, DEV COMP IMMUNOL, V21, P1, DOI 10.1016/S0145-305X(97)00004-9; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; Bulgakov AA, 2004, FISH SHELLFISH IMMUN, V16, P487, DOI 10.1016/j.fsi.2003.08.006; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; Choi KS, 2002, J SHELLFISH RES, V21, P119; Cremonte F, 2005, DIS AQUAT ORGAN, V64, P85, DOI 10.3354/dao064085; DAM TK, 1992, MOL CELL BIOCHEM, V117, P1; Dodds Alister W., 1996, P303; Dyrynda EA, 1997, CELL TISSUE RES, V289, P527, DOI 10.1007/s004410050898; Endo Y, 2003, J IMMUNOL, V170, P4701, DOI 10.4049/jimmunol.170.9.4701; FAYE I, 1990, RES IMMUNOL, V141, P927, DOI 10.1016/0923-2494(90)90195-5; FISHER WS, 1992, J EXP MAR BIOL ECOL, V162, P1, DOI 10.1016/0022-0981(92)90121-P; GAMULIN V, 1994, BIOL CHEM H-S, V375, P583; Gaphurov JM, 1999, TOXICON, V37, P1591, DOI 10.1016/S0041-0101(99)00107-5; GIGA Y, 1987, J BIOL CHEM, V262, P6197; Goto A, 2003, DEV BIOL, V264, P582, DOI 10.1016/j.ydbio.2003.06.001; Green PL, 2003, DEV COMP IMMUNOL, V27, P3, DOI 10.1016/S0145-305X(02)00067-8; HATAKEYAMA T, 1995, BIOSCI BIOTECH BIOCH, V59, P1314, DOI 10.1271/bbb.59.1314; Hatakeyama T, 1996, J BIOL CHEM, V271, P16915, DOI 10.1074/jbc.271.28.16915; HIMESHIMA T, 1994, J BIOCHEM-TOKYO, V115, P689, DOI 10.1093/oxfordjournals.jbchem.a124397; Hine PM, 1996, REV SCI TECH OIE, V15, P563, DOI 10.20506/rst.15.2.940; Jenny MJ, 2002, MAR BIOTECHNOL, V4, P81, DOI 10.1007/s10126-001-0072-8; Kawai F, 1999, J IND MICROBIOL BIOT, V23, P400, DOI 10.1038/sj.jim.2900730; Kenjo A, 2001, J BIOL CHEM, V276, P19959, DOI 10.1074/jbc.M011723200; Ling EJ, 2006, DEV COMP IMMUNOL, V30, P289, DOI 10.1016/j.dci.2005.05.005; Mann K, 2000, EUR J BIOCHEM, V267, P5257, DOI 10.1046/j.1432-1327.2000.01602.x; Marques MRF, 2000, AQUACULTURE, V191, P23, DOI 10.1016/S0044-8486(00)00417-8; MATSUI T, 1994, J BIOCHEM-TOKYO, V116, P1127, DOI 10.1093/oxfordjournals.jbchem.a124638; Miarons PB, 2000, J BIOL CHEM, V275, P29283, DOI 10.1074/jbc.M001366200; Mitta G, 1999, J CELL SCI, V112, P4233; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; Montes JF, 1996, DIS AQUAT ORGAN, V26, P149, DOI 10.3354/dao026149; Muller WEG, 1999, TRANSPLANTATION, V68, P1215; Nair SV, 2001, COMP BIOCHEM PHYS C, V129, P11, DOI 10.1016/S1532-0456(01)00179-X; Nair SV, 2000, COMP BIOCHEM PHYS B, V125, P279, DOI 10.1016/S0305-0491(99)00180-7; NAVAS JI, 1992, AQUACULTURE, V107, P193, DOI 10.1016/0044-8486(92)90067-U; Oda T, 1997, J BIOCHEM, V121, P560; OLAFSEN JA, 1995, ADV EXP MED BIOL, V371, P343; Ordas MC, 2000, FISH SHELLFISH IMMUN, V10, P597, DOI 10.1006/fsim.2000.0274; Ordas MC, 1998, DIS AQUAT ORGAN, V33, P129, DOI 10.3354/dao033129; Park KI, 2001, AQUACULTURE, V203, P9, DOI 10.1016/S0044-8486(01)00619-6; Ray S.M., 1966, P NATL SHELLFISH ASS, V54, P55, DOI DOI 10.2983/0730-8000(2006)25; RENWRANTZ L, 1983, J COMP PHYSIOL, V149, P535, DOI 10.1007/BF00690013; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sekine H, 2001, J IMMUNOL, V167, P4504, DOI 10.4049/jimmunol.167.8.4504; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; SUH-CHAE Y A, 1988, Korean Biochemical Journal, V21, P46; TAKAHASHI Y, 1995, FISH PATHOL, V30, P141, DOI 10.3147/jsfp.30.141; Tunkijjanukij S, 1998, DEV COMP IMMUNOL, V22, P139, DOI 10.1016/S0145-305X(98)00017-2; VASTA GR, 1990, UCLA SYM BI, V121, P183; Wootton EC, 2003, AQUAT TOXICOL, V65, P13, DOI 10.1016/S0166-445X(03)00098-5	51	48	52	4	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26854	26864		10.1074/jbc.M601251200	http://dx.doi.org/10.1074/jbc.M601251200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16785239	hybrid			2022-12-27	WOS:000240397700012
J	Albor, A; El-Hizawi, S; Horn, EJ; Laederich, M; Frosk, P; Wrogemann, K; Kulesz-Martin, M				Albor, Amador; El-Hizawi, Sally; Horn, Elizabeth J.; Laederich, Melanie; Frosk, Patrick; Wrogemann, Klaus; Kulesz-Martin, Molly			The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NF kappa b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER; SUMO-1 MODIFICATION; PROTEIN INHIBITOR; STAGE PROGRESSION; UBIQUITIN LIGASE; GENE-ACTIVATION; DNA MICROARRAY; FAMILY-MEMBER; NUCLEAR; PATHWAY	Protein inhibitors of activated STATs (PIAS) family members are ubiquitin-protein isopeptide ligase-small ubiquitin-like modifier ligases for diverse transcription factors. However, the regulation of PIAS protein activity in cells is poorly understood. Previously, we reported that expression of Trim32, a RING domain ubiquitin-protein isopeptide ligase-ubiquitin ligase mutated in human limb-girdle muscular dystrophy type 2H (LGMD2H) and Bardet-Biedl syndrome, is elevated during mouse skin carcinogenesis, protecting keratinocytes from apoptosis induced by UVB and tumor necrosis factor-alpha (TNF alpha). Here we report that Trim32 interacts with Piasy and promotes Piasy ubiquitination and degradation. Ubiquitination of Piasy by Trim32 could be reproduced in vitro using purified components. Their interaction was induced by treatment with UVB/TNF alpha and involved redistribution of Piasy from the nucleus to the cytoplasm, where it accumulated in cytoplasmic granules that colocalized with Trim32. Piasy destabilization and ubiquitination required an intact RING domain in Trim32. The LGMD2H-associated missense point mutation prevented Trim32 binding to Piasy, and human Piasy failed to colocalize with human Trim32 in fibroblasts isolated from an LGMD2H patient. Trim32 expression increased the transcriptional activity of NF kappa B in epidermal keratinocytes, both under basal treatment and after UVB/TNF alpha treatment. Conversely, Piasy inhibited NF kappa B activity under the same conditions and sensitized keratinocytes to apoptosis induced by TNF alpha and UVB. Our results indicate that, by controlling Piasy stability, Trim32 regulates UVB-induced keratinocyte apoptosis through induction of NF kappa B and suggests loss of function of Trim32 in LGMD2H.	Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Cell & Mol Biol Program, Portland, OR 97239 USA; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W3, Canada	Oregon Health & Science University; Oregon Health & Science University; University of Manitoba	Albor, A (corresponding author), Oregon Hlth & Sci Univ, Dept Dermatol, Mail Code OP06,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	albora@ohsu.edu		Frosk, Patrick/0000-0002-9673-795X	NCI NIH HHS [CA69533, CA098577, R01 CA098577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA069533, R01CA098577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baghdiguian S, 2001, J MOL MED, V79, P254, DOI 10.1007/s001090100225; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Banno T, 2005, J BIOL CHEM, V280, P18973, DOI 10.1074/jbc.M411758200; Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; Cao TY, 1998, J CELL SCI, V111, P1319; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chiang AP, 2006, P NATL ACAD SCI USA, V103, P6287, DOI 10.1073/pnas.0600158103; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Frosk P, 2005, HUM MUTAT, V25, P38, DOI 10.1002/humu.20110; Frosk P, 2002, AM J HUM GENET, V70, P663, DOI 10.1086/339083; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Glasscock E, 2005, GENETICS, V170, P1677, DOI 10.1534/genetics.105.043174; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Horn EJ, 2004, CARCINOGENESIS, V25, P157, DOI 10.1093/carcin/bgh003; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kudryashova E, 2005, J MOL BIOL, V354, P413, DOI 10.1016/j.jmb.2005.09.068; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Matsuura T, 2005, EXP CELL RES, V308, P65, DOI 10.1016/j.yexcr.2005.04.022; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nair R, 2003, NUCLEIC ACIDS RES, V31, P397, DOI 10.1093/nar/gkg001; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Roth W, 2004, J IMMUNOL, V173, P6189, DOI 10.4049/jimmunol.173.10.6189; Saenko V, 2003, MUTAT RES-FUND MOL M, V527, P81, DOI 10.1016/S0027-5107(03)00056-3; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schoser BGH, 2005, ANN NEUROL, V57, P591, DOI 10.1002/ana.20441; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Sturm S, 2000, J MOL NEUROSCI, V14, P107, DOI 10.1385/JMN:14:1-2:107; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Takahashi Y, 2005, J BIOL CHEM, V280, P35822, DOI 10.1074/jbc.M506794200; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tussie-Luna MI, 2002, J BIOL CHEM, V277, P43185, DOI 10.1074/jbc.M207635200; Ueda M, 2003, BRIT J HAEMATOL, V123, P288, DOI 10.1046/j.1365-2141.2003.04601.x; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004; Zhang J, 2004, FEBS LETT, V570, P97, DOI 10.1016/j.febslet.2004.05.081; Zoumpoulidou G, 2004, MOL ENDOCRINOL, V18, P1988, DOI 10.1210/me.2003-0467	56	69	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25850	25866		10.1074/jbc.M601655200	http://dx.doi.org/10.1074/jbc.M601655200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16816390	hybrid			2022-12-27	WOS:000240031300087
J	Wei, CC; Zhang, SL; Chen, YW; Guo, DF; Ingelfinger, JR; Bomsztyk, K; Chan, JSD				Wei, Chih-Chang; Zhang, Shao-Ling; Chen, Yun-Wen; Guo, Deng-Fu; Ingelfinger, Julie R.; Bomsztyk, Karol; Chan, John S. D.			Heterogeneous nuclear ribonucleoprotein K modulates angiotensinogen gene expression in kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PROXIMAL TUBULE; PROTEIN-KINASE PATHWAY; HNRNP-K; MOLECULAR-CLONING; RESPONSE ELEMENT; BINDING-PROTEIN; MESSENGER-RNA; INSULIN; DNA; GLUCOSE	The present studies aimed to identify the 70-kDa nuclear protein that binds to an insulin-responsive element in the rat angiotensinogen gene promoter and to define its action on angiotensinogen gene expression. Nuclear proteins were isolated from rat kidney proximal tubular cells and subjected to two-dimensional electrophoresis. The 70-kDa nuclear protein was detected by Southwestern blotting and subsequently identified by mass spectrometry, which revealed that it was identical to 65-kDa heterogeneous nuclear ribonucleoprotein K (hnRNP K). hnRNP K bound to the insulin-responsive element of the rat angiotensinogen gene was revealed by a gel mobility shift assay and chromatin immunoprecipitation assay. hnRNP K inhibited angiotensinogen mRNA expression and promoter activity. In contrast, hnRNP K down-expression by small interference RNA enhanced angiotensinogen mRNA expression. Moreover, hnRNP K interacted with hnRNP F in pulldown and co-immunoprecipitation assays. Co-transfection of hnRNP K and hnRNP F further suppressed angiotensinogen mRNA expression. Finally, in vitro and in vivo studies demonstrated that high glucose increases and insulin inhibits hnRNP K expression in rat kidney proximal tubular cells. In conclusion, our experiments revealed that hnRNP K is a nuclear protein that binds to the insulin-responsive element of the rat angiotensinogen gene promoter and modulates angiotensinogen gene transcription in the kidney.	Ctr Hosp Univ Montreal, Hotel Dieu, Ctr Rech, Montreal, PQ H2W 1T8, Canada; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Laval University; Universite de Montreal; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Washington; University of Washington Seattle	Chan, JSD (corresponding author), Ctr Hosp Univ Montreal, Hotel Dieu, Ctr Rech, Montreal, PQ H2W 1T8, Canada.	john.chan@umontreal.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048455] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48455] Funding Source: Medline; NIDDK NIH HHS [DK49578] Funding Source: Medline; NIGMS NIH HHS [GM45134] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen S, 2000, KIDNEY INT, V57, P601, DOI 10.1046/j.1523-1755.2000.t01-1-00880.x; ANDERSON S, 1993, AM J PHYSIOL, V265, pF477, DOI 10.1152/ajprenal.1993.265.4.F477; BAKRIS GL, 1993, ANN INTERN MED, V118, P643, DOI 10.7326/0003-4819-118-8-199304150-00013; BERNEG RTV, 1996, ANN INTERN MED, V121, P912; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; CHAN JSD, 1990, PEDIATR NEPHROL, V4, P429, DOI 10.1007/BF00862531; CHEN M, 1994, J CLIN INVEST, V94, P237, DOI 10.1172/JCI117312; Chen X, 2001, ENDOCRINOLOGY, V142, P2577, DOI 10.1210/en.142.6.2577; Da Silva N, 2002, BLOOD, V100, P3536, DOI 10.1182/blood.V100.10.3536; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DZAU VJ, 1989, J HYPERTENS S7, V7, P53; Groggel GC, 1996, ARCH FAM MED, V5, P513, DOI 10.1001/archfami.5.9.513; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Hsieh TJ, 2003, ENDOCRINOLOGY, V144, P4338, DOI 10.1210/en.2003-0220; Hsieh TJ, 2002, ENDOCRINOLOGY, V143, P2975, DOI 10.1210/en.143.8.2975; Ingelfinger JR, 1999, AM J PHYSIOL-RENAL, V276, pF218, DOI 10.1152/ajprenal.1999.276.2.F218; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JOHNSTON CI, 1993, KIDNEY INT       S42, V44, P559; KAGEYAMA R, 1984, BIOCHEMISTRY-US, V23, P3603, DOI 10.1021/bi00311a006; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; KWASTWELFELD J, 1993, J BIOL CHEM, V268, P19581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; LAVERMAN GD, 2004, J AM SOC NEPHROL S1, V15, P60; Li NJ, 2005, AM J PHYSIOL-RENAL, V288, pF353, DOI 10.1152/ajprenal.00144.2004; LoghmanAdham M, 1997, KIDNEY INT, V52, P229, DOI 10.1038/ki.1997.325; MATSUNIS MJ, 1992, MOL CELL BIOL, V12, P164; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; NAKAMURA T, 1995, J AM SOC NEPHROL, V5, P1492; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; Ostrowski J, 2003, NUCLEIC ACIDS RES, V31, P3954, DOI 10.1093/nar/gkg452; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; Ritchie SA, 2003, NUCLEIC ACIDS RES, V31, P1502, DOI 10.1093/nar/gkg246; Sachetelli S, 2006, KIDNEY INT, V69, P1016, DOI 10.1038/sj.ki.5000210; SEUNINGEN I, 1995, J BIOL CHEM, V270, P26976; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shannon H, 2000, NEW ENGL J MED, V342, P381; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Stains JP, 2005, BIOCHEM J, V385, P613, DOI 10.1042/BJ20040680; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TANG SS, 1995, AM J PHYSIOL-RENAL, V268, pF435, DOI 10.1152/ajprenal.1995.268.3.F435; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; US Renal Data System, 2005, US REN DAT SYST USRD; VINAY P, 1981, AM J PHYSIOL, V241, pF403, DOI 10.1152/ajprenal.1981.241.4.F403; Wang LS, 1998, KIDNEY INT, V53, P287, DOI 10.1046/j.1523-1755.1998.00759.x; Wei CC, 2005, J AM SOC NEPHROL, V16, P616, DOI 10.1681/ASN.2004080715; Wolf G, 2005, KIDNEY INT, V67, P799, DOI 10.1111/j.1523-1755.2005.00145.x; WOLF G, 1992, KIDNEY INT S 39, V43, P100; Zhang SL, 1999, KIDNEY INT, V55, P454, DOI 10.1046/j.1523-1755.1999.00271.x; Zhang SL, 2002, ENDOCRINOLOGY, V143, P4627, DOI 10.1210/en.2002-220408; Zhang SL, 2002, J AM SOC NEPHROL, V13, P302, DOI 10.1681/ASN.V132302; Zhang SL, 2002, J ENDOCRINOL, V172, P333, DOI 10.1677/joe.0.1720333; Zhang SL, 2001, EXP NEPHROL, V9, P109; Zhang SL, 1999, ENDOCRINOLOGY, V140, P5285, DOI 10.1210/en.140.11.5285; Zhang SL, 2000, ENDOCRINOLOGY, V141, P4637, DOI 10.1210/endo.141.12.7844	66	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25344	25355		10.1074/jbc.M601945200	http://dx.doi.org/10.1074/jbc.M601945200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16837467	hybrid			2022-12-27	WOS:000240031300036
J	D'Abramo, CM; Deval, J; Cameron, CE; Cellai, L; Gotte, M				D'Abramo, Claudia M.; Deval, Jerome; Cameron, Craig E.; Cellai, Luciano; Gotte, Matthias			Control of template positioning during de novo initiation of RNA synthesis by the bovine viral diarrhea virus NS5B polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; PROTEIN 5B POLYMERASE; CRYSTAL-STRUCTURE; IDENTIFICATION; POLYMERIZATION; REQUIREMENTS; EXPRESSION; MECHANISM; BINDING; REGION	The RNA-dependent RNA polymerase of the hepatitis C virus and the bovine viral diarrhea virus (BVDV) is able to initiate RNA synthesis de novo in the absence of a primer. Previous crystallographic data have pointed to the existence of a GTP-specific binding site (G-site) that is located in the vicinity of the active site of the BVDV enzyme. Here we have studied the functional role of the G-site and present evidence to show that specific GTP binding affects the positioning of the template during de novo initiation. Following the formation of the first phosphodiester bond, the polymerase translocates relative to the newly synthesized dinucleotide, which brings the 5'-end of the primer into the G-site, releasing the previously bound GTP. At this stage, the 3'-end of the template can remain opposite to the 5'-end of the primer or be repositioned to its original location before RNA synthesis proceeds. We show that the template can freely move between the two locations, and both complexes can isomerize to equilibrium. These data suggest that the bound GTP can stabilize the interaction between the 3'-end of the template and the priming nucleotide, preventing the template to overshoot and extend beyond the active site during de novo initiation. The hepatitis C virus enzyme utilizes a dinucleotide primer exclusively from the blunt end; the existence of a functionally equivalent G-site is therefore uncertain. For the BVDV polymerase we showed that de novo initiation is severely compromised by the T320A mutant that likely affects hydrogen bonding between the G-site and the guanine base. Dinucleotide-primed reactions are not influenced by this mutation, which supports the notion that the G-site is located in close proximity but not at the active site of the enzyme.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; CNR, Ist Cristallog, I-00016 Rome, Italy	McGill University; McGill University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Consiglio Nazionale delle Ricerche (CNR); Istituto Di Cristallografia (IC-CNR)	Gotte, M (corresponding author), McGill Univ, Dept Microbiol & Immunol, Duff Med Bldg,D-6,3775 Univ St, Montreal, PQ H3A 2B4, Canada.	matthias.gotte@mcgill.ca			NIAID NIH HHS [AI060563] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060563, R56AI060563] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cai ZH, 2005, J VIROL, V79, P11607, DOI 10.1128/JVI.79.18.11607-11617.2005; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; D'Abramo CM, 2004, J MOL BIOL, V337, P1, DOI 10.1016/j.jmb.2004.01.030; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Ferron F, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-255; Ishii K, 1999, HEPATOLOGY, V29, P1227, DOI 10.1002/hep.510290448; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; Lai VCH, 1999, J VIROL, V73, P10129, DOI 10.1128/JVI.73.12.10129-10136.1999; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Lohmann V, 1999, J BIOL CHEM, V274, P10807, DOI 10.1074/jbc.274.16.10807; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Mendez E, 1998, J VIROL, V72, P4737, DOI 10.1128/JVI.72.6.4737-4745.1998; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Shim JH, 2002, J VIROL, V76, P7030, DOI 10.1128/JVI.76.14.7030-7039.2002; Steitz T A, 1997, Harvey Lect, V93, P75; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; van Dijk AA, 2004, J GEN VIROL, V85, P1077, DOI 10.1099/vir.0.19731-0; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 1998, J VIROL, V72, P9365, DOI 10.1128/JVI.72.11.9365-9369.1998; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	41	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24991	24998		10.1074/jbc.M600474200	http://dx.doi.org/10.1074/jbc.M600474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16831816	Green Published, hybrid			2022-12-27	WOS:000239847800091
J	Tashiro, K; Konishi, H; Sano, E; Nabeshi, H; Yamauchi, E; Taniguchi, H				Tashiro, Kyoko; Konishi, Hiroaki; Sano, Etsuko; Nabeshi, Hiromi; Yamauchi, Emiko; Taniguchi, Hisaaki			Suppression of the ligand-mediated down-regulation of epidermal growth factor receptor by Ymer, a novel tyrosine-phosphorylated and ubiquitinated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING NETWORKS; ERBB RECEPTORS; CANCER-CELLS; RABEX-5; DOMAIN; DEGRADATION; PROTEOMICS; SITES; CBL	The ligand-mediated down-regulation of the growth factor receptors is preceded by the involvement of various other factors. In particular, a ubiquitin ligase, Cbl, plays a central role in this event. Several candidates that have potential effects on the negative control of the epidermal growth factor (EGF) receptor have now been identified by our recent studies in phospho-proteomics. Among these molecules, we focus on characterizing a novel protein, Ymer, which is a tyrosine-phosphorylated and ubiquitinated protein. Ymer is found to be phosphorylated at tyrosine 145 and 146 upon EGF stimulation, and lysine 129 of Ymer has been identified as a ubiquitination site. Ymer has two motifs interacting with the ubiquitin (MIU) domains that might function as a binding site for the ubiquitinated EGF receptor. Although Ymer and EGF receptors are associated in an EGF-dependent manner, their interaction is required not only for MIU domains but also for the tyrosine phosphorylation of Ymer. Phosphorylated Ymer is mainly located at the plasma membrane with EGF receptor and functions in its endocytosis and degradation. Furthermore, EGF-mediated secondary modifications of an activated-EGF receptor are inhibited by overexpressing Ymer in COS7 cells. Therefore, Ymer may have competitive effects on the activation of the EGF receptor. Our findings suggest that Ymer functions as a novel inhibitor for the down-regulation of the EGF receptor and plays a crucial role for regulating the amount of the EGF receptor on the cell surface membrane.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; RIKEN, Harima Inst, Spring 8, Hyogo 6795148, Japan	Tokushima University; RIKEN	Konishi, H (corresponding author), Univ Tokushima, Inst Enzyme Res, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	konishi@ier.tokushima-u.ac.jp	Taniguchi, Hisaaki/I-9171-2012					Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; de Hoog CL, 2004, ANNU REV GENOM HUM G, V5, P267, DOI 10.1146/annurev.genom.4.070802.110305; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627; Lee S, 2006, NAT STRUCT MOL BIOL, V13, P264, DOI 10.1038/nsmb1064; Mattera R, 2006, J BIOL CHEM, V281, P6874, DOI 10.1074/jbc.M509939200; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Vazza G, 2003, GENE, V314, P113, DOI 10.1016/S0378-1119(03)00710-8; Zhang Y, 2005, MOL CELL PROTEOMICS, V4, P1240, DOI 10.1074/mcp.M500089-MCP200	26	27	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24612	24622		10.1074/jbc.M604184200	http://dx.doi.org/10.1074/jbc.M604184200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803894	hybrid			2022-12-27	WOS:000239847800056
J	Timmen, M; Bassler, BL; Jung, K				Timmen, Melanie; Bassler, Bonnie L.; Jung, Kirsten			AI-1 influences the kinase activity but not the phosphatase activity of LuxN of Vibrio harveyi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SIGNAL-TRANSDUCTION; QUORUM-SENSING SIGNAL; ESCHERICHIA-COLI; GENETIC-ANALYSIS; PROTEIN; PHOSPHORELAY; SYSTEM; EXPRESSION; SENSOR; LUMINESCENCE	The Gram-negative bacterium Vibrio harveyi produces and responds to three autoinducers, AI-1, AI-2, and CAI-1 to regulate cell density dependent gene expression by a process referred to as quorum sensing. The concentration of the autoinducers is sensed by three cognate hybrid sensor kinases, and information is channeled via the HPt protein LuxU to the response regulator LuxO. Here, a detailed biochemical study on the enzymatic activities of the membrane-integrated hybrid sensor kinase LuxN, the sensor for N-(D-3-hydroxybutanoyl) homoserine lactone (AI-1), is provided. LuxN was heterologously overproduced as the full-length protein in Escherichia coli. LuxN activities were characterized in vitro and are an autophosphorylation activity with an unusually high ATP turnover rate, stable LuxU phosphorylation, and a slow phosphatase activity with LuxU similar to P as substrate. The presence of AI-1 affected the kinase but not the phosphatase activity of LuxN. The influence of AI-1 on the LuxN -> LuxU signaling step was monitored, and in the presence of AI-1, the kinase activity of LuxN, and hence the amount of LuxU similar to P produced, were significantly reduced. Half-maximal inhibition of kinase activity by AI-1 occurred at 20 mu M. Together, these results indicate that AI-1 directly interacts with LuxN to down-regulate its autokinase activity and suggest that the key regulatory step of the AI-1 quorum sensing system of Vibrio harveyi is AI-1-mediated repression of the LuxN kinase activity.	Univ Munich, Dept Biol 1, Bereich Mikrobiol, D-80638 Munich, Germany; Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA	University of Munich; Howard Hughes Medical Institute; Princeton University	Jung, K (corresponding author), Univ Munich, Dept Biol 1, Bereich Mikrobiol, Maria Ward Str 1A, D-80638 Munich, Germany.	kirsten.jung@lrz.uni-muenchen.de		Bassler, Bonnie/0000-0002-0043-746X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065859] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 065859] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSLER BL, 1994, MOL MICROBIOL, V13, P273, DOI 10.1111/j.1365-2958.1994.tb00422.x; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Freeman JA, 1999, J BACTERIOL, V181, P899, DOI 10.1128/JB.181.3.899-906.1999; Freeman JA, 1999, MOL MICROBIOL, V31, P665, DOI 10.1046/j.1365-2958.1999.01208.x; Freeman JA, 2000, MOL MICROBIOL, V35, P139, DOI 10.1046/j.1365-2958.2000.01684.x; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Henke JM, 2004, J BACTERIOL, V186, P6902, DOI 10.1128/JB.186.20.6902-6914.2004; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jung H, 2002, J BIOL CHEM, V277, P39251, DOI 10.1074/jbc.M206319200; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; Kremling A, 2004, BIOSYSTEMS, V78, P23, DOI 10.1016/j.biosystems.2004.06.003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenz DH, 2005, MOL MICROBIOL, V58, P1186, DOI 10.1111/j.1365-2958.2005.04902.x; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; Mok KC, 2003, EMBO J, V22, P870, DOI 10.1093/emboj/cdg085; Neiditch MB, 2005, MOL CELL, V18, P507, DOI 10.1016/j.molcel.2005.04.020; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Qin L, 2001, P NATL ACAD SCI USA, V98, P908, DOI 10.1073/pnas.031383098; Schuster M, 2001, P NATL ACAD SCI USA, V98, P6003, DOI 10.1073/pnas.101571298; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; Uhl MA, 1996, J BIOL CHEM, V271, P33176, DOI 10.1074/jbc.271.52.33176; Ulrich DL, 2005, J MOL BIOL, V347, P297, DOI 10.1016/j.jmb.2005.01.039; Waters CM, 2005, ANNU REV CELL DEV BI, V21, P319, DOI 10.1146/annurev.cellbio.21.012704.131001; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	47	48	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24398	24404		10.1074/jbc.M604108200	http://dx.doi.org/10.1074/jbc.M604108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807235	hybrid			2022-12-27	WOS:000239847800033
J	Relic, B; Benoit, V; Franchimont, N; Kaiser, MJ; Hauzeur, JP; Gillet, P; Merville, MP; Bours, V; Malaise, MG				Relic, Biserka; Benoit, Valerie; Franchimont, Nathalie; Kaiser, Marie-Joelle; Hauzeur, Jean-Philippe; Gillet, Philippe; Merville, Marie-Paule; Bours, Vincent; Malaise, Michel G.			Peroxisome proliferator-activated receptor-gamma 1 is dephosphorylated and degraded during BAY11-7085-induced synovial fibroblast apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; MAP KINASE; RHEUMATOID-ARTHRITIS; CELLS; PHOSPHORYLATION; EXPRESSION; PROTEIN; DEGRADATION; AGONISTS; DIFFERENTIATION	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) plays a central role in whole body metabolism by regulating adipocyte differentiation and energy storage. Recently, however, PPAR-gamma has also been demonstrated to affect proliferation, differentiation, and apoptosis of different cell types. As we have previously shown that BAY 11-7085-induced synovial fibroblast apoptosis is prevented by PPAR-gamma agonist 15d-PGJ2; the expression of PPAR-gamma in these cells was studied. Both PPAR-gamma 1 and PPAR-gamma 2 isoforms were cloned from synovial fibroblast RNA, but only PPAR-gamma 1 was detected by Western blot, showing constitutive nuclear expression. Within minutes of BAY 11-7085 treatment, a PPAR-1 gamma-specific band was shifted into a form of higher mobility, suggesting dephosphorylation, as confirmed by phosphatase treatment of cell extracts. Of interest, BAY 11-7085-induced PPAR-gamma 1 dephosphorylation was followed by PARP and caspase-8 cleavage as well as by PPAR-gamma 1 protein degradation. PPAR-gamma 1 dephosphorylation was followed by the loss of PPAR-DNA binding activity ubiquitously present in synovial fibroblast nuclear extracts. Unlike the phosphorylated form, dephosphorylated PPAR-gamma 1 was found in insoluble membrane cell fraction and was not ubiquitinated before degradation. PPAR-gamma 1 dephosphorylation coincided with ERK1/2 phosphorylation that accompanies BAY 11-7085-induced synovial fibroblasts apoptosis. 15d-PGJ2, PGD2, and partially UO126, down-regulated ERK1/2 phosphorylation, protected cells from BAY 11-7085-induced apoptosis, and reversed both PPAR-gamma dephosphorylation and degradation. Furthermore, PPAR-gamma antagonist BADGE induced PPAR-gamma 1 degradation, ERK1/2 phosphorylation, and synovial fibroblasts apoptosis. The results presented suggest an anti-apoptotic role for PPAR-gamma 1 in synovial fibroblasts. Since apoptotic marker PARP is cleaved after PPAR-gamma 1 dephosphorylation but before PPAR-gamma 1 degradation, dephosphorylation event might be enough to mediate BAY 11-7085-induced apoptosis in synovial fibroblasts.	Univ Liege, Dept Rheumatol, B-4000 Liege, Belgium; Univ Liege, Dept Med Chem & Human Genet, B-4000 Liege, Belgium; Univ Liege, Dept Orthoped Surg, B-4000 Liege, Belgium; Univ Liege, CBIG, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege	Malaise, MG (corresponding author), CHU Sart Tilman, Dept Rheumatol, B35, B-4000 Liege, Belgium.	Michel.Malaise@ulg.ac.be		BENOIT, Valerie/0000-0002-1098-9452				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Al-Rasheed NM, 2004, J BIOL CHEM, V279, P49747, DOI 10.1074/jbc.M408268200; Appel S, 2005, BLOOD, V106, P3888, DOI 10.1182/blood-2004-12-4709; Baier A, 2003, CURR OPIN RHEUMATOL, V15, P274, DOI 10.1097/00002281-200305000-00015; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; Bren-Mattison Y, 2005, ONCOGENE, V24, P1412, DOI 10.1038/sj.onc.1208333; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Compe E, 2005, MOL CELL BIOL, V25, P6065, DOI 10.1128/MCB.25.14.6065-6076.2005; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Desmet C, 2005, BIOCHEM PHARMACOL, V69, P255, DOI 10.1016/j.bcp.2004.09.017; Eucker J, 2004, ANTI-CANCER DRUG, V15, P955, DOI 10.1097/00001813-200411000-00004; Gardner OS, 2003, J BIOL CHEM, V278, P46261, DOI 10.1074/jbc.M307827200; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Klotz L, 2005, J IMMUNOL, V175, P4948, DOI 10.4049/jimmunol.175.8.4948; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Liu HT, 2004, RHEUM DIS CLIN N AM, V30, P603, DOI 10.1016/j.rdc.2004.04.010; Liu HT, 2003, CURR OPIN PHARMACOL, V3, P317, DOI 10.1016/S1471-4892(03)00037-7; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Relic B, 2004, J BIOL CHEM, V279, P22399, DOI 10.1074/jbc.M314118200; Sabichi AL, 2004, CANCER EPIDEM BIOMAR, V13, P1704; Scaglia N, 2005, BBA-MOL CELL BIOL L, V1687, P141, DOI 10.1016/j.bbalip.2004.11.015; Shiojiri T, 2002, EUR J PHARMACOL, V448, P231, DOI 10.1016/S0014-2999(02)01946-5; Simonin MA, 2002, AM J PHYSIOL-CELL PH, V282, pC125, DOI 10.1152/ajpcell.2002.282.1.C125; Smith TG, 2005, DEVELOPMENT, V132, P1305, DOI 10.1242/dev.01699; Takashima T, 2005, ONCOL REP, V13, P601; Tanabe Yoshiyuki, 2004, Nihon Yakurigaku Zasshi, V124, P337; Theocharis S, 2004, CANCER TREAT REV, V30, P545, DOI 10.1016/j.ctrv.2004.04.004; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Varley CL, 2004, J CELL SCI, V117, P2029, DOI 10.1242/jcs.01042; Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Yamasaki S, 2002, CLIN EXP IMMUNOL, V129, P379, DOI 10.1046/j.1365-2249.2002.01876.x; Zingarelli B, 2005, SHOCK, V23, P393, DOI 10.1097/01.shk.0000160521.91363.88	42	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22597	22604		10.1074/jbc.M512807200	http://dx.doi.org/10.1074/jbc.M512807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766531	hybrid			2022-12-27	WOS:000239542600020
J	Weeks, CS; Tanabe, H; Cummings, JE; Crampton, SP; Sheynis, T; Jelinek, R; Vanderlick, TK; Cocco, MJ; Ouellette, AJ				Weeks, Colby S.; Tanabe, Hiroki; Cummings, Jason E.; Crampton, Steve P.; Sheynis, Tanya; Jelinek, Raz; Vanderlick, T. Kyle; Cocco, Melanie J.; Ouellette, Andre J.			Matrix metalloproteinase-7 activation of mouse Paneth cell pro-alpha-defensins - SER43 down arrow ILE44 proteolysis enables membrane-disruptive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE DEFENSINS; SMALL-INTESTINE; HOST-DEFENSE; CRYPTDIN-4; RESISTANCE; MICE; DETERMINANTS; CYTOLYSIS; MECHANISM; PROTEINS	Small intestinal Paneth cells secrete alpha-defensin microbicidal peptides as mediators of innate enteric immunity. In mice, production of mature Paneth cell alpha-defensins, termed cryptdins (Crps), requires proteolytic activation of inactive precursors (pro-Crps) by the convertase matrix metalloproteinase-7. Proteolysis of mouse (pro-Crp4)(20-92) produces the specific cleavage intermediates pro-Crp4(44-92), pro-Crp4(54-92), and pro-Crp4(59-92). To identify which cleavage event enables bactericidal activity, recombinant pro-Crp4-processing intermediates were purified to homogeneity and assayed for bactericidal peptide activity. The in vitro bactericidal activities of pro-Crp4-processing intermediates were very similar to fully processed Crp4, contrasting the lack of bactericidal and membrane-disruptive activity shown by pro-Crp4(20-92). Thus, cleavage of proCrp4(20-92) at Ser(43)down arrow Ile(44) is sufficient to activate bactericidal activity, and amino acids in the pro-Crp4(20-43) of the proregion maintain the precursor in an inactive state. Because cationic Arg residues are determinants of Crp4 bactericidal peptide activity, we hypothesized that Asp and Glu residues in proCrp4(20-43) neutralize Crp4 Arg side chains in pro-Crp4(20-92). Therefore, a pro-Crp4(20-92) variant with Gly substitutions at all pro-Crp4(20-43) Asp and Glu positions ((DE/G)-pro-Crp4) was prepared, and it was bactericidal and lysed phospholipid vesicles under conditions where native pro-Crp4(20-92) lacks activity. These findings show that MMP-7 proteolysis of pro-Crp4(20-92) at Ser(43)down arrow Ile(44) converts inactive precursors to bactericidal forms by removal of covalently associated, inhibitory acidic amino acids from proximity with the Crp4 component of the molecule.	Univ Calif Irvine, Coll Hlth Sci, Sch Med, Dept Pathol & Lab Med, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Hlth Sci, Sch Med, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Hlth Sci, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Hlth Sci, Sch Med, Ctr Immunol, Irvine, CA 92697 USA; Asahikawa Med Coll, Dept Internal Med 3, Asahikawa, Hokkaido 078, Japan; Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Asahikawa Medical College; Princeton University; Ben Gurion University	Ouellette, AJ (corresponding author), Univ Calif Irvine, Coll Hlth Sci, Sch Med, Dept Pathol & Lab Med, C440, Irvine, CA 92697 USA.	aouellet@uci.edu	Cocco, Melanie J/B-7929-2010; JELINEK, RAZ/F-2023-2012	Cocco, Melanie J/0000-0003-4039-5863; jelinek, raz/0000-0002-0336-1384	NIDDK NIH HHS [DK044632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044632, R01DK044632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Clarke LL, 2004, AM J PHYSIOL-GASTR L, V286, pG1050, DOI 10.1152/ajpgi.00393.2003; Cummings JE, 2003, AUST J CHEM, V56, P1031, DOI 10.1071/CH03110; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; Ghosh D, 2002, NAT IMMUNOL, V3, P583, DOI 10.1038/ni797; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; Jelinek R, 2001, BIOTECHNOL ADV, V19, P109, DOI 10.1016/S0734-9750(00)00064-1; Jing WG, 2004, BIOCHEMISTRY-US, V43, P15759, DOI 10.1021/bi048645p; Kolusheva S, 2000, BIOCHEMISTRY-US, V39, P15851, DOI 10.1021/bi000570b; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; LICHTENSTEIN AK, 1988, J IMMUNOL, V140, P2686; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; Maemoto A, 2004, J BIOL CHEM, V279, P44188, DOI 10.1074/jbc.M406154200; MICHAELSON D, 1992, J LEUKOCYTE BIOL, V51, P634, DOI 10.1002/jlb.51.6.634; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; Norkina O, 2004, INFECT IMMUN, V72, P6040, DOI 10.1128/IAI.72.10.6040-6049.2004; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Putsep K, 2000, J BIOL CHEM, V275, P40478, DOI 10.1074/jbc.M007816200; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; SMOLARSKY M, 1977, J IMMUNOL METHODS, V15, P255, DOI 10.1016/0022-1759(77)90063-1; Tanabe H, 2004, J BIOL CHEM, V279, P11976, DOI 10.1074/jbc.M310251200; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; VALORE EV, 1992, BLOOD, V79, P1538; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Wu Z, 2003, J PEPT RES, V62, P53, DOI 10.1034/j.1399-3011.2003.00068.x; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	36	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28932	28942		10.1074/jbc.M602041200	http://dx.doi.org/10.1074/jbc.M602041200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16822871	hybrid			2022-12-27	WOS:000240680500047
J	Inomata, K; Noack, S; Hammam, MAS; Khawn, H; Kinoshita, H; Murata, Y; Michael, N; Scheerer, P; Krauss, N; Lamparter, T				Inomata, Katsuhiko; Noack, Steffi; Hammam, Mostafa A. S.; Khawn, Htoi; Kinoshita, Hideki; Murata, Yasue; Michael, Norbert; Scheerer, Patrick; Krauss, Norbert; Lamparter, Tilman			Assembly of synthetic locked chromophores with Agrobacterium phytochromes AGP1 and AGP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN DERIVATIVE BEARING; INDUCED PROTON RELEASE; HISTIDINE KINASES; EFFICIENT METHOD; OAT PHYTOCHROME; TUMEFACIENS; RING; BACTERIOPHYTOCHROME; FORM; PHYCOCYANOBILIN	Phytochromes are photoreceptors with a bilin chromophore in which light triggers the conversion between the red-absorbing form Pr and the far-red-absorbing form Pfr. Agrobacterium tumefaciens has two phytochromes, Agp1 and Agp2, with antagonistic properties: in darkness, Agp1 converts slowly from Pfr to Pr, whereas Agp2 converts slowly from Pr to Pfr. In a previous study, we have assembled Agp1 with synthetic locked chromophores 15Za, 15Zs, 15Ea, and 15Es in which the C15 = C16 double bond is fixed in either the E or Z configuration and the C14 - C15 single bond is fixed in either the syn(s) or anti ( a) conformation. In the present study, the locked chromophores 5Za and 5Zs were used for assembly with Agp1; in these chromophores, the C4 = C5 double bond is fixed in the Z configuration, and the C5 - C6 single bond is fixed in either the syn or anti conformation. All locked chromophores were also assembled with Agp2. The data showed that in both phytochromes the Pr chromophore adopts a C4 = C5 Z C5 - C6 syn C15 = C16 Z C14 - C15 anti stereochemistry and that in the Pfr chromophore the C15 = C16 double bond has isomerized to the E configuration, whereas the C14 - C15 single bond remains in the anti conformation. Photoconversion shifted the absorption maxima of the 5Zs adducts to shorter wavelengths, whereas the 5Za adducts were shifted to longer wavelengths. Thus, the C5 - C6 single bond of the Pfr chromophore is rather in an anti conformation, supporting the previous suggestion that during photoconversion of phytochromes, a rotation around the ring A-B connecting single bond occurs.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan; Free Univ Berlin, D-14195 Berlin, Germany; Univ Med Berlin, Charite, Inst Biochem, D-10117 Berlin, Germany	Kanazawa University; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Inomata, K (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan.	inomata@cacheibm.s.kanazawa-u.ac.jp; lamparte@zedat.fu-berlin.de	Lamparter, Tilman/E-4421-2013; Hammam, Mostafa/M-6126-2016	Lamparter, Tilman/0000-0003-4327-9737; Hammam, Mostafa/0000-0003-4299-2231; Scheerer, Patrick/0000-0001-5028-2075; Krauss, Norbert/0000-0002-7128-4632				Andel F, 1996, BIOCHEMISTRY-US, V35, P15997, DOI 10.1021/bi962175k; Andel F, 2000, BIOCHEMISTRY-US, V39, P2667, DOI 10.1021/bi991688z; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Blumenstein A, 2005, CURR BIOL, V15, P1833, DOI 10.1016/j.cub.2005.08.061; Borucki B, 2005, J BIOL CHEM, V280, P34358, DOI 10.1074/jbc.M505493200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen EF, 1996, BIOCHEMISTRY-US, V35, P843, DOI 10.1021/bi952115z; DeLano W. L., 2002, PYMOL MOL GRAPHICS S, DOI DOI 10.1007/S10822-016-9944-X; Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375; EILFELD P, 1985, Z NATURFORSCH C, V40, P109; FALK H, 1987, MONATSH CHEM, V118, P1301, DOI 10.1007/BF00816873; Falk H., 1989, CHEM LINEAR OLIGOPYR; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Giraud E, 2005, J BIOL CHEM, V280, P32389, DOI 10.1074/jbc.M506890200; Giraud E, 2004, PHOTOCH PHOTOBIO SCI, V3, P587, DOI 10.1039/b315770a; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Hammam MAS, 2004, CHEM LETT, V33, P1258, DOI 10.1246/cl.2004.1258; HAMMAM MAS, 2006, IN PRESS B CHEM SOC; Heyne K, 2002, BIOPHYS J, V82, P1004, DOI 10.1016/S0006-3495(02)75460-X; Hubschmann T, 2001, EUR J BIOCHEM, V268, P2055, DOI 10.1046/j.1432-1327.2001.02083.x; Inomata K, 2005, J BIOL CHEM, V280, P24491, DOI 10.1074/jbc.M504710200; Kakiuchi T, 1998, CHEM LETT, P1001, DOI 10.1246/cl.1998.1001; Kakiuchi T, 1999, SYNLETT, P901; Karniol B, 2003, P NATL ACAD SCI USA, V100, P2807, DOI 10.1073/pnas.0437914100; Kinoshita H, 2005, CHEM LETT, V34, P800, DOI 10.1246/cl.2005.800; Lamparter T, 2005, BIOCHEMISTRY-US, V44, P8461, DOI 10.1021/bi047510g; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Mroginski MA, 2004, J AM CHEM SOC, V126, P16734, DOI 10.1021/ja043959l; Oberpichler I, 2006, FEBS LETT, V580, P437, DOI 10.1016/j.febslet.2005.12.035; Rentsch S, 1997, PHOTOCHEM PHOTOBIOL, V66, P585, DOI 10.1111/j.1751-1097.1997.tb03193.x; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; Rudiger W., 1994, PHOTOMORPHOGENESIS P, V2nd, P51; Sawamoto D, 2001, CHEM LETT, P588, DOI 10.1246/cl.2001.588; Scheerer P, 2006, J STRUCT BIOL, V153, P97, DOI 10.1016/j.jsb.2005.11.002; STAROSTZIK C, 1995, FEBS LETT, V370, P146, DOI 10.1016/0014-5793(95)00820-Y; Takeda S, 2001, CHEM LETT, P590, DOI 10.1246/cl.2001.590; Tasler R, 2005, FEBS J, V272, P1927, DOI 10.1111/j.1742-4658.2005.04623.x; Tu SL, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P121, DOI 10.1002/352760510X.ch6; van Thor JJ, 2001, BIOCHEMISTRY-US, V40, P11460, DOI 10.1021/bi002651d; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	43	48	48	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28162	28173		10.1074/jbc.M603983200	http://dx.doi.org/10.1074/jbc.M603983200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16803878	Green Submitted, hybrid			2022-12-27	WOS:000240534400054
J	Lebrun, AH; Wunder, C; Hildebrand, J; Churin, Y; Zahringer, U; Lindner, B; Meyer, TF; Heinz, E; Warnecke, D				Lebrun, Anne-Helene; Wunder, Christian; Hildebrand, Janosch; Churin, Yuri; Zaehringer, Ulrich; Lindner, Buko; Meyer, Thomas F.; Heinz, Ernst; Warnecke, Dirk			Cloning of a cholesterol-alpha-glucosyltransferase from Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; PICHIA-PASTORIS; FUNCTIONAL EXPRESSION; ESCHERICHIA-COLI; STEROL GLUCOSYLTRANSFERASES; BORRELIA-BURGDORFERI; STRUCTURAL-ANALYSIS; HEAT-SHOCK; GLYCOSYLTRANSFERASES; GLUCOSIDE	O-Glycans of the human gastric mucosa show antimicrobial activity against the pathogenic bacterium Helicobacter pylori by inhibiting the bacterial cholesterol-alpha-glucosyltransferase (Kawakubo, M., Ito, Y., Okimura, Y., Kobayashi, M., Sakura, K., Kasama, S., Fukuda, M. N., Fukuda, M., Katsuyama, T., and Nakayama, J. (2004) Science 305, 1003 - 1006). This enzyme catalyzes the first step in the biosynthesis of four unusual glycolipids: cholesteryl-alpha-glucoside, cholesteryl-6'-O-acyl-alpha-glucoside, cholesteryl-6'-O-phosphatidyl-alpha-glucoside, and cholesteryl-6'-O-lysophosphatidyl-alpha-glucoside. Here we report the identification, cloning, and functional characterization of the cholesterol-alpha-glucosyltransferase from H. pylori. The hypothetical protein HP0421 from H. pylori belongs to the glycosyltransferase family 4 and shows similarities to some bacterial diacylglycerol-alpha-glucosyltransferases. Deletion of the HP0421 gene in H. pylori resulted in the loss of cholesteryl-alpha-glucoside and all of its three derivatives. Heterologous expression of HP0421 in the yeast Pichia pastoris led to the biosynthesis of ergosteryl-alpha-lucoside as demonstrated by purification of the lipid and subsequent structural analysis by nuclear magnetic resonance spectroscopy and mass spectrometry. In vitro enzyme assays were performed with cell-free homogenates obtained from cells of H. pylori or from transgenic Escherichia coli, which express HP0421. These assays revealed that the enzyme represents a membrane-bound, UDP-glucose-dependent cholesterol-alpha-glucosyltransferase.	Univ Hamburg, Bioctr Klein Flottbek & Bot Garden, D-22609 Hamburg, Germany; Max Planck Inst Infect Biol, Dept Mol Biol, D-10117 Berlin, Germany; Leibniz Ctr Med & Biosci, Res Ctr, D-23845 Borstel, Germany	University of Hamburg; Max Planck Society; Forschungszentrum Borstel	Warnecke, D (corresponding author), Univ Hamburg, Bioctr Klein Flottbek & Bot Garden, Ohnhorststr 18, D-22609 Hamburg, Germany.	warnecke@botanik.uni-hamburg.de	Wunder, Christian/K-8542-2017; Meyer, Thomas F. F/J-2485-2013; Lindner, Buko/G-9731-2014	Wunder, Christian/0000-0001-9091-0080; Meyer, Thomas F. F/0000-0002-6120-8679; Hildebrand, Janosch/0000-0001-7030-7495				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ben-Menachem G, 2003, P NATL ACAD SCI USA, V100, P7913, DOI 10.1073/pnas.1232451100; Berg S, 2001, J BIOL CHEM, V276, P22056, DOI 10.1074/jbc.M102576200; Bok JW, 1999, PHYTOCHEMISTRY, V51, P891, DOI 10.1016/S0031-9422(99)00128-4; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cereghino GPL, 2001, GENE, V263, P159, DOI 10.1016/S0378-1119(00)00576-X; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; Edman M, 2003, J BIOL CHEM, V278, P8420, DOI 10.1074/jbc.M211492200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; HAQUE M, 1995, J BACTERIOL, V177, P5334, DOI 10.1128/jb.177.18.5334-5337.1995; Hillig I, 2003, FEBS LETT, V553, P365, DOI 10.1016/S0014-5793(03)01058-5; HIRAI Y, 1995, J BACTERIOL, V177, P5327, DOI 10.1128/jb.177.18.5327-5333.1995; Holzl G, 2005, PLANT CELL PHYSIOL, V46, P1766, DOI 10.1093/pcp/pci189; Holzl G, 2005, GLYCOBIOLOGY, V15, P874, DOI 10.1093/glycob/cwi066; Hu Y, 2004, CHEM BIOL, V11, P703, DOI 10.1016/j.chembiol.2004.02.024; Jorasch P, 1998, MOL MICROBIOL, V29, P419, DOI 10.1046/j.1365-2958.1998.00930.x; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; Kawakubo M, 2004, SCIENCE, V305, P1003, DOI 10.1126/science.1099250; Kim YK, 2002, PLANT J, V30, P177, DOI 10.1046/j.1365-313X.2002.01284.x; Kunimoto S, 2003, CELL STRUCT FUNCT, V28, P179; Kunimoto S, 2000, CELL STRESS CHAPERON, V5, P3, DOI 10.1379/1466-1268(2000)005<0003:EOCGBH>2.0.CO;2; Leipelt M, 2001, J BIOL CHEM, V276, P33621, DOI 10.1074/jbc.M104952200; LIVERMORE BP, 1978, INFECT IMMUN, V20, P215, DOI 10.1128/IAI.20.1.215-220.1978; MAYBERRY WR, 1983, BIOCHIM BIOPHYS ACTA, V752, P434, DOI 10.1016/0005-2760(83)90273-4; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Oku M, 2003, EMBO J, V22, P3231, DOI 10.1093/emboj/cdg331; PATEL KR, 1978, J BACTERIOL, V136, P829, DOI 10.1128/JB.136.2.829-831.1978; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; Sakaki T, 2001, YEAST, V18, P679, DOI 10.1002/yea.720; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schroder NWJ, 2003, J BIOL CHEM, V278, P33645, DOI 10.1074/jbc.M305799200; Shimomura H, 2004, FEMS MICROBIOL LETT, V237, P407, DOI 10.1016/j.femsle.2004.07.004; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SMITH PF, 1971, J BACTERIOL, V108, P986, DOI 10.1128/JB.108.3.986-991.1971; Stasyk OV, 2003, CELL BIOL INT, V27, P947, DOI 10.1016/j.cellbi.2003.08.004; Tannaes T, 2000, APMIS, V108, P349, DOI 10.1034/j.1600-0463.2000.d01-67.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Warnecke D, 1999, J BIOL CHEM, V274, P13048, DOI 10.1074/jbc.274.19.13048; Warnecke DC, 1997, PLANT MOL BIOL, V35, P597, DOI 10.1023/A:1005806119807; WARNECKE DC, 1994, PLANT PHYSIOL, V105, P1067, DOI 10.1104/pp.105.4.1067; Yu B, 2002, P NATL ACAD SCI USA, V99, P5732, DOI 10.1073/pnas.082696499	44	71	76	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					27765	27772		10.1074/jbc.M603345200	http://dx.doi.org/10.1074/jbc.M603345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16844692	hybrid			2022-12-27	WOS:000240534400012
J	Owen, RP; Badagnani, I; Giacomini, KM				Owen, Ryan P.; Badagnani, Ilaria; Giacomini, Kathleen M.			Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; PYRIMIDINE; CLONING; PURINE; IDENTIFICATION; INACTIVATION; SELECTIVITY; EXPRESSION; HCNT2; CELLS	Members of the concentrative nucleoside transporter ( CNT) family (SLC28) mediate the transport of naturally-occurring nucleosides, and nucleoside analog drugs across the plasma membrane of epithelial cells. Each of the three CNT family members has a distinct specificity for naturally occurring nucleosides, and residues that contribute to the specificity of each transporter have been identified. In contrast, the molecular determinants of specificity for synthetic nucleoside analogs are not known. In this study, we take advantage of the large species difference that exists between human and rat CNT2 (hCNT2 and rCNT2) in their ability to transport the nucleoside analog drug cladribine, 2CdA, (rCNT2 > > > hCNT2) to identify the critical domains and amino acid residues that contribute to the observed difference in specificity between CNT2 orthologs. Using chimeric proteins of human and rat CNT2, we determined that the C-terminal half of CNT2 contained the determinants of 2CdA selectivity. We replaced key residues in the C terminus of hCNT2 with the equivalent residue in rCNT2. One residue in the C-terminal portion of CNT2 was found to significantly contribute to 2CdA selectivity: hCNT2-S354A. This mutant caused an increase of 5 -6-fold over hCNT2. The 2-chloro pharmacophore, rather than the 2'-deoxyribose was responsible for the reduced 2CdA uptake by hCNT2. Our data are consistent with a model in which an increased capability for hydrogen bonding in critical amino acids that reside in the C terminus of rCNT2 contributes to its enhanced selectivity for 2CdA.	Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94158 USA	University of California System; University of California San Francisco	Giacomini, KM (corresponding author), Univ Calif San Francisco, Dept Biopharmaceut Sci, 1550 4th St, San Francisco, CA 94158 USA.	kmg@itsa.ucsf.edu	Giacomini, Kathleen/AEF-2452-2022		NIGMS NIH HHS [GM36780, GM42230, GM61390] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036780, U01GM061390, U19GM061390, R01GM042230] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Byrd John C, 2004, Hematology Am Soc Hematol Educ Program, P163; Chang C, 2004, MOL PHARMACOL, V65, P558, DOI 10.1124/mol.65.3.558; Fischer U, 2005, ONCOGENE, V24, P1231, DOI 10.1038/sj.onc.1208290; Gerstin KM, 2000, PHARMACEUT RES, V17, P906, DOI 10.1023/A:1007510801253; Gerstin KM, 2002, AM J PHYSIOL-RENAL, V283, pF344, DOI 10.1152/ajprenal.00274.2001; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Jegla T, 1997, J NEUROSCI, V17, P32, DOI 10.1523/JNEUROSCI.17-01-00032.1997; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Owen RP, 2005, PHARMACOGENET GENOM, V15, P83, DOI 10.1097/01213011-200502000-00004; Pennycooke M, 2001, BIOCHEM BIOPH RES CO, V280, P951, DOI 10.1006/bbrc.2000.4205; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Wang J, 1997, J BIOL CHEM, V272, P28845, DOI 10.1074/jbc.272.46.28845; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Wang J, 1999, MOL PHARMACOL, V55, P234, DOI 10.1124/mol.55.2.234; Yin YZ, 2001, LEUKEMIA RES, V25, P423, DOI 10.1016/S0145-2126(00)00147-8	17	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26675	26682		10.1074/jbc.M513421200	http://dx.doi.org/10.1074/jbc.M513421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840788	hybrid			2022-12-27	WOS:000240249500085
J	Chakravarthy, S; Luger, K				Chakravarthy, Srinivas; Luger, Karolin			The histone variant macro-H2A preferentially forms "hybrid nucleosomes"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-CHARACTERIZATION; CRYSTAL-STRUCTURE; CORE PARTICLE; MACROH2A; TRANSCRIPTION; CHROMATIN; BINDING; STABILITY; OCTAMER; COMPLEX	The histone domain of macro-H2A, which constitutes the N-terminal one third of this histone variant, is only 64% identical to major H2A. We have shown previously that the main structural differences in a nucleosome in which both H2A moieties have been replaced by macro-H2A reside in the only point of contact between the two histone dimers, the L1-L1 interface of macro-H2A. Here we show that the L1 loop of macro-H2A is responsible for the increased salt-dependent stability of the histone octamer, with implications for the nucleosome assembly pathway. It is unknown whether only one or both of the H2A-H2B dimers within a nucleosome are replaced with H2A variant containing nucleosomes in vivo. We demonstrate that macroH2A preferentially forms hybrid nucleosomes containing one chain each of major H2A and macro-HA in vitro. The 2.9-angstrom crystal structure of such a hybrid nucleosome shows significant structural differences in the L1-L1 interface when comparing with homotypic major H2A-and macro-H2A-containing nucleosomes. Both homotypic and hybrid macro-nucleosome core particles ( NCPs) are resistant to chaperone-assisted H2A-H2B dimer exchange. Together, our findings suggest that the histone domain of macro-H2A modifies the dynamic properties of the nucleosome. We propose that the possibility of forming hybrid macro-NCP adds yet another level of complexity to variant nucleosome structure and function.	Colorado State Univ, Howard Hughes Med Inst, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University; Howard Hughes Medical Institute; Colorado State University	Luger, K (corresponding author), Colorado State Univ, Howard Hughes Med Inst, Ft Collins, CO 80523 USA.	karolin.luger@colostate.edu		SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331				Abbott DW, 2005, J BIOL CHEM, V280, P16437, DOI 10.1074/jbc.M500170200; Abbott DW, 2004, BIOCHEMISTRY-US, V43, P1352, DOI 10.1021/bi035859i; Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; Bao YH, 2004, EMBO J, V23, P3314, DOI 10.1038/sj.emboj.7600316; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; Chadwick BP, 2002, J CELL BIOL, V157, P1113, DOI 10.1083/jcb.200112074; Chadwick BP, 2001, NUCLEIC ACIDS RES, V29, P2699, DOI 10.1093/nar/29.13.2699; Chakravarthy S, 2004, COLD SPRING HARB SYM, V69, P227, DOI 10.1101/sqb.2004.69.227; Chakravarthy S, 2005, MOL CELL BIOL, V25, P7616, DOI 10.1128/MCB.25.17.7616-7624.2005; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; ENDO S, 1983, ANAL BIOCHEM, V131, P108, DOI 10.1016/0003-2697(83)90141-0; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Gautier T, 2004, EMBO REP, V5, P715, DOI 10.1038/sj.embor.7400182; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Luger K, 1999, METHOD ENZYMOL, V304, P3; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 2003, CURR OPIN GENET DEV, V13, P127, DOI 10.1016/S0959-437X(03)00026-1; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; Muthurajan UM, 2004, EMBO J, V23, P260, DOI 10.1038/sj.emboj.7600046; Muthurajan UM, 2003, BIOPOLYMERS, V68, P547, DOI 10.1002/bip.10317; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Rice LM, 1998, J APPL CRYSTALLOGR, V31, P798, DOI 10.1107/S0021889898006645; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Tsunaka Y, 2005, NUCLEIC ACIDS RES, V33, P3424, DOI 10.1093/nar/gki663	37	53	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25522	25531		10.1074/jbc.M602258200	http://dx.doi.org/10.1074/jbc.M602258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803903	hybrid			2022-12-27	WOS:000240031300055
J	Wang, YS; Bogenhagen, DF				Wang, Yousong; Bogenhagen, Daniel F.			Human mitochondrial DNA nucleoids are linked to protein folding machinery and metabolic enzymes at the mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-AAA PROTEASE; BINDING-PROTEIN; MESSENGER-RNA; TRANSCRIPTION; NUCLEAR; INITIATION; COMPLEXES; MOUSE; PHOSPHORYLATION; IDENTIFICATION	Mitochondrial DNA (mtDNA) is packaged into bacterial nucleoid-like structures, each containing several mtDNA molecules. The distribution of nucleoids during mitochondrial fission and fusion events and during cytokinesis is important to the segregation of mitochondrial genomes in heteroplasmic cells bearing a mixture of wild-type and mutant mtDNA molecules. We report fractionation of HeLa cell mtDNA nucleoids into two subsets of complexes that differ in their sedimentation velocity and their association with cytoskeletal proteins. Pulse labeling studies indicated that newly replicated mtDNA molecules are evenly represented in the rapidly and slowly sedimenting fractions. Slowly sedimenting nucleoids were immunoaffinity purified using antibodies to either of two abundant mtDNA-binding proteins, TFAM or mtSSB. These two different immunoaffinity procedures yielded very similar sets of proteins, with 21 proteins in common, including most of the proteins previously shown to play roles in mtDNA replication and transcription. In addition to previously identified mitochondrial proteins, multiple peptides were observed for one novel DNA metabolic protein, the DEAH-box helicase DHX30. Antibodies raised against a recombinant fragment of this protein confirmed the mitochondrial localization of a specific isoform of DHX30.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bogenhagen, DF (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	dan@pharm.sunysb.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES012039] Funding Source: Medline; NIGMS NIH HHS [R01GM29681] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams DJ, 2003, J BIOL CHEM, V278, P44894, DOI 10.1074/jbc.M307782200; Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251; ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ANTOSHECHKIN I, 1995, MOL CELL BIOL, V15, P7032; Banfi S, 1999, GENOMICS, V59, P51, DOI 10.1006/geno.1999.5818; BARAT M, 1985, EXP CELL RES, V157, P207, DOI 10.1016/0014-4827(85)90163-6; Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; BOGENHAGEN D, 1978, J MOL BIOL, V119, P49, DOI 10.1016/0022-2836(78)90269-3; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708; Cheng XL, 2005, J BIOCHEM, V138, P673, DOI 10.1093/jb/mvi169; Ciesla J, 2006, ACTA BIOCHIM POL, V53, P11; Da Cruz S, 2003, J BIOL CHEM, V278, P41566, DOI 10.1074/jbc.M304940200; DellOrco RT, 1996, EXP GERONTOL, V31, P245, DOI 10.1016/0531-5565(95)02009-8; Dimmer KS, 2005, J CELL BIOL, V168, P103, DOI 10.1083/jcb.200410030; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950; Hobbs AEA, 2001, J CELL BIOL, V152, P401, DOI 10.1083/jcb.152.2.401; Iborra FJ, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-9; Jackson DA, 1996, NUCLEIC ACIDS RES, V24, P1212, DOI 10.1093/nar/24.7.1212; John GB, 2005, MOL BIOL CELL, V16, P1543, DOI 10.1091/mbc.e04-08-0697; Kanki T, 2004, ANN NY ACAD SCI, V1011, P61, DOI 10.1196/annals.1293.007; Kaufman BA, 2003, J CELL BIOL, V163, P457, DOI 10.1083/jcb.200306132; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Malka F, 2006, BBA-MOL CELL RES, V1763, P463, DOI 10.1016/j.bbamcr.2006.04.001; Martin M, 2005, CELL, V123, P1227, DOI 10.1016/j.cell.2005.09.040; Meeusen S, 1999, J CELL BIOL, V145, P291, DOI 10.1083/jcb.145.2.291; Meeusen S, 2003, J CELL BIOL, V163, P503, DOI 10.1083/jcb.200304040; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; Minczuk M, 2002, NUCLEIC ACIDS RES, V30, P5074, DOI 10.1093/nar/gkf647; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Nolden M, 2005, CELL, V123, P277, DOI 10.1016/j.cell.2005.08.003; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Odgren PR, 1996, J CELL SCI, V109, P2253; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Schagger H, 2001, J BIOL CHEM, V276, P37861; Shen EL, 2001, NUCLEIC ACIDS RES, V29, P2822, DOI 10.1093/nar/29.13.2822; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Stillman B, 2005, FEBS LETT, V579, P877, DOI 10.1016/j.febslet.2004.12.011; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; Tolstonog GV, 2001, DNA CELL BIOL, V20, P531, DOI 10.1089/104454901317094954; Tsuchiya N, 2004, BIOCHEM BIOPH RES CO, V317, P736, DOI 10.1016/j.bbrc.2004.03.103; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WHITFORD T, 1993, THESIS STATE U NY ST; Youngman MJ, 2004, J CELL BIOL, V164, P677, DOI 10.1083/jcb.200308012	60	224	233	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25791	25802		10.1074/jbc.M604501200	http://dx.doi.org/10.1074/jbc.M604501200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825194	hybrid			2022-12-27	WOS:000240031300081
J	Andreotti, G; Mendez, BL; Amodeo, P; Morelli, MAC; Nakamuta, H; Motta, A				Andreotti, Giuseppina; Mendez, Blanca Lopez; Amodeo, Pietro; Morelli, Maria A. Castiglione; Nakamuta, Hiromichi; Motta, Andrea			Structural determinants of salmon calcitonin bioactivity - The role of the Leu-based amphipathic alpha-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECYL-SULFATE MICELLES; BIOLOGICAL POTENCY; 2-DIMENSIONAL NMR; CONFORMATIONAL FLEXIBILITY; MOLECULAR-DYNAMICS; ADENYLATE-CYCLASE; AMINO-TERMINUS; MODEL PEPTIDE; RECEPTOR; ANALOGS	Salmon calcitonin ( sCT) forms an amphipathic helix in the region 9 - 19, with the C-terminal decapeptide interacting with the helix ( Amodeo, P., Motta, A., Strazzullo, G., Castiglione Morelli, M. A. ( 1999) J. Biomol. NMR 13, 161 - 174). To uncover the structural requirements for the hormone bioactivity, we investigated several sCT analogs. They were designed so as to alter the length of the central helix by removal and/or replacement of flanking residues and by selectively mutating or deleting residues inside the helix. The helix content was assessed by circular dichroism and NMR spectroscopies; the receptor binding affinity in human breast cancer cell line T 47D and the in vivo hypocalcemic activity were also evaluated. In particular, by NMR spectroscopy and molecular dynamics calculations we studied Leu(23), Ala(24)-sCT in which Pro(23) and Arg(24) were replaced by helix inducing residues. Compared with sCT, it assumes a longer amphipathic alpha-helix, with decreased binding affinity and one-fifth of the hypocalcemic activity, therefore supporting the idea of a relationship between a definite helix length and bioactivity. From the analysis of other sCT mutants, we inferred that the correct helix length is located in the 9 - 19 region and requires long range interactions and the presence of specific regions of residues within the sequence for high binding affinity and hypocalcemic activity. Taken together, the structural and biological data identify well defined structural parameters of the helix for sCT bioactivity.	CNR, Ist Chim Biomol, Comprensorio Olivetti, I-80078 Pozzuoli, Napoli, Italy; Univ Basilicata, Dipartimento Chim, I-85100 Potenza, Italy; Hiroshima Int Univ, Fac Pharmaceut Sci, Dept Pharmaceut Sci, Pharmacol Lab, Hiroshima 7370112, Japan	Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Basilicata	Motta, A (corresponding author), CNR, Ist Chim Biomol, Comprensorio Olivetti, Edificio A,Via Campi Flegrei 34, I-80078 Pozzuoli, Napoli, Italy.	amotta@icmib.na.cnr.it	Amodeo, Pietro/P-1800-2015; ANDREOTTI, GIUSEPPINA/AAX-8952-2020	Amodeo, Pietro/0000-0002-6439-7575; ANDREOTTI, GIUSEPPINA/0000-0002-1594-0156; Castiglione Morelli, Maria Antonietta/0000-0003-3967-3117; Motta, Andrea/0000-0002-8643-658X				Amodeo P, 1999, J BIOMOL NMR, V13, P161, DOI 10.1023/A:1008365322148; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Andreotti G, 2004, J BIOL CHEM, V279, P6364, DOI 10.1074/jbc.M310882200; ARVINTE T, 1993, J BIOL CHEM, V268, P6415; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Chen WJ, 1997, MOL PHARMACOL, V52, P1164, DOI 10.1124/mol.52.6.1164; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dong MQ, 2004, J BIOL CHEM, V279, P31177, DOI 10.1074/jbc.M404113200; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; Epand RF, 2004, BIOPOLYMERS, V76, P258, DOI 10.1002/bip.20030; EPAND RM, 1985, INT J PEPT PROT RES, V25, P105; EPAND RM, 1988, BIOCHEM BIOPH RES CO, V152, P203, DOI 10.1016/S0006-291X(88)80700-9; EPAND RM, 1986, BIOCHEMISTRY-US, V25, P1964, DOI 10.1021/bi00356a019; EPAND RM, 1990, EUR J BIOCHEM, V188, P633, DOI 10.1111/j.1432-1033.1990.tb15444.x; EPAND RM, 1988, J MED CHEM, V31, P1595, DOI 10.1021/jm00403a019; EPAND RM, 1986, EUR J BIOCHEM, V159, P125, DOI 10.1111/j.1432-1033.1986.tb09841.x; EPAND RM, 1986, INT J PEPT PROT RES, V26, P501; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; FINDLAY DM, 1983, ENDOCRINOLOGY, V112, P1288, DOI 10.1210/endo-112-4-1288; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; GORN AH, 1995, J CLIN INVEST, V95, P2680, DOI 10.1172/JCI117970; GREEN FR, 1987, P NATL ACAD SCI USA, V84, P8340, DOI 10.1073/pnas.84.23.8340; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUNTERT P, 1989, J AM CHEM SOC, V111, P3997; HOUSSAMI S, 1995, MOL PHARMACOL, V47, P798; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Jourdan F, 2003, PROTEINS, V52, P534, DOI 10.1002/prot.10418; KAPURNIOTU A, 1995, J MED CHEM, V38, P836, DOI 10.1021/jm00005a011; Kazantzis A, 2002, EUR J BIOCHEM, V269, P780, DOI 10.1046/j.0014-2956.2001.02689.x; LAMP SJ, 1981, J BIOL CHEM, V256, P2269; LYBRAND TP, 1986, P NATL ACAD SCI USA, V83, P833, DOI 10.1073/pnas.83.4.833; MAIER R, 1976, CLIN ENDOCRINOL, V5, P327; Manicourt D.-H., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P285; MEADOWS RP, 1991, BIOCHEMISTRY-US, V30, P1247, DOI 10.1021/bi00219a012; MEYER JP, 1991, BIOPOLYMERS, V31, P233, DOI 10.1002/bip.360310210; MOE GR, 1983, J AM CHEM SOC, V105, P4100, DOI 10.1021/ja00350a064; MOE GR, 1985, BIOCHEMISTRY-US, V24, P1971, DOI 10.1021/bi00329a026; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; MORELLI MAC, 1992, J BIOMOL NMR, V2, P335, DOI 10.1007/BF01874812; MOTTA A, 1991, BIOCHEMISTRY-US, V30, P10444, DOI 10.1021/bi00107a012; Motta A, 1998, PROTEINS, V32, P314, DOI 10.1002/(SICI)1097-0134(19980815)32:3<314::AID-PROT7>3.3.CO;2-J; NAKAMUTA H, 1990, ENDOCRINOLOGY, V127, P163, DOI 10.1210/endo-127-1-163; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pham V, 2004, J BIOL CHEM, V279, P6720, DOI 10.1074/jbc.M307214200; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Rajashankar KR, 1996, PROTEIN SCI, V5, P932; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; SINGER FR, 1972, J CLIN INVEST, V51, P2331, DOI 10.1172/JCI107044; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; WADA S, 1995, ENDOCRINOLOGY, V136, P2611, DOI 10.1210/en.136.6.2611; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WURTICH K, 1986, NMR PROTEINS NUCLEIC, P162; ZAIDI M, 2002, PRINCIPLES BONE BIOL, V2, P1423	58	52	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24193	24203		10.1074/jbc.M603528200	http://dx.doi.org/10.1074/jbc.M603528200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16766525	hybrid			2022-12-27	WOS:000239847800013
J	Bassler, J; Kallas, M; Hurt, E				Bassler, Jochen; Kallas, Martina; Hurt, Ed			The NUG1 GTPase reveals an N-terminal RNA-binding domain that is essential for association with 60 S pre-ribosomal particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEXES; MESSENGER-RNA; ESCHERICHIA-COLI; 3-HYBRID SYSTEM; IN-VITRO; BIOGENESIS; SUBUNIT; MATURATION; CYTOPLASM	The putative yeast GTPase Nug1, which is associated with several pre-60 S particles in the nucleolus and nucleoplasm, consists of an N-terminal domain, which is found only in eukaryotic orthologues, and middle and C-terminal domains that are conserved throughout eukaryotes, bacteria, and archaea. Here, we analyzed the role of the eukaryote- specific Nug1 N-domain (Nug1-N). We show that the essential Nug1-N is sufficient and necessary for nucle(ol)ar targeting and association with pre-60 S particles. Nug1-N exhibits RNA binding activity and is genetically linked in an allele- specific way to the pre-60 S factors Noc2, Noc3, and Dbp10. In contrast, the middle domain, which exhibits a circularly permuted GTPase fold and an intrinsic GTP hydrolysis activity in vitro, is not essential for cell growth. The conserved Nug1 C-domain, which has a yet uncharacterized fold, is also essential for ribosome biogenesis. Our findings suggest that Nug1 associates with pre-60 S subunits via its essential N-terminal RNA-binding domain and exerts a non-essential regulative role in pre-60 S subunit biogenesis via its central GTPase domain.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Hurt, E (corresponding author), Univ Heidelberg, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Baßler, Jochen/AAC-5336-2021; Ed Hurt, Dr./AAE-8874-2019	Baßler, Jochen/0000-0002-7441-7867; Ed Hurt, Dr./0000-0002-4535-8255				Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; Barrientos A, 2003, MOL BIOL CELL, V14, P2292, DOI 10.1091/mbc.E02-10-0636; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; Burger F, 2000, NUCLEIC ACIDS RES, V28, P2315, DOI 10.1093/nar/28.12.2315; Daigle DM, 2004, J BACTERIOL, V186, P1381, DOI 10.1128/JB.186.5.1381-1387.2004; Daigle DM, 2002, BIOCHEMISTRY-US, V41, P11109, DOI 10.1021/bi020355q; De Antoni A, 2002, J BIOL CHEM, V277, P41023, DOI 10.1074/jbc.M205783200; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Du XM, 2006, MOL BIOL CELL, V17, P460, DOI 10.1091/mbc.E05-09-0848; Fewell SW, 1999, MOL CELL BIOL, V19, P826; FISKE LM, 1925, J BIOL CHEM, V66, P375; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Granneman S, 2004, EXP CELL RES, V296, P43, DOI 10.1016/j.yexcr.2004.03.016; Hedges J, 2005, EMBO J, V24, P567, DOI 10.1038/sj.emboj.7600547; Himeno H, 2004, NUCLEIC ACIDS RES, V32, P5303, DOI 10.1093/nar/gkh861; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Kallstrom G, 2003, MOL CELL BIOL, V23, P4344, DOI 10.1128/MCB.23.12.4344-4355.2003; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Liu SJ, 2004, WORLD J GASTROENTERO, V10, P1246; Maniatis T., 1982, MOL CLONING; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Nissan TA, 2004, MOL CELL, V15, P295, DOI 10.1016/j.molcel.2004.06.033; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Osheim YN, 2004, MOL CELL, V16, P943, DOI 10.1016/j.molcel.2004.11.031; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saveanu C, 2003, MOL CELL BIOL, V23, P4449, DOI 10.1128/MCB.23.13.4449-4460.2003; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Schafer T, 2006, NATURE, V441, P651, DOI 10.1038/nature04840; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Shin DH, 2004, P NATL ACAD SCI USA, V101, P13198, DOI 10.1073/pnas.0405202101; Sijin L, 2004, J EXP CLIN CANC RES, V23, P529; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tsai RYL, 2005, J CELL BIOL, V168, P179, DOI 10.1083/jcb.200409053; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Uicker WC, 2006, MOL MICROBIOL, V59, P528, DOI 10.1111/j.1365-2958.2005.04948.x; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; West M, 2005, MOL CELL BIOL, V25, P3802, DOI 10.1128/MCB.25.9.3802-3813.2005	44	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24737	24744		10.1074/jbc.M604261200	http://dx.doi.org/10.1074/jbc.M604261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803892	hybrid			2022-12-27	WOS:000239847800070
J	Chen, XH; Kokkotou, EG; Mustafa, N; Bhaskar, KR; Sougioultzis, S; O'Brien, M; Pothoulakis, C; Kelly, CP				Chen, Xinhua; Kokkotou, Efi G.; Mustafa, Nasima; Bhaskar, K. Ramakrishnan; Sougioultzis, Stavros; O'Brien, Michael; Pothoulakis, Charalabos; Kelly, Ciaran P.			Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; T84 CELLS; PREVENTS CYTOKINE; CHOLERA-TOXIN; RABBIT ILEUM; RAT ILEUM; KAPPA-B; RECEPTOR; INDUCTION; INTESTINE	Saccharomyces boulardii (Sb), a probiotic yeast, protects against intestinal injury and inflammation caused by a wide variety of enteric pathogens, including Clostridium difficile. Given the broad range of protective effects of Sb in multiple gastrointestinal disorders, we hypothesize that Sb modulates host signaling pathways involved in intestinal inflammatory responses. In this study, we found that Sb culture supernatant (SbS) inhibits interleukin-8 production induced by C. difficile toxin A or IL-1 beta in human colonocyte NCM460 cells in a dose-dependent fashion. Furthermore, SbS inhibited IL-1 beta and toxin A induced Erk1/2 and JNK/SAPK but not p38 activation in NCM460 cells. To test whether this inhibition also occurs in vivo, we used a previously established mouse ileal loop model. On its own, SbS had no significant effect on basal fluid secretion or intestinal histology. However, Erk1/2 activation was significantly inhibited by SbS in toxin A exposed mouse ileal mucosa. In control loops, toxin A increased fluid secretion (2.2-fold), histological score (3.3-fold), and levels of the chemokine KC (4.5-fold). SbS pretreatment completely normalized toxin A mediated fluid secretion (p < 0.01), and histopathologic changes (p < 0.01) and substantially inhibited toxin A-associated KC increases (p < 0.001). In summary, the probiotic yeast S. boulardii inhibits C. difficile toxin A-associated enteritis by blocking the activation of Erk1/2 MAP kinases. This study indicates a new mechanism whereby Sb protects against intestinal inflammation and supports the hypothesis that Sb modulates host inflammatory signaling pathways to exert its beneficial effects.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Boston Univ, Dept Pathol, Sch Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Pediat Gastroenterol & Nutr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kelly, CP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 601A,330 Brookline Ave, Boston, MA 02215 USA.	ckelly2@bidmc.harvard.edu		O'Brien, Michael J/0000-0003-1124-3537	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506] Funding Source: NIH RePORTER; NIAID NIH HHS [AI53069] Funding Source: Medline; NIDDK NIH HHS [P01 DK033506] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; Brandao RL, 1998, APPL ENVIRON MICROB, V64, P564; BUTS JP, 1986, PEDIATR RES, V20, P192, DOI 10.1203/00006450-198602000-00020; BUTS JP, 1990, DIGEST DIS SCI, V35, P251, DOI 10.1007/BF01536771; Castagliuolo I, 1996, INFECT IMMUN, V64, P5225, DOI 10.1128/IAI.64.12.5225-5232.1996; Castagliuolo I, 1999, INFECT IMMUN, V67, P302, DOI 10.1128/IAI.67.1.302-307.1999; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Czerucka D, 1999, DIGEST DIS SCI, V44, P2359, DOI 10.1023/A:1026689628136; CZERUCKA D, 1994, GASTROENTEROLOGY, V106, P65, DOI 10.1016/S0016-5085(94)94403-2; Czerucka D, 2002, MICROBES INFECT, V4, P733, DOI 10.1016/S1286-4579(02)01592-7; Czerucka D, 2000, INFECT IMMUN, V68, P5998, DOI 10.1128/IAI.68.10.5998-6004.2000; Dahan S, 2003, INFECT IMMUN, V71, P766, DOI 10.1128/IAI.71.2.766-773.2003; DOVE CH, 1990, INFECT IMMUN, V58, P480, DOI 10.1128/IAI.58.2.480-488.1990; Elmer GW, 1996, JAMA-J AM MED ASSOC, V275, P870, DOI 10.1001/jama.275.11.870; Guslandi M, 2000, DIGEST DIS SCI, V45, P1462, DOI 10.1023/A:1005588911207; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee Sang Kil, 2005, Korean J Gastroenterol, V45, P328; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; Petrof EO, 2004, GASTROENTEROLOGY, V127, P1474, DOI 10.1053/j.gastro.2004.09.001; POTHOULAKIS C, 1991, J CLIN INVEST, V88, P119, DOI 10.1172/JCI115267; POTHOULAKIS C, 1993, GASTROENTEROLOGY, V104, P1108, DOI 10.1016/0016-5085(93)90280-P; Qamar A, 2001, INFECT IMMUN, V69, P2762, DOI 10.1128/IAI.69.4.2762-2765.2001; Rodrigues ACP, 1996, J APPL BACTERIOL, V81, P251, DOI 10.1111/j.1365-2672.1996.tb04325.x; Scherle PA, 1998, J IMMUNOL, V161, P5681; Sougioultzis S, 2006, BIOCHEM BIOPH RES CO, V343, P69, DOI 10.1016/j.bbrc.2006.02.080; Sullivan A, 2002, INT J ANTIMICROB AG, V20, P313, DOI 10.1016/S0924-8579(02)00199-1; TORRES J, 1990, GUT, V31, P781, DOI 10.1136/gut.31.7.781; TRIADAFILOPOULOS G, 1989, GASTROENTEROLOGY, V97, P1186, DOI 10.1016/0016-5085(89)91689-2; TRIADAFILOPOULOS G, 1987, GASTROENTEROLOGY, V93, P273, DOI 10.1016/0016-5085(87)91014-6; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; Xavier RJ, 2000, SCIENCE, V289, P1483, DOI 10.1126/science.289.5484.1483; Yan F, 2002, J BIOL CHEM, V277, P50959, DOI 10.1074/jbc.M207050200	37	112	116	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24449	24454		10.1074/jbc.M605200200	http://dx.doi.org/10.1074/jbc.M605200200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16816386	hybrid			2022-12-27	WOS:000239847800039
J	Culbert, AA; Skaper, SD; Howlett, DR; Evans, NA; Facci, L; Soden, PE; Seymour, ZM; Guillot, F; Gaestel, M; Richardson, JC				Culbert, Ainsley A.; Skaper, Stephen D.; Howlett, David R.; Evans, Nicholas A.; Facci, Laura; Soden, Peter E.; Seymour, Zoe M.; Guillot, Florence; Gaestel, Matthias; Richardson, Jill C.			MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity - Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; TNF-ALPHA; IN-VITRO; TAU-HYPERPHOSPHORYLATION; MAPKAP KINASE-2; P38 KINASE; MICE; BRAIN	MAPK-activated protein kinase 2 (MAPKAP K2 or MK2) is one of several kinases directly regulated by p38 MAPK. A role for p38 MAPK in the pathology of Alzheimer disease (AD) has previously been suggested. Here, we provide evidence to suggest that MK2 also plays a role in neuroinflammatory and neurodegenerative pathology of relevance to AD. MK2 activation and expression were increased in lipopolysaccharide (LPS) + interferon gamma-stimulated microglial cells, implicating a role for MK2 in eliciting a pro-inflammatory response. Microglia cultured ex vivo from MK2-deficient (MK2(-/-)) mice demonstrated significant inhibition in release of tumor necrosis factor alpha, KC (mouse chemokine with highest sequence identity to human GROs and interleukin-8), and macrophage inflammatory protein 1 alpha on stimulation with LPS + interferon gamma or amyloid-beta peptide (1-42) compared with MK2(+/+) wild-type microglia. Consistent with an inhibition in pro- inflammatory mediator release, cortical neurons co-cultured with LPS + interferon gamma-stimulated or amyloid-beta peptide (1-42) stimulated MK2(+/+) microglia were protected from microglial-mediated neuronal cell toxicity. In a transgenic mouse model of AD in which amyloid precursor protein and presenilin-1 harboring familial AD mutations are over-expressed in specific regions of the brain, elevated activation and expression of MK2 correlated with beta-amyloid deposition, microglial activation, and up-regulation of tumor necrosis factor alpha, macrophage inflammatory protein 1 alpha, and KC gene expression in the same brain regions. Our data propose a role for MK2 in AD brain pathology, for which neuroinflammation involving cytokines and chemokines and overt neuronal loss have been documented.	GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	GlaxoSmithKline; Hannover Medical School	Culbert, AA (corresponding author), GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	ainsley.a.culbert@gsk.com	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Richardson, Jill/0000-0001-6564-3187; Seymour, Zoe/0000-0002-8977-1519; , Florence/0000-0002-8491-4269				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aloe L, 1999, CYTOKINE, V11, P45, DOI 10.1006/cyto.1998.0397; Aloe L, 1999, BRAIN RES, V840, P125, DOI 10.1016/S0006-8993(99)01748-5; Atzori C, 2001, J NEUROPATH EXP NEUR, V60, P1190, DOI 10.1093/jnen/60.12.1190; Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chessell IP, 1997, BRIT J PHARMACOL, V121, P1429, DOI 10.1038/sj.bjp.0701278; Cross D, 2000, METH MOL B, V124, P147; Diemel LT, 1998, NEUROCHEM RES, V23, P341, DOI 10.1023/A:1022405516630; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.3.CO;2-#; Ginham R, 2001, NEUROSCI LETT, V302, P113, DOI 10.1016/S0304-3940(01)01687-1; Giovannini MG, 2002, NEUROBIOL DIS, V11, P257, DOI 10.1006/nbdi.2002.0538; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Golde S, 2002, J NEUROCHEM, V82, P269, DOI 10.1046/j.1471-4159.2002.00973.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Howlett DR, 2004, BRAIN RES, V1017, P130, DOI 10.1016/j.brainres.2004.05.029; Hwang DY, 2004, EXP NEUROL, V186, P20, DOI 10.1016/j.expneurol.2003.09.021; KARP HL, 1994, GLIA, V11, P284, DOI 10.1002/glia.440110310; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Koistinaho M, 2002, P NATL ACAD SCI USA, V99, P1610, DOI 10.1073/pnas.032670899; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kotlyarov A, 2002, BIOCHEM SOC T, V30, P959, DOI 10.1042/BST0300959; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; McGeer EG, 2003, PROG NEURO-PSYCHOPH, V27, P741, DOI 10.1016/S0278-5846(03)00124-6; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Puig B, 2004, NEUROPATH APPL NEURO, V30, P491, DOI 10.1111/j.1365-2990.2004.00569.x; Reynolds LJ, 2001, TOXICOLOGY, V165, P145, DOI 10.1016/S0300-483X(01)00417-6; Richardson JC, 2003, NEUROSCIENCE, V122, P213, DOI 10.1016/S0306-4522(03)00389-0; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; Stein TD, 2002, J NEUROSCI, V22, P7380; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Streit WJ, 2001, NEUROBIOL AGING, V22, P909, DOI 10.1016/S0197-4580(01)00290-1; Sudo T, 2005, BIOCHEM BIOPH RES CO, V337, P415, DOI 10.1016/j.bbrc.2005.09.063; Vician LJ, 2004, J NEUROSCI RES, V78, P315, DOI 10.1002/jnr.20251; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wang XK, 2002, J BIOL CHEM, V277, P43968, DOI 10.1074/jbc.M206837200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wu YP, 2004, P NATL ACAD SCI USA, V101, P8425, DOI 10.1073/pnas.0400625101; Xia MQ, 2002, J NEUROIMMUNOL, V122, P55, DOI 10.1016/S0165-5728(01)00463-5; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880	55	125	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23658	23667		10.1074/jbc.M513646200	http://dx.doi.org/10.1074/jbc.M513646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16774924	hybrid			2022-12-27	WOS:000239702900041
J	Li, XM; Thyssen, G; Beliakoff, J; Sun, ZJ				Li, Xiaomeng; Thyssen, Gregory; Beliakoff, Jason; Sun, Zijie			The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; RECEPTOR-MEDIATED TRANSCRIPTION; TGF-BETA; ANDROGEN RECEPTOR; DEPENDENT TRANSCRIPTION; INTERACTING PROTEIN-3; SIGNAL-TRANSDUCTION; TUMOR SUPPRESSORS; GENE-EXPRESSION; FAMILY-MEMBERS	Transforming growth factor beta (TGF-beta) plays critical roles in the control of cell proliferation, differentiation, and apoptosis. Smad proteins are substrates of the TGF-beta type I receptor and are responsible for transducing receptor signals to target genes in the nucleus. The PIAS (protein inhibitor of activated STAT) proteins were originally identified as transcriptional co-regulators of the JAK-STAT pathway. Subsequently, cross-talk between the PIAS proteins and other signaling pathways has been shown to be involved in various cellular processes. Importantly, PIAS proteins modulate TGF-beta signaling by regulating the transcriptional activity of Smad3. In this study we tested whether hZimp10, a novel PIAS-like protein, acts as other PIAS proteins to regulate Smad3-mediated transcription. We show that expression of exogenous hZimp10 enhances the transcriptional activity of Smad3, which appears to be Smad4-dependent and responsive to TGF-beta induction. Furthermore, knockdown of endogenous hZimp10 reduced the transcriptional activity of Smad3. A protein-protein interaction between Smad3 and Smad4 with hZimp10 was identified in glutathione S-transferase-pulldown and co-immunoprecipitation assays. The Miz domain of hZimp10 and the MH2 domains of Smad3 and Smad4 were mapped as the regions responsible for binding. Results from immunostaining assays further demonstrated that Smad3, Smad4, and hZimp10 co-localize within cell nuclei. Finally, we demonstrated that Smad3/4-mediated transcription is significantly impaired in response to TGF-beta induction in Zimp10 null (zimp10 -/-) embryonic fibroblasts. Taken together, these results provide the first line of evidence to demonstrate a role for Zimp10 in regulating the TGF-beta/Smad signaling pathway.	Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Sun, ZJ (corresponding author), Stanford Univ, Dept Urol, Sch Med, 300 Pasteur Dr,Grant Bldg,S287, Stanford, CA 94305 USA.	zsun@stanford.edu		Li, Xiaomeng/0000-0002-7811-3457	NATIONAL CANCER INSTITUTE [R29CA070297, R01CA087767, R01CA070297, T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061002, R56DK061002] Funding Source: NIH RePORTER; NCI NIH HHS [CA087767, R01 CA087767-04, R01 CA070297-08, R01 CA070297-12, R01 CA070297-09, R01 CA070297-10, R01 CA070297-06A1, R01 CA070297-07, R01 CA070297-11A2, R01 CA070297, CA070297, R01 CA087767-03, R01 CA087767-02, 5T32 CA09302-27, R01 CA087767, R01 CA087767-01A2, R01 CA087767-05] Funding Source: Medline; NIDDK NIH HHS [R56 DK061002, R01 DK061002-01A1, R01 DK061002, DK061002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gutierrez L, 2003, DEVELOPMENT, V130, P343, DOI 10.1242/dev.00222; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayes SA, 2001, CANCER RES, V61, P2112; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Huang CY, 2005, MOL ENDOCRINOL, V19, P2915, DOI 10.1210/me.2005-0097; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lange D, 1999, INT J ONCOL, V14, P1049; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sharma M, 2001, MOL ENDOCRINOL, V15, P1918, DOI 10.1210/me.15.11.1918; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	52	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23748	23756		10.1074/jbc.M508365200	http://dx.doi.org/10.1074/jbc.M508365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777850	hybrid			2022-12-27	WOS:000239702900050
J	Berteau, O; Guillot, A; Benjdia, A; Rabot, S				Berteau, Olivier; Guillot, Alain; Benjdia, Alhosna; Rabot, Sylvie			A new type of bacterial sulfatase reveals a novel maturation pathway in prokaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLGLYCINE-GENERATING ENZYME; SULFUR PROTEIN ATSB; ARYLSULFATASE GENE; MOLECULAR-CLONING; BIOCHEMICAL-CHARACTERIZATION; POSTTRANSLATIONAL FORMATION; CHONDRODYSPLASIA PUNCTATA; SEA-URCHIN; MECHANISM; DEFICIENCY	Sulfatases are a highly conserved family of enzymes found in all three domains of life. To be active, sulfatases undergo a unique post-translational modification leading to the conversion of either a critical cysteine ("Cys-type" sulfatases) or a serine ("Ser-type" sulfatases) into a C alpha-formylglycine (FGly). This conversion depends on a strictly conserved sequence called "sulfatase signature" (C/S)XPXR. In a search for new enzymes from the human microbiota, we identified the first sulfatase from Firmicutes. Matrix-assisted laser desorption ionization time-of-flight analysis revealed that this enzyme undergoes conversion of its critical cysteine residue into FGly, even though it has a modified (C/S)XAXR sulfatase signature. Examination of the bacterial and archaeal genomes sequenced to date has identified many genes bearing this new motif, suggesting that the definition of the sulfatase signature should be expanded. Furthermore, we have also identified a new Cys-type sulfatase-maturating enzyme that catalyzes the conversion of cysteine into FGly, in anaerobic conditions, whereas the only enzyme reported so far to be able to catalyze this reaction is oxygen-dependent. The new enzyme belongs to the radical S-adenosyl-L-methionine enzyme superfamily and is related to the Ser-type sulfatase-maturating enzymes. This finding leads to the definition of a new enzyme family of sulfatase-maturating enzymes that we have named anSME (anaerobic sulfatase-maturating enzyme). This family includes enzymes able to maturate Cys-type as well as Ser-type sulfatases in anaerobic conditions. In conclusion, our results lead to a new scheme for the biochemistry of sulfatases maturation and suggest that the number of genes and bacterial species encoding sulfatase enzymes is currently underestimated.	INRA, Unite Ecol & Physiol Syst Digest, F-78352 Jouy En Josas, France; INRA, Unite Biochim Bacterienne, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Berteau, O (corresponding author), INRA, Unite Ecol & Physiol Syst Digest, F-78352 Jouy En Josas, France.	Olivier.Berteau@jouy.inra.fr	Benjdia, Alhosna/AAM-7415-2021; Berteau, Olivier/AAF-9080-2019	Benjdia, Alhosna/0000-0002-3544-2541; Berteau, Olivier/0000-0002-3434-5168; Rabot, Sylvie/0000-0002-4603-2038				BEIL S, 1995, EUR J BIOCHEM, V229, P385, DOI 10.1111/j.1432-1033.1995.0385k.x; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 2005, CELL, V121, P541, DOI 10.1016/j.cell.2005.03.001; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; Diez-Roux G, 2005, ANNU REV GENOM HUM G, V6, P355, DOI 10.1146/annurev.genom.6.080604.162334; DORFMAN A, 1976, P NATL ACAD SCI USA, V73, P630, DOI 10.1073/pnas.73.2.630; Dotson SB, 1996, J BIOL CHEM, V271, P25754, DOI 10.1074/jbc.271.42.25754; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Fang QH, 2004, J BIOL CHEM, V279, P14570, DOI 10.1074/jbc.M313855200; Ferrante P, 2004, GENE, V336, P155, DOI 10.1016/j.gene.2004.04.001; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; Gieselmann V, 1998, J INHERIT METAB DIS, V21, P564, DOI 10.1023/A:1005471106088; HALLMANN A, 1994, EUR J BIOCHEM, V221, P143, DOI 10.1111/j.1432-1033.1994.tb18723.x; Hanson SR, 2004, ANGEW CHEM INT EDIT, V43, P5736, DOI 10.1002/anie.200300632; Haugen AC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-r95; Hernandez-Guzman FG, 2003, J BIOL CHEM, V278, P22989, DOI 10.1074/jbc.M211497200; Hoffman JA, 2000, INFECT IMMUN, V68, P5062, DOI 10.1128/IAI.68.9.5062-5067.2000; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; Leoni O, 1998, IND CROP PROD, V7, P335, DOI 10.1016/S0926-6690(97)00066-6; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Marquordt C, 2003, J BIOL CHEM, V278, P2212, DOI 10.1074/jbc.M209435200; MODARESSI S, 1993, BIOL CHEM H-S, V374, P327, DOI 10.1515/bchm3.1993.374.1-6.327; Morokuma J, 1997, DEV GROWTH DIFFER, V39, P469; Mougous JD, 2002, CHEM BIOL, V9, P767, DOI 10.1016/S1074-5521(02)00175-8; Myette JR, 2003, J BIOL CHEM, V278, P12157, DOI 10.1074/jbc.M211420200; PAIETTA JV, 1989, MOL CELL BIOL, V9, P3630, DOI 10.1128/MCB.9.9.3630; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Peng JH, 2003, J MASS SPECTROM, V38, P80, DOI 10.1002/jms.404; Preusser-Kunze A, 2005, J BIOL CHEM, V280, P14900, DOI 10.1074/jbc.M413383200; Quaiser A, 2003, MOL MICROBIOL, V50, P563, DOI 10.1046/j.1365-2958.2003.03707.x; Ravina CG, 2002, PLANT PHYSIOL, V130, P2076, DOI 10.1104/pp.012484; Roeser D, 2006, P NATL ACAD SCI USA, V103, P81, DOI 10.1073/pnas.0507592102; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sardiello M, 2005, HUM MOL GENET, V14, P3203, DOI 10.1093/hmg/ddi351; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YANG Q, 1989, DEV BIOL, V135, P53, DOI 10.1016/0012-1606(89)90157-7	46	81	92	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22464	22470		10.1074/jbc.M602504200	http://dx.doi.org/10.1074/jbc.M602504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766528	hybrid, Green Published			2022-12-27	WOS:000239542600007
J	York, SJ; Modrich, P				York, Sally J.; Modrich, Paul			Mismatch repair-dependent iterative excision at irreparable O-6-methylguanine lesions in human nuclear extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRO-N-NITROSOGUANIDINE; DNA-POLYMERASE ETA; COLORECTAL-CANCER; METHYLATING AGENTS; INDUCED APOPTOSIS; CELL-LINE; DAMAGE; ALKYLATION; ALPHA; RESISTANCE	The response of mammalian cells to S(n)1 DNA methylators depends on functional MutS alpha and MutL alpha. Cells deficient in either of these activities are resistant to the cytotoxic effects of this class of chemotherapeutic drug. Because killing by Sn1 methylators has been attributed to O-6-methylguanine (MeG), we have constructed nicked circular heteroduplexes that contain a single MeG-T mis-pair, and we have examined processing of these molecules by mismatch repair in nuclear extracts of human cells. Excision provoked by MeG-T is restricted to the incised heteroduplex strand, leading to removal of the MeG when it resides on this strand. However, when the MeG is located on the continuous strand, the heteroduplex is irreparable. MeG-T-dependent repair DNA synthesis is observed on both reparable and irreparable 3' and 5' heteroduplexes as judged by [P-32]dAMP incorporation. Labeling with [alpha-P-32]dATP followed by a cold dATP chase has demonstrated that newly synthesized DNA on irreparable molecules is subject to re-excision in a reaction that is MutL alpha-dependent, an effect attributable to the presence of MeG on the template strand. Processing of the irreparable 3' heteroduplex is also associated with incision of the discontinuous strand of a few percent of molecules near the thymidylate of the MeG-T base pair. These results provide the first direct evidence for mismatch repair-mediated iterative processing of DNA methylator damage, an effect that may be relevant to damage signaling events triggered by this class of chemotherapeutic agent.	Duke Univ, Ctr Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Med, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	York, SJ (corresponding author), Duke Univ, Ctr Med, Howard Hughes Med Inst, Box 3711, Durham, NC 27710 USA.	modrich@biochem.duke.edu	Classen, Scott/AAY-8176-2020	Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [P50CA108786, P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P01 CA092584, P01 CA92584, 1P50CA108786, P01 CA092584-060005, P50 CA108786] Funding Source: Medline; NIGMS NIH HHS [GM45190, R01 GM045190, R01 GM045190-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BROOKS P, 1989, P NATL ACAD SCI USA, V86, P4425, DOI 10.1073/pnas.86.12.4425; Caporali S, 2004, MOL PHARMACOL, V66, P478; Cejka P, 2005, CURR BIOL, V15, P1395, DOI 10.1016/j.cub.2005.07.032; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Debiak M, 2004, DNA REPAIR, V3, P359, DOI 10.1016/j.dnarep.2003.11.013; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; FANG WH, 1993, J BIOL CHEM, V268, P11838; Friedman HS, 1997, CANCER RES, V57, P2933; Genschel J, 2003, MOL CELL, V12, P1077, DOI 10.1016/S1097-2765(03)00428-3; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Khare V, 2001, J BIOL CHEM, V276, P24286, DOI 10.1074/jbc.M011025200; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Li GM, 1999, ONCOL RES, V11, P393; Liu LL, 2002, CANCER RES, V62, P3070; Lynch HT, 1999, J MED GENET, V36, P801; Meira LB, 2002, DNA REPAIR, V1, P929, DOI 10.1016/S1568-7864(02)00143-X; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1036, DOI 10.1021/bi00353a013; Perrino FW, 2003, CHEM RES TOXICOL, V16, P1616, DOI 10.1021/tx034164f; Rowley PT, 2005, ANNU REV MED, V56, P539, DOI 10.1146/annurev.med.56.061704.135235; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; Spratt TE, 1997, NUCLEIC ACIDS RES, V25, P3354, DOI 10.1093/nar/25.16.3354; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Stojic L, 2004, GENE DEV, V18, P1331, DOI 10.1101/gad.294404; Surtees JA, 2004, CYTOGENET GENOME RES, V107, P146, DOI 10.1159/000080593; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200; Wang HX, 2001, MOL BIOTECHNOL, V19, P133, DOI 10.1385/MB:19:2:133; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Yamane K, 2004, BIOCHEM BIOPH RES CO, V318, P297, DOI 10.1016/j.bbrc.2004.04.030	45	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22674	22683		10.1074/jbc.M603667200	http://dx.doi.org/10.1074/jbc.M603667200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772289	Green Accepted, hybrid			2022-12-27	WOS:000239542600028
J	Chang, HC; Tan, KM; Hsu, YM				Chang, Hsiu-Ching; Tan, Kemin; Hsu, Yen-Ming			CD8 alpha beta has two distinct binding modes of interaction with peptide-major histocompatibility complex class I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CD8 CORECEPTOR FUNCTION; DIFFERENTIAL EXPRESSION; STRUCTURAL BASIS; CD8-BETA CHAINS; LIGAND-BINDING; ALPHA-3 DOMAIN; LYMPHOCYTES-T; CELL; TCR	Interaction of CD8 (CD8 alpha alpha or CD8 alpha beta) with the peptide-major histocompatibility complex (MHC) class I (pMHCI) is critical for the development and function of cytolytic T cells. Although the crystal structure of CD8 alpha alpha(.)pMHCI complex revealed that two symmetric CD8 alpha subunits interact with pMHCI asymmetrically, with one subunit engaged in more extensive interaction than the other, the details of the interaction between the CD8 alpha beta heterodimer and pMHCI remained unknown. The Ig-like domains of mouse CD8 alpha beta and CD8 alpha alpha are similar in the size, shape, and surface electrostatic potential of their pMHCI-binding regions, suggesting that their interactions with pMHCI could be very similar. Indeed, we found that the CD8 alpha variants CD8 alpha(R8A) and CD8 alpha(E27A), which were functionally inactive as homodimers, could form an active co-receptor with wildtype (WT) CD8 beta as a CD8 alpha(R8A)beta or CD8 alpha(E27A)beta heterodimer. We also identified CD8 beta variants that could form active receptors with WT CD8 beta but not with CD8 alpha(R8A). This observation is consistent with the notion that the CD8 beta subunit may replace either CD8 beta subunit in CD8 alpha alpha(.) pMHCI complex. In addition, we showed that both anti-CD8 alpha and anti-CD8 beta antibodies were unable to completely block the co-receptor activity of WT CD8 alpha beta. We propose that CD8 alpha beta binds to pMHCI in at least two distinguishable orientations.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Biogen Inc, Mol Discovery Dept, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Biogen	Chang, HC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 77 Ave Louis Pasteur,HIM-442, Boston, MA 02115 USA.	hsiu-ching_chang@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045789] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45789] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; AUPHAN N, 1991, MOL IMMUNOL, V28, P827, DOI 10.1016/0161-5890(91)90046-M; Bosselut R, 2000, IMMUNITY, V12, P409, DOI 10.1016/S1074-7613(00)80193-4; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; CANTOR H, 1975, J EXP MED, V141, P1376, DOI 10.1084/jem.141.6.1376; Chang HC, 2005, IMMUNITY, V23, P661, DOI 10.1016/j.immuni.2005.11.002; Chang HC, 1997, J MOL BIOL, V271, P278, DOI 10.1006/jmbi.1997.1169; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; DETOTERO D, 1992, BLOOD, V80, P1765; Devine L, 1999, J IMMUNOL, V162, P846; Devine L, 2000, J IMMUNOL, V164, P833, DOI 10.4049/jimmunol.164.2.833; Doucey MA, 2004, NAT IMMUNOL, V5, P328, DOI 10.1038/ni1043; Gangadharan D, 2004, CURR OPIN IMMUNOL, V16, P264, DOI 10.1016/j.coi.2004.03.015; Gao GF, 2002, TRENDS IMMUNOL, V23, P408, DOI 10.1016/S1471-4906(02)02282-2; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Hayday A, 2001, NAT IMMUNOL, V2, P997, DOI 10.1038/ni1101-997; Irie HY, 1998, J IMMUNOL, V161, P183; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Konig R, 2002, CURR OPIN IMMUNOL, V14, P75, DOI 10.1016/S0952-7915(01)00300-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MOEBIUS U, 1991, EUR J IMMUNOL, V21, P1793, DOI 10.1002/eji.1830210803; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; Renard V, 1996, J EXP MED, V184, P2439, DOI 10.1084/jem.184.6.2439; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; Sun JR, 1997, J IMMUNOL, V159, P6077; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; Wheeler CJ, 1998, J IMMUNOL, V160, P4199; Witte T, 1999, CELL IMMUNOL, V191, P90, DOI 10.1006/cimm.1998.1412; Wong JS, 2003, J IMMUNOL, V171, P867, DOI 10.4049/jimmunol.171.2.867; Zuniga-Pflucker J C, 1991, Semin Immunol, V3, P167	36	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28090	28096		10.1074/jbc.M604931200	http://dx.doi.org/10.1074/jbc.M604931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16840780	hybrid			2022-12-27	WOS:000240534400046
J	Ferri-Fioni, ML; Fromant, M; Bouin, AP; Aubard, C; Lazennec, C; Plateau, P; Blanquet, S				Ferri-Fioni, Maria-Laura; Fromant, Michel; Bouin, Anne-Pascale; Aubard, Caroline; Lazennec, Christine; Plateau, Pierre; Blanquet, Sylvain			Identification in archaea of a novel D-Tyr-tRNA(Tyr) deacylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA HYDROLASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; SULFOLOBUS-SOLFATARICUS; ANGSTROM RESOLUTION; ARABIDOPSIS; SYNTHETASES; METABOLISM; PROTEIN	Most bacteria and eukarya contain an enzyme capable of specifically hydrolyzing D-aminoacyl-tRNA. Here, the archaea Sulfolobus solfataricus is shown to also contain an enzyme activity capable of recycling misaminoacylated D-Tyr-tRNA(Tyr). N-terminal sequencing of this enzyme identifies open reading frame SS02234 (dtd2), the product of which does not present any sequence homology with the known D-Tyr-tRNA(Tyr) deacylases of bacteria or eukaryotes. On the other hand, homologs of dtd2 occur in archaea and plants. The Pyrococcus abyssi dtd2 ortholog (PAB2349) was isolated. It rescues the sensitivity to D-tyrosine of a mutant Escherichia coli strain lacking dtd, the gene of its endogeneous D-Tyr-tRNATyr deacylase. Moreover, in vitro, the PAB2349 product, which behaves as a monomer and carries 2 mol of zinc/mol of protein, catalyzes the cleavage of D-Tyr-tRNATyr. The three-dimensional structure of the product of the Archaeoglobus fulgidus dtd2 ortholog has been recently solved by others through a structural genomics approach (Protein Data Bank code 1YQE). This structure does not resemble that of Escherichia coli D-Tyr-tRNATyr deacylase. Instead, it displays homology with that of a bacterial peptidyl-tRNA hydrolase. We show, however, that the archaeal PAB2349 enzyme does not act against diacetyl-Lys-tRNA(Lys), a model substrate of peptidyl-tRNA hydrolase. Based on the Protein Data Bank 1YQE structure, site-directed mutagenesis experiments were undertaken to remove zinc from the PAB2349 enzyme. Several residues involved in zinc binding and supporting the activity of the deacylase were identified. Taken together, these observations suggest evolutionary links between the various hydrolases in charge of the recycling of metabolically inactive tRNAs during translation.	Ecole Polytech, Biochim Lab, UMR 7654, CNRS,Dept Biol, F-91128 Palaiseau, France; Ecole Polytech, Lab Mecanismes React, UMR 7651, CNRS,Dept Chim, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, Biochim Lab, UMR 7654, CNRS,Dept Biol, F-91128 Palaiseau, France.	plateau@bioc.polytechnique.fr	bouin, anne pascale/M-2734-2013	bouin, anne pascale/0000-0002-9616-6173; launay, caroline/0000-0002-6587-6631				BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; de Pereda JM, 2004, J BIOL CHEM, V279, P8111, DOI 10.1074/jbc.M311449200; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; Fromant M, 2003, NUCLEIC ACIDS RES, V31, P3227, DOI 10.1093/nar/gkg428; Fromant M, 2005, BIOCHEMISTRY-US, V44, P4294, DOI 10.1021/bi047711k; Fujishige N, 2004, PLANT CELL PHYSIOL, V45, P659, DOI 10.1093/pcp/pch086; GIEGE R, 1972, BIOCHIMIE, V54, P1245, DOI 10.1016/S0300-9084(72)80065-8; Goodall JJ, 2004, BIOCHEMISTRY-US, V43, P4583, DOI 10.1021/bi0302200; Guillon L, 2005, BIOCHEMISTRY-US, V44, P15594, DOI 10.1021/bi051514j; Hirayama T, 2004, PLANT CELL PHYSIOL, V45, P703, DOI 10.1093/pcp/pch078; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; Jenkins BD, 2001, EMBO J, V20, P872, DOI 10.1093/emboj/20.4.872; Koonin EV, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; Soutourina O, 2004, J BIOL CHEM, V279, P42560, DOI 10.1074/jbc.M402931200; Takayama T, 2005, BIOSCI BIOTECH BIOCH, V69, P1040, DOI 10.1271/bbb.69.1040; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; YARUS M, 1976, ARCH BIOCHEM BIOPHYS, V174, P350, DOI 10.1016/0003-9861(76)90355-6; ZILLIG W, 1994, SYST APPL MICROBIOL, V16, P609	26	23	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27575	27585		10.1074/jbc.M605860200	http://dx.doi.org/10.1074/jbc.M605860200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844682	hybrid			2022-12-27	WOS:000240397700083
J	Jastrebova, N; Vanwildemeersch, M; Rapraeger, AC; Gimenez-Gallego, G; Lindahl, U; Spillmann, D				Jastrebova, Nadja; Vanwildemeersch, Maarten; Rapraeger, Alan C.; Gimenez-Gallego, Guillermo; Lindahl, Ulf; Spillmann, Dorothe			Heparan sulfate-related oligosaccharides in ternary complex formation with fibroblast growth factors 1 and 2 and their receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR FGF; HEPARIN/HEPARAN SULFATE; CRYSTAL-STRUCTURE; BINDING-SITES; CELL-SURFACE; SEQUENCE; IDENTIFICATION; PROTEOGLYCANS; DIVERSITY; GLYPICAN	Biosynthesis of heparan sulfate (HS) is strictly regulated to yield products with cell/tissue-specific composition. Interactions between HS and a variety of proteins, including growth factors and morphogens, are essential for embryonic development and for homeostasis in the adult. Fibroblast growth factors (FGFs) and their various receptors (FRs) form ternary complexes with HS, as required for receptor signaling. Libraries of HS-related, radiolabeled oligosaccharides were generated by chemo-enzymatic modification of heparin and tested for affinity to immobilized FR ectodomains in the presence of FGF1 or FGF2. Experiments were designed to enable assessment of N-sulfated 8- and 10-mers with defined numbers of iduronic acid 2-O-sulfate and glucosamine 6-O-sulfate groups. FGF1 and FGF2 were found to require similar oligosaccharides in complex formation with FR1c-3c, FGF2 affording somewhat more efficient oligosaccharide recruitment than FGF1. FR4, contrary to FR1c-3c, bound oligosaccharides at physiological ionic conditions even in the absence of FGFs, and this interaction was further promoted by FGF1 but not by FGF2. In all systems studied, the stability of FGF-oligosaccharide-FR complexes correlated with the overall level of saccharide O-sulfation rather than on the precise distribution of sulfate groups.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Ctr Invest Biol, Madrid 28040, Spain	Uppsala University; University of Wisconsin System; University of Wisconsin Madison; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Spillmann, D (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Dorothe.Spillmann@imbim.uu.se			NIGMS NIH HHS [R01 GM048850] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Belenkaya TY, 2004, CELL, V119, P231, DOI 10.1016/j.cell.2004.09.031; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Ford-Perriss M, 2001, CLIN EXP PHARMACOL P, V28, P493, DOI 10.1046/j.1440-1681.2001.03477.x; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Garcia-Maya M, 2006, J CELL PHYSIOL, V206, P386, DOI 10.1002/jcp.20483; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Kreuger J, 2004, DEV CELL, V7, P503, DOI 10.1016/j.devcel.2004.08.005; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavine KJ, 2005, DEV CELL, V8, P85, DOI 10.1016/j.devcel.2004.12.002; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Li JP, 2005, P NATL ACAD SCI USA, V102, P6473, DOI 10.1073/pnas.0502287102; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; ten Dam GB, 2006, J BIOL CHEM, V281, P4654, DOI 10.1074/jbc.M506357200; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Vanwildemeersch M, 2006, J BIOL CHEM, V281, P10298, DOI 10.1074/jbc.M508483200; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; Wilson VA, 2002, GLYCOCONJUGATE J, V19, P347, DOI 10.1023/A:1025325222530; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZAZO M, 1992, GENE, V15, P231; Zhang XQ, 2006, DEVELOPMENT, V133, P173, DOI 10.1242/dev.02175	66	63	67	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26884	26892		10.1074/jbc.M600806200	http://dx.doi.org/10.1074/jbc.M600806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16807244	Green Published, hybrid			2022-12-27	WOS:000240397700015
J	Plaisance, V; Abderrahmani, A; Perret-Menoud, V; Jacquemin, P; Lemaigre, F; Regazzi, R				Plaisance, Valerie; Abderrahmani, Amar; Perret-Menoud, Veronique; Jacquemin, Patrick; Lemaigre, Frederic; Regazzi, Romano			MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCRINE; GRANULES; EXOCYTOSIS; BINDING; DIFFERENTIATION; PROLIFERATION; INVOLVEMENT; EXOCRINE; RAB27; MOUSE	Insulin release from pancreatic beta-cells plays an essential role in blood glucose homeostasis. Several proteins controlling insulin exocytosis have been identified, but the factors determining the expression of the components of the secretory machinery of beta-cells remain largely unknown. MicroRNAs are newly discovered small non-coding RNAs acting as repressors of gene expression. We found that overexpression of mir-9 in insulin-secreting cells causes a reduction in exocytosis elicited by glucose or potassium. We show that mir-9 acts by diminishing the expression of the transcription factor Onecut-2 and, in turn, by increasing the level of Granuphilin/Slp4, a Rab GTPase effector associated with beta-cell secretory granules that exerts a negative control on insulin release. Indeed, electrophoretic mobility shift assays, chromatin immunoprecipitation, and transfection experiments demonstrated that Onecut-2 is able to bind to the granuphilin promoter and to repress its transcriptional activity. Moreover, we show that silencing of Onecut-2 by RNA interference increases Granuphilin expression and mimics the effect of mir-9 on stimulus-induced exocytosis. Our data provide evidence that in insulin-producing cells adequate levels of mir-9 are mandatory for maintaining appropriate Granuphilin levels and optimal secretory capacity.	Univ Lausanne, Dept Cell Biol & Morphol, CH-1005 Lausanne, Switzerland; CHU Vaudois, Dept Internal Med, CH-1005 Lausanne, Switzerland; Catholic Univ Louvain, Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Universite Catholique Louvain	Regazzi, R (corresponding author), Univ Lausanne, Dept Cell Biol & Morphol, Rue Bugnon 9, CH-1005 Lausanne, Switzerland.	Romano.Regazzi@unil.ch	Abderrahmani, Amar/O-3124-2017; Jacquemin, Patrick/ABA-7932-2021	Abderrahmani, Amar/0000-0003-0752-0343; Regazzi, Romano/0000-0002-9773-2915				Abderrahmani A, 2001, MOL CELL BIOL, V21, P7256, DOI 10.1128/MCB.21.21.7256-7267.2001; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Briancon N, 2004, J BIOL CHEM, V279, P33398, DOI 10.1074/jbc.M405312200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheviet S, 2004, MOL ENDOCRINOL, V18, P117, DOI 10.1210/me.2003-0300; Cheviet S, 2004, TRENDS CELL BIOL, V14, P525, DOI 10.1016/j.tcb.2004.08.001; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Gannon M, 2000, DEVELOPMENT, V127, P2883; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Gomi H, 2005, J CELL BIOL, V171, P99, DOI 10.1083/jcb.200505179; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Izumi T, 2003, CELL STRUCT FUNCT, V28, P465, DOI 10.1247/csf.28.465; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 2003, GENE EXPR PATTERNS, V3, P639, DOI 10.1016/S1567-133X(03)00110-8; Jacquemin P, 2003, DEV BIOL, V258, P105, DOI 10.1016/S0012-1606(03)00115-5; Jacquemin P, 1999, J BIOL CHEM, V274, P2665, DOI 10.1074/jbc.274.5.2665; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Matsumoto M, 2004, P NATL ACAD SCI USA, V101, P8313, DOI 10.1073/pnas.0306709101; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pierreux CE, 1999, P NATL ACAD SCI USA, V96, P8961, DOI 10.1073/pnas.96.16.8961; Plaisance V, 2005, J BIOL CHEM, V280, P401, DOI 10.1074/jbc.M411825200; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wilding L, 2004, DIABETES-METAB RES, V20, P114, DOI 10.1002/dmrr.429; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Yaekura K, 2003, J BIOL CHEM, V278, P9715, DOI 10.1074/jbc.M211352200; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zeng Y, 2004, NUCLEIC ACIDS RES, V32, P4776, DOI 10.1093/nar/gkh824; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	50	273	295	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26932	26942		10.1074/jbc.M601225200	http://dx.doi.org/10.1074/jbc.M601225200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16831872	hybrid			2022-12-27	WOS:000240397700020
J	Joly, D; Ishibe, S; Nickel, C; Yu, ZH; Somlo, S; Cantley, LG				Joly, Dominique; Ishibe, Shuta; Nickel, Christian; Yu, Zhiheng; Somlo, Stefan; Cantley, Lloyd G.			The polycystin 1-C-terminal fragment stimulates ERK-dependent spreading of renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; KIDNEY-DISEASE GENE; PKD1 GENE; EXTRACELLULAR-MATRIX; ADHESION; PROTEIN; PAXILLIN; PRODUCT; PHOSPHORYLATION; ACTIVATION	Polycystin 1, the product of the PKD1 gene, is mutated in autosomal dominant polycystic kidney disease, a disease characterized by renal cyst formation and progressive renal failure. We show that expression of the C-terminal domain of human polycystin-1 (PKD1-CT) triggers spreading of isolated inner medullary collecting duct cells, a process mediated by Erk. As inner medullary collecting duct cells spread, PKD1-CT localizes to cell-extracellular matrix contacts, interacts with focal adhesion proteins Fak and paxillin, and stimulates Fak phosphorylation, paxillin phosphorylation, Fak-paxillin association, and formation of small focal complexes. PKD1-CT-mediated spreading requires membrane localization and the integrity of the C-terminal protein binding sites. We additionally show that Pkd1 null proximal tubule cells generated from Pkd1(flox/-): TSLargeT mice by in vitro Cre recombinase transfection demonstrate diminished spreading when compared with Pkd(flox/-) heterozygous parental cells. These findings suggest that membrane-bound PC1 has a central role in regulating morphogenic protein signaling at cell-matrix interfaces in non-confluent cells.	Univ Paris 05, INSERM, Fac Med, Hop Necker Enfants Malad,U813, F-75743 Paris 15, France; Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, New Haven, CT 06520 USA; Univ Freiburg, D-79085 Freiburg, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Yale University; University of Freiburg	Joly, D (corresponding author), Univ Paris 05, INSERM, Fac Med, Hop Necker Enfants Malad,U813, F-75743 Paris 15, France.	joly@necker.fr			NIDDK NIH HHS [DK065109, DK057328] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065109, P50DK057328] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; Bono P, 2001, MOL BIOL CELL, V12, P891, DOI 10.1091/mbc.12.4.891; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; ILLC D, 1995, NATURE, V377, P539; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; NAULI SM, 2003, NAT GENET; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ong ACM, 2003, LANCET, V361, P774, DOI 10.1016/S0140-6736(03)12662-1; Parr C, 2001, BIOCHEM BIOPH RES CO, V285, P1330, DOI 10.1006/bbrc.2001.5307; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rossetti S, 2001, AM J HUM GENET, V68, P46, DOI 10.1086/316939; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; Streets AJ, 2003, J AM SOC NEPHROL, V14, P1804, DOI 10.1097/01.ASN.0000076075.49819.9B; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wilson PD, 1999, LAB INVEST, V79, P1311; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Xu GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/jbc.M107828200; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25	42	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26329	26339		10.1074/jbc.M601373200	http://dx.doi.org/10.1074/jbc.M601373200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16790429	hybrid			2022-12-27	WOS:000240249500050
J	Kitada, S; Abe, Y; Shimada, H; Kusaka, Y; Matsuo, Y; Katayama, H; Okumura, S; Akao, T; Mizuki, E; Kuge, O; Sasaguri, Y; Ohba, M; Ito, A				Kitada, Sakae; Abe, Yuichi; Shimada, Hiroyasu; Kusaka, Yoshitomo; Matsuo, Yoko; Katayama, Hideki; Okumura, Shiro; Akao, Tetsuyuki; Mizuki, Eiichi; Kuge, Osamu; Sasaguri, Yasuyuki; Ohba, Michio; Ito, Akio			Cytocidal actions of parasporin-2, an anti-tumor crystal toxin from Bacillus thuringiensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MISFOLDING DISEASES; SOLUBLE AMYLOID OLIGOMERS; HUMAN CANCER-CELLS; ENDOPLASMIC-RETICULUM; CYTOTOXIC PROTEIN; COMMON MECHANISM; LIPID-BILAYERS; PORE FORMATION; MEMBRANE; INCLUSIONS	Parasporin-2, a new crystal protein derived from noninsecticidal and nonhemolytic Bacillus thuringiensis, recognizes and kills human liver and colon cancer cells as well as some classes of human cultured cells. Here we report that a potent proteinase K-resistant parasporin-2 toxin shows specific binding to and a variety of cytocidal effects against human hepatocyte cancer cells. Cleavage of the N-terminal region of parasporin-2 was essential for the toxin activity, whereas C-terminal digestion was required for rapid cell injury. Protease-activated parasporin-2 induced remarkable morphological alterations, cell blebbing, cytoskeletal alterations, and mitochondrial and endoplasmic reticulum fragmentation. The plasma membrane permeability was increased immediately after the toxin treatment and most of the cytoplasmic proteins leaked from the cells, whereas mitochondrial and endoplasmic reticulum proteins remained in the intoxicated cells. Parasporin-2 selectively bound to cancer cells in slices of liver tumor tissues and susceptible human cultured cells and became localized in the plasma membrane until the cells were damaged. Thus, parasporin-2 acts as a cytolysin that permeabilizes the plasma membrane with target cell specificity and subsequently induces cell decay.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Fukuoka Ind Technol Ctr, Biotechnol & Food Res Inst, Fukuoka 8390861, Japan; Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Fukuoka 8078555, Japan; Kyushu Univ, Fac Agr, Dept Appl Genet & Pest Management, Fukuoka 8128581, Japan	Kyushu University; University of Occupational & Environmental Health - Japan; Kyushu University	Kitada, S (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.	s.kitscc@mbox.nc.kyushu-u.ac.jp		Kuge, Osamu/0000-0003-4962-3519; Shimada, Hiroyasu/0000-0002-7120-5850				Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Akiba T, 2006, PROTEINS, V63, P243, DOI 10.1002/prot.20843; Amano H, 2005, BIOSCI BIOTECH BIOCH, V69, P2063, DOI 10.1271/bbb.69.2063; BRAUNER T, 1984, BIOCHIM BIOPHYS ACTA, V771, P208, DOI 10.1016/0005-2736(84)90535-2; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cannon RJC, 1996, BIOL REV, V71, P561, DOI 10.1111/j.1469-185X.1996.tb01285.x; Crickmore N, 1998, MICROBIOL MOL BIOL R, V62, P807, DOI 10.1128/MMBR.62.3.807-813.1998; Czajkowsky DM, 2004, EMBO J, V23, P3206, DOI 10.1038/sj.emboj.7600350; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; HOFTE H, 1989, MICROBIOL REV, V53, P242; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Ito A, 2004, J BIOL CHEM, V279, P21282, DOI 10.1074/jbc.M401881200; Katayama H, 2005, J BIOCHEM, V137, P17, DOI 10.1093/jb/mvi003; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HS, 2000, J APPL MICROBIOL, V89, P16, DOI 10.1046/j.1365-2672.2000.01087.x; Kondo S, 2002, PARASITOL RES, V88, P1090, DOI 10.1007/s00436-002-0692-6; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee DW, 2001, BBA-PROTEIN STRUCT M, V1547, P57, DOI 10.1016/S0167-4838(01)00169-8; MAHILLON J, 1994, GENETICA, V93, P13, DOI 10.1007/BF01435236; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; MEADOWS MP, 1992, APPL ENVIRON MICROB, V58, P1344, DOI 10.1128/AEM.58.4.1344-1350.1992; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; Miyata S, 2002, J BIOL CHEM, V277, P39463, DOI 10.1074/jbc.M206731200; Mizuki E, 1999, J APPL MICROBIOL, V86, P477, DOI 10.1046/j.1365-2672.1999.00692.x; Mizuki E, 2000, CLIN DIAGN LAB IMMUN, V7, P625, DOI 10.1128/CDLI.7.4.625-634.2000; OHBA M, 1986, J INVERTEBR PATHOL, V47, P12, DOI 10.1016/0022-2011(86)90158-8; Okumura S, 2005, J AGR FOOD CHEM, V53, P6313, DOI 10.1021/jf0506129; Petit L, 2001, J BIOL CHEM, V276, P15736, DOI 10.1074/jbc.M010412200; SASAGURI Y, 1992, AM J PATHOL, V141, P611; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033; Vie V, 2001, J MEMBRANE BIOL, V180, P195, DOI 10.1007/s002320010070; Wei JZ, 2003, P NATL ACAD SCI USA, V100, P2760, DOI 10.1073/pnas.0538072100; Yamashita S, 2005, J BIOCHEM, V138, P663, DOI 10.1093/jb/mvi177	36	50	57	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26350	26360		10.1074/jbc.M602589200	http://dx.doi.org/10.1074/jbc.M602589200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809341	hybrid			2022-12-27	WOS:000240249500052
J	Kotsyfakis, M; Sa-Nunes, A; Francischetti, IMB; Mather, TN; Andersen, JF; Ribeiro, JMC				Kotsyfakis, Michalis; Sa-Nunes, Anderson; Francischetti, Ivo M. B.; Mather, Thomas N.; Andersen, John F.; Ribeiro, Jose M. C.			Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; LYSOSOMAL CYSTEINE PROTEASES; CATHEPSIN-L; EXTRACELLULAR-MATRIX; IMMUNE-RESPONSES; STRUCTURAL BASIS; PROTEIN; INHIBITORS; EXPRESSION; COLLAGEN	Here we report the ability of the tick Ixodes scapularis, the main vector of Lyme disease in the United States, to actively and specifically affect the host proteolytic activity in the sites of infestation through the release of a cystatin constituent of its saliva. The cystatin presence in the saliva was verified both biochemically and immunologically. We named the protein sialostatin L because of its inhibitory action against cathepsin L. We also show that the proteases it targets, although limited in number, have a prominent role in the proteolytic cascades that take place in the extracellular and intracellular environment. As a result, sialostatin L displays an antiinflammatory role and inhibits proliferation of cytotoxic T lymphocytes. Beyond unraveling another component accounting for the properties of tick saliva, contributing to feeding success and pathogen transmission, we describe a novel tool for studying the role of papain-like proteases in diverse biologic phenomena and a protein with numerous potential pharmaceutical applications.	NIAID, Lab Malaria & Vector Res, Vector Biol Sect, NIH, Rockville, MD 20852 USA; Univ Rhode Isl, Ctr Vector Borne Dis, Kingston, RI 02881 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Rhode Island	Ribeiro, JMC (corresponding author), NIAID, Lab Malaria & Vector Res, Vector Biol Sect, NIH, 12735 Twinbrook Pkwy,Rm 2E-32, Rockville, MD 20852 USA.	jribeiro@niaid.nih.gov	Sa-Nunes, Anderson/M-5654-2019; Sa-Nunes, Anderson/D-8667-2012; Kotsyfakis, Michail/G-9525-2014	Sa-Nunes, Anderson/0000-0002-1859-4973; Sa-Nunes, Anderson/0000-0002-1859-4973; Kotsyfakis, Michail/0000-0002-7526-1876; Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000810, ZIAAI001012, ZIAAI000810, Z01AI001012] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Andersen JF, 1997, BIOCHEMISTRY-US, V36, P4423, DOI 10.1021/bi9628883; BARNA JB, 1995, INFLAMMATION, V19, P561, DOI 10.1007/BF01539136; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, V2, P1051; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BJORK I, 1994, BIOCHEM J, V299, P219, DOI 10.1042/bj2990219; BJORK I, 2006, BIOCHEMISTRY-US, V35, P10720; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; Dahl SW, 2001, BIOCHEMISTRY-US, V40, P1671, DOI 10.1021/bi001693z; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; FOSSUM K, 1968, ARCH BIOCHEM BIOPHYS, V125, P367, DOI 10.1016/0003-9861(68)90672-3; GERN L, 1993, J INFECT DIS, V167, P971, DOI 10.1093/infdis/167.4.971; Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x; Hartmann S, 2003, INT J PARASITOL, V33, P1291, DOI 10.1016/S0020-7519(03)00163-2; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Honey K, 2002, NAT IMMUNOL, V3, P1069, DOI 10.1038/ni844; Houle S, 2005, BRIT J PHARMACOL, V146, P670, DOI 10.1038/sj.bjp.0706371; Ishidoh K, 1995, BIOCHEM BIOPH RES CO, V217, P624, DOI 10.1006/bbrc.1995.2820; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Karim S, 2005, BIOCHEM BIOPH RES CO, V334, P1336, DOI 10.1016/j.bbrc.2005.07.036; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; Kotsyfakis M, 2005, INSECT MOL BIOL, V14, P555, DOI 10.1111/j.1365-2583.2005.00586.x; Kotsyfakis M, 2005, MOL MICROBIOL, V57, P171, DOI 10.1111/j.1365-2958.2005.04664.x; LEUNGTACK J, 1990, INFLAMMATION, V14, P247, DOI 10.1007/BF00915809; LEVY L, 1969, LIFE SCI PT 1 PHYSI, V8, P601, DOI 10.1016/0024-3205(69)90021-6; Lombardi G, 2005, J IMMUNOL, V174, P7022, DOI 10.4049/jimmunol.174.11.7022; MACIEWICZ RA, 1987, COLLAGEN REL RES, V7, P295; Maniatis T., 1989, MOL CLONING LAB MAN; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; *NAT I HLTH, 1996, GUID CAR US LAB AN; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V263, P107, DOI 10.1016/0003-9861(88)90618-2; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085; Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; POL E, 1995, BIOCHEM J, V311, P275, DOI 10.1042/bj3110275; Puzer L, 2005, BIOL CHEM, V386, P699, DOI 10.1515/BC.2005.081; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; RIBEIRO JMC, 1985, J EXP MED, V161, P332, DOI 10.1084/jem.161.2.332; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SAUER JR, 1995, ANNU REV ENTOMOL, V40, P245, DOI 10.1146/annurev.en.40.010195.001333; Schonemeyer A, 2001, J IMMUNOL, V167, P3207, DOI 10.4049/jimmunol.167.6.3207; Serveau-Avesque C, 2006, BIOL CELL, V98, P15, DOI 10.1042/BC20040512; Thiele DL, 1997, J IMMUNOL, V158, P5200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; Vray B, 2002, CELL MOL LIFE SCI, V59, P1503, DOI 10.1007/s00018-002-8525-4; WARFEL AH, 1987, J EXP MED, V166, P1912, DOI 10.1084/jem.166.6.1912; Wikel SK, 1997, PARASITOL TODAY, V13, P383, DOI 10.1016/S0169-4758(97)01126-5; Wille A, 2004, BIOL CHEM, V385, P665, DOI 10.1515/BC.2004.082; Williams J W, 1979, Methods Enzymol, V63, P437; Wolters PJ, 2001, J BIOL CHEM, V276, P18551, DOI 10.1074/jbc.M100223200	64	165	172	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26298	26307		10.1074/jbc.M513010200	http://dx.doi.org/10.1074/jbc.M513010200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16772304	hybrid, Green Published			2022-12-27	WOS:000240249500047
J	Chaudhary, K; Ting, LM; Kim, K; Roos, DS				Chaudhary, Kshitiz; Ting, Li Min; Kim, Kami; Roos, David S.			Toxoplasma gondii purine nucleoside phosphorylase biochemical characterization, inhibitor profiles, and comparison with the Plasmodium falciparum ortholog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; ESCHERICHIA-COLI; SEQUENCE; MALARIA; CLONING; TOOLS	Purine nucleoside phosphorylase ( PNP) is an important component of the nucleotide salvage pathway in apicomplexan parasites and a potential target for drug development. The intracellular pathogen Toxoplasma gondii was therefore tested for sensitivity to immucillins, transition state analogs that exhibit high potency against PNP in the malaria parasite Plasmodium falciparum. Growth of wild-type T. gondii is unaffected by up to 10 mu M immucillin-H (ImmH), but mutants lacking the ( redundant) purine salvage pathway enzyme adenosine kinase are susceptible to the drug, with an IC50 of 23 nM. This effect is rescued by the reaction product hypoxanthine, but not the substrate inosine, indicating that ImmH acts via inhibition of T. gondii PNP. The primary amino acid sequence of TgPNP is > 40% identical to PfPNP, and recombinant enzymes exhibit similar kinetic parameters for most substrates. Unlike the Plasmodium enzyme, however, TgPNP cannot utilize 5'-methylthio- inosine (MTI). Moreover, TgPNP is insensitive to methylthio-immucillin-H (MT-ImmH), which inhibits PfPNP with a K*(i) of 2.7 nM. MTI arises through the deamination of methylthio-adenosine, a product of the polyamine biosynthetic pathway, and its further metabolism to hypoxanthine involves PfPNP in purine recycling ( in addition to salvage). Remarkably, analysis of the recently completed T. gondii genome indicates that polyamine biosynthetic machinery is completely lacking in this species, obviating the need for TgPNP to metabolize MTI. Differences in purine and polyamine metabolic pathways among members of the phylum Apicomplexa and these parasites and their human hosts are likely to influence drug target selection strategies. Targeting T. gondii PNP alone is unlikely to be efficacious for treatment of toxoplasmosis.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	University of Pennsylvania; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Roos, DS (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu		Roos, David Siker/0000-0001-6725-4089; Kim, Kami/0000-0003-3384-152X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Berens R. I., 1995, BIOCH MOL BIOL PARAS, P323; Chaudhary K, 2005, J BIOL CHEM, V280, P22053, DOI 10.1074/jbc.M503178200; Chaudhary K, 2004, J BIOL CHEM, V279, P31221, DOI 10.1074/jbc.M404232200; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Hill D, 2002, CLIN MICROBIOL INFEC, V8, P634, DOI 10.1046/j.1469-0691.2002.00485.x; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Keithly JS, 1997, MOL BIOCHEM PARASIT, V88, P35, DOI 10.1016/S0166-6851(97)00063-7; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; Kissinger JC, 2003, NUCLEIC ACIDS RES, V31, P234, DOI 10.1093/nar/gkg072; KRUG EC, 1989, J BIOL CHEM, V264, P10601; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; MORGUNOVA EY, 1995, FEBS LETT, V367, P183, DOI 10.1016/0014-5793(95)00489-V; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Pugmire MJ, 2002, BIOCHEM J, V361, P1, DOI 10.1042/0264-6021:3610001; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; Seabra SH, 2004, J PARASITOL, V90, P455, DOI 10.1645/GE-179R; Shi WX, 2004, J BIOL CHEM, V279, P18103, DOI 10.1074/jbc.C400068200; Sullivan WJ, 1999, MOL BIOCHEM PARASIT, V103, P1, DOI 10.1016/S0166-6851(99)00114-0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ting LM, 2005, J BIOL CHEM, V280, P9547, DOI 10.1074/jbc.M412693200; WILLIAMS SR, 1984, NUCLEIC ACIDS RES, V12, P5779, DOI 10.1093/nar/12.14.5779	28	38	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25652	25658		10.1074/jbc.M602624200	http://dx.doi.org/10.1074/jbc.M602624200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829527	hybrid			2022-12-27	WOS:000240031300068
J	Ding, J; Li, JX; Xue, CF; Wu, KJ; Ouyang, WM; Zhang, DY; Yan, Y; Huang, CS				Ding, Jin; Li, Jingxia; Xue, Caifang; Wu, Kangjian; Ouyang, Weiming; Zhang, Dongyun; Yan, Yan; Huang, Chuanshu			Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; SODIUM ARSENITE; LUNG-CANCER; RAT LUNG; MOLECULAR-MECHANISMS; DRINKING-WATER; TUMOR PROMOTER; C/EBP-BETA; EXPRESSION	Arsenite is a well known metalloid human carcinogen, and epidemiological evidence has demonstrated its association with the increased incidence of lung cancer. However, the mechanism involved in its lung carcinogenic effect remains obscure. The current study demonstrated that exposure of human bronchial epithelial cells (Beas-2B) to arsenite resulted in a marked induction of cyclooxygenase (COX)-2, an important mediator for inflammation and tumor promotion. Exposure of the Beas-2B cells to arsenite also led to significant transactivation of nuclear factor of activated T-cells (NFAT), but not activator protein-1 (AP-1) and NF kappa B, suggesting that NFAT, rather than AP-1 or NF kappa B, is implicated in the responses of Beas-2B cells to arsenite exposure. Furthermore, we found that inhibition of the NFAT pathway by either chemical inhibitors, dominant negative mutants of NFAT, or NFAT3 small interference RNA resulted in the impairment of COX-2 induction and caused cell apoptosis in Beas-2B cells exposed to arsenite. Site- directed mutation of two putative NFAT binding sites between -111 to +65 in the COX-2 promoter region eliminated the COX-2 transcriptional activity induced by arsenite, confirming that those two NFAT binding sites in the COX-2 promoter region are critical for COX-2 induction by arsenite. Moreover, knockdown of COX-2 expression by COX-2-specific small interference RNA also led to an increased cell apoptosis in Beas-2B cells upon arsenite exposure. Together, our results demonstrate that COX-2 induction by arsenite is through NFAT3-dependent and AP-1- or NF kappa B-independent pathways and plays a crucial role in antagonizing arsenite-induced cell apoptosis in human bronchial epithelial Beas-2B cells.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Fourth Mil Med Univ, Dept Etiol, Xian 710032, Shaanxi, Peoples R China	New York University; Air Force Military Medical University	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096	NCI NIH HHS [CA112557, CA103180, CA094964] Funding Source: Medline; NIEHS NIH HHS [ES012451, ES000260] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA103180, R01CA112557, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451, P30ES000260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ali-Fehmi R, 2005, AM J OBSTET GYNECOL, V192, P819, DOI 10.1016/j.ajog.2004.10.587; Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; BATES MN, 1995, AM J EPIDEMIOL, V141, P523, DOI 10.1093/oxfordjournals.aje.a117467; BETTLEY FR, 1975, BRIT J DERMATOL, V92, P563; Chakravortty D, 2001, J IMMUNOL, V166, P2011, DOI 10.4049/jimmunol.166.3.2011; Chappell WR, 1997, ENVIRON HEALTH PERSP, V105, P1060, DOI 10.1289/ehp.971051060; Chen J, 2005, J BIOL CHEM, V280, P16354, DOI 10.1074/jbc.M411134200; CHIOU HY, 1995, CANCER RES, V55, P1296; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Clarke A R, 2000, Symp Soc Exp Biol, V52, P265; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Correa P, 1998, BRIT MED BULL, V54, P151; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; Daum G, 2001, MOL CELL BIOCHEM, V217, P131, DOI 10.1023/A:1007276812824; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; El-Bayoumy K, 1999, CANCER RES, V59, P1400; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; Harris RE, 2005, ONCOL REP, V13, P559; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang CS, 2004, MOL CELL BIOCHEM, V255, P57, DOI 10.1023/B:MCBI.0000007261.04684.78; Huang CS, 1999, CANCER RES, V59, P3053; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 2001, ANTICANCER RES, V21, P261; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; ISHINISHI N, 1977, ENVIRON HEALTH PERSP, V19, P191, DOI 10.2307/3428474; Khuri FR, 2001, CLIN CANCER RES, V7, P861; KNOWLES F C, 1984, Zeitschrift fuer die Gesamte Hygiene und ihre Grenzgebiete, V30, P625; Koyama Y, 1999, J NEUROCHEM, V73, P1004, DOI 10.1046/j.1471-4159.1999.0731004.x; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; LANDOLPH JR, 1994, ENVIRON HEALTH PERSP, V102, P119, DOI 10.2307/3431774; LEE TC, 1988, SCIENCE, V241, P79, DOI 10.1126/science.3388020; LI J-H, 1989, Molecular Toxicology, V2, P1; LI JH, 1989, BIOL TRACE ELEM RES, V21, P373, DOI 10.1007/BF02917278; Li JX, 2004, MOL CARCINOGEN, V40, P104, DOI 10.1002/mc.20020; Li LY, 2003, RADIAT RES, V160, P617, DOI 10.1667/RR3076; Liu ZG, 2005, CELL RES, V15, P24, DOI 10.1038/sj.cr.7290259; Liu ZG, 2001, METHOD CELL BIOL, V66, P187; Morris RD, 1995, ENVIRON HEALTH PERSP, V103, P225, DOI 10.2307/3432315; Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003; Ouyang WM, 2005, CANCER RES, V65, P9287, DOI 10.1158/0008-5472.CAN-05-0469; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pold M, 2004, CANCER RES, V64, P6549, DOI 10.1158/0008-5472.CAN-04-1225; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Riedl K, 2004, DRUG RESIST UPDATE, V7, P169, DOI 10.1016/j.drup.2004.04.003; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Scott KA, 2003, MOL CANCER THER, V2, P445; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Subbaramaiah K, 2001, J BIOMOL SCREEN, V6, P101; Sugimoto T, 2001, J AM SOC NEPHROL, V12, P1359, DOI 10.1681/ASN.V1271359; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; TSUDA T, 1995, AM J EPIDEMIOL, V141, P198, DOI 10.1093/oxfordjournals.aje.a117421; Wijeweera JB, 2001, TOXICOL SCI, V61, P283, DOI 10.1093/toxsci/61.2.283; Wyllie AH, 1999, BRIT J CANCER, V80, P34; YAN Y, 2006, IN PRESS J CELL SCI; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	63	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24405	24413		10.1074/jbc.M600751200	http://dx.doi.org/10.1074/jbc.M600751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16809336	hybrid			2022-12-27	WOS:000239847800034
J	Durgan, DJ; Trexler, NA; Egbejimi, O; McElfresh, TA; Suk, HY; Petterson, LE; Shaw, CA; Hardin, PE; Bray, MS; Chandler, MP; Chow, CW; Young, ME				Durgan, David J.; Trexler, Nowice A.; Egbejimi, Oluwaseun; McElfresh, Tracy A.; Suk, Hee Yun; Petterson, Lauren E.; Shaw, Chad A.; Hardin, Paul E.; Bray, Molly S.; Chandler, Margaret P.; Chow, Chi-Wing; Young, Martin E.			The circadian clock within the cardiomyocyte is essential for responsiveness of the heart to fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; 24-HOUR BLOOD-PRESSURE; SHIFT WORKERS; DIURNAL-VARIATIONS; ENERGY-METABOLISM; GENE-EXPRESSION; INCREASED RISK; RHYTHMS; DISEASE; OXIDATION	Cells/organs must respond both rapidly and appropriately to increased fatty acid availability; failure to do so is associated with the development of skeletal muscle and hepatic insulin resistance, pancreatic beta-cell dysfunction, and myocardial contractile dysfunction. Here we tested the hypothesis that the intrinsic circadian clock within the cardiomyocytes of the heart allows rapid and appropriate adaptation of this organ to fatty acids by investigating the following: 1) whether circadian rhythms in fatty acid responsiveness persist in isolated adult rat cardiomyocytes, and 2) whether manipulation of the circadian clock within the heart, either through light/dark ( L/D) cycle or genetic disruptions, impairs responsiveness of the heart to fasting in vivo. We report that both the intramyocellular circadian clock and diurnal variations in fatty acid responsiveness observed in the intact rat heart in vivo persist in adult rat cardiomyocytes. Reversal of the 12-h/12-h L/D cycle was associated with a re-entrainment of the circadian clock within the rat heart, which required 5-8 days for completion. Fasting rats resulted in the induction of fatty acid-responsive genes, an effect that was dramatically attenuated 2 days after L/D cycle reversal. Similarly, a targeted disruption of the circadian clock within the heart, through overexpression of a dominant negative CLOCK mutant, severely attenuated induction of myocardial fatty acid-responsive genes during fasting. These studies expose a causal relationship between the circadian clock within the cardiomyocyte with responsiveness of the heart to fatty acids and myocardial triglyceride metabolism.	USDA ARS, Childrens Nutr Res Ctr, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77204 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Case Western Reserve University; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Young, ME (corresponding author), USDA ARS, Childrens Nutr Res Ctr, Baylor Coll Med, Dept Pediat, 1100 Bates St, Houston, TX 77030 USA.	meyoung@bcm.edu		Shaw, Chad/0000-0001-7267-5398; Hardin, Paul/0000-0002-3370-9011	NHLBI NIH HHS [HL-074259-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074259] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barger PM, 2000, TRENDS CARDIOVAS MED, V10, P238, DOI 10.1016/S1050-1738(00)00077-3; Carson PA, 2000, J AM COLL CARDIOL, V36, P541, DOI 10.1016/S0735-1097(00)00728-2; Chandler MP, 2002, AM J PHYSIOL-HEART C, V282, pH1871, DOI 10.1152/ajpheart.00976.2001; CHAU NP, 1989, CIRCULATION, V80, P341, DOI 10.1161/01.CIR.80.2.341; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Davidson AJ, 2005, CLIN EXP HYPERTENS, V27, P307, DOI 10.1081/CEH-200048933; DEGAUTE JP, 1994, HYPERTENSION, V23, P244, DOI 10.1161/01.HYP.23.2.244; DEGAUTE JP, 1991, HYPERTENSION, V18, P199, DOI 10.1161/01.HYP.18.2.199; Durgan DJ, 2005, AM J PHYSIOL-HEART C, V289, pH1530, DOI 10.1152/ajpheart.00406.2005; Edery I, 2000, PHYSIOL GENOMICS, V3, P59, DOI 10.1152/physiolgenomics.2000.3.2.59; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Harma MI, 1999, SCAND J WORK ENV HEA, V25, P610; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Kassam A, 1999, J BIOL CHEM, V274, P22895, DOI 10.1074/jbc.274.32.22895; KHATRI IM, 1967, J APPL PHYSIOL, V22, P867, DOI 10.1152/jappl.1967.22.5.867; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNUTSSON A, 1986, LANCET, V2, P89; KOLLER M, 1983, INT ARCH OCC ENV HEA, V53, P59, DOI 10.1007/BF00406178; Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200; LOPASCHUK GD, 1994, BBA-LIPID LIPID MET, V1213, P263, DOI 10.1016/0005-2760(94)00082-4; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; MILLARCRAIG MW, 1978, LANCET, V1, P795; Mukamal KJ, 2000, AM HEART J, V140, P438, DOI 10.1067/mhj.2000.108830; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; PRINZ PN, 1979, J CLIN ENDOCR METAB, V49, P300, DOI 10.1210/jcem-49-2-300; RICHARDS AM, 1986, CLIN EXP HYPERTENS A, V8, P153, DOI 10.3109/10641968609074769; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Sharma S, 2004, FASEB J, V18, P1692, DOI 10.1096/fj.04-2263com; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Stavinoha MA, 2004, AM J PHYSIOL-ENDOC M, V287, pE878, DOI 10.1152/ajpendo.00189.2004; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; SUNDBERG S, 1988, J HYPERTENS, V6, P393; TURTON MB, 1974, CLIN CHIM ACTA, V55, P389, DOI 10.1016/0009-8981(74)90014-X; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; van den Buuse M, 1999, PHYSIOL BEHAV, V68, P9, DOI 10.1016/S0031-9384(99)00148-1; VEERMAN DP, 1995, HYPERTENSION, V26, P55, DOI 10.1161/01.HYP.26.1.55; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Wu PF, 2001, BIOCHEM BIOPH RES CO, V287, P391, DOI 10.1006/bbrc.2001.5608; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Young ME, 2001, CIRC RES, V89, P1199, DOI 10.1161/hh2401.100741; Young ME, 2006, AM J PHYSIOL-HEART C, V290, pH1, DOI 10.1152/ajpheart.00582.2005; Young ME, 2003, CURR HYPERTENS REP, V5, P445, DOI 10.1007/s11906-003-0051-8; Young ME, 2002, J MOL CELL CARDIOL, V34, P223, DOI 10.1006/jmcc.2001.1504; Young ME, 2002, CIRCULATION, V105, P1861, DOI 10.1161/01.CIR.0000012467.61045.87; Young ME, 2001, CIRC RES, V88, P1142, DOI 10.1161/hh1101.091190; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com; Zhang BL, 2000, AM J PHYSIOL-REG I, V279, pR169, DOI 10.1152/ajpregu.2000.279.1.R169	50	116	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24254	24269		10.1074/jbc.M601704200	http://dx.doi.org/10.1074/jbc.M601704200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798731	hybrid			2022-12-27	WOS:000239847800019
J	Ji, P; Goldin, L; Ren, H; Sun, DQ; Guardavaccaro, D; Pagano, M; Zhu, L				Ji, Peng; Goldin, Luba; Ren, Hao; Sun, Daqian; Guardavaccaro, Daniele; Pagano, Michele; Zhu, Liang			Skp2 contains a novel cyclin a binding domain that directly protects cyclin a from inhibition by p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; F-BOX; UBIQUITIN LIGASE; PROSTATE-CANCER; S-PHASE; DEPENDENT KINASES; CRYSTAL-STRUCTURE; IN-VIVO; COMPLEX; P27	Skp2 is well known as the F-box protein of the SCF(Skp2.)Roc1 complex targeting p27 for ubiquitylation. Skp2 also forms complexes with cyclin A, which is particularly abundant in cancer cells due to frequent Skp2 overexpression, but the mechanism and significance of this interaction remain unknown. Here, we report that Skp2-cyclin A interaction is mediated by novel interaction sequences on both Skp2 and cyclin A, distinguishing it from the well known RXL-hydrophobic patch interaction between cyclins and cyclin-binding proteins. Furthermore, a short peptide derived from the mapped cyclin A binding sequences of Skp2 can block Skp2-cyclin A interaction but not p27-cyclin A interaction, whereas a previously identified RXL peptide can block p27-cyclin A interaction but not Skp2- cyclin A interaction. Functionally, Skp2- cyclin A interaction is separable from Skp2 ability to mediate p27 ubiquitylation. Rather, Skp2- cyclin A interaction serves to directly protect cyclin A-Cdk2 from inhibition by p27 through competitive binding. Finally, we show that disruption of cyclin A binding with point mutations in the cyclin A binding domain of Skp2 compromises the ability of overexpressed Skp2 to counter cell cycle arrest by a p53/p21-mediated cell cycle checkpoint without affecting its ability to cause degradation of cellular p27 and p21. These findings reveal a new functional mechanism of Skp2 and a new regulatory mechanism of cyclin A.	Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Liver Res Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; NYU, Sch Med, Canc Inst, Dept Pathol, New York, NY 10016 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York University	Zhu, L (corresponding author), Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA.	lizhu@aecom.yu.edu		pagano, michele/0000-0003-3210-2442; Guardavaccaro, Daniele/0000-0002-4517-1765				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Ben-Izhak O, 2003, J UROLOGY, V170, P241, DOI 10.1097/01.ju.0000072113.34524.a7; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Follenzi A, 2002, HUM GENE THER, V13, P243, DOI 10.1089/10430340252769770; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Shim EH, 2003, CANCER RES, V63, P1583; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Wang W, 2003, J BIOL CHEM, V278, P32390, DOI 10.1074/jbc.M305241200; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yang G, 2002, CLIN CANCER RES, V8, P3419; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058-6066.2004	37	26	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					24058	24069		10.1074/jbc.M603105200	http://dx.doi.org/10.1074/jbc.M603105200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16774918	hybrid			2022-12-27	WOS:000239702900079
J	Kortholt, A; Rehmann, H; Kae, H; Bosgraaf, L; Keizer-Gunnink, I; Weeks, G; Wittinghofer, A; Van Haastert, PJM				Kortholt, Arjan; Rehmann, Holger; Kae, Helmut; Bosgraaf, Leonard; Keizer-Gunnink, Ineke; Weeks, Gerald; Wittinghofer, Alfred; Van Haastert, Peter J. M.			Characterization of the GbpD-activated Rap1 pathway regulating adhesion and cell polarity in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MEDIATES RAP1-INDUCED ADHESION; RAS-RELATED GENE; SOCIAL AMEBA; H-RAS; R-RAS; KINASE; CHEMOTAXIS; PROTEINS; FAMILY	The regulation of cell polarity plays an important role in chemotaxis. GbpD, a putative nucleotide exchange factor for small G-proteins of the Ras family, has been implicated in adhesion, cell polarity, and chemotaxis in Dictyostelium. Cells overexpressing GbpD are flat, exhibit strongly increased cell-substrate attachment, and extend many bifurcated and lateral pseudopodia. These cells overexpressing GbpD are severely impaired in chemotaxis, most likely due to the induction of many protrusions rather than an enhanced adhesion. The GbpD-overexpression phenotype is similar to that of cells overexpressing Rap1. Here we demonstrate that GbpD activates Rap1 both in vivo and in vitro but not any of the five other characterized Ras proteins. In a screen for Rap1 effectors, we overexpressed GbpD in several mutants defective in adhesion or cell polarity and identified Phg2 as Rap1 effector necessary for adhesion, but not cell polarity. Phg2, a serine/threonine-specific kinase, directly interacts with Rap1 via its Ras association domain.	Univ Groningen, Dept Mol Cell Biol, NL-9751 NN Haren, Netherlands; Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	University of Groningen; Utrecht University; Utrecht University; University of British Columbia; Max Planck Society	Van Haastert, PJM (corresponding author), Univ Groningen, Dept Mol Cell Biol, Kerklaan 30, NL-9751 NN Haren, Netherlands.	P.J.M.van.Haastert@rug.nl	kortholt, arjan/L-9795-2017	kortholt, arjan/0000-0001-8174-6397				Arigoni M, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-43; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Blaauw M, 2000, GENE, V252, P71, DOI 10.1016/S0378-1119(00)00227-4; Blanc C, 2005, EUR J CELL BIOL, V84, P951, DOI 10.1016/j.ejcb.2005.09.014; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Bosgraaf L, 2005, J CELL SCI, V118, P1899, DOI 10.1242/jcs.02317; Bosgraaf L, 2003, BBA-MOL CELL RES, V1643, P5, DOI 10.1016/j.bbamcr.2003.08.008; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chubb JR, 2002, CELL MOTIL CYTOSKEL, V53, P150, DOI 10.1002/cm.10064; Chubb JR, 2001, BBA-GEN SUBJECTS, V1525, P262, DOI 10.1016/S0304-4165(01)00111-8; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Fey P, 2002, J CELL BIOL, V159, P1109, DOI 10.1083/jcb.200206067; Gebbie L, 2004, MOL BIOL CELL, V15, P3915, DOI 10.1091/mbc.E03-12-0908; Goldberg JM, 2002, P NATL ACAD SCI USA, V99, P6749, DOI 10.1073/pnas.102167299; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Insall RH, 1996, CURR BIOL, V6, P719, DOI 10.1016/S0960-9822(09)00453-9; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kae H, 2004, EMBO REP, V5, P602, DOI 10.1038/sj.embor.7400151; Kang RJ, 2002, J CELL SCI, V115, P3675, DOI 10.1242/jcs.00039; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Khosla M, 1996, MOL CELL BIOL, V16, P4156; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Kuiperij HB, 2003, BBA-MOL CELL RES, V1593, P141, DOI 10.1016/S0167-4889(02)00365-8; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lim CJ, 2001, EMBO J, V20, P4490, DOI 10.1093/emboj/20.16.4490; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Niewohner J, 1997, J CELL BIOL, V138, P349, DOI 10.1083/jcb.138.2.349; REBSTEIN PJ, 1993, DEV GENET, V14, P347, DOI 10.1002/dvg.1020140504; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Seastone DJ, 1999, MOL BIOL CELL, V10, P393, DOI 10.1091/mbc.10.2.393; Soll DR, 1999, COMPUT MED IMAG GRAP, V23, P3, DOI 10.1016/S0895-6111(98)00058-5; Sutherland BW, 2001, EMBO REP, V2, P1024, DOI 10.1093/embo-reports/kve222; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; Tuxworth RI, 1997, J CELL BIOL, V138, P605, DOI 10.1083/jcb.138.3.605; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Weeks G, 2005, DICTYOSTELIUM GENOMI, P173; Wilkins A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r68; Wilkins A, 2000, GENE DEV, V14, P1407; Wilkins A, 2000, CURR BIOL, V10, P1427, DOI 10.1016/S0960-9822(00)00797-1; Wilkins A, 2001, TRENDS GENET, V17, P41, DOI 10.1016/S0168-9525(00)02181-8; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638	48	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23367	23376		10.1074/jbc.M600804200	http://dx.doi.org/10.1074/jbc.M600804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16769729	hybrid, Green Published, Green Submitted			2022-12-27	WOS:000239702900011
J	Sawakami, K; Robling, AG; Ai, MR; Pitner, ND; Liu, DW; Warden, SJ; Li, JL; Maye, P; Rowe, DW; Duncan, RL; Warman, ML; Turner, CH				Sawakami, Kimihiko; Robling, Alexander G.; Ai, Minrong; Pitner, Nathaniel D.; Liu, Dawei; Warden, Stuart J.; li, Jiang Li; Maye, Peter; Rowe, David W.; Duncan, Randall L.; Warman, Matthew L.; Turner, Charles H.			The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; OSCILLATORY FLUID-FLOW; INTRACELLULAR CALCIUM MOBILIZATION; LONG-TERM IMMOBILIZATION; IN-VIVO; SIGNALING PATHWAY; GENE-EXPRESSION; MC3T3-E1 OSTEOBLASTS; MISSENSE MUTATIONS; WNT/BETA-CATENIN	The cell surface receptor, low-density lipoprotein receptor-related protein 5 (LRP5) is a key regulator of bone mass. Loss-of-function mutations in LRP5 cause the human skeletal disease osteoporosis-pseudoglioma syndrome, an autosomal recessive disorder characterized by severely reduced bone mass and strength. We investigated the role of LRP5 on bone strength using mice engineered with a loss-of-function mutation in the gene. We then tested whether the osteogenic response to mechanical loading was affected by the loss of Lrp5 signaling. Lrp5-null (Lrp5(-/-)) mice exhibited significantly lower bone mineral density and decreased strength. The osteogenic response to mechanical loading of the ulna was reduced by 88 to 99% in Lrp5(-/-) mice, yet osteoblast recruitment and/or activation at mechanically strained surfaces was normal. Subsequent experiments demonstrated an inability of Lrp5(-/-) osteoblasts to synthesize the bone matrix protein osteopontin after a mechanical stimulus. We then tested whether Lrp5(-/-) mice increased bone formation in response to intermittent parathyroid hormone (PTH), a known anabolic treatment. A 4-week course of intermittent PTH (40 mu g/kg/day; 5 days/week) enhanced skeletal mass equally in Lrp5(-/-) and Lrp5(-/-) mice, suggesting that the anabolic effects of PTH do not require Lrp5 signaling. We conclude that Lrp5 is critical for mechanotransduction in osteoblasts. Lrp5 is a mediator of mature osteoblast function following loading. Our data suggest an important component of the skeletal fragility phenotype in individuals affected with osteoporosis-pseudoglioma is inadequate processing of signals derived from mechanical stimulation and that PTH might be an effective treatment for improving bone mass in these patients.	Indiana Univ, Sch Med, Dept Orthoped Surg, Biomech & Biomat Res Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA; Case Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of Connecticut	Turner, CH (corresponding author), Indiana Univ, Sch Med, Dept Orthoped Surg, Biomech & Biomat Res Ctr, 1120 South Dr,FH 115, Indianapolis, IN 46202 USA.	turnerch@iupui.edu	Duncan, Randall/AAK-3888-2020; Warden, Stuart/C-5287-2012	Warden, Stuart/0000-0002-6415-4936; Maye, Peter/0000-0003-0098-4399; Duncan, Randall/0000-0001-5733-6603	NIAMS NIH HHS [AR053237, AR046530] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046530, R01AR053237] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946-4955.2005; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; BIKLE DD, 1987, ENDOCRINOLOGY, V120, P678, DOI 10.1210/endo-120-2-678; Boppart MD, 1998, BONE, V23, P409, DOI 10.1016/S8756-3282(98)00119-7; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BRUDE E, 1986, 7 INT C HUM GEN ABST, P35; Clement-Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102; Cullen DM, 2004, J BONE MINER RES, V19, pS396; David V, 2003, J BONE MINER RES, V18, P1622, DOI 10.1359/jbmr.2003.18.9.1622; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009; Gere J. G, 1990, MECH MAT; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010; HARELL A, 1977, CALC TISS RES, V22, P202; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; Hsieh YF, 2001, J BONE MINER RES, V16, P2291, DOI 10.1359/jbmr.2001.16.12.2291; Iwaniec UT, 2004, J BONE MINER RES, V19, pS18; JAWORSKI ZFG, 1980, J BONE JOINT SURG BR, V62, P104, DOI 10.1302/0301-620X.62B1.6985912; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Kreke MR, 2005, BONE, V36, P1047, DOI 10.1016/j.bone.2005.03.008; Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Miles RR, 1998, J CELL BIOCHEM, V68, P355, DOI 10.1002/(SICI)1097-4644(19980301)68:3<355::AID-JCB6>3.0.CO;2-T; Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223-004-0213-y; Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002; Owan I, 1997, AM J PHYSIOL-CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562; RAWLINSON SCF, 1993, CALCIFIED TISSUE INT, V53, P324, DOI 10.1007/BF01351837; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756-3282(02)00871-2; Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545; Robling AG, 2002, MED SCI SPORT EXER, V34, P196, DOI 10.1097/00005768-200202000-00003; SOMJEN D, 1980, BIOCHIM BIOPHYS ACTA, V627, P91, DOI 10.1016/0304-4165(80)90126-9; Tanaka SM, 2005, CALCIFIED TISSUE INT, V76, P261, DOI 10.1007/s00223-004-0238-2; Tanaka SM, 2002, FASEB J, V16, P313, DOI 10.1096/fj.02-0561fje; Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626; TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686; TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K; Turner CH, 2001, J BONE MINER RES, V16, P206, DOI 10.1359/jbmr.2001.16.2.206; Turner CH, 1998, BONE, V22, P463, DOI 10.1016/S8756-3282(98)00041-6; UHTHOFF HK, 1978, J BONE JOINT SURG BR, V60, P420, DOI 10.1302/0301-620X.60B3.681422; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266; Wang Y, 2004, J BONE MINER RES, V19, pS106; Warden SJ, 2005, J BONE MINER RES, V20, P809, DOI 10.1359/JBMR.041222; WOLF G, 1980, ACTA BIOL MED GER, V39, P1243; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yao GQ, 2005, J BONE MINER RES, V20, pS48; YEH CK, 1984, CALCIFIED TISSUE INT, V36, pS67, DOI 10.1007/BF02406136; You J, 2000, J BIOMECH ENG-T ASME, V122, P387, DOI 10.1115/1.1287161; You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200	65	300	312	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23698	23711		10.1074/jbc.M601000200	http://dx.doi.org/10.1074/jbc.M601000200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790443	hybrid			2022-12-27	WOS:000239702900045
J	Tong, EHY; Guo, JJ; Huang, AL; Liu, H; Hu, CD; Chung, SSM; Ko, BCB				Tong, Edith H. Y.; Guo, Jin-Jun; Huang, Ai-Long; Liu, Han; Hu, Chang-Deng; Chung, Stephen S. M.; Ko, Ben C. B.			Regulation of nucleocytoplasmic trafficking of transcription factor OREBP/TonEBP/NFAT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; NUCLEAR EXPORT SIGNAL; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; DAMAGE-INDUCIBLE KINASE; ALDOSE REDUCTASE GENE; FACTOR TONEBP/OREBP; OSMOTIC-STRESS; HIGH NACL; SUBCELLULAR-LOCALIZATION; STIMULATES TRANSCRIPTION	The osmotic response element-binding protein ( OREBP), also known as tonicity enhancer-binding protein ( TonEBP) or NFAT5, regulates the hypertonicity-induced expression of a battery of genes crucial for the adaptation of mammalian cells to extracellular hypertonic stress. The activity of OREBP/TonEBP is regulated at multiple levels, including nucleocytoplasmic trafficking. OREBP/TonEBP protein can be detected in both the cytoplasm and nucleus under isotonic conditions, although it accumulates exclusively in the nucleus or cytoplasm when subjected to hypertonic or hypotonic challenges, respectively. Using immunocytochemistry and green fluorescent protein fusions, the protein domains that determine its subcellular localization were identified and characterized. We found that OREBP/TonEBP nuclear import is regulated by a nuclear localization signal. However, under isotonic conditions, nuclear export of OREBP/TonEBP is mediated by a CRM1-dependent, leucine-rich canonical nuclear export sequence ( NES) located in the N terminus. Disruption of NES by site-directed mutagenesis yielded a mutant OREBP/TonEBP protein that accumulated in the nucleus under isotonic conditions but remained a target for hypotonicity-induced nuclear export. More importantly, a putative auxiliary export domain distal to the NES was identified. Disruption of the auxiliary export domain alone is sufficient to abolish the nuclear export of OREBP/TonEBP induced by hypotonicity. By using bimolecular fluorescence complementation assay, we showed that CRM1 interacts with OREBP/TonEBP, but not with a mutant protein deficient in NES. Our findings provide insight into how nucleocytoplasmic trafficking of OREBP/TonEBP is regulated by changes in extracellular tonicity.	Univ Hong Kong, Hong Kong Adm Reg, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Open Lab Chem Biol, Inst Mol Technol Drug Discovery & Synth, Hong Kong Special Adm Reg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Physiol, Hong Kong Special Adm Reg, Hong Kong, Hong Kong, Peoples R China; Chongqing Univ Med Sci, Key Lab Mol Biol Infect Dis, Minist Educ, Inst Viral Hepatitis, Chongqing, Peoples R China; Purdue Univ, Sch Pharm, Dept Med Chem & Pharmacol, W Lafayette, IN 47907 USA	University of Hong Kong; University of Hong Kong; University of Hong Kong; Chongqing Medical University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chung, SSM (corresponding author), Univ Hong Kong, Hong Kong Adm Reg, Dept Chem, Hong Kong, Hong Kong, Peoples R China.	smchung@hkucc.hku.hk; cbko@hkucc.hku.hk	Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899				Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Brown VM, 2004, J BIOL CHEM, V279, P5984, DOI 10.1074/jbc.M307071200; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P16800, DOI 10.1073/pnas.222659799; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200; Handler JS, 2001, KIDNEY INT, V60, P408, DOI 10.1046/j.1523-1755.2001.060002408.x; Haussinger D, 1996, BIOCHEM J, V313, P697; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito T, 2004, BIOCHEM J, V382, P177, DOI 10.1042/BJ20031838; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang ZR, 2000, INVEST OPHTH VIS SCI, V41, P1467; Kitamura H, 1998, KIDNEY INT, V53, P146, DOI 10.1046/j.1523-1755.1998.00747.x; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Kondoh K, 2006, MOL CELL BIOL, V26, P1679, DOI 10.1128/MCB.26.5.1679-1690.2006; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Lopez-Rodriguez C, 1999, COLD SPRING HARB SYM, V64, P517, DOI 10.1101/sqb.1999.64.517; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Maallem S, 2006, NEUROSCIENCE, V137, P51, DOI 10.1016/j.neuroscience.2005.07.037; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Mingot JM, 2004, EMBO J, V23, P3227, DOI 10.1038/sj.emboj.7600338; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Neuhofer W, 2005, ANNU REV PHYSIOL, V67, P531, DOI 10.1146/annurev.physiol.67.031103.154456; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Sheikh-Hamad D, 2001, J AM SOC NEPHROL, V12, P2732, DOI 10.1681/ASN.V12122732; Shim EH, 2002, EMBO REP, V3, P857, DOI 10.1093/embo-reports/kvf175; Shyu YJ, 2006, BIOTECHNIQUES, V40, P61, DOI 10.2144/000112036; Song ZT, 2003, MOL CELL NEUROSCI, V23, P638, DOI 10.1016/S1044-7431(03)00096-4; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Warskulat U, 2004, J INVEST DERMATOL, V123, P516, DOI 10.1111/j.0022-202X.2004.23313.x; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Woo SK, 2000, AM J PHYSIOL-RENAL, V278, pF1006; Woo SK, 2000, AM J PHYSIOL-CELL PH, V278, pC323, DOI 10.1152/ajpcell.2000.278.2.C323; Woo SK, 2002, PFLUG ARCH EUR J PHY, V444, P579, DOI 10.1007/s00424-002-0849-2; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhang Z, 2005, AM J PHYSIOL-RENAL, V289, pF506, DOI 10.1152/ajprenal.00417.2004; Zhou XM, 2006, AM J PHYSIOL-RENAL, V290, pF1169, DOI 10.1152/ajprenal.00378.2005	65	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23870	23879		10.1074/jbc.M602556200	http://dx.doi.org/10.1074/jbc.M602556200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782704	hybrid			2022-12-27	WOS:000239702900062
J	LeFebvre, AK; Korneeva, NL; Trutschl, M; Cvek, U; Duzan, RD; Bradley, CA; Hershey, JWB; Rhoads, RE				LeFebvre, Aaron K.; Korneeva, Nadejda L.; Trutschl, Marjan; Cvek, Urska; Duzan, Roy D.; Bradley, Christopher A.; Hershey, John W. B.; Rhoads, Robert E.			Translation initiation factor eIF4G-1 binds to eIF3 through the eIF3e subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; CAP-DEPENDENT TRANSLATION; AMINO-ACID-SEQUENCE; MAMMARY-TUMOR VIRUS; HEPATITIS-C VIRUS; PROTEIN-SYNTHESIS; POLY(A)-BINDING PROTEIN; PREINITIATION COMPLEX; MULTIFACTOR COMPLEX; CORE COMPLEX	eIF3 in mammals is the largest translation initiation factor (similar to 800 kDa) and is composed of 13 nonidentical subunits designated eIF3a-m. The role of mammalian eIF3 in assembly of the 48 S complex occurs through high affinity binding to eIF4G. Interactions of eIF4G with eIF4E, eIF4A, eIF3, poly(A)-binding protein, and Mnk1/2 have been mapped to discrete domains on eIF4G, and conversely, the eIF4G-binding sites on all but one of these ligands have been determined. The only eIF4G ligand for which this has not been determined is eIF3. In this study, we have sought to identify the mammalian eIF3 subunit(s) that directly interact(s) with eIF4G. Established procedures for detecting protein-protein interactions gave ambiguous results. However, binding of partially proteolyzed HeLa eIF3 to the eIF3-binding domain of human eIF4G-1, followed by high throughput analysis of mass spectrometric data with a novel peptide matching algorithm, identified a single subunit, eIF3e (p48/Int-6). In addition, recombinant FLAG-eIF3e specifically competed with HeLa eIF3 for binding to eIF4G in vitro. Adding FLAG-eIF3e to a cell-free translation system (i) inhibited protein synthesis, (ii) caused a shift of mRNA from heavy to light polysomes, (iii) inhibited cap-dependent translation more severely than translation dependent on the HCV or CSFV internal ribosome entry sites, which do not require eIF4G, and (iv) caused a dramatic loss of eIF4G and eIF2 alpha from complexes sedimenting at similar to 40 S. These data suggest a specific, direct, and functional interaction of eIF3e with eIF4G during the process of cap-dependent translation initiation, although they do not rule out participation of other eIF3 subunits.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Res Core Facil, Shreveport, LA 71130 USA; Louisiana State Univ, Dept Comp Sci, Shreveport, LA 71115 USA; Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Shreveport; University of California System; University of California Davis	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu	Cvek, Urska/ABA-4578-2020	Cvek, Urska/0000-0003-2042-6415; Bradley, Christopher/0000-0001-9531-996X	NIGMS NIH HHS [F32 GM020818, GM22135, R01 GM022135, R01 GM020818, GM20818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020818, R01GM020818, R01GM022135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; Bandyopadhyay A, 2002, J BIOL CHEM, V277, P2360, DOI 10.1074/jbc.M107790200; Bradley CA, 2002, J BIOL CHEM, V277, P12559, DOI 10.1074/jbc.M111134200; Browning KS, 2001, TRENDS BIOCHEM SCI, V26, P284, DOI 10.1016/S0968-0004(01)01825-4; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; Cai A, 1999, BIOCHEMISTRY-US, V38, P8538, DOI 10.1021/bi9830213; Clark BFC, 1996, BIOCHIMIE, V78, P1119, DOI 10.1016/S0300-9084(97)86738-7; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dunand-Sauthier I, 2002, MOL BIOL CELL, V13, P1626, DOI 10.1091/mbc.01-06-0301; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Grudzien E, 2006, J BIOL CHEM, V281, P1857, DOI 10.1074/jbc.M509121200; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; He H, 2003, MOL CELL BIOL, V23, P5431, DOI 10.1128/MCB.23.15.5431-5445.2003; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOAREAU AK, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hui DJ, 2005, J BIOL CHEM, V280, P3433, DOI 10.1074/jbc.M406700200; Hui DJ, 2003, J BIOL CHEM, V278, P39477, DOI 10.1074/jbc.M305038200; HUNTER T, 1975, J BIOL CHEM, V250, P409; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Jemielity J, 2003, RNA, V9, P1108, DOI 10.1261/rna.5430403; Jivotovskaya AV, 2006, MOL CELL BIOL, V26, P1355, DOI 10.1128/MCB.26.4.1355-1372.2006; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Kim TH, 2004, PLANT CELL, V16, P3341, DOI 10.1105/tpc.104.026880; Korneeva NL, 2005, J BIOL CHEM, V280, P1872, DOI 10.1074/jbc.M406168200; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; Morris-Desbois C, 2001, J BIOL CHEM, V276, P45988, DOI 10.1074/jbc.M104966200; Nielsen KH, 2006, MOL CELL BIOL, V26, P2984, DOI 10.1128/MCB.26.8.2984-2998.2006; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Olsen DS, 2003, EMBO J, V22, P193, DOI 10.1093/emboj/cdg030; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; Park HS, 2004, EMBO J, V23, P1381, DOI 10.1038/sj.emboj.7600140; Park HS, 2001, CELL, V106, P723, DOI 10.1016/S0092-8674(01)00487-1; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RHOADS RE, 2005, WORMBOOK C ELEGANS R, DOI DOI 10.1895/WORMBOOK.1.7.1; Scheel H, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-71; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Shalev A, 2001, J BIOL CHEM, V276, P34948, DOI 10.1074/jbc.M102161200; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; Siridechadilok B, 2005, SCIENCE, V310, P1513, DOI 10.1126/science.1118977; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Valasek L, 2004, MOL CELL BIOL, V24, P9437, DOI 10.1128/MCB.24.21.9437-9455.2004; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; Vende P, 2000, J VIROL, V74, P7064, DOI 10.1128/JVI.74.15.7064-7071.2000; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; von Arnim AG, 2003, CURR BIOL, V13, pR323, DOI 10.1016/S0960-9822(03)00238-0; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14	89	127	141	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22917	22932		10.1074/jbc.M605418200	http://dx.doi.org/10.1074/jbc.M605418200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766523	hybrid, Green Accepted			2022-12-27	WOS:000239542600054
J	Neuenschwander, PF; Williamson, SR; Nalian, A; Baker-Deadmond, KJ				Neuenschwander, Pierre F.; Williamson, Stephen R.; Nalian, Armen; Baker-Deadmond, Kimberly J.			Heparin modulates the 99-loop of factor IXa - Effects on reactivity with isolated Kunitz-type inhibitor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN PRECURSOR; FACTOR-PATHWAY INHIBITOR; COAGULATION-FACTOR IXA; ACTIVATED FACTOR-IX; TISSUE-FACTOR; FACTOR-X; FACTOR VIIA; CONFORMATIONAL-CHANGE; INTRINSIC TENASE; ANTITHROMBIN-III	Reactivity of factor IXa with basic pancreatic trypsin inhibitor is enhanced by low molecular weight heparin (enoxaparin). Previous studies by us have suggested that this effect involves allosteric modulation of factor IXa. We examined the reactivity of factor IXa with several isolated Kunitz-type inhibitor domains: basic pancreatic trypsin inhibitor, the Kunitz inhibitor domain of protease Nexin-2, and the first two inhibitor domains of tissue factor pathway inhibitor. We find that enhancement of factor IXa reactivity by enoxaparin is greatest for basic pancreatic trypsin inhibitor (> 10-fold), followed by the second tissue factor pathway inhibitor domain (1.7-fold) and the Kunitz inhibitor domain of protease Nexin-2 (1.4-fold). Modeling studies of factor IXa with basic pancreatic trypsin inhibitor suggest that binding of this inhibitor is sterically hindered by the 99-loop of factor IXa, specifically residue Lys(98). Slow-binding kinetic studies support the formation of a weak initial enzyme-inhibitor complex between factor IXa and basic pancreatic trypsin inhibitor that is facilitated by enoxaparin binding. Mutation of Lys(98) to Ala in factor IXa results in enhanced reactivity with all inhibitors examined, whereas almost completely abrogating the enhancing effects of enoxaparin. The results implicate Lys(98) and the 99-loop of factor IXa in defining enzyme inhibitor specificity. More importantly, these results demonstrate the ability of factor IXa to be allosterically modulated by occupation of the heparin-binding exosite.	Univ Texas, Hlth Sci Ctr, Biomed Res Lab C8, Dept Biochem,Biomed Res Program, Tyler, TX 75708 USA; Stephen F Austin State Univ, Dept Biotechnol, Nacogdoches, TX 75962 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Neuenschwander, PF (corresponding author), Univ Texas, Hlth Sci Ctr, Biomed Res Lab C8, Dept Biochem,Biomed Res Program, 11937 US Hwy 271, Tyler, TX 75708 USA.	Pierre.Neuenschwander@uthct.edu			NHLBI NIH HHS [R01 HL075696-04, R01 HL075696-03, HL075696, R01 HL075696, R01 HL075696-05, R01 HL075696-02, R01 HL075696-05S2, R01 HL075696-02S1, R01 HL075696-05S1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075696] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERER FA, 1965, Z NATURFORSCH PT B, VB 20, P457; ANDERSON JA, 1965, THORAX, V20, P462, DOI 10.1136/thx.20.5.462; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; Clark ED, 1998, BIOTECHNOL PROGR, V14, P47, DOI 10.1021/bp970123w; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P225; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hsu YC, 2001, BIOCHEMISTRY-US, V40, P11261, DOI 10.1021/bi010262t; JESTY J, 1995, WILLIAMS HEMATOLOGY, P1227; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P373, DOI 10.1021/bi00647a021; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MANN KG, 1990, BLOOD, V76, P755; MERTENS K, 1984, BIOCHEM J, V223, P607, DOI 10.1042/bj2230607; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Neuenschwander P.F., 2006, ENCY RESP MED, P509; Neuenschwander PF, 2004, BIOCHEMISTRY-US, V43, P2978, DOI 10.1021/bi035452d; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P8701, DOI 10.1021/bi00027a020; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; Neuenschwander PF, 1997, THROMB HAEMOST S, V78, P428; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1992, ADV EXP MED BIOL, V313, P155; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Petersen LC, 1996, EUR J BIOCHEM, V235, P310, DOI 10.1111/j.1432-1033.1996.0310f.x; Piro O, 2004, CIRCULATION, V110, P3567, DOI 10.1161/01.CIR.0000148778.76917.89; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Rezaie AR, 1998, BIOCHEMISTRY-US, V37, P693, DOI 10.1021/bi971271y; ROSENBERG JS, 1975, J BIOL CHEM, V250, P8883; SCHMAIER AH, 1995, BIOCHEMISTRY-US, V34, P1171, DOI 10.1021/bi00004a010; Sheehan JP, 2003, BIOCHEMISTRY-US, V42, P11316, DOI 10.1021/bi0342923; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VILLANUEVA GB, 1984, J BIOL CHEM, V259, P2531; VILLANUEVA GB, 1977, BIOCHEM BIOPH RES CO, V74, P803, DOI 10.1016/0006-291X(77)90374-6; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WUN TC, 1988, J BIOL CHEM, V263, P6001; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200; Yuan QP, 2005, BIOCHEMISTRY-US, V44, P3615, DOI 10.1021/bi047934a; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	45	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23066	23074		10.1074/jbc.M603743200	http://dx.doi.org/10.1074/jbc.M603743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766524	Green Accepted, hybrid			2022-12-27	WOS:000239542600070
J	Allard, B; Magloire, H; Couble, ML; Maurin, JC; Bleicher, F				Allard, Bruno; Magloire, Henry; Couble, Marie Lise; Maurin, Jean Christophe; Bleicher, Francoise			Voltage-gated sodium channels confer excitability to human odontoblasts - Possible role in tooth pain transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; RAT; PULP; LOCALIZATION; CELLS; ANKYRIN; PROTEIN; INACTIVATION; GENES; AXONS	Odontoblasts are responsible for the dentin formation. They are suspected to play a role in tooth pain transmission as sensor cells because of their close relationship with nerve, but this role has never been evidenced. We demonstrate here that human odontoblasts in vitro produce voltage-gated tetrodotoxin-sensitive Na+ currents in response to depolarization under voltage clamp conditions and are able to generate action potentials. Odontoblasts express neuronal isoforms of alpha 2 and beta 2 subunits of sodium channels. Co-cultures of odontoblasts with trigeminal neurons indicate a clustering of alpha 2 and alpha 2 sodium channel subunits and, at the sites of cell-cell contact, a co-localization of odontoblasts beta 2 subunits with peripherin. In vivo, sodium channels are expressed in odontoblasts. Ankyrin(G) and beta 2 co-localize, suggesting a link for signal transduction between axons and odontoblasts. Evidence for excitable properties of odontoblasts and clustering of key molecules at the site of odontoblast-nerve contact strongly suggest that odontoblasts may operate as sensor cells that initiate tooth pain transmission.	Univ Lyon 1, F-69100 Villeurbanne, France; CNRS, UMR 5123, F-69100 Villeurbanne, France; Univ Lyon 1, EA 1892, IFR 62, Fac Odontol, F-69008 Lyon, France; INSERM, ERI 16, F-69008 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm)	Magloire, H (corresponding author), Univ Lyon 1, F-69100 Villeurbanne, France.	magloire@sante.univ-lyon1.fr	ALLARD, Bruno/O-1852-2017	ALLARD, Bruno/0000-0001-8547-5483				Allard B, 2000, J BIOL CHEM, V275, P25556, DOI 10.1074/jbc.M002327200; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; Black JA, 1996, DEV NEUROSCI-BASEL, V18, P139, DOI 10.1159/000111403; BLACK JA, 1995, MOL BRAIN RES, V34, P89, DOI 10.1016/0169-328X(95)00141-E; Bleicher F, 1999, MATRIX BIOL, V18, P133, DOI 10.1016/S0945-053X(99)00007-4; Bokil H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0004.2001; BRODY BA, 1989, J NEUROSCI, V9, P2391; Buchaille R, 2000, MATRIX BIOL, V19, P421, DOI 10.1016/S0945-053X(00)00091-3; BYERS MR, 1984, INT REV NEUROBIOL, V25, P39, DOI 10.1016/S0074-7742(08)60677-7; Byers MR, 2003, MICROSC RES TECHNIQ, V60, P503, DOI 10.1002/jemt.10291; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Couble ML, 2000, CALCIFIED TISSUE INT, V66, P129, DOI 10.1007/PL00005833; Davidson RM, 2000, J MEMBRANE BIOL, V178, P21, DOI 10.1007/s002320010011; DAVIDSON RM, 1994, ARCH ORAL BIOL, V39, P613, DOI 10.1016/0003-9969(94)90137-6; HILDEBRAND C, 1995, PROG NEUROBIOL, V45, P165, DOI 10.1016/0301-0082(94)00045-J; Ibuki T, 1996, J DENT RES, V75, P1963, DOI 10.1177/00220345960750120801; Isom LL, 2002, FRONT BIOSCI, V7, P12; Kamermans M, 2004, CURR OPIN NEUROBIOL, V14, P531, DOI 10.1016/j.conb.2004.08.016; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kobayashi N, 1998, CELL TISSUE RES, V291, P163, DOI 10.1007/s004410050988; Magloire H, 2003, J DENT RES, V82, P542, DOI 10.1177/154405910308200711; MAGLOIRE H, 1979, J BIOL BUCCALE, V7, P251; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Maurin JC, 2004, MATRIX BIOL, V23, P277, DOI 10.1016/j.matbio.2004.06.005; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; Novakovic SD, 2001, TRENDS NEUROSCI, V24, P473, DOI 10.1016/S0166-2236(00)01884-1; OXFORD GS, 1978, J GEN PHYSIOL, V71, P227, DOI 10.1085/jgp.71.3.227; SEUX D, 1994, ARCH ORAL BIOL, V39, P167, DOI 10.1016/0003-9969(94)90113-9; USHIYAMA J, 1989, CELL TISSUE RES, V258, P611; Van Wart A, 2005, MOL CELL NEUROSCI, V28, P661, DOI 10.1016/j.mcn.2004.11.012; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	36	75	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29002	29010		10.1074/jbc.M601020200	http://dx.doi.org/10.1074/jbc.M601020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16831873	hybrid			2022-12-27	WOS:000240680500055
J	Joyce, MG; Levy, C; Gabor, K; Pop, SM; Biehl, BD; Doukov, TI; Ryter, JM; Mazon, H; Smidt, H; van den Heuvel, RHH; Ragsdale, SW; van der Oost, J; Leys, D				Joyce, M. Gordon; Levy, Colin; Gabor, Krisztina; Pop, Stelian M.; Biehl, Benjamin D.; Doukov, Tzanko I.; Ryter, Jodi M.; Mazon, Hortense; Smidt, Hauke; van den Heuvel, Robert H. H.; Ragsdale, Stephen W.; van der Oost, John; Leys, David			CprK crystal structures reveal mechanism for transcriptional control of halorespiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; PROTEIN; CAMP; PURIFICATION; REGULATOR; CHLORINE; LIGAND; ENZYME	Halorespiration is a bacterial respiratory process in which haloorganic compounds act as terminal electron acceptors. This process is controlled at transcriptional level by CprK, a member of the ubiquitous CRP-FNR family. Here we present the crystal structures of oxidized CprK in presence of the ligand orthochlorophenolacetic acid and of reduced CprK in absence of this ligand. These structures reveal that highly specific binding of chlorinated, rather than the corresponding non-chlorinated, phenolic compounds in the NH2-terminal beta-barrels causes reorientation of these domains with respect to the central alpha-helix at the dimer interface. Unexpectedly, the COOH-terminal DNA-binding domains dimerize in the non-DNA binding state. We postulate the ligand-induced conformational change allows formation of interdomain contacts that disrupt the DNA domain dimer interface and leads to repositioning of the helix-turn-helix motifs. These structures provide a structural framework for further studies on transcriptional control by CRP-FNR homologs in general and of halorespiration regulation by CprK in particular.	Manchester Interdisciplinary Bioctr, Manchester M60 1QD, Lancs, England; Univ Wageningen & Res Ctr, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA; Nebraska Wesleyan Univ, Dept Chem, Lincoln, NE 68504 USA; Univ Utrecht, Bijvoet Ctr, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands	University of Manchester; Wageningen University & Research; University of Nebraska System; University of Nebraska Lincoln; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Utrecht University; Utrecht University	Leys, D (corresponding author), Manchester Interdisciplinary Bioctr, POB 88, Manchester M60 1QD, Lancs, England.	david.leys@manchester.ac.uk	van+der+Oost, John/Y-2548-2019; Smidt, Hauke/D-7054-2014	Smidt, Hauke/0000-0002-6138-5026; Doukov, Tzanko/0000-0001-8625-2572; Levy, Colin/0000-0002-9724-310X	Biotechnology and Biological Sciences Research Council [BB/C00521X/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benoff B, 2002, SCIENCE, V297, P1562, DOI 10.1126/science.1076376; Boyer A, 2003, BIOCHEM J, V373, P297, DOI 10.1042/BJ20021837; Chen R, 2003, J BIOL CHEM, V278, P13235, DOI 10.1074/jbc.M211551200; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Eiting M, 2005, MOL MICROBIOL, V56, P433, DOI 10.1111/j.1365-2958.2005.04561.x; El Fantroussi S, 1998, BIOTECHNOL PROGR, V14, P167, DOI 10.1021/bp980011k; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Furukawa K, 2003, TRENDS BIOTECHNOL, V21, P187, DOI 10.1016/S0167-7799(03)00054-4; Gabor K, 2006, J BACTERIOL, V188, P2604, DOI 10.1128/JB.188.7.2604-2613.2006; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; HENSCHLER D, 1994, ANGEW CHEM INT EDIT, V33, P1920, DOI 10.1002/anie.199419201; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Korner H, 2003, FEMS MICROBIOL REV, V27, P559, DOI 10.1016/S0168-6445(03)00066-4; Krutchinsky AN, 1998, J AM SOC MASS SPECTR, V9, P569, DOI 10.1016/S1044-0305(98)00027-0; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lawson CL, 2004, CURR OPIN STRUC BIOL, V14, P10, DOI 10.1016/j.sbi.2004.01.012; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oberg G, 2002, APPL MICROBIOL BIOT, V58, P565, DOI 10.1007/s00253-001-0895-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palfey BA, 1999, BIOCHEMISTRY-US, V38, P1153, DOI 10.1021/bi9826613; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Pop SM, 2004, J BIOL CHEM, V279, P49910, DOI 10.1074/jbc.M409435200; RIGAKU MSC, 1999, CRYSAL CLEAR PROGRAM; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SHABB JB, 1992, J BIOL CHEM, V267, P5723; Smidt H, 2004, ANNU REV MICROBIOL, V58, P43, DOI 10.1146/annurev.micro.58.030603.123600; Smidt H, 2000, J BACTERIOL, V182, P5683, DOI 10.1128/JB.182.20.5683-5691.2000; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; Tibbs GR, 1998, J BIOL CHEM, V273, P4497, DOI 10.1074/jbc.273.8.4497; van de Pas BA, 2001, APPL ENVIRON MICROB, V67, P3958, DOI 10.1128/AEM.67.9.3958-3963.2001; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; Villemur R, 2002, CAN J MICROBIOL, V48, P697, DOI 10.1139/w02-057; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yu SN, 2004, BIOCHEMISTRY-US, V43, P4662, DOI 10.1021/bi0362166	40	30	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28318	28325		10.1074/jbc.M602654200	http://dx.doi.org/10.1074/jbc.M602654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16803881	Green Published, hybrid			2022-12-27	WOS:000240534400069
J	Rahier, A; Darnet, S; Bouvier, F; Camara, B; Bard, M				Rahier, Alain; Darnet, Sylvain; Bouvier, Florence; Camara, Bilal; Bard, Martin			Molecular and enzymatic characterizations of novel bifunctional 3 beta-hydroxysteroid dehydrogenases/C-4 decarboxylases from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT STEROL BIOSYNTHESIS; PROTEIN-PROTEIN INTERACTIONS; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; MALIC ENZYME; BRASSINOSTEROID BIOSYNTHESIS; OXIDATIVE DECARBOXYLATION; PARTIAL-PURIFICATION; CHEMICAL MECHANISM; REDUCTASE	We have isolated two cDNAs from Arabidopsis thaliana encoding bifunctional 3 beta-hydroxysteroid dehydrogenase/C-4 decarboxylases (3 beta HSD/D) involved in sterol synthesis, termed At3 beta HSD/D1 and At3 beta HSD/D2. Transformation of the yeast ergosterol auxotroph erg26 mutant, which lacks 3 beta HSD/D activity, with the At3 beta HSD/D1 isoform or with At3 beta HSD/D2 isoform containing a C-terminal At3 beta HSD/D1 endoplasmic reticulum-retrieval sequence restored growth and ergosterol synthesis in erg26. An in vitro enzymatic assay revealed high 3 beta HSD/D activity for both isoenzymes in the corresponding microsomal extracts. The two At3 beta HSD/D isoenzymes showed similar substrate specificities that required free 3 beta-hydroxyl and C-4-carboxyl groups but were quite tolerant in terms of variations of the sterol nucleus and side chain structures. Data obtained with 4 alpha-carboxy-cholest-7-en-3 beta-ol and its 3 alpha-deuterated analog revealed that 3 alpha-hydrogen-carbon bond cleavage is not the rate-limiting step of the reaction. In planta reduction on the expression of the 3 beta HSD/D gene as a consequence of VIGS-mediated gene silencing in Nicotiana benthamiana led to a substantial accumulation of 3 beta-hydroxy-4 beta,14-dimethyl-5 alpha-ergosta-9 beta,19-cyclo-24(24(1))-en-4 alpha-carboxylic acid, consistent with a decrease in 3 beta HSD/D activity. These two novel oxidative decarboxylases constitute the first molecularly and functionally characterized HSDs from a short chain dehydrogenase/reductase family in plants.	CNRS, Inst Biol Mol Plantes, UPR2357, F-67083 Strasbourg, France; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Indiana University System; Indiana University-Purdue University Indianapolis	Rahier, A (corresponding author), CNRS, Inst Biol Mol Plantes, UPR2357, 28 Rue Goethe, F-67083 Strasbourg, France.	enzymo@bota-ulp.u-strasbg.fr	DARNET, Sylvain Henri/G-4912-2012	DARNET, Sylvain Henri/0000-0001-6351-0903	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062104] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bach TJ, 1997, PROG LIPID RES, V36, P197, DOI 10.1016/S0163-7827(97)00009-X; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; Benveniste P, 2004, ANNU REV PLANT BIOL, V55, P429, DOI 10.1146/annurev.arplant.55.031903.141616; Bill RM, 2001, CURR GENET, V40, P157, DOI 10.1007/s002940100252; Bouvier F, 2005, PROG LIPID RES, V44, P357, DOI 10.1016/j.plipres.2005.09.003; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choe S, 1999, PLANT PHYSIOL, V119, P897, DOI 10.1104/pp.119.3.897; Choe SW, 1999, PLANT CELL, V11, P207, DOI 10.1105/tpc.11.2.207; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; Cleland WW, 2003, J BIOL CHEM, V278, P51975, DOI 10.1074/jbc.X300005200; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1797, DOI 10.1021/bi00510a014; Darnet S, 2004, BIOCHEM J, V378, P889, DOI 10.1042/BJ20031572; Darnet S, 2003, BBA-MOL CELL BIOL L, V1633, P106, DOI 10.1016/S1388-1981(03)00093-3; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; Edens WA, 1997, BIOCHEMISTRY-US, V36, P1141, DOI 10.1021/bi962128s; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRISSOM CB, 1988, BIOCHEMISTRY-US, V27, P2934, DOI 10.1021/bi00408a040; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; HORINOUCHI S, 1991, APPL ENVIRON MICROB, V57, P1386, DOI 10.1128/AEM.57.5.1386-1393.1991; Hwang CC, 2005, J BIOL CHEM, V280, P3522, DOI 10.1074/jbc.M411751200; Hwang CC, 1998, BIOCHEMISTRY-US, V37, P12596, DOI 10.1021/bi980611s; Hyndman D, 2003, CHEM-BIOL INTERACT, V143, P621, DOI 10.1016/S0009-2797(02)00193-X; Jang JC, 2000, GENE DEV, V14, P1485; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; KARSTEN WE, 1994, BIOCHEMISTRY-US, V33, P2096, DOI 10.1021/bi00174a016; Kumagai MH, 1998, PLANT J, V14, P305, DOI 10.1046/j.1365-313X.1998.00128.x; KUMAGAI MH, 1995, P NATL ACAD SCI USA, V92, P1679, DOI 10.1073/pnas.92.5.1679; LACHANCE Y, 1990, J BIOL CHEM, V265, P20469; LEES ND, 1995, LIPIDS, V30, P221, DOI 10.1007/BF02537824; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; Mo C, 2002, P NATL ACAD SCI USA, V99, P9739, DOI 10.1073/pnas.112202799; Mo CQ, 2005, BBA-MOL CELL BIOL L, V1737, P152, DOI 10.1016/j.bbalip.2005.11.002; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; Northrop DB, 1999, ADV ENZYMOL RAMB, V73, P25, DOI 10.1002/9780470123195.ch2; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; Northrop DB, 2001, METHODS, V24, P117, DOI 10.1006/meth.2001.1173; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; PASCAL S, 1993, J BIOL CHEM, V268, P11639; PASCAL S, 1994, ARCH BIOCHEM BIOPHYS, V312, P260, DOI 10.1006/abbi.1994.1308; Rahier A, 2001, BIOCHEMISTRY-US, V40, P256, DOI 10.1021/bi001696b; Rahier A., 1989, ANAL STEROLS OTHER B, P223, DOI [10.1016/B978-0-12-515445-1.50016-1, DOI 10.1016/B978-0-12-515445-1.50016-1]; RAHIMTULA AD, 1972, J BIOL CHEM, V247, P9; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; Rondet S, 1999, ARCH BIOCHEM BIOPHYS, V366, P249, DOI 10.1006/abbi.1999.1218; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Schrick K, 2000, GENE DEV, V14, P1471; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Shirabe K, 1998, BBA-PROTEIN STRUCT M, V1384, P16, DOI 10.1016/S0167-4838(97)00146-5; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; Taton M, 2000, BIOCHEMISTRY-US, V39, P701, DOI 10.1021/bi991467t; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7	62	30	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27264	27277		10.1074/jbc.M604431200	http://dx.doi.org/10.1074/jbc.M604431200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835224	hybrid			2022-12-27	WOS:000240397700053
J	Youngblood, B; Reich, NO				Youngblood, Ben; Reich, Norbert O.			Conformational transitions as determinants of specificity for the DNA methyltransferase EcoRI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE METHYLTRANSFERASE; HAEIII METHYLTRANSFERASE; SUBSTRATE-RECOGNITION; FACILITATED DIFFUSION; POLYMERASE FIDELITY; DIRECTED EVOLUTION; ENZYME; BASE; BINDING; PROTEIN	Changes in DNA bending and base flipping in a previously characterized specificity-enhanced M. EcoRI DNA adenine methyltransferase mutant suggest a close relationship between precatalytic conformational transitions and specificity (Allan, B. W., Garcia, R., Maegley, K., Mort, J., Wong, D., Lindstrom, W., Beechem, J. M., and Reich, N. O. (1999) J. Biol. Chem. 274, 19269-19275). The direct measurement of the kinetic rate constants for DNA bending, intercalation, and base flipping with cognate and noncognate substrates (GAATTT, GGATTC) of wild type M. EcoRI using fluorescence resonance energy transfer and 2-aminopurine fluorescence studies reveals that DNA bending precedes both intercalation and base flipping, and base flipping precedes intercalation. Destabilization of these intermediates provides a molecular basis for understanding how conformational transitions contribute to specificity. The 3500- and 23,000-fold decreases in sequence specificity for noncognate sites GAATTT and GGATTC are accounted for largely by an similar to 2500-fold increase in the reverse rate constants for intercalation and base flipping, respectively. Thus, a predominant contribution to specificity is a partitioning of enzyme intermediates away from the Michaelis complex prior to catalysis. Our results provide a basis for understanding enzyme specificity and, in particular, sequence-specific DNA modification. Because many DNA methyltransferases and DNA repair enzymes induce similar DNA distortions, these results are likely to be broadly relevant.	Univ Calif Santa Barbara, Program Biomol Sci & Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Reich, NO (corresponding author), Univ Calif Santa Barbara, Program Biomol Sci & Engn, Santa Barbara, CA 93106 USA.	reich@chem.ucsb.edu	Youngblood, Benjamin/N-2508-2018	Youngblood, Benjamin/0000-0002-1261-9957				Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1999, J BIOL CHEM, V274, P19269, DOI 10.1074/jbc.274.27.19269; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BLACKLOW SC, 1991, BIOCHEMISTRY-US, V30, P8470, DOI 10.1021/bi00098a026; Bruice TC, 2005, J AM CHEM SOC, V127, P12478, DOI 10.1021/ja053714o; Cao CY, 2004, NAT STRUCT MOL BIOL, V11, P1230, DOI 10.1038/nsmb864; Cohen HM, 2004, PROTEIN ENG DES SEL, V17, P3, DOI 10.1093/protein/gzh001; Cohen HM, 2002, NUCLEIC ACIDS RES, V30, P3880, DOI 10.1093/nar/gkf507; Daujotyte D, 2004, STRUCTURE, V12, P1047, DOI 10.1016/j.str.2004.04.007; Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432; Fersht A, 1999, STRUCTURE MECH PROTE, P132; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; HERMES JD, 1987, COLD SPRING HARB SYM, V52, P597, DOI 10.1101/SQB.1987.052.01.068; Hiller DA, 2005, J MOL BIOL, V354, P121, DOI 10.1016/j.jmb.2005.09.046; Hiller DA, 2003, BIOCHEMISTRY-US, V42, P14375, DOI 10.1021/bi035520w; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HOPFIELD JJ, 1980, P NATL ACAD SCI-BIOL, V77, P5248, DOI 10.1073/pnas.77.9.5248; Hopkins BB, 2004, J BIOL CHEM, V279, P37049, DOI 10.1074/jbc.M404573200; Horton JR, 2006, J MOL BIOL, V358, P559, DOI 10.1016/j.jmb.2006.02.028; Horton JR, 2005, CELL, V121, P349, DOI 10.1016/j.cell.2005.02.021; Huang N, 2005, J MOL BIOL, V345, P265, DOI 10.1016/j.jmb.2004.10.042; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kobayashi I, 2001, NUCLEIC ACIDS RES, V29, P3742, DOI 10.1093/nar/29.18.3742; Krosky DJ, 2005, BIOCHEMISTRY-US, V44, P5949, DOI 10.1021/bi050084u; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; MASHHOON N, 1994, BIOCHEMISTRY-US, V33, P7113, DOI 10.1021/bi00189a014; Mashhoon N, 2004, J BIOL CHEM, V279, P52075, DOI 10.1074/jbc.M408182200; Mathieu O, 2004, J CELL SCI, V117, P4881, DOI 10.1242/jcs.01479; Matzke M, 2004, BBA-GENE STRUCT EXPR, V1677, P129, DOI 10.1016/j.bbaexp.2003.10.015; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; Nixon AE, 1999, P NATL ACAD SCI USA, V96, P3568, DOI 10.1073/pnas.96.7.3568; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; Quemeneur E, 1998, NATURE, V391, P301, DOI 10.1038/34687; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; REICH NO, 1992, J BIOL CHEM, V267, P15802; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Samuelson JC, 2002, J MOL BIOL, V319, P673, DOI 10.1016/S0022-2836(02)00343-1; Su TJ, 2005, NUCLEIC ACIDS RES, V33, P3235, DOI 10.1093/nar/gki618; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2201, DOI 10.1021/bi951883n; Svedruzic ZM, 2005, BIOCHEMISTRY-US, V44, P14977, DOI 10.1021/bi050988f; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i	50	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26821	26831		10.1074/jbc.M603388200	http://dx.doi.org/10.1074/jbc.M603388200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16845123	hybrid			2022-12-27	WOS:000240397700009
J	Andriotis, VME; Rathjen, JP				Andriotis, Vasilios M. E.; Rathjen, John P.			The Pto kinase of tomato, which regulates plant immunity, is repressed by its myristoylated N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE RESISTANCE; III EFFECTOR; HYPERSENSITIVE RESPONSE; ARABIDOPSIS-THALIANA; SIGNAL-TRANSDUCTION; PEPTIDE SUBSTRATE; STRUCTURAL BASIS; FATTY ACYLATION; PROTEIN-KINASES; PLASMA-MEMBRANE	Specific recognition of the Pseudomonas syringae effector proteins AvrPto and AvrPtoB in tomato is mediated by Pto kinase resulting in induction of defense responses, including hypersensitive cell death via a signaling pathway requiring the nucleotide-binding leucine-rich repeats protein Prf. Pto is a myristoylated protein, and N-myristoylation is required for signaling. Here we demonstrated a role for Nmyristoylation in controlling Pto kinase activity. A myristoylated peptide corresponding to Pto residues 2 10 significantly impaired the kinase activity of Ntruncated Pto. We show that kinase inhibition was specific to the myristoylated form of the peptide and that free myristate supplied in trans was a potent suppressor of Pto kinase activity. Thus, myristate, but not Pto residues 2 10, contributes to suppression of kinase activity in vitro. Accordingly, elimination of the in vivo myristoylation potential of Pto derepressed kinase activity. The increased potency of free myristate relative to the myristoylated Npeptide inhibitor suggested that the peptide moiety is antagonistic to repression by myristate. Suppression of related protein kinases by myristate declined with similarity to Pto, and the inhibitory activity could be attributed to hydrophobicity. We present evidence that inhibition of Pto by the myristoylated Npeptide is mediated through a previously identified surface regulatory patch. The data show a role for negative regulation of Pto by Nmyristoylation, in addition to the previously demonstrated positive role, and are consistent with a model in which the acylated N terminus is sequestered in the catalytic cleft prior to release by Pto activation.	John Innes Inst, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Rathjen, JP (corresponding author), John Innes Inst, Sainsbury Lab, Coloney Lane,Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	john.rathjen@sainsbury-laboratory.ac.uk	rathjen, john p/C-9327-2009	rathjen, john p/0000-0003-4073-8088; Andriotis, Vasilios/0000-0003-2304-843X				Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Boisson B, 2003, J BIOL CHEM, V278, P43418, DOI 10.1074/jbc.M307321200; Chang JH, 2002, MOL PLANT MICROBE IN, V15, P281, DOI 10.1094/MPMI.2002.15.3.281; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; de Vries JS, 2006, PLANT J, V45, P31, DOI 10.1111/j.1365-313X.2005.02590.x; del Pozo O, 2004, EMBO J, V23, P3072, DOI 10.1038/sj.emboj.7600283; Deslandes L, 2003, P NATL ACAD SCI USA, V100, P8024, DOI 10.1073/pnas.1230660100; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Matsubara M, 2003, J BIOL CHEM, V278, P48898, DOI 10.1074/jbc.M305488200; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032; Qi QG, 2000, J BIOL CHEM, V275, P9673, DOI 10.1074/jbc.275.13.9673; Ramdas L, 1999, J PEPT RES, V53, P569, DOI 10.1034/j.1399-3011.1999.00063.x; Rathjen JP, 2003, CURR OPIN PLANT BIOL, V6, P300, DOI 10.1016/S1369-5266(03)00057-8; Rathjen JP, 1999, EMBO J, V18, P3232, DOI 10.1093/emboj/18.12.3232; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Sessa G, 1998, J BIOL CHEM, V273, P15860, DOI 10.1074/jbc.273.25.15860; Shan LB, 2000, PLANT CELL, V12, P2323, DOI 10.1105/tpc.12.12.2323; Shao F, 2003, SCIENCE, V301, P1230, DOI 10.1126/science.1085671; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Wu AJ, 2004, PLANT CELL, V16, P2809, DOI 10.1105/tpc.104.024141; Yoshida S, 2005, J BIOL CHEM, V280, P9203, DOI 10.1074/jbc.M411665200; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	35	15	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26578	26586		10.1074/jbc.M603197200	http://dx.doi.org/10.1074/jbc.M603197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16785235	Green Published, hybrid			2022-12-27	WOS:000240249500076
J	Thomas, AV; Herl, L; Spoelgen, R; Hiltunen, M; Jones, PB; Tanzi, RE; Hyman, BT; Berezovska, O				Thomas, Anne V.; Herl, Lauren; Spoelgen, Robert; Hiltunen, Mikko; Jones, Phill B.; Tanzi, Rudolph E.; Hyman, Bradley T.; Berezovska, Oksana			Interaction between presenilin 1 and ubiquilin 1 as detected by fluorescence lifetime imaging microscopy and a high-throughput fluorescent plate reader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; CAENORHABDITIS-ELEGANS; MEMBRANE TOPOLOGY; SEL-12 PRESENILIN; ENDOPROTEOLYSIS; CONFORMATION; ASSOCIATION; NICASTRIN	Presenilin 1 (PS1) in its active heterodimeric form is the catalytic center of the gamma-secretase complex, an enzymatic activity that cleaves amyloid precursor protein (APP) to produce amyloid beta (A beta). Ubiquilin 1 is a recently described PS1 interacting protein, the overexpression of which increases PS1 holoprotein levels and leads to reduced levels of functionally active PS1 heterodimer. In addition, it has been suggested that splice variants of the UBQLN1 gene are associated with an increased risk of developing Alzheimer disease ( AD). However, it is still unclear whether PS1 and ubiquilin 1 interact when expressed at endogenous levels under normal physiological conditions. Here, we employ three novel fluorescence resonance energy transfer-based techniques to investigate the interaction between PS1 and ubiquilin 1 in intact cells. We consistently find that the ubiquilin 1N terminus is in close proximity to several epitopes on PS1. We show that ubiquilin 1 interacts both with PS1 holoprotein and heterodimer and that the interaction between PS1 and ubiquilin 1 takes place near the cell surface. Furthermore, we show that the PS1-ubiquilin 1 interaction can be detected between endogenous proteins in primary neurons in vitro as well as in brain tissue of healthy controls and Alzheimer disease patients, providing evidence of its physiological relevance.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Berezovska, O (corresponding author), Dept Neurol, Alzheimers Unit, 114 16th St, Charlestown, MA 02129 USA.	oberezovska@partners.org	Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454; Jones, Phill/0000-0003-0525-6323	NATIONAL INSTITUTE ON AGING [P01AG015379] Funding Source: NIH RePORTER; NIA NIH HHS [5 P01 AG015379-08] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Berezovska O, 2005, J NEUROSCI, V25, P3009, DOI 10.1523/JNEUROSCI.0364-05.2005; Berezovska O, 2003, J NEUROSCI, V23, P4560; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Brouwers N, 2006, NEUROSCI LETT, V392, P72, DOI 10.1016/j.neulet.2005.08.064; Brunkan AL, 2005, J NEUROCHEM, V93, P769, DOI 10.1111/j.1471-4159.2005.03099.x; Cervantes S, 2004, J BIOL CHEM, V279, P36519, DOI 10.1074/jbc.M404832200; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Herl L, 2006, BIOCHEM BIOPH RES CO, V340, P668, DOI 10.1016/j.bbrc.2005.12.063; JONES PJ, 2006, IN PRESS J BIOMED OP; Kamboh MI, 2006, MOL PSYCHIATR, V11, P273, DOI 10.1038/sj.mp.4001775; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Laudon H, 2005, J BIOL CHEM, V280, P35352, DOI 10.1074/jbc.M507217200; Laudon H, 2004, J BIOL CHEM, V279, P23925, DOI 10.1074/jbc.M401277200; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Mah AL, 2000, J CELL BIOL, V151, P847, DOI 10.1083/jcb.151.4.847; Massey LK, 2005, BIOCHEM J, V391, P513, DOI 10.1042/BJ20050491; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Slifer MA, 2005, NEW ENGL J MED, V352, P2752; Smemo S, 2006, ANN NEUROL, V59, P21, DOI 10.1002/ana.20673; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	32	19	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26400	26407		10.1074/jbc.M601085200	http://dx.doi.org/10.1074/jbc.M601085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16815845	hybrid			2022-12-27	WOS:000240249500057
J	Valeva, A; Hellmann, N; Walev, I; Strand, D; Plate, M; Boukhallouk, F; Brack, A; Hanada, K; Decker, H; Bhakdi, S				Valeva, Angela; Hellmann, Nadja; Walev, Iwan; Strand, Dennis; Plate, Markus; Boukhallouk, Fatima; Brack, Antje; Hanada, Kentaro; Decker, Heinz; Bhakdi, Sucharit			Evidence that clustered phosphocholine head groups serve as sites for binding and assembly of an oligomeric protein pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-TOXIN; HAMSTER OVARY CELLS; TRANSMEMBRANE CHANNEL; CHOLESTEROL DEPLETION; HEPTAMERIC PORE; FORMING PROTEIN; PHASE-DIAGRAM; LIPID RAFTS; MEMBRANE; HEMOLYSIN	High susceptibility of rabbit erythrocytes toward the pore-forming action of staphylococcal alpha-toxin correlates with the presence of saturable, high affinity binding sites. All efforts to identify a protein or glycolipid receptor have failed, and the fact that liposomes composed solely of phosphatidylcholine are efficiently permeabilized adds to the enigma. A novel concept is advanced here to explain the puzzle. We propose that low affinity binding moieties can assume the role of high affinity binding sites due to their spatial arrangement in the membrane. Evidence is presented that phosphocholine head groups of sphingomyelin, clustered in sphingomyelin-cholesterol microdomains, serve this function for alpha-toxin. Clustering is required so that oligomerization, which is prerequisite for stable attachment of the toxin to the membrane, can efficiently occur. Outside these clusters, binding to phosphocholine is too transient for toxin monomers to find each other. The principle of membrane targeting in the absence of any genuine, high affinity receptor may also underlie the assembly of other lipid-inserted oligomers including cytotoxic peptides, protein toxins, and immune effector molecules.	Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Univ Mainz, Inst Mol Biophys, D-55099 Mainz, Germany; Univ Mainz, Med Clin 1, D-55101 Mainz, Germany; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Tokyo 1628640, Japan	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; National Institute of Infectious Diseases (NIID)	Bhakdi, S (corresponding author), Inst Med Microbiol & Hyg, Hochhaus Augustuspl, D-55101 Mainz, Germany.	sbhakdi@uni-mainz.de		Hanada, Kentaro/0000-0003-1383-2781				Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; BAYLEY H, 1994, J CELL BIOCHEM, V56, P177, DOI 10.1002/jcb.240560210; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; EISINGER J, 1987, BIOPHYS CHEM, V28, P273, DOI 10.1016/0301-4622(87)80098-4; Feigenson GW, 2001, BIOPHYS J, V80, P2775, DOI 10.1016/S0006-3495(01)76245-5; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRENKEL EJ, 1986, BIOCHIM BIOPHYS ACTA, V855, P293, DOI 10.1016/0005-2736(86)90177-X; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; GIRAUD F, 1984, BIOCHIM BIOPHYS ACTA, V778, P191, DOI 10.1016/0005-2736(84)90462-0; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; MOLLBY R, 1978, BACTERIAL TOXINS CEL, P477; Olson R, 1999, NAT STRUCT BIOL, V6, P134; PALMER M, 1993, J BIOL CHEM, V268, P11963; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PORN MI, 1995, BIOCHEM J, V308, P269; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TITBALL RW, 1993, MICROBIOL REV, V57, P347, DOI 10.1128/MMBR.57.2.347-366.1993; TSCHOPP J, 1989, NATURE, V337, P272, DOI 10.1038/337272a0; Valeva A, 1997, BBA-BIOMEMBRANES, V1325, P281, DOI 10.1016/S0005-2736(96)00266-0; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Valeva A, 1997, BIOCHEMISTRY-US, V36, P13298, DOI 10.1021/bi971075r; VALEVA A, 1995, BBA-BIOMEMBRANES, V1236, P213, DOI 10.1016/0005-2736(95)00060-G; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; WALKER B, 1993, J BIOL CHEM, V268, P5285; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zitzer A, 2000, BBA-BIOMEMBRANES, V1509, P264, DOI 10.1016/S0005-2736(00)00303-5	42	87	89	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26014	26021		10.1074/jbc.M601960200	http://dx.doi.org/10.1074/jbc.M601960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829693	hybrid			2022-12-27	WOS:000240249500016
J	Wang, Q; Lu, RJ; Zhao, JL; Limbird, LE				Wang, Qin; Lu, Roujian; Zhao, Jiali; Limbird, Lee E.			Arrestin serves as a molecular switch, linking endogenous alpha 2-adrenergic receptor to SRC-dependent, but not SRC-independent, ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASE; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR; PHOSPHODIESTERASE ACTIVATION; ALPHA(2A)-ADRENERGIC RECEPTOR; CLATHRIN ADAPTER; C-SRC; ENDOCYTOSIS; PHOSPHORYLATION	Our previous studies have demonstrated that neither receptor endocytosis nor arrestin is required for ERK activation by the alpha(2)-adrenergic receptor (Wang, Q., Zhao, J., Brady, A. E., Feng, J., Allen, P. B., Lefkowitz, R. J., Greengard, P., and Limbird, L. E. (2004) Science 304, 1940 -1944). The present studies address whether arrestin plays a role in determining the route of alpha(2)AR-evoked ERK signaling activation, taking advantage of endogenous expression of the alpha(2A)AR subtype in mouse embryonic fibroblasts (MEFs) and the availability of MEFs without arrestin expression (derived from Arr2,3(-/)-mice). Our data demonstrate that the endogenous alpha(2A)AR evokes ERK phosphorylation through both a Src-dependent and a Src-independent pathway, both of which are G protein dependent and converge on the Ras-Raf-MEK pathway. Arrestin is essential to recruit Src to this process, as alpha(2A)AR-mediated ERK signaling in Arr2,3(-/)-MEFs does not involve Src. Stimulation of alpha(2A)AR enhances arrestin-Src interaction and promotes activation of Src. alpha(2) agonists have similar potencies in stimulating Src-dependent and Src-independent ERK phosphorylation in wild-type and Arr2,3(-/)-cells, respectively. However, Src-independent alpha(2A)AR-mediated ERK stimulation has both a longer duration of activation and a more rapid translocation of pERK into the nucleus when compared with Src-dependent activation. These data not only affirm the role of arrestin as an escort for signaling molecules such as Src family kinases but also demonstrate the impact of arrestin-dependent modulation on both the temporal and spatial properties of ERK activation.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Meharry Med Coll, Dept Biomed Sci, Nashville, TN 37208 USA	University of Alabama System; University of Alabama Birmingham; Vanderbilt University; Meharry Medical College	Wang, Q (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 958 MCLM,1918 Univ Blvd, Birmingham, AL 35294 USA.	qwang@uab.edu		Wang, Qin/0000-0002-1079-5914	NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [HL25182] Funding Source: Medline; NICHD NIH HHS [HD15052] Funding Source: Medline; NIDDK NIH HHS [DK58404, DK43879, DK20593] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD015052] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK043879, P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Beom SR, 2004, J BIOL CHEM, V279, P28304, DOI 10.1074/jbc.M403899200; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Edwards SW, 1999, J BIOL CHEM, V274, P16331, DOI 10.1074/jbc.274.23.16331; FAURE M, 1994, J BIOL CHEM, V269, P7851; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Irby RB, 2002, CANCER RES, V62, P2669; KENAKIN TP, 1984, BRIT J PHARMACOL, V81, P131, DOI 10.1111/j.1476-5381.1984.tb10753.x; Lai YJ, 2005, MOL CELL BIOL, V25, P5859, DOI 10.1128/MCB.25.14.5859-5868.2005; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oomen SPMA, 2001, FEBS LETT, V503, P163, DOI 10.1016/S0014-5793(01)02729-6; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PFISTER C, 1985, SCIENCE, V228, P891, DOI 10.1126/science.2988124; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; Tan CM, 2002, P NATL ACAD SCI USA, V99, P12471, DOI 10.1073/pnas.122368499; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Werry TD, 2005, J NEUROCHEM, V93, P1603, DOI 10.1111/j.1471-4159.2005.03161.x; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; ZUCKERMAN R, 1986, FEBS LETT, V207, P35, DOI 10.1016/0014-5793(86)80008-4	46	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25948	25955		10.1074/jbc.M605415200	http://dx.doi.org/10.1074/jbc.M605415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809338	hybrid			2022-12-27	WOS:000240249500009
J	Hontz, JS; Villar-Lecumberri, MT; Potter, BM; Yoder, MD; Dreyfus, LA; Laity, JH				Hontz, Jill S.; Villar-Lecumberri, Maria T.; Potter, Belinda M.; Yoder, Marilyn D.; Dreyfus, Lawrence A.; Laity, John H.			Differences in crystal and solution structures of the cytolethal distending toxin B subunit - Relevance to nuclear translocation and functional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; PROTEIN SECONDARY STRUCTURE; ESCHERICHIA-COLI CDTB; MODEL-FREE APPROACH; CELL-CYCLE ARREST; BACKBONE DYNAMICS; CRYSTALLOGRAPHIC ANALYSIS; LOCALIZATION SEQUENCES; BACTERIAL GENOTOXIN; DEOXYRIBONUCLEASE-I	Cytolethal distending toxin (CDT) induces cell cycle arrest and apoptosis in eukaryotic cells, which are mediated by the DNA-damaging CdtB subunit. Here we report the first x-ray structure of an isolated CdtB subunit (Escherichia coli-II CdtB, EcCdtB). In conjunction with previous structural and biochemical observations, active site structural comparisons between free and holotoxin-assembled CdtBs suggested that CDT intoxication is contingent upon holotoxin disassembly. Solution NMR structural and N-15 relaxation studies of free EcCdtB revealed disorder in the interface with the CdtA and CdtC subunits (residues Gly(233)-Asp(242)). Residues Leu(186)-Thr(209) of EcCdtB, which encompasses tandem arginine residues essential for nuclear translocation and intoxication, were also disordered in solution. In stark contrast, nearly identical well defined alpha-helix and beta-strand secondary structures were observed in this region of the free and holotoxin CdtB crystallographic models, suggesting that distinct changes in structural ordering characterize subunit disassembly and nuclear localization factor binding functions.	Univ Missouri, Dept Cell Biol & Biophys, Sch Biol Sci, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Laity, JH (corresponding author), Univ Missouri, Dept Cell Biol & Biophys, Sch Biol Sci, 5007 Rockhill Rd,103 BSB, Kansas City, MO 64110 USA.	laityj@umkc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047999] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 047999] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aragon V, 1997, INFECT IMMUN, V65, P3774, DOI 10.1128/IAI.65.9.3774-3780.1997; Arnold, 2001, CRYSTALLOGRAPHY BIOL, P720; BRAUN D, 1994, J AM CHEM SOC, V116, P8466, DOI 10.1021/ja00098a005; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cortes-Bratti X, 2000, INFECT IMMUN, V68, P6903, DOI 10.1128/IAI.68.12.6903-6911.2000; De Rycke J, 2001, FEMS MICROBIOL LETT, V203, P141, DOI 10.1016/S0378-1097(01)00344-5; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; DREYFUS LA, 2003, BACTERIAL PROTEIN TO, P257; Elwell C, 2001, INFECT IMMUN, V69, P3418, DOI 10.1128/IAI.69.5.3418-3422.2001; Elwell CA, 2000, MOL MICROBIOL, V37, P952, DOI 10.1046/j.1365-2958.2000.02070.x; FARROW NA, 1995, BIOCHEMISTRY-US, V34, P868, DOI 10.1021/bi00003a021; Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Guerra L, 2005, CELL MICROBIOL, V7, P921, DOI 10.1111/j.1462-5822.2005.00520.x; GUEX N, 2006, PROTEIN DATA BANK Q, V77, P7; Hontz JS, 2006, ACTA CRYSTALLOGR F, V62, P192, DOI 10.1107/S1744309106002454; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Lara-Tejero M, 2001, INFECT IMMUN, V69, P4358, DOI 10.1128/IAI.69.7.4358-4365.2001; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; McSweeney LA, 2004, CELL MICROBIOL, V6, P447, DOI 10.1111/j.1462-5822.2004.00373.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nesic D, 2004, NATURE, V429, P429, DOI 10.1038/nature02532; Nishikubo S, 2003, J BIOL CHEM, V278, P50671, DOI 10.1074/jbc.M305062200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Pickett CL, 1999, TRENDS MICROBIOL, V7, P292, DOI 10.1016/S0966-842X(99)01537-1; PICKETT CL, 1994, INFECT IMMUN, V62, P1046, DOI 10.1128/IAI.62.3.1046-1051.1994; Potter BM, 2005, J BIOL CHEM, V280, P28529, DOI 10.1074/jbc.M505217200; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; VILLARLECUMBERR.M, 2006, J BIOMOL NMR, V34; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Yamada T, 2006, PROTEIN SCI, V15, P362, DOI 10.1110/ps.051790506; [No title captured]	46	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25365	25372		10.1074/jbc.M603727200	http://dx.doi.org/10.1074/jbc.M603727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16809347	hybrid			2022-12-27	WOS:000240031300038
J	Madureira, PA; Varshochi, R; Constantinidou, D; Francis, RE; Coombes, RC; Yao, KM; Lam, EWF				Madureira, Patricia A.; Varshochi, Rana; Constantinidou, Demetra; Francis, Richard E.; Coombes, R. Charles; Yao, Kwok-Ming; Lam, Eric W. -F.			The forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ACTIVATION; BETA; PROLIFERATION; MECHANISM; FOXO3A; FOXM1; IDENTIFICATION; INHIBITION; THERAPY	In this study, we have identified the Forkhead transcription factor FoxM1 as a physiological regulator of estrogen receptor alpha (ER alpha) expression in breast carcinoma cells. Our survey of a panel of 16 different breast cell lines showed a good correlation (13/16) between FoxM1 expression and expression of ER alpha at both protein and mRNA levels. We have also demonstrated that ectopic expression of FoxM1 in two different estrogen receptor positive breast cancer cell lines, MCF-7 and ZR-75-30, led to up-regulation of ER alpha expression at protein and transcript levels. Furthermore, treatment of MCF-7 cells with the MEK inhibitor U0126, which blocks ERK1/2-dependent activation of FoxM1, also repressed ER alpha expression. Consistent with this, silencing of FoxM1 expression in MCF-7 cells using small interfering RNA resulted in the almost complete abrogation of ER alpha expression. We also went on to show that FoxM1 can activate the transcriptional activity of human ER alpha promoter primarily through two closely located Forkhead response elements located at the proximal region of the ER alpha promoter. Chromatin immunoprecipitation and biotinylated oligonucleotide pulldown assays have allowed us to confirm these Forkhead response elements as important for FoxM1 binding. Further co-immunoprecipitation experiments showed that FoxO3a and FoxM1 interact in vivo. Together with the chromatin immunoprecipitation and biotinylated oligonucleotide pulldown data, the co-immunoprecipitation results also suggest the possibility that FoxM1 and FoxO3a cooperate to regulate ER alpha gene transcription.	Hammersmith Hosp, Canc Res United Kingdom Labs, Dept Oncol, MRC,Imperial Coll London, London W12 0NN, England; Univ Hong Kong, Dept Biochem, Pokfulam, Hong Kong, Peoples R China	Cancer Research UK; Imperial College London; University of Hong Kong	Lam, EWF (corresponding author), Hammersmith Hosp, Canc Res United Kingdom Labs, Dept Oncol, MRC,Imperial Coll London, Du Cane Rd,Cyclotron Bldg, London W12 0NN, England.	eric.lam@imperial.ac.uk	Yao, Kwok Ming/C-4457-2009; Madureira, Patricia/F-4656-2012; Lam, Eric W-F/AAW-8566-2020; Madureira, Patricia A/C-9666-2013	Madureira, Patricia/0000-0002-4856-3908; Lam, Eric W-F/0000-0003-1274-3576; Madureira, Patricia A/0000-0002-4856-3908; Coombes, Raoul Charles/0000-0002-4811-1100	Engineering and Physical Sciences Research Council [GR/S45713/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Altucci L, 1996, ONCOGENE, V12, P2315; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Clarke RB, 1997, CANCER RES, V57, P4987; COOMBES RC, 1987, LANCET, V2, P701; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dimitrakakis C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1374; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; DUBIK D, 1992, ONCOGENE, V7, P1587; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Geum DH, 1997, MOL REPROD DEV, V46, P450, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;450::AID-MRD2&gt;3.0.CO;2-N; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004; Gustafsson JA, 2000, J STEROID BIOCHEM, V74, P245, DOI 10.1016/S0960-0760(00)00130-8; Hayashi S, 1997, CARCINOGENESIS, V18, P459, DOI 10.1093/carcin/18.3.459; Hopp TA, 2004, CLIN CANCER RES, V10, P7490, DOI 10.1158/1078-0432.CCR-04-1114; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kushner P J, 2000, Novartis Found Symp, V230, P20, DOI 10.1002/0470870818.ch3; Laganiere J, 2005, MOL ENDOCRINOL, V19, P1584, DOI 10.1210/me.2005-0040; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; RICKETTS D, 1991, CANCER RES, V51, P1817; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seo HS, 2002, J STEROID BIOCHEM, V80, P109, DOI 10.1016/S0960-0760(01)00175-3; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; TAYLOR RE, 1982, BRIT J CANCER, V45, P80, DOI 10.1038/bjc.1982.10; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097	37	138	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25167	25176		10.1074/jbc.M603906200	http://dx.doi.org/10.1074/jbc.M603906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16809346	hybrid			2022-12-27	WOS:000240031300017
J	Mullin, MJ; Lightfoot, K; Marklund, U; Cantrell, DA				Mullin, Michael J.; Lightfoot, Kurt; Marklund, Ulrica; Cantrell, Doreen A.			Differential requirement for RhoA GTPase depending on the cellular localization of protein kinase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMOCYTE DEVELOPMENT; IN-VIVO; RECEPTOR ACTIVATION; PHORBOL ESTERS; NUCLEAR EXPORT; T-CELLS; D PKD; C-MU; EXPRESSION; SIGNALS	This study explores the links between the GTPase RhoA and the serine kinase protein kinase D (PKD) during thymocyte development. The rationale is that RhoA and PKD regulate common biological responses during T cell development, but there is nothing known about their interdependence. In fibroblasts, Rho function is required for activation of PKD catalytic activity. However, the data show that activation of Rho is neither sufficient nor essential for PKD activation in T cells. One alternative explanation for the apparent convergence of PKD and Rho signaling in T cells is that PKD responses might be Rho-dependent. To address this latter possibility, we probed the Rho requirements for the actions of constitutively active PKD mutants in pre-T cells of transgenic mice. Active PKD can localize to either the plasma membrane or the cytosol, and we therefore compared the Rho requirements for the actions of membrane- or cytosol-localized PKD. Here we show that membrane-localized PKD regulation of pre-T cell differentiation is Rho-dependent, but the actions of cytosol-localized PKD are not. These studies demonstrate that a Rho requirement for PKD activation is not ubiquitous. Moreover, links between PKD and Rho are determined by the cellular location of PKD.	Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Gothenburg, Dept Clin Immunol, S-41346 Gothenburg, Sweden	University of Dundee; University of Gothenburg	Cantrell, DA (corresponding author), Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	d.a.cantrell@dundee.ac.uk		Cantrell, Doreen/0000-0001-7525-3350	Wellcome Trust [GR065975] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aktories K, 2005, REV PHYSIOL BIOCH P, V152, P1, DOI 10.1007/s10254-004-0034-4; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; Cleverley S, 1999, CURR BIOL, V9, P657, DOI 10.1016/S0960-9822(99)80289-9; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; GODFREY DI, 1994, J IMMUNOL, V152, P4783; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Henning SW, 1998, J EXP MED, V188, P931, DOI 10.1084/jem.188.5.931; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Li J, 2004, J BIOL CHEM, V279, P28466, DOI 10.1074/jbc.M314307200; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Marklund U, 2003, IMMUNITY, V19, P491, DOI 10.1016/S1074-7613(03)00260-7; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Medeiros RB, 2005, IMMUNITY, V23, P213, DOI 10.1016/j.immuni.2005.07.006; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; Oancea E, 2003, DEV CELL, V4, P561, DOI 10.1016/S1534-5807(03)00087-X; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; Song J, 2006, AM J PHYSIOL-CELL PH, V290, pC1469, DOI 10.1152/ajpcell.00486.2005; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Vielkind S, 2005, J IMMUNOL, V175, P350, DOI 10.4049/jimmunol.175.1.350; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; von Boehmer H, 1999, COLD SPRING HARB SYM, V64, P283, DOI 10.1101/sqb.1999.64.283; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wood CD, 2005, J BIOL CHEM, V280, P6245, DOI 10.1074/jbc.M411564200; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200	43	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25089	25096		10.1074/jbc.M603591200	http://dx.doi.org/10.1074/jbc.M603591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16772297	hybrid			2022-12-27	WOS:000240031300010
J	Tsai, TT; Danielson, KG; Guttapalli, A; Oguz, E; Albert, TJ; Shapiro, IM; Risbud, MV				Tsai, Tsung-Ting; Danielson, Keith G.; Guttapalli, Asha; Oguz, Erbil; Albert, Todd J.; Shapiro, Irving M.; Risbud, Makarand V.			TonEBP/OREBP is a regulator of nucleus pulposus cell function and survival in the intervertebral disc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN OREBP; STIMULATES TRANSCRIPTION; OSMOTIC-STRESS; EXPRESSION; GENE; NFAT5; IDENTIFICATION; DIFFUSION; SOLUTES; CULTURE	The nucleus pulposus is an aggrecan-rich hydrated tissue that permits the intervertebral disc to resist compressive loads. Adaptation to loading is achieved through an elevation in disc osmolarity mediated by the numerous charged glycosoaminoglycan side chains of the aggrecan molecule. The goal of this investigation was to determine the functional role of the osmoregulatory protein, TonEBP, in cells of the nucleus pulposus. We found that TonEBP and its downstream target genes were robustly expressed in the tissues of the disc. Above 330 mosmol/kg, cultured nucleus pulposus cells up-regulated target genes TauT, BGT-1, and SMIT; above 450 mosmol/kg, there was raised expression of HSP-70. In hypertonic media there was activation of TauT and heat shock protein-70 (HSP-70) reporter activity and increased binding of TonEBP to the TonE motif. When cells were transfected with the dominant-negative form of TonEBP (DN-TonEBP) there was suppression of TauT and HSP-70 reporter gene expression; pTonEBP enhanced reporter gene expression. Moreover, in hypertonic media, forced expression of DN-TonEBP induced apoptosis. We suppressed TonEBP using small interfering RNA technique and noted a decrease in TauT reporter activity in isotonic as well as hyperosmolar media. Finally, we report that the aggrecan promoter contains two conserved TonE motifs. To evaluate the importance of these motifs, we overexpressed DN-TonEBP and partially silenced TonEBP using small interfering RNA. Both approaches resulted in suppression of aggrecan promoter activity. It is concluded that TonEBP permits the disc cells to adapt to the hyperosmotic milieu while autoregulating the expression of molecules that generate the unique extracellular environment.	Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; Chang Gung Univ, Chang Gung Mem Hosp, Dept Orthopaed Surg, Taoyuan 33305, Taiwan; Gulhane Mil Med Acad, Dept Orthopaed & Traumatol, TR-06018 Ankara, Turkey	Jefferson University; Chang Gung Memorial Hospital; Chang Gung University; Gulhane Military Medical Academy	Risbud, MV (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, 1015 Walnut St,Suite 501 Curtis Bldg, Philadelphia, PA 19107 USA.	makarand.risbud@jefferson.edu		Tsai, Tsung-Ting/0000-0002-7776-7627	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050087] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050087] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducat DC, 2003, BIOTECHNIQUES, V34, P1140, DOI 10.2144/03346bm04; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V272, pC1499; Ito T, 2004, BIOCHEM J, V382, P177, DOI 10.1042/BJ20031838; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; KRAEMER J, 1985, SPINE, V10, P69, DOI 10.1097/00007632-198501000-00011; Lam AKM, 2004, J BIOL CHEM, V279, P48048, DOI 10.1074/jbc.M407224200; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; MAROUDAS A, 1970, BIOPHYS J, V10, P365, DOI 10.1016/S0006-3495(70)86307-X; MAROUDAS A, 1969, BIOCHIM BIOPHYS ACTA, V177, P492, DOI 10.1016/0304-4165(69)90311-0; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; Na KY, 2003, J AM SOC NEPHROL, V14, P283, DOI 10.1097/01.ASN.0000045050.19544.B2; Rajpurohit R, 2002, CELL TISSUE RES, V308, P401, DOI 10.1007/s00441-002-0563-6; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Risbud MV, 2006, SPINE, V31, P884, DOI 10.1097/01.brs.0000209335.57767.b5; Risbud MV, 2006, J CELL BIOCHEM, V98, P152, DOI 10.1002/jcb.20765; Risbud MV, 2005, SPINE, V30, P2503, DOI 10.1097/01.brs.0000186326.82747.13; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Shim EH, 2002, EMBO REP, V3, P857, DOI 10.1093/embo-reports/kvf175; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; Urban JPG, 2002, BIOCHEM SOC T, V30, P858, DOI 10.1042/bst0300858; URBAN JPG, 1978, BIORHEOLOGY, V15, P203; Wang Y, 2005, J BIOL CHEM, V280, P19986, DOI 10.1074/jbc.M501689200; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Zhang Z, 2003, AM J PHYSIOL-RENAL, V285, pF688, DOI 10.1152/ajprenal.00028.2003	31	89	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25416	25424		10.1074/jbc.M601969200	http://dx.doi.org/10.1074/jbc.M601969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16772300	hybrid			2022-12-27	WOS:000240031300044
J	Hong, IK; Jin, YJ; Byun, HJ; Jeoung, DI; Kim, YM; Lee, H				Hong, In-Kee; Jin, Young-June; Byun, Hee-Jung; Jeoung, Doo-Il; Kim, Young-Myeong; Lee, Hansoo			Homophilic interactions of tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; GENE-EXPRESSION; TRANSMEMBRANE-4 SUPERFAMILY; CANCER-CELLS; INTEGRIN ALPHA-3-BETA-1; CLINICAL-SIGNIFICANCE; PROSTATE-CANCER; CARCINOMA CELLS; TUMOR-CELLS; IN-VIVO	The tetraspanin membrane protein CD151 has been suggested to regulate cancer invasion and metastasis by initiating signaling events. The CD151-mediated signaling pathways involved in this regulation remain to be revealed. In this study, we found that stable transfection of CD151 into MelJuSo human melanoma cells lacking CD151 expression significantly increased cell motility, matrix metalloproteinase-9 ( MMP-9) expression, and invasiveness. The enhancement of cell motility and MMP-9 expression by CD151 overexpression was abrogated by inhibitors and small interfering RNAs targeted to focal adhesion kinase ( FAK), Src, p38 MAPK, and JNK, suggesting an essential role of these signaling components in CD151 signaling pathways. Also, CD151-induced MMP-9 expression was shown to be mediated by c-Jun binding to AP-1 sites in the MMP-9 gene promoter, indicating AP-1 activation by CD151 signaling pathways. Meanwhile, CD151 was found to be associated with alpha(3)beta(1) and alpha(6)beta(1) integrins in MelJuSo cells, and activation of associated integrins was a prerequisite for CD151-stimulated MMP-9 expression and activation of FAK, Src, p38 MAPK, JNK, and c-Jun. Furthermore, CD151 on one cell was shown to bind to neighboring cells expressing CD151, suggesting that CD151 is a homophilic interacting protein. The homophilic interactions of CD151 increased motility and MMP-9 expression of CD151-transfected MelJuSo cells, along with FAK-, Src-, p38 MAPK-, and JNK-mediated activation of c-Jun in an adhesion-dependent manner. Furthermore, C8161 melanoma cells with endogenous CD151 were also shown to respond to homophilic CD151 interactions for the induction of adhesion-dependent activation of FAK, Src, and c-Jun. These results suggest that homophilic interactions of CD151 stimulate integrin-dependent signaling to c-Jun through FAK- Src- MAPKs pathways in human melanoma cells, leading to enhanced cell motility and MMP-9 expression.	Kangwon Natl Univ, Div Life Sci, Coll Nat Sci, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Vasc Syst Res Ctr, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea	Kangwon National University; Kangwon National University; Kangwon National University	Lee, H (corresponding author), Kangwon Natl Univ, Div Life Sci, Coll Nat Sci, Chunchon 200701, Kangwon Do, South Korea.	hslee@kangwon.ac.kr						Ang J, 2004, CANCER EPIDEM BIOMAR, V13, P1717; ATKINSON B, 1984, CANCER RES, V44, P2577; Bahassi EM, 2004, CLIN EXP METASTAS, V21, P293, DOI 10.1023/B:CLIN.0000046132.46946.dd; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Gabarra-Niecko V, 2002, BIOCHEM J, V365, P591, DOI 10.1042/BJ20020065; GIL ML, 1992, J IMMUNOL, V148, P2826; Hah N, 2003, BIOCHEM BIOPH RES CO, V305, P428, DOI 10.1016/S0006-291X(03)00788-5; Hasegawa H, 1996, J VIROL, V70, P3258, DOI 10.1128/JVI.70.5.3258-3263.1996; Hashida H, 2003, BRIT J CANCER, V89, P158, DOI 10.1038/sj.bjc.6601015; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Hong S, 2005, J BIOL CHEM, V280, P25202, DOI 10.1074/jbc.M413985200; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Jang HI, 2003, EXP MOL MED, V35, P317, DOI 10.1038/emm.2003.43; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kohno M, 2002, INT J CANCER, V97, P336, DOI 10.1002/ijc.1605; KONDOH M, 1993, MELANOMA RES, V3, P241; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; Lau LM, 2004, BLOOD, V104, P2368, DOI 10.1182/blood-2003-12-4430; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; Na HJ, 2004, J IMMUNOL, V173, P1276, DOI 10.4049/jimmunol.173.2.1276; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishiuchi R, 2005, P NATL ACAD SCI USA, V102, P1939, DOI 10.1073/pnas.0409493102; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; Radford KJ, 1997, J IMMUNOL, V158, P3353; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; SATO H, 1993, ONCOGENE, V8, P395; Sawada S, 2003, J BIOL CHEM, V278, P26323, DOI 10.1074/jbc.C300210200; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; SCHICK MR, 1993, J IMMUNOL, V151, P1918; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; Sterk LMT, 2002, J CELL SCI, V115, P1161; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; Stipp CS, 2000, J CELL SCI, V113, P1871; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Stokes KD, 2003, GENE, V320, P97, DOI 10.1016/S0378-1119(03)00814-X; Testa JE, 1999, CANCER RES, V59, P3812; Tokuhara T, 2001, CLIN CANCER RES, V7, P4109; Vitha S, 2003, PLANT CELL, V15, P1918, DOI 10.1105/tpc.013292; Waetzig V, 2005, MOL CELL NEUROSCI, V30, P67, DOI 10.1016/j.mcn.2005.06.001; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yanez-Mo M, 2001, MICROCIRCULATION, V8, P153; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2002, MOL BIOL CELL, V13, P1, DOI 10.1091/mbc.01-10-0481; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	70	88	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24279	24292		10.1074/jbc.M601209200	http://dx.doi.org/10.1074/jbc.M601209200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798740	hybrid			2022-12-27	WOS:000239847800021
J	Lopes, FL; Desmarais, J; Ledoux, S; Gevry, NY; Lefevre, P; Murphy, BD				Lopes, Flavia L.; Desmarais, Joelle; Ledoux, Sandra; Gevry, Nicolas Y.; Lefevre, Pavine; Murphy, Bruce D.			Transcriptional regulation of uterine vascular endothelial growth factor during early gestation in a carnivore model, Mustela vison	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECIDUAL CELL REACTION; PROSTAGLANDIN E-2 RECEPTOR; FACTOR EXPRESSION; GENE-EXPRESSION; CANCER CELLS; PERMEABILITY FACTOR; OBLIGATE DIAPAUSE; LUTEAL FUNCTION; E SYNTHASE; IN-VITRO	Vascular endothelial growth factor ( VEGF) is an essential angiogenic signaling element that acts through its two tyrosine kinase receptors, inducing both proliferation of endothelial cells and vascular permeability. Given the importance of vasculogenesis and angiogenesis to early pregnancy, it is of interest to understand the mechanisms regulating vascular development at this stage. We previously demonstrated that VEGF and receptors are up-regulated during embryo implantation in an unique animal model, the mink, a species displaying obligate embryonic diapause. Herein we examined the role of prostaglandin E2 (PGE(2)) as a regulator of VEGF during early pregnancy and established the mechanisms of this regulation. We demonstrate that activated embryos secrete PGE(2) and that expression of PGE synthase protein in the uterus is dependent upon direct contact with invading trophoblast cells during implantation. Using mink uterine stromal cells transfected with mink VEGF promoter driving the luciferase reporter gene, we show that PGE(2) induces promoter transactivation and that this response can be eliminated by blockade of protein kinase A. Treatment with antagonists to PGE(2) receptors EP2 and EP4 eliminated the PGE(2)-induced response in transfected cells. Deletional studies of the promoter revealed that a region of 99 bp upstream of the transcription start site is required for PGE(2)-induced transactivation. Mutation of an AP2/Sp1 cluster, found within the 99 bp, completely eliminated the PGE(2) response. Furthermore, chromatin immunoprecipitation assays confirmed binding of the AP2 and Sp1 transcription factors to the endogenous mink VEGF promoter in uterine cells. PGE(2) stimulated acetylation of histone H3 associated with the promoter region containing the AP2/Sp1 cluster. Taken together, these results demonstrate that PGE(2) plays an important role in regulating uterine and thus placental vascular development, acting through its receptors EP2 and EP4, provoking protein kinase A activation of AP2 and Sp1 as well as acetylation of histone H3 to transactivate the VEGF promoter.	Univ Montreal, Fac Med Vet, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada	Universite de Montreal	Lopes, FL (corresponding author), McGill Univ, Montreal Childrens Hosp Res Inst, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.	flavia.lopes@mail.mcgill.ca	Lopes, Flavia Lombardi/A-6608-2009	Lopes, Flavia Lombardi/0000-0002-3173-3712; Murphy, Bruce/0000-0001-7158-3360				Abdel-Majid RM, 2004, J IMMUNOL, V172, P1227, DOI 10.4049/jimmunol.172.2.1227; Arosh JA, 2004, ENDOCRINOLOGY, V145, P2551, DOI 10.1210/en.2003-1607; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; BREIER G, 1992, DEVELOPMENT, V114, P521; Brenneisen P, 2003, BIOCHEM J, V369, P341, DOI 10.1042/BJ20021032; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Desmarais JA, 2004, BIOL REPROD, V70, P662, DOI 10.1095/biolreprod.103.023572; Ding YB, 2005, EXP ONCOL, V27, P108; Eibl G, 2003, BIOCHEM BIOPH RES CO, V306, P887, DOI 10.1016/S0006-291X(03)01079-9; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Fukuda R, 2003, CANCER RES, V63, P2330; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; JOHNSTON MEA, 1984, BIOL REPROD, V31, P959, DOI 10.1095/biolreprod31.5.959; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENNEDY TG, 1977, BIOL REPROD, V16, P286, DOI 10.1095/biolreprod16.3.286; KENNEDY TG, 1979, BIOL REPROD, V20, P560, DOI 10.1095/biolreprod20.3.560; KENNEDY TG, 1988, PROSTAG OTH LIPID M, V35, P207, DOI 10.1016/0090-6980(88)90088-3; Kimura M, 2001, ENDOCRINOLOGY, V142, P4428, DOI 10.1210/en.142.10.4428; Klauber N, 1997, NAT MED, V3, P443, DOI 10.1038/nm0497-443; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LALA PK, 1989, AM J REPROD IMMUNOL, V20, P147, DOI 10.1111/j.1600-0897.1989.tb00987.x; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lopes FL, 2003, BIOL REPROD, V68, P1926, DOI 10.1095/biolreprod.102.013441; Martinet L, 1981, J Reprod Fertil Suppl, V29, P119; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; MOREAU GM, 1995, BIOL REPROD, V53, P511, DOI 10.1095/biolreprod53.3.511; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murphy B.D., 1993, Journal of Reproduction and Fertility Supplement, V47, P181; MURPHY BD, 1981, BIOL REPROD, V25, P487, DOI 10.1095/biolreprod25.3.487; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Ni H, 2002, BIOL REPROD, V67, P351, DOI 10.1095/biolreprod67.1.351; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; PAPKE RL, 1980, J ANIM SCI, V50, P1102, DOI 10.2527/jas1980.5061102x; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Smith SK, 1998, HUM REPROD UPDATE, V4, P509, DOI 10.1093/humupd/4.5.509; Song JH, 1998, ENDOCRINOLOGY, V139, P3629, DOI 10.1210/en.139.8.3629; Tilley SL, 1999, J CLIN INVEST, V103, P1539, DOI 10.1172/JCI6579; Wang XH, 2004, J BIOL CHEM, V279, P30579, DOI 10.1074/jbc.M400573200; Xiao CW, 1999, BIOL REPROD, V60, P656, DOI 10.1095/biolreprod60.3.656; Zhang GQ, 2004, ENDOCRINOLOGY, V145, P2760, DOI 10.1210/en.2003-1545	52	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24602	24611		10.1074/jbc.M602146200	http://dx.doi.org/10.1074/jbc.M602146200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790435	hybrid			2022-12-27	WOS:000239847800055
J	McMahon, M; Thomas, N; Itoh, K; Yamamoto, M; Hayes, JD				McMahon, Michael; Thomas, Nerys; Itoh, Ken; Yamamoto, Masayuki; Hayes, John D.			Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "Tethering" mechanism - A two-site interaction model for the Nrf2-Keap1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT RESPONSE ELEMENT; UBIQUITIN LIGASE COMPLEX; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; HUMAN KEAP1; PROTEASOMAL DEGRADATION; DESTRUCTION MOTIF; CRYSTAL-STRUCTURE; PHASE-2 RESPONSE	The prevalence and mechanistic significance of self-association among substrate adaptors for the Cul-Rbx family of ubiquitin ligases remain unclear. We now report that it is as a homodimer that the substrate adaptor Keap1 interacts with Cul3. The resulting complex facilitates ubiquitylation of the Nrf2 transcription factor but only when this substrate possesses within its Neh2 domain a second cryptic Keap1-binding site, the DLG motif, in addition to its previously described ETGE site. Both motifs recognize overlapping surfaces on Keap1, and the seven lysine residues of Nrf2 that act as ubiquitin acceptors lie between them. Based on these data, we propose a "fixed-ends" model for Nrf2 ubiquitylation in which each binding site becomes tethered to a separate subunit of the Keap1 homodimer. This two-site interaction between Keap1 and Nrf2 constrains the mobility of the target lysine residues in the Neh2 domain, increasing their average concentration in the vicinity of the Rbx-bound ubiquitin-conjugating enzyme, and thus the rate at which the transcription factor is ubiquitylated. We show that self-association is a general feature of Cul3 substrate adaptors and propose that the fixed-ends mechanism is commonly utilized to recruit, orientate, and ubiquitylate substrates upon this family of ubiquitin ligases.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	University of Dundee; University of Tsukuba; University of Tsukuba	McMahon, M (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	mjmmcmahon@dundee.ac.uk	Itoh, Ken/B-9506-2013; McMahon, Michael J/A-1702-2008; McMahon, Michael J/F-7070-2010; Yamamoto, Masayuki/A-4873-2010	Itoh, Ken/0000-0002-5518-0729; McMahon, Michael J/0000-0001-8615-9351; Yamamoto, Masayuki/0000-0002-9073-9436; Hayes, John/0000-0002-2927-5548				Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; An JH, 2005, P NATL ACAD SCI USA, V102, P16275, DOI 10.1073/pnas.0508105102; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dinkova-Kostova AT, 2005, BIOCHEMISTRY-US, V44, P6889, DOI 10.1021/bi047434h; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li XC, 2004, J BIOL CHEM, V279, P54750, DOI 10.1074/jbc.M410073200; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Seibert V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-22; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	51	363	376	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24756	24768		10.1074/jbc.M601119200	http://dx.doi.org/10.1074/jbc.M601119200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790436	hybrid			2022-12-27	WOS:000239847800072
J	Rutz, C; Renner, A; Alken, M; Schulz, K; Beyermann, M; Wiesner, B; Rosenthal, W; Schulein, R				Rutz, Claudia; Renner, Armin; Alken, Martina; Schulz, Katharina; Beyermann, Michael; Wiesner, Burkhard; Rosenthal, Walter; Schuelein, Ralf			The corticotropin-releasing factor receptor type 2a contains an N-terminal pseudo signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOPRESSIN V-2 RECEPTOR; PRION PROTEIN; TRANSMEMBRANE FORM; MEMBRANE-PROTEINS; TRANSLOCATION; CRF; EXPRESSION; PREDICTION; SEQUENCES; TRANSPORT	The corticotropin-releasing factor receptor type 2a (CRF2(a) receptor) belongs to the family of G protein-coupled receptors. The receptor possesses a putative N-terminal signal peptide that is believed to be cleaved-off after mediating the endoplasmic reticulum targeting/insertion process, like the corresponding sequence of the homologous CRF1 receptor. Here, we have assessed the functional significance of the putative signal peptide of the CRF2(a) receptor and show that it is surprisingly completely incapable of mediating endoplasmic reticulum targeting, despite meeting all sequence criteria for a functional signal by prediction algorithms. Moreover, it is uncleaved and forms part of the mature receptor protein. Replacement of residue Asn(13) by hydrophobic or positively charged residues converts the sequence into a fully functional and cleaved signal peptide demonstrating that conventional signal peptide functions are inhibited by a single amino acid residue. Deletion of the domain leads to an increase in the amount of immature, intracellularly retained receptors demonstrating that the sequence has adopted a new function in receptor trafficking through the early secretory pathway. Taken together, our results identify a novel hydrophobic receptor domain in the family of the heptahelical G protein-coupled receptors and the first pseudo signal peptide of a eukaryotic membrane protein. Our data also show that the extreme N termini of the individual CRF receptor subtypes differ substantially.	Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; Charite Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schulein, R (corresponding author), Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	schuelein@fmp-berlin.de						Alken M, 2005, BIOCHEM J, V390, P455, DOI 10.1042/BJ20050113; Andersson H, 2003, MOL PHARMACOL, V64, P570, DOI 10.1124/mol.64.3.570; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; Dautzenberg FM, 2002, TRENDS PHARMACOL SCI, V23, P71, DOI 10.1016/S0165-6147(02)01946-6; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Halic M, 2005, CURR OPIN STRUC BIOL, V15, P116, DOI 10.1016/j.sbi.2005.01.013; Hauger RL, 2003, PHARMACOL REV, V55, P21, DOI 10.1124/pr.55.1.3; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Higy M, 2004, BIOCHEMISTRY-US, V43, P12716, DOI 10.1021/bi048368m; Hofmann BA, 2001, PROTEIN SCI, V10, P2050, DOI 10.1110/ps.12101; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; Kochl R, 2002, J BIOL CHEM, V277, P16131, DOI 10.1074/jbc.M111674200; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Sambrook J., 2001, MOL CLONING LAB MANU; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 2004, REV PHYSIOL BIOCH P, V151, P45, DOI 10.1007/s10254-004-0022-8; Schulein R, 2001, J BIOL CHEM, V276, P8384, DOI 10.1074/jbc.M007045200; Shan SO, 2005, FEBS LETT, V579, P921, DOI 10.1016/j.febslet.2004.11.049; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; Wietfeld D, 2004, J BIOL CHEM, V279, P38386, DOI 10.1074/jbc.M405335200	34	46	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24910	24921		10.1074/jbc.M601554200	http://dx.doi.org/10.1074/jbc.M601554200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16766521	hybrid			2022-12-27	WOS:000239847800084
J	Donahue, CP; Muratore, C; Wu, JY; Kosik, KS; Wolfe, MS				Donahue, Christine P.; Muratore, Christina; Wu, Jane Y.; Kosik, Kenneth S.; Wolfe, Michael S.			Stabilization of the tau exon 10 stem loop alters pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL FRONTOTEMPORAL DEMENTIA; TAU-GENE; EXON 10; SECONDARY STRUCTURE; REGULATORY ELEMENT; MUTATIONS; PARKINSONISM; EXPRESSION; CHROMOSOME-17; FTDP-17	Neurofibrillary tangles containing filaments of the microtubuleassociated protein tau are found in a variety of neurodegenerative diseases. Mutations in the tau gene itself cause frontotemporal dementia with parkinsonism, demonstrating the critical role of tau in pathogenesis. Many of these mutations in tau are silent, are found at the 5'-splice site of exon 10, and lead to increased inclusion of exon 10. These silent mutations are predicted to destabilize a stem loop structure at the exon 10 5'-splice site; however, the existence of this stem loop under physiological conditions and its role in splice regulation are controversial. Here we show that base changes that stabilize this stem loop in vitro substantially decrease exon 10 inclusion in a wild type tau minigene and rescue the increase in exon 10 splicing caused by a dementia-causing point mutation. Moreover, we probed the intracellular structure of the tau stem loop with antisense RNA and demonstrate that the stability of the stem loop dictates antisense effectiveness. Together these results validate the stem loop as a bonafide structure regulating tau exon 10 splicing.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Northwestern University; Feinberg School of Medicine; University of California System; University of California Santa Barbara	Wolfe, MS (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu			NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967, R01 GM070967-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 2005, BBA-MOL BASIS DIS, V1739, P104, DOI 10.1016/j.bbadis.2004.08.009; D'Souza I, 2002, J BIOL CHEM, V277, P26587, DOI 10.1074/jbc.M203794200; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Donahue CP, 2002, HIPPOCAMPUS, V12, P821, DOI 10.1002/hipo.10058; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 2003, J BIOL CHEM, V278, P18997, DOI 10.1074/jbc.M301800200; Kalbfuss B, 2001, J BIOL CHEM, V276, P42986, DOI 10.1074/jbc.M105113200; Kosik KS, 2005, BBA-MOL BASIS DIS, V1739, P298, DOI 10.1016/j.bbadis.2004.10.011; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Miyamoto K, 2001, ANN NEUROL, V50, P117, DOI 10.1002/ana.1083; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Sczakiel G, 1997, ANTISENSE NUCLEIC A, V7, P439, DOI 10.1089/oli.1.1997.7.439; Toulme JJ, 1996, BIOCHIMIE, V78, P663, DOI 10.1016/S0300-9084(96)80012-5; Toulme JJ, 2001, PROG NUCLEIC ACID RE, V69, P1, DOI 10.1016/S0079-6603(01)69043-3; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Varani L, 2000, NUCLEIC ACIDS RES, V28, P710, DOI 10.1093/nar/28.3.710; Vickers TA, 2000, NUCLEIC ACIDS RES, V28, P1340, DOI 10.1093/nar/28.6.1340; Yasuda M, 2000, ANN NEUROL, V47, P422, DOI 10.1002/1531-8249(200004)47:4<422::AID-ANA4>3.0.CO;2-G; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	28	74	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23302	23306		10.1074/jbc.C600143200	http://dx.doi.org/10.1074/jbc.C600143200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782711	Green Accepted, hybrid			2022-12-27	WOS:000239702900003
J	Soboloff, J; Spassova, MA; Tang, XD; Hewavitharana, T; Xu, W; Gill, DL				Soboloff, Jonathan; Spassova, Maria A.; Tang, Xiang D.; Hewavitharana, Thamara; Xu, Wen; Gill, Donald L.			Orai1 and STIM reconstitute store-operated calcium channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE RECEPTOR; CRAC CHANNELS; CA2+ SENSOR; IDENTIFICATION; ACTIVATION; BORATE	The two membrane proteins, STIM1 and Orail, have each been shown to be essential for the activation of store-operated channels ( SOC). Yet, how these proteins functionally interact is not known. Here, we reveal that STIM1 and Orail expressed together reconstitute functional SOCs. Expressed alone, Orail strongly reduces store-operated Ca2+ entry ( SOCE) in human embryonic kidney 293 cells and the Ca2+ release-activated Ca2+ current ( ICRAC) in rat basophilic leukemia cells. However, expressed along with the store-sensing STIM1 protein, Orail causes a massive increase in SOCE, enhancing the rate of Ca2+ entry by up to 103-fold. This entry is entirely store-dependent since the same coexpression causes no measurable store-independent Ca2+ entry. The entry is completely blocked by the SOC blocker, 2-aminoethoxydiphenylborate. Orail and STIM1 coexpression also caused a large gain in CRAC channel function in rat basophilic leukemia cells. The close STIM1 homologue, STIM2, inhibited SOCE when expressed alone but coexpressed with Orail caused substantial constitutive ( store-independent) Ca2+ entry. STIM proteins are known to mediate Ca2+ store-sensing and endoplasmic reticulum-plasma membrane coupling with no intrinsic channel properties. Our results revealing a powerful gain in SOC function dependent on the presence of both Orail and STIM1 strongly suggest that Orail contributes the PM channel component responsible for Ca2+ entry. The suppression of SOC function by Orail overexpression likely reflects a required stoichiometry between STIM1 and Orail.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	dgill@umaryland.edu	Soboloff, Jonathan/I-6995-2012	Soboloff, Jonathan/0000-0001-5192-1297	NHLBI NIH HHS [HL55426] Funding Source: Medline; NIAID NIH HHS [AI058173] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058173] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BIAN JH, 1991, J BIOL CHEM, V266, P8801; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; PEINELT C, 2006, IN PRESS NAT CELL BI; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Putney JW, 2001, J CELL SCI, V114, P2223; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; SOBOLOFF J, 2006, IN PRESS CURR BIOL; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; SPASSSOVA MA, 2006, BIOPHYS J; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	24	442	473	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20661	20665		10.1074/jbc.C600126200	http://dx.doi.org/10.1074/jbc.C600126200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16766533	hybrid			2022-12-27	WOS:000239187300002
J	Watanabe, S; Kodaki, T; Makino, K				Watanabe, Seiya; Kodaki, Tsutomu; Makino, Keisuke			A novel alpha-ketoglutaric semialdehyde dehydrogenase Evolutionary insight into an alternative pathway of bacterial L-arabinose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-XYLULOSE REDUCTASE; ALDEHYDE DEHYDROGENASE; CATABOLIC PATHWAY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PSEUDOMONAS SACCHAROPHILA; GENE; IDENTIFICATION; CLONING; EXPRESSION	Azospirillum brasilense possesses an alternative pathway of L-arabinose metabolism, which is different from the known bacterial and fungal pathways. In a previous paper (Watanabe, S., Kodaki, T., and Makino, K. (2006) J. Biol. Chem. 281, 2612-2623), we identified and characterized L-arabinose 1-dehydrogenase, which catalyzes the first reaction step in this pathway, and we cloned the corresponding gene. Here we focused on the fifth enzyme, alpha-ketoglutaric semialdehyde (alpha KGSA) dehydrogenase, catalyzing the conversion of alpha KGSA to alpha-ketoglutarate. alpha KGSA dehydrogenase was purified tentatively as a NAD(+)-preferring aldehyde dehydrogenase (ALDH) with high activity for glutaraldehyde. The gene encoding this enzyme was cloned and shown to be located on the genome of A. brasilense separately from a gene cluster containing the L-arabinose 1-dehydrogenase gene, in contrast with Burkholderia thailandensis in which both genes are located in the same gene cluster. Higher catalytic efficiency of ALDH was found with alpha KGSA and succinic semialdehyde among the tested aldehyde substrates. In zymogram staining analysis with the cell-free extract, a single active band was found at the same position as the purified enzyme. Furthermore, a disruptant of the gene did not grow on L-arabinose. These results indicated that this ALDH gene was the only gene of the NAD(+)-preferring alpha KGSA dehydrogenase in A. brasilense. In the phylogenetic tree of the ALDH family, alpha KGSA dehydrogenase from A. brasilense falls into the succinic semialdehyde dehydrogenase (SSALDH) subfamily. Several putative alpha KGSA dehydrogenases from other bacteria belong to a different ALDH subfamily from SSALDH, suggesting strongly that their substrate specificities for alpha KGSA are acquired independently during the evolutionary stage. This is the first evidence of unique "convergent evolution" in the ALDH family.	Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Japan Sci & Technol Agcy, CREST, Uji, Kyoto 6110011, Japan; Kyoto Univ, Int Innovat Ctr, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Engn, Saikyo Ku, Kyoto 6158530, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Kyoto University	Makino, K (corresponding author), Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan.	kmak@iae.kyoto-u.ac.jp						ADAMS E, 1967, J BIOL CHEM, V242, P1802; Ahvazi B, 2000, BIOCHEM J, V349, P853, DOI 10.1042/bj3490853; Barbosa JARG, 2000, J MOL BIOL, V303, P405, DOI 10.1006/jmbi.2000.4138; BARTSCH K, 1990, J BACTERIOL, V172, P7035, DOI 10.1128/jb.172.12.7035-7042.1990; Bateman OA, 2003, BIOCHEMISTRY-US, V42, P4349, DOI 10.1021/bi027367w; Busch KB, 1999, PLANT PHYSIOL, V121, P589, DOI 10.1104/pp.121.2.589; CHAMBLISS KL, 1995, J BIOL CHEM, V270, P461, DOI 10.1074/jbc.270.1.461; CHANG YF, 1977, J BIOL CHEM, V252, P7979; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; DAGLEY S, 1965, BIOCHEM J, V95, P48, DOI 10.1042/bj0950048; DAHMS AS, 1969, BIOCHEM BIOPH RES CO, V36, P809, DOI 10.1016/0006-291X(69)90681-0; DUNCAN MJ, 1979, J GEN MICROBIOL, V113, P177, DOI 10.1099/00221287-113-1-177; DUNCAN MJ, 1979, J BACTERIOL, V137, P415, DOI 10.1128/JB.137.1.415-419.1979; GENNADY PM, 2002, HDB DETECTION ENZYME, P27; Gros E., 1967, METHOD ENZYMOL, V11, P238; Gruez A, 2004, J MOL BIOL, V343, P29, DOI 10.1016/j.jmb.2004.08.030; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; Hosoya S, 2002, FEMS MICROBIOL LETT, V210, P193, DOI 10.1111/j.1574-6968.2002.tb11180.x; Iwaki H, 1999, APPL ENVIRON MICROB, V65, P5158; Junker F, 1997, J BACTERIOL, V179, P919, DOI 10.1128/jb.179.3.919-927.1997; KOO PH, 1974, J BIOL CHEM, V249, P1704; Kuznetsova E, 2005, FEMS MICROBIOL REV, V29, P263, DOI 10.1016/j.femsre.2004.12.006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutke-Eversloh T, 1999, FEMS MICROBIOL LETT, V181, P63; MATHIAS AL, 1989, J BACTERIOL, V171, P5206, DOI 10.1128/jb.171.9.5206-5209.1989; Moore RA, 2004, INFECT IMMUN, V72, P4172, DOI 10.1128/IAI.72.7.4172-4187.2004; Moore S, 1940, J BIOL CHEM, V133, P293; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; NOVICK NJ, 1982, J BACTERIOL, V149, P364, DOI 10.1128/JB.149.1.364-367.1982; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; Richard P, 2002, BIOCHEMISTRY-US, V41, P6432, DOI 10.1021/bi025529i; Richard P, 2001, J BIOL CHEM, V276, P40631, DOI 10.1074/jbc.M104022200; Schneider BL, 1998, J BACTERIOL, V180, P4278, DOI 10.1128/JB.180.16.4278-4286.1998; SIMON R, 1983, BIOTECHNOLOGY, V1, P789; SINGH RMM, 1964, SCIENCE, V144, P67, DOI 10.1126/science.144.3614.67; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; STOOLMILLER AC, 1966, J BIOL CHEM, V241, P5764; STRYER L, 1988, BIOCHEMISTRY-US, P805; Verho R, 2004, J BIOL CHEM, V279, P14746, DOI 10.1074/jbc.M312533200; Watanabe S, 2006, J BIOL CHEM, V281, P2612, DOI 10.1074/jbc.M506477200; WEIMBERG R, 1955, J BIOL CHEM, V217, P607; Zaldivar J, 2001, APPL MICROBIOL BIOT, V56, P17, DOI 10.1007/s002530100624	45	42	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28876	28888		10.1074/jbc.M602585200	http://dx.doi.org/10.1074/jbc.M602585200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16835232	Green Submitted, hybrid			2022-12-27	WOS:000240680500042
J	Sullivan, MM; Barker, TH; Funk, SE; Karchin, A; Seo, NS; Hook, M; Sanders, J; Starcher, B; Wight, TN; Puolakkainen, P; Sage, EH				Sullivan, Millicent M.; Barker, Thomas H.; Funk, Sarah E.; Karchin, Ari; Seo, Neung S.; Hook, Magnus; Sanders, Joan; Starcher, Barry; Wight, Thomas N.; Puolakkainen, Pauli; Sage, E. Helene			Matricellular hevin regulates decorin production and collagen assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEOGLYCAN DECORIN; SPARC-NULL MICE; TARGETED DISRUPTION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; I COLLAGEN; MATRIX; FIBRILLOGENESIS; ADHESION; EXPRESSION	Matricellular proteins such as SPARC, thrombospondin 1 and 2, and tenascin C and X subserve important functions in extracellular matrix synthesis and cellular adhesion to extracellular matrix. By virtue of its reported interaction with collagen I and deadhesive activity on cells, we hypothesized that hevin, a member of the SPARC gene family, regulates dermal extracellular matrix and collagen fibril formation. We present evidence for an altered collagen matrix and levels of the proteoglycan decorin in the normal dermis and dermal wound bed of hevin-null mice. The dermal elastic modulus was also enhanced in hevin-null animals. The levels of decorin protein secreted by hevin-null dermal fibroblasts were increased by exogenous hevin in vitro, data indicating that hevin might regulate both decorin and collagen fibrillogenesis. We also report a decorin-independent function for hevin in collagen fibrillogenesis. In vitro fibrillogenesis assays indicated that hevin enhanced fibril formation kinetics. Furthermore, cell adhesion assays indicated that cells adhered differently to collagen fibrils formed in the presence of hevin. Our observations support the capacity of hevin to modulate the structure of dermal extracellular matrix, specifically by its regulation of decorin levels and collagen fibril assembly.	Benaroya Res Inst Virginia Mason, Hope Heart Program, Seattle, WA 98101 USA; Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; Emory Univ, Atlanta, GA 30332 USA; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas Hlth Ctr, Dept Biochem, Tyler, TX 75708 USA; Helsinki Cent Univ, Dept Surg, Helsinki 00290, Finland	Benaroya Research Institute; Virginia Mason Medical Center; University System of Georgia; Georgia Institute of Technology; Emory University; University of Washington; University of Washington Seattle; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Sage, EH (corresponding author), Benaroya Res Inst Virginia Mason, Hope Heart Program, 1201 9th Ave, Seattle, WA 98101 USA.	hsage@benaroyaresearch.org	Sullivan, Millicent/D-1568-2012	Sullivan, Millicent/0000-0002-4787-7534	NCI NIH HHS [CA109559] Funding Source: Medline; NIGMS NIH HHS [GM40711, 5F32 GM073363] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM073363, R01GM040711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker TH, 2005, AM J PATHOL, V166, P923, DOI 10.1016/S0002-9440(10)62312-7; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Brekken RA, 2004, J HISTOCHEM CYTOCHEM, V52, P735, DOI 10.1369/jhc.3A6245.2004; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; Corbett SA, 1997, J BIOL CHEM, V272, P24999, DOI 10.1074/jbc.272.40.24999; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAYAN D, 1989, HISTOCHEMISTRY, V93, P27, DOI 10.1007/BF00266843; Eming SA, 2004, EXPERT OPIN BIOL TH, V4, P1373, DOI 10.1517/14712598.4.9.1373; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Girard JP, 1996, J BIOL CHEM, V271, P4511; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Graham HK, 2000, J MOL BIOL, V295, P891, DOI 10.1006/jmbi.1999.3384; GRINNELL F, 1989, EXP CELL RES, V181, P483, DOI 10.1016/0014-4827(89)90105-5; Gu JG, 1996, J BIOCHEM-TOKYO, V119, P743; Guidetti G, 2002, BLOOD, V100, P1707, DOI 10.1182/blood.V100.5.1707.h81702001707_1707_1714; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hambrock HO, 2003, J BIOL CHEM, V278, P11351, DOI 10.1074/jbc.M212291200; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; Keene DR, 1998, J HISTOCHEM CYTOCHEM, V46, P215, DOI 10.1177/002215549804600210; KING GS, 1980, CONNECT TISSUE RES, V7, P263, DOI 10.3109/03008208009152362; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; Merle B, 1997, J CELL BIOCHEM, V67, P75; Minamitani T, 2004, EXP CELL RES, V298, P305, DOI 10.1016/j.yexcr.2004.04.030; Mothe AJ, 2001, HEARING RES, V155, P161, DOI 10.1016/S0378-5955(01)00246-5; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; Puolakkainen PA, 2005, J HISTOCHEM CYTOCHEM, V53, P571, DOI 10.1369/jhc.4A6425.2005; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; RIDGE MICHAEL, 1964, BIORHEOLOGY, V2, P67; Sanders JE, 1997, IEEE T BIO-MED ENG, V44, P290, DOI 10.1109/10.563298; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Sini P, 1997, GLYCOCONJUGATE J, V14, P871, DOI 10.1023/A:1018550307649; St Croix B, 2000, SCIENCE, V289, P1197; STARCHER B, 1995, CONNECT TISSUE RES, V31, P133, DOI 10.3109/03008209509028401; Sullivan MM, 2004, INT J BIOCHEM CELL B, V36, P991, DOI 10.1016/j.biocel.2004.01.017; Takeda U, 2002, J INVEST DERMATOL, V119, P678, DOI 10.1046/j.1523-1747.2002.01863.x; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10	48	53	56	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27621	27632		10.1074/jbc.M510507200	http://dx.doi.org/10.1074/jbc.M510507200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844696	hybrid			2022-12-27	WOS:000240397700087
J	Finoux, AL; Seraphin, B				Finoux, Anne-Laure; Seraphin, Bertrand			In vivo targeting of the yeast Pop2 deadenylase subunit to reporter transcripts induces their rapid degradation and generates new decay intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLASE; SACCHAROMYCES-CEREVISIAE; POLY(A)-BINDING PROTEIN; CCR4-NOT COMPLEX; CAF1 PROTEINS; POLY(A); NUCLEASE; TURNOVER; PURIFICATION; TRANSLATION	Deadenylation is the rate-limiting step of mRNA decay, yet little is known about the mechanism regulating this process. In yeast, deadenylation is mainly mediated by the Pop2-Ccr4 complex. We tested whether the selective recruitment of this deadenylase to target mRNAs was sufficient to stimulate their decay in vivo. For this purpose, the Pop2 factor was fused to a U1A RNA binding domain while U1A binding sites were inserted in untranslated regions of a reporter transcript. Analysis of the reporter fate in strains expressing the Pop2-U1A-RBD fusion demonstrated a specific activation of target mRNA decay. Increased mRNA degradation involved accumulation of deadenylated mRNAs that was not detected when the control factors Dcp2 or Pub1 were tethered to the same transcript. The rapid target mRNA degradation was also accompanied by the appearance of new decay intermediates generated by the 3'-5' trimming of the corresponding 3'-untranslated region. Interestingly, this process was not mediated by the exosome but may result from the activity of the Pop2-Ccr4 deadenylase itself. These results indicate that selective recruitment of the Pop2-Ccr4 deadenylase is sufficient to activate mRNA decay, even though this process can also be stimulated by additional mechanisms. Furthermore, deadenylase recruitment affects the downstream path of mRNA decay.	Univ Paris 06, CNRS, Unite Propre Rech 2167, Ctr Mol Genet,Equipe Labelisee La Ligue, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Seraphin, B (corresponding author), Univ Paris 06, CNRS, Unite Propre Rech 2167, Ctr Mol Genet,Equipe Labelisee La Ligue, Ave Terrasse, F-91198 Gif Sur Yvette, France.	seraphin@cgm.cnrs-gif.fr		Seraphin, Bertrand/0000-0002-5168-1921				Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; Bianchin C, 2005, RNA, V11, P487, DOI 10.1261/rna.7135305; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Collart MA, 2004, PROG NUCLEIC ACID RE, V77, P289, DOI 10.1016/S0079-6603(04)77008-7; Coller JM, 1998, GENE DEV, V12, P3226, DOI 10.1101/gad.12.20.3226; Cougot N, 2004, TRENDS BIOCHEM SCI, V29, P436, DOI 10.1016/j.tibs.2004.06.008; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; HARLOW E, 1998, ANTIBODIES LAB MANUA, P471; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Khanna R, 2004, EMBO J, V23, P1968, DOI 10.1038/sj.emboj.7600213; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; LIAO XL, 1990, GENE DEV, V4, P1766, DOI 10.1101/gad.4.10.1766; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Nagai K, 1995, Nucleic Acids Symp Ser, P1; Puig O, 1998, YEAST, V14, P1139; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SIKORSKI RS, 1989, GENETICS, V122, P19; Temme C, 2004, EMBO J, V23, P2862, DOI 10.1038/sj.emboj.7600273; Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van Dijk EL, 2001, NUCLEIC ACIDS RES, V29, P3477, DOI 10.1093/nar/29.17.3477; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Viswanathan P, 2004, J BIOL CHEM, V279, P23988, DOI 10.1074/jbc.M402803200; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25940	25947		10.1074/jbc.M600132200	http://dx.doi.org/10.1074/jbc.M600132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16793769	hybrid			2022-12-27	WOS:000240249500008
J	Gonzalez, RR; Cherfils, S; Escobar, M; Yoo, JH; Carino, C; Styer, AK; Sullivan, BT; Sakamoto, H; Olawaiye, A; Serikawa, T; Lynch, MP; Rueda, BR				Gonzalez, Ruben R.; Cherfils, Salandre; Escobar, Maria; Yoo, Jin H.; Carino, Cecilia; Styer, Aaron K.; Sullivan, Brian T.; Sakamoto, Hideo; Olawaiye, Alex; Serikawa, Takehiro; Lynch, Maureen P.; Rueda, Bo R.			Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FEMALE MICE; UP-REGULATION; CYCLIN D1; PROLIFERATION; ACTIVATION; SEQUENCES; ISOFORMS; PEPTIDE; CASCADE	To gain insight into the mechanism(s) by which leptin contributes to mammary tumor (MT) development we investigated the effects of leptin, kinase inhibitors, and/or leptin receptor antagonists (LPrA2) on 4T1 mouse mammary cancer cells in vitro and LPrA2 on 4T1-MT development in vivo. Leptin increases the expression of vascular endothelial growth factor (VEGF), its receptor (VEGF-R2), and cyclin D1 through phosphoinositide 3-kinase, Janus kinase 2/signal transducer and activator of transcription 3, and/or extracellular signal-activated kinase 1/2 signaling pathways. In contrast to leptin-induced levels of cyclin D1 the changes in VEGF or VEGF-R2 were more dependent on specific signaling pathways. Incubation of 4T1 cells with anti-VEGF-R2 antibody increased leptin-mediated VEGF expression suggesting an autocrine/paracrine loop. Pretreatment of syngeneic mice with LPrA2 prior to inoculation with 4T1 cells delayed the development and slowed the growth of MT (up to 90%) compared with controls. Serum VEGF levels and VEGF/VEGF-R2 expression in MT were significantly lower in mice treated with LPrA2. Interestingly, LPrA2-induced effects were more pronounced in vivo than in vitro suggesting paracrine actions in stromal, endothelial, and/or inflammatory cells that may impact the growth of MT. Although all the mechanism(s) by which leptin contributes to tumor development are unknown, it appears leptin stimulates an increase in cell numbers, and the expression of VEGF/VEGF-R2. Together, these results provide further evidence suggesting leptin is a MT growth-promoting factor. The inhibition of leptin signaling could serve as a potential adjuvant therapy for treatment of breast cancer and/or provide a new target for the designing strategies to prevent MT development.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Rueda, BR (corresponding author), Morehouse Sch Med, 720 Westview Dr, Atlanta, GA 30310 USA.	brueda@partners.org						Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Catalano S, 2004, J BIOL CHEM, V279, P19908, DOI 10.1074/jbc.M313191200; Catalano S, 2003, J BIOL CHEM, V278, P28668, DOI 10.1074/jbc.M301695200; Chen CC, 2006, BREAST CANCER RES TR, V98, P121, DOI 10.1007/s10549-005-9139-y; Cleary MP, 2004, NUTR CANCER, V50, P174, DOI 10.1207/s15327914nc5002_7; Cleary MP, 2004, EXP BIOL MED, V229, P182, DOI 10.1177/153537020422900207; Cleary MP, 2003, BREAST CANCER RES TR, V77, P205, DOI 10.1023/A:1021891825399; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Eisenberg A, 2004, FEBS LETT, V565, P139, DOI 10.1016/j.febslet.2004.03.089; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gonzalez RR, 2004, ENDOCRINOLOGY, V145, P3850, DOI 10.1210/en.2004-0383; Gonzalez RR, 2003, ENDOCRINE, V21, P185, DOI 10.1385/ENDO:21:2:185; Gonzalez RR, 2001, ENDOCRINE, V16, P21, DOI 10.1385/ENDO:16:1:21; Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Kloek C, 2002, J BIOL CHEM, V277, P41547, DOI 10.1074/jbc.M205148200; KLURFELD DM, 1991, P SOC EXP BIOL MED, V196, P381; Miyoshi Y, 2006, INT J CANCER, V118, P1414, DOI 10.1002/ijc.21543; Okumura M, 2002, BBA-MOL CELL RES, V1592, P107, DOI 10.1016/S0167-4889(02)00276-8; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Ramos MP, 2005, ENDOCRINOLOGY, V146, P694, DOI 10.1210/en.2004-1186; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Saitoh M, 2005, ENDOCRINOLOGY, V146, P4917, DOI 10.1210/en.2004-1535; SEILKOP SK, 1995, FUND APPL TOXICOL, V24, P247, DOI 10.1006/faat.1995.1028; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Somasundar P, 2004, J SURG RES, V118, P71, DOI 10.1016/j.jss.2004.01.017; Somasundar P, 2004, J SURG RES, V116, P337, DOI 10.1016/j.jss.2003.09.004; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Veronese FM, 2002, ADV DRUG DELIVER REV, V54, P453; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Yin N, 2004, CANCER RES, V64, P5870, DOI 10.1158/0008-5472.CAN-04-0655; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416	40	191	199	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26320	26328		10.1074/jbc.M601991200	http://dx.doi.org/10.1074/jbc.M601991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825198	hybrid			2022-12-27	WOS:000240249500049
J	Hidalgo, C; Sanchez, G; Barrientos, G; Aracena-Parks, P				Hidalgo, Cecilia; Sanchez, Gina; Barrientos, Genaro; Aracena-Parks, Paula			A transverse tubule NADPH oxidase activity stimulates calcium release from isolated triads via ryanodine receptor type 1 S-glutathionylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; RAT SKELETAL-MUSCLE; RYANODINE RECEPTOR COMPLEX; HUMAN ENDOTHELIAL-CELLS; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; CA2+ RELEASE; OXIDATIVE STRESS; CONTRACTING DIAPHRAGM; NAD(P)H OXIDASES	We report here the presence of an NADPH oxidase (NOX) activity both in intact and in isolated transverse tubules and in triads isolated from mammalian skeletal muscle, as established by immunochemical, enzymatic, and pharmacological criteria. Immunohistochemical determinations with NOX antibodies showed that the gp91(phox) membrane subunit and the cytoplasmic regulatory p47(phox) subunit co-localized in transverse tubules of adult mice fibers with the alpha(1s) subunit of dihydropyridine receptors. Western blot analysis revealed that isolated triads contained the integral membrane subunits gp91(phox) and p22(phox), which were markedly enriched in isolated transverse tubules but absent from junctional sarcoplasmic reticulum vesicles. Isolated triads and transverse tubules, but not junctional sarcoplasmic reticulum, also contained varying amounts of the cytoplasmic NOX regulatory subunits p47phox and p67phox. NADPH or NADH elicited superoxide anion and hydrogen peroxide generation by isolated triads; both activities were inhibited by NOX inhibitors but not by rotenone. NADH diminished the total thiol content of triads by one-third; catalase or apocynin, a NOX inhibitor, prevented this effect. NADPH enhanced the activity of ryanodine receptor type 1 (RyR1) in triads, measured through [H-3] ryanodine binding and calcium release kinetics, and increased significantly RyR1 S-glutathionylation over basal levels. Preincubation with reducing agents or NOX inhibitors abolished the enhancement of RyR1 activity produced by NADPH and prevented NADPH- induced RyR1 S-glutathionylation. We propose that reactive oxygen species generated by the transverse tubule NOX activate via redox modification the neighboring RyR1 Ca2+ release channels. Possible implications of this	Univ Chile, Fac Med, ICBM, Ctr FONDAP Estudios Mol Celula, Santiago 7, Chile; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 7, Chile; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Patol, Santiago 7, Chile	Universidad de Chile; Universidad de Chile; Universidad de Chile	Hidalgo, C (corresponding author), Univ Chile, Fac Med, ICBM, Ctr FONDAP Estudios Mol Celula, Casilla 70005, Santiago 7, Chile.	chidalgo@med.uchile.cl	Barrientos, Genaro/I-2778-2013; Aracena, Paula/A-5607-2012	Aracena, Paula/0000-0002-2144-6875				Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; Aracena P, 2005, ANTIOXID REDOX SIGN, V7, P870, DOI 10.1089/ars.2005.7.870; Aracena P, 2003, J BIOL CHEM, V278, P42927, DOI 10.1074/jbc.M306969200; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bal-Price A, 2002, J NEUROCHEM, V80, P73, DOI 10.1046/j.0022-3042.2001.00675.x; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Brotto MAP, 1996, J APPL PHYSIOL, V81, P731, DOI 10.1152/jappl.1996.81.2.731; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; Byrne JA, 2003, CIRC RES, V93, P802, DOI 10.1161/01.RES.0000099504.30207.F5; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P489, DOI 10.1016/S0968-0004(02)02191-6; DeCoursey TE, 2003, NATURE, V422, P531, DOI 10.1038/nature01523; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Griendling KK, 2004, HEART, V90, P491, DOI 10.1136/hrt.2003.029397; Grozdanovic Z, 2001, MICROSC RES TECHNIQ, V55, P148, DOI 10.1002/jemt.1165; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Haugaard N, 2000, ANN NY ACAD SCI, V899, P148; HIDALGO C, 1983, J BIOL CHEM, V258, P3937; HIDALGO C, 1993, J BIOL CHEM, V268, P15111; Hidalgo C, 2005, IUBMB LIFE, V57, P315, DOI 10.1080/15216540500092328; Jackson MJ, 2005, PHILOS T R SOC B, V360, P2285, DOI 10.1098/rstb.2005.1773; Javesghani D, 2002, AM J RESP CRIT CARE, V165, P412, DOI 10.1164/ajrccm.165.3.2103028; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; Kishida KT, 2005, J NEUROCHEM, V94, P299, DOI 10.1111/j.1471-4159.2005.03189.x; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Matsuzaki I, 2005, AM J PHYSIOL-HEART C, V288, pH336, DOI 10.1152/ajpheart.00025.2004; Nethery D, 1999, J APPL PHYSIOL, V87, P792, DOI 10.1152/jappl.1999.87.2.792; Noh KM, 2000, J NEUROSCI, V20; Oba T, 2000, AM J PHYSIOL-CELL PH, V279, pC1366, DOI 10.1152/ajpcell.2000.279.5.C1366; Oba T, 2002, AM J PHYSIOL-CELL PH, V282, pC684, DOI 10.1152/ajpcell.01273.2000; Pessah IN, 2001, PEST MANAG SCI, V57, P941, DOI 10.1002/ps.391; Pessah IN, 2002, FRONT BIOSCI-LANDMRK, V7, pA72, DOI 10.2741/pessah; Posterino GS, 2003, J PHYSIOL-LONDON, V547, P807, DOI 10.1113/jphysiol.2002.035204; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Reid MB, 2002, ANN NY ACAD SCI, V959, P108, DOI 10.1111/j.1749-6632.2002.tb02087.x; Reid MB, 2001, J APPL PHYSIOL, V90, P724, DOI 10.1152/jappl.2001.90.2.724; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; RHEE SG, 2000, SCI STKE, pE1; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Sanchez G, 2005, J MOL CELL CARDIOL, V39, P982, DOI 10.1016/j.yjmcc.2005.08.010; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Stofan DA, 2000, AM J RESP CRIT CARE, V161, P891; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Suzuki YJ, 1998, FREE RADICAL BIO MED, V24, P318, DOI 10.1016/S0891-5849(97)00227-X; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Tammariello SP, 2000, J NEUROSCI, V20; Tejada-Simon MV, 2005, MOL CELL NEUROSCI, V29, P97, DOI 10.1016/j.mcn.2005.01.007; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zuo L, 2000, AM J PHYSIOL-CELL PH, V279, pC1058, DOI 10.1152/ajpcell.2000.279.4.C1058	79	142	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26473	26482		10.1074/jbc.M600451200	http://dx.doi.org/10.1074/jbc.M600451200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16762927	hybrid			2022-12-27	WOS:000240249500065
J	Holinstat, M; Voss, B; Bilodeau, ML; McLaughlin, JN; Cleator, J; Hamm, HE				Holinstat, Michael; Voss, Bryan; Bilodeau, Matthew L.; McLaughlin, Joseph N.; Cleator, John; Hamm, Heidi E.			PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y(12) receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE CORONARY SYNDROMES; THROMBIN RECEPTOR; INTEGRIN ALPHA(IIB)BETA(3); CARDIOVASCULAR EVENTS; RAP1B; TRIAL; RISK; PROTEIN; CLONING; ADP	Regulation of platelet activation plays a central role in hemostasis and pathophysiological processes such as coronary artery disease. Thrombin is the most potent activator of platelets. Human platelets express two thrombin receptors, PAR1 and PAR4, both of which signal platelet activation. Evidence is lacking on the mechanism by which PAR1 and PAR4 may differentially signal platelet aggregation. Here we show that at the relatively high concentration of agonist most likely found at the site of a local thrombus, dual inhibition of the P2Y(12) receptor and calcium mobilization result in a complete inhibition of PAR4-induced aggregation, while having no effect on either thrombin or PAR1-mediated platelet aggregation. Both PAR1-and PAR4-mediated aggregation are independent of calcium mobilization. Furthermore, we show that P2Y(12) receptor activation is not required for protease-activated receptor-mediated aggregation at higher agonist concentrations and is only partially required for Rap1 as well as GPIIbIIIa activation. P2Y(12) receptor inhibitors clinically in use such as clopidogrel are postulated to decrease platelet aggregation through partial inhibition of PAR1 signaling. Our data, however, indicate that at high local concentrations of thrombin, it is the signaling through PAR4 rather than PAR1 that may be regulated through purinergic feedback. Thus, our data identify an intra-platelet mechanism that may function as a future site for therapeutic intervention.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60608 USA	Vanderbilt University; Vanderbilt University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hamm, HE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 23rd Ave S & Pierce,442 Robinson Res Bldg, Nashville, TN 37232 USA.	heidi.hamm@vanderbilt.edu	Hamm, Heidi E/G-2374-2014		NATIONAL EYE INSTITUTE [R01EY010291] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL082068, T32HL076133, R01HL084388] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010291, EY010291] Funding Source: Medline; NHLBI NIH HHS [HL-082068-01, T32 HL076133, HL-076133-02, HL084388, F32 HL082068-01, R01 HL084388, F32 HL082068] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam F, 2003, J THROMB HAEMOST, V1, P798, DOI 10.1046/j.1538-7836.2003.00138.x; Ali A, 2004, J CLIN PHARMACOL, V44, P1328, DOI 10.1177/0091270004269559; Bernardi B, 2006, BLOOD, V107, P2728, DOI 10.1182/blood-2005-07-3023; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Boekholdt SM, 2004, AM HEART J, V147, P181, DOI 10.1016/j.ahj.2003.07.008; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Crittenden JR, 2004, NAT MED, V10, P982, DOI 10.1038/nm1098; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; Dorsam RT, 2004, J THROMB HAEMOST, V2, P804, DOI 10.1111/j.1538-7836.2004.00692.x; Dorsam RT, 2004, J CLIN INVEST, V113, P340, DOI 10.1172/JCI200420986; Espana F., 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P119, DOI 10.2174/1568016053544336; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Graff J, 2004, THROMB RES, V113, P295, DOI 10.1016/j.thromres.2004.03.014; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jamieson GA, 1997, THROMB HAEMOSTASIS, V78, P242; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; LAPOSATA M, 1983, BLOOD, V62, P549; Larson MK, 2003, BLOOD, V101, P1409, DOI 10.1182/blood-2002-05-1533; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maroo A, 2004, SEMIN THROMB HEMOST, V30, P329, DOI 10.1055/s-2004-831045; Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x; Murugappan S, 2005, BLOOD, V106, P550, DOI 10.1182/blood-2004-12-4866; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Reed GL, 2004, SEMIN THROMB HEMOST, V30, P441, DOI 10.1055/s-2004-833479; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; Scase TJ, 1997, BLOOD, V90, P2113, DOI 10.1182/blood.V90.5.2113; Schultess J, 2005, BLOOD, V105, P3185, DOI 10.1182/blood-2004-09-3605; SHATTIL SJ, 1987, BLOOD, V70, P307; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Tendera M, 2003, THROMB RES, V110, P355, DOI 10.1016/j.thromres.2003.08.003; van der Meijden PEJ, 2005, THROMB HAEMOSTASIS, V93, P1128, DOI 10.1160/TH04-09-0597; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Yusuf S, 2001, NEW ENGL J MED, V345, P494	49	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26665	26674		10.1074/jbc.M602174200	http://dx.doi.org/10.1074/jbc.M602174200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837456	Green Accepted, hybrid			2022-12-27	WOS:000240249500084
J	Ochotny, N; Van Vliet, A; Chan, N; Yao, YQ; Morel, M; Kartner, N; von Schroeder, HP; Heersche, JNM; Manolson, MF				Ochotny, Noelle; Van Vliet, Aaron; Chan, Nelson; Yao, Yeqi; Morel, Mario; Kartner, Norbert; von Schroeder, Herbert P.; Heersche, Johan N. M.; Manolson, Morris F.			Effects of human a3 and a4 mutations that result in osteopetrosis and distal renal tubular acidosis on yeast V-ATPase expression and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; INFANTILE MALIGNANT OSTEOPETROSIS; AUTOSOMAL RECESSIVE OSTEOPETROSIS; AMINO-TERMINAL DOMAIN; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; SUBUNIT VPH1P; GENE ENCODES; IN-VIVO	V-ATPases are multimeric proton pumps. The 100-kDa " a" subunit is encoded by four isoforms (a1-a4) in mammals and two (Vph1p and Stv1p) in yeast. a3 is enriched in osteoclasts and is essential for bone resorption, whereas a4 is expressed in the distal nephron and acidifies urine. Mutations in human a3 and a4 result in osteopetrosis and distal renal tubular acidosis, respectively. Human a3 (G405R and R444L) and a4 (P524L and G820R) mutations were recreated in the yeast ortholog Vph1p, a3 (G424R and R462L), and a4 (W520L and G812R). Mutations in a3 resulted in wild type vacuolar acidification and growth on media containing 4 mM ZnCl2, 200 mM CaCl2, or buffered to pH 7.5 with V-ATPase hydrolytic and pumping activity decreased by 30-35%. Immunoblots confirmed wild type levels for V-ATPase a, A, and B subunits on vacuolar membranes. a4 G812R resulted in defective growth on selective media with V-ATPase hydrolytic and pumping activity decreased by 83-85% yet with wild type levels of a, A, and B subunits on vacuolar membranes. The a4 W520L mutation had defective growth on selective media with no detectable V-ATPase activity and reduced expression of a, A, and B subunits. The a4 W520L mutation phenotypes were dominant negative, as overexpression of wild type yeast a isoforms, Vph1p, or Stv1p, did not restore growth. However, deletion of endoplasmic reticulum assembly factors (Vma12p, Vma21p, and Vma22p) partially restored a and B expression. That a4 W520L affects both V-o and V-1 subunits is a unique phenotype for any V-ATPase subunit mutation and supports the concerted pathway for V-ATPase assembly in vivo.	Univ Toronto, Fac Dent, Res Inst, Toronto, ON M5G 1G6, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5G 1G6, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 1G6, Canada	University of Toronto; University of Toronto; University of Toronto	Manolson, MF (corresponding author), Univ Toronto, Fac Dent, Res Inst, 124 Edward St, Toronto, ON M5G 1G6, Canada.	m.manolson@utoronto.ca	Ochotny, Noelle/M-6480-2019; von Schroeder, Herbert/AAA-3592-2020	Ochotny, Noelle/0000-0001-7697-4360; Manolson, Morris/0000-0001-8755-5460				BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Brisseau GF, 1996, J BIOL CHEM, V271, P2005, DOI 10.1074/jbc.271.4.2005; Brown D, 2000, J EXP BIOL, V203, P137; Clarke M, 2002, J CELL SCI, V115, P2893; Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673; Fasth A, 1999, Pediatr Transplant, V3 Suppl 1, P102; FORGAC M, 1992, J EXP BIOL, V172, P155; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HO MN, 1993, J BIOL CHEM, V268, P18286; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jackson DD, 1997, J BIOL CHEM, V272, P25928, DOI 10.1074/jbc.272.41.25928; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; Manolson MF, 2003, J BIOL CHEM, V278, P49271, DOI 10.1074/jbc.M309914200; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Michigami T, 2002, BONE, V30, P436, DOI 10.1016/S8756-3282(01)00684-6; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Ruf R, 2003, PEDIATR NEPHROL, V18, P105, DOI 10.1007/s00467-002-1018-8; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; Stehberger PA, 2003, J AM SOC NEPHROL, V14, P3027, DOI 10.1097/01.ASN.0000099375.74789.AB; Stover EH, 2002, J MED GENET, V39, P796, DOI 10.1136/jmg.39.11.796; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; Susani L, 2004, HUM MUTAT, V24, P225, DOI 10.1002/humu.20076; Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002-9440(10)63798-4; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Whyteside G, 2005, FEBS LETT, V579, P2981, DOI 10.1016/j.febslet.2005.04.049; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909	61	25	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26102	26111		10.1074/jbc.M601118200	http://dx.doi.org/10.1074/jbc.M601118200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840787	hybrid			2022-12-27	WOS:000240249500025
J	Braun, RJ; Zischka, H; Madeo, F; Eisenberg, T; Wissing, S; Buttner, S; Engelhardt, SM; Buringer, D; Ueffing, M				Braun, Ralf J.; Zischka, Hans; Madeo, Frank; Eisenberg, Tobias; Wissing, Silke; Buettner, Sabrina; Engelhardt, Silvia M.; Bueringer, Dietmute; Ueffing, Marius			Crucial mitochondrial impairment upon CDC48 mutation in apoptotic yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALOSIN-CONTAINING PROTEIN; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; FRONTOTEMPORAL DEMENTIA; POLYACRYLAMIDE-GELS; ACTIN CYTOSKELETON; OXIDATIVE STRESS; ER	Mutation in CDC48 (cdc48(S565G)), a gene essential in the endoplasmic reticulum (ER)-associated protein degradation (ERAD) pathway, led to the discovery of apoptosis as a mechanism of cell death in the unicellular organism Saccharomyces cerevisiae. Elucidating Cdc48p-mediated apoptosis in yeast is of particular interest, because Cdc48p is the highly conserved yeast orthologue of human valosin-containing protein (VCP), a pathological effector for polyglutamine disorders and myopathies. Here we show distinct proteomic alterations in mitochondria in the cdc48S565G yeast strain. These observed molecular alterations can be related to functional impairment of these organelles as suggested by respiratory deficiency of cdc48S565G cells. Mitochondrial dysfunction in the cdc48S565G strain is accompanied by structural damage of mitochondria indicated by the accumulation of cytochrome c in the cytosol and mitochondrial enlargement. We demonstrate accumulation of reactive oxygen species produced predominantly by the cytochrome bc(1) complex of the mitochondrial respiratory chain as suggested by the use of inhibitors of this complex. Concomitantly, emergence of caspase-like enzymatic activity occurs suggesting a role for caspases in the cell death process. These data strongly point for the first time to a mitochondrial involvement in Cdc48p/VCP-dependent apoptosis.	GSF, Natl Res Ctr Environm & Hlth, Inst Human Genet, D-85764 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Toxicol, D-85764 Munich, Germany; Graz Univ, Inst Mol Biosci, A-8010 Graz, Austria; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany; Max Planck Inst Neurobiol, Dept Syst & Computat Neurobiol, D-82152 Martinsried, Germany; Tech Univ Munich, Inst Human Genet, Klinikum Rechts Isar, D-81675 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Graz; Eberhard Karls University of Tubingen; Max Planck Society; Technical University of Munich	Zischka, H (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Human Genet, Ingolstaedter Landstr 1, D-85764 Munich, Germany.	zischka@gsf.de	Eisenberg, Tobias/AAV-7806-2021; Braun, Ralf/B-9123-2008; Zischka, Hans/M-1490-2017	Braun, Ralf/0000-0003-4234-8163; Zischka, Hans/0000-0002-4047-1566; Madeo, Frank/0000-0002-5070-1329; Eisenberg, Tobias/0000-0003-3559-1130; Buttner, Sabrina/0000-0002-2786-8542				Arevalo-Rodriguez M, 2004, FRONT BIOSCI-LANDMRK, V9, P2420, DOI 10.2741/1405; Barros MH, 2003, FREE RADICAL BIO MED, V35, P179, DOI 10.1016/S0891-5849(03)00307-1; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Breitenbach M, 2005, TRENDS CELL BIOL, V15, P637, DOI 10.1016/j.tcb.2005.09.011; BYERS B, 1991, GUIDE YEAST GENETICS, P603; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Drakulic T, 2005, FEMS YEAST RES, V5, P1215, DOI 10.1016/j.femsyr.2005.06.001; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Fang J, 2003, FREE RADICAL BIO MED, V34, P478, DOI 10.1016/S0891-5849(02)01328-X; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Imamura S, 2003, FEBS LETT, V549, P14, DOI 10.1016/S0014-5793(03)00723-3; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kussmann M, 2000, METH MOL B, V146, P405, DOI 10.1385/1-59259-045-4:405; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; Laun P, 2005, FEMS YEAST RES, V5, P1261, DOI 10.1016/j.femsyr.2005.07.006; Ludovico P, 2005, IUBMB LIFE, V57, P129, DOI 10.1080/15216540500090553; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Madeo F, 1997, GENE, V204, P145, DOI 10.1016/S0378-1119(97)00535-0; Madeo F, 2004, CURR OPIN MICROBIOL, V7, P655, DOI 10.1016/j.mib.2004.10.012; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Miyake T, 1999, YEAST, V15, P1449, DOI 10.1002/(SICI)1097-0061(199910)15:14<1449::AID-YEA469>3.0.CO;2-S; Mizuno Y, 2003, NEUROSCI LETT, V343, P77, DOI 10.1016/S0304-3940(03)00280-5; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicchitta CV, 2002, CURR OPIN CELL BIOL, V14, P412, DOI 10.1016/S0955-0674(02)00353-8; OGUR M, 1956, J BACTERIOL, V72, P500, DOI 10.1128/JB.72.4.500-504.1956; Oxelmark E, 2000, MOL CELL BIOL, V20, P7784, DOI 10.1128/MCB.20.20.7784-7797.2000; Pozniakovsky AI, 2005, J CELL BIOL, V168, P257, DOI 10.1083/jcb.200408145; Rabilloud T, 2001, PROTEOMICS, V1, P699, DOI 10.1002/1615-9861(200104)1:5<699::AID-PROT699>3.3.CO;2-3; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Rinnerthaler M, 2006, BBA-BIOENERGETICS, V1757, P631, DOI 10.1016/j.bbabio.2006.05.022; RUOHOLA H, 1987, P NATL ACAD SCI USA, V84, P8468, DOI 10.1073/pnas.84.23.8468; Schroder R, 2005, ANN NEUROL, V57, P457, DOI 10.1002/ana.20407; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Wakabayashi T, 1999, ACTA BIOCHIM POL, V46, P223, DOI 10.18388/abp.1999_4156; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Weinberger M, 2003, IUBMB LIFE, V55, P467, DOI 10.1080/15216540310001612336; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; ZELENAYATROITSKAYA O, 1995, EMBO J, V14, P3268, DOI 10.1002/j.1460-2075.1995.tb07330.x; Zischka H, 2003, PROTEOMICS, V3, P906, DOI 10.1002/pmic.200300376	57	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25757	25767		10.1074/jbc.M513699200	http://dx.doi.org/10.1074/jbc.M513699200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16822868	hybrid			2022-12-27	WOS:000240031300078
J	Helle, F; Wychowski, C; Vu-Dac, N; Gustafson, KR; Voisset, C; Dubuisson, J				Helle, Francois; Wychowski, Czeslaw; Vu-Dac, Ngoc; Gustafson, Kirk R.; Voisset, Cecile; Dubuisson, Jean			Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; INACTIVATING PROTEIN; GLYCOPROTEIN E2; PSEUDOTYPE PARTICLES; CELL-CULTURE; GP120; HIV; GLYCOSYLATION; LOCALIZATION; COMPLEXES	Inhibition of viruses at the stage of viral entry provides a route for therapeutic intervention. Because of difficulties in propagating hepatitis C virus (HCV) in cell culture, entry inhibitors have not yet been reported for this virus. However, with the development of retroviral particles pseudotyped with HCV envelope glycoproteins (HCVpp) and the recent progress in amplification of HCV in cell culture (HCVcc), studying HCV entry is now possible. In addition, these systems are essential for the identification and the characterization of molecules that block HCV entry. The lectin cyanovirin-N (CV-N) has initially been discovered based on its potent activity against human immunodeficiency virus. Because HCV envelope glycoproteins are highly glycosylated, we sought to determine whether CV-N has an antiviral activity against this virus. CV-N inhibited the infectivity of HCVcc and HCVpp at low nanomolar concentrations. This inhibition is attributed to the interaction of CV-N with HCV envelope glycoproteins. In addition, we showed that the carbohydrate binding property of CV-N is involved in the anti-HCV activity. Finally, CV-N bound to HCV envelope glycoproteins and blocked the interaction between the envelope protein E2 and CD81, a cell surface molecule involved in HCV entry. These data demonstrate that targeting the glycans of HCV envelope proteins is a promising approach in the development of antiviral therapies to combat a virus that is a major cause of chronic liver diseases. Furthermore, CV-N is a new invaluable tool to further dissect the early steps of HCV entry into host cells.	Inst Pasteur, Ctr Natl Rech Sci, Inst Biol, Unite Mixt Rech 8161,Hepatitis C Lab,UMR8161, F-59021 Lille, France; NCI, Mol Targets Dev Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dubuisson, J (corresponding author), Inst Pasteur, Ctr Natl Rech Sci, Inst Biol, Unite Mixt Rech 8161,Hepatitis C Lab,UMR8161, 1 Rue Calmette,BP447, F-59021 Lille, France.	jean.dubuisson@ibl.fr	Voisset, Cecile/AAK-1636-2020; HELLE, Francois/G-7427-2011; Dubuisson, Jean/E-6813-2016	HELLE, Francois/0000-0001-6884-2456; Voisset, Cecile/0000-0001-7505-1927; Dubuisson, Jean/0000-0003-1626-7693				Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200; Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3; Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e; Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949, DOI 10.1124/mol.59.5.949; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Ciczora Y, 2005, J GEN VIROL, V86, P2793, DOI 10.1099/vir.0.81140-0; Cocquerel L, 2006, J GEN VIROL, V87, P1075, DOI 10.1099/vir.0.81646-0; Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629; De Beeck AO, 2004, J VIROL, V78, P2994, DOI 10.1128/JVI.78.6.2994-3002.2004; De Francesco R, 2005, NATURE, V436, P953, DOI 10.1038/nature04080; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082; Flint M, 2004, J VIROL, V78, P6875, DOI 10.1128/JVI.78.13.6875-6882.2004; Flint M, 2000, J VIROL, V74, P702, DOI 10.1128/JVI.74.2.702-709.2000; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Goffard A, 2005, J VIROL, V79, P8400, DOI 10.1128/JVI.79.13.8400-8409.2005; Goffard A, 2003, BIOCHIMIE, V85, P295, DOI 10.1016/S0300-9084(03)00004-X; Heile JM, 2000, J VIROL, V74, P6885, DOI 10.1128/JVI.74.15.6885-6892.2000; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Lavillette D, 2005, HEPATOLOGY, V41, P265, DOI 10.1002/hep.20542; Lindenbach B.D., 2020, FIELDS VIROLOGY, V7, P246; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200; MAJOR ME, 2001, FIELDS VIROLOGY; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; Mori T, 2002, PROTEIN EXPRES PURIF, V26, P42, DOI 10.1016/S1046-5928(02)00513-2; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; O'Keefe BR, 2000, MOL PHARMACOL, V58, P982, DOI 10.1124/mol.58.5.982; O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003; Pawlotsky Jean-Michel, 2003, Clin Liver Dis, V7, P45, DOI 10.1016/S1089-3261(02)00065-X; Pawlotsky JM, 2006, HEPATOLOGY, V43, pS207, DOI 10.1002/hep.21064; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Rouille Y, 2006, J VIROL, V80, P2832, DOI 10.1128/JVI.80.6.2832-2841.2006; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5; Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005; Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	48	139	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25177	25183		10.1074/jbc.M602431200	http://dx.doi.org/10.1074/jbc.M602431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16809348	hybrid			2022-12-27	WOS:000240031300018
J	Hobe, S; Trostmann, I; Raunser, S; Paulsen, H				Hobe, Stephan; Trostmann, Inga; Raunser, Stefan; Paulsen, Harald			Assembly of the major light-harvesting chlorophyll-a/b complex - Thermodynamics and kinetics of neoxanthin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; ABSCISIC-ACID; IN-VITRO; PROTEIN COMPLEX; FLUORESCENCE; XANTHOPHYLLS; CAROTENOIDS; ARABIDOPSIS; SITES; PHOTOPROTECTION	The major light-harvesting chlorophyll-a/b complex in most higher plants contains three carotenoids, lutein, neoxanthin, and violaxanthin. How these pigments are assembled into the complex during its biogenesis is largely unknown. Here we show that neoxanthin but not lutein can dissociate from the fully assembled complex. Its equilibrium binding constant in a detergent system (0.1% n-dodecyl-beta-D-maltoside) was determined to be >= 106 M-1. Neoxanthin insertion into light-harvesting chlorophyll-a/b complex prefolded from overexpressed apoprotein (Lhcb1*2 from Pisum sativum) in the presence of chlorophylls a, b, and lutein as the sole carotenoid is kinetically controlled by an activation energy barrier of similar to 120 kJ mol(-1). This is the first thermodynamic and kinetic description of a binding equilibrium between a non-covalently bound pigment of the photosynthetic apparatus and its protein complex. Dissociation of neoxanthin from the major light-harvesting chlorophyll-a/b complex upon temperature increase is discussed in terms of providing a readily available substrate pool for synthesizing abscisic acid as part of a heat and drought stress response.	Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Johannes Gutenberg University of Mainz; Harvard University; Harvard Medical School	Paulsen, H (corresponding author), Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, Mullerweg 6, D-55099 Mainz, Germany.	paulsen@uni-mainz.de	Raunser, Stefan/AHE-1573-2022; Paulsen, Harald/D-3742-2011	Raunser, Stefan/0000-0001-9373-3016				Adamska I, 2001, J BIOL CHEM, V276, P8582, DOI 10.1074/jbc.M010447200; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; Booth PJ, 1996, BIOCHEMISTRY-US, V35, P5103, DOI 10.1021/bi953053f; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Cseh Z, 2000, BIOCHEMISTRY-US, V39, P15250, DOI 10.1021/bi001600d; Cutler AJ, 1999, TRENDS PLANT SCI, V4, P472, DOI 10.1016/S1360-1385(99)01497-1; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; DREYFUSS BW, 1994, PLANT PHYSIOL, V106, P829, DOI 10.1104/pp.106.3.829; EUGSTER CH, 1995, CAROTENOIDS; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; Holt NE, 2004, BIOCHEMISTRY-US, V43, P8281, DOI 10.1021/bi0494020; Horn R, 2004, J BIOL CHEM, V279, P44400, DOI 10.1074/jbc.M407188200; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071; KRUPA Z, 1987, PLANT PHYSIOL, V84, P19, DOI 10.1104/pp.84.1.19; LINDAHL M, 1995, EUR J BIOCHEM, V231, P503, DOI 10.1111/j.1432-1033.1995.tb20725.x; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Lokstein H, 2002, BBA-BIOENERGETICS, V1553, P309, DOI 10.1016/S0005-2728(02)00184-6; MARTINSON TA, 1995, ANAL BIOCHEM, V228, P123, DOI 10.1006/abio.1995.1323; Mercadante AZ, 1998, J AGR FOOD CHEM, V46, P128, DOI 10.1021/jf9702860; Mick V, 2004, BIOCHEMISTRY-US, V43, P5467, DOI 10.1021/bi036198s; Milborrow BV, 2001, J EXP BOT, V52, P1145, DOI 10.1093/jexbot/52.359.1145; MOLNAR P, 1980, PHYTOCHEMISTRY, V19, P623, DOI 10.1016/0031-9422(80)87027-0; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Niyogi KK, 2001, PHOTOSYNTH RES, V67, P139, DOI 10.1023/A:1010661102365; Palacios MA, 2004, BBA-BIOENERGETICS, V1656, P177, DOI 10.1016/j.bbabio.2004.04.002; PARRY AD, 1991, PHYTOCHEMISTRY, V30, P815, DOI 10.1016/0031-9422(91)85258-2; PARRY AD, 1990, PLANTA, V182, P118, DOI 10.1007/BF00239993; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Phillip D, 2002, J BIOL CHEM, V277, P25160, DOI 10.1074/jbc.M202002200; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Reinsberg D, 2001, J MOL BIOL, V308, P59, DOI 10.1006/jmbi.2001.4573; Rodrigo MJ, 2006, J EXP BOT, V57, P633, DOI 10.1093/jxb/erj048; Rogl H, 1998, FEBS LETT, V432, P21, DOI 10.1016/S0014-5793(98)00825-4; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Schwartz SH, 2003, BBA-GEN SUBJECTS, V1619, P9, DOI 10.1016/S0304-4165(02)00422-1; Snyder AM, 2004, J BIOL CHEM, V279, P5162, DOI 10.1074/jbc.M309676200; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; Strand A, 2000, BIOCHEM SYST ECOL, V28, P443, DOI 10.1016/S0305-1978(99)00078-2; Takaichi S, 1998, PLANT CELL PHYSIOL, V39, P968, DOI 10.1093/oxfordjournals.pcp.a029461; Tardy F, 1996, J PHOTOCH PHOTOBIO B, V34, P87, DOI 10.1016/1011-1344(95)07272-1; Yang CH, 2003, BIOCHEMISTRY-US, V42, P4527, DOI 10.1021/bi0273157; Yang DH, 2000, FEBS LETT, V466, P385, DOI 10.1016/S0014-5793(00)01107-8	54	26	29	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25156	25166		10.1074/jbc.M604828200	http://dx.doi.org/10.1074/jbc.M604828200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803876	hybrid			2022-12-27	WOS:000240031300016
J	Lammerding, J; Fong, LG; Ji, JY; Reue, K; Stewart, CL; Young, SG; Lee, RT				Lammerding, Jan; Fong, Loren G.; Ji, Julie Y.; Reue, Karen; Stewart, Colin L.; Young, Stephen G.; Lee, Richard T.			Lamins A and C but not lamin B1 regulate nuclear mechanics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; GILFORD-PROGERIA-SYNDROME; DILATED CARDIOMYOPATHY; BUILDING-BLOCKS; HUMAN-DISEASE; PRELAMIN-A; ENVELOPE; CELLS; LAMINOPATHIES; MUTATIONS	Mutations in the nuclear envelope proteins lamins A and C cause a broad variety of human diseases, including Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy, and Hutchinson-Gilford progeria syndrome. Cells lacking lamins A and C have reduced nuclear stiffness and increased nuclear fragility, leading to increased cell death under mechanical strain and suggesting a potential mechanism for disease. Here, we investigated the contribution of major lamin subtypes (lamins A, C, and B1) to nuclear mechanics by analyzing nuclear shape, nuclear dynamics over time, nuclear deformations under strain, and cell viability under prolonged mechanical stimulation in cells lacking both lamins A and C, cells lacking only lamin A (i.e. "lamin C-only" cells), cells lacking wild-type lamin B1, and wild-type cells. Lamin A/C-deficient cells exhibited increased numbers of misshapen nuclei and had severely reduced nuclear stiffness and decreased cell viability under strain. Lamin C-only cells had slightly abnormal nuclear shape and mildly reduced nuclear stiffness but no decrease in cell viability under strain. Interestingly, lamin B1-deficient cells exhibited normal nuclear mechanics despite having a significantly increased frequency of nuclear blebs. Our study indicates that lamins A and C are important contributors to the mechanical stiffness of nuclei, whereas lamin B1 contributes to nuclear integrity but not stiffness.	Harvard Univ, Sch Med, Div Cardiovasc, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02139 USA; Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angelese Healthcare Syst, Los Angeles, CA 90073 USA; NCI, Canc & Dev Biol Lab, Frederick, MD 21702 USA	Harvard University; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lammerding, J (corresponding author), Partners Res Facil, Rm 283,65 Landsdowne St, Cambridge, MA 02139 USA.	jlammerding@rics.bwh.harvard.edu	Lammerding, Jan/A-9498-2016	Lammerding, Jan/0000-0003-4335-8611; Young, Stephen/0000-0001-7270-3176	NATIONAL CANCER INSTITUTE [R01CA099506, Z01BC010377] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082792, P01HL064858, R01HL073809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER; NCI NIH HHS [CA099506] Funding Source: Medline; NHLBI NIH HHS [HL073809, HL64858, R01 HL082792] Funding Source: Medline; NIAID NIH HHS [AI05438] Funding Source: Medline; NIAMS NIH HHS [AR050200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arimura T, 2005, HUM MOL GENET, V14, P155, DOI 10.1093/hmg/ddi017; Broers JLV, 2005, EXP CELL RES, V304, P582, DOI 10.1016/j.yexcr.2004.11.020; Broers JLV, 2004, J PATHOL, V204, P478, DOI 10.1002/path.1655; Broers JLV, 2004, HUM MOL GENET, V13, P2567, DOI 10.1093/hmg/ddh295; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Delbarre E, 2006, HUM MOL GENET, V15, P1113, DOI 10.1093/hmg/ddl026; DIAZ G, 1989, COMPUT BIOMED RES, V22, P405, DOI 10.1016/0010-4809(89)90034-7; Fidzianska A, 2003, J NEUROL SCI, V210, P47, DOI 10.1016/S0022-510X(03)00012-1; Fidzianska A, 1998, J NEUROL SCI, V159, P88, DOI 10.1016/S0022-510X(98)00130-0; Fong LG, 2004, P NATL ACAD SCI USA, V101, P18111, DOI 10.1073/pnas.0408558102; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; GEORGATOS SD, 1988, P NATL ACAD SCI USA, V85, P4325, DOI 10.1073/pnas.85.12.4325; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Harborth J, 2001, J CELL SCI, V114, P4557; Hutchison CJ, 2004, NAT CELL BIOL, V6, P1062, DOI 10.1038/ncb1104-1062; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; Lammerding J, 2005, J CELL BIOL, V170, P781, DOI 10.1083/jcb.200502148; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Melcon G, 2006, HUM MOL GENET, V15, P637, DOI 10.1093/hmg/ddi479; Motsch I, 2005, EUR J CELL BIOL, V84, P765, DOI 10.1016/j.ejcb.2005.04.004; Muchir A, 2004, PHYSIOLOGY, V19, P309, DOI 10.1152/physiol.00022.2004; Niebroj-Dobosz I, 2003, Acta Myol, V22, P52; Nikolova V, 2004, J CLIN INVEST, V113, P357, DOI 10.1172/JCI200419448; Ostlund C, 2006, BIOCHEMISTRY-US, V45, P1374, DOI 10.1021/bi052156n; Pugh GE, 1997, J CELL SCI, V110, P2483; Raharjo WH, 2001, J CELL SCI, V114, P4447; Schirmer EC, 2004, J BIOL CHEM, V279, P42811, DOI 10.1074/jbc.M407705200; Schutz W, 2005, EUR J CELL BIOL, V84, P649, DOI 10.1016/j.ejcb.2005.03.001; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Tsai MY, 2006, SCIENCE, V311, P1887, DOI 10.1126/science.1122771; Vaughan OA, 2001, J CELL SCI, V114, P2577; Vergnes L, 2004, P NATL ACAD SCI USA, V101, P10428, DOI 10.1073/pnas.0401424101; Vigouroux C, 2001, J CELL SCI, V114, P4459; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7; YE QA, 1995, EXP CELL RES, V219, P292, DOI 10.1006/excr.1995.1230; Zastrow MS, 2004, J CELL SCI, V117, P979, DOI 10.1242/jcs.01102	42	446	452	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25768	25780		10.1074/jbc.M513511200	http://dx.doi.org/10.1074/jbc.M513511200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825190	hybrid			2022-12-27	WOS:000240031300079
J	Patel, M; Siegel, AJ; Berry, JO				Patel, Minesh; Siegel, Alan J.; Berry, James O.			Untranslated regions of FbRbcS1 mRNA mediate bundle sheath cell-specific gene expression in leaves of a C-4 plant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLASE SMALL-SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; PHOSPHOENOLPYRUVATE CARBOXYLASE; POSTTRANSCRIPTIONAL CONTROL; AMARANTH COTYLEDONS; PHOTOSYNTHESIS; PROMOTER; TOMATO; MAIZE; MESOPHYLL	C-4 photosynthesis typically requires two specialized leaf cell types, bundle sheath (bs) and mesophyll (mp), which provide the foundation for this highly efficient carbon assimilation pathway. In leaves of Flaveria bidentis, a dicotyledonous C-4 plant, ribulose 1,5-bisphosphate carboxylase (rubisco) accumulates only in bs cells surrounding the vascular centers and not in mp cells. This is in contrast to the more common C-3 plants, which accumulate rubisco in all photosynthetic cells. Many previous studies have focused on transcriptional control of C-4 cell type-specificity; however, post-transcriptional regulation has also been implicated in the bs-specific expression of genes encoding the rubisco subunits. In this current study, a biolistic leaf transformation assay has provided direct evidence that the 5 '- and 3 '-untranslated regions (UTRs) of F. bidentis FbRbcS1 mRNA ( from a nuclear gene encoding the rubisco small subunit), in themselves, confer strong bs cell-specific expression to gfpA reporter gene transcripts when transcribed from a constitutive CaMV promoter. In transformed leaf regions, strong bs cell-specific GFP expression was accompanied by corresponding bs cell-specific accumulation of the constitutively transcribed FbRbcS1 5 '-UTR-gfpA-3 '-UTR mRNAs. Control constructs lacking any RbcS mRNA sequences were expressed in all leaf cell types. These findings demonstrate that characteristic cell type-specific FbRbcS1 expression patterns in C-4 leaves can be established entirely by sequences contained within the transcribed UTRs of FbRbcS1 mRNAs. We conclude that selective transcript stabilization (in bs cells) or degradation (in mp cells) plays a key role in determining bs cell-specific localization of the rubisco enzyme.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Berry, JO (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.	camjob@buffalo.edu						BANSAL KC, 1992, P NATL ACAD SCI USA, V89, P3654, DOI 10.1073/pnas.89.8.3654; Berger S, 2004, PHYSIOL PLANTARUM, V122, P419, DOI 10.1111/j.1399-3054.2004.00433.x; BERRY JO, 1990, PLANT CELL, V2, P795, DOI 10.1105/tpc.2.8.795; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; BOINSKI JJ, 1993, PLANT MOL BIOL, V22, P397, DOI 10.1007/BF00015971; Brown NJ, 2005, TRENDS PLANT SCI, V10, P215, DOI 10.1016/j.tplants.2005.03.003; Cheng SH, 1998, PLANT PHYSIOL, V116, P715, DOI 10.1104/pp.116.2.715; Cheng YL, 2004, CURR OPIN PLANT BIOL, V7, P20, DOI 10.1016/j.pbi.2003.11.005; Curie C, 1997, PLANT CELL, V9, P2025; Edwards GE, 2001, J EXP BOT, V52, P577, DOI 10.1093/jexbot/52.356.577; Ehleringer JR, 1997, OECOLOGIA, V112, P285, DOI 10.1007/s004420050311; Fedoroff NV, 2002, CURR OPIN PLANT BIOL, V5, P452, DOI 10.1016/S1369-5266(02)00280-7; FURBANK RT, 1995, PLANT CELL, V7, P797, DOI 10.2307/3870037; FURBANK RT, 2000, ADV PHOTOSYNTHESIS P, P459; Gowik U, 2004, PLANT CELL, V16, P1077, DOI 10.1105/tpc.019729; GREEN PJ, 1993, PLANT PHYSIOL, V102, P1065, DOI 10.1104/pp.102.4.1065; Gutierrez RA, 2002, P NATL ACAD SCI USA, V99, P11513, DOI 10.1073/pnas.152204099; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; He XY, 2002, NUCLEIC ACIDS RES, V30, P497, DOI 10.1093/nar/30.2.497; HENSEL LL, 1993, PLANT CELL, V5, P553, DOI 10.1105/tpc.5.5.553; Hu WW, 2005, PLANT PHYSIOL, V138, P276, DOI 10.1104/pp.104.056770; JIANG CZ, 1993, PLANT PHYSIOL, V101, P105, DOI 10.1104/pp.101.1.105; Kanai R., 1999, C4 PLANT BIOL, P49, DOI [10.5860/choice.36-6275, DOI 10.5860/CHOICE.36-6275, DOI 10.1016/B978-012614440-6/50004-5]; LANGDALE JA, 1991, MOL GEN GENET, V225, P49, DOI 10.1007/BF00282641; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Long JJ, 1996, PLANT PHYSIOL, V112, P473, DOI 10.1104/pp.112.2.473; McCormac D, 1997, PLANT PHYSIOL, V114, P801, DOI 10.1104/pp.114.3.801; Nomura M, 2000, PLANT J, V22, P211, DOI 10.1046/j.1365-313x.2000.00726.x; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Patel M, 2004, PLANT PHYSIOL, V136, P3550, DOI 10.1104/pp.104.051508; Ramsperger VC, 1996, PLANT PHYSIOL, V111, P999, DOI 10.1104/pp.111.4.999; Rodermel S, 1996, P NATL ACAD SCI USA, V93, P3881, DOI 10.1073/pnas.93.9.3881; Sage RF, 2004, NEW PHYTOL, V161, P341, DOI 10.1111/j.1469-8137.2004.00974.x; SEELEY KA, 1992, PLANT CELL, V4, P29, DOI 10.1105/tpc.4.1.29; Sheen J, 1999, ANNU REV PLANT PHYS, V50, P187, DOI 10.1146/annurev.arplant.50.1.187; SHIRLEY BW, 1990, NUCLEIC ACIDS RES, V18, P3377, DOI 10.1093/nar/18.11.3377; Sinha AK, 2002, PLANT PHYSIOL, V128, P1480, DOI 10.1104/pp.010771; Staton JM, 2000, J MOL ENDOCRINOL, V25, P17, DOI 10.1677/jme.0.0250017; THOMPSON DM, 1990, NUCLEIC ACIDS RES, V18, P3621, DOI 10.1093/nar/18.12.3621; VIRET JF, 1994, P NATL ACAD SCI USA, V91, P8577, DOI 10.1073/pnas.91.18.8577; von Caemmerer S, 2003, PHOTOSYNTH RES, V77, P191, DOI 10.1023/A:1025830019591; WANG JL, 1992, PLANT CELL, V4, P173, DOI 10.1105/tpc.4.2.173; WANG JL, 1993, PLANT PHYSIOL, V102, P1085, DOI 10.1104/pp.102.4.1085; WANG JL, 1993, PLANT CELL, V5, P289, DOI 10.1105/tpc.5.3.289; WANNER LA, 1991, PLANT CELL, V3, P1289, DOI 10.1105/tpc.3.12.1289; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Zhou JL, 2001, PLANT CELL PHYSIOL, V42, P1049, DOI 10.1093/pcp/pce131; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	48	34	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25485	25491		10.1074/jbc.M604162200	http://dx.doi.org/10.1074/jbc.M604162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803877	hybrid			2022-12-27	WOS:000240031300051
J	Ricard-Blum, S; Beraud, M; Raynal, N; Farndale, RW; Ruggiero, F				Ricard-Blum, Sylvie; Beraud, Mickael; Raynal, Nicolas; Farndale, Richard W.; Ruggiero, Florence			Structural requirements for heparin/heparan sulfate binding to type V collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; HEPARIN-COFACTOR-II; GLYCOSAMINOGLYCAN INTERACTIONS; PROTEIN INTERACTIONS; DIVALENT-CATIONS; PEPTIDE MODELS; CELL-ADHESION; PROTEOGLYCANS; SITES; MECHANISM	Collagen-proteoglycan interactions participate in the regulation of matrix assembly and in cell-matrix interactions. We reported previously that a fragment (Ile824-Pro950) of the collagen alpha 1(V) chain, HepV, binds to heparin via a cluster of three major basic residues, Arg(912), Arg(918), and Arg(921), and two additional residues, Lys(905) and Arg(909) (Delacoux, F., Fichard, A., Cogne, S., Garrone, R., and Ruggiero, F. ( 2000) J. Biol. Chem. 275, 29377-29382). Here, we further characterized the binding of HepV and collagen V to heparin and heparan sulfate by surface plasmon resonance assays. HepV bound heparin and heparan sulfate with a similar affinity (K-D similar to 18 and 36 nM, respectively) in a cation-dependent manner, and 2-O-sulfation of heparin was shown to be crucial for the binding. An octasaccharide of heparin and a decasaccharide of heparan sulfate were required for HepV binding. Studies with HepV mutants showed that the same basic residues were involved in the binding to heparin, to heparan sulfate, and to the cell surface. The contribution of Lys905 and Arg909 was found to be significant. The triple-helical peptide GPC(GPP)(5)G(904)-R-918(GPP)(5)GPC-NH2 and native collagen V molecules formed much more stable complexes with heparin than HepV, and collagen V bound to heparin/heparan sulfate with a higher affinity (in the nanomolar range) than HepV. Heat and chemical denaturation strongly decreased the binding, indicating that the triple helix plays a major role in stabilizing the interaction with heparin. Collagen V and HepV may play different roles in cell-matrix interactions and in matrix assembly or remodeling mediated by their specific interactions with heparan sulfate.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot,Inst Fed Rech, F-69367 Lyon 07, France; Univ Grenoble 1, CNRS, CEA, UMR 5075,Inst Biol Struct, F-38027 Grenoble, France; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; University of Cambridge	Ruggiero, F (corresponding author), Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot,Inst Fed Rech, 128 BioSci Gerland,7 Passage Vercors, F-69367 Lyon 07, France.	f.ruggiero@ibcp.fr		RUGGIERO, Florence/0000-0003-2915-5359; RICARD-BLUM, Sylvie/0000-0001-9263-1851	MRC [G0400701] Funding Source: UKRI; Medical Research Council [G0400701] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chanut-Delalande H, 2001, J BIOL CHEM, V276, P24352, DOI 10.1074/jbc.M101182200; Coombe DR, 2005, CELL MOL LIFE SCI, V62, P410, DOI 10.1007/s00018-004-4293-7; Delacoux F, 2000, J BIOL CHEM, V275, P29377, DOI 10.1074/jbc.M004724200; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; Doss-Pepe E, 2004, BBA-PROTEINS PROTEOM, V1698, P187, DOI 10.1016/j.bbapap.2003.11.034; Doss-Pepe E, 2000, BIOCHEMISTRY-US, V39, P14884, DOI 10.1021/bi001108u; Eckert R, 2003, FEBS LETT, V541, P121, DOI 10.1016/S0014-5793(03)00322-3; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Guimond S, 2001, BIOCHEM SOC T, V29, P177, DOI 10.1042/BST0290177; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KODA JE, 1985, J BIOL CHEM, V260, P8157; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Munakata H, 1999, GLYCOBIOLOGY, V9, P1023, DOI 10.1093/glycob/9.10.1023; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Raman R, 2005, CHEM BIOL, V12, P267, DOI 10.1016/j.chembiol.2004.11.020; Raynal N, 2006, J BIOL CHEM, V281, P3821, DOI 10.1074/jbc.M509818200; Ricard-Blum S, 2004, J BIOL CHEM, V279, P2927, DOI 10.1074/jbc.M309868200; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Ricard-Blum S, 2006, ANAL BIOCHEM, V352, P252, DOI 10.1016/j.ab.2006.02.011; Ruggiero F, 1996, J CELL SCI, V109, P1865; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; Takagaki K, 2002, J BIOL CHEM, V277, P8882, DOI 10.1074/jbc.M106479200; Tillet E, 1997, J BIOL CHEM, V272, P10769; Vaughan-Thomas A, 2001, J BIOL CHEM, V276, P5303, DOI 10.1074/jbc.M008764200; WHINNA HC, 1993, J BIOL CHEM, V268, P3920	41	37	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25195	25204		10.1074/jbc.M603096200	http://dx.doi.org/10.1074/jbc.M603096200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16815843	hybrid			2022-12-27	WOS:000240031300020
J	Vandebroek, T; Terwel, D; Vanhelmont, T; Gysemans, M; Van Haesendonck, C; Engelborghs, Y; Winderickx, J; Van Leuven, F				Vandebroek, Tom; Terwel, Dick; Vanhelmont, Thomas; Gysemans, Maarten; Van Haesendonck, Chris; Engelborghs, Yves; Winderickx, Joris; Van Leuven, Fred			Microtubule binding and clustering of human Tau-4R and Tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3 beta or cdk5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE KINASE 3-BETA; TRANSGENIC MICE; FTDP-17 MUTATIONS; ALZHEIMERS-DISEASE; PHOSPHORYLATION; ABILITY; HYPERPHOSPHORYLATION; AXONOPATHY; TRANSPORT; FILAMENTS	Phosphorylation of Tau protein and binding to microtubules is complex in neurons and was therefore studied in the less complicated model of humanized yeast. Human Tau was readily phosphorylated at pathological epitopes, but in opposite directions regulated by kinases Mds1 and Pho85, orthologues of glycogen synthase kinase-3 beta and cdk5, respectively (1). We isolated recombinant Tau-4R and mutant Tau-P301L from wild type, Delta mds1 and Delta pho85 yeast strains and measured binding to Taxol-stabilized mammalian microtubules in relation to their phosphorylation patterns. Tau-4R isolated from yeast lacking mds1 was less phosphorylated and bound more to microtubules than Tau-4R isolated from wild type yeast. Paradoxically, phosphorylation of Tau-4R isolated from kinase Pho85-deficient yeast was dramatically increased resulting in very poor binding to microtubules. Dephosphorylation promoted binding to microtubules to uniform high levels, excluding other modifications. Isolated hyperphosphorylated, conformationally altered Tau-4R completely failed to bind microtubules. In parallel to Tau-4R, we expressed, isolated, and analyzed mutant Tau-P301L. Total dephosphorylated Tau-4R and Tau-P301L bound to microtubules very similarly. Surprisingly, Tau-P301L isolated from all yeast strains bound to microtubules more extensively than Tau-4R. Atomic force microscopy demonstrated, however, that the high apparent binding of Tau-P301L was due to aggregation on the microtubules, causing their deformation and bundling. Our data explain the pathological presence of granular Tau aggregates in neuronal processes in tauopathies.	Katholieke Univ Leuven, Expt Genet Grp, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Funct Biol, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Lab Solid State Phys & Magnetism, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven	Van Leuven, F (corresponding author), KULeuven Campus,Campus Gasthuisberg ON1-06-602, B-3000 Louvain, Belgium.	fredvl@med.kuleuven.be						Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Arrasate M, 1999, FEBS LETT, V446, P199, DOI 10.1016/S0014-5793(99)00210-0; Baas PW, 2005, TRENDS CELL BIOL, V15, P183, DOI 10.1016/j.tcb.2005.02.001; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Boekhoorn K, 2006, J NEUROSCI, V26, P3514, DOI 10.1523/JNEUROSCI.5425-05.2006; Bunker JM, 2006, J BIOL CHEM, V281, P11856, DOI 10.1074/jbc.M509420200; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; D'Souza I, 2006, J BIOL CHEM, V281, P2460, DOI 10.1074/jbc.M505809200; Dehmelt L, 2005, GENOME BIOL, V6; Drewes G, 2004, TRENDS BIOCHEM SCI, V29, P548, DOI 10.1016/j.tibs.2004.08.001; Geschwind DH, 2003, NEURON, V40, P457, DOI 10.1016/S0896-6273(03)00681-0; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; Hallows JL, 2003, J NEUROSCI, V23, P10633; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Heutink P, 2000, HUM MOL GENET, V9, P979, DOI 10.1093/hmg/9.6.979; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Iqbal K, 2005, ACTA NEUROPATHOL, V109, P25, DOI 10.1007/s00401-004-0951-y; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; Le Corre S, 2006, P NATL ACAD SCI USA, V103, P9673, DOI 10.1073/pnas.0602913103; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Lim F, 2001, MOL CELL NEUROSCI, V18, P702, DOI 10.1006/mcne.2001.1051; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; Mandelkow EM, 2004, J CELL BIOL, V167, P99, DOI 10.1083/jcb.200401085; Masliah E, 2001, J NEUROPATH EXP NEUR, V60, P357, DOI 10.1093/jnen/60.4.357; Mitchell TW, 2000, J HISTOCHEM CYTOCHEM, V48, P1627, DOI 10.1177/002215540004801206; Mukhopadhyay R, 2001, FEBS LETT, V505, P374, DOI 10.1016/S0014-5793(01)02844-7; Sang HC, 2001, NEUROSCI LETT, V312, P141, DOI 10.1016/S0304-3940(01)02206-6; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Terwel D, 2002, NEUROMOL MED, V2, P151, DOI 10.1385/NMM:2:2:151; Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; Vandebroek T, 2005, BIOCHEMISTRY-US, V44, P11466, DOI 10.1021/bi0506775; Wilson WA, 2002, CELL, V111, P155, DOI 10.1016/S0092-8674(02)01043-7	48	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25388	25397		10.1074/jbc.M602792200	http://dx.doi.org/10.1074/jbc.M602792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16818492	hybrid			2022-12-27	WOS:000240031300041
J	Bushell, SR; Bottomley, SP; Rossjohn, J; Beddoe, T				Bushell, Simon R.; Bottomley, Stephen P.; Rossjohn, Jamie; Beddoe, Travis			Tracking the unfolding pathway of a multirepeat protein via tryptophan scanning - Evidence of localized instability in the mitochondrial import receptor Tom70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT; MOTIF; PREPROTEINS; DOMAIN; IDENTIFICATION; RECOGNITION; CONSENSUS; DESIGN; FAMILY; PROBES	The tetratricopeptide repeat ( TPR) is a degenerate 34-amino acid repeating motif that forms a repeating helix-turn-helix structure and is a well characterized mediator of protein-protein interactions. Recently, a biophysical investigation on one naturally occurring TPR protein, Tom70, found that the mitochondrial receptor displayed an unusual three-state unfolding pathway, distinct from the two-state model usually displayed by TPR proteins. To investigate this unusual behavior, we undertook a tryptophan-scanning analysis of Tom70, where both native and engineered tryptophan residues are used as fluorescent reporters to monitor the range of local and global unfolding events that comprise the unfolding pathway of Tom70. Specifically, seven Tom70 variants were constructed, each with a single tryptophan residue in each of the seven TPR repeats of Tom70. By combining equilibrium and kinetic fluorescent unfolding assays, with circular dichroism experiments, our study reveals that the unusual folding pathway of Tom70 is a consequence of the unfolding of two separate, autonomous TPR arrays, with the less stable region appearing to account for the low structural stability of Tom70.	Monash Univ, Prot Crystallog Unit, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia; Monash Univ, Dept Biochem & Mol Biol, Sch Biomed Sci, Clayton, Vic 3800, Australia	Monash University; Monash University	Rossjohn, J (corresponding author), Monash Univ, Prot Crystallog Unit, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia.	Jamie.Rossjohn@med.monash.edu.au	Rossjohn, Jamie/F-9032-2013; Beddoe, Travis/F-3415-2014	Rossjohn, Jamie/0000-0002-2020-7522; Beddoe, Travis/0000-0003-4550-2277; Bushell, Simon/0000-0001-5477-6777				BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beddoe T, 2004, J BIOL CHEM, V279, P46448, DOI 10.1074/jbc.M405639200; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BOTTOMLEY SP, 1994, PROTEIN ENG, V7, P1463, DOI 10.1093/protein/7.12.1463; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Cirillo SLG, 2000, MICROBIOL-SGM, V146, P1345, DOI 10.1099/00221287-146-6-1345; Clark PL, 1996, PROTEIN SCI, V5, P1108; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; Main ERG, 2003, CURR OPIN STRUC BIOL, V13, P482, DOI 10.1016/S0959-440X(03)00105-2; Main ERG, 2003, STRUCTURE, V11, P497, DOI 10.1016/S0969-2126(03)00076-5; Makarova KS, 2005, NUCLEIC ACIDS RES, V33, P4626, DOI 10.1093/nar/gki775; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; Perry AJ, 2006, CURR BIOL, V16, P221, DOI 10.1016/j.cub.2005.12.034; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH CJ, 1991, BIOCHEMISTRY-US, V30, P1028, DOI 10.1021/bi00218a021; Stumpp MT, 2003, J MOL BIOL, V332, P471, DOI 10.1016/S0022-2836(03)00897-0; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	28	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24345	24350		10.1074/jbc.M602966200	http://dx.doi.org/10.1074/jbc.M602966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803880	hybrid			2022-12-27	WOS:000239847800027
J	Chen, L; Necela, BM; Su, WD; Yanagisawa, M; Anastasiadis, PZ; Fields, AP; Thompson, EA				Chen, Lu; Necela, Brian M.; Su, Weidong; Yanagisawa, Masahiro; Anastasiadis, Panos Z.; Fields, Alan P.; Thompson, E. Aubrey			Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by rho GTPase-dependent activation of ERK1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-CASCADE ACTIVATION; TGF-BETA RECEPTOR; COLON TUMORS; SIGNALING PATHWAYS; ESTROGEN ACTION; GROWTH; EXPRESSION; PHOSPHORYLATION; CARCINOGENESIS; KINASE	Peroxisome proliferator-activated receptor gamma (PPAR gamma) causes epithelial to mesenchymal transformation (EMT) in intestinal epithelial cells, as evidenced by reorganization of the actin cytoskeleton, acquisition of a polarized, mesenchymal cellular morphology, increased cellular motility, and colony scattering. This response is due to activation of Cdc42, resulting in p21-activated kinase-dependent phosphorylation and activation of MEK1 Ser(298) and activation of ERK1/2. Dominant negative MEK1, MEK2, and ERK2 block PPAR gamma-induced EMT, whereas constitutively active MEK1 and MEK2 induce a mesenchymal phenotype similar to that evoked by PPAR gamma. PPAR gamma also stimulates ERK1/2 phosphorylation in the intestinal epithelium in vivo. PPAR gamma induces the p110 alpha subunit of phosphoinositide 3-kinase (PI3K), and inhibition of PI3K blocks PPAR gamma-dependent phosphorylation of MEK1 Ser298, activation of ERK1/2, and EMT. We conclude that PPAR gamma regulates the motility of intestinal epithelial cells through a mitogen-activated protein kinase cascade that involves PI3K, Cdc42, p21-activated kinase, MEK1, and ERK1/2. Regulation of cellular motility through Rho family GTPases has not been previously reported for nuclear receptors, and elucidation of the mechanism that accounts for the role of PPAR gamma in regulating motility of intestinal epithelial cells provides fundamental new insight into the function of this receptor during renewal of the intestinal epithelium.	Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Thompson, EA (corresponding author), 4500 San Pablo Rd,Griffin Canc Res Bldg,Rm 304, Jacksonville, FL 32224 USA.	thompson.aubrey@mayo.edu			NCI NIH HHS [CA24347, CA121349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA121349, R01CA024347, R37CA024347] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 2006, GUT, V55, P1104, DOI 10.1136/gut.2005.081745; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Alahari SK, 2002, INT REV CYTOL, V220, P145; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Chen L, 2006, MOL CELL ENDOCRINOL, V251, P17, DOI 10.1016/j.mce.2006.02.006; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Copland JA, 2006, ONCOGENE, V25, P2304, DOI 10.1038/sj.onc.1209267; Driggers PH, 2002, TRENDS ENDOCRIN MET, V13, P422, DOI 10.1016/S1043-2760(02)00634-3; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FUJITA TFT, 2001, Patent No. 6706746; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Lange CA, 2004, MOL ENDOCRINOL, V18, P269, DOI 10.1210/me.2003-0331; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Pino MV, 2004, TOXICOL PATHOL, V32, P58, DOI 10.1080/01926230490261320; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Tanaka T, 2001, CANCER RES, V61, P2424; Temple KA, 2005, J BIOL CHEM, V280, P3529, DOI 10.1074/jbc.M411422200; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Turner CE, 2000, J CELL SCI, V113, P4139; VAN AL, 1997, GENE DEV, V11, P2295; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; Yang K, 2005, INT J CANCER, V116, P495, DOI 10.1002/ijc.21018; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	42	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24575	24587		10.1074/jbc.M604147200	http://dx.doi.org/10.1074/jbc.M604147200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16815847	hybrid			2022-12-27	WOS:000239847800053
J	Rahman, MM; Barrett, JW; Brouckaert, P; McFadden, G				Rahman, Masmudur M.; Barrett, John W.; Brouckaert, Peter; McFadden, Grant			Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-RECEPTOR HOMOLOG; IMMUNE EVASION; ALPHA MUTANTS; CD30 HOMOLOG; VIRUS; GENOME; DISTINCT; SUPERFAMILY; ECTROMELIA; INHIBITION	The Yatapoxviruses encode a distinct class of secreted TNF-binding protein (TNF-BP) that resembles an MHC class I heavy chain but distinct from any other known TNF inhibitor. Characterization of these viral TNF inhibitors from Tanapox virus, Yaba monkey tumor virus (YMTV) and a closely related version from Swinepox virus revealed dramatically differential TNF binding specificities for different mammalian species. The Tanapox virus 2L protein (TPV-2L) formed inhibitory complexes with human TNF, and interacted with monkey and canine TNF with high affinity but rabbit TNF with low affinity. On the other hand, YMTV-2L bound human and monkey TNF with high affinity but rabbit TNF with only low affinity. The TNF-BP from swinepox virus (SPV003/148) only interacted with porcine TNF with high affinity. The observed TNF binding analysis mirrored the biological activity of these TNF-binding protein to block TNF-induced cellular cytolysis. TPV-2L and YMTV-2L also inhibited the human TNF-mediated signaling in cells but TPV-2L exhibited higher affinity for human TNF (K-D, 43 pM) compared with monkey (K-D, 120 pM) whereas for YMTV-2L, the affinities were reversed (human TNF K-D, 440 pM; monkey TNF K-D, 230 pM). The interaction domain of human TNF with TNF-binding proteins is significantly different from that of TNFRs, as determined using human TNF mutants. We conclude that these poxvirus TNF-binding proteins represent a new class of TNF inhibitors and are distinct from the viral TNF receptor homologues characterized to date.	Robarts Res Inst, Biotherapeut Res Grp, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada; Univ Ghent VIB, Mol Pathophysiol & Expt Therapy Unit, Dept Mol Biomed Res, B-9052 Ghent, Belgium	Western University (University of Western Ontario); Western University (University of Western Ontario); Flanders Institute for Biotechnology (VIB); Ghent University	McFadden, G (corresponding author), Robarts Res Inst, Biotherapeut Res Grp, SDRI Rm 133,1400 Western Rd, London, ON N6G 2V4, Canada.	mcfadden@robarts.ca	barrett, john/ABD-8414-2020	McFadden, Grant/0000-0002-2556-3526				Afonso CL, 2005, J VIROL, V79, P966, DOI 10.1128/JVI.79.2.966-977.2005; Afonso CL, 2002, J VIROL, V76, P783, DOI 10.1128/JVI.76.2.783-790.2002; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alcami A, 1999, J GEN VIROL, V80, P949, DOI 10.1099/0022-1317-80-4-949; Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Alejo A, 2006, P NATL ACAD SCI USA, V103, P5995, DOI 10.1073/pnas.0510462103; Ameloot P, 2001, J BIOL CHEM, V276, P27098, DOI 10.1074/jbc.M104486200; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Benedict CA, 2003, CYTOKINE GROWTH F R, V14, P349, DOI 10.1016/S1359-6101(03)00030-3; Brunetti CR, 2003, P NATL ACAD SCI USA, V100, P4831, DOI 10.1073/pnas.0737244100; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cunnion KM, 1999, MOL GENET METAB, V67, P278, DOI 10.1006/mgme.1999.2878; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Gubser C, 2004, J GEN VIROL, V85, P105, DOI 10.1099/vir.0.19565-0; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; Lee HJ, 2001, VIROLOGY, V281, P170, DOI 10.1006/viro.2000.0761; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; Loparev VN, 1998, P NATL ACAD SCI USA, V95, P3786, DOI 10.1073/pnas.95.7.3786; Mocellin S, 2005, CYTOKINE GROWTH F R, V16, P35, DOI 10.1016/j.cytogfr.2004.11.001; Nazarian SH, 2006, FUTURE VIROL, V1, P123; Panus JF, 2002, P NATL ACAD SCI USA, V99, P8348, DOI 10.1073/pnas.122238599; Rahman Masmudur M, 2006, PLoS Pathog, V2, pe4; Saraiva M, 2002, J EXP MED, V196, P829, DOI 10.1084/jem.20020319; Saraiva M, 2001, J VIROL, V75, P226, DOI 10.1128/JVI.75.1.226-233.2001; SCHREIBER M, 1994, VIROLOGY, V204, P692, DOI 10.1006/viro.1994.1585; Schreiber M, 1997, J VIROL, V71, P2171, DOI 10.1128/JVI.71.3.2171-2181.1997; Schreiber M, 1996, J BIOL CHEM, V271, P13333, DOI 10.1074/jbc.271.23.13333; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Senkevich TG, 1998, VIROLOGY, V250, P397, DOI 10.1006/viro.1998.9390; Smith CA, 1996, VIROLOGY, V223, P132, DOI 10.1006/viro.1996.0462; Smith VP, 2000, J GEN VIROL, V81, P1223, DOI 10.1099/0022-1317-81-5-1223; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; Ware CF, 2005, ANNU REV IMMUNOL, V23, P787, DOI 10.1146/annurev.immunol.23.021704.115719	36	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22517	22526		10.1074/jbc.M604645200	http://dx.doi.org/10.1074/jbc.M604645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16782702	hybrid			2022-12-27	WOS:000239542600012
J	Ralf, C; Hickson, ID; Wu, L				Ralf, Christine; Hickson, Ian D.; Wu, Leonard			The Bloom's syndrome helicase can promote the regression of a model replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; SISTER-CHROMATID EXCHANGES; TOPOISOMERASE-III-ALPHA; HOLLIDAY JUNCTIONS; SYNDROME PROTEINS; ESCHERICHIA-COLI; LAGGING-STRAND; HRDC DOMAIN; HOMOLOGOUS RECOMBINATION; SUBSTRATE-SPECIFICITY	Homozygous inactivation of BLM gives rise to Bloom's syndrome, a disorder associated with genomic instability and cancer predisposition. BLM encodes a member of the RecQ DNA helicase family that is required for the maintenance of genome stability and the suppression of sister-chromatid exchanges. BLM has been proposed to function in the rescue of replication forks that have collapsed or stalled as a result of encountering lesions that block fork progression. One proposed mechanism of fork rescue involves regression in which the nascent leading and lagging strands anneal to create a so-called "chicken foot" structure. Here we have developed an in vitro system for analysis of fork regression and show that BLM, but not Escherichia coli RecQ, can promote the regression of a model replication fork. BLM-mediated fork regression is ATP-dependent and occurs processively, generating regressed arms of > 250 bp in length. These data establish the existence of a eukaryotic protein that could promote replication fork regression in vivo and suggest a novel pathway through which BLM might suppress genetic exchanges.	Univ Oxford, John Radcliffe Hosp, Canc Res UK Labs, Weatherall Inst Mol Med, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Wu, L (corresponding author), Univ Oxford, John Radcliffe Hosp, Canc Res UK Labs, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	leonard.wu@cancer.org.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2005, STRUCTURE, V13, P1173, DOI 10.1016/j.str.2005.04.018; Bolt EL, 2002, MOL CELL, V10, P187, DOI 10.1016/S1097-2765(02)00560-9; Brosh RM, 2001, EMBO J, V20, P5791; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Cheok CF, 2005, NUCLEIC ACIDS RES, V33, P3932, DOI 10.1093/nar/gki712; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Friedberg EC, 2005, NAT REV MOL CELL BIO, V6, P943, DOI 10.1038/nrm1781; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Hu YD, 2005, MOL CELL BIOL, V25, P3431, DOI 10.1128/MCB.25.9.3431-3442.2005; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Lopes M, 2006, MOL CELL, V21, P15, DOI 10.1016/j.molcel.2005.11.015; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Machwe A, 2005, J BIOL CHEM, V280, P23397, DOI 10.1074/jbc.M414130200; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McInerney P, 2004, J BIOL CHEM, V279, P21543, DOI 10.1074/jbc.M401649200; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Pages V, 2003, SCIENCE, V300, P1300, DOI 10.1126/science.1083964; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Rao VA, 2005, MOL CELL BIOL, V25, P8925, DOI 10.1128/MCB.25.20.8925-8937.2005; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Rothstein R, 2000, GENE DEV, V14, P1; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Svoboda DL, 1995, P NATL ACAD SCI USA, V92, P11975, DOI 10.1073/pnas.92.26.11975; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang WS, 2003, MOL CELL BIOL, V23, P3527, DOI 10.1128/MCB.23.10.3527-3535.2003; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2005, EMBO J, V24, P2679, DOI 10.1038/sj.emboj.7600740; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	41	178	179	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22839	22846		10.1074/jbc.M604268200	http://dx.doi.org/10.1074/jbc.M604268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766518	hybrid			2022-12-27	WOS:000239542600046
J	Castang, S; Reverchon, S; Gouet, P; Nasser, W				Castang, Sandra; Reverchon, Sylvie; Gouet, Patrice; Nasser, William			Direct evidence for the modulation of the activity of the Erwinia chrysanthemi quorum-sensing regulator ExpR by acylhomoserine lactone pheromone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTOVORA SUBSP CAROTOVORA; ACYL-HOMOSERINE LACTONES; VIBRIO-FISCHERI LUXR; PROMOTERS IN-VITRO; C-TERMINAL DOMAIN; RNA-POLYMERASE; TRANSCRIPTIONAL ACTIVATION; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	In Erwinia chrysanthemi production of pectic enzymes is controlled by a complex network involving several regulators. Among them is ExpR, the quorum-sensing regulatory protein. ExpR is a member of the LuxR family of transcriptional regulators, the activity of which is modulated by the binding of diffusible N-acylhomoserine lactone pheromones to the N-terminal receptor site of the proteins. Previous in vitro DNA-ExpR binding studies suggested that ExpR might activate pectic enzyme production and repress its cognate gene expression. This report presents genetic evidence that ExpR represses its own gene expression in the absence of pheromone and that the addition of pheromone promotes concentration-dependent de-repression. In vitro experiments show that (i) ExpR binds target DNA in the absence of pheromone and that the pheromone dissociates ExpR-DNA complexes, (ii) ExpR binds target DNA in a noncooperative fashion, and (iii) two molecules of pheromone are bound per molecule of ExpR dimer. In the absence of N-(3-oxohexanoyl)homoserine lactone, ExpR prevents RNA polymerase access to the expR promoter, thereby directly repressing transcription initiation. The presence of pheromone renders the expR promoter accessible to RNA polymerase and results in the de-repression of transcription initiation. Overall we have established that there is a direct modulation of the repressive activity of a LuxR family regulator by a pheromone. Furthermore, site-directed mutagenesis experiments strongly suggest that the ExpR residues Leu-19, Tyr-31, and Ser-125 are involved in the transduction of conformational changes induced by ligand binding, and this provides new insights into the structure-function relationship of this bacterial regulator family.	Univ Lyon 1, CNRS, UMR, Unite Microbiol & Genet,Inst Natl Sci Appl Lyon 5, F-69365 Villeurbanne, France; UCBL, UMR 5086, CNRS, Lab BioCristallog,Inst Biochim & Chim Prot, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Nasser, W (corresponding author), Univ Lyon 1, CNRS, UMR, Unite Microbiol & Genet,Inst Natl Sci Appl Lyon 5, Domaine Sci Dpua,Batiment Andre Lwoff 10 Rue Dubo, F-69365 Villeurbanne, France.	william.nasser@insa-lyon.fr	NASSER, William/C-9611-2019; Sylvie, Reverchon/P-7932-2016	NASSER, William/0000-0001-9848-3597; Sylvie, Reverchon/0000-0002-0478-3474; gouet, patrice/0000-0001-9485-6157				Andersson RA, 2000, MOL PLANT MICROBE IN, V13, P384, DOI 10.1094/MPMI.2000.13.4.384; Bachhawat P, 2005, STRUCTURE, V13, P1353, DOI 10.1016/j.str.2005.06.006; BARRAS F, 1994, ANNU REV PHYTOPATHOL, V32, P201, DOI 10.1146/annurev.py.32.090194.001221; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Burr T, 2006, MOL MICROBIOL, V59, P113, DOI 10.1111/j.1365-2958.2005.04939.x; Chai YR, 2004, MOL MICROBIOL, V51, P765, DOI 10.1046/j.1365-2958.2003.03857.x; Collins CH, 2005, MOL MICROBIOL, V55, P712, DOI 10.1111/j.1365-2958.2004.04437.x; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; Cui YY, 2005, J BACTERIOL, V187, P4792, DOI 10.1128/JB.187.14.4792-4803.2005; Ducros VMA, 2001, J MOL BIOL, V306, P759, DOI 10.1006/jmbi.2001.4443; Egland KA, 2001, J BACTERIOL, V183, P382, DOI 10.1128/JB.183.1.382-386.2001; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Finney AH, 2002, J BACTERIOL, V184, P4520, DOI 10.1128/JB.184.16.4520-4528.2002; Frezza M, 2006, BIOORGAN MED CHEM, V14, P4781, DOI 10.1016/j.bmc.2006.03.017; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Halkides CJ, 2000, BIOCHEMISTRY-US, V39, P5280, DOI 10.1021/bi9925524; Hastings CA, 2003, BIOCHEMISTRY-US, V42, P9081, DOI 10.1021/bi0273866; HugouvieuxCottePattat N, 1996, ANNU REV MICROBIOL, V50, P213, DOI 10.1146/annurev.micro.50.1.213; Johnson DC, 2003, FEMS MICROBIOL LETT, V228, P193, DOI 10.1016/S0378-1097(03)00750-X; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; Kiratisin P, 2002, J BACTERIOL, V184, P4912, DOI 10.1128/JB.184.17.4912-4919.2002; Koch B, 2005, MICROBIOL-SGM, V151, P3589, DOI 10.1099/mic.0.27954-0; KOOP AH, 1987, GENE, V52, P245, DOI 10.1016/0378-1119(87)90051-5; Lamb JR, 2003, J BACTERIOL, V185, P7129, DOI 10.1128/JB.185.24.7129-7139.2003; LAZARUS LR, 1993, EMBO J, V12, P2483, DOI 10.1002/j.1460-2075.1993.tb05903.x; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Luo ZQ, 2003, J BIOL CHEM, V278, P13173, DOI 10.1074/jbc.M210035200; Miller J. H., 1972, EXPT MOL GENETICS, P431; Minogue TD, 2002, MOL MICROBIOL, V44, P1625, DOI 10.1046/j.1365-2958.2002.02987.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nasser W, 1998, MOL MICROBIOL, V29, P1391, DOI 10.1046/j.1365-2958.1998.01022.x; Nasser W, 2002, MOL MICROBIOL, V43, P733, DOI 10.1046/j.1365-2958.2002.02782.x; Nasser W, 1997, MOL MICROBIOL, V26, P1071, DOI 10.1046/j.1365-2958.1997.6472020.x; Nomura K, 1998, P NATL ACAD SCI USA, V95, P14034, DOI 10.1073/pnas.95.24.14034; PAO GM, 1994, RES MICROBIOL, V145, P356, DOI 10.1016/0923-2508(94)90082-5; Pappas KM, 2004, MOL MICROBIOL, V53, P755, DOI 10.1111/j.1365-2958.2004.04212.x; Qin YP, 2004, J BIOL CHEM, V279, P40844, DOI 10.1074/jbc.M405299200; Reverchon S, 1998, MOL MICROBIOL, V29, P1407, DOI 10.1046/j.1365-2958.1998.01023.x; Reverchon S, 2002, BIOORG MED CHEM LETT, V12, P1153, DOI 10.1016/S0960-894X(02)00124-5; Roussel A., 1989, SILICON GRAPHICS GEO; Schuster M, 2004, P NATL ACAD SCI USA, V101, P15833, DOI 10.1073/pnas.0407229101; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SLOCK J, 1990, J BACTERIOL, V172, P3974, DOI 10.1128/jb.172.7.3974-3979.1990; Stevens AM, 1999, J BACTERIOL, V181, P4704, DOI 10.1128/JB.181.15.4704-4707.1999; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Surgey N, 1996, J BACTERIOL, V178, P1593, DOI 10.1128/jb.178.6.1593-1599.1996; Urbanowski AL, 2004, J BACTERIOL, V186, P631, DOI 10.1128/JB.186.3.631-637.2004; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; von Bodman SB, 2003, J BACTERIOL, V185, P7001, DOI 10.1128/JB.185.23.7001-7007.2003; von Bodman SB, 1998, P NATL ACAD SCI USA, V95, P7687, DOI 10.1073/pnas.95.13.7687; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Weingart CL, 2005, MOL MICROBIOL, V57, P452, DOI 10.1111/j.1365-2958.2005.04656.x; Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631; White CE, 2005, MOL MICROBIOL, V55, P1473, DOI 10.1111/j.1365-2958.2004.04482.x; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832	62	40	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29972	29987		10.1074/jbc.M601666200	http://dx.doi.org/10.1074/jbc.M601666200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16831870	hybrid			2022-12-27	WOS:000240896300058
J	Chaar, Z; O'Reilly, P; Gelman, I; Sabourin, LA				Chaar, Ziad; O'Reilly, Paul; Gelman, Irwin; Sabourin, Luc A.			v-Src-dependent down-regulation of the Ste20-like kinase SLK by casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-KINASE; STE20-RELATED KINASE; CATALYTIC-ACTIVITY; CELL MOTILITY; CK2; CANCER; APOPTOSIS; FIBRONECTIN; INDUCTION	We have previously shown that the Ste20-like kinase SLK is a microtubule-associated protein inducing actin stress fiber disassembly. Here, we show that v-Src expression can down-regulate SLK activity. This down-regulation is independent of focal adhesion kinase but requires v-Src kinase activity and membrane translocation. SLK down-regulation by v-Src is indirect and is accompanied by SLK hyperphosphorylation on serine residues. Deletion analysis revealed that casein kinase II (CK2) sites at position 347/348 are critical for v-Src-dependent modulation of SLK activity. Further studies show that CK2 can directly phosphorylate SLK at these positions and that inhibition of CK2 in v-Src-transformed cells results in normal kinase activity. Finally, CK2 and SLK can be co-localized in fibroblasts spreading on fibronectin-coated substrates, suggesting a mechanism whereby SLK may be regulated at sites of actin remodeling, such as membrane lamellipodia and ruffles, through CK2.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Ottawa Hlth Res Inst, Canc Therapeut Program, Ottawa, ON K1H 8L6, Canada; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Roswell Park Cancer Institute	Sabourin, LA (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	lsab@uottawa.ca						Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Donella-Deana A, 2003, BIOCHEM J, V372, P841, DOI 10.1042/BJ20021905; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hao W, 2006, J BIOL CHEM, V281, P3075, DOI 10.1074/jbc.M511744200; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ruoslahti E, 1997, KIDNEY INT, V51, P1413, DOI 10.1038/ki.1997.193; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200	29	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28193	28199		10.1074/jbc.M605665200	http://dx.doi.org/10.1074/jbc.M605665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16837460	hybrid			2022-12-27	WOS:000240534400057
J	Bhalla, V; Oyster, NM; Fitch, AC; Wijngaarden, MA; Neumann, D; Schlattner, U; Pearce, D; Hallows, KR				Bhalla, Vivek; Oyster, Nicholas M.; Fitch, Adam C.; Wijngaarden, Marjolein A.; Neumann, Dietbert; Schlattner, Uwe; Pearce, David; Hallows, Kenneth R.			AMP-activated kinase inhibits the epithelial Na+ channel through functional regulation of the ubiquitin ligase Nedd4-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; TOAD URINARY-BLADDER; PROTEIN-KINASE; SODIUM-CHANNEL; LIDDLES-SYNDROME; SUBUNIT STOICHIOMETRY; MEMBRANE-TRANSPORT; GLUCOSE-TRANSPORT; GAMMA-SUBUNIT; BETA-SUBUNIT	We recently found that the metabolic sensor AMP-activated kinase (AMPK) inhibits the epithelial Na+ channel (ENaC) through decreased plasma membrane ENaC expression, an effect requiring the presence of a binding motif in the cytoplasmic tail of the beta-ENaC subunit for the ubiquitin ligase Nedd4-2. To further examine the role of Nedd4-2 in the regulation of ENaC by AMPK, we studied the effects of AMPK activation on ENaC currents in Xenopus oocytes co-expressing ENaC and wild-type (WT) or mutant forms of Nedd4-2. ENaC inhibition by AMPK was preserved in oocytes expressing WT Nedd4-2 but blocked in oocytes expressing either a dominant-negative (DN) or constitutively active (CA) Nedd4-2 mutant, suggesting that AMPK-dependent modulation of Nedd4-2 function is involved. Similar experiments utilizing WT or mutant forms of the serum- and glucocorticoid-regulated kinase (SGK1), modulators of protein kinase A(PKA), or extracellular-regulated kinase (ERK) did not affect ENaC inhibition by AMPK, suggesting that these pathways known to modulate the Nedd4-2-ENaC interaction are not responsible. AMPK-dependent phosphorylation of Nedd4-2 expressed in HEK-293 cells occurred both in vitro and in vivo, suggesting a potential mechanism for modulation of Nedd4-2 and thus cellular ENaC activity. Moreover, cellular AMPK activation significantly enhanced the interaction of the beta-ENaC subunit with Nedd4-2, as measured by co-immunoprecipitation assays in HEK-293 cells. In summary, these results suggest a novel mechanism for ENaC regulation in which AMPK promotes ENaC-Nedd4-2 interaction, thereby inhibiting ENaC by increasing Nedd4-2-dependent ENaC retrieval from the plasma membrane. AMPK-dependent ENaC inhibition may limit cellular Na+ loading under conditions of metabolic stress when AMPK becomes activated.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94107 USA; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hallows, KR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, 5976 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hallows@pitt.edu	Schlattner, Uwe/D-1267-2009; Wijngaarden, Marjolein A/F-9438-2010	Schlattner, Uwe/0000-0003-1159-5911; Wijngaarden, Marjolein A/0000-0002-4697-0286; Hallows, Kenneth/0000-0002-2964-2440; Neumann, Dietbert/0000-0002-4316-684X; Bhalla, Vivek/0000-0002-5420-9657	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059477, R01DK075048, K08DK071648, R01DK056695, R03DK068390] Funding Source: NIH RePORTER; NIDDK NIH HHS [R03 DK068390, R01 DK075048-01A1, R01 DK075048, R03 DK068390-01, R01 DK056695, K08 DK071648, R03 DK068390-02, K08 DK059477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Bhalla V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Boehmer C, 2003, J NEUROCHEM, V86, P1181, DOI 10.1046/j.1471-4159.2003.01937.x; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dieter M, 2004, OBES RES, V12, P862, DOI 10.1038/oby.2004.104; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; FRINDT G, 1995, AM J PHYSIOL-RENAL, V268, pF480, DOI 10.1152/ajprenal.1995.268.3.F480; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1983, J MEMBRANE BIOL, V74, P15, DOI 10.1007/BF01870591; GULLANS SR, 2000, KIDNEY PHYSL PATHOPH, P443; Hallows KR, 2005, CURR OPIN NEPHROL HY, V14, P464, DOI 10.1097/01.mnh.0000174145.14798.64; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; Kamynina E, 2002, AM J PHYSIOL-RENAL, V283, pF377, DOI 10.1152/ajprenal.00143.2002; Kamynina E, 2001, KIDNEY INT, V60, P466, DOI 10.1046/j.1523-1755.2001.060002466.x; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; Knight KK, 2006, P NATL ACAD SCI USA, V103, P2805, DOI 10.1073/pnas.0511184103; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; Liang XB, 2006, J BIOL CHEM, V281, P16323, DOI 10.1074/jbc.M601360200; Malik B, 2005, AM J PHYSIOL-RENAL, V289, pF107, DOI 10.1152/ajprenal.00179.2002; Michlig S, 2005, J BIOL CHEM, V280, P38264, DOI 10.1074/jbc.M506308200; Nagaki K, 2006, BIOCHEMISTRY-US, V45, P6733, DOI 10.1021/bi052640q; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Palmada M, 2004, AM J PHYSIOL-GASTR L, V287, pG143, DOI 10.1152/ajpgi.00121.2003; PALMER LG, 1980, J MEMBRANE BIOL, V57, P59, DOI 10.1007/BF01868986; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shearwin-Whyatt L, 2006, BIOESSAYS, V28, P617, DOI 10.1002/bies.20422; Sheng S, 2006, AM J PHYSIOL-RENAL, V290, pF1488, DOI 10.1152/ajprenal.00439.2005; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Soundararajan R, 2005, J BIOL CHEM, V280, P39970, DOI 10.1074/jbc.M508658200; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Thome UH, 2003, AM J PHYSIOL-LUNG C, V284, pL376, DOI 10.1152/ajplung.00218.2002; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woollhead AM, 2005, J PHYSIOL-LONDON, V566, P781, DOI 10.1113/jphysiol.2005.088674; Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200; Yang LM, 2006, J BIOL CHEM, V281, P9859, DOI 10.1074/jbc.M512046200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	65	128	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26159	26169		10.1074/jbc.M606045200	http://dx.doi.org/10.1074/jbc.M606045200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844684	hybrid			2022-12-27	WOS:000240249500032
J	Croteau, DL; DellaVecchia, MJ; Wang, H; Bienstock, RJ; Melton, MA; Van Houten, B				Croteau, Deborah L.; DellaVecchia, Matthew J.; Wang, Hong; Bienstock, Rachelle J.; Melton, Mark A.; Van Houten, Bennett			The C-terminal zinc finger of UvrA does not bind DNA directly but regulates damage-specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI UVRA; NUCLEOTIDE EXCISION-REPAIR; SITE-SPECIFIC MUTAGENESIS; ATP-BINDING; CRYSTAL-STRUCTURE; ABC TRANSPORTER; (A)BC EXCINUCLEASE; CASSETTE DIMER; XPA PROTEIN; RECOGNITION	In prokaryotic nucleotide excision repair, UvrA recognizes DNA perturbations and recruits UvrB for the recognition and processing steps in the reaction. One of the most remarkable aspects of UvrA is that it can recognize a wide range of DNA lesions that differ in chemistry and structure. However, how UvrA interacts with DNA is unknown. To examine the role that the UvrA C-terminal zinc finger domain plays in DNA binding, an eleven amino acid deletion was constructed (ZnG UvrA). Biochemical characterization of the ZnG UvrA protein was carried out using UvrABC DNA incision, DNA binding and ATPase assays. Although ZnG UvrA was able to bind dsDNA slightly better than wild-type UvrA, the ZnG UvrA mutant only supported 50-75% of wild type incision. Surprisingly, the ZnG UvrA mutant, while retaining its ability to bind dsDNA, did not support damage-specific binding. Furthermore, this mutant protein only provided 10% of wild-type Bca UvrA complementation for UV survival of an uvrA deletion strain. In addition, ZnG UvrA failed to stimulate the UvrB DNA damage-associated ATPase activity. Electrophoretic mobility shift analysis was used to monitor UvrB loading onto damaged DNA with wildtype UvrA or ZnG UvrA. The ZnG UvrA protein showed a 30-60% reduction in UvrB loading as compared with the amount of UvrB loaded by wild-type UvrA. These data demonstrate that the C-terminal zinc finger of UvrA is required for regulation of damage-specific DNA binding.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Sci Comp Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Summers Discovery Program, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Van Houten, B (corresponding author), NIEHS, Mol Genet Lab, NIH, 111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.	vanhout1@niehs.nih.gov	Messier, Claude/A-2322-2008; Croteau, Deb/AAP-5933-2020; Wang, Hong/F-3164-2014; Van Houten, Bennett/K-2284-2019	Messier, Claude/0000-0002-4791-1763; Wang, Hong/0000-0003-0165-3559; Bienstock, Rachelle/0000-0001-5228-3610; Croteau, Deborah/0000-0002-6094-4084	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061060] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES061060-09] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; CROTEAU DL, 2005, DNA DAMAGE RECOGNITI, P111; DellaVecchia MJ, 2004, J BIOL CHEM, V279, P45245, DOI 10.1074/jbc.M408659200; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; Gattiker A, 2003, COMPUT BIOL CHEM, V27, P49, DOI 10.1016/S1476-9271(02)00094-4; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Kulkarni Amit S, 2006, Indian J Exp Biol, V44, P7; Kuraoka I, 1996, MUTAT RES-DNA REPAIR, V362, P87, DOI 10.1016/0921-8777(95)00038-0; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; LIN JJ, 1992, J BIOL CHEM, V267, P17693; Lu G, 2005, P NATL ACAD SCI USA, V102, P17969, DOI 10.1073/pnas.0506039102; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; Moolenaar GF, 2001, EMBO J, V20, P6140, DOI 10.1093/emboj/20.21.6140; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3834, DOI 10.1021/bi00230a005; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; Park SM, 2002, BIOCHEMISTRY-US, V41, P4137, DOI 10.1021/bi015961k; Reardon JT, 2004, CELL CYCLE, V3, P141; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; Skorvaga M, 2002, J BIOL CHEM, V277, P1553, DOI 10.1074/jbc.M108847200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; Truglio JJ, 2006, CHEM REV, V106, P233, DOI 10.1021/cr040471u; Truglio JJ, 2004, EMBO J, V23, P2498, DOI 10.1038/sj.emboj.7600263; Van Houten B, 2005, MUTAT RES-FUND MOL M, V577, P92, DOI 10.1016/j.mrfmmm.2005.03.013; VISSE R, 1993, MUTAT RES, V294, P263, DOI 10.1016/0921-8777(93)90009-6; WANG JT, 1993, J BIOL CHEM, V268, P5323; WANG JT, 1994, J BIOL CHEM, V269, P10771; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	45	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26370	26381		10.1074/jbc.M603093200	http://dx.doi.org/10.1074/jbc.M603093200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829526	Green Accepted, hybrid			2022-12-27	WOS:000240249500054
J	Sherman, DH; Li, SY; Yermalitskaya, LV; Kim, YC; Smith, JA; Waterman, MR; Podust, LM				Sherman, David H.; Li, Shengying; Yermalitskaya, Liudmila V.; Kim, Youngchang; Smith, Jarrod A.; Waterman, Michael R.; Podust, Larissa M.			The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL BIOSYNTHESIS; MACROLIDE ANTIBIOTICS; THERMOPHILIC CYTOCHROME-P450; SULFOLOBUS-SOLFATARICUS; ABSOLUTE CONFIGURATION; POLYKETIDE SYNTHASES; CRYSTAL-STRUCTURE; DESOSAMINE; HYDROXYLATION; CONSTRUCTION	The pikromycin (Pik)/methymycin biosynthetic pathway of Streptomyces venezuelae represents a valuable system for dissecting the fundamental mechanisms of modular polyketide biosynthesis, aminodeoxysugar assembly, glycosyltransfer, and hydroxylation leading to the production of a series of macrolide antibiotics, including the natural ketolides narbomycin and pikromycin. In this study, we describe four x-ray crystal structures and allied functional studies for PikC, the remarkable P450 monooxygenase responsible for production of a number of related macrolide products from the Pik pathway. The results provide important new insights into the structural basis for the C10/C12 and C12/C14 hydroxylation patterns for the 12-(YC-17) and 14-membered ring (narbomycin) macrolides, respectively. This includes two different ligand-free structures in an asymmetric unit (resolution 2.1 angstrom) and two co-crystal structures with bound endogenous substrates YC-17 (resolution 2.35 angstrom) or narbomycin (resolution 1.7 angstrom). A central feature of the enzyme-substrate interaction involves anchoring of the desosamine residue in two alternative binding pockets based on a series of distinct amino acid residues that form a salt bridge and a hydrogen-bonding network with the deoxysugar C3' dimethylamino group. Functional significance of the salt bridge was corroborated by site-directed mutagenesis that revealed a key role for Glu-94 in YC-17 binding and Glu-85 for narbomycin binding. Taken together, the x-ray structure analysis, site-directed mutagenesis, and corresponding product distribution studies reveal that PikC substrate tolerance and product diversity result from a combination of alternative anchoring modes rather than an induced fit mechanism.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Struct Biol, Nashville, TN 37232 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Vanderbilt University; Vanderbilt University; United States Department of Energy (DOE); Argonne National Laboratory	Sherman, DH (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	davidhs@umich.edu; m.podust@vanderbilt.edu	Podust, Larissa/ABB-7940-2020	Podust, Larissa/0000-0002-8537-8760; Kim, Youngchang/0000-0002-1610-4889	NIEHS NIH HHS [ES00627] Funding Source: Medline; NIGMS NIH HHS [R37 GM037942, GM69970, GM37942, R01 GM078553, GM078553, R01 GM069970, R37 GM037942-14, R01 GM078553-01, R01 GM069970-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069970, R01GM037942, R01GM078553, R37GM037942] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackermann G, 2003, J ANTIMICROB CHEMOTH, V51, P497, DOI 10.1093/jac/dkg123; ANLIKER R, 1956, HELV CHIM ACTA, V39, P1785, DOI 10.1002/hlca.19560390637; Auerbach T, 2004, TRENDS BIOTECHNOL, V22, P570, DOI 10.1016/j.tibtech.2004.09.006; Baltz RH, 1998, TRENDS MICROBIOL, V6, P76, DOI 10.1016/S0966-842X(97)01161-X; Berisio R, 2003, NAT STRUCT BIOL, V10, P366, DOI 10.1038/nsb915; Borisova SA, 1999, ORG LETT, V1, P133, DOI 10.1021/ol9906007; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandrasena REP, 2004, J AM CHEM SOC, V126, P115, DOI 10.1021/ja038237t; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; de Visser SP, 2002, J AM CHEM SOC, V124, P11809, DOI 10.1021/ja026872d; DJERASSI C, 1958, TETRAHEDRON, V4, P369, DOI 10.1016/0040-4020(58)80058-7; DJERASSI C, 1957, J AM CHEM SOC, V79, P3926, DOI 10.1021/ja01571a088; Furneri P M, 1991, J Chemother, V3 Suppl 1, P24; GOLDMAN RC, 1990, ANTIMICROB AGENTS CH, V34, P426, DOI 10.1128/AAC.34.3.426; Goldman Robert C., 2004, Current Drug Targets - Infectious Disorders, V4, P241, DOI 10.2174/1568005043340812; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hilal SH, 1995, QUANT STRUCT-ACT REL, V14, P348, DOI 10.1002/qsar.19950140405; Hutchinson CR, 1998, CURR OPIN MICROBIOL, V1, P319, DOI 10.1016/S1369-5274(98)80036-2; Jin SX, 2003, J AM CHEM SOC, V125, P3406, DOI 10.1021/ja029272n; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee SK, 2006, J NAT PROD, V69, P847, DOI 10.1021/np060026p; Menzella HG, 2005, NAT BIOTECHNOL, V23, P1171, DOI 10.1038/nbt1128; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Nagano S, 2003, J BIOL CHEM, V278, P44886, DOI 10.1074/jbc.M308115200; Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200; OMURA T, 1964, J BIOL CHEM, V239, P2379; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Reeves CD, 2003, CRIT REV BIOTECHNOL, V23, P95, DOI 10.1080/713609311; Retsema J, 2001, INT J ANTIMICROB AG, V18, pS3, DOI 10.1016/S0924-8579(01)00401-0; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Schlunzen F, 2003, STRUCTURE, V11, P329, DOI 10.1016/S0969-2126(03)00022-4; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Tang L, 2001, CHEM BIOL, V8, P547, DOI 10.1016/S1074-5521(01)00032-1; Vaz ADN, 1998, P NATL ACAD SCI USA, V95, P3555, DOI 10.1073/pnas.95.7.3555; Xue YQ, 1998, CHEM BIOL, V5, P661, DOI 10.1016/S1074-5521(98)90293-9; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; Yonath A, 2005, MOL CELLS, V20, P1; Yoon YJ, 2002, CHEM BIOL, V9, P203, DOI 10.1016/S1074-5521(02)00095-9; Zhang QB, 2001, J NAT PROD, V64, P1447, DOI 10.1021/np010146r; ZHAO L, 1999, J AM CHEM SOC, V121; Zhao LS, 1998, J AM CHEM SOC, V120, P10256, DOI 10.1021/ja981782n; Zhao LS, 1998, J AM CHEM SOC, V120, P12159, DOI 10.1021/ja982942y	49	115	120	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26289	26297		10.1074/jbc.M605478200	http://dx.doi.org/10.1074/jbc.M605478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825192	Green Accepted, hybrid			2022-12-27	WOS:000240249500046
J	Jana, SS; Kawamoto, S; Adelstein, RS				Jana, Siddhartha S.; Kawamoto, Sachiyo; Adelstein, Robert S.			A specific isoform of nonmuscle myosin II-C is required for cytokinesis in a tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-DEPENDENT KINASE; HEAVY-CHAIN ISOFORMS; CLEAVAGE FURROW; EXPRESSION; GENE; CLONING; PHOSPHORYLATION; IDENTIFICATION; SEQUENCES; ADHESION	Nonmuscle myosin IIs play an essential role during cytokinesis. Here, we explore the function of an alternatively spliced isoform of nonmuscle myosin heavy chain(NMHC) II-C, called NMHCII-C1, in the A549 human lung tumor cell line during cytokinesis. NMHC II-C1 contains an insert of 8 amino acids in the head region of NMHCII-C. First, we show that there is a marked increase in both the mRNA encoding NMHC II-C1 and protein in tumor cell lines compared with nontumor cell lines derived from the same tissue. Quantification of the amount of myosin II isoforms in the A549 cells shows that the amounts of NMHCII-A and II-C1 protein are about equal and substantially greater than NMHCII-B. Using specific siRNAs to decrease NMHC II-C1 in cultured A549 cells resulted in a 5.5-fold decrease in the number of cells at 120 h, whereas decreasing NMHC II-A with siRNA does not affect cell proliferation. This decreased proliferation can be rescued by reintroducing NMHCII-C1 but not NMHCII-A or II-B into A549 cells, although noninserted NMHCII-C does rescue to a limited extent. Time lapse video microscopy revealed that loss of NMHC II-C1 leads to a delay in cytokinesis and prolongs it from 2 to 8-10 h. These findings are consistent with the localization of NMHCII-C1 to the intercellular bridge that attaches the two dividing cells during the late phases of cytokinesis. The results suggest a specific function for NMHC II-C1 in cytokinesis in the A549 tumor cell line.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adelstein, RS (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.	adelster@nhlbi.nih.gov		Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004230, ZIAHL004230] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao JJ, 2005, J BIOL CHEM, V280, P19594, DOI 10.1074/jbc.M501573200; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200; Dean SO, 2005, P NATL ACAD SCI USA, V102, P13473, DOI 10.1073/pnas.0506810102; DeBiasio RL, 1996, MOL BIOL CELL, V7, P1259, DOI 10.1091/mbc.7.8.1259; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; Kamijo K, 2006, MOL BIOL CELL, V17, P43, DOI 10.1091/mbc.e05-06-0569; Kanada M, 2005, MOL BIOL CELL, V16, P3865, DOI 10.1091/mbc.E05-03-0233; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kim KY, 2005, J BIOL CHEM, V280, P22769, DOI 10.1074/jbc.M503488200; Kolega J, 1998, J CELL SCI, V111, P2085; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; Mar XF, 2006, MOL BIOL CELL, V17, P2138, DOI 10.1091/mbc.E05-10-0097; Matsumura F, 2005, TRENDS CELL BIOL, V15, P371, DOI 10.1016/j.tcb.2005.05.004; MAUPIN P, 1994, J CELL SCI, V107, P3077; McCollum D, 2005, CURR BIOL, V15, pR998, DOI 10.1016/j.cub.2005.11.049; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; Neujahr R, 1997, J CELL SCI, V110, P123; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; Piekny A, 2005, TRENDS CELL BIOL, V15, P651, DOI 10.1016/j.tcb.2005.10.006; Schweitzer JK, 2004, EXP CELL RES, V295, P1, DOI 10.1016/j.yexcr.2003.12.023; Sellers J. R., 1999, MYOSINS; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Uren D, 2000, J CLIN INVEST, V105, P663, DOI 10.1172/JCI8199; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; Zang JH, 1997, MOL BIOL CELL, V8, P2617, DOI 10.1091/mbc.8.12.2617	37	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24662	24670		10.1074/jbc.M604606200	http://dx.doi.org/10.1074/jbc.M604606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790446	hybrid			2022-12-27	WOS:000239847800061
J	Dall'Acqua, WF; Kiener, PA; Wu, HR				Dall'Acqua, William F.; Kiener, Peter A.; Wu, Herren			Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-RELATED RECEPTOR; RESPIRATORY-SYNCYTIAL-VIRUS; SERUM HALF-LIVES; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN-G; MHC; COMPLEX; EXPRESSION; THERAPY	We describe here the functional implications of an increase in IgG binding to the neonatal Fc receptor. We have defined in a systematic fashion the relationship between enhanced FcRn binding of a humanized anti-respiratory sincytial virus (RSV) monoclonal antibody (MEDI-524) and the corresponding biological consequences in cynomolgus monkeys. The triple mutation M252Y/S254T/T256E (YTE) was introduced into the Fc portion of MEDI-524. Whereas these substitutions did not affect the ability of MEDI-524 to bind to its cognate antigen and inhibit RSV replication, they resulted in a 10-fold increase in its binding to both cynomolgus monkey and human FcRn at pH 6.0. MEDI-524-YTE was efficiently released from FcRn at pH 7.4 in both cases. We show that MEDI-524-YTE consistently exhibited a nearly 4-fold increase in serum half-life in cynomolgus monkeys when compared with MEDI-524. This constituted the largest half-life improvement described to date for an IgG in a primate. For the first time, we demonstrate that these sustained serum levels resulted in an up to 4-fold increase in lung bioavailability. Importantly, we also establish that our non-human primate model is relevant to human. Finally, we report that the YTE triple substitution provided a means to modulate the antibody-dependent cell-mediated cytotoxicity (ADCC) activity of a humanized IgG1 directed against the human integrin alpha(v)beta(3). Therefore, the YTE substitutions allow the simultaneous modulation of serum half-life, tissue distribution and activity of a given human IgG1.	Medimmune Inc, Dept Antibody Discovery & Prot Engn, Gaithersburg, MD 20878 USA	AstraZeneca; Medimmune	Dall'Acqua, WF (corresponding author), Medimmune Inc, Dept Antibody Discovery & Prot Engn, Gaithersburg, MD 20878 USA.	dall'acquaw@medimmune.com; wuh@medimmune.com						Adams CW, 2006, CANCER IMMUNOL IMMUN, V55, P717, DOI 10.1007/s00262-005-0058-x; Adamski FM, 2000, MOL IMMUNOL, V37, P435, DOI 10.1016/S0161-5890(00)00065-1; AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; Anderson DR, 1997, BIOCHEM SOC T, V25, P705, DOI 10.1042/bst0250705; Bitonti AJ, 2004, P NATL ACAD SCI USA, V101, P9763, DOI 10.1073/pnas.0403235101; Borvak J, 1998, INT IMMUNOL, V10, P1289, DOI 10.1093/intimm/10.9.1289; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; Cardenas Silvia, 2005, Expert Rev Anti Infect Ther, V3, P719, DOI 10.1586/14787210.3.5.719; Choy EHS, 1996, ARTHRITIS RHEUM, V39, P52, DOI 10.1002/art.1780390107; Dall'Acqua WF, 2002, J IMMUNOL, V169, P5171, DOI 10.4049/jimmunol.169.9.5171; Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; Fishwild DM, 1999, CLIN IMMUNOL, V92, P138, DOI 10.1006/clim.1999.4734; Ghetie V, 1997, NAT BIOTECHNOL, V15, P637, DOI 10.1038/nbt0797-637; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; Gillies SD, 1999, CANCER RES, V59, P2159; Green MC, 2000, CANCER TREAT REV, V26, P269, DOI 10.1053/ctrv.2000.0176; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Haymann JP, 2000, J AM SOC NEPHROL, V11, P632, DOI 10.1681/ASN.V114632; Hinton PR, 2006, J IMMUNOL, V176, P346, DOI 10.4049/jimmunol.176.1.346; Hinton PR, 2004, J BIOL CHEM, V279, P6213, DOI 10.1074/jbc.C300470200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Israel EJ, 1997, IMMUNOLOGY, V92, P69, DOI 10.1046/j.1365-2567.1997.00326.x; Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kabat EA, 1991, SEQUENCES PROTEINS I; Kacskovics I, 2000, J IMMUNOL, V164, P1889, DOI 10.4049/jimmunol.164.4.1889; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Lazar GA, 2006, P NATL ACAD SCI USA, V103, P4005, DOI 10.1073/pnas.0508123103; Lin YS, 1999, J PHARMACOL EXP THER, V288, P371; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Medesan C, 1996, EUR J IMMUNOL, V26, P2533, DOI 10.1002/eji.1830261038; Mejias A, 2005, ANTIMICROB AGENTS CH, V49, P4700, DOI 10.1128/AAC.49.11.4700-4707.2005; Ober RJ, 2001, INT IMMUNOL, V13, P1551, DOI 10.1093/intimm/13.12.1551; RAASVELD MHM, 1993, KIDNEY INT, V43, P1140, DOI 10.1038/ki.1993.160; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Shinkura H, 1997, TOXICOLOGY, V122, P163, DOI 10.1016/S0300-483X(97)00092-9; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400; Spiekermann GM, 2003, J EXP MED, V197, P1601; STEPHENS S, 1995, IMMUNOLOGY, V85, P668; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; Vallhonrat H, 1999, TRANSPLANTATION, V67, P253, DOI 10.1097/00007890-199901270-00011; West AP, 2000, BIOCHEMISTRY-US, V39, P9698, DOI 10.1021/bi000749m; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; Wilder RL, 2002, ANN RHEUM DIS, V61, P96, DOI 10.1136/ard.61.suppl_2.ii96; Wu H, 2005, J MOL BIOL, V350, P126, DOI 10.1016/j.jmb.2005.04.049; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037	52	391	758	1	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23514	23524		10.1074/jbc.M604292200	http://dx.doi.org/10.1074/jbc.M604292200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793771	hybrid			2022-12-27	WOS:000239702900026
J	Rocnik, EF; Liu, PJ; Sato, K; Walsh, K; Vaziri, C				Rocnik, Edward F.; Liu, Peijun; Sato, Kaori; Walsh, Kenneth; Vaziri, Cyrus			The novel SPARC family member SMOC-2 potentiates angiogenic growth factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRICELLULAR PROTEIN SPARC; ENDOTHELIAL-CELLS; MICE DEFICIENT; BINDING; GLYCOPROTEIN; OSTEONECTIN; EXPRESSION; CLONING; BM-40; IDENTIFICATION	SMOC-2 is a novel member of the SPARC family of matricellular proteins. The purpose of this study was to determine whether SMOC-2 can modulate angiogenic growth factor activity and angiogenesis. SMOC-2 was localized in the extracellular periphery of cultured human umbilical vein endothelial cells (HUVECs). Ectopically expressed SMOC-2 was also secreted into the tissue culture medium. In microarray profiling experiments, a recombinant SMOC-2 adenovirus induced the expression of transcripts required for cell cycle progression in HUVECs. Consistent with a growth-stimulatory role for SMOC-2, its overexpression stimulated DNA synthesis in a dose-dependent manner. Overexpressed SMOC-2 also synergized with vascular endothelial growth factor or with basic fibroblast growth factor to stimulate DNA synthesis. Ectopically expressed SMOC-2 stimulated formation of network-like structures as determined by in vitro matrigel angiogenesis assays. Fetal calf serum enhanced the stimulatory effect of overexpressed SMOC-2 in this assay. Conversely, small interference RNA directed toward SMOC-2 inhibited network formation and proliferation. The angiogenic activity of SMOC-2 was also examined in experimental mice by subdermal implantation of Matrigel((R)) plugs containing SMOC-2 adenovirus. SMOC-2 adenovirus induced a 3-fold increase in the number of cells invading Matrigel((R)) plugs when compared with a control adenoviral vector. Basic fibroblast growth factor and SMOC-2 elicited a synergistic effect on cell invasion. Taken together, our results demonstrate that SMOC-2 is a novel angiogenic factor that potentiates angiogenic effects of growth factors.	Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University; Boston University	Rocnik, EF (corresponding author), Boston Univ, Sch Med, Dept Genet & Genom, 715 Albany St,E633, Boston, MA 02118 USA.	efrocnik@yahoo.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017241] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL77774] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG17241] Funding Source: Medline; NIEHS NIH HHS [R01 ES09558] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; Basu A, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-15; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bradshaw AD, 2001, WOUND REPAIR REGEN, V9, P522, DOI 10.1046/j.1524-475x.2001.00522.x; Chlenski A, 2004, CANCER RES, V64, P7420, DOI 10.1158/0008-5472.CAN-04-2141; Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kozian DH, 1997, LAB INVEST, V76, P267; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; Leopold JA, 2003, J BIOL CHEM, V278, P32100, DOI 10.1074/jbc.M301293200; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nishimoto S, 2002, BBA-GENE STRUCT EXPR, V1576, P225, DOI 10.1016/S0167-4781(02)00345-7; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; Rocnik EF, 2002, J BIOL CHEM, V277, P38571, DOI 10.1074/jbc.M206689200; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Schneyer A, 2001, MOL CELL ENDOCRINOL, V180, P33, DOI 10.1016/S0303-7207(01)00501-9; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Strandjord TP, 1999, AM J PHYSIOL-LUNG C, V277, pL628, DOI 10.1152/ajplung.1999.277.3.L628; Vannahme C, 2003, BIOCHEM J, V373, P805, DOI 10.1042/BJ20030532; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; Wang QF, 2000, ENDOCRINOLOGY, V141, P3183, DOI 10.1210/en.141.9.3183; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201	39	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22855	22864		10.1074/jbc.M513463200	http://dx.doi.org/10.1074/jbc.M513463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774925	hybrid			2022-12-27	WOS:000239542600048
J	Patwari, P; Higgins, LJ; Chutkow, WA; Yoshioka, J; Lee, RT				Patwari, Parth; Higgins, Luke J.; Chutkow, William A.; Yoshioka, Jun; Lee, Richard T.			The interaction of thioredoxin with Txnip - Evidence for formation of a mixed disulfide by disulfide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; UP-REGULATED PROTEIN-1; OXIDATIVE STRESS; ASK1-MEDIATED APOPTOSIS; INDEPENDENT MANNER; CRYSTAL-STRUCTURE; CELLS; DEGRADATION; RESOLUTION; PEPTIDE	The thioredoxin system plays an important role in maintaining a reducing environment in the cell. Recently, several thioredoxin binding partners have been identified and proposed to mediate aspects of redox signaling, but the significance of these interactions is unclear in part due to incomplete understanding of the mechanism for thioredoxin binding. Thioredoxin-interacting protein (Txnip) is critical for regulation of glucose metabolism, the only currently known function of which is to bind and inhibit thioredoxin. We explored the mechanism of the Txnip-thioredoxin interaction and present evidence that Txnip and thioredoxin form a stable disulfide-linked complex. We identified two Txnip cysteines that are important for thioredoxin binding and showed that this interaction is consistent with a disulfide exchange reaction between oxidized Txnip and reduced thioredoxin. These cysteines are not conserved in the broader family of arrestin domain-containing proteins, and we demonstrate that the thioredoxin-binding property of Txnip is unique. These data suggest that Txnip is a target of reduced thioredoxin and provide insight into the potential role of Txnip as a redox-sensitive signaling protein.	Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University	Patwari, P (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Partners Res Bldg,Rm 280,65 Landsdowne St, Cambridge, MA 02139 USA.	ppatwari@rics.bwh.harvard.edu			NHLBI NIH HHS [R01 HL073809, T32 HL007604] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073809, T32HL007604] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen JF, 1997, BIOCHEMISTRY-US, V36, P13979, DOI 10.1021/bi971004s; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Dias-Gunasekara S, 2005, J BIOL CHEM, V280, P33066, DOI 10.1074/jbc.M505023200; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Goldberg SF, 2003, CANCER RES, V63, P432; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Guo Y, 2004, STEM CELLS, V22, P259, DOI 10.1634/stemcells.22-3-259; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Henrotin Y, 2005, OSTEOARTHR CARTILAGE, V13, P643, DOI 10.1016/j.joca.2005.04.002; Hitchon CA, 2004, ARTHRITIS RES THER, V6, P265, DOI 10.1186/ar1447; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hui TY, 2004, J BIOL CHEM, V279, P24387, DOI 10.1074/jbc.M401280200; Hwang CY, 2004, ONCOGENE, V23, P8868, DOI 10.1038/sj.onc.1208116; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LeMaster DM, 1997, J BIOL CHEM, V272, P29998, DOI 10.1074/jbc.272.48.29998; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Meuillet EJ, 2004, ARCH BIOCHEM BIOPHYS, V429, P123, DOI 10.1016/j.abb.2004.04.020; Nichols CD, 2004, J NEUROCHEM, V90, P576, DOI 10.1111/j.1471-4159.2004.02515.x; Nishinaka Y, 2004, CANCER RES, V64, P1287, DOI 10.1158/0008-5472.CAN-03-0908; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Oka S, 2005, FASEB J, V19, P121, DOI 10.1096/fj.05-443fje; OKA SI, 2005, ENDOCRINOPLOGY; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Sheth SS, 2005, J LIPID RES, V46, P123, DOI 10.1194/jlr.M400341-JLR200; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; Yamamoto Y, 2001, CLIN CANCER RES, V7, P297; Yamanaka H, 2000, BIOCHEM BIOPH RES CO, V271, P796, DOI 10.1006/bbrc.2000.2699; Yoshioka J, 2004, CIRCULATION, V109, P2581, DOI 10.1161/01.CIR.0000129771.32215.44; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7	44	231	247	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21884	21891		10.1074/jbc.M600427200	http://dx.doi.org/10.1074/jbc.M600427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16766796	hybrid, Green Accepted			2022-12-27	WOS:000239387100035
J	Shao, SJ; Wang, Y; Jin, SQ; Song, YM; Wang, XX; Fan, WH; Zhao, ZY; Fu, M; Tong, T; Dong, LJ; Fan, FY; Xu, NZ; Zhan, QM				Shao, Shujuan; Wang, Yang; Jin, Shunqian; Song, Yongmei; Wang, Xiaoxia; Fan, Wenhong; Zhao, Zhiying; Fu, Ming; Tong, Tong; Dong, Lijia; Fan, Feiyue; Xu, Ningzhi; Zhan, Qimin			Gadd45a interacts with Aurora-A and inhibits its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTROSOME AMPLIFICATION; PROTEIN-KINASE; DUPLICATION; BRCA1; CELLS; INSTABILITY; ANEUPLOIDY; INDUCTION; RADIATION; ABSENCE	Centrosome stability is required for successful mitosis in mammalian cells. Amplification of the centrosome leads to chromosomal missegregation and generation of aneuploidy, which are closely associated with cell transformation and tumorigenesis (Doxsey, S. J. (2001) Nat. Cell Biol. 3, E105-E108; Hinchcliffe, E. H., and Sluder, G. (2001) Genes Dev. 15, 1167 1181; Pihan, G. A., Purohit, A., Wallace, J., Malhotra, R., Liotta, L., and Doxsey, S. J. (2001) Cancer Res. 61, 2212-2219). However, there are currently limited insights into mechanism(s) for this critical biological event. Here we show that Gadd45a, a DNA damage-inducible protein that is regulated by tumor suppressors p53 and BRCA1, participates in the maintenance of centrosome stability. Mouse embryonic fibroblasts derived from gadd45a knock-out mice exhibit centrosome amplification (designated as increased centrosome numbers). Introduction of exogenous Gadd45a into mouse embryonic fibroblasts isolated from gadd45a-null mice substantially restored the normal centrosome profile. In contrast to p21(waf1/cip1), which ensures coordinated initiation of centrosome, Gadd45a had no significant effect on centrosome duplication in S phase. Interestingly Gadd45a was found to physically associate with Aurora-A protein kinase, whose deregulated expression results in centrosome abnormality. Furthermore Gadd45a was demonstrated to strongly inhibit Aurora-A kinase activity and to antagonize Aurora-A-induced centrosome amplification. These findings identify a novel mechanism for Gadd45a in the maintenance of centrosome stability and broaden understandings of p53-and BRCA1-regulated signaling pathways in maintaining genomic fidelity.	Chinese Acad Med Sci, State Key Lab Mol Oncol, Inst Canc, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China; Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Inst Radiat Med, Tianjin 300192, Peoples R China; Dalian Med Univ, Dalian 116027, Peoples R China; Inst Basic Med Sci, Dept Neurobiol, Beijing 100850, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Radiation Medicine - CAMS; Dalian Medical University	Zhan, QM (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Inst Canc, Beijing 100021, Peoples R China.	Zhanqimin@pumc.edu.cn	Wang, Yang/A-1849-2010	Wang, Yang/0000-0001-9385-7393; song, yongmei/0000-0002-7789-0158	NCI NIH HHS [R01 CA93640] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093640] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Donaldson MM, 2001, J CELL SCI, V114, P2357; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2000, J CELL SCI, V113, P1973; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Giet R, 1999, J CELL SCI, V112, P3591; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Pihan GA, 2001, CANCER RES, V61, P2212; Raff JW, 2001, CURR BIOL, V11, pR159, DOI 10.1016/S0960-9822(01)00082-3; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Wang XY, 2004, J BIOL CHEM, V279, P29606, DOI 10.1074/jbc.M312279200; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	31	49	53	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28943	28950		10.1074/jbc.M600235200	http://dx.doi.org/10.1074/jbc.M600235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16772293	hybrid			2022-12-27	WOS:000240680500048
J	Fukui, N; Ikeda, Y; Ohnuki, T; Hikita, A; Tanaka, S; Yamane, S; Suzuki, R; Sandell, LJ; Ochi, T				Fukui, Naoshi; Ikeda, Yasuko; Ohnuki, Toshiyuki; Hikita, Atsuhiko; Tanaka, Sakae; Yamane, Shoji; Suzuki, Ryuji; Sandell, Linda J.; Ochi, Takahiro			Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; 3' UNTRANSLATED REGION; GENE-EXPRESSION; IN-VITRO; 3'-UNTRANSLATED REGION; OSTEOPHYTE FORMATION; KINASE; CELLS; GROWTH; CARTILAGE	In articular chondrocytes, the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) induces the expression of bone morphogenetic protein-2 (BMP-2), a growth factor known to be involved in the induction of cartilage and bone. A study was performed to clarify the mechanism(s) underlying the induction of BMP-2 in chondrogenic ATDC5 cells and primary cultured adult human articular chondrocytes. In ATDC5 cells, the endogenous BMP-2 expression was consistently low throughout the process of chondrogenic differentiation, and TNF-alpha induced BMP-2 expression only after the cells acquired the chondrogenic phenotype. The results of nuclear run-off assay and cycloheximide treatment consistently indicated that ATDC5 cells acquire the capacity to synthesize BMP-2 mRNA in the nuclei during the differentiation process. In an attempt to explain the discrepancy between the active nuclear mRNA synthesis and the observed low expression level in differentiated ATDC5 cells, the stability of BMP-2 mRNA was evaluated, and the cells were found to regulate the expression of BMP-2 at the post-transcriptional level. Human chondrocytes were confirmed to have a similar post-transcriptional regulation. The result of 3'-rapid amplification of cDNA end revealed that both human and mouse BMP-2 mRNAs contain multiple pentameric AUUUA motifs in a conserved manner in the 3'-untranslated regions, and transient transfection experiments demonstrated that TNF-alpha increases the stability of BMP-2 mRNA through the pentameric motifs. Further experiments revealed that TNF-alpha modulates mRNA stability via p38 signal transduction pathway, whereas the cytokine also augmented the expression of BMP-2 through transcriptional up-regulation via the transcriptional factor NF-kappa B.	Sagamihara Hosp, Natl Hosp Org, Clin Res Ctr, Dept Pathomech, Sagamihara, Kanagawa 2288522, Japan; Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1130033, Japan; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA	University of Tokyo; Washington University (WUSTL)	Fukui, N (corresponding author), Sagamihara Hosp, Natl Hosp Org, Clin Res Ctr, Dept Pathomech, Sagamihara, Kanagawa 2288522, Japan.	n-fukui@sagamihara-hosp.gr.jp	Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414				Abrams KL, 2004, J BIOL CHEM, V279, P15916, DOI 10.1074/jbc.M313531200; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Bashirullah A, 2001, P NATL ACAD SCI USA, V98, P7025, DOI 10.1073/pnas.111145698; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; DORSSERS L, 1987, GENE, V55, P115, DOI 10.1016/0378-1119(87)90254-X; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Fowler MJ, 1998, BIOCHEM BIOPH RES CO, V248, P450, DOI 10.1006/bbrc.1998.8988; Fritz DT, 2004, J BIOL CHEM, V279, P48950, DOI 10.1074/jbc.M409620200; Fukuda H, 2003, J BONE JOINT SURG BR, V85B, P3, DOI 10.1302/0301-620X.85B1.13846; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Grunder T, 2004, OSTEOARTHR CARTILAGE, V12, P559, DOI 10.1016/j.joca.2004.04.001; Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Lories RJU, 2003, ARTHRITIS RHEUM, V48, P2807, DOI 10.1002/art.11389; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Macias D, 1997, DEVELOPMENT, V124, P1109; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Nakase T, 2003, OSTEOARTHR CARTILAGE, V11, P278, DOI 10.1016/S1063-4584(03)00004-9; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355; Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Seto H, 2004, J CLIN INVEST, V113, P718, DOI 10.1172/JCI200419899; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shi J, 2004, INFLAMM RES, V53, P377, DOI 10.1007/s00011-004-1271-3; Short S, 2000, J BIOL CHEM, V275, P12963, DOI 10.1074/jbc.275.17.12963; Si SH, 1997, EUR J ORAL SCI, V105, P325, DOI 10.1111/j.1600-0722.1997.tb00248.x; Stewart MC, 2000, J BONE MINER RES, V15, P166, DOI 10.1359/jbmr.2000.15.1.166; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; van Lent PLEM, 2004, ARTHRITIS RHEUM, V50, P103, DOI 10.1002/art.11422; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zhang DH, 2002, J BONE MINER RES, V17, P293, DOI 10.1359/jbmr.2002.17.2.293; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002-0210; Zoricic S, 2003, J ANAT, V202, P269, DOI 10.1046/j.1469-7580.2003.00158.x	64	74	75	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27229	27241		10.1074/jbc.M603385200	http://dx.doi.org/10.1074/jbc.M603385200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835229	hybrid			2022-12-27	WOS:000240397700050
J	Schieke, SM; Phillips, D; Mccoy, JP; Aponte, AM; Shen, RF; Balaban, RS; Finkel, T				Schieke, Stefan M.; Phillips, Darci; McCoy, J. Philip, Jr.; Aponte, Angel M.; Shen, Rong-Fong; Balaban, Robert S.; Finkel, Toren			The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMATIC RNAI SCREEN; LIFE-SPAN; CALORIE RESTRICTION; C-ELEGANS; SACCHAROMYCES-CEREVISIAE; BINDING PARTNER; CELL-GROWTH; TOR; PROTEIN; RAPTOR	Metabolic rate and the subsequent production of reactive oxygen species are thought to contribute to the rate of aging in a wide range of species. The target of rapamycin (TOR) is a well conserved serine/threonine kinase that regulates cell growth in response to nutrient status. Here we demonstrate that in mammalian cells the mammalian TOR (mTOR) pathway plays a significant role in determining both resting oxygen consumption and oxidative capacity. In particular, we demonstrate that the level of complex formation between mTOR and one of its known protein partners, raptor, correlated with overall mitochondrial activity. Disruption of this complex following treatment with the mTOR pharmacological inhibitor rapamycin lowered mitochondrial membrane potential, oxygen consumption, and ATP synthetic capacity. Subcellular fractionation revealed that mTOR as well as mTOR-raptor complexes can be purified in the mitochondrial fraction. Using two-dimensional difference gel electrophoresis, we further demonstrated that inhibiting mTOR with rapamycin resulted in a dramatic alteration in the mitochondrial phosphoproteome. RNA interference-mediated knockdown of TSC2, p70 S6 kinase (S6K1), raptor, or rictor demonstrates that mTOR regulates mitochondrial activity independently of its previously identified cellular targets. Finally we demonstrate that mTOR activity may play an important role in determining the relative balance between mitochondrial and non-mitochondrial sources of ATP generation. These results may provide insight into recent observations linking the TOR pathway to life span regulation of lower organisms.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Cardiac Energet, NIH, Bethesda, MD 20892 USA; NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD 20892 USA; NHLBI, Proteom Core Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, Bldg 10CR-5-3330,10 Ctr Dr, Bethesda, MD 20892 USA.	finkelt@nih.gov	mccoy, john philip/ABD-9348-2021; Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948; Phillips, Darci/0000-0002-0804-3342	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005012, ZIAHL005012, Z01HL004601, ZIAHL004601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hoffert JD, 2004, AM J PHYSIOL-RENAL, V286, pF170, DOI 10.1152/ajprenal.00223.2003; Hopper RK, 2006, BIOCHEMISTRY-US, V45, P2524, DOI 10.1021/bi052475e; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Rea S, 2003, DEV CELL, V5, P197, DOI 10.1016/S1534-5807(03)00242-9; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; SARIBANSOHRABY S, 1983, CANCER RES, V43, P4662; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Unwin RD, 2005, J BIOL CHEM, V280, P6316, DOI 10.1074/jbc.M410598200; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	33	467	483	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27643	27652		10.1074/jbc.M603536200	http://dx.doi.org/10.1074/jbc.M603536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16847060	hybrid			2022-12-27	WOS:000240397700089
J	Winn, RA; Van Scoyk, M; Hammond, M; Rodriguez, K; Crossno, JT; Heasley, LE; Nemenoff, RA				Winn, Robert A.; Van Scoyk, Michelle; Hammond, Mandy; Rodriguez, Karen; Crossno, Joseph T., Jr.; Heasley, Lynn E.; Nemenoff, Raphael A.			Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EPITHELIAL-MESENCHYMAL TRANSITIONS; PPAR-GAMMA; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; INHIBITION; EXPRESSION; GROWTH; DIFFERENTIATION	The Wnt pathway is critical for normal development, and mutation of specific components is seen in carcinomas of diverse orgins. The role of this pathway in lung tumorigenesis has not been clearly established. Recent studies from our laboratory indicate that combined expression of the combination of Wnt 7a and Frizzled 9 (Fzd 9) in Non-small Cell Lung Cancer (NSCLC) cell lines inhibits transformed growth. We have also shown that increased expression of peroxisome proliferator-activated receptor gamma(PPAR gamma) inhibits transformed growth of NSCLC and promotes epithelial differentiation of these cells. The goal of this study was to determine whether the effects of Wnt 7a/Fzd 9 were mediated through PPAR gamma. We found that Wnt 7a and Fzd 9 expression led to increased PPAR gamma activity. This effect was not mediated by altered expression of the protein. Wnt 7a and Fzd 9 expression resulted in activation of ERK5, which was required for PPAR gamma activation in NSCLC. SR 202, a known PPAR gamma inhibitor, blocked the increase in PPAR gamma activity and restored anchorage-independent growth in NSCLC expressing Wnt 7a and Fzd 9. SR 202 also reversed the increase in E-cadherin expression mediated by Wnt 7a and Fzd 9. These data suggest that ERK5-dependent activation of PPAR gamma represents a major effector pathway mediating the anti-tumorigenic effects of Wnt 7a and Fzd 9 in NSCLC.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care Med, Dept Med, Denver, CO 80262 USA; Vet Adm Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Winn, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care Med, Dept Med, 4200 E 9th Ave, Denver, CO 80262 USA.	robert.winn@uchsc.edu			NATIONAL CANCER INSTITUTE [R01CA103618, R01CA108610, R01CA116527, P50CA058187] Funding Source: NIH RePORTER; NCI NIH HHS [CA103618, CA58187, CA108610, R01 CA116527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akaike M, 2004, MOL CELL BIOL, V24, P8691, DOI 10.1128/MCB.24.19.8691-8704.2004; Bren-Mattison Y, 2005, ONCOGENE, V24, P1412, DOI 10.1038/sj.onc.1208333; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Chang TH, 2000, CANCER RES, V60, P1129; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Gelman L, 2005, CURR OPIN CELL BIOL, V17, P216, DOI 10.1016/j.ceb.2005.02.002; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Hajra KM, 2002, CANCER RES, V62, P1613; Hayashi M, 2004, J MOL MED, V82, P800, DOI 10.1007/s00109-004-0602-8; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JANSSON EA, 2005, P NATL ACAD SCI US; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirikoshi H, 2002, INT J ONCOL, V21, P895; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Nemenoff RA, 2005, EUR J CANCER, V41, P2561, DOI 10.1016/j.ejca.2005.08.015; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Polakis P, 2000, GENE DEV, V14, P1837; Rieusset J, 2002, MOL ENDOCRINOL, V16, P2628, DOI 10.1210/me.2002-0036; Santini E, 2004, DIABETES, V53, pS79, DOI 10.2337/diabetes.53.suppl_3.S79; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Sasaki H, 2002, LUNG CANCER-J IASLC, V36, P71, DOI 10.1016/S0169-5002(01)00449-4; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Winn RA, 2005, J BIOL CHEM, V280, P19625, DOI 10.1074/jbc.M409392200; Yu C, 2005, J BIOL CHEM, V280, P13600, DOI 10.1074/jbc.M409468200	38	98	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26943	26950		10.1074/jbc.M604145200	http://dx.doi.org/10.1074/jbc.M604145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835228	hybrid			2022-12-27	WOS:000240397700021
J	Chhabra, ES; Higgs, HN				Chhabra, Ekta Seth; Higgs, Henry N.			INF2 is a WASP homology 2 motif-containing formin that severs actin filaments and accelerates both polymerization and depolymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING PROTEIN; ATP-ACTIN; ADP-ACTIN; INDUCED NUCLEATION; BUNDLING ACTIVITY; STRUCTURAL BASIS; MOUSE FORMIN; DOMAIN; MECHANISM; PROFILIN	Formin proteins modulate both nucleation and elongation of actin filaments through processive movement of their dimeric formin homology 2 (FH2) domains with filament barbed ends. Mammals possess at least 15 formin genes. A subset of formins termed "diaphanous formins" are regulated by autoinhibition through interaction between an N-terminal diaphanous inhibitory domain (DID) and a C-terminal diaphanous autoregulatory domain (DAD). Here, we found several striking features for the mouse formin, INF2. First, INF2 interacted directly with actin through a region C-terminal to the FH2. This second interacting region sequesters actin monomers, an activity that is dependent on a WASP homology 2 (WH2) motif. Second, the combination of the FH2 and C-terminal regions of INF2 resulted in its curious ability to accelerate both polymerization and depolymerization of actin filaments. The mechanism of the depolymerization activity, which is novel for formin proteins, involves both the monomer binding ability of the WH2 and a potent severing activity that is dependent on covalent attachment of the FH2 to the C terminus. Phosphate inhibits both the depolymerization and severing activities of INF2, suggesting that phosphate release from actin subunits in the filament is a trigger for depolymerization. Third, INF2 contains an N-terminal DID, and the WH2 motif likely doubles as a DAD in an autoinhibitory interaction.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Higgs, HN (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.	henry.higgs@dartmouth.edu		Higgs, Henry/0000-0002-2917-9644	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069818] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-069818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Bindschadler M, 2004, BIOPHYS J, V86, P2720, DOI 10.1016/S0006-3495(04)74326-X; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Bugyi B, 2006, J BIOL CHEM, V281, P10727, DOI 10.1074/jbc.M510252200; CARLIER MF, 1988, J BIOL CHEM, V263, P817; Chereau D, 2005, P NATL ACAD SCI USA, V102, P16644, DOI 10.1073/pnas.0507021102; Domanski M, 2004, J BIOL CHEM, V279, P23637, DOI 10.1074/jbc.M311413200; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Harris ES, 2006, J BIOL CHEM, V281, P14383, DOI 10.1074/jbc.M510923200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Harris ES, 2006, METHOD ENZYMOL, V406, P190, DOI 10.1016/S0076-6879(06)06015-0; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2006, CURR OPIN CELL BIOL, V18, P11, DOI 10.1016/J.CEB.2005.12.011; Kovar DR, 2006, CELL, V124, P423, DOI 10.1016/j.cell.2005.11.038; Kovar DR, 2005, MOL BIOL CELL, V16, P2313, DOI 10.1091/mbc.E04-09-0781; Lammers M, 2005, EMBO J, V24, P4176, DOI 10.1038/sj.emboj.7600879; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Michelot A, 2005, PLANT CELL, V17, P2296, DOI 10.1105/tpc.105.030908; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Moseley JB, 2005, J BIOL CHEM, V280, P28023, DOI 10.1074/jbc.M503094200; MOSELEY JB, 2004, MOL BIOL CELL, V116, P711; Nezami AG, 2006, STRUCTURE, V14, P257, DOI 10.1016/j.str.2005.12.003; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Paunola E, 2002, FEBS LETT, V513, P92, DOI 10.1016/S0014-5793(01)03242-2; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Quinlan ME, 2005, NATURE, V433, P382, DOI 10.1038/nature03241; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Vavylonis D, 2006, MOL CELL, V21, P455, DOI 10.1016/j.molcel.2006.01.016; Vavylonis D, 2005, P NATL ACAD SCI USA, V102, P8543, DOI 10.1073/pnas.0501435102; Wallar BJ, 2006, J BIOL CHEM, V281, P4300, DOI 10.1074/jbc.M510277200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; WANGER M, 1987, BIOCHIM BIOPHYS ACTA, V914, P105, DOI 10.1016/0167-4838(87)90052-5; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	50	142	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26754	26767		10.1074/jbc.M604666200	http://dx.doi.org/10.1074/jbc.M604666200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16818491	hybrid			2022-12-27	WOS:000240249500093
J	Fernandez, E; Jimenez-Vidal, M; Calvo, M; Zorzano, A; Tebar, F; Palacin, M; Chillaron, J				Fernandez, Esperanza; Jimenez-Vidal, Maite; Calvo, Maria; Zorzano, Antonio; Tebar, Francesc; Palacin, Manuel; Chillaron, Josep			The structural and functional units of heteromeric amino acid transporters - The heavy subunit rBAT dictates oligomerization of the heteromeric amino acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; GENOTYPE-PHENOTYPE CORRELATION; MEMBRANE-PROTEIN COMPLEXES; PLASMA-MEMBRANE; LIGHT SUBUNIT; LIVING CELLS; L-CYSTINE; SYSTEM; MUTATIONS; EXCHANGE	Heteromeric amino acid transporters are composed of a catalytic light subunit and a heavy subunit linked by a disulfide bridge. We analyzed the structural and functional units of systems b(0,+) and x(C)(-), formed by the heterodimers b(0,+) AT-rBAT and xCT-4F2hc, respectively. Blue Native gel electrophoresis, cross-linking, and fluorescence resonance energy transfer in vivo indicate that system b(0,+) is a heterotetramer [b(0,+) AT-rBAT](2), whereas xCT-4F2hc seems not to stably or efficiently oligomerize. However, substitution of the heavy subunit 4F2hc for rBAT was sufficient to form a heterotetrameric [xCT-\rBAT](2) structure. The functional expression of concatamers of two light subunits ( which differ only in their sensitivity to inactivation by a sulfhydryl reagent) suggests that a single heterodimer is the functional unit of systems b(0,+) and x(C)(-).	IRB, PCB, Barcelona 08028, Spain; Univ Barcelona, Dept Biochem & Mol Biol, Fac Biol, E-08028 Barcelona, Spain; Univ Barcelona, Fac Med, Dept Biol Cellular, Inst Invest Biomed August Pi Suyer, Barcelona 08036, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Barcelona; University of Barcelona	Palacin, M (corresponding author), IRB, PCB, Barcelona Sci Pk,Josep Samitier 1-5, Barcelona 08028, Spain.	mpalacin@pcb.ub.es	Chillaron, Josep/ABF-7663-2021; Calvo, Maria/I-1872-2015; Zorzano, Antonio/R-5479-2018; Tebar, Francesc/H-1498-2015	Chillaron, Josep/0000-0003-3068-7598; Calvo, Maria/0000-0002-7473-0474; Tebar, Francesc/0000-0002-9522-9726; Palacin, Manuel/0000-0002-8670-293X				Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; Bauch C, 2003, J BIOL CHEM, V278, P1316, DOI 10.1074/jbc.M210449200; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Feliubadalo L, 2003, HUM MOL GENET, V12, P2097, DOI 10.1093/hmg/ddg228; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Fernandez E, 2003, J AM SOC NEPHROL, V14, P837, DOI 10.1097/01.ASN.0000057852.35075.AC; Fernandez E, 2002, AM J PHYSIOL-RENAL, V283, pF540, DOI 10.1152/ajprenal.00071.2002; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Font-Llitjos M, 2005, J MED GENET, V42, P58, DOI 10.1136/jmg.2004.022244; FRANCOIS V, 2004, PFLUEGERS ARCH EUR J, V447, P532; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Herrick-Davis K, 2004, BIOCHEMISTRY-US, V43, P13963, DOI 10.1021/bi048398p; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Jimenez-Vidal M, 2004, J BIOL CHEM, V279, P11214, DOI 10.1074/jbc.M309866200; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kohler K, 2000, J BIOL CHEM, V275, P26113, DOI 10.1074/jbc.M003564200; Kunji ERS, 2004, FEBS LETT, V564, P239, DOI 10.1016/S0014-5793(04)00242-X; Lin CW, 2000, J GEN PHYSIOL, V116, P535, DOI 10.1085/jgp.116.4.535; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torras-Llort M, 2001, J MEMBRANE BIOL, V180, P213, DOI 10.1007/s002320010072; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809	48	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26552	26561		10.1074/jbc.M604049200	http://dx.doi.org/10.1074/jbc.M604049200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825196	hybrid			2022-12-27	WOS:000240249500073
J	Thomas, DD; Ridnour, LA; Espey, MG; Donzelli, S; Ambs, S; Hussain, SP; Harris, CC; DeGraff, W; Roberts, DD; Mitchell, JB; Wink, DA				Thomas, Douglas D.; Ridnour, Lisa A.; Espey, Michael Graham; Donzelli, Sonia; Ambs, Stefan; Hussain, S. Perwez; Harris, Curtis C.; DeGraff, William; Roberts, David D.; Mitchell, James B.; Wink, David A.			Superoxide fluxes limit nitric oxide-induced signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE NITRATION; PEROXYNITRITE-MEDIATED OXIDATION; ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST-CANCER; INDUCIBLE FACTOR-1-ALPHA; XANTHINE-OXIDASE; REGULATED KINASE; CARCINOMA-CELLS; SYNTHASE GENE; TUMOR-GROWTH	Independently, superoxide (O-2(-)) and nitric oxide (NO) are biologically important signaling molecules. When co-generated, these radicals react rapidly to form powerful oxidizing and nitrating intermediates. Although this reaction was once thought to be solely cytotoxic, herein we demonstrate using MCF7, macrophage, and endothelial cells that when nanomolar levels of NO and O-2(-) were produced concomitantly, the effective NO concentration was established by the relative fluxes of these two radicals. Differential regulation of sGC, pERK, HIF-1 alpha, and p53 were used as biological dosimeters for NO concentration. Introduction of intracellular-or extracellular-generated O-2-during NO generation resulted in a concomitant increase in oxidative intermediates with a decrease in steady-state NO concentrations and a proportional reduction in the levels of sGC, ERK, HIF-1 alpha, and p53 regulation. NO responses were restored by addition of SOD. The intermediates formed from the reactions of NO with O-2(-) were non-toxic, did not form 3-nitrotyrosine, nor did they elicit any signal transduction responses. H2O2 in bolus or generated from the dismutation of O-2-by SOD, was cytotoxic at high concentrations and activated p53 independent of NO. This effect was completely inhibited by catalase, suppressed by NO, and exacerbated by intracellular catalase inhibition. We conclude that the reaction of O-2(-) with NO is an important regulatory mechanism, which modulates signaling pathways by limiting steady-state levels of NO and preventing H2O2 formation from O-2(-).	NCI, Radiat Biol Branch, Tumor Biol Sect, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thomas, DD (corresponding author), NCI, Radiat Biol Branch, Tumor Biol Sect, NIH, Bldg 10,Rm B3-B69, Bethesda, MD 20892 USA.	thomasdo@mail.nih.gov	Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Ridnour, Lisa A./0000-0001-9446-8349; Wink, David/0000-0002-5652-7480; Thomas, Douglas/0000-0003-1252-0786; Azad, Mahan/0000-0002-8633-3513; Ambs, Stefan/0000-0001-7651-9309; Hussain, S. Perwez/0000-0002-2294-522X	NATIONAL CANCER INSTITUTE [ZIABC010033, Z01BC010033, ZIASC006387, Z01SC006387, Z01SC009172, ZIASC009172] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Branco MR, 2004, J BIOL CHEM, V279, P6501, DOI 10.1074/jbc.M311818200; Brune B, 2005, ANTIOXID REDOX SIGN, V7, P497, DOI 10.1089/ars.2005.7.497; Ekmekcioglu S, 2000, CLIN CANCER RES, V6, P4768; Erker L, 2005, HUM MOL GENET, V14, P1699, DOI 10.1093/hmg/ddi181; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Feng CW, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-8; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; Hirota K, 2005, BIOCHEM BIOPH RES CO, V338, P610, DOI 10.1016/j.bbrc.2005.08.193; Houston M, 1999, J BIOL CHEM, V274, P4985, DOI 10.1074/jbc.274.8.4985; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Juang SH, 1998, HUM GENE THER, V9, P845, DOI 10.1089/hum.1998.9.6-845; Kohl R, 2006, FREE RADICAL BIO MED, V40, P1430, DOI 10.1016/j.freeradbiomed.2005.12.012; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Le XD, 2005, P NATL ACAD SCI USA, V102, P8758, DOI 10.1073/pnas.0409581102; Liu PT, 1998, AM J PHYSIOL-HEART C, V275, pH2191, DOI 10.1152/ajpheart.1998.275.6.H2191; Makino N, 2004, BBA-GEN SUBJECTS, V1673, P149, DOI 10.1016/j.bbagen.2004.04.011; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; Morandini R, 1999, CELL MOL BIOL, V45, P1053; Nourooz-Zadeh J, 1999, METHOD ENZYMOL, V300, P58; Pervin S, 2003, CANCER RES, V63, P8853; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Ridnour LA, 2005, P NATL ACAD SCI USA, V102, P13147, DOI 10.1073/pnas.0502979102; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Schmid T, 2004, J CELL MOL MED, V8, P423, DOI 10.1111/j.1582-4934.2004.tb00467.x; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101; Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.98.1.355; Wang C, 2003, CHEM RES TOXICOL, V16, P1004, DOI 10.1021/tx0340448; Wang Liwei, 2005, Gastric Cancer, V8, P18, DOI 10.1007/s10120-004-0310-7; Watanabe N, 2003, ARCH BIOCHEM BIOPHYS, V411, P145, DOI 10.1016/S0003-9861(02)00716-6; Wink DA, 1995, TOXICOL LETT, V82-3, P221, DOI 10.1016/0378-4274(95)03557-5; WINK DA, 1995, ARCH BIOCHEM BIOPHYS, V319, P402, DOI 10.1006/abbi.1995.1310; Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203, DOI 10.1089/152308601300185179; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Zhou H, 2005, TOXICOLOGY, V208, P223, DOI 10.1016/j.tox.2004.11.021; Zhou J, 2003, AM J PHYSIOL-CELL PH, V284, pC439, DOI 10.1152/ajpcell.00294.2002	56	89	89	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25984	25993		10.1074/jbc.M602242200	http://dx.doi.org/10.1074/jbc.M602242200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16829532	hybrid			2022-12-27	WOS:000240249500013
J	Waters, EK; Yegneswaran, S; Morrissey, JH				Waters, Emily K.; Yegneswaran, Subramanian; Morrissey, James H.			Raising the active site of factor VIIa above the membrane surface reduces its procoagulant activity but not factor VII autoactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; BLOOD-COAGULATION FACTOR; SOLUBLE TISSUE FACTOR; CRYSTAL-STRUCTURE; FACTOR-X; COFACTOR FUNCTION; GLA DOMAIN; PROTEIN-C; ACTIVATION; CALCIUM	Tissue factor, the physiologic trigger of blood clotting, is the membrane-anchored protein cofactor for the plasma serine protease, factor VIIa. Tissue factor is hypothesized to position and align the active site of factor VIIa relative to the membrane surface for optimum proteolytic attack on the scissile bonds of membrane-bound protein substrates such as factor X. We tested this hypothesis by raising the factor VIIa binding site above the membrane surface by creating chimeras containing the tissue factor ectodomain linked to varying portions of the membrane-anchored protein, P-selectin. The tissue factor/P-selectin chimeras bound factor VIIa with high affinity and supported full allosteric activation of factor VIIa toward tripeptidyl-amide substrates. That the active site of factor VIIa was raised above the membrane surface when bound to tissue factor/P-selectin chimeras was confirmed using resonance energy transfer techniques in which appropriate fluorescent dyes were placed in the active site of factor VIIa and at the membrane surface. The chimeras were deficient in supporting factor X activation by factor VIIa due to decreased k(cat). The chimeras were also markedly deficient in clotting plasma, although incubating factor VII or VIIa with the chimeras prior to the addition of plasma restored much of their procoagulant activity. Interestingly, all chimeras fully supported tissue factor-dependent factor VII autoactivation. These studies indicate that proper positioning of the factor VII/VIIa binding site on tissue factor above the membrane surface is important for efficient rates of activation of factor X by this membrane-bound enzyme/cofactor complex.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Urbana-Champaign; Scripps Research Institute	Morrissey, JH (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 417 Med Sci Bldg,MC-714,506 S Mathews, Urbana, IL 61801 USA.	jhmorris@uiuc.edu	Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NHLBI NIH HHS [R01 HL047014-14A1, R01 HL47014, R01 HL047014] Funding Source: Medline; NIGMS NIH HHS [T32 GM007283] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; FIORE MM, 1994, J BIOL CHEM, V269, P143; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Hathcock JJ, 2006, BLOOD CELL MOL DIS, V36, P194, DOI 10.1016/j.bcmd.2005.12.032; Hu PS, 2003, CANCER RES, V63, P5046; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; McCallum CD, 1997, J BIOL CHEM, V272, P30160, DOI 10.1074/jbc.272.48.30160; Moons AHM, 2002, CARDIOVASC RES, V53, P313, DOI 10.1016/S0008-6363(01)00452-7; Morrissey J. H., 2006, HEMOSTASIS THROMBOSI, P91; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Rippmann JF, 2000, BIOCHEM J, V349, P805, DOI 10.1042/bj3490805; RUF W, 1991, J BIOL CHEM, V266, P2158; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Smith SA, 2004, J THROMB HAEMOST, V2, P1155, DOI 10.1111/j.1538-7836.2004.00772.x; THORPE PE, 2000, CANC J SCI AM S3, V6, P237; Waters EK, 2006, BIOCHEMISTRY-US, V45, P3769, DOI 10.1021/bi052600m; Yegneswaran S, 1999, J BIOL CHEM, V274, P5462, DOI 10.1074/jbc.274.9.5462; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	32	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26062	26068		10.1074/jbc.M604915200	http://dx.doi.org/10.1074/jbc.M604915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16835245	hybrid			2022-12-27	WOS:000240249500021
J	Lieskovska, J; Ling, Y; Badley-Clarke, J; Clemmons, DR				Lieskovska, Jaroslava; Ling, Yan; Badley-Clarke, Jane; Clemmons, David R.			The role of Src kinase in insulin-like growth factor-dependent mitogenic signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHATASE SHP-2; C-SRC; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA-V-BETA-3 INTEGRIN; SHC PHOSPHORYLATION; EPIDERMAL-GROWTH; BINDING-PROTEINS	Activation of the MAPK pathway mediates insulin-like growth factor-I (IGF-I)-dependent proliferation in vascular smooth muscle cells (SMC). Our previous studies have shown that IGF-I-induced Shc phosphorylation is necessary for sustained activation of MAPK and increased cell proliferation of SMCs, and both Shc and the tyrosine phosphatase SHP-2 must be recruited to the membrane protein SHPS-1 in order for Shc to be phosphorylated. These studies were undertaken to determine whether Src kinase activity is required to phosphorylate Shc in response to IGF-I in SMC and because SHP-2 binds to Src whether their interaction was also required for IGF-I-stimulated mitogenesis. Our results show that IGF-I induces activation of Src kinase and that is required for Shc phosphorylation and for optimal MAPK activation. We tested whether Shc is a substrate of c-Src in SMC by disrupting Src/Shc association using a peptide containing a YXXL (Tyr328) motif sequence derived from Src. The peptide blocked the binding of Src and Shc in vitro and in vivo. Cells expressing a mutant Src (Src-FF) that had Tyr328/Tyr358 substituted with phenylalanines (Src-FF) showed defective Src/Shc binding, impaired IGF-I-dependent Shc phosphorylation, and impaired mitogenesis. This supports the conclusion that Src phosphorylates Shc. IGF-I induced both Src/SHP-2 and Src/SHPS-1 association. SMCs expressing an SHP-2 mutant that had the polyproline-rich region of SH2 deleted (SHP-2 Delta 10) had disrupted SHP-2/Src association, impaired IGF-I-dependent Shc phosphorylation, and an attenuated mitogenic response. IGF-I-induced association of Src and SHPS-1 was also impaired in SHP-2 Delta 10-expressing cells, although SHP-2/SHPS-1 association was unaffected. Upon IGF-I stimulation, a complex assembles on SHPS-1 that contains SHP-2, c-Src, and Shc wherein Src phosphorylates Shc, a signaling step that is necessary for an optimal mitogenic response.	Univ N Carolina, Sch Med, Dept Med, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Clemmons, DR (corresponding author), Univ N Carolina, Sch Med, Dept Med, Div Endocrinol, CB 7170,5030 Burnett Womack, Chapel Hill, NC 27599 USA.	endo@med.unc.edu	Lieskovska, Jaroslava/G-9309-2014	Lieskovska, Jaroslava/0000-0001-6626-4912	NIA NIH HHS [AG-02331] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Biedi C, 2003, ENDOCRINOLOGY, V144, P5497, DOI 10.1210/en.2003-0417; Bjorndahl M, 2005, P NATL ACAD SCI USA, V102, P15593, DOI 10.1073/pnas.0507865102; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; Cho HM, 2005, MOL CELLS, V19, P60; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corjay MH, 1999, J CELL BIOCHEM, V75, P492, DOI 10.1002/(SICI)1097-4644(19991201)75:3<492::AID-JCB13>3.3.CO;2-Q; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; Cui QL, 2005, J BIOL CHEM, V280, P8918, DOI 10.1074/jbc.M414267200; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Ho A, 2001, CANCER RES, V61, P474; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Knowlden JM, 2005, ENDOCRINOLOGY, V146, P4609, DOI 10.1210/en.2005-0247; Kuemmerle JF, 2006, AM J PHYSIOL-GASTR L, V290, pG1194, DOI 10.1152/ajpgi.00345.2005; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Ling Y, 2005, MOL BIOL CELL, V16, P3353, DOI 10.1091/mbc.E04-10-0918; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Maile LA, 2002, ENDOCRINOLOGY, V143, P4259, DOI 10.1210/en.2002-220395; Morita N, 2004, MOL CELL BIOCHEM, V262, P71, DOI 10.1023/B:MCBI.0000038218.09259.1c; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sakata T, 2004, J BONE MINER RES, V19, P436, DOI 10.1359/JBMR.0301241; Sasaoka T, 2001, ENDOCRINOLOGY, V142, P5226, DOI 10.1210/en.142.12.5226; Sato H, 2005, CARDIOVASC RES, V67, P714, DOI 10.1016/j.cardiores.2005.04.017; Sato K, 2005, J BIOCHEM, V137, P61, DOI 10.1093/jb/mvi011; Sato K, 1997, BIOCHEM BIOPH RES CO, V240, P399, DOI 10.1006/bbrc.1997.7667; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Sayeski PP, 2003, EXP CELL RES, V287, P339, DOI 10.1016/S0014-4827(03)00154-X; Sekimoto H, 2005, MOL ENDOCRINOL, V19, P1859, DOI 10.1210/me.2004-0481; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Soon L, 1999, MOL CELL BIOL, V19, P3816; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Yang K, 2005, J BIOL CHEM, V280, P39058, DOI 10.1074/jbc.M506921200; Zahradka P, 2004, ENDOCRINOLOGY, V145, P2978, DOI 10.1210/en.2004-0029; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	53	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25041	25053		10.1074/jbc.M602866200	http://dx.doi.org/10.1074/jbc.M602866200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825188	hybrid, Green Published			2022-12-27	WOS:000240031300006
J	Plattner, F; Angelo, M; Giese, KP				Plattner, Florian; Angelo, Marco; Giese, K. Peter			The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; AMYLOID PRECURSOR PROTEIN; PHOSPHORYLATES TAU; ACTIVATOR P25; CDK5; LITHIUM; PHOSPHATASE-1; MODULATION; SUBSTRATE; TRANSPORT	Hyperphosphorylation of the microtubule-associated protein tau is a characteristic feature of neurodegenerative tauopathies including Alzheimer disease. Over-activation of proline-directed kinases, such as cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3 (GSK3), has been implicated in the aberrant phosphorylation of tau at proline-directed sites. In this study we tested the roles of Cdk5 and GSK3 in tau hyperphosphorylation in vivo using transgenic mice with p25-induced Cdk5 over-activation. We found that over-activation of Cdk5 in young transgenic animals does not induce tau hyperphosphorylation at sites recognized by the antibodies AT8, AT100, PHF-1, and TG3. In fact, we observed that Cdk5 over-activation leads to inhibition of GSK3. However, in old transgenic animals the inhibition of GSK3 is lost and results in increased GSK3 activity, which coincides with tau hyperphosphorylation at the AT8 and PHF-1 sites. Pharmacological inhibition of GSK3 in old transgenic mice by chronic treatment with lithium leads to a reduction of the age-dependent increase in tau hyperphosphorylation. Furthermore, we found that Cdk5, GSK3, and PP2A co-immunoprecipitate, suggesting a functional association of these molecules. Together, these results reveal the role of GSK3 as a key mediator of tau hyperphosphorylation, whereas Cdk5 acts as a modulator of tau hyperphosphorylation via the inhibitory regulation of GSK3. Furthermore, these findings suggest that disruption of regulation of GSK3 activity underlies tau hyperphosphorylation in neurodegenerative tauopathies. Hence, GSK3 may be a prime target for therapeutic intervention in tauopathies including Alzheimer disease.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Giese, KP (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	f.plattner@ucl.ac.uk; p.giese@ucl.ac.uk	Giese, Karl P/A-3112-2011	Giese, Karl P/0000-0003-4503-7344; Plattner, Florian/0000-0002-3150-1866	MRC [G0400983] Funding Source: UKRI; Medical Research Council [G0400983] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; Agarwal-Mawal A, 2003, J BIOL CHEM, V278, P12722, DOI 10.1074/jbc.M211491200; Angelo M, 2003, EUR J NEUROSCI, V18, P423, DOI 10.1046/j.1460-9568.2003.02746.x; Angelo M, 2006, J NEUROCHEM, V99, P353, DOI 10.1111/j.1471-4159.2006.04040.x; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cohen PTW, 2002, J CELL SCI, V115, P241; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Giese KP, 2005, NEUROREPORT, V16, P1725, DOI 10.1097/01.wnr.0000185019.67434.d2; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hallows JL, 2003, J NEUROSCI, V23, P10633; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Ishizawa T, 2003, AM J PATHOL, V163, P1057, DOI 10.1016/S0002-9440(10)63465-7; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lau LF, 2002, J MOL NEUROSCI, V19, P267, DOI 10.1385/JMN:19:3:267; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Li T, 2006, BIOCHEMISTRY-US, V45, P3134, DOI 10.1021/bi051635j; Li T, 2006, BIOCHEMISTRY-US, V45, P3125, DOI 10.1021/bi051634r; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; Liu F, 2003, FEBS LETT, V547, P193, DOI 10.1016/S0014-5793(03)00714-2; Liu SJ, 2004, J BIOL CHEM, V279, P50078, DOI 10.1074/jbc.M406109200; Mandelkow EM, 2004, J CELL BIOL, V167, P99, DOI 10.1083/jcb.200401085; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; Nakamura S, 1997, NEUROLOGY, V48, P267, DOI 10.1212/WNL.48.1.267; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Ris L, 2005, EUR J NEUROSCI, V21, P3023, DOI 10.1111/j.1460-9568.2005.04137.x; Sengupta A, 1997, MOL CELL BIOCHEM, V167, P99, DOI 10.1023/A:1006883924775; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; Shelton SB, 2004, J NEUROCHEM, V88, P1313, DOI 10.1111/j.1471-4159.2003.02328.x; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Takashima A, 2001, NEUROSCI LETT, V306, P37, DOI 10.1016/S0304-3940(01)01864-X; Vandebroek T, 2005, BIOCHEMISTRY-US, V44, P11466, DOI 10.1021/bi0506775	52	272	282	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25457	25465		10.1074/jbc.M603469200	http://dx.doi.org/10.1074/jbc.M603469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803897	hybrid			2022-12-27	WOS:000240031300048
J	Spofford, LS; Abel, EV; Boisvert-Adamo, K; Aplin, AE				Spofford, Laurie S.; Abel, Ethan V.; Boisvert-Adamo, Karen; Aplin, Andrew E.			Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G(1)-S progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT/PROTEIN KINASE-B; MALIGNANT-MELANOMA; D1; PROLIFERATION; GROWTH; GENE; ACTIVATION; MUTATIONS; PATHWAY; BRAF	D-type cyclins regulate G(1) cell cycle progression by enhancing the activities of cyclin-dependent kinases (CDKs), and their expression is frequently altered in malignant cells. We and others have previously shown that cyclin D1 is up-regulated in melanoma cells through adhesion-independent MEK-ERK1/2 signaling initiated by mutant B-RAF. Here, we describe the regulation and role of cyclin D3 in human melanoma cells. Cyclin D3 expression was enhanced in a cell panel of human melanoma cell lines compared with melanocytes and was regulated by fibronectin-mediated phosphatidylinositol 3-kinase/Akt signaling but not MEK activity. RNA interference experiments demonstrated that cyclin D3 contributed to G(1)-S cell cycle progression and proliferation in melanoma cells. Overexpression of cyclin D1 did not recover the effects of cyclin D3 knockdown. Finally, immunoprecipitation studies showed that CDK6 is a major binding partner for cyclin D3, whereas CDK4 preferentially associated with cyclin D1. Together, these findings demonstrate that cyclin D3 is an important regulator of melanoma G(1)-S cell cycle progression and that D-type cyclins are differentially regulated in melanoma cells.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA.	aplina@mail.amc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM067893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bales E, 2005, CANCER RES, V65, P692; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; BOISVETADAMO K, 2006, ONCOGENE; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Vita G, 2000, CANCER RES, V60, P3916; Dhawan P, 2002, CANCER RES, V62, P7335; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Florenes VA, 2000, CLIN CANCER RES, V6, P3614; Guldberg P, 1997, CANCER RES, V57, P3660; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Jetzt A, 2003, CANCER RES, V63, P6697; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; Rieber M, 1999, CELL DEATH DIFFER, V6, P1209, DOI 10.1038/sj.cdd.4400606; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Sauter ER, 2002, CANCER RES, V62, P3200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stahl JM, 2003, CANCER RES, V63, P2881; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Teng DHF, 1997, CANCER RES, V57, P5221; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594; Zhu XY, 2001, CANCER RES, V61, P4569	43	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25644	25651		10.1074/jbc.M600197200	http://dx.doi.org/10.1074/jbc.M600197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16815849	Green Accepted, hybrid			2022-12-27	WOS:000240031300067
J	Hidalgo, P; Gonzalez-Gutierrez, G; Garcia-Olivares, J; Neely, A				Hidalgo, Patricia; Gonzalez-Gutierrez, Giovanni; Garcia-Olivares, Jennie; Neely, Alan			The alpha(1)-beta-subunit interaction that modulates calcium channel activity is reversible and requires a competent alpha-interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; CA2+ CHANNELS; CHARGE MOVEMENT; AMINO-TERMINUS; TRAFFICKING; EXPRESSION; DELETIONS	High voltage-gated calcium channels consist of a pore-forming subunit (alpha(1)) and three nonhomologous subunits (alpha(2)/delta,beta, and gamma). Although it is well established that the beta-subunit promotes traffic of channels to the plasma membrane and modifies their activity, the reversible nature of the interaction with the alpha(1)-subunit remains controversial. Here, we address this issue by examining the effect of purified beta(2)a protein on Ca(V)1.2 and Ca(V)2.3 channels expressed in Xenopus oocytes. The beta(2a)-subunit binds to the alpha(1)-interaction domain ( AID) in vitro, and when injected into oocytes, it shifts the voltage dependence of activation and increases charge movement to ionic current coupling of CaV1.2 channels. This increase depended on the integrity of AID but was not abolished by bafilomycin, demonstrating that the alpha(1)-beta interaction through the AID site can take place at the plasma membrane. Furthermore, injection of beta(2a) protein inhibited inactivation of CaV2.3 channels and converted fast inactivating Ca(V)2.3/beta(1b) channels to slow inactivating channels. Inhibition of inactivation required larger concentration of beta(2a) in oocytes expressing Ca(V)2.3/beta(1b) channels than expressing CaV2.3 alone but reached the same maximal level as expected for a competitive interaction through a single binding site. Together, our data show that the alpha(1)-beta interaction is reversible in intact cells and defines calcium channels beta-subunits as regulatory proteins rather than stoichiometric subunits.	Univ Valparaiso, Fac Ciencias, Ctr Neurociencia Valparaiso, Valparaiso 2349400, Chile; Hannover Med Sch, Abt Neurophysiol, D-30625 Hannover, Germany; Ctr Estudios Cient, Valdivia 509000, Chile	Universidad de Valparaiso; Hannover Medical School	Neely, A (corresponding author), Univ Valparaiso, Fac Ciencias, Ctr Neurociencia Valparaiso, Gran Bretana 1111, Valparaiso 2349400, Chile.	alan@cnv.cl	Neely, Alan/A-8715-2009; Hidalgo, Patricia/I-7506-2013	Hidalgo, Patricia/0000-0002-4162-6590; Gonzalez-Gutierrez, Giovanni/0000-0002-1044-943X; Neely, Alan/0000-0002-6007-2159				Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Berrou L, 2002, BIOPHYS J, V83, P1429, DOI 10.1016/S0006-3495(02)73914-3; Berrou L, 2005, J BIOL CHEM, V280, P494, DOI 10.1074/jbc.M410859200; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Dalton S, 2005, J PHYSIOL-LONDON, V567, P757, DOI 10.1113/jphysiol.2005.093195; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Drose S, 1997, J EXP BIOL, V200, P1; Garcia R, 2002, J PHYSIOL-LONDON, V545, P407, DOI 10.1113/jphysiol.2002.027433; Maltez JM, 2005, NAT STRUCT MOL BIOL, V12, P372, DOI 10.1038/nsmb909; Neely A, 2004, J BIOL CHEM, V279, P21689, DOI 10.1074/jbc.M312675200; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Olcese R, 1996, J PHYSIOL-LONDON, V497, P675, DOI 10.1113/jphysiol.1996.sp021799; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; REYES EP, 1992, J BIOL CHEM, V267, P1792; Sandoz G, 2004, P NATL ACAD SCI USA, V101, P6267, DOI 10.1073/pnas.0306804101; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1994, J BIOL CHEM, V269, P1635; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348	24	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24104	24110		10.1074/jbc.M605930200	http://dx.doi.org/10.1074/jbc.M605930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793763	hybrid			2022-12-27	WOS:000239847800005
J	Kaminaga, Y; Schnepp, J; Peel, G; Kish, CM; Ben-Nissan, G; Weiss, D; Orlova, I; Lavie, O; Rhodes, D; Wood, K; Porterfield, DM; Cooper, AJL; Schloss, JV; Pichersky, E; Vainstein, A; Dudareva, N				Kaminaga, Yasuhisa; Schnepp, Jennifer; Peel, Greg; Kish, Christine M.; Ben-Nissan, Gili; Weiss, David; Orlova, Irina; Lavie, Orly; Rhodes, David; Wood, Karl; Porterfield, D. Marshall; Cooper, Arthur J. L.; Schloss, John V.; Pichersky, Eran; Vainstein, Alexander; Dudareva, Natalia			Plant phenylacetaldehyde synthase is a bifunctional homotetrameric enzyme that catalyzes phenylalanine decarboxylation and oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DECARBOXYLASES; FLORAL SCENT PRODUCTION; BETA-D-GLUCOPYRANOSIDE; DOPA DECARBOXYLASE; VOLATILE COMPOUNDS; TRYPTOPHAN DECARBOXYLASE; SACCHAROMYCES-CEREVISIAE; ANAEROBIC CONDITIONS; ROSE FLOWERS; OPIUM POPPY	We have isolated and characterized Petunia hybrida cv. Mitchell phenylacetaldehyde synthase (PAAS), which catalyzes the formation of phenylacetaldehyde, a constituent of floral scent. PAAS is a cytosolic homotetrameric enzyme that belongs to group II pyridoxal 5'-phosphate-dependent amino-acid decarboxylases and shares extensive amino acid identity (similar to 65%) with plant L-tyrosine/ 3,4-dihydroxy-L-phenylalanine and L-tryptophan decarboxylases. It displays a strict specificity for phenylalanine with an apparent Km of 1.2 mM. PAAS is a bifunctional enzyme that catalyzes the unprecedented efficient coupling of phenylalanine decarboxylation to oxidation, generating phenylacetaldehyde, CO2, ammonia, and hydrogen peroxide in stoichiometric amounts.	Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Agr & Biol Engn, W Lafayette, IN 47907 USA; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel; Cornell Univ, Weil Med Coll, White Plains, NY 10605 USA; Cornell Univ, Coll Med, Burke Med Res Inst, White Plains, NY 10605 USA; NeuroSystec Corp, Valencia, CA 91355 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Hebrew University of Jerusalem; Cornell University; Cornell University; University of Michigan System; University of Michigan	Dudareva, N (corresponding author), Purdue Univ, Dept Hort & Landscape Architecture, 625 Agr Mall Dr, W Lafayette, IN 47907 USA.	dudareva@purdue.edu	Rhodes, David/L-4602-2019; Dudareva, Natalia/S-8710-2017; Weiss, David/I-1084-2012; porterfield, D. Marshall/ABE-7441-2021; Cooper, Arthur J.L./H-5171-2016	Dudareva, Natalia/0000-0003-0777-7763; porterfield, D. Marshall/0000-0003-3339-4766; Schloss, John/0000-0002-6586-7508				ABELL LM, 1991, BIOCHEMISTRY-US, V30, P7883, DOI 10.1021/bi00246a002; Agnihotri G, 2004, BIOCHEMISTRY-US, V43, P14265, DOI 10.1021/bi048841w; Agnihotri G, 2001, BIOORG CHEM, V29, P234, DOI 10.1006/bioo.2001.1211; AMRHEIN N, 1976, PLANTA, V131, P33, DOI 10.1007/BF00387342; BARCLAY KD, 1994, LIPIDS, V29, P877, DOI 10.1007/BF02536256; Bartels D, 2001, TRENDS PLANT SCI, V6, P284, DOI 10.1016/S1360-1385(01)01983-5; Berkovitch F, 2004, P NATL ACAD SCI USA, V101, P15870, DOI 10.1073/pnas.0407074101; Bertoldi M, 2005, FEBS LETT, V579, P5175, DOI 10.1016/j.febslet.2005.08.029; Bertoldi M, 2003, BBA-PROTEINS PROTEOM, V1647, P42, DOI 10.1016/S1570-9639(03)00046-3; Bertoldi M, 2002, J BIOL CHEM, V277, P36357, DOI 10.1074/jbc.M204867200; Bertoldi M, 1999, BIOCHEM J, V342, P509, DOI 10.1042/0264-6021:3420509; Bertoldi M, 2000, BIOCHEM J, V352, P533, DOI 10.1042/0264-6021:3520533; Bertoldi M, 1999, J BIOL CHEM, V274, P5514, DOI 10.1074/jbc.274.9.5514; Bertoldi M, 1998, BIOCHEMISTRY-US, V37, P6552, DOI 10.1021/bi9718898; Boatright J, 2004, PLANT PHYSIOL, V135, P1993, DOI 10.1104/pp.104.045468; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTERY RG, 1993, FLAVOR SCI SENSIBLE; Davis K, 2001, J BIOMED SCI, V8, P359, DOI 10.1159/000054055; DEML R, 1995, ENTOMOL GEN, V19, P239; Dickinson JR, 2003, J BIOL CHEM, V278, P8028, DOI 10.1074/jbc.M211914200; Dolphin D., 1986, VITAMIN B6 PYRIDOXAL; DONATH J, 1995, PHYTOCHEMISTRY, V39, P785, DOI 10.1016/0031-9422(95)00082-I; Facchini PJ, 2000, PHYTOCHEMISTRY, V54, P121, DOI 10.1016/S0031-9422(00)00050-9; FACCHINI PJ, 1995, PHYTOCHEMISTRY, V38, P1119, DOI 10.1016/0031-9422(94)00814-A; FACCHINI PJ, 1994, J BIOL CHEM, V269, P26684; Garcia E, 2003, FOOD SCI TECHNOL INT, V9, P33, DOI [10.1177/1082013203009001006, 10.1177/1082013202008001941]; Guterman I, 2002, PLANT CELL, V14, P2325, DOI 10.1105/tpc.005207; Hayashi S, 2004, TETRAHEDRON, V60, P7005, DOI 10.1016/j.tet.2003.10.130; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; JONES KC, 1986, J BIOL CHEM, V261, P2553; KAWALLECK P, 1993, J BIOL CHEM, V268, P2189; Klinman JP, 2003, BBA-PROTEINS PROTEOM, V1647, P131, DOI 10.1016/S1570-9639(03)00077-3; KNUDSEN JT, 1993, PHYTOCHEMISTRY, V33, P253, DOI 10.1016/0031-9422(93)85502-I; Kocsis MG, 2000, PLANT PHYSIOL, V123, P1153, DOI 10.1104/pp.123.3.1153; Lavid N, 2002, PLANT PHYSIOL, V129, P1899, DOI 10.1104/pp.005330; Lepore BW, 2005, P NATL ACAD SCI USA, V102, P13819, DOI 10.1073/pnas.0505726102; LopezMeyer M, 1997, PLANT J, V11, P1167, DOI 10.1046/j.1365-313X.1997.11061167.x; Negre F, 2002, ARCH BIOCHEM BIOPHYS, V406, P261, DOI 10.1016/S0003-9861(02)00458-7; NIE Y, 1993, LIPIDS, V28, P949, DOI 10.1007/BF02537506; Ouwerkerk PBF, 1999, PLANT MOL BIOL, V41, P491, DOI 10.1023/A:1006321100550; Pino JA, 2004, J ESSENT OIL RES, V16, P318, DOI 10.1080/10412905.2004.9698731; Ravichandran R, 1998, FOOD CHEM, V62, P347, DOI 10.1016/S0308-8146(97)00229-X; Rigby SE, 2005, BIOCHEM SOC T, V33, P754, DOI 10.1042/BST0330754; Rontein D, 2001, J BIOL CHEM, V276, P35523, DOI 10.1074/jbc.M106038200; Sakai K, 1997, J BIOCHEM-TOKYO, V122, P961; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; Schloss JV, 2002, PLANTA, V216, P38, DOI 10.1007/s00425-002-0905-3; Seo M, 1998, PLANT PHYSIOL, V116, P687, DOI 10.1104/pp.116.2.687; Shalit M, 2004, ISR J PLANT SCI, V52, P245, DOI 10.1560/P7G3-FT41-XJCP-1XFM; Stites TE, 2000, J NUTR, V130, P719, DOI 10.1093/jn/130.4.719; TANASE S, 1985, J BIOL CHEM, V260, P6738; Tieman D, 2006, P NATL ACAD SCI USA, V103, P8287, DOI 10.1073/pnas.0602469103; VANTUNEN AJ, 1988, EMBO J, V7, P1257, DOI 10.1002/j.1460-2075.1988.tb02939.x; Verdonk JC, 2003, PHYTOCHEMISTRY, V62, P997, DOI 10.1016/S0031-9422(02)00707-0; Vuralhan Z, 2003, APPL ENVIRON MICROB, V69, P4534, DOI 10.1128/AEM.69.8.4534-4541.2003; WADA H, 1961, J BIOL CHEM, V236, P2089; Watanabe S, 2002, BIOSCI BIOTECH BIOCH, V66, P943, DOI 10.1271/bbb.66.943; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wetmore SD, 2001, J AM CHEM SOC, V123, P8678, DOI 10.1021/ja010211j; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; ZON J, 1992, LIEBIGS ANN CHEM, P625, DOI 10.1002/jlac.1992199201107	61	204	231	4	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23357	23366		10.1074/jbc.M602708200	http://dx.doi.org/10.1074/jbc.M602708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16766535	hybrid			2022-12-27	WOS:000239702900010
J	Kuhnel, K; Blankenfeldt, W; Terner, J; Schlichting, I				Kuehnel, Karin; Blankenfeldt, Wulf; Terner, James; Schlichting, Ilme			Crystal structures of chloroperoxidase with its bound substrates and complexed with formate, acetate, and nitrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; COMPOUND-I FORMATION; HORSERADISH-PEROXIDASE; ENANTIOSELECTIVE EPOXIDATION; BIOLOGICAL CHLORINATION; HYDROGEN-PEROXIDE; CATALYTIC CYCLE; LOW-TEMPERATURE; ACTIVE-SITE; CALDARIOMYCIN	Chloroperoxidase (CPO) is a heme-thiolate enzyme that catalyzes hydrogen peroxide-dependent halogenation reactions. Structural data on substrate binding have not been available so far. CPO was therefore crystallized in the presence of iodide or bromide. One halide binding site was identified at the surface near a narrow channel that connects the surface with the heme. Two other halide binding sites were identified within and at the other end of this channel. Together, these sites suggest a pathway for access of halide anions to the active site. The structure of CPO complexed with its natural substrate cyclopentanedione was determined at a resolution of 1.8 angstrom. This is the first example of a CPO structure with a bound organic substrate. In addition, structures of CPO bound with nitrate, acetate, and formate and of a ternary complex with dimethylsulfoxide (Me2SO) and cyanide were determined. These structures have implications for the mechanism of compound I formation. Before binding to the heme, the incoming hydrogen peroxide first interacts with Glu-183. The deprotonated Glu-183 abstracts a proton from hydrogen peroxide. The hydroperoxo-anion then binds at the heme, yielding compound 0. Glu-183 protonates the distal oxygen of compound 0, water is released, and compound I is formed.	Max Planck Inst Med Res, Abt Biomol Mechanismen, D-69120 Heidelberg, Germany; Max Planck Inst Mol Physiol, Abt Phys Biochem, D-44227 Dortmund, Germany; Virginia Commonwealth Univ, Dept Chem, Richmond, VA 23284 USA	Max Planck Society; Max Planck Society; Virginia Commonwealth University	Schlichting, I (corresponding author), Max Planck Inst Med Res, Abt Biomol Mechanismen, Jahnstr 29, D-69120 Heidelberg, Germany.	ilme.schlichting@mpimf-heidelberg.mpg.de	Schlichting, Ilme/I-1339-2013; Blankenfeldt, Wulf/F-8877-2010	Blankenfeldt, Wulf/0000-0001-9886-9668; Kuehnel, Karin/0000-0002-2663-703X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057042] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57042] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN EJ, 1993, J AM CHEM SOC, V115, P4415, DOI 10.1021/ja00063a091; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; BECKWITH JR, 1963, J BIOL CHEM, V238, P3091; BECKWITH JR, 1963, J BIOL CHEM, V238, P3086; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; BLANKE SR, 1989, BIOTECHNOL LETT, V11, P769, DOI 10.1007/BF01026094; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlsson GH, 2005, BIOCHEMISTRY-US, V44, P635, DOI 10.1021/bi0483211; CASELLA L, 1994, BIOCHEMISTRY-US, V33, P6377, DOI 10.1021/bi00187a001; COLONNA S, 1993, TETRAHEDRON-ASYMMETR, V4, P1325, DOI 10.1016/S0957-4166(00)80243-8; COLONNA S, 1990, BIOCHEMISTRY-US, V29, P10465, DOI 10.1021/bi00498a006; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fedorov R, 2003, ARCH BIOCHEM BIOPHYS, V409, P25, DOI 10.1016/S0003-9861(02)00555-6; Filizola M, 2000, J AM CHEM SOC, V122, P3599, DOI 10.1021/ja993000b; GEIGERT J, 1983, BIOCHEM BIOPH RES CO, V116, P82, DOI 10.1016/0006-291X(83)90383-2; GRIFFIN BW, 1983, BIOCHEM BIOPH RES CO, V116, P873, DOI 10.1016/S0006-291X(83)80223-X; GRIFFIN BW, 1991, PEROXIDASES CHEM BIO, V2, P85; HAGER LP, 1966, J BIOL CHEM, V241, P1769; Howes BD, 2000, J BIOL INORG CHEM, V5, P227, DOI 10.1007/s007750050367; Ibrahim M, 2003, J AM CHEM SOC, V125, P13714, DOI 10.1021/ja036949d; Indiani C, 2000, J INORG BIOCHEM, V79, P269, DOI 10.1016/S0162-0134(99)00156-7; ITOH N, 1987, BIOCHEMISTRY-US, V26, P282, DOI 10.1021/bi00375a039; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVINE SD, 1968, TETRAHEDRON, V24, P2979, DOI 10.1016/S0040-4020(01)98705-8; Libby RD, 1996, J BIOL CHEM, V271, P21820, DOI 10.1074/jbc.271.36.21820; LIBBY RD, 1982, J BIOL CHEM, V257, P5030; LIU KKC, 1992, J ORG CHEM, V57, P3748, DOI 10.1021/jo00039a050; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NEIDLEMA.SL, 1966, TETRAHEDRON LETT, P5337; PATTERSON EL, 1967, APPL MICROBIOL, V15, P528, DOI 10.1128/AEM.15.3.528-530.1967; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; POULOS TL, 1980, J BIOL CHEM, V255, P8199; RAMAKRISHNAN K, 1983, BIOCHEMISTRY-US, V22, P3271, DOI 10.1021/bi00282a036; Redaelli C, 2002, CHEMBIOCHEM, V3, P226, DOI 10.1002/1439-7633(20020301)3:2/3<226::AID-CBIC226>3.0.CO;2-7; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; Shintaku M, 2005, J BIOL CHEM, V280, P40934, DOI 10.1074/jbc.M503472200; SONO M, 1986, BIOCHEMISTRY-US, V25, P347, DOI 10.1021/bi00350a011; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Sundaramoorthy M, 1998, CHEM BIOL, V5, P461, DOI 10.1016/S1074-5521(98)90003-5; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; Wagenknecht HA, 1997, CHEM BIOL, V4, P367, DOI 10.1016/S1074-5521(97)90127-7; Wang XT, 1997, BBA-PROTEIN STRUCT M, V1339, P88, DOI 10.1016/S0167-4838(96)00216-6; Yi XW, 2003, J BIOL CHEM, V278, P13855, DOI 10.1074/jbc.M210906200	47	68	68	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23990	23998		10.1074/jbc.M603166200	http://dx.doi.org/10.1074/jbc.M603166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790441	Green Published, hybrid			2022-12-27	WOS:000239702900073
J	Mahmood, NABN; Biemans-Oldehinkel, E; Patzlaff, JS; Schuurman-Wolters, GK; Poolman, B				Mahmood, N. A. B. Nik; Biemans-Oldehinkel, Esther; Patzlaff, Jason S.; Schuurman-Wolters, Gea K.; Poolman, Bert			Ion specificity and ionic strength dependence of the osmoregulatory ABC transporter OpuA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETAINE CARRIER BETP; CORYNEBACTERIUM-GLUTAMICUM; ESCHERICHIA-COLI; OSMOTIC ACTIVATION; CRYSTAL-STRUCTURE; MEMBRANE; BINDING; SYSTEM; PROP; PROTEIN	The ATPase subunit of the osmoregulatory ATP- binding cassette transporterOpuAfrom Lactococcus lactis has a C- terminal extension, the tandem cystathionine beta- synthase ( CBS) domain, which constitutes the sensor that allows the transporter to sense and respond to osmotic stress ( Biemans- Oldehinkel, E., Mahmood, N. A. B. N., and Poolman, B. ( 2006) Proc. Natl. Acad. Sci. U. S. A. 103, 10624 - 10629). C- terminal of the tandem CBS domain is an 18- residue anionic tail ( DIPDEDEVEEIEKEEENK). To investigate the ion specificity of the full transporter, we probed the activity of inside- out reconstituted wild- type OpuA and the anionic tail deletion mutant OpuA Delta 12; these molecules have the tandem CBS domains facing the external medium. At a mole fraction of 40% of anionic lipids in the membrane, the threshold ionic strength for activation of OpuA was similar to 0.15, irrespective of the electrolyte composition of the medium. At equivalent concentrations, bivalent cations (Mg2+ and Ba2+) were more effective in activating OpuA than NH4+, K+, Na+, or Li+, consistent with an ionic strength-based sensing mechanism. Surprisingly, Rb+ and Cs+ were potent inhibitors of wild- type OpuA, and 0.1 mM RbCl was sufficient to completely inhibit the transporter even in the presence of 0.2 M KCl. Rb+ and Cs+ were no longer inhibitory in OpuA Delta 12, indicating that the anionic C- terminal tail participates in the formation of a binding site for large alkali metal ions. Compared with OpuA Delta 12, wild- type OpuA required substantially less potassium ions ( the dominant ion under physiological conditions) for activation. Our data lend new support for the contention that the CBS module in OpuA constitutes the ionic strength sensor whose activity is modulated by the C- terminal anionic tail.	Univ Groningen, Membrane Enzymol Grp, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Poolman, B (corresponding author), Univ Groningen, Membrane Enzymol Grp, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@rug.nl	Poolman, Bert/D-1882-2012					Avdeef A, 1998, PHARMACEUT RES, V15, P209, DOI 10.1023/A:1011954332221; Bennetts B, 2005, J BIOL CHEM, V280, P32452, DOI 10.1074/jbc.M502890200; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BENTAL N, 1997, BIOPHYS J, V73, P17117; Biemans-Oldehinkel E, 2003, EMBO J, V22, P5983, DOI 10.1093/emboj/cdg581; Biemans-Oldehinkel E, 2006, P NATL ACAD SCI USA, V103, P10624, DOI 10.1073/pnas.0603871103; Bockris J.OM., 1970, MODERN ELECTROCHEMIS, P1, DOI DOI 10.1007/B114168; Cotton F.A., 1988, ADV INORGANIC CHEM, V5th, P1385; Culham DE, 2003, BIOCHEMISTRY-US, V42, P11815, DOI 10.1021/bi034939j; Culham DE, 2003, BIOCHEMISTRY-US, V42, P410, DOI 10.1021/bi0264364; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; Horn C, 2003, J MOL BIOL, V334, P403, DOI 10.1016/j.jmb.2003.09.079; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Miller MD, 2004, PROTEINS, V57, P213, DOI 10.1002/prot.20024; Patzlaff JS, 2003, J BIOL CHEM, V278, P29546, DOI 10.1074/jbc.M304796200; Poolman B, 2005, METHOD ENZYMOL, V400, P429, DOI 10.1016/S0076-6879(05)00025-X; Poolman B, 2004, BBA-BIOMEMBRANES, V1666, P88, DOI 10.1016/j.bbamem.2004.06.013; Racher KI, 2001, BIOCHEMISTRY-US, V40, P7324, DOI 10.1021/bi002331u; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Schiller D, 2006, J BIOL CHEM, V281, P7737, DOI 10.1074/jbc.M513052200; Schiller D, 2004, BIOCHEMISTRY-US, V43, P5583, DOI 10.1021/bi0359628; Schiller D, 2004, FEBS LETT, V563, P108, DOI 10.1016/S0014-5793(04)00279-0; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; Spitzer JJ, 2005, TRENDS BIOCHEM SCI, V30, P536, DOI 10.1016/j.tibs.2005.08.002; Tsatskis Y, 2005, J BIOL CHEM, V280, P41387, DOI 10.1074/jbc.M508362200; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2002, EMBO REP, V3, P938, DOI 10.1093/embo-reports/kvf201; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Zhang RG, 1999, BIOCHEMISTRY-US, V38, P4691, DOI 10.1021/bi982858v	33	30	31	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29830	29839		10.1074/jbc.M604907200	http://dx.doi.org/10.1074/jbc.M604907200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16844687	hybrid, Green Published			2022-12-27	WOS:000240896300045
J	Weiske, J; Huber, O				Weiske, Joerg; Huber, Otmar			The histidine triad protein Hint1 triggers apoptosis independent of its enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; C-INTERACTING PROTEIN-1; BETA-CATENIN; CANCER-CELLS; SUPPRESSOR GENE; FHIT GENE; KINASE; EXPRESSION; SUBSTRATE; TARGET	Hint1 is a member of the evolutionarily conserved family of histidine triad proteins that acts as a haplo-insufficient tumor suppressor inducing spontaneous tumor formation in Hint(+/-) and Hint(-/-) mouse models. However, the molecular mechanisms for the tumor-suppressing activity are poorly defined. In this respect, we have recently shown that Hint1, by interaction with Pontin and Reptin, inhibits T-cell factor/beta-catenin-mediated transcription of Wnt target genes. In this study, we have found that, after transient transfection with Hint1, SW480 and MCF-7 cells undergo apoptosis as analyzed by pro-caspase-3 and poly(ADP-ribose) polymerase cleavage, M30 CytoDEATH staining, cytochrome c release, and DNA fragmentation enzyme-linked immunosorbent assay. Hint1 is involved in the regulation of apoptotic pathways by inducing an up-regulation of p53 expression coinciding with an up-regulation of the proapoptotic factor Bax and a concomitant down-regulation of the apoptosis inhibitor Bcl-2. Bad and Puma levels remained unchanged. Further analyses revealed that Hint1 is associated with the Bax promoter and is a component of the Tip60 histone acetyltransferase complex and, in this context, appears to be involved in the regulation of Bax expression. Knockdown of Hint1 by short hairpin RNA resulted in down-regulation of p53 and Bax but had no effect on Bcl-2 expression. A mutant Hint1 (H112N) protein defective in enzymatic activity as anAMP-NH2 hydrolase was not impaired in induction of apoptosis, suggesting that the Hint1 pro-apoptotic activity is independent of the Hint1 enzymatic activity.	Dept Lab Med & Pathobiochem, D-12200 Berlin, Germany		Huber, O (corresponding author), Univ Med Berlin, Inst Klin Chem & Pathobiochem, Charite, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	otmar.huber@charite.de	Huber, Otmar/AAA-4548-2021	Huber, Otmar/0000-0003-4359-1747				Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BRZOSKA PM, 1995, P NATL ACAD SCI USA, V92, P7824, DOI 10.1073/pnas.92.17.7824; Choi EK, 2001, INT J RADIAT ONCOL, V49, P397, DOI 10.1016/S0360-3016(00)01485-1; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Dumon KR, 2001, CANCER RES, V61, P4827; Feng Y, 2003, CANCER RES, V63, P8726; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Jin JY, 2005, J BIOL CHEM, V280, P41207, DOI 10.1074/jbc.M509128200; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Korsisaari N, 2003, MOL CELL BIOL, V23, P3929, DOI 10.1128/MCB.23.11.3929-3935.2003; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Li H, 2006, ONCOGENE, V25, P713, DOI 10.1038/sj.onc.1209111; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Lolli G, 2005, CELL CYCLE, V4, P572, DOI 10.4161/cc.4.4.1607; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Parks KP, 2004, PHYSIOL GENOMICS, V20, P12, DOI 10.1152/physiolgenomics.00204.2004; PEARSON JD, 1990, J BIOL CHEM, V265, P4583; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Weiske J, 2005, J CELL SCI, V118, P3117, DOI 10.1242/jcs.02437; Weiske J, 2001, J BIOL CHEM, V276, P41175, DOI 10.1074/jbc.M105769200; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490	56	109	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27356	27366		10.1074/jbc.M513452200	http://dx.doi.org/10.1074/jbc.M513452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835243	hybrid			2022-12-27	WOS:000240397700062
J	Chi, P; Kwon, Y; Seong, C; Epshtein, A; Lam, I; Sung, P; Klein, HL				Chi, Peter; Kwon, Youngho; Seong, Changhyun; Epshtein, Anastasiya; Lam, Isabel; Sung, Patrick; Klein, Hannah L.			Yeast recombination factor Rdh54 functionally interacts with the Rad51 recombinase and catalyzes Rad51 removal from DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; STRAND EXCHANGE; HOMOLOGOUS RECOMBINATION; CHROMATIN; PROTEIN; REPAIR; DMC1; HELICASE; COMPLEX; BRCA2	The Saccharomyces cerevisiae RDH54-encoded product, a member of the Swi2/Snf2 protein family, is needed for mitotic and meiotic interhomologue recombination and DNA repair. Previous biochemical studies employing Rdh54 purified from yeast cells have shown DNA-dependent ATP hydrolysis and DNA supercoiling by this protein, indicative of a DNA translocase function. Importantly, Rdh54 physically interacts with the Rad51 recombinase and promotes D-loop formation by the latter. Unfortunately, the low yield of Rdh54 from the yeast expression system has greatly hampered the progress on defining the functional interactions of this Swi2/Snf2-like factor with Rad51. Here we describe an E. coli expression system and purification scheme that together provide milligram quantities of nearly homogeneous Rdh54. Using this material, we demonstrate that Rdh54-mediated DNA supercoiling leads to transient DNA strand opening. Furthermore, at the expense of ATP hydrolysis, Rdh54 removes Rad51 from DNA. We furnish evidence that the Rad51 binding domain resides within the N terminus of Rdh54. Accordingly, N-terminal truncation mutants of Rdh54 that fail to bind Rad51 are also impaired for functional interactions with the latter. Interestingly, the rdh54 K352R mutation that ablates ATPase activity engenders a DNA repair defect even more severe than that seen in the rdh54 Delta mutant. These results provide molecular information concerning the role of Rdh54 in homologous recombination and DNA repair, and they also demonstrate the functional significance of Rdh54 (.) Rad51 complex formation. The Rdh54 expression and purification procedures described here should facilitate the functional dissection of this DNA recombination/repair factor.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	Yale University; New York University; New York University	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu; hannah.klein@med.nyu.edu	Chi, Peter/AAI-1580-2019; Huang, Wenchi/F-3981-2010	Chi, Peter/0000-0001-9229-8729; Huang, Wenchi/0000-0001-5556-1460; Klein, Hannah/0000-0003-4228-8535; Lam, Isabel/0000-0002-6247-8080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814, R01GM053738] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES07061] Funding Source: Medline; NIGMS NIH HHS [R01GM57814, GM053738] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1988, GENETICS, V119, P779; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2004, J BIOL CHEM, V279, P27824, DOI 10.1074/jbc.M402648200; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Arbel A, 1999, EMBO J, V18, P2648, DOI 10.1093/emboj/18.9.2648; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Catlett MG, 2003, MOL BIOL CELL, V14, P4707, DOI 10.1091/mbc.E03-05-0288; Cheok CF, 2005, BIOCHEM SOC T, V33, P1456, DOI 10.1042/BST0331456; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Dresser ME, 1997, GENETICS, V147, P533; Durr H, 2005, CELL, V121, P363, DOI 10.1016/j.cell.2005.03.026; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Klein HL, 1997, GENETICS, V147, P1533; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lia G, 2006, MOL CELL, V21, P417, DOI 10.1016/j.molcel.2005.12.013; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Raschle M, 2004, J BIOL CHEM, V279, P51973, DOI 10.1074/jbc.M410101200; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Shinohara M, 1997, GENETICS, V147, P1545; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Thoma NH, 2005, NAT STRUCT MOL BIOL, V12, P350, DOI 10.1038/nsmb919; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498	47	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26268	26279		10.1074/jbc.M602983200	http://dx.doi.org/10.1074/jbc.M602983200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831867	hybrid			2022-12-27	WOS:000240249500044
J	Kim, JH; Johnston, M				Kim, Jeong-Ho; Johnston, Mark			Two glucose-sensing pathways converge on Rgt1 to regulate expression of glucose transporter genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GTPASE-ACTIVATING PROTEIN; TRANSCRIPTION FACTOR; COUPLED RECEPTOR; S-CEREVISIAE; CAMP PATHWAY; YEAST; REPRESSOR; RAS; SPECIFICITY	The yeast Saccharomyces cerevisiae deploys two different types of glucose sensors on its cell surface that operate in distinct glucose signaling pathways: the glucose transporter-like Snf3 and Rgt2 proteins and the Gpr1 receptor that is coupled to Gpa2, a G-protein alpha subunit. The ultimate target of the Snf3/Rgt2 pathway is Rgt1, a transcription factor that regulates expression of HXT genes encoding glucose transporters. We have found that the cAMP-dependent protein kinase A (PKA), which is activated by the Gpr1/Gpa2 glucose-sensing pathway and by a glucose-sensing pathway that works through Ras1 and Ras2, catalyzes phosphorylation of Rgt1 and regulates its function. Rgt1 is phosphorylated in vitro by all three isoforms of PKA, and this requires several serine residues located in PKA consensus sequences within Rgt1. PKA and the consensus serine residues of Rgt1 are required for glucose-induced removal of Rgt1 from the HXT promoters and for induction of HXT expression. Conversely, overexpression of the TPK genes led to constitutive expression of the HXT genes. The PKA consensus phosphorylation sites of Rgt1 are required for an intramolecular interaction that is thought to regulate its DNA binding activity. Thus, two different glucose signal transduction pathways converge on Rgt1 to regulate expression of glucose transporters.	Univ So Mississippi, Dept Biol Sci, MFGN, Hattiesburg, MS 39406 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	University of Southern Mississippi; Washington University (WUSTL)	Kim, JH (corresponding author), Univ So Mississippi, Dept Biol Sci, MFGN, 118 Coll Dr 5018, Hattiesburg, MS 39406 USA.	jeongho.kim@mfgn.usm.edu	Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; 	NCRR NIH HHS [RR016476-04] Funding Source: Medline; NIGMS NIH HHS [GM32540] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032540] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Broach JR, 1991, CURR OPIN GENET DEV, V1, P370, DOI 10.1016/S0959-437X(05)80302-8; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Flick KM, 2003, MOL BIOL CELL, V14, P3230, DOI 10.1091/mbc.E03-03-0135; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; James P, 1996, GENETICS, V144, P1425; Johnston M, 2005, BIOCHEM SOC T, V33, P247, DOI 10.1042/BST0330247; Kaniak A, 2004, EUKARYOT CELL, V3, P221, DOI 10.1128/EC.3.1.221-231.2004; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim JH, 2006, EUKARYOT CELL, V5, P167, DOI 10.1128/EC.5.1.167-173.2006; Kim JH, 2003, MOL CELL BIOL, V23, P5208, DOI 10.1128/MCB.23.15.5208-5216.2003; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; LAGUNAS R, 1979, MOL CELL BIOCHEM, V27, P139, DOI 10.1007/BF00215362; LAGUNAS R, 1986, YEAST, V2, P221, DOI 10.1002/yea.320020403; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; Moriya H, 2004, P NATL ACAD SCI USA, V101, P1572, DOI 10.1073/pnas.0305901101; Mosley AL, 2003, J BIOL CHEM, V278, P10322, DOI 10.1074/jbc.M212802200; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Ozcan S, 1996, MOL CELL BIOL, V16, P6419; Palomino A, 2006, NUCLEIC ACIDS RES, V34, P1427, DOI 10.1093/nar/gkl028; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Polish JA, 2005, GENETICS, V169, P583, DOI 10.1534/genetics.104.034512; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Santangelo GM, 2006, MICROBIOL MOL BIOL R, V70, P253, DOI 10.1128/MMBR.70.1.253-282.2006; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; Thevelein JM, 2005, BIOCHEM SOC T, V33, P253, DOI 10.1042/BST0330253; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Versele M, 1999, EMBO J, V18, P5577, DOI 10.1093/emboj/18.20.5577; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576	42	126	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26144	26149		10.1074/jbc.M603636200	http://dx.doi.org/10.1074/jbc.M603636200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16844691	hybrid, Green Published			2022-12-27	WOS:000240249500030
J	Musson, JA; Morton, M; Walker, N; Harper, HM; McNeill, HV; Williamson, ED; Robinson, JH				Musson, Julie A.; Morton, Margaret; Walker, Nicola; Harper, Helen M.; McNeill, Hesta V.; Williamson, E. Diane; Robinson, John H.			Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ANTIGEN; SUBUNIT VACCINE; SALMONELLA-TYPHIMURIUM; MONOCLONAL-ANTIBODIES; PNEUMONIC PLAGUE; IMMUNE-RESPONSE; CELL EPITOPES; PROTECTION; PROTEIN; MICE	We studied the mechanisms of antigen presentation of CD4 T cell epitopes of the capsular Caf1 antigen of Yersinia pestis using murine bone marrow macrophages as antigen presenting cells and T cell hybridomas specific for major histocompatibility complex (MHC) class II-restricted epitopes distributed throughout the Caf1 sequence. The data revealed diversity in the pathways used and the degrees of antigen processing required depending on the structural context of epitopes within the Caf1 molecule. Two epitopes in the carboxyl-terminal globular domain were presented by newly synthesized MHC class II after low pH-dependent lysosomal processing, whereas an epitope located in a flexible amino-terminal strand was presented by mature MHC class II independent of low pH and with no detectable requirement for proteolytic processing. A fourth epitope located between the two regions of Caf1 showed intermediate behavior. The data are consistent with progressive unfolding and cleavage of rCaf1 from the amino terminus as it traverses the endosomal pathway, the availability of epitopes determining which pool of MHC class II is preferentially loaded. The Caf1 capsular protein is a component of second generation plague vaccines and an understanding of the mechanisms and pathways of MHC class II-restricted presentation of multiple epitopes from this candidate vaccine antigen should inform the choice of delivery systems and adjuvants that target vaccines successfully to appropriate intracellular locations to induce protective immune responses against as wide a T cell repertoire as possible.	Univ Newcastle, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England	Newcastle University - UK; Defence Science & Technology Laboratory	Robinson, JH (corresponding author), Univ Newcastle, Inst Cellular Med, Musculoskeletal Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.h.robinson@ncl.ac.uk	Williamson, Ethel Diane/AAQ-8878-2020					Anderson GW, 1998, AM J TROP MED HYG, V58, P793, DOI 10.4269/ajtmh.1998.58.793; Anderson GW, 1997, AM J TROP MED HYG, V56, P471, DOI 10.4269/ajtmh.1997.56.471; Andrews GP, 1996, INFECT IMMUN, V64, P2180, DOI 10.1128/IAI.64.6.2180-2187.1996; Chianese-Bullock KA, 1998, J IMMUNOL, V161, P1599; Conte MP, 1996, J MED MICROBIOL, V44, P418, DOI 10.1099/00222615-44-6-418; Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932; Elvin SJ, 2004, MICROB PATHOGENESIS, V37, P177, DOI 10.1016/j.micpath.2004.06.009; Elvin SJ, 2000, MICROB PATHOGENESIS, V29, P223, DOI 10.1006/mpat.2000.0385; Eyles JE, 1998, VACCINE, V16, P2000, DOI 10.1016/S0264-410X(98)00089-9; Eyles JE, 1998, VACCINE, V16, P698, DOI 10.1016/S0264-410X(97)00249-1; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; FISCHER HG, 1988, EUR J IMMUNOL, V18, P1151, DOI 10.1002/eji.1830180802; GAGE K. L., 1998, TOPLEY WILSONS MICRO, V3, P885; Goddard J, 1999, INFECT MED, V16, P21; Grosfeld H, 2003, INFECT IMMUN, V71, P374, DOI 10.1128/IAI.71.1.374-383.2003; Hill J, 2003, INFECT IMMUN, V71, P2234, DOI 10.1128/IAI.71.4.2234-2238.2003; KARLYSHEV AV, 1992, FEBS LETT, V305, P37, DOI 10.1016/0014-5793(92)80650-6; Leary SEC, 1997, MICROB PATHOGENESIS, V23, P167, DOI 10.1006/mpat.1997.0141; Lennon-Dumenil AM, 2002, CURR OPIN IMMUNOL, V14, P15, DOI 10.1016/S0952-7915(01)00293-X; Levy CE, 1999, INFECT MED, V16, P54; Miller J, 1998, FEMS IMMUNOL MED MIC, V21, P213, DOI 10.1111/j.1574-695X.1998.tb01168.x; Musson JA, 2003, J BIOL CHEM, V278, P52425, DOI 10.1074/jbc.M309034200; ORCI L, 1991, CELL, V64, P1183; OYSTON PCF, 1995, INFECT IMMUN, V63, P563, DOI 10.1128/IAI.63.2.563-568.1995; Panda SK, 1996, CURR SCI INDIA, V71, P794; PERROW C, 1997, ORG ENV, V10, P66, DOI DOI 10.1177/0921810697101009; PURI J, 1988, J IMMUNOL, V141, P3313; Reddin KM, 1998, VACCINE, V16, P761, DOI 10.1016/S0264-410X(97)00305-8; Robinson JH, 2002, IMMUNOLOGY, V105, P252, DOI 10.1046/j.0019-2805.2001.01358.x; Sabhnani L, 2003, FEMS IMMUNOL MED MIC, V38, P215, DOI 10.1016/S0928-8244(03)00170-6; SHIM HK, 2006, IN PRESS IMMUNOLOGY, V119; SIMPSON WJ, 1990, AM J TROP MED HYG, V43, P389, DOI 10.4269/ajtmh.1990.43.389; Smego RA, 1999, EUR J CLIN MICROBIOL, V18, P1, DOI 10.1007/s100960050219; STPIERRE Y, 1990, J IMMUNOL, V145, P812; Titball RW, 1997, INFECT IMMUN, V65, P1926, DOI 10.1128/IAI.65.5.1926-1930.1997; Titball RW, 2003, ADV EXP MED BIOL, V529, P397; Unanue ER, 2002, IMMUNOL REV, V185, P86, DOI 10.1034/j.1600-065X.2002.18510.x; von Delwig A, 2003, EUR J IMMUNOL, V33, P3359, DOI 10.1002/eji.200324461; Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088; WILCOX D, 1992, BIOCHEM J, V285, P495, DOI 10.1042/bj2850495; Williamson ED, 2005, INFECT IMMUN, V73, P3598, DOI 10.1128/IAI.73.6.3598-3608.2005; Williamson ED, 2002, BRIT MED BULL, V62, P163, DOI 10.1093/bmb/62.1.163; WILLIAMSON ED, 1995, FEMS IMMUNOL MED MIC, V12, P223, DOI 10.1111/j.1574-695X.1995.tb00196.x; Williamson ED, 1997, VACCINE, V15, P1079, DOI 10.1016/S0264-410X(96)00303-9; Williamson ED, 1996, VACCINE, V14, P1613, DOI 10.1016/S0264-410X(96)00151-X; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9	46	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26129	26135		10.1074/jbc.M605482200	http://dx.doi.org/10.1074/jbc.M605482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16840777	hybrid			2022-12-27	WOS:000240249500028
J	Shen, Y; Cranmer, SL; Aprico, A; Whisstock, JC; Jackson, SP; Berndt, MC; Andrews, RK				Shen, Yang; Cranmer, Susan L.; Aprico, Andrea; Whisstock, James C.; Jackson, Shaun P.; Berndt, Michael C.; Andrews, Robert K.			Leucine-rich repeats 2-4 (Leu(60)-Glu(128)) of platelet glycoprotein Ib alpha regulate shear-dependent cell adhesion to von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR A1 DOMAIN; IX-V COMPLEX; CRYSTAL-STRUCTURE; BINDING REGION; REVEALS; ACTIVATION; MECHANISM	Glycoprotein (GP) Ib-IX-V binds von Willebrand factor (VWF), initiating thrombosis at high shear stress. The VWF-A1 domain binds the N-terminal domain of GPIb alpha (His(1)-Glu(282)); this region contains seven leucine-rich repeats (LRR) plus N- and C-terminal flanking sequences and an anionic sequence containing three sulfated tyrosines. Our previous analysis of canine/human and human/canine chimeras of GPIb alpha expressed on Chinese hamster ovary (CHO) cells demonstrated that LRR2-4(Leu(60)-Glu(128)) were crucial for GPIb alpha-dependent adhesion to VWF. Paradoxically, co-crystal structures of the GPIb alpha N-terminal domain and GPIb alpha-binding VWF-A1 under static conditions revealed that the LRR2-4 sequence made minimal contact with VWF-A1. To resolve the specific functional role of LRR2-4, we compared wildtype human GPIb alpha with human GPIb alpha containing a homology domain swap of canine for human sequence within Leu(60)-Glu(128) and a reverse swap (canine GPIb alpha with human Leu(60)-Glu(128)) for the ability to support adhesion to VWF under flow. Binding of conformation-specific anti-GPIb alpha antibodies and VWF binding in the presence of botrocetin (which does not discriminate between species) confirmed equivalent expression of wild-type and mutant receptors in a functional form competent to bind ligand. Compared with CHO cells expressing wild-type GPIb alpha, cells expressing GPIb alpha, where human Leu(60)-Glu(128) sequence was replaced by canine sequence, supported adhesion to VWF at low shear rates but became increasingly ineffective as shear increased from 50 to 2000 s-(1). Together, these data demonstrate that LRR2-4, encompassing a pronounced negative charge patch on human GPIb alpha, is essential for GPIb alpha(VWF)-V-.-dependent adhesion as hydrodynamic shear increases.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Dept Immunol, Clayton, Vic 3800, Australia; Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia	Monash University; Monash University; Monash University	Andrews, RK (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	rob.andrews@med.monash.edu.au	Berndt, Michael C/D-5580-2012	Andrews, Robert Keith/0000-0001-9577-8082; Whisstock, James/0000-0003-4200-5611; Jackson, Shaun/0000-0002-4750-1991				Andrews RK, 2003, INT J BIOCHEM CELL B, V35, P1170, DOI 10.1016/S1357-2725(02)00280-7; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Cranmer SL, 2005, BIOCHEM J, V387, P849, DOI 10.1042/BJ20041836; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; De Luca M, 2000, BLOOD, V95, P164; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Kroll MH, 1996, BLOOD, V88, P1525; Ozaki Y, 2005, J THROMB HAEMOST, V3, P1745, DOI 10.1111/j.1538-7836.2005.01379.x; Phillips DR, 2005, J THROMB HAEMOST, V3, P1577, DOI 10.1111/j.1538-7836.2005.01418.x; Sadler JE, 2002, SCIENCE, V297, P1128, DOI 10.1126/science.1075452; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; Shen Y, 2002, BLOOD, V99, P145, DOI 10.1182/blood.V99.1.145; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Whisstock JC, 2002, THROMB HAEMOSTASIS, V87, P329; Williamson D, 2002, J BIOL CHEM, V277, P2151, DOI 10.1074/jbc.M109384200	18	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26419	26423		10.1074/jbc.M604296200	http://dx.doi.org/10.1074/jbc.M604296200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16774914	hybrid			2022-12-27	WOS:000240249500059
J	Murooka, TT; Wong, MM; Rahbar, R; Majchrzak-Kita, B; Proudfoot, AEI; Fish, EN				Murooka, Thomas T.; Wong, Mark M.; Rahbar, Ramtin; Majchrzak-Kita, Beata; Proudfoot, Amanda E. I.; Fish, Eleanor N.			CCL5-CCR5-mediated apoptosis in T cells - Requirement for glycosaminoglycan binding and CCL5 aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; CHEMOKINE RANTES; HEPARIN-BINDING; IN-VIVO; ACTIVATION; RECEPTOR; DEATH; CCR5; OLIGOMERIZATION; IDENTIFICATION	CCL5 (RANTES (regulated on activation normal T cell expressed and secreted)) and its cognate receptor, CCR5, have been implicated in T cell activation. CCL5 binding to glycosaminoglycans (GAGs) on the cell surface or in extracellular matrix sequesters CCL5, thereby immobilizing CCL5 to provide the directional signal. In two CCR5-expressing human T cell lines, PM1. CCR5 and MOLT4.CCR5, and in human peripheral blood-derived T cells, micromolar concentrations of CCL5 induce apoptosis. CCL5-induced cell death involves the cytosolic release of cytochrome c, the activation of caspase-9 and caspase-3, and poly(ADP-ribose) polymerase cleavage. CCL5-induced apoptosis is CCR5-dependent, since native PM1 and MOLT4 cells lacking CCR5 expression are resistant to CCL5-induced cell death. Furthermore, we implicate tyrosine 339 as a critical residue involved in CCL5-induced apoptosis, since PM1 cells expressing a tyrosine mutant receptor, CCR5Y339F, do not undergo apoptosis. We show that CCL5-CCR5-mediated apoptosis is dependent on cell surface GAG binding. The addition of exogenous heparin and chondroitin sulfate and GAG digestion from the cell surface protect cells from apoptosis. Moreover, the non-GAG binding variant, (44AANA47)-CCL5, fails to induce apoptosis. To address the role of aggregation in CCL5-mediated apoptosis, nonaggregating CCL5 mutant E66S, which forms dimers, and E26A, which form tetramers at micromolar concentrations, were utilized. Unlike native CCL5, the E66S mutant fails to induce apoptosis, suggesting that tetramers are the minimal higher ordered CCL5 aggregates required for CCL5-induced apoptosis. Viewed altogether, these data suggest that CCL5-GAG binding and CCL5 aggregation are important for CCL5 activity in T cells, specifically in the context of CCR5-mediated apoptosis.	Univ Toronto, Div Cellular & Mol Biol, Toronto Gen Res Inst, Canadian Blood Serv,Univ Hlth Network, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada; Serono Pharmaceut Res Inst, Geneva, Switzerland	Canadian Blood Services; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Fish, EN (corresponding author), Univ Toronto, Div Cellular & Mol Biol, Toronto Gen Res Inst, Canadian Blood Serv,Univ Hlth Network, Bldg 67 Coll St,Rm 4-424, Toronto, ON M5G 2M1, Canada.	en.fish@utoronto.ca		Murooka, Thomas/0000-0002-3030-2726				Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Appay V, 2000, INT IMMUNOL, V12, P1173, DOI 10.1093/intimm/12.8.1173; Appay V, 1999, J BIOL CHEM, V274, P27505, DOI 10.1074/jbc.274.39.27505; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baltus T, 2003, BLOOD, V102, P1985, DOI 10.1182/blood-2003-04-1175; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; Burns JM, 1998, J EXP MED, V188, P1917, DOI 10.1084/jem.188.10.1917; Cartier L, 2003, J NEUROIMMUNOL, V145, P27, DOI 10.1016/j.jneuroim.2003.09.008; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002; Cinamon G, 2001, J LEUKOCYTE BIOL, V69, P860; Colamussi ML, 2001, J LEUKOCYTE BIOL, V69, P263; Collette Y, 1998, BLOOD, V92, P1350, DOI 10.1182/blood.V92.4.1350.416k24_1350_1363; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Dairaghi DJ, 1998, J IMMUNOL, V160, P426; Dong HF, 2005, GENES IMMUN, V6, P609, DOI 10.1038/sj.gene.6364247; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776; Karpus WJ, 1997, J IMMUNOL, V158, P4129; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kawai T, 1999, J IMMUNOL, V163, P3269; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Koopmann W, 1999, J IMMUNOL, V163, P2120; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Makino Y, 2002, CLIN IMMUNOL, V102, P302, DOI 10.1006/clim.2001.5178; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Mellado M, 1998, J IMMUNOL, V161, P805; Mellado M, 2001, CURR BIOL, V11, P691, DOI 10.1016/S0960-9822(01)00199-3; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Netelenbos T, 2002, J LEUKOCYTE BIOL, V72, P353; Noel PJ, 1996, J IMMUNOL, V157, P636; Pablos JL, 2003, J IMMUNOL, V170, P2147, DOI 10.4049/jimmunol.170.4.2147; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Rabin RL, 1999, J IMMUNOL, V162, P3840; Rahbar R, 2006, J VIROL, V80, P7245, DOI 10.1128/JVI.00463-06; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Siveke JT, 1998, J IMMUNOL, V160, P550; Szabo MC, 1997, EUR J IMMUNOL, V27, P1061, DOI 10.1002/eji.1830270504; Szekanecz Z, 2000, ARTHRITIS RES, V2, P368, DOI 10.1186/ar114; Tan JQ, 2003, J IMMUNOL, V171, P1722, DOI 10.4049/jimmunol.171.4.1722; Taub DD, 1996, J IMMUNOL, V156, P2095; Turner L, 1996, BIOCHEM SOC T, V24, pS93, DOI 10.1042/bst024093s; Tyner JW, 2005, NAT MED, V11, P1180, DOI 10.1038/nm1303; Uddin S, 1997, BLOOD, V90, P2574; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Vita C, 2002, J IMMUNOL METHODS, V266, P53, DOI 10.1016/S0022-1759(02)00096-0; Wong MM, 2003, SEMIN IMMUNOL, V15, P5, DOI 10.1016/S1044-5323(02)00123-9; Zhang HFM, 2005, MOL CELL BIOL, V25, P6247, DOI 10.1128/MCB.25.14.6247-6258.2005	62	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25184	25194		10.1074/jbc.M603912200	http://dx.doi.org/10.1074/jbc.M603912200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807236	hybrid			2022-12-27	WOS:000240031300019
J	Fitzgerald, JB; Jin, M; Grodzinsky, AJ				Fitzgerald, Jonathan B.; Jin, Moonsoo; Grodzinsky, Alan J.			Shear and compression differentially regulate clusters of functionally related temporal transcription patterns in cartilage tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR CHONDROCYTES; INTERMITTENT HYDROSTATIC-PRESSURE; GENE-EXPRESSION; FLUID-FLOW; DYNAMIC COMPRESSION; MECHANICAL COMPRESSION; INTRACELLULAR CALCIUM; INTERSTITIAL FLUID; CYTOSOLIC CALCIUM; II COLLAGEN	Chondrocytes are subjected to a variety of biophysical forces and flows during physiological joint loading, including mechanical deformation, fluid flow, hydrostatic pressure, and streaming potentials; however, the role of these physical stimuli in regulating chondrocyte behavior is still being elucidated. To isolate the effects of these forces, we subjected intact cartilage explants to 1 - 24 h of continuous dynamic compression or dynamic shear loading at 0.1 Hz. We then measured the transcription levels of 25 genes known to be involved in cartilage homeostasis using real-time PCR and compared the gene expression profiles obtained from dynamic compression, dynamic shear, and our recent results on static compression amplitude and duration. Using clustering analysis, we determined that transcripts for proteins with similar function had correlated responses to loading. However, the temporal expression patterns were strongly dependent on the type of loading applied. Most matrix proteins were up-regulated by 24 h of dynamic compression or dynamic shear, but down-regulated by 24 h of 50% static compression, suggesting that cyclic matrix deformation is a key stimulator of matrix protein expression. Most matrix proteases were up-regulated by 24 h under all loading types. Transcription factors c-Fos and c-Jun maximally responded within 1 h to all loading types. Pre-incubating cartilage explants with either a chelator of intracellular calcium or an inhibitor of the cyclic AMP pathway demonstrated the involvement of both pathways in transcription induced by dynamic loading.	MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Grodzinsky, AJ (corresponding author), MIT, Ctr Biomed Engn, 77 Massachusetts Ave,NE47-377, Cambridge, MA 02139 USA.	alg@mit.edu	Jin, Moonsoo/D-6128-2011		NIAMS NIH HHS [AR33236] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR033236, R01AR033236] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alford AI, 2003, J CELL BIOCHEM, V90, P938, DOI 10.1002/jcb.10715; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; BEHRENS F, 1989, J ORTHOPAED RES, V7, P335, DOI 10.1002/jor.1100070305; Blain EJ, 2001, ARCH BIOCHEM BIOPHYS, V396, P49, DOI 10.1006/abbi.2001.2575; Bonassar LJ, 2001, J ORTHOP RES, V19, P11, DOI 10.1016/S0736-0266(00)00004-8; Buschmann MD, 1999, ARCH BIOCHEM BIOPHYS, V366, P1, DOI 10.1006/abbi.1999.1197; D'Andrea P, 2000, BIORHEOLOGY, V37, P75; Davisson T, 2002, J ORTHOPAED RES, V20, P842, DOI 10.1016/S0736-0266(01)00160-7; Dougherty ER, 2002, J COMPUT BIOL, V9, P105, DOI 10.1089/10665270252833217; Edlich M, 2001, J BIOMECH, V34, P59, DOI 10.1016/S0021-9290(00)00158-5; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Fitzgerald JB, 2004, J BIOL CHEM, V279, P19502, DOI 10.1074/jbc.M400437200; Frank EH, 2000, J BIOMECH, V33, P1523, DOI 10.1016/S0021-9290(00)00100-7; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; GRUSHKO G, 1989, CONNECT TISSUE RES, V19, P149, DOI 10.3109/03008208909043895; Guilak F, 1994, Osteoarthritis Cartilage, V2, P91, DOI 10.1016/S1063-4584(05)80059-7; Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356; Holter NS, 2000, P NATL ACAD SCI USA, V97, P8409, DOI 10.1073/pnas.150242097; Hunter CJ, 2004, OSTEOARTHR CARTILAGE, V12, P117, DOI 10.1016/j.joca.2003.08.009; Ikenoue T, 2003, J ORTHOPAED RES, V21, P110, DOI 10.1016/S0736-0266(02)00091-8; Jin M, 2001, ARCH BIOCHEM BIOPHYS, V395, P41, DOI 10.1006/abbi.2001.2543; Jortikka MO, 2000, ARCH BIOCHEM BIOPHYS, V374, P172, DOI 10.1006/abbi.1999.1543; Jortikka MO, 1997, ANN RHEUM DIS, V56, P255, DOI 10.1136/ard.56.4.255; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIM YJ, 1995, J BIOMECH, V28, P1055, DOI 10.1016/0021-9290(94)00159-2; KIM YJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P1, DOI 10.1006/abbi.1994.1201; Kisiday JD, 2004, J BIOMECH, V37, P595, DOI 10.1016/j.jbiomech.2003.10.005; KISIDAY JD, 2005, T ORTHOP RES SOC, V51, P1632; Lee JH, 2005, ARTHRITIS RHEUM-US, V52, P2386, DOI 10.1002/art.21215; Li KW, 2003, ARTHRITIS RHEUM-US, V48, P689, DOI 10.1002/art.10849; Liacini A, 2003, EXP CELL RES, V288, P208, DOI 10.1016/S0014-4827(03)00180-0; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; LOHMANDER LS, 1993, J RHEUMATOL, V20, P1362; Mauck RL, 2000, J BIOMECH ENG-T ASME, V122, P252, DOI 10.1115/1.429656; Millward-Sadler SJ, 2000, ARTHRITIS RHEUM, V43, P2091, DOI 10.1002/1529-0131(200009)43:9<2091::AID-ANR21>3.0.CO;2-C; Millward-Sadler SJ, 1999, J CELL BIOL, V145, P183, DOI 10.1083/jcb.145.1.183; Mow VC, 1999, OSTEOARTHR CARTILAGE, V7, P41, DOI 10.1053/joca.1998.0161; Roberts SR, 2001, J APPL PHYSIOL, V90, P1385, DOI 10.1152/jappl.2001.90.4.1385; SAAMAMEN AM, 1994, CONNECT TISSUE RES, V30, P191, DOI 10.3109/03008209409061971; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; Salter DM, 2001, CLIN ORTHOP RELAT R, pS49; Sauerland K, 2003, OSTEOARTHR CARTILAGE, V11, P343, DOI 10.1016/S1063-4584(03)00007-4; SLOWMAN SD, 1986, ARTHRITIS RHEUM, V29, P88, DOI 10.1002/art.1780290112; Smith RL, 2000, J REHABIL RES DEV, V37, P153; Smith RL, 2000, BIORHEOLOGY, V37, P95; Valhmu WB, 1998, ARCH BIOCHEM BIOPHYS, V353, P29, DOI 10.1006/abbi.1998.0633; Valhmu WB, 2002, BIOCHEM J, V361, P689, DOI 10.1042/0264-6021:3610689; Verzijl N, 2002, ARTHRITIS RHEUM, V46, P114, DOI 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yellowley CE, 1997, AM J PHYSIOL-CELL PH, V273, pC30, DOI 10.1152/ajpcell.1997.273.1.C30; Yellowley CE, 1999, J CELL PHYSIOL, V180, P402, DOI 10.1002/(SICI)1097-4652(199909)180:3<402::AID-JCP11>3.0.CO;2-4	52	80	82	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24095	24103		10.1074/jbc.M510858200	http://dx.doi.org/10.1074/jbc.M510858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16782710	hybrid			2022-12-27	WOS:000239847800004
J	Zeidan, YH; Pettus, BJ; Elojeimy, S; Taha, T; Obeid, LM; Kawamori, T; Norris, JS; Hannun, YA				Zeidan, Youssef H.; Pettus, Benjamin J.; Elojeimy, Saeed; Taha, Tarek; Obeid, Lina M.; Kawamori, Toshihiko; Norris, James S.; Hannun, Yusuf A.			Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-alpha-induced PGE(2) production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICYCLIC ANTI-DEPRESSANTS; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE-1-PHOSPHATE; INTERNALIZATION; ROLES; PURIFICATION; INFLAMMATION; MACROPHAGES; ACTIVATION; EXPRESSION	Sphingolipids are well established effectors of signal transduction downstream of the tumor necrosis factor (TNF) receptor. In a previous study, we showed that the sphingosine kinase/sphingosine 1-phosphate (S1P) pathway couples TNF receptor to induction of the cyclooxygenase 2 gene and prostaglandin synthesis (Pettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L., Johnson, K. R., Morrow, J., Chalfant, C. E., Obeid, L. M., and Hannun, Y. A. ( 2003) FASEB J. 17, 1411-1421). In this study, the requirement for acid sphingomyelinase and sphingomyelin metabolites in the TNF alpha/prostaglandin E-2 (PGE(2)) pathway was investigated. The amphiphilic compound desipramine, a frequently employed inhibitor of acid sphingomyelinase (ASMase), blocked PGE2 production. However, the action of desipramine was independent of its action on ASMase, since neither genetic loss of ASMase ( Niemann- Pick fibroblasts) nor knockdown of ASMase using RNA interference affected TNF alpha-induced PGE2 synthesis. Further investigations revealed that desipramine down-regulated acid ceramidase (AC), but not sphingosine kinase, at the protein level. This resulted in a time-dependent drop in sphingosine and S1P levels. Moreover, exogenous administration of either sphingosine or S1P rescued PGE(2) biosynthesis after desipramine treatment. Interestingly, knockdown of endogenous AC by RNA interference attenuated cyclooxygenase 2 induction by TNF alpha and subsequent PGE(2) biosynthesis. Taken together, these results define a novel role for AC in the TNF alpha/ PGE(2) pathway. In addition, the results of this study warrant careful reconsideration of desipramine as a specific inhibitor for ASMase.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 175 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Kawamori, Toshihiko/G-7636-2012; Zeidan, Youssef H./H-7578-2019	Zeidan, Youssef H./0000-0002-1951-8585; obeid, lina/0000-0002-0734-0847	NCI NIH HHS [CA87584] Funding Source: Medline; NCRR NIH HHS [P20-RR017677] Funding Source: Medline; NIGMS NIH HHS [GM62887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBOUZ S, 1981, BIOMED EXPRESS, V35, P218; ALBOUZ S, 1983, NEUROSCI LETT, V36, P311, DOI 10.1016/0304-3940(83)90018-6; Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Baumruker T, 2005, IMMUNOL LETT, V96, P175, DOI 10.1016/j.imlet.2004.09.001; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Colell A, 2002, FEBS LETT, V526, P15, DOI 10.1016/S0014-5793(02)03106-X; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Gulbins Erich, 2002, Subcell Biochem, V36, P229; He XX, 2003, J BIOL CHEM, V278, P32978, DOI 10.1074/jbc.M301936200; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Karakashian AA, 2004, FASEB J, V18, P968, DOI 10.1096/fj.03-0875fje; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kolzer M, 2004, FEBS LETT, V559, P96, DOI 10.1016/S0014-5793(04)00033-X; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; MacKinnon AC, 2002, J IMMUNOL, V169, P6394, DOI 10.4049/jimmunol.169.11.6394; Manthey CL, 1998, CYTOKINE, V10, P654, DOI 10.1006/cyto.1998.0344; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; Pettus BJ, 2004, CURR MOL MED, V4, P405, DOI 10.2174/1566524043360573; Samsel L, 2004, PROSTATE, V58, P382, DOI 10.1002/pros.10350; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Seelan RS, 2000, GENE CHROMOSOME CANC, V29, P137, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; WATANABE N, 1988, J BIOL CHEM, V263, P10262; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004	38	56	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24695	24703		10.1074/jbc.M604713200	http://dx.doi.org/10.1074/jbc.M604713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803890	hybrid			2022-12-27	WOS:000239847800065
J	Lu, DM; Huang, J; Basu, A				Lu, Dongmei; Huang, Jie; Basu, Alakananda			Protein kinase C epsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; SIGNALING PATHWAY; INDUCED APOPTOSIS; B-ALPHA; PHOSPHORYLATION; AKT; EXPRESSION; RECEPTOR	We have previously shown that protein kinase C epsilon(PKC epsilon) protects breast cancer cells from tumor necrosis factor-alpha (TNF)-induced cell death. In the present study, we have investigated if the antiapoptotic function of PKC epsilon is mediated via Akt and the mechanism by which PKC epsilon regulates Akt activity. TNF caused a transient increase in Akt phosphorylation at Ser(473) in MCF-7 cells. Overexpression of PKC epsilon in MCF-7 cells increased TNF-induced Akt phosphorylation at Ser(473) resulting in its activation. Knockdown of PKC epsilon by small interfering RNA (siRNA) decreased TNF-induced Akt phosphorylation/activation and increased cell death. Introduction of constitutively active Akt protected breast cancer MCF-7 cells from TNF-mediated cell death and partially restored cell survival in PKC epsilon-depleted cells. Depletion of Akt in MCF-7 cells abolished the antiapoptotic effect of PKC epsilon on TNF-mediated cell death. Akt was constitutively associated with PKC epsilon and DNA-dependent protein kinase (DNA-PK), and this association was increased by TNF treatment. Overexpression of PKC epsilon enhanced the interaction between Akt and DNA-PK. Knockdown of DNA-PK by siRNA inhibited TNF-induced Akt phosphorylation and the antiapoptotic effect of Akt and PKC epsilon. These results suggest that PKC epsilon activates Akt via DNA-PK to mediate its antiapoptotic function. Furthermore, we report for the first time that DNA-PK can regulate receptor-initiated apoptosis via Akt.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Basu, A (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	abasu@hsc.unt.edu		Basu, Alakananda/0000-0002-1656-0788	NATIONAL CANCER INSTITUTE [R01CA071727] Funding Source: NIH RePORTER; NCI NIH HHS [CA71727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Bauer B, 2003, FEBS LETT, V541, P155, DOI 10.1016/S0014-5793(03)00287-4; Bauer B, 2002, MOL IMMUNOL, V38, P1087, DOI 10.1016/S0161-5890(02)00011-1; Bauer B, 2001, J BIOL CHEM, V276, P31627, DOI 10.1074/jbc.M103098200; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; CACACE AM, 1993, ONCOGENE, V8, P2095; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Cowell IG, 2005, BIOCHEM PHARMACOL, V71, P13, DOI 10.1016/j.bcp.2005.09.029; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Gillespie S, 2005, MOL CANCER THER, V4, P668, DOI 10.1158/1535-7163.MCT-04-0332; Gliki G, 2002, CELL BIOL INT, V26, P751, DOI 10.1016/S1065-6995(02)90926-1; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Hennequin C, 1999, Cancer Radiother, V3, P289, DOI 10.1016/S1278-3218(99)80070-5; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P561, DOI 10.1021/bi010719z; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li LW, 2006, J BIOL CHEM, V281, P3237, DOI 10.1074/jbc.M512167200; Lu DM, 2004, INT J ONCOL, V25, P671; Mao ML, 2000, BIOCHEM J, V352, P475, DOI 10.1042/0264-6021:3520475; Matsumoto M, 2001, J BIOL CHEM, V276, P14400, DOI 10.1074/jbc.M011093200; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; O'Toole A, 2001, BIOCHEM J, V359, P119, DOI 10.1042/0264-6021:3590119; Okhrimenko H, 2005, CANCER RES, V65, P7301, DOI 10.1158/0008-5472.CAN-05-1064; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Venkatesan BA, 2006, CELL SIGNAL, V18, P508, DOI 10.1016/j.cellsig.2005.05.022; Wen HC, 2003, CELL SIGNAL, V15, P37, DOI 10.1016/S0898-6568(02)00047-5; Zhou HZ, 2002, AM J PHYSIOL-HEART C, V283, pH165, DOI 10.1152/ajpheart.00408.2001	49	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22799	22807		10.1074/jbc.M603390200	http://dx.doi.org/10.1074/jbc.M603390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785234	hybrid			2022-12-27	WOS:000239542600041
J	Ohira, M; Smardon, AM; Charsky, CMH; Liu, JZ; Tarsio, M; Kane, PM				Ohira, Masashi; Smardon, Anne M.; Charsky, Colleen M. H.; Liu, Jianzhong; Tarsio, Maureen; Kane, Patricia M.			The E and G subunits of the yeast V-ATPase interact tightly and are both present at more than one copy per V1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; MEDIATED CROSS-LINKING; COLI F1F0-ATP SYNTHASE; ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; ALPHA-SUBUNIT; B-SUBUNIT; IN-VIVO; STATOR	The E and G subunits of the yeast V-ATPase are believed to be part of the peripheral or stator stalk(s) responsible for physically and functionally linking the peripheral V-1 sector, responsible for ATP hydrolysis, to the membrane V-0 sector, containing the proton pore. The E and G subunits interact tightly and specifically, both on a far Western blot of yeast vacuolar proteins and in the yeast two-hybrid assay. Amino acids 13-79 of the E subunit are critical for the E-G two-hybrid interaction. Different tagged versions of the G subunit were expressed in a diploid cell, and affinity purification of cytosolic V-1 sectors via a FLAG-tagged G subunit resulted in copurification of a Myc-tagged G subunit, implying more than one G subunit was present in each V-1 complex. Similarly, hemagglutinin-tagged E subunit was able to affinity-purify V-1 sectors containing an untagged version of the E subunit from heterozygous diploid cells, suggesting that more than one E subunit is present. Overexpression of the subunit G results in a destabilization of subunit E similar to that seen in the complete absence of subunit G (Tomashek, J. J., Graham, L. A., Hutchins, M. U., Stevens, T. H., and Klionsky, D. J. (1997) J. Biol. Chem. 272, 26787 - 26793). These results are consistent with recent models showing at least two peripheral stalks connecting the V-1 and V-0 sectors of the V-ATPase and would allow both stalks to be based on an EG dimer.	SUNY, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; SUNY Maritime College	Kane, PM (corresponding author), SUNY, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050322, R01 GM50322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Armbruster A, 2003, FEBS LETT, V546, P395, DOI 10.1016/S0014-5793(03)00643-4; Carbajo RJ, 2005, J MOL BIOL, V351, P824, DOI 10.1016/j.jmb.2005.06.012; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fethiere J, 2005, BIOCHEMISTRY-US, V44, P15906, DOI 10.1021/bi051762f; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P11924, DOI 10.1021/bi058022r; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Kersten MV, 2000, BIOCHEMISTRY-US, V39, P3856, DOI 10.1021/bi992699v; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Liu ML, 2005, J BIOL CHEM, V280, P36978, DOI 10.1074/jbc.M505296200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Motz C, 2004, J BIOL CHEM, V279, P49074, DOI 10.1074/jbc.M404543200; Muller V, 2003, CELL MOL LIFE SCI, V60, P474, DOI 10.1007/s000180300040; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHYA Y, 1994, GENETICS, V138, P1041; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Supekova L, 1996, J EXP BIOL, V199, P1147; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Venzke D, 2005, J MOL BIOL, V349, P659, DOI 10.1016/j.jmb.2005.04.033; Weber J, 2004, J BIOL CHEM, V279, P11253, DOI 10.1074/jbc.M312576200; Wilkens S, 2005, BIOCHEMISTRY-US, V44, P11786, DOI 10.1021/bi0510678; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470; Zhang ZY, 2003, J BIOL CHEM, V278, P47299, DOI 10.1074/jbc.M309445200	50	54	57	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22752	22760		10.1074/jbc.M601441200	http://dx.doi.org/10.1074/jbc.M601441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774922	hybrid			2022-12-27	WOS:000239542600036
J	Anong, WA; Weis, TL; Low, PS				Anong, William A.; Weis, Tahlia L.; Low, Philip S.			Rate of rupture and reattachment of the band 3-ankyrin bridge on the human erythrocyte membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-CELL MEMBRANE; CYTOPLASMIC DOMAIN; ANKYRIN; PROTEIN; SKELETON; DEFORMABILITY; STABILITY; DEFORMATION; EQUILIBRIUM; ASSOCIATION	The principal bridge connecting the erythrocyte membrane to the spectrin-based skeleton is established by band 3 and ankyrin; mutations leading to reduced bridge formation or increased bridge rupture result in morphological and mechanical abnormalities. Because membrane mechanical properties are determined in part by the protein interactions that stabilize the membrane, we have evaluated the rates of rupture and reattachment of band 3-ankyrin bridges under both resting and mechanically stressed conditions. To accomplish this, we have examined the rate of ankyrin displacement from inside-out vesicles by the hexahistidine-tagged cytoplasmic domain of band 3, cdb3-(His)(6) and the rate of substitution of cdb3-(His) 6 into endogenous band 3-ankyrin bridges in resealed erythrocytes in the presence and absence of shear stress. We demonstrate that 1) exogenous cdb3-(His) 6 displaces endogenous ankyrin from IOVs with a half-time and first order rate constant of 42 +/- 14 min and 0.017 +/- 0.0058 min(-1), respectively; 2) exogenous cdb3-(His) 6 substitutes endogenous band 3 in its linkage to ankyrin in resealed cells with a half-time and first order rate constant of 12 +/- 3.6 min and 0.060 +/- 0.019 min(-1), respectively; 3) cdb3-(His)(6)-mediated rupture of the band 3-ankyrin bridge in resealed cells results in decreased membrane mechanical stability, decreased deformability, abnormal morphology, and spontaneous vesiculation of the cells; and 4) the above on/off rates are not significantly accelerated by mechanical shear stress. We conclude that the off rates of the band 3-ankyrin interaction are sufficiently slow to allow sustained erythrocyte deformation without loss of elasticity.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, 560 Oval Dr, W Lafayette, IN 47907 USA.	plow@purdue.edu		Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM24417-26, T32-GM008296-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417, T32GM008296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An XL, 2002, J BIOL CHEM, V277, P31796, DOI 10.1074/jbc.M204567200; An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; BENNETT V, 1980, J BIOL CHEM, V255, P6424; CARTER DP, 1984, J CELL BIOCHEM, V24, P385, DOI 10.1002/jcb.240240408; CHASIS JA, 1986, J CELL BIOL, V103, P343, DOI 10.1083/jcb.103.2.343; Ding Y, 2004, PROTEIN EXPRES PURIF, V34, P167, DOI 10.1016/j.pep.2003.10.019; Evans E. A., 1978, CURR TOP MEMBR TRANS, P1; HEBBEL RP, 1991, BIOPHYS J, V60, P712, DOI 10.1016/S0006-3495(91)82100-2; JINBU Y, 1984, BIOCHIM BIOPHYS ACTA, V773, P237, DOI 10.1016/0005-2736(84)90087-7; Khan I, 2001, ARCH BIOCHEM BIOPHYS, V391, P25, DOI 10.1006/abbi.2001.2387; Lee JCM, 2001, BIOPHYS J, V81, P3178, DOI 10.1016/S0006-3495(01)75954-1; LI ZP, 1993, J BIOL CHEM, V268, P11489; LIU SC, 1995, BLOOD, V86, P349, DOI 10.1182/blood.V86.1.349.bloodjournal861349; MOHANDAS N, 1980, J CLIN INVEST, V66, P563, DOI 10.1172/JCI109888; MOHANDAS N, 1982, BLOOD, V59, P768; Mohler PJ, 2005, CURR OPIN CARDIOL, V20, P189, DOI 10.1097/01.hco.0000160372.95116.3e; Nicolas V, 2003, J BIOL CHEM, V278, P25526, DOI 10.1074/jbc.M302816200; PALEK J, 1992, BLOOD, V80, P308; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; Rybicki AC, 1996, BLOOD, V88, P2745, DOI 10.1182/blood.V88.7.2745.bloodjournal8872745; Shi ZT, 1999, J CLIN INVEST, V103, P331, DOI 10.1172/JCI3858; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; Van Dort HM, 2001, J BIOL CHEM, V276, P46968, DOI 10.1074/jbc.M107855200; Van Dort HM, 1998, J BIOL CHEM, V273, P14819, DOI 10.1074/jbc.273.24.14819	26	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22360	22366		10.1074/jbc.M513839200	http://dx.doi.org/10.1074/jbc.M513839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16762928	hybrid			2022-12-27	WOS:000239387100081
J	Yang, J; Zhang, W; Evans, PM; Chen, X; He, X; Liu, CM				Yang, Jun; Zhang, Wen; Evans, Paul M.; Chen, Xi; He, Xi; Liu, Chunming			Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; KAPPA-B-ALPHA; COLORECTAL-CANCER; CRYSTAL-STRUCTURE; COMPLEX; AXIN; DEGRADATION; TRCP; MECHANISM; PATHWAY	Most colorectal cancers have mutations of the adenomatous polyposis coli (APC) gene or the beta-catenin gene that stabilize beta-catenin and activate beta-catenin target genes, leading ultimately to cancer. The molecular mechanisms of APC function in beta-catenin degradation are not completely known. APC binds beta-catenin and is involved in the Axin complex, suggesting that APC regulates beta-catenin phosphorylation. Some evidence also suggests that APC regulates beta-catenin nuclear export. Here, we examine the effects of APC mutations on beta-catenin phosphorylation, ubiquitination, and degradation in the colon cancer cell lines SW480, DLD-1, and HT29, each of which contains a different APC truncation. Although the current models suggest that beta-catenin phosphorylation should be inhibited by APC mutations, we detected significant beta-catenin phosphorylation in these cells. However, beta-catenin ubiquitination and degradation were inhibited in SW480 but not in DLD-1 and HT29cells. The ubiquitination of beta-catenin in SW480 cells can be rescued by exogenous expression of APC. The APC domains required for beta-catenin ubiquitination were analyzed. Our results suggest that APC regulates beta-catenin phosphorylation and ubiquitination by distinct domains and by separate molecular mechanisms.	Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Harvard University; Boston Children's Hospital; Harvard Medical School	Liu, CM (corresponding author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA.	chliu@utmb.edu	高, 雨莉/HGU-8187-2022		NCI NIH HHS [CA 112007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA112007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; *AM CANC SOC, 2005, CANC FACTS FIG, P10; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Davies ML, 2004, ONCOGENE, V23, P1412, DOI 10.1038/sj.onc.1207266; Evans PM, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-22; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Matsumoto T, 2002, GUT, V50, P402, DOI 10.1136/gut.50.3.402; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sadot E, 2002, J CELL SCI, V115, P2771; Shih IM, 2000, CANCER RES, V60, P1671; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Wang ZH, 2003, CANCER RES, V63, P5234; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733	37	154	156	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17751	17757		10.1074/jbc.M600831200	http://dx.doi.org/10.1074/jbc.M600831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16798748	hybrid			2022-12-27	WOS:000238490300025
J	Gory-Faure, S; Windscheid, V; Bosc, C; Peris, L; Proietto, D; Franck, R; Denarier, E; Job, D; Andrieux, A				Gory-Faure, Sylvie; Windscheid, Vanessa; Bosc, Christophe; Peris, Leticia; Proietto, Dominique; Franck, Ronald; Denarier, Eric; Job, Didier; Andrieux, Annie			STOP-like protein 21 is a novel member of the STOP family, revealing a Golgi localization of STOP proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-STABLE MICROTUBULES; SECRETORY TRAFFICKING; DENDRITIC SPINES; SPOT-SYNTHESIS; PALMITOYLATION; MEMBRANE; CELLS; IDENTIFICATION; CALMODULIN; STABILITY	Neuronal microtubules are stabilized by two calmodulin-regulated microtubule-associated proteins, E-STOP and N-STOP, which when suppressed in mice induce severe synaptic and behavioral deficits. Here we show that mature neurons also contain a 21-kDa STOP-like protein, SL21, which shares calmodulin-binding and microtubule-stabilizing homology domains with STOP proteins. Accordingly, in different biochemical or cellular assays, SL21 has calmodulin binding and microtubule stabilizing activity. However, in cultured hippocampal neurons, SL21 antibodies principally stain the somatic Golgi and punctate Golgi material in neurites. In cycling cells, transfected SL21 decorates microtubules when expressed at high levels but is otherwise principally visible at the Golgi. The Golgi targeting of SL21 depends on the presence of cysteine residues located within the SL21 N-terminal domain, suggesting that Golgi targeting may require SL21 palmitoylation. Accordingly we find that SL21 is palmitoylated in vivo. N-STOP and E-STOP, which contain the Golgi targeting sequences present in SL21, also display distinct Golgi staining when expressed at low level in cycling cells. Thus neuronal proteins of the STOP family have the capacity to associate with Golgi material, which could be important for STOP synaptic functions.	CEA, INSERM, U366, DRDC CS,Commissariat Energie Atom, F-38054 Grenoble 9, France; Gessell Biotechnol Forschung, AG Mol Recognit, D-38124 Braunschweig, Germany	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Andrieux, A (corresponding author), CEA, INSERM, U366, DRDC CS,Commissariat Energie Atom, 17 Rue Martyrs, F-38054 Grenoble 9, France.	annie.andrieux@cea.fr	peris, leticia/P-9249-2017; ANDRIEUX, ANNIE/B-2134-2017; Bosc, Christophe/Q-8877-2019; Denarier, Eric/X-6137-2019; Denarier, Eric/H-3555-2017; Bosc, Christophe/P-3401-2017	peris, leticia/0000-0002-0668-1252; ANDRIEUX, ANNIE/0000-0002-4022-6405; Bosc, Christophe/0000-0002-3195-6692; Denarier, Eric/0000-0002-4169-397X; Denarier, Eric/0000-0002-4169-397X; Bosc, Christophe/0000-0002-3195-6692; Gory, Sylvie/0000-0001-5743-8079				Andrieux A, 2002, GENE DEV, V16, P2350, DOI 10.1101/gad.223302; Baratier J, 2006, J BIOL CHEM, V281, P19561, DOI 10.1074/jbc.M509602200; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Bosc C, 2001, J BIOL CHEM, V276, P30904, DOI 10.1074/jbc.M011614200; Brun P, 2005, J NEUROCHEM, V94, P63, DOI 10.1111/j.1471-4159.2005.03166.x; Denarier E, 1998, BIOCHEM BIOPH RES CO, V243, P791, DOI 10.1006/bbrc.1998.8179; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DOTTI CG, 1988, J NEUROSCI, V8, P1454; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Galiano MR, 2004, J NEUROSCI RES, V78, P329, DOI 10.1002/jnr.20260; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; Horton AC, 2005, NEURON, V48, P757, DOI 10.1016/j.neuron.2005.11.005; Horton AC, 2004, NAT CELL BIOL, V6, P585, DOI 10.1038/ncb0704-585; Horton AC, 2003, J NEUROSCI, V23, P6188; Huang K, 2005, CURR OPIN NEUROBIOL, V15, P527, DOI 10.1016/j.conb.2005.08.001; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Pierce JP, 2000, NAT NEUROSCI, V3, P311, DOI 10.1038/73868; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; PIROLLET F, 1992, BIOCHEMISTRY-US, V31, P8849, DOI 10.1021/bi00152a022; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476	30	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28387	28396		10.1074/jbc.M603380200	http://dx.doi.org/10.1074/jbc.M603380200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16837464	Green Submitted, hybrid			2022-12-27	WOS:000240534400076
J	Wang, SZ; Chen, Y; Sun, ZH; Zhou, Q; Sui, SF				Wang, Shi-Zhen; Chen, Yong; Sun, Zhan-Hua; Zhou, Qiang; Sui, Sen-Fang			Escherichia coli CorA periplasmic domain functions as a homotetramer to bind substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNESIUM TRANSPORT-SYSTEMS; SALMONELLA-TYPHIMURIUM; MG2+ TRANSPORTER; CONSERVED RESIDUES; PROTEIN; CRYSTALLIZATION; CLONING; MGTB; MUTAGENESIS; TOPOLOGY	CorA is a primary Mg2+ transporter in bacteria, which also mediates influx of Ni2+ and Co2+. Topological studies suggested that it could be divided into a large soluble periplasmic domain (PPD) and three membrane-spanning alpha-helixes. In the present study, glutathione S-transferase (GST) fusion Escherichia coli CorA PPD was purified by GST affinity chromatography, and PPD was obtained by on-column thrombin digestion. Size-exclusion chromatography indicated that purified PPD exists as a homotetramer. Single particle electron microscopy analysis of PPD and two-dimensional crystals of GST-PPD indicated that E. coli CorA PPD is a pyramid-like homotetramer with a central cavity. Comparison of the CD spectra of full-length CorA and PPD also suggested that PPD has similar secondary structure to the full- length CorA. Dissociation constants for CorA and PPD with their substrates, determined by dose-dependent fluorescence quench of ligands, suggested that purified PPD retains its substrate binding ability as native CorA. The CorA PPD structure described here may provide structural information for the E. coli CorA functional oligomeric state.	Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembranes & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Sui, SF (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembranes & Membrane Biotechnol, Beijing 100084, Peoples R China.	suisf@mail.tsinghua.edu.cn	chen, Yong/F-3938-2010; Wang, Shizhen/N-6577-2017; Chen, Yong/AAF-9915-2020	Wang, Shizhen/0000-0003-1065-4756; Chen, Yong/0000-0001-5857-6086				Chen Y, 2003, PROTEIN EXPRES PURIF, V32, P221, DOI 10.1016/S1046-5928(03)00233-X; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Daley DO, 2005, SCIENCE, V308, P1321, DOI 10.1126/science.1109730; Gardner RC, 2003, CURR OPIN PLANT BIOL, V6, P263, DOI 10.1016/S1369-5266(03)00032-3; GRUBBS RD, 1987, MAGNESIUM, V6, P113; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hartwig A, 2001, MUTAT RES-FUND MOL M, V475, P113, DOI 10.1016/S0027-5107(01)00074-4; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; Kehres D G, 1998, Microb Comp Genomics, V3, P151, DOI 10.1089/omi.1.1998.3.151; Kucharski LM, 2000, J BIOL CHEM, V275, P16767, DOI 10.1074/jbc.M001507200; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Lunin VV, 2006, NATURE, V440, P833, DOI 10.1038/nature04642; MAGUIRE ME, 1992, J BIOENERG BIOMEMBR, V24, P319; Moncrief MBC, 1998, INFECT IMMUN, V66, P3802, DOI 10.1128/IAI.66.8.3802-3809.1998; NELSON DL, 1971, J BIOL CHEM, V246, P3042; Payandeh J, 2006, ACTA CRYSTALLOGR F, V62, P148, DOI 10.1107/S1744309106000996; ROMANI A, 1993, MINER ELECTROL METAB, V19, P282; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; ROOF SK, 1994, J AM COLL NUTR, V13, P424; Saris NEL, 2000, CLIN CHIM ACTA, V294, P1, DOI 10.1016/S0009-8981(99)00258-2; SMITH DL, 1993, MINER ELECTROL METAB, V19, P266; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Smith RL, 1998, J BIOL CHEM, V273, P28663, DOI 10.1074/jbc.273.44.28663; Smith RL, 1998, MOL MICROBIOL, V28, P217, DOI 10.1046/j.1365-2958.1998.00810.x; SMITH RL, 1995, J BACTERIOL, V177, P1638, DOI 10.1128/jb.177.6.1638-1640.1995; SMITH RL, 1995, J BACTERIOL, V177, P1233, DOI 10.1128/jb.177.5.1233-1238.1995; Smyth DR, 2003, PROTEIN SCI, V12, P1313, DOI 10.1110/ps.0243403; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; Szegedy MA, 1999, J BIOL CHEM, V274, P36973, DOI 10.1074/jbc.274.52.36973; TAO T, 1995, J BACTERIOL, V177, P2654, DOI 10.1128/jb.177.10.2654-2662.1995; TOWNSEND DE, 1995, J BACTERIOL, V177, P5350, DOI 10.1128/jb.177.18.5350-5354.1995; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WALKER GM, 1986, MAGNESIUM, V5, P9; Walmsley AR, 2000, PRACT APPROACH SER, P167; Wang HW, 2001, J STRUCT BIOL, V134, P46, DOI 10.1006/jsbi.2001.4364; Wang HW, 1999, J STRUCT BIOL, V127, P283, DOI 10.1006/jsbi.1999.4161; Warren MA, 2004, J BACTERIOL, V186, P4605, DOI 10.1128/JB.186.14.4605-4612.2004; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4	40	11	12	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26813	26820		10.1074/jbc.M602342200	http://dx.doi.org/10.1074/jbc.M602342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16835234	hybrid			2022-12-27	WOS:000240397700008
J	Head, BP; Patel, HH; Roth, DM; Murray, F; Swaney, JS; Niesman, IR; Farquhar, MG; Insel, PA				Head, Brian P.; Patel, Hemal H.; Roth, David M.; Murray, Fiona; Swaney, James S.; Niesman, Ingrid R.; Farquhar, Marilyn G.; Insel, Paul A.			Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GTPASE-ACTIVATING PROTEIN; CYCLIC-AMP ACCUMULATION; SMOOTH-MUSCLE CELLS; S49 LYMPHOMA-CELLS; PLASMA-MEMBRANE; FOCAL ADHESIONS; PHOSPHORYLATED CAVEOLIN; CYTOSKELETAL ROLE; CARDIAC MYOCYTES	Microtubules and actin filaments regulate plasma membrane topography, but their role in compartmentation of caveolae-resident signaling components, in particular G protein-coupled receptors (GPCR) and their stimulation of cAMP production, has not been defined. We hypothesized that the microtubular and actin cytoskeletons influence the expression and function of lipid rafts/caveolae, thereby regulating the distribution of GPCR signaling components that promote cAMP formation. Depolymerization of microtubules with colchicine (Colch) or actin microfilaments with cytochalasin D (CD) dramatically reduced the amount of caveolin-3 in buoyant (sucrose density) fractions of adult rat cardiac myocytes. Colch or CD treatment led to the exclusion of caveolin-1, caveolin-2, beta 1-adrenergic receptors (beta(1)-AR), beta(2)-AR, G alpha(s), and adenylyl cyclase (AC)(5/6) from buoyant fractions, decreasing AC(5/6) and tyrosine-phosphorylated caveolin-1 in caveolin-1 immunoprecipitates but in parallel increased isoproterenol (beta-AR agonist)-stimulated cAMP production. Incubation with Colch decreased co-localization (by immunofluorescence microscopy) of caveolin-3 and alpha-tubulin; both Colch and CD decreased co-localization of caveolin-3 and filamin (an F-actin cross-linking protein), decreased phosphorylation of caveolin-1, Src, and p38 MAPK, and reduced the number of caveolae/mu m of sarcolemma (determined by electron microscopy). Treatment of S49 T-lymphoma cells (which possess lipid rafts but lack caveolae) with CD or Colch redistributed a lipid raft marker (linker for activation of T cells (LAT)) and G alpha s from lipid raft domains. We conclude that microtubules and actin filaments restrict cAMP formation by regulating the localization and interaction of GPCR-Gs-AC in lipid rafts/caveolae.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,BSB 3076, La Jolla, CA 92093 USA.	pinsel@ucsd.edu	; Patel, Hemal/C-7325-2019	Niesman, Ingrid/0000-0001-9767-6629; Patel, Hemal/0000-0001-6722-9625	NHLBI NIH HHS [HL66941] Funding Source: Medline; NIGMS NIH HHS [GM66232] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066232] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Capozza F, 2005, AM J PHYSIOL-CELL PH, V288, pC677, DOI 10.1152/ajpcell.00232.2004; Caselli A, 2001, J BIOL CHEM, V276, P18849, DOI 10.1074/jbc.M100705200; CHALDAKOV GN, 1989, CELL TISSUE RES, V255, P435; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Deng LH, 2005, J APPL PHYSIOL, V99, P634, DOI 10.1152/japplphysiol.00025.2005; Donati RJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1238, DOI 10.1038/sj.npp.1300697; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GALLI A, 1994, BIOPHYS J, V67, P2296, DOI 10.1016/S0006-3495(94)80715-5; GOLDMAN RD, 1971, J CELL BIOL, V51, P752, DOI 10.1083/jcb.51.3.752; GOTO Y, 1990, J SUBMICR CYTOL PATH, V22, P535; Gundersen GG, 2002, NAT REV MOL CELL BIO, V3, P296, DOI 10.1038/nrm777; Halayko AJ, 2005, CAN J PHYSIOL PHARM, V83, P877, DOI 10.1139/Y05-107; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Howarth FC, 1999, J PHYSIOL-LONDON, V516, P409, DOI 10.1111/j.1469-7793.1999.0409v.x; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; INSEL PA, 1978, NATURE, V273, P471, DOI 10.1038/273471a0; Isshiki M, 2003, TRAFFIC, V4, P717, DOI 10.1034/j.1600-0854.2003.00130.x; JASPER JR, 1995, J PHARMACOL EXP THER, V274, P937; KENNEDY MS, 1979, MOL PHARMACOL, V16, P215; KOLODNEY MS, 1995, P NATL ACAD SCI USA, V92, P10252, DOI 10.1073/pnas.92.22.10252; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Lee H, 2006, BIOCHEMISTRY-US, V45, P234, DOI 10.1021/bi051560j; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; LEIBER D, 1993, J BIOL CHEM, V268, P3833; Mons S, 2000, BBA-BIOMEMBRANES, V1468, P381, DOI 10.1016/S0005-2736(00)00279-0; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; NAITO M, 1989, ARTERY, V17, P21; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; Ratajczak P, 2003, CARDIOVASC RES, V57, P358, DOI 10.1016/S0008-6363(02)00660-0; Revenu C, 2004, NAT REV MOL CELL BIO, V5, P635, DOI 10.1038/nrm1437; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Swaney JS, 2006, J BIOL CHEM, V281, P17173, DOI 10.1074/jbc.M513097200; Tagawa H, 1998, CIRC RES, V82, P751, DOI 10.1161/01.RES.82.7.751; Thomas S, 2004, MOL IMMUNOL, V41, P399, DOI 10.1016/j.molimm.2004.03.022; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; van der Heyden MAG, 2005, CARDIOVASC RES, V65, P28, DOI 10.1016/j.cardiores.2004.09.028; vanDeurs B, 1996, J CELL SCI, V109, P1655; Volonte D, 2003, MOL BIOL CELL, V14, P4075, DOI 10.1091/mbc.E03-03-0161; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Webster DR, 2000, AM J PHYSIOL-HEART C, V278, pH1653, DOI 10.1152/ajpheart.2000.278.5.H1653; Zile MR, 2001, J AM COLL CARDIOL, V37, P1080, DOI 10.1016/S0735-1097(00)01207-9; Zinchuk O, 2004, CELL TISSUE RES, V317, P265, DOI 10.1007/s00441-004-0919-1; ZOR U, 1983, ENDOCR REV, V4, P1	57	221	225	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26391	26399		10.1074/jbc.M602577200	http://dx.doi.org/10.1074/jbc.M602577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16818493	hybrid, Green Submitted			2022-12-27	WOS:000240249500056
J	Morrison, CJ; Overall, CM				Morrison, Charlotte J.; Overall, Christopher M.			TIMP independence of matrix metalloproteinase (MMP)-2 activation by membrane type 2 (MT2)-MMP is determined by contributions of both the MT2-MMP catalytic and hemopexin C domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GELATINASE-A; II-LIKE MODULES; CELL-SURFACE; TISSUE INHIBITOR; 1-MATRIX METALLOPROTEINASE; EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; EFFICIENT ACTIVATION; ENDOTHELIAL-CELLS; COLLAGEN-BINDING	The important and distinct contribution that membrane type 2 (MT2)-matrix metalloproteinase (MMP) makes to physiological and pathological processes is now being recognized. This contribution may be mediated in part through MMP-2 activation by MT2-MMP. Using Timp2(-/-) cells, we previously demonstrated that MT2-MMP activates MMP-2 to the fully active form in a pathway that is TIMP-2-independent but MMP-2 hemopexin carboxyl (C) domain-dependent. In this study cells expressing MT2-MMP as well as chimera proteins in which the C-terminal half of MT2-MMP and MT1-MMP were exchanged showed that the MT2-MMP catalytic domain has a higher propensity than that of MT1-MMP to initiate cleavage of the MMP-2 prodomain in the absence of TIMP-2. Although we demonstrate that MT2-MMP is a weak collagenase, this first activation cleavage was enhanced by growing the cells in type I collagen gels. The second activation cleavage to generate fully active MMP-2 was specifically enhanced by a soluble factor expressed by Timp2(-/-) cells and was MT2-MMP hemopexin C domain-dependent; however, the RGD sequence within this domain was not involved. Interestingly, in the presence of TIMP-2, a MT2-MMP.MMP-2 trimolecular complex formed, but activation was not enhanced. Similarly, TIMP-3 did not promote MT2-MMP-mediated MMP-2 activation but inhibited activation at higher concentrations. This study demonstrates the influence that both the catalytic and hemopexin C domains of MT2-MMP exert in determining TIMP independence in MMP-2 activation. In tissues or pathologies characterized by low TIMP-2 expression, this pathway may represent an alternative means of rapidly generating low levels of active MMP-2.	Univ British Columbia, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Ctr Blood Res, Life Sci Bldg,2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca						Abraham R, 2005, J BIOL CHEM, V280, P34123, DOI 10.1074/jbc.M508155200; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Bigg HF, 2001, CANCER RES, V61, P3610; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Davidson B, 2001, AM J CLIN PATHOL, V115, P517; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kinoshita T, 1996, CANCER RES, V56, P2535; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lafleur MA, 2006, J BIOL CHEM, V281, P6826, DOI 10.1074/jbc.M513084200; Lafleur MA, 2002, J CELL SCI, V115, P3427; Lafleur MA, 2001, BIOCHEM J, V357, P107, DOI 10.1042/0264-6021:3570107; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Mahloogi H, 2002, CARCINOGENESIS, V23, P565, DOI 10.1093/carcin/23.4.565; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Monea S, 2002, J CELL PHYSIOL, V192, P160, DOI 10.1002/jcp.10126; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nisato RE, 2005, CANCER RES, V65, P9377, DOI 10.1158/0008-5472.CAN-05-1512; Ogiwara K, 2005, P NATL ACAD SCI USA, V102, P8442, DOI 10.1073/pnas.0502423102; Osenkowski P, 2005, J BIOL CHEM, V280, P26160, DOI 10.1074/jbc.M414379200; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pelman GR, 2005, J BIOL CHEM, V280, P2370, DOI 10.1074/jbc.M409603200; Puente XS, 1996, CANCER RES, V56, P944; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shimokawa K, 2001, Methods Mol Biol, V151, P275; Sounni NE, 2005, BIOCHIMIE, V87, P329, DOI 10.1016/j.biochi.2004.07.012; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Szabova L, 2005, J CELL PHYSIOL, V205, P123, DOI 10.1002/jcp.20385; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tam EM, 2004, J BIOL CHEM, V279, P43336, DOI 10.1074/jbc.M407186200; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Ueno H, 1997, CANCER RES, V57, P2055; Velasco G, 2000, CANCER RES, V60, P877; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang P, 2004, J BIOL CHEM, V279, P51148, DOI 10.1074/jbc.M409074200; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wong H, 2000, METH MOL B, V151, P305, DOI 10.1385/1-59259-046-2:305; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Zhang J, 2005, CARCINOGENESIS, V26, P2069, DOI 10.1093/carcin/bgi183; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	79	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26528	26539		10.1074/jbc.M603331200	http://dx.doi.org/10.1074/jbc.M603331200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16825197	hybrid			2022-12-27	WOS:000240249500071
J	Simic, P; Culej, JB; Orlic, I; Grgurevic, L; Draca, N; Spaventi, R; Vukicevic, S				Simic, Petra; Culej, Jasminka Buljan; Orlic, Iva; Grgurevic, Lovorka; Draca, Natasa; Spaventi, Radan; Vukicevic, Slobodan			Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	27th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research	SEP 23-27, 2005	Nashville, TN	Amer Soc Bone & Mineral Res			GROWTH-FACTOR; PARATHYROID-HORMONE; CANCELLOUS BONE; OSTEOGENIC PROTEIN; MINERAL DENSITY; EXPRESSION; ESTROGEN; STRENGTH; CELLS; FEMUR	Although recombinant human bone morphogenetic proteins (BMPs) are used locally for treating bone defects in humans, their systemic effect on bone augmentation has not been explored. We have previously demonstrated that demineralized bone (DB) from ovariectomized (OVX) rats cannot induce bone formation when implanted ectopically at the subcutaneous site. Here we showed in vitro that 17 beta-estradiol (E-2) specifically induced expression of Bmp6 mRNA in MC3T3-E1 preosteoblastic cells and that bone extracts from OVX rats lack BMPs. Next we demonstrated that I-125-BMP-6 administered systemically accumulated in the skeleton and also restored the osteoinductive capacity of ectopically implanted DB from OVX rats. BMP-6 applied systemically to aged OVX rats significantly increased bone volume and mechanical characteristics of both the trabecular and cortical bone, the osteoblast surface, serum osteocalcin and osteoprotegerin levels, and decreased the osteoclast surface, serum C-telopeptide, and interleukin-6. E-2 was significantly less effective, and was not synergistic with BMP-6. Animals that discontinued BMP-6 therapy maintained bone mineral density gains for another 12 weeks. BMP-6 increased in vivo the bone expression of Acvr-1, Bmpr1b, Smad5, alkaline phosphatase, and collagen type I and decreased expression of Bmp3 and BMP antagonists, chordin and cerberus. These results show, for the first time, that systemically administered BMP-6 restores the bone inductive capacity, microarchitecture, and quality of the skeleton in osteoporotic rats.	Univ Zagreb, Sch Med, Lab Mineralized Tissues, Zagreb 10000, Croatia; Pliva Res Inst, Zagreb 10000, Croatia	University of Zagreb; Teva Pharmaceutical Industries; Pliva	Vukicevic, S (corresponding author), Univ Zagreb, Sch Med, Lab Mineralized Tissues, Salata 11, Zagreb 10000, Croatia.	vukicev@mef.hr	Vukicevic, Slobodan/AEG-2646-2022	Vukicevic, Slobodan/0000-0003-4076-0285				Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Ahmed N, 2001, CELL BIOL INT, V25, P429, DOI 10.1006/cbir.2000.0662; Aspenberg P, 2000, ACTA ORTHOP SCAND, V71, P558, DOI 10.1080/000164700317362172; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bosukonda D, 2000, KIDNEY INT, V58, P1902, DOI 10.1046/j.1523-1755.2000.00362.x; Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546; CESNJAJ M, 1991, ACTA ORTHOP SCAND, V62, P471; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151; Friedlaender GE, 2004, PROG INFLAM RES, P157; Gao YH, 2004, P NATL ACAD SCI USA, V101, P16618, DOI 10.1073/pnas.0404888101; HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756-3282(92)90078-B; Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167; Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692; Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756-3282(00)00316-1; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Ito M, 1998, BONE, V23, P163, DOI 10.1016/S8756-3282(98)00083-0; Iwaniec UT, 2002, ENDOCRINOLOGY, V143, P2515, DOI 10.1210/en.143.7.2515; Jamsa T, 1998, BONE, V23, P155, DOI 10.1016/S8756-3282(98)00076-3; JONES WK, 1994, GROWTH FACTORS, V11, P215, DOI 10.3109/08977199409046919; Karahan S, 2002, COMPARATIVE MED, V52, P143; KE HZ, 1995, ENDOCRINOLOGY, V136, P2435, DOI 10.1210/en.136.6.2435; KREMPIEN B, 1988, J BONE MINER RES, V3, P573; Kucia M, 2005, BIOL CELL, V97, P133, DOI 10.1042/BC20040069; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Liang K, 1999, ENDOCRINOLOGY, V140, P5780; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lotinun S, 2004, J BONE MINER RES, V19, P1165, DOI 10.1359/JBMR.040404; Marcus R., 2001, OSTEOPOROSIS; Maric I, 2003, J CELL PHYSIOL, V196, P258, DOI 10.1002/jcp.10275; MARINOVIC S, 2004, BONE MORPHOGENETIC P, P45; Meng XW, 1996, J BONE MINER RES, V11, P421; Mundy GR, 2002, ANNU REV MED, V53, P337, DOI 10.1146/annurev.med.53.082901.104047; Ong DB, 2004, J BONE MINER RES, V19, P447, DOI 10.1359/JBMR.0301249; Oxlund H, 2002, EUR J ENDOCRINOL, V146, P431, DOI 10.1530/eje.0.1460431; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Papadopoulos NG, 1997, CLIN RHEUMATOL, V16, P162, DOI 10.1007/BF02247845; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Plant A, 2002, J BONE MINER RES, V17, P782, DOI 10.1359/jbmr.2002.17.5.782; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889-8529(02)00055-5; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; Rhee Y, 2004, J BONE MINER RES, V19, P931, DOI 10.1359/JBMR.040123; Rickard DJ, 1998, J CLIN INVEST, V101, P413, DOI 10.1172/JCI119880; ROSEN HN, 1995, J BONE MINER RES, V10, P1352; Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SAMPATH TK, 1984, P NATL ACAD SCI-BIOL, V81, P3419, DOI 10.1073/pnas.81.11.3419; Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112; SHEN V, 1995, J CLIN INVEST, V96, P2331, DOI 10.1172/JCI118289; Simic P, 2005, CYTOKINE GROWTH F R, V16, P299, DOI 10.1016/j.cytogfr.2005.02.010; Simic P, 2004, PROG INFLAM RES, P73; Srivastava AK, 2005, CURR MED RES OPIN, V21, P1015, DOI 10.1185/030079905X49635; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; VUKICEVIC S, 1987, J BONE MINER RES, V2, P533; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730; Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200; Wozney JM, 2004, CURR OPIN BIOTECH, V15, P392, DOI 10.1016/j.copbio.2004.08.001; Wronski TJ, 1998, PHARM TOXIC, P59	66	89	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25509	25521		10.1074/jbc.M513276200	http://dx.doi.org/10.1074/jbc.M513276200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	077LQ	16798745	hybrid, Green Accepted			2022-12-27	WOS:000240031300054
J	Henle, F; Fischer, C; Meyer, DK; Leemhuis, J				Henle, Frank; Fischer, Catharina; Meyer, Dieter K.; Leemhuis, Jost			Vasoactive intestinal peptide and PACAP38 control N-methyl-D-aspartic acid-induced dendrite motility by modifying the activities of rho GTPases and phosphatidylinositol 3-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; CENTRAL-NERVOUS-SYSTEM; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; PROTEIN-KINASE; PC12 CELLS; GROWTH; EXPRESSION; BRAIN; PHOSPHORYLATION	Dendrite morphogenesis is highly dynamic and characterized by the addition and elongation of processes and also by their selective maintenance, retraction, and elimination. Glutamate can influence these events via N-methyl-D-aspartic acid ( NMDA) receptors. The neuropeptides vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide-38 (PACAP38) affect neurogenesis and differentiation in the developing nervous system. We report here that the peptides and NMDA acted synergistically on dendrite and branch formation. In stage III hippocampal neurons, NMDA increased not only the addition but also the elimination of new dendrites and branches by activating Rac and Cdc42 and phosphatidylinositol 3-kinases, respectively. When applied alone, the neuropeptides did not influence dendrite or branch formation. However, they reduced the elimination of newly formed dendrites and branches caused by NMDA by preventing the NMDA-induced activation of phosphatidylinositol 3-kinases. This led to the formation of persistent dendrites and branches. Additional timelapse studies on the dynamics of dendrite elongation showed alternating periods of elongation and retraction. Phosphatidylinositol 3-kinases increased the velocities of dendrite elongation and retraction, whereas the neuropeptides prolonged the periods of elongation. By modifying NMDA-induced activation of Rho GTPases and phosphatidylinositol 3-kinases, vasoactive intestinal peptide and PACAP38 could play an important role in the control of dendrite growth and branching during development and in response to neuronal activity.	Univ Freiburg, Zentrum Neurowissensch, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Leemhuis, J (corresponding author), Univ Freiburg, Zentrum Neurowissensch, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany.	jost.leemhuis@pharmakol.uni-freiburg.de						Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Basille M, 2000, J COMP NEUROL, V425, P495; Blondel O, 2000, J NEUROSCI, V20, P8012; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Brenneman DE, 1998, ANN NY ACAD SCI, V865, P207, DOI 10.1111/j.1749-6632.1998.tb11180.x; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cazillis M, 2004, EUR J NEUROSCI, V19, P798, DOI 10.1111/j.0953-816X.2004.03138.x; de Anda FC, 2005, NATURE, V436, P704, DOI 10.1038/nature03811; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; Guirland C, 2003, J NEUROSCI, V23, P2274; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hua JYY, 2004, NAT NEUROSCI, V7, P327, DOI 10.1038/nn1218; Ikenoya M, 2002, J NEUROCHEM, V81, P9, DOI 10.1046/j.1471-4159.2002.00801.x; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KIRBY MA, 1986, J COMP NEUROL, V251, P532, DOI 10.1002/cne.902510408; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Konur S, 2005, NEURON, V46, P401, DOI 10.1016/j.neuron.2005.04.022; Leemhuis J, 2004, J BIOL CHEM, V279, P585, DOI 10.1074/jbc.M307066200; Li Z, 2003, NAT REV MOL CELL BIO, V4, P833, DOI 10.1038/nrm1242; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Lohmann C, 2005, CELL CALCIUM, V37, P403, DOI 10.1016/j.ceca.2005.01.008; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Meyer DK, 2005, J BIOL CHEM, V280, P25258, DOI 10.1074/jbc.M501630200; Miller FD, 2003, CURR OPIN NEUROBIOL, V13, P391, DOI 10.1016/s0959-4388(03)00072-2; Nakazawa T, 2003, MOL BIOL CELL, V14, P2921, DOI 10.1091/mbc.e02-09-0623; Oh JS, 2004, J BIOL CHEM, V279, P17980, DOI 10.1074/jbc.M314109200; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pei L, 1997, REGUL PEPTIDES, V71, P153, DOI 10.1016/S0167-0115(97)01012-4; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Perez V, 2005, EUR J NEUROSCI, V21, P26, DOI 10.1111/j.1460-9568.2004.03845.x; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; Portera-Cailliau C, 2003, J NEUROSCI, V23, P7129, DOI 10.1523/JNEUROSCI.23-18-07129.2003; Rao A, 1998, J NEUROSCI, V18, P1217; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Sin WC, 2002, NATURE, V419, P475, DOI 10.1038/nature00987; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van Aelst L, 2004, CURR OPIN NEUROBIOL, V14, P297, DOI 10.1016/j.conb.2004.05.012; Vaudry D, 2000, PHARMACOL REV, V52, P269; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; Washbourne P, 2002, CURR OPIN NEUROBIOL, V12, P566, DOI 10.1016/S0959-4388(02)00365-3; Wong ROL, 2002, NAT REV NEUROSCI, V3, P803, DOI 10.1038/nrn941; Wong WT, 2000, J NEUROSCI, V20, P5024; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	63	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24955	24969		10.1074/jbc.M604114200	http://dx.doi.org/10.1074/jbc.M604114200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803895	hybrid			2022-12-27	WOS:000239847800088
J	Mercer, JC; DeHaven, WI; Smyth, JT; Wedel, B; Boyles, RR; Bird, GS; Putney, JW				Mercer, Jason C.; DeHaven, Wayne I.; Smyth, Jeremy T.; Wedel, Barbara; Boyles, Rebecca R.; Bird, Gary S.; Putney, James W., Jr.			Large store-operated calcium selective currents due to co-expression of Orai1 or Orai2 with the intracellular calcium sensor, Stim1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; CA2+ SENSOR; RELEASE; CHANNELS; ENTRY; CRAC; POTENTIATION; DEPLETION; FAMILY; CELLS	The molecular nature of store-operated Ca2+-selective channels has remained an enigma, due largely to the continued inability to convincingly demonstrate Ca2+-selective store-operated currents resulting from exogenous expression of known genes. Recent findings have implicated two proteins, Stim1 and Orai1, as having essential roles in store-operated Ca2+ entry across the plasma membrane. However, transient overexpression of these proteins on their own results in little or no increase in store-operated entry. Here we demonstrate dramatic synergism between these two mediators; co-transfection of HEK293 cells with Stim1 and Orai1 results in an approximate 20-fold increase in store-operated Ca2+ entry and Ca2+-selective current. This demonstrates that these two proteins are limiting for both the signaling and permeation mechanisms for Ca2+-selective store-operated Ca2+ entry. There are three mammalian homologs of Orai1, and in expression experiments they all produced or augmented store-operated Ca2+ entry with efficacies in the order Orai1 > Orai2 > Orai3. Stim1 apparently initiates the signaling process by acting as a Ca2+ sensor in the endoplasmic reticulum. This results in rearrangement of Stim1 within the cell and migration toward the plasma membrane to regulate in some manner Orai1 located in the plasma membrane. However, we demonstrate that Stim1 does not incorporate in the surface membrane, and thus likely regulates or interacts with Orai1 at sites of close apposition between the plasma membrane and an intracellular Stim1-containing organelle.	NIEHS, NIH, Lab Signal Transduct, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, NIH, Lab Signal Transduct, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	putney@niehs.nih.gov	Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789; Boyles, Rebecca/0000-0003-0073-6854	Intramural NIH HHS [Z99 ES999999] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090087] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bolotina VM, 2005, TRENDS BIOCHEM SCI, V30, P378, DOI 10.1016/j.tibs.2005.05.009; Borszcz PD, 2003, EUR J IMMUNOL, V33, P1084, DOI 10.1002/eji.200323582; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Manji SSM, 2000, BBA-PROTEIN STRUCT M, V1481, P147, DOI 10.1016/S0167-4838(00)00105-9; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney J W Jr, 2001, Mol Interv, V1, P84; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Smyth JT, 2006, J BIOL CHEM, V281, P11712, DOI 10.1074/jbc.M510541200; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597	37	430	466	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24979	24990		10.1074/jbc.M604589200	http://dx.doi.org/10.1074/jbc.M604589200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807233	hybrid, Green Accepted			2022-12-27	WOS:000239847800090
J	Mueller-Planitz, F; Herschlag, D				Mueller-Planitz, Felix; Herschlag, Daniel			Interdomain communication in DNA topoisomerase II - DNA binding and enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; ATP-OPERATED CLAMP; QUINOLONE ACTION; STRAND-PASSAGE; DOUBLE HELIX; CLEAVAGE; MECHANISM; ALPHA; TRANSPORT; DOMAIN	Topoisomerase II catalyzes the ATP-dependent transport of a DNA segment (T-DNA) through a transient double strand break in another DNA segment (G-DNA). A fundamental mechanistic question is how the individual steps in this process are coordinated. We probed communication between the DNA binding sites and the individual enzymatic activities, ATP hydrolysis, and DNA cleavage. We employed short DNA duplexes to control occupancy at the two binding sites of wild-type enzyme and a variant with a G-DNA site mutation. The DNA concentration dependence of ATP hydrolysis and a fluorescence anisotropy assay provided thermodynamic information about DNA binding. The results suggest that G-DNA binds with higher affinity than T-DNA. Enzyme with only G-DNA bound is competent to cleave DNA, indicating that T-DNA is dispensable for DNA cleavage. The ATPase activity of enzyme bound solely to G-DNA is partially stimulated. Full stimulation requires binding of T-DNA. Both DNA binding sites therefore signal to the ATPase domains. The results support and extend current mechanistic models for topoisomerase II-catalyzed DNA transport and provide a framework for future mechanistic dissection.	Stanford Univ, Sch Med, Beckman Ctr B400, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Herschlag, D (corresponding author), Stanford Univ, Sch Med, Beckman Ctr B400, Dept Biochem, 279 Campus Dr, Stanford, CA 94305 USA.	herschla@cmgm.stanford.edu	Mueller-Planitz, Felix/P-8461-2014	Mueller-Planitz, Felix/0000-0001-8273-6473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064798] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; Bromberg KD, 2003, BIOCHEMISTRY-US, V42, P3393, DOI 10.1021/bi027383t; Burden DA, 2000, METH MOL B, V95, P283; Campbell S, 2002, J MOL BIOL, V320, P171, DOI 10.1016/S0022-2836(02)00461-8; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; CORBETT AH, 1992, J BIOL CHEM, V267, P683; Corbett KD, 2005, STRUCTURE, V13, P873, DOI 10.1016/j.str.2005.03.013; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Horst M, 1996, PROTEIN SCI, V5, P759; Hu T, 2002, J BIOL CHEM, V277, P5944, DOI 10.1074/jbc.M111394200; Kallansrud G, 1996, ANAL BIOCHEM, V236, P134, DOI 10.1006/abio.1996.0141; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; Kraut DA, 2006, PLOS BIOL, V4, P501, DOI 10.1371/journal.pbio.0040099; Lindsley JE, 2000, METH MOL B, V95, P57; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1983, J BIOL CHEM, V258, P8421; Schoeffler AJ, 2005, BIOCHEM SOC T, V33, P1465, DOI 10.1042/BST0331465; Strumberg D, 2002, ANTIMICROB AGENTS CH, V46, P2735, DOI 10.1128/AAC.46.9.2735-2746.2002; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	38	16	16	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23395	23404		10.1074/jbc.M604119200	http://dx.doi.org/10.1074/jbc.M604119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782968	hybrid			2022-12-27	WOS:000239702900014
J	Pullmann, R; Abdelmohsen, K; Lal, A; Martindale, JL; Ladner, RD; Gorospe, M				Pullmann, Rudolf, Jr.; Abdelmohsen, Kotb; Lal, Ashish; Martindale, Jennifer L.; Ladner, Robert D.; Gorospe, Myriam			Differential stability of thymidylate synthase 3 '-untranslated region polymorphic variants regulated by AUF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TURNOVER; BINDING-PROTEINS; COMMON POLYMORPHISM; GENE-EXPRESSION; LUNG-CANCER; HUR; CLONING; RISK; 5-FLUOROURACIL; IDENTIFICATION	A 6-nucleotide insertion (I)/deletion (D) polymorphism in the 3'-untranslated region of the thymidylate synthase gene was shown to influence mRNA stability, but the molecular basis of this effect has not been elucidated. Here, studies of both endogenous and ectopically expressed thymidylate synthase alleles revealed that the mRNA-binding, decay-promoting protein AUF1 has higher affinity for allele D mRNA. AUF1 overexpression preferentially suppressed D allele mRNA levels, whereas AUF1 silencing selectively elevated D allele mRNA levels. Our results illustrate the functional consequences of ribonucleoprotein associations involving a polymorphic RNA sequence and uncover a novel mechanism of action for non-coding RNA polymorphisms.	NIA, Cellular & Mol Biol Lab, IRP, NIH, Baltimore, MD 21224 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Southern California	Pullmann, R (corresponding author), NIA, Cellular & Mol Biol Lab, IRP, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	pullmannru@nih.gov	Martindale, Jennifer Luethy/AAD-1963-2022; Abdelmohsen, Kotb/AAX-4191-2020	Martindale, Jennifer Luethy/0000-0002-3234-6861; Abdelmohsen, Kotb/0000-0001-6240-5810	NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; BUU NT, 1995, IMMUNOGENETICS, V42, P428; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DOLNICK BJ, 1993, NUCLEIC ACIDS RES, V21, P1747, DOI 10.1093/nar/21.8.1747; Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gouble A, 2002, CANCER RES, V62, P1489; Hieronymus H, 2004, GENE DEV, V18, P2845, DOI 10.1101/gad.1256904; Horie N, 1997, J BIOL CHEM, V272, P18375, DOI 10.1074/jbc.272.29.18375; Hu Z, 2005, LUNG CANCER, V48, P11, DOI 10.1016/j.lungcan.2004.09.004; Khabar KSA, 2005, J INTERF CYTOK RES, V25, P1, DOI 10.1089/jir.2005.25.1; Kumagai K, 2003, INT J MOL MED, V11, P593; Lafon I, 1998, ONCOGENE, V16, P3413, DOI 10.1038/sj.onc.1201895; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lal A, 2005, EMBO J, V24, P1852, DOI 10.1038/sj.emboj.7600661; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Mandola MV, 2004, PHARMACOGENETICS, V14, P319, DOI 10.1097/00008571-200405000-00007; Mandola MV, 2003, CANCER RES, V63, P2898; Marsh S, 2005, INVEST NEW DRUG, V23, P533, DOI 10.1007/s10637-005-4021-7; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Morahan G, 2001, NAT GENET, V27, P218, DOI 10.1038/84872; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; RUSTUM YM, 2003, FLUOPYRIMIDINES CANC; Shi QL, 2005, CARCINOGENESIS, V26, P649, DOI 10.1093/carcin/bgh351; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; SHUEY DL, 1995, TOXICOLOGY, V102, P207, DOI 10.1016/0300-483X(95)03049-L; Skibola CF, 2004, BLOOD, V104, P2155, DOI 10.1182/blood-2004-02-0557; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Ulrich CM, 2000, CANCER EPIDEM BIOMAR, V9, P1381; Volcik KA, 2003, BIRTH DEFECTS RES A, V67, P924, DOI 10.1002/bdra.10029; Wang TL, 2004, P NATL ACAD SCI USA, V101, P3089, DOI 10.1073/pnas.0308716101; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	38	47	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23456	23463		10.1074/jbc.M600282200	http://dx.doi.org/10.1074/jbc.M600282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787927	hybrid			2022-12-27	WOS:000239702900020
J	Turella, P; Filomeni, G; Dupuis, ML; Ciriolo, MR; Molinari, A; De Maria, F; Tombesi, M; Cianfriglia, M; Federici, G; Ricci, G; Caccuri, AM				Turella, Paola; Filomeni, Giuseppe; Dupuis, Maria Luisa; Ciriolo, Maria Rosa; Molinari, Agnese; De Maria, Francesca; Tombesi, Marina; Cianfriglia, Maurizio; Federici, Giorgio; Ricci, Giorgio; Caccuri, Anna Maria			A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells - 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE MONOCLONAL-ANTIBODY; MULTIDRUG-RESISTANCE; SUBSTRATE RECOGNITION; DEATH; ACTIVATION; VARIANTS; PROTEINS	The new glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol- 4-ylthio)hexanol (NBDHEX) is cytotoxic toward P-glycoprotein-overexpressing tumor cell lines, i.e. CEM-VBL10, CEM-VBL100, and U-2 OS/DX580. The mechanism of cell death triggered by NBDHEX has been deeply investigated in leukemia cell lines. Kinetic data indicate a similar NBDHEX membrane permeability between multidrug resistance cells and their sensitive counterpart revealing that NBDHEX is not a substrate of the P-glycoprotein export pump. Unexpectedly, this molecule promotes a caspase-dependent apoptosis that is unusual in the P-glycoprotein-overexpressing cells. The primary event of the apoptotic pathway is the dissociation of glutathione S-transferase P1-1 from the complex with c-Jun N-terminal kinase. Interestingly, leukemia MDR1-expressing cells show lower LC50 values and a higher degree of apoptosis and caspase-3 activity than their drug-sensitive counterparts. The increased susceptibility of the multidrug resistance cells toward the NBDHEX action may be related to a lower content of glutathione S-transferase P1-1. Given the low toxicity of NBDHEX in vivo, this compound may represent an attractive basis for the selective treatment of MDR1 P-glycoproteinpositive tumors.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy; Ist Super Sanita, Dept Technol & Hlth, I-00161 Rome, Italy; Childrens Hosp, IRCCS Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); IRCCS Bambino Gesu	Caccuri, AM (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I-00133 Rome, Italy.	caccuri@uniroma2.it	CACCURI, ANNA MARIA/AFU-2643-2022; DUPUIS, MARIA LUISA/D-7949-2016; Molinari, Agnese/E-7588-2015; Ciriolo, Maria Rosa/K-6572-2016; Molinari, Agnese/AAC-2918-2021	Molinari, Agnese/0000-0002-9592-5465; Molinari, Agnese/0000-0002-9592-5465; Ricci, Giorgio/0000-0002-7108-2846; Filomeni, Giuseppe/0000-0002-2719-1412; CACCURI, ANNA MARIA/0000-0002-3756-4163; Ciriolo, Maria Rosa/0000-0002-7863-9029				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Bielak-Zmijewska A, 2000, NUTR CANCER, V38, P131, DOI 10.1207/S15327914NC381_18; Borst P, 1997, SEMIN CANCER BIOL, V8, P131, DOI 10.1006/scbi.1997.0072; CENCIARELLI C, 1991, INT J CANCER, V47, P533, DOI 10.1002/ijc.2910470411; CIANFRIGLIA M, 1990, INT J CANCER, V45, P95, DOI 10.1002/ijc.2910450118; CIANFRIGLIA M, 1994, INT J CANCER, V56, P153; Dai DJ, 2005, WORLD J GASTROENTERO, V11, P193, DOI 10.3748/wjg.v11.i2.193; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Ishisaki A, 2001, J NEUROCHEM, V77, P1362, DOI 10.1046/j.1471-4159.2001.00351.x; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; LING V, 1997, CANC CHEMOTHER PHA S, V40, P3; Nilsson E, 1997, HISTOCHEM J, V29, P857, DOI 10.1023/A:1026441907803; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; Ricci G, 2005, J BIOL CHEM, V280, P26397, DOI 10.1074/jbc.M503295200; Ruefli AA, 2002, INT J CANCER, V99, P292, DOI 10.1002/ijc.10327; Ruefli AA, 2000, BLOOD, V95, P2378, DOI 10.1182/blood.V95.7.2378.007k10_2378_2385; Schultz M, 1997, ADV DRUG DELIVER REV, V26, P91, DOI 10.1016/S0169-409X(97)00029-X; Scotlandi K, 1996, CANCER RES, V56, P2434; Seelig A, 2000, INT J CLIN PHARM TH, V38, P111; Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432-1327.1998.2510252.x; Tainton KM, 2000, BIOCHEM BIOPH RES CO, V276, P231, DOI 10.1006/bbrc.2000.3459; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; TSURUO T, 1983, CANCER RES, V43, P2267; Turella P, 2005, CANCER RES, V65, P3751, DOI 10.1158/0008-5472.CAN-04-3903; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200	26	38	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23725	23732		10.1074/jbc.M604372200	http://dx.doi.org/10.1074/jbc.M604372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16769721	hybrid, Green Published			2022-12-27	WOS:000239702900047
J	Ren, XY; Nicoll, DA; Philipson, KD				Ren, Xiaoyan; Nicoll, Debora A.; Philipson, Kenneth D.			Helix packing of the cardiac Na+-Ca2+ exchanger - Proximity of transmembrane segments 1, 2, and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA/CA-K EXCHANGER; NA+/CA2+ EXCHANGER; PURIFICATION; EXPRESSION; MECHANISM; TOPOLOGY; CHANNELS; REPEATS	The cardiac Na+-Ca2+ exchanger (NCX1) is a membrane protein that extrudes Ca2+ from cells using the energy of the Na+ gradient and is a key protein in regulating intracellular Ca2+ and contractility. Based on the current topological model, NCX1 consists of nine transmembrane segments (TMSs). The N-terminal five TMSs are separated from the C-terminal four TMSs by a large intracellular loop. Cysteine 768 is modeled to be in TMS 6 close to the intracellular surface. In this study, the proximity of TMS 6 to TMSs 1 and 2 was examined. Insect High Five cells were transfected with cDNAs encoding mutant NCX1 proteins. Each mutant contained cysteine 768 and an introduced cysteine in TMS 1 or 2. Cross-linking between cysteines was determined after reaction with thiol-specific cross-linkers containing spacer arms of 6.5-12 angstrom. The data indicate that residues in TMSs 1 and 2 are close to cysteine 768 in TMS 6. Cysteine 768 cross-linked with residues at both ends of TMSs 1 and 2 and is likely located toward the middle of TMS 6. Based on these results, we present an expanded helix-packing model for NCX1.	Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Lab, MRL 3-645, Los Angeles, CA 90095 USA.	KPhilipson@mednet.ucla.edu			NHLBI NIH HHS [HL-49101] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bers D. M., 2001, EXCITATION CONTRACTI, V2nd, P133, DOI [10.1007/978-94-010-0658-3_6, DOI 10.1007/978-94-010-0658-3_6]; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; GIMPL G, 1995, BIOCHEMISTRY-US, V34, P13794, DOI 10.1021/bi00042a010; Grottesi A, 2005, BIOCHEMISTRY-US, V44, P14586, DOI 10.1021/bi0510429; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Ottolia M, 2005, J BIOL CHEM, V280, P1061, DOI 10.1074/jbc.M411899200; Philipson KD, 2002, ANN NY ACAD SCI, V976, P1; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Tomiya N, 2004, GLYCOCONJUGATE J, V21, P343, DOI 10.1023/B:GLYC.0000046275.28315.87; VEMURI R, 1989, J BIOL CHEM, V264, P8680; VEMURI R, 1988, BIOCHIM BIOPHYS ACTA, V937, P258, DOI 10.1016/0005-2736(88)90248-9; Winkfein RJ, 2003, BIOCHEMISTRY-US, V42, P543, DOI 10.1021/bi026982x; Yang NB, 1997, BIOPHYS J, V73, P2260, DOI 10.1016/S0006-3495(97)78258-4; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	23	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22808	22814		10.1074/jbc.M604753200	http://dx.doi.org/10.1074/jbc.M604753200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785232	hybrid			2022-12-27	WOS:000239542600042
J	Sheckler, LR; Henry, L; Sugita, S; Sudhof, TC; Rudenko, G				Sheckler, Lauren R.; Henry, Lisa; Sugita, Shuzo; Sudhof, Thomas C.; Rudenko, Gabby			Crystal structure of the second LNS/LG domain from neurexin 1 alpha - Ca2+ binding and the effects of alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-NEUREXINS; CELL-ADHESION; SYNAPSE FORMATION; DIFFRACTION DATA; DYSTROGLYCAN; BETA; LATROTOXIN; RECEPTOR; HEPARIN; LIGAND	Neurexins mediate protein interactions at the synapse, playing an essential role in synaptic function. Extracellular domains of neurexins, and their fragments, bind a distinct profile of different proteins regulated by alternative splicing and Ca2+. The crystal structure of n1 alpha_LNS#2 (the second LNS/LG domain of bovine neurexin 1 alpha) reveals large structural differences compared with n1 alpha_LNS#6 (or n1 beta_LNS), the only other LNS/LG domain for which a structure has been determined. The differences overlap the so-called hyper-variable surface, the putative protein interaction surface that is reshaped as a result of alternative splicing. A Ca2+-binding site is revealed at the center of the hyper-variable surface next to splice insertion sites. Isothermal titration calorimetry indicates that the Ca2+-binding site in n1 alpha_LNS#2 has low affinity (K-d similar to 400 mu M). Ca2+-binding ceases to be measurable when an 8- or 15-residue splice insert is present at the splice site SS#2 indicating that alternative splicing can affect Ca2+-binding sites of neurexin LNS/LG domains. Our studies initiate a framework for the putative protein interaction sites of neurexin LNS/LG domains. This framework is essential to understand how incorporation of alternative splice inserts expands the information from a limited set of neurexin genes to produce a large array of synaptic adhesion molecules with potentially very different synaptic function.	Univ Michigan, Life Sci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75390 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rudenko, G (corresponding author), Univ Michigan, Life Sci Inst, 210 Washtenaw Ave,Rm 3163A, Ann Arbor, MI 48109 USA.	rudenko@umich.edu	Rudenko, Gabrielle (Gabby)/O-7938-2018	Rudenko, Gabrielle (Gabby)/0000-0002-7372-0530; Sugita, Shuzo/0000-0002-9182-873X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH077303] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR001646] Funding Source: Medline; NIGMS NIH HHS [DMR0225180] Funding Source: Medline; NIMH NIH HHS [R01 MH077303-02, R01MH077303, R01 MH077303-01, R01 MH077303, R01 MH077303-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boucard AA, 2005, NEURON, V48, P229, DOI 10.1016/j.neuron.2005.08.026; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Cantallops I, 2000, CURR BIOL, V10, pR620, DOI 10.1016/S0960-9822(00)00663-1; Cline H, 2005, CURR BIOL, V15, pR203, DOI 10.1016/j.cub.2005.03.010; Cooper A, 2001, BIOPHYS CHEM, V93, P215, DOI 10.1016/S0301-4622(01)00222-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Craig AM, 2006, TRENDS NEUROSCI, V29, P8, DOI 10.1016/j.tins.2005.11.002; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Dean C, 2006, TRENDS NEUROSCI, V29, P21, DOI 10.1016/j.tins.2005.11.003; Dudev T, 2003, CHEM REV, V103, P773, DOI 10.1021/cr020467n; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Grant SGN, 2006, BIOCHEM SOC T, V34, P59, DOI 10.1042/BST0340059; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hopf C, 1996, J BIOL CHEM, V271, P5231; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kattenstroth G, 2004, P NATL ACAD SCI USA, V101, P2607, DOI 10.1073/pnas.0308626100; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kummer TT, 2006, CURR OPIN NEUROBIOL, V16, P74, DOI 10.1016/j.conb.2005.12.003; Levi S, 2002, J NEUROSCI, V22, P4274, DOI 10.1523/JNEUROSCI.22-11-04274.2002; Li G, 2005, J NEUROSCI, V25, P10188, DOI 10.1523/JNEUROSCI.3560-05.2005; Littleton JT, 2003, NATURE, V423, P931, DOI 10.1038/423931a; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; Missler M, 2003, TRENDS NEUROSCI, V26, P176, DOI 10.1016/S0166-2236(03)00066-3; Missler M, 1998, J BIOL CHEM, V273, P34716, DOI 10.1074/jbc.273.52.34716; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nam CI, 2005, P NATL ACAD SCI USA, V102, P6137, DOI 10.1073/pnas.0502038102; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patzke H, 2000, MOL CELL NEUROSCI, V15, P561, DOI 10.1006/mcne.2000.0853; Petrenko AG, 1996, J NEUROSCI, V16, P4360; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Rowen L, 2002, GENOMICS, V79, P587, DOI 10.1006/geno.2002.6734; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Smith SM, 2004, NEURON, V41, P243, DOI 10.1016/S0896-6273(03)00837-7; Sons MS, 2006, NEUROSCIENCE, V138, P433, DOI 10.1016/j.neuroscience.2005.11.040; Stetefeld J, 2004, STRUCTURE, V12, P503, DOI 10.1016/j.str.2004.02.001; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Tabuchi K, 2002, GENOMICS, V79, P849, DOI 10.1006/geno.2002.6780; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Waites CL, 2005, ANNU REV NEUROSCI, V28, P251, DOI 10.1146/annurev.neuro.27.070203.144336; Wizemann H, 2003, J MOL BIOL, V332, P635, DOI 10.1016/S0022-2836(03)00848-9; Zeng ZH, 2006, INT J DEV BIOL, V50, P39, DOI 10.1387/ijdb.052068zz; Zhang WQ, 2005, J NEUROSCI, V25, P4330, DOI 10.1523/JNEUROSCI.0497-05.2005	67	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22896	22905		10.1074/jbc.M603464200	http://dx.doi.org/10.1074/jbc.M603464200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772286	hybrid, Green Accepted			2022-12-27	WOS:000239542600052
J	Joy, S; Siow, RCM; Rowlands, DJ; Becker, M; Wyatt, AW; Aaronson, PI; Coen, CW; Kallo, I; Jacob, R; Mann, GE				Joy, Sheeja; Siow, Richard C. M.; Rowlands, David J.; Becker, Marko; Wyatt, Amanda W.; Aaronson, Philip I.; Coen, Clive W.; Kallo, Imre; Jacob, Ron; Mann, Giovanni E.			The isoflavone equol mediates rapid vascular relaxation - Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; DEPENDENT PROTEIN-KINASE; HUMAN UMBILICAL VEIN; POSTMENOPAUSAL WOMEN; NONGENOMIC ACTIVATION; PHYTO-ESTROGENS; SOY ISOFLAVONES; PLASMA-MEMBRANE; IN-VITRO; BETA	We recently reported that soy isoflavones increase gene expression of endothelial nitric-oxide synthase (eNOS) and antioxidant defense enzymes, resulting in improved endothelial function and lower blood pressure in vivo. In this study, we establish that equol (1-100 nM) causes acute endothelium- and nitric oxide (NO)-dependent relaxation of aortic rings and rapidly (2 min) activates eNOS in human aortic and umbilical vein endothelial cells. Intracellular Ca2+ and cyclic AMP levels were unaffected by treatment (100 nM, 2 min) with equol, daidzein, or genistein. Rapid phosphorylation of ERK1/2, protein kinase B/Akt, and eNOS serine 1177 by equol was paralleled by association of eNOS with heat shock protein 90 (Hsp90) and NO synthesis in human umbilical vein endothelial cells, expressing estrogen receptors (ER)alpha and ER beta. Inhibition of phosphatidylinositol 3-kinase and ERK1/2 inhibited eNOS activity, whereas pertussis toxin and the ER antagonists ICI 182,750 and tamoxifen had negligible effects. Our findings provide the first evidence that nutritionally relevant plasma concentrations of equol (and other soy protein isoflavones) rapidly stimulate phosphorylation of ERK1/2 and phosphatidylinositol 3-kinase/Akt, leading to the activation of NOS and increased NO production at resting cytosolic Ca2+ levels. Identification of the nongenomic mechanisms by which equol mediates vascular relaxation provides a basis for evaluating potential benefits of equol in the treatment of postmenopausal women and patients at risk of cardiovascular disease.	Kings Coll London, Div Cardiovasc, London SE1 1UL, England; Kings Coll London, Reprod & Endocrinol Div, London SE1 1UL, England; Kings Coll London, Asthma Allergy & Lung Biol Div, Sch Biomed & Hlth Sci, London SE1 1UL, England; Kings Coll London, Asthma Allergy & Lung Biol Div, Sch Med, London SE1 1UL, England; Inst Expt Med, Lab Endocrinol & Behav Neurobiol, H-1083 Budapest, Hungary	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine	Mann, GE (corresponding author), Kings Coll London, Div Cardiovasc, Guys Campus, London SE1 1UL, England.	giovanni.mann@kcl.ac.uk	Kalló, Imre/C-6262-2016	Kalló, Imre/0000-0003-3412-4100; Aaronson, Philip Irving/0000-0003-1086-1202; Coen, Clive/0000-0003-1303-216X; Mann, Giovanni/0000-0001-7311-2044	Wellcome Trust [060202] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; Anselm E, 2005, FASEB J, V19, pA1230; Anter E, 2004, J BIOL CHEM, V279, P46637, DOI 10.1074/jbc.M405547200; Bachetti T, 2004, J MOL CELL CARDIOL, V37, P939, DOI 10.1016/j.yjmcc.2004.07.006; Borras C, 2005, AGING CELL, V4, P113, DOI 10.1111/j.1474-9726.2005.00151.x; Cassidy A, 2006, P NUTR SOC, V65, P76, DOI 10.1079/PNS2005476; Cassidy A, 2006, J NUTR, V136, P45, DOI 10.1093/jn/136.1.45; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chambliss KL, 2005, MOL ENDOCRINOL, V19, P277, DOI 10.1210/me.2004-0008; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Chen DB, 2004, ENDOCRINOLOGY, V145, P113, DOI 10.1210/en.2003-0547; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Chin-Dusting JPF, 2004, ATHEROSCLEROSIS, V176, P45, DOI 10.1016/j.atherosclerosis.2004.03.025; Chin-Dusting JPF, 2001, BRIT J PHARMACOL, V133, P595, DOI 10.1038/sj.bjp.0704088; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Cuevas AM, 2003, EUR J CLIN NUTR, V57, P889, DOI 10.1038/sj.ejcn.1601622; Dan P, 2003, AM J PHYSIOL-HEART C, V284, pH1295, DOI 10.1152/ajpheart.00781.2002; de Kleijn MJJ, 2002, AM J EPIDEMIOL, V155, P339, DOI 10.1093/aje/155.4.339; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Evinger AJ, 2005, STEROIDS, V70, P361, DOI 10.1016/j.steroids.2005.02.015; Figtree GA, 2000, J AM COLL CARDIOL, V35, P1977, DOI 10.1016/S0735-1097(00)00645-8; Figtree GA, 2003, CIRCULATION, V107, P120, DOI 10.1161/01.CIR.0000043805.11780.F5; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hisamoto K, 2005, STEROIDS, V70, P382, DOI 10.1016/j.steroids.2005.02.011; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Hrabovszky E, 2004, J COMP NEUROL, V473, P315, DOI 10.1002/cne.20127; Hwang J, 2003, FREE RADICAL BIO MED, V34, P1271, DOI 10.1016/S0891-5849(03)00104-7; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kim-Schulze S, 1998, CIRCULATION, V98, P413, DOI 10.1161/01.CIR.98.5.413; Klinge CM, 2005, J BIOL CHEM, V280, P7460, DOI 10.1074/jbc.M411565200; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; KUPPUSAMY UR, 1992, BIOCHEM PHARMACOL, V44, P1307, DOI 10.1016/0006-2952(92)90531-M; Lissin LW, 2000, J AM COLL CARDIOL, V35, P1403; Liu DM, 2004, ENDOCRINOLOGY, V145, P5532, DOI 10.1210/en.2004-0102; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; Mahn K, 2005, FASEB J, V19, P1755, DOI 10.1096/fj.05-4008fje; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Mishra SK, 2000, CARDIOVASC RES, V46, P539, DOI 10.1016/S0008-6363(00)00049-3; NAKASHIMA S, 1991, MOL PHARMACOL, V39, P475; Ou JS, 2004, AM J PHYSIOL-HEART C, V286, pH561, DOI 10.1152/ajpheart.00736.2003; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; Quattrone S, 2004, MOL HUM REPROD, V10, P325, DOI 10.1093/molehr/gah040; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Rivas M, 2002, J NUTR, V132, P1900, DOI 10.1093/jn/132.7.1900; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Schulz E, 2005, CIRCULATION, V111, P3473, DOI 10.1161/CIRCULATIONAHA.105.546812; Setchell KDR, 2005, AM J CLIN NUTR, V81, P1072; Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Squadrito F, 2003, AM J MED, V114, P470, DOI 10.1016/S0002-9343(03)00059-7; Squadrito F, 2000, CARDIOVASC RES, V45, P454, DOI 10.1016/S0008-6363(99)00359-4; Stefano GB, 2000, CIRCULATION, V101, P1594, DOI 10.1161/01.CIR.101.13.1594; Sumi D, 2003, P NATL ACAD SCI USA, V100, P14451, DOI 10.1073/pnas.2235590100; Teede HJ, 2003, ARTERIOSCL THROM VAS, V23, P1066, DOI 10.1161/01.ATV.0000072967.97296.4A; Valverde Miguel A., 2002, Trends in Biochemical Sciences, V27, P172, DOI 10.1016/S0968-0004(02)02075-3; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Vera R, 2005, J PHARMACOL EXP THER, V314, P1300, DOI 10.1124/jpet.105.085530; Walker HA, 2001, CIRCULATION, V103, P258, DOI 10.1161/01.CIR.103.2.258; Wyatt AW, 2002, FASEB J, V16, P1584, DOI 10.1096/fasebj.16.12.1584; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200	68	117	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27335	27345		10.1074/jbc.M602803200	http://dx.doi.org/10.1074/jbc.M602803200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16840783	hybrid			2022-12-27	WOS:000240397700060
J	Elbing, K; Rubenstein, EM; McCartney, RR; Schmidt, MC				Elbing, Karin; Rubenstein, Eric M.; McCartney, Rhonda R.; Schmidt, Martin C.			Subunits of the Snf1 kinase heterotrimer show interdependence for association and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; 3 SNF1-ACTIVATING KINASES; SACCHAROMYCES-CEREVISIAE; YEAST SNF1; GAMMA-SUBUNITS; CATALYTIC DOMAIN; UPSTREAM KINASES; BETA-SUBUNITS; COMPLEX; PURIFICATION	The Snf1 kinase and its mammalian orthologue, the AMP-activated protein kinase ( AMPK), function as heterotrimers composed of a catalytic alpha-subunit and two non-catalytic subunits, beta and gamma. The beta-subunit is thought to hold the complex together and control subcellular localization whereas the gamma-subunit plays a regulatory role by binding to and blocking the function of an auto-inhibitory domain (AID) present in the alpha-subunit. In addition, catalytic activity requires phosphorylation by a distinct upstream kinase. In yeast, any one of three Snf1-activating kinases, Sak1, Tos3, or Elm1, can fulfill this role. We have previously shown that Sak1 is the only Snf1-activating kinase that forms a stable complex with Snf1. Here we show that the formation of the Sak1 (.) Snf1 complex requires the beta- and gamma-subunits in vivo. However, formation of the Sak1 (.) Snf1 complex is not necessary for glucose-regulated phosphorylation of the Snf1 activation loop. Snf1 kinase purified from cells lacking the beta-subunits do not contain any gamma-subunit, indicating that the Snf1 kinase does not form a stable alpha gamma dimer in vivo. In vitro kinase assays using purified full-length and truncated Snf1 proteins demonstrate that the kinase domain, which lacks the AID, is significantly more active than the full-length Snf1 protein. Addition of purified beta- and gamma-subunits could stimulate the kinase activity of the full-length alpha-subunit but only when all three subunits were present, suggesting an interdependence of all three subunits for assembly of a functional complex.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schmidt, MC (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.	mcs2@pitt.edu		Rubenstein, Eric/0000-0003-4983-1430	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046443, R29GM046443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Caspary F, 1999, EMBO J, V18, P3463, DOI 10.1093/emboj/18.12.3463; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Elbing K, 2006, BIOCHEM J, V393, P797, DOI 10.1042/BJ20051213; ERICKSON JR, 1993, GENETICS, V135, P655; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hedbacker K, 2004, MOL CELL BIOL, V24, P8255, DOI 10.1128/MCB.24.18.8255-8263.2004; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Iseli TJ, 2005, J BIOL CHEM, V280, P13395, DOI 10.1074/jbc.M412993200; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Leech A, 2003, EUKARYOT CELL, V2, P265, DOI 10.1128/EC.2.2.265-273.2003; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; McCartney R, 2005, CURR GENET, V47, P335, DOI 10.1007/s00294-005-0576-2; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Nath N, 2002, J BIOL CHEM, V277, P50403, DOI 10.1074/jbc.M207058200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rubenstein EM, 2006, EUKARYOT CELL, V5, P620, DOI 10.1128/EC.5.4.620-627.2006; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; SIKORSKI RS, 1989, GENETICS, V122, P19; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	32	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26170	26180		10.1074/jbc.M603811200	http://dx.doi.org/10.1074/jbc.M603811200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16847059	hybrid			2022-12-27	WOS:000240249500033
J	Rossi, ML; Bambara, RA				Rossi, Marie L.; Bambara, Robert A.			Reconstituted Okazaki fragment processing indicates two pathways of primer removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; CELL NUCLEAR ANTIGEN; ESSENTIAL IN-VIVO; FLAP ENDONUCLEASE-1; DEOXYRIBONUCLEIC ACID; LIGATABLE NICK; YEAST; REPLICATION; CLEAVAGE; BINDING	Eukaryotic Okazaki fragments are initiated by an RNA/DNA primer and extended by DNA polymerase delta(pol delta) and the replication clamp proliferating cell nuclear antigen (PCNA). Joining of the fragments by DNA ligase I to generate the continuous double- stranded DNA requires complete removal of the RNA/DNA primer. Pol delta extends the upstream Okazaki fragment and displaces the downstream RNA/DNA primer into a flap removed by nuclease cleavage. One proposed pathway for flap removal involves pol delta displacement of long flaps, coating of those flaps by replication protein A(RPA), and sequential cleavage of the flap by Dna2 nuclease followed by flap endonuclease 1 (FEN1). A second pathway involves reiterative single nucleotide or short oligonucleotide displacement by pol delta and cleavage by FEN1. We measured the length of FEN1 cleavage products on flaps strand- displaced by pol delta in an oligonucleotide system reconstituted with Saccharomyces cerevisiae proteins. Results showed that in the presence of PCNA and FEN1, pol delta displacement synthesis favors formation and cleavage of primarily short flaps, up to eight nucleotides in length; still, a portion of flaps grows to 20 - 30 nucleotides. The proportion of long flaps can be altered by mutations in the relevant proteins, sequence changes in the DNA, and reaction conditions. These results suggest that FEN1 is sufficient to remove a majority of Okazaki fragment primers. However, some flaps become long and require the two-nuclease pathway. It appears that both pathways, operating in parallel, are required for processing of all flaps.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	Robert_Bambara@urmc.rochester.edu			NIGMS NIH HHS [GM024441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Budd ME, 2006, MOL CELL BIOL, V26, P2490, DOI 10.1128/MCB.26.7.2490-2500.2006; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Budd ME, 2000, MUTAT RES-DNA REPAIR, V459, P173, DOI 10.1016/S0921-8777(99)00072-5; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Jin YH, 2003, J BIOL CHEM, V278, P1626, DOI 10.1074/jbc.M209803200; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kao HI, 2004, J BIOL CHEM, V279, P50840, DOI 10.1074/jbc.M409231200; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; KELLY RB, 1970, J BIOL CHEM, V245, P39; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Liu Y, 2003, J BIOL CHEM, V278, P13728, DOI 10.1074/jbc.M212061200; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Rossi ML, 2006, CHEM REV, V106, P453, DOI 10.1021/cr040497l; SETLOW P, 1972, J BIOL CHEM, V247, P232; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199	35	70	71	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26051	26061		10.1074/jbc.M604805200	http://dx.doi.org/10.1074/jbc.M604805200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16837458	hybrid			2022-12-27	WOS:000240249500020
J	Chatterjee, S; Home, P; Mukherjee, S; Mahata, B; Goswami, S; Dhar, G; Adhya, S				Chatterjee, Saibal; Home, Pratik; Mukherjee, Saikat; Mahata, Bidesh; Goswami, Srikanta; Dhar, Gunjan; Adhya, Samit			An RNA-binding respiratory component mediates import of type II tRNAs into Leishmania mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC TRANSFER-RNA; CYTOCHROME-C-OXIDASE; CRITHIDIA-FASCICULATA; DISTINCT MECHANISMS; INNER MEMBRANE; MESSENGER-RNA; COMPLEX; RECEPTORS; PROTEIN; YEAST	Transport of tRNAs across the inner mitochondrial membrane of the kinetoplastid protozoon Leishmania requires interactions with specific binding proteins (receptors) in a multi-subunit complex. The allosteric model of import regulation proposes cooperative and antagonistic interactions between two or more receptors with binding specificities for distinct tRNA families (types I and II, respectively). To identify the type II receptor, the gene encoding RIC8A, a subunit of the complex, was cloned. The C-terminal region of RIC8A is homologous to subunit 6b of ubiquinol cytochrome c reductase (respiratory complex III), while the N-terminal region has intrinsic affinity for type II, but not for type I, tRNAs. RIC8A is shared by the import complex and complex III, indicating its bi-functionality, but is assembled differently in the two complexes. Knockdown of RIC8A in Leishmania lowered the mitochondrial content of type II tRNAs but raised that of type I tRNAs, with downstream effects on mitochondrial translation and respiration, and cell death. In RIC8A knockdown cells, a subcomplex was formed that interacted with type I tRNA, but the negative regulation by type II tRNA was lost. Mitochondrial extracts from these cells were defective for type II, but not type I, import; import and regulation were restored by purified RIC8A. These results provide evidence for the relevance of allosteric regulation in vivo and indicate that acquisition of new tRNA-binding domains by ancient respiratory components have played a key role in the evolution of mitochondrial tRNA import.	Indian Inst Chem Biol, Genet Engn Lab, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, 4 Raja Sc Mullick Rd, Kolkata 700032, W Bengal, India.	sadhya@iicb.res.in	Home, Pratik/D-5061-2014; MUKHERJEE, SAIKAT/ABF-1050-2021	Mahata, Bidesh/0000-0002-4506-0184; Dhar, Gunjan/0000-0003-2754-4254				Bhattacharyya SN, 2004, J BIOL CHEM, V279, P11259, DOI 10.1074/jbc.C300540200; Bhattacharyya SN, 2003, MOL CELL BIOL, V23, P5217, DOI 10.1128/MCB.23.15.5217-5224.2003; Bhattacharyya SN, 2002, MOL CELL BIOL, V22, P4372, DOI 10.1128/MCB.22.12.4372-4382.2002; Bhattacharyya SN, 2000, MOL CELL BIOL, V20, P7410, DOI 10.1128/MCB.20.19.7410-7417.2000; Bhattacharyya Suvendra Nath, 2004, RNA Biol, V1, P84, DOI 10.4161/rna.1.2.1180; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; Esseiva AC, 2004, MOL BIOL CELL, V15, P2750, DOI 10.1091/mbc.E03-11-0821; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; GHOSH A, 1994, NUCLEIC ACIDS RES, V22, P1663, DOI 10.1093/nar/22.9.1663; Goswami S, 2003, NUCLEIC ACIDS RES, V31, P5552, DOI 10.1093/nar/gkg773; Goswami S, 2006, P NATL ACAD SCI USA, V103, P8354, DOI 10.1073/pnas.0510869103; HANCOCK K, 1990, J BIOL CHEM, V265, P19203; Horvath A, 2000, J BIOL CHEM, V275, P17160, DOI 10.1074/jbc.M907246199; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; Mahata B, 2005, J BIOL CHEM, V280, P5141, DOI 10.1074/jbc.C400572200; Maslov DA, 1999, MOL BIOCHEM PARASIT, V99, P207, DOI 10.1016/S0166-6851(99)00028-6; Nabholz CE, 1999, MOL BIOL CELL, V10, P2547, DOI 10.1091/mbc.10.8.2547; Schagger H, 1996, Methods Enzymol, V264, P555, DOI 10.1016/S0076-6879(96)64048-8; Schneider A, 2000, TRENDS CELL BIOL, V10, P509, DOI 10.1016/S0962-8924(00)01854-7; SCHOPPINK PJ, 1989, EUR J BIOCHEM, V181, P475, DOI 10.1111/j.1432-1033.1989.tb14749.x; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; Speijer D, 1997, MOL BIOCHEM PARASIT, V85, P171, DOI 10.1016/S0166-6851(96)02823-X; Speijer D, 1996, MOL BIOCHEM PARASIT, V79, P47, DOI 10.1016/0166-6851(96)02648-5; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026	27	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25270	25277		10.1074/jbc.M604126200	http://dx.doi.org/10.1074/jbc.M604126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16825195	hybrid			2022-12-27	WOS:000240031300028
J	Levin, MH; Sullivan, S; Nielson, D; Yang, BX; Finkbeiner, WE; Verkman, AS				Levin, Marc H.; Sullivan, Shannon; Nielson, Dennis; Yang, Baoxue; Finkbeiner, Walter E.; Verkman, A. S.			Hypertonic saline therapy in cystic fibrosis - Evidence against the proposed mechanism involving aquaporins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG FLUID TRANSPORT; MUCOCILIARY CLEARANCE; WATER PERMEABILITY; INHALED MANNITOL; MUCUS CLEARANCE; SURFACE LIQUID; AMILORIDE; INHALATION; CHANNELS; SPUTUM	Recent data indicate the clinical benefit of nebulized hypertonic saline in cystic fibrosis lung disease, with a proposed mechanism involving sustained increase in airway surface liquid volume. To account for the paradoxical observation that amiloride suppresses the beneficial effect of hypertonic saline, it has been previously concluded (Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., and Boucher, R. C. (2006) N. Engl. J. Med. 354, 241 - 250) that amiloride-inhibitable aquaporin (AQP) water channels in airway epithelia modulate airway surface liquid volume. Here, we have characterized water permeability and amiloride effects in well differentiated, primary cultures of human airway epithelial cells, stably transfected Fisher rat thyroid epithelial cells expressing individual airway/lung AQPs, and perfused mouse lung. We found high transepithelial water permeability (P-f, 54 +/- 5 mu m/s) in airway epithelial cells that was weakly temperature-dependent and inhibited by > 90% by reduced pH in the basal membrane-facing solution. Reverse transcription-PCR and immunofluorescence suggested the involvement of AQPs 3, 4, and 5 in high airway water permeability. Experiments using several sensitive measurement methods indicated that amiloride does not inhibit water permeability in non-cystic fibrosis (non-CF) or CF airway epithelia, AQP-transfected Fisher rat thyroid cells, or intact lung. Our data provide evidence against the mechanism proposed by Donaldson et al. to account for the effects of amiloride and hypertonic saline in CF lung disease, indicating the need to identify alternate mechanisms.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574, P30EY002162] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Borok Z, 2002, J APPL PHYSIOL, V93, P2199, DOI 10.1152/japplphysiol.01171.2001; Carter EP, 1996, J GEN PHYSIOL, V108, P133, DOI 10.1085/jgp.108.3.133; Daviskas E, 1997, EUR RESPIR J, V10, P2449, DOI 10.1183/09031936.97.10112449; Daviskas E, 2005, RESPIROLOGY, V10, P46, DOI 10.1111/j.1440-1843.2005.00659.x; Daviskas E, 1996, EUR RESPIR J, V9, P725, DOI 10.1183/09031936.96.09040725; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Durairaj L, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-13; Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; Fang X, 2002, J GEN PHYSIOL, V119, P199, DOI 10.1085/jgp.119.2.199; Feng W, 1998, AM J RESP CRIT CARE, V157, P710, DOI 10.1164/ajrccm.157.3.9703059; FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970; Folkesson HG, 1996, J CLIN INVEST, V97, P664, DOI 10.1172/JCI118463; Fulcher M Leslie, 2005, Methods Mol Med, V107, P183; HASEGAWA H, 1994, AM J PHYSIOL, V266, pC893, DOI 10.1152/ajpcell.1994.266.4.C893; Hirsh AJ, 2004, J PHARMACOL EXP THER, V311, P929, DOI 10.1124/jpet.104.071886; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; King M, 1997, AM J RESP CRIT CARE, V156, P173, DOI 10.1164/ajrccm.156.1.9512074; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; Levin MH, 2004, INVEST OPHTH VIS SCI, V45, P4423, DOI 10.1167/iovs.04-0816; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matthay MA, 1996, AM J PHYSIOL-LUNG C, V270, pL487, DOI 10.1152/ajplung.1996.270.4.L487; PAVIA D, 1978, AM REV RESPIR DIS, V117, P199; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Pedersen PS, 2005, PFLUG ARCH EUR J PHY, V451, P464, DOI 10.1007/s00424-005-1484-5; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1999, EUR RESPIR J, V14, P678, DOI 10.1034/j.1399-3003.1999.14c30.x; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Sajjan U, 2004, J HEART LUNG TRANSPL, V23, P1382, DOI 10.1016/j.healun.2003.09.023; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; Sood N, 2003, AM J RESP CRIT CARE, V167, P158, DOI 10.1164/rccm.200204-293OC; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Zabner J, 2000, P NATL ACAD SCI USA, V97, P11614, DOI 10.1073/pnas.97.21.11614; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	42	43	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25803	25812		10.1074/jbc.M604332200	http://dx.doi.org/10.1074/jbc.M604332200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16829520	hybrid			2022-12-27	WOS:000240031300082
J	Smyczynski, C; Roudier, F; Gissot, L; Vaillant, E; Grandjean, O; Morin, H; Masson, T; Bellec, Y; Geelen, D; Faure, JD				Smyczynski, Cybelle; Roudier, Francois; Gissot, Lionel; Vaillant, Emilie; Grandjean, Olivier; Morin, Halima; Masson, Thimote; Bellec, Yannick; Geelen, Danny; Faure, Jean-Denis			The C terminus of the immunophilin PASTICCINO1 is required for plant development and for interaction with a NAC-like transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLPROLYL ISOMERASE DOMAIN; RED FLUORESCENT PROTEIN; ARABIDOPSIS-THALIANA; CYTOPLASMIC DYNEIN; GLUCOCORTICOID-RECEPTOR; FK506-BINDING PROTEINS; CELL-PROLIFERATION; MERISTEM FORMATION; GENE FAMILY; FKBP52	PASTICCINO1 (PAS1) is a high molecular weight FK506-binding protein (FKBP) involved in the control of cell proliferation and differentiation during plant development. Mutations in the C-terminal region of PAS1 result in severe developmental defects. We show here that the C-terminal domain of PAS1 controls the subcellular distribution of this protein. We also demonstrated in vitro and in vivo, by Forster resonance energy transfer, that this C-terminal region is required for interaction with FAN (FKBP-associated NAC), a new member of the plant-specific family of NAC transcription factors. PAS1 and FAN are translocated into the nucleus upon auxin treatment in plant seedlings. The nuclear translocation of PAS1 is dependent on the presence of the C terminus of the protein. Finally, we showed that FAN is involved in PAS1-regulated processes because FAN overproduction partly complemented the pas1 phenotype. We suggest that PAS1 regulates the function of this NAC-like transcription factor by controlling its targeting to the nucleus upon plant cell division.	INRA, Inst Jean Pierre Bourgin, Biol Cellulaire Lab, F-78026 Versailles, France; INRA, Inst Jean Pierre Bourgin, Lab Commun Cytol, F-78026 Versailles, France; Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Flanders Institute for Biotechnology (VIB); Ghent University	Faure, JD (corresponding author), INRA, Inst Jean Pierre Bourgin, Biol Cellulaire Lab, Route St Cyr, F-78026 Versailles, France.	faure@versailles.inra.fr						Aghdasi B, 2001, P NATL ACAD SCI USA, V98, P2425, DOI 10.1073/pnas.041614198; Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; Bellec Y, 2002, PLANT J, V32, P713, DOI 10.1046/j.1365-313X.2002.01456.x; Berardini TZ, 2001, SCIENCE, V291, P2405, DOI 10.1126/science.1057144; Breiman A, 2002, TRANSGENIC RES, V11, P321, DOI 10.1023/A:1016331814412; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Carol RJ, 2001, PLANT SCI, V161, P527, DOI 10.1016/S0168-9452(01)00437-X; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dornan J, 2003, CURR TOP MED CHEM, V3, P1392, DOI 10.2174/1568026033451899; Duval M, 2002, PLANT MOL BIOL, V50, P237, DOI 10.1023/A:1016028530943; Dwivedi RS, 2003, J EXP BOT, V54, P2679, DOI 10.1093/jxb/erg307; Faure JD, 1998, DEVELOPMENT, V125, P909; Fong S, 2003, P NATL ACAD SCI USA, V100, P14253, DOI 10.1073/pnas.2332307100; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Geisler M, 2004, MOL BIOL CELL, V15, P3393, DOI 10.1091/mbc.E03-11-0831; Geisler M, 2003, MOL BIOL CELL, V14, P4238, DOI 10.1091/mbc.E02-10-0698; Goodin MM, 2002, PLANT J, V31, P375, DOI 10.1046/j.1365-313X.2002.01360.x; Harrar Y, 2003, PLANT PHYSIOL, V132, P1217, DOI 10.1104/pp.102.019026; Harrar Y, 2001, TRENDS PLANT SCI, V6, P426, DOI 10.1016/S1360-1385(01)02044-1; Harrell JM, 2002, BIOCHEMISTRY-US, V41, P5581, DOI 10.1021/bi020073q; He ZY, 2004, PLANT PHYSIOL, V134, P1248, DOI 10.1104/pp.103.031005; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Kamphausen T, 2002, PLANT J, V32, P263, DOI 10.1046/j.1365-313X.2002.01420.x; KATO K, 1972, FERMENTATION TECHNOL; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Laufs P, 1998, DEVELOPMENT, V125, P1253; Lehnart SE, 2003, CURR TOP MED CHEM, V3, P1383, DOI 10.2174/1568026033451907; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mas P, 2000, NATURE, V408, P207, DOI 10.1038/35041583; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Ooka H, 2003, DNA RES, V10, P239, DOI 10.1093/dnares/10.6.239; Peeters NM, 2000, J MOL EVOL, V50, P413, DOI 10.1007/s002390010044; Rathjen JP, 1999, EMBO J, V18, P3232, DOI 10.1093/emboj/18.12.3232; Reddy RK, 1998, PLANT PHYSIOL, V118, P1395, DOI 10.1104/pp.118.4.1395; Romano PGN, 2004, PLANT PHYSIOL, V134, P1268, DOI 10.1104/pp.103.022160; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; Takada S, 2001, DEVELOPMENT, V128, P1127; Vittorioso P, 1998, MOL CELL BIOL, V18, P3034, DOI 10.1128/MCB.18.5.3034; Vroemen CW, 2003, PLANT CELL, V15, P1563, DOI 10.1105/tpc.012203; Weir I, 2004, DEVELOPMENT, V131, P915, DOI 10.1242/dev.00993; Xie Q, 2000, GENE DEV, V14, P3024, DOI 10.1101/gad.852200; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; Yao DY, 2000, J BIOL CHEM, V275, P13149, DOI 10.1074/jbc.275.17.13149	51	49	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25475	25484		10.1074/jbc.M601815200	http://dx.doi.org/10.1074/jbc.M601815200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803883	hybrid, Green Published			2022-12-27	WOS:000240031300050
J	Doshida, M; Ohmichi, M; Tsutsumi, S; Kawagoe, J; Takahashi, T; Du, BT; Mori-Abe, A; Ohta, T; Saitoh-Sekiguchi, M; Takahashi, K; Kurachi, H				Doshida, Masakazu; Ohmichi, Masahide; Tsutsumi, Seiji; Kawagoe, Jun; Takahashi, Toshifumi; Du, Botao; Mori-Abe, Akiko; Ohta, Tsuyoshi; Saitoh-Sekiguchi, Maki; Takahashi, Kazuhiro; Kurachi, Hirohisa			Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR INJURY RESPONSE; PROTEIN-KINASE CASCADE; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; BREAST-CANCER; AKT CASCADE; PHOSPHORYLATION; ACTIVATION	Vascular endothelial senescence is involved in human atherosclerosis. Telomerase activity is known to be critical in cellular senescence and its level is modulated by regulation of telomerase catalytic subunit ( telomerase reverse transcriptase ( TERT)) at both the transcriptional and post-transcriptional levels. Since the cardioprotective effect of estrogen itself has not been ruled out, we examined that of raloxifene, which has been classified as a selective estrogen receptor modulator, on the proliferation and telomerase activity of human umbilical vein endothelial cells ( HUVECs). Raloxifene, like estrogen, clearly induced the telomerase activity and human TERT ( hTERT) expression via estrogen receptor ( ER) alpha and ER beta. Treatment with raloxifene for 5 days significantly induced cell growth, and either cotreatment with a telomerase inhibitor, 3'-azido-3'-deoxythymidine, or transfection with hTERT-specific small interfering RNA significantly attenuated the raloxifene-induced cell growth. Raloxifene also induced the phosphorylation of Akt, and pretreatment with a phosphatidylinositol 3-kinase inhibitor, LY294002, significantly attenuated the raloxifene-induced telomerase activity. In addition, raloxifene induced both the phosphorylation of hTERT and I kappa B. Moreover, cotreatment with an I kappa B alpha phosphorylation inhibitor, BAY-11-7082, or a specific NF kappa B nuclear translocation inhibitor, SN50, significantly attenuated the raloxifene-induced telomerase activity and the association of NF kappa B with hTERT. These results show that raloxifene induced the up-regulation of telomerase activity not only by the transcriptional regulation of hTERT but also by post-translational regulation of the phosphorylation of Akt and hTERT and the association of hTERT with NF kappa B in HUVECs. Thus, the up-regulation of telomerase activity in vascular endothelial cells might be one mechanism contributing to the potential atheroprotective effect of raloxifene.	Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan	Yamagata University; Osaka University	Ohmichi, M (corresponding author), Yamagata Univ, Sch Med, Dept Obstet & Gynecol, 2-2-2 Lidanishi, Yamagata 9909585, Japan.	masa@gyne.med.osaka-u.ac.jp	Takahashi, Toshifumi/AAU-1848-2020; Takahashi, Toshifumi/AAN-2416-2020	Takahashi, Toshifumi/0000-0003-0955-4248				Akiyama M, 2003, CANCER RES, V63, P18; Akiyama M, 2002, CANCER RES, V62, P3876; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Barrett-Connor E, 2002, JAMA-J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847; Buys CHCM, 2000, NEW ENGL J MED, V342, P1282, DOI 10.1056/NEJM200004273421710; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Du BT, 2004, J ENDOCRINOL, V183, P605, DOI 10.1677/joe.1.05775; Evans MJ, 2002, ENDOCRINOLOGY, V143, P3785, DOI 10.1210/en.2002-220356; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Hayakawa J, 2000, CANCER RES, V60, P5988; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Karas RH, 1999, P NATL ACAD SCI USA, V96, P15133, DOI 10.1073/pnas.96.26.15133; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kimura A, 2004, ONCOGENE, V23, P4505, DOI 10.1038/sj.onc.1207582; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; Kyo S, 1999, CANCER RES, V59, P5917; Liu JG, 2002, HORM RES, V58, P16, DOI 10.1159/000063211; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P1302, DOI 10.1210/en.2003-0709; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Miller VM, 1999, CIRC RES, V85, P979; Minamino T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17; Mori-Abe A, 2003, J ENDOCRINOL, V178, P417, DOI 10.1677/joe.0.1780417; Oishi A, 2004, BIOCHEM BIOPH RES CO, V324, P193, DOI 10.1016/j.bbrc.2004.09.032; ORSHAL IM, 2004, AM J PHYSIOL, V286, pR233; Ozes ON, 1999, NATURE, V401, P82; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; Takahashi K, 2003, J ENDOCRINOL, V178, P319, DOI 10.1677/joe.0.1780319; Vasa M, 2000, CIRC RES, V87, P540, DOI 10.1161/01.RES.87.7.540; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; Williams MRI, 2004, J CLIN ENDOCR METAB, V89, P4708, DOI 10.1210/jc.2003-031560; Xiao XM, 1999, J PEDIATR SURG, V34, P1603, DOI 10.1016/S0022-3468(99)90625-5; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yegorov YE, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1296	48	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24270	24278		10.1074/jbc.M513251200	http://dx.doi.org/10.1074/jbc.M513251200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798746	hybrid			2022-12-27	WOS:000239847800020
J	Wojciechowska, M; Napierala, M; Larson, JE; Wells, RD				Wojciechowska, Marzena; Napierala, Marek; Larson, Jacquelynn E.; Wells, Robert D.			Non-B DNA conformations formed by long repeating tracts of myotonic dystrophy type 1, myotonic dystrophy type 2, and Friedreich's ataxia genes, not the sequences per se, promote mutagenesis in flanking regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; REPLICATION IN-VIVO; ESCHERICHIA-COLI; TRIPLET REPEATS; TRINUCLEOTIDE REPEATS; FORMING SEQUENCES; NEUROLOGICAL DISEASES; DYNAMIC MUTATIONS; MAMMALIAN-CELLS; GROSS DELETIONS	The expansions of long repeating tracts of CTG(.)CAG, CCTG(.)CAGG, and GAA(.)TTC are integral to the etiology of myotonic dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2), and Friedreich's ataxia ( FRDA). Essentially all studies on the molecular mechanisms of this expansion process invoke an important role for non-B DNA conformations which may be adopted by these repeat sequences. We have directly evaluated the role(s) of the repeating sequences per se, or of the non-B DNA conformations formed by these sequences, in the mutagenic process. Studies in Escherichia coli and three types of mammalian (COS-7, CV-1, and HEK-293) fibroblast-like cells revealed that conditions which promoted the formation of the non-B DNA structures enhanced the genetic instabilities, both within the repeat sequences and in the flanking sequences of up to similar to 4 kbp. The three strategies utilized included: the in vivo modulation of global negative supercoil density using topA and gyrB mutant E. coli strains; the in vivo cleavage of hairpin loops, which are an obligate consequence of slipped-strand structures, cruciforms, and intramolecular triplexes, by inactivation of the SbcC protein; and by genetic instability studies with plasmids containing long repeating sequence inserts that do, and do not, adopt non-B DNA structures in vitro. Hence, non-B DNA conformations are critical for these mutagenesis mechanisms.	Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Syst Hlth Sci Ctr, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Syst Hlth Sci Ctr, Houston, TX 77030 USA.	rwells@ibt.tamhsc.edu	wojciechowska, marzena/H-4900-2014		NIEHS NIH HHS [ES11347] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 2004, J BIOL CHEM, V279, P47411, DOI 10.1074/jbc.R400028200; Bacolla A, 2004, P NATL ACAD SCI USA, V101, P14162, DOI 10.1073/pnas.0405974101; Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Bacolla A, 2006, NUCLEIC ACIDS RES, V34, P2663, DOI 10.1093/nar/gkl354; Blaszak RT, 1999, NUCLEIC ACIDS RES, V27, P2610, DOI 10.1093/nar/27.13.2610; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; Bzymek M, 2001, P NATL ACAD SCI USA, V98, P8319, DOI 10.1073/pnas.111008398; Connelly JC, 1999, NUCLEIC ACIDS RES, V27, P1039, DOI 10.1093/nar/27.4.1039; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Dere R, 2004, J BIOL CHEM, V279, P41715, DOI 10.1074/jbc.M406415200; Edamura KN, 2005, HUM GENET, V118, P301, DOI 10.1007/s00439-005-0037-5; Fan HX, 2005, AM J MED GENET A, V136A, P214, DOI 10.1002/ajmg.a.30807; FEIGON J, 1985, SCIENCE, V230, P82, DOI 10.1126/science.4035359; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Marcadier JL, 2003, J BIOL CHEM, V278, P33848, DOI 10.1074/jbc.M304284200; Meservy JL, 2003, MOL CELL BIOL, V23, P3152, DOI 10.1128/MCB.23.9.3152-3162.2003; Mirkin EV, 2005, MOL CELL BIOL, V25, P888, DOI 10.1128/MCB.25.3.888-895.2005; Mochmann LH, 2004, NUCLEIC ACIDS RES, V32, P4469, DOI 10.1093/nar/gkh787; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Napierala M, 2005, J BIOL CHEM, V280, P37366, DOI 10.1074/jbc.M508065200; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Oussatcheva EA, 2001, J BIOL CHEM, V276, P30878, DOI 10.1074/jbc.M104697200; Pearson CE, 2005, NAT REV GENET, V6, P729, DOI 10.1038/nrg1689; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; SCHROTH GP, 1995, NUCLEIC ACIDS RES, V23, P1977, DOI 10.1093/nar/23.11.1977; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; Sinden RR, 1998, ADV GENOM B, V5, P1; Sinden RR, 2002, J BIOSCIENCES, V27, P53, DOI 10.1007/BF02703683; Sinden RR, 1999, AM J HUM GENET, V64, P346, DOI 10.1086/302271; Sobczak K, 2003, NUCLEIC ACIDS RES, V31, P5469, DOI 10.1093/nar/gkg766; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Van Raay T J, 1996, Microb Comp Genomics, V1, P317; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Vetcher AA, 2002, J BIOL CHEM, V277, P39228, DOI 10.1074/jbc.M205210200; WANG G, 2006, IN PRESS MUTAT RES; Wang GL, 2006, P NATL ACAD SCI USA, V103, P2677, DOI 10.1073/pnas.0511084103; Wang GL, 2004, P NATL ACAD SCI USA, V101, P13448, DOI 10.1073/pnas.0405116101; Wells R.D., 1998, GENETIC INSTABILITIE; Wells R.D., 2006, GENETIC INSTABILITIE; Wells R.D., 1988, UNUSUAL DNA STRUCTUR; WELLS RD, 1988, J BIOL CHEM, V263, P1095; Wells RD, 2005, NUCLEIC ACIDS RES, V33, P3785, DOI 10.1093/nar/gki697; Wojciechowska M, 2005, J BIOL CHEM, V280, P941, DOI 10.1074/jbc.M410427200; Yang Z, 2003, AM J HUM GENET, V73, P1092, DOI 10.1086/379523	54	24	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24531	24543		10.1074/jbc.M603888200	http://dx.doi.org/10.1074/jbc.M603888200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793772	hybrid			2022-12-27	WOS:000239847800049
J	Pasquato, A; Pullikotil, P; Asselin, MC; Vacatello, M; Paolillo, L; Ghezzo, F; Basso, F; Di Bello, C; Dettin, M; Seidah, NG				Pasquato, Antonella; Pullikotil, Philomena; Asselin, Marie-Claude; Vacatello, Manuela; Paolillo, Livio; Ghezzo, Francesca; Basso, Federica; Di Bello, Carlo; Dettin, Monica; Seidah, Nabil G.			The proprotein convertase SKI-1/S1P - In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; REGULATED INTRAMEMBRANE PROTEOLYSIS; ENDOPLASMIC-RETICULUM STRESS; BOUND TRANSCRIPTION FACTOR; SITE-1 PROTEASE; SUBTILASE SKI-1/S1P; FACTOR ATF6; CLEAVAGE; FURIN; SREBPS	Herein we designed, synthesized, tested, and validated fluorogenic methylcoumarinamide (MCA) and chloromethylketonepeptides spanning the Lassa virus GPC cleavage site as substrates and inhibitors for the proprotein convertase SKI-1/ S1P. The 7-mer MCA(YISRRLL-MCA) and 8-mer MCA (IYISRRLL-MCA) are very efficiently cleaved with respect to both the 6-mer MCA (YISRRLL-MCA) and point mutated fluorogenic analogues, except for the 7-mer mutant Y253F. The importance of the P7 phenylic residue was confirmed by digestions of two 16-mer non-fluorogenic peptidyl substrates that differ by a single point mutation (Y253A). Because NMR analysis of these 16-mer peptides did not reveal significant structural differences at recognition motif RRLL, the P7 Tyr residue is likely important in establishing key interactions within the catalytic pocket of SKI-1. Based on these data, we established through analysis of pro-ATF6 and pro-SREBP-2 cellular processing that decanoylated chloromethylketone 7-mer, 6-mer, and 4-mer peptides containing the core RRLL sequence are irreversible and potent ex vivo SKI-1 inhibitors. Although caution must be exercised in using these inhibitors in in vitro reactions, as they can also inhibit the basic amino acid-specific convertase furin, within cells and when used at concentrations <= 100 mu M these inhibitors are relatively specific for inhibition of SKI-1 processing events, as opposed to those performed by furin-like convertases.	Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Univ Padua, Dept Chem Proc Engn, I-35131 Padua, Italy; Univ Naples Federico II, Dept Chem, I-80126 Naples, Italy	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Padua; University of Naples Federico II	Seidah, NG (corresponding author), 110 Pine Ave,W, Montreal, PQ H2W 1R7, Canada.	seidahn@ircm.qc.ca	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; Pasquato, Antonella/0000-0002-9428-0722				Basak A, 2005, J MOL MED, V83, P844, DOI 10.1007/s00109-005-0710-0; Basak A, 2002, FEBS LETT, V514, P333, DOI 10.1016/S0014-5793(02)02394-3; Basak A, 2001, J BIOL CHEM, V276, P32720, DOI 10.1074/jbc.M104064200; Basak A, 2001, BIOCHEM J, V353, P537, DOI 10.1042/0264-6021:3530537; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Bergeron E, 2005, BIOCHEM BIOPH RES CO, V326, P554, DOI 10.1016/j.bbrc.2004.11.063; Beyer WR, 2003, J VIROL, V77, P2866, DOI 10.1128/JVI.77.5.2866-2872.2003; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Callihan DE, 1999, J MOL BIOL, V285, P2161, DOI 10.1006/jmbi.1998.2440; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; Dufour EK, 2005, PROTEIN SCI, V14, P303, DOI 10.1110/ps.04843305; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Ha T, 2001, METHODS, V25, P78, DOI 10.1006/meth.2001.1217; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JIMENEZ MA, 1993, EUR J BIOCHEM, V211, P569, DOI 10.1111/j.1432-1033.1993.tb17584.x; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kunz S, 2003, VIROLOGY, V314, P168, DOI 10.1016/S0042-6822(03)00421-5; Lenz O, 2001, P NATL ACAD SCI USA, V98, P12701, DOI 10.1073/pnas.221447598; Mercure C, 1996, HYPERTENSION, V28, P840, DOI 10.1161/01.HYP.28.5.840; Mouchantaf R, 2004, REGUL PEPTIDES, V120, P133, DOI 10.1016/j.regpep.2004.02.022; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Pullikotil P, 2004, J BIOL CHEM, V279, P17338, DOI 10.1074/jbc.M313764200; Rabah N, 2006, J BIOL CHEM, V281, P7556, DOI 10.1074/jbc.M510607200; Raggo C, 2002, MOL CELL BIOL, V22, P5639, DOI 10.1128/MCB.22.16.5639-5649.2002; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 2003, BIOCHEM SOC SYMP, V70, P221, DOI 10.1042/bss0700221; Reymond MT, 1997, BIOCHEMISTRY-US, V36, P5234, DOI 10.1021/bi970038x; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Schlombs K, 2003, P NATL ACAD SCI USA, V100, P14024, DOI 10.1073/pnas.2331794100; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Siegfried G, 2003, CANCER RES, V63, P1458; Stirling J, 2006, MOL BIOL CELL, V17, P413, DOI 10.1091/mbc.E05-06-0500; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Vincent MJ, 2003, J VIROL, V77, P8640, DOI 10.1128/JVI.77.16.8640-8649.2003; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	57	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23471	23481		10.1074/jbc.M513675200	http://dx.doi.org/10.1074/jbc.M513675200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790437	hybrid			2022-12-27	WOS:000239702900022
J	Spillmann, D; Lookene, A; Olivecrona, G				Spillmann, Dorothe; Lookene, Aivar; Olivecrona, Gunilla			Isolation and characterization of low sulfated heparan sulfate sequences with affinity for lipoprotein lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; TERMINAL DOMAIN; STRUCTURAL DIVERSITY; HEPATIC-CLEARANCE; BINDING DOMAIN; PROTEOGLYCAN; METABOLISM; OLIGOSACCHARIDE; IDENTIFICATION; GLYCOSAMINOGLYCANS	Lipoprotein lipase (LPL), which is an important enzyme in lipid metabolism, binds to heparan sulfate (HS) proteoglycans. This interaction is crucial for several aspects of LPL function, such as intracellular/ extracellular transport and high capacity attachment to cell surfaces. Retention of LPL on the capillary walls, and elsewhere, via HS chains is most likely affected by the quality and quantity of HS present. Earlier studies have demonstrated that LPL interacts with highly sulfated HS and heparin oligosaccharides. Since such structures are relatively rare in endothelial HS, we have re-addressed the question of physiological ligand structures for LPL by affinity purification of endlabeled oligosaccharides originating from heparin and HS on immobilized LPL. By a combination of chemical modification and fragmentation of the bound material we identified that the bound fraction contained modestly sulfated oligosaccharides with an average sulfation of one O-sulfate per disaccharide unit and tolerates N-acetylated glucosamine residues. Therefore LPL, containing several clusters of positive charges on each subunit, may constitute an ideal structure for a protein that needs to bind with reasonable affinity to a variety of modestly sulfated sequences of the type that is abundant in HS chains.	Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Umea Univ, Dept Med Biosci Physiol Chem, SE-90187 Umea, Sweden; Tallinn Univ Technol, Dept Gene Technol, EE-12618 Tallinn, Estonia	Uppsala University; Umea University; Tallinn University of Technology	Spillmann, D (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Box 582, SE-75123 Uppsala, Sweden.	Dorothe.Spillmann@imbim.uu.se						BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BERRYMAN DE, 1993, J BIOL CHEM, V268, P3272; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chevreuil O, 1996, BIOCHEM J, V320, P437, DOI 10.1042/bj3200437; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; HATA A, 1993, J BIOL CHEM, V268, P8447; Heeren J, 2002, J MOL MED-JMM, V80, P576, DOI 10.1007/s00109-002-0351-5; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; KJELLEN L, 1980, J BIOL CHEM, V255, P407; Kobayashi Y, 2002, EUR J BIOCHEM, V269, P4701, DOI 10.1046/j.1432-1033.2002.03179.x; Kolset SO, 1999, CELL MOL LIFE SCI, V56, P857, DOI 10.1007/s000180050031; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; LARNKJAER A, 1995, BIOCHEM J, V307, P205, DOI 10.1042/bj3070205; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDBLOM A, 1990, GLYCOCONJUGATE J, V7, P545, DOI 10.1007/BF01189076; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LIU GQ, 1992, BIOCHEM J, V285, P731, DOI 10.1042/bj2850731; LIU GQ, 1991, BIOCHEM J, V273, P747, DOI 10.1042/bj2730747; Lookene A, 2005, J BIOL CHEM, V280, P25383, DOI 10.1074/jbc.M501589200; Lookene A, 2000, BIOCHEM BIOPH RES CO, V271, P15, DOI 10.1006/bbrc.2000.2530; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Lutz EP, 2001, J CLIN INVEST, V107, P1183, DOI 10.1172/JCI11774; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Mahley RW, 1999, J LIPID RES, V40, P1; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; Olivecrona G, 1996, ISRAEL J MED SCI, V32, P430; OLIVECRONA T, 1989, HEPARIN, P335; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Stein Y, 2003, ATHEROSCLEROSIS, V170, P1, DOI 10.1016/S0021-9150(03)00014-5; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767	49	18	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23405	23413		10.1074/jbc.M604702200	http://dx.doi.org/10.1074/jbc.M604702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782967	hybrid			2022-12-27	WOS:000239702900015
J	Liu, F; Arce, FT; Ramachandran, S; Lal, R				Liu, Fei; Arce, Fernando Teran; Ramachandran, Srinivasan; Lal, Ratnesh			Nanomechanics of hemichannel conformations - Connexin flexibility underlying channel opening and closing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; SINGLE-MOLECULE; FORCE SPECTROSCOPY; MIMETIC PEPTIDES; CALCIUM; BINDING; RECOGNITION; ELASTICITY; INHIBITORS; MEMBRANES	Gap junctional hemichannels mediate cell-extracellular communication. A hemichannel is made of six connexin (Cx) sub-units; each connexin has four transmembrane domains, two extracellular loops, and cytoplasmic amino- and carboxyl-terminals (CTs). The extracellular domains are arranged differently at non-junctional and junctional (gap junction) regions, although very little is known about their flexibility and conformational energetics. The cytoplasmic tail differs considerably in the size and amino acid sequence for different connexins and is predicted to be involved in the channel open and closed conformations. For large connexins, such as Cx43, the CT makes large cytoplasmic fuzz visible under electron microscopy. If this CT domain controls channel permeability by physical occlusion of the pore mouth, movement of this portion could open or close the channel. We used atomic force microscopy-based single molecule spectroscopy with antibody-modified atomic force microscopy tips and connexin mimetic peptide modified tips to examine the flexibility of extracellular loop and CT domains and to estimate the energetics of their movements. Antibody to the CT portion closer to the membrane stretches the tail to a shorter length, and the antibody to CT tail stretches the tail to a longer length. The stretch length and the energy required for stretching the various portions of the carboxyl tail support the ball and chain model for hemichannel conformational changes.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Lal, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, 5126 BioSci 2 Bldg, Santa Barbara, CA 93106 USA.	lal@lifesci.ucsb.edu	Ramachandran, Srinivasan/G-5300-2010; Teran Arce, Fernando/I-7835-2018; Lal, Ratnesh/AAG-5424-2019	Ramachandran, Srinivasan/0000-0002-6155-4002; Teran Arce, Fernando/0000-0002-6518-8695; 				Almqvist N, 2004, BIOPHYS J, V86, P1753, DOI 10.1016/S0006-3495(04)74243-5; Arce FT, 2004, BIOPHYS J, V87, P4284, DOI 10.1529/biophysj.104.043307; Avci R, 2004, LANGMUIR, V20, P11053, DOI 10.1021/la036376i; Bao XY, 2005, J BIOL CHEM, V280, P8647, DOI 10.1074/jbc.M413536200; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; Berthoud VM, 2000, AM J PHYSIOL-LUNG C, V279, pL619, DOI 10.1152/ajplung.2000.279.4.L619; BEYER EC, 1991, J BIOL CHEM, V266, P7971; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Boitano S, 2000, AM J PHYSIOL-LUNG C, V279, pL623, DOI 10.1152/ajplung.2000.279.4.L623; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Carrion-Vazquez M, 2000, PROG BIOPHYS MOL BIO, V74, P63, DOI 10.1016/S0079-6107(00)00017-1; Chaytor AT, 1997, J PHYSIOL-LONDON, V503, P99, DOI 10.1111/j.1469-7793.1997.099bi.x; Chaytor AT, 1999, J PHYSIOL-LONDON, V520, P539, DOI 10.1111/j.1469-7793.1999.00539.x; CLEVELAND JP, 1993, REV SCI INSTRUM, V64, P403, DOI 10.1063/1.1144209; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DAHL G, 1994, BIOPHYS J, V67, P1816, DOI 10.1016/S0006-3495(94)80663-0; De Vuyst E, 2006, EMBO J, V25, P34, DOI 10.1038/sj.emboj.7600908; Delmar M, 2004, CARDIOVASC RES, V62, P268, DOI 10.1016/j.cardiores.2003.12.030; DELMAR M, 2000, MOL BASIS CELL COMMU, P22; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; EBIHARA L, 1993, J GEN PHYSIOL, V102, P59, DOI 10.1085/jgp.102.1.59; Evans WH, 2001, BIOCHEM SOC T, V29, P606, DOI 10.1042/BST0290606; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; Gomez-Hernandez JM, 2003, P NATL ACAD SCI USA, V100, P16030, DOI 10.1073/pnas.2530348100; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Hinterdorfer P, 2002, METHOD CELL BIOL, V68, P115; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; Horton M, 2002, J RECEPT SIGNAL TR R, V22, P169, DOI 10.1081/RRS-120014594; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Jiang JX, 2005, BBA-BIOMEMBRANES, V1711, P208, DOI 10.1016/j.bbamem.2004.10.001; Kessler M, 2006, STRUCTURE, V14, P521, DOI 10.1016/j.str.2005.11.023; Kienberger F, 2005, J MOL BIOL, V347, P597, DOI 10.1016/j.jmb.2005.01.042; Kienberger F, 2004, EMBO REP, V5, P579, DOI 10.1038/sj.embor.7400149; Kreuzer HJ, 1999, NEW J PHYS, V1, DOI 10.1088/1367-2630/1/1/321; Kufer SK, 2005, EUR BIOPHYS J BIOPHY, V35, P72, DOI 10.1007/s00249-005-0010-1; KUMAR NM, 1995, J CELL SCI, V108, P3725; LAIRD DW, 1990, J CELL SCI, V97, P109; LAL R, 1995, AM J PHYSIOL-CELL PH, V268, pC968, DOI 10.1152/ajpcell.1995.268.4.C968; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; Marszalek PE, 1998, NATURE, V396, P661, DOI 10.1038/25322; Martin PEM, 2000, BIOCHEM J, V349, P281, DOI 10.1042/0264-6021:3490281; Mou JX, 1996, BIOCHEMISTRY-US, V35, P3222, DOI 10.1021/bi9520242; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; Oesterhelt F, 1999, NEW J PHYS, V1, DOI 10.1088/1367-2630/1/1/006; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Riener CK, 2003, ANAL CHIM ACTA, V479, P59, DOI 10.1016/S0003-2670(02)01373-9; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Sorgen PL, 2004, J BIOL CHEM, V279, P54695, DOI 10.1074/jbc.M409552200; Sorgen PL, 2002, J BIOMOL NMR, V23, P245, DOI 10.1023/A:1019892719979; Sosinsky GE, 2005, BBA-BIOMEMBRANES, V1711, P99, DOI 10.1016/j.bbamem.2005.04.001; Srinivas M, 2006, J GEN PHYSIOL, V127, P67, DOI 10.1085/jgp.200509397; Srinivas M, 2005, BIOPHYS J, V88, P1725, DOI 10.1529/biophysj.104.054023; Sulchek TA, 2005, P NATL ACAD SCI USA, V102, P16638, DOI 10.1073/pnas.0505208102; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Tortonese M, 1997, P SOC PHOTO-OPT INS, V3009, P53, DOI 10.1117/12.271229; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241	69	59	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23207	23217		10.1074/jbc.M605048200	http://dx.doi.org/10.1074/jbc.M605048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769719	hybrid			2022-12-27	WOS:000239542600083
J	Radichev, I; Kwon, SW; Zhao, YM; DePamphilis, ML; Vassilev, A				Radichev, Ilian; Kwon, Sung Won; Zhao, Yingming; DePamphilis, Melvin L.; Vassilev, Alex			Genetic analysis of human ORC2 reveals specific domains that are required in vivo for assembly and nuclear localization of the origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; DNA-REPLICATION; CELL-CYCLE; MAMMALIAN-CELLS; CHROMATIN ASSOCIATION; PROTEINS; INITIATION; BINDING; SUBUNITS; CDC6	Eukaryotic DNA replication begins with the binding of a six subunit origin recognition complex (ORC) to DNA. To study the assembly and function of mammalian ORC proteins in their native environment, HeLa cells were constructed that constitutively expressed an epitope-tagged, recombinant human Orc2 subunit that had been genetically altered. Analysis of these cell lines revealed that Orc2 contains a single ORC assembly domain that is required in vivo for interaction with all other ORC subunits, as well as two nuclear localization signals (NLSs) that are required for ORC accumulation in the nucleus. The recombinant Orc2 existed in the nucleus either as an ORC-(2-5) or ORC-(1-5) complex; no other combinations of ORC subunits were detected. Moreover, only ORC-(1-5) was bound to the chromatin fraction, suggesting that Orc1 is required in vivo to load ORC-(2-5) onto chromatin. Surprisingly, recombinant Orc2 suppressed expression of endogenous Orc2, revealing that mammalian cells limit the intracellular level of Orc2, and thereby limit the amount of ORC-(2-5) in the nucleus. Because this suppression required only the ORC assembly and NLS domains, these domains appear to constitute the functional domain of Orc2.	NICHD, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Vassilev, A (corresponding author), NICHD, Natl Inst Hlth, Bldg 6-3A-02,9000 Rockville Pike, Bethesda, MD 20892 USA.	vassilev@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000506] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000506] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abdurashidova G, 2003, EMBO J, V22, P4294, DOI 10.1093/emboj/cdg404; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; DePamphilis ML, 2005, CELL CYCLE, V4, P70, DOI 10.4161/cc.4.1.1333; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Iyer Lakshminarayan M., 2006, V47, P751; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; Kneissl M, 2003, J MOL BIOL, V327, P111, DOI 10.1016/S0022-2836(03)00079-2; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; McNairn AJ, 2005, J CELL BIOCHEM, V96, P879, DOI 10.1002/jcb.20609; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Ohta S, 2003, J BIOL CHEM, V278, P41535, DOI 10.1074/jbc.M307535200; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Ranjan A, 2006, P NATL ACAD SCI USA, V103, P4864, DOI 10.1073/pnas.0510305103; Ritzi M, 2003, J CELL SCI, V116, P3971, DOI 10.1242/jcs.00708; Saha T, 2006, J CELL SCI, V119, P1371, DOI 10.1242/jcs.02851; Saitoh Y, 2002, NUCLEIC ACIDS RES, V30, P5205, DOI 10.1093/nar/gkf642; Takeda DY, 2005, GENE DEV, V19, P2827, DOI 10.1101/gad.1369805; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Zhou G, 2005, PROTEOMICS, V5, P3814, DOI 10.1002/pmic.200401230	31	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23264	23273		10.1074/jbc.M603873200	http://dx.doi.org/10.1074/jbc.M603873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16762929	hybrid			2022-12-27	WOS:000239542600089
J	Bourne, Y; Radic, Z; Sulzenbacher, G; Kim, E; Taylor, P; Marchot, P				Bourne, Yves; Radic, Zoran; Sulzenbacher, Gerlind; Kim, Esther; Taylor, Palmer; Marchot, Pascale			Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATION; CRYSTAL-STRUCTURE; STRUCTURAL INSIGHTS; PERIPHERAL SITE; MOUSE ACETYLCHOLINESTERASE; TORPEDO-CALIFORNICA; NANOSECOND DYNAMICS; LIGAND-BINDING; OMEGA-LOOP; BACK DOOR	Hydrolysis of acetylcholine catalyzed by acetylcholinesterase (AChE), one of the most efficient enzymes in nature, occurs at the base of a deep and narrow active center gorge. At the entrance of the gorge, the peripheral anionic site provides a binding locus for allosteric ligands, including substrates. To date, no structural information on substrate entry to the active center from the peripheral site of AChE or its subsequent egress has been reported. Complementary crystal structures of mouse AChE and an inactive mouse AChE mutant with a substituted catalytic serine (S203A), in various complexes with four substrates (acetylcholine, acetylthiocholine, succinyldicholine, and butyrylthiocholine), two non-hydrolyzable substrate analogues (m-(N, N, N-trimethylammonio)trifluoroacetophenone and 4-ketoamyltrimethylammonium), and one reaction product (choline) were solved in the 2.05-2.65-angstrom resolution range. These structures, supported by binding and inhibition data obtained on the same complexes, reveal the successive positions and orientations of the substrates bound to the peripheral site and proceeding within the gorge toward the active site, the conformations of the presumed transition state for acylation and the acyl-enzyme intermediate, and the positions and orientations of the dissociating and egressing products. Moreover, the structures of the AChE mutant in complexes with acetylthiocholine and succinyldicholine reveal additional substrate binding sites on the enzyme surface, distal to the gorge entry. Hence, we provide a comprehensive set of structural snapshots of the steps leading to the intermediates of catalysis and the potential regulation by substrate binding to various allosteric sites at the enzyme surface.	CNRS, Architecture & Fonct Macromol Biol, UMR 6098, F-13288 Marseille 09, France; Univ Mediterranee, Fac Med Secteur Nord, Inst Federat Rech Jean Roche, CNRS FRE2738, F-13916 Marseille 20, France; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of California System; University of California San Diego	Bourne, Y (corresponding author), CNRS, Architecture & Fonct Macromol Biol, UMR 6098, Campus Luminy,Case 932, F-13288 Marseille 09, France.	Yves.Bourne@afmb.univ-mrs.fr; marchot.p@jean-roche.univ-mrs.fr	Bourne, Yves/AAC-4635-2022; MARCHOT, Pascale/AAC-4752-2022; Sulzenbacher, Gerlind/A-6801-2018	Bourne, Yves/0000-0003-3850-0548; MARCHOT, Pascale/0000-0003-0630-0541; Sulzenbacher, Gerlind/0000-0003-4844-2820	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRIDGE WN, 1969, BIOCHEM J, V115, P147, DOI 10.1042/bj1150147; AXELSEN PH, 1994, PROTEIN SCI, V3, P188; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bar-On P, 2002, BIOCHEMISTRY-US, V41, P3555, DOI 10.1021/bi020016x; BARAK D, 1994, J BIOL CHEM, V269, P6296; BAROLUCCI C, 2001, PROTEINS, V42, P182; Bartolucci C, 1999, BIOCHEMISTRY-US, V38, P5714, DOI 10.1021/bi982723p; Bencharit S, 2002, NAT STRUCT BIOL, V9, P337, DOI 10.1038/nsb790; BERMAN HA, 1986, BIOCHIM BIOPHYS ACTA, V872, P125, DOI 10.1016/0167-4838(86)90155-X; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Bourne Y, 2004, P NATL ACAD SCI USA, V101, P1449, DOI 10.1073/pnas.0308206100; Boyd AE, 2004, J BIOL CHEM, V279, P26612, DOI 10.1074/jbc.M401482200; Bui JM, 2005, CHEM-BIOL INTERACT, V157, P357, DOI 10.1016/j.cbi.2005.10.049; CANEPA FG, 1966, NATURE, V210, P907, DOI 10.1038/210907a0; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; Colletier JP, 2006, EMBO J, V25, P2746, DOI 10.1038/sj.emboj.7601175; DeLano W.L, PYMOL MOL GRAPHICS S; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Felder CE, 2002, ACTA CRYSTALLOGR D, V58, P1765, DOI 10.1107/S0907444902011642; FROEDE HC, 1984, J BIOL CHEM, V259, P1010; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HODGE AS, 1992, MOL PHARMACOL, V41, P937; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; Johnson JL, 2003, J BIOL CHEM, V278, P38948, DOI 10.1074/jbc.M304797200; Johnson JL, 2003, BIOCHEMISTRY-US, V42, P5438, DOI 10.1021/bi027065u; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; Kryger G, 1998, J PHYSIOLOGY-PARIS, V92, P191, DOI 10.1016/S0928-4257(98)80008-9; Kryger G, 1999, STRUCTURE, V7, P297, DOI 10.1016/S0969-2126(99)80040-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mallender WD, 2000, BIOCHEMISTRY-US, V39, P7753, DOI 10.1021/bi000210o; Marcel V, 1998, BIOCHEM J, V329, P329, DOI 10.1042/bj3290329; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MASSOULIE J, 1993, PROG BRAIN RES, V98, P139; Millard CB, 1999, BIOCHEMISTRY-US, V38, P7032, DOI 10.1021/bi982678l; MOOSER G, 1974, BIOCHEMISTRY-US, V13, P2299, DOI 10.1021/bi00708a010; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NACHMANSOHN D, 1951, ADV ENZYMOL REL S BI, V12, P259; Nicolet Y, 2003, J BIOL CHEM, V278, P41141, DOI 10.1074/jbc.M210241200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARTINGTON P, 1972, MOL PHARMACOL, V8, P269; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 2001, J BIOL CHEM, V276, P4622, DOI 10.1074/jbc.M006855200; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Ravelli RBG, 1998, ACTA CRYSTALLOGR D, V54, P1359, DOI 10.1107/S0907444998005277; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; Shi JX, 2003, J BIOL CHEM, V278, P30905, DOI 10.1074/jbc.M303730200; Simon S, 1999, J BIOL CHEM, V274, P27740, DOI 10.1074/jbc.274.39.27740; Stojan J, 1998, FEBS LETT, V440, P85, DOI 10.1016/S0014-5793(98)01434-3; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029	65	109	109	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29256	29267		10.1074/jbc.M603018200	http://dx.doi.org/10.1074/jbc.M603018200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16837465	hybrid			2022-12-27	WOS:000240680500081
J	Hatch, NE; Hudson, M; Seto, ML; Cunningham, ML; Bothwell, M				Hatch, Nan E.; Hudson, Mark; Seto, Marianne L.; Cunningham, Michael L.; Bothwell, Mark			Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome- associated FGFR2(C278F)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SUBSTRATE-DEPENDENCE; SYNDROME MUTATIONS; LIGAND-BINDING; IN-VITRO; BONE; DIFFERENTIATION; ACTIVATION; APOPTOSIS; SITES	Fibroblast growth factors (FGFs) and their receptors (FGFRs) are known to play a critical role in a variety of fundamental processes, including wound healing, angiogenesis, and development of multiple organ systems. Mutations in the FGFR gene family have been linked to a series of syndromes (the craniosynostosis syndromes) whose primary phenotype involves aberrant development of the craniofacial skeleton. Craniosynostosis syndrome-linked FGFR mutations have been shown to be gain of function in terms of receptor activation and have been presumed to result in increased levels of FGF/FGFR signaling. Unfortunately, studies attempting to link expression of mutant FGFRs with changes in cellular phenotype have yielded conflicting results. In an effort to better understand the biochemical consequences of these mutations on receptor function, here we have investigated the effect of the FGFR2(C278F) mutation of Crouzon craniosynostosis syndrome on receptor trafficking, ubiquitination, degradation, and signaling. We find that FGFR2(C278F) exhibits diminished glycosylation, increased degradation, and limited cellular sublocalization in the osteoblastic cell line, MC3T3E1(C4). Additionally, we show that trafficking and autoactivation of wild type FGFR2 is glycosylation-dependent. Both FGFR2(C278F) and unglycosylated wild type FGFR2 signal through phospholipase C gamma in a ligand-independent manner as well as exhibit dramatically increased binding to the adaptor protein, Frs2. These findings suggest that autoactive FGFR2 can signal from intracellular compartments. Based upon our results, we propose that the functional signaling of craniosynostosis mutant, autoactive receptors is limited in some cell types by protective cellular responses, such as increased trafficking to lysosomes and proteasomes for degradation.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hatch, NE (corresponding author), Univ Michigan, Dept Orthodont, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	nhatch@umich.edu	Hatch, Nan/ABC-9177-2020; Hatch, Nan/AAQ-8465-2020	Hatch, Nan/0000-0002-2632-0841; Bothwell, Mark/0000-0001-5423-2702	NIDCR NIH HHS [DE00161] Funding Source: Medline; NINDS NIH HHS [NS33200] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033200] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Ceridono M, 2005, BIOCHEM BIOPH RES CO, V327, P523, DOI 10.1016/j.bbrc.2004.12.031; DePollack C, 1996, J BONE MINER RES, V11, P401; Dry GM, 2001, PLAST RECONSTR SURG, V107, P425, DOI 10.1097/00006534-200102000-00019; Eswarakumar VP, 2002, DEVELOPMENT, V129, P3783; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; Fioretos T, 2001, GENE CHROMOSOME CANC, V32, P302, DOI 10.1002/gcc.1195; Fragale A, 1999, AM J PATHOL, V154, P1465, DOI 10.1016/S0002-9440(10)65401-6; Galvin BD, 1996, P NATL ACAD SCI USA, V93, P7894, DOI 10.1073/pnas.93.15.7894; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hattori Y, 1996, CLIN CANCER RES, V2, P1373; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671; HUSAM A, 2003, J BIOL CHEM, V278, P35781; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Lemonnier J, 2001, AM J PATHOL, V158, P1833, DOI 10.1016/S0002-9440(10)64139-9; Lemonnier J, 2000, EXP CELL RES, V256, P158, DOI 10.1006/excr.2000.4820; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Lomri A, 1998, J CLIN INVEST, V101, P1310; Mangasarian K, 1997, J CELL PHYSIOL, V172, P117, DOI 10.1002/(SICI)1097-4652(199707)172:1<117::AID-JCP13>3.3.CO;2-S; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; Quirk PL, 2004, J NEUROSCI RES, V77, P498, DOI 10.1002/jnr.20185; Rice DPC, 1999, EUR J ORAL SCI, V107, P265, DOI 10.1046/j.0909-8836.1999.eos107406.x; Ridyard MS, 2003, J BIOL CHEM, V278, P13803, DOI 10.1074/jbc.M210245200; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Takahashi S, 2002, NEUROCHEM INT, V40, P441, DOI 10.1016/S0197-0186(01)00097-3; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Yoshida Y, 2003, J BIOCHEM, V134, P183, DOI 10.1093/jb/mvg128; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200; 2004, J NAT CANC I, V96, P1805	48	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27292	27305		10.1074/jbc.M600448200	http://dx.doi.org/10.1074/jbc.M600448200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16844695	hybrid			2022-12-27	WOS:000240397700056
J	Wang, ZY; Sun, ZH; Li, AV; Yarema, KJ				Wang, Zhiyun; Sun, Zhonghui; Li, Adrienne V.; Yarema, Kevin J.			Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase outside of sialic acid biosynthesis - Modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation, and apoptosis, and ERK1/2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY MYOPATHY; DISTAL MYOPATHY; CELL-PROLIFERATION; ALPHA-DYSTROGLYCAN; RIMMED VACUOLES; GANGLIOSIDE GD3; O-ACETYLATION; STEM-CELLS; GENE; GNE	Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase (GNE) beyond controlling flux into the sialic acid biosynthetic pathway by converting UDP-GlcNAc to N-acetylmannosamine are described in this report. Overexpression of recombinant GNE in human embryonic kidney (HEK AD293) cells led to an increase in mRNA levels for ST3Gal5 (GM3 synthase) and ST8Sia1 (GD3 synthase) as well as the biosynthetic products of these sialyltransferases, the GM3 and GD3 gangliosides. Conversely, down-regulation of GNE by RNA interference methods had the opposite, but consistent, effect of lowering ST3Gal5 and ST8Sia1 mRNAs and reducing GM3 and GD3 levels. Control experiments ensured that GNE-mediated changes in sialyltransferase expression and ganglioside biosynthesis were not the result of altered flux through the sialic acid pathway. Interestingly, exogenous GM3 and GD3 also changed the expression of GNE and led to reduced ST3Gal5 and ST8Sia1 mRNA levels, demonstrating a reciprocating feedback mechanism where gangliosides regulate upstream biosynthetic enzymes. Cellular responses to the GNE-mediated changes in ST3Gal5 and ST8Sia1 expression and GM3 and GD3 levels were investigated next. Conditions that led to reduced ganglioside production (e.g. short hairpin RNA exposure) stimulated proliferation, whereas conditions that resulted in increased ganglioside levels (e.g. recombinant GNE and exogenous gangliosides) led to reduced proliferation with a concomitant increase in apoptosis. Finally, changes to BiP expression and ERK1/2 phosphorylation consistent with apoptosis and proliferation, respectively, were observed. These results provide examples of specific biochemical pathways, other than sialic acid metabolism, that are influenced by GNE.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA	Johns Hopkins University	Yarema, KJ (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.	kyarema1@jhu.edu			NATIONAL CANCER INSTITUTE [R01CA112314] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA112314-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aerts JL, 2004, BIOTECHNIQUES, V36, P84, DOI 10.2144/04361ST04; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Aoki T, 1997, J BIOCHEM-TOKYO, V121, P122; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Broccolini A, 2005, NEUROMUSCULAR DISORD, V15, P177, DOI 10.1016/j.nmd.2004.10.001; CALLIES R, 1977, EUR J BIOCHEM, V80, P425, DOI 10.1111/j.1432-1033.1977.tb11897.x; Castro-Palomino JC, 2001, CHEM-EUR J, V7, P2178, DOI 10.1002/1521-3765(20010518)7:10<2178::AID-CHEM2178>3.3.CO;2-5; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Chefalo P, 2006, BIOCHEMISTRY-US, V45, P3733, DOI 10.1021/bi052161r; Chen H, 2005, HANDBOOK OF CARBOHYDRATE ENGINEERING, P1; Chen HY, 2006, J BIOL CHEM, V281, P7825, DOI 10.1074/jbc.M512379200; Chen HY, 2002, J EXP MED, V196, P1529, DOI 10.1084/jem.20021915; Chung TW, 2005, GLYCOBIOLOGY, V15, P233, DOI 10.1093/glycob/cwh156; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Eisenberg I, 1999, GENOMICS, V55, P43, DOI 10.1006/geno.1998.5630; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; FURUKAWA K, 1989, J IMMUNOL, V142, P848; Hakomori S, 2004, GLYCOCONJUGATE J, V21, P125, DOI 10.1023/B:GLYC.0000044844.95878.cf; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Heffer-Lauc M, 2005, BBA-MOL CELL BIOL L, V1686, P200, DOI 10.1016/j.bbalip.2004.10.002; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Hinderlich S, 2004, FEBS LETT, V566, P105, DOI 10.1016/j.febslet.2004.04.013; Huizing M, 2004, MOL GENET METAB, V81, P196, DOI 10.1016/j.ymgme.2003.11.012; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jeffery CJ, 2003, TRENDS GENET, V19, P415, DOI 10.1016/S0168-9525(03)00167-7; Jones MB, 2004, BIOTECHNOL BIOENG, V85, P394, DOI 10.1002/bit.10901; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Kamimura Y, 2005, INT J ONCOL, V26, P337; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Kim EJ, 2004, BIOTECHNOL PROGR, V20, P1674, DOI 10.1021/bp049841q; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Krause S, 2005, EXP CELL RES, V304, P365, DOI 10.1016/j.yexcr.2004.11.010; Li A, 2004, GLYCOBIOLOGY, V14, P1150; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Lu PY, 2005, ADV GENET, V54, P117, DOI 10.1016/S0065-2660(05)54006-9; Malisan F, 2005, IUBMB LIFE, V57, P477, DOI 10.1080/15216540500167179; Malisan F, 2002, EXP GERONTOL, V37, P1273, DOI 10.1016/S0531-5565(02)00138-9; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; Mitsuzuka K, 2005, J BIOL CHEM, V280, P35545, DOI 10.1074/jbc.M505630200; Moon SK, 2004, J BIOL CHEM, V279, P33063, DOI 10.1074/jbc.M313462200; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nakano J, 1996, J INVEST DERMATOL, V107, P543, DOI 10.1111/1523-1747.ep12582802; Nishino I, 2002, NEUROLOGY, V59, P1689, DOI 10.1212/01.WNL.0000041631.28557.C6; Noguchi S, 2004, J BIOL CHEM, V279, P11402, DOI 10.1074/jbc.M313171200; Oetke C, 2003, BIOCHEM BIOPH RES CO, V308, P892, DOI 10.1016/S0006-291X(03)01471-2; Pekarik V, 2005, BRAIN RES BULL, V68, P115, DOI 10.1016/j.brainresbull.2005.08.007; Penner J, 2006, BIOCHEMISTRY-US, V45, P2968, DOI 10.1021/bi0522504; Pilkington GJ, 2005, CELL PROLIFERAT, V38, P423, DOI 10.1111/j.1365-2184.2005.00358.x; Rozen S, 2000, Methods Mol Biol, V132, P365; Salama I, 2005, BIOCHEM BIOPH RES CO, V328, P221, DOI 10.1016/j.bbrc.2004.12.157; Saqr HE, 2006, J NEUROCHEM, V96, P1301, DOI 10.1111/j.1471-4159.2005.03640.x; Schauer R, 2004, ARCH BIOCHEM BIOPHYS, V426, P132, DOI 10.1016/j.abb.2004.03.008; Schuit F, 2002, DIABETES, V51, pS326, DOI 10.2337/diabetes.51.2007.S326; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; SEPPALA R, 1991, J BIOL CHEM, V266, P7456; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; Siddiqui RA, 2003, BIOCHEM J, V371, P621, DOI 10.1042/BJ20021667; Tanner ME, 2005, BIOORG CHEM, V33, P216, DOI 10.1016/j.bioorg.2005.01.005; Tessitore A, 2004, MOL CELL, V15, P753, DOI 10.1016/j.molcel.2004.08.029; Toledo MS, 2004, J BIOL CHEM, V279, P34655, DOI 10.1074/jbc.M403857200; Tomimitsu H, 2004, NEUROLOGY, V62, P1607, DOI 10.1212/01.WNL.0000123115.23652.6C; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Villavicencio-Lorini P, 2002, J MOL MED-JMM, V80, P671, DOI 10.1007/s00109-002-0382-y; Watts GDJ, 2003, NEUROMUSCULAR DISORD, V13, P559, DOI 10.1016/S0960-8966(03)00070-1; WEISS P, 1989, J BIOL CHEM, V264, P17635; Yamada A, 2005, ARCH ORAL BIOL, V50, P393, DOI 10.1016/j.archoralbio.2004.09.014; Yarema KJ, 2001, NAT BIOTECHNOL, V19, P553, DOI 10.1038/89305; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u; Zou W, 2004, J BIOL CHEM, V279, P25390, DOI 10.1074/jbc.M402787200	75	71	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27016	27028		10.1074/jbc.M604903200	http://dx.doi.org/10.1074/jbc.M604903200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16847058	hybrid			2022-12-27	WOS:000240397700028
J	Zernichow, L; Abrink, M; Hallgren, J; Grujic, M; Pejler, G; Kolset, SO				Zernichow, Lillian; Abrink, Magnus; Hallgren, Jenny; Grujic, Mirjana; Pejler, Gunnar; Kolset, Svein O.			Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-alpha secretion in response to lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; MOUSE MAST-CELLS; HEPARAN-SULFATE; CORE PROTEIN; TNF-ALPHA; MATRIX METALLOPROTEINASE-2; PERITONEAL-MACROPHAGES; OSTEOSARCOMA CELLS; INDUCED ACTIVATION; HUMAN-MONOCYTES	It has recently been shown that serglycin is essential for maturation of mast cell secretory granules. However, serglycin is expressed also by other cell types, and in this study we addressed the role of serglycin in macrophages. Adherent cells were prepared from murine peritoneal cell populations and from spleens, and analyzed for proteoglycan synthesis by biosynthetic labeling with [S-35] sulfate. Conditioned media from serglycin(-/-) peritoneal macrophages and adherent spleen cells displayed a 65-80% reduction of S-35-labeled proteoglycans, compared with corresponding material from serglycin(+/+) cells, indicating that serglycin is the dominant secretory proteoglycan in macrophages of these origins. In contrast, the levels of intracellular proteoglycans were similar in serglycin(+/+) and serglycin(-/-) cells, suggesting that serglycin is not stored intracellularly to a major extent in macrophages. This is in contrast to mast cells, in which serglycin is predominantly stored intracellularly. Transmission electron microscopy revealed that the absence of serglycin did not cause any major morphological effects on peritoneal macrophages, in contrast to dramatic defects in intracellular storage vesicles in peritoneal mast cells. Several secretory products were not found to be affected by the lack of serglycin. However, the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide stimulation was markedly higher in serglycin(-/-) cultures than in those of serglycin(+/+). The present report thus demonstrates that serglycin is the major proteoglycan secreted by peritoneal macrophages and suggests that the macrophage serglycin may have a role in regulating secretion of tumor necrosis factor-alpha.	Univ Oslo, Inst Basic Med Sci, Dept Nutr, N-0316 Oslo, Norway; Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, S-75123 Uppsala, Sweden	University of Oslo; Swedish University of Agricultural Sciences	Kolset, SO (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Nutr, Box 1046 Blindern, N-0316 Oslo, Norway.	s.o.kolset@medisin.uio.no	Hallgren Martinsson, Jenny/AAZ-6356-2021; Åbrink, Magnus/AAK-8346-2020; Hallgren Martinsson, Jenny/AAZ-5937-2021	Hallgren Martinsson, Jenny/0000-0002-3685-5364; Abrink, Magnus/0000-0002-1335-3927				Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; Armstrong L, 2006, AM J RESP CELL MOL, V34, P219, DOI 10.1165/rcmb.2005-0087OC; Biederbick A, 2003, EUR J CELL BIOL, V82, P19, DOI 10.1078/0171-9335-00287; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Grujic M, 2005, J BIOL CHEM, V280, P33411, DOI 10.1074/jbc.M501708200; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Henningsson F, 2002, BIOL CHEM, V383, P793, DOI 10.1515/BC.2002.083; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kaartinen M, 1996, CIRCULATION, V94, P2787, DOI 10.1161/01.CIR.94.11.2787; Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kolset SO, 1999, CELL MOL LIFE SCI, V56, P857, DOI 10.1007/s000180050031; KOLSET SO, 1988, ACTA HISTOCHEM, V84, P67, DOI 10.1016/S0065-1281(88)80011-4; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; KOLSET SO, 1986, BIOCHEM BIOPH RES CO, V139, P377, DOI 10.1016/S0006-291X(86)80001-8; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; Lemansky P, 2003, J LEUKOCYTE BIOL, V74, P542, DOI 10.1189/jlb.1202616; Loennechen T, 2003, BIOCHEM PHARMACOL, V66, P2341, DOI 10.1016/j.bcp.2003.08.014; Makatsori E, 2003, ANTICANCER RES, V23, P3303; Mathisen B, 2003, CLIN EXP METASTAS, V20, P701, DOI 10.1023/B:CLIN.0000006819.21361.03; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Ohno N, 1998, PROG CLIN BIOL RES, V397, P179; PEJLER G, 1993, J BIOL CHEM, V268, P11817; PEJLER G, 1994, J BIOL CHEM, V269, P14451; Princivalle M, 2001, GLYCOBIOLOGY, V11, P183, DOI 10.1093/glycob/11.3.183; RAZIN E, 1982, J BIOL CHEM, V257, P7229; Schick BP, 2001, BLOOD, V97, P449, DOI 10.1182/blood.V97.2.449; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; Shurety W, 2000, J INTERF CYTOK RES, V20, P427, DOI 10.1089/107999000312379; SKUTELSKY E, 1995, HISTOCHEM CELL BIOL, V104, P453, DOI 10.1007/BF01464335; STERK AR, 1982, J IMMUNOL, V128, P838; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; SVENNEVIG K, 1995, BIOCHEM J, V311, P881, DOI 10.1042/bj3110881; Tufvesson E, 2002, FEBS LETT, V530, P124, DOI 10.1016/S0014-5793(02)03439-7; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; UHLINHANSEN L, 1993, BLOOD, V82, P2880; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; WARFEL AH, 1986, J IMMUNOL, V137, P651; Winberg JO, 2003, EUR J BIOCHEM, V270, P3996, DOI 10.1046/j.1432-1033.2003.03788.x; Winberg JO, 2000, J MOL BIOL, V304, P669, DOI 10.1006/jmbi.2000.4235; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941; YURT RW, 1977, J BIOL CHEM, V252, P518	54	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26792	26801		10.1074/jbc.M512889200	http://dx.doi.org/10.1074/jbc.M512889200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16807245	hybrid			2022-12-27	WOS:000240397700006
J	Dong, W; Liu, YL; Peng, JH; Chen, L; Zou, TT; Xiao, HZ; Liu, ZX; Li, W; Bu, YW; Qi, YP				Dong, Wei; Liu, Yingle; Peng, Jinhong; Chen, Lu; Zou, Tingting; Xiao, Huazhong; Liu, Zhengxue; Li, Wen; Bu, Yiwen; Qi, Yipeng			The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappa B from toll-like Receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL; FACTOR-6 TRAF6; BCL10; ACTIVATION; KINASE; MALT1; TAK1; UBIQUITINATION; IDENTIFICATION; TRANSLOCATION	Our previous studies have revealed that the signaling protein BCL10 plays a major role in adaptive immunity by mediating NF-kappa B activation in the LPS/ TLR4 pathway. In this study, we show that IRAK-1 acts as the essential upstream adaptor that recruits BCL10 to the TLR4 signaling complex and mediates signaling to NF-kappa B through the BCL10-MALT1-TRAF6-TAK1 cascade. Following dissociation from IRAK-1, BCL10 is translocated into the cytosol along with TRAF6 and TAK1, in a process bridged by a direct BCL10-Pellino2 interaction. RNA interference against MALT1 markedly reduced the level of NF-kappa B activation stimulated by lipopolysaccharide (LPS) in macrophages, which suggests that MALT1 plays a major role in the LPS/ TLR4 pathway. MALT1 interacted with BCL10 and TRAF6 to facilitate TRAF6 self-ubiquitination in the cytosol, which was strictly dependent on the dissociation of BCL10 from IRAK-1. We show that BCL10 oligomerization is a prerequisite for BCL10 function in LPS signaling to NF-kappa B and that IRAK-1 dimerization is an important event in this process.	Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China	Wuhan University	Liu, YL (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.	mvlwu@whu.edu.cn; qiyipeng@whu.edu.cn	Dong, Wei/D-2399-2015					Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cavalli F, 2001, Hematology Am Soc Hematol Educ Program, P241; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Deng C, 2003, J IMMUNOL, V170, P2833, DOI 10.4049/jimmunol.170.6.2833; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Fischer KD, 2004, TRENDS IMMUNOL, V25, P113, DOI 10.1016/j.it.2003.12.007; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Jensen LE, 2003, J IMMUNOL, V171, P1500, DOI 10.4049/jimmunol.171.3.1500; Jensen LE, 2001, J BIOL CHEM, V276, P29037, DOI 10.1074/jbc.M103815200; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Liu YL, 2004, J BIOL CHEM, V279, P37436, DOI 10.1074/jbc.M400241200; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Ross K, 2002, J BIOL CHEM, V277, P37414, DOI 10.1074/jbc.M205160200; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Strelow A, 2003, FEBS LETT, V547, P157, DOI 10.1016/S0014-5793(03)00697-5; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takatsuna H, 2003, J BIOL CHEM, V278, P12144, DOI 10.1074/jbc.M300720200; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	34	76	82	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26029	26040		10.1074/jbc.M513057200	http://dx.doi.org/10.1074/jbc.M513057200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16831874	hybrid			2022-12-27	WOS:000240249500018
J	Kloosterman, TG; Hendriksen, WT; Bijlsma, JJE; Bootsma, HJ; van Hijum, SAFT; Kok, J; Hermans, PWM; Kuipers, OP				Kloosterman, Tomas G.; Hendriksen, Wouter T.; Bijlsma, Jetta J. E.; Bootsma, Hester J.; van Hijum, Sacha A. F. T.; Kok, Jan; Hermans, Peter W. M.; Kuipers, Oscar P.			Regulation of glutamine and glutamate metabolism by GlnR and GlnA in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED GENE-EXPRESSION; BACILLUS-SUBTILIS; LACTOCOCCUS-LACTIS; NITROGEN-METABOLISM; SYNTHETASE MUTANTS; TNRA; PROMOTER; CODY; IDENTIFICATION; VIRULENCE	Several genes involved in nitrogen metabolism are known to contribute to the virulence of pathogenic bacteria. Here, we studied the function of the nitrogen regulatory protein GlnR in the Gram-positive human pathogen Streptococcus pneumoniae. We demonstrate that GlnR mediates transcriptional repression of genes involved in glutamine synthesis and uptake (glnA and glnPQ), glutamate synthesis (gdhA), and the gene encoding the pentose phosphate pathway enzyme Zwf, which forms an operon with glnPQ. Moreover, the expression of gdhA is also repressed by the pleiotropic regulator CodY. The GlnR-dependent regulation occurs through a conserved operator sequence and is responsive to the concentration of glutamate, glutamine, and ammonium in the growth medium. By means of in vitro binding studies and transcriptional analyses, we show that the regulatory function of GlnR is dependent on GlnA. Mutants of glnA and glnP displayed significantly reduced adhesion to Detroit 562 human pharyngeal epithelial cells, suggesting a role for these genes in the colonization of the host by S. pneumoniae. Thus, our results provide a thorough insight into the regulation of glutamine and glutamate metabolism of S. pneumoniae mediated by both GlnR and GlnA.	Univ Groningen, Dept Mol Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands; Sophia Childrens Univ Hosp, Dept Pediat, Erasmus Med Ctr, NL-3000 DR Rotterdam, Netherlands; Radboud Univ, Dept Pediat, Med Ctr, NL-6500 HB Nijmegen, Netherlands	University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Radboud University Nijmegen	Kuipers, OP (corresponding author), Univ Groningen, Dept Mol Genet, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.	o.p.kuipers@rug.nl	Hermans, Peter W.M./H-8042-2014; Kok, Jan/C-9972-2012; Kuipers, Oscar/B-6752-2009; Hermans, Peter P.W.M./F-4655-2010; van Hijum, Sacha/F-6445-2014	Kuipers, Oscar/0000-0001-5596-7735; van Hijum, Sacha/0000-0003-0741-2991				ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; AVERY OT, 1995, MOL MED, V1, P344, DOI 10.1007/BF03401572; Baerends RJS, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r37; Belitsky BR, 2000, J BACTERIOL, V182, P5939, DOI 10.1128/JB.182.21.5939-5947.2000; Belitsky BR, 2004, J BACTERIOL, V186, P3392, DOI 10.1128/JB.186.11.3392-3398.2004; Bergara F, 2003, J BACTERIOL, V185, P3118, DOI 10.1128/JB.185.10.3118-3126.2003; Brandenburg JL, 2002, J BACTERIOL, V184, P6060, DOI 10.1128/JB.184.21.6060-6064.2002; Brown SW, 1996, J BACTERIOL, V178, P2450, DOI 10.1128/jb.178.8.2450-2454.1996; den Hengst CD, 2005, J BIOL CHEM, V280, P34332, DOI 10.1074/jbc.M502349200; den Hengst CD, 2005, J BACTERIOL, V187, P512, DOI 10.1128/JB.187.2.512-521.2005; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; EBNER E, 1970, METHOD ENZYMOL, V17, P922; FISHER SH, 1984, J BACTERIOL, V157, P612, DOI 10.1128/JB.157.2.612-621.1984; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; Guedon E, 2005, MICROBIOL-SGM, V151, P3895, DOI 10.1099/mic.0.28186-0; Guedon E, 2001, MOL MICROBIOL, V40, P1227, DOI 10.1046/j.1365-2958.2001.02470.x; GUTOWSKI JC, 1992, J BACTERIOL, V174, P671, DOI 10.1128/jb.174.3.671-681.1992; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.03106.x; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; ISRAELSEN H, 1995, APPL ENVIRON MICROB, V61, P2540, DOI 10.1128/AEM.61.7.2540-2547.1995; Kharat AS, 2003, INFECT IMMUN, V71, P2758, DOI 10.1128/IAI.71.5.2758-2765.2003; Kim HJ, 2003, J BACTERIOL, V185, P1672, DOI 10.1128/JB.185.5.1672-1680.2003; Kloosterman TG, 2006, MICROBIOL-SGM, V152, P351, DOI 10.1099/mic.0.28521-0; Klose KE, 1997, INFECT IMMUN, V65, P587, DOI 10.1128/IAI.65.2.587-596.1997; Kuipers OP, 2002, ANTON LEEUW INT J G, V82, P113, DOI 10.1023/A:1020691801251; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; Leenhouts K, 1998, APPL MICROBIOL BIOT, V49, P417, DOI 10.1007/s002530051192; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Molle V, 2003, J BACTERIOL, V185, P1911, DOI 10.1128/JB.185.6.1911-1922.2003; Nakano MM, 1998, J BACTERIOL, V180, P5344, DOI 10.1128/JB.180.20.5344-5350.1998; NAKANO Y, 1991, J BIOCHEM-TOKYO, V109, P223; Paterson GK, 2006, MICROBES INFECT, V8, P145, DOI 10.1016/j.micinf.2005.06.009; Pearce BJ, 2002, RES MICROBIOL, V153, P243, DOI 10.1016/S0923-2508(02)01312-8; Polissi A, 1998, INFECT IMMUN, V66, P5620, DOI 10.1128/IAI.66.12.5620-5629.1998; Sanders JW, 1998, MOL GEN GENET, V257, P681, DOI 10.1007/s004380050697; SCHREIER HJ, 1986, J BACTERIOL, V167, P35, DOI 10.1128/jb.167.1.35-43.1986; SCHREIER HJ, 1985, P NATL ACAD SCI USA, V82, P3375, DOI 10.1073/pnas.82.10.3375; SCHREIER HJ, 1989, J MOL BIOL, V210, P51, DOI 10.1016/0022-2836(89)90290-8; Schultz AC, 2001, J BACTERIOL, V183, P3293, DOI 10.1128/JB.183.11.3293-3302.2001; Shivers RP, 2005, MOL MICROBIOL, V56, P1549, DOI 10.1111/j.1365-2958.2005.04634.x; Song JH, 2005, MOL CELLS, V19, P365; Tamura GS, 2002, INFECT IMMUN, V70, P2877, DOI 10.1128/IAI.70.6.2877-2885.2002; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Tullius MV, 2003, INFECT IMMUN, V71, P3927, DOI 10.1128/IAI.71.7.3927-3936.2003; van Hijum Sacha A F T, 2003, Appl Bioinformatics, V2, P241; van Hijum SAFT, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-77; Varmanen P, 2000, J BACTERIOL, V182, P146, DOI 10.1128/JB.182.1.146-154.2000; Wray LV, 1998, J BACTERIOL, V180, P2943, DOI 10.1128/JB.180.11.2943-2949.1998; Wray LV, 1996, P NATL ACAD SCI USA, V93, P8841, DOI 10.1073/pnas.93.17.8841; Wray LV, 1997, J BACTERIOL, V179, P5494, DOI 10.1128/jb.179.17.5494-5501.1997; Wray LV, 2001, CELL, V107, P427, DOI 10.1016/S0092-8674(01)00572-4; Yoshida K, 2003, MOL MICROBIOL, V49, P157, DOI 10.1046/j.1365-2958.2003.03567.x	53	96	99	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25097	25109		10.1074/jbc.M601661200	http://dx.doi.org/10.1074/jbc.M601661200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16787930	Green Published, hybrid			2022-12-27	WOS:000240031300011
J	Yakovleva, L; Shuman, S				Yakovleva, Lyudmila; Shuman, Stewart			Nucleotide misincorporation, 3 '-mismatch extension, and responses to abasic sites and DNA adducts by the polymerase component of bacterial DNA ligase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRICK HYDROGEN-BONDS; END-JOINING FUNCTION; CRYSTAL-STRUCTURE; SULFOLOBUS-SOLFATARICUS; SOLUTION CONFORMATION; TRANSLESION SYNTHESIS; OPPOSITE DT; PRIMASE; COMPLEX; MECHANISM	DNA ligase D (LigD) participates in a mutagenic pathway of nonhomologous end joining in bacteria. LigD consists of an ATP-dependent ligase domain fused to a polymerase domain (POL) and a phosphoesterase module. The POL domain performs templated and nontemplated primer extension reactions with either dNTP or rNTP substrates. Here we report that Pseudomonas LigD POL is an unfaithful nucleic acid polymerase. Although the degree of infidelity in nucleotide incorporation varies according to the mispair produced, we find that a correctly paired ribonucleotide is added to the DNA primer terminus more rapidly than the corresponding correct deoxyribonucleotide and incorrect nucleotides are added much more rapidly with rNTP substrates than with dNTPs, no matter what the mispair configuration. We find that 3' mispairs are extended by LigDPOL, albeit more slowly than 3' paired primer-templates. The magnitude of the rate effect on mismatch extension varies with the identity of the 3' mispair, but it was generally the case that mispaired ends were extended more rapidly with rNTP substrates than with dNTPs. These results lend credence to the suggestion that LigD POL might fill in short 5'-overhangs with ribonucleotides when repairing double strand breaks in quiescent cells. We report that LigD POL can add a deoxynucleotide opposite an abasic lesion in the template strand, albeit slowly. Ribonucleotides are inserted more rapidly at an abasic lesion than are deoxys. LigD POL displays feeble activity in extending a preformed primer terminus opposing an abasic site, but can readily bypass the lesion by slippage of the primer 3' di- or trinucleotide and realignment to the template sequence distal to the abasic site. Covalent benzo[a] pyrene-dG and benzo[c] phenanthrene-dA adducts in the template strand are durable roadblocks to POL elongation. POL can slowly insert a dNMP opposite the adduct, but is impaired in the subsequent extension step.			Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akey D, 2006, J BIOL CHEM, V281, P13412, DOI 10.1074/jbc.M513550200; Augustin MA, 2001, NAT STRUCT BIOL, V8, P57, DOI 10.1038/83060; Bocquier AA, 2001, CURR BIOL, V11, P452, DOI 10.1016/S0960-9822(01)00119-1; Chiapperino D, 2005, J BIOL CHEM, V280, P39684, DOI 10.1074/jbc.M508008200; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P12488, DOI 10.1021/bi00097a029; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P1295, DOI 10.1021/bi00004a024; De Falco M, 2004, NUCLEIC ACIDS RES, V32, P5223, DOI 10.1093/nar/gkh865; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Desogus G, 1999, NUCLEIC ACIDS RES, V27, P4444, DOI 10.1093/nar/27.22.4444; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Gibbs PEM, 2005, GENETICS, V169, P575, DOI 10.1534/genetics.104.034611; Gon S, 2006, EMBO J, V25, P1137, DOI 10.1038/sj.emboj.7600990; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Hsu GW, 2005, J BIOL CHEM, V280, P3764, DOI 10.1074/jbc.M411276200; Ito N, 2003, GENES CELLS, V8, P913, DOI 10.1111/j.1365-2443.2003.00693.x; Kirk BW, 1999, BIOCHEMISTRY-US, V38, P10126, DOI 10.1021/bi990351u; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Lao-Sirieix SH, 2005, NAT STRUCT MOL BIOL, V12, P1137, DOI 10.1038/nsmb1013; Lao-Sirieix SH, 2004, J MOL BIOL, V344, P1251, DOI 10.1016/j.jmb.2004.10.018; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Lipps G, 2004, NAT STRUCT MOL BIOL, V11, P157, DOI 10.1038/nsmb723; Liu LD, 2001, J BIOL CHEM, V276, P45484, DOI 10.1074/jbc.M106391200; Matsui E, 2003, BIOCHEMISTRY-US, V42, P14968, DOI 10.1021/bi035556o; Moore CL, 2004, BIOCHEMISTRY-US, V43, P12367, DOI 10.1021/bi0490791; Pitcher RS, 2005, J MOL BIOL, V351, P531, DOI 10.1016/j.jmb.2005.06.038; Potapova O, 2006, BIOCHEMISTRY-US, V45, P890, DOI 10.1021/bi051792i; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; SHEAFF RJ, 1994, J BIOL CHEM, V269, P19225; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Tian LG, 2004, J BIOL CHEM, V279, P39718, DOI 10.1074/jbc.M407376200; Washington MT, 2003, MOL CELL BIOL, V23, P5107, DOI 10.1128/MCB.23.14.5107-5112.2003; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Wolfle WT, 2005, MOL CELL BIOL, V25, P7137, DOI 10.1128/MCB.25.16.7137-7143.2005; Yakovleva L, 2004, J BIOL CHEM, V279, P23335, DOI 10.1074/jbc.M401203200; Zerbe LK, 1999, BIOCHEMISTRY-US, V38, P12908, DOI 10.1021/bi991075m; ZHANG SS, 1990, J MOL BIOL, V216, P475, DOI 10.1016/0022-2836(90)90370-2; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P33707, DOI 10.1074/jbc.M506838200; Zhu H, 2005, J BIOL CHEM, V280, P25973, DOI 10.1074/jbc.M504002200; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200	45	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25026	25040		10.1074/jbc.M603302200	http://dx.doi.org/10.1074/jbc.M603302200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16816388	hybrid			2022-12-27	WOS:000240031300005
J	Han, C; Demetris, AJ; Stolz, DB; Xu, L; Lim, K; Wu, T				Han, Chang; Demetris, A. Jake; Stolz, Donna B.; Xu, Lihong; Lim, Kyu; Wu, Tong			Modulation of Stat3 activation by the cytosolic phospholipase A(2)alpha and cyclooxygenase-2-controlled prostaglandin E-2 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLANGIOCARCINOMA CELL-LINE; GROWTH-FACTOR RECEPTOR; CELECOXIB-INDUCED APOPTOSIS; MEDIATED ACTIVATION; AKT INACTIVATION; SRC ONCOPROTEIN; PROTEIN-KINASE; UP-REGULATION; CANCER CELLS; IN-VITRO	A variety of human cancers show constitutive activation of signal transducer and activator of transcription-3 (Stat3) and overexpression of cyclooxygenase-2 (COX-2). This study describes a novel cross-talk between the COX-2-controlled prostaglandin E-2 (PGE(2)) and Stat3 signaling pathways that coordinately regulate human cancer cell growth. COX-2-derived PGE(2) induces interleukin-6 production through activation of EP4 receptor and subsequent phosphorylation of gp130/Stat3 in human cholangiocarcinoma cells. In parallel, activation of COX-2/PGE(2) signaling also enhances Stat3 phosphorylation and reporter activity through EP1 receptor-induced activation of c-Src and EGFR in these cells. Moreover, the observations that EP1 receptor is detected in the nucleus as well as in the Stat3 center dot DNA binding complex and that activation of EP1 receptor in the nuclei enhances Stat3 activation depicts a previously undescribed G protein-coupled receptor in the nucleus for Stat3 activation and tumor cell growth.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Han, C (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, BST E1514, Pittsburgh, PA 15261 USA.	changhan+@pitt.edu; wut@upmc.edu			NATIONAL CANCER INSTITUTE [R01CA102325, R01CA076541, R01CA106280, R29CA076541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049615] Funding Source: NIH RePORTER; NCI NIH HHS [CA102325, CA106280, CA 76541] Funding Source: Medline; NIDDK NIH HHS [DK49615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berthiaume EP, 2004, SEMIN LIVER DIS, V24, P127, DOI 10.1055/s-2004-828890; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Boivin B, 2003, J BIOL CHEM, V278, P29153, DOI 10.1074/jbc.M301738200; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Endo K, 2002, HEPATOLOGY, V36, P439, DOI 10.1053/jhep.2002.34435; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Gores GJ, 2003, HEPATOLOGY, V37, P961, DOI 10.1053/jhep.2003.50200; Goydos JS, 1998, ANN SURG, V227, P398, DOI 10.1097/00000658-199803000-00012; Han C, 2004, J BIOL CHEM, V279, P44344, DOI 10.1074/jbc.M404852200; Han C, 2005, J BIOL CHEM, V280, P24053, DOI 10.1074/jbc.M500562200; Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hirano T, 1998, Int Rev Immunol, V16, P249; Horn F, 2000, IMMUNOBIOLOGY, V202, P151, DOI 10.1016/S0171-2985(00)80061-3; Kiguchi K, 2001, CANCER RES, V61, P6971; Lai GH, 2000, HEPATOLOGY, V31, P1257, DOI 10.1053/jhep.2000.8108; Lai GH, 2003, MOL CANCER THER, V2, P265; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Nzeako UC, 2002, HEPATOLOGY, V35, P552, DOI 10.1053/jhep.2002.31774; OKADA K, 1994, J GASTROEN HEPATOL, V9, P462, DOI 10.1111/j.1440-1746.1994.tb01275.x; Park J, 1999, HEPATOLOGY, V29, P1037, DOI 10.1002/hep.510290423; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Sirica AE, 2005, HEPATOLOGY, V41, P5, DOI 10.1002/hep.20537; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Su JL, 2004, CANCER RES, V64, P554, DOI 10.1158/0008-5472.CAN-03-1301; Sugawara H, 1998, HISTOPATHOLOGY, V33, P145, DOI 10.1046/j.1365-2559.1998.00445.x; Tadlock L, 2001, HEPATOLOGY, V33, P43, DOI 10.1053/jhep.2001.20676; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Werneburg NW, 2003, AM J PHYSIOL-GASTR L, V285, pG31, DOI 10.1152/ajpgi.00536.2002; Wu T, 2005, BBA-REV CANCER, V1755, P135, DOI 10.1016/j.bbcan.2005.04.002; Wu T, 2004, MOL CANCER THER, V3, P299; Wu T, 2002, HEPATOLOGY, V36, P363, DOI 10.1053/jhep.2002.34743; Yokomuro S, 2000, CYTOKINE, V12, P727, DOI 10.1006/cyto.1999.0612; Yoon JH, 2004, HEPATOLOGY, V39, P732, DOI 10.1002/hep.20125; Yoon JH, 2002, GASTROENTEROLOGY, V122, P985, DOI 10.1053/gast.2002.32410; Yoon JH, 2002, CANCER RES, V62, P6500; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang ZC, 2004, HEPATOLOGY, V39, P1028, DOI 10.1002/hep.20143	58	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24831	24846		10.1074/jbc.M602201200	http://dx.doi.org/10.1074/jbc.M602201200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790433	hybrid			2022-12-27	WOS:000239847800078
J	Glaaser, IW; Bankston, JR; Liu, HJ; Tateyama, M; Kass, RS				Glaaser, Ian W.; Bankston, John R.; Liu, Huajun; Tateyama, Michihiro; Kass, Robert S.			A carboxyl-terminal hydrophobic interface is critical to sodium channel function - Relevance to inherited disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; TRYPTOPHANYL RESIDUES; LQT-3 MUTATION; ALPHA-SUBUNIT; CARDIAC NA+; EF-HAND; LONG-QT; DOMAIN; INACTIVATION; CALMODULIN	Perturbation of sodium channel inactivation, a finely tuned process that critically regulates the flow of sodium ions into excitable cells, is a common functional consequence of inherited mutations associated with epilepsy, skeletal muscle disease, autism, and cardiac arrhythmias. Understanding the structural basis of inactivation is key to understanding these disorders. Here we identify a novel role for a structural motif in the COOH terminus of the heart Na(V)1.5 sodium channel in determining channel inactivation. Structural modeling predicts an interhelical hydrophobic interface between paired EF hands in the proximal region of the Na(V)1.5COOH terminus. The predicted interface is conserved among almost all EF hand-containing proteins and is the locus of a number of disease-associated mutations. Using the structural model as a guide, we provide biochemical and biophysical evidence that the structural integrity of this interface is necessary for proper Na+ channel inactivation gating. We thus demonstrate a novel role of the sodium channel COOH terminus structure in the control of channel inactivation and in pathologies caused by inherited mutations that disrupt it.	Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Columbia University	Kass, RS (corresponding author), Columbia Univ, Dept Pharmacol, New York, NY 10032 USA.	rsk20@columbia.edu	Bankston, John/I-7429-2019	Bankston, John/0000-0002-9478-2335	PHS HHS [R01-056810-07] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abriel H, 2005, TRENDS CARDIOVAS MED, V15, P35, DOI 10.1016/j.tcm.2005.01.001; An RH, 1998, CIRC RES, V83, P141, DOI 10.1161/01.RES.83.2.141; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; Berggard T, 2001, BIOCHEMISTRY-US, V40, P1257, DOI 10.1021/bi0014812; Bezzina C, 1999, CIRC RES, V85, P1206; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Clancy CE, 2005, PHYSIOL REV, V85, P33, DOI 10.1152/physrev.00005.2004; Cormier JW, 2002, J BIOL CHEM, V277, P9233, DOI 10.1074/jbc.M110204200; Davis JP, 2004, J BIOL CHEM, V279, P17348, DOI 10.1074/jbc.M314095200; EFTINK MR, 1977, BIOCHEMISTRY-US, V16, P5546, DOI 10.1021/bi00644a024; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P1193, DOI 10.1021/bi00219a005; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fujiwara T, 2003, BRAIN, V126, P531, DOI 10.1093/brain/awg053; Hubner CA, 2002, HUM MOL GENET, V11, P2435, DOI 10.1093/hmg/11.20.2435; Julenius K, 1998, BIOCHEMISTRY-US, V37, P8915, DOI 10.1021/bi972642d; Jurkat-Rott K, 2002, J NEUROL, V249, P1493, DOI 10.1007/s00415-002-0871-5; Kass RS, 2003, J CLIN INVEST, V112, P810, DOI 10.1172/JCI200319844; Kim J, 2004, J BIOL CHEM, V279, P45004, DOI 10.1074/jbc.M407286200; Kretsinger RH, 1996, NAT STRUCT BIOL, V3, P12, DOI 10.1038/nsb0196-12; Linse S, 2000, J MOL BIOL, V296, P473, DOI 10.1006/jmbi.1999.3452; Mantegazza M, 2001, P NATL ACAD SCI USA, V98, P15348, DOI 10.1073/pnas.211563298; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Meyer DF, 1996, J BIOL CHEM, V271, P11284, DOI 10.1074/jbc.271.19.11284; Motoike HK, 2004, J GEN PHYSIOL, V123, P155, DOI 10.1085/jgp.200308929; Nabbout R, 2003, NEUROLOGY, V60, P1961, DOI 10.1212/01.WNL.0000069463.41870.2F; Nanda V, 2000, PROTEINS, V40, P112, DOI 10.1002/(SICI)1097-0134(20000701)40:1<112::AID-PROT130>3.0.CO;2-C; Rivolta I, 2001, J BIOL CHEM, V276, P30623, DOI 10.1074/jbc.M104471200; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Shah VN, 2006, P NATL ACAD SCI USA, V103, P3592, DOI 10.1073/pnas.0507397103; Spampanato J, 2004, J NEUROSCI, V24, P10022, DOI 10.1523/JNEUROSCI.2034-04.2004; Subramaniam V, 2001, J BIOL CHEM, V276, P21506, DOI 10.1074/jbc.M102292200; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tateyama M, 2004, BIOPHYS J, V86, P1843, DOI 10.1016/S0006-3495(04)74251-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Veldkamp MW, 2000, CIRC RES, V86, pE91, DOI 10.1161/01.RES.86.9.e91; Wingo TL, 2004, NAT STRUCT MOL BIOL, V11, P219, DOI 10.1038/nsmb737; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	39	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					24015	24023		10.1074/jbc.M605473200	http://dx.doi.org/10.1074/jbc.M605473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16798729	hybrid			2022-12-27	WOS:000239702900075
J	Thompson, D; Simonson, T				Thompson, Damien; Simonson, Thomas			Molecular dynamics simulations show that bound Mg2+ contributes to amino acid and aminoacyl adenylate binding specificity in aspartyl-tRNA synthetase through long range electrostatic interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-ENERGY SIMULATIONS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACTIVE-SITE; THERMUS-THERMOPHILUS; CONTINUUM MODEL; PROTON BINDING; RECOGNITION; MECHANISM; PROTEINS	Molecular recognition between the aminoacyl-tRNA synthetase enzymes and their cognate amino acid ligands is essential for the faithful translation of the genetic code. In aspartyl-tRNA synthetase (AspRS), the co-substrate ATP binds preferentially with three associated Mg2+ cations in an unusual, bent geometry. The Mg2+ cations play a structural role and are thought to also participate catalytically in the enzyme reaction. Co-binding of the ATP(.)Mg(3)(2+) complex was shown recently to increase the Asp/Asn binding free energy difference, indicating that amino acid discrimination is substrate-assisted. Here, we used molecular dynamics free energy simulations and continuum electrostatic calculations to resolve two related questions. First, we showed that if one of the Mg2+ cations is removed, the Asp/Asn binding specificity is strongly reduced. Second, we computed the relative stabilities of the three-cation complex and the 2- cation complexes. We found that the 3-cation complex is overwhelmingly favored at ordinary magnesium concentrations, so that the protein is protected against the 2- cation state. In the homologous LysRS, the 3-cation complex was also strongly favored, but the third cation did not affect Lys binding. In tRNA-bound AspRS, the single remaining Mg2+ cation strongly favored the Asp-adenylate substrate relative to Asn-adenylate. Thus, in addition to their structural and catalytic roles, the Mg2+ cations contribute to specificity in AspRS through long range electrostatic interactions with the Asp side chain in both the pre- and post-adenylation states.	Ecole Polytech, Dept Biol, CNRS, UMR7654,Lab Biochim, F-91128 Palaiseau, France; Natl Univ Ireland Univ Coll Cork, Tyndall Natl Inst, Cork, Ireland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris; University College Cork	Simonson, T (corresponding author), Ecole Polytech, Dept Biol, CNRS, UMR7654,Lab Biochim, F-91128 Palaiseau, France.	thomas.simonson@polytechnique.fr	Thompson, Damien/AFP-1709-2022; thompson, damien/G-6138-2015; Simonson, Thomas/A-5733-2008	Thompson, Damien/0000-0003-2340-5441; thompson, damien/0000-0003-2340-5441; Simonson, Thomas/0000-0002-5117-7338				Ador L, 2004, BIOCHEMISTRY-US, V43, P7028, DOI 10.1021/bi049617+; ALBERTS B, 2002, MOL BIOL CELL, P161; Archontis G, 1998, J MOL BIOL, V275, P823, DOI 10.1006/jmbi.1997.1470; Archontis G, 2005, BIOPHYS J, V88, P3888, DOI 10.1529/biophysj.104.055996; Archontis G, 2001, J MOL BIOL, V306, P307, DOI 10.1006/jmbi.2000.4285; Archontis G, 2001, J AM CHEM SOC, V123, P11047, DOI 10.1021/ja010716+; Arnez JG, 1998, PROTEINS, V32, P362; Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; Arnez JG, 1994, RNA PROTEIN INTERACT, P52; ARTYMIUK PJ, 1994, NAT STRUCT BIOL, V1, P758, DOI 10.1038/nsb1194-758; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BEGLOV D, 1994, J CHEM PHYS, V100, P9050, DOI 10.1063/1.466711; Berthet-Colominas C, 1998, EMBO J, V17, P2947, DOI 10.1093/emboj/17.10.2947; BLANQUET S, 1974, EUR J BIOCHEM, V44, P343, DOI 10.1111/j.1432-1033.1974.tb03491.x; BLANQUET S, 1975, J MOL BIOL, V94, P1, DOI 10.1016/0022-2836(75)90401-5; Bovee ML, 2003, BIOCHEMISTRY-US, V42, P15102, DOI 10.1021/bi0355701; Briand C, 2000, J MOL BIOL, V299, P1051, DOI 10.1006/jmbi.2000.3819; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CAVERELLI J, 1993, NATURE, V362, P181; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; da Silva J. J. R. Frausto, 2001, BIOL CHEM ELEMENTS; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; Desogus G, 2000, BIOCHEMISTRY-US, V39, P8418, DOI 10.1021/bi0006722; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; FERSHT A, 1999, STRUCTURE MECHANISM; FERSHT AR, 1986, ACCURACY MOL PROCESS, P67; FOTHERGILL M, 1995, J AM CHEM SOC, V117, P11619, DOI 10.1021/ja00152a001; Francklyn C, 2003, P NATL ACAD SCI USA, V100, P9650, DOI 10.1073/pnas.1934245100; GAO J, 1989, SCIENCE, V244, P1069, DOI 10.1126/science.2727695; Henin J, 2005, J AM CHEM SOC, V127, P8478, DOI 10.1021/ja050581y; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Hughes Samantha J, 2003, BMC Struct Biol, V3, P5, DOI 10.1186/1472-6807-3-5; Ibba M., 2005, AMINOACYL TRNA SYNTH; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Meinnel Thierry, 1995, P251; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moulinier L, 2001, EMBO J, V20, P5290, DOI 10.1093/emboj/20.18.5290; Pallanck Leo, 1995, P371; Pezo V, 2004, P NATL ACAD SCI USA, V101, P8593, DOI 10.1073/pnas.0402893101; POTERSZMAN A, 1994, J MOL BIOL, V244, P158, DOI 10.1006/jmbi.1994.1716; Rees B, 2000, J MOL BIOL, V299, P1157, DOI 10.1006/jmbi.2000.3792; RUFF M, 1991, SCIENCE, V252, P1685; Sauter C, 2000, J MOL BIOL, V299, P1313, DOI 10.1006/jmbi.2000.3791; Schimmel P, 2000, TRENDS BIOCHEM SCI, V25, P207, DOI 10.1016/S0968-0004(00)01553-X; Schmitt E, 1998, EMBO J, V17, P5227, DOI 10.1093/emboj/17.17.5227; Simonson T, 1997, J PHYS CHEM B, V101, P8349, DOI 10.1021/jp9711499; Simonson T, 2000, J PHYS CHEM B, V104, P6509, DOI 10.1021/jp0014317; Simonson T, 2004, J AM CHEM SOC, V126, P4167, DOI 10.1021/ja039788m; Simonson T, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P169; Simonson T, 2003, REP PROG PHYS, V66, P737, DOI 10.1088/0034-4885/66/5/202; Simonson T, 2002, P NATL ACAD SCI USA, V99, P6544, DOI 10.1073/pnas.082657099; Simonson T, 2002, ACCOUNTS CHEM RES, V35, P430, DOI 10.1021/ar010030m; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; STOTE RH, 1991, J CHIM PHYS PCB, V88, P2419, DOI 10.1051/jcp/1991882419; Thompson D, 2006, CHEMBIOCHEM, V7, P337, DOI 10.1002/cbic.200500364; Zeng J, 1999, PROTEIN SCI, V8, P50	60	36	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23792	23803		10.1074/jbc.M602870200	http://dx.doi.org/10.1074/jbc.M602870200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16774919	hybrid			2022-12-27	WOS:000239702900055
J	Villagra, A; Cruzat, F; Carvallo, L; Paredes, R; Olate, J; van Wijnen, AJ; Stein, GS; Lian, JB; Stein, JL; Imbalzano, AN; Montecino, M				Villagra, Alejandro; Cruzat, Fernando; Carvallo, Loreto; Paredes, Roberto; Olate, Juan; van Wijnen, Andre J.; Stein, Gary S.; Lian, Jane B.; Stein, Janet L.; Imbalzano, Anthony N.; Montecino, Martin			Chromatin remodeling and transcriptional activity of the bone-specific osteocalcin gene require CCAAT/enhancer-binding protein beta-dependent recruitment of SWI/SNF activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST DIFFERENTIATION; GLUCOCORTICOID-RECEPTOR; MUSCLE DIFFERENTIATION; PROMOTER SEQUENCES; C/EBP-BETA; IN-VITRO; COMPLEX; EXPRESSION; CELLS; ACTIVATION	Tissue-specific activation of the osteocalcin (OC) gene is associated with changes in chromatin structure at the promoter region. Two nuclease-hypersensitive sites span the key regulatory elements that control basal tissue-specific and vitamin D-3-enhanced OC gene transcription. To gain understanding of the molecular mechanisms involved in chromatin remodeling of the OC gene, we have examined the requirement for SWI/SNF activity. We inducibly expressed an ATPase-defective BRG1 catalytic subunit that forms inactive SWI/SNF complexes that bind to the OC promoter. This interaction results in inhibition of both basal and vitamin D-3-enhanced OC gene transcription and a marked decrease in nuclease hypersensitivity. We find that SWI/SNF is recruited to the OC promoter via the transcription factor CCAAT/enhancer-binding protein beta, which together with Runx2 forms a stable complex to facilitate RNA polymerase II binding and activation of OC gene transcription. Together, our results indicate that the SWI/SNF complex is a key regulator of the chromatin-remodeling events that promote tissue-specific transcription in osteoblasts.	Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Concepcion, Chile; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Universidad de Concepcion; University of Massachusetts System; University of Massachusetts Worcester	Montecino, M (corresponding author), Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Casilla 160-C 4079100, Concepcion, Chile.	mmonteci@udec.cl	Carvallo, Loreto/C-2237-2019; van Wijnen, Andre J./AAG-3578-2019	Carvallo, Loreto/0000-0001-9943-1342; van Wijnen, Andre J./0000-0002-4458-0946; Paredes, Roberto/0000-0002-6793-5404; Villagra, Alejandro/0000-0001-9346-8355	FIC NIH HHS [5R03TW00990] Funding Source: Medline; NIAMS NIH HHS [R01 AR049069, P01AR48818] Funding Source: Medline; NIDCR NIH HHS [DE12528] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069, P01AR048818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gutierrez J, 2000, BIOCHEMISTRY-US, V39, P13565, DOI 10.1021/bi0013896; Gutierrez S, 2004, J BIOL CHEM, V279, P43581, DOI 10.1074/jbc.M408335200; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Javed A, 1999, MOL CELL BIOL, V19, P7491; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lian JB, 2001, STEROIDS, V66, P159, DOI 10.1016/S0039-128X(00)00160-4; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; Montecino M, 1996, J CELL BIOCHEM, V63, P221, DOI 10.1002/(SICI)1097-4644(19961101)63:2<221::AID-JCB9>3.0.CO;2-#; Montecino M, 1999, BIOCHEMISTRY-US, V38, P1338, DOI 10.1021/bi982171a; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Paredes R, 2004, MOL CELL BIOL, V24, P8847, DOI 10.1128/MCB.24.20.8847-8861.2004; Paredes R, 2002, BIOCHEM J, V363, P667, DOI 10.1042/0264-6021:3630667; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Sullivan EK, 2001, MOL CELL BIOL, V21, P5826, DOI 10.1128/MCB.21.17.5826-5837.2001; Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332	40	64	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22695	22706		10.1074/jbc.M511640200	http://dx.doi.org/10.1074/jbc.M511640200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772287	hybrid			2022-12-27	WOS:000239542600030
